PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mano, I; Straud, S; Driscoll, M				Mano, Itzhak; Straud, Sarah; Driscoll, Monica			Caenorhabditis elegans glutamate transporters influence synaptic function and behavior at sites distant from the synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; CHLORIDE CHANNEL; NERVOUS-SYSTEM; HOMOLOG; SUBUNIT; PROTEIN; CLONING; NEUROTRANSMISSION; SENSITIVITY; GENETICS	To ensure precise neurotransmission and prevent neurotoxic accumulation, L-glutamate (Glu), the major excitatory neurotransmitter in the brain, is cleared from the synapse by glutamate transporters (GluTs). The molecular components of Glu synapses are highly conserved between Caenorhabditis elegans and mammals, yet the absence of synaptic insulation in C. elegans raises fundamental questions about Glu clearance strategies in the nematode nervous system. To gain insight into how Glu clearance is accomplished and how GluTs impact neurotransmission, we probed expression and function of all 6 GluTs found in the C. elegans genome. Disruption of each GluT impacts multiple Glu-dependent behaviors, with GluT combinations commonly increasing the severity of behavioral deficits. Interestingly, the sole GluT that we find expressed in neurons is localized predominantly in presynaptic neurons, in contrast to the postsynaptic concentration of neuronal GluTs typical in mammals. Moreover, 3 of the 6 GluT genes appear strongly expressed on the capillary excretory canal cell, where they affect Glu-dependent behaviors from positions distal to glutamatergic circuits. Indeed, our focused study of GLT-3, one of the distally expressed GluTs, shows that despite this distance, GLT-3 function can balance the activity mediated by synaptic release and synaptic receptors. The effects of distal GluTs on glutamatergic circuits support that Glu diffusion outside the vicinity of the synapse is a critical factor in C. elegans neurotransmission. Together with the presynaptic localization of neuronal GluTs, these observations suggest an unusual strategy for Glu clearance in C. elegans.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	Rutgers State University New Brunswick; University of Texas System; University of Texas Southwestern Medical Center Dallas	Driscoll, M (corresponding author), 604 Allison Rd, Piscataway, NJ 08854 USA.	driscoll@biology.rutgers.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046154, R37HL046154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034435, R01NS041632] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46154] Funding Source: Medline; NINDS NIH HHS [NS 41632, NS 34435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; Barger AJ, 1998, J NEUROSCI, V18, P2871; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; BIANCHI L, 2004, TRANSDUCTION CHANNEL, P1; Boulin Thomas, 2006, WormBook, P1, DOI 10.1895/wormbook.1.106.1; Brockie Penelope J, 2006, WormBook, P1; Brockie PJ, 2001, NEURON, V31, P617, DOI 10.1016/S0896-6273(01)00394-4; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chaudhry FA, 2002, J CELL BIOL, V157, P349, DOI 10.1083/jcb.200201070; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Hasegawa J, 2006, NEURON, V50, P63, DOI 10.1016/j.neuron.2006.02.022; He Y, 2000, J COMP NEUROL, V418, P255; Hope IA, 2004, GENOME RES, V14, P2070, DOI 10.1101/gr.2463804; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kanner BI, 2002, BBA-BIOENERGETICS, V1555, P92, DOI 10.1016/S0005-2728(02)00260-8; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kawano T, 1996, BIOCHEM BIOPH RES CO, V228, P415, DOI 10.1006/bbrc.1996.1676; Kawano T, 1997, BIOSCI BIOTECH BIOCH, V61, P927, DOI 10.1271/bbb.61.927; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zheng Y, 1999, NEURON, V24, P347, DOI 10.1016/S0896-6273(00)80849-1; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	42	29	41	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2007	282	47					34412	34419		10.1074/jbc.M704134200	http://dx.doi.org/10.1074/jbc.M704134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234FI	17681948	hybrid			2022-12-27	WOS:000251145700057
J	Kypriotou, M; Beauchef, G; Chadjichristos, C; Widom, R; Renard, E; Jimenez, SA; Korn, J; Maquart, FX; Oddos, T; Von Stetten, O; Pujol, JP; Galera, P				Kypriotou, Magdalini; Beauchef, Gallic; Chadjichristos, Christos; Widom, Russell; Renard, Emmanuelle; Jimenez, Sergio A.; Korn, Joseph; Maquart, Francois-Xavier; Oddos, Thierry; Von Stetten, Otto; Pujol, Jean-Pierre; Galera, Philippe			Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA 2(I) COLLAGEN; HUMAN COL2A1 GENE; C-KROX; FACTOR YY1; DERMAL FIBROBLASTS; PROMOTER ACTIVITY; DOWN-REGULATION; COL1A1; BINDING; ELEMENTS	Despite several investigations, the transcriptional mechanisms that regulate the expression of both type I collagen genes (COL1A1 and COL1A2) in either physiological or pathological situations, such as scleroderma, are not completely known. We have investigated the role of hc-Krox transcription factor on type I collagen expression by human dermal fibroblasts. hc-Krox exerted a stimulating effect on type I collagen protein synthesis and enhanced the corresponding mRNA steady-state levels of COL1A1 and COL1A2 in foreskin fibroblasts (FF), adult normal fibroblasts (ANF), and scleroderma fibroblasts (SF). Forced hc-Krox expression was found to up-regulate COL1A1 transcription through a -112/-61-bp sequence in FF, ANF, and SF. Knockdown of hc-Krox by short interfering RNA and decoy strategies confirmed the transactivating effect of hc-Krox and decreased substantially COL1A1 transcription levels in all fibroblast types. The -112/-61-bp sequence bound specifically hc-Krox but also Sp1 and CBF. Attempts to elucidate the potential interactions between hc-Krox, Sp1, and Sp3 revealed that all of them co-immunoprecipitate from FF cellular extracts when a c-Krox antibody was used and bind to the COL1A1 promoter in chromatin immunoprecipitation assays. Moreover, hc-Krox DNA binding activity to its COL1A1-responsive element is increased in SF, cells producing higher amounts of type I collagen compared with ANF and FF. These data suggest that the regulation of COL1A1 gene transcription in human dermal fibroblasts involves a complex machinery that implicates at least three transcription proteins, hc-Krox, Sp1, and Sp3, which could act in concert to up-regulate COL1A1 transcriptional activity and provide evidence for a pro-fibrotic role of hc-Krox.	Johnson & Johnson Consumer France, R & D Europe, F-27100 Val De Reuil, France; Univ Caen Basse Normandie, Lab Biochim Tissu Conjonctif, Fac Med, CHU Niveau 3, F-14032 Caen, France; Boston Univ, Sch Med, Dept Med, Ctr Arthritis, Boston, MA 02118 USA; Boston Vet Affairs Med Ctr, Boston, MA 02118 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19017 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Biol, Philadelphia, PA 19017 USA; UFR Med, IFR Biomol 53, CNRS, FRE 2534,Lab Biochim Med & Biol Mol, F-51095 Reims, France	Johnson & Johnson; CHU de Caen NORMANDIE; Universite de Caen Normandie; Boston University; Jefferson University; Jefferson University; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Galera, P (corresponding author), Johnson & Johnson Consumer France, R & D Europe, Campus Maigremont, F-27100 Val De Reuil, France.	philippe.galera@unicaen.fr	Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Jimenez, Sergio/0000-0001-5213-1203				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; Beauchef G, 2005, BIOCHEM BIOPH RES CO, V333, P1123, DOI 10.1016/j.bbrc.2005.06.020; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cicchillitti L, 2004, BIOCHEM J, V378, P609, DOI 10.1042/BJ20031110; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; FERRARINI M, 1990, CLIN EXP IMMUNOL, V79, P346; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GALERA P, 1994, M S-MED SCI, V10, P1253, DOI 10.4267/10608/2564; Garcia Ruiz Inmaculada, 2000, DNA and Cell Biology, V19, P167; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; He X, 2005, NATURE, V433, P826, DOI 10.1038/nature03338; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ihn H, 2001, J INVEST DERMATOL, V117, P301, DOI 10.1046/j.0022-202x.2001.01371.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; LEE B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P173; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE TC, 1994, ONCOGENE, V9, P1047; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Rincon-Arano H, 2005, J MOL BIOL, V349, P961, DOI 10.1016/j.jmb.2005.04.040; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Sorrell JM, 2004, J CELL SCI, V117, P667, DOI 10.1242/jcs.01005; Sun GP, 2005, NAT IMMUNOL, V6, P373, DOI 10.1038/ni1183; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Weill L, 2003, J VIROL, V77, P2903, DOI 10.1128/JVI.77.5.2903-2914.2003; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706	56	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					32000	32014		10.1074/jbc.M705197200	http://dx.doi.org/10.1074/jbc.M705197200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17698844	hybrid, Green Submitted			2022-12-27	WOS:000250480300021
J	Devos, JM; Tomanicek, SJ; Jones, CE; Nossal, NG; Mueser, TC				Devos, Juliette M.; Tomanicek, Stephen J.; Jones, Charles E.; Nossal, Nancy G.; Mueser, Timothy C.			Crystal structure of bacteriophage T4 5' nuclease in complex with a branched DNA reveals how flap endonuclease-1 family nucleases bind their substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION PROTEIN-A; T4 RNASE-H; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; PCNA BINDING; FEN-1; STIMULATION; EXONUCLEASE; CATALYSIS	Bacteriophage T4 RNase H, a flap endonuclease- 1 family nuclease, removes RNA primers from lagging strand fragments. It has both 5' nuclease and flap endonuclease activities. Our previous structure of native T4 RNase H(PD B code 1TFR) revealed an active site composed of highly conserved Asp residues and two bound hydrated magnesium ions. Here, we report the crystal structure of T4 RNase H in complex with a fork DNA substrate bound in its active site. This is the first structure of a flap endonuclease- 1 family protein with its complete branched substrate. The fork duplex interacts with an extended loop of the helix-hairpin-helix motif class 2. The 5' armcrosses over the active site, extending below the bridge ( helical arch) region. Cleavage assays of this DNA substrate identify a primary cut site 7-bases in from the 5' arm. The scissile phosphate, the first bond in the duplex DNA adjacent to the 5' arm, lies above a magnesium binding site. The less ordered 3' arm reaches toward the C and N termini of the enzyme, which are binding sites for T432 protein and T445 clamp, respectively. In the crystal structure, the scissile bond is located within the double-stranded DNA, between the first two duplex nucleotides next to the 5' arm, and lies above a magnesium binding site. This complex provides important insight into substrate recognition and specificity of the flap endonuclease- 1 enzymes.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA; NIDDK, NIH, Mol & Cellular Biol Lab, Bethesda, MD 20892 USA	University System of Ohio; University of Toledo; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mueser, TC (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.	timothy.mueser@utoledo.edu	Jones, Charles/GVS-9497-2022		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057816] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2001, EMBO J, V20, P5791; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Cowan JA, 2002, BIOMETALS, V15, P225, DOI 10.1023/A:1016022730880; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Feng M, 2004, NAT STRUCT MOL BIOL, V11, P450, DOI 10.1038/nsmb754; Gangisetty O, 2005, J BIOL CHEM, V280, P12876, DOI 10.1074/jbc.M414025200; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Matsui E, 2002, J BIOL CHEM, V277, P37840, DOI 10.1074/jbc.M205235200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; Tock MR, 2003, EMBO J, V22, P995, DOI 10.1093/emboj/cdg098; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Woodworth DL, 1996, GENETICS, V143, P1081; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013	55	43	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31713	31724		10.1074/jbc.M703209200	http://dx.doi.org/10.1074/jbc.M703209200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17693399	hybrid			2022-12-27	WOS:000250309200062
J	Ruffolo, SC; Forsell, PKA; Yuan, XL; Desmarais, S; Himms-Hagen, J; Cromlish, W; Wong, KK; Kennedy, BP				Ruffolo, Salvatore C.; Forsell, Pontus K. A.; Yuan, Xiling; Desmarais, Sylvie; Himms-Hagen, Jean; Cromlish, Wanda; Wong, Kenny K.; Kennedy, Brian P.			Basal activation of p70S6K results in adipose-specific insulin resistance in protein-tyrosine phosphatase 1B(-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; AMINO-ACIDS; S6 KINASE; GLUCOSE-TRANSPORT; RECEPTOR; PHOSPHORYLATION; RAPAMYCIN; OBESITY; DEPHOSPHORYLATION; 3T3-L1	Although protein-tyrosine phosphatase 1B (PTP-1B) is a negative regulator of insulin action, adipose tissue from PTP-1B(-/-) mice does not show enhanced insulin-stimulated insulin receptor phosphorylation. Investigation of glucose uptake in isolated adipocytes revealed that the adipocytes from PTP-1B(-/-) mice have a significantly attenuated insulin response as compared with PTP-1B(+/+) adipocytes. This insulin resistance manifests in PTP-1B(-/-) animals older than 16 weeks of age and could be partially rescued by adenoviral expression of PTP-1B in null adipocytes. Examination of adipose signaling pathways found that the basal p70S6K activity was at least 50% higher in adipose from PTP-1B(-/-) mice compared with wild type animals. The increased basal activity of p70S6K in PTP-1B(-/-) adipose correlated with decreases in IR substrate-1 protein levels and insulin-stimulated Akt/protein kinase B activity, explaining the decrease in insulin sensitivity even as insulin receptor phosphorylation was unaffected. The insulin resistance of the of the PTP-1B(+/+) adipocytes could also be rescued by treatment with rapamycin, suggesting that in adipose the loss of PTP-1B results in basal activation of mTOR (mammalian target of rapamycin) complex 1 leading to a tissue-specific insulin resistance.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Metab Disorders, Rahway, NJ 07065 USA; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	Merck & Company; Merck & Company; University of Ottawa	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, 16711 Trans Canada Hwy, Kirkland, PQ H9H 3L1, Canada.	brian_Kennedy@merck.com		Forsell, Pontus/0000-0002-8384-1547; Yuan, Xiling/0000-0002-2735-877X				Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fisher TL, 2004, CURR BIOL, V14, pR1005, DOI 10.1016/j.cub.2004.11.024; FROST SC, 1985, J BIOL CHEM, V260, P2646; Haj FG, 2005, J BIOL CHEM, V280, P15038, DOI 10.1074/jbc.M413240200; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hertzel AV, 2000, J LIPID RES, V41, P1082; Hinault C, 2006, J NUTR BIOCHEM, V17, P374, DOI 10.1016/j.jnutbio.2006.02.008; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JE, 2004, DIABETES, V53, P2748, DOI 10.2337/diabetes.53.11.2748; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Large V, 2004, DIABETES METAB, V30, P294, DOI 10.1016/S1262-3636(07)70121-0; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sheehan Michael T, 2003, Clin Med Res, V1, P189; Shirakami A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740309; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; ZICK Y, 2005, SCI STKE, pE4	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30423	30433		10.1074/jbc.M700697200	http://dx.doi.org/10.1074/jbc.M700697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17664276	hybrid			2022-12-27	WOS:000250136300010
J	Kim, JS; Ryoo, ZY; Chun, JS				Kim, Jae-Sung; Ryoo, Zae Young; Chun, Jang-Soo			Cytokine-like 1 (CYTL1) regulates the chondrogenesis of mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CHONDROCYTES; GENE; P38; DIFFERENTIATION; IDENTIFICATION; MECHANISMS; APOPTOSIS; SOX9	To identify novel molecules regulating chondrogenesis and cartilage development, we screened a cartilage-specific expressed sequence tag data base. Cytokine-like 1 (Cytl1), a possible cytokine candidate with unknown function that was originally identified in bone marrow-derived CD34-positive cells, was selected for functional characterization. In view of the initial observation that Cytl1 is predominantly expressed in chondrocytes and cartilage, we investigated its possible role in chondrogenesis and hypertrophic maturation of chondrocytes. Cytl1 expression was very low in mesenchymal cells, dramatically increased during chondrogenesis, and decreased during hypertrophic maturation, both in vivo and in vitro. The role of Cytl1 in chondrogenesis and hypertrophic maturation was examined by treating chondrifying mesenchymal cells with exogenous Cytl1 or ectopic expression of Cytl1. Notably, exogenous Cytl1 caused chondrogenic differentiation of mouse limb bud mesenchymal cells during micromass culture. Lentivirus-mediated overexpression of Cytl1 additionally induced chondrogenic differentiation of mesenchymal cells. However, Cytl1 did not affect the hypertrophic maturation of chondrocytes. Cytl1 exerted its chondrogenic effect via stimulation of Sox9 transcriptional activity. In addition, Cytl1 caused expression of insulin-like growth factor 1, which has a capacity to induce chondrogenesis. Thus, our results collectively suggest that chondrocyte-specific Cytl1 regulates chondrogenesis as a novel autocrine factor, but not hypertrophic maturation of chondrocytes during cartilage development.	Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea; Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Kim, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea.	jschun@gist.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ficker M, 2004, DEV BIOL, V268, P7, DOI 10.1016/j.ydbio.2003.11.023; Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Hearn MTW, 2000, J MOL RECOGNIT, V13, P223, DOI 10.1002/1099-1352(200009/10)13:5<223::AID-JMR501>3.3.CO;2-C; Hermansson M, 2004, J BIOL CHEM, V279, P43514, DOI 10.1074/jbc.M407041200; Hong S, 2005, J BIOL CHEM, V280, P7685, DOI 10.1074/jbc.M412444200; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102; Kim JS, 2005, CELL DEATH DIFFER, V12, P201, DOI 10.1038/sj.cdd.4401511; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kumar S, 2001, OSTEOARTHR CARTILAGE, V9, P641, DOI 10.1053/joca.2001.0421; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Liu X, 2000, GENOMICS, V65, P283, DOI 10.1006/geno.2000.6170; Mariani FV, 2003, NATURE, V423, P319, DOI 10.1038/nature01655; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Oh J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-314; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [10.1005667/978-3-642-86659-3.567, 10.1007/978-3-642-86659-3, DOI 10.1007/978-3-642-86659-3, 10. 1007/978-3-642-86659-3]; Peale FV, 2001, J PATHOL, V195, P7, DOI 10.1002/path.888; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Ryu JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601804200; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Tickle C, 2002, AM J MED GENET, V112, P250, DOI 10.1002/ajmg.10774; Zhang XP, 2004, BONE, V34, P809, DOI 10.1016/j.bone.2003.12.026; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	32	59	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29359	29367		10.1074/jbc.M700965200	http://dx.doi.org/10.1074/jbc.M700965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17644814	hybrid			2022-12-27	WOS:000249788000032
J	Rogers, K; Gao, GH; Simpson, L				Rogers, Kestrel; Gao, Guanghan; Simpson, Larry			Uridylate-specific 3 '-5 '-exoribonucleases involved in uridylate-deletion RNA editing in trypanosomatid mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; MESSENGER-RNA; DNA-REPAIR; LEISHMANIA-TARENTOLAE; U-DELETION; IN-VITRO; BRUCEI; COMPLEX; IDENTIFICATION; EXONUCLEASE	In kinetoplastid protists, maturation of mitochondrial pre-mRNAs involves the insertion and deletion of uridylates (Us) within coding regions, as specified by mitochondrial DNA-encoded guide RNAs. U-deletion editing involves endonucleolytic cleavage of the pre-mRNA at the editing site followed by U-specific 3'-5'-exonucleolytic removal of nonbase-paired Us prior to ligation of the two mRNA cleavage fragments. We showed previously that an exonuclease/endonuclease/phosphatase (EEP) motif protein from Leishmania major, designated RNA editing exonuclease 1 (REX1) (Kang, X., Rogers, K., Gao, G., Falick, A. M., Zhou, S.-L., and Simpson, L. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 1017-1022), exhibits 3'-5'-exonuclease activity. Two EEP motif proteins have also been identified in the Trypanosoma brucei editing complex. TbREX1 is a homologue of LmREX1, and TbREX2 shows homology to another editing protein in L. major, which lacks the EEP motif (LmREX2*). Here we have expressed the T. brucei EEP motif proteins in insect cells and purified them to homogeneity. We showed that these are U-specific 3'-5'-exonucleases that are inhibited by base pairing of 3' Us. The recombinant EEP motif alone also showed 3'-5'-U-specific exonuclease activity, and mutations of the REX EEP motifs greatly reduced exonuclease activity. The absence of enzymatic activity in LmREX2* was confirmed with a purified recombinant protein. We showed that pre-cleaved U-deletion editing could be reconstituted with either TbREX1 or TbREX2 in combination with either RNA ligase, LmREL1, or LmREL2. Down-regulation of TbREX2 expression by conditional RNA interference had little effect on parasite viability or sedimentation of the L-complex, suggesting either that TbREX2 is inactive in vivo or that TbREX1 can compensate for the loss of TbREX2 function in down-regulated cells.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Simpson, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu		Rogers, Kestrel/0000-0002-0233-3613	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aphasizhev R, 2003, P NATL ACAD SCI USA, V100, P10617, DOI 10.1073/pnas.1833120100; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Carnes J, 2005, P NATL ACAD SCI USA, V102, P16614, DOI 10.1073/pnas.0506133102; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; Gao GH, 2005, P NATL ACAD SCI USA, V102, P4712, DOI 10.1073/pnas.0500553102; Hutchings NR, 2002, J CELL BIOL, V156, P867, DOI 10.1083/jcb.200201036; Igo RP, 2002, EUKARYOT CELL, V1, P112, DOI 10.1128/EC.1.1.112-118.2002; Kang XD, 2005, P NATL ACAD SCI USA, V102, P1017, DOI 10.1073/pnas.0409275102; Kang XD, 2006, P NATL ACAD SCI USA, V103, P13944, DOI 10.1073/pnas.0604476103; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Mian IS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-305; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2006, RNA, V12, P1038, DOI 10.1261/rna.45506; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schimanski B, 2005, EUKARYOT CELL, V4, P1942, DOI 10.1128/EC.4.11.1942-1950.2005; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Stuart K, 2002, PHILOS T ROY SOC B, V357, P71, DOI 10.1098/rstb.2001.0994; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Stuart Kenneth, 2004, Methods Mol Biol, V265, P273; Trotter JR, 2005, MOL CELL, V20, P403, DOI 10.1016/j.molcel.2005.09.016; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P6392, DOI 10.1093/nar/gkg870; Zhelonkina AG, 2006, RNA, V12, P476, DOI 10.1261/rna.2243206	42	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29073	29080		10.1074/jbc.M704551200	http://dx.doi.org/10.1074/jbc.M704551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699520	hybrid			2022-12-27	WOS:000249788000002
J	Zimmermann, AK; Loucks, FA; Schroeder, EK; Bouchard, RJ; Tyler, KL; Linseman, DA				Zimmermann, Angela K.; Loucks, F. Alexandra; Schroeder, Emily K.; Bouchard, Ron J.; Tyler, Kenneth L.; Linseman, Daniel A.			Glutathione binding to the Bcl-2 homology-3 domain groove - A molecular basis for Bcl-2 antioxidant function at mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOUSE MODEL; SUPEROXIDE DISMUTASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; MOTOR-NEURONS; APOPTOSIS; DEATH; MICE; CELLS	Bcl-2 protects cells against mitochondrial oxidative stress and subsequent apoptosis. However, the mechanism underlying the antioxidant function of Bcl-2 is currently unknown. Recently, Bax and several Bcl-2 homology-3 domain (BH3)-only proteins (Bid, Puma, and Noxa) have been shown to induce a pro-oxidant state at mitochondria (1-4). Given the opposing effects of Bcl-2 and Bax/BH3-only proteins on the redox state of mitochondria, we hypothesized that the antioxidant function of Bcl-2 is antagonized by its interaction with the BH3 domains of pro-apoptotic family members. Here, we show that BH3 mimetics that bind to a hydrophobic surface (the BH3 groove) of Bcl-2 induce GSH-sensitive mitochondrial dysfunction and apoptosis in cerebellar granule neurons. BH3 mimetics displace a discrete mitochondrial GSH pool in neurons and suppress GSH transport into isolated rat brain mitochondria. Moreover, BH3 mimetics and the BH3-only protein, Bim, inhibit a novel interaction between Bcl-2 and GSH in vitro. These results suggest that Bcl-2 regulates an essential pool of mitochondrial GSH and that this regulation may depend upon Bcl-2 directly interacting with GSH via the BH3 groove. We conclude that this novel GSH binding property of Bcl-2 likely plays a central role in its antioxidant function at mitochondria.	Univ Denver, Eleanor Roosevelt Inst, Denver, CO 80208 USA; Univ Denver, Dept Biol Sci, Denver, CO 80208 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol & Immunol, Denver, CO 80262 USA	University of Denver; University of Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Linseman, DA (corresponding author), Univ Denver, Eleanor Roosevelt Inst, FW Olin Hall,Rm 102,2190 E Iliff Ave, Denver, CO 80208 USA.	daniel.linseman@du.edu	Linseman, Daniel/L-3846-2019; Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050138, R01NS051403] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS051403, R01 NS051403-03, 1R01 NS051403, R01 NS050138, R01 NS050138-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; Hochman A, 1998, J NEUROCHEM, V71, P741; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Kong JM, 1998, J NEUROSCI, V18, P3241; Lash LH, 2006, CHEM-BIOL INTERACT, V163, P54, DOI 10.1016/j.cbi.2006.03.001; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; Merad-Saidoune M, 1999, EXP NEUROL, V158, P428, DOI 10.1006/exnr.1999.7108; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Petri S, 2006, J NEUROCHEM, V98, P1141, DOI 10.1111/j.1471-4159.2006.04018.x; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Sasaki E, 2003, HISTOCHEM CELL BIOL, V120, P327, DOI 10.1007/s00418-003-0572-x; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Yang LC, 1998, J NEUROSCI, V18, P8145; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53	35	113	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29296	29304		10.1074/jbc.M702853200	http://dx.doi.org/10.1074/jbc.M702853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690097	Green Accepted, hybrid			2022-12-27	WOS:000249788000026
J	Carnes, CA; Janssen, PML; Ruehr, ML; Nakayama, H; Nakayama, T; Haase, H; Bauer, JA; Chung, MK; Fearon, IM; Gillinov, AM; Hamlin, RL; Van Wagoner, DR				Carnes, Cynthia A.; Janssen, Paul M. L.; Ruehr, Mary L.; Nakayama, Hitomi; Nakayama, Tomohiro; Haase, Hannelore; Bauer, John Anthony; Chung, Mina K.; Fearon, Ian M.; Gillinov, A. Marc; Hamlin, Robert L.; Van Wagoner, David R.			Atrial glutathione content, calcium current, and contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ALPHA(1C) SUBUNITS; NITRIC-OXIDE; OXIDATIVE STRESS; CA2+ CHANNEL; RYANODINE RECEPTORS; MOLECULAR-MECHANISMS; VENTRICULAR MYOCYTES; REDOX MODULATION; S-NITROSYLATION; DOWN-REGULATION	Atrial fibrillation (AF) is characterized by decreased L-type calcium current (I-Ca,I-L) in atrial myocytes and decreased atrial contractility. Oxidant stress and redox modulation of calcium channels are implicated in these pathologic changes. We evaluated the relationship between glutathione content (the primary cellular reducing moiety) and I-Ca,I-L in atrial specimens from AF patients undergoing cardiac surgery. Left atrial glutathione content was significantly lower in patients with either paroxysmal or persistent AF relative to control patients with no history of AF. Incubation of atrial myocytes from AF patients (but not controls) with the glutathione precursor N-acetylcysteine caused a marked increase in I-Ca,I-L. To test the hypothesis that glutathione levels were mechanistically linked with the reduction in I-Ca,I-L, dogs were treated for 48 h with buthionine sulfoximine, an inhibitor of glutathione synthesis. Buthiontine sulfoximine treatment resulted in a 24% reduction in canine atrial glutathione content, a reduction in atrial contractility, and an attenuation Of I-Ca,I-L in the canine atrial myocytes. Incubation of these myocytes with exogenous glutathione also restored I-Ca,I-L to normal or greater than normal levels. To probe the mechanism linking decreased glutathione levels to down-regulation Of I-Ca, the biotin switch technique was used to evaluate S-nitrosylation of calcium channels. S-Nitrosylation was apparent in left atrial tissues from AF patients; the extent of S-nitrosylation was inversely related to tissue glutathione content. S-Nitrosylation was also detectable in HEK cells expressing recombinant human cardiac calcium channel subunits following exposure to nitrosoglutathione. S-Nitrosylation may contribute to the glutathione-sensitive attenuation of I-Ca,I-L observed in AF.	Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA; Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Max Delbruck Ctr Mol Med, Berlin, Germany; Ctr Cardiovasc Med, Res Inst, Columbus, OH 43205 USA; Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England	Cleveland Clinic Foundation; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of Manchester	Van Wagoner, DR (corresponding author), Cleveland Clin, Dept Mol Cardiol, M-S NE-61,9500 Euclid Ave, Cleveland, OH 44195 USA.	vanwagd@ccf.org	Janssen, Paul ML/E-3307-2011; Carnes, Cynthia A/C-9540-2012; Nakayama, Tomohiro/GYU-0303-2022; Van Wagoner, David R/C-6783-2008	Carnes, Cynthia A/0000-0003-0420-6973; Van Wagoner, David R/0000-0001-8250-9828; Janssen, Paul/0000-0002-9682-3014	NHLBI NIH HHS [R01 HL-78316, R01 HL-65412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abete P, 1999, J MOL CELL CARDIOL, V31, P227, DOI 10.1006/jmcc.1998.0862; Adamy C, 2005, ARCH MAL COEUR VAISS, V98, P906; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Bosch RF, 1999, CARDIOVASC RES, V44, P121, DOI 10.1016/S0008-6363(99)00178-9; Bosch RF, 2003, J AM COLL CARDIOL, V41, P858, DOI 10.1016/S0735-1097(02)02922-4; Brundel BJJM, 2002, CARDIOVASC RES, V54, P380, DOI 10.1016/S0008-6363(02)00289-4; Burkard N, 2007, CIRC RES, V100, pE32, DOI 10.1161/01.RES.0000259042.04576.6a; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Cargnoni A, 2002, J MOL CELL CARDIOL, V34, P997, DOI 10.1006/jmcc.2002.2046; Carnes CA, 2001, CIRC RES, V89, pE32, DOI 10.1161/hh1801.097644; Cheong E, 2005, CELL CALCIUM, V38, P481, DOI 10.1016/j.ceca.2005.07.001; Christ T, 2004, CIRCULATION, V110, P2651, DOI 10.1161/01.CIR.0000145659.80212.6A; Chung MK, 2004, NAT CLIN PRACT CARD, V1, P56, DOI 10.1038/ncpcardio0027; CIA H, 2002, CIRCULATION, V106, P2854; De Vecchi E, 1998, HEART, V79, P242, DOI 10.1136/hrt.79.3.242; Dudley SC, 2005, CIRCULATION, V112, P1266, DOI 10.1161/CIRCULATIONAHA.105.538108; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Fearon IM, 2006, CARDIOVASC RES, V69, P855, DOI 10.1016/j.cardiores.2005.11.019; Fearon IM, 1999, J PHYSIOL-LONDON, V514, P629, DOI 10.1111/j.1469-7793.1999.629ad.x; Fukuda K, 2005, CIRC RES, V97, P1262, DOI 10.1161/01.RES.0000195844.31466.e9; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Han D, 2006, AM J PHYSIOL-GASTR L, V291, pG1, DOI 10.1152/ajpgi.00001.2006; Hidalgo C, 2005, IUBMB LIFE, V57, P315, DOI 10.1080/15216540500092328; Hool LC, 2002, CIRC RES, V91, P601, DOI 10.1161/01.RES.0000035528.00678.D5; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Hudasek K, 2004, BIOCHEM BIOPH RES CO, V318, P135, DOI 10.1016/j.bbrc.2004.04.011; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE 2001, P61; Janssen PML, 1999, J MOL CELL CARDIOL, V31, P1419, DOI 10.1006/jmcc.1999.0978; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Leung JM, 2004, EUR HEART J, V25, P1836, DOI 10.1016/j.ehj.2004.07.014; Levy S, 1997, PACE, V20, P2670, DOI 10.1111/j.1540-8159.1997.tb06115.x; Li SM, 2003, J MOL CELL CARDIOL, V35, P1145, DOI 10.1016/S0022-2828(03)00230-X; Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Martin-Gallan P, 2003, FREE RADICAL BIO MED, V34, P1563, DOI 10.1016/S0891-5849(03)00185-0; Mihm MJ, 2001, CIRCULATION, V104, P174, DOI 10.1161/01.CIR.104.2.174; Mueller CFH, 2005, CIRC RES, V97, P637, DOI 10.1161/01.RES.0000183734.21112.b7; Pacher P, 2006, CURR OPIN PHARMACOL, V6, P136, DOI 10.1016/j.coph.2006.01.001; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; Schotten U, 2003, J MOL CELL CARDIOL, V35, P437, DOI 10.1016/S0022-2828(03)00012-9; Schotten U, 2003, CIRCULATION, V107, P1433, DOI 10.1161/01.CIR.0000055314.10801.4F; Schotten U, 2001, CIRCULATION, V103, P691; Skasa M, 2001, BASIC RES CARDIOL, V96, P151, DOI 10.1007/s003950170065; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STIO M, 1994, BIOCHEM CELL BIOL, V72, P58, DOI 10.1139/o94-010; Sun JH, 2006, CIRC RES, V98, P403, DOI 10.1161/01.RES.0000202707.79018.0a; Takimoto E, 2005, J CLIN INVEST, V115, P1221, DOI 10.1172/JCI200521968; Van Wagoner DR, 1999, CIRC RES, V85, P428, DOI 10.1161/01.RES.85.5.428; Van Wagoner DR, 2001, J CARDIOVASC ELECTR, V12, P183; Whiteman M, 2006, BIOCHEM BIOPH RES CO, V339, P255, DOI 10.1016/j.bbrc.2005.10.200; Xu Z, 2002, CARDIOVASC RES, V53, P80, DOI 10.1016/S0008-6363(01)00446-1; Yagi T, 2002, CARDIOVASC RES, V54, P405, DOI 10.1016/S0008-6363(02)00279-1; Yue LX, 1999, CIRC RES, V84, P776; Yue LX, 1997, CIRC RES, V81, P512, DOI 10.1161/01.RES.81.4.512	56	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28063	28073		10.1074/jbc.M704893200	http://dx.doi.org/10.1074/jbc.M704893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656369	hybrid			2022-12-27	WOS:000249455600056
J	de Almeida, SF; Picarote, G; Fleming, JV; Carmo-Fonseca, M; Azevedo, JE; de Sousa, M				de Almeida, Srgio F.; Picarote, Goncalo; Fleming, John V.; Carmo-Fonseca, Maria; Azevedo, Jorge E.; de Sousa, Maria			Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CELL-SURFACE EXPRESSION; ER STRESS; HEREDITARY HEMOCHROMATOSIS; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; ATF6; BETA(2)-MICROGLOBULIN; 4-PHENYLBUTYRATE; BINDING	HFE C282Y, the mutant protein associated with hereditary hemochromatosis (HH), fails to acquire the correct conformation in the endoplasmic reticulum (ER) and is targeted for degradation. We have recently shown that an active unfolded protein response (UPR) is present in the cells of patients with HH. Now, by using HE K 293T cells, we demonstrate that the stability of HFE C282Y is influenced by the UPR signaling pathway that promotes its degradation. Treatment of HFE C282Y-expressing cells with tauroursodeoxycholic acid (TUDCA), a bile acid derivative with chaperone properties, or with the chemical chaperone sodium 4-phenylbutyrate (4PBA) impeded the UPR activation. However, although TUDCA led to an increased stability of the mutant protein, 4PBA contributed to a more efficient disposal of HFE C282Y to the degradation route. Fluorescence microscopy and biochemical analysis of the subcellular localization of HFE revealed that a major portion of the C282Y mutant protein forms intracellular aggregates. Although neither TUDCA nor 4PBA restored the correct folding and intracellular trafficking of HFE C282Y, 4PBA prevented its aggregation. These data suggest that TUDCA hampers the UPR activation by acting directly on its signal transduction pathway, whereas 4PBA suppresses ER stress by chemically enhancing the ER capacity to cope with the expression of misfolded HFE, facilitating its degradation. Together, these data shed light on the molecular mechanisms involved in HFE C282Y-related HH and open new perspectives on the use of orally active chemical chaperones as a therapeutic approach for HH.	Univ Porto, Inst Ciencias Biomed Abel Salazar, Inst Biol Mol & Celular, Iron Genes & Imune Syst Lab, P-4150 Oporto, Portugal; Univ Lisbon, Fac Med, Inst Mol Med, P-1649 Lisbon, Portugal; Inst Ciencias Biomed Abel Salazar, Inst Biol Mol & Celular, P-4150 Oporto, Portugal	Universidade do Porto; Universidade de Lisboa; Universidade do Porto	de Sousa, M (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, Oporto, Portugal.	mdesousa@ibmc.up.pt	de Almeida, Sergio/H-3002-2019; de Almeida, Sergio F/F-9197-2010; Azevedo, Jorge E/A-4113-2008	de Almeida, Sergio/0000-0002-7774-1355; de Almeida, Sergio F/0000-0002-7774-1355; Azevedo, Jorge E/0000-0001-7714-5302; Carmo-Fonseca, Maria/0000-0002-3402-7143; de sousa, maria/0000-0002-4552-185X				Ben-Arieh SV, 2001, J VIROL, V75, P10557, DOI 10.1128/JVI.75.21.10557-10562.2001; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; de Almeida SF, 2007, J IMMUNOL, V178, P3612, DOI 10.4049/jimmunol.178.6.3612; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fleming JV, 2004, BIOCHEM J, V379, P253, DOI 10.1042/BJ20031525; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kubota K, 2006, J NEUROCHEM, V97, P1259, DOI 10.1111/j.1471-4159.2006.03782.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	30	136	140	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27905	27912		10.1074/jbc.M702672200	http://dx.doi.org/10.1074/jbc.M702672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17626021	hybrid			2022-12-27	WOS:000249455600039
J	Ott, M; Norberg, E; Walter, KM; Schreiner, P; Kemper, C; Rapaport, D; Zhivotovsky, B; Orrenius, S				Ott, Martin; Norberg, Erik; Walter, Katharina M.; Schreiner, Patrick; Kemper, Christian; Rapaport, Doron; Zhivotovsky, Boris; Orrenius, Sten			The mitochondrial TOM complex is required for tBid/Bax-induced cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CONFORMATIONAL-CHANGE; INTERMEMBRANE SPACE; IMPORT PORE; BAX; PROTEINS; INSERTION; CARDIOLIPIN; ACTIVATION; PATHWAY	Cytochrome c release from mitochondria is a key event in apoptosis signaling that is regulated by Bcl-2 family proteins. Cleavage of the BH3-only protein Bid by multiple proteases leads to the formation of truncated Bid (tBid), which, in turn, promotes the oligomerization/insertion of Bax into the mitochondrial outer membrane and the resultant release of proteins residing in the intermembrane space. Bax, a monomeric protein in the cytosol, is targeted by a yet unknown mechanism to the mitochondria. Several hypotheses have been put forward to explain this targeting specificity. Using mitochondria isolated from different mutants of the yeast Saccharomyces cerevisiae and recombinant proteins, we have now investigated components of the mitochondrial outer membrane that might be required for tBid/Bax-induced cytochrome c release. Here, we show that the protein translocase of the outer mitochondrial membrane is required for Bax insertion and cytochrome c release.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm, Div Toxicol, S-17177 Stockholm, Sweden; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Univ Tubingen, Interfacultry Inst Biochem, D-72076 Tubingen, Germany	Karolinska Institutet; Karolinska Institutet; University of Munich; Eberhard Karls University of Tubingen	Orrenius, S (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	Sten.Orrenius@ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Schreiner, Patrick/0000-0002-3141-9133; Ott, Martin/0000-0001-6367-3091				Ahting U, 2005, J BIOL CHEM, V280, P48, DOI 10.1074/jbc.M410905200; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Choi SY, 2007, CELL DEATH DIFFER, V14, P597, DOI 10.1038/sj.cdd.4402020; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DAUM G, 1982, J BIOL CHEM, V257, P3028; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Nakamura Y, 2004, J BIOL CHEM, V279, P21223, DOI 10.1074/jbc.M314156200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Rapaport D, 2005, J CELL BIOL, V171, P419, DOI 10.1083/jcb.200507147; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Szklarz LKS, 2007, J MOL BIOL, V368, P44, DOI 10.1016/j.jmb.2007.01.016; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200	28	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27633	27639		10.1074/jbc.M703155200	http://dx.doi.org/10.1074/jbc.M703155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635912	hybrid			2022-12-27	WOS:000249455600010
J	Valmsen, K; Boeglin, WE; Jarving, R; Jarving, I; Varvas, K; Brash, AR; Samel, N				Valmsen, Karin; Boeglin, William E.; Jarving, Reet; Jarving, Ivar; Varvas, Kuelliki; Brash, Alan R.; Samel, Nigulas			A critical role of non-active site residues on cyclooxygenase helices 5 and 6 in the control of prostaglandin stereochemistry at carbon 15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; CORAL PLEXAURA-HOMOMALLA; MOLECULAR-CLONING; ARACHIDONIC-ACID; MECHANISM; BINDING; BIOSYNTHESIS; OXYGENATION; EXPRESSION	The correct stereochemistry of prostaglandins is a prerequisite of their biological activity and thus is under a strict enzymatic control. Recently, we cloned and characterized two cyclooxygenase (COX) isoforms in the coral Plexaura homomalla that share 97% amino acid sequence identity, yet form prostaglandins with opposite stereochemistry at carbon 15. The difference in oxygenation specificity is only partially accounted for by the single amino acid substitution in the active site (Ile or Val at position 349). For further elucidation of residues involved in the C-15 stereocontrol, a series of sequence swapping and site-directed mutagenesis experiments between 15R- and 15S-COX were performed. Our results show that the change in stereochemistry at carbon 15 of prostaglandins relates mainly to five amino acid substitutions on helices 5 and 6 of the coral COX. In COX proteins, these helices form a helix-turn-helix motif that traverses through the entire protein, contributing to the second shell of residues around the oxygenase active site; it constitutes the, most highly conserved region where even slight changes result in loss of catalytic activity. The finding that this region is among the least conserved between the P. homomalla 15S- and 15R-specific COX further supports its significance in maintaining. the desired prostaglandin stereochernistry at C-15. The results are particularly remarkable because, based on its strong conservation, the conserved middle of helix 5 is considered as central to the core structure of peroxidases, of which COX proteiris are derivatives. Now we show that the same parts of the protein are involved in the control of oxygenation with 15R or 15S stereospecificity in the dioxygenase active site.	Tallinn Univ Technol, EE-12618 Tallinn, Estonia; Tallinn Univ Technol, Dept Chem, EE-12618 Tallinn, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA	Tallinn University of Technology; Tallinn University of Technology; Vanderbilt University	Samel, N (corresponding author), Tallinn Univ Technol, Akadeemia tee 15, EE-12618 Tallinn, Estonia.	samel@chemnet.ee	Samel, Nigulas/A-1420-2019	Valmsen, Karin/0000-0001-5303-6654	NIGMS NIH HHS [GM-53638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Daiyasu H, 2000, J MOL EVOL, V51, P433, DOI 10.1007/s002390010106; Garavito RM, 2003, ANNU REV BIOPH BIOM, V32, P183, DOI 10.1146/annurev.biophys.32.110601.141906; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KENNEDY TA, 1994, J BIOL CHEM, V269, P27357; Koljak R, 2001, J BIOL CHEM, V276, P7033, DOI 10.1074/jbc.M009803200; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LIGHT RJ, 1972, EUR J BIOCHEM, V28, P232, DOI 10.1111/j.1432-1033.1972.tb01906.x; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NAKANO J, 1972, BRIT J PHARMACOL, V44, P63, DOI 10.1111/j.1476-5381.1972.tb07238.x; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SCHNEIDER WP, 1972, J AM CHEM SOC, V94, P2122, DOI 10.1021/ja00761a060; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Valmsen K, 2004, EUR J BIOCHEM, V271, P3533, DOI 10.1111/j.0014-2956.2004.04289.x; Valmsen K, 2001, P NATL ACAD SCI USA, V98, P7700, DOI 10.1073/pnas.131022398; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185	28	3	3	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28157	28163		10.1074/jbc.M704950200	http://dx.doi.org/10.1074/jbc.M704950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652088	hybrid			2022-12-27	WOS:000249455600065
J	Wise, EL; Duchesnes, C; da Fonseca, PCA; Allen, RA; Williams, TJ; Pease, JE				Wise, Emma L.; Duchesnes, Cecile; da Fonseca, Paula C. A.; Allen, Rodger A.; Williams, Timothy J.; Pease, James E.			Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL EOTAXIN RECEPTOR; BACKBONE DYNAMICS; IDENTIFICATION; EXPRESSION; BINDING; DETERMINANTS; INFLAMMATION; DOMAINS; CLONING; POTENT	Chemokine receptor CCR3 is highly expressed by eosinophils and signals in response to binding of the eotaxin family of chemokines, which are up-regulated in allergic disorders. Consequently, CCR3 blockade is of interest as a possible therapeutic approach for the treatment of allergic disease. We have described previously a bispecific antagonist of CCR1 and CCR3 named UCB35625 that was proposed to interact with the transmembrane residues Tyr-41, Tyr-113, and Glu-287 of CCR1, all of which are conserved in CCR3. Here, we show that cells expressing the CCR3 constructs Y113A and E287Q are insensitive to antagonism by UCB35625 and also exhibit impaired chemotaxis in response to CCL11/eotaxin, suggesting that these residues are important for antagonist binding and also receptor activation. Furthermore, mutation of the residue Tyr-113 to alanine was found to turn the antagonist UCB35625 into a CCR3 agonist. Screens of small molecule libraries identified a novel specific agonist of CCR3 named CH0076989. This was able to activate eosinophils and transfectants expressing both wild-type CCR3 and a CCR1-CCR3 chimeric receptor lacking the CCR3 amino terminus, indicating that this region of CCR3 is not required for CH0076989 binding. A direct interaction with the transmembrane helices of CCR3 was supported by mutation of the residues Tyr-41, Tyr-113, and Glu-287 that resulted in complete loss of CH0076989 activity, suggesting that the compound mimics activation by CCL11. We conclude that both agonists and antagonists of CCR3 appear to occupy overlapping sites within the transmembrane helical bundle, suggesting a fine line between agonism and antagonism of chemokine receptors.	Imperial Coll London, Fac Med, Natl Heart & Lung Inst Div, Leukocyte Biol Sect, London SW7 2AZ, England; Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, Struct Elect Microscopy Team, London SW3 6JB, England; UCB Celltech, Slough SL1 3WE, Berks, England	Imperial College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Celltech Group Ltd	Pease, JE (corresponding author), Imperial Coll London, Fac Med, Natl Heart & Lung Inst Div, Leukocyte Biol Sect, S Kensington Campus, London SW7 2AZ, England.	j.pease@imperial.ac.uk	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341; da Fonseca, Paula/0000-0001-8656-5747	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust [076036/Z/04/Z, 076036] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Anderskewitz R, 2005, BIOORG MED CHEM LETT, V15, P669, DOI 10.1016/j.bmcl.2004.11.039; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Crump MP, 1999, PROTEIN SCI, V8, P2041, DOI 10.1110/ps.8.10.2041; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Duchesnes UE, 2006, MOL IMMUNOL, V43, P1221, DOI 10.1016/j.molimm.2005.07.015; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Haskell CA, 2006, MOL PHARMACOL, V69, P309, DOI 10.1124/mol.105.014779; HASLETT C, 1985, AM J PATHOL, V119, P101; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Phillips RM, 2003, J IMMUNOL, V170, P6190, DOI 10.4049/jimmunol.170.12.6190; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 2005, EUR J IMMUNOL, V35, P1301, DOI 10.1002/eji.200425171; Sabroe I, 1999, J IMMUNOL, V162, P2946; Saita Y, 2006, J IMMUNOL, V177, P3116, DOI 10.4049/jimmunol.177.5.3116; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Stroke IL, 2006, BIOCHEM BIOPH RES CO, V349, P221, DOI 10.1016/j.bbrc.2006.08.019; Struyf S, 1999, J IMMUNOL, V162, P4903; Tang CM, 2005, EXPERT OPIN THER TAR, V9, P1247, DOI 10.1517/14728222.9.6.1247; Ting PC, 2005, BIOORG MED CHEM LETT, V15, P1375, DOI 10.1016/j.bmcl.2005.01.016; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Vaidehi N, 2006, J BIOL CHEM, V281, P27613, DOI 10.1074/jbc.M601389200; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Ye JP, 2000, J BIOL CHEM, V275, P27250; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Ye JQ, 2001, BIOCHEMISTRY-US, V40, P7820, DOI 10.1021/bi010252s	44	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27935	27943		10.1074/jbc.M703255200	http://dx.doi.org/10.1074/jbc.M703255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635911	Green Accepted, hybrid			2022-12-27	WOS:000249455600042
J	Berkhout, B; Jeang, KT				Berkhout, Ben; Jeang, Kuan-Teh			RISCy business: MicroRNAs, pathogenesis, and viruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							X MENTAL-RETARDATION; RNA-BINDING PROTEIN; B-CELL LYMPHOMAS; EXPRESSION PROFILES; ONCOGENIC MICRORNA; SILENCING PATHWAY; MOUSE DEVELOPMENT; BURKITT-LYMPHOMA; MAMMALIAN-CELLS; GENE-EXPRESSION		Acad Med Centrum, NL-1105 AZ Amsterdam, Netherlands; NIAID, Mol Microbiol Lab, Natl Inst Hlth, Bethesda, MD 20892 USA	University of Amsterdam; Academic Medical Center Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Acad Med Centrum, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Babak T, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-33; Backofen R, 2007, J EXP ZOOL PART B, V308B, P1, DOI 10.1002/jezb.21130; Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Bennasser Y, 2006, J BIOL CHEM, V281, P27674, DOI 10.1074/jbc.C600072200; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906; Berkhout B, 2006, FEBS LETT, V580, P2896, DOI 10.1016/j.febslet.2006.02.070; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Carmell MA, 2007, DEV CELL, V12, P503, DOI 10.1016/j.devcel.2007.03.001; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Cobb BS, 2005, J EXP MED, V201, P1367, DOI 10.1084/jem.20050572; Cui C, 2006, J VIROL, V80, P5499, DOI 10.1128/JVI.00200-06; Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Haasnoot J, 2003, J BIOMED SCI, V10, P607, DOI 10.1007/BF02256311; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Hariharan M, 2005, BIOCHEM BIOPH RES CO, V337, P1214, DOI 10.1016/j.bbrc.2005.09.183; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048; Jin P, 2004, NAT NEUROSCI, V7, P113, DOI 10.1038/nn1174; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kluiver J, 2007, ONCOGENE, V26, P3769, DOI 10.1038/sj.onc.1210147; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lum AM, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-5; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Maroney PA, 2006, NAT STRUCT MOL BIOL, V13, P1102, DOI 10.1038/nsmb1174; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Meng FY, 2007, J BIOL CHEM, V282, P8256, DOI 10.1074/jbc.M607712200; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Omoto Shinya, 2004, Retrovirology, V1, P44, DOI 10.1186/1742-4690-1-44; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pfeffer S, 2006, ONCOGENE, V25, P6211, DOI 10.1038/sj.onc.1209915; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Rossi JJ, 2007, NAT CHEM BIOL, V3, P136, DOI 10.1038/nchembio0307-136; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68; Schiff ER, 2007, NAT CLIN PRACT GASTR, V4, pS17, DOI 10.1038/ncpgasthep0691; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tam W, 2006, GENE CHROMOSOME CANC, V45, P211, DOI 10.1002/gcc.20282; Tenllado F, 2004, VIRUS RES, V102, P85, DOI 10.1016/j.virusres.2004.01.019; Tillmann HL, 2007, WORLD J GASTROENTERO, V13, P125, DOI 10.3748/wjg.v13.i1.125; Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang CL, 2006, P NATL ACAD SCI USA, V103, P18680, DOI 10.1073/pnas.0609030103; Washietl S, 2005, NAT BIOTECHNOL, V23, P1383, DOI 10.1038/nbt1144; Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706; Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200; Yeung ML, 2007, CURR MED CHEM, V14, P191, DOI 10.2174/092986707779313417; Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	103	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26641	26645		10.1074/jbc.R700023200	http://dx.doi.org/10.1074/jbc.R700023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627941	hybrid			2022-12-27	WOS:000249304900002
J	Nikolaev, VO; Boettcher, C; Dees, C; Bunemann, M; Lohse, MJ; Zenk, MH				Nikolaev, Viacheslav O.; Boettcher, Chotima; Dees, Christian; Buenemann, Moritz; Lohse, Martin J.; Zenk, Meinhart H.			Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; BINDING; RETICULINE; DISSOCIATION; METABOLITES; MODULATION; AGONISTS; RATS; MICE	G-protein activation by receptors is generally measured using S-35-GTP gamma S binding assays in cell membranes and cannot be well assessed in intact cells. We have recently developed a fluorescence resonance energy transfer (FRET)-based approach to monitor G(i)-protein activation in living cells. Here we report that this technique can be used to determine structure-activity relationships of receptor agonists in intact cells. We have recently shown that morphine is biosynthesized de novo by mammals via a multistep pathway different from that in plants. However, the pharmacological properties of morphine precursors are poorly understood. Here, we directly monitored mu-opioid receptor (MOR)-mediated G(i)-protein activation in living cells by FRET and validated this method with classical GTP gamma S binding assays. Receptor binding studies and FRET measurements demonstrated that several (R)-configurated morphine precursors such as (R)-reticuline, salutaridine, salutaridinol, thebaine, and codeine were partial MOR agonists. Some closer precursors such as oripavine, codeinone, and morphinone activated G(i)-proteins as strongly as morphine, but with slightly lower potencies. The more distant the precursors were positioned in the pathway with respect to morphine, the less efficient and potent they were at MOR. Comparison of pharmacological properties of close morphine precursors and concentrations in which they occur in animal tissues suggests that they might activate MOR signaling under physiological conditions. Taken together, our data indicate that FRET-based assays of G-protein activation can serve to determine the abilities of compounds to activate G-protein signaling directly and in living cells.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Bio Imaging Ctr, D-97078 Wurzburg, Germany; Univ Halle Wittenberg, Bioctr, D-06120 Halle, Germany	University of Wurzburg; University of Wurzburg; Martin Luther University Halle Wittenberg	Nikolaev, VO (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacherstr 9, D-97078 Wurzburg, Germany.	nikolaev@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Nikolaev, Vyacheslav/AAT-7746-2020	Lohse, Martin J/0000-0002-0599-3510; Bottcher, Chotima/0000-0002-6226-586X				ACETO MD, 1990, NIDA RES MG, V95, P578; Aceto MD, 1999, EUR J PHARMACOL, V365, P143, DOI 10.1016/S0014-2999(98)00862-0; Allen RS, 2004, NAT BIOTECHNOL, V22, P1559, DOI 10.1038/nbt1033; Boettcher C, 2005, P NATL ACAD SCI USA, V102, P8495, DOI 10.1073/pnas.0503244102; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Chen JJ, 2000, PLANTA MED, V66, P251, DOI 10.1055/s-2000-8562; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; Cowan A, 2003, INT J CLIN PRACT, P3; Dias KLG, 2004, PLANTA MED, V70, P328, DOI 10.1055/s-2004-818944; FANG S, 1984, J MED CHEM, V27, P1361, DOI 10.1021/jm00376a026; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gibson SK, 2006, P NATL ACAD SCI USA, V103, P212, DOI 10.1073/pnas.0509763102; Jordan B, 1998, BRIT J ANAESTH, V81, P12, DOI 10.1093/bja/81.1.12; KARDOS J, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1758; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; KODAIRA H, 1989, P NATL ACAD SCI USA, V86, P716, DOI 10.1073/pnas.86.2.716; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P69; Morais LCSL, 1998, J ETHNOPHARMACOL, V62, P57, DOI 10.1016/S0378-8741(98)00044-0; Nikolaev VO, 2006, J BIOL CHEM, V281, P24506, DOI 10.1074/jbc.M603266200; Poeaknapo C, 2004, P NATL ACAD SCI USA, V101, P14091, DOI 10.1073/pnas.0405430101; Raehal KM, 2005, AAPS J, V7, pE587, DOI 10.1208/aapsj070360; Saidak Z, 2006, BRIT J PHARMACOL, V147, P671, DOI 10.1038/sj.bjp.0706661; Thompson CM, 2004, J PHARMACOL EXP THER, V308, P547, DOI 10.1124/jpet.103.058602; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; YEH SY, 1981, ARCH INT PHARMACOD T, V254, P223; Zhu W, 2003, MOL BRAIN RES, V117, P83, DOI 10.1016/S0169-328X(03)00323-1; Zhu W, 2005, J IMMUNOL, V175, P7357, DOI 10.4049/jimmunol.175.11.7357	32	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27126	27132		10.1074/jbc.M703272200	http://dx.doi.org/10.1074/jbc.M703272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17616524	hybrid			2022-12-27	WOS:000249304900053
J	Prante, C; Milting, H; Kassner, A; Farr, M; Ambrosius, M; Schon, S; Seidler, DG; El Banayosy, A; Korfer, R; Kuhn, J; Kleesiek, K; Gotting, C				Prante, Christian; Milting, Hendrik; Kassner, Astrid; Farr, Martin; Ambrosius, Michael; Schoen, Sylvia; Seidler, Daniela G.; El Banayosy, Aly; Koerfer, Reiner; Kuhn, Joachim; Kleesiek, Knut; Goetting, Christian			Transforming growth factor beta(1)-regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; CORE PROTEIN; GENE-EXPRESSION; XT-II; DILATED CARDIOMYOPATHY; SULFATE PROTEOGLYCANS; CHONDROITIN SULFATE; FIBRILLAR COLLAGEN; NONHUMAN PRIMATE	In cardiac fibrosis remodeling of the failing myocardium is associated with a complex reorganization of the extracellular matrix (ECM). Xylosyltransferase I and Xylosyltransferase II (XT- I and XT- II) are the key enzymes in proteoglycan biosynthesis, which are an important fraction of the ECM. XT- I was shown to be a measure for the proteoglycan biosynthesis rate and a biochemical fibrosis marker. Here, we investigated the XT- I and XT- II expression in cardiac fibroblasts and in patients with dilated cardiomyopathy and compared our findings with nonfailing donor hearts. We analyzed XT- I and XT- II expression and the glycosaminoglycan ( GAG) content in human cardiac fibroblasts incubated with transforming growth factor (TGF)- beta 1 or exposed to cyclic mechanical stretch. In vitro and in vivo no significant changes in the XT- II expression were detected. For XT- I we found an increased expression in parallel with an elevated chondroitin sulfate-GAG content after incubation with TGF-beta(1) and after mechanical stretch. XT- I expression and subsequently increased levels of GAGs could be reduced with neutralizing anti-TGF- beta 1 antibodies or by specific inhibition of the activin receptor-like kinase 5 or the p38 mitogen-activated protein kinase pathway. Usage of XT- I small interfering RNA could specifically block the increased XT- I expression under mechanical stress and resulted in a significantly reduced chondroitin sulfate-GAG content. In the left and right ventricular samples of dilated cardiomyopathy patients, our data show increased amounts of XT- I mRNA compared with nonfailing controls. Patients had raised levels of XT- I enzyme activity and an elevated proteoglycan content. Myocardial remodeling is characterized by increased XT- I expression and enhanced proteoglycan deposition. TGF-beta(1) and mechanical stress induce XT- I expression in cardiac fibroblasts and have impact for ECM remodeling in the dilated heart. Specific blocking of XT- I expression confirmed that XT- I catalyzes a rate-limiting step during fibrotic GAG biosynthesis.	Inst Lab & Transfus Med, Herz & Diabet Zentrum NRW, D-32545 Bad Oeynhausen, Germany; Ruhr Univ Bochum, Herz & Diabet Zentrum NRW, Erich & Hanna Klessmann, Inst Kardiovask Forschung & Entwicklung, D-32545 Bochum, Germany; Ruhr Univ Bochum, Univ Klin, Herz & Diabet Zentrum NRW, Kardiol Klin, D-32545 Bad Oeynhausen, Germany; Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany	Ruhr University Bochum; Ruhr University Bochum; Ruhr University Bochum; University of Munster	Gotting, C (corresponding author), Inst Lab & Transfus Med, Herz & Diabet Zentrum NRW, Georgstr 11, D-32545 Bad Oeynhausen, Germany.	cgoetting@hdz-nrw.de						Ahmed MS, 2003, CARDIOVASC RES, V60, P557, DOI 10.1016/j.cardiores.2003.08.017; BASHEY RI, 1993, MATRIX, V13, P363, DOI 10.1016/S0934-8832(11)80041-7; BISHOP JE, 1990, J MOL CELL CARDIOL, V22, P1157, DOI 10.1016/0022-2828(90)90079-H; Cuellar K, 2007, J BIOL CHEM, V282, P5195, DOI 10.1074/jbc.M611048200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Douglas T, 2006, BIOMACROMOLECULES, V7, P2388, DOI 10.1021/bm0603746; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GARG AK, 1989, BIOMATERIALS, V10, P413, DOI 10.1016/0142-9612(89)90133-6; Gotting C, 2007, CELL MOL LIFE SCI, V64, P1498, DOI 10.1007/s00018-007-7069-z; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gotting C, 1999, J INVEST DERMATOL, V112, P919, DOI 10.1046/j.1523-1747.1999.00590.x; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; HEIMER R, 1995, J MOL CELL CARDIOL, V27, P2191, DOI 10.1016/S0022-2828(95)91479-X; Hwang JJ, 2002, PHYSIOL GENOMICS, V10, P31, DOI 10.1152/physiolgenomics.00122.2001; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KITAGAWA H, 1995, ANAL BIOCHEM, V232, P114, DOI 10.1006/abio.1995.9952; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Lee AA, 1999, J MOL CELL CARDIOL, V31, P1833, DOI 10.1006/jmcc.1999.1017; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; Medeiros DM, 2002, CONNECT TISSUE RES, V43, P32, DOI 10.1080/713713431; Papakrivopoulou J, 2004, CARDIOVASC RES, V61, P736, DOI 10.1016/j.cardiores.2003.12.018; Ponighaus C, 2007, J BIOL CHEM, V282, P5201, DOI 10.1074/jbc.M611665200; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Schon S, 2006, J BIOL CHEM, V281, P14224, DOI 10.1074/jbc.M510690200; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCOTT JE, 1981, BIOCHEM J, V195, P573, DOI 10.1042/bj1950573; Spinale FG, 1996, J MOL CELL CARDIOL, V28, P1591, DOI 10.1006/jmcc.1996.0150; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; Tyagi SC, 1996, J CELL BIOCHEM, V63, P185, DOI 10.1002/(SICI)1097-4644(19961101)63:2<185::AID-JCB6>3.0.CO;2-U; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; van Wamel AJET, 2002, MOL CELL BIOCHEM, V236, P147, DOI 10.1023/A:1016138813353; Vogel K, 2006, ELECTROPHORESIS, V27, P1363, DOI 10.1002/elps.200500578; Voglmeir J, 2007, J BIOL CHEM, V282, P5984, DOI 10.1074/jbc.M608087200; WEBER KT, 1988, CIRC RES, V62, P757, DOI 10.1161/01.RES.62.4.757; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YOSHIKANE H, 1992, JPN CIRC J, V56, P899, DOI 10.1253/jcj.56.899	39	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26441	26449		10.1074/jbc.M702299200	http://dx.doi.org/10.1074/jbc.M702299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635914	hybrid			2022-12-27	WOS:000249239600049
J	Wu, F; Vij, N; Roberts, L; Lopez-Briones, S; Joyce, S; Chakravarti, S				Wu, Feng; Vij, Neeraj; Roberts, Luke; Lopez-Briones, S.; Joyce, Sarah; Chakravarti, Shukti			A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; KERATAN SULFATE PROTEOGLYCAN; CRYSTAL-STRUCTURE; CORNEAL OPACITY; FIBROMODULIN; CD14; LPS; TOLL-LIKE-RECEPTOR-4; DECORIN; RECOGNITION	Lumican is an extracellular matrix protein modified as a proteoglycan in some tissues. The core protein with leucinerich repeats, characteristic of the leucine-rich-repeat superfamily, binds collagen fibrils and regulates its structure. In addition, we believe that lumican sequestered in the pericellular matrix interacts with cell surface proteins for specific cellular functions. Here we show that bacterial lipopolysaccharide sensing by the Toll-like receptor 4 signaling pathway and innate immune response is regulated by lumican. Primary cultures of lumican-deficient ( Lum (-/-)) macrophages show impaired innate immune response to lipopolysaccharides with lower induction of tumor necrosis factor alpha(TNF alpha) and interleukin-6. Macrophage response to other pathogen-associated molecular patterns is not adversely affected by lumican deficiency, suggesting a specific role for the lumican core protein in the Toll-like receptor 4 pathway. An exogenous recombinant lumican core protein increases lipopolysaccharide-mediated TNF alpha induction and partially rescues innate immune response in Lum (-/-) macrophages. We further show that the core protein binds lipopolysaccharide. Immunoprecipitation of lumican from peritoneal lavage coprecipitates CD14, a cell surface lipopolysaccharide-binding protein that is involved in its presentation to Toll-like receptor 4. The Lum (-/-) mice are hypo-responsive to lipopolysaccharide-induced septic shock, with poor induction of proinflammatory cytokines, TNF alpha, and interleukins 1 beta and 6 in the serum. Taken together, the data indicates a novel role for lumican in the presentation of bacterial lipopolysaccharide to CD14 and host response to this bacterial endotoxin.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Chakravarti, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	schakra1@jhmi.edu	lopez, sergio/AAE-5784-2021	Lopez-Briones, Sergio/0000-0003-0273-0958	NEI NIH HHS [EY11654, R01 EY011654] Funding Source: Medline; NATIONAL EYE INSTITUTE [R56EY011654, R01EY011654] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Beutler B, 2001, J ENDOTOXIN RES, V7, P277, DOI 10.1177/09680519010070040901; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chakravarti S, 2002, GLYCOCONJUGATE J, V19, P287, DOI 10.1023/A:1025348417078; Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; DURIEUX JJ, 1994, EUR J IMMUNOL, V24, P2006, DOI 10.1002/eji.1830240911; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; Funderburgh JL, 1997, INVEST OPHTH VIS SCI, V38, P1159; He YW, 2004, NAT IMMUNOL, V5, P88, DOI 10.1038/ni1021; Hocking AM, 1998, MATRIX BIOL, V17, P1; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; Knapp S, 2006, AM J RESP CRIT CARE, V173, P122, DOI 10.1164/rccm.200505-730OC; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; O'Neill LAJ, 2005, NAT MED, V11, P1161, DOI 10.1038/nm1105-1161; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2004, BIOCHEM SOC T, V32, P636, DOI 10.1042/BST0320636; Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833; Vij N, 2004, EXP EYE RES, V78, P957, DOI 10.1016/j.exer.2003.12.006; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Waterer GW, 2003, CRIT CARE, V7, P308, DOI 10.1186/cc2164; Waterer GW, 2003, CRIT CARE MED, V31, P1367, DOI 10.1097/01.CCM.0000063088.86079.03; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Wunderink Richard G, 2003, Curr Opin Crit Care, V9, P384, DOI 10.1097/00075198-200310000-00008	47	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26409	26417		10.1074/jbc.M702402200	http://dx.doi.org/10.1074/jbc.M702402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616530	hybrid			2022-12-27	WOS:000249239600046
J	Cheeran, A; Kolli, NR; Sen, R				Cheeran, Anoop; Kolli, Nanci R.; Sen, Ranjan			The site of action of the antiterminator protein N from the lambdoid phage H-19B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; TRANSCRIPT CLEAVAGE FACTORS; 3.3 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ELONGATION COMPLEX; ALPHA-SUBUNIT; NASCENT RNA; DNA HYBRID	Transcription antitermination by N proteins of lambdoid phages involves specific interactions of the C-terminal domain of N with the elongation complex (EC). The interacting surface of N on the EC is unknown, knowledge of which is essential to understand the mechanism of antitermination. Specific cleavage patterns were generated near the active site Mg2+ of the RNA polymerase of an N-modified stalled EC using iron-(S)-1-(p-bromoacetamidobenzyl) ethylenediaminetetraacetate conjugated to the only cysteine residue in the C-terminal domain of N from a lambdoid phage H-19B. Modification of EC by N also induced conformational changes around the same region as revealed from the limited trypsin digestion and in situ Fe-dithiothreitol cleavage pattern of the same EC. These data, together with the previously obtained H-19B N-specific mutations in RNA polymerase, beta(G1045D), and beta '(P251S, P254L, G336S, and R270C) subunits, suggest that the active center cleft of the EC could be the site of action of this antiterminator. H-19B N induced altered interactions in this region of EC, prevented the backtracking of the stalled EC at the ops pause site and destabilized RNA hairpin-beta subunit flap domain interactions at the his pause site. We propose that the physical proximity of the C-terminal domain of H-19B N to the active center cleft of the EC is required for the process of transcription antitermination and that it involves both stabilization of the weak RNA-DNA hybrid at a terminator and destabilization of the interactions of terminator hairpin in the RNA exit channel.	Ctr DNA Fingerpriting & Diagnost, Lab Transcript Biol, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Sen, R (corresponding author), Ctr DNA Fingerpriting & Diagnost, Lab Transcript Biol, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	rsen@cdfd.org.in	Sen, Ranjan/AAP-7075-2021		FOGARTY INTERNATIONAL CENTER [R01TW006185] Funding Source: NIH RePORTER; FIC NIH HHS [TW06185] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Banerjee S, 2006, J MICROBIOL, V44, P11; Bonin I, 2004, P NATL ACAD SCI USA, V101, P13762, DOI 10.1073/pnas.0405883101; Borukhov S, 2005, MOL MICROBIOL, V55, P1315, DOI 10.1111/j.1365-2958.2004.04481.x; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Cheeran A, 2005, J MOL BIOL, V352, P28, DOI 10.1016/j.jmb.2005.06.052; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; Das A, 1996, METHOD ENZYMOL, V274, P374; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GEORGOPO.CP, 1971, P NATL ACAD SCI USA, V68, P2977, DOI 10.1073/pnas.68.12.2977; GHYSEN A, 1972, J MOL BIOL, V65, P259, DOI 10.1016/0022-2836(72)90281-1; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; King RA, 2003, METHOD ENZYMOL, V371, P207; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Meares CF, 2003, METHOD ENZYMOL, V371, P82; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nechaev S, 2002, J MOL BIOL, V320, P11, DOI 10.1016/S0022-2836(02)00420-5; Neely MN, 2000, MOL MICROBIOL, V38, P1074, DOI 10.1046/j.1365-2958.2000.02217.x; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Obuchowski M, 1997, MOL MICROBIOL, V23, P211, DOI 10.1046/j.1365-2958.1997.2101576.x; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; Schauer AT, 1996, MOL MICROBIOL, V21, P839, DOI 10.1046/j.1365-2958.1996.451409.x; Sen R, 2002, MOL MICROBIOL, V46, P215, DOI 10.1046/j.1365-2958.2002.03154.x; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; STERNBERG N, 1976, VIROLOGY, V73, P139, DOI 10.1016/0042-6822(76)90068-4; Szalewska-Palasz A, 2003, ARCH MICROBIOL, V180, P161, DOI 10.1007/s00203-003-0571-2; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Van Gilst MR, 2000, METHOD ENZYMOL, V323, P1; VanGilst MR, 1997, J MOL BIOL, V274, P160, DOI 10.1006/jmbi.1997.1389; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Watnick RS, 1999, SCIENCE, V286, P2337, DOI 10.1126/science.286.5448.2337; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WHALEN W A, 1990, New Biologist, V2, P975; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30997	31007		10.1074/jbc.M704864200	http://dx.doi.org/10.1074/jbc.M704864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17698847	hybrid			2022-12-27	WOS:000250136300067
J	Garstka, M; Borchert, B; Al-Balushi, M; Praveen, PVK; Kuehl, N; Majoul, I; Duden, R; Springer, S				Garstka, Malgorzata; Borchert, Britta; Al-Balushi, Mohammed; Praveen, P. V. K.; Kuehl, Nicole; Majoul, Irina; Duden, Rainer; Springer, Sebastian			Peptide-receptive major histocompatibility complex class I molecules cycle between endoplasmic reticulum and cis-golgi in wild-type lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; INTERMEDIATE COMPARTMENT; MONOCLONAL-ANTIBODIES; HEAVY-CHAINS; QUALITY-CONTROL; INTRACELLULAR-TRANSPORT; MEMBRANE GLYCOPROTEIN; RETROGRADE TRANSPORT; ANTIGEN PRESENTATION; PROTEIN-TRANSPORT	Prior to binding to a high affinity peptide and transporting it to the cell surface, major histocompatibility complex class I molecules are retained inside the cell by retention in the endoplasmic reticulum ( ER), recycling through the ER-Golgi intermediate compartment and possibly the cis-Golgi, or both. Using fluorescence microscopy and a novel in vitro COPII ( ER-to-ER-Golgi intermediate compartment) vesicle formation assay, we find that in both lymphocytes and fibroblasts that lack the functional transporter associated with antigen presentation, class I molecules exit the ER and reach the cis-Golgi. Intriguingly, in wild-type T1 lymphoma cells, peptide-occupied and peptide-receptive class I molecules are simultaneously exported from ER membranes with similar efficiencies. Our results suggest that binding of high affinity peptide and exit from the ER are not coupled, that the major histocompatibility complex class I quality control compartment extends into the Golgi apparatus under standard conditions, and that peptide loading onto class I molecules may occur in post-ER compartments.	Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany; Sultan Qaboos Univ, Dept Microbiol & Immunol, Muscat 123, Oman; Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	Jacobs University; Sultan Qaboos University; University of London; Royal Holloway University London	Springer, S (corresponding author), Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany.	s.springer@jacobs-university.de	Majoul, Irina V/K-5339-2013; Pvk, Praveen/C-3833-2013; Garstka, Malgorzata A./AAU-4401-2020; Duden, Rainer/C-8917-2011; Springer, Sebastian/AAJ-7036-2021	Garstka, Malgorzata A./0000-0003-2896-7275; Springer, Sebastian/0000-0002-5527-6149	Wellcome Trust [047578] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON KS, 1993, J IMMUNOL, V151, P3407; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Appenzeller-Herzog C, 2006, J CELL SCI, V119, P2173, DOI 10.1242/jcs.03019; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BALCH WE, 1986, J BIOL CHEM, V261, P4690; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Barre L, 2005, FEBS J, V272, P1063, DOI 10.1111/j.1742-4658.2005.04548.x; Boyle LH, 2006, J IMMUNOL, V176, P6464, DOI 10.4049/jimmunol.176.11.6464; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; De Silva AD, 1999, J IMMUNOL, V163, P4413; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2007, CURR OPIN IMMUNOL, V19, P99, DOI 10.1016/j.coi.2006.11.013; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Glithero A, 2006, J BIOL CHEM, V281, P12699, DOI 10.1074/jbc.M511683200; Greenfield JJA, 1999, J CELL SCI, V112, P1477; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Groothuis T, 2005, CURR TOP MICROBIOL, V300, P127; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hermosilla R, 2004, TRAFFIC, V5, P993, DOI 10.1111/j.1600-0854.2004.00239.x; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Ito M, 2002, BIOCHEM J, V361, P473, DOI 10.1042/0264-6021:3610473; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kienast A, 2007, NAT IMMUNOL, V8, P864, DOI 10.1038/ni1483; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kincaid MM, 2007, MOL BIOL CELL, V18, P455, DOI 10.1091/mbc.E06-08-0696; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Koch J, 2006, CELL MOL LIFE SCI, V63, P653, DOI 10.1007/s00018-005-5462-z; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Moldovan L, 2004, HISTOCHEM CELL BIOL, V122, P395, DOI 10.1007/s00418-004-0676-y; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Murshid A, 2004, CELL MOL LIFE SCI, V61, P133, DOI 10.1007/s00018-003-3352-9; Neisig A, 1996, J IMMUNOL, V156, P3196; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nyfeler B, 2006, TRAFFIC, V7, P1473, DOI 10.1111/j.1600-0854.2006.00483.x; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Otsu M, 2006, ANTIOXID REDOX SIGN, V8, P274, DOI 10.1089/ars.2006.8.274; OZATO K, 1981, J IMMUNOL, V126, P317; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Park B, 2006, CELL, V127, P369, DOI 10.1016/j.cell.2006.08.041; Paulsson KM, 2002, J BIOL CHEM, V277, P18266, DOI 10.1074/jbc.M201388200; Paulsson KM, 2001, INT IMMUNOL, V13, P1063, DOI 10.1093/intimm/13.8.1063; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Shastri N, 2005, IMMUNOL REV, V207, P31, DOI 10.1111/j.0105-2896.2005.00321.x; Shugrue CA, 1999, J CELL SCI, V112, P4547; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Spear ED, 2003, MOL BIOL CELL, V14, P2756, DOI 10.1091/mbc.E02-11-0717; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STAM NJ, 1986, J IMMUNOL, V137, P2299; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Thammavongsa V, 2006, J IMMUNOL, V177, P3150, DOI 10.4049/jimmunol.177.5.3150; Tourdot S, 2005, J IMMUNOL, V174, P925, DOI 10.4049/jimmunol.174.2.925; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; Wright CA, 2004, BIOL CHEM, V385, P763, DOI 10.1515/BC.2004.100; Zernich D, 2004, J EXP MED, V200, P13, DOI 10.1084/jem.20031680; Zhang YN, 2006, IMMUNOL RES, V35, P151, DOI 10.1385/IR:35:1:151; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0	83	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30680	30690		10.1074/jbc.M701721200	http://dx.doi.org/10.1074/jbc.M701721200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17656363	hybrid			2022-12-27	WOS:000250136300036
J	Barber, MA; Donald, S; Thelen, S; Anderson, KE; Thelen, M; Welch, HCE				Barber, Mark A.; Donald, Sarah; Thelen, Sylvia; Anderson, Karen E.; Thelen, Marcus; Welch, Heidi C. E.			Membrane translocation of P-Rex1 is mediated by G protein beta gamma subunits and phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; PLASMA-MEMBRANE; NEUTROPHIL FUNCTION; FACTOR TIAM1; RHO-GTPASES; ACTIVATION; RAC; RECRUITMENT; BINDING	P-Rex1 is a guanine-nucleotide exchange factor (GEF) for the small GTPase Rac that is directly activated by the beta gamma subunits of heterotrimeric G proteins and by the lipid second messenger phosphatidylinositol ( 3,4,5)-trisphosphate (PIP3), which is generated by phosphoinositide 3-kinase (PI3K). G beta gamma subunits and PIP3 are membrane-bound, whereas the intracellular localization of P-Rex1 in basal cells is cytosolic. Activation of PI3K alone is not sufficient to promote significant membrane translocation of P-Rex1. Here we investigated the subcellular localization of P-Rex1 by fractionation of Sf9 cells co-expressing P-Rex1 with G beta gamma and/or PI3K. In basal, serum-starved cells, P-Rex1 was mainly cytosolic, but 7% of the total was present in the 117,000 x g membrane fraction. Co-expression of P-Rex1 with either G beta gamma or PI3K caused only an insignificant increase in P-Rex1 membrane localization, whereas G beta gamma and PI3K together synergistically caused a robust increase in membrane-localized P-Rex1 to 23% of the total. PI3K-driven P-Rex1 membrane recruitment was wortmannin-sensitive. The use of P-Rex1 mutants showed that the isolated Dbl homology/pleckstrin homology domain tandem of P-Rex1 is sufficient for synergistic G beta gamma- and PI3K-driven membrane localization; that the enzymatic GEF activity of P-Rex1 is not required for membrane translocation; and that the other domains of P-Rex1 ( DEP, PDZ, and IP4P) contribute to keeping the enzyme localized in the cytosol of basal cells. In vitro Rac2-GEF activity assays showed that membrane-derived purified P-Rex1 has a higher basal activity than cytosol-derived P-Rex1, but both can be further activated by PIP3 and G beta gamma subunits.	Inst Res Biomed, CH-6500 Bellinzona, Switzerland; Babraham Inst, Inositide Lab, Cambridge CB22 3AT, England	Universita della Svizzera Italiana; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Welch, HCE (corresponding author), Babraham Inst, Inositide Lab, Babraham Res Campus, Cambridge CB22 3AT, England.	heidi.welch@bbsrc.ac.uk		Welch, Heidi/0000-0001-7865-7000; Anderson, Karen/0000-0002-7394-6660	Biotechnology and Biological Sciences Research Council [C19943, BBS/E/B/0000M090] Funding Source: Medline; Medical Research Council [G120/825] Funding Source: Medline; MRC [G120/825] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Baumeister MA, 2006, BIOCHEM J, V400, P563, DOI 10.1042/BJ20061020; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Dong XM, 2005, CURR BIOL, V15, P1874, DOI 10.1016/j.cub.2005.09.014; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleming IN, 2004, BIOCHEM J, V382, P857, DOI 10.1042/BJ20040916; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Hill K, 2006, METHOD ENZYMOL, V406, P26, DOI 10.1016/S0076-6879(06)06003-4; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Koh CG, 2001, J CELL SCI, V114, P4239; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li Z, 2005, PROSTAG OTH LIPID M, V76, P95, DOI 10.1016/j.prostaglandins.2005.02.002; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1913, DOI 10.1074/jbc.M506034200; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; PITTCHER JA, 1992, SCIENCE, V257, P1264; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sun YJ, 2006, MOL CELL BIOL, V26, P6923, DOI 10.1128/MCB.02474-05; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Vazquez-Prado J, 2004, J BIOL CHEM, V279, P54283, DOI 10.1074/jbc.M410594200; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yang L, 2006, NEURON, V52, P595, DOI 10.1016/j.neuron.2006.09.039; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005; Zegers MMP, 2003, EMBO J, V22, P4155, DOI 10.1093/emboj/cdg398; Zhao TM, 2007, J LEUKOCYTE BIOL, V81, P1127, DOI 10.1189/jlb.0406251	41	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29967	29976		10.1074/jbc.M701877200	http://dx.doi.org/10.1074/jbc.M701877200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698854	hybrid			2022-12-27	WOS:000249981200026
J	Bol, R; de Wit, JG; Driessen, AJM				Bol, Redmar; de Wit, Janny G.; Driessen, Arnold J. M.			The active protein-conducting channel of Escherichia coli contains an apolar patch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER MEMBRANE; TRANSLOCATION CHANNEL; PREPROTEIN TRANSLOCASE; PRECURSOR PROTEIN; PLASMA-MEMBRANE; CHAPERONE SECB; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; DISULFIDE BRIDGE; CATALYTIC CYCLE	Protein translocation across the cytoplasmic membrane of Escherichia coli is mediated by translocase, a complex of a protein conducting channel, SecYEG, and a peripheral motor domain, SecA. SecYEG has been proposed to constitute an aqueous path for proteins to pass the membrane in an unfolded state. To probe the solvation state of the active channel, the polarity sensitive fluorophore N-(( 2-( iodoacetoxy) ethyl)- N- methyl) amino- 7- nitrobenz- 2- oxa- 1,3- diazole was introduced at specific positions in the C- terminal region of the secretory protein proOmpA. Fluorescence measurements with defined proOmpA- DHFR translocation intermediates indicate mostly a water- exposed environment with a hydrophobic region in the center of the channel.	Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Groningen, Zernike Inst Adv Mat, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Institute, Zernike/W-7033-2019; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cannon KS, 2005, J CELL BIOL, V169, P219, DOI 10.1083/jcb.200412019; Clemons WM, 2004, CURR OPIN STRUC BIOL, V14, P390, DOI 10.1016/j.sbi.2004.07.006; Crane JM, 2005, J MOL BIOL, V353, P295, DOI 10.1016/j.jmb.2005.08.022; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; Duong F, 1998, EMBO J, V17, P696, DOI 10.1093/emboj/17.3.696; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Gumbart J, 2006, BIOPHYS J, V90, P2356, DOI 10.1529/biophysj.105.075291; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HIRATSUKA T, 1987, J BIOL CHEM, V262, P6318; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Junne T, 2006, MOL BIOL CELL, V17, P4063, DOI 10.1091/mbc.E06-03-0200; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li WK, 2007, MOL CELL, V26, P511, DOI 10.1016/j.molcel.2007.05.002; MACINTYRE S, 1991, MOL GEN GENET, V227, P224; Maillard AP, 2007, J BIOL CHEM, V282, P1281, DOI 10.1074/jbc.M610060200; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; MITRA K, 2006, NAT STRUCT BIOL, V157, P262; Papanikou E, 2005, J BIOL CHEM, V280, P43209, DOI 10.1074/jbc.M509990200; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; Scheuring J, 2005, J MOL BIOL, V354, P258, DOI 10.1016/j.jmb.2005.09.058; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; TANI K, 1991, FEBS LETT, V285, P127, DOI 10.1016/0014-5793(91)80741-K; TANI K, 1990, J BIOL CHEM, V265, P17341; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; VRONTOU E, 2004, BIOCHIM BIOPHYS ACTA, V11, P67; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Zhou JH, 2005, MOL MICROBIOL, V58, P349, DOI 10.1111/j.1365-2958.2005.04842.x	57	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29785	29793		10.1074/jbc.M702140200	http://dx.doi.org/10.1074/jbc.M702140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699162	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000249981200007
J	Greco, SJ; Smirnov, SV; Murthy, RG; Rameshwar, P				Greco, Steven J.; Smirnov, Sergey V.; Murthy, Raghav G.; Rameshwar, Pranela			Synergy between the RE-1 silencer of transcription and NF kappa B in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMERGING IMMUNE-SYSTEM; BREAST-CANCER CELLS; BONE-MARROW; EXPRESSION; REST; PLASTICITY; NEURONS; BIOLOGY; DIFFERENTIATION; NEUROGENESIS	The RE-1 silencer of transcription ( REST) is a transcriptional regulator that represses neuron-specific genes in non-neuronal tissues by remodeling chromatin structure. We have utilized human mesenchymal stem cells (MSCs) as a research tool to understand the molecular mechanisms that regulate a neurogenic program of differentiation in non-neuronal tissue. MSCs are mesoderm-derived cells that generate specialized cells such as stroma, fat, bone, and cartilage. We have reported previously the transdifferentiation of MSCs into functional neuronal cells (Cho, K. J., Trzaska, K. A., Greco, S. J., McArdle, J., Wang, F. S., Ye, J.-H., and Rameshwar, P. ( 2005) Stem Cells 23, 383-391). Expression of the neurotransmitter gene TAC1 was detected only in neuronal cells and thus served as a model to study transcriptional regulation of neuron-specific genes in undifferentiated MSCs. Bone marrow stromal cells are known to transiently express TAC1 following stimulation with the microenvironmental factor interleukin-1 alpha. We thus compared the effects of interleukin-1 alpha stimulation and neuronal induction of MSCs on TAC1 regulation. Transcription factor mapping of the 5'-flanking region of the TAC1 promoter predicted two REST-binding sites adjacent to one NF kappa B site within exon 1. Chromatin immunoprecipitation, mutagenesis, and loss-of-function studies showed that both transcription factors synergistically mediated repression of TAC1 in the neurogenic and microenvironmental models. Together, the results support the novel finding of synergism between REST and NF kappa B in the suppression of TAC1 in non-neuronal cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol,MSB, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rameshwar, P (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol,MSB, Rm E-579,185 S Orange Ave, Newark, NJ 07103 USA.	rameshwa@umdnj.edu						Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Baharvand H, 2006, DEV GROWTH DIFFER, V48, P323, DOI 10.1111/j.1440-169x.2006.00867.x; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corcoran KE, 2007, J IMMUNOL, V178, P2075, DOI 10.4049/jimmunol.178.4.2075; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Greco SJ, 2004, FRONT BIOSCI-LANDMRK, V9, P1782, DOI 10.2741/1373; Jiang WH, 2006, TRANSPL INT, V19, P570, DOI 10.1111/j.1432-2277.2006.00307.x; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; Lerou PH, 2005, BLOOD REV, V19, P321, DOI 10.1016/j.blre.2005.01.005; Lotem J, 2006, ONCOGENE, V25, P7663, DOI 10.1038/sj.onc.1209816; Lunyak VV, 2005, CELL, V121, P499, DOI 10.1016/j.cell.2005.05.003; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495; Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426; Qian J, 2001, J IMMUNOL, V166, P2553, DOI 10.4049/jimmunol.166.4.2553; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rao G, 2004, CANCER RES, V64, P2874, DOI 10.1158/0008-5472.CAN-03-3121; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Snyder BJ, 2005, CURR OPIN NEUROL, V18, P376, DOI 10.1097/01.wco.0000174298.27765.91; Spencer EM, 2006, NEUROBIOL DIS, V24, P41, DOI 10.1016/j.nbd.2006.04.020; Sun YM, 2005, MOL BIOL CELL, V16, P5630, DOI 10.1091/mbc.E05-07-0687; Wang QH, 2006, J MED INVESTIG, V53, P61, DOI 10.2152/jmi.53.61; Yan J, 2006, STEM CELLS, V24, P1976, DOI 10.1634/stemcells.2005-0518	33	35	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30039	30050		10.1074/jbc.M703026200	http://dx.doi.org/10.1074/jbc.M703026200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709376	hybrid			2022-12-27	WOS:000249981200034
J	Kobayashi, A; Asano, M; Mohri, S; Kitamoto, T				Kobayashi, Atsushi; Asano, Masahiro; Mohri, Shirou; Kitamoto, Tetsuyuki			Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERSTMANN-STRAUSSLER SYNDROME; DURA-MATER GRAFT; FLORID PLAQUES; KNOCK-IN; VARIANT CJD; PROTEIN; MOUSE; SUSCEPTIBILITY; WOMAN; MICE	The genotype ( methionine or valine) at polymorphic codon 129 of the human prion protein (PrP) gene and the type ( type 1 or type 2) of abnormal isoform of PrP ( PrPSc) are major determinants of the clinicopathological phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD). Here we found that the transmission of sCJD prions from a patient with valine homozygosity (129V/V) and type 2 PrPSc (sCJD-VV2 prions) to mice expressing human PrP with methionine homozygosity (129M/M) generated unusual PrPSc intermediate in size between type 1 and type 2. The intermediate type PrPSc was seen in all examined dura mater graft-associated CJD cases with 129M/M and plaque-type PrP deposits (p-dCJD). p-dCJD prions and sCJD-VV2 prions exhibited similar transmissibility and neuropathology, and the identical type of PrPSc when inoculated into PrP-humanized mice with 129M/M or 129V/V. These findings suggest that p-dCJD could be caused by cross-sequence transmission of sCJD-VV2 prions.	Tohoku Univ, Grad Sch Med, Dept Prion Res, Div CJD Sci & Technol,Aoba Ku, Sendai, Miyagi 9808575, Japan; Natl Inst Anim Hlth, Prion Dis Res Ctr, Tsukuba, Ibaraki 3050856, Japan	Tohoku University; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan	Kitamoto, T (corresponding author), Tohoku Univ, Grad Sch Med, Dept Prion Res, Div CJD Sci & Technol,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kitamoto@mail.tains.tohoku.ac.jp	Mohri, Shirou/AAK-1281-2020					Asano M, 2006, BIOCHEM BIOPH RES CO, V342, P293, DOI 10.1016/j.bbrc.2006.01.149; Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082; Belay ED, 2001, ARCH NEUROL-CHICAGO, V58, P1673, DOI 10.1001/archneur.58.10.1673; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; Brown P, 2006, NEUROLOGY, V67, P389, DOI 10.1212/01.wnl.0000231528.65069.3f; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1179; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; DELISLE MB, 1993, REV NEUROL, V149, P524; DESLYS JP, 1994, J GEN VIROL, V75, P23, DOI 10.1099/0022-1317-75-1-23; DEVILLEMEUR TB, 1994, NEUROPATH APPL NEURO, V20, P111; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; Grathwohl KUD, 1996, ARCH VIROL, V141, P1863, DOI 10.1007/BF01718200; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hoshi K, 2000, NEUROLOGY, V55, P718, DOI 10.1212/WNL.55.5.718; Kimura K, 2001, J NEUROL NEUROSUR PS, V70, P696, DOI 10.1136/jnnp.70.5.696; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V191, P709, DOI 10.1006/bbrc.1993.1275; Kitamoto T, 1996, BIOCHEM BIOPH RES CO, V222, P742, DOI 10.1006/bbrc.1996.0814; Kitamoto T, 2002, BIOCHEM BIOPH RES CO, V294, P280, DOI 10.1016/S0006-291X(02)00476-X; KITAMOTO T, 1991, BRAIN RES, V545, P319, DOI 10.1016/0006-8993(91)91306-L; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; Kopp N, 1996, LANCET, V348, P1239, DOI 10.1016/S0140-6736(05)65510-9; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Kretzschmar HA, 2003, BRAIN PATHOL, V13, P245; LANE KL, 1994, NEUROSURGERY, V34, P737, DOI 10.1227/00006123-199404000-00026; Lee HS, 2001, J INFECT DIS, V183, P192, DOI 10.1086/317935; Mochizuki Y, 2003, NEUROPATHOLOGY, V23, P136, DOI 10.1046/j.1440-1789.2003.00489.x; PALMER MS, 1993, HUM MOL GENET, V2, P541, DOI 10.1093/hmg/2.5.541; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Satoh K, 2003, J GEN VIROL, V84, P2885, DOI 10.1099/vir.0.19236-0; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; Shimizu S, 1999, ARCH NEUROL-CHICAGO, V56, P357, DOI 10.1001/archneur.56.3.357; Taguchi Y, 2003, AM J PATHOL, V163, P2585, DOI 10.1016/S0002-9440(10)63613-9; Takashima S, 1997, LANCET, V350, P865, DOI 10.1016/S0140-6736(05)62035-1; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Zeidler M, 1997, LANCET, V350, P668, DOI 10.1016/S0140-6736(05)63366-1	41	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30022	30028		10.1074/jbc.M704597200	http://dx.doi.org/10.1074/jbc.M704597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709374	hybrid			2022-12-27	WOS:000249981200032
J	Eisinger, AL; Nadauld, LD; Shelton, DN; Prescott, SM; Stafforini, DM; Jones, DA				Eisinger, Annie L.; Nadauld, Lincoln D.; Shelton, Dawne N.; Prescott, Stephen M.; Stafforini, Diana M.; Jones, David A.			Retinoic acid inhibits beta-catenin through suppression of Cox-2 - A role for truncated adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; NEGATIVE REGULATOR; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; INTESTINAL DEVELOPMENT; PROTEIN INTERACTIONS; 9-CIS-RETINOIC ACID; GROWTH-INHIBITION; BREAST-CANCER; GENE-PRODUCT; AXIN	Mutations in adenomatous polyposis coli (APC) underlie the earliest stages of colorectal carcinogenesis. Consequences of APC mutation include stabilization of beta-catenin, dysregulation of cyclooxygenase-2 (COX-2) expression, and loss of retinoic acid production, events with poorly defined interactions. Here we showed that treatment of zebrafish expressing a truncated form of Apc with either retinoic acid or a selective COX-2 inhibitor decreased beta-catenin protein levels and downstream signaling events. Interestingly, the destruction of beta-catenin in apc mutant embryos following Cox-2 inhibition required the presence of truncated Apc. These findings support roles for retinoic acid and Cox-2 in regulating the stability of beta-catenin following Apc loss. Furthermore, truncated Apc appears to retain the ability to target beta-catenin for destruction, but only in the absence of Cox-2 activity. This novel function of truncated Apc may provide a molecular basis for the efficacy of COX-2 inhibitors in the treatment of colon cancer.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu; david.jones@hci.utah.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANZANO MA, 1994, CANCER RES, V54, P4614; Begemann G, 2001, DEVELOPMENT, V128, P3081; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Delaunay F, 2000, SCIENCE, V289, P297, DOI 10.1126/science.289.5477.297; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EDWARD M, 1992, CLIN EXP METASTAS, V10, P61, DOI 10.1007/BF00163577; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fitzgerald P, 1997, CANCER RES, V57, P2642; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; HONG WK, 1994, LEUKEMIA BALTIMOR S3, V8, P33; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Li JJ, 1996, CANCER RES, V56, P483; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Nadauld LD, 2005, J BIOL CHEM, V280, P30490, DOI 10.1074/jbc.M504973200; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Nadauld LD, 2006, J BIOL CHEM, V281, P37828, DOI 10.1074/jbc.M602119200; Nadauld LD, 2006, P NATL ACAD SCI USA, V103, P13409, DOI 10.1073/pnas.0601634103; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shih IM, 2000, CANCER RES, V60, P1671; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	43	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29394	29400		10.1074/jbc.M609768200	http://dx.doi.org/10.1074/jbc.M609768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673467	hybrid			2022-12-27	WOS:000249788000036
J	Reddi, AL; Ying, GG; Duan, L; Chen, GS; Dimri, M; Douillard, P; Druker, BJ; Naramura, M; Band, V; Band, H				Reddi, Alagarsamy Lakku; Ying, GuoGuang; Duan, Lei; Chen, Gengsheng; Dimri, Manjari; Douillard, Patrice; Druker, Brian J.; Naramura, Mayumi; Band, Vimla; Band, Hamid			Binding of Cbl to a phospholipase C gamma 1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; DOWN-REGULATION; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; CSF-1 RECEPTOR; DOMAIN BINDING; BREAST-CANCER; SH2 DOMAIN; B-CELLS	Ubiquitin conjugation to receptor tyrosine kinases is a critical biochemical step in attenuating their signaling through lysosomal degradation. Our previous studies have established Cbl as an E3 ubiquitin ligase for ubiquitinylation and degradation of platelet-derived growth factor receptor (PDGFR) alpha and PDGFR beta. However, the role of endogenous Cbl in PDGFR regulation and the molecular mechanisms of this regulation remain unclear. Here, we demonstrate that endogenous Cbl is essential for ligand-induced ubiquitinylation and degradation of PDGFR beta; this involves the Cbl TKB domain binding to PDGFR beta phosphotyrosine 1021, a known phospholipase C (PLC) gamma 1 SH2 domain-binding site. Lack of Cbl or ablation of the Cbl-binding site on PDGFR beta impedes receptor sorting to the lysosome. Cbl-deficient cells also show more PDGF-induced PLC gamma 1 association with PDGFR beta and enhanced PLC-mediated cell migration. Thus, Cbl-dependent negative regulation of PDGFR beta involves a dual mechanism that concurrently promotes ubiquitin-dependent lysosomal sorting of the receptor and competitively reduces the recruitment of a positive mediator of receptor signaling.	ENH Res Inst, Div Mol Oncol, Evanston, IL 60201 USA; ENH Res Inst, Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Weinberg Coll Arts & Sci, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA; Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA; Eucodis GmbH, A-1230 Vienna, Austria	Northwestern University; Feinberg School of Medicine; Northwestern University; Oregon Health & Science University	Band, H (corresponding author), ENH Res Inst, Div Mol Oncol, 1001 Univ Pl, Evanston, IL 60201 USA.	h-band@northwestern.edu		Naramura, Mayumi/0000-0003-3658-0767; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA 87986, CA94143, CA81076, CA99163, CA96844, CA76118, 1U54 CA119341-01, CA 99900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119341, R01CA094143, R01CA096844, R01CA099163, R01CA076118, R01CA081076, R01CA087986, R01CA099900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Betsholtz C, 2004, CURR OPIN NEPHROL HY, V13, P45, DOI 10.1097/00041552-200401000-00007; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304; Cho SD, 2006, INT J ONCOL, V28, P1361; Choi JH, 2003, MOL CELLS, V15, P245; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; Ding H, 2004, NAT GENET, V36, P1111, DOI 10.1038/ng1415; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Finerty PJ, 2005, BIOCHEMISTRY-US, V44, P694, DOI 10.1021/bi048641k; Firth JD, 2001, WOUND REPAIR REGEN, V9, P86, DOI 10.1046/j.1524-475x.2001.00086.x; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hamilton TG, 2003, MOL CELL BIOL, V23, P4013, DOI 10.1128/MCB.23.11.4013-4025.2003; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jeon MS, 2004, IMMUNITY, V21, P167, DOI 10.1016/j.immuni.2004.07.013; Kitadai Y, 2006, INT J CANCER, V119, P2567, DOI 10.1002/ijc.22229; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lev DC, 2005, CLIN CANCER RES, V11, P306; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1993, J BIOL CHEM, V268, P577; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ohrt T, 2004, CELL SIGNAL, V16, P1291, DOI 10.1016/j.cellsig.2004.03.017; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; PLATE KH, 1992, LAB INVEST, V67, P529; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Schmahl J, 2007, NAT GENET, V39, P52, DOI 10.1038/ng1922; Schmidt MHH, 2006, ONCOGENE, V25, P3071, DOI 10.1038/sj.onc.1209329; Slagsvold T, 2006, TRENDS CELL BIOL, V16, P317, DOI 10.1016/j.tcb.2006.04.004; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Zeng S, 2005, BLOOD, V105, P226, DOI 10.1182/blood-2004-05-1768	71	32	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29336	29347		10.1074/jbc.M701797200	http://dx.doi.org/10.1074/jbc.M701797200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17620338	hybrid			2022-12-27	WOS:000249788000030
J	Schneider, L; Essmann, F; Kletke, A; Rio, P; Hanenberg, H; Wetzel, W; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schneider, Leonid; Essmann, Frank; Kletke, Anja; Rio, Paula; Hanenberg, Helmut; Wetzel, Wiebke; Schulze-Osthoff, Klaus; Nuernberg, Bernd; Piekorz, Roland P.			The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC COILED-COIL; MESSENGER-RNA; CENTROSOME ABERRATIONS; ASSEMBLY CHECKPOINT; POLE ORGANIZATION; TUMOR-SUPPRESSOR; HUMAN CANCERS; GENE FAMILY; ZYG-9 FORM; CELL-DEATH	Cancer-associated centrosomal transforming acidic coiled coil (TACC) proteins are involved in mitotic spindle function. By employing gene targeting, we have recently described a non-redundant and essential role of TACC3 in regulating cell proliferation. In this study, we used an inducible RNA interference approach to characterize the molecular function of TACC3 and its role in mitotic progression and cell survival. Our data demonstrate that a TACC3 knockdown arrests G1 checkpoint-compromised HeLa cells prior to anaphase with aberrant spindle morphology and severely misaligned chromosomes. Interestingly, TACC3-depleted cells fail to accumulate the mitotic kinase Aurora B and the checkpoint protein BubR1 to normal levels at kinetochores. Moreover, localization of the structural protein Ndc80 at outer kinetochores is reduced, indicating a defective kinetochore-microtubule attachment in TACC3-deficient cells. As a consequence of prolonged TACC3 depletion, cells undergo caspase-dependent cell death that relies on a spindle checkpoint-dependent mitotic arrest. TACC3 knockdown cells that escape from this arrest by mitotic slippage become highly polyploid and accumulate supernumerary centrosomes. Similarly, deficiency of the post-mitotic cell cycle inhibitor p21(WAF) exacerbates the effects of TACC3 depletion. Our findings therefore point to an essential role of TACC3 in spindle assembly and cellular survival and identify TACC3 as a potential therapeutic target in cancer cells.	Univ Dusseldorf, Univ Klinikum, Inst BIochem & Mol Biol 2, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Univ Klinikum, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Univ Klinikum, Klin Kinder Onkol Hamatol & Klin Immunol, D-40225 Dusseldorf, Germany; Indiana Univ, Riley Hosp Children, Sch Med, Wells Ctr Pediat Res,Dept Pediat, Indianapolis, IN 46223 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Piekorz, RP (corresponding author), Univ Dusseldorf, Univ Klinikum, Inst BIochem & Mol Biol 2, D-40225 Dusseldorf, Germany.	Roland.Piekorz@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013; Rio, Paula/G-8681-2015; Schneider, Leonid/H-3275-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Rio, Paula/0000-0002-5424-5543; Schneider, Leonid/0000-0002-6204-9470; Nurnberg, Bernd/0000-0002-5995-6555				Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Ciferri C, 2007, FEBS LETT, V581, P2862, DOI 10.1016/j.febslet.2007.05.012; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Holmfeldt P, 2004, EMBO J, V23, P627, DOI 10.1038/sj.emboj.7600076; HU GY, 1995, CANCER GENE THER, V2, P19; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; Kline SL, 2006, J CELL BIOL, V173, P9, DOI 10.1083/jcb.200509158; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; Meek DW, 2000, PATHOL BIOL, V48, P246; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; SCHNEIDER L, 2007, ONCOGENE; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Sluder G, 2005, NAT REV MOL CELL BIO, V6, P743, DOI 10.1038/nrm1712; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-16; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	60	72	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29273	29283		10.1074/jbc.M704151200	http://dx.doi.org/10.1074/jbc.M704151200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675670	hybrid			2022-12-27	WOS:000249788000024
J	Thomas, NA; Deng, WY; Baker, N; Puente, J; Finlay, BB				Thomas, Nikhil A.; Deng, Wanyin; Baker, Noel; Puente, Jose; Finlay, B. Brett			Hierarchical delivery of an essential host colonization factor in enteropathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATED INTIMIN RECEPTOR; ACTIN PEDESTAL FORMATION; III SECRETION CHAPERONE; ENTEROCYTE EFFACEMENT; PATHOGENICITY ISLAND; BACTERIAL PATHOGENS; VIRULENCE FACTOR; YERSINIA-PESTIS; TIR BINDS; EPEC	Many significant bacterial pathogens use a type III secretion system to inject effector proteins into host cells to disrupt specific cellular functions, enabling disease progression. The injection of these effectors into host cells is often dependent on dedicated chaperones within the bacterial cell. In this report, we demonstrate that the enteropathogenic Escherichia coli (EPEC) chaperone CesT interacts with a variety of known and putative type III effector proteins. Using pull-down and secretion assays, a degenerate CesT binding domain was identified within multiple type III effectors. Domain exchange experiments between selected type III effector proteins revealed a modular nature for the CesT binding domain, as demonstrated by secretion, chaperone binding, and infection assays. The CesT-interacting type III effector Tir, which is crucial for in vivo intestinal colonization, had to be expressed and secreted for efficient secretion of other type III effectors. In contrast, the absence of other CesT-interacting type III effectors did not abrogate effector secretion, indicating an unexpected hierarchy with respect to Tir for type III effector delivery. Coordinating the expression of other type III effectors with cesT in the absence of tir partially restored total type III effector secretion, thereby implicating CesT in secretion events. Collectively, the results suggest a coordinated mechanism involving both Tir and CesT for type III effector injection into host cells.	Dalhousie Univ, Dept Immunol & Microbiol, Halifax, NS B3X 1H5, Canada; Dalhousie Univ, Dept Med, Halifax, NS B3X 1H5, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Microbiol, Cuernavaca 62210, Morelos, Mexico	Dalhousie University; Dalhousie University; University of British Columbia; Universidad Nacional Autonoma de Mexico	Thomas, NA (corresponding author), Dalhousie Univ, Dept Immunol & Microbiol, Halifax, NS B3X 1H5, Canada.	n.thomas@dal.ca		Thomas, Nikhil/0000-0003-3037-425X				Abe A, 1999, MOL MICROBIOL, V33, P1162, DOI 10.1046/j.1365-2958.1999.01558.x; Batchelor M, 2004, EMBO REP, V5, P104, DOI 10.1038/sj.embor.7400038; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Campellone KG, 2002, MOL MICROBIOL, V43, P1227, DOI 10.1046/j.1365-2958.2002.02817.x; Caron E, 2006, CURR OPIN MICROBIOL, V9, P40, DOI 10.1016/j.mib.2005.12.008; Crawford JA, 2002, MOL MICROBIOL, V46, P855, DOI 10.1046/j.1365-2958.2002.03214.x; Creasey EA, 2003, MICROBIOL-SGM, V149, P2093, DOI 10.1099/mic.0.26355-0; Creasey EA, 2003, MOL MICROBIOL, V47, P209, DOI 10.1046/j.1365-2958.2003.03290.x; Dean P, 2005, CURR OPIN MICROBIOL, V8, P28, DOI 10.1016/j.mib.2004.12.010; Deng WY, 2005, INFECT IMMUN, V73, P2135, DOI 10.1128/IAI.73.4.2135-2146.2005; Deng WY, 2003, MOL MICROBIOL, V48, P95, DOI 10.1046/j.1365-2958.2003.03429.x; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Elliott SJ, 2002, INFECT IMMUN, V70, P2271, DOI 10.1128/IAI.70.5.2271-2277.2002; Elliott SJ, 1999, MOL MICROBIOL, V33, P1176, DOI 10.1046/j.1365-2958.1999.01559.x; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Garmendia J, 2005, INFECT IMMUN, V73, P2573, DOI 10.1128/IAI.73.5.2573-2585.2005; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; Goosney DL, 2000, CURR BIOL, V10, P735, DOI 10.1016/S0960-9822(00)00543-1; Gruenheid S, 2004, MOL MICROBIOL, V51, P1233, DOI 10.1046/j.1365-2958.2003.03911.x; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Kenny B, 2002, MOL MICROBIOL, V44, P1095, DOI 10.1046/j.1365-2958.2002.02952.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; LEVINE MM, 1978, LANCET, V1, P1119; Lilic M, 2006, MOL CELL, V21, P653, DOI 10.1016/j.molcel.2006.01.026; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Marches O, 2000, INFECT IMMUN, V68, P2171, DOI 10.1128/IAI.68.4.2171-2182.2000; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; Mellies JL, 2001, INFECT IMMUN, V69, P315, DOI 10.1128/IAI.69.1.315-324.2001; Nougayrede JP, 2004, CELL MICROBIOL, V6, P1097, DOI 10.1111/j.1462-5822.2004.00421.x; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; Patel A, 2006, CELL MICROBIOL, V8, P55, DOI 10.1111/j.1462-5822.2005.00600.x; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Phan J, 2004, ACTA CRYSTALLOGR D, V60, P1591, DOI 10.1107/S0907444904017597; Phillips N, 2004, NAT CELL BIOL, V6, P618, DOI 10.1038/ncb1148; Ritchie JM, 2003, INFECT IMMUN, V71, P7129, DOI 10.1128/IAI.71.12.7129-7139.2003; Sanchez-SanMartin C, 2001, J BACTERIOL, V183, P2823, DOI 10.1128/JB.183.9.2823-2833.2001; Sorg I, 2007, EMBO J, V26, P3015, DOI 10.1038/sj.emboj.7601731; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Thomas NA, 2005, MOL MICROBIOL, V57, P1762, DOI 10.1111/j.1365-2958.2005.04802.x; Tobe T, 2006, P NATL ACAD SCI USA, V103, P14941, DOI 10.1073/pnas.0604891103; Tomson FL, 2005, MOL MICROBIOL, V56, P447, DOI 10.1111/j.1365-2958.2005.04571.x; van Eerde A, 2004, EMBO REP, V5, P477, DOI 10.1038/sj.embor.7400144; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x	45	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29634	29645		10.1074/jbc.M706019200	http://dx.doi.org/10.1074/jbc.M706019200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681945	hybrid			2022-12-27	WOS:000249788000060
J	Teng, CH; Huang, WN; Meng, TC				Teng, Chun-Hung; Huang, Wen-Nin; Meng, Tzu-Ching			Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; TERMINAL KINASE ACTIVATION; MAP KINASE; C-JUN; REACTIVE OXYGEN; TRANSCRIPTIONAL ACTIVATION; INDUCED PHOSPHORYLATION; CELL-CYCLE; P53; TRANSDUCTION	Mitogen-activated protein kinases (MAPKs) are important mediators that integrate signaling from upstream pathways in response to various environmental cues. In order to control appropriate gene expression through phosphorylation of transcription factors, the activity of MAPKs must be tightly regulated by the actions coordinated between protein kinases and phosphatases. In this study, we explore the underlying mechanism through which the oxidative stress-activated c-Jun N-terminal kinases (JNKs), members of MAPKs, are regulated by dual specificity phosphatases (DUSPs). DUSPs are a group of enzymes that belong to the superfamily of protein-tyrosine phosphatases. They are able to recognize phospho-Ser/Thr and phospho-Tyr residues in substrates. Using quantitative real time PCR, we found that stimulation of human embryonic kidney 293T cells with H2O2 or xanthine/xanthine oxidase led to inducible expression of multiple DUSPs. We used RNA interference to characterize the functional role of these DUSPs and found rapid and transient induction of DUSP1 and DUSP10 to be essential for determining the appropriate magnitude of JNK activation in response to oxidative stress. The transcription factor ATF2, which is phosphorylated and activated by JNK, is a critical mediator for inducible expression of DUSP1 and DUSP10 in this signaling pathway. We further demonstrated that DUSP4 and DUSP16, both showing significant late phase induction, dephosphorylate JNK effectively, causing the down-regulation of the signaling cascade. Thus, this study provides new insights into the role of several DUSPs that coordinate with each other to control the magnitude and duration of JNK activity in response to oxidative stress.	Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Meng, TC (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	tcmeng@gate.sinica.edu.tw	Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng WH, 2003, BIOCHEM J, V370, P927, DOI 10.1042/BJ20021870; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fernandez-Sanchez ME, 2003, HUM MOL GENET, V12, P3161, DOI 10.1093/hmg/ddg340; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; TONKS NK, 2003, HDB CELL SIGNALLING, V108, P641; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Worby CA, 2006, J BIOL CHEM, V281, P30412, DOI 10.1074/jbc.M606117200; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang T, 2006, J MOL ENDOCRINOL, V36, P41, DOI 10.1677/jme.1.01881	58	47	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28395	28407		10.1074/jbc.M705142200	http://dx.doi.org/10.1074/jbc.M705142200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681939	hybrid			2022-12-27	WOS:000249642100014
J	Zhao, ZF; Li, XH; Hao, JF; Winston, JH; Weinman, SA				Zhao, Zhifang; Li, Xinhua; Hao, Junfang; Winston, John H.; Weinman, Steven A.			The CIC-3 chloride transport protein traffics through the plasma membrane via interaction of an N-terminal dileucine cluster with clathrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOMAL ACIDIFICATION; RECEPTOR TRAFFICKING; GROWTH-FACTOR; CLC PROTEINS; KINASE-C; CHANNEL; CELLS; LOCALIZATION; DISRUPTION; EXPRESSION	ClC-3 is a ubiquitously expressed chloride transport protein that is present in synaptic vesicles and endosome/lysosome compartments. It is largely intracellular but has been observed at the plasma membrane as well. The aim of this study was to identify the pathways and regulation of ClC-3 trafficking to intracellular sites. At the steady state, similar to 94% of transfected ClC-3 was localized intracellularly, and only 6% was at the plasma membrane. Pulse labeling with [S-35]methionine and biotinylation demonstrated that about 25% of newly synthesized ClC-3 traffics through the plasma membrane. We used both immunofluorescence microscopy and biotinylation assays to assess the trafficking of ClC-3. Plasma membrane ClC-3 was rapidly endocytosed ( t1/2 similar to 9 min); a portion entered a recycling pool that returned to the cell surface after internalization, and the remainder trafficked to more distal intracellular compartments. ClC-3 associated with clathrin at the plasma membrane. Coimmunoprecipitation and glutathione S-transferase pulldown assays demonstrated that the N terminus of ClC-3 binds to clathrin. Alanine replacement of a dileucine acidic cluster within the cytosolic N terminus ( amino acids 13-19) resulted in a molecule that had decreased endocytosis and increased surface expression. This replacement also abolished interaction with clathrin as assessed both by coimmunoprecipitation and glutathione S-transferase pulldown assays. We conclude that ClC-3 is primarily an intracellular transport protein that is transiently inserted into the plasma membrane where it is rapidly endocytosed. Internalization of ClC-3 depends on the interaction between an N-terminal dileucine cluster and clathrin.	Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Cell Biol & Neurosci, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Weinman, Steven/E-7012-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042917, R01DK042917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK042917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Jentsch TJ, 2007, J PHYSIOL-LONDON, V578, P633, DOI 10.1113/jphysiol.2006.124719; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; Wang T, 2004, GASTROENTEROLOGY, V126, P1157, DOI 10.1053/j.gastro.2004.01.015; Wang XQ, 2006, NEURON, V52, P321, DOI 10.1016/j.neuron.2006.08.035; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Yoshikawa M, 2002, GENES CELLS, V7, P597, DOI 10.1046/j.1365-2443.2002.00539.x	31	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29022	29031		10.1074/jbc.M703506200	http://dx.doi.org/10.1074/jbc.M703506200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652080	hybrid			2022-12-27	WOS:000249642100076
J	Harman, CA; Turman, MV; Kozak, KR; Marnett, LJ; Smith, WL; Garavito, RM				Harman, Christine A.; Turman, Melissa V.; Kozak, Kevin R.; Marnett, Lawrence J.; Smith, William L.; Garavito, R. Michael			Sturctural basis of enantioselective inhibition of cyclooxygenase-1 S-alpha-Substituted indomethacin ethanolamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE-H SYNTHASE-1; SELECTIVE-INHIBITION; ARACHIDONIC-ACID; ARGININE 120; ACTIVE-SITE; PROSTAGLANDIN; BINDING; FLUORESCENCE; PROTEOLYSIS	The modification of the nonselective nonsteroidal anti-inflammatory drug, indomethacin, by amidation presents a promising strategy for designing novel cyclooxygenase (COX)-2-selective inhibitors. A series of alpha-substituted indomethacin ethanolamides, which exist as R/S-enantiomeric pairs, provides a means to study the impact of stereochemistry on COX inhibition. Comparative studies revealed that the R- and S-enantiomers of the alpha-substituted analogs inhibit COX-2 with almost equal efficacy, whereas COX-1 is selectively inhibited by the S-enantiomers. Mutagenesis studies have not been able to identify residues that manifest the enantioselectivity in COX-1. In an effort to understand the structural impact of chirality on COX-1 selectivity, the crystal structures of ovine COX-1 in complexes with an enantiomeric pair of these indomethacin ethanolamides were determined at resolutions between 2.75 and 2.85 angstrom. These structures reveal unique, enantiomer-selective interactions within the COX-1 side pocket region that stabilize drug binding and account for the chiral selectivity observed with the (S)-alpha-substituted indomethacin ethanolamides. Kinetic analysis of binding demonstrates that both inhibitors bind quickly utilizing a two-step mechanism. However, the second binding step is readily reversible for the R-enantiomer, whereas for the S-enantiomer, it is not. These studies establish for the first time the structural and kinetic basis of high affinity binding of a neutral inhibitor to COX-I and demonstrate that the side pocket of COX-1, previously thought to be sterically inaccessible, can serve as a binding pocket for inhibitor association.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Inst Biol Chem, Nashville, TN 37232 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Michigan State University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Michigan System; University of Michigan	Garavito, RM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 513 Biochem,E Lansing, E Lansing, MI 48824 USA.	garavito@msu.edu		Vaught, Melissa/0000-0001-7627-8330	NATIONAL CANCER INSTITUTE [R01CA089450] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA89450] Funding Source: Medline; NHLBI NIH HHS [R01HL56773] Funding Source: Medline; NIDA NIH HHS [F31DA02014] Funding Source: Medline; NIEHS NIH HHS [T32ES07028] Funding Source: Medline; NIGMS NIH HHS [R01GM68868, P01GM57323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; Garavito RM, 1999, BBA-MOL CELL BIOL L, V1441, P278, DOI 10.1016/S1388-1981(99)00147-X; GARAVITO RM, 2001, HDB METALLOPROTEINS, P245; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Kalgutkar AS, 1996, BIOCHEMISTRY-US, V35, P9076, DOI 10.1021/bi9605752; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kozak KR, 2002, BIOORG MED CHEM LETT, V12, P1315, DOI 10.1016/S0960-894X(02)00133-6; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lanzo CA, 2000, BIOCHEMISTRY-US, V39, P6228, DOI 10.1021/bi992761o; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2000, ARCH BIOCHEM BIOPHYS, V380, P39, DOI 10.1006/abbi.2000.1906; Moth CW, 2005, J MED CHEM, V48, P3613, DOI 10.1021/jm0494164; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Prusakiewicz JJ, 2004, BIOCHEMISTRY-US, V43, P15439, DOI 10.1021/bi048534q; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Seibold SA, 2004, J PHYS CHEM B, V108, P9297, DOI 10.1021/jp049844l; Seibold SA, 2003, J BIOL CHEM, V278, P46163, DOI 10.1074/jbc.M306319200; SMITH WL, 1971, J BIOL CHEM, V246, P6700; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Walker MC, 2001, BIOCHEM J, V357, P709, DOI 10.1042/0264-6021:3570709; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	32	73	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28096	28105		10.1074/jbc.M701335200	http://dx.doi.org/10.1074/jbc.M701335200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656360	hybrid			2022-12-27	WOS:000249455600059
J	Huttunen, HJ; Guenette, SY; Peach, C; Greco, C; Xia, WM; Kim, DY; Barren, C; Tanzi, RE; Kovacs, DM				Huttunen, Henri J.; Guenette, Suzanne Y.; Peach, Camilla; Greco, Christopher; Xia, Weiming; Kim, Doo Yeon; Barren, Cory; Tanzi, Rudolph E.; Kovacs, Dora M.			HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; LIPID RAFTS; CLEAVAGE; INHIBITOR; DOMAIN; PRESENILIN-1; OMI/HTRA2; STRESS	Alzheimer disease-associated beta-amyloid peptide is generated from its precursor protein APP. By using the yeast two-hybrid assay, here we identified HtrA2/Omi, a stress-responsive chaperone-protease as a protein binding to the N-terminal cysteine-rich region of APP. HtrA2 coimmunoprecipitates exclusively with immature APP from cell lysates as well as mouse brain extracts and degrades APP in vitro. A subpopulation of HtrA2 localizes to the cytosolic side of the endoplasmic reticulum (ER) membrane where it contributes to ER-associated degradation of APP together with the proteasome, Inhibition of the proteasome results in accumulation of retrotranslocated forms of APP and increased association of APP with HtrA2 and Derlin-1 in microsomal membranes. In cells lacking HtrA2, APP holoprotein is stabilized and accumulates in the early secretory pathway correlating with elevated levels of APP C-terminal fragments and increased All secretion. Inhibition of ER-associated degradation (either HtrA2 or proteasome) promotes binding of APP to the COPII protein Sec23 suggesting enhanced trafficking of APP out of the ER. Based on these results we suggest a novel function for HtrA2 as a regulator of APP metabolism through ER-associated degradation.	Massachusetts Gen Hosp, Harvard Med Sch, Neurobiol Dis Lab, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Harvard Med Sch, Massachussetts Gen Inst Nuerodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Harvard Med Sch, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kovacs, DM (corresponding author), Massachusetts Gen Hosp, Harvard Med Sch, Neurobiol Dis Lab, 114 16th St, Charlestown, MA 02129 USA.	Dora_Kovacs@hms.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; xia, weiming/E-5465-2016	Tanzi, Rudolph/0000-0002-7032-1454; xia, weiming/0000-0002-7463-3295; Huttunen, Henri/0000-0002-9867-4438				Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; d'Abramo C, 2005, BIOCHEM J, V391, P693, DOI 10.1042/BJ20050560; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Forster ML, 2006, J CELL BIOL, V173, P853, DOI 10.1083/jcb.200602046; Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hare JF, 2006, ARCH BIOCHEM BIOPHYS, V451, P79, DOI 10.1016/j.abb.2006.05.002; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hiltunen M, 2006, J BIOL CHEM, V281, P32240, DOI 10.1074/jbc.M603106200; Johnson RJ, 2001, NEUROBIOL AGING, V22, P387, DOI 10.1016/S0197-4580(00)00247-5; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kincaid MM, 2007, MOL BIOL CELL, V18, P455, DOI 10.1091/mbc.E06-08-0696; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kudo T, 2006, BIOCHEM BIOPH RES CO, V344, P525, DOI 10.1016/j.bbrc.2006.03.173; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lott IT, 2005, NEUROBIOL AGING, V26, P383, DOI 10.1016/j.neurobiolaging.2004.08.005; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Park HJ, 2004, NEUROSCI LETT, V357, P63, DOI 10.1016/j.neulet.2003.11.068; Park HJ, 2006, J BIOL CHEM, V281, P34277, DOI 10.1074/jbc.M603443200; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Rechards M, 2006, TRAFFIC, V7, P354, DOI 10.1111/j.1600-0854.2006.00388.x; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-4; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4; Yang L, 2007, J BIOL CHEM, V282, P10981, DOI 10.1074/jbc.M700445200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	57	60	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28285	28295		10.1074/jbc.M702951200	http://dx.doi.org/10.1074/jbc.M702951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17684015	hybrid			2022-12-27	WOS:000249455600078
J	Bengrine, A; Li, JQ; Hamm, LL; Awayda, MS				Bengrine, Abderrahmane; Li, Jinqing; Hamm, L. Lee; Awayda, Mouhamed S.			Indirect activation of the epithelial Na+ channel by trypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; XENOPUS OOCYTES; INHIBITION; EXPRESSION; SUBUNIT; PROTEASES; CLEAVAGE; ENAC	We tested the hypothesis that the serine protease trypsin can indirectly activate the epithelial Na+ channel (ENaC). Experiments were carried out in Xenopus oocytes and examined the effects on the channel formed by all three human ENaC subunits and that formed by Xenopus epsilon and human beta and gamma subunits ( epsilon beta gamma ENaC). Low levels of trypsin (1- 10 ng/ml) were without effects on the oocyte endogenous conductances and were specifically used to test the effects on ENaC. Addition of 1 ng/ml trypsin for 60 min stimulated the amiloride-sensitive human ENaC conductance (gNa) by similar to 6-fold. This effect on the gNa was [Na+]-independent, thereby ruling out an interaction with channel feedback inhibition by Na+. The indirect nature of this activation was confirmed in cell-attached patch clamp experiments with trypsin added to the outside of the pipette. Trypsin was comparatively ineffective at activating epsilon beta gamma ENaC, a channel that exhibited a high spontaneous open probability. These observations, in combination with surface binding experiments, indicated that trypsin indirectly activated membrane-resident channels. Activation by trypsin was also dependent on catalytic activity of this protease but was not accompanied by channel subunit proteolysis. Channel activation was dependent on downstream activation of G-proteins and was blocked by G-protein inhibition by injection of guanyl-5 '-yl thiophosphate and by pre-stimulation of phospholipase C. These data indicate a receptor-mediated activation of ENaC by trypsin. This trypsin-activated receptor is distinct from that of protease-activated receptor-2, because the response to trypsin was unaffected by protease-activated receptor-2 overexpression or knockdown.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Tulane Univ, Ctr Hlth Sci, Dept Med, New Orleans, LA 70112 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Tulane University	Awayda, MS (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall,3435 Main St, Buffalo, NY 14214 USA.	awayda@buffalo.edu			NIDDK NIH HHS [DK 55626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasen D, 2006, J AM SOC NEPHROL, V17, P968, DOI 10.1681/ASN.2005060637; Awayda Mouhamed S., 2006, V337, P101; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Bachhuber T, 2005, J BIOL CHEM, V280, P31587, DOI 10.1074/jbc.M504347200; Bengrine A, 2007, FASEB J, V21, P1189, DOI 10.1096/fj.06-6046com; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC761, DOI 10.1152/ajpcell.1997.272.3.C761; Bueno OF, 1998, MOL BRAIN RES, V59, P165, DOI 10.1016/S0169-328X(98)00129-6; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; DURIEUX ME, 1994, FEBS LETT, V337, P235, DOI 10.1016/0014-5793(94)80198-3; ELS WJ, 1991, J GEN PHYSIOL, V98, P1197, DOI 10.1085/jgp.98.6.1197; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; Harris M, 2007, J BIOL CHEM, V282, P58, DOI 10.1074/jbc.M605125200; Helms MN, 2005, J BIOL CHEM, V280, P40885, DOI 10.1074/jbc.M509646200; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Horowitz LF, 2005, J GEN PHYSIOL, V126, P243, DOI 10.1085/jgp.200509309; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Jovov B, 2002, J BIOL CHEM, V277, P4134, DOI 10.1074/jbc.M108354200; Kamatchi GL, 2003, BRAIN RES, V968, P227, DOI 10.1016/S0006-8993(03)02245-5; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; LEWIS SA, 1986, P NATL ACAD SCI USA, V83, P5345, DOI 10.1073/pnas.83.14.5345; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu L, 2002, HYPERTENSION, V39, P860, DOI 10.1161/01.HYP.0000013055.48885.8D; Ma HP, 2005, J AM SOC NEPHROL, V16, P3182, DOI 10.1681/ASN.2005040434; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McSorley T, 2006, EUR J CELL BIOL, V85, P673, DOI 10.1016/j.ejcb.2006.01.005; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OGrady SM, 1996, J BIOL CHEM, V271, P29080, DOI 10.1074/jbc.271.46.29080; ORCE GG, 1980, AM J PHYSIOL, V239, pF459, DOI 10.1152/ajprenal.1980.239.5.F459; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Schultheiss M, 1997, CELL MOL LIFE SCI, V53, P842, DOI 10.1007/s000180050104; Shapira H, 1998, J BIOL CHEM, V273, P19431, DOI 10.1074/jbc.273.31.19431; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Verghese GM, 2006, AM J PHYSIOL-CELL PH, V291, pC1258, DOI 10.1152/ajpcell.00637.2005; Vesey DA, 2007, NEPHROLOGY, V12, P36, DOI 10.1111/j.1440-1797.2006.00746.x; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828	52	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26884	26896		10.1074/jbc.M611829200	http://dx.doi.org/10.1074/jbc.M611829200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627947	hybrid			2022-12-27	WOS:000249304900028
J	Leipold, MD; Vinogradov, E; Whitfield, C				Leipold, Michael D.; Vinogradov, Evgeny; Whitfield, Chris			Glycosyltransferases involved in biosynthesis of the outer core region of Escherichia coli lipopolysaccharides exhibit broader substrate Specificities than is predicted from lipopolysaccharide structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-ENTERICA; POLYACRYLAMIDE GELS; ASSEMBLY SYSTEM; OLIGOSACCHARIDE; ENZYMES; LIPOOLIGOSACCHARIDE; ENTEROBACTERIACEAE; DIVERSITY; PORTION; GENES	The waaJ, waaT, and waaR genes encode alpha- 1,2-glycosyltransferases involved in synthesis of the outer core region of the lipopolysaccharide of Escherichia coli. They belong to the glycosyltransferase CAZy family 8, characterized by the GT-A fold, DXD motifs, and by retention of configuration at the anomeric carbon of the donor sugar. Each enzyme adds a hexose residue at the same stage of core oligosaccharide backbone extension. However, they differ in the epimers for their donor nucleotide sugars, and in their acceptor residues. WaaJ is a UDP-glucose: ( galactosyl) LPS alpha- 1,2-glucosyltransferase, whereas WaaR and WaaT have UDP-glucose:( glucosyl) LPS alpha- 1,2-glucosyltransferase and UDP-galactose:( glucosyl) LPS alpha- 1,2-galactosyltransferase activities, respectively. The objective of this work was to examine their ability to utilize alternate donors and acceptors. When expressed in the heterologous host, each enzyme was able to extend the alternate LPS acceptor in vivo but they retained their natural donor specificity. In vitro assays were then performed to test the effect of substituting the epimeric donor sugar on incorporation efficiency with the natural LPS acceptor of the enzyme. Although each enzyme could utilize the alternate donor epimer, activity was compromised because of significant decreases in k(cat) and corresponding increases in K-m( donor). Finally, in vitro assays were performed to probe acceptor preference in the absence of the cellular machinery. The results were enzyme-dependent: while an alternate acceptor had no significant effect on the kinetic behavior of His(6)-WaaT, His(6)-WaaJ showed a significantly decreased k(cat) and increased K-m( acceptor). These results illustrate the differences in behavior between closely related glycosyltransferase enzymes involved in the synthesis of similar glycoconjugates and have implications for glycoengineering applications.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca	Leipold, Michael/A-9452-2013	Leipold, Michael/0000-0001-5389-0906; Vinogradov, Evgeny/0000-0002-5364-1376				Aharoni A, 2006, NAT METHODS, V3, P609, DOI 10.1038/NMETH899; Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2004, J BIOL CHEM, V279, P31237, DOI 10.1074/jbc.M401879200; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; Leipold MD, 2007, J BIOL CHEM, V282, P1257, DOI 10.1074/jbc.M608164200; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SCHMIDT G, 1970, EUR J BIOCHEM, V14, P357, DOI 10.1111/j.1432-1033.1970.tb00297.x; Seeberger PH, 2005, NAT REV DRUG DISCOV, V4, P751, DOI 10.1038/nrd1823; Thibodeaux CJ, 2007, NATURE, V446, P1008, DOI 10.1038/nature05814; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WILSON DB, 1964, J BIOL CHEM, V239, P2469; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323	25	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26786	26792		10.1074/jbc.M704131200	http://dx.doi.org/10.1074/jbc.M704131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631498	hybrid			2022-12-27	WOS:000249304900018
J	Park, MJ; Kwak, HJ; Lee, HC; Yoo, DH; Park, IC; Kim, MS; Lee, SH; Rhee, CH; Hong, SI				Park, Myung-Jin; Kwak, Hee-Jin; Lee, Hyung-Chahn; Yoo, Doo-Hyun; Park, In-Chul; Kim, Mi-Suk; Lee, Seung-Hoon; Rhee, Chang Hun; Hong, Seok-Il			Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IN-VITRO ANGIOGENESIS; PHOSPHATASE GENE; PC12 CELLS; MIGRATION; PROLIFERATION; CANCER; AKT; IDENTIFICATION; NEUROTROPHINS	Nerve growth factor (NGF) is a well characterized neurotrophic agonist in the nervous system that triggers angiogenesis. In this study, we investigated the signaling mechanisms involved in NGF-induced angiogenesis. NGF stimulated endothelial cell invasion and cord formation on Matrigel in vitro but had marginal effect on proliferation and migration of these cells. NGF stimulated matrix metalloproteinase (MMP)-2 mRNA expression and protein secretion in human umbilical vein endothelial cells. Using synthetic and endogenous inhibitors of MMP-2 and MMP-2 small interfering RNA suppressed NGF-induced invasion and cord formation. We demonstrated that NGF-induced MMP-2 secretion, invasion, and cord formation are regulated via activation of the NGF receptor, TrkA, phosphatidylinositol 3-kinase (PI3K), and Akt using various pharmacological inhibitors. Specifically, NGF enhanced TrkA phosphorylation, PI3K activity, and Akt phosphorylation. Introduction of NGF-neutralizing antibodies, dominant-negative Akt, or wild-typePTEN effectively inhibited NGF-induced MMP-2 secretion and cord formation. Deletion and site-directed mutagenesis analysis of the MMP-2 promoter demonstrated that the AP-2-binding site is critical for NGF-induced MMP-2 promoter activity. NGF increased the DNA binding activity of AP-2, which was suppressed by inhibitors of TrkA and PI3K. Furthermore, transfection of AP-2 small interfering RNA effectively blocked NGF-induced MMP-2 secretion and cord formation. Finally, NGF promoted neovessel formation in Matrigel plugs in vivo, which was significantly inhibited by K252a and LY294002, but it failed to promote angiogenesis using MMP-2 knock-out mice. Our data collectively suggest that NGF stimulates endothelial cell invasion and cord formation by augmenting MMP-2 via the PI3K/Akt signaling pathway and AP-2 transcription factor, which may be responsible for triggering angiogenesis.	Korea Inst Radiol & Med Sci, Lab Funct Genom, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Dept Neurosurg, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Med & Clin Pathol, Seoul 139706, South Korea; Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; National Cancer Center - Korea (NCC)	Hong, SI (corresponding author), Korea Inst Radiol & Med Sci, Lab Funct Genom, 215-4 Gongneung Dong, Seoul 139706, South Korea.	hongsicp@kcch.re.kr						Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Choi YA, 2004, J BIOL CHEM, V279, P36579, DOI 10.1074/jbc.M314235200; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giuliani R, 1999, J CELL SCI, V112, P2597; Graiani G, 2004, DIABETOLOGIA, V47, P1047, DOI 10.1007/s00125-004-1414-7; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Guccione M, 2002, AM J PHYSIOL-RENAL, V282, pF164, DOI 10.1152/ajprenal.0318.2000; Haas TL, 2005, CAN J PHYSIOL PHARM, V83, P1, DOI 10.1139/Y04-120; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Inoue K, 2006, J BIOL CHEM, V281, P33814, DOI 10.1074/jbc.M607290200; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kumar R, 1998, INT J ONCOL, V12, P749; Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056; Lee OH, 2000, BRIT J CANCER, V82, P385; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Park MJ, 2002, CANCER RES, V62, P6318; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rahbek UL, 2005, PFLUG ARCH EUR J PHY, V450, P355, DOI 10.1007/s00424-005-1436-0; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risinger GM, 2006, J BIOL CHEM, V281, P25915, DOI 10.1074/jbc.M513513200; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Schonhoff CM, 2001, J NEUROCHEM, V78, P631, DOI 10.1046/j.1471-4159.2001.00432.x; Seo K, 2001, J Vet Sci, V2, P125; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Steinle JJ, 2003, AUTON NEUROSCI-BASIC, V108, P57, DOI 10.1016/S1566-0702(03)00151-6; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	46	83	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30485	30496		10.1074/jbc.M701081200	http://dx.doi.org/10.1074/jbc.M701081200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17666398	hybrid			2022-12-27	WOS:000250136300016
J	Yao, Y; Nowak, S; Yochelis, A; Garfinkel, A; Bostroem, KI				Yao, Yucheng; Nowak, Sarah; Yochelis, Arik; Garfinkel, Alan; Bostroem, Kristina I.			Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BRANCHING MORPHOGENESIS; GENE-EXPRESSION; LUNG MORPHOGENESIS; ENDOTHELIAL-CELLS; MESENCHYMAL CELLS; PATTERN-FORMATION; EPITHELIAL-CELLS; KEUTEL-SYNDROME; MOUSE LUNG	Deficiency of matrix GLA protein (MGP), an inhibitor of bone morphogenetic protein (BMP)-2/4, is known to cause arterial calcification and peripheral pulmonary artery stenosis. Yet the vascular role of MGP remains poorly understood. To further investigate MGP, we created a new MGP transgenic mouse model with high expression of the transgene in the lungs. The excess MGP led to a disruption of the pulmonary pattern of BMP-4, and resulted in significant morphological defects in the pulmonary artery tree. Specifically, the vascular branching pattern lacked characteristic side branching, whereas control lungs had extensive side branching accounting for as much as 40% of the vascular endothelium. The vascular changes could be explained by a dramatic reduction of phosphorylated SMAD1/5/8 in the alveolar epithelium, and in epithelial expression of the activin-like kinase receptor 1 and vascular endothelial growth factor, both critical in vascular formation. Abnormalities were also found in the terminal airways and in lung cell differentiation; high levels of surfactant protein-B were distributed in an abnormal pattern suggesting lost coordination between vasculature and airways. Ex vivo, lung cells from MGP transgenic mice showed higher proliferation, in particular surfactant protein B-expressing cells, and conditioned medium from these cells poorly supported in vitro angiogenesis compared with normal lung cells. The vascular branching defect can be mechanistically explained by a computational model based on activator/inhibitor reaction-diffusion dynamics, where BMP-4 and MGP are considered as an activating and inhibitory morphogen, respectively, suggesting that morphogen interactions are important for vascular branching.	Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Bostroem, KI (corresponding author), Box 951679, Los Angeles, CA 90095 USA.	kbostrom@mednet.ucla.edu	Yochelis, Arik/AAF-8523-2019; Yochelis, Arik/C-6782-2013	Yochelis, Arik/0000-0002-1516-0766; Yochelis, Arik/0000-0002-1516-0766	NHLBI NIH HHS [HL78931, HL30568, HL81397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078931, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acarregui MJ, 1999, AM J RESP CELL MOL, V20, P14, DOI 10.1165/ajrcmb.20.1.3251; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Bragg AD, 2001, MECH DEVELOP, V109, P13, DOI 10.1016/S0925-4773(01)00508-1; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Del Moral PM, 2006, DEV BIOL, V290, P177, DOI 10.1016/j.ydbio.2005.11.022; Dobens LL, 2000, DEVELOPMENT, V127, P745; Eblaghie MC, 2006, DEV BIOL, V291, P67, DOI 10.1016/j.ydbio.2005.12.006; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Fan CW, 2001, CANCER LETT, V165, P63, DOI 10.1016/S0304-3835(01)00416-5; Frank DB, 2005, CIRC RES, V97, P496, DOI 10.1161/01.RES.0000181152.65534.07; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; Furthauer M, 2004, DEVELOPMENT, V131, P2853, DOI 10.1242/dev.01156; Garfinkel A, 2004, P NATL ACAD SCI USA, V101, P9247, DOI 10.1073/pnas.0308436101; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gilbert KA, 2004, AM J PHYSIOL-LUNG C, V286, pL1179, DOI 10.1152/ajplung.00188.2003; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Harris MP, 2005, P NATL ACAD SCI USA, V102, P11734, DOI 10.1073/pnas.0500781102; Hossler FE, 2001, MICROSC MICROANAL, V7, P253, DOI 10.1017/S1431927601010261; Hur DJ, 2005, AM J MED GENET A, V135A, P36, DOI 10.1002/ajmg.a.30680; Jiang TX, 1999, DEVELOPMENT, V126, P4997; KONDO S, 1995, NATURE, V376, P765, DOI 10.1038/376765a0; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Maini PK, 2006, SCIENCE, V314, P1397, DOI 10.1126/science.1136396; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; Marshall Vikki M, 2004, Methods Mol Biol, V256, P159; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Murray James D., 2002, MATH BIOL SPATIAL MO, V2; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Painter KJ, 1999, P NATL ACAD SCI USA, V96, P5549, DOI 10.1073/pnas.96.10.5549; Panchenko MP, 1996, AM J PHYSIOL-LUNG C, V270, pL547, DOI 10.1152/ajplung.1996.270.4.L547; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Parmar H, 2006, PEDIATR RADIOL, V36, P241, DOI 10.1007/s00247-005-0036-7; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Schachtner SK, 2000, AM J RESP CELL MOL, V22, P157, DOI 10.1165/ajrcmb.22.2.3766; Shin V, 2004, J VASC RES, V41, P193, DOI 10.1159/000077394; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vincent S, 2001, NATURE, V411, P533, DOI 10.1038/35079214; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; Weaver M, 2000, DEVELOPMENT, V127, P2695; Yao YC, 2007, CARDIOVASC RES, V74, P279, DOI 10.1016/j.cardiores.2006.09.014; Yao YC, 2006, J BIOL CHEM, V281, P33921, DOI 10.1074/jbc.M604239200; Yelon D, 2002, CURR BIOL, V12, pR707, DOI 10.1016/S0960-9822(02)01213-7; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1997, AM J PHYSIOL-LUNG C, V273, pL282, DOI 10.1152/ajplung.1997.273.1.L282; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	58	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30131	30142		10.1074/jbc.M704297200	http://dx.doi.org/10.1074/jbc.M704297200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17670744	hybrid			2022-12-27	WOS:000249981200043
J	Hamdan, FF; Rochdi, MD; Breton, B; Fessart, D; Michaud, DE; Charest, PG; Laporte, SA; Bouvier, M				Hamdan, Fadi F.; Rochdi, Moulay Driss; Breton, Billy; Fessart, Delphine; Michaud, Douce E.; Charest, Pascale G.; Laporte, Stephane A.; Bouvier, Michel			Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between beta-arrestins and AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; CLATHRIN-INDEPENDENT ENDOCYTOSIS; N-FORMYL PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; INDUCED INTERNALIZATION; VASOPRESSIN RECEPTORS; HUMAN ENDOTHELIN; VISUAL ARRESTIN; TYPE-1 RECEPTOR; C5A RECEPTOR	The most widely studied pathway underlying agonist-promoted internalization of G protein-coupled receptors (GPCRs) involves beta-arrestin and clathrin-coated pits. However, both beta-arrestin- and clathrin-independent processes have also been reported. Classically, the endocytic routes are characterized using pharmacological inhibitors and various dominant negative mutants, resulting sometimes in conflicting results and interpretational difficulties. Here, taking advantage of the fact that beta-arrestin binding to the beta 2 subunit of the clathrin adaptor AP-2 (beta 2-adaptin) is needed for the beta-arrestin-mediated targeting of GPCRs to clathrin-coated pits, we developed a bioluminescence resonance energy transfer-based approach directly assessing the molecular steps involved in the endocytosis of GPCRs in living cells. For 10 of the 12 receptors tested, including some that were previously suggested to internalize via clathrinin-dependent pathways, agonist stimulation promoted beta-arrestin 1 and 2 interaction with beta 2-adaptin, indicating a beta-arrestin- and clathrin-dependent endocytic process. Detailed analyses of beta-arrestin interactions with both the receptor and beta 2-adaptin also allowed us to demonstrate that recruitment of beta-arrestins to the receptor and the ensuing conformational changes are the leading events preceding AP-2 engagement and subsequent clathrin-mediated endocytosis. Among the receptors tested, only the endothelin A and B receptors failed to promote interaction between beta-arrestins and beta 2-adaptin. However, both receptors recruited beta-arrestins upon agonist stimulation, suggesting a beta-arrestin-dependent but clathrin-independent route of internalization for these two receptors. In addition to providing a new tool to dissect the molecular events involved in GPCR endocytosis, the bioluminescence resonance energy transfer-based beta-arrestin/beta 2-adaptin interaction assay represents a novel biosensor to assess receptor activation.	Univ Montreal, Inst Res Immunol & Canc, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Res Immunol & Canc, Grp Rech Univ Medicament, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	Universite de Montreal; Universite de Montreal; McGill University	Bouvier, M (corresponding author), Univ Montreal, St Justine Hosp, Res Ctr, Dept Genet, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014; Laporte, Stephane A/F-3282-2012; FESSART, Delphine/J-2784-2014; Laporte, Stephane/ABC-4228-2021	Bouvier, Michel/0000-0003-1128-0100; FESSART, Delphine/0000-0001-7566-5670; Laporte, Stephane/0000-0002-0633-543X				Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Benmerah A, 1999, J CELL SCI, V112, P1303; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Charest PG, 2007, CELL SIGNAL, V19, P32, DOI 10.1016/j.cellsig.2006.05.020; Charest PG, 2005, EMBO REP, V6, P334, DOI 10.1038/sj.embor.7400373; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Droese J, 2004, BIOCHEM BIOPH RES CO, V322, P42, DOI 10.1016/j.bbrc.2004.07.076; Edeling MA, 2006, DEV CELL, V10, P329, DOI 10.1016/j.devcel.2006.01.016; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fessart D, 2007, J CELL SCI, V120, P1723, DOI 10.1242/jcs.03444; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hamdan FF, 2005, J BIOMOL SCREEN, V10, P463, DOI 10.1177/1087057105275344; HAMDAN FF, 2006, CURR PROT NEUROSCI; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Neuschafer-Rube F, 2004, BIOCHEM J, V379, P573, DOI 10.1042/BJ20031820; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orem NR, 2006, J CELL SCI, V119, P3141, DOI 10.1242/jcs.03052; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; PFLEGER KD, 2004, BIOCHEM J, V85, P625; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Prossnitz ER, 2004, LIFE SCI, V75, P893, DOI 10.1016/j.lfs.2004.04.003; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Roseberry AG, 2001, J CELL SCI, V114, P739; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Shetzline MA, 2002, J BIOL CHEM, V277, P25519, DOI 10.1074/jbc.M201815200; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Simaan M, 2005, CELL SIGNAL, V17, P1074, DOI 10.1016/j.cellsig.2004.12.001; Suvorova ES, 2005, TRAFFIC, V6, P100, DOI 10.1111/j.1600-0854.2004.00256.x; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WILLIAMS DL, 1993, LIFE SCI, V53, P407, DOI 10.1016/0024-3205(93)90644-I; Zapata-Hommer O, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-5; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	72	61	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29089	29100		10.1074/jbc.M700577200	http://dx.doi.org/10.1074/jbc.M700577200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675294	hybrid			2022-12-27	WOS:000249788000004
J	Tocilescu, MA; Fendel, U; Zwicker, K; Kerscher, S; Brandt, U				Tocilescu, Maja A.; Fendel, Uta; Zwicker, Klaus; Kerscher, Stefan; Brandt, Ulrich			Exploring the ubiquinone binding cavity of respiratory complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-QUINONE OXIDOREDUCTASE; SULFUR CLUSTER N2; 49-KDA SUBUNIT; 3-DIMENSIONAL STRUCTURE; YARROWIA-LIPOLYTICA; MITOCHONDRIAL NADH; CATALYTIC CORE; RESIDUES; DOMAIN	Proton pumping respiratory complex I is a major player in mitochondrial energy conversion. Yet little is known about the molecular mechanism of this large membrane protein complex. Understanding the details of ubiquinone reduction will be prerequisite for elucidating this mechanism. Based on a recently published partial structure of the bacterial enzyme, we scanned the proposed ubiquinone binding cavity of complex I by site-directed mutagenesis in the strictly aerobic yeast Yarrowia lipolytica. The observed changes in catalytic activity and inhibitor sensitivity followed a consistent pattern and allowed us to define three functionally important regions near the ubiquinone-reducing iron-sulfur cluster N2. We identified a likely entry path for the substrate ubiquinone and defined a region involved in inhibitor binding within the cavity. Finally, we were able to highlight a functionally critical structural motif in the active site that consisted of Tyr-144 in the 49-kDa subunit, surrounded by three conserved hydrophobic residues.	Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, Fachbereich Med, Ctr Excellence Frankfurt Macromol Complexes, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Brandt, U (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem Mol Bioenerget, Fachbereich Med, Ctr Excellence Frankfurt Macromol Complexes, Theodor Stern Kai 7,Haus 26, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539; Chen DC, 1997, APPL MICROBIOL BIOT, V48, P232, DOI 10.1007/s002530051043; CLASON T, 2007, IN PRESS J STRUCT BI; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kerscher S, 2005, RSC BIOMOLEC SCI, P156; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Prieur I, 2001, BBA-BIOENERGETICS, V1504, P173, DOI 10.1016/S0005-2728(01)00158-X; Radermacher M, 2006, J STRUCT BIOL, V154, P269, DOI 10.1016/j.jsb.2006.02.011; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Wittig I, 2007, MOL CELL PROTEOMICS, V6, P1215, DOI 10.1074/mcp.M700076-MCP200; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200; Zwicker K, 2006, J BIOL CHEM, V281, P23013, DOI 10.1074/jbc.M603442200	32	84	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29514	29520		10.1074/jbc.M704519200	http://dx.doi.org/10.1074/jbc.M704519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681940	hybrid			2022-12-27	WOS:000249788000048
J	Trouw, LA; Bengtsson, AA; Gelderman, KA; Dahlback, B; Sturfelt, G; Blom, AM				Trouw, Leendert A.; Bengtsson, Anders A.; Gelderman, Kyra A.; Dahlback, Bjorn; Sturfelt, Gunnar; Blom, Anna M.			C4b-binding protein and factor h compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; C-REACTIVE PROTEIN; BINDING LECTIN ENGAGEMENT; NECROTIC CELLS; ACTIVATES COMPLEMENT; IMPAIRED UPTAKE; RESIDUES 14-26; PLASMA-LEVELS; ALPHA-CHAIN; HUMAN C1Q	Apoptotic cells have been reported to down- regulate membrane-bound complement regulatory proteins ( m- C- Reg) and to activate complement. Nonetheless, most apoptotic cells do not undergo complement- mediated lysis. Therefore, we hypothesized that fluid phase complement inhibitors would bind to apoptotic cells and compensate functionally for the loss of m- C- Reg. We observed that m- C- Reg are down- regulated rapidly upon apoptosis but that complement activation follows only after a gap of several hours. Coinciding with, but independent from, complement activation, fluid phase complement inhibitors C4b- binding protein ( C4BP) and factorH( fH) bind to the cells. C4BP and fH do not entirely prevent complement activation but strongly limit C3 and C9 deposition. Late apoptotic cells, present in blood of healthy controls and systemic lupus erythematosus patients, are also positive for C4BP and fH. Upon culture, the percentage of late apoptotic cells increases, paralleled by increased C4BP binding. C4BP binds to dead cells mainly via phosphatidylserine, whereas fH binds via multiple interactions with CRP playing no major role for binding of C4BP or fH. In conclusion, during late apoptosis, cells acquire fluid phase complement inhibitors that compensate for the downregulation of m- C- Reg and protect against excessive complement activation and lysis.	Malmo Univ Hosp, Dept Lab Med, S-20502 Malmo, Sweden; Lund Univ, Dept Clin Sci Rheumatol, S-22184 Lund, Sweden; Lund Univ, Unit Med Inflammat Res, S-22184 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Lund University	Blom, AM (corresponding author), Lund Univ, Dept Lab Med, Wallenberg Lab, MAS Entrance 46,Floor 4, S-20502 Malmo, Sweden.	Anna.Blom@med.lu.se	Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Trouw, Leendert/AGK-5202-2022	Blom, Anna/0000-0002-1348-1734; Trouw, Leendert/0000-0001-5186-2290; Gelderman, Kyra/0000-0002-7815-032X; Dahlback, Bjorn/0000-0003-1546-0328				Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Bengtsson AA, 2004, CLIN EXP IMMUNOL, V135, P535, DOI 10.1111/j.1365-2249.2003.02386.x; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Carroll MC, 2004, NAT REV IMMUNOL, V4, P825, DOI 10.1038/nri1456; Ciurana CLF, 2004, EUR J IMMUNOL, V34, P2609, DOI 10.1002/eji.200425045; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; DE FRUTOS PG, 1994, BLOOD, V84, P815; Denny MF, 2006, J IMMUNOL, V176, P2095, DOI 10.4049/jimmunol.176.4.2095; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Gaipl US, 2006, CURR DIRECT AUTOIMMU, V9, P173; Gaipl Udo S, 2004, Curr Rheumatol Rep, V6, P401, DOI 10.1007/s11926-004-0016-1; Gaipl US, 2001, CELL DEATH DIFFER, V8, P327, DOI 10.1038/sj.cdd.4400826; Gardai SJ, 2006, J LEUKOCYTE BIOL, V79, P896, DOI 10.1189/jlb.1005550; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gladman DD, 2002, J RHEUMATOL, V29, P288; Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Hart Simon P, 2005, J Inflamm (Lond), V2, P5, DOI 10.1186/1476-9255-2-5; Jarva H, 1999, J IMMUNOL, V163, P3957; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Jones J, 1995, IMMUNOLOGY, V86, P651; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Leers MPG, 2002, CELL MOL LIFE SCI, V59, P1358, DOI 10.1007/s00018-002-8513-8; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; MARCOVINA SM, 1991, INT J CLIN LAB RES, V21, P171; Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7; Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sheriff A, 2004, RHEUM DIS CLIN N AM, V30, P505, DOI 10.1016/j.rdc.2004.04.006; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; Tas SW, 2006, ANN RHEUM DIS, V65, P216, DOI 10.1136/ard.2005.037143; TENNER AJ, 1981, J IMMUNOL, V127, P648; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Walport MJ, 2002, ARTHRITIS RES THER, V4, pS279, DOI 10.1186/ar586; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Webb JH, 2003, BLOOD COAGUL FIBRIN, V14, P355, DOI 10.1097/00001721-200306000-00006; Webb JH, 2002, J IMMUNOL, V169, P2580, DOI 10.4049/jimmunol.169.5.2580; WILCOX LA, 1991, BLOOD, V78, P820, DOI 10.1182/blood.V78.3.820.bloodjournal783820; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144; Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015; Zwart B, 2004, AUTOIMMUNITY, V37, P95, DOI 10.1080/0891693042000196183	56	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28540	28548		10.1074/jbc.M704354200	http://dx.doi.org/10.1074/jbc.M704354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17699521	hybrid			2022-12-27	WOS:000249642100028
J	Tubb, MR; Silva, RAGD; Pearson, KJ; Tso, P; Liu, M; Davidson, WS				Tubb, Matthew R.; Silva, R. A. Gangani D.; Pearson, Kevin J.; Tso, Patrick; Liu, Min; Davidson, W. Sean			Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CORONARY-ARTERY-DISEASE; EXCHANGEABLE APOLIPOPROTEINS; CIRCULAR-DICHROISM; SLIDING CLAMP; APOA-IV; PLASMA; MICE; POLYMORPHISM; POLYMERASE	Apolipoprotein A-IV (apoA-IV) is a 376-amino acid exchangeable apolipoprotein made in the small intestine of humans. Although it has many proposed roles in vascular disease, satiety, and chylomicron metabolism, there is no known structural basis for these functions. The ability to associate with lipids may be a key step in apoA-IV functionality. We recently identified a single amino acid, Phe(334), which seems to inhibit the lipid binding capability of apoA-IV. We also found that an intact N terminus was necessary for increased lipid binding of Phe334 mutants. Here, we identify Trp(12) and Phe(15) as the N-terminal amino acids required for the fast lipid binding seen with the F334A mutant. Furthermore, we found that individual disruption of putative amphipathic alpha-helices 3-11 had little effect on lipid binding, suggesting that the N terminus of apoA-IV may be the operational site for initial lipid binding. We also provide three independent pieces of experimental evidence supporting a direct intramolecular interaction between sequences near amino acids 12/15 and 334. This interaction could represent a unique "switch" mechanism by which apoA-IV changes lipid avidity in vivo.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; NIA, Lab Exp Gerontol, NIH, Baltimore, MD 21224 USA	University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989; Tubb, Matthew/0000-0002-4543-2742	NHLBI NIH HHS [HL67093, HL82734] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082734, R01HL067093] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Bhattacharyya R, 2004, PROTEIN ENG DES SEL, V17, P795, DOI 10.1093/protein/gzh093; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Davidson WS, 2006, J LIPID RES, V47, P440, DOI 10.1194/jlr.D500034-JLR200; DIEPLINGER H, 1992, EUR J CLIN INVEST, V22, P166, DOI 10.1111/j.1365-2362.1992.tb01822.x; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Ezeh B, 2003, J LIPID RES, V44, P1523, DOI 10.1194/jlr.M300060-JLR200; Gallagher JW, 2004, J LIPID RES, V45, P1826, DOI 10.1194/jlr.M400188-JLR200; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; KALOGERIS TJ, 1997, J NUTR S, V127, P537; Kronenberg F, 2000, J AM COLL CARDIOL, V36, P751, DOI 10.1016/S0735-1097(00)00775-0; Kronenberg F, 2002, J AM SOC NEPHROL, V13, P461, DOI 10.1681/ASN.V132461; LAGROST L, 1989, J LIPID RES, V30, P1525; LOHSE P, 1991, J BIOL CHEM, V266, P13513; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lu S, 2006, J BIOL CHEM, V281, P3473, DOI 10.1074/jbc.M502501200; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Ostos MA, 2000, ATHEROSCLEROSIS, V153, P209, DOI 10.1016/S0021-9150(00)00400-7; Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; Silva RAGD, 2007, J BIOL CHEM, V282, P9713, DOI 10.1074/jbc.M610380200; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Tanaka M, 2006, BIOCHEMISTRY-US, V45, P10351, DOI 10.1021/bi060726t; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Warner MM, 2001, CHINESE MED J-PEKING, V114, P275; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinstock PH, 1997, J LIPID RES, V38, P1782; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	39	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28385	28394		10.1074/jbc.M704070200	http://dx.doi.org/10.1074/jbc.M704070200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686771	hybrid			2022-12-27	WOS:000249642100013
J	Battle, DJ; Kasim, M; Wang, J; Dreyfuss, G				Battle, Daniel J.; Kasim, Mumtaz; Wang, Jin; Dreyfuss, Gideon			SMN-independent subunits of the SMN complex - Identification of a small nuclear ribonucleoprotein assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DEAD-BOX PROTEIN; MOTOR-NEURON COMPLEX; STRESS GRANULES; GENE-PRODUCT; SURVIVAL; COMPONENT; DP103; RNA; TRANSLATION	The survival of motor neurons (SMN) complex is essential for the biogenesis of small nuclear ribonucleoprotein (snRNP) complexes in eukaryotic cells. Reduced levels of SMN cause the motor neutron degenerative disease, spinal muscular atrophy. We identify here stable subunits of the SMN complex that do not contain SMN. Sedimentation and immunoprecipitation experiments using cell extracts reveal at least three complexes composed of Gemin3, -4, and -5; Gemin6, -7, and unrip; and SMN with Gemin2, as well as free Gemin5. Complexes containing Gemin3-Gemin4-Gemin5 and Gemin6-Gemin7-unrip persist at similar levels when SMN is reduced. In cells, immunofluorescence microscopy shows differential localization of Gemin5 after cell stress. We further show that the Gemin5-containing subunits bind small nuclear RNA independently of the SMN complex and without a requirement for exogenous ATP. ATP hydrolysis is, however, required for displacement of small nuclear RNAs from the Gemin5-containing subunits and their assembly into snRNPs. These findings demonstrate a modular nature of the SMN complex and identify a new intermediate in the snRNP assembly process.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Dreyfuss, G (corresponding author), 415 Curie Blvd,328 CRB, Philadelphia, PA 19147 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Carissimi C, 2006, J BIOL CHEM, V281, P37009, DOI 10.1074/jbc.M607505200; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Fierro-Monti I, 2006, J PROTEOME RES, V5, P1367, DOI 10.1021/pr0504539; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Hua YM, 2004, FEBS LETT, V572, P69, DOI 10.1016/j.febslet.2004.07.010; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Otter S, 2007, J BIOL CHEM, V282, P5825, DOI 10.1074/jbc.M608528200; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; Voss MD, 2001, J VIROL, V75, P11781, DOI 10.1128/JVI.75.23.11781-11790.2001; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Xu PL, 2003, ACTA BIOCH BIOPH SIN, V35, P909; Yong J, 2004, MOL CELL BIOL, V24, P2747, DOI 10.1128/MCB.24.7.2747-2756.2004; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188	46	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27953	27959		10.1074/jbc.M702317200	http://dx.doi.org/10.1074/jbc.M702317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640873	hybrid			2022-12-27	WOS:000249455600044
J	Dam, TK; Gerken, TA; Cavada, BS; Nascimento, KS; Moura, TR; Brewer, CF				Dam, Tarun K.; Gerken, Thomas A.; Cavada, Benildo S.; Nascimento, Kyria S.; Moura, Tales R.; Brewer, C. Fred			Binding studies of alpha-GaINAc-specific lectins to the alpha-GaINAc (Tn-antigen) form of porcine submaxillary mucin and its smaller fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC ANALYSIS; CANCER; OLIGOSACCHARIDES; GLYCOSYLATION; PURIFICATION; ASIALOFETUIN; CONSTANTS; RESPONSES; SEQUENCE; RESIDUES	Isothermal titration microcalorimetry (ITC) and hemagglutination inhibition measurements demonstrate that a chemically and enzymatically prepared form of porcine submaxillary mucin that possesses a molecular mass of similar to 10(6) daltons and similar to 2300 alpha-GalNAc residues (Tn-PSM) binds to the soybean agglutinin (SBA) with a K-d of 0.2 nM, which is similar to 10(6) -fold enhanced affinity relative to GalNAc alpha 1-O-Ser (Tn), the pancarcinoma carbohydrate antigen. The enzymatically derived 81 amino acid tandem repeat domain of Tn-PSM containing similar to 23 alpha-GalNAc residues binds with similar to 10(3) -fold enhanced affinity, while the enzymatically derived 38/40 amino acid cleavage product(s) of Tn-PSM containing similar to 11-12 alpha-GaINAc residues shows similar to 10(2) -fold enhanced affinity. A natural carbohydrate decorated form of PSM (Fd-PSM) containing 40% of the core 1 blood group type A tetrasaccharide, and 58% peptide-linked GalNAc alpha 1-O-Ser/Thr residues, with 45% of the peptide-linked a-GaINAc residues linked alpha-(2,6) to N-glycolylneuraminic acid, shows similar to 10(4) enhanced affinity for SBA. Vatairea macrocarpa lectin (VML), which is also a GalNAc binding lectin, displays a similar pattern of binding to the four forms of PSM, although there are quantitative differences in its affinities as compared with SBA. The higher affinities of SBA and VML for Tn-PSM relative to Fd-PSM indicate the importance of carbohydrate composition and epitope density of mucins on their affinities for lectins. The higher affinities of SBA and VML for Tn-PSM relative to its two shorter chain analogs demonstrate that the length of a mucin polypeptide and hence total carbohydrate valence determines the affinities of the three Tn-PSM analogs. The results suggest a binding model in which lectin molecules "bind and jump" from alpha-GaINAc residue to alpha-GalNAc residue along the polypeptide chain of Tn-PSM before dissociating. The complete thermodynamic binding parameters for these mucins including their binding stoichiometries are presented. The results have important implications for the biological activities of mucins including those expressing the Tn cancer antigen.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Univ Fed Ceara, Dept Bioquim Biol Mol, Fortaleza, Ceara, Brazil; Case Western Reserve Univ, WA Bernbaum Ctr Cyst Fibrosis Res, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Federal do Ceara; Case Western Reserve University; Case Western Reserve University	Brewer, CF (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.	brewer@aecom.yu.edu	Cavada, Benildo/CEA-4997-2022	Cavada, Benildo/0000-0002-5791-6170; Rocha de Moura, Tales/0000-0001-5492-8419	NATIONAL CANCER INSTITUTE [R01CA016054, R01CA078834, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078834, CA-16054, CA-78834, P30 CA-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Calvete JJ, 1998, FEBS LETT, V425, P286, DOI 10.1016/S0014-5793(98)00243-9; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Cavada BS, 1998, PHYTOCHEMISTRY, V49, P675, DOI 10.1016/S0031-9422(98)00144-7; Dam TK, 2005, BIOCHEMISTRY-US, V44, P12564, DOI 10.1021/bi051144z; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Dam TK, 2002, BIOCHEMISTRY-US, V41, P1351, DOI 10.1021/bi015830j; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Gestwicki JE, 2002, CHEM BIOL, V9, P163, DOI 10.1016/S1074-5521(02)00102-3; Goldstein I.J., 1986, LECTINS; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P8465, DOI 10.1021/bi00151a012; Osawa TMI, 1972, METHODS ENZYMOL B, V28, P323; Pace KE, 1999, J IMMUNOL, V163, P3801; Ramos MV, 1999, PROTEIN PEPTIDE LETT, V6, P163; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5526; SINGHAL A, 1991, CANCER RES, V51, P1406; Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; von Hippel PH, 2007, ANNU REV BIOPH BIOM, V36, P79, DOI 10.1146/annurev.biophys.34.040204.144521; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu AM, 2004, BIOCHIMIE, V86, P317, DOI 10.1016/j.biochi.2004.03.007; Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200	35	73	73	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28256	28263		10.1074/jbc.M704677200	http://dx.doi.org/10.1074/jbc.M704677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652089	hybrid			2022-12-27	WOS:000249455600075
J	Kuhn, JR; Pollard, TD				Kuhn, Jeffrey R.; Pollard, Thomas D.			Single molecule kinetic analysis of actin filament capping - Polyphosphoinositides do not dissociate capping proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; ARP2/3 COMPLEX; BARBED-END; FISSION YEAST; ADP-ACTIN; ENA/VASP PROTEINS; STRUCTURAL BASIS; POLYMERIZATION; LOCALIZATION; MYOSIN	We investigated how heterodimeric capping proteins bind to and dissociate from the barbed ends of actin filaments by observing single muscle actin filaments by total internal reflection fluorescence microscopy. The barbed end rate constants for mouse capping protein (CP) association of 2.6 x 10(6) M-1 s(-1) and dissociation of 0.0003 s(-1) agree with published values measured in bulk assays. The polyphosphoinositides (PPIs), phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-2), PI(4,5)P-2, and PI(3,4,5)P-3, prevent CP from binding to barbed ends, but three different assays showed that none of these lipids dissociate CP from filaments at concentrations that block CP binding to barbed ends. The affinity of fission yeast CP for barbed ends is a thousandfold less than mouse CP, because of a slower association rate constant (1.1 x 10(5) M-1 s(-1)) and a faster dissociation rate constant (0.004 s(-1)). PPIs do not inhibit binding of fission yeast CP to filament ends. Comparison of homology models revealed that fission yeast CP lacks a large patch of basic residues along the actin-binding surface on mouse CP. PPIs binding to this site might interfere sterically with capping, but this site would be inaccessible when CP is bound to the end of a filament.	Yale Univ, MCDB, KBT548, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University	Pollard, TD (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA.	thomas.pollard@yale.edu			NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; BAUM LE, 1970, ANN MATH STAT, V41, P164, DOI 10.1214/aoms/1177697196; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; HARRIS HE, 1984, FEBS LETT, V177, P184, DOI 10.1016/0014-5793(84)81280-6; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; Kim K, 2007, J BIOL CHEM, V282, P5871, DOI 10.1074/jbc.M609850200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; Maly IV, 2001, P NATL ACAD SCI USA, V98, P11324, DOI 10.1073/pnas.181338798; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Narita A, 2006, EMBO J, V25, P5626, DOI 10.1038/sj.emboj.7601395; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Qin F, 2004, BIOPHYS J, V86, P1488, DOI 10.1016/S0006-3495(04)74217-4; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Sabanayagam CR, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e33; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sirotkin V, 2005, J CELL BIOL, V170, P637, DOI 10.1083/jcb.200502053; Smith J, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-30; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Uruno T, 2006, J BIOL CHEM, V281, P10635, DOI 10.1074/jbc.M513186200; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167	43	63	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28014	28024		10.1074/jbc.M705287200	http://dx.doi.org/10.1074/jbc.M705287200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656356	hybrid			2022-12-27	WOS:000249455600051
J	Moretti, FA; Chauhan, AK; Iaconcig, A; Porro, F; Baralle, FE; Muro, AF				Moretti, Federico A.; Chauhan, Anil K.; Iaconcig, Alessandra; Porro, Fabiola; Baralle, Francisco E.; Muro, Andres F.			A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INJURED ARTERIOLES; THROMBUS GROWTH; MESSENGER-RNA; SECRETION; EXPRESSION; SUBSTRATE; PROTEINS; BINDING; REGION; CELLS	The origin of the fibronectin (FN) found in the extracellular matrix of tissues has not been defined experimentally. Previous studies suggest that there is contribution from both local tissue production and transfer from plasma, but the extent of this phenomenon has not been addressed. We have shown before that engineered mice constitutively expressing extra domain A-containing FN (EDA(+)FN) have a significant decrease of FN levels in plasma and most tissues. We showed that hepatocytes modified to produce EDA(+)FN have normal extracellular matrix-FN levels but secrete less soluble FN. When we performed a liver-specific EDiA-exon deletion in these animals, FN levels were restored both in plasma and tissues. Therefore, an important fraction of tissue FN, approximately an equal amount of that produced by the tissue itself, is actually plasma-derived, suggesting that plasma is an important source of tissue FN. The present results halve potential significance for understanding the contributions of plasma FN, and perhaps other plasma proteins, in the modulation of cellular activities and in the formation of the extracellular matrix of tissues.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Muro, AF (corresponding author), Harvard Univ, Harvard Med Sch, CBR Inst Biomed Res, Dept Pathol, Boston, MA 02115 USA.	muro@icgeb.org	Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494; Moretti, Federico Andrea/0000-0003-3187-3683; Chauhan, Anil/0000-0001-8554-0898				Bae E, 2004, J BIOL CHEM, V279, P35749, DOI 10.1074/jbc.M406283200; Chauhan AK, 2004, GENE, V324, P55, DOI 10.1016/j.gene.2003.09.026; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; Hynes RO, 1990, FIBRONECTINS; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; KOWALCZYK AP, 1990, BLOOD, V75, P2335; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Matuskova J, 2006, ARTERIOSCL THROM VAS, V26, P1391, DOI 10.1161/01.ATV.0000216282.58291.c6; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Ni HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI 10.1073/pnas.2628067100; Nyberg P, 2004, EMBO J, V23, P2166, DOI 10.1038/sj.emboj.7600214; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; OWENS MR, 1982, BLOOD, V59, P1305; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PRICE J, 1985, J NEUROSCI, V5, P2205; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sottile J, 1998, J CELL SCI, V111, P2933; TAMKUN JW, 1983, J BIOL CHEM, V258, P4641; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; WANG A, 1991, J BIOL CHEM, V266, P15598; Yang ZS, 2006, J NEUROSCI, V26, P3829, DOI 10.1523/JNEUROSCI.4247-05.2006; Yi M, 2003, P NATL ACAD SCI USA, V100, P11435, DOI 10.1073/pnas.1635112100	33	89	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28057	28062		10.1074/jbc.M611315200	http://dx.doi.org/10.1074/jbc.M611315200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644525	hybrid, Green Published			2022-12-27	WOS:000249455600055
J	Niwa, J; Yamada, S; Ishigaki, S; Sone, J; Takahashi, M; Katsuno, M; Tanaka, F; Doyu, M; Sobue, G				Niwa, Jun-ichi; Yamada, Shin-ichi; Ishigaki, Shinsuke; Sone, Jun; Takahashi, Miho; Katsuno, Masahisa; Tanaka, Fumiaki; Doyu, Manabu; Sobue, Gen			Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEATH; CU,ZN-SUPEROXIDE DISMUTASE; DISEASE PROGRESSION; TRANSGENIC MICE; MOUSE MODEL; PROTEIN; SUPEROXIDE-DISMUTASE-1; PROTEASOME	Mutations in the Cu/Zn-superoxide dismutase (SOD1) gene cause familial amyotrophic lateral sclerosis (ALS) through the gain of a toxic function; however, the nature of this toxic function remains largely unknown. Ubiquitylated aggregates of mutant SOD 1 proteins in affected brain lesions are pathological hallmarks of the disease and are suggested to be involved in several proposed mechanisms of motor neuron death. Recent studies suggest that mutant SODI readily forms an incorrect disulfide bond upon mild oxidative stress in vitro, and the insoluble SOD 1 aggregates in spinal cord of ALS model mice contain multimers cross-linked via intermolecular disulfide bonds. Here we show that a non-physiological intermolecular disulfide bond between cysteines at positions 6 and 111 of mutant SOD 1 is important for high molecular weight aggregate formation, ubliquitylation, and neurotoxicity, all of which were dramatically reduced when the pertinent cysteines were replaced in mutant SOD 1 expressed in Neuro-2a cells. Dorfin is a ubiquityl ligase that specifically binds familial ALS-linked mutant SOD 1 and ubiquitylates it, thereby promoting its degradation. We found that Dorfin ubiquitylated mutant SOD1 by recognizing the CYS6- and Cys(111)-disulfide cross-linked form and targeted it for proteasomal degradation.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 466, Japan; Aichi Med Univ, Ctr Stroke, Aichi 480, Japan	Nagoya University; Aichi Medical University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 466, Japan.	sobueg@med.nagoya-u.ac.jp	ISHIGAKI, Shinsuke/I-7305-2014; KATSUNO, MASAHISA/I-7502-2014; Sone, Jun/M-5027-2014	KATSUNO, MASAHISA/0000-0001-9453-9311; Sone, Jun/0000-0002-9057-7609; Ishigaki, Shinsuke/0000-0002-9555-0659				Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BRIGGS RG, 1978, BIOCHIM BIOPHYS ACTA, V537, P86, DOI 10.1016/0005-2795(78)90605-0; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cheroni C, 2005, NEUROBIOL DIS, V18, P509, DOI 10.1016/j.nbd.2004.12.007; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Di Noto L, 2005, J BIOL CHEM, V280, P39907, DOI 10.1074/jbc.M506247200; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; FISHER CL, 1994, PROTEINS, V19, P24, DOI 10.1002/prot.340190105; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee JP, 2002, J NEUROCHEM, V82, P1229, DOI 10.1046/j.1471-4159.2002.01056.x; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCREE DE, 1990, J BIOL CHEM, V265, P14234; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2006, J NEUROCHEM, V96, P1277, DOI 10.1111/j.1471-4159.2005.03642.x; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443	48	127	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28087	28095		10.1074/jbc.M704465200	http://dx.doi.org/10.1074/jbc.M704465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666395	hybrid			2022-12-27	WOS:000249455600058
J	Wakabayashi, K; Nakagawa, H; Tamura, A; Koshiba, S; Hoshijima, K; Komada, M; Ishikawa, T				Wakabayashi, Kanako; Nakagawa, Hiroshi; Tamura, Ai; Koshiba, Shoko; Hoshijima, Kazuyuki; Komada, Masayuki; Ishikawa, Toshihisa			Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; ENDOPLASMIC-RETICULUM STRESS; STEM-CELLS; IDENTIFICATION; POLYMORPHISMS; MITOXANTRONE; GLUTATHIONE; AGGRESOMES; PROTECTION; ENDOSOMES	Human ABCG2 belongs to the ATP-binding cassette (ABC) transporter family and plays an important role in various biological reactions, such as xenobiotic elimination and homeostasis of protoporphyrin. We previously reported that ABCG2 exists in the plasma membrane as a homodimer bound via a disulfide bond at Cys-603. In the present study, we examined the importance of an intramolecular disulfide bond for stability of the ABCG2 protein. Substitution of either Cys-592 or Cys-608 located in the extracellular loop to glycine resulted in a significant decrease in protein levels of ABCG2 when expressed in Flp-In-293 cells. Interestingly, the protein levels of those ABCG2 variants were remarkably enhanced by treatment with the proteasome inhibitor MG132. Concomitantly, increases in ubiquitinated forms of those variant proteins were detected by immunoprecipitation. In contrast, neither the protein level nor the ubiquitinated state of the ABCG2 wild-type (WT) was affected by MG132 treatment. Ubiquitin-mediated protein degradation is suggested to be involved in degradation, of misfolded ABCG2 proteins lacking the intramolecular disulfide bond. On the other hand, the protein level of ABCG2 WT increased more than 4-fold when cells were treated with bafilomycin A(1), which inhibits lysosomal degradation, whereas the C592G or C608G variant was little affected by the same treatment. These results strongly suggest that two distinct pathways exist for protein degradation of ABCG2 WT and mutants lacking the intramolecular disulfide bond. Namely, the WT ABCG2 is degraded in lysosomes, and the misfolded ABCG2 lacking intramolecular disulfide bond undergoes ubiquitin-mediated protein degradation in proteasomes.	Tokyo Inst Technol, Grad Sch BIosci & Biotechnol, Dept Biomol Engn, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology	Ishikawa, T (corresponding author), Tokyo Inst Technol, Grad Sch BIosci & Biotechnol, Dept Biomol Engn, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	tishikaw@bio.titech.ac.jp						Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Henriksen U, 2005, J BIOL CHEM, V280, P36926, DOI 10.1074/jbc.M502937200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kage K, 2005, CANCER SCI, V96, P866, DOI 10.1111/j.1349-7006.2005.00126.x; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Mitomo H, 2003, BIOCHEM J, V373, P767, DOI 10.1042/BJ20030150; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2006, TRAFFIC, V7, P1017, DOI 10.1111/j.1600-0854.2006.00452.x; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Tamura A, 2006, MOL PHARMACOL, V70, P287, DOI 10.1124/mol.106.023556; Tamura A, 2007, CANCER SCI, V98, P231, DOI 10.1111/j.1349-7006.2006.00371.x; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wakabayashi K, 2006, J EXP THER ONCOL, V5, P205; Wakabayashi K, 2006, DRUG METAB REV, V38, P371, DOI 10.1080/03602530600727947; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	28	64	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27841	27846		10.1074/jbc.C700133200	http://dx.doi.org/10.1074/jbc.C700133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17686774	hybrid			2022-12-27	WOS:000249455600032
J	Waldmann, I; Walde, S; Kehlenbach, RH				Waldmann, Inga; Waelde, Sarah; Kehlenbach, Ralph H.			Nuclear import of c-Jun is mediated by multiple transport receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; TRANSCRIPTION FACTOR; LEUCINE-ZIPPER; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; MAMMALIAN-CELLS; BINDING DOMAIN; CORE HISTONES; EXPORT; FOS	c-Jun and c-Fos are major components of the transcriptional complex AP-1. Here, we investigate the nuclear import pathway(s) of the transcription factor c-Jun. c-Jun bound specifically to the nuclear import receptors importin 113, transportin, importin 5, importin 7, importin 9, and importin 13. In digitonin-permeabilized cells, importin 13, transportin, importin 7, and importin 9 promoted efficient import of c-Jun into the nucleus. Importin a, by contrast, inhibited nuclear import of c-Jun in vitro. A single basic region preceding the leucine zipper of c-Jun functions as a nuclear localization signal (NLS) and was required for interaction with all tested import receptors. In vivo, nuclear import of a c-Jun reporter protein lacking the leucine zipper strictly depended on this NLS. In a leucine zipper-dependent manner, c-Jun with mutations in its NLS was still imported into the nucleus in a complex with endogenous leucine zipper proteins or, for example, with cotransfected c-Fos. Together, these results explain the highly efficient nuclear import of the transcription factor c-Jun.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Kehlenbach, RH (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	rkehlen@gwdg.de		Kehlenbach, Ralph/0000-0003-4920-9916; Walde, Sarah/0000-0001-8544-2323				ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Arnold M, 2006, J BIOL CHEM, V281, P5492, DOI 10.1074/jbc.M513281200; Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Camuzeaux B, 2005, BIOCHEM BIOPH RES CO, V332, P1107, DOI 10.1016/j.bbrc.2005.05.057; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; Dean KA, 2001, J CELL SCI, V114, P3479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MIKAELIAN I, 1993, J VIROL, V67, P734; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Plafker SM, 2000, EMBO J, V19, P5502, DOI 10.1093/emboj/19.20.5502; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wohlwend D, 2007, J BIOL CHEM, V282, P10707, DOI 10.1074/jbc.M610409200; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	48	61	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27685	27692		10.1074/jbc.M703301200	http://dx.doi.org/10.1074/jbc.M703301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652081	hybrid			2022-12-27	WOS:000249455600016
J	Patel, DN; King, CA; Bailey, SR; Holt, JW; Venkatachalam, K; Agrawal, A; Valente, AJ; Chandrasekar, B				Patel, Devang N.; King, Carter A.; Bailey, Steven R.; Holt, Jeffrey W.; Venkatachalam, Kaliyamurthi; Agrawal, Alok; Valente, Anthony J.; Chandrasekar, Bysani			Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappa B and C/EBP beta activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; SERUM AMYLOID-A; CARDIOVASCULAR-DISEASE; NUCLEAR-FACTOR; TNF-ALPHA; ENDOTHELIAL-CELLS; INFLAMMATION; COMPLEMENT; CYTOKINE	Elevated systemic levels of the acute phase C-reactive protein (CRP) are predictors of future cardiovascular events. There is evidence that CRP may also play a direct role in atherogenesis. Here we determined whether the proinflammatory interleukin (IL)-17 stimulates CRP expression in hepatocytes (Hep3B cell line and primary hepatocytes) and coronary artery smooth muscle cells (CASMC). Our results demonstrate that IL-17 potently induces CRP expression in Hep3B cells independent of IL-1 beta and IL-6. IL-17 induced CRP promoter-driven reporter gene activity that could be attenuated by dominant negative I kappa B alpha or C/EBP beta knockdown and stimulated both NF-kappa B and C/EBP DNA binding and reporter gene activities. Targeting NF-kappa B and C/EBP beta activation by pharmacological inhibitors, small interfering RNA interference and adenoviral transduction of dominant negative expression vectors blocked IL-17-mediated CRP induction. Overexpression of wild type p50, p65, and C/EBP beta stimulated CRP transcription. IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappa B and C/EBP activation and CRP transcription. These results, confirmed in primary human hepatocytes and CASMC, demonstrate for the first time that IL-17 is a potent inducer of CRP expression via p38 MAPK and ERK1/2-dependent NF-kappa B and C/EBP beta activation and suggest that IL-17 may mediate chronic inflammation, atherosclerosis, and thrombosis.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; E Tennessee State Univ, Dept Pharmacol, Johnson City, TN 37614 USA; S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; East Tennessee State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Venkatachalam, Kaliyamurthi/GXM-4890-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020, R01HL071233] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071233, R01 HL068020, HL 68020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal A, 2003, IMMUNOLOGY, V108, P539, DOI 10.1046/j.1365-2567.2003.01608.x; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200; Chen K, 2006, NAT MED, V12, P425, DOI 10.1038/nm1372; Clapp BR, 2005, CIRCULATION, V111, P1530, DOI 10.1161/01.CIR.0000159336.31613.31; Csiszar A, 2003, FASEB J, V17, P1183, DOI 10.1096/fj.02-1049fje; DEBEER FC, 1982, BRIT HEART J, V47, P239; Fujii H, 2006, ARTERIOSCL THROM VAS, V26, P2476, DOI 10.1161/01.ATV.0000242794.65541.02; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Hattori Y, 2003, CARDIOVASC RES, V58, P186, DOI 10.1016/S0008-6363(02)00855-6; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365; Inoue Nobutaka, 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P227; Ivashchenko Y, 2005, ARTERIOSCL THROM VAS, V25, P186, DOI 10.1161/01.ATV.0000150041.81963.68; Jabs WJ, 2003, CIRCULATION, V108, P1428, DOI 10.1161/01.CIR.0000092184.43176.91; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Koenders MI, 2006, J IMMUNOL, V176, P6262, DOI 10.4049/jimmunol.176.10.6262; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; KUSHNER I, 1978, J EXP MED, V148, P466, DOI 10.1084/jem.148.2.466; Kwon WJ, 2004, MOL CELLS, V18, P200; Labbozzetta M, 2006, ANN NY ACAD SCI, V1089, P268, DOI 10.1196/annals.1386.014; Li SH, 2004, CIRCULATION, V109, P833, DOI 10.1161/01.CIR.0000117087.27524.0E; Liu XKK, 2004, J BIOL CHEM, V279, P52762, DOI 10.1074/jbc.M405764200; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Mazer SP, 2004, J THROMB THROMBOLYS, V17, P95, DOI 10.1023/B:THRO.0000037664.77460.d8; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Pasceri V, 2000, CIRCULATION, V102, P2165; Patel DN, 2006, BIOCHEM BIOPH RES CO, V347, P1113, DOI 10.1016/j.bbrc.2006.07.015; Paul A, 2004, CIRCULATION, V109, P647, DOI 10.1161/01.CIR.0000114526.50618.24; POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rifai N, 2001, CLIN CHEM, V47, P403; Rost NS, 2001, STROKE, V32, P2575, DOI 10.1161/hs1101.098151; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Shen F, 2006, J BIOL CHEM, V281, P24138, DOI 10.1074/jbc.M604597200; Sternik L, 2002, ARTERIOSCL THROM VAS, V22, P1865, DOI 10.1161/01.ATV.0000033821.96354.90; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; Venugopal SK, 2005, CURR OPIN NEPHROL HY, V14, P33, DOI 10.1097/00041552-200501000-00006; Voleti B, 2005, J IMMUNOL, V175, P3386, DOI 10.4049/jimmunol.175.5.3386; Wang CH, 2003, CIRCULATION, V107, P1783, DOI 10.1161/01.CIR.0000061916.95736.E5; Wu Y, 2003, ACTA CRYSTALLOGR D, V59, P922, DOI 10.1107/S0907444903004414; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Yeh TC, 2007, BIOCHEM PHARMACOL, V73, P782, DOI 10.1016/j.bcp.2006.11.027; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004; Zwaka TP, 2001, CIRCULATION, V103, P1194	58	157	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27229	27238		10.1074/jbc.M703250200	http://dx.doi.org/10.1074/jbc.M703250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652082	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000249304900064
J	Cohen, L; Ilan, N; Gur, M; Stuhmer, W; Gordon, D; Gurevitz, M				Cohen, Lior; Ilan, Nitza; Gur, Maya; Stuhmer, Walter; Gordon, Dalia; Gurevitz, Michael			Design of a specific activator for skeletal muscle sodium channels uncovers channel architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODIC PARALYSIS TYPE-2; SCORPION BETA-TOXINS; GATED ION CHANNELS; VOLTAGE-SENSOR; ENHANCED INACTIVATION; FUNCTIONAL SURFACE; MUTATIONS; COMMON; INSECT; LOOP	Gating modifiers of voltage-gated sodium channels (Na(v)s) are important tools in neuroscience research and may have therapeutic potential in medicinal disorders. Analysis of the bioactive surface of the scorpion beta-toxin Css4 (from Centruroides suffusus suffusus) toward rat brain (rNa(v)1.2a) and skeletal muscle (rNa(v)1.4) channels using binding studies revealed commonality but also substantial differences, which were used to design a specific activator, Css4(F14A/E15A/E28R), of rNa(v)1.4 expressed in Xenopus oocytes. The therapeutic potential of Css4(F14A/E15A/E28R) was tested using an rNa(v)1.4 mutant carrying the same mutation present in the genetic disorder hypokalemic periodic paralysis. The activator restored the impaired gating properties of the mutant channel expressed in oocytes, thus offering a tentative new means for treatment of neuromuscular disorders with reduced muscle excitability. Mutant double cycle analysis employing toxin residues involved in the construction of Css4(F14A/E15A/E28R) and residues whose equivalents in the rat brain channel rNa(v)1.2a were shown to affect Css4 binding revealed significant coupling energy (> 1.3 kcal/mol) between F14A and E592A at Domain-2/voltage sensor segments 1-2 (D2/S1-S2), R27Q and E1251N at D3/SS2-S6, and E28R with both E650A at D2/S3-S4 and E1251N at D3/SS2-S6. These results show that despite the differences in interactions with the rat brain and skeletal muscle Navs, Css4 recognizes a similar region on both channel subtypes. Moreover, our data indicate that the S3-S4 loop of the voltage sensor module in Domain-2 is in very close proximity to the SS2-S6 segment of the pore module of Domain-3 in rNa(v)1.4. This is the first experimental evidence that the inter-domain spatial organization of mammalian Na(v)s resembles that of voltage-gated potassium channels.				dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764	NINDS NIH HHS [1 U01 NS058039-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS058039] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bosmans F, 2007, TOXICOL APPL PHARM, V218, P45, DOI 10.1016/j.taap.2006.10.009; Cannon SC, 2002, NEUROMUSCULAR DISORD, V12, P533, DOI 10.1016/S0960-8966(02)00007-X; Cannon SC, 2001, CLIN NEUROSCI RES, V1, P104, DOI 10.1016/S1566-2772(00)00011-6; Carle T, 2006, BIOCHEM BIOPH RES CO, V348, P653, DOI 10.1016/j.bbrc.2006.07.101; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Chen H, 2001, J GEN PHYSIOL, V117, P505, DOI 10.1085/jgp.117.6.505; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; GERSHON E, 1992, J NEUROSCI, V12, P3743; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Goldin AL, 1999, ANN NY ACAD SCI, V868, P38, DOI 10.1111/j.1749-6632.1999.tb11272.x; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; Jurkat-Rott K, 2002, J NEUROL, V249, P1493, DOI 10.1007/s00415-002-0871-5; Jurkat-Rott K, 2000, P NATL ACAD SCI USA, V97, P9549, DOI 10.1073/pnas.97.17.9549; Karbat I, 2007, J MOL BIOL, V366, P586, DOI 10.1016/j.jmb.2006.10.085; Kuzmenkin A, 2002, BRAIN, V125, P835, DOI 10.1093/brain/awf071; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Leipold E, 2006, MOL PHARMACOL, V70, P340, DOI 10.1124/mol.106.024034; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Richardson J, 2006, P NATL ACAD SCI USA, V103, P15865, DOI 10.1073/pnas.0607532103; Schiavon E, 2006, J BIOL CHEM, V281, P20326, DOI 10.1074/jbc.M600565200; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Sokolov S, 2007, NATURE, V446, P76, DOI 10.1038/nature05598; Sternberg D, 2001, BRAIN, V124, P1091, DOI 10.1093/brain/124.6.1091; Vicart S, 2005, NEUROL SCI, V26, P194, DOI 10.1007/s10072-005-0461-x; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q	35	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29424	29430		10.1074/jbc.M704651200	http://dx.doi.org/10.1074/jbc.M704651200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686768	hybrid			2022-12-27	WOS:000249788000039
J	Higgins, MJ; Graves, PR; Graves, LM				Higgins, Matthew J.; Graves, Paul R.; Graves, Lee M.			Regulation of human cytidine triphosphate synthetase 1 by glycogen synthase kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; ATP-CITRATE-LYASE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; LYMPHOBLASTIC-LEUKEMIA; PHOSPHORYLASE-KINASE	Cytidine triphosphate synthetase (CTPS) catalyzes the rate-limiting step in the de novo synthesis of CTP, and both the yeast and human enzymes have been reported to be regulated by protein kinase A or protein kinase C phosphorylation. Here, we provide evidence that stimulation or inhibition of protein kinase A and protein kinase C does not alter the phosphorylation of endogenous human CTPS1 in human embryonic kidney 293 cells under the conditions tested. Unexpectedly, we found that low serum conditions increased phosphorylation of endogenous CTPS1 and this phosphorylation was inhibited by the glycogen synthase kinase 3 (GSK3) inhibitor indirubin-3'-monoxime and GSK3 beta short interfering RNAs, demonstrating the involvement of GSK3 in phosphorylation of endogenous human CTPS1. Separating tryptic peptides from [P-32] orthophosphate-labeled cells and analyzing the phosphopeptides by mass spectrometry identified Ser-574 and Ser-575 as phosphorylated residues. Mutation of Ser-571 demonstrated that Ser-571 was the major site phosphorylated by GSK3 in intact human embryonic kidney 293 cells by GSK3 in vitro. Furthermore, mutation of Ser-575 prevented the phosphorylation of Ser-571, suggesting that phosphorylation of Ser-575 was necessary for priming the GSK3 phosphorylation of Ser-571. Low serum was found to decrease CTPS1 activity, and incubation with the GSK3 inhibitor indirubin-3'-monoxime protected against this decrease in activity. Incubation with an alkaline phosphatase increased CTPS1 activity in a time-dependent manner, demonstrating that phosphorylation inhibits CTPS1 activity. This is the first study to investigate the phosphorylation and regulation of human CTPS1 in human cells and suggests that GSK3 is a novel regulator of CTPS activity.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University	Graves, LM (corresponding author), 116 Manning Dr,936A Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	lmg@med.unc.edu	Graves, Lee/AAG-5470-2021					Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chabes A, 2007, P NATL ACAD SCI USA, V104, P1183, DOI 10.1073/pnas.0610585104; Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; DEKORTE D, 1987, INT J CANCER, V40, P192, DOI 10.1002/ijc.2910400211; DEKORTE D, 1987, CANCER RES, V47, P1841; DEKORTE D, 1985, ANAL BIOCHEM, V147, P197, DOI 10.1016/0003-2697(85)90028-4; DEKORTE D, 1986, LEUKEMIA RES, V10, P389, DOI 10.1016/0145-2126(86)90068-8; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; Han GS, 2005, J BIOL CHEM, V280, P38328, DOI 10.1074/jbc.M509622200; HARMENBERG J, 1990, J CHROMATOGR, V508, P75, DOI 10.1016/S0021-9673(00)91241-X; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PULVERER BJ, 1994, ONCOGENE, V9, P59; Raska CS, 2002, J AM SOC MASS SPECTR, V13, P1034, DOI 10.1016/S1044-0305(02)00433-6; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SHEWACH DS, 1992, ANAL BIOCHEM, V206, P178, DOI 10.1016/S0003-2697(05)80030-2; SIDI Y, 1985, BRIT J HAEMATOL, V61, P125, DOI 10.1111/j.1365-2141.1985.tb04067.x; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; VANDENBERG AA, 1994, LEUKEMIA, V8, P1375; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	32	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29493	29503		10.1074/jbc.M703948200	http://dx.doi.org/10.1074/jbc.M703948200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681942	hybrid, Green Published			2022-12-27	WOS:000249788000046
J	Schietroma, C; Yu, HY; Wagner, MC; Umbach, JA; Bement, WM; Gundersen, CB				Schietroma, Cataldo; Yu, Hoi-Ying; Wagner, Mark C.; Umbach, Joy A.; Bement, William M.; Gundersen, Cameron B.			A role for myosin 1e in cortical granule exocytosis in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-STRING-PROTEIN; NEUROTRANSMITTER RELEASE; UNCONVENTIONAL MYOSINS; MEIOTIC MATURATION; LAEVIS OOCYTES; SUBCELLULAR-LOCALIZATION; COMPENSATORY ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; VESICLE TRANSPORT; ACTIN	Xenopus oocytes undergo dynamic structural changes during maturation and fertilization. Among these, cortical granule exocytosis and compensatory endocytosis provide effective models to study membrane trafficking. This study documents an important role for myosin1e in cortical granule exocytosis. Myosin1e is expressed at the earliest stage that cortical granule exocytosis can be detected in oocytes. Prior to exocytosis, myosin1e relocates to the surface of cortical granules. Overexpression of myosin1e augments the kinetics of cortical granule exocytosis, whereas tail-derived fragments of myosin1e inhibit this secretory event (but not constitutive exocytosis). Finally, intracellular injection of myosin1e antibody inhibits cortical granule exocytosis. Further experiments identified cysteine string proteins as interacting partners for myosin1e. As constituents of the membrane of cortical granules, cysteine string proteins are also essential for cortical granule exocytosis. Future investigation of the link between myosin1e and cysteine string proteins should help to clarify basic mechanisms of regulated exocytosis.	Univ Calif Los Angeles, David Geffen UCLA Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Indiana University System; Indiana University-Purdue University Indianapolis; University of Wisconsin System; University of Wisconsin Madison	Gundersen, CB (corresponding author), Univ Calif Los Angeles, David Geffen UCLA Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	cgundersen@mednet.ucla.edu	Bement, William/AAA-5444-2021	Gundersen, Cameron/0000-0002-1552-6086; Schietroma, Cataldo/0000-0002-0865-9956	NIGMS NIH HHS [R01 GM052932-10, R01 GM052932, GM52932] Funding Source: Medline; NINDS NIH HHS [NS31934, R01 NS031934-06, R01 NS031934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barylko B, 2005, ACTA BIOCHIM POL, V52, P373; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BEMENT WM, 1989, CELL TISSUE RES, V255, P183; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CAMPANELLA C, 1984, J EXP ZOOL, V229, P283, DOI 10.1002/jez.1402290214; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chang BY, 2004, COMP BIOCHEM PHYS A, V137, P115, DOI 10.1016/S1095-6433(03)00269-1; CHARBONNEAU M, 1984, DEV BIOL, V102, P90, DOI 10.1016/0012-1606(84)90177-5; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Dumont RA, 2002, JARO-J ASSOC RES OTO, V3, P375, DOI 10.1007/s101620020049; Gillespie PG, 2001, J CELL BIOL, V155, P703, DOI 10.1083/jcb.200110032; Gundersen CB, 2002, J CELL SCI, V115, P1313; Gundersen CB, 2001, CELL TISSUE RES, V303, P211, DOI 10.1007/s004410000314; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Hokanson DE, 2006, P NATL ACAD SCI USA, V103, P3118, DOI 10.1073/pnas.0505685103; Hubner K, 2002, INT REV CYTOL, V214, P103; Kohan SA, 2003, J EXP ZOOL PART A, V300A, P113, DOI 10.1002/jez.a.10317; Krendel M, 2007, FEBS LETT, V581, P644, DOI 10.1016/j.febslet.2007.01.021; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; LARABELL CA, 1988, CELL TISSUE RES, V251, P129, DOI 10.1007/BF00215457; MOZINGO NM, 1995, RAPID FREEZING FREEZ, P285; Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200; NISHIHARA T, 1986, BIOCHEMISTRY-US, V25, P6013, DOI 10.1021/bi00368a027; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Poage RE, 1999, J NEUROPHYSIOL, V82, P50, DOI 10.1152/jn.1999.82.1.50; Provance DW, 1999, CELL MOL LIFE SCI, V56, P233, DOI 10.1007/s000180050425; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Smith GB, 2005, J BIOL CHEM, V280, P32669, DOI 10.1074/jbc.M501806200; Sokac AM, 2000, INT REV CYTOL, V200, P197, DOI 10.1016/S0074-7696(00)00005-X; Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025; Sokac AM, 2006, DEV CELL, V11, P629, DOI 10.1016/j.devcel.2006.09.002; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; Stoffler HE, 1998, J CELL SCI, V111, P2779; Sudhof TC, 2001, SYNAPSES, P177; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Wu XF, 2000, CURR OPIN CELL BIOL, V12, P42, DOI 10.1016/S0955-0674(99)00055-1; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	50	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29504	29513		10.1074/jbc.M705825200	http://dx.doi.org/10.1074/jbc.M705825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702742	Green Accepted, hybrid			2022-12-27	WOS:000249788000047
J	Shin, N; Lee, S; Ahn, N; Kim, SA; Ahn, SG; YongPark, Z; Chang, S				Shin, Narae; Lee, Suho; Ahn, Namhui; Kim, Soo-A; Ahn, Sang-Gun; YongPark, Zee; Chang, Sunghoe			Sorting nexin 9 interacts with dynamin 1 and N-WASP and coordinates synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; MEDIATED ENDOCYTOSIS; SORTING NEXIN-9; SH3 DOMAINS; RECEPTOR; NCK; SYNAPTOJANIN-1; ASSOCIATION; KINETICS; ADAPTER	Sorting nexin 9 (SNX9) is a member of the sorting nexin family of proteins, each of which contains a characteristic Phox homology domain. SNX9 is widely expressed and plays a role in clathrin-mediated endocytosis, but it is not known if it is present in neuronal cells. We report that SNX9 is expressed in the presynaptic compartment of cultured hippocampal neurons, where it binds to dynamin-1 and N-WASP. Overexpression of full-length SNX9 or a C-terminal truncated version caused severe defects in synaptic vesicle endocytosis during, as well as after, stimulation. Knockdown of SNX9 with short interfering RNA also reduced synaptic vesicle endocytosis, and the W39A mutation of SNX9 abolished the inhibitory effect of SNX9 on endocytosis. Rescue experiments showed that most of the effect of SNX9 on endocytosis results from its interaction with dynamin 1, although its interaction with N-WASP contributes in some degree. We further showed that SNX9 dimerizes through its C-terminal domain, suggesting that it may interact simultaneously with dynamin 1 and N-WASP. We propose that SNX9 interacts with dynamin-1 and N-WASP in presynaptic terminals, where it links actin dynamics and synaptic vesicle endocytosis.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Dongguk Univ, Dept Biochem, Coll Oriental Med, Gyeongju 780714, South Korea; Chosun Univ, Coll Dent, Dept Pathol, Kwangju 501759, South Korea	Gwangju Institute of Science & Technology (GIST); Dongguk University; Chosun University	Chang, S (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong song, Kwangju 500712, South Korea.	sunghoe@gist.ac.kr	Chang, Sunghoe/J-2784-2012	Kim, Soo-A/0000-0001-6777-739X; chang, sunghoe/0000-0002-3446-7288				Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Childress C, 2006, BIOCHEM J, V394, P693, DOI 10.1042/BJ20050576; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim WT, 2002, P NATL ACAD SCI USA, V99, P17143, DOI 10.1073/pnas.222657399; Kim Y, 2005, J NEUROSCI, V25, P9515, DOI 10.1523/JNEUROSCI.1643-05.2005; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lundmark R, 2004, J BIOL CHEM, V279, P42694, DOI 10.1074/jbc.M407430200; Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Micheva KD, 2003, NAT NEUROSCI, V6, P925, DOI 10.1038/nn1114; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Solomaha E, 2005, J BIOL CHEM, V280, P23147, DOI 10.1074/jbc.M501745200; Soulet F, 2005, MOL BIOL CELL, V16, P2058, DOI 10.1091/mbc.E04-11-1016; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Yeow-Fong L, 2005, FEBS LETT, V579, P5040, DOI 10.1016/j.febslet.2005.07.093; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	41	54	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28939	28950		10.1074/jbc.M700283200	http://dx.doi.org/10.1074/jbc.M700283200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681954	hybrid			2022-12-27	WOS:000249642100068
J	Tripathi, V; Ali, A; Bhat, R; Pati, U				Tripathi, Veenu; Ali, Amjad; Bhat, Rajiv; Pati, Uttam			CHIP chaperones wild type p53 tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; MUTANT P53; TARGET; DEGRADATION; HSP90; IDENTIFICATION; CONFORMATION; RESCUE; CANCER	Wild type p53 exists in a constant state of equilibrium between wild type and mutant conformation and undergoes conformational changes at elevated temperature. We have demonstrated that the co-chaperone CHIP (carboxyl terminus of Hsp70-interacting protein), which suppressed aggregation of several misfolded substrates and induced the proteasomal degradation of both wild type and mutant p53, physically interacts with the amino terminus of WT53 and prevented it from irreversible thermal inactivation. CHIP preferentially binds to the p53 mutant phenotype and restored the DNA binding activity of heat-denatured p53 in an ATP-independent manner. In cells under elevated temperatures that contained a higher level of p53 mutant phenotype, CHIP restored the native-like conformation of p53 in the presence of geldanamycin, whereas CHIP-small interfering RNA considerably increased the mutant form. Further, under elevated temperatures, the levels of CHIP and p53 were higher in nucleus, and chromatin immunoprecipitation shows the presence of p53 and CHIP together upon the DNA binding site in the p21 and p53 promoters. We propose that CHIP might be a direct chaperone of wild type p53 that helps p53 in maintaining wild type conformation under physiological condition as well as help resurrect p53 mutant phenotype into a folded native state under stress condition.	Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Pati, U (corresponding author), Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.	uttam@mail.jnu.ac.in	Pati, Uttam/L-9345-2019					Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; BIAGOSKLONNY MV, 1996, P NATL ACAD SCI USA, V93, P8379; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; DIXIT P, 2007, BIOCHEM BIOPH RES CO, V357, P761; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Rosser MFN, 2007, J BIOL CHEM, V282, P22267, DOI 10.1074/jbc.M700513200; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	42	32	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28441	28454		10.1074/jbc.M703698200	http://dx.doi.org/10.1074/jbc.M703698200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666403	hybrid			2022-12-27	WOS:000249642100018
J	Xuan, CH; Qiao, WT; Gao, JM; Liu, M; Zhang, XH; Cao, YJ; Chen, QM; Geng, YQ; Zhou, J				Xuan, Chenghao; Qiao, Wentao; Gao, Jinmin; Liu, Min; Zhang, Xihui; Cao, Youjia; Chen, Qimin; Geng, Yunqi; Zhou, Jun			Regulation of microtubule assembly and stability by the transactivator of transcription protein of Jembrana disease virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT; APOPTOSIS; CELLS; DYNAMICS; PROLIFERATION; CYTOSKELETON; REPLICATION; SEQUENCE; PATHWAY; DRUGS	Microtubules are cytoskeletal polymers consisting of tubulin subunits that take part in diverse cell activities. Many viruses hijack cellular motor proteins to move on microtubules toward the cell interior during the entry process and toward the plasma membrane during the egress period. In addition, viruses often remodel microtubules to facilitate the generation of infectious progeny. In this study, we found that the transactivator of transcription protein of Jembrana disease virus (Jtat) bound tubulin and microtubules both in cells and in the purified system. Microtubule co-sedimentation and co-localization assays revealed a robust interaction of Jtat with microtubules. Tubulin turbidity assay further showed that Jtat promoted tubulin polymerization in vitro in a concentration-dependent manner. Moreover, Jtat promoted the partitioning of cellular tubulin toward the polymeric form, increased the level of tubulin acetylation, and significantly enhanced the cold stability of cellular microtubules. In addition, Jtat-mediated disruption of microtubule dynamics induced the release of Bim from microtubules, leading to profound apoptosis. These results not only identify Jtat as an important viral regulator of microtubule dynamics but also indicate that Jtat-induced apoptosis might contribute to Jembrana disease pathogenesis.	Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China	Nankai University	Geng, YQ (corresponding author), Nankai Univ, Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.	gengyq@nankai.edu.cn	Zhou, Jun/D-4654-2017; Gao, Jinmin/J-8967-2015	Zhou, Jun/0000-0001-7858-8260; 				Amos LA, 2005, ADV PROTEIN CHEM, V71, P257, DOI 10.1016/S0065-3233(04)71007-4; Aneja R, 2006, BLOOD, V107, P2486, DOI 10.1182/blood-2005-08-3516; CHADWICK BJ, 1995, J GEN VIROL, V76, P189, DOI 10.1099/0022-1317-76-1-189; Chen HX, 2000, J VIROL, V74, P2703, DOI 10.1128/JVI.74.6.2703-2713.2000; Chen HX, 1999, J VIROL, V73, P658, DOI 10.1128/JVI.73.1.658-666.1999; Deng G, 2006, VIRUS RES, V121, P122, DOI 10.1016/j.virusres.2006.01.023; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; Gibellini D, 2005, NEW MICROBIOL, V28, P95; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matarrese P, 2005, CELL DEATH DIFFER, V12, P932, DOI 10.1038/sj.cdd.4401582; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; SOESANTO M, 1990, J COMP PATHOL, V103, P61, DOI 10.1016/S0021-9975(08)80135-1; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WILCOX GE, 1995, VET MICROBIOL, V46, P249, DOI 10.1016/0378-1135(95)00089-S; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Zagury J F, 1998, J Hum Virol, V1, P282; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2006, CANCER RES, V66, P445, DOI 10.1158/0008-5472.CAN-05-1779	31	15	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28800	28806		10.1074/jbc.M702823200	http://dx.doi.org/10.1074/jbc.M702823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656359	hybrid			2022-12-27	WOS:000249642100054
J	Lam, QLK; Zheng, BJ; Jin, DY; Cao, XT; Lu, LW				Lam, Queenie Lai Kwan; Zheng, Bo-Jian; Jin, Dong-Yan; Cao, Xuetao; Lu, Liwei			Leptin induces CD40 expression through the activation of Akt in murine dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERFERON-GAMMA; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; IMMUNE-RESPONSES; IKK-ALPHA; OB-R; RECEPTOR; PHOSPHORYLATION	Increasing evidence suggests a regulatory role for leptin, an adipocyte-derived hormone, in immunity. Although recent studies indicated an essential role of leptin signaling in dendritic cell (DC) maturation, the molecular mechanisms by which leptin modulates DC functional maturation remained unclear. In this study, we showed that leptin induced CD40 expression in murine DC and significantly up-regulated their immunostimulatory function in driving T cell proliferation. Moreover, leptin markedly enhanced lipopolysaccharide-mediated DC activation. Using pharmacological inhibitors for Akt, STAT-1 alpha, or NF-kappa B and the dominant negative forms of Akt and I kappa B kinase alpha/beta/gamma,,y, as well as small interfering RNA for STAT-1 alpha, we showed that Akt, STAT-1 alpha, and NF-kappa B were important for the leptin- or lipopolysaccharide-induced CD40 expression. Coimmunoprecipitation analysis revealed that leptin promoted immune complex formation between Akt and the I kappa B kinase subunits as well as STAT-1 alpha. Blocking the activity of Akt demonstrated a crucial role for Akt in translocation of STAT-1 alpha and NF-kappa B to the nucleus and activation of the CD40 promoter. Further analysis with chromatin immunoprecipitation assay confirmed that leptin recruited STAT-1 alpha, NF-kappa Bp65, and RNA polymerase II to the CD40 promoter and enhanced histone 4 acetylation in a time-dependent manner. Thus, our results have elucidated the molecular mechanisms underlying leptin-induced CD40 expression and DC maturation.	Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; Univ Hong Kong, Ctr Infect & Immunol, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Peoples R China; Second Mil Med Univ, Inst Immunol, Shanghai, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; Naval Medical University	Lu, LW (corresponding author), Univ Hong Kong, Dept Pathol, Pokfulam Rd, Hong Kong, Peoples R China.	liweilu@hkucc.hku.hk	Lu, Liwei/C-4357-2009	Lu, Liwei/0000-0002-8634-0967				Busso N, 2002, J IMMUNOL, V168, P875, DOI 10.4049/jimmunol.168.2.875; Carayol N, 2006, J BIOL CHEM, V281, P31142, DOI 10.1074/jbc.M603417200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Guo ZH, 2003, BLOOD, V102, P4441, DOI 10.1182/blood-2002-11-3420; Hekerman P, 2005, FEBS J, V272, P109, DOI 10.1111/j.1432-1033.2004.04391.x; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kimura A, 2005, P NATL ACAD SCI USA, V102, P17089, DOI 10.1073/pnas.0508517102; Kristof AS, 2003, J BIOL CHEM, V278, P33637, DOI 10.1074/jbc.M301053200; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lam QLK, 2007, CELL MOL IMMUNOL, V4, P1; Lam QLK, 2006, EUR J IMMUNOL, V36, P3118, DOI 10.1002/eji.200636602; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Matarese G, 2002, DIABETES, V51, P1356, DOI 10.2337/diabetes.51.5.1356; Mattioli B, 2005, J IMMUNOL, V174, P6820, DOI 10.4049/jimmunol.174.11.6820; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Park D, 2006, NAT BIOTECHNOL, V24, P1581, DOI 10.1038/nbt1262; Qin HW, 2005, BLOOD, V106, P3114, DOI 10.1182/blood-2005-02-0759; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; Quezada SA, 2003, ARTHRITIS RHEUM, V48, P2541, DOI 10.1002/art.11230; Samoilova EB, 1997, J MOL MED, V75, P603, DOI 10.1007/s001090050145; Sanchez-Margalet V, 2002, CLIN EXP IMMUNOL, V129, P119, DOI 10.1046/j.1365-2249.2002.01900.x; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Shen ZH, 1997, J IMMUNOL, V158, P2723; Siegmund B, 2004, GUT, V53, P965, DOI 10.1136/gut.2003.027136; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tian ZG, 2002, BIOCHEM BIOPH RES CO, V298, P297, DOI 10.1016/S0006-291X(02)02462-2; Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang MH, 2004, NAT IMMUNOL, V5, P1124, DOI 10.1038/ni1130; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	37	42	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27587	27597		10.1074/jbc.M704579200	http://dx.doi.org/10.1074/jbc.M704579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660512	hybrid			2022-12-27	WOS:000249455600006
J	Noguchi, TQP; Kanzaki, N; Ueno, H; Hirose, K; Uyeda, TQP				Noguchi, Taro Q. P.; Kanzaki, Noriko; Ueno, Hironori; Hirose, Keiko; Uyeda, Taro Q. P.			A novel system for expressing toxic actin mutants in Dictyostelium and purification and characterization of a dominant lethal yeast actin mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; IN-VITRO; FUNCTIONAL INTERACTIONS; MOTOR DOMAIN; N-TERMINUS; MYOSIN; FILAMENT; BINDING; PROTEIN; CELLS	We have developed a novel system for expressing recombinant actin in Dictyostelium. In this system, the C terminus of actin is fused to thymosin 6 via a glycine-based linker. The fusion protein is purified using a His tag attached to the thymosin beta moiety and then cleaved by chymotrypsin immediately after the native final residue of actin to yield intact actin. Wildtype actin prepared in this way was functionally normal in terms of its polymerization kinetics and muscle myosin-mediated motility. We expected that this system would be particularly useful for expressing toxic actin mutants, because the actin moiety of the fusion protein is unlikely to interact with the actin cytoskeleton of the host cells. We therefore chose to express the E2016A/R207A/E208A mutant, which appears to be dominant lethal in yeast, as a model case of a toxic actin mutant that is difficult to express. We found that the E206A/R207A/E208A mutant could be expressed and purified with a yield comparable to the wild-type molecule (3-4 mg/20 g cells), even though green fluorescent protein-fused actin carrying the E206A/R207A/E208A mutation was expressed at a much lower level than wild-type actin. Purified E206A/R207A/E208A actin did not polymerize, even in the presence of muscle actin; however, it accelerated polymerization of muscle actin and inhibited the nucleating and severing activities of gelsolin. Given that the location of the substituted residues is near the pointed end face of the mutant, we suggest that E206A/R207A/E208A actin behaves like a weak pointed end-capping protein that perturbs the actin cytoskeleton of the host cells.	Univ Tsukuba, Res Inst Cell Engn, Tsukuba, Ibaraki 3058562, Japan; Univ Tsukuba, Inst Human Sci & Biomed Engn, Nalt Inst Adv Ind Sci & Technol Tsukuba Cent 4, Tsukuba, Ibaraki 3058562, Japan; Univ Tsukuba, Grad Sch Life Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; University of Tsukuba	Uyeda, TQP (corresponding author), Univ Tsukuba, Res Inst Cell Engn, 1-1-1 Highashi, Tsukuba, Ibaraki 3058562, Japan.	t-uyeda@aist.go.jp	Hirose, Keiko/M-5429-2018	Hirose, Keiko/0000-0003-4587-8346				Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; An HS, 1996, J MOL BIOL, V260, P492, DOI 10.1006/jmbi.1996.0417; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; Asano Y, 2004, CELL MOTIL CYTOSKEL, V59, P17, DOI 10.1002/cm.20015; ASPENSTROM P, 1991, EUR J BIOCHEM, V200, P35, DOI 10.1111/j.1432-1033.1991.tb21045.x; COOK RK, 1992, J BIOL CHEM, V267, P9430; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; DRUMMOND DR, 1991, BIOCHEM J, V274, P301, DOI 10.1042/bj2740301; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JACOBSON GR, 1976, P NATL ACAD SCI USA, V73, P2742, DOI 10.1073/pnas.73.8.2742; Joel PB, 2004, BIOCHEMISTRY-US, V43, P11554, DOI 10.1021/bi048899a; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LEE RJ, 1994, J CELL SCI, V107, P2875; Liu X, 1998, P NATL ACAD SCI USA, V95, P14124, DOI 10.1073/pnas.95.24.14124; MIKI M, 1982, BIOCHEMISTRY-US, V21, P3661, DOI 10.1021/bi00258a021; Oosawa F., 1972, COLD SPRING HARB SYM, V37, P277; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; PROCHNIEWICZ E, 1993, BIOPHYS J, V65, P113, DOI 10.1016/S0006-3495(93)81057-9; ROMANS P, 1985, J MOL BIOL, V186, P321, DOI 10.1016/0022-2836(85)90108-1; RUBENSTEIN P, 1979, J BIOL CHEM, V254, P1142; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; Terada N, 2007, BIOPHYS J, V92, P2162, DOI 10.1529/biophysj.106.098871; VANDEKERCKHOVE J, 1980, NATURE, V284, P475, DOI 10.1038/284475a0; WERTMAN KF, 1992, GENETICS, V132, P337; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Yokoyama K, 2002, BIOCHEM BIOPH RES CO, V299, P825, DOI 10.1016/S0006-291X(02)02758-4	38	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27721	27727		10.1074/jbc.M703165200	http://dx.doi.org/10.1074/jbc.M703165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656358	hybrid			2022-12-27	WOS:000249455600020
J	Raybaud, A; Baspinar, EE; Dionne, F; Dodier, Y; Sauve, R; Parent, L				Raybaud, Alexandra; Baspinar, Ebru-Eylem; Dionne, Francois; Dodier, Yolaine; Sauve, Remy; Parent, Lucie			The role of distal s6 hydrophobic residues in the voltage-dependent Gating of Ca(v)2.3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; GATED SODIUM-CHANNELS; CALCIUM-CHANNEL; CA2+ CHANNEL; K+ CHANNEL; BETA-SUBUNIT; MOLECULAR DETERMINANTS; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE	The hydrophobic locus VAVIM is conserved in the S6 transmembrane segment of domain IV (IVS6) in Ca(V)1 and Ca(V)2 families. Herein we show that glycine substitution of the VAVIM motif in Ca(V)2.3 produced whole cell currents with inactivation kinetics that were either slower (A1719G approximate to V1720G), similar (V1718G), or faster (I1721G approximate to M1722G) than the wild-type channel. The fast kinetics of I1721G were observed with a approximate to + 10 mV shift in its voltage dependence of activation (E-0.5,E-act). In contrast, the slow kinetics of A1719G and V1720G were accompanied by a significant shift of approximate to-20 mV in their E-0.5,E-act indicating that the relative stability of the channel closed state was decreased in these mutants. Glycine scan performed with Val(349) in IS6, Ile(701) in IIS6, and Leu(1420) in IIIS6 at positions predicted to face Val(1720) in IVS6 also produced slow inactivating currents with hyperpolarizing shifts in the activation and inactivation potentials, again pointing out a decrease in the stability of the channel closed state. Mutations to other hydrophobic residues at these positions nearly restored the channel gating. Altogether these data indicate that residues at positions equivalent to 1720 exert a critical control upon the relative stability of the channel closed and open states and more specifically, that hydrophobic residues at these positions promote the channel closed state. We discuss a three-dimensional homology model of Ca(V)2.3 based upon Kv1.2 where hydrophobic residues at positions facing Val(1720) in IS6, IIS6, and IIIS6 play a critical role in stabilizing the closed state in Ca(V)2.3.	Univ Montreal, Dept Physiol, Membrane Protein Res Grp, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Parent, L (corresponding author), PO Box 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	lucie.parent@umontreal.ca						Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Armstrong Clay M, 2003, Sci STKE, V2003, pre10, DOI 10.1126/stke.2003.188.re10; Bernatchez G, 2001, BBA-BIOMEMBRANES, V1514, P217, DOI 10.1016/S0005-2736(01)00373-X; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; Beyl S, 2007, J BIOL CHEM, V282, P3864, DOI 10.1074/jbc.M609153200; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Cao YQ, 2005, P NATL ACAD SCI USA, V102, P2590, DOI 10.1073/pnas.0409896102; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dafi O, 2004, BIOPHYS J, V87, P3181, DOI 10.1529/biophysj.104.045559; Dodier Y, 2004, J BIOL CHEM, V279, P6853, DOI 10.1074/jbc.M310534200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ferrer T, 2006, J BIOL CHEM, V281, P12858, DOI 10.1074/jbc.M513518200; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hans M, 1999, J NEUROSCI, V19, P1610; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hohaus A, 2005, J BIOL CHEM, V280, P38471, DOI 10.1074/jbc.M507013200; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; Kitaguchi T, 2004, J GEN PHYSIOL, V124, P319, DOI 10.1085/jgp.200409098; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lipkind GM, 2005, MOL PHARMACOL, V68, P1611, DOI 10.1124/mol.105.014803; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Meza U, 2007, MOL PHARMACOL, V71, P284, DOI 10.1124/mol.106.028530; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Raybaud A, 2006, J BIOL CHEM, V281, P39424, DOI 10.1074/jbc.M607405200; Scheib H, 2006, J MOL MODEL, V12, P813, DOI 10.1007/s00894-005-0066-y; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Scholle A, 2004, BIOPHYS J, V87, P873, DOI 10.1529/biophysj.104.040550; Serikov V, 2002, BIOCHEM BIOPH RES CO, V293, P1405, DOI 10.1016/S0006-291X(02)00396-0; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Simoes M, 2002, J GEN PHYSIOL, V120, P99, DOI 10.1085/jgp.20028586; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Terwindt GM, 1998, EUR J HUM GENET, V6, P297, DOI 10.1038/sj.ejhg.5200206; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; Wang SY, 2007, PFLUG ARCH EUR J PHY, V454, P277, DOI 10.1007/s00424-006-0202-2; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Xie C, 2005, J GEN PHYSIOL, V126, P205, DOI 10.1085/jgp.200509293; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhen XG, 2005, J GEN PHYSIOL, V126, P193, DOI 10.1085/jgp.200509292	55	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27944	27952		10.1074/jbc.M703895200	http://dx.doi.org/10.1074/jbc.M703895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660294	hybrid			2022-12-27	WOS:000249455600043
J	Begley, LA; MacDonald, JW; Day, ML; Macoska, JA				Begley, Lesa A.; MacDonald, James W.; Day, Mark L.; Macoska, Jill A.			CXCL12 activates a robust transcriptional response in human prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER CELLS; IN-VITRO; SIGNALING PATHWAYS; TUMOR-GROWTH; METASTASIS; SECRETION; KINASE; MICROENVIRONMENT; ANGIOGENESIS	CXCL12 is a CXC-type chemokine that plays important roles in hematopoiesis, development, and organization of the immune system and supports the survival or growth of a variety of normal or malignant cell types. Our laboratory recently showed that CXCL12 is secreted by aging stromal fibroblast cells and is a major paracrine factor that specifically stimulates the proliferation of prostate epithelial cells. The current study shows that this CXCL12-mediated proliferative response may be either ERK-dependent or ERK-independent. Moreover, CXCL12 initiates a previously undefined and complex global transcriptional response in prostate epithelial cells. This CXCL12-mediated transcriptional response directly stimulates the expression of genes encoding proteins that are involved in the promotion of cellular proliferation and progression through the cell cycle, tumor metastasis, and cellular motility, and directly represses the transcription of genes encoding proteins involved in cell-cell adhesion and resistance to apoptosis. Thus, CXCL12 may play a major role in the etiology of benign proliferative disease in the context of an aging tissue microenvironment.	Univ Michigan, Dept Urol, Canc Ctr & Geriatr Ctr 6217, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Macoska, JA (corresponding author), Univ Michigan, Dept Urol, Canc Ctr & Geriatr Ctr 6217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jcoska@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065313] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA 46592] Funding Source: Medline; NIDDK NIH HHS [P50 DK 065313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Begley L, 2006, GENE CHROMOSOME CANC, V45, P136, DOI 10.1002/gcc.20274; Begley L, 2005, AGING CELL, V4, P291, DOI 10.1111/j.1474-9726.2005.00173.x; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Chaib H, 2001, CANCER RES, V61, P2390; Chen YC, 2003, CANCER RES, V63, P4801; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Cunha GR, 1996, ACTA ANAT, V155, P63; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Hoffmann R, 2004, NAT GENET, V36, P664, DOI 10.1038/ng0704-664; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jacobsen SJ, 2001, UROLOGY, V58, P5, DOI 10.1016/S0090-4295(01)01298-5; Jakobsen H, 1988, Scand J Urol Nephrol Suppl, V107, P26; Koch AE, 2005, ARTHRITIS RHEUM, V52, P710, DOI 10.1002/art.20932; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770; Macoska JA, 2004, CANCER GENET CYTOGEN, V154, P36, DOI 10.1016/j.cancergencyto.2004.02.013; Mochizuki H, 2004, BIOCHEM BIOPH RES CO, V320, P656, DOI 10.1016/j.bbrc.2004.06.013; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Olumi AF, 1998, CANCER RES, V58, P4525; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Spano JP, 2004, ANN ONCOL, V15, P613, DOI 10.1093/annonc/mdh136; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Taichman RS, 2002, CANCER RES, V62, P1832; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022	36	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26767	26774		10.1074/jbc.M700440200	http://dx.doi.org/10.1074/jbc.M700440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631494	hybrid			2022-12-27	WOS:000249304900016
J	Denisov, IG; Grinkova, YV; McLean, MA; Sligar, SG				Denisov, Ilia G.; Grinkova, Yelena V.; McLean, Mark A.; Sligar, Stephen G.			The one-electron autoxidation of human cytochrome p450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PHOSPHOLIPID-BILAYER NANODISCS; NANOSCALE LIPID-BILAYERS; CYANIDE BINDING; ACTIVE-SITE; LIGAND-BINDING; NITRIC-OXIDE; MEMBRANE-PROTEINS; HORSERADISH-PEROXIDASE; GEMINATE RECOMBINATION	Monomeric cytochrome P450 3A4 ( CYP3A4), the most prevalent cytochrome P450 in human liver, can simultaneously bind one, two, or three molecules of substrates and effectors. The difference in the functional properties of such binding intermediates gives rise to homotropic and heterotropic cooperative kinetics of this enzyme. To understand the overall kinetic processes operating in CYP3A4, we documented the kinetics of autoxidation of the oxy-ferrous intermediate of CYP3A4 as a function of testosterone concentration. The rate of autoxidation in the presence of testosterone was significantly lower than that observed with no substrate present. Stability of the oxy-ferrous complex in CYP3A4 and the amplitude of the geminate CO rebinding increased significantly as a result of binding of just one testosterone molecule. In contrast, the slow phase in the kinetics of cyanide binding to the ferric CYP3A4 correlated with a shift of the heme iron spin state, which is only caused by the association of a second molecule of testosterone. Our results show that the first substrate binding event prevents the escape of diatomic ligands from the distal heme binding pocket, stabilizes the oxy-ferrous complex, and thus serves as an important modulator of the uncoupling channel in the cytochromes P450.	Univ Illinois, Ctr Biophys & Computat Biol, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Dept Biochem, 116 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Denisov, Ilia G/J-6590-2013; Denisov, Gleb/J-6549-2013	Denisov, Ilia G/0000-0002-7878-2626; Denisov, Gleb/0000-0002-1246-0552; McLean, Mark/0000-0001-9125-293X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31756, GM 33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1990, BIOCHEMISTRY-US, V29, P1271, DOI 10.1021/bi00457a024; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BANCI L, 1993, BIOPHYS J, V65, P806, DOI 10.1016/S0006-3495(93)81122-6; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; BLANCK J, 1991, XENOBIOTICA, V21, P121, DOI 10.3109/00498259109039456; Cao WX, 2004, BIOCHEMISTRY-US, V43, P7017, DOI 10.1021/bi0497291; Clark JP, 2006, J INORG BIOCHEM, V100, P1075, DOI 10.1016/j.jinorgbio.2005.11.020; Cojocaru V, 2007, BBA-GEN SUBJECTS, V1770, P390, DOI 10.1016/j.bbagen.2006.07.005; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Denisov IG, 2007, J BIOL CHEM, V282, P7066, DOI 10.1074/jbc.M609589200; Denisov IG, 2006, J BIOL CHEM, V281, P23313, DOI 10.1074/jbc.M605511200; DOLMAN D, 1968, BIOCHEMISTRY-US, V7, P3991, DOI 10.1021/bi00851a028; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; DUNFORD HB, 1978, CAN J CHEM, V56, P2844, DOI 10.1139/v78-468; ERMAN JE, 1974, BIOCHEMISTRY-US, V13, P39, DOI 10.1021/bi00698a007; FISHER MT, 1987, BIOCHEMISTRY-US, V26, P4797, DOI 10.1021/bi00389a029; FISHER MT, 1985, BIOCHEMISTRY-US, V24, P6696, DOI 10.1021/bi00344a059; Gautier C, 2004, J BIOL CHEM, V279, P4358, DOI 10.1074/jbc.M305048200; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; Gustafsson MCU, 2004, BIOCHEMISTRY-US, V43, P5474, DOI 10.1021/bi035904m; Henry ER, 1997, BIOPHYS J, V72, P652, DOI 10.1016/S0006-3495(97)78703-4; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Jakopitsch C, 2005, J BIOL CHEM, V280, P42411, DOI 10.1074/jbc.M508009200; KELLIS JT, 1987, J BIOL CHEM, V262, P8840; LAMBEIR AM, 1983, J INORG BIOCHEM, V19, P291, DOI 10.1016/0162-0134(83)80002-6; LAMBEIR AM, 1983, BIOPHYS CHEM, V18, P195, DOI 10.1016/0301-4622(83)80031-3; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MAUREL P, 1979, MICROSOMES DRUG OXID, V1, P359; MCKENNA CE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P109, DOI 10.1016/0304-4165(91)90082-R; McLean MA, 1996, BIOCHIMIE, V78, P700, DOI 10.1016/S0300-9084(97)82527-8; Mouawad L, 2007, PROTEIN SCI, V16, P781, DOI 10.1110/ps.062374707; Nath A, 2007, BIOCHEMISTRY-US, V46, P2059, DOI 10.1021/bi602371n; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Nienhaus K, 2004, J BIOL CHEM, V279, P22944, DOI 10.1074/jbc.M401561200; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; ROHLFS RJ, 1988, J BIOL CHEM, V263, P1803; Rydberg P, 2007, J PHYS CHEM B, V111, P5445, DOI 10.1021/jp070390c; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SEGEL IH, 1975, ENZYME KINETICS, P72; Sligar SG, 2003, BIOCHEM BIOPH RES CO, V312, P115, DOI 10.1016/j.bbrc.2003.09.188; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; SLIGAR SG, 2007, IN PRESS DRUG METAB; Tetreau C, 2005, BBA-GEN SUBJECTS, V1724, P411, DOI 10.1016/j.bbagen.2005.04.024; TIAN WD, 1995, J BIOL CHEM, V270, P8673, DOI 10.1074/jbc.270.15.8673; TOTANI K, 1983, ARCH BIOCHEM BIOPHYS, V222, P207, DOI 10.1016/0003-9861(83)90518-0; Wade RC, 2004, J INORG BIOCHEM, V98, P1175, DOI 10.1016/j.jinorgbio.2004.02.007; Wang LH, 2001, J BIOL CHEM, V276, P14737, DOI 10.1074/jbc.M009177200; Wienkers LC, 2005, NAT REV DRUG DISCOV, V4, P825, DOI 10.1038/nrd1851; Ye X, 2006, J AM CHEM SOC, V128, P1444, DOI 10.1021/ja057172m; Ye X, 2005, J AM CHEM SOC, V127, P5854, DOI 10.1021/ja042365f; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018	63	53	53	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26865	26873		10.1074/jbc.M704747200	http://dx.doi.org/10.1074/jbc.M704747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650504	hybrid			2022-12-27	WOS:000249304900026
J	Di Matteo, A; Gianni, S; Schinina, ME; Giorgi, A; Altieri, F; Calosci, N; Brunori, M; Travaglini-Allocatelli, C				Di Matteo, Adele; Gianni, Stefano; Schinina, M. Eugenia; Giorgi, Alessandra; Altieri, Fabio; Calosci, Nicoletta; Brunori, Maurizio; Travaglini-Allocatelli, Carlo			A strategic protein in cytochrome C maturation - Three-dimensional structure of CcmH and binding to apocytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; DISULFIDE BONDS; ACTIVE-SITE; IN-VITRO; HEME; REACTIVITY; PATHWAY; SPECIFICITY; BIOGENESIS; IONIZATION	CcmH ((c) under bar ytochromes (c) under bar (m) under bar aturation protein H) is an essential component of the assembly line necessary for the maturation of c-type cytochromes in the periplasm of Gram-negative bacteria. The protein is a membrane-anchored thiol-oxidoreductase that has been hypothesized to be involved in the recognition and reduction of apocytochrome c, a prerequisite for covalent heme attachment. Here, we present the 1.7 angstrom crystal structure of the soluble periplasmic domain of CcmH from the opportunistic pathogen Pseudomonas aeruginosa (Pa-CcmH*). The protein contains a three-helix bundle, i.e. a fold that is different from that of all other thiol-oxidoreductases reported so far. The catalytic Cys residues of the conserved LRCXXC motif (Cys(25) and Cys(28)), located in a long loop connecting the first two helices, form a disulfide bond in the oxidized enzyme. We have determined the pK(a) values of these 2 Cys residues of Pa-CcmH* ( both > 8) and propose a possible mechanistic role for a conserved Ser(36) and a water molecule in the active site. The interaction between Pa-CcmH* and Pa-apocyt c(551) ( where cyt c(551) represents cytochrome c(551)) was characterized in vitro following the binding kinetics by stopped-flow using a Trp-containing fluorescent variant of Pa-CcmH* and a dansylated peptide, mimicking the apocytochrome c551 heme binding motif. The kinetic results show that the protein has a moderate affinity to its apocyt substrate, consistent with the role of Pa-CcmH as an intermediate component of the assembly line for c-type cytochrome biogenesis.	Univ Rome, Dipartimento Sci Biochim & Ist Biol & Patol Mol C, I-00815 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Brunori, M (corresponding author), Univ Rome, Dipartimento Sci Biochim & Ist Biol & Patol Mol C, Piazzale A Morro 5, I-00815 Rome, Italy.	maurizio.brunori@uniroma1.it	gianni, stefano/C-8536-2009; Altieri, Fabio/D-2790-2009; Di Matteo, Adele/AAC-8338-2019	Altieri, Fabio/0000-0002-6546-2738; Di Matteo, Adele/0000-0002-5921-7365; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Brunori, Maurizio/0000-0002-7795-1635; Gianni, Stefano/0000-0003-1653-1925				Ahuja U, 2005, J BIOL CHEM, V280, P236, DOI 10.1074/jbc.M410912200; Bhattacharyya R, 2004, PROTEIN ENG DES SEL, V17, P795, DOI 10.1093/protein/gzh093; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; Colbert CL, 2006, P NATL ACAD SCI USA, V103, P4410, DOI 10.1073/PNAS.0600552103; Crow A, 2004, J BIOL CHEM, V279, P23654, DOI 10.1074/jbc.M402823200; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DALTROP O, 2003, J BIOL CHEM, V278, P23408; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Edeling MA, 2004, J BACTERIOL, V186, P4030, DOI 10.1128/JB.186.12.4030-4033.2004; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Feissner RE, 2006, MOL MICROBIOL, V61, P219, DOI 10.1111/j.1365-2958.2006.05221.x; Fersht A, 1999, STRUCTURE MECH PROTE, P132; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOMGREN A, 1995, STRUCTURE CAMB, V3, P239; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Lamzin VS, 2000, NAT STRUCT BIOL, V7, P978, DOI 10.1038/80763; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewin A, 2006, J BIOL CHEM, V281, P35467, DOI 10.1074/jbc.M607047200; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Menchise V, 2001, BIOCHEM J, V359, P65, DOI 10.1042/0264-6021:3590065; Meyer EH, 2005, P NATL ACAD SCI USA, V102, P16113, DOI 10.1073/pnas.0503473102; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Rios-Velazquez C, 2003, J BACTERIOL, V185, P422, DOI 10.1128/JB.185.2.422-431.2003; Setterdahl AT, 2000, BIOCHEMISTRY-US, V39, P10172, DOI 10.1021/bi000663t; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stirnimann CU, 2005, STRUCTURE, V13, P985, DOI 10.1016/j.str.2005.04.014; Tan JT, 2004, CHEMBIOCHEM, V5, P1479, DOI 10.1002/cbic.200400036; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; Turkarslan S, 2006, MOL MICROBIOL, V60, P537, DOI 10.1111/j.1365-2958.2006.05148.x	47	33	33	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27012	27019		10.1074/jbc.M702702200	http://dx.doi.org/10.1074/jbc.M702702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623665	hybrid			2022-12-27	WOS:000249304900042
J	Pei, XH; Guo, XH; Coppel, R; Mohandas, N; An, XL				Pei, Xinhong; Guo, Xinhua; Coppel, Ross; Mohandas, Narla; An, Xiuli			Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) destabilizes erythrocyte membrane skeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH PROTEIN; RED-BLOOD-CELLS; SURFACE-ANTIGEN; FUNCTIONAL-CHARACTERIZATION; MALARIAL INFECTION; GENE DISRUPTION; BETA-SPECTRIN; BINDING-SITES; STABILITY; DOMAINS	Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) is a parasite-derived protein that appears on the cytoplasmic surface of the host cell membrane in the later stages of the parasite's development where it associates with membrane skeleton. We have recently demonstrated that a 60-residue fragment (FIa1, residues 38-97) of PfEMP3 bound to spectrin. Here we show that this polypeptide binds specifically to a site near the C terminus of alpha-spectrin at the point that spectrin attaches to actin and protein 4.1R in forming the junctions of the membrane skeletal network. We further show that this polypeptide disrupts formation of the ternary spectrin-actin-4.1R complex in solution. Importantly, when incorporated into the cell, the PfEMP3 fragment causes extensive reduction in shear resistance of the cell. We conjecture that the loss of mechanical cohesion of the membrane may facilitate the exit of the mature merozoites from the cell.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10065 USA; Monash Univ, Dept Microbiol, Monash, Vic 3800, Australia	New York Blood Center; Monash University	An, XL (corresponding author), Red Cell Physiol Lab, 310 E 37th St, New York, NY 10021 USA.	xan@nybloodcenter.org	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263, P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 2005, BIOCHEMISTRY-US, V44, P10681, DOI 10.1021/bi047331z; An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BECKER PS, 1987, J CLIN INVEST, V80, P557, DOI 10.1172/JCI113104; Bennett BJ, 1997, J BIOL CHEM, V272, P15299, DOI 10.1074/jbc.272.24.15299; COHEN CM, 1980, CELL, V21, P875, DOI 10.1016/0092-8674(80)90451-1; CONBOY JG, 1991, BLOOD, V78, P2438, DOI 10.1182/blood.V78.9.2438.bloodjournal7892438; Cooke BM, 2002, BRIT J HAEMATOL, V117, P203, DOI 10.1046/j.1365-2141.2002.03404.x; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Cowman AF, 2006, SCIENCE, V313, P1245, DOI 10.1126/science.1132940; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; DASILVA E, 1994, MOL BIOCHEM PARASIT, V66, P59, DOI 10.1016/0166-6851(94)90036-1; FOLEY M, 1991, MOL BIOCHEM PARASIT, V46, P137, DOI 10.1016/0166-6851(91)90207-M; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; MAGOWAN C, 1995, BLOOD, V86, P3196; MOHANDAS N, 1982, BLOOD, V59, P768; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; Pei XH, 2005, J BIOL CHEM, V280, P31166, DOI 10.1074/jbc.M505298200; Pei XH, 2007, BLOOD, V110, P1036, DOI 10.1182/blood-2007-02-076919; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Silva MD, 2005, MOL MICROBIOL, V56, P990, DOI 10.1111/j.1365-2958.2005.04603.x; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; Waller KL, 2003, BLOOD, V102, P1911, DOI 10.1182/blood-2002-11-3513; Waller KL, 2002, MOL BIOCHEM PARASIT, V119, P125, DOI 10.1016/S0166-6851(01)00395-4; Wandersee N J, 2000, Hematol J, V1, P235, DOI 10.1038/sj.thj.6200030; Wandersee NJ, 2003, BLOOD, V101, P325, DOI 10.1182/blood-2002-01-0113	31	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26754	26758		10.1074/jbc.M701612200	http://dx.doi.org/10.1074/jbc.M701612200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626011	hybrid			2022-12-27	WOS:000249304900014
J	Thon, M; Al-Abdallah, Q; Hortschansky, P; Brakhage, AA				Thoen, Marcel; Al-Abdallah, Qusai; Hortschansky, Peter; Brakhage, Axel A.			The thioredoxin system of the filamentous fungus Aspergillus nidulans - Impact on development and oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; PARASITE PLASMODIUM-FALCIPARUM; ESCHERICHIA COLI B; PENICILLIN BIOSYNTHESIS; SEXUAL DEVELOPMENT; GLUTATHIONE-REDUCTASE; DROSOPHILA-MELANOGASTER; ALDEHYDE DEHYDROGENASE; CATALASE GENES; FUMIGATUS	Redox regulation has been shown to be of increasing importance for many cellular processes. Here, redox homeostasis was addressed in Aspergillus nidulans, an important model organism for fundamental biological questions such as development, gene regulation or the regulation of the production of secondary metabolites. We describe the characterization of a thioredoxin system from the filamentous fungus A. nidulans. The A. nidulans thioredoxin A(AnTrxA) is an 11.6-kDa protein with a characteristic thioredoxin active site motif (WCGPC) encoded by the trxA gene. The corresponding thioredoxin reductase (AnTrxR), encoded by the trxR gene, represents a homodimeric flavoprotein with a native molecular mass of 72.2 kDa. When combined in vitro, the in Escherichia coli overproduced recombinant proteins AnTrxA and AnTrxR were able to reduce insulin and oxidized glutathione in an NADPH-dependent manner indicating that this in vitro redox system is functional. Moreover, we have created a thioredoxin A deletion strain that shows decreased growth, an increased catalase activity, and the inability to form reproductive structures like conidiophores or cleistothecia when cultivated under standard conditions. However, addition of GSH at low concentrations led to the development of sexual cleistothecia, whereas high GSH levels resulted in the formation of asexual conidiophores. Furthermore, by applying the principle of thioredoxin-affinity chromatography we identified several novel putative targets of thioredoxin A, including a hypothetical protein with peroxidase activity and an aldehyde dehydrogenase.	Leibniz Inst Nat Prod Res & Infect Bio HKI, Dept Mol & Apll Microbiol, D-07745 Jena, Germany; Univ Jena, D-07745 Jena, Germany	Hans Knoll Institute (HKI); Friedrich Schiller University of Jena	Brakhage, AA (corresponding author), Leibniz Inst Nat Prod Res & Infect Bio HKI, Dept Mol & Apll Microbiol, D-07745 Jena, Germany.	Axel.Brakhage@hki-jena.de		Al Abdallah, Qusai/0000-0002-6532-0617				Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Aguirre J, 2005, TRENDS MICROBIOL, V13, P111, DOI 10.1016/j.tim.2005.01.007; Aguirre J, 2006, MED MYCOL, V44, pS101, DOI 10.1080/13693780600900080; AHARONOWITZ Y, 1993, J BACTERIOL, V175, P623, DOI 10.1128/JB.175.3.623-629.1993; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Bauer H, 2003, EUR J BIOCHEM, V270, P4272, DOI 10.1046/j.1432-1033.2003.03812.x; Bauer H, 2002, J BIOL CHEM, V277, P17457, DOI 10.1074/jbc.M200636200; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brakhage AA, 2005, PHYTOCHEMISTRY, V66, P1200, DOI 10.1016/j.phytochem.2005.02.030; BRAKHAGE AA, 1995, J BACTERIOL, V177, P2781, DOI 10.1128/jb.177.10.2781-2788.1995; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; COHEN G, 1994, J BACTERIOL, V176, P973, DOI 10.1128/JB.176.4.973-984.1994; DIAMOND RD, 1982, INFECT IMMUN, V38, P487, DOI 10.1128/IAI.38.2.487-495.1982; Dubuisson M, 2004, FEBS LETT, V571, P161, DOI 10.1016/j.febslet.2004.06.080; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Flipphi M, 2001, J BIOL CHEM, V276, P6950, DOI 10.1074/jbc.M005769200; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GOLDBERG I, 1989, BIOCHIM BIOPHYS ACTA, V991, P330, DOI 10.1016/0304-4165(89)90124-4; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann B, 2001, GENETICS, V157, P141; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hortschansky P, 2007, EMBO J, V26, P3157, DOI 10.1038/sj.emboj.7601752; Ito JI, 2006, INFECT IMMUN, V74, P5075, DOI 10.1128/IAI.00815-06; Jeon SJ, 2002, EUR J BIOCHEM, V269, P5423, DOI 10.1046/j.1432-1033.2002.03231.x; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kawasaki L, 2002, MOL MICROBIOL, V45, P1153, DOI 10.1046/j.1365-2958.2002.03087.x; Kawasaki L, 1997, J BACTERIOL, V179, P3284, DOI 10.1128/jb.179.10.3284-3292.1997; Kawasaki L, 2001, J BACTERIOL, V183, P1434, DOI 10.1128/JB.183.4.1434-1440.2001; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Kniemeyer O, 2006, CURR GENET, V49, P178, DOI 10.1007/s00294-005-0047-9; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; Lara-Ortiz T, 2003, MOL MICROBIOL, V50, P1241, DOI 10.1046/j.1365-2958.2003.03800.x; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEMARECHAL P, 1992, EUR J BIOCHEM, V210, P421; Litzka O, 1995, MOL GEN GENET, V249, P557, DOI 10.1007/BF00290581; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATHIEU I, 1992, BIOCHEM J, V285, P255, DOI 10.1042/bj2850255; MOONEY JL, 1990, GENE DEV, V4, P1473, DOI 10.1101/gad.4.9.1473; MOORE EC, 1964, J BIOL CHEM, V239, P3453; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nayak T, 2006, GENETICS, V172, P1557, DOI 10.1534/genetics.105.052563; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scherer M, 2002, EUKARYOT CELL, V1, P725, DOI 10.1128/EC.1.5.725-735.2002; Serrato AJ, 2002, BIOCHEM J, V367, P491, DOI 10.1042/BJ20020103; Shen ML, 2000, BIOCHEM PHARMACOL, V60, P947, DOI 10.1016/S0006-2952(00)00435-4; Sprote P, 2007, ARCH MICROBIOL, V188, P69, DOI 10.1007/s00203-007-0224-y; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; Weidner G, 1998, CURR GENET, V33, P378, DOI 10.1007/s002940050350; WICKES B, 2004, EPICENTRE FORUM, V11, P7; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; XU XM, 1991, J BIOCHEM-TOKYO, V109, P678, DOI 10.1093/oxfordjournals.jbchem.a123440; Yager L N, 1992, Biotechnology, V23, P19	69	82	90	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27259	27269		10.1074/jbc.M704298200	http://dx.doi.org/10.1074/jbc.M704298200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631497	hybrid			2022-12-27	WOS:000249304900067
J	Zhu, J; Jia, X; Xiao, G; Kang, Y; Partridge, NC; Qin, L				Zhu, Ji; Jia, Xun; Xiao, Guozhi; Kang, Yibin; Partridge, Nicola C.; Qin, Ling			EGF-like Ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by Osteoblasts - Implications for osteolytic bone metastases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; KAPPA-B-LIGAND; RECEPTOR ACTIVATOR; CANCER METASTASIS; CELLS; RESORPTION; MICE; DIFFERENTIATION; OSTEOPROTEGERIN; MC3T3-E1	Epidermal growth factor ( EGF)-like ligands and their receptors constitute one of the most important signaling networks functioning in normal tissue development and cancer biology. Recent in vivo mouse models suggest this signaling network plays an essential role in bone metabolism. Using a coculture system containing bone marrow macrophage and osteoblastic cells, here we report that EGF-like ligands stimulate osteoclastogenesis by acting on osteoblastic cells. This stimulation is not a direct effect because osteoclasts do not express functional EGF receptors ( EGFRs). Further studies reveal that EGF-like ligands strongly regulate the expression of two secreted osteoclast regulatory factors in osteoblasts by decreasing osteoprotegerin ( OPG) expression and increasing monocyte chemoattractant protein 1 ( MCP1) expression in an EGFR-dependent manner and consequently stimulate TRAP-positive osteoclast formation. Addition of exogenous OPG completely inhibited osteoclast formation stimulated by EGF-like ligands, while addition of a neutralizing antibody against MCP-1 exhibited partial inhibition. Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035. Because a high percentage of human carcinomas express EGF-like ligands, our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing to bone.	UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Princeton University	Qin, L (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	qinl1@umdnj.edu		Partridge, Nicola/0000-0002-5406-4814; Kang, Yibin/0000-0002-1626-6730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK071988] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01 DK 071988] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200; Davideau JL, 1995, CONNECT TISSUE RES, V32, P47, DOI 10.3109/03008209509013705; HATA RI, 1984, ENDOCRINOLOGY, V115, P867, DOI 10.1210/endo-115-3-867; Hirata A, 2002, CANCER RES, V62, P2554; IBBOTSON KJ, 1986, P NATL ACAD SCI USA, V83, P2228, DOI 10.1073/pnas.83.7.2228; Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood-2004-09-3645; KUMEGAWA M, 1983, CALCIFIED TISSUE INT, V35, P542, DOI 10.1007/BF02405091; LORENZO JA, 1986, J CLIN INVEST, V77, P1897, DOI 10.1172/JCI112517; Miettinen PJ, 1999, NAT GENET, V22, P69, DOI 10.1038/8773; NG KW, 1983, CALCIFIED TISSUE INT, V35, P298, DOI 10.1007/BF02405050; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078-0432.CCR-05-1806; Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Schneider MR, 2005, ENDOCRINOLOGY, V146, P5237, DOI 10.1210/en.2005-0418; Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; Younes MN, 2005, CANCER RES, V65, P4716, DOI 10.1158/0008-5472.CAN-04-4196	40	88	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26656	26665		10.1074/jbc.M705064200	http://dx.doi.org/10.1074/jbc.M705064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636266	hybrid			2022-12-27	WOS:000249304900004
J	Han, S; Liu, Y; Chang, A				Han, Sumin; Liu, Yu; Chang, Amy			Cytoplasmic hsp70 promotes ubiquitination for endoplasmic reticulum-associated degradation of a misfolded mutant of the yeast plasma membrane ATPase, PMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; ER-ASSOCIATED DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNFOLDED PROTEIN RESPONSE; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; MOLECULAR CHAPERONES; QUALITY-CONTROL; H+-ATPASE; STRESS-RESPONSE	Cells have a variety of strategies for dealing with misfolded proteins. Heat shock response involves transcriptional induction of chaperones to promote and/or correct folding, and also activation of the ubiquitin/proteasome system to degrade defective proteins. In the secretory pathway, it is primarily luminal misfolded or unassembled proteins that trigger the unfolded protein response which, like heat shock, induces chaperones and components of the endoplasmic reticulum (ER)-associated degradation ( ERAD) pathway. To understand cellular response to a misfolded polytopic membrane protein of the secretory pathway, we studied Pma1-D378S, a model ERAD substrate. Expression of misfolded Pma1 induces heat shock response in the absence of increased temperature. Overexpression of HSF1, the transcription factor that mediates heat shock response, increases degradation of Pma1-D378S without temperature upshift. Nevertheless, efficient Pma1-D378S degradation occurs in an hsf1 mutant that maintains basal transcription levels but cannot mediate transcriptional activation. Thus, heat shock protein induction enhances but is not necessary for ERAD. The Ssa group of cytoplasmic Hsp70 chaperones is required for ERAD of both Pma1-D378S and another transmembrane ERAD substrate, Ste6*. In the absence of Ssa chaperones, ubiquitination of both substrates is impaired, resulting in stabilization. We suggest a role for Hsp70 cytoplasmic chaperones in recognition by the endoplasmic reticulum-associated ubiquitination machinery.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chang, A (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	amychang@umich.edu	Chang, Amy/AAS-5491-2020; Liu, Yu/X-5864-2019	Chang, Amy/0000-0003-3682-6456; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058212, R01GM058212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Cashikar AG, 2005, J BIOL CHEM, V280, P23869, DOI 10.1074/jbc.M502854200; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Huyer G, 2004, MOL BIOL CELL, V15, P908, DOI 10.1091/mbc.E03-07-0546; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; PARK HO, 1991, GENE DEV, V5, P1299, DOI 10.1101/gad.5.7.1299; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Ravid T, 2006, EMBO J, V25, P533, DOI 10.1038/sj.emboj.7600946; Rose MD., 1990, METHODS YEAST GENETI; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SHERMAN F, 1986, METHODS YEAT GENETIC; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trotter EW, 2002, J BIOL CHEM, V277, P44817, DOI 10.1074/jbc.M204686200; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	50	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26140	26149		10.1074/jbc.M701969200	http://dx.doi.org/10.1074/jbc.M701969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17631501	hybrid			2022-12-27	WOS:000249239600017
J	Dzeja, PP; Bast, P; Pucar, D; Wieringa, B; Terzic, A				Dzeja, Petras P.; Bast, Peter; Pucar, Darko; Wieringa, Be; Terzic, Andre			Defective metabolic signaling in adenylate kinase AK1 gene knock-out hearts compromises post-ischemic coronary reflow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTACT SKELETAL-MUSCLE; O-18-ASSISTED P-31 NMR; SENSITIVE K+ CHANNELS; CREATINE-KINASE; ENDOTHELIAL-CELLS; ENERGY-METABOLISM; SMOOTH-MUSCLE; CATALYZED PHOSPHOTRANSFER; NITRIC-OXIDE	Matching blood flow to myocardial energy demand is vital for heart performance and recovery following ischemia. The molecular mechanisms responsible for transduction of myocardial energetic signals into reactive vasodilatation are, however, elusive. Adenylate kinase, associated with AMP signaling, is a sensitive reporter of the cellular energy state, yet the contribution of this phosphotransfer system in coupling myocardial metabolism with coronary flow has not been explored. Here, knock out of the major adenylate kinase isoform, AK1, disrupted the synchrony between inorganic phosphate Pi turnover at ATP-consuming sites and gamma-ATP exchange at ATP synthesis sites, as revealed by O-18-assisted P-31 NMR. This reduced energetic signal communication in the post-ischemic heart. AK1 gene deletion blunted vascular adenylate kinase phosphotransfer, compromised the contractility-coronary flow relationship, and precipitated inadequate coronary reflow following ischemia-reperfusion. Deficit in adenylate kinase activity abrogated AMP signal generation and reduced the vascular adenylate kinase/ creatine kinase activity ratio essential for the response of metabolic sensors. The sarcolemma-associated splice variant AK1 beta facilitated adenosine production, a function lost in the absence of adenylate kinase activity. Adenosine treatment bypassed AK1 deficiency and restored post-ischemic flow to wild-type levels, achieving phenotype rescue. AK1 phosphotransfer thus transduces stress signals into adequate vascular response, providing linkage between cell bioenergetics and coronary flow.	Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Radboud Univ Nijmegen Med Ctr, Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands	Mayo Clinic; Mayo Clinic; Mayo Clinic; Radboud University Nijmegen	Dzeja, PP (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	dzeja.petras@mayo.edu	Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020	NHLBI NIH HHS [R01 HL085744-02W1, R01 HL085744-02, R01 HL085744-01A1, R01 HL085744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 2002, J BIOL CHEM, V277, P24427, DOI 10.1074/jbc.M201777200; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; Brewster LM, 2006, CIRCULATION, V114, P2034, DOI 10.1161/CIRCULATIONAHA.105.584490; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; da Silva CG, 2006, CIRC RES, V98, pE39, DOI 10.1161/01.RES.0000215436.92414.1d; DAUT J, 1994, CARDIOVASC RES, V28, P811, DOI 10.1093/cvr/28.6.811; DAWIS SM, 1989, BIOPHYS J, V55, P79, DOI 10.1016/S0006-3495(89)82782-1; Decking UKM, 1997, CIRC RES, V81, P154, DOI 10.1161/01.RES.81.2.154; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 2004, MOL CELL BIOCHEM, V256, P13, DOI 10.1023/B:MCBI.0000009856.23646.38; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 2003, J EXP BIOL, V206, P2039, DOI 10.1242/jeb.00426; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; DZEJA PP, 2002, MAGMA, V14, P180; DZEJA PP, 2006, HDB NEUROCHEMISTRY M, P641; Evans AM, 2005, J BIOL CHEM, V280, P41504, DOI 10.1074/jbc.M510040200; Flood AJ, 2002, CARDIOVASC RES, V55, P161, DOI 10.1016/S0008-6363(02)00329-2; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Goirand F, 2007, J PHYSIOL-LONDON, V581, P1163, DOI 10.1113/jphysiol.2007.132589; Gumina RJ, 2003, AM J PHYSIOL-HEART C, V284, pH2106, DOI 10.1152/ajpheart.00057.2003; Guns PJDF, 2005, BRIT J PHARMACOL, V146, P288, DOI 10.1038/sj.bjp.0706326; Hancock CR, 2006, J APPL PHYSIOL, V100, P406, DOI 10.1152/japplphysiol.00885.2005; Hancock CR, 2005, AM J PHYSIOL-CELL PH, V288, pC1287, DOI 10.1152/ajpcell.00567.2004; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; Ikeno F, 2007, CARDIOVASC RES, V73, P699, DOI 10.1016/j.cardiores.2006.12.011; Ingwall JS, 2004, J MOL CELL CARDIOL, V37, P613, DOI 10.1016/j.yjmcc.2004.05.020; Ishibashi Y, 1998, CIRC RES, V82, P346, DOI 10.1161/01.RES.82.3.346; ISHIDA Y, 1994, MOL CELL BIOCHEM, V133, P39, DOI 10.1007/BF01267946; Ito H, 2001, J Cardiol, V37 Suppl 1, P39; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Janssen E, 2004, MOL CELL BIOCHEM, V256, P59, DOI 10.1023/B:MCBI.0000009859.15267.db; Janssen E, 2003, J BIOL CHEM, V278, P30441, DOI 10.1074/jbc.M303150200; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; JONES CJH, 1995, CIRCULATION, V91, P1807, DOI 10.1161/01.CIR.91.6.1807; Kakkar R, 2006, CIRC RES, V98, P682, DOI 10.1161/01.RES.0000207498.40005.e7; Kane GC, 2006, FASEB J, V20, P2271, DOI 10.1096/fj.06-6349com; KROLL K, 1993, CIRC RES, V73, P846, DOI 10.1161/01.RES.73.5.846; KUROKAWA Y, 1990, ENZYME, V43, P57, DOI 10.1159/000468708; Melchert PJ, 1999, AM J PHYSIOL-HEART C, V277, pH617, DOI 10.1152/ajpheart.1999.277.2.H617; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Morrison RR, 2002, AM J PHYSIOL-HEART C, V282, pH437, DOI 10.1152/ajpheart.00723.2001; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; NITENBERG A, 1995, EUR HEART J, V16, P7, DOI 10.1093/eurheartj/16.suppl_I.7; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; PAUL RJ, 1989, ANNU REV PHYSIOL, V51, P331, DOI 10.1146/annurev.physiol.51.1.331; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; Pucar D, 2004, MOL CELL BIOCHEM, V256, P281, DOI 10.1023/B:MCBI.0000009875.30308.7a; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; Rubin LJ, 2005, J APPL PHYSIOL, V98, P296, DOI 10.1152/japplphysiol.00075.2004; Saks V, 2006, J PHYSIOL-LONDON, V571, P253, DOI 10.1113/jphysiol.2005.101444; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; Seccia TM, 1998, CLIN EXP HYPERTENS, V20, P345, DOI 10.3109/10641969809052126; Selivanov VA, 2004, MOL CELL BIOCHEM, V256, P243, DOI 10.1023/B:MCBI.0000009872.35940.7d; Sutherland FJ, 2003, CLIN EXP PHARMACOL P, V30, P879, DOI 10.1046/j.1440-1681.2003.03926.x; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Tune JD, 2004, J APPL PHYSIOL, V97, P404, DOI 10.1152/japplphysiol.01345.2003; Vial C., 2006, CREATINE KINASE, P195; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110; Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98	67	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31366	31372		10.1074/jbc.M705268200	http://dx.doi.org/10.1074/jbc.M705268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17704060	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000250309200026
J	Arthur, JF; Shen, Y; Kahn, ML; Berndt, MC; Andrews, RK; Gardiner, EE				Arthur, Jane F.; Shen, Yang; Kahn, Mark L.; Berndt, Michael C.; Andrews, Robert K.; Gardiner, Elizabeth E.			Ligand binding rapidly induces disulfide-dependent dimerization of glycoprotein VI on the platelet plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GPVI DOWN-REGULATION; C-TYPE LECTIN; GPIB-IX-V; COLLAGEN RECEPTOR; FC-RECEPTOR; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; ACTIVATION	Thrombus formation in hemostasis or thrombotic disease is initiated by adhesion of circulating platelets to damaged blood vessel walls. Exposed subendothelial collagen interacting with platelet glycoprotein (GP) VI leads to platelet activation and integrin alpha(IIb)beta(3)-mediated aggregation. We previously showed that ligand binding to GPVI also induces metalloproteinase-dependent shedding, generating an similar to 55-kDa soluble ectodomain fragment and an similar to 10-kDa membrane-associated remnant. Here, treatment of platelets with collagen or the GPVI-targeting rattlesnake toxin convulxin also induces rapid (10-30 s) formation of a high molecular weight GPVI complex (GPVIc) under nonreducing conditions, as detected by immunoblotting with anti-GPVI antibodies. The appearance of an similar to 20-kDa remnant detectable using a polyclonal antibody against the GPVI cytoplasmic tail under nonreducing, but not reducing, conditions after ectodomain shedding and nonreduced/reduced two-dimensional SDS-polyacrylamide gel analysis of biotinylated platelets confirmed that that GPVIc was a homodimer. Formation of disulfide-linked GPVIc was prolonged in the presence of metalloproteinase inhibitor GM6001 and was independent of GPVI signaling because it was unaffected by inhibitors of Src kinases, Syk, or phosphoinositide 3-kinase. To identify the thiol involved in disulfide bond formation, wild-type or mutant GPVI, where two available sulfhydryls (Cys-274 and Cys-338) were individually mutated to serine, was expressed in rat basophilic leukemia cells. Dimerization of wild-type and C274S GPVI, but not the C338S mutant, was observed after treating cells with convulxin. We conclude that (i) a subpopulation of GPVI forms a constitutive dimer on the platelet surface, facilitating rapid disulfide cross-linking, (ii) convulxin or other GPVI agonists induce disulfide-linked GPVI dimerization independent of GPVI signaling, and (iii) the penultimate residue of the GPVI cytoplasmic tail, Cys338, mediates disulfide-dependent dimer formation.	Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Monash University; University of Pennsylvania	Gardiner, EE (corresponding author), Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.	elizabeth.gardiner@med.monash.edu.au	ARTHUR, JANE/AAW-9983-2020; Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011; Berndt, Michael C/D-5580-2012	Gardiner, Elizabeth/0000-0001-9453-9688; Andrews, Robert Keith/0000-0001-9577-8082				Andrews RK, 2004, IUBMB LIFE, V56, P13, DOI 10.1080/15216540310001649831; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; Andrews RK, 2001, J BIOL CHEM, V276, P28092, DOI 10.1074/jbc.M011352200; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Arthur JF, 2005, THROMB HAEMOSTASIS, V93, P716, DOI 10.1160/TH04-09-0584; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Baker J, 2004, PLATELETS, V15, P207, DOI 10.1080/09537100410001701010; Batuwangala T, 2004, ACTA CRYSTALLOGR D, V60, P46, DOI 10.1107/S0907444903021620; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Bergmeier W, 2004, THROMB HAEMOSTASIS, V91, P951, DOI 10.1160/TH03-12-0795; Berlanga O, 2007, J THROMB HAEMOST, V5, P1026, DOI 10.1111/j.1538-7836.2007.02449.x; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Boylan B, 2006, BLOOD, V108, P908, DOI 10.1182/blood-2005-07-2937; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Gardiner EE, 2007, J THROMB HAEMOST, V5, P1530, DOI 10.1111/j.1538-7836.2007.02590.x; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hisamitsu T, 2004, BIOCHEMISTRY-US, V43, P11135, DOI 10.1021/bi049367x; Horii K, 2006, BLOOD, V108, P936, DOI 10.1182/blood-2006-01-010215; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kato K, 2006, J THROMB HAEMOST, V4, P1107, DOI 10.1111/j.1538-7836.2006.01874.x; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kuijpers MJE, 2004, J PHYSIOL-LONDON, V558, P403, DOI 10.1113/jphysiol.2004.062414; Lecut C, 2004, J BIOL CHEM, V279, P52293, DOI 10.1074/jbc.M406342200; Locke D, 2003, J BIOL CHEM, V278, P15441, DOI 10.1074/jbc.M212338200; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Moroi M, 2004, THROMB RES, V114, P221, DOI 10.1016/j.thromres.2004.06.046; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Newton JP, 1999, BIOCHEM BIOPH RES CO, V261, P283, DOI 10.1006/bbrc.1999.1018; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Powell MS, 2006, J IMMUNOL, V176, P7489, DOI 10.4049/jimmunol.176.12.7489; Rabie T, 2005, J BIOL CHEM, V280, P14462, DOI 10.1074/jbc.M500041200; Rabie T, 2007, BLOOD, V110, P529, DOI 10.1182/blood-2006-11-058107; Sarratt KL, 2005, BLOOD, V106, P1268, DOI 10.1182/blood-2004-11-4434; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Smethurst PA, 2007, J BIOL CHEM, V282, P1296, DOI 10.1074/jbc.M606479200; Stephens G, 2005, BLOOD, V105, P186, DOI 10.1182/blood-2004-07-2842; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; Takeda K, 2001, ANTIOXID REDOX SIGN, V3, P473, DOI 10.1089/15230860152409103	59	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30434	30441		10.1074/jbc.M701330200	http://dx.doi.org/10.1074/jbc.M701330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690106	hybrid			2022-12-27	WOS:000250136300011
J	de Vega, S; Iwamoto, T; Nakamura, T; Hozumi, K; McKnight, DA; Fisher, LW; Fukumoto, S; Yamada, Y				de Vega, Susana; Iwamoto, Tsutomu; Nakamura, Takashi; Hozumi, Kentaro; McKnight, Dianalee A.; Fisher, Larry W.; Fukumoto, Satoshi; Yamada, Yoshihiko			TM14 is a new member of the fibulin family (fibulin-7) that interacts with extracellular matrix molecules and is active for cell binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ODONTOBLAST DIFFERENTIATION; TOOTH DEVELOPMENT; TISSUE LOCALIZATION; MEMBRANE-PROTEIN; CARCINOMA CELLS; IN-VIVO; EXPRESSION; FIBRONECTIN; GENE; DOMAINS	We identified a new extracellular protein, TM14, by differential hybridization using mouse tooth germ cDNA microarrays. TM14 cDNA encodes 440 amino acids containing a signal peptide. The protein contains 3 EGF modules at the center, aC-terminal domain homologous to the fibulin module, and a unique Sushi domain at the N terminus. In situ hybridization revealed that TM14 mRNA was expressed by preodontoblasts and odontoblasts in developing teeth. TM14 mRNA was also expressed in cartilage, hair follicles, and extraembryonic tissues of the placenta. Immunostaining revealed that TM14 was localized at the apical pericellular regions of preodontoblasts. When the dentin matrix was fully formed and dentin mineralization occurred, TM14 was present in the predentin matrix and along the dentinal tubules. We found that the recombinant TM14 protein was glycosylated with N-linked oligosaccharides and interacted with heparin, fibronectin, fibulin-1, and dentin sialophosphoprotein. We also found that TM14 preferentially bound dental mesenchyme cells and odontoblasts but not dental epithelial cells or nondental cells such as HeLa, COS7, or NIH3T3 cells. Heparin, EDTA, and anti-integrin beta 1 antibody inhibited TM14 binding to dental mesenchyme cells, suggesting that both a heparan sulfate-containing cell surface receptor and an integrin are involved in TM14 cell binding. Our findings indicate that TM14 is a cell adhesion molecule that interacts with extracellular matrix molecules in teeth and suggest that TM14 plays important roles in both the differentiation and maintenance of odontoblasts as well as in dentin formation. Because of its protein characteristics, TM14 can be classified as a new member of the fibulin family: fibulin-7.	NIDCR, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA; Kyushu Univ, Fac Dent Sci, Dept Pediat Dent, Fukuoka 8128582, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kyushu University	Yamada, Y (corresponding author), NIDCR, Lab Cell & Dev Biol, NIH, Bldg 30,Rm 407,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov	Iwamoto, Tsutomu/AAI-8952-2021; Iwamoto, Tsutomu/AAA-6597-2019; Nakamura, Takashi/A-8931-2012; Nakamura, Takashi/P-7796-2016; de Vega, Susana/AAH-4775-2020	Iwamoto, Tsutomu/0000-0001-8472-605X; Nakamura, Takashi/0000-0001-9904-1037; Nakamura, Takashi/0000-0001-9904-1037; Hozumi, Kentaro/0000-0002-6671-4386; Fukumoto, Satoshi/0000-0002-5046-6891	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000483, ZIADE000074, ZIADE000720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000720, Z01DE000483, Z01DE000074] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; BRONCKERS ALJJ, 1987, J HISTOCHEM CYTOCHEM, V35, P825, DOI 10.1177/35.8.3298423; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; Ehlermann J, 2003, GENE EXPR PATTERNS, V3, P441, DOI 10.1016/S1567-133X(03)00084-X; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FUJISAWA R, 1989, ARCH ORAL BIOL, V34, P89, DOI 10.1016/0003-9969(89)90131-3; Fukumoto S, 2005, CELLS TISSUES ORGANS, V181, P189, DOI 10.1159/000091380; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806; Hozumi K, 2006, J BIOL CHEM, V281, P32929, DOI 10.1074/jbc.M605708200; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; KLUBER MD, 1988, ROUX ARCH DEVEL BIOL, V197, P212; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; LESOT H, 1992, DIFFERENTIATION, V49, P109, DOI 10.1111/j.1432-0436.1992.tb00775.x; LESOT H, 1988, DIFFERENTIATION, V37, P62, DOI 10.1111/j.1432-0436.1988.tb00797.x; LESOT H, 1990, DIFFERENTIATION, V44, P25, DOI 10.1111/j.1432-0436.1990.tb00533.x; LESOT H, 1985, DIFFERENTIATION, V29, P176, DOI 10.1111/j.1432-0436.1985.tb00312.x; LESOT H, 1981, DEV BIOL, V82, P371, DOI 10.1016/0012-1606(81)90460-7; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; Matsuura T, 2001, MATRIX BIOL, V20, P367, DOI 10.1016/S0945-053X(01)00142-1; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Nakamura T, 2004, J BIOL CHEM, V279, P626, DOI 10.1074/jbc.M307502200; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; REICHERT T, 1992, CALCIFIED TISSUE INT, V50, P468, DOI 10.1007/BF00296779; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Ruch J V, 1987, Revis Biol Celular, V14, P1; Saito T, 2004, J ENDODONT, V30, P205, DOI 10.1097/00004770-200404000-00005; SAMBROOK J, 1989, EXTRACTION PURIFICAT; Singh U, 2006, PLACENTA, V27, P1014, DOI 10.1016/j.placenta.2005.10.009; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Tran H, 1997, J BIOL CHEM, V272, P22600, DOI 10.1074/jbc.272.36.22600; Utani A, 2003, J BIOL CHEM, V278, P34483, DOI 10.1074/jbc.M304827200; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Weigell-Weber M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1184, DOI 10.1001/archopht.121.8.1184; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0	55	73	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30878	30888		10.1074/jbc.M705847200	http://dx.doi.org/10.1074/jbc.M705847200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699513	hybrid			2022-12-27	WOS:000250136300056
J	Mohs, A; Silva, T; Yoshida, T; Amin, R; Lukomski, S; Inouye, M; Brodsky, B				Mohs, Angela; Silva, Teresita; Yoshida, Takeshi; Amin, Ravish; Lukomski, Slawomir; Inouye, Masayori; Brodsky, Barbara			Mechanism of stabilization of a bacterial collagen triple helix in the absence of hydroxyproline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; AMINO-ACID-SEQUENCE; GLY-X-Y; MOLECULAR-STRUCTURE; SURFACE PROTEIN; BACILLUS-ANTHRACIS; SCL2 PROTEINS; STABILITY; IDENTIFICATION; PEPTIDES	The Streptococcus pyogenes cell- surface protein Scl2 contains a globular N- terminal domain and a collagen- like domain, ( GlyXaa- X ' aa) 79, which forms a triple helix with a thermal stability close to that seen for mammalian collagens. Hyp is a major contributor to triple- helix stability in animal collagens, but is not present in bacteria, which lack prolyl hydroxylase. To explore the basis of bacterial collagen triple- helix stability in the absence of Hyp, biophysical studies were carried out on recombinant Scl2 protein, the isolated collagen- like domain from Scl2, and a set of peptides modeling the Scl2 highly charged repetitive ( GlyXaa- X ' aa) n sequences. At pH 7, CD spectroscopy, dynamic light scattering, and differential scanning calorimetry of the Scl2 protein all showed a very sharp thermal transition near 36 C, indicating a highly cooperative unfolding of both the globular and triple- helix domains. The collagen- like domain isolated by trypsin digestion showed a sharp transition at the same temperature, with an enthalpy of 12.5 kJ/ mol of tripeptide. At low pH, Scl2 and its isolated collagen- like domain showed substantial destabilization from the neutral pH value, with two thermal transitions at 24 and 27 C. A similar destabilization at low pH was seen for Scl2 charged model peptides, and the degree of destabilization was consistent with the strong pH dependence arising from the GKD tripeptide unit. The Scl2 protein contained twice as much charge as human fibril- forming collagens, and the degree of electrostatic stabilization observed for Scl2 was similar to the contribution Hyp makes to the stability of mammalian collagens. The high enthalpic contribution to the stability of the Scl2 collagenous domain supports the presence of a hydration network in the absence of Hyp.	Univ Med & Dent New Jersey, Dept Biochem, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; West Virginia University	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Dept Biochem, Robert Wood Johnson Med Sch, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu		Yoshida, Takeshi/0000-0003-0133-5067	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB007198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060048] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50666] Funding Source: Medline; NIBIB NIH HHS [R21EB007198] Funding Source: Medline; NIGMS NIH HHS [GM60048] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Boydston JA, 2005, J BACTERIOL, V187, P5310, DOI 10.1128/JB.187.15.5310-5317.2005; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURJANADZE TV, 1982, BIOPOLYMERS, V21, P1489, DOI 10.1002/bip.360210803; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Daubenspeck JM, 2004, J BIOL CHEM, V279, P30945, DOI 10.1074/jbc.M401613200; de Bruin Eric C., 2002, FEMS Yeast Research, V1, P291, DOI 10.1016/S1567-1356(01)00042-3; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; Han RL, 2006, APPL MICROBIOL BIOT, V72, P109, DOI 10.1007/s00253-006-0387-5; HAYASHI T, 1979, BIOCHEMISTRY-US, V18, P4182, DOI 10.1021/bi00586a022; Humtsoe JO, 2005, J BIOL CHEM, V280, P13848, DOI 10.1074/jbc.M410605200; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JIMENEZ S, 1973, BIOCHEM BIOPH RES CO, V52, P106, DOI 10.1016/0006-291X(73)90960-1; JOSSE J, 1964, J MOL BIOL, V9, P269, DOI 10.1016/S0022-2836(64)80207-2; Kar K, 2006, J BIOL CHEM, V281, P33283, DOI 10.1074/jbc.M605747200; KRAMER JM, 1994, FASEB J, V8, P329, DOI 10.1096/fasebj.8.3.8143939; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; MIGCHELS.C, 1973, J CHEM PHYS, V59, P296, DOI 10.1063/1.1679805; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Perret S, 2001, J BIOL CHEM, V276, P43693, DOI 10.1074/jbc.M105507200; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Qing GL, 2004, NAT BIOTECHNOL, V22, P877, DOI 10.1038/nbt984; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Rasmussen M, 2001, MOL MICROBIOL, V40, P1427, DOI 10.1046/j.1365-2958.2001.02493.x; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RIGBY BJ, 1968, NATURE, V219, P166, DOI 10.1038/219166a0; SUTOH K, 1974, BIOPOLYMERS, V13, P2477, DOI 10.1002/bip.1974.360131207; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu YJ, 2003, BIOCHEMISTRY-US, V42, P8696, DOI 10.1021/bi034006n	49	103	109	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29757	29765		10.1074/jbc.M703991200	http://dx.doi.org/10.1074/jbc.M703991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693404	hybrid, Green Published			2022-12-27	WOS:000249981200004
J	Friedrichs, J; Torkko, JM; Helenius, J; Teravainen, TP; Fullekrug, J; Muller, DJ; Simons, K; Manninen, A				Friedrichs, Jens; Torkko, Juha M.; Helenius, Jonne; Teravainen, Terhi P.; Fullekrug, Joachim; Muller, Daniel J.; Simons, Kai; Manninen, Aki			Contributions of galectin-3 and-9 to epithelial cell adhesion analyzed by single cell force spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS LECTIN; MEMBRANE; LAMININ; POLARIZATION; POLARITY; BINDING; PROTEIN; BETA-1-INTEGRINS; TUBULOGENESIS; EXPRESSION	Galectins are widely expressed in epithelial tissues and have been implicated in a variety of cellular processes, including adhesion and polarization. Here we studied the contributions of galectins in cell adhesion and cyst formation of Madin-Darby canine kidney cells. Quantitative single cell force spectroscopy and standard adhesion assays were employed to study both early (< 2 min) and long term (90 min) adhesion of cells to different extracellular matrix components. Inhibitors were used to examine the contribution of integrins and galectins in general and RNA interference to specifically address the role of two abundantly expressed galectins, galectin-3 and -9. We found that both galectin-3 and -9 were required for optimal long term cell adhesion to both collagen I and laminin-III. Early adhesion to laminin was found to be integrin-independent and was instead mediated by carbohydrate interactions and galectin-3 and -9. The opposite was observed for early adhesion to collagen. Although similar, the contributions of galectin-3 and -9 to adhesion appeared to be by distinct processes. These defects in adhesion of the two galectin knockdown cell lines may underlie the epithelial phenotypes observed in the cyst assays. Our findings emphasize the complex regulation of epithelial cell functions by galectins.	Oulu Univ, Bioctr Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Tech Univ Dresden, Biotechnol Ctr, D-01307 Dresden, Germany; Heidelberg Univ, Dept Internal Med Gastroenterol 4, D-69120 Heidelberg, Germany	University of Oulu; Max Planck Society; Technische Universitat Dresden; Ruprecht Karls University Heidelberg	Manninen, A (corresponding author), Oulu Univ, Bioctr Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	aki.manninen@oulu.fi	Friedrichs, Jens/D-4833-2015; Manninen, Aki/AAC-8067-2019; Füllekrug, Joachim/A-6581-2008; Müller, Daniel J./A-5967-2010	Manninen, Aki/0000-0002-6263-8101; Müller, Daniel J./0000-0003-3075-0665; Simons, Kai/0000-0002-9231-9996				Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Bao Q, 1999, GLYCOBIOLOGY, V9, P489, DOI 10.1093/glycob/9.5.489; BAO Q, 1995, J CELL SCI, V108, P2791; Bullock SL, 2001, J AM SOC NEPHROL, V12, P515, DOI 10.1681/ASN.V123515; Carcamo C, 2006, EXP CELL RES, V312, P374, DOI 10.1016/j.yexcr.2005.10.025; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Delacour D, 2006, CURR BIOL, V16, P408, DOI 10.1016/j.cub.2005.12.046; Delacour D, 2005, J CELL BIOL, V169, P491, DOI 10.1083/jcb.200407073; Furtak V, 2001, BIOCHEM BIOPH RES CO, V289, P845, DOI 10.1006/bbrc.2001.6064; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GRANT DS, 1985, AM J ANAT, V174, P387, DOI 10.1002/aja.1001740403; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hughes RC, 2001, BIOCHIMIE, V83, P667; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang FZ, 2004, MICROSC RES TECHNIQ, V64, P435, DOI 10.1002/jemt.20101; Lagana A, 2006, MOL CELL BIOL, V26, P3181, DOI 10.1128/MCB.26.8.3181-3193.2006; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; Matlin KS, 2003, METHODS, V30, P235, DOI 10.1016/S1046-2023(03)00030-6; Meder D, 2005, J CELL BIOL, V168, P303, DOI 10.1083/jcb.200407072; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Nelson WJ, 2003, NEWS PHYSIOL SCI, V18, P143, DOI 10.1152/nips.01435.2002; Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Poirier F, 2002, BIOCHEM SOC SYMP, V69, P95; Puech PH, 2005, J CELL SCI, V118, P4199, DOI 10.1242/jcs.02547; Puech PH, 2006, ULTRAMICROSCOPY, V106, P637, DOI 10.1016/j.ultramic.2005.08.003; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schuck S, 2004, P NATL ACAD SCI USA, V101, P4912, DOI 10.1073/pnas.0401285101; Taubenberger A, 2007, MOL BIOL CELL, V18, P1634, DOI 10.1091/mbc.E06-09-0777; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zinkl GM, 1996, J CELL BIOL, V133, P695, DOI 10.1083/jcb.133.3.695	41	69	69	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29375	29383		10.1074/jbc.M701867200	http://dx.doi.org/10.1074/jbc.M701867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675292	hybrid			2022-12-27	WOS:000249788000034
J	Dashti, N; Manchekar, M; Liu, YW; Sun, ZH; Segrest, JP				Dashti, Nassrin; Manchekar, Medha; Liu, Yanwen; Sun, Zhihuan; Segrest, Jere P.			Microsomal triglyceride transfer protein activity is not required for the initiation of apolipoprotein B-containing lipoprotein assembly in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; TRIACYLGLYCEROL TRANSFER PROTEIN; RAT HEPATOMA MCA-RH7777; N-TERMINAL 17-PERCENT; APO-B; HEPG2 CELLS; PLASMA-LIPOPROTEINS; RICH LIPOPROTEINS; GENE-EXPRESSION; LIPID-BINDING	We previously demonstrated that the N-terminal 1000 amino acid residues of human apolipoprotein (apo) B (designated apoB: 1000) are competent to fold into a three-sided lipovitellin-like lipid binding cavity to form the apoB " lipid pocket" without a structural requirement for microsomal triglyceride transfer protein (MTP). Our results established that this primordial apoB-containing particle is phospholipid-rich (Manchekar, M., Richardson, P. E., Forte, T. M., Datta, G., Segrest, J. P., and Dashti, N. (2004) J. Biol. Chem. 279, 39757-39766). In this study we have investigated the putative functional role of MTP in the initial lipidation of apoB: 1000 in stable transformants of McA-RH7777 cells. Inhibition of MTP lipid transfer activity by 0.1 mu M BMS-197636 and 5, 10, and 20 mu M of BMS-200150 had no detectable effect on the synthesis, lipidation, and secretion of apoB: 1000-containing particles. Under identical experimental conditions, the synthesis, lipidation, and secretion of endogenous apoB100-containing particles in HepG2 and parental untransfected McARH7777 cells were inhibited by 86-94%. BMS-200150 at 40 mu M nearly abolished the secretion of endogenous apoB100-containing particles in HepG2 and parental McA-RH cells but caused only 15-20% inhibition in the secretion of apoB: 1000-containing particles. This modest decrease was attributable to the nonspecific effect of a high concentration of this compound on hepatic protein synthesis, as reflected in a similar (20-25%) reduction in albumin secretion. Suppression of MTP gene expression in stable transformants of McARH7777 cells by micro-interfering RNA led to 60-70% decrease in MTP mRNA and protein levels, but it had no detectable effect on the secretion of apoB: 1000. Our results provide a compelling argument that the initial addition of phospholipids to apoB: 1000 and initiation of apoB-containing lipoprotein assembly occur independently of MTP lipid transfer activity.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Basic Sci Sect, Atherosclerosis Res Unit, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Dashti, N (corresponding author), Univ Alabama Birmingham, Dept Med, 1808 7th Ave S,BDB-D680, Birmingham, AL 35292 USA.	ndashti@uab.edu			NHLBI NIH HHS [HL084685, P01 HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, R01HL084685] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1994, J BIOL CHEM, V269, P25879; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; Dashti N, 2004, J LIPID RES, V45, P1919, DOI 10.1194/jlr.M400251-JLR200; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Dashti N, 2002, J NUTR, V132, P2651, DOI 10.1093/jn/132.9.2651; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DECOURCELLES DDC, 1980, J BIOL CHEM, V255, P6727; Dixon JL, 2002, J HISTOCHEM CYTOCHEM, V50, P629, DOI 10.1177/002215540205000504; Du EZ, 1996, J LIPID RES, V37, P1309; ELOVSON J, 1988, J LIPID RES, V29, P1461; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hamilton RL, 1998, J LIPID RES, V39, P1543; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Jiang ZHG, 2006, BIOCHEMISTRY-US, V45, P11799, DOI 10.1021/bi060600w; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson SL, 2004, J BIOL CHEM, V279, P831, DOI 10.1074/jbc.M303057200; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; LIN MCM, 1995, J LIPID RES, V36, P1073; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; OHLENDORF DH, 1977, J BIOL CHEM, V252, P7992; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; PEREZ LE, 1991, COMP BIOCHEM PHYS B, V100, P821, DOI 10.1016/0305-0491(91)90297-Q; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rava P, 2006, J BIOL CHEM, V281, P11019, DOI 10.1074/jbc.M512823200; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; STEYRER E, 1990, J BIOL CHEM, V265, P19575; Stillemark-Billton P, 2005, J LIPID RES, V46, P104, DOI 10.1194/jlr.M400296-JLR200; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; van Greevenbroek MMJ, 1998, J LIPID RES, V39, P173; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Yamaguchi J, 2006, J BIOL CHEM, V281, P27063, DOI 10.1074/jbc.M606809200; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175	69	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28597	28608		10.1074/jbc.M700229200	http://dx.doi.org/10.1074/jbc.M700229200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690102	hybrid			2022-12-27	WOS:000249642100034
J	Riekhof, WR; Wu, J; Jones, JL; Voelker, DR				Riekhof, Wayne R.; Wu, James; Jones, Jennifer L.; Voelker, Dennis R.			Identification and characterization of the major lysophosphatidylethanolamine acyltransferase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; II CELLS; YEAST; GENE; CLONING; ACID; PHOSPHATIDYLETHANOLAMINE; CYTIDYLYLTRANSFERASE; BIOSYNTHESIS	We recently demonstrated that yeast actively import lysophosphatidylethanolamine (lyso-PtdEtn) through the action of plasma membrane P-type ATPases and rapidly acylate it to form PtdEtn. The predominant lyso-PtdEtn acyltransferase (LPEAT) activity present in cellular extracts is acyl-CoA dependent, but the identity of the gene encoding this activity was unknown. We now demonstrate that a previously uncharacterized open reading frame, YOR175C, encodes the major acyl-CoA-dependent LPEAT activity in yeast and henceforth refer to it as ALE1 ((a) under bar cyltransferase for (l) under bar yso-Ptd (E) under bar tn). Ale1p is an integral membrane protein and is highly enriched in the mitochondria-associated endoplasmic reticulum membrane. It is a member of the membrane-bound O-acyltransferase family and possesses a dibasic motif at its C terminus that is likely responsible for Golgi retrieval and retention in the endoplasmic reticulum. An ale1 Delta strain retains only trace amounts of acyl-CoA-dependent LPEAT activity, and strains lacking the capacity for PtdEtn synthesis via the phosphatidylserine decarboxylase and Kennedy pathways show a stringent requirement for both exogenous lyso-PtdEtn and a functional ALE1 gene for viability. Ale1p catalytic activity has a pH optimum between pH 7 and 7.5 and a strong preference for unsaturated acyl-CoA substrates.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [R01 GM081461, R01 GM032453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081461, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Bosson R, 2006, MOL BIOL CELL, V17, P2636, DOI 10.1091/mbc.E06-02-0104; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; Choi JY, 1996, J BIOL CHEM, V271, P3581; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; Nakashima A, 1997, J BIOL CHEM, V272, P9567; Riekhof WR, 2006, J BIOL CHEM, V281, P36588, DOI 10.1074/jbc.M608851200; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu Y, 2006, J BIOL CHEM, V281, P39217, DOI 10.1074/jbc.M606100200; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zarini S, 2006, J BIOL CHEM, V281, P10134, DOI 10.1074/jbc.M510783200	27	118	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28344	28352		10.1074/jbc.M705256200	http://dx.doi.org/10.1074/jbc.M705256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652094	hybrid			2022-12-27	WOS:000249642100008
J	Selvendiran, K; Tong, L; Vishwanath, S; Bratasz, A; Trigg, NJ; Kutala, VK; Hideg, K; Kuppusamy, P				Selvendiran, Karuppaiyah; Tong, Liyue; Vishwanath, Shilpa; Bratasz, Anna; Trigg, Nancy J.; Kutala, Vijay K.; Hideg, Kalman; Kuppusamy, Periannan			EF24 induces G(2)/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; TRANSCRIPTIONAL INDUCTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; KINASE PATHWAY; CYCLE ARREST; FAS LIGAND; AKT; P53	We report that EF24, a synthetic compound 3,5-bis( 2-flurobenzylidene) piperidin-4-one, greatly inhibits cisplatin-resistant ( CR) human ovarian cancer cell proliferation. The inhibitory effect of EF24 on cell proliferation is associated with G(2)/Mphase cell cycle arrest and increased G2/M checkpoint protein ( pp53, p53, and p21) levels. Within 24 h following treatment, EF24 induced apoptosis in CR cells. The apoptosis was partially blocked by the general caspase inhibitor z-VAD. Within 12 h, EF24 induced a membranous FasL expression, consistent with a substantial decrease in the Ser(473) and Thr(308) phosphorylation of Akt, a known negative regulator of FasL transcription. Also, EF24 activated the phosphorylated PTEN and marginally upregulated total PTEN expression through the inhibition of ubiquitin-mediated PTEN degradation. Suppression of PTEN expression with siRNA significantly reduced the p53 and p21 levels and activated Akt phosphorylation at Ser473 and Thr308, resulting in decreased apoptosis and increased cell survival. On the other hand, overexpression of PTEN markedly induced apoptosis. Our results clearly suggested that EF24 induced significant increase in PTEN expression. The up-regulation of PTEN inhibited Akt and MDM2, which enhanced the level of p53, thereby inducing G2/M arrest and apoptosis. Therefore, EF24 appears to have a potential therapeutic role in human ovarian cancer through the activation of PTEN.	Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Pecs, Inst Organ & Med Chem, H-7643 Pecs, Hungary	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Pecs	Kuppusamy, P (corresponding author), Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, 420 W 12th Ave, Columbus, OH 43210 USA.	kuppusamy.1@osu.edu		Kutala, Vijay Kumar/0000-0002-7253-8999	NCI NIH HHS [R01 CA102264-04, CA102264, R01 CA102264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams BK, 2005, ANTI-CANCER DRUG, V16, P263, DOI 10.1097/00001813-200503000-00005; Adams BK, 2004, BIOORGAN MED CHEM, V12, P3871, DOI 10.1016/j.bmc.2004.05.006; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ANDREWS PA, 1990, CANCER COMMUN-US, V2, P93, DOI 10.3727/095535490820874641; Bratasz A, 2006, P NATL ACAD SCI USA, V103, P3914, DOI 10.1073/pnas.0511250103; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Garrison JB, 2006, CANCER RES, V66, P464, DOI 10.1158/0008-5472.CAN-05-2039; Honjo S, 2005, DNA CELL BIOL, V24, P141, DOI 10.1089/dna.2005.24.141; JOHNSON SW, 1993, CANCER-AM CANCER SOC, V71, P644; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051; Li J, 1998, CANCER RES, V58, P5667; Liu XS, 2006, MOL CANCER THER, V5, P494, DOI 10.1158/1535-7163.MCT-05-0049; MARKMAN M, 1984, J CLIN ONCOL, V2, P1321, DOI 10.1200/JCO.1984.2.12.1321; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McNeish IA, 2004, GENE THER, V11, P497, DOI 10.1038/sj.gt.3302238; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Panka DJ, 2003, J BIOL CHEM, V278, P37632, DOI 10.1074/jbc.M307339200; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Saito Y, 2003, CANCER GENE THER, V10, P803, DOI 10.1038/sj.cgt.7700644; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Selvendiran K, 2006, CANCER RES, V66, P4826, DOI 10.1158/0008-5472.CAN-05-4062; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Weng LP, 1999, CANCER RES, V59, P5808; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhou MX, 2003, CANCER RES, V63, P6357	49	120	127	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28609	28618		10.1074/jbc.M703796200	http://dx.doi.org/10.1074/jbc.M703796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684018	Green Accepted, hybrid			2022-12-27	WOS:000249642100035
J	Singh, A; Kaur, N; Kosman, DJ				Singh, Arvinder; Kaur, Navjot; Kosman, Daniel J.			The metalloreductase Fre6p in Fe-Efflux from the yeast vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR-MECHANISMS; METAL TRANSPORTERS; GENE-EXPRESSION; MODEL ORGANISM; COPPER; HOMEOSTASIS; MUTANTS; STORAGE	The yeast vacuole is the storage depot for cellular iron. In this report we quantify the import-export balance in the vacuole because of the import of iron by Ccc1p and to export by the combined activity of Smf3p and the ferroxidase, permease pair of proteins, Fet5p and Fth1p. Our data indicate that the two efflux pathways are equally efficient in trafficking iron out of the vacuole. A major focus of this work was to identify the ferrireductase( s) that supplies the FeII for efflux whether by Smf3p or the Fet5p-Fth1p complex. Using a combination of flameless atomic absorption spectrophotometry to quantify vacuolar and whole cell iron content and a reporter assay for cytoplasmic iron we demonstrate that Fre6p supplies FeII to both efflux systems, while Fre7p plays no role in Fe-efflux from the vacuole. Enzymatic assay shows the two fusions to have similar reductase activity, however. Confocal fluorescence microscopy demonstrates that Fre6: GFP localizes to the vacuolar membrane; in contrast, Fre7: GFP fusions exhibit a variable and diffuse cellular distribution. Demonstrating a role for a vacuolar metalloreductase in Fe-efflux supports the model that iron is stored in the vacuole in the ferric state.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@buffalo.edu			NIDDK NIH HHS [DK77826] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077826] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Curie C, 2003, ANNU REV PLANT BIOL, V54, P183, DOI 10.1146/annurev.arplant.54.031902.135018; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; De Freitas JM, 2004, J BIOL CHEM, V279, P4450, DOI 10.1074/jbc.M212308200; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Hell R, 2003, PLANTA, V216, P541, DOI 10.1007/s00425-002-0920-4; Herman EM, 1999, PLANT CELL, V11, P601, DOI 10.1105/tpc.11.4.601; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Kucharczyk R, 2001, ACTA BIOCHIM POL, V48, P1025; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Mao XC, 2002, CURR MICROBIOL, V45, P37, DOI 10.1007/s00284-001-0046-0; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Miller JH., 1972, EXPT MOL GENETICS, P353; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Ohgami RS, 2005, NAT GENET, V37, P1264, DOI 10.1038/ng1658; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Rees EM, 2007, J BIOL CHEM, V282, P21629, DOI 10.1074/jbc.M703397200; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SIKORSKI RS, 1989, GENETICS, V122, P19; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200	43	60	65	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28619	28626		10.1074/jbc.M703398200	http://dx.doi.org/10.1074/jbc.M703398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681937	hybrid			2022-12-27	WOS:000249642100036
J	Hong, BS; Senisterra, G; Rabeh, WM; Vedadi, M; Leonardi, R; Zhang, YM; Rock, CO; Jackowski, S; Park, HW				Hong, Bum Soo; Senisterra, Guillermo; Rabeh, Wael M.; Vedadi, Masoud; Leonardi, Roberta; Zhang, Yong-Mei; Rock, Charles O.; Jackowski, Suzanne; Park, Hee-Won			Crystal structures of human pantothenate kinases - Insights into allosteric regulation and mutations linked to a neurodegeneration disordew	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN IRON ACCUMULATION; HALLERVORDEN-SPATZ-SYNDROME; SURFACE SALT BRIDGES; COENZYME-A; PROTEIN STABILITY; FEEDBACK-REGULATION; ESCHERICHIA-COLI; BINDING; PANK2; FOLD	Pantothenate kinase (PanK) catalyzes the first step in CoA biosynthesis and there are three human genes that express four isoforms with highly conserved catalytic core domains. Here we report the homodimeric structures of the catalytic cores of PanK1 alpha and PanK3 in complex with acetyl-CoA, a feedback inhibitor. Each monomer adopts a fold of the actin kinase superfamily and the inhibitor-bound structures explain the basis for the allosteric regulation by CoA thiciesters. These structures also provide an opportunity to investigate the structural effects of the PanK2 mutations that have been implicated in neurodegeneration. Biochemical and thermodynamic analyses of the PanK3 mutant proteins corresponding to PanK2 mutations show that mutant proteins with compromised activities and/or stabilities correlate with a higher incidence of the early onset of disease.	Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1L5, Canada; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	University of Toronto; Structural Genomics Consortium; University of Toronto; St Jude Children's Research Hospital	Park, HW (corresponding author), Univ Toronto, Struct Genom Consortium, 100 Coll St, Toronto, ON M5G 1L5, Canada.	heewon.park@utoronto.ca	Rabeh, Wael/AAO-4647-2020; Jackowski, Suzanne/N-8168-2018	Rabeh, Wael/0000-0001-6071-8581; Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM062896, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM62896, GM34496] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Das S, 2006, ACTA CRYSTALLOGR D, V62, P628, DOI 10.1107/S0907444906012728; Gregory A, 2005, FOLIA NEUROPATHOL, V43, P286, DOI 10.1016/B978-0-444-63233-3.00019-1; Hartig MB, 2006, ANN NEUROL, V59, P248, DOI 10.1002/ana.20771; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Hong BS, 2006, STRUCTURE, V14, P1251, DOI 10.1016/j.str.2006.06.008; Hortnagel K, 2003, HUM MOL GENET, V12, P321, DOI 10.1093/hmg/ddg026; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; Johnson MA, 2004, ANN NY ACAD SCI, V1012, P282, DOI 10.1196/annals.1306.023; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kotzbauer PT, 2005, J NEUROSCI, V25, P689, DOI 10.1523/JNEUROSCI.4265-04.2005; Lee CF, 2005, BIOCHEMISTRY-US, V44, P16817, DOI 10.1021/bi0519654; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Leonardi R, 2007, P NATL ACAD SCI USA, V104, P1494, DOI 10.1073/pnas.0607621104; Lindman S, 2006, BIOPHYS J, V90, P2911, DOI 10.1529/biophysj.105.071050; Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X; Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pokkuluri PR, 2002, BIOPHYS J, V82, P391, DOI 10.1016/S0006-3495(02)75403-9; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sarver RW, 2002, J BIOMOL SCREEN, V7, P21, DOI 10.1177/108705710200700104; Schwehm JM, 1998, BIOPHYS J, V74, pA234; Senisterra GA, 1997, BIOCHEMISTRY-US, V36, P11002, DOI 10.1021/bi9711590; Senisterra GA, 2006, J BIOMOL SCREEN, V11, P940, DOI 10.1177/1087057106294699; SONG WJ, 1994, J BIOL CHEM, V269, P27051; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Stadtman ER, 2003, ANTIOXID REDOX SIGN, V5, P577, DOI 10.1089/152308603770310239; Strop P, 2000, BIOCHEMISTRY-US, V39, P1251, DOI 10.1021/bi992257j; Takano K, 1999, BIOCHEMISTRY-US, V38, P6623, DOI 10.1021/bi9901228; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thomas M, 2004, MOVEMENT DISORD, V19, P36, DOI 10.1002/mds.10650; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang K, 2006, J BACTERIOL, V188, P5532, DOI 10.1128/JB.00469-06; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang YM, 2006, J BIOL CHEM, V281, P107, DOI 10.1074/jbc.M508825200; Zhang YM, 2005, J BIOL CHEM, V280, P32594, DOI 10.1074/jbc.M506275200; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	46	63	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27984	27993		10.1074/jbc.M701915200	http://dx.doi.org/10.1074/jbc.M701915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17631502	hybrid			2022-12-27	WOS:000249455600048
J	Tan, KR; Gonthier, A; Baur, R; Ernst, M; Goeldner, M; Sigel, E				Tan, Kelly R.; Gonthier, Anne; Baur, Roland; Ernst, Margot; Goeldner, Maurice; Sigel, Erwin			Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type a receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; ALPHA-SUBUNIT; COVALENT MODIFICATION; XENOPUS OOCYTES; SUBTYPES; STOICHIOMETRY; EXPRESSION; CHANNELS; LIGANDS; MUTAGENESIS	Benzodiazepines are widely used drugs. They exert sedative/hypnotic, anxiolytic, muscle relaxant, and anticonvulsant effects and act through a specific high affinity binding site on the major inhibitory neurotransmitter receptor, the gamma-aminobutyric acid type A (GABA(A)) receptor. Ligands of the benzodiazepine-binding site are classified into three groups depending on their mode of action: positive and negative allosteric modulators and antagonists. To rationally design ligands of the benzodiazepine site in different isoforms of the GABAA receptor, we need to understand the relative positioning and overlap of modulators of different allosteric properties. To solve these questions, we used a proximity-accelerated irreversible chemical coupling reaction. GABAA receptor residues thought to reside in the benzodiazepine-binding site were individually mutated to cysteine and combined with a cysteine-reactive benzodiazepine site ligand. Direct apposition of reaction partners is expected to lead to a covalent reaction. We describe here such a reaction of predominantly alpha(1)H101C and also three other mutants (alpha(1)G157C, alpha (1)V202C, and alpha (1)V211C) with an Imid-NCS derivative in which a reactive isothiocyanate group (-NCS) replaces the azide group ( -N-3) in the partial negative allosteric modulator Ro15-4513. Our results show four contact points of imidazobenzodiazepines with the receptor, alpha(1)H101C being shared by classical benzodiazepines. Taken together with previous data, a similar orientation of these ligands within the benzodiazepine-binding pocket may be proposed.	Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; Univ Louis Pasteur Strasbourg 1, Fac Pharm, CNRS, Lab Chim Bioorgan,Unite Mixte Rech 7175LC1, F-67401 Illkirch Graffenstaden, France; Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria	University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Medical University of Vienna	Sigel, E (corresponding author), Univ Bern, Inst Biochem & Mol Med, Buhlstr 28, CH-3012 Bern, Switzerland.	Erwin.sigel@mci.unibe.ch	Sigel, Erwin/F-7736-2015	Ernst, Margot/0000-0002-9809-2649				Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Baur R, 2006, FEBS LETT, V580, P1616, DOI 10.1016/j.febslet.2006.02.002; Berezhnoy D, 2004, J BIOL CHEM, V279, P3160, DOI 10.1074/jbc.M311371200; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Davies M, 1998, J NEUROCHEM, V70, P2188; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Dunn SMJ, 1999, MOL PHARMACOL, V56, P768; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; He XH, 2001, MED CHEM RES, V10, P269; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Huang Q, 1998, J MED CHEM, V41, P4130, DOI 10.1021/jm980317y; Huang Q, 2000, J MED CHEM, V43, P71, DOI 10.1021/jm990341r; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kotzyba-Hibert F, 1999, MOL NEUROBIOL, V20, P45, DOI 10.1007/BF02741364; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Rizk MS, 2006, BIOCHEMISTRY-US, V45, P543, DOI 10.1021/bi0516632; Sawyer GW, 2002, J BIOL CHEM, V277, P50036, DOI 10.1074/jbc.M209281200; Sigel E, 2005, MOL NUTR FOOD RES, V49, P228, DOI 10.1002/mnfr.200400104; Sigel E, 1998, MOL PHARMACOL, V54, P1097, DOI 10.1124/mol.54.6.1097; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Strakhova MI, 2000, MOL PHARMACOL, V58, P1434, DOI 10.1124/mol.58.6.1434; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728	40	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26316	26325		10.1074/jbc.M702153200	http://dx.doi.org/10.1074/jbc.M702153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626010	hybrid			2022-12-27	WOS:000249239600036
J	Lee, HR; Helquist, SA; Kool, ET; Johnson, KA				Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.			Importance of hydrogen bonding for efficiency and specificity of the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE; NONPOLAR ISOSTERE; ACTIVE-SITE; FIDELITY; REPLICATION; DIFLUOROTOLUENE; SELECTIVITY; MECHANISM	To assess the contribution to discrimination afforded by base pair hydrogen bonding during DNA replication by the human mitochondrial DNA polymerase, we examined nucleoside mimics lacking hydrogen bond forming capability but retaining the overall steric shape of the natural nucleotide. We employed oligonucleotide templates containing either a deoxyadenosine shape mimic (dQ) or a deoxythymidine shape mimic (dF). Additionally, the nucleoside triphosphate analogs difluorotoluene deoxynucleoside triphosphate, 9-methyl-1-H-imidazo[(4,5)-b] pyridine deoxyribose triphosphate, and 4-methylbenzimidazole deoxyribose triphosphate (dZTP; another dATP shape mimic) were assayed. We used pre-steady state methods to determine the kinetic parameters governing nucleotide incorporation, k(pol) and K-d. In general, the loss of hydrogen bonding potential led to 2 -3 kcal/mol reduction in ground state binding free energy, whereas effects on the maximum rate of polymerization were quite variable, ranging from negligible (dATP: dF) to nearly 4 kcal/mol (dZTP: dT). Although we observed only a 46-fold reduction in discrimination when dF was present in the template, there was a complete elimination of discrimination when dQ was present in the template. Our data with dF indicate that hydrogen bonding contributes 2.2 kcal/mol toward the efficiency of incorporation, whereas data with dQ (which may overestimate the effect due to poor steric mimicry) suggest a contribution of up to 6.8 kcal/mol. Taken together, the data suggest that sterics are necessary but not sufficient to achieve optimal efficiency and fidelity for DNA polymerase. Base pair hydrogen bonding contributes at least a third of the energy underlying nucleoside incorporation efficiency and specificity.	[Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; Stanford University	Johnson, KA (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu		Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [R01 GM044613-17A1, R01 GM044613, GM 044613, GM 072705] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, R01GM072705] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2005, STRUCTURE, V13, P1653, DOI 10.1016/j.str.2005.07.020; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GAO JL, 1994, BIOPHYS CHEM, V51, P253, DOI 10.1016/0301-4622(94)00046-8; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Guckian KM, 1997, ANGEW CHEM INT EDIT, V36, P2825, DOI 10.1002/anie.199728251; Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim TW, 2006, J BIOL CHEM, V281, P2289, DOI 10.1074/jbc.M510744200; Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102; Kool ET, 2006, CHEM COMMUN, P3665, DOI 10.1039/b605414e; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Lee HR, 2008, J BIOL CHEM, V283, P14411, DOI 10.1074/jbc.M705006200; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; SCHWEITZER BA, 1995, J AM CHEM SOC, V117, P1863, DOI 10.1021/ja00112a001; Spratt TE, 2001, BIOCHEMISTRY-US, V40, P2647, DOI 10.1021/bi002641c; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14402	14410		10.1074/jbc.M705007200	http://dx.doi.org/10.1074/jbc.M705007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	17650502	hybrid, Green Published			2022-12-27	WOS:000255941400027
J	Xu, YC; Zhou, YL; Gonzalez, FJ; Snead, ML				Xu, Yucheng; Zhou, Yan Larry; Gonzalez, Frank J.; Snead, Malcolm L.			CCAAT/Enhancer-binding protein delta(C/EBP delta) maintains amelogenin expression in the absence of C/EBP alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA; GENE-EXPRESSION; ADIPOSE-TISSUE; NF-Y; TRANSCRIPTION; DIFFERENTIATION; MORPHOGENESIS; DISRUPTION; LOCUS; LIVER	C/ EBP alpha is implicated to regulate mouse amelogenin gene expression during tooth enamel formation in vitro. Because enamel formation occurs during postnatal development and C/ EBP alpha- deficient mice die at birth, we used the Cre/ loxP recombination system to characterize amelogenin expression in C/ EBP alpha conditional knock- out mice. Mice carrying the Cre transgene under the control of the human keratin- 14 promoter show robust Cre expression in the ameloblast cell lineage. Mating between mice bearing the floxed C/ EBP alpha allele with keratin14- Cre mice generate C/ EBP alpha conditional knock- out mice. Real- time PCR analysis shows that removal of one C/EBP alpha allele from the molar enamel epithelial organ of 3- day postnatal mice results in dramatic decrease in endogenous C/EBP alpha mRNAlevels and coordinately altered amelogeninm RNA abundance. Conditional deletion of both C/ EBP alpha alleles further diminishes C/ EBP alpha mRNAlevels; however, rather than ablating amelogenin expression, we observe wild- type amelogenin mRNA abundance levels. We examined C/ EBP beta and nuclear factor YA expression, two transcription factors that had previously been shown to modestly participate in amelogenin expression, in vitro but found no significant changes in either of their mRNA abundance levels comparing conditional knock- out mice with wild- type counterparts. Although the abundance of C/ EBP delta is also unchanged in C/ EBP alpha\ conditional knock- out mice, in vitro we find that C/ EBP delta activates the mouse amelogenin promoter and synergistically cooperates with nuclear factor Y, suggesting that C/ EBP delta can functionally substitute for C/ EBP alpha to produce an enamel matrix competent to direct biomineralization.	Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; NCI, NIH, Lab Metab, Bethesda, MD 20892 USA	University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Snead, ML (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, CSA 142,2250 Alcazar St, Los Angeles, CA 90033 USA.	mlsnead@usc.edu			NIDCR NIH HHS [DE-06988, R01 DE006988] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Li M, 2001, DEVELOPMENT, V128, P675; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Mustonen T, 2004, DEVELOPMENT, V131, P4907, DOI 10.1242/dev.01377; Osada S, 1996, J BIOL CHEM, V271, P3891; Plikus MV, 2005, EVOL DEV, V7, P440, DOI 10.1111/j.1525-142X.2005.05048.x; SNEAD ML, 1988, DEVELOPMENT, V104, P77; SNEAD ML, 1984, DEV BIOL, V104, P255, DOI 10.1016/0012-1606(84)90053-8; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 2004, DEV DYNAM, V231, P98, DOI 10.1002/dvdy.20118; Xu YC, 2007, BIOCHEM BIOPH RES CO, V354, P56, DOI 10.1016/j.bbrc.2006.12.182; Xu YC, 2006, EUR J ORAL SCI, V114, P169, DOI 10.1111/j.1600-0722.2006.00319.x; Xu Y, 2006, J BIOL CHEM, V281, P16090, DOI 10.1074/jbc.M510514200; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273; Zhu QS, 2004, J BIOL CHEM, V279, P29902, DOI 10.1074/jbc.M400438200	22	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29882	29889		10.1074/jbc.M702097200	http://dx.doi.org/10.1074/jbc.M702097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17704518	Green Accepted, hybrid			2022-12-27	WOS:000249981200017
J	Payne, HL; Connelly, WM; Ives, JH; Lehner, R; Furtmuller, B; Sieghart, W; Tiwari, P; Lucocq, JM; Lees, G; Thompson, CL				Payne, Helen L.; Connelly, William M.; Ives, Jane H.; Lehner, Reinhard; Furtmuller, Birgit; Sieghart, Werner; Tiwari, Priyanka; Lucocq, John M.; Lees, George; Thompson, Christopher L.			GABA(A) alpha 6-containing receptors are selectively compromised in cerebellar granule cells of the ataxic mouse, stargazer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORAL-LOBE EPILEPSY; SUBUNIT MESSENGER-RNAS; NEUROTROPHIC FACTOR; DELTA-SUBUNIT; A RECEPTOR; MUTANT MOUSE; QUANTITATIVE IMPORTANCE; POSTNATAL-DEVELOPMENT; SYNAPTIC INHIBITION; BETA-3 SUBUNITS	Stargazer mice fail to express the gamma 2 isoform of transmembrane alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate ( AMPA) receptor regulatory proteins that has been shown to be absolutely required for the trafficking and synaptic targeting of excitatory AMPA receptors in adult murine cerebellar granule cells. Here we show that 30 +/- 6% fewer inhibitory gamma-aminobutyric acid, type A (GABA(A)), receptors were expressed in adult stargazer cerebellum compared with controls because of a specific loss of GABAA receptor expression in the cerebellar granule cell layer. Radioligand binding assays allied to in situ immunogold-EM analysis and furosemide-sensitive tonic current estimates revealed that expression of the extrasynaptic (alpha 6 beta x delta) alpha 6-containing GABA(A) receptor were markedly and selectively reduced in stargazer. These observations were compatible with a marked reduction in expression of GABAA receptor alpha 6,delta (mature cerebellar granule cell-specific proteins), and beta 3 subunit expression in stargazer. The subunit composition of the residual alpha 6-containing GABA(A) receptors was unaffected by the stargazer mutation. However, we did find evidence of an similar to 4-fold up-regulation of alpha 1 beta delta receptors that may compensate for the loss of alpha 6-containing GABA(A) receptors. PCR analysis identified a dramatic reduction in the steady-state level of alpha 6 mRNA, compatible with alpha 6 being the primary target of the stargazer mutation-mediated GABAA receptor abnormalities. We propose that some aspects of assembly, trafficking, targeting, and/or expression of extrasynaptic alpha 6-containing GABA(A) receptors in cerebellar granule cells are selectively regulated by AMPA receptor-mediated signaling.	Univ Durham, Sch Biol & Biomed Sci, Sci Res Labs, Durham DH1 3LE, England; Med Univ Vienna, Ctr Brain Res, Vienna, Austria; Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand	Durham University; Medical University of Vienna; University of Vienna; University of Dundee; University of Otago	Payne, HL (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Sci Res Labs, South Rd, Durham DH1 3LE, England.	H.L.Payne@durham.ac.uk	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302; Connelly, William/0000-0002-0986-6260; lucocq, john/0000-0002-5191-0093	Austrian Science Fund FWF [P 17203] Funding Source: Medline; Medical Research Council [G0401395] Funding Source: Medline; Wellcome Trust [066204, 0543478, 059767/Z99/Z] Funding Source: Medline; MRC [G0401395] Funding Source: UKRI	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Brickley SG, 1999, J NEUROSCI, V19, P2960; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Bulleit RF, 2000, DEV BRAIN RES, V119, P1, DOI 10.1016/S0165-3806(99)00119-4; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DRESCHER DG, 1993, J NEUROCHEM, V61, P1167, DOI 10.1111/j.1471-4159.1993.tb03638.x; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Gault LM, 1997, J NEUROSCI, V17, P2391; Gault LM, 1998, J NEUROCHEM, V70, P1907; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Ives JH, 2004, J BIOL CHEM, V279, P31002, DOI 10.1074/jbc.M402214200; Ives JH, 2002, NEUROPHARMACOLOGY, V43, P715, DOI 10.1016/S0028-3908(02)00164-8; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones A, 1997, J NEUROSCI, V17, P1350; Jovanovic JN, 2004, J NEUROSCI, V24, P522, DOI 10.1523/JNEUROSCI.3606-03.2004; KORPI ER, 1995, MOL PHARMACOL, V47, P283; KORPI ER, 1993, NEUROSCIENCE, V53, P483, DOI 10.1016/0306-4522(93)90212-X; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; Leroy C, 2004, J PHYSIOL-LONDON, V557, P473, DOI 10.1113/jphysiol.2003.059246; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCOCQ J, 1994, J ANAT, V184, P1; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Nusser Z, 1998, J NEUROSCI, V18, P1693; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Poltl A, 2003, J NEUROCHEM, V87, P1444, DOI 10.1046/j.1471-4159.2003.02135.x; QIAO X, 1998, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Rouach N, 2005, NAT NEUROSCI, V8, P1525, DOI 10.1038/nn1551; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; SLANY A, 1995, MOL PHARMACOL, V48, P385; Suzuki K, 2005, J NEUROSCI, V25, P9535, DOI 10.1523/JNEUROSCI.2191-05.2005; Thompson CL, 1996, NEUROPHARMACOLOGY, V35, P1337, DOI 10.1016/S0028-3908(96)00114-1; Thompson CL, 2000, NEUROSCI LETT, V283, P85, DOI 10.1016/S0304-3940(00)00930-7; Thompson CL, 1998, MOL BRAIN RES, V60, P282, DOI 10.1016/S0169-328X(98)00205-8; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Tia S, 1996, J NEUROSCI, V16, P3630; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tretter V, 1997, J NEUROSCI, V17, P2728; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Yamada MK, 2002, J NEUROSCI, V22, P7580; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29130	29143		10.1074/jbc.M700111200	http://dx.doi.org/10.1074/jbc.M700111200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17646167	hybrid, Green Accepted			2022-12-27	WOS:000249788000008
J	Bleijerveld, OB; Brouwers, JFHM; Vaandrager, AB; Helms, JB; Houweling, M				Bleijerveld, Onno B.; Brouwers, Jos F. H. M.; Vaandrager, Arie B.; Helms, J. Bernd; Houweling, Martin			The CDP-ethanolamine pathway and phosphatidylserine decarboxylation generate different phosphatidylethanolamine molecular species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE PHOSPHOLIPIDS; HAMSTER OVARY CELLS; ELECTROSPRAY-IONIZATION; QUANTITATIVE-ANALYSIS; BIOSYNTHETIC DEFECT; MASS-SPECTROMETRY; SERINE RACEMASE; MITOCHONDRIA; PHOSPHATIDYLCHOLINE; LIVER	In mammalian cells, phosphatidylethanolamine (PtdEtn) is mainly synthesized via the CDP-ethanolamine (Kennedy) pathway and by decarboxylation of phosphatidylserine (PtdSer). However, the extent to which these two pathways contribute to overall PtdEtn synthesis both quantitatively and qualitatively is still not clear. To assess their contributions, PtdEtn species synthesized by the two routes were labeled with pathway-specific stable isotope precursors, d(3)-serine and d(4)-ethanolamine, and analyzed by high performance liquid chromatography-mass spectrometry. The major conclusions from this study are that (i) in both McA-RH7777 and Chinese hamster ovary K1 cells, the CDP-ethanolamine pathway was favored over PtdSer decarboxylation, and (ii) both pathways for PtdEtn synthesis are able to produce all diacyl-PtdEtn species, but most of these species were preferentially made by one pathway. For example, the CDP-ethanolamine pathway preferentially synthesized phospholipids with mono- or di-unsaturated fatty acids on the sn-2 position (e. g. (16:0-18:2) PtdEtn and (18:1-18:2) PtdEtn), whereas PtdSer decarboxylation generated species with mainly polyunsaturated fatty acids on the sn-2 position (e. g. (18:0-20:4) PtdEtn and (18:0-20:5) PtdEtn in McArdle and (18: 0-20:4) PtdEtn and (18:0-22:6) PtdEtn in Chinese hamster ovary K1 cells). (iii) The main PtdEtn species newly synthesized from the Kennedy pathway in the microsomal fraction appeared to equilibrate rapidly between the endoplasmic reticulum and mitochondria. (iv) Newly synthesized PtdEtn species preferably formed in the mitochondria, which is at least in part due to the substrate specificity of the phosphatidylserine decarboxylase, seemed to be retained in this organelle. Our data suggest a potentially essential role of the PtdSer decarboxylation pathway in mitochondrial functioning.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 TD Utrecht, Netherlands	Utrecht University; Utrecht University	Houweling, M (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	M.Houweling@uu.nl	Brouwers, Jos F/AAH-1444-2019	Brouwers, Jos F/0000-0003-2924-3279; Vaandrager, Arie/0000-0001-9394-9239				ARTHUR G, 1987, BIOCHEM CELL BIOL, V65, P1016, DOI 10.1139/o87-133; ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN LF, 1961, J BIOL CHEM, V236, P28; Brouwers JFHM, 1999, J LIPID RES, V40, P164; Brouwers JFHM, 1998, J LIPID RES, V39, P344; DE BERNARDO S, 1974, ARCH BIOCHEM BIOPHYS, V163, P390, DOI 10.1016/0003-9861(74)90490-1; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; Foltyn VN, 2005, J BIOL CHEM, V280, P1754, DOI 10.1074/jbc.M405726200; Heikinheimo L, 2002, TRAFFIC, V3, P367, DOI 10.1034/j.1600-0854.2002.30506.x; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491; Kevala JH, 2001, ANAL BIOCHEM, V292, P130, DOI 10.1006/abio.2001.5076; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1991, J BIOL CHEM, V266, P6370; Kuksis A, 2005, METHODS, V36, P172, DOI 10.1016/j.ymeth.2004.11.001; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILLER MA, 1986, J BIOL CHEM, V261, P9753; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SCHMID PC, 1991, J BIOL CHEM, V266, P13690; Schmid PC, 1997, LIPIDS, V32, P1181, DOI 10.1007/s11745-997-0152-7; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Steenbergen R, 2005, J BIOL CHEM, V280, P40032, DOI 10.1074/jbc.M506510200; Steenbergen R, 2006, BBA-MOL CELL BIOL L, V1761, P313, DOI 10.1016/j.bbalip.2006.03.005; TIJBURG LBM, 1989, BIOCHEM BIOPH RES CO, V160, P1275, DOI 10.1016/S0006-291X(89)80141-X; Vance D.E., 1996, BIOCH LIPIDS LIPOPRO, P1; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Vance JE, 2005, PROG LIPID RES, V44, P207, DOI 10.1016/j.plipres.2005.05.001; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; Xia MH, 2004, MOL BRAIN RES, V125, P96, DOI 10.1016/j.molbrainres.2004.03.007; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200; YAMANE T, 2003, Patent No. 6660504; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7	48	66	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28362	28372		10.1074/jbc.M703786200	http://dx.doi.org/10.1074/jbc.M703786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673461	hybrid, Green Published			2022-12-27	WOS:000249642100010
J	Koenigsknecht, MJ; Ramos, I; Downs, DM				Koenigsknecht, Mark J.; Ramos, Itzel; Downs, Diana M.			Glutamine phosphoribosylpyrophosphate amidotransferase-independent phosphoribosyl amine synthesis from ribose 5-phosphate and glutamine or asparagine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MG1655; SALMONELLA-TYPHIMURIUM; PYRIMIDINE MOIETY; THIAMINE SYNTHESIS; ANTHRANILATE SYNTHASE; ACID-PHOSPHATASE; BIOSYNTHESIS; PATHWAY; INVOLVEMENT; PROTEINS	Phosphoribosylamine (PRA) is the first intermediate in the common pathway to purines and thiamine and is generated in bacteria by glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase (EC 2.4.2.14) from PRPP and glutamine. Genetic data have indicated that multiple, non-PRPP amidotransferase mechanisms exist to generate PRA sufficient for thiamine but not purine synthesis. Here we describe the purification and identification of an activity (present in both Escherichia coli and Salmonella enterica) that synthesizes PRA from ribose 5-phosphate and glutamine/asparagine. Apurification resulting in greater than a 625-fold increase in specific activity identified 8 candidate proteins. Of the candidates, overexpression of AphA (EC 3.1.3.2), a periplasmic class B nonspecific acid phosphatase, significantly increased activity in partially purified extracts. Native purification of AphA to >95% homogeneity determined that the periplasmic L-asparaginase II, AnsB (EC 3.5.1.1), co-purified with AphA and was also necessary for PRA formation. The potential physiological relevance of AphA and AnsB in contributing to thiamine biosynthesis in vivo is discussed.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	downs@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne BA, 2006, J BACTERIOL, V188, P6786, DOI 10.1128/JB.00745-06; Downs DM, 2006, ANNU REV MICROBIOL, V60, P533, DOI 10.1146/annurev.micro.60.080805.142308; DOWNS DM, 1991, J BACTERIOL, V173, P6597, DOI 10.1128/jb.173.20.6597-6604.1991; Enos-Berlage JL, 1999, J BACTERIOL, V181, P841, DOI 10.1128/JB.181.3.841-848.1999; Enos-Berlage JL, 1998, J BACTERIOL, V180, P6519, DOI 10.1128/JB.180.24.6519-6528.1998; EnosBerlage JL, 1996, J BACTERIOL, V178, P1476, DOI 10.1128/jb.178.5.1476-1479.1996; ESTRAMAREIX B, 1984, J AM CHEM SOC, V106, P3857, DOI 10.1021/ja00325a025; LEGAL ML, 1967, BIOCHEM BIOPH RES CO, V27, P618, DOI 10.1016/S0006-291X(67)80079-2; MILLER HK, 1969, BIOCHEM PHARMACOL, V18, P2225, DOI 10.1016/0006-2952(69)90329-3; NEWELL PC, 1968, BIOCHEM J, V106, P271, DOI 10.1042/bj1060271; NEWELL PC, 1968, BIOCHEM J, V106, P279, DOI 10.1042/bj1060279; NIERLICH D, 1961, J BIOL CHEM, V236, pPC32; NIERLICH.DP, 1965, J BIOL CHEM, V240, P366; Passariello C, 2006, BBA-PROTEINS PROTEOM, V1764, P13, DOI 10.1016/j.bbapap.2005.08.028; Petersen L, 1996, GENETICS, V143, P37; Ramos I, 2003, J BACTERIOL, V185, P5125, DOI 10.1128/JB.185.17.5125-5132.2003; Reshetnyak E, 1999, MOL MICROBIOL, V31, P167, DOI 10.1046/j.1365-2958.1999.01156.x; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Thaller MC, 1997, FEMS MICROBIOL LETT, V146, P191, DOI 10.1016/S0378-1097(96)00474-0; Zilles JL, 1996, GENETICS, V144, P883	23	7	7	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28379	28384		10.1074/jbc.M704024200	http://dx.doi.org/10.1074/jbc.M704024200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686772	hybrid, Green Accepted			2022-12-27	WOS:000249642100012
J	Davies, JQ; Chang, GW; Yona, S; Gordon, S; Stacey, M; Lin, HH				Davies, John Q.; Chang, Gin-Wen; Yona, Simon; Gordon, Siamon; Stacey, Martin; Lin, Hsi-Hsien			The role of receptor oligomerization in modulating the expression and function of leukocyte adhesion-G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; EGF-TM7 FAMILY; SURFACE EXPRESSION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PLANAR POLARITY; CELLULAR LIGAND; SECRETIN FAMILY; HUMAN EMR2; GROWTH	The human leukocyte adhesion-G protein-coupled receptors (GPCRs), the epidermal growth factor (EGF)-TM7 proteins, are shown here to function as homo- and hetero-oligomers. Using cell surface cross-linking, co-immunoprecipitation, and fluorescence resonance energy transfer analysis of EMR2, an EGF-TM7 receptor predominantly expressed in myeloid cells, we demonstrate that it forms dimers in a reaction mediated exclusively by the TM7 moiety. We have also identified a naturally occurring but structurally unstable EMR2 splice variant that acts as a dominant negative modulator by dimerizing with the wild type receptor and down-regulating its expression. Additionally, heterodimerization between closely related EGF-TM7 members is shown to result in the modulation of expression and ligand binding properties of the receptors. These findings suggest that receptor homo- and hetero-oligomerization play a regulatory role in modulating the expression and function of leukocyte adhesion-GPCRs.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Chang Gung Univ, Coll Med, Dept Microbiol & Immunol, Tao Yuan, Taiwan	University of Oxford; Chang Gung University	Stacey, M (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	martin.stacey@path.ox.ac.uk; hhlin@mail.cgu.edu.tw	LIN, Hsi-Hsien/N-1488-2015; Yona, Simon/ABE-6572-2020	Yona, Simon/0000-0002-3984-2008	MRC [G0500623] Funding Source: UKRI; Medical Research Council [G0500623] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Boanca G, 2007, J BIOL CHEM, V282, P534, DOI 10.1074/jbc.M607694200; Chang GW, 2007, BIOCHEM BIOPH RES CO, V353, P133, DOI 10.1016/j.bbrc.2006.11.148; Chang GW, 2003, FEBS LETT, V547, P145, DOI 10.1016/S0014-5793(03)00695-1; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Davies B, 2004, MOL CELL BIOL, V24, P8642, DOI 10.1128/MCB.24.19.8642-8648.2004; FRASER CM, 1982, BIOCHEM BIOPH RES CO, V109, P21, DOI 10.1016/0006-291X(82)91560-1; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Kwakkenbos MJ, 2006, FASEB J, V20, P2582, DOI 10.1096/fj.06-6500fje; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; Lippiat JD, 2002, DIABETES, V51, pS377, DOI 10.2337/diabetes.51.2007.S377; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Michalska K, 2006, J MOL BIOL, V360, P105, DOI 10.1016/j.jmb.2006.04.066; Milligan G, 2004, SEMIN CELL DEV BIOL, V15, P263, DOI 10.1016/j.semcdb.2003.12.012; Milligan G, 2003, LIFE SCI, V74, P181, DOI 10.1016/j.lfs.2003.09.005; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Okada T, 2006, P NATL ACAD SCI USA, V103, P6471, DOI 10.1073/pnas.0511020103; Okada T, 2007, J BIOL CHEM, V282, P2433, DOI 10.1074/jbc.M607490200; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Sarmiento JM, 2004, J BIOL CHEM, V279, P47017, DOI 10.1074/jbc.M410011200; Seck T, 2003, J BIOL CHEM, V278, P23085, DOI 10.1074/jbc.M211280200; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Shima Y, 2004, DEV CELL, V7, P205, DOI 10.1016/j.devcel.2004.07.007; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Volynski KE, 2004, EMBO J, V23, P4423, DOI 10.1038/sj.emboj.7600443; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Wang YM, 2003, J BIOL CHEM, V278, P3210, DOI 10.1074/jbc.M210431200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Zal T, 2002, IMMUNITY, V16, P521, DOI 10.1016/S1074-7613(02)00301-1	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27343	27353		10.1074/jbc.M704096200	http://dx.doi.org/10.1074/jbc.M704096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620333	hybrid			2022-12-27	WOS:000249304900076
J	Koropatkin, N; Randich, AM; Bhattacharyya-Pakrasi, M; Pakrasi, HB; Smith, TJ				Koropatkin, Nicole; Randich, Amelia M.; Bhattacharyya-Pakrasi, Maitrayee; Pakrasi, Himadri B.; Smith, Thomas J.			The structure of the iron-binding protein, FutA1, from Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC TRANSPORT PROTEIN; CRYSTAL-STRUCTURE; FERRIC REDUCTASE; METAL-BINDING; ANION; NEISSERIA; MANGANESE; SYSTEM	Cyanobacteria account for a significant percentage of aquatic primary productivity even in areas where the concentrations of essential micronutrients are extremely low. To better understand the mechanism of iron selectivity and transport, the structure of the solute binding domain of an ATP binding cassette iron transporter, FutA1, was determined in the presence and absence of iron. The iron ion is bound within the "C-clamp" structure via four tyrosine and one histidine residues. There are extensive interactions between these ligating residues and the rest of the protein such that the conformations of the side chains remain relatively unchanged as the iron is released by the opening of the metal binding cleft. This is in stark contrast to the zinc-binding protein, ZnuA, where the domains of the metalbinding protein remain relatively fixed, whereas the ligating residues rotate out of the binding pocket upon metal release. The rotation of the domains in FutA1 is facilitated by two flexible beta-strands running along the back of the protein that act like a hinge during domain motion. This motion may require relatively little energy since total contact area between the domains is the same whether the protein is in the open or closed conformation. Consistent with the pH dependence of iron binding, the main trigger for iron release is likely the histidine in the iron-binding site. Finally, neither FutA1 nor FutA2 binds iron as a siderophore complex or in the presence of anions, and both preferentially bind ferrous over ferric ions.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Donald Danforth Plant Science Center; Washington University (WUSTL)	Smith, TJ (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	tsmith@danforthcenter.org	Randich, Amelia/AAY-8606-2020; Smith, Thomas J/K-9086-2013	Randich, Amelia/0000-0002-5172-7280; Smith, Thomas J/0000-0003-3528-6793	NIGMS NIH HHS [GM 078800] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM078800] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Borer PM, 2005, MAR CHEM, V93, P179, DOI 10.1016/j.marchem.2004.08.006; Bouige P, 2002, CURR PROTEIN PEPT SC, V3, P541, DOI 10.2174/1389203023380486; Bruker, 1997, SMART SAINT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Gould S. J., 2001, BOOK LIFE ILLUSTRATE; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Khan AG, 2007, BIOCHEM J, V403, P43, DOI 10.1042/BJ20061589; King GM, 1999, APPL ENVIRON MICROB, V65, P4393; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rukhman V, 2005, J MOL BIOL, V348, P961, DOI 10.1016/j.jmb.2005.03.006; SHERIFF S, 1985, P NATL ACAD SCI USA, V82, P1104, DOI 10.1073/pnas.82.4.1104; Shouldice SR, 2004, J BACTERIOL, V186, P3903, DOI 10.1128/JB.186.12.3903-3910.2004; Smith TJ, 2004, J APPL CRYSTALLOGR, V37, P654, DOI 10.1107/S0021889804009859; Takeda K, 2007, FEBS J, V274, P1318, DOI 10.1111/j.1742-4658.2007.05680.x; Tom-Yew SAL, 2005, J BIOL CHEM, V280, P9283, DOI 10.1074/jbc.M412479200; VOGEL AI, 1963, TXB QUANTITATIVE INO, P3899; Waldron KJ, 2007, J BIOL CHEM, V282, P3837, DOI 10.1074/jbc.M609916200; Wei BX, 2007, BIOCHEMISTRY-US, V46, P8734, DOI 10.1021/bi700763w; Zarnowski R, 2005, MICROBIOL-SGM, V151, P2233, DOI 10.1099/mic.0.27918-0	35	28	30	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27468	27477		10.1074/jbc.M704136200	http://dx.doi.org/10.1074/jbc.M704136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626019	hybrid			2022-12-27	WOS:000249304900088
J	Treede, I; Braun, A; Sparla, R; Kuhnel, M; Giese, T; Turner, JR; Anes, E; Kulaksiz, H; Fullekrug, J; Stremmel, W; Griffiths, G; Ehehalt, R				Treede, Irina; Braun, Annika; Sparla, Richard; Kuehnel, Mark; Giese, Thomas; Turner, Jerrold R.; Anes, Elsa; Kulaksiz, Hasan; Fuellekrug, Joachim; Stremmel, Wolfgang; Griffiths, Gareth; Ehehalt, Robert			Anti-inflammatory effects of phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA; KAPPA-B; ULCERATIVE-COLITIS; EPITHELIAL-CELLS; MUCOSAL BARRIER; GASTRIC-MUCOSA; FATTY-ACIDS; TNF-ALPHA	We recently showed that mucus from patients with ulcerative colitis, a chronic inflammatory disorder of the colon, is characterized by a low level of phosphatidylcholine (PC) while clinical studies reveal that therapeutic addition of PC using slow release preparations is beneficial. The positive role of PC in this disease is still elusive. Here we tested the hypothesis that exogenous application of PC has anti-inflammatory properties using three model systems. First, human Caco-2 cells were treated with tumor necrosis factor-alpha (TNF-alpha) to induce a pro-inflammatory response via activation of NF-kappa B. Second, latex bead phagosomes were analyzed for their ability to assemble actin in vitro, a process linked to pro-inflammatory signaling and correlating with the growth versus killing of mycobacteria in macrophages. The third system used was the rapid assembly of plasma membrane actin in macrophages in response to sphingosine 1-phosphate. TNF-alpha induced a pro-inflammatory response in Caco-2 cells, including 1) assembly of plasma membrane actin; 2) activation of both MAPKs ERK and p38; 3) transport of NF-kappa B subunits to the nucleus; and 4) subsequent up-regulation of the synthesis of pro-inflammatory gene products. Exogenous addition of most PCs tested significantly inhibited these processes. Other phospholipids like sphingomyelin or phosphatidylethanolamine showed no effects in these assays . PC also inhibited latex bead phagosome actin assembly, the killing of Mycobacterium tuberculosis in macrophages, and the sphingosine 1-phosphate-induced actin assembly in macrophages. TNF-alpha induces the activation of signaling molecules and the reorganization of the actin cytoskeleton in human intestinal cells. Exogenous application of PC blocks pro-inflammatory signaling in Caco-2 cells, in phagosomes in vitro and facilitates intracellular survival of mycobacteria. We provide further evidence that actin assembly by membranes is part of the pro-inflammatory response. Collectively, these results provide a molecular foundation for the clinical studies showing a beneficial effect of PC therapy in ulcerative colitis.	Univ Hosp Heidelberg, Dept Gastroenterol, D-69120 Heidelberg, Germany; European Mol Biol Lab, Cell Biol Program, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Univ Lisbon, Fac Pharm, URIA, Mol Pathogenesis Ctr, P-1600083 Lisbon, Portugal; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; Universidade de Lisboa; University of Chicago	Ehehalt, R (corresponding author), Univ Hosp Heidelberg, Dept Gastroenterol, INF 345, D-69120 Heidelberg, Germany.	robert_ehehalt@med.uni-heidelberg.de	Anes, Elsa/K-3124-2013; Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009; iMed.ULisboa, HPI/B-4239-2014; Füllekrug, Joachim/A-6581-2008	Anes, Elsa/0000-0001-5934-0198; Turner, Jerrold R/0000-0003-0627-9455; iMed.ULisboa, HPI/0000-0001-5934-0198; Ehehalt, Robert/0000-0003-4252-5801; Stremmel, Wolfgang/0000-0002-8545-1753	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061931, R01DK068271] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061931-07, R01 DK068271-03, R01 DK061931, R01 DK068271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Anes E, 2006, CELL MICROBIOL, V8, P939, DOI 10.1111/j.1462-5822.2005.00675.x; Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; ASLAN A, 1992, AM J GASTROENTEROL, V87, P432; Barrios JM, 2000, GASTROENTEROLOGY, V118, P1179, DOI 10.1016/S0016-5085(00)70371-4; Belluzzi A, 2002, P NUTR SOC, V61, P391, DOI 10.1079/PNS2002171; Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; BENGMARK S, 1995, JPEN-PARENTER ENTER, V19, P410, DOI 10.1177/0148607195019005410; BERNHARD W, 1995, BBA-LIPID LIPID MET, V1255, P99, DOI 10.1016/0005-2760(94)00221-J; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; BUTLER BD, 1983, AM J PHYSIOL, V244, pG645, DOI 10.1152/ajpgi.1983.244.6.G645; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; DESCHRYVERKECSKEMETI K, 1989, J CLIN INVEST, V84, P1355, DOI 10.1172/JCI114306; DIAL EJ, 1984, GASTROENTEROLOGY, V87, P379; DUNJIC BS, 1993, SCAND J GASTROENTERO, V28, P89, DOI 10.3109/00365529309096051; Ehehalt R, 2004, SCAND J GASTROENTERO, V39, P737, DOI 10.1080/00365520410006233; ELHARIRI LM, 1992, J PHARM PHARMACOL, V44, P651, DOI 10.1111/j.2042-7158.1992.tb05487.x; FABIA R, 1992, DIGESTION, V53, P35, DOI 10.1159/000200969; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hanauer Stephen B, 2003, Rev Gastroenterol Disord, V3, P81; HILLS BA, 1989, GASTROENTEROLOGY, V97, P294, DOI 10.1016/0016-5085(89)90064-4; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; KAO YCJ, 1991, GASTROENTEROLOGY, V101, P7, DOI 10.1016/0016-5085(91)90454-S; KIVILUOTO T, 1991, GASTROENTEROLOGY, V100, P38, DOI 10.1016/0016-5085(91)90580-E; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; LICHTENBERGER LM, 1983, SCIENCE, V219, P1327, DOI 10.1126/science.6828859; LICHTENBERGER LM, 1995, ANNU REV PHYSIOL, V57, P565, DOI 10.1146/annurev.ph.57.030195.003025; Lichtenstein GR, 2006, CLIN GASTROENTEROL H, V4, P621, DOI 10.1016/j.cgh.2006.03.002; Lichtenstein GR, 2006, GASTROENTEROLOGY, V130, P940, DOI 10.1053/j.gastro.2006.01.048; LUGEA A, 1994, GASTROENTEROLOGY, V107, P720, DOI 10.1016/0016-5085(94)90119-8; Maaser C, 2002, Z GASTROENTEROL, V40, P525, DOI 10.1055/s-2002-32808; Manjari V, 2000, PROSTAG LEUKOTR ESS, V62, P85, DOI 10.1054/plef.1999.0125; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; MARTIN GP, 1981, J PHARM PHARMACOL, V33, P754, DOI 10.1111/j.2042-7158.1981.tb13926.x; Mehran M, 1995, AM J PHYSIOL-GASTR L, V269, pG953, DOI 10.1152/ajpgi.1995.269.6.G953; Mourelle M, 1996, GASTROENTEROLOGY, V110, P1093, DOI 10.1053/gast.1996.v110.pm8612998; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Nervi F, 2000, GASTROENTEROLOGY, V118, P1265, DOI 10.1016/S0016-5085(00)70380-5; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PACHECO S, 1987, CLIN SCI, V73, P361, DOI 10.1042/cs0730361; Patel B, 2002, INFLAMM BOWEL DIS, V8, P340, DOI 10.1097/00054725-200209000-00005; Pedron T, 2003, J BIOL CHEM, V278, P33878, DOI 10.1074/jbc.M303749200; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; PUGLIELLI L, 1994, GASTROENTEROLOGY, V107, P244, DOI 10.1016/0016-5085(94)90083-3; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Stremmel W, 2005, GUT, V54, P966, DOI 10.1136/gut.2004.052316; SWARM RA, 1987, AM J SURG, V153, P48, DOI 10.1016/0002-9610(87)90200-5; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Vallee S, 2004, EXP CELL RES, V297, P165, DOI 10.1016/j.yexcr.2004.03.007; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516	63	183	193	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27155	27164		10.1074/jbc.M704408200	http://dx.doi.org/10.1074/jbc.M704408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636253	Green Accepted, hybrid			2022-12-27	WOS:000249304900056
J	Qahwash, IM; Boire, A; Lanning, J; Pytel, TKP; Meredith, SC				Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.			Site-specific effects of peptide lipidation on beta-Amyloid aggregation and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; EXPERIMENTAL CONSTRAINTS; ALZHEIMERS DEMENTIA; PROTEIN ADDUCTS; OXIDIZED LDL; FIBRILS; DISEASE; INJURY	beta-Amyloid (A beta) aggregates at low concentrations in vivo, and this may involve covalently modified forms of these peptides. Modification of A beta by 4-hydroxynonenal (4-HNE) initially increases the hydrophobicity of these peptides and subsequently leads to additional reactions, such as peptide cross-linking. To model these initial events, without confounding effects of subsequent reactions, we modified A beta at each of its amino groups using a chemically simpler, close analogue of 4-HNE, the octanoyl group: K16-octanoic acid (OA)-A beta, K28-OA-A beta, and N alpha-OA-A beta. Octanoylation of these sites on A beta-(1-40) had strikingly different effects on fibril formation. K16-OA-A beta and K28-OA-A beta, but not N alpha-OA-A beta, had increased propensity to aggregate. The type of aggregate ( electron microscopic appearance) differed with the site of modification. The ability of octanoyl-A beta peptides to cross-seed solutions of A beta was the inverse of their ability to form fibrils on their own (i.e. A approximate to N alpha-OA-A beta >> K16-OA-A beta >> K28-OA-A beta). By CD spectroscopy, K16-OA-A beta and K28-OA-A beta had increased beta-sheet propensity compared with A beta-(1-40) or N alpha-OA-A beta. K16-OA-A beta and K28-OA-A beta were more amphiphilic than A beta-(1-40) or N alpha-OA-A beta, as shown by lower "critical micelle concentrations" and higher monolayer collapse pressures. Finally, K16-OA-A beta and K28-OA-A beta are much more cytotoxic to N2A cells than A beta-(1-40) or N alpha-OA-A beta. The greater cytotoxicity of K16-OA-A beta and K28-OA-A beta may reflect their greater amphiphilicity. We conclude that lipidation can make A beta more prone to aggregation and more cytotoxic, but these effects are highly site-specific.	[Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; [Qahwash, Isam M.; Boire, Adrienne; Lanning, Jennifer; Pytel, Thomas Krausz Peter; Meredith, Stephen C.] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Meredith, SC (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	scmeredi@uchicago.edu	Boire, Adrienne/AAA-3578-2022; Boire, Adrienne/AAJ-9352-2021	Boire, Adrienne/0000-0002-9029-1248; Boire, Adrienne/0000-0002-9029-1248	NINDS NIH HHS [R01 NS042852] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042852] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdi F, 2006, J ALZHEIMERS DIS, V9, P293; Aoyama K, 2006, EUR J NEUROL, V13, P89, DOI 10.1111/j.1468-1331.2006.01139.x; Bieschke J, 2006, ACCOUNTS CHEM RES, V39, P611, DOI 10.1021/ar0500766; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2; Dalfo E, 2005, J NEUROPATH EXP NEUR, V64, P816, DOI 10.1097/01.jnen.0000179050.54522.5a; Ding QX, 2007, CURR ALZHEIMER RES, V4, P73, DOI 10.2174/156720507779939788; Ege C, 2004, BIOPHYS J, V87, P1732, DOI 10.1529/biophysj.104.043265; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FUKUSHIMA D, 1979, J AM CHEM SOC, V101, P3703, DOI 10.1021/ja00507a068; Fukuyama R, 2000, EUR NEUROL, V43, P155, DOI 10.1159/000008156; Gordon DJ, 2004, BIOPHYS J, V86, P428, DOI 10.1016/S0006-3495(04)74119-3; Gustafson DR, 2007, J NEUROL NEUROSUR PS, V78, P461, DOI 10.1136/jnnp.2006.100529; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X; Kheterpal I, 2006, J MOL BIOL, V361, P785, DOI 10.1016/j.jmb.2006.06.066; Koppaka V, 2003, J BIOL CHEM, V278, P36277, DOI 10.1074/jbc.M301334200; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Lewczuk P, 2004, NEUROBIOL AGING, V25, P273, DOI 10.1016/S0197-4580(03)00086-1; LEWCZUK P, 2007, NEUROBIOL AGING; Leyvraz F., 1986, On Growth and Form - Fractal and Non-Fractal Patterns in Physics. Proceedings of the NATO Advanced Study Institute, P136; Li DY, 2005, CARDIOVASC RES, V68, P353, DOI 10.1016/j.cardiores.2005.09.009; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8; MINAKATA H, 1989, J BIOL CHEM, V264, P7907; Murray IVJ, 2007, J BIOL CHEM, V282, P9335, DOI 10.1074/jbc.M608589200; Murray IVJ, 2005, BIOCHEMISTRY-US, V44, P12606, DOI 10.1021/bi050926p; O'Nuallain B, 2006, METHOD ENZYMOL, V413, P34, DOI 10.1016/S0076-6879(06)13003-7; Odetti P, 2000, J NEUROPATH EXP NEUR, V59, P393, DOI 10.1093/jnen/59.5.393; Olkkonen VM, 2004, ANN MED, V36, P562, DOI 10.1080/07853890410018907; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; Pasternack RF, 2000, BIOPHYS J, V79, P550, DOI 10.1016/S0006-3495(00)76316-8; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; Qin ZJ, 2007, J BIOL CHEM, V282, P5862, DOI 10.1074/jbc.M608126200; Raby CA, 1998, J NEUROCHEM, V71, P2505; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Riemenschneider M, 2000, NEUROSCI LETT, V284, P85, DOI 10.1016/S0304-3940(00)00976-9; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Sciarretta KL, 2006, BIOCHEMISTRY-US, V45, P9485, DOI 10.1021/bi0605585; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5; SHEN BW, 1973, CIRCULATION, V48, P218; Siegel SJ, 2007, BIOCHEMISTRY-US, V46, P1503, DOI 10.1021/bi061853s; Simonsen AH, 2007, DEMENT GERIATR COGN, V23, P246, DOI 10.1159/000100020; Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Teunissen CE, 2002, NEUROBIOL AGING, V23, P485, DOI 10.1016/S0197-4580(01)00328-1; Tycko R, 2006, Q REV BIOPHYS, V39, P1, DOI 10.1017/S0033583506004173; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; VANGOOL WA, 1994, NEUROSCI LETT, V172, P122, DOI 10.1016/0304-3940(94)90677-7; Whittemore NA, 2005, BIOCHEMISTRY-US, V44, P4434, DOI 10.1021/bi048292u; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6; Yamashita T, 2000, J NEUROL SCI, V175, P107, DOI 10.1016/S0022-510X(00)00296-3; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101; Zhang XC, 1996, J BIOCHEM BIOPH METH, V31, P145, DOI 10.1016/0165-022X(95)00032-M; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	74	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2007	282	51					36987	36997		10.1074/jbc.M702146200	http://dx.doi.org/10.1074/jbc.M702146200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241GX	17693400	hybrid			2022-12-27	WOS:000251646000025
J	Perrotton, T; Trompier, D; Chang, XB; Di Pietro, A; Baubichon-Cortay, H				Perrotton, Thomas; Trompier, Doriane; Chang, Xiu-Bao; Di Pietro, Attilio; Baubichon-Cortay, Helen			(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE TRANSPORT; ATPASE ACTIVITY; VERAPAMIL ANALOGS; MEMBRANE-VESICLES; LEUKOTRIENE C-4; LEUKEMIA-CELLS; P-GLYCOPROTEIN; TUMOR-CELLS; BINDING; APOPTOSIS	The multidrug-resistant protein MRP1 (involved in the cancer cell multidrug resistance phenotype) has been found to be modulated by racemic verapamil (through stimulation of glutathione transport), inducing apoptosis of human MRP1 cDNA-transfected baby hamster kidney 21 (BHK-21) cells and not of control BHK-21 cells. In this study, we show that the two enantiomers of verapamil have different effects on MRP1 activity. Only the S-isomer (not the R-isomer) potently induced the death of MRP1-transfected BHK-21 cells. The decrease in cellular glutathione content induced by the S-isomer, which was not observed with the R-isomer, was stronger than that induced by the racemic mixture, indicating that the R-isomer antagonized the S-isomer effect. Both enantiomers altered leukotriene C-4 and calcein transport by MRP1. Thus, the R-isomer behaved as an inhibitor, which was confirmed by its ability to revert the multidrug resistance phenotype toward vincristine. Molecular studies on purified MRP1 using fluorescence spectroscopy showed that both enantiomers bound to MRP1 with high affinity, with the binding being prevented by glutathione. Furthermore, conformational changes induced by the two enantiomers (monitored by sodium iodide accessibility of MRP1 tryptophan residues) were quite different, correlating with their distinct effects. (S)-Verapamil induces the death of potentially resistant tumor cells, whereas (R)-verapamil sensitizes MRP1-overexpressing cells to chemotherapeutics. These results might be of great potential interest in the design of new compounds able to modulate MRP1 in chemotherapy.	CNRS, Univ Lyon, Inst Biol Chim Proteins, Lab Proteins Resist Agents Chimtherapeut, Lyon 69367, France; Mayo Clin, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Centre National de la Recherche Scientifique (CNRS); Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Baubichon-Cortay, H (corresponding author), Inst Chim Biol Prot, 7,passage Vercors, F-69367 Lyon, France.	h.cortay@ibcp.fr	TROMPIER, Doriane/D-5862-2017	Trompier, Doriane/0000-0002-0746-1753	NATIONAL CANCER INSTITUTE [R01CA089078] Funding Source: NIH RePORTER; NCI NIH HHS [CA89078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Boumendjel A, 2005, MED RES REV, V25, P453, DOI 10.1002/med.20032; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; COLE SPC, 1994, CANCER RES, V54, P5902; Cullen KV, 2001, BIOCHEM PHARMACOL, V62, P417, DOI 10.1016/S0006-2952(01)00681-5; DAVEY RA, 1995, LEUKEMIA RES, V19, P275, DOI 10.1016/0145-2126(94)00159-8; Deeley RG, 2006, FEBS LETT, V580, P1103, DOI 10.1016/j.febslet.2005.12.036; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036; Grech KV, 1998, BIOCHEM PHARMACOL, V55, P1283, DOI 10.1016/S0006-2952(97)00562-5; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hooijberg JH, 2000, FEBS LETT, V469, P47, DOI 10.1016/S0014-5793(00)01238-2; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Kachadourian R, 2006, FREE RADICAL BIO MED, V41, P65, DOI 10.1016/j.freeradbiomed.2006.03.002; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kwon Y, 1996, J PHARM SCI, V85, P935, DOI 10.1021/js9600540; Laberge RM, 2007, BIOCHEM PHARMACOL, V73, P1727, DOI 10.1016/j.bcp.2007.02.005; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAITO M, 1989, CANCER RES, V49, P1452; PEREIRA E, 1995, BIOCHEM PHARMACOL, V50, P451, DOI 10.1016/0006-2952(95)00174-X; Szabo D, 1998, ANTICANCER RES, V18, P3039; Teodori E, 1999, J MED CHEM, V42, P1687, DOI 10.1021/jm980440p; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143; Trompier D, 2003, CELL MOL LIFE SCI, V60, P2164, DOI 10.1007/s00018-003-3177-6	33	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31542	31548		10.1074/jbc.M703964200	http://dx.doi.org/10.1074/jbc.M703964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17646169	hybrid			2022-12-27	WOS:000250309200046
J	Simoes, I; Faro, R; Bur, D; Faro, C				Simoes, Isaura; Faro, Rosario; Bur, Daniel; Faro, Carlos			Characterization of recombinant CDR1, an Arabidopsis aspartic proteinase involved in disease resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; SIGNALING PATHWAYS; CRYSTAL-STRUCTURE; HUMAN RENIN; CATHEPSIN-E; TOBACCO; ZINC; SPECIFICITY	The Arabidopsis thaliana constitutive disease resistance 1 (CDR1) gene product is an aspartic proteinase that has been implicated in disease resistance signaling (Xia, Y., Suzuki, H., Borevitz, J., Blount, J., Guo, Z., Patel, K., Dixon, R. A., and Lamb, C. (2004) EMBO J. 23, 980-988). This apoplastic enzyme is a member of the group of "atypical" plant aspartic proteinases. As for other enzymes of this subtype, CDR1 has remained elusive until recently as a result of its unusual properties and localization. Here we report on the heterologous expression and characterization of recombinant CDR1, which displays unique enzymatic properties among plant aspartic proteinases. The highly restricted specificity requirements, insensitivity toward the typical aspartic proteinase inhibitor pepstatin A, an unusually high optimal pH of 6.0-6.5, proteinase activity without irreversible prosegment removal, and dependence of catalytic activity on formation of a homo-dimer are some of the unusual properties observed for recombinant CDR1. These findings unveil a pattern of unprecedented functional complexity for Arabidopsis CDR1 and are consistent with a highly specific and regulated biological function.	Univ Coimbra, Ctr Neurosci & Biol Celular, Dept Mol Biol & Biotechnol, P-3000 Coimbra, Portugal; Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland	Universidade de Coimbra; Actelion Pharmaceuticals Ltd	Faro, C (corresponding author), Univ Coimbra, Ctr Neurosci & Biol Celular, Dept Mol Biol & Biotechnol, Apt 3126, P-3000 Coimbra, Portugal.	cfaro@imagem.ibili.uc.pt	Simões, Isaura/N-4210-2019; Simões, Isaura I G/F-3239-2010	Simões, Isaura/0000-0002-9331-6340; Simões, Isaura I G/0000-0002-9331-6340; Faro, Carlos/0000-0002-0480-8379				Athauda SBP, 2004, BIOCHEM J, V381, P295, DOI 10.1042/BJ20031575; Beers EP, 2004, PHYTOCHEMISTRY, V65, P43, DOI 10.1016/j.phytochem.2003.09.005; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bi XZ, 2005, PLANT CELL PHYSIOL, V46, P87, DOI 10.1093/pcp/pci002; Castanheira P, 2005, J BIOL CHEM, V280, P13047, DOI 10.1074/jbc.M412076200; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; EVANS DB, 1990, BIOTECHNOL APPL BIOC, V12, P161; Faro C, 2005, CURR PROTEIN PEPT SC, V6, P493, DOI 10.2174/138920305774933268; Fobert PR, 2005, CURR OPIN PLANT BIOL, V8, P378, DOI 10.1016/j.pbi.2005.05.003; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Ge XC, 2005, EMBO REP, V6, P282, DOI 10.1038/sj.embor.7400357; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Kato Y, 2005, PLANTA, V222, P643, DOI 10.1007/s00425-005-0011-4; Kato Y, 2004, PLANTA, V220, P97, DOI 10.1007/s00425-004-1328-0; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maldonado AM, 2002, NATURE, V419, P399, DOI 10.1038/nature00962; Maret W, 2005, J TRACE ELEM MED BIO, V19, P7, DOI 10.1016/j.jtemb.2005.02.003; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; Murakami S, 2000, FEBS LETT, V468, P15, DOI 10.1016/S0014-5793(00)01186-8; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; Ostermann N, 2004, J MOL BIOL, V342, P889, DOI 10.1016/j.jmb.2004.07.073; Pieterse CM, 2004, CURR OPIN PLANT BIOL, V7, P456, DOI 10.1016/j.pbi.2004.05.006; PITARRESI TM, 1992, J BIOL CHEM, V267, P11753; Simoes I, 2004, EUR J BIOCHEM, V271, P2067, DOI 10.1111/j.1432-1033.2004.04136.x; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SLATER EE, 1981, J BIOL CHEM, V256, P8164; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Xia YJ, 2004, EMBO J, V23, P980, DOI 10.1038/sj.emboj.7600086; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	39	44	46	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31358	31365		10.1074/jbc.M702477200	http://dx.doi.org/10.1074/jbc.M702477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17650510	hybrid			2022-12-27	WOS:000250309200025
J	Lengyel, CSE; Willis, LJ; Mann, P; Baker, D; Kortemme, T; Strong, RK; McFarland, BJ				Lengyel, Candice S. E.; Willis, Lindsey J.; Mann, Patrick; Baker, David; Kortemme, Tanja; Strong, Roland K.; McFarland, Benjamin J.			Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING IMMUNORECEPTOR NKG2D; PROTEIN COMPLEXES; CRYSTAL-STRUCTURE; RATIONAL DESIGN; T-CELLS; BINDING; RECOGNITION; ANTIGEN; LIGAND; MICA	MICA is a major histocompatibility complex-like protein that undergoes a structural transition from disorder to order upon binding its immunoreceptor, NKG2D. We redesigned the disordered region of MICA with RosettaDesign to increase NKG2D binding. Mutations that stabilize this region were expected to increase association kinetics without changing dissociation kinetics, increase affinity of interaction, and reduce entropy loss upon binding. MICA mutants were stable in solution, and they were amenable to surface plasmon resonance evaluation of NKG2D binding kinetics and thermodynamics. Several MICA mutants bound NKG2D with enhanced affinity, kinetic changes were primarily observed during association, and thermodynamic changes in entropy were as expected. However, none of the 15 combinations of mutations predicted to stabilize the receptor-bound MICA conformation enhanced NKG2D affinity, whereas all 10 mutants predicted to be destabilized bound NKG2D with increased on-rates. Five of these had affinities enhanced by 0.9-1.8 kcal/ mol over wild type by one to three non-contacting substitutions. Therefore, in this case, mutations designed to mildly destabilize a protein enhanced association and affinity.	Seattle Pacific Univ, Dept Chem & Biochem, Seattle, WA 98119 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center	McFarland, BJ (corresponding author), 3307 3rd Ave W,Suite 205, Seattle, WA 98119 USA.	bjm@spu.edu	Kortemme, Tanja/AAN-3180-2021; Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Kortemme, Tanja/0000-0002-8494-680X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI058972] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI058972-02, R15 AI058972-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Avbelj F, 2000, P NATL ACAD SCI USA, V97, P10786, DOI 10.1073/pnas.200343197; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; CALHOUN D B, 1986, Proteins Structure Function and Genetics, V1, P109, DOI 10.1002/prot.340010202; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; Clark LA, 2006, PROTEIN SCI, V15, P949, DOI 10.1110/ps.052030506; Dantas G, 2003, J MOL BIOL, V332, P449, DOI 10.1016/S0022-2836(03)00888-X; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Holmes MA, 2002, J IMMUNOL, V169, P1395, DOI 10.4049/jimmunol.169.3.1395; Horn JR, 2006, BIOCHEMISTRY-US, V45, P8488, DOI 10.1021/bi0604328; Keeble AH, 2006, BIOCHEMISTRY-US, V45, P3243, DOI 10.1021/bi052373o; Kiel C, 2004, P NATL ACAD SCI USA, V101, P9223, DOI 10.1073/pnas.0401160101; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Krishnamurthy VM, 2006, J AM CHEM SOC, V128, P5802, DOI 10.1021/ja060070r; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2001, BIOCHEMISTRY-US, V40, P2011, DOI 10.1021/bi0014148; Lipschultz CA, 2002, J MOL RECOGNIT, V15, P44, DOI 10.1002/jmr.559; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; McFarland BJ, 2003, IMMUNITY, V19, P803, DOI 10.1016/S1074-7613(03)00320-0; McFarland BJ, 2003, STRUCTURE, V11, P411, DOI 10.1016/S0969-2126(03)00047-9; Miley MJ, 2004, J EXP MED, V200, P1445, DOI 10.1084/jem.20040217; Natarajan K, 2006, J MOL BIOL, V358, P157, DOI 10.1016/j.jmb.2006.01.068; Reichmann D, 2007, J MOL BIOL, V365, P663, DOI 10.1016/j.jmb.2006.09.076; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Song G, 2006, J BIOL CHEM, V281, P5042, DOI 10.1074/jbc.M510454200; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325	33	23	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30658	30666		10.1074/jbc.M704513200	http://dx.doi.org/10.1074/jbc.M704513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690100	hybrid			2022-12-27	WOS:000250136300033
J	Kitayama, K; Hayashida, Y; Nishida, K; Akama, TO				Kitayama, Kazuko; Hayashida, Yasutaka; Nishida, Kohji; Akama, Tomoya O.			Enzymes responsible for synthesis of corneal keratan sulfate glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; DYSTROPHY; GLYCOSYLATION; PROTEOGLYCAN; LUMICAN; CLONING; FAMILY; CELLS	Keratan sulfate glycosaminoglycans are among the most abundant carbohydrate components of the cornea and are suggested to play an important role in maintaining corneal extracellular matrix structure. Keratan sulfate carbohydrate chains consist of repeating N-acetyllactosamine disaccharides with sulfation on the 6-O positions of N-acetylglucosamine and galactose. Despite its importance for corneal function, the biosynthetic pathway of the carbohydrate chain and particularly the elongation steps are poorly understood. Here we analyzed enzymatic activity of two glycosyltransferases, beta 1,3-N-acetylglucosaminyltansferase-7 (beta 3GnT7) and beta 1,4-galactosyltransferase-4 (beta 4GalT4), in the production of keratan sulfate carbohydrate in vitro. These glycosyltransferases produced only short, elongated carbohydrates when they were reacted with substrate in the absence of a carbohydrate sulfotransferase; however, they produced extended GlcNAc-sulfated poly-N-acetyllactosamine structures with more than four repeats of the GlcNAc-sulfated N-acetyllactosamine unit in the presence of corneal N-acetylglucosamine 6-O sulfotransferase (CGn6ST). Moreover, we detected production of highly sulfated keratan sulfate by a two-step reaction in vitro with a mixture of beta 3GnT7/beta 4GalT4/CGn6ST followed by keratan sulfate galactose 6-O sulfotransferase treatment. We also observed that production of highly sulfated keratan sulfate in cultured human corneal epithelial cells was dramatically reduced when expression of beta 3GnT7 or beta 4GalT4 was suppressed by small interfering RNAs, indicating that these glycosyltransferases are responsible for elongation of the keratan sulfate carbohydrate backbone.	Burnham Inst Med Res, Glycobiol Program, La Jolla, CA 92037 USA; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan	Sanford Burnham Prebys Medical Discovery Institute; Osaka University	Akama, TO (corresponding author), Burnham Inst Med Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takama@burnham.org		Nishida, Kohji/0000-0001-9069-3610; Kitayama, Kazuko/0000-0003-2829-762X	NATIONAL EYE INSTITUTE [R01EY014620] Funding Source: NIH RePORTER; NEI NIH HHS [EY014620] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2002, J BIOL CHEM, V277, P42505, DOI 10.1074/jbc.M207412200; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; Connon CJ, 2004, EXP EYE RES, V78, P909, DOI 10.1016/j.exer.2004.01.005; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; DOANE KJ, 1992, EXP CELL RES, V202, P113, DOI 10.1016/0014-4827(92)90410-A; EDWARD DP, 1990, OPHTHALMOLOGY, V97, P1194; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; Funderburgh JL, 2002, IUBMB LIFE, V54, P187, DOI 10.1080/15216540214932; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; Greiling H, 1994, EXS, V70, P101; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; Hayashida Y, 2006, P NATL ACAD SCI USA, V103, P13333, DOI 10.1073/pnas.0605441103; Kataoka K, 2002, BIOCHEM BIOPH RES CO, V294, P843, DOI 10.1016/S0006-291X(02)00553-3; Klintworth GK, 2003, FRONT BIOSCI-LANDMRK, V8, pD687, DOI 10.2741/1018; KRESSE H, 1981, J BIOL CHEM, V256, P2926; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Musselmann K, 2006, EXP EYE RES, V83, P707, DOI 10.1016/j.exer.2005.11.020; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Seko A, 2004, FEBS LETT, V556, P216, DOI 10.1016/S0014-5793(03)01440-6; Seko A, 2003, J BIOL CHEM, V278, P9150, DOI 10.1074/jbc.M211480200; Tai GH, 1997, J BIOL CHEM, V272, P28227, DOI 10.1074/jbc.272.45.28227; TAI GH, 1993, BIOCHEM J, V291, P889, DOI 10.1042/bj2910889; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; YANG CJ, 1988, AM J OPHTHALMOL, V106, P65, DOI 10.1016/S0002-9394(14)76390-1	34	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30085	30096		10.1074/jbc.M703695200	http://dx.doi.org/10.1074/jbc.M703695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17690104	hybrid			2022-12-27	WOS:000249981200039
J	Kotsyfakis, M; Karim, S; Andersen, JF; Mather, TN; Ribeiro, JMC				Kotsyfakis, Michalis; Karim, Shahid; Andersen, John F.; Mather, Thomas N.; Ribeiro, Jose M. C.			Selective cysteine protease inhibition contributes to blood-feeding success of the tick Ixodes scapularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGEN TRANSMISSION; CATHEPSIN-S; CYSTATIN; PROTEINASES; IMMUNITY; DISRUPTION; SIALOME	Ixodes scapularis is the main vector of Lyme disease in the eastern and central United States. Tick salivary secretion has been shown as important for both blood-meal completion and pathogen transmission. Here we report a duplication event of cystatin genes in its genome that results in a transcription-regulated boost of saliva inhibitory activity against a conserved and relatively limited number of vertebrate papain-like cysteine proteases during blood feeding. We further show that the polypeptide products of the two genes differ in their binding affinity for some enzyme targets, and they display different antigenicity. Moreover, our reverse genetic approach employing RNA interference uncovered a crucial mediation in tick-feeding success. Given the role of the targeted enzymes in vertebrate immunity, we also show that host immunomodulation is implicated in the deleterious phenotype of silenced ticks making I. scapularis cystatins attractive targets for development of antitick vaccines.	NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rhode Island	Ribeiro, JMC (corresponding author), NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.	jribeiro@niaid.nih.gov	Kotsyfakis, Michail/G-9525-2014	Kotsyfakis, Michail/0000-0002-7526-1876; Karim, Shahid/0000-0001-5596-3304; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, R01AI037230, Z01AI001012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [5R01AI037230] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson JF, 2002, MED CLIN N AM, V86, P205, DOI 10.1016/S0025-7125(03)00083-X; Bjork I, 1996, BIOCHEMISTRY-US, V35, P10720, DOI 10.1021/bi960420u; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Estrada-Pena A, 1999, EXP APPL ACAROL, V23, P685, DOI 10.1023/A:1006241108739; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Grunclova L, 2006, BIOL CHEM, V387, P1635, DOI 10.1515/BC.2006.204; Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Karim S, 2005, BIOCHEM BIOPH RES CO, V334, P1336, DOI 10.1016/j.bbrc.2005.07.036; Kotsyfakis M, 2006, J BIOL CHEM, V281, P26298, DOI 10.1074/jbc.M513010200; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Narasimhan S, 2004, P NATL ACAD SCI USA, V101, P1141, DOI 10.1073/pnas.0307669100; Pedra JHF, 2006, AM J TROP MED HYG, V75, P677, DOI 10.4269/ajtmh.2006.75.677; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; SCHORDERET S, 1993, MED VET ENTOMOL, V7, P186, DOI 10.1111/j.1365-2915.1993.tb00673.x; Serveau-Avesque C, 2006, BIOL CELL, V98, P15, DOI 10.1042/BC20040512; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; Wikel SK, 1999, INT J PARASITOL, V29, P851, DOI 10.1016/S0020-7519(99)00042-9; Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5; Zavasnik-Bergant T, 2006, TISSUE ANTIGENS, V67, P349, DOI 10.1111/j.1399-0039.2006.00585.x; Zhou JL, 2006, INSECT BIOCHEM MOLEC, V36, P527, DOI 10.1016/j.ibmb.2006.03.003	28	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29256	29263		10.1074/jbc.M703143200	http://dx.doi.org/10.1074/jbc.M703143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698852	Green Published, hybrid			2022-12-27	WOS:000249788000022
J	Gutternigg, M; Kretschmer-Lubich, D; Paschinger, K; Rendic, D; Hader, J; Geier, P; Ranftl, R; Jantsch, V; Lochnit, G; Wilson, IBH				Gutternigg, Martin; Kretschmer-Lubich, Dorothea; Paschinger, Katharina; Rendic, Dubravko; Hader, Josef; Geier, Petra; Ranftl, Ramona; Jantsch, Verena; Lochnit, Guenter; Wilson, Iain B. H.			Biosynthesis of truncated N-linked oligosaccharides results from non-orthologous hexosaminidase-mediated mechanisms in nematodes, plants, and insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; CORE ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE-ACTIVE ENZYMES; CAENORHABDITIS-ELEGANS; ARABIDOPSIS-THALIANA; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; ACETYLGLUCOSAMINYLTRANSFERASE-I; STREPTOCOCCUS-PNEUMONIAE; BETA-HEXOSAMINIDASE	In many invertebrates and plants, the N-glycosylation profile is dominated by truncated paucimannosidic N-glycans, i.e. glycans consisting of a simple trimannosylchitobiosyl core often modified by core fucose residues. Even though they lack antennal N-acetylglucosamine residues, the biosynthesis of these glycans requires the sequential action of GlcNAc transferase I, Golgi mannosidase II, and, finally, beta-N-acetylglucosaminidases. In Drosophila, the recently characterized enzyme encoded by the fused lobes (fdl) gene specifically removes the non-reducing N-acetylglucosamine residue from the alpha 1,3-antenna of N-glycans. In the present study, we examined the products of five beta-N-acetylhexosaminidase genes from Caenorhabditis elegans (hex-1 to hex-5, corresponding to reading frames T14F9.3, C14C11.3, Y39A1C.4, Y51F10.5, and Y70D2A.2) in addition to three from Arabidopsis thaliana (AtHEX1, AtHEX2, and AtHEX3, corresponding to reading frames At1g65590, At3g55260, and At1g05590). Based on homology, the Caenorhabditis HEX-1 and all three Arabidopsis enzymes are members of the same sub-family as the aforementioned Drosophila fused lobes enzyme but either act as chitotriosidases or non-specifically remove N-acetylglucosamine from both N-glycan antennae. The other four Caenorhabditis enzymes are members of a distinct sub-family; nevertheless, two of these enzymes displayed the same alpha 1,3-antennal specificity as the fused lobes enzyme. Furthermore, a deletion of part of the Caenorhabditis hex-2 gene drastically reduces the native N-glycan-specific hexosaminidase activity in mutant worm extracts and results in a shift in the N-glycan profile, which is a demonstration of its in vivo enzymatic relevance. Based on these data, it is hypothesized that the genetic origin of pauci-mannosidic glycans in nematodes, plants, and insects involves highly divergent members of the same hexosaminidase gene family.	Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, A-1190 Vienna, Austria; Vienna Bioctr 2, Abt Chromosomenbiol, A-1030 Vienna, Austria; Univ Giessen, Inst Biochem, D-35292 Giessen, Germany	University of Natural Resources & Life Sciences, Vienna; Vienna Biocenter (VBC); Justus Liebig University Giessen	Wilson, IBH (corresponding author), Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, Muthgasse 18, A-1190 Vienna, Austria.	iain.wilson@boku.ac.at	Wilson, Iain/B-3326-2009; Jantsch, Verena/A-3910-2017; Rendic, Dubravko/A-9368-2010	Wilson, Iain/0000-0001-8996-1518; Jantsch, Verena/0000-0002-1978-682X; Paschinger, Katharina/0000-0002-3594-7136	Austrian Science Fund FWF [P 18447] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Aoki K, 2007, J BIOL CHEM, V282, P9127, DOI 10.1074/jbc.M606711200; Aumiller JJ, 2006, PROTEIN EXPRES PURIF, V47, P571, DOI 10.1016/j.pep.2005.11.026; Bakker H, 1999, BIOCHEM BIOPH RES CO, V261, P829, DOI 10.1006/bbrc.1999.1117; Bencurova M, 2003, BIOCHIMIE, V85, P413, DOI 10.1016/S0300-9084(03)00072-5; Betenbaugh MJ, 2004, CURR OPIN STRUC BIOL, V14, P601, DOI 10.1016/j.sbi.2004.09.001; BOLANOWSKI MA, 1983, MECH AGEING DEV, V21, P295, DOI 10.1016/0047-6374(83)90048-9; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; Coutinho PM, 1999, ROY SOC CH, P3; Diez B, 2005, FEMS MICROBIOL LETT, V242, P257, DOI 10.1016/j.femsle.2004.11.017; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Fan XL, 2005, GLYCOBIOLOGY, V15, P952, DOI 10.1093/glycob/cwi075; Faveeuw C, 2003, EUR J IMMUNOL, V33, P1271, DOI 10.1002/eji.200323717; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; Gao BL, 2002, INT J PARASITOL, V32, P1293, DOI 10.1016/S0020-7519(02)00110-8; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Gradnig G, 1996, CARBOHYD RES, V287, P49, DOI 10.1016/0008-6215(96)00065-1; Griffitts JS, 2005, SCIENCE, V307, P922, DOI 10.1126/science.1104444; Gutternigg M, 2004, EUR J BIOCHEM, V271, P1348, DOI 10.1111/j.1432-1033.2004.04045.x; Hanneman AJ, 2006, GLYCOBIOLOGY, V16, P874, DOI 10.1093/glycob/cwl011; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 1999, J BIOL CHEM, V274, P20953, DOI 10.1074/jbc.274.30.20953; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; HORI H, 1983, ARCH BIOCHEM BIOPHYS, V220, P415, DOI 10.1016/0003-9861(83)90431-9; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Hou YM, 2001, BIOCHEMISTRY-US, V40, P2201, DOI 10.1021/bi002018s; Iseli B, 1996, FEBS LETT, V382, P186, DOI 10.1016/0014-5793(96)00174-3; Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Leonard R, 2006, J BIOL CHEM, V281, P4867, DOI 10.1074/jbc.M511023200; LI SC, 1970, J BIOL CHEM, V245, P5153; LIU PS, 1991, TETRAHEDRON LETT, V32, P719, DOI 10.1016/S0040-4039(00)74866-0; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Mucha J, 2004, BIOCHEM J, V382, P67, DOI 10.1042/BJ20040535; MULDER H, 1995, EUR J BIOCHEM, V232, P272, DOI 10.1111/j.1432-1033.1995.tb20809.x; PARKER GF, 1991, FEBS LETT, V290, P58, DOI 10.1016/0014-5793(91)81225-W; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Paschinger K, 2006, J BIOL CHEM, V281, P28265, DOI 10.1074/jbc.M602878200; Poltl G, 2007, FEBS J, V274, P714, DOI 10.1111/j.1742-4658.2006.05615.x; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; Sarkar M, 2006, J BIOL CHEM, V281, P12776, DOI 10.1074/jbc.M512769200; Shi H, 2006, METHOD ENZYMOL, V417, P359, DOI 10.1016/S0076-6879(06)17022-6; Strasser R, 1999, GLYCOCONJUGATE J, V16, P787, DOI 10.1023/A:1007127815012; Strasser R, 2006, PLANT J, V45, P789, DOI 10.1111/j.1365-313X.2005.02648.x; Strasser R, 2004, GLYCOCONJUGATE J, V21, P275, DOI 10.1023/B:GLYC.0000045099.29038.04; Strasser R, 2000, FEBS LETT, V472, P105, DOI 10.1016/S0014-5793(00)01443-5; Takahashi N, 2003, EUR J BIOCHEM, V270, P2627, DOI 10.1046/j.1432-1033.2003.03636.x; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Tomiya N, 2006, J BIOL CHEM, V281, P19545, DOI 10.1074/jbc.M603312200; Van Patten SM, 2007, GLYCOBIOLOGY, V17, P467, DOI 10.1093/glycob/cwm008; van Remoortere A, 2003, GLYCOBIOLOGY, V13, P217, DOI 10.1093/glycob/cwg025; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; VONSCHAEWEN A, 1993, PLANT PHYSIOL, V102, P1109, DOI 10.1104/pp.102.4.1109; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Wilson IBH, 2001, BBA-GEN SUBJECTS, V1527, P88, DOI 10.1016/S0304-4165(01)00151-9; Wu Y, 2001, J BIOL CHEM, V276, P42557, DOI 10.1074/jbc.M103479200; Wuhrer M, 2004, BIOCHEM J, V378, P625, DOI 10.1042/BJ20031380; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zhang YH, 2005, DEV BIOL, V285, P330, DOI 10.1016/j.ydbio.2005.06.037; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	76	74	86	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27825	27840		10.1074/jbc.M704235200	http://dx.doi.org/10.1074/jbc.M704235200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17636254	hybrid, Green Accepted			2022-12-27	WOS:000249455600031
J	Moker, N; Reihlen, P; Kramer, R; Morbach, S				Moeker, Nina; Reihlen, Philipp; Kraemer, Reinhard; Morbach, Susanne			Osmosensing properties of the histidine protein kinase MtrB from Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI K-12; BETAINE CARRIER BETP; OSMOTIC-STRESS; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; RESPONSE REGULATOR; BACILLUS-SUBTILIS; GLYCINE BETAINE; SYSTEM	The MtrB-MtrA two component system of Corynebacterium glutamicum was recently shown to be in involved in the osmostress response as well as cell wall metabolism. To address the question of whether the histidine protein kinase MtrB is an osmosensor, the kinase was purified and reconstituted into liposomes in a functionally active form. The activity regulation was investigated by varying systematically physicochemical parameters, which are putative stimuli that could be used by the bacterial cell to detect osmotic conditions. Membrane shrinkage was ruled out as a stimulus for activation of MtrB. Instead, MtrB was shown to be activated upon the addition of various chemical compounds, like sugars, amino acids, and polyethylene glycols. Because of the different chemical nature of the solutes, it seems unlikely that they bind to a specific binding site. Instead, they are proposed to act via a change of the hydration state of the protein shifting MtrB into the active state. For MtrB activation it was essential that these solutes were added at the same side as the cytoplasmic domains of the kinase were located, indicating that hypertonicity is sensed by MtrB via cytoplasmatically located protein domains. This was confirmed by the analysis of two MtrB mutants in which either the large periplasmic loop or the HAMP domain was deleted. These mutants were regulated similar to wild type MtrB. Thus, we postulate that MtrB belongs to a class of histidine protein kinases that sense environmental changes at cytoplasmatic protein domains independently of the periplasmic loop and the cytoplasmic HAMP domain.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	University of Cologne	Morbach, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	s.morbach@uni-koeln.de						Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; BHAT R, 1992, PROTEIN SCI, V1, P1133, DOI 10.1002/pro.5560010907; Brocker M, 2006, FEMS MICROBIOL LETT, V264, P205, DOI 10.1111/j.1574-6968.2006.00456.x; Cangelosi GA, 2006, ANTIMICROB AGENTS CH, V50, P461, DOI 10.1128/AAC.50.2.461-468.2006; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Fleischer R, 2007, J BIOL CHEM, V282, P8583, DOI 10.1074/jbc.M605785200; Fol M, 2006, MOL MICROBIOL, V60, P643, DOI 10.1111/j.1365-2958.2006.05137.x; Gerharz T, 2003, BIOCHEMISTRY-US, V42, P5917, DOI 10.1021/bi0340595; GOLBY P, 1999, J BACTERIOL, V181, P1248; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Guillouet S, 1995, APPL MICROBIOL BIOT, V44, P496, DOI 10.1007/s002530050588; Heermann R, 2003, MOL MICROBIOL, V47, P839, DOI 10.1046/j.1365-2958.2003.03348.x; Hoskisson PA, 2006, TRENDS MICROBIOL, V14, P444, DOI 10.1016/j.tim.2006.08.005; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Hulko M, 2006, CELL, V126, P929, DOI 10.1016/j.cell.2006.06.058; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Janausch IG, 2002, J BIOL CHEM, V277, P39809, DOI 10.1074/jbc.M204482200; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Jung K, 2000, J BIOL CHEM, V275, P40142, DOI 10.1074/jbc.M008917200; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kneuper H, 2005, J BIOL CHEM, V280, P20596, DOI 10.1074/jbc.M502015200; Mascher T, 2004, ANTIMICROB AGENTS CH, V48, P2888, DOI 10.1128/AAC.48.8.2888-2896.2004; Mascher T, 2006, FEMS MICROBIOL LETT, V264, P133, DOI 10.1111/j.1574-6968.2006.00444.x; Moker N, 2004, MOL MICROBIOL, V54, P420, DOI 10.1111/j.1365-2958.2004.04249.x; Moker N, 2007, J BACTERIOL, V189, P3645, DOI 10.1128/JB.01920-06; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; Nottebrock D, 2003, FEMS MICROBIOL LETT, V218, P305, DOI 10.1111/j.1574-6968.2003.tb11533.x; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Ronsch H, 2003, J BIOTECHNOL, V104, P87, DOI 10.1016/S0168-1656(03)00166-4; Rothenbucher MC, 2006, J BACTERIOL, V188, P1950, DOI 10.1128/JB.188.5.1950-1958.2006; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Sanowar S, 2005, BIOCHEM J, V390, P769, DOI 10.1042/BJ20050060; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; Tropis M, 2005, J BIOL CHEM, V280, P26573, DOI 10.1074/jbc.M502104200; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Weiss V, 2002, J MOL MICROB BIOTECH, V4, P229; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200; Zahrt TC, 2000, J BACTERIOL, V182, P3832, DOI 10.1128/JB.182.13.3832-3838.2000	50	20	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27666	27677		10.1074/jbc.M701749200	http://dx.doi.org/10.1074/jbc.M701749200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650500	hybrid			2022-12-27	WOS:000249455600014
J	Bai, S; Datta, J; Jacob, ST; Ghoshal, K				Bai, Shoumei; Datta, Jharna; Jacob, Samson T.; Ghoshal, Kalpana			RETRACTED: Treatment of PC12 cells with nerve growth factor induces proteasomal degradation of T-cadherin that requires tyrosine phosphorylation of its cadherin domain (Retracted article. See vol. 293, pg. 3590, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							DNA METHYLTRANSFERASE 3B; UBIQUITIN LIGASE; PROTEIN-DEGRADATION; ADHESION MOLECULE; CBL-B; CYCLE; RECEPTOR; IDENTIFICATION; METHYLATION; EXPRESSION	T-cadherin (T-Cad), a unique member of the cadherin family of proteins, plays an important role in cell adhesion and cell signaling. Recently, we demonstrated that T-Cad is transcriptionally repressed by DNA methyltransferase 3b during nerve growth factor (NGF)-induced neuronal differentiation of PC12 cells. Here, we show that T-Cad expression is also regulated at the post-translational level by the proteasomal pathway in these cells, which is facilitated upon NGF treatment. Pulse-chase experiments demonstrated that NGF treatment significantly reduced the half-life of T-Cad. Degradation of T-Cad was blocked upon treatment of PC12 cells with the proteasomal inhibitor ZLLL or lactacystin. Ectopic expression of Cdh1 (CDC20 homolog 1), one of the substrate recognition components of anaphase promoting complex (E3 ligase), stimulated T-Cad degradation. Deletion of CD1, one of the five extracellular cadherin domains (CD), promoted degradation of T-Cad, especially in the presence of NGF. On the contrary, deletion of CD2 stabilized this protein maximally. Ubiquitination of different deletion mutants indicates that T-Cad harbors multiple ubiquitination signals. Furthermore, genistein, a protein-tyrosine kinase inhibitor, impeded T-Cad degradation in PC12 cells, implicating requirement of tyrosine phosphorylation in this process. Mutation at tyrosine 327 (Y327F) markedly increased the half-life of T-Cad, suggesting that phosphorylation of this tyrosine residue located within CD2 is critical for this process. These results show that T-cadherin is subject to dual regulation during NGF-induced differentiation of PC12 cells, namely transcriptional repression mediated by Dnmt3b and post-translational degradation through the proteasomal pathway. These data, together with the inhibitory role of T-Cad in neurite outgrowth of PC12 cells upon NGF treatment, underscore the significance of its stringent regulation during this differentiation process.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	jacob.42@osu.edu	Jacob, Samson/H-3135-2011		NATIONAL CANCER INSTITUTE [P01CA101956, R01CA086978] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA086978-06A1, P01 CA101956-01A25284, CA 86978, CA 10195, R01 CA086978-04, R01 CA086978-05, P01 CA101956-020003, P01 CA101956-01A2, P01 CA101956, P01 CA101956-02, R01 CA086978-02, R01 CA086978-03, R01 CA086978-01A2, P01 CA101956-01A20003, R01 CA086978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Angst BD, 2001, J CELL SCI, V114, P629; Bai SM, 2006, J BIOL CHEM, V281, P13604, DOI 10.1074/jbc.M513278200; Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2004, CELL CYCLE, V3, P138; Bromhead C, 2006, GENE, V374, P58, DOI 10.1016/j.gene.2006.01.013; Buschhorn BA, 2006, NAT CELL BIOL, V8, P209, DOI 10.1038/ncb0306-209; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Goubaeva F, 2005, BIOCHEM BIOPH RES CO, V329, P624, DOI 10.1016/j.bbrc.2005.02.020; Hershko A, 2005, CELL DEATH DIFFER, V12, P1191, DOI 10.1038/sj.cdd.4401702; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kumar KGS, 2003, EMBO J, V22, P5480; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Niermann T, 2003, BIOCHEM BIOPH RES CO, V300, P943, DOI 10.1016/S0006-291X(02)02970-4; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Patel SD, 2006, CELL, V124, P1255, DOI 10.1016/j.cell.2005.12.046; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Stegmuller J, 2005, TRENDS NEUROSCI, V28, P596, DOI 10.1016/j.tins.2005.09.003; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Toyooka S, 2002, CANCER RES, V62, P3382; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796	39	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27171	27180		10.1074/jbc.M700691200	http://dx.doi.org/10.1074/jbc.M700691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631504	Green Accepted, hybrid			2022-12-27	WOS:000249304900058
J	Baker, BM; Tortorella, D				Baker, Brooke M.; Tortorella, Domenico			Dislocation of an endoplasmic reticulum membrane glycoprotein involves the formation of partially dislocated ubiquitinated polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; I HEAVY-CHAINS; INTRACELLULAR DEGRADATION; RECEPTOR SUBUNITS; ER; COMPLEX; RETROTRANSLOCATION; PROTEASOME; RECOGNITION; DOMAIN	Accumulation of improperly folded polypeptides in the endoplasmic reticulum ( ER) can trigger a stress response that leads to the export of aberrant proteins into the cytosol and their ultimate proteasomal degradation. Human cytomegalovirus encodes a type I glycoprotein, US11, that binds to nascent MHC class I heavy chain molecules and causes their dislocation from the ER to the cytosol where they are degraded by the proteasome. Examination of US11-mediated class I degradation has identified a host of cellular proteins involved in the dislocation reaction, including the cytosolic AAA ATPase p97, the membrane protein Derlin-1, and the E3 ubiquitin ligase Sel1L. However, the intermediate steps occurring between the initiation of dislocation and full extraction of the misfolded substrate into the cytosol are not known. We demonstrate that US11 itself undergoes ER export and proteasomal degradation and utilize this system to define multiple steps of US11 dislocation. Treatment of US11-expressing cells with proteasome inhibitor resulted in the accumulation of glycosylated and ubiquitinated species as well as a deglycosylated US11 intermediate. Subcellular fractionation of proteasome-inhibited US11 cells demonstrated that deglycosylated intermediates continued to be integrated within the ER membrane, suggesting that the proteasome functions in the latter steps of dislocation. The data supports a model in which US11 is modified with ubiquitin, whereas the transmembrane region is integrated in the ER membrane, and deglycosylation occurs before complete dislocation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tortorella, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl,Box 1124, New York, NY 10029 USA.	domenico.tortorella@mssm.edu		Tortorella, Domenico/0000-0003-0961-3535	NIAID NIH HHS [AI 060905, AI 07647] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060905] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Ben-Saadon R, 2004, J BIOL CHEM, V279, P41414, DOI 10.1074/jbc.M407201200; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Chen XC, 1998, J BACTERIOL, V180, P527, DOI 10.1128/JB.180.3.527-537.1998; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Faitova J, 2006, CELL MOL BIOL LETT, V11, P488, DOI 10.2478/s11658-006-0040-4; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jessop CE, 2007, EMBO J, V26, P28, DOI 10.1038/sj.emboj.7601505; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JONES TR, 1991, J VIROL, V65, P2024, DOI 10.1128/JVI.65.4.2024-2036.1991; Kalies KU, 2005, EMBO J, V24, P2284, DOI 10.1038/sj.emboj.7600731; KOIDE N, 1974, J BIOL CHEM, V249, P4897; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; LE A, 1990, J BIOL CHEM, V265, P14001; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lilley BN, 2003, MOL BIOL CELL, V14, P3690, DOI 10.1091/mbc.E03-03-0192; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Meusser B, 2004, MOL CELL, V14, P247, DOI 10.1016/S1097-2765(04)00212-6; Mueller B, 2006, J CELL BIOL, V175, P261, DOI 10.1083/jcb.200605196; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Oresic K, 2006, J BIOL CHEM, V281, P19395, DOI 10.1074/jbc.M601026200; PARHAM P, 1979, J IMMUNOL, V123, P342; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wahlman J, 2007, CELL, V129, P943, DOI 10.1016/j.cell.2007.03.046; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wang XL, 2007, J CELL BIOL, V177, P613, DOI 10.1083/jcb.200611063; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164	67	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26845	26856		10.1074/jbc.M704315200	http://dx.doi.org/10.1074/jbc.M704315200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650499	hybrid			2022-12-27	WOS:000249304900024
J	Firulli, BA; Redick, BA; Conway, SJ; Firulli, AB				Firulli, Beth A.; Redick, Bradley A.; Conway, Simon J.; Firulli, Anthony B.			Mutations within helix I of twist1 result in distinct limb defects and variation of DNA binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH PROTEIN; TRANSCRIPTION; DIMERIZATION; IDENTIFICATION; DHAND; EXPRESSION; PARTNERS; HAND2; BUD	Twist1 is a basic helix-loop-helix ( bHLH) factor that plays an important role in limb development. Haploinsufficiency of Twist1 results in polydactyly via the inability of Twist1 to antagonistically regulate the related factor Hand2. The mechanism modulating Twist1-Hand2 antagonism is via phosphoregulation of conserved threonine and serine residues in helix I of the bHLH domain. Phosphoregulation alters the dimerization affinities for both proteins. Here we show that the expression of Twist1 and Twist1 phosphoregulation mutants results in distinct limb phenotypes in mice. In addition to dimer regulation, Twist1 phosphoregulation affects the DNA binding affinities of Twist1 in a partner-dependent and cis-element-dependent manner. In order to gain a better understanding of the specific Twist1 transcriptional complexes that function during limb morphogensis, we employ a series of Twist1-tethered dimers that include the known Twist1 partners, E12 and Hand2, as well as a tethered Twist1 homodimer. We show that these dimers behave in a manner similar to monomerically expressed bHLH factors and result in distinct limb phenotypes that correlate well with those observed from the limb expression of Twist1 and Twist1 phosphoregulation mutants. Taken together, this study shows that the Twist1 dimer affinity for a given partner can modulate the DNA binding affinity and that Twist1 dimer choice determines phenotypic outcome during limb development.	Indiana Med Sch, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Div Cardiol,Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children	Firulli, AB (corresponding author), Indiana Med Sch, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Div Cardiol,Dept Pediat, 1044 W Walnut,R4 371, Indianapolis, IN 46202 USA.	tfirulli@iupui.edu		/0000-0001-6687-8949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085098, R01HL061677] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL085098-029002, P01 HL085098, R01 HL061677, P01 HL085098-01A10001, R01 HL061677-09, 2R01 HI 061677-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cai JL, 2005, BIOESSAYS, V27, P1102, DOI 10.1002/bies.20313; Castanon I, 2001, DEVELOPMENT, V128, P3145; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dickman ED, 1999, ANAT REC, V255, P353, DOI 10.1002/(SICI)1097-0185(19990701)255:3<353::AID-AR11>3.0.CO;2-H; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 2003, GENE, V312, P27, DOI 10.1016/S0378-1119(03)00669-3; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Firulli Beth A., 2004, Biol Proced Online, V6, P16, DOI 10.1251/bpo69; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hornik C, 2004, ANAT EMBRYOL, V209, P31, DOI 10.1007/s00429-004-0412-3; Hu D, 2006, DEV BIOL, V295, P369, DOI 10.1016/j.ydbio.2006.04.134; Jabs Ethylin Wang, 2004, P401; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; Martin JF, 2000, GENESIS, V26, P225, DOI 10.1002/(SICI)1526-968X(200004)26:4<225::AID-GENE10>3.0.CO;2-F; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; O'Rourke MP, 2002, INT J DEV BIOL, V46, P401; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Tavares AT, 2001, INT J DEV BIOL, V45, P707; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; Zuniga A, 2002, MECH DEVELOP, V114, P51, DOI 10.1016/S0925-4773(02)00048-5	24	68	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27536	27546		10.1074/jbc.M702613200	http://dx.doi.org/10.1074/jbc.M702613200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652084	Green Accepted, hybrid			2022-12-27	WOS:000249304900094
J	Kurosu, H; Choi, M; Ogawa, Y; Dickson, AS; Goetz, R; Eliseenkova, AV; Mohammadi, M; Rosenblatt, KP; Kliewer, SA; Kuro-o, M				Kurosu, Hiroshi; Choi, Mihwa; Ogawa, Yasushi; Dickson, Addie S.; Goetz, Regina; Eliseenkova, Anna V.; Mohammadi, Moosa; Rosenblatt, Kevin P.; Kliewer, Steven A.; Kuro-o, Makoto			Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor Isoforms determines metabolic activity of FGF19 and FGF21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; DOMINANT HYPOPHOSPHATEMIC RICKETS; NEGATIVE FEEDBACK-REGULATION; PHOSPHATE HOMEOSTASIS; STRUCTURAL BASIS; FACTOR FAMILY; PPAR-ALPHA; MICE; FIBROBLAST-GROWTH-FACTOR-21; SUPPRESSION	The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors ( FGFR1-4). We demonstrated that Klotho and beta Klotho, homologous single-pass transmembrane proteins that bind to FGFRs, are required for metabolic activity of FGF23 and FGF21, respectively. Here we show that, like FGF21, FGF19 also requires beta Klotho. Both FGF19 and FGF21 can signal through FGFR1-3 bound by beta Klotho and increase glucose uptake in adipocytes expressing FGFR1. Additionally, both FGF19 and FGF21 bind to the beta Klotho-FGFR4 complex; however, only FGF19 signals efficiently through FGFR4. Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis. We conclude that the expression of beta Klotho, in combination with particular FGFR isoforms,determines the tissue-specific metabolic activities of FGF19 and FGF21.	Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University	Kuro-o, M (corresponding author), 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Makoto.Kuro-o@UTSouthwestern.edu	Goetz, Regina/M-2411-2019; kasaei, fahime/T-7197-2018; Ogawa, Yasushi/I-1140-2012; Ogawa, Yasushi/M-8900-2014; Mohammadi, Moosa/ABA-6745-2020	Goetz, Regina/0000-0003-3681-4703; Ogawa, Yasushi/0000-0003-3553-9607; Mohammadi, Moosa/0000-0003-2434-9437	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015326, R01AG019712, R01AG025326] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019712-06, R01 AG 15326, R01 AG 19712, R01 AG025326, R01 AG025326-04, R01 AG019712] Funding Source: Medline; NIDCR NIH HHS [R01 DE 13686, R01 DE013686] Funding Source: Medline; NIDDK NIH HHS [DK 067158, R01 DK067158] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Bauer I, 2005, ARCH BIOCHEM BIOPHYS, V438, P36, DOI 10.1016/j.abb.2005.03.016; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Schiavi SC, 2004, KIDNEY INT, V65, P1, DOI 10.1111/j.1523-1755.2004.00355.x; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	32	568	653	0	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26687	26695		10.1074/jbc.M704165200	http://dx.doi.org/10.1074/jbc.M704165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623664	Green Accepted, hybrid			2022-12-27	WOS:000249304900007
J	Lee, J; Michael, AJ; Martynowski, D; Goldsmith, EJ; Phillips, MA				Lee, Jeongmi; Michael, Anthony J.; Martynowski, Dariusz; Goldsmith, Elizabeth J.; Phillips, Margaret A.			Phylogenetic diversity and the structural basis of substrate specificity in the beta/alpha-barrel fold basic amino acid decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC ORNITHINE DECARBOXYLASES; BIOSYNTHETIC ARGININE DECARBOXYLASE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; DIAMINOPIMELATE DECARBOXYLASE; POLYAMINE BIOSYNTHESIS; IRREVERSIBLE INHIBITORS; MOLECULAR REPLACEMENT; ANGSTROM RESOLUTION; TRYPANOSOMA-BRUCEI	The beta/alpha-barrel fold type basic amino acid decarboxylases include eukaryotic ornithine decarboxylases (ODC) and bacterial and plant enzymes with activity on L-arginine and meso-diaminopimelate. These enzymes catalyze essential steps in polyamine and lysine biosynthesis. Phylogenetic analysis suggests that diverse bacterial species also contain ODC-like enzymes from this fold type. However, in comparison with the eukaryotic ODCs, amino acid differences were identified in the sequence of the 3(10)-helix that forms a key specificity element in the active site, suggesting they might function on novel substrates. Putative decarboxylases from a phylogenetically diverse range of bacteria were characterized to determine their substrate preference. Enzymes from species within Methanosarcina, Pseudomonas, Bartonella, Nitrosomonas, Thermotoga, and Aquifex showed a strong preference for L-ornithine, whereas the enzyme from Vibrio vulnificus (VvL/ODC) had dual specificity functioning well on both L-ornithine and L-lysine. The x-ray structure of VvL/ODC was solved in the presence of the reaction products putrescine and cadaverine to 1.7 and 2.15 A, respectively. The overall structure is similar to eukaryotic ODC; however, reorientation of the 310-helix enlarging the substrate binding pocket allows L-lysine to be accommodated. The structure of the putrescine-bound enzyme suggests that a bridging water molecule between the shorter L-ornithine and key active site residues provides the structural basis for VvL/ODC to also function on this substrate. Our data demonstrate that there is greater structural and functional diversity in bacterial polyamine biosynthetic decarboxylases than previously suspected.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	margaret.phillips@UTSouthwestern.edu	Lee, Jeongmi/AAJ-7720-2020; Martynowski, Dariusz/AAU-6083-2020	Lee, Jeongmi/0000-0002-9948-7554; Martynowski, Dariusz/0000-0001-7617-7716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34432, R01 AI034432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; Cavalier-Smith T, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-19; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; Gokulan K, 2003, J BIOL CHEM, V278, P18588, DOI 10.1074/jbc.M301549200; Graham DE, 2002, J BIOL CHEM, V277, P23500, DOI 10.1074/jbc.M203467200; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Heby O, 1995, INT J DEV BIOL, V39, P737; HIATT AC, 1986, J BIOL CHEM, V261, P1293; Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642; Jackson LK, 2004, BIOCHEMISTRY-US, V43, P12990, DOI 10.1021/bi048933l; KALLIO A, 1981, BIOCHEM J, V200, P69, DOI 10.1042/bj2000069; Karatan E, 2005, J BACTERIOL, V187, P7434, DOI 10.1128/JB.187.21.7434-7443.2005; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kidron H, 2007, MOL BIOL EVOL, V24, P79, DOI 10.1093/molbev/msl133; KITZ R, 1962, J BIOL CHEM, V237, P3245; KOSSIAKOFF A, 1987, BIOL MACROMOLECULES; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Momany C, 2002, ACTA CRYSTALLOGR D, V58, P549, DOI 10.1107/S0907444902000148; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel CN, 2006, J BACTERIOL, V188, P2355, DOI 10.1128/JB.188.7.2355-2363.2006; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; Qu N, 2003, BIOCHEM J, V375, P465, DOI 10.1042/BJ20030382; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Seiler N, 1998, INT J ONCOL, V13, P993; Shah R, 2004, J BIOL CHEM, V279, P35760, DOI 10.1074/jbc.M405366200; Shah R, 2007, BIOCHEMISTRY-US, V46, P2831, DOI 10.1021/bi6023447; Sturgill G, 2004, MOL MICROBIOL, V51, P437, DOI 10.1046/j.1365-2958.2003.03835.x; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WU WH, 1973, J BIOL CHEM, V248, P1687; YAMAMOTO S, 1994, MICROBIOL-UK, V140, P3117, DOI 10.1099/13500872-140-11-3117	50	45	66	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27115	27125		10.1074/jbc.M704066200	http://dx.doi.org/10.1074/jbc.M704066200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626020	hybrid			2022-12-27	WOS:000249304900052
J	Shikata, K; Fukui, T; Atomi, H; Imanaka, T				Shikata, Kenichi; Fukui, Toshiaki; Atomi, Haruyuki; Imanaka, Tadayuki			A novel ADP-forming Succinyl-CoA synthetase in Thermococcus kodakaraensis structurally related to the archaeal nucleoside diphosphate-forming Acetyl-CoA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; PYROCOCCUS-FURIOSUS; FERREDOXIN OXIDOREDUCTASE; ESCHERICHIA-COLI; HALOARCULA-MARISMORTUI; PEPTIDE FERMENTATION; ACETATE FORMATION; ATP SYNTHESIS; ENZYME; COENZYME	We have identified and characterized a structurally novel succinyl-CoA synthetase (SCS) from the hyperthermophilic Archaea Thermococcus kodakaraensis. The presence of an SCS completes the metabolic pathway from glutamate to succinate in Thermococcales, which had not been clarified because of the absence of classical SCS homologs on their genomes. The SCS from T. kodakaraensis (SCSTk) is a heteromeric enzyme(alpha(2)beta(2)) encoded by TK1880 (alpha-subunit) and TK0943 (beta-subunit). Although both SCSTk and classical SCSs harbor the five domains present in enzymes of the acyl-CoA synthetase ( nucleoside diphosphate-forming) superfamily, the domain order and distribution among subunits in SCSTk (alpha-subunit domains 1-2-5; beta- subunit, domains 3-4) are distinct from those of classical SCSs (alpha-subunit, domains 1-2; beta- subunit, domains 3-4-5) and instead resemble the acetyl-CoA synthetases from Pyrococcus furiosus (ACSs I-Pf and IIPf). Comparison of the four Thermococcales genomes revealed that each strain harbors five alpha- and two beta-subunit homologs. Sequence similarity suggests that the beta-subunit of SCSTk is also a component of the presumed ACS II from T. kodakaraensis (ACS IITk). We coexpressed the alpha/beta-genes of SCSTk (TK1880/TK0943) and of ACS IITk (TK0139/ TK0943). ACS IITk recognizes a broad range of hydrophobic/aromatic acid compounds, as is the case with ACS IIPf, whereas SCSTk displays a distinct and relatively strict substrate specificity for several acids, including succinate. This indicates that the alpha-subunits are responsible for the distinct substrate specificities of SCSTk and ACS IITk.	Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp	福居, 俊昭/K-5056-2012; Fukui, Toshiaki/S-6882-2019	福居, 俊昭/0000-0003-4557-6284; Fukui, Toshiaki/0000-0003-4557-6284; Atomi, Haruyuki/0000-0001-9687-6426				ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; Atomi Haruyuki, 2004, Archaea, V1, P263, DOI 10.1155/2004/204953; Brasen C, 2004, FEMS MICROBIOL LETT, V241, P21, DOI 10.1016/j.femsle.2004.09.033; Brasen C, 2004, ARCH MICROBIOL, V182, P277, DOI 10.1007/s00203-004-0702-4; Cohen GN, 2003, MOL MICROBIOL, V47, P1495, DOI 10.1046/j.1365-2958.2003.03381.x; DeLano W.L, PYMOL MOL GRAPHICS S; Field J, 2000, MOL MICROBIOL, V38, P446, DOI 10.1046/j.1365-2958.2000.02143.x; Fraser ME, 2006, J BIOL CHEM, V281, P11058, DOI 10.1074/jbc.M511785200; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Fraser ME, 2002, BIOCHEMISTRY-US, V41, P537, DOI 10.1021/bi011518y; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Fukui T, 2005, GENOME RES, V15, P352, DOI 10.1101/gr.3003105; Heider J, 1996, J BACTERIOL, V178, P780, DOI 10.1128/jb.178.3.780-787.1996; Itoh T, 2003, J BIOSCI BIOENG, V96, P203, DOI 10.1263/jbb.96.203; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; Kanai T, 2005, J BIOTECHNOL, V116, P271, DOI 10.1016/j.jbiotec.2004.11.002; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Krahe M, 1996, FEMS MICROBIOL REV, V18, P271, DOI 10.1111/j.1574-6976.1996.tb00243.x; Labes A, 2001, ARCH MICROBIOL, V176, P329, DOI 10.1007/s002030100330; Ma K, 1997, P NATL ACAD SCI USA, V94, P9608, DOI 10.1073/pnas.94.18.9608; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MAI XH, 1994, J BIOL CHEM, V269, P16726; Mai XH, 1996, J BACTERIOL, V178, P5890, DOI 10.1128/jb.178.20.5890-5896.1996; Musfeldt M, 2002, J BACTERIOL, V184, P636, DOI 10.1128/JB.184.3.636-644.2002; Musfeldt M, 1999, J BACTERIOL, V181, P5885, DOI 10.1128/JB.181.18.5885-5888.1999; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; Robb FT, 2001, METHOD ENZYMOL, V330, P134; Sanchez LB, 2000, J BIOL CHEM, V275, P5794, DOI 10.1074/jbc.275.8.5794; SCHAFER T, 1991, ARCH MICROBIOL, V155, P366; SCHAFER T, 1993, ARCH MICROBIOL, V159, P72, DOI 10.1007/BF00244267; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	33	31	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26963	26970		10.1074/jbc.M702694200	http://dx.doi.org/10.1074/jbc.M702694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640871	hybrid			2022-12-27	WOS:000249304900036
J	Beevers, AJ; Kukol, A				Beevers, Andrew J.; Kukol, Andreas			Phospholemman transmembrane structure reveals potential interactions with Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; MOLECULAR-DYNAMICS; SECONDARY STRUCTURE; FXYD PROTEINS; ION CURRENTS; INFRARED DICHROISM; NA+/CA2+ EXCHANGE; CHANNEL MOLECULES; LIPID-BILAYER; PHOSPHORYLATION	Phospholemman ( PLM) is a 72- residue bitopic cardiac transmembrane protein, which acts as a modulator of the Na+/K+-ATPase and the Na+/Ca2+ exchanger and possibly forms taurine channels in nonheart tissue. This work presents a high resolution structural model obtained from a combination of site- specific infrared spectroscopy and experimentally constrained high throughput molecular dynamics ( MD) simulations. Altogether, 37 experimental constraints, including nine long range orientational constraints, have been used during MD simulations in an explicit lipid bilayer/ water system. The resulting tetrameric alpha- helical bundle has an average helix tilt of 7.3 degrees and a crossing angle close to 0 degrees. It does not reveal a hydrophilic pore, but instead strong interactions between various residues occlude any pore. The helix- helix packing is unusual, with Gly(19) and Gly(20) pointing to the outside of the helical bundle, facilitating potential interaction with other transmembrane proteins, thus providing a structural basis for the modulatory effect of PLM on the Na+/K+-ATPase. A two- stage model of interaction between PLM and the Na+/K+- ATPase is discussed involving PLM- ATPase interaction and subsequent formation of an unstable PLM trimer, which readily interacts with surrounding ATPase molecules. Further unconstrained MD simulations identified other packing models of PLM, one of which could potentially undergo a conformational transition to an open pore.	Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Hertfordshire; University of Warwick	Kukol, A (corresponding author), Univ Hertfordshire, Sch Life Sci, Hatfield AL10 9AB, Herts, England.	a.kukol@herts.ac.uk	Kukol, Andreas/AAR-4569-2020	Kukol, Andreas/0000-0002-8859-010X				Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arkin IT, 1997, J AM CHEM SOC, V119, P8973, DOI 10.1021/ja964253x; Beevers AJ, 2006, PROTEIN SCI, V15, P1127, DOI 10.1110/ps.051899406; Beevers AJ, 2006, J MOL BIOL, V361, P945, DOI 10.1016/j.jmb.2006.07.004; Beevers AJ, 2006, J MOL GRAPH MODEL, V25, P226, DOI 10.1016/j.jmgm.2005.12.008; Bogaev RC, 2001, GENE, V271, P69, DOI 10.1016/S0378-1119(01)00497-8; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; Chen ZH, 1999, RECEPTOR CHANNEL, V6, P435; Dalskov SM, 2005, NEUROCHEM INT, V46, P489, DOI 10.1016/j.neuint.2004.11.010; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 2005, J BIOENERG BIOMEMBR, V37, P387, DOI 10.1007/s10863-005-9476-x; Gurtovenko AA, 2004, BIOPHYS J, V86, P3461, DOI 10.1529/biophysj.103.038760; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Kass I, 2004, BIOPHYS J, V86, P2502, DOI 10.1016/S0006-3495(04)74305-2; Kortenaar P. B. W. T., 1986, INT J PEPT PROT RES, V27, P398; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; Kukol A, 2005, SPECTROSC-INT J, V19, P1; Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; Marsh D, 2000, BIOPHYS J, V78, P2499, DOI 10.1016/S0006-3495(00)76795-6; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; Mounsey JP, 1999, BBA-MOL CELL RES, V1451, P305, DOI 10.1016/S0167-4889(99)00102-0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Torres J, 2000, J MOL BIOL, V300, P677, DOI 10.1006/jmbi.2000.3885; Torres J, 2001, BIOPOLYMERS, V59, P396, DOI 10.1002/1097-0282(200111)59:6<396::AID-BIP1044>3.3.CO;2-P; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002	41	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32742	32748		10.1074/jbc.M703676200	http://dx.doi.org/10.1074/jbc.M703676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17698851	hybrid, Green Submitted			2022-12-27	WOS:000250625400022
J	Bursy, J; Pierik, AJ; Pica, N; Bremer, E				Bursy, Jan; Pierik, Antonio J.; Pica, Nathalie; Bremer, Erhard			Osmotically induced synthesis of the compatible solute hydroxyectoine is mediated by an evolutionarily conserved ectoine hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HALOMONAS-ELONGATA; TETRAHYDROPYRIMIDINE DERIVATIVES; PROLINE 4-HYDROXYLASE; BACILLUS-SUBTILIS; HIGH OSMOLARITY; AMINO-ACID; BIOSYNTHESIS; GENES; TRANSPORT	By using natural abundance C-13 NMR spectroscopy, we investigated the types of compatible solutes synthesized in a variety of Bacilli under high salinity growth conditions. Glutamate, proline, and ectoine were the dominant compatible solutes synthesized by the various Bacillus species. The majority of the inspected Bacilli produced the tetrahydropyrimidine ectoine in response to high salinity stress, and a subset of these also synthesized a hydroxylation derivative of ectoine, 5-hydroxyectoine. In Salibacillus salexigens, a representative of the ectoine- and 5-hydroxyectoine-producing species, ectoine production was linearly correlated with the salinity of the growth medium and dependent on an ectABC biosynthetic operon. The formation of 5-hydroxyectoine was primarily a stationary growth phase phenomenon. The enzyme responsible for ectoine hydroxylation (EctD) was purified from S. salexigens to apparent homogeneity. The EctD protein was shown in vitro to directly hydroxylate ectoine in a reaction dependent on iron(II), molecular oxygen, and 2-oxoglutarate. We identified the structural gene (ectD) for the ectoine hydroxylase in S. salexigens. Northern blot analysis showed that the transcript levels of the ectABC and ectD genes increased as a function of salinity. Many EctD-related proteins can be found in data base searches in various Bacteria. Each of these bacterial species also contains an ectABC ectoine biosynthetic gene cluster, suggesting that 5-hydroxyectoine biosynthesis strictly depends on the prior synthesis of ectoine. Our data base searches and the biochemical characterization of the EctD protein from S. salexigens suggest that the EctD-related ectoine hydroxylases are members of a new subfamily within the non-heme-containing, iron(II)and 2-oxoglutarate-dependent dioxygenase superfamily (EC 1.14.11).	Univ Marburg, Dept Biol, Microbiol Lab, D-35032 Marburg, Germany	Philipps University Marburg	Bremer, E (corresponding author), Univ Marburg, Dept Biol, Microbiol Lab, Karl-von-Frisch-Str, D-35032 Marburg, Germany.	bremer@staff.uni-marburg.de	Pierik, Antonio J/G-1108-2010	Pierik, Antonio J/0000-0002-1509-6370				Alekshun MN, 1999, TRENDS MICROBIOL, V7, P410, DOI 10.1016/S0966-842X(99)01589-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Borges N, 2002, EXTREMOPHILES, V6, P209, DOI 10.1007/s007920100236; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Canovas D, 1998, SYST APPL MICROBIOL, V21, P487, DOI 10.1016/S0723-2020(98)80060-X; Canovas D, 1997, J BIOL CHEM, V272, P25794, DOI 10.1074/jbc.272.41.25794; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; da Costa M. S., 1998, V61, P117; DULANEY EUGENE L., 1968, DEVELOP IND MICROBIOL, V9, P260; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; Garabito MJ, 1997, INT J SYST BACTERIOL, V47, P735, DOI 10.1099/00207713-47-3-735; Garcia-Estepa R, 2006, J BACTERIOL, V188, P3774, DOI 10.1128/JB.00136-06; Goller K, 1998, FEMS MICROBIOL LETT, V161, P293; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; Heyrman J, 2003, INT J SYST EVOL MICR, V53, P501, DOI 10.1099/ijs.0.02371-0; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1993, EUR J BIOCHEM, V214, P897, DOI 10.1111/j.1432-1033.1993.tb17993.x; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; Kappes RM, 1998, MICROBIOL-UK, V144, P83, DOI 10.1099/00221287-144-1-83; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Kuhlmann AU, 2002, APPL ENVIRON MICROB, V68, P772, DOI 10.1128/AEM.68.2.772-783.2002; KUNTE HJ, 1993, J MICROBIOL METH, V17, P129; Lawrence CC, 1996, BIOCHEM J, V313, P185, DOI 10.1042/bj3130185; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; LIPPERT K, 1992, APPL MICROBIOL BIOT, V37, P61; Louis P, 1997, MICROBIOL-UK, V143, P1141, DOI 10.1099/00221287-143-4-1141; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Manzanera M, 2004, FEMS MICROBIOL LETT, V233, P347, DOI 10.1016/j.femsle.2004.03.005; Manzanera M, 2002, APPL ENVIRON MICROB, V68, P4328, DOI 10.1128/AEM.68.9.4328-4333.2002; Mori H, 1997, J BACTERIOL, V179, P5677, DOI 10.1128/jb.179.18.5677-5683.1997; Nau-Wagner G, 1999, APPL ENVIRON MICROB, V65, P560; Ono H, 1999, J BACTERIOL, V181, P91, DOI 10.1128/JB.181.1.91-99.1999; PETERS P, 1990, FEMS MICROBIOL LETT, V71, P157; Pflughoeft KJ, 2003, APPL ENVIRON MICROB, V69, P5919, DOI 10.1128/AEM.69.10.5919-5927.2003; Prabhu J, 2004, APPL ENVIRON MICROB, V70, P3130, DOI 10.1128/AEM.70.5.3130-3132.2004; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; Reshetnikov AS, 2006, ARCH MICROBIOL, V184, P286, DOI 10.1007/s00203-005-0042-z; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Roessler M, 2001, ENVIRON MICROBIOL, V3, P743, DOI 10.1046/j.1462-2920.2001.00252.x; Sauer T, 1998, BIOTECHNOL BIOENG, V57, P306, DOI 10.1002/(SICI)1097-0290(19980205)57:3<306::AID-BIT7>3.0.CO;2-L; Schnoor M, 2004, BIOCHEM BIOPH RES CO, V322, P867, DOI 10.1016/j.bbrc.2004.07.200; Shibasaki T, 1999, APPL ENVIRON MICROB, V65, P4028; Solomon EI, 2003, P NATL ACAD SCI USA, V100, P3589, DOI 10.1073/pnas.0336792100; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; TALIBART R, 1994, J BACTERIOL, V176, P5210, DOI 10.1128/JB.176.17.5210-5217.1994; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527; Wood JM, 2001, COMP BIOCHEM PHYS A, V130, P437, DOI 10.1016/S1095-6433(01)00442-1; Zhao B, 2006, CURR MICROBIOL, V53, P183, DOI 10.1007/s00284-005-0396-0	54	114	123	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31147	31155		10.1074/jbc.M704023200	http://dx.doi.org/10.1074/jbc.M704023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17636255	hybrid			2022-12-27	WOS:000250309200004
J	Ma, H; Jiang, WR; Robledo, N; Leveque, V; Ali, S; Lara-Jaime, T; Masjedizadeh, M; Smith, DB; Cammack, N; Klumpp, K; Symons, J				Ma, Han; Jiang, Wen-Rong; Robledo, Nicole; Leveque, Vincent; Ali, Samir; Lara-Jaime, Teresa; Masjedizadeh, Mohammad; Smith, David B.; Cammack, Nick; Klumpp, Klaus; Symons, Julian			Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2 '-Deoxy-2 '-fluoro-2 '-C-methylcytidine (PSI-6130) and identification of a novel active 5 '-triphosphate species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-SYNTHESIS; DEOXYCYTIDYLATE DEAMINASE; POTENT INHIBITOR; REPLICATION; RIBONUCLEOSIDES; NUCLEOTIDE; RIBAVIRIN; ANALOGS; DESIGN	beta- D- 2'- Deoxy- 2'- fluoro- 2'- C- methylcytidine ( PSI- 6130) is a potent inhibitor of hepatitis C virus ( HCV) replication in the subgenomic HCV replicon system, and its corresponding 5 '- triphosphate is a potent inhibitor of the HCV RNA polymerase in vitro. In this study the formation of PSI- 6130- triphosphate was characterized in primary human hepatocytes. PSI6130 and its 5 '- phosphorylated derivatives were identified, and the intracellular concentrations were determined. In addition, the deaminated derivative of PSI- 6130, '- D- 2 '- deoxy- 2 '- fluoro2 '- C- methyluridine ( RO2433, PSI- 6026) and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI- 6130. The formation of the 5 '- triphosphate ( TP) of PSI- 6130 ( PSI- 6130- TP) and RO2433 ( RO2433- TP) increased with time and reached steady state levels at 48 h. The formation of both PSI- 6130- TP and RO2433- TP demonstrated a linear relationship with the extracellular concentrations of PSI- 6130 up to 100 mu M, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half- lives of PSI- 6130- TP and RO2433- TP were 4.7 and 38 h, respectively. RO2433- TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinantHCVpolymerase NS5B with potencies comparable with those of PSI- 6130- TP. Incorporation of RO2433- 5 'monophosphate ( MP) into nascent RNA by NS5B led to chain termination similar to that of PSI- 6130- MP. These results demonstrate that PSI- 6130 is metabolized to two pharmacologically active species in primary human hepatocytes.	Roche Palo Alto LLC, Palo Alto, CA 94304 USA	Roche Holding	Ma, H (corresponding author), Roche Palo Alto LLC, 3431 Hillview Ave, Palo Alto, CA 94304 USA.	han.ma@roche.com						AFDHAL N, 2005, 40 ANN M EUR ASS STU; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Carroll S. S., 2006, Infectious Disorders - Drug Targets, V6, P17, DOI 10.2174/187152606776056698; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Clark JL, 2005, J MED CHEM, V48, P5504, DOI 10.1021/jm0502788; DUARTE MIS, 1989, J SUBMICR CYTOL PATH, V21, P275; Eldrup AB, 2004, J MED CHEM, V47, P5284, DOI 10.1021/jm040068f; FRIED, 2002, NEJM, V347, P975; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hardy RW, 2003, J VIROL, V77, P2029, DOI 10.1128/JVI.77.3.2029-2037.2003; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; Klumpp K, 2006, J BIOL CHEM, V281, P3793, DOI 10.1074/jbc.M510195200; Le Pogam S, 2006, VIROLOGY, V351, P349, DOI 10.1016/j.virol.2006.03.045; Ma H, 2005, VIROLOGY, V332, P8, DOI 10.1016/j.virol.2004.11.024; MANCINI WR, 1983, MOL PHARMACOL, V23, P159; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Murakami E, 2007, ANTIMICROB AGENTS CH, V51, P503, DOI 10.1128/AAC.00400-06; Perrone P, 2007, J MED CHEM, V50, P1840, DOI 10.1021/jm0613370; Roberts S, 2006, HEPATOLOGY, V44, p692A; Smith DB, 2007, BIOORG MED CHEM LETT, V17, P2570, DOI 10.1016/j.bmcl.2007.02.004; Stuyver Lieven J., 2006, Antiviral Chemistry & Chemotherapy, V17, P79; Tomassini JE, 2005, ANTIMICROB AGENTS CH, V49, P2050, DOI 10.1128/AAC.49.5.2050-2058.2005; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	25	91	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29812	29820		10.1074/jbc.M705274200	http://dx.doi.org/10.1074/jbc.M705274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698842	hybrid			2022-12-27	WOS:000249981200010
J	Wiegert, JS; Bengtson, CP; Bading, H				Wiegert, J. Simon; Bengtson, C. Peter; Bading, Hilmar			Diffusion and not active transport underlies and limits ERK1/2 synapse-to-nucleus signaling in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE PATHWAY; MAP KINASE; REGULATED KINASE; NMDA RECEPTORS; LATE-PHASE; NUCLEOCYTOPLASMIC TRANSPORT; RETROGRADE TRANSPORT; RESPONSE ELEMENT; GENE-EXPRESSION	The propagation of signals from synapses and dendrites to the nucleus is crucial for long lasting adaptive changes in the nervous system. The ERK-MAPK pathway can link neuronal activity and cell surface receptor activation to the regulation of gene transcription, and it is often considered the principal mediator of synapse-to-nucleus communication in late-phase plasticity and learning. However, the mechanisms underlying ERK1/2 trafficking in dendrites and nuclear translocation in neurons remain to be determined leaving it unclear whether ERK1/2 activated at the synapse can contribute to nuclear signaling and transcriptional regulation. Using the photobleachable and photoactivable fluorescent tag Dronpa on ERK1 and ERK2, we show here that ERK1/2 translocation to the nucleus of hippocampal neurons is induced by the stimulation of N-methyl-D-aspartate receptors or TrkB stimulation and is apparently mediated by facilitated diffusion. In contrast, ERK1/2 trafficking within dendrites is not signal-regulated and is mediated by passive diffusion. Within dendrites, the reach of a locally activated pool of ERK1/2 is very limited and follows an exponential decay with distance. These results indicate that successful signal propagation to the nucleus by the ERK-MAPK pathway depends on the distance of the nucleus from the site of ERK1/2 activation. ERK1/2 activated within or near the soma may rapidly reach the nucleus to induce gene expression, whereas ERK1/2 activated at distal synapses may only contribute to local signaling.	Univ Heidelberg, Interdisciplinary Ctr Neurosci, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bading, H (corresponding author), Univ Heidelberg, Interdisciplinary Ctr Neurosci, Dept Neurobiol, Bergheimer Str 58, D-69120 Heidelberg, Germany.	Hilmar.Bading@uni-hd.de	Wiegert, J. Simon/ABE-4199-2020	Wiegert, J. Simon/0000-0003-0893-9349; Bengtson, C Peter/0000-0002-8245-3323				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi N, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-42; Adams JP, 2005, NAT REV NEUROSCI, V6, P737, DOI 10.1038/nrn1749; Akashi M, 2000, GENE DEV, V14, P645; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Arnold FJL, 2005, J PHYSIOL-LONDON, V564, P3, DOI 10.1113/jphysiol.2004.077446; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen RH, 1996, ONCOGENE, V12, P1493; Costa M, 2006, J CELL SCI, V119, P4952, DOI 10.1242/jcs.03272; Deisseroth K, 2003, CURR OPIN NEUROBIOL, V13, P354, DOI 10.1016/S0959-4388(03)00076-X; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dudek SM, 2002, P NATL ACAD SCI USA, V99, P3962, DOI 10.1073/pnas.062510599; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Fujioka A, 2006, J BIOL CHEM, V281, P8917, DOI 10.1074/jbc.M509344200; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Horiuchi KY, 1998, BIOCHEMISTRY-US, V37, P8879, DOI 10.1021/bi972731q; Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010; Hu HJ, 2006, NEURON, V50, P89, DOI 10.1016/j.neuron.2006.03.010; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nakamura T, 1996, ONCOGENE, V13, P1111; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osawa M, 2004, J BIOL CHEM, V279, P29691, DOI 10.1074/jbc.M309371200; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PETERS R, 1986, BIOCHEM SOC T, V14, P821, DOI 10.1042/bst0140821; Raymond CR, 2006, J PHYSIOL-LONDON, V570, P97, DOI 10.1113/jphysiol.2005.098947; Reynolds AJ, 2001, NEUROSCIENCE, V105, P761, DOI 10.1016/S0306-4522(01)00235-4; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sindreu CB, 2007, NEURON, V53, P79, DOI 10.1016/j.neuron.2006.11.024; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Thiels E, 2001, REV NEUROSCIENCE, V12, P327; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Valjent E, 2000, J NEUROSCI, V20, P8701; Wellmann H, 2001, J BIOL CHEM, V276, P11821, DOI 10.1074/jbc.M009253200; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhao ML, 2005, J NEUROSCI, V25, P7032, DOI 10.1523/JNEUROSCI.1579-05.2005; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	70	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29621	29633		10.1074/jbc.M701448200	http://dx.doi.org/10.1074/jbc.M701448200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675293	hybrid			2022-12-27	WOS:000249788000059
J	Belevich, I; Borisov, VB; Verkhovsky, MI				Belevich, Ilya; Borisov, Vitaliy B.; Verkhovsky, Michael I.			Discovery of the true peroxy intermediate in the catalytic cycle of terminal oxidases by real-time measurement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RESONANCE RAMAN-SPECTROSCOPY; BD UBIQUINOL OXIDASE; COMPOUND-I FORMATION; HEME ACTIVE-SITE; ESCHERICHIA-COLI; CARBON-MONOXIDE; QUINOL OXIDASE; HORSERADISH-PEROXIDASE; OXYGENATED COMPLEX	The sequence of the catalytic intermediates in the reaction of cytochrome bd terminal oxidases from Escherichia coli and Azotobacter vinelandii with oxygen was monitored in real time by absorption spectroscopy and electrometry. The initial binding of O-2 to the fully reduced enzyme is followed by the fast (5 mu s) conversion of the oxy complex to a novel, previously unresolved intermediate. In this transition, low spin heme b(558) remains reduced while high spin heme b(595) is oxidized with formation of a new heme d-oxygen species with an absorption maximum at 635 nm. Reduction of O-2 by two electrons is sufficient to produce ( hydro) peroxide bound to ferric heme d. In this case, the O-O bond is left intact and the newly detected intermediate must be a peroxy complex of heme d (Fe-d(3+)-O-O-( H)) corresponding to compound 0 in peroxidases. The alternative scenario where the O-O bond is broken as in the P-M intermediate of heme-copper oxidases and compound I of peroxidases is not very likely, because it would require oxidation of a nearby amino acid residue or the porphyrin ring that is energetically unfavorable in the presence of the reduced heme b558 in the proximity of the catalytic center. The formation of the peroxy intermediate is not coupled to membrane potential generation, indicating that hemes d and b595 are located at the same depth of the membrane dielectric. The lifetime of the new intermediate is 47 mu s; it decays into oxoferryl species due to oxidation of low spin heme b558 that is linked to significant charge translocation across the membrane.	Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, FI-00014 Helsinki, Finland; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Dept Mol Energet Microorganisms, Moscow 119991, Russia	University of Helsinki; Lomonosov Moscow State University	Verkhovsky, MI (corresponding author), Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, POB 65,Viikinkaari 1, FI-00014 Helsinki, Finland.	michael.verkhovsky@helsinki.fi	Borisov, Vitaliy B/C-9504-2012	Borisov, Vitaliy B/0000-0002-3400-9068; Belevich, Ilya/0000-0003-2190-4909				ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; Belevich I, 2005, P NATL ACAD SCI USA, V102, P3657, DOI 10.1073/pnas.0405683102; Belevich I, 2005, FEBS LETT, V579, P4567, DOI 10.1016/j.febslet.2005.07.011; BELEVICH I, 2007, IN PRESS BIOCHEMISTR; Belevich I, 2007, P NATL ACAD SCI USA, V104, P2685, DOI 10.1073/pnas.0608794104; Borisov V, 1999, BIOCHEMISTRY-US, V38, P740, DOI 10.1021/bi981908t; Borisov V, 1995, BIOCHEM MOL BIOL INT, V37, P975; Borisov VB, 2002, BIOCHEMISTRY-US, V41, P1654, DOI 10.1021/bi0158019; Borisov VB, 2001, J BIOL CHEM, V276, P22095, DOI 10.1074/jbc.M011542200; BORISOV VB, 1995, BIOCHEMISTRY-MOSCOW+, V60, P231; Borisov VB, 1996, BIOCHEMISTRY-MOSCOW+, V61, P565; Borisov VB, 2007, BIOCHEM BIOPH RES CO, V355, P97, DOI 10.1016/j.bbrc.2007.01.118; Borisov VB, 2006, FEBS LETT, V580, P4823, DOI 10.1016/j.febslet.2006.07.072; Brunori M, 2005, J INORG BIOCHEM, V99, P324, DOI 10.1016/j.jinorgbio.2004.10.011; Brzezinski P, 2004, TRENDS BIOCHEM SCI, V29, P380, DOI 10.1016/j.tibs.2004.05.008; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HILL BC, 1994, BIOCHEMISTRY-US, V33, P15110, DOI 10.1021/bi00254a021; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1994, J BIOL CHEM, V269, P2419; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; Hosler JP, 2006, ANNU REV BIOCHEM, V75, P165, DOI 10.1146/annurev.biochem.75.062003.101730; Iwaki M, 2006, BIOCHEMISTRY-US, V45, P10873, DOI 10.1021/bi061114b; Jasaitis A, 2000, BIOCHEMISTRY-US, V39, P13800, DOI 10.1021/bi001165n; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Jones P, 2005, J INORG BIOCHEM, V99, P2292, DOI 10.1016/j.jinorgbio.2005.08.009; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P14664, DOI 10.1021/bi0013748; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P1051, DOI 10.1021/bi00301a003; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; LORENCE RM, 1989, J BIOL CHEM, V264, P7135; MILLER MJ, 1986, METHOD ENZYMOL, V126, P87; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Morgan JE, 2001, BIOCHEMISTRY-US, V40, P6882, DOI 10.1021/bi010246w; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Shintaku M, 2005, J BIOL CHEM, V280, P40934, DOI 10.1074/jbc.M503472200; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sucheta A, 1998, BIOCHEMISTRY-US, V37, P17905, DOI 10.1021/bi981092w; TAKAHASHI S, 1995, J BIOL CHEM, V270, P8405, DOI 10.1074/jbc.270.15.8405; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; Vos MH, 2000, P NATL ACAD SCI USA, V97, P1554, DOI 10.1073/pnas.030528197; Yoshikawa S, 2006, BBA-BIOENERGETICS, V1757, P395, DOI 10.1016/j.bbabio.2006.04.028; Zhang J, 2001, BIOCHEMISTRY-US, V40, P8548, DOI 10.1021/bi010469m	58	44	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28514	28519		10.1074/jbc.M705562200	http://dx.doi.org/10.1074/jbc.M705562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690093	hybrid			2022-12-27	WOS:000249642100025
J	Lu, HAJ; Sun, TX; Matsuzaki, T; Yi, XH; Eswara, J; Bouley, R; Mckee, M; Brown, D				Lu, Hua A. J.; Sun, Tian-Xiao; Matsuzaki, Toshiyuki; Yi, Xian-Hua; Eswara, Jairam; Bouley, Richard; Mckee, Mary; Brown, Dennis			Heat shock protein 70 interacts with aquaporin-2 and regulates its trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT; MOLECULAR CHAPERONE; WATER CHANNEL; COATED PITS; INTRACELLULAR VESICLES; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; RAT-KIDNEY; HSC70; CLATHRIN	The trafficking of aquaporin-2 (AQP2) involves multiple complex pathways, including regulated, cAMP-, and cGMP-mediated pathways, as well as a constitutive recycling pathway. Although several accessory proteins have been indirectly implicated in AQP2 recycling, the direct protein-protein interactions that regulate this process remain largely unknown. Using yeast two-hybrid screening of a human kidney cDNA library, we have identified the 70-kDa heat shock proteins as AQP2-interacting proteins. Interaction was confirmed by mass spectrometry of proteins pulled down from rat kidney papilla extract using a GST-AQP2 C-terminal fusion protein (GST-A2C) as a bait, by co-immunoprecipitation (IP) assays, and by direct binding assays using purified hsc70 and the GST-A2C. The direct interaction of AQP2 with hsc70 is partially inhibited by ATP, and the Ser-256 residue in the AQP2 C terminus is important for this direct interaction. Vasopressin stimulation in cells enhances the interaction of hsc70 with AQP2 in IP assays, and vasopressin stimulation in vivo induces an increased co-localization of hsc70 and AQP2 on the apical membrane of principal cells in rat kidney collecting ducts. Functional knockdown of hsc70 activity in AQP2 expressing cells results in membrane accumulation of AQP2 and reduced endocytosis of rhodaminetransferrin. Our data also show that AQP2 interacts with hsp70 in multiple in vitro binding assays. Finally, in addition to hsc70 and hsp70, AQP2 interacts with several other key components of the endocytotic machinery in co-IP assays, including clathrin, dynamin, and AP2. To summarize, we have identified the 70-kDa heat shock proteins as a AQP2 interactors and have shown for hsc70 that this interaction is involved in AQP2 trafficking.	Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Brown, D (corresponding author), Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA.	brown@receptor.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, P30DK043351, P30DK057521, K08DK075940] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK075940, DK57521, DK38452, DK43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brive L, 2001, BIOCHEM BIOPH RES CO, V289, P1099, DOI 10.1006/bbrc.2001.6087; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; BROWN D, 1983, NATURE, V302, P253, DOI 10.1038/302253a0; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Callahan MK, 2002, J BIOL CHEM, V277, P33604, DOI 10.1074/jbc.M202890200; Carrello A, 2004, CELL STRESS CHAPERON, V9, P167, DOI 10.1379/CSC-26R.1; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Clay JR, 2002, J NEUROSCI RES, V67, P745, DOI 10.1002/jnr.10182; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; Noda Y, 2004, FEBS LETT, V568, P139, DOI 10.1016/j.febslet.2004.05.021; Procino G, 2003, FASEB J, V17, P1886, DOI 10.1096/fj.02-0870fje; Russo LM, 2006, AM J PHYSIOL-RENAL, V291, pF246, DOI 10.1152/ajprenal.00437.2005; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; Sasaki S, 2000, NEPHROL DIAL TRANSPL, V15, P21, DOI 10.1093/ndt/15.suppl_6.21; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Tutar Y, 2006, GENETICS, V172, P851, DOI 10.1534/genetics.105.048926; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Valenti G, 2000, J CELL SCI, V113, P1985; Valenti G, 2005, ENDOCRINOLOGY, V146, P5063, DOI 10.1210/en.2005-0868; van Balkom BWM, 2004, AM J PHYSIOL-RENAL, V286, pF216, DOI 10.1152/ajprenal.00307.2003; van Balkom BWM, 2003, J BIOL CHEM, V278, P1101, DOI 10.1074/jbc.M207339200; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	58	94	99	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28721	28732		10.1074/jbc.M611101200	http://dx.doi.org/10.1074/jbc.M611101200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636261	hybrid			2022-12-27	WOS:000249642100046
J	Ma, L; Wang, HY				Ma, Li; Wang, Hsien-Yu			Mitogen-activated protein kinase p38 regulates the Wnt/Cyclic GMP/Ca2+ non-canonical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PROTEIN-KINASE; WNT; WINGLESS; CA2+; JNK; CGMP	The non-canonical Wnt/cyclic GMP/Ca2+/ NF-AT pathway operates via Frizzled-2, a member of the superfamily of G protein-coupled receptors. In scanning for signaling events downstream of the Frizzled-2/G alpha t2/PDE6 triad activated in response to Wnt5a, we observed a strong activation of the mitogen-activated protein kinase p38 in mouse F9 teratocarcinoma embryonal cells. The activation of p38 is essential for NF-AT transcriptional activation mediated via Frizzled2. Wnt5a-stimulated p38 activation was rapid, sensitive to pertussis toxin, to siRNA against either G alpha t2 or p38 alpha, and to the p38 inhibitor SB203580. Real-time analysis of intracellular cyclic GMP using the Cygnet2 biosensor revealed p38 to act at the level of cyclic GMP, upstream of the mobilization of intracellular Ca2+. Fluorescence resonance energy transfer (FRET) imaging reveals the changes in cyclic GMP in response to Wnt5a predominate about the cell membrane, and likewise sensitive to either siRNA targeting p38 or to treatment with SB203580. Dishevelled is not required for Wnt5a activation of p38; siRNAs targeting Dishevelleds and expression of the Dishevelled antagonist Dapper-1 do not suppress the p38 response to Wnt5a stimulation. These novel results are the first to detail a Dishevelled-independent Wnt response, demonstrating a critical role of the mitogen-activated protein kinase p38 in regulating the Wnt non-canonical pathway.	SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Sch Med, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	wangh@pharm.stonybrook.edu	Ma, Li/AAG-4109-2020	Ma, Li/0000-0001-8470-0378	NIGMS NIH HHS [GM069375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen CM, 1999, DEVELOPMENT, V126, P5441; Chen LY, 1997, AM J PHYSIOL-HEART C, V273, pH1854, DOI 10.1152/ajpheart.1997.273.4.H1854; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Honda Akira, 2005, V307, P27; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Katanaev VL, 2006, P NATL ACAD SCI USA, V103, P6524, DOI 10.1073/pnas.0601853103; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma L, 2006, J BIOL CHEM, V281, P30990, DOI 10.1074/jbc.M603603200; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Wang H, 2004, BIOCHEM SOC T, V32, P792, DOI 10.1042/BST0320792; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; WOLFE L, 1987, J BIOL CHEM, V262, P16906; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008	32	63	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28980	28990		10.1074/jbc.M702840200	http://dx.doi.org/10.1074/jbc.M702840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684012	hybrid			2022-12-27	WOS:000249642100072
J	Mah, AK; Armstrong, KR; Chew, DS; Chu, JS; Tu, DK; Johnsen, RC; Chen, N; Chamberlin, HM; Baillie, DL				Mah, Allan K.; Armstrong, Kristin R.; Chew, Derek S.; Chu, Jeffrey S.; Tu, Dornena K.; Johnsen, Robert C.; Chen, Nansheng; Chamberlin, Helen M.; Baillie, David L.			Transcriptional regulation of AQP-8, a Caenorhabditis elegans aquaporin exclusively expressed in the excretory system, by the POU homeobox transcription factor CEH-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL; FUNCTIONAL-CHARACTERIZATION; NERVOUS-SYSTEM; GENE; CELL; IDENTIFICATION; PROTEIN; NEMATODE; DOMAIN; MEMBRANE	Due to the ever changing environmental conditions in soil, regulation of osmotic homeostasis in the soil-dwelling nematode Caenorhabditis elegans is critical. AQP-8 is a C. elegans aquaporin that is expressed in the excretory cell, a renal equivalent tissue, where the protein participates in maintaining water balance. To better understand the regulation of AQP-8, we undertook a promoter analysis to identify the aqp-8 cis-regulatory elements. Using progressive 5' deletions of upstream sequence, we have mapped an essential regulatory region to roughly 300 bp upstream of the translational start site of aqp-8. Analysis of this region revealed a sequence corresponding to a known DNA functional element (octamer motif), which interacts with POU homeobox transcription factors. Phylogenetic footprinting showed that this site is perfectly conserved in four nematode species. The octamer site's function was further confirmed by deletion analyses, mutagenesis, functional studies, and electrophoretic mobility shift assays. Of the three POU homeobox proteins encoded in the C. elegans genome, CEH-6 is the only member that is expressed in the excretory cell. We show that expression of AQP-8 is regulated by CEH-6 by performing RNA interference experiments. CEH-6's mammalian ortholog, Brn1, is expressed both in the kidney and the central nervous system and binds to the same octamer consensus binding site to drive gene expression. These parallels in transcriptional control between Brn1 and CEH-6 suggest that C. elegans may well be an appropriate model for determining gene-regulatory networks in the developing vertebrate kidney.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Simon Fraser University; University System of Ohio; Ohio State University	Mah, AK (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	amaha@sfu.ca	Chamberlin, Helen/L-4206-2019; Chen, Nansheng/E-6450-2012	Chamberlin, Helen/0000-0001-7203-2691; Chew, Derek/0000-0003-3539-7485				AGRE P, 1993, AM J PHYSIOL, V265, pF463; Baranek C, 2005, NUCLEIC ACIDS RES, V33, P6277, DOI 10.1093/nar/gki947; Blacque OE, 2005, CURR BIOL, V15, P935, DOI 10.1016/j.cub.2005.04.059; BRENNER S, 1974, GENETICS, V77, P71; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; Buechner M, 2002, TRENDS CELL BIOL, V12, P479, DOI 10.1016/S0962-8924(02)02364-4; Burglin TR, 2001, DEVELOPMENT, V128, P779; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Castle NA, 2005, DRUG DISCOV TODAY, V10, P485, DOI 10.1016/S1359-6446(05)03390-8; Chavez M, 1999, MECH DEVELOP, V87, P207, DOI 10.1016/S0925-4773(99)00152-5; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Frand AR, 2005, PLOS BIOL, V3, P1719, DOI 10.1371/journal.pbio.0030312; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Gazzarrini S, 2006, P NATL ACAD SCI USA, V103, P5355, DOI 10.1073/pnas.0600848103; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; Hauptmann G, 2000, DEV DYNAM, V218, P345, DOI 10.1002/(SICI)1097-0177(200006)218:2<345::AID-DVDY8>3.0.CO;2-V; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Huang CG, 2007, AM J PHYSIOL-CELL PH, V292, pC1867, DOI 10.1152/ajpcell.00514.2006; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; KALDENHOFF R, 1995, PLANT J, V7, P87, DOI 10.1046/j.1365-313X.1995.07010087.x; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kuwahara M, 2000, BBA-GENE STRUCT EXPR, V1517, P107, DOI 10.1016/S0167-4781(00)00268-2; Kuwahara M, 1998, AM J PHYSIOL-CELL PH, V275, pC1459, DOI 10.1152/ajpcell.1998.275.6.C1459; Lan L, 2006, DEV DYNAM, V235, P1107, DOI 10.1002/dvdy.20703; Li HP, 2005, BIOL CELL, V97, P823, DOI 10.1042/BC20040091; McCarroll SA, 2005, CURR BIOL, V15, P347, DOI 10.1016/j.cub.2005.02.023; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Nakai S, 2003, DEVELOPMENT, V130, P4751, DOI 10.1242/dev.00666; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Rai T, 1997, AM J PHYSIOL-RENAL, V273, pF264, DOI 10.1152/ajprenal.1997.273.2.F264; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rose KL, 1997, DEV BIOL, V192, P59, DOI 10.1006/dbio.1997.8728; Ross DA, 1998, J IMMUNOL, V160, P3874; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Spaniol P, 1996, NUCLEIC ACIDS RES, V24, P4874, DOI 10.1093/nar/24.24.4874; Stein LD, 2002, GENOME RES, V12, P1599, DOI 10.1101/gr.403602; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Sze JY, 2003, P NATL ACAD SCI USA, V100, P9560, DOI 10.1073/pnas.1530752100; Thacker C, 2006, CELL MOL LIFE SCI, V63, P1193, DOI 10.1007/s00018-006-6012-z; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Wang LL, 1996, MECH DEVELOP, V56, P183, DOI 10.1016/0925-4773(96)00523-0; Yuh CH, 2005, DEV BIOL, V281, P286, DOI 10.1016/j.ydbio.2005.02.034; Zhang TY, 2004, BIOCHEM J, V380, P255, DOI 10.1042/BJ20031482; Zhao ZY, 2005, J BIOL CHEM, V280, P38787, DOI 10.1074/jbc.M505701200	64	23	26	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28074	28086		10.1074/jbc.M703305200	http://dx.doi.org/10.1074/jbc.M703305200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660295	hybrid			2022-12-27	WOS:000249455600057
J	Wang, ZX; Wu, JW				Wang, Zhi-Xin; Wu, Jia-Wei			The complete pathway for ERK2-catalyzed reaction - Evidence for an iso random BiBi mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; KINETIC MECHANISM; SUBSTRATE; PHOSPHORYLATION; EQUILIBRIUM	In the present study, the enzymatic mechanism of ERK2 is re-examined by a combination of steady-state kinetic studies in the absence and presence of viscosogenic agents. Kinetic studies carried out in various concentrations of sucrose revealed that both k(cat) and k(cat)/K-m for either ATP or Ets Delta 138 were highly sensitive to solvent viscosity, suggesting that the rapid equilibrium assumption is not valid for the phosphorylation of protein substrate by ERK2. Furthermore, the kinetic analysis with the minimal random Bi Bi reaction mechanism is shown to be inconsistent with the principle of the detailed balance. This inconsistent calculation strongly suggests that there is isomerization of the enzyme-substrate ternary complex. The viscosity-dependent steady-state kinetic data are combined to establish a kinetic mechanism for the ERK2-catalyzed reaction that predicts initial reaction velocities under varying concentrations of ATP and substrate. These results complement previous structure-function studies of mitogen-activated protein kinases and provide important insight for mechanistic interpretation of the kinase functions.	Tsinghua Univ, Dept Biol Sci, Beijing 100084, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZX (corresponding author), Tsinghua Univ, Dept Biol Sci, Beijing 100084, Peoples R China.	zxwang@sun5.ibp.ac.cn; Jiaweiwu@mail.tsinghua.edu.cn	wang, zhixin/GZH-2500-2022					ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; [Anonymous], 1982, PHYS BIOCH APPL BIOC; CHA S, 1968, J BIOL CHEM, V243, P820; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DALZIEL K, 1958, T FARADAY SOC, V54, P1247, DOI 10.1039/tf9585401247; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FRIEDEN C, 1976, BIOCHEM BIOPH RES CO, V68, P914, DOI 10.1016/0006-291X(76)91232-8; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; GUTFREUND H, 1995, KINETICS LIFE SCI, P248; HAMMES GG, 1995, THERMODYNAMICS KINET; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; PETTERSSON G, 1969, ACTA CHEM SCAND, V23, P2717, DOI 10.3891/acta.chem.scand.23-2717; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Waas WF, 2002, J BIOL CHEM, V277, P12532, DOI 10.1074/jbc.M110523200; Waas WF, 2001, PROTEIN EXPRES PURIF, V23, P191, DOI 10.1006/prep.2001.1491; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilsbacher JL, 2001, METHOD ENZYMOL, V332, P387	26	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27678	27684		10.1074/jbc.M703161200	http://dx.doi.org/10.1074/jbc.M703161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652083	hybrid			2022-12-27	WOS:000249455600015
J	Wittrup, A; Sandgren, S; Lilja, J; Bratt, C; Gustavsson, N; Moergelin, M; Belting, M				Wittrup, Anders; Sandgren, Staffan; Lilja, Johanna; Bratt, Charlotte; Gustavsson, Niklas; Moergelin, Matthias; Belting, Mattias			Identification of proteins released by mammalian cells that mediate DNA internalization through proteoglycan-dependent macropinocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; PLASMID DNA; BINDING PROTEIN; HEPATIC-UPTAKE; GENE-TRANSFER; SURFACE PROTEOGLYCANS; INTRAVENOUS-INJECTION; CYCLOPHILIN-B; TARGET-CELLS; ENDOCYTOSIS	Naked DNA plasmid represents the simplest vehicle for gene therapy and DNA-based vaccination purposes; however, the, molecular mechanisms of DNA uptake in mammalian cells are poorly understood. Here, we show that naked DNA uptake occurs via proteoglycan-dependent macropinocytosis, thus challenging the concept of a specific DNA-internalizing receptor. Cells genetically deficient in proteoglycans, which constitute a major source of cell-surface polyanions, exhibited substantially decreased uptake of likewise polyanionic DNA. The apparent paradox was explained by the action of DNA-transporting proteins present in conditioned medium. Complexes between these proteins and DNA require proteoglycans for cellular entry. Mass spectrometry analysis of cell medium components identified several proteins previously shown to associate with DNA and to participate in membrane transport of macromolecular cargo. The major pathway for proteoglycan-dependent DNA uptake was macropinocytosis, whereas caveolae-dependent and clathrin-dependent pathways were not involved, as determined by using caveolin-1 knock-out cells, dominant-negative constructs for dynamin and Eps15, and macropinocytosis- disruptive drugs, as well as confocal fluorescence co-localization studies. Importantly, a significant fraction of internalized DNA was translocated to the nucleus for expression. Our results provide novel insights into the mechanism of DNA uptake by mammalian cells and extend the emerging role of proteoglycans in macromolecular transport.	Lund Univ, Dept Clin Sci, Sect Oncol, S-22185 Lund, Sweden; Lund Univ, Sect Clin & Expt Infect Dis, S-22185 Lund, Sweden; Lund Univ, Dept Biochem, Mass Spectrometry Grp, S-22185 Lund, Sweden	Lund University; Lund University; Lund University	Belting, M (corresponding author), Lund Univ, Dept Clin Sci, Sect Oncol, Barngatan 21, S-22185 Lund, Sweden.	mattias.belting@med.lu.se	Gustavsson, Niklas/D-5712-2011; Welinder, Charlotte/G-1144-2014	Welinder, Charlotte/0000-0001-9626-0576; Belting, Mattias/0000-0003-1585-5434; Wittrup, Anders/0000-0003-4918-0500				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; ALLAIN F, 1994, J BIOL CHEM, V269, P16537; Basner-Tschakarjan E, 2004, GENE THER, V11, P765, DOI 10.1038/sj.gt.3302221; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; EHRLICH M, 1976, BIOCHIM BIOPHYS ACTA, V454, P397, DOI 10.1016/0005-2787(76)90266-5; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Hisazumi J, 2004, PHARM RES-DORDR, V21, P1223, DOI 10.1023/B:PHAM.0000033009.17594.e5; Joo EJ, 2005, GLYCOBIOLOGY, V15, P1, DOI 10.1093/glycob/cwh132; Kaneda Yasufumi, 2001, Current Molecular Medicine (Hilversum), V1, P493, DOI 10.2174/1566524013363519; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; Laktionov PP, 1999, NUCLEIC ACIDS RES, V27, P2315, DOI 10.1093/nar/27.11.2315; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; OLSEN I, 1974, IMMUNOLOGY, V27, P973; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Satkauskas S, 2001, MOL THER, V4, P317, DOI 10.1006/mthe.2001.0465; Takagi T, 1998, BIOCHEM BIOPH RES CO, V245, P729, DOI 10.1006/bbrc.1998.8521; Takakura Y, 1999, PHARMACEUT RES, V16, P503, DOI 10.1023/A:1018842210588; Vogel JC, 2000, HUM GENE THER, V11, P2253, DOI 10.1089/104303400750035780; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Watson K, 1999, J BIOL CHEM, V274, P21707, DOI 10.1074/jbc.274.31.21707; WOLFF JA, 1992, J CELL SCI, V103, P1249; Yasuda K, 2004, IMMUNOLOGY, V111, P282, DOI 10.1111/j.1365-2567.2004.01814.x	48	39	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27897	27904		10.1074/jbc.M701611200	http://dx.doi.org/10.1074/jbc.M701611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623661	hybrid			2022-12-27	WOS:000249455600038
J	An, ZB; Wang, H; Song, P; Zhang, M; Geng, XM; Zou, MH				An, Zhibo; Wang, Hong; Song, Ping; Zhang, Miao; Geng, Xuemei; Zou, Ming-Hui			Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 Adipocytes - A role for oxidant stress (Publication with Expression of Concern. See vol. 294, pg. 10025, 2019) (Withdrawn Publication. See vol. 295, pg. 667, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							DEPENDENT ARTERIOLAR DILATATION; ACETYLCHOLINE-RECEPTORS; UPSTREAM KINASE; ADIPOSE-TISSUE; IN-VIVO; PEROXYNITRITE; EXPRESSION; GENE; BETA; LKB1	Recent studies suggest that the AMP-activated protein kinase ( AMPK) acts as a major energy sensor and regulator in adipose tissues. The objective of this study was to investigate the role of AMPK in nicotine-induced lipogenesis and lipolysis in 3T3L1 adipocytes. Exposure of 3T3L1 adipocytes to smoking-related concentrations of nicotine increased lipolysis and inhibited fatty acid synthase ( FAS) activity in a time-and dose-dependent manner. The effects of nicotine on FAS activity were accompanied by phosphorylation of both AMPK ( Thr(172)) and acetyl-CoA carboxylase ( ACC; Ser(79)). Nicotine-induced AMPK phosphorylation appeared to be mediated by reactive oxygen species based on the finding that nicotine significantly increased superoxide anions and 3-nitrotyrosine positive proteins, exogenous peroxynitrite( ONOO (-)) mimicked the effects of nicotineon AMPK, and N-acetylcysteine( NAC) abolished nicotine-enhanced AMPK phosphorylation. Inhibition of AMPK using either pharmacologic ( insulin, compound C) or genetic means ( overexpression of dominant negative AMPK; AMPK-DN) abolished FAS inhibition induced by nicotine or ONOO (-). Conversely, activation of AMPK by pharmacologic ( nicotine, ONOO (-), metformin, and AICAR) or genetic ( overexpression of constitutively active AMPK) means inhibited FAS activity. Notably, AMPK activation increased threonine phosphorylation of FAS, and this effect was blocked by adenovirus encoding dominant negative AMPK. Finally, AMPK-dependent FAS phosphorylation was confirmed by P-32 incorporation into FAS in adipocytes. Taken together, our results strongly suggest that nicotine, via ONOO (-), activates AMPK, resulting in enhanced threonine phosphorylation and consequent inhibition of FAS.	Univ Tennessee, Grad Sch Med, Dept Surg, Vasc Biol Lab, Knoxville, TN 37922 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Endocrinol & Diabet, Oklahoma City, OK 73104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zou, MH (corresponding author), BSEB 325, 941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	ming-hui-zou@ouhsc.edu	Song, Ping/D-6972-2011; Song, Ping/N-8456-2018	Song, Ping/0000-0002-2654-6162; Song, Ping/0000-0002-6143-4270	NHLBI NIH HHS [HL 079584, HL 074399, HL 080499] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079584, R01HL074399, R01HL080499] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson K, 2001, INT J OBESITY, V25, P1225, DOI 10.1038/sj.ijo.0801654; Caraballo RS, 2004, NICOTINE TOB RES, V6, P19, DOI 10.1080/14622200310001656821; Chalon S, 2000, CLIN PHARMACOL THER, V67, P391, DOI 10.1067/mcp.2000.105153; Chirala SS, 2004, LIPIDS, V39, P1045, DOI 10.1007/s11745-004-1329-9; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; Davis BJ, 2006, DIABETES, V55, P496, DOI 10.2337/diabetes.55.02.06.db05-1064; EISERICH JP, 1994, FEBS LETT, V353, P53, DOI 10.1016/0014-5793(94)01011-0; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; Fukuda H, 1999, EUR J BIOCHEM, V260, P505, DOI 10.1046/j.1432-1327.1999.00183.x; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; John U, 2005, INT J OBESITY, V29, P1289, DOI 10.1038/sj.ijo.0803028; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Liu RH, 2004, J PHARMACOL EXP THER, V310, P52, DOI 10.1124/jpet.103.065037; Mayhan WG, 1998, J APPL PHYSIOL, V85, P1292, DOI 10.1152/jappl.1998.85.4.1292; Mayhan WG, 1999, J APPL PHYSIOL, V86, P1126, DOI 10.1152/jappl.1999.86.4.1126; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Nepokroeff CM., 1975, METHOD ENZYMOL, V35, P37, DOI DOI 10.1016/0076-6879(75; Petruzzelli S, 1997, AM J RESP CRIT CARE, V156, P1902, DOI 10.1164/ajrccm.156.6.9702075; Pignatelli B, 2001, CANCER RES, V61, P778; Raij L, 2001, J HYPERTENS, V19, P891, DOI 10.1097/00004872-200105000-00009; Ronnett GV, 2005, PHYSIOL BEHAV, V85, P25, DOI 10.1016/j.physbeh.2005.04.014; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; WETSCHER GJ, 1995, FREE RADICAL BIO MED, V18, P877, DOI 10.1016/0891-5849(94)00221-5; WETSCHER GJ, 1998, DIGEST DIS SCI, V40, P853; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yildiz D, 1998, TOXICOLOGY, V130, P155, DOI 10.1016/S0300-483X(98)00105-X; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200; Zou MH, 2004, ENDOTHELIUM-J ENDOTH, V11, P89, DOI 10.1080/10623320490482619	49	85	90	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26793	26801		10.1074/jbc.M703701200	http://dx.doi.org/10.1074/jbc.M703701200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635921	hybrid			2022-12-27	WOS:000249304900019
J	Barreyro, FJ; Kobayashi, S; Bronk, SF; Werneburg, NW; Malhi, H; Gores, GJ				Barreyro, Fernando J.; Kobayashi, Shogo; Bronk, Steven F.; Werneburg, Nathan W.; Malhi, Harmeet; Gores, Gregory J.			Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; FATTY LIVER-DISEASE; PALMITATE-INDUCED APOPTOSIS; BETA-CELL APOPTOSIS; FAMILY-MEMBER BIM; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; INDUCE APOPTOSIS; TYROSINE PHOSPHORYLATION; PROAPOPTOTIC FUNCTION	Hepatocyte lipoapoptosis, a critical feature of nonalcoholic steatohepatitis, can be replicated in vitro by incubating hepatocytes with saturated free fatty acids (FFA). These toxic FFA induce Bim expression, which is requisite for their cytotoxicity. Because the FoxO3a transcription factor has been implicated in Bim expression, our aim was to determine if FFA induce Bim by a FoxO3a-dependent mechanism. In Huh-7 cells, the saturated FFA, palmitic and stearic acid, increased Bim mRNA 16-fold. Treatment of cells with the saturated FFA induced FoxO3a dephosphorylation (activation) and nuclear translocation and stimulated a FoxO luciferase-based reporter assay; direct binding of FoxO3a to the Bim promoter was also confirmed by a chromatin immunoprecipitation assay. A small interfering RNA-targeted knockdown of FoxO3a abrogated FFA-mediated Bim induction and apoptosis. FoxO3a was activated by a phosphatase 2A-dependent mechanism, since okadaic acid- and small interfering RNA-targeted knockdown of this phosphatase blocked FoxO3a dephosphorylation, Bim expression, and apoptosis. Consistent with these data, phosphatase 2A activity was also stimulated 3-fold by saturated FFA. Immunoprecpitation studies revealed an FFA-dependent association between FoxO3a and protein phosphatase 2A. FFA-mediated FoxO3a activation by protein phosphatase 2A was also observed in HepG2 cells and murine hepatocytes. In conclusion, saturated FFA stimulate protein phosphatase 2A activity, which activates FoxO3a, inducing expression of the intracellular death mediator Bim.	Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alvarado-Kristensson M, 2005, J BIOL CHEM, V280, P6238, DOI 10.1074/jbc.M409718200; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Artwohl M, 2004, FASEB J, V18, P146, DOI 10.1096/fj.03-0301fje; Baskin-Bey ES, 2005, AM J PHYSIOL-GASTR L, V289, pG987, DOI 10.1152/ajpgi.00371.2005; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bouillet P, 2000, ANN NY ACAD SCI, V926, P83; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feldstein AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4; Fernandez-Real JM, 2003, DIABETES CARE, V26, P1362, DOI 10.2337/diacare.26.5.1362; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guicciardi ME, 2005, GUT, V54, P1024, DOI 10.1136/gut.2004.053850; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Harmala-Brasken AS, 2003, ONCOGENE, V22, P7677, DOI 10.1038/sj.onc.1207077; Hickson-Bick DLM, 2002, AM J PHYSIOL-HEART C, V282, pH656, DOI 10.1152/ajpheart.00726.2001; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kowluru A, 2005, BIOCHEM PHARMACOL, V69, P1681, DOI 10.1016/j.bcp.2005.03.018; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Leskinen MH, 2005, SCAND J CLIN LAB INV, V65, P485, DOI 10.1080/00365510510025836; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Malhi H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590; Nehra V, 2001, DIGEST DIS SCI, V46, P2347, DOI 10.1023/A:1012338828418; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Pagano G, 2002, HEPATOLOGY, V35, P367, DOI 10.1053/jhep.2002.30690; Patil S, 2005, NEUROSCI LETT, V384, P288, DOI 10.1016/j.neulet.2005.05.003; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; RICHIERI GV, 1995, J LIPID RES, V36, P229; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieckowska A, 2006, HEPATOLOGY, V44, P27, DOI 10.1002/hep.21223; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010; Yin KJ, 2006, J NEUROSCI, V26, P2290, DOI 10.1523/JNEUROSCI.5103-05.2006; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353	65	154	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27141	27154		10.1074/jbc.M704391200	http://dx.doi.org/10.1074/jbc.M704391200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626006	hybrid			2022-12-27	WOS:000249304900055
J	Lee, WS; Payne, BJ; Gelfman, CM; Vogel, P; Kornfeld, S				Lee, Wang-Sik; Payne, Bobby Joe; Gelfman, Claire M.; Vogel, Peter; Kornfeld, Stuart			Murine UDP-GlcNAc : Lysosomal enzyme N-acetylglucosamine-1-phosphotransferase lacking the gamma-subunit retains substantial activity toward acid hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-HURLER POLYDYSTROPHY; PHOSPHOTRANSFERASE ALPHA/BETA-SUBUNITS; I-CELL DISEASE; N-ACETYLGLUCOSAMINE; MUCOLIPIDOSIS-III; PROCATHEPSIN-D; PHOSPHORYLATION; MUTATIONS; IDENTIFICATION; RECOGNITION	UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase) mediates the first step in the synthesis of the mannose 6-phosphate recognition marker on acid hydrolases. The transferase exists as an alpha(2)beta(2)gamma(2) hexameric complex with the alpha- and beta-subunits derived from a single precursor molecule. The catalytic function of the transferase is attributed to the alpha- and beta-subunits, whereas the gamma-subunit is believed to be involved in the recognition of a conformation-dependent protein determinant common to acid hydrolases. Using knock-out mice with mutations in either the alpha/beta gene or the gamma gene, we show that disruption of the alpha/beta gene completely abolishes phosphorylation of high mannose oligosaccharides on acid hydrolases whereas knock-out of the gamma gene results in only a partial loss of phosphorylation. These findings demonstrate that the alpha/beta-subunits, in addition to their catalytic function, have some ability to recognize acid hydrolases as specific substrates. This process is enhanced by the gamma-subunit.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Lexicon Pharmaceut Inc, The Woodlands, TX 77381 USA	Washington University (WUSTL); Lexicon Pharmaceuticals	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.	skornfel@wustl.edu	Vogel, Peter/N-2490-2018	Vogel, Peter/0000-0002-7535-0545	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bargal R, 2006, MOL GENET METAB, V88, P359, DOI 10.1016/j.ymgme.2006.03.003; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; GELFMAN C, 2007, IN PRESS INVEST OPHT; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Joyner AL, 2000, GENE TARGETING PRACT; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Kornfeld S., 2001, METABOLIC MOL BASES, P3469; Kudo M, 2006, AM J HUM GENET, V78, P451, DOI 10.1086/500849; Kudo M, 2005, J BIOL CHEM, V280, P36141, DOI 10.1074/jbc.m509008200; LANG L, 1984, J BIOL CHEM, V259, P4663; LANG L, 1985, J CLIN INVEST, V76, P2191, DOI 10.1172/JCI112227; LITTLE LE, 1986, J BIOL CHEM, V261, P733; Mazrier H, 2003, J HERED, V94, P363, DOI 10.1093/jhered/esg080; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Schierau A, 1999, J BIOL CHEM, V274, P3651, DOI 10.1074/jbc.274.6.3651; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Steet R, 2005, J BIOL CHEM, V280, P33318, DOI 10.1074/jbc.M505994200; Steet RA, 2005, AM J MED GENET A, V132A, P369, DOI 10.1002/ajmg.a.30498; Steet R, 2007, BIOCHEM PHARMACOL, V73, P1376, DOI 10.1016/j.bcp.2006.12.015; Tiede S, 2005, AM J MED GENET A, V137A, P235, DOI 10.1002/ajmg.a.30868; Tiede S, 2005, NAT MED, V11, P1109, DOI 10.1038/nm1305; Tiede Stephan, 2004, Hum Mutat, V24, P535, DOI 10.1002/humu.9293; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; VARKI A, 1982, AM J HUM GENET, V34, P717; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; Yaghootfam A, 2003, J BIOL CHEM, V278, P32653, DOI 10.1074/jbc.M304865200; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27198	27203		10.1074/jbc.M704067200	http://dx.doi.org/10.1074/jbc.M704067200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652091	hybrid			2022-12-27	WOS:000249304900061
J	Bernatchez, PN; Acevedo, L; Fernandez-Hernando, C; Murata, T; Chalouni, C; Kim, J; Erdjument-Bromage, H; Shah, V; Gratton, JP; Mcnally, EM; Tempst, P; Sessa, WC				Bernatchez, Pascal N.; Acevedo, Lisette; Fernandez-Hernando, Carlos; Murata, Takahisa; Chalouni, Cecile; Kim, Jiae; Erdjument-Bromage, Hediye; Shah, Vijay; Gratton, Jean-Philippe; Mcnally, Elizabeth M.; Tempst, Paul; Sessa, William C.			Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; MEMBRANE REPAIR; MUSCULAR-DYSTROPHY; IN-VIVO; FUSION; CELLS; DYSFERLIN; PATHWAYS; PROTEIN; GENE	Myoferlin and dysferlin are members of the ferlin family of membrane proteins. Recent studies have shown that mutation or genetic disruption of myoferlin or dysferlin promotes muscular dystrophy-related phenotypes in mice, which are the result of impaired plasma membrane integrity. However, no biological functions have been ascribed to myoferlin in non-muscle tissues. Herein, using a proteomic analysis of endothelial cell ( EC) caveolae/lipid raft microdomains we identified myoferlin in these domains and show that myoferlin is highly expressed in ECs and vascular tissues. The loss of myoferlin results in lack of proliferation, migration, and nitric oxide ( NO) release in response to vascular endothelial growth factor ( VEGF). Western blotting and surface biotinylation experiments show that loss of myoferlin reduces the expression level and autophosphorylation of VEGF receptor-2 ( VEGFR-2) in native ECs. In a reconstituted cell system, transfection of myoferlin increases VEGFR-2 membrane expression and autophosphorylation in response to VEGF. In vivo, VEGFR-2 levels and VEGF-induced permeability are impaired in myoferlin-deficient mice. Mechanistically, myoferlin forms a complex with dynamin-2 and VEGFR-2, which prevents CBL-dependent VEGFR-2 polyubiquitination and proteasomal degradation. These data are the first to report novel biological activities for myoferlin and reveal the role of membrane integrity to VEGF signaling.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol & Vasc Biol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Transplantat Program, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Genet, Chicago, IL 60637 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mayo Clin, GI Res Unit, Rochester, MN 55905 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Yale University; Yale University; Yale University; University of Chicago; University of Chicago; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol & Vasc Biol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011; McNally, Elizabeth/W-4909-2019	Sessa, William C/0000-0001-5759-1938; McNally, Elizabeth/0000-0002-1221-719X; Gratton, Jean-Philippe/0000-0001-9877-8520; Murata, Takahisa/0000-0002-3328-0796; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NHLBI NIH HHS [P01 HL 70295, R01 HL61371, N01-HV-28186, R01 HL 57665, HL64793] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064793, P01HL070295, R01HL057665, R01HL061371] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Achanzar WE, 1997, J CELL SCI, V110, P1073; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Bhattacharya R, 2005, FASEB J, V19, P1692, DOI 10.1096/fj.05-3889fje; Britton S, 2000, GENOMICS, V68, P313, DOI 10.1006/geno.2000.6290; Cenacchi G, 2005, J CLIN PATHOL, V58, P190, DOI 10.1136/jcp.2004.018978; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Dubois C, 2006, BLOOD, V107, P3902, DOI 10.1182/blood-2005-09-3687; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Karsan A, 2005, J PROTEOME RES, V4, P349, DOI 10.1021/pr049824w; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Peplowska K, 2005, NAT CELL BIOL, V7, P103, DOI 10.1038/ncb0205-103; Washington NL, 2006, J CELL SCI, V119, P2552, DOI 10.1242/jcs.02980; ZARRINPAR A, 2003, SCI STKE 2003	21	85	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30745	30753		10.1074/jbc.M704798200	http://dx.doi.org/10.1074/jbc.M704798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702744	hybrid			2022-12-27	WOS:000250136300043
J	Kanno, K; Wu, MK; Agate, DS; Fanelli, BJ; Wagle, N; Scapa, EF; Ukomadu, C; Cohen, DE				Kanno, Keishi; Wu, Michele K.; Agate, Diana S.; Fanelli, Brandon J.; Wagle, Neil; Scapa, Erez F.; Ukomadu, Chinweike; Cohen, David E.			Interacting proteins dictate function of the minimal START domain phosphatidylcholine transfer protein/StarD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA HYDROLASE; THIOESTERASE SUPERFAMILY MEMBER-2; INTRACELLULAR LIPID-METABOLISM; PHOSPHOLIPID TRANSFER PROTEINS; TISSUE-SPECIFIC EXPRESSION; BROWN ADIPOSE-TISSUE; BINDING DOMAIN; CDNA CLONING; RAT-LIVER; C-RET	The Star ( steroidogenic acute regulatory protein)-related transfer ( START) domain superfamily is characterized by a distinctive lipid-binding motif. START domains typically reside in multidomain proteins, suggesting their function as lipid sensors that trigger biological activities. Phosphatidylcholine transfer protein ( PC-TP, also known as StarD2) is an example of a START domain minimal protein that consists only of the lipid-binding motif. PC-TP, which binds phosphatidylcholine exclusively, is expressed during embryonic development and in several tissues of the adult mouse, including liver. Although it catalyzes the intermembrane exchange of phosphatidylcholines in vitro, this activity does not appear to explain the various metabolic alterations observed in mice lacking PC-TP. Here we demonstrate that PC-TP function may be mediated via interacting proteins. Yeast two-hybrid screening using libraries prepared from mouse liver and embryo identified Them2 ( thioesterase superfamily member 2) and the homeodomain transcription factor Pax3 ( paired box gene 3), respectively, as PC-TP-interacting proteins. These were notable because the START domain superfamily contains multidomain proteins in which the START domain coexists with thioesterase domains in mammals and with homeodomain transcription factors in plants. Interactions were verified in pulldown assays, and colocalization with PC-TP was confirmed within tissues and intracellularly. The acyl-CoA thioesterase activity of purified recombinant Them2 was markedly enhanced by recombinant PC-TP. In tissue culture, PC-TP coactivated the transcriptional activity of Pax3. These findings suggest that PC-TP functions as a phosphatidylcholine-sensing molecule that engages in diverse regulatory activities that depend upon the cellular expression of distinct interacting proteins.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol,Dept Med, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; Harvard Univ, MIT, Div Hlth & Sci & Technol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Massachusetts Institute of Technology (MIT)	Cohen, DE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol,Dept Med, 75 Francis St, Boston, MA 02115 USA.	dcohen@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R01DK048873, R01DK056626, R29DK048873, R37DK048873] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34854, DK56626, DK48873] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams SH, 2001, BIOCHEM J, V360, P135, DOI 10.1042/bj3600135; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Baez JM, 2002, J BIOL CHEM, V277, P6198, DOI 10.1074/jbc.M106799200; Berger UV, 2000, J COMP NEUROL, V421, P385, DOI 10.1002/(SICI)1096-9861(20000605)421:3<385::AID-CNE7>3.0.CO;2-S; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Cheng ZJ, 2006, BIOCHEM BIOPH RES CO, V350, P850, DOI 10.1016/j.bbrc.2006.09.105; Cheng ZJ, 2006, BIOCHEM BIOPH RES CO, V349, P172, DOI 10.1016/j.bbrc.2006.08.025; Cohen DE, 1999, BBA-GENE STRUCT EXPR, V1447, P265, DOI 10.1016/S0167-4781(99)00163-3; de Brouwer APM, 2002, EXP CELL RES, V274, P100, DOI 10.1006/excr.2001.5460; Epstein JA, 2000, METH MOL B, V137, P459; Feng L, 2000, BIOCHEMISTRY-US, V39, P15399, DOI 10.1021/bi001076a; Geijtenbeek TBH, 1996, BIOCHEM J, V316, P49; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hunt MC, 2005, J LIPID RES, V46, P2029, DOI 10.1194/jlr.E500003-JLR200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; ISOHASHI F, 1983, EUR J BIOCHEM, V134, P447, DOI 10.1111/j.1432-1033.1983.tb07587.x; Kanno K, 2007, BBA-MOL CELL BIOL L, V1771, P654, DOI 10.1016/j.bbalip.2007.04.003; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Machado AF, 2001, CURR PHARM DESIGN, V7, P751, DOI 10.2174/1381612013397726; MATSUNAGA T, 1985, EUR J BIOCHEM, V152, P331, DOI 10.1111/j.1432-1033.1985.tb09202.x; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; Pan HJ, 2006, FEBS LETT, V580, P5953, DOI 10.1016/j.febslet.2006.09.066; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Schrick K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r41; Shoda J, 2001, HEPATOLOGY, V33, P1194, DOI 10.1053/jhep.2001.23936; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Suematsu N, 2002, ACTA BIOCHIM POL, V49, P937; Suematsu N, 2001, EUR J BIOCHEM, V268, P2700, DOI 10.1046/j.1432-1327.2001.02162.x; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wirtz KWA, 2006, FEBS LETT, V580, P5436, DOI 10.1016/j.febslet.2006.06.065; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020	41	56	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30728	30736		10.1074/jbc.M703745200	http://dx.doi.org/10.1074/jbc.M703745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704541	hybrid			2022-12-27	WOS:000250136300041
J	Tanaka, T; Suh, KS; Lo, AM; De Luca, LM				Tanaka, Takemi; Suh, Kwang S.; Lo, Angela M.; De Luca, Luigi M.			P21(WAF1/CIP1) is a common transcriptional target of retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; X-RECEPTOR; BREAST-CANCER; RESPONSE ELEMENT; 9-CIS-RETINOIC ACID; HORMONE-RECEPTORS; OVARIAN-CARCINOMA; PROSTATE-CANCER; MOUSE SKIN; VITAMIN-A	The divergent response and the molecular mechanisms underlying the anti-cancer effects of retinoid X receptor (RXR) ligand (rexinoid) therapy are poorly understood. This study demonstrates that ligand-activated RXR homodimer facilitated G(1) arrest by up-regulation of p21 in vitro and in vivo but failed to induce G1 arrest when p21 expression was blocked by p21 small interfering RNA. RXR ligand-dependent p21 up-regulation was transcriptionally controlled through the direct binding of RXR homodimers to two consecutive retinoid X response elements in the p21 promoter. Structural overlap of a retinoic acid response element with these retinoid X response elements led to a high affinity binding of retinoic acid receptor/RXR heterodimer to the retinoic acid response element, resulting in the prevention of RXR ligand-mediated p21 transactivation. These data show that p21 is a potential and novel molecular target for RXR ligand-mediated anti-cancer therapy and that the expression level of retinoic acid receptor and RXR in tumors may be crucial to induce p21-mediated cell growth arrest in RXR ligand therapy.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tanaka, T (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med, 1825 Herman Pressler,Rm 537C, Houston, TX 77030 USA.	Takemi.Tanaka@uth.tmc.edu			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 2005, CLIN LUNG CANCER, V7, P17, DOI 10.1016/S1525-7304(11)70385-0; Balasubramanian S, 2004, CARCINOGENESIS, V25, P1377, DOI 10.1093/carcin/bgh122; Barger PM, 1997, J BIOL CHEM, V272, P2722, DOI 10.1074/jbc.272.5.2722; Cheng SX, 2001, ARCH DERMATOL, V137, P649; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; Didierjean L, 1996, J INVEST DERMATOL, V107, P714, DOI 10.1111/1523-1747.ep12365603; Disdier B, 2000, SKIN PHARMACOL APPL, V13, P9, DOI 10.1159/000029904; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Friedrich M, 2002, HISTOCHEM J, V34, P35, DOI 10.1023/A:1021343825552; Geisler HE, 2001, CANCER-AM CANCER SOC, V92, P781, DOI 10.1002/1097-0142(20010815)92:4<781::AID-CNCR1383>3.0.CO;2-P; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Huang JP, 2002, CANCER RES, V62, P4812; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LANCILLOTTI F, 1992, CANCER RES, V52, P6144; Lawrence JA, 1998, CANCER EPIDEM BIOMAR, V7, P29; LEE MO, 1995, MOL CELL BIOL, V15, P4194; Li M, 2001, DEVELOPMENT, V128, P675; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Mao GE, 2004, CANCER EPIDEM BIOMAR, V13, P383; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Naka K, 1997, DIFFERENTIATION, V61, P313, DOI 10.1046/j.1432-0436.1997.6150313.x; Rose SL, 2003, CLIN CANCER RES, V9, P1028; Schondorf T, 2004, PATHOBIOLOGY, V71, P217, DOI 10.1159/000078676; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wan HS, 1998, J BIOL CHEM, V273, P26915, DOI 10.1074/jbc.273.41.26915; Weinberg WC, 1999, CANCER RES, V59, P2050; Wu KD, 2002, CANCER RES, V62, P6376; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	43	54	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29987	29997		10.1074/jbc.M701700200	http://dx.doi.org/10.1074/jbc.M701700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17656367	hybrid			2022-12-27	WOS:000249981200028
J	Vong, L; D'Acquisto, F; Pederzoli-Ribeil, M; Lavagno, L; Flower, RJ; Witko-Sarsat, R; Perretti, M				Vong, Linda; D'Acquisto, Fulvio; Pederzoli-Ribeil, Magali; Lavagno, Luisa; Flower, Roderick J.; Witko-Sarsat, Ronique; Perretti, Mauro			Annexin 1 cleavage in activated neutrophils - A pivotal role for proteinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; LAVAGE FLUID; LIPOCORTIN 1; DEGRADATION; PHOSPHORYLATION; DIFFERENTIATION; EXPRESSION; MECHANISM; ELASTASE; GRANULES	Annexin 1 is an anti-inflammatory protein that plays a key role in innate immunity by modulating the activation of several types of cells, including neutrophils. Here we have developed a cleavage assay using tagged annexin 1 and observed marked activity in the membrane fraction of activated neutrophils. A combination of inhibitors, transfected cells, and proteomic analyses allowed us to identify proteinase 3 as the main enzyme responsible for this cleavage in the N terminus region of the protein, at least in the context of neutrophil activation. Because annexin 1 is an important endogenous anti-inflammatory mediator, blocking its cleavage by proteinase 3 would augment its homeostatic pro-resolving actions and could represent an opportunity for innovative anti-inflammatory drug discovery.	Barts & London, William Harvey Res Inst, London EC1M 6BQ, England; INSERM, U845, F-75015 Paris, France; Univ Paris 05, Necker Hosp, F-75015 Paris, France	University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Perretti, M (corresponding author), Barts & London, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	M.Perretti@qmul.ac.uk	D'Acquisto, Fulvio/E-7204-2018; Witko-Sarsat, Veronique/L-9714-2017	D'Acquisto, Fulvio/0000-0002-4513-1608; Witko-Sarsat, Veronique/0000-0002-5296-9601	Arthritis Research UK [15755] Funding Source: Medline; British Heart Foundation [PG/06/153/22042] Funding Source: Medline; Medical Research Council [G0400327] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400327] Funding Source: UKRI	Arthritis Research UK(Versus Arthritis); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Dublet B, 2005, J BIOL CHEM, V280, P30242, DOI 10.1074/jbc.M414609200; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hajjar E, 2006, J MED CHEM, V49, P1248, DOI 10.1021/jm051018t; Harper L, 2000, J PATHOL, V190, P349, DOI 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A; HUANG KS, 1987, J BIOL CHEM, V262, P7639; Korkmaz B, 2007, J BIOL CHEM, V282, P1989, DOI 10.1074/jbc.M608700200; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; Mulla A, 2004, CLIN ENDOCRINOL, V60, P107, DOI 10.1111/j.1365-2265.2004.01936.x; Pederzoli M, 2005, J IMMUNOL, V174, P6381, DOI 10.4049/jimmunol.174.10.6381; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; Perretti M, 2004, J LEUKOCYTE BIOL, V76, P25, DOI 10.1189/jlb.1103552; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Rescher U, 2006, BBA-MOL CELL RES, V1763, P1320, DOI 10.1016/j.bbamcr.2006.08.041; Rosales JL, 1997, J IMMUNOL, V159, P6195; Schreiber A, 2003, J AM SOC NEPHROL, V14, P68, DOI 10.1097/01.ASN.0000040751.83734.D1; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; van der Geld YM, 2001, J LEUKOCYTE BIOL, V69, P177; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Vishwanatha JK, 1998, CLIN CANCER RES, V4, P2559; Wiesner O, 2005, FEBS LETT, V579, P5305, DOI 10.1016/j.febslet.2005.08.056; Witko-Sarsat V, 1999, BLOOD, V94, P2487, DOI 10.1182/blood.V94.7.2487.419k07_2487_2496; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Witko-Sarsat V, 1999, J AM SOC NEPHROL, V10, P1224; Witko-Sarsat V, 2002, J BIOL CHEM, V277, P47338, DOI 10.1074/jbc.M202789200	35	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29998	30004		10.1074/jbc.M702876200	http://dx.doi.org/10.1074/jbc.M702876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681950	Green Accepted, hybrid			2022-12-27	WOS:000249981200029
J	Hakansson, AP; Smith, AW				Hakansson, Anders P.; Smith, Alexander W.			Enzymatic characterization of dihydrolipoamide dehydrogenase from Streptococcus pneumoniae harboring its own substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEPENDENT TRANSPORT; REFINED CRYSTAL-STRUCTURE; COMPLETE GENOME SEQUENCE; LIPOIC ACID METABOLISM; LIPOAMIDE DEHYDROGENASE; ESCHERICHIA-COLI; PYRUVATE-DEHYDROGENASE; AZOTOBACTER-VINELANDII; MOLECULAR-CLONING; IDENTIFICATION	This study describes the enzymatic characterization of dihydrolipoamide dehydrogenase (DLDH) from Streptococcus pneumoniae and is the first characterization of a DLDH that carries its own substrate (a lipoic acid covalently attached to a lipoyl protein domain) within its own sequence. Full-length recombinant DLDH (rDLDH) was expressed and compared with enzyme expressed in the absence of lipoic acid (rDLDH(-LA)) or with enzyme lacking the first 112 amino acids constituting the lipoyl protein domain (rDLDH(-LIPOYL)). All three proteins contained 1 mol of FAD/mol of protein, had a higher activity for the conversion of NAD(+) to NADH than for the reaction in the reverse direction, and were unable to use NADP(+) and NADPH as substrates. The enzymes had similar substrate specificities, with the K-m for NAD(+) being similar to 20 times higher than that for dihydrolipoamide. The kinetic pattern suggested a Ping Pong Bi Bi mechanism, which was verified by product inhibition studies. The protein expressed without lipoic acid was indistinguishable from the wild-type protein in all analyses. On the other hand, the protein without a lipoyl protein domain had a 2-3-fold higher turnover number, a lower K-I for NADH, and a higher K-I for lipoamide compared with the other two enzymes. The results suggest that the lipoyl protein domain (but not lipoic acid alone) plays a regulatory role in the enzymatic characteristics of pneumococcal DLDH.	SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA; New York State Ctr Excellence Bioinformat & Life, Buffalo, NY 14203 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Alabama System; University of Alabama Birmingham	Hakansson, AP (corresponding author), SUNY Buffalo, Dept Microbiol & Immunol, 145 Biomed Res Bldg,3435 Main St, Buffalo, NY 14214 USA.	andersh@buffalo.edu	Hakansson, Anders/H-8190-2014; Hakansson, Anders P/AAX-1225-2020	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009	NHLBI NIH HHS [HL54818] Funding Source: Medline; NIAID NIH HHS [AI07051, AI21548, T32 AI007051] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021548, T32AI007051, R56AI021548] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; Argyrou A, 2001, BIOCHEMISTRY-US, V40, P11353, DOI 10.1021/bi010575o; BRINGAS R, 1995, PROTEINS, V21, P303, DOI 10.1002/prot.340210404; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DANSON MJ, 1988, BIOCHEM SOC T, V16, P87, DOI 10.1042/bst0160087; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; delaSierra IL, 1997, J MOL BIOL, V269, P129, DOI 10.1006/jmbi.1997.1009; DIETRICHS D, 1990, J BACTERIOL, V172, P243, DOI 10.1128/JB.172.1.243-251.1990; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Jang YJ, 1997, BBA-MOL CELL RES, V1358, P229, DOI 10.1016/S0167-4889(97)00078-5; KRUGER N, 1994, J BACTERIOL, V176, P3614; Marcinkeviciene J, 1997, ARCH BIOCHEM BIOPHYS, V340, P168, DOI 10.1006/abbi.1997.9926; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; NAKAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V267, P249, DOI 10.1016/0005-2728(72)90113-2; OPPERMANN FB, 1991, J BACTERIOL, V173, P757, DOI 10.1128/jb.173.2.757-767.1991; OWEN P, 1980, FEMS MICROBIOL LETT, V7, P345, DOI 10.1111/j.1574-6941.1980.tb01619.x; Palmer JM, 1999, HEPATOLOGY, V30, P21, DOI 10.1002/hep.510300106; PERHAM RN, 1987, BIOCHEM SOC SYMP, P67; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; Raya NE, 1999, BIOTECHNOL APPL BIOC, V29, P113; REED JK, 1973, J BIOL CHEM, V248, P4834; REED LJ, 1958, J BIOL CHEM, V232, P143; RICHARME G, 1989, J BACTERIOL, V171, P6580, DOI 10.1128/jb.171.12.6580-6585.1989; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; RICHARME G, 1987, BIOCHIM BIOPHYS ACTA, V893, P373, DOI 10.1016/0005-2728(87)90058-2; RICHARME G, 1986, EUR J BIOCHEM, V156, P399, DOI 10.1111/j.1432-1033.1986.tb09596.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAHLMAN L, 1989, J BIOL CHEM, V264, P8039; Smith AW, 2002, MOL MICROBIOL, V44, P431, DOI 10.1046/j.1365-2958.2002.02883.x; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; VETTAKKORUMAKANKAV NN, 1992, BIOCHEM CELL BIOL, V70, P656, DOI 10.1139/o92-101; VIENOZINSKIS J, 1990, BIOCHEM J, V269, P101, DOI 10.1042/bj2690101; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55; WREN A, 1966, BIOCHIM BIOPHYS ACTA, V122, P436, DOI 10.1016/0926-6593(66)90036-1; Youn H, 1998, BBA-PROTEIN STRUCT M, V1388, P405, DOI 10.1016/S0167-4838(98)00200-3; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016; Zhu PP, 1996, PROTEIN SCI, V5, P1719, DOI 10.1002/pro.5560050825	47	15	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29521	29530		10.1074/jbc.M703144200	http://dx.doi.org/10.1074/jbc.M703144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690105	hybrid			2022-12-27	WOS:000249788000049
J	Paul, R; Abel, S; Wassmann, P; Beck, A; Heerklotz, H; Jenal, U				Paul, Ralf; Abel, Soren; Wassmann, Paul; Beck, Andreas; Heerklotz, Heiko; Jenal, Urs			Activation of the diguanylate cyclase PleD by phosphorylation-mediated dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL RESPONSE REGULATORS; CAULOBACTER-CRESCENTUS; SIGNAL-TRANSDUCTION; CELL-CYCLE; MIMICS PHOSPHORYLATION; DYNAMIC LOCALIZATION; ALLOSTERIC CONTROL; RECEIVER DOMAIN; DI-GMP; PROTEINS	Diguanylate cyclases (DGCs) are key enzymes of second messenger signaling in bacteria. Their activity is responsible for the condensation of two GTP molecules into the signaling compound cyclic di-GMP. Despite their importance and abundance in bacteria, catalytic and regulatory mechanisms of this class of enzymes are poorly understood. In particular, it is not clear if oligomerization is required for catalysis and if it represents a level for activity control. To address this question we perform in vitro and in vivo analysis of the Caulobacter crescentus diguanylate cyclase PleD. PleD is a member of the response regulator family with two N-terminal receiver domains and a C-terminal diguanylate cyclase output domain. PleD is activated by phosphorylation but the structural changes inflicted upon activation of PleD are unknown. We show that PleD can be specifically activated by beryllium fluoride in vitro, resulting in dimerization and c-di-GMP synthesis. Cross-linking and fractionation experiments demonstrated that the DGC activity of PleD is contained entirely within the dimer fraction, confirming that the dimer represents the enzymatically active state of PleD. In contrast to the catalytic activity, allosteric feedback regulation of PleD is not affected by the activation status of the protein, indicating that activation by dimerization and product inhibition represent independent layers of DGC control. Finally, we present evidence that dimerization also serves to sequester activated PleD to the differentiating Caulobacter cell pole, implicating protein oligomerization in spatial control and providing a molecular explanation for the coupling of PleD activation and subcellular localization.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Jenal, U (corresponding author), Univ Basel, Biozentrum, Kingelbergstr 70, CH-4056 Basel, Switzerland.	urs.jenal@unibas.ch		Wassmann, Paul/0000-0001-7391-1065; Heerklotz, Heiko/0000-0003-4615-7022; Abel, Soren/0000-0002-4041-6989				Aldridge P, 1999, MOL MICROBIOL, V32, P379, DOI 10.1046/j.1365-2958.1999.01358.x; Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Christen B, 2006, J BIOL CHEM, V281, P32015, DOI 10.1074/jbc.M603589200; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Gomelsky M, 2002, TRENDS BIOCHEM SCI, V27, P497, DOI 10.1016/S0968-0004(02)02181-3; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HECHT GB, 1995, J BACTERIOL, V177, P6223, DOI 10.1128/jb.177.21.6223-6229.1995; Heinzel FP, 1997, J IMMUNOL, V158, P4381; Huitema E, 2006, CELL, V124, P1025, DOI 10.1016/j.cell.2006.01.019; HURLEY JH, 2003, SCI STKE, pPE1; Jacobs C, 2001, P NATL ACAD SCI USA, V98, P4095, DOI 10.1073/pnas.051609998; Jenal U, 2006, ANNU REV GENET, V40, P385, DOI 10.1146/annurev.genet.40.110405.090423; Lam H, 2006, CELL, V124, P1011, DOI 10.1016/j.cell.2005.12.040; Levi A, 2006, J BACTERIOL, V188, P5315, DOI 10.1128/JB.01725-05; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Sinha SC, 2007, REV PHYSIOL BIOCH P, V157, P105, DOI 10.1007/112_0603; Toro-Roman A, 2005, PROTEIN SCI, V14, P3077, DOI 10.1110/ps.051722805; Toro-Roman A, 2005, J MOL BIOL, V349, P11, DOI 10.1016/j.jmb.2005.03.059; Ulrich LE, 2005, TRENDS MICROBIOL, V13, P52, DOI 10.1016/j.tim.2004.12.006; Viollier PH, 2002, P NATL ACAD SCI USA, V99, P13831, DOI 10.1073/pnas.182411999; Wassmann P, 2007, STRUCTURE, V15, P915, DOI 10.1016/j.str.2007.06.016; Wemmer DE, 2005, J BACTERIOL, V187, P8229, DOI 10.1128/JB.187.24.8229-8230.2005; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zhang XF, 2006, MOL MICROBIOL, V60, P658, DOI 10.1111/j.1365-2958.2006.05138.x; Zhang ZY, 2006, J AM CHEM SOC, V128, P7015, DOI 10.1021/ja0613714	34	137	143	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29170	29177		10.1074/jbc.M704702200	http://dx.doi.org/10.1074/jbc.M704702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17640875	hybrid			2022-12-27	WOS:000249788000012
J	Yogev, O; Karniely, S; Pines, O				Yogev, Ohad; Karniely, Sharon; Pines, Ophry			Translation-coupled translocation of yeast fumarase into mitochondria in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN IMPORT; ADENYLATE KINASE; COMPLEX; RIBOSOMES; SEQUENCE; CHANNEL; CYTOSOL; TOM40	Fumarase represents proteins that cannot be imported into mitochondria after the termination of translation (post-translationally). Utilizing mitochondrial and cytosolic versions of the tobacco etch virus (TEV) protease, we show that mitochondrially targeted fumarase harboring a TEV protease recognition sequence is efficiently cleaved by the mitochondrial but not by the cytosolic TEV protease. Nonetheless, fumarase was readily cleaved by cytosolic TEV when its import into mitochondria was slowed down by either (i) disrupting the activity of the TOM complex, (ii) lowering the growth temperature, or (iii) reducing the inner membrane electrochemical potential. Accessibility of the fumarase nascent chain to TEV protease under such conditions was prevented by low cycloheximide concentrations, which impede translation. In addition, depletion of the ribosome-associated nascent polypeptide-associated complex (NAC) reduced the fumarase rate of translocation into mitochondria and exposed it to TEV cleavage in the cytosol. These results indicate that cytosolic exposure of the fumarase nascent chain depends on both translocation and translation rates, allowing us to discuss the possibility that import of fumarase into mitochondria occurs while the ribosome is still attached to the nascent chain.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.	ophryp@ekmd.huji.ac.il	Karniely, Sharon/AAY-5499-2020; Karniely, Sharon/AAN-7886-2021; pines, ophry/C-4086-2011	Yogev, Ohad/0000-0001-8216-6386; pines, ophry/0000-0001-7126-2575				ADES IZ, 1980, J BIOL CHEM, V255, P9925; ADES IZ, 1980, J BIOL CHEM, V255, P9918; Angermayr M, 2001, FEBS LETT, V508, P427, DOI 10.1016/S0014-5793(01)03122-2; BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; HARMEY MA, 1977, EUR J BIOCHEM, V81, P533, DOI 10.1111/j.1432-1033.1977.tb11979.x; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Karniely S, 2006, J MOL BIOL, V358, P396, DOI 10.1016/j.jmb.2006.02.023; KARNIELY S, 2006, THESIS HEBREW U JERU; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KELLEMS RE, 1974, J BIOL CHEM, V249, P3297; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Luk E, 2005, J BIOL CHEM, V280, P22715, DOI 10.1074/jbc.M504257200; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; Regev-Rudzki N, 2005, MOL BIOL CELL, V16, P4163, DOI 10.1091/mbc.e04-11-1028; Sagot I, 1999, FEBS LETT, V447, P53, DOI 10.1016/S0014-5793(99)00258-6; Sass E, 2003, J BIOL CHEM, V278, P45109, DOI 10.1074/jbc.M302344200; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Waizengger T, 2005, EMBO REP, V6, P57, DOI 10.1038/sj.embor.7400318; Weaver T, 1998, J MOL BIOL, V280, P431, DOI 10.1006/jmbi.1998.1862; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200	36	61	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29222	29229		10.1074/jbc.M704201200	http://dx.doi.org/10.1074/jbc.M704201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666392	hybrid			2022-12-27	WOS:000249788000018
J	Chen, CF; Brill, SJ				Chen, Chi-Fu; Brill, Steven J.			Binding and activation of DNA topoisomerase III by the Rmi1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BLOOMS-SYNDROME HELICASE; DOUBLE HOLLIDAY JUNCTION; SYNDROME GENE-PRODUCT; REPLICATION PROTEIN-A; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; OB-FOLD; BRANCH MIGRATION	Rmi1 is a conserved oligonucleotide and oligosaccharide binding-fold protein that is associated with RecQ DNA helicase complexes from humans (BLM-TOP3 alpha) and yeast (Sgs1-Top3). Although human RMI1 stimulates the dissolution activity of BLM-TOP3 alpha, its biochemical function is unknown. Here we examined the role of Rmi1 in the yeast complex. Consistent with the similarity of top3 Delta and rmi1 Delta phenotypes, we find that a stable Top3.Rmi1 complex can be isolated from yeast cells over-expressing these two subunits. Compared with Top3 alone, this complex displays increased superhelical relaxation activity. The isolated Rmi1 subunit also stimulates Top3 activity in reconstitution experiments. In both cases elevated temperatures are required for optimal relaxation unless the substrate contains a single-strand DNA (ssDNA) bubble. Interestingly, Rmi1 binds only weakly to ssDNA on its own, but it stimulates the ssDNA binding activity of Top3 5-fold. Top3 and Rmi1 also cooperate to bind the Sgs1 N terminus and promote its interaction with ssDNA. These results demonstrate that Top3-Rmi1 functions as a complex and suggest that Rmi1 stimulates Top3 by promoting its interaction with ssDNA.	Rutgers State Univ, Dept Biochem & Mol Biol, CABM, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Brill, SJ (corresponding author), Rutgers State Univ, Dept Biochem & Mol Biol, CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.	brill@mbcl.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071268] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM071268, R01 GM071268-08, R01GM072569] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal V, 2003, CURR PROTEIN PEPT SC, V4, P195, DOI 10.2174/1389203033487207; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fricke WM, 2001, J BIOL CHEM, V276, P8848, DOI 10.1074/jbc.M009719200; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1964, SCIENCE, V144, P298, DOI 10.1126/science.144.3616.298; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; HOOK GJ, 1984, MUTAT RES, V131, P223, DOI 10.1016/0167-8817(84)90029-4; Hsieh TS, 2006, J BIOL CHEM, V281, P5640, DOI 10.1074/jbc.M513252200; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM RA, 1992, J BIOL CHEM, V267, P17178; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lindsley JE, 1999, METH MOL B, V94, P187; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Mullen JR, 2005, MOL CELL BIOL, V25, P4476, DOI 10.1128/MCB.25.11.4476-4487.2005; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; Plank JL, 2006, J BIOL CHEM, V281, P17510, DOI 10.1074/jbc.M602933200; Plank JL, 2006, P NATL ACAD SCI USA, V103, P11118, DOI 10.1073/pnas.0604873103; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; Rose MD., 1990, METHODS YEAST GENETI; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yin JH, 2005, EMBO J, V24, P1465, DOI 10.1038/sj.emboj.7600622	46	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28971	28979		10.1074/jbc.M705427200	http://dx.doi.org/10.1074/jbc.M705427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17693398	hybrid, Green Accepted			2022-12-27	WOS:000249642100071
J	Gao, YT; Roman, LJ; Martasek, P; Panda, SP; Ishimura, Y; Masters, BSS				Gao, Ying Tong; Roman, Linda J.; Martasek, Pavel; Panda, Satya Prakash; Ishimura, Yuzuru; Masters, Bettie Sue S.			Oxygen metabolism by endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; TETRAHYDROBIOPTERIN RADICAL FORMATION; HEME-DIOXY REDUCTION; L-ARGININE; SUPEROXIDE GENERATION; NO SYNTHASE; ISOCITRATE DEHYDROGENASE; SUBSTRATE-ANALOGS; ESCHERICHIA-COLI; MECHANISM	Nitric- oxide synthase ( NOS) catalyzes both coupled and uncoupled reactions that generate nitric oxide and reactive oxygen species. Oxygen is often the overlooked substrate, and the oxygen metabolism catalyzed by NOS has been poorly defined. In this paper we focus on the oxygen stoichiometry and effects of substrate/ cofactor binding on the endothelial NOS isoform ( eNOS). In the presence of both L- arginine and tetrahydrobiopterin, eNOS is highly coupled (> 90%), and the measured stoichiometry of O-2/ NADPH is very close to the theoretical value. We report for the first time that the presence of L- arginine stimulates oxygen uptake by eNOS. The fact that nonhydrolyzable L- arginine analogs are not stimulatory indicates that the occurrence of the coupled reaction, rather than the accelerated uncoupled reaction, is responsible for the L- arginine- dependent stimulation. The presence of 5,6,7,8- tetrahydrobiopterin quenched the uncoupled reactions and resulted in much less reactive oxygen species formation, whereas the presence of redox- incompetent 7,8- dihydrobiopterin demonstrates little quenching effect. These results reveal different mechanisms for oxygen metabolism for eNOS as opposed to nNOS and, perhaps, partially explain their functional differences.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Charles Univ Prague, Sch Med 1, Dept Pediat, Prague 12808, Czech Republic; Keio Univ, Sch Med, Dept Biochem & Integrated Biol, Tokyo 1608582, Japan	University of Texas System; University of Texas Health San Antonio; Charles University Prague; Keio University	Masters, BSS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	masters@uthscsa.edu	Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Alp NJ, 2004, ARTERIOSCL THROM VAS, V24, P413, DOI 10.1161/01.ATV.0000110785.96039.f6; Barua RS, 2003, CIRCULATION, V107, P2342, DOI 10.1161/01.CIR.0000066691.52789.BE; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bendall JK, 2005, CIRC RES, V97, P864, DOI 10.1161/01.RES.0000187447.03525.72; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Bevers LM, 2006, HYPERTENSION, V47, P87, DOI 10.1161/01.HYP.0000196735.85398.0e; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Cunningham MA, 1998, BIOPHYS J, V74, pA133; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Dixon LJ, 2005, AM J HYPERTENS, V18, P839, DOI 10.1016/j.amjhyper.2005.01.004; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Gao YT, 2007, J BIOL CHEM, V282, P7921, DOI 10.1074/jbc.M609814200; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2005, METHOD ENZYMOL, V396, P456, DOI 10.1016/S0076-6879(05)96038-2; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Higman DJ, 1996, ARTERIOSCL THROM VAS, V16, P546, DOI 10.1161/01.ATV.16.4.546; Kawashima S, 2004, ARTERIOSCL THROM VAS, V24, P998, DOI 10.1161/01.ATV.0000125114.88079.96; Khoo JP, 2005, CIRCULATION, V111, P2126, DOI 10.1161/01.CIR.0000162470.26840.89; KORTH HG, 1994, J BIOL CHEM, V269, P17776; KWON NS, 1989, J BIOL CHEM, V264, P20496; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2007, J AM CHEM SOC, V129, P6943, DOI 10.1021/ja070683j; Lowe ER, 2005, DRUG METAB DISPOS, V33, P131, DOI 10.1124/dmd.104.001891; Madeddu P, 2005, J HYPERTENS, V23, P1335, DOI 10.1097/01.hjh.0000173513.37740.7c; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MAKINO R, 1972, J BIOCHEM-TOKYO, V72, P655, DOI 10.1093/oxfordjournals.jbchem.a129943; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1991, FASEB J, V5, pA864; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; McMillan K, 1996, METHOD ENZYMOL, V268, P460; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAKAMURA Y, 1989, J BIOL CHEM, V264, P4759; Porasuphatana S, 2003, COMP BIOCHEM PHYS C, V134, P281, DOI 10.1016/S1532-0456(02)00271-5; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, BIOCHEMISTRY-US, V36, P11821, DOI 10.1021/bi963003q; Satoh M, 2005, AM J PHYSIOL-RENAL, V288, pF1144, DOI 10.1152/ajprenal.00221.2004; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Sullivan JC, 2006, CIRC RES, V98, P717, DOI 10.1161/01.RES.0000217594.97174.c2; Takaya T, 2007, ARTERIOSCL THROM VAS, V27, P1632, DOI 10.1161/ATVBAHA.107.142182; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Tierney DL, 1999, J INORG BIOCHEM, V74, P32; Tierney DL, 1999, J INORG BIOCHEM, V74, P314; Tierney DL, 2000, J AM CHEM SOC, V122, P5405, DOI 10.1021/ja993685f; Tierney DL, 1999, BIOCHEMISTRY-US, V38, P3704, DOI 10.1021/bi982904r; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 2003, FREE RADICAL RES, V37, P121, DOI 10.1080/1071576021000040655; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; WANG JL, 1993, J BIOL CHEM, V268, P22255; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wang X, 2007, EUR J PHARMACOL, V555, P48, DOI 10.1016/j.ejphar.2006.10.017; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	77	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28557	28565		10.1074/jbc.M704890200	http://dx.doi.org/10.1074/jbc.M704890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17698846	hybrid			2022-12-27	WOS:000249642100030
J	Ye, XC; Paroo, Z; Liu, QH				Ye, Xuecheng; Paroo, Zain; Liu, Qinghua			Functional anatomy of the Drosophila MicroRNA- generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NUCLEAR EXPORT; MICROPROCESSOR COMPLEX; INTERFERENCE; DICER; MATURATION; PATHWAY; PROTEIN; SIRNA; MIRNA	In Drosophila melanogaster, the multidomain RNase III Dicer-1 (Dcr-1) functions in tandem with the doublestranded (ds) RNA-binding protein Loquacious (Loqs) to catalyze the maturation of microRNAs (miRNAs) from precursor (pre)-miRNAs. Here we dissect the molecular mechanism of pre-miRNA processing by the Dcr-1-Loqs complex. The tandem RNase III (RIII) domains of Dcr-1 form an intramolecular dimer such that one RIII domain cleaves the 3' strand, whereas the other cuts the 5' strand of pre-miRNA. We show that the functional core of Dcr-1 consists of a DUF283 domain, a PAZ domain, and two RIII domains. Dcr-1 preferentially associates with the Loqs-PB splice isoform. Loqs-PB uses the second dsRNA-binding domain to bind pre-miRNA and the third dsRNA-binding domain to interact with Dcr-1. Both domains of Loqs-PB are required for efficient miRNA production by enhancing the affinity of Dcr-1 for pre-miRNA. Thus, our results provide further insights into the functional anatomy of the Drosophila miRNA-generating enzyme.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ye, XC (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd,K3-219, Dallas, TX 75390 USA.	Qinghua.Liu@UTsouthwestern.edu			NIGMS NIH HHS [GM078163] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078163] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Dlakic M, 2006, BIOINFORMATICS, V22, P2711, DOI 10.1093/bioinformatics/btl468; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; LEE Y, 2007, EMBO J, V25, P533; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Liu X, 2006, RNA, V12, P1514, DOI 10.1261/rna.101606; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Park JK, 2007, CURR BIOL, V17, P533, DOI 10.1016/j.cub.2007.01.060; Pham JW, 2005, J BIOL CHEM, V280, P39278, DOI 10.1074/jbc.M509202200; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Tang GL, 2005, TRENDS BIOCHEM SCI, V30, P106, DOI 10.1016/j.tibs.2004.12.007; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017	32	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28373	28378		10.1074/jbc.M705208200	http://dx.doi.org/10.1074/jbc.M705208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666393	hybrid			2022-12-27	WOS:000249642100011
J	Falasca, M; Hughes, WE; Dominguez, V; Sala, G; Fostira, F; Fang, MQ; Cazzolli, R; Shepherd, PR; James, DE; Maffucci, T				Falasca, Marco; Hughes, William E.; Dominguez, Veronica; Sala, Gianluca; Fostira, Florentia; Fang, Michelle Q.; Cazzolli, Rosanna; Shepherd, Peter R.; James, David E.; Maffucci, Tania			The role of phosphoinositide 3-kinase C2 alpha in insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE PTDINS(3)P; STIMULATED GLUCOSE-TRANSPORT; GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; ALPHA-ISOFORM; C2 DOMAIN; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; CELL-MIGRATION	The members of the class II phosphoinositide 3-kinase (PI3K) family can be activated by several stimuli, indicating that these enzymes can regulate many intracellular processes. Nevertheless, to date, there has been no definitive identification of their in vivo product, their mechanism(s) of activation, or their precise intracellular roles. By metabolic labeling, we here identify phosphatidylinositol 3-phosphate as the sole in vivo product of the insulin-dependent activation of PI3K-C2 alpha, confirming the emerging role of such a phosphoinositide in signaling. We demonstrate that activation of PI3K-C2 alpha involves its recruitment to the plasma membrane and that activation is mediated by the GTPase TC10. This is the first report showing a membrane targeting-mediated mechanism of activation for PI3K-C2 alpha and that a small GTP-binding protein can activate a class II PI3K isoform. We also demonstrate that PI3K-C2 alpha contributes to maximal insulin-induced translocation of the glucose transporter GLUT4 to the plasma membrane and subsequent glucose uptake, definitely assessing the role of this enzyme in insulin signaling.	Univ London, Ctr Diabet & Metabol Med, Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, London E1 2AT, England; Garvan Inst Med Res, Phospholipid Biol Grp, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Diabetes & Obesity Res program, Sydney, NSW 2010, Australia; Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand	University of London; Queen Mary University London; Garvan Institute of Medical Research; Garvan Institute of Medical Research; University of Auckland	Falasca, M (corresponding author), Univ London, Ctr Diabet & Metabol Med, Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, 4 Newark St, London E1 2AT, England.	m.falasca@qmul.ac.uk	Sala, Gianluca/C-2056-2017; Fostira, Florentia/Z-5730-2019; Falasca, Marco/S-4020-2016	Sala, Gianluca/0000-0002-4494-915X; James, David/0000-0001-5946-5257; Falasca, Marco/0000-0002-9801-7235; Hughes, William/0000-0002-7149-3987				Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 2001, BIOCHEM SOC T, V29, P535, DOI 10.1042/BST0290535; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chang L, 2007, ENDOCRINOLOGY, V148, P27, DOI 10.1210/en.2006-1167; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Falasca M, 2007, BIOCHEM SOC T, V35, P211, DOI 10.1042/BST0350211; Falasca Marco, 2006, Archives of Physiology and Biochemistry, V112, P274, DOI 10.1080/13813450601094664; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Gaidarov I, 2005, J BIOL CHEM, V280, P40766, DOI 10.1074/jbc.M507731200; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Hodgkinson CP, 2005, DIABETOLOGIA, V48, P1627, DOI 10.1007/s00125-005-1819-y; Inoue M, 2006, MOL BIOL CELL, V17, P2303, DOI 10.1091/mbc.E06-01-0030; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Ishiki M, 2005, J BIOL CHEM, V280, P28792, DOI 10.1074/jbc.M500501200; James DE, 2005, J CLIN INVEST, V115, P219, DOI 10.1172/JCI200524158; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Kawase K, 2006, DEV CELL, V11, P411, DOI 10.1016/j.devcel.2006.07.008; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kong AM, 2006, MOL CELL BIOL, V26, P6065, DOI 10.1128/MCB.00203-06; Koumanov F, 2005, CELL METAB, V2, P179, DOI 10.1016/j.cmet.2005.08.007; Ktori C, 2003, BIOCHEM BIOPH RES CO, V306, P139, DOI 10.1016/S0006-291X(03)00933-1; Li CH, 2004, CELL RES, V14, P480, DOI 10.1038/sj.cr.7290251; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Maffucci T, 2003, MOL ENDOCRINOL, V17, P1568, DOI 10.1210/me.2001-0211; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sindic A, 2001, J BIOL CHEM, V276, P17754, DOI 10.1074/jbc.M006533200; Soos MA, 2001, ARCH BIOCHEM BIOPHYS, V396, P244, DOI 10.1006/abbi.2001.2587; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; van Dam EM, 2005, MOL ENDOCRINOL, V19, P1067, DOI 10.1210/me.2004-0413; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Visnjic D, 2002, FEBS LETT, V529, P268, DOI 10.1016/S0014-5793(02)03357-4; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang Y, 2006, BIOCHEM J, V394, P581, DOI 10.1042/BJ20051471; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	71	118	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28226	28236		10.1074/jbc.M704357200	http://dx.doi.org/10.1074/jbc.M704357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644513	hybrid			2022-12-27	WOS:000249455600072
J	Lichtinger, M; Ingram, R; Hornef, M; Bonifer, C; Rehli, M				Lichtinger, Monika; Ingram, Richard; Hornef, Mathias; Bonifer, Constanze; Rehli, Michael			Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; INTESTINAL EPITHELIAL-CELLS; EXPRESSION; GENE; INITIATION; BINDING; MICE; LIPOPOLYSACCHARIDE; MYELOPOIESIS; ACTIVATION	Human and mouse show markedly different sensitivities toward bacterial endotoxins, and recent evidence suggests that a species-specific regulation of the lipopolysaccharide receptor Toll-like receptor 4 ( Tlr4) may contribute to this phenomenon. To gain further insight into mechanisms of Tlr4 regulation, we conducted a detailed in vivo and in vitro study of the murine Tlr4 gene, including analysis of transcription start site location, transcription factor occupancy, and activities of its proximal regulatory sequences. Our analyses identified a PU. 1-dependent myeloid promoter, which is conserved between humans and mouse. We also identified an additional, distal promoter, located similar to 200 bp upstream of the myeloid-specific promoter, which is a functional target of E-box binding factors. In contrast to humans, where non-myeloid cells utilize both promoters, the distal Tlr4 promoter initiates all Tlr4 transcripts in murine non-myeloid cells, indicating that species-specific differences in TLR4 mRNA regulation may primarily exist in non-myeloid cell types. Interestingly, PU. 1 null murine myeloid progenitor cells predominantly use the distal promoter, and the conditional induction of PU. 1 expression in these cells leads to the rapid switch of transcription initiation to the proximal myeloid promoter. This indicates a direct role for PU. 1 in determining the transcriptional start site and in recruiting the basal transcription machinery to myeloid promoters.	Univ Regensburg, Sch Med, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Univ Clin Freiburg, Dept Med Microbiol & Hygiene, D-79104 Freiburg, Germany; St James Univ Hosp, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England	University of Regensburg; University of Freiburg; Saint James's University Hospital	Rehli, M (corresponding author), Univ Regensburg, Sch Med, Dept Hematol & Oncol, D-93042 Regensburg, Germany.	michael.rehli@klinik.uni-regensburg.de	Bonifer, Constanze/B-3000-2009; Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Hornef, Mathias/0000-0001-6096-9110; Bonifer, Constanze/0000-0002-4267-0825	Biotechnology and Biological Sciences Research Council [BBS/B/07438] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Friedman AD, 2002, INT J HEMATOL, V75, P466, DOI 10.1007/BF02982108; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Huan CM, 2005, J BIOL CHEM, V280, P30225, DOI 10.1074/jbc.M502380200; Kalis C, 2003, EUR J IMMUNOL, V33, P798, DOI 10.1002/eji.200323431; Kiessling S, 2004, J BIOL CHEM, V279, P10304, DOI 10.1074/jbc.M312757200; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mehta A, 2006, GENE DEV, V20, P939, DOI 10.1101/gad.1388706; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Rehli M, 1999, J IMMUNOL, V162, P1559; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Roger T, 2005, BIOCHEM J, V387, P355, DOI 10.1042/BJ20041243; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy MF, 2006, GENES IMMUN, V7, P372, DOI 10.1038/sj.gene.6364309; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 1999, COLD SPRING HARB SYM, V64, P13, DOI 10.1101/sqb.1999.64.13; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; Tagoh H, 2006, METH MOL B, V325, P285; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tsatsanis C, 2006, J IMMUNOL, V176, P1869, DOI 10.4049/jimmunol.176.3.1869; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wolf G, 2006, J AM SOC NEPHROL, V17, P1585, DOI 10.1681/ASN.2005070699; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	37	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26874	26883		10.1074/jbc.M703856200	http://dx.doi.org/10.1074/jbc.M703856200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623651	hybrid			2022-12-27	WOS:000249304900027
J	Longin, S; Zwaenepoel, K; Louis, JV; Dilworth, S; Goris, J; Janssens, V				Longin, Sari; Zwaenepoel, Karen; Louis, Justin V.; Dilworth, Stephen; Goris, Jozef; Janssens, Veerle			Selection of protein phosphatase 2A regulatory Subunits is mediated by the C terminus of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE CARBOXYL METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; SPLICE VARIANT; PP2A; METHYLATION; ASSOCIATION; METHYLESTERASE; IDENTIFICATION; APOPTOSIS	Protein phosphatase 2A (PP2A) is a family of multifunctional serine/threonine phosphatases all composed of a catalytic C, a structural A, and a regulatory B subunit. Assembly of the complex with the appropriate B subunit forms the key to the functional specificity and regulation of PP2A. Emerging evidence suggests a crucial role for methylation and phosphorylation of the PP2A C subunit in this process. In this study, we show that PP2A C subunit methylation was not absolutely required for binding the PR61/B ' and PR72/B '' subunit families, whereas binding of the PR55/B subunit family was determined by methylation and the nature of the C-terminal amino acid side chain. Moreover mutation of the phosphorylatable Tyr(307) or Thr(304) residues differentially affected binding of distinct B subunit family members. Down-regulation of the PP2A methyltransferase LCMT1 by RNA interference gradually reduced the cellular amount of methylated C subunit and induced a dynamic redistribution of the remaining methylated PP2A(C) between different PP2A trimers consistent with their methylation requirements. Persistent knockdown of LCMT1 eventually resulted in specific degradation of the PR55/B subunit and apoptotic cell death. Together these results establish a crucial foundation for understanding PP2A regulatory subunit selection.	Katholieke Univ Leuven, Fac Med, Dept Mol Biol, Prot Phosphorylat & Proteom Lab, B-3000 Louvain, Belgium; Hammersmith Hosp, Imperial Coll Fac Med, Dept Metab Med, London W12 0NN, England	KU Leuven; Imperial College London	Janssens, V (corresponding author), Katholieke Univ Leuven, Fac Med, Dept Mol Biol, Prot Phosphorylat & Proteom Lab, Campus Gasthuisberg O&N1,Herestr 49bus 901, B-3000 Louvain, Belgium.	Janssens@med.kuleuven.be	Janssens, Veerle/I-7059-2016	Janssens, Veerle/0000-0002-6772-8448				Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Evans DRH, 2000, MOL GEN GENET, V264, P425; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Gentry MS, 2005, EUKARYOT CELL, V4, P1029, DOI 10.1128/EC.4.6.1029-1040.2005; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Leulliot N, 2004, J BIOL CHEM, V279, P8351, DOI 10.1074/jbc.M311484200; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Longin S, 2006, ENZYMES, V24, P303, DOI 10.1016/S1874-6047(06)80013-2; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Nunbhakdi-Craig V, 2007, J NEUROCHEM, V101, P959, DOI 10.1111/j.1471-4159.2007.04503.x; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P1080, DOI 10.1093/jnen/63.10.1080; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; XIE HY, 1993, J BIOL CHEM, V268, P13364; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	42	131	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26971	26980		10.1074/jbc.M704059200	http://dx.doi.org/10.1074/jbc.M704059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635907	hybrid			2022-12-27	WOS:000249304900037
J	Ostrowski, SM; Wilkinson, BL; Golde, TE; Landreth, G				Ostrowski, Stephen M.; Wilkinson, Brandy L.; Golde, Todd E.; Landreth, Gary			Statins reduce amyloid-beta production through inhibition of protein Isoprenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; DIET-INDUCED HYPERCHOLESTEROLEMIA; GAMMA-SECRETASE CLEAVAGE; TRANSGENIC MOUSE MODEL; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IN-VITRO; ENDOPLASMIC-RETICULUM; A-BETA; DEPENDENT MECHANISM	Epidemiological evidence suggests that long term treatment with hydroxymethylglutaryl- CoA reductase inhibitors, or statins, decreases the risk for developing Alzheimer disease (AD). However, statin-mediated AD protection cannot be fully explained by reduction of cholesterol levels. In addition to their cholesterol lowering effects, statins have pleiotropic actions and act to lower the concentrations of isoprenoid intermediates, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate. The Rho and Rab family small G-proteins require addition of these isoprenyl moieties at their C termini for normal GTPase function. In neuroblastoma cell lines, treatment with statins inhibits the membrane localization of Rho and Rab proteins at statin doses as low as 200 nM, without affecting cellular cholesterol levels. In addition, we show for the first time that at low, physiologically relevant, doses statins preferentially inhibit the isoprenylation of a subset of GTPases. The amyloid precursor protein (APP) is proteolytically cleaved to generate beta-amyloid ( A beta), which is the major component of senile plaques found in AD. We show that inhibition of protein isoprenylation by statins causes the accumulation of APP within the cell through inhibition of Rab family proteins involved in vesicular trafficking. Moreover, inhibition of Rho family protein function reduces levels of APP C-terminal fragments due to enhanced lysosomal dependent degradation. Statin inhibition of protein isoprenylation results in decreased A beta secretion. In summary, we show that statins selectively inhibit GTPase isoprenylation at clinically relevant doses, leading to reduced A beta production in an isoprenoid-dependent manner. These studies provide insight into the mechanisms by which statins may reduce AD pathogenesis.	Case Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	Case Western Reserve University; Case Western Reserve University; Mayo Clinic	Landreth, G (corresponding author), Case Sch Med, 10900 Euclid Ave,Rm E504, Cleveland, OH 44106 USA.	gel2@case.edu			NIGMS NIH HHS [T32 GM 07250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bellosta S, 2000, DIABETES CARE, V23, pB72; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1980, J LIPID RES, V21, P505; Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Desire L, 2005, J BIOL CHEM, V280, P37516, DOI 10.1074/jbc.M507913200; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; ENDO A, 1992, J LIPID RES, V33, P1569; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; George AJ, 2004, NEUROBIOL DIS, V16, P124, DOI 10.1016/j.nbd.2004.01.009; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Khvotchev M, 2004, J BIOL CHEM, V279, P47101, DOI 10.1074/jbc.M408474200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; KNOPS J, 1992, J BIOL CHEM, V267, P16022; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kouchi Z, 1998, EUR J BIOCHEM, V258, P291, DOI 10.1046/j.1432-1327.1998.2580291.x; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Larijani B, 2003, J BIOL CHEM, V278, P46798, DOI 10.1074/jbc.M307799200; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PEFRINI S, 2005, PLOS MED, V2, pE18; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; Rockwood K, 2003, NEUROL RES, V25, P601, DOI 10.1179/016164103101202039; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stewart R, 2007, ARCH NEUROL-CHICAGO, V64, P103, DOI 10.1001/archneur.64.1.103; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; TSUZUKI K, 1994, BRAIN RES, V659, P213, DOI 10.1016/0006-8993(94)90881-8; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wood WG, 2005, MOL NEUROBIOL, V31, P185, DOI 10.1385/MN:31:1-3:185; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zamvil SS, 2002, NEUROLOGY, V59, P970, DOI 10.1212/WNL.59.7.970; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	75	139	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26832	26844		10.1074/jbc.M702640200	http://dx.doi.org/10.1074/jbc.M702640200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646164	hybrid			2022-12-27	WOS:000249304900023
J	Yuan, K; Hu, H; Guo, Z; Fu, G; Shaw, AP; Hu, R; Yao, X				Yuan, Kai; Hu, Haiying; Guo, Zhen; Fu, Guosheng; Shaw, Andrew P.; Hu, Renming; Yao, Xuebiao			Phospho-regulation of HsCdc14A by polo-like kinase 1 is essential for mitotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC14A PHOSPHATASE; CHROMOSOME SEGREGATION; SPINDLE; PHOSPHORYLATION; LOCALIZATION; MICROTUBULES; KINETOCHORES	Chromosome segregation in mitosis is orchestrated by dynamic interactions between spindle microtubules and centromeres, which in turn are governed by protein kinase- and phosphatase-signaling cascades. Previous studies showed that overexpression of human phosphatase HsCdc14A, an antagonist of cyclin-dependent kinase 1, affects several aspects of cell division. However, the molecular mechanism underlying HsCdc14A regulation in mitosis has remained elusive. Here we show that HsCdc14A activity is regulated by an auto-inhibitory mechanism via its intra-molecular association. Our biochemical study demonstrated that Polo-like kinase 1 (PLK1) interacts with and phosphorylates HsCdc14A. This phosphorylation partially releases the auto-inhibition of HsCdc14A judged by its phosphatase activity in vitro. To examine the functional relevance of such phospho-regulation of HsCdc14A in vivo, a phospho-mimicking mutant of HsCdc14A was expressed in HeLa cells. Importantly, overexpression of the phospho-mimicking mutants caused aberrant chromosome alignment with a prometaphase delay, suggesting the temporal regulation of HsCdc14A activity is critical for orchestrating mitotic events. Given the fact that HsCdc14A forms an intra-molecular association and PLK1-mediated phospho-regulation promotes HsCdc14A phosphatase activity, we propose that PLK1-HsCdc14A interaction provides a temporal regulation of HsCdc14A in chromosome segregation during mitosis.	Fudan Univ, Sch Med, Hua Shan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China; Hefei Natl Lab, Div Cellular Dynam, Hefei 230027, Peoples R China; Chinese Univ Sci & Technol, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA	Fudan University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine	Hu, R (corresponding author), Fudan Univ, Sch Med, Hua Shan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China.	renminghu@fudan.edu.cn; yaoxb@ustc.edu.cn	Yuan, Kai/A-1294-2009; Yuan, Kai/ABH-2688-2020	Yuan, Kai/0000-0001-7002-5703; 	NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89019, CA 92080] Funding Source: Medline; NIDDK NIH HHS [DK 56292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Cho HP, 2005, MOL CELL BIOL, V25, P4541, DOI 10.1128/MCB.25.11.4541-4551.2005; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Stegmeier F, 2004, ANNU REV GENET, V38, P203, DOI 10.1146/annurev.genet.38.072902.093051; Trautmann S, 2002, CURR BIOL, V12, pR733, DOI 10.1016/S0960-9822(02)01250-2; Trinkle-Mulcahy L, 2006, CURR OPIN CELL BIOL, V18, P623, DOI 10.1016/j.ceb.2006.09.001; Vazquez-Novelle MD, 2005, J BIOL CHEM, V280, P29144, DOI 10.1074/jbc.M413328200; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.E03-02-0095; Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200; Xue Y, 2005, NUCLEIC ACIDS RES, V33, pW184, DOI 10.1093/nar/gki393; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Yao XB, 1996, AM J PHYSIOL-CELL PH, V271, pC61, DOI 10.1152/ajpcell.1996.271.1.C61; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	19	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27414	27423		10.1074/jbc.M703555200	http://dx.doi.org/10.1074/jbc.M703555200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623655	hybrid			2022-12-27	WOS:000249304900083
J	Zimnicka, AM; Maryon, EB; Kaplan, JH				Zimnicka, Adriana M.; Maryon, Edward B.; Kaplan, Jack H.			Human copper transporter hCTR1 mediates basolateral uptake of copper into enterocytes - Implications for copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; CTR1; LOCALIZATION; EXPRESSION; PROTEIN; IRON; MEMBRANE; COMPLEMENTATION	Copper is essential for human growth and survival. Enterocytes mediate the absorption of dietary copper from the intestinal lumen into blood as well as utilizing copper for their biosynthetic needs. Currently, the pathways for copper entry into enterocytes remain poorly understood. We demonstrate that the basolateral copper uptake into intestinal cells greatly exceeds the apical uptake. The basolateral but not apical transport is mediated by the high affinity copper transporter hCTR1. This unanticipated conclusion is supported by cell surface biotinylation and confocal microscopy of endogenous hCTR1 in Caco2 cells as well as copper influx measurements that show saturable high affinity uptake at the basolateral but not the apical membrane. Basolateral localization of hCTR1 and polarized copper uptake are also conserved in T84 cells, models for intestinal crypt cells. The lateral localization of hCTR1 seen in intestinal cell lines is recapitulated in immunohistochemical staining of mouse intestinal sections. Biochemical and functional assays reveal the basolateral localization of hCTR1 also in renal Madin-Darby canine kidney cells and opossum kidney cells. Overexpression of hCTR1 in Madin-Darby canine kidney cells results in both apical and basolateral delivery of the overexpressed protein and greatly enhanced copper uptake at both cell surfaces. We propose a model of intestinal copper uptake in which basolateral hCTR1 plays a key role in the physiologically important delivery of copper from blood to intracellular proteins, whereas its role in the initial apical uptake of dietary copper is indirect.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Mol Biol Res Bldg MC 669,900 S Ashland Ave, Chicago, IL 60607 USA.	kaplanj@uic.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM067166] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; Balamurugan K, 2007, EMBO J, V26, P1035, DOI 10.1038/sj.emboj.7601543; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Eisses JF, 2005, J BIOL CHEM, V280, P37159, DOI 10.1074/jbc.M508822200; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hardman B, 2006, PLACENTA, V27, P968, DOI 10.1016/j.placenta.2005.10.011; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kuo YM, 2006, J NUTR, V136, P21, DOI 10.1093/jn/136.1.21; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Laughery MD, 2007, AM J PHYSIOL-RENAL, V292, pF1718, DOI 10.1152/ajprenal.00360.2006; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Maryon EB, 2007, J BIOL CHEM, V282, P20376, DOI 10.1074/jbc.M701806200; Nose Y, 2006, CELL METAB, V4, P235, DOI 10.1016/j.cmet.2006.08.009; Picard V, 2000, J BIOL CHEM, V275, P35738, DOI 10.1074/jbc.M005387200; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Sharp PA, 2003, INT J BIOCHEM CELL B, V35, P288, DOI 10.1016/S1357-2725(02)00134-6; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Tennant J, 2002, FEBS LETT, V527, P239, DOI 10.1016/S0014-5793(02)03253-2; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	32	79	82	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26471	10.1074/jbc.M702653200	http://dx.doi.org/10.1074/jbc.M702653200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17627945	hybrid			2022-12-27	WOS:000249239600052
J	Malnou, CE; Salem, T; Brockly, F; Wodrich, H; Piechaczyk, M; Jariel-Encontre, I				Malnou, Cecile E.; Salem, Tamara; Brockly, Frederique; Wodrich, Harald; Piechaczyk, Marc; Jariel-Encontre, Isabelle			Heterodimerization with jun family members regulates c-fos nucleocytoplasmic traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED NUCLEAR IMPORT; CELL-CYCLE PROGRESSION; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; G0-TO-G1 TRANSITION; PROTO-ONCOPROTEIN; MOUSE FIBROBLASTS; LEUCINE-ZIPPER; PROTEINS; AP-1	c-Fos proto-oncoprotein forms AP-1 transcription complexes with heterodimerization partners such as c-Jun, JunB, and JunD. Thereby, it controls essential cell functions and exerts tumorigenic actions. The dynamics of c-Fos intracellular distribution is poorly understood. Hence, we have combined genetic, cell biology, and microscopic approaches to investigate this issue. In addition to a previously characterized basic nuclear localization signal (NLS) located within the central DNA-binding domain, we identified a second NLS within the c-Fos N-terminal region. This NLS is non-classic and its activity depends on transportin 1 in vivo. Under conditions of prominent nuclear localization, c-Fos can undergo nucleocytoplasmic shuttling through an active Crm-1 exportin-independent mechanism. Dimerization with the Jun proteins inhibits c-Fos nuclear exit. The strongest effect is observed with c-Jun probably in accordance with the relative stabilities of the different c-Fos: Jun dimers. Retrotransport inhibition is not caused by binding of dimers to DNA and, therefore, is not induced by indirect effects linked to activation of c-Fos target genes. Monomeric, but not dimeric, Jun proteins also shuttle actively. Thus, our work unveils a novel regulation operating on AP-1 by demonstrating that dimerization is crucial, not only for active transcription complex formation, but also for keeping them in the compartment where they exert their transcriptional function.	CNRS, Inst Genet Mol Montpellier, UMR 5535, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Jariel-Encontre, I (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, 1919 Route Mende, F-34293 Montpellier, France.	isabelle.jariel@igmm.cnrs.fr	Wodrich, Harald/P-1777-2019; PIECHACZYK, Marc/E-7896-2013; MALNOU, Cécile/O-9970-2019; MALNOU, Cécile E/K-1569-2014	Wodrich, Harald/0000-0002-4764-1708; PIECHACZYK, Marc/0000-0003-1367-2597; MALNOU, Cécile/0000-0002-1223-0247; MALNOU, Cécile E/0000-0002-1223-0247				Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Arnold M, 2006, J BIOL CHEM, V281, P5492, DOI 10.1074/jbc.M513281200; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BASBOUS J, 2007, IN PRESS BIOCHIMIE P; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Bussolino DF, 2001, FASEB J, V15, P556; Campos MAS, 1999, CELL BIOL INT, V23, P81, DOI 10.1006/cbir.1998.0323; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.e03-09-0705; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JARIELENCONTRE I, 2007, IN PRESS TARGETED PR; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Mason JM, 2006, P NATL ACAD SCI USA, V103, P8989, DOI 10.1073/pnas.0509880103; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Sambrook J, 1989, MOL CLONNING; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; TRATNER I, 1991, ONCOGENE, V6, P2049; Verhagen J, 2006, J VIROL, V80, P10021, DOI 10.1128/JVI.01322-06; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; YOUNG JS, 1979, SCI DIG, V1, P11	56	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31046	31059		10.1074/jbc.M702833200	http://dx.doi.org/10.1074/jbc.M702833200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17681951	Green Published, hybrid			2022-12-27	WOS:000250136300072
J	Butler, MP; Hanly, JA; Moynagh, PN				Butler, Marion P.; Hanly, Jennifer A.; Moynagh, Paul N.			Kinase-active interleukin-1 receptor-associated kinases promote polyubiquitination and degradation of the Pellino family - Direct evidence for pellino proteins being ubiquitin-protein isopeptide ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; MICE LACKING; IRAK FAMILY; IL-1; MEMBER; ACTIVATION; COMPLEX; TRAF6; EXPRESSION; REGULATOR	Members of the Pellino family are interleukin- 1 receptor- associated kinase ( IRAK)- interacting proteins that possess RINGlike domains. The presence of these domains led to the suggestion that Pellino proteins are ubiquitin- protein isopeptide ligases ( E3). However, no conclusive data currently exist to prove this proposal. This study provides the first direct evidence that Pellino proteins possess E3 activity. Recombinant forms of Pellino1 and Pellino2 and both spliced variants of Pellino3 are shown in an in vitro ubiquitination assay to be E3 ligases that catalyze Lys(63)- linked polyubiquitination, with Pellino3 exhibiting the greatest ligase activity. Whereas the Pellino proteins cause polyubiquitination of IRAK- 1, we also show that kinaseactive members of the IRAK family ( IRAK- 1 and IRAK- 4) promote reciprocal polyubiquitination of the Pellino proteins and that this is associated with IRAK- induced degradation of the Pellino family. In contrast, IRAK- 2 ( which lacks a functional kinase domain) and kinase- dead forms of IRAK- 1 and IRAK- 4 fail to degrade the Pellino proteins. We show that these kinaseinactive IRAK proteins can associate with Pellino proteins, thus excluding the possibility that their inability to regulate Pellino degradation is due to lack of association with the Pellino proteins. The physiological relevance of IRAK- induced degradation of Pellino proteins is confirmed by the demonstration that lipopolysaccharide causes degradation of endogenous forms of Pellino3 in peripheral blood mononuclear cells. In summary, this study not only demonstrates Pellino proteins to be E3 ligases that can catalyze Lys(63)- linked polyubiquitination but also shows bidirectional signaling between the IRAK and Pellino families and highlights a novel function for IRAK kinase activity.	Natl Univ Ireland, Inst Immunol, Maynooth, Kildare, Ireland	Maynooth University	Moynagh, PN (corresponding author), Natl Univ Ireland, Inst Immunol, Maynooth, Kildare, Ireland.	Paul.Moynagh@nuim.ie		Moynagh, Paul/0000-0002-4139-3061; Hanly, Jennifer/0000-0002-1553-7228				Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fukushima T, 2007, P NATL ACAD SCI USA, V104, P6371, DOI 10.1073/pnas.0700548104; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Koziczak-Holbro M, 2007, J BIOL CHEM, V282, P13552, DOI 10.1074/jbc.M700548200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thomas JA, 1999, J IMMUNOL, V163, P978; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075	29	64	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29729	29737		10.1074/jbc.M704558200	http://dx.doi.org/10.1074/jbc.M704558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17675297	hybrid			2022-12-27	WOS:000249981200001
J	Meng, XW; Lee, SH; Dai, HM; Loegering, D; Yu, C; Flatten, K; Schneider, P; Dai, NT; Kumar, SK; Smith, BD; Karp, JE; Adjei, AA; Kaufmann, SH				Meng, Xue Wei; Lee, Sun-Hee; Dai, Haiming; Loegering, David; Yu, Chunrong; Flatten, Karen; Schneider, Paula; Dai, Nga T.; Kumar, Shaji K.; Smith, B. Douglas; Karp, Judith E.; Adjei, Alex A.; Kaufmann, Scott H.			MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR INHIBITOR; CYTOCHROME-C RELEASE; X-LINKED INHIBITOR; N-TERMINAL KINASE; CANCER-CELLS; TUMOR-CELLS; MOLECULAR DETERMINANTS; CLINICAL-TRIALS; TARGETING DEATH; DOWN-REGULATION	Previous studies have suggested that Mcl- 1, an antiapoptotic Bcl- 2 homolog that does not exhibit appreciable affinity for the caspase 8- generated C- terminal Bid fragment ( tBid), diminishes sensitivity to tumor necrosis factor- alpha related apoptosis- inducing ligand ( TRAIL). This study was performed to determine the mechanism by which Mcl- 1 confers TRAIL resistance and to evaluate methods for overcoming this resistance. Affinity purification/ immunoblotting assays using K562 human leukemia cells, which contain Mcl- 1 and Bcl- x(L) as the predominant antiapoptotic Bcl- 2 homologs, demonstrated that TRAIL treatment resulted in binding of tBid to Bcl- xL but not Mcl- 1. In contrast, TRAIL caused increased binding between Mcl- 1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-( N-alpha- acetylisoleucylglutamylthreonyl) asparticacid( O- methylester)- fluoromethylketone ( IETD( OMe)- fmk) or the c- Jun N- terminal kinase inhibitor SP600125. In addition, TRAIL caused increased binding of Bim and Puma to Mcl- 1 that was inhibited by IETD( OMe)- fmk but not SP600125. Further experiments demonstrated that down- regulation of Mcl- 1 by short hairpin RNA or the kinase inhibitor sorafenib increased TRAIL- induced Bak activation and death ligand- induced apoptosis in a wide variety of neoplastic cell lines as well as clinical acute myelogenous leukemia specimens. Collectively, these observations not only suggest a model in which Mcl- 1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity.	Mayo Clin, Div Oncol Res, Dept Oncol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Div Med Oncol, Dept Oncol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Div Hematol, Coll Med, Rochester, MN 55905 USA; Johns Hopkins Univ Hosp, Sidney Kimmel Canc Ctr, Adult Leukemia Program, Baltimore, MD 21287 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Dept Oncol, Coll Med, Guggenheim 1342 C,200 1rst St,SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu	Kumar, Shaji K/A-9853-2008	Kumar, Shaji K/0000-0001-5392-9284; Kaufmann, Scott/0000-0002-4900-7145; Dai, Haiming/0000-0002-0484-7407	NCI NIH HHS [R01 CA69008, R01 CA069008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Arnt CR, 2003, CELL DEATH DIFFER, V10, P1118, DOI 10.1038/sj.cdd.4401294; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Burns TF, 2001, J BIOL CHEM, V276, P37879; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078-0432.CCR-04-2658; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Jurewicz A, 2006, GLIA, V53, P158, DOI 10.1002/glia.20249; Kandasamy K, 2003, CANCER RES, V63, P1712; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; Kaufmann SH, 2005, LEUKEMIA, V19, P2195, DOI 10.1038/sj.leu.2403946; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lamothe B, 2002, J INTERF CYTOK RES, V22, P269, DOI 10.1089/107999002753536248; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MCCULLOCH EA, 1983, BLOOD, V62, P1; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Meng XW, 2006, CURR OPIN CELL BIOL, V18, P668, DOI 10.1016/j.ceb.2006.10.008; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; Puduvalli VK, 2005, APOPTOSIS, V10, P233, DOI 10.1007/s10495-005-6078-3; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Ravi R, 2004, CANCER RES, V64, P9105, DOI 10.1158/0008-5472.CAN-04-2488; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; ROSATO RR, 2007, IN PRESS CANC RES, V67; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Szczepankiewicz BG, 2006, J MED CHEM, V49, P3563, DOI 10.1021/jm060199b; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tong FK, 2006, CYTOM PART B-CLIN CY, V70B, P107, DOI 10.1002/cyto.b.20092; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wirth T, 2005, CANCER RES, V65, P7393, DOI 10.1158/0008-5472.CAN-04-3664; Wright JJ, 2005, ONCOLOGY-NY, V19, P499; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang XD, 2001, CANCER RES, V61, P7339	98	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29831	29846		10.1074/jbc.M706110200	http://dx.doi.org/10.1074/jbc.M706110200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698840	hybrid			2022-12-27	WOS:000249981200012
J	Gupta, SK; Guo, X; Durkin, SS; Fryrear, KF; Ward, MD; Semmes, OJ				Gupta, Saurabh K.; Guo, Xin; Durkin, Sarah S.; Fryrear, Kimberly F.; Ward, Michael D.; Semmes, O. John			Human T-cell leukemia virus type 1 tax oncoprotein prevents DNA damage-induced chromatin egress of hyperphosphorylated Chk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I TAX; PROTEIN-KINASE; GENETIC INSTABILITY; TRANSACTIVATOR TAX; CYCLE CHECKPOINTS; MUTATION ANALYSIS; MAMMALIAN-CELLS; PHOSPHORYLATION; ACTIVATION; P53	De novo expression of human T-cell leukemia virus type 1 Tax results in cellular genomic instability. We demonstrated previously that Tax associates with the cell cycle check point regulator Chk2 and proposed that the inappropriate activation of Chk2 provides a model for Tax-induced loss of genetic integrity (Haoudi, A., Daniels, R. C., Wong, E., Kupfer, G., and Semmes, O. J. (2003) J. Biol. Chem. 278, 37736-37744). Here we provide an explanation for how Tax induces some Chk2 activities but represses others. We show that Tax interaction with Chk2 generates two activation signals in Chk2, oligomerization and autophosphorylation. However, egress of Chk2 from chromatin, normally observed in response to ionizing radiation, was repressed in Tax-expressing cells. Analysis of chromatin-bound Chk2 from Tax-expressing cells revealed phosphorylation at Thr(378), Ser(379), Thr(383), Thr(387), and Thr(389). In contrast, chromatin-bound Chk2 in the absence of Tax was phosphorylated at Thr(383) and Thr(387) in response to ionizing radiation. We further establish that Tax binds to the kinase domain of Chk2. Confocal microscopy revealed a redistribution of Chk2 to colocalize with Tax in Tax speckled structures, which we have shown previously to coincide with interchromatin granules. We propose that Tax binding via the Chk2 kinase domain sequesters phosphorylated Chk2 within chromatin, thus hindering chromatin egress and appropriate response to DNA damage.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23507 USA	Eastern Virginia Medical School	Semmes, OJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Lewis Hall,700 W Olney Rd, Norfolk, VA 23507 USA.	Semmesoj@evms.edu	Semmes, Oliver/GQA-5179-2022		NATIONAL CANCER INSTITUTE [R01CA076595] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA076595, CA076595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Coleman WB, 2006, EXP SUPPL, V96, P321; Durkin SS, 2006, J BIOL CHEM, V281, P31705, DOI 10.1074/jbc.M607011200; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; Gaspar M, 2006, P NATL ACAD SCI USA, V103, P2821, DOI 10.1073/pnas.0511148103; GESSAIN A, 1985, LANCET, V2, P407; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Li J, 2005, J BIOL CHEM, V280, P37948, DOI 10.1074/jbc.M509299200; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; MARUYAMA K, 1992, LEUKEMIA, V6, pS60; Matsuoka S, 2001, CANCER RES, V61, P5362; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Oliver AW, 2006, EMBO J, V25, P3179, DOI 10.1038/sj.emboj.7601209; OSAME M, 1986, LANCET, V1, P1031; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Raptis S, 2006, EXP SUPPL, V96, P303; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Semmes OJ, 2006, J CLIN INVEST, V116, P858, DOI 10.1172/JCI28140; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Sibon D, 2006, J CLIN INVEST, V116, P974, DOI 10.1172/JCI27198; Sieber O, 2005, SEMIN CANCER BIOL, V15, P61, DOI 10.1016/j.semcancer.2004.09.005; Strom L, 2005, CELL CYCLE, V4, P536, DOI 10.4161/cc.4.4.1613; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang XA, 2006, ENVIRON TOXICOL CHEM, V25, P3035, DOI 10.1897/05-706R.1; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	61	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29431	29440		10.1074/jbc.M704110200	http://dx.doi.org/10.1074/jbc.M704110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698850	hybrid			2022-12-27	WOS:000249788000040
J	Jacobs, MT; Zhang, YW; Campbell, SD; Rudnick, G				Jacobs, Miriam T.; Zhang, Yuan-Wei; Campbell, Scott D.; Rudnick, Gary			Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; ANTI-ADDICTIVE DRUG; PLATELET 5-HYDROXYTRYPTAMINE; ION DEPENDENCE; LIGAND-BINDING; KINETICS; CONFORMATION; EQUILIBRIA; EXPRESSION; POTASSIUM	Ibogaine, a hallucinogenic alkaloid with purported anti-addiction properties, inhibited serotonin transporter (SERT) noncompetitively by decreasing V-max with little change in the K-m for serotonin (5-HT). Ibogaine also inhibited binding to SERT of the cocaine analog 2 beta-2-carbomethoxy-3-(4[I-125] iodophenyl) tropane. However, inhibition of binding was competitive, increasing the apparent K-D without much change in B-max. Ibogaine increased the reactivity of cysteine residues positioned in the proposed cytoplasmic permeation pathway of SERT but not at nearby positions out of that pathway. In contrast, cysteines placed at positions in the extracellular permeation pathway reacted at slower rates in the presence of ibogaine. These results are consistent with the proposal that ibogaine binds to and stabilizes the state of SERT from which 5-HT dissociates to the cytoplasm, in contrast with cocaine, which stabilizes the state that binds extracellular 5-HT.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	gary.rudnick@yale.edu		ZHANG, YUAN-WEI/0000-0002-4276-9251; Jacobs, Miriam/0000-0002-8831-7592	NIDA NIH HHS [DA012408] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BOWEN WD, 1995, EUR J PHARMACOL, V279, pR1, DOI 10.1016/0014-2999(95)00247-I; BUCHANAN BB, 1976, P NATL ACAD SCI USA, V73, P2280, DOI 10.1073/pnas.73.7.2280; Forrest LR, 2007, P NATL ACAD SCI USA, V104, P12761, DOI 10.1073/pnas.0705600104; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GU H, 1994, J BIOL CHEM, V269, P7124; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; MACH RH, 1995, LIFE SCI, V57, P57; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MASH DC, 1995, LIFE SCI, V57, P45; Mitchell SM, 2004, J BIOL CHEM, V279, P24089, DOI 10.1074/jbc.M311173200; NELSON PJ, 1979, J BIOL CHEM, V254, P84; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; POPIK P, 1995, PHARMACOL REV, V47, P235; POPIK P, 1994, PSYCHOPHARMACOLOGY, V114, P672, DOI 10.1007/BF02245000; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Staley JK, 1996, PSYCHOPHARMACOLOGY, V127, P10, DOI 10.1007/BF02805969; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; SWEETNAM PM, 1995, PSYCHOPHARMACOLOGY, V118, P369, DOI 10.1007/BF02245936; Toll L, 1998, NIDA Res Monogr, V178, P440; Vastag B, 2005, SCIENCE, V308, P345, DOI 10.1126/science.308.5720.345; WALL SC, 1993, MOL PHARMACOL, V43, P264; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200	30	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29441	29447		10.1074/jbc.M704456200	http://dx.doi.org/10.1074/jbc.M704456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698848	hybrid			2022-12-27	WOS:000249788000041
J	Lou, H; Kaplowitz, N				Lou, Huan; Kaplowitz, Neil			Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappa B activity via I kappa B kinase-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; OXIDATIVE STRESS; CYSTEINE RESIDUE; TNF RECEPTOR; ACTIVATION; UBIQUITINATION; COMPLEX; PROTEIN; IKK	Reduced glutathione (GSH) plays a crucial role in hepatocyte function, and GSH depletion by diethyl maleate was shown previously to inhibit expression of NF-beta B target genes induced by tumor necrosis factor alpha(TNF alpha) and sensitize primary cultured mouse hepatocytes to TNF-mediated apoptotic killing. Here we demonstrate in the same system that GSH depletion down-regulates TNF-induced NF-kappa B transactivation via two mechanisms, depending on the extent of the depletion. With moderate GSH depletion (similar to 50%), the down-regulation is I kappa B kinase (IKK)-independent and likely acts on NF-kappa B transcriptional activity because TNF-induced IKK activation, I kappa B alpha phosphorylation and degradation, NF-kappa B nuclear translocation, NF-kappa B DNA binding in vitro, and NF-kappa B subunit RelA(p65) recruitment to kappa B sites of target gene promoters all appear unaltered. On the other hand, with profound GSH depletion (similar to 80%), the down-regulation also is IKK-dependent, and a timeline is established linking the inhibition of polyubiquitination of receptor-interacting protein 1 in TNF receptor 1 complex to partial blockage of IKK activation, I kappa B alpha phosphorylation and degradation, and NF-kappa B nuclear translocation. Of note, pretreatment with antioxidant trolox protects against the inhibitory effect of profound GSH depletion on IKK activation and NF-kappa B nuclear translocation but fails to restore expression of NF-kappa B target genes, revealing both IKK-dependent and -independent inhibition. These findings provide new insights into the complex effects of oxidative stress and redox perturbations on the NF-kappa B pathway.	Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Kaplowitz, N (corresponding author), Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, 2011 Zonal Ave,HMR 101, Los Angeles, CA 90033 USA.	kaplowit@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R01DK067215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522, DK067215] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albano E, 2006, P NUTR SOC, V65, P278, DOI 10.1079/PNS2006496; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BOYLAND E, 1967, BIOCHEM J, V104, P95, DOI 10.1042/bj1040095; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Feng GP, 2002, AM J PHYSIOL-GASTR L, V282, pG825, DOI 10.1152/ajpgi.00467.2001; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Han D, 2006, FREE RADICAL BIO MED, V41, P627, DOI 10.1016/j.freeradbiomed.2006.05.002; Han D, 2006, AM J PHYSIOL-GASTR L, V291, pG1, DOI 10.1152/ajpgi.00001.2006; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Kaplowitz N, 2005, NAT REV DRUG DISCOV, V4, P489, DOI 10.1038/nrd1750; KUBAL G, 1995, CHEM RES TOXICOL, V8, P780, DOI 10.1021/tx00047a019; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Ma H, 2003, METHOD ENZYMOL, V364, P284; Matsumaru K, 2003, HEPATOLOGY, V37, P1425, DOI 10.1053/jhep.2003.50230; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Panopoulos A, 2005, J BIOL CHEM, V280, P2912, DOI 10.1074/jbc.M409524200; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	41	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29470	29481		10.1074/jbc.M706145200	http://dx.doi.org/10.1074/jbc.M706145200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690092	hybrid			2022-12-27	WOS:000249788000044
J	Sullivan, SM; Lee, A; Bjorkman, ST; Miller, SM; Sullivan, RKP; Poronnik, P; Colditz, PB; Pow, DV				Sullivan, Susan M.; Lee, Aven; Bjorkman, S. Tracey; Miller, Stephanie M.; Sullivan, Robert K. P.; Poronnik, Philip; Colditz, Paul B.; Pow, David V.			Cytoskeletal anchoring of GLAST determines susceptibility to brain damage - An identified role for GFAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIAL GLUTAMATE TRANSPORTER; AMYOTROPHIC-LATERAL-SCLEROSIS; RAT-BRAIN; HYPOXIA-ISCHEMIA; EXPRESSION; INJURY; HIPPOCAMPUS; WIDESPREAD; ASTROCYTES; MECHANISMS	Glial fibrillary acidic protein (GFAP) is an enigmatic protein; it currently has no unambiguously defined role. It is expressed in the cytoskeleton of astrocytes in the mammalian brain. We have used co-immunoprecipitation to identify in vivo binding partners for GFAP in the rat and pig brain. We demonstrate interactions between GFAP, the glutamate transporter GLAST, the PDZ-binding protein NHERF1, and ezrin. These interactions are physiologically relevant; we demonstrate in vitro that transport of D-aspartate (a glutamate analogue) is significantly increased in the presence of GFAP and NHERF1. Moreover, we demonstrate in vivo that expression of GFAP is essential in retaining GLAST in the plasma membranes of astrocytes after an hypoxic insult. These data indicate that the cytoskeleton of the astrocyte plays an important role in protecting the brain against glutamate-mediated excitotoxicity.	Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Queensland, Perinatal Res Ctr, Royal Brisbane & Womens Hosp, Brisbane, Qld 4029, Australia	University of Newcastle; University of Queensland; Royal Brisbane & Women's Hospital; University of Queensland	Pow, DV (corresponding author), Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia.	d.pow@eaats.org	Bjorkman, Stella/C-9589-2011; Sullivan, Susan/C-7489-2011; Lee, Aven/M-2416-2016; Pow, David/F-8198-2010; Sullivan, Robert KP/A-8639-2012; Pow, David V/A-2064-2016; Colditz, Paul B/F-6772-2010; Miller, Stephanie M./F-9815-2011	Bjorkman, Stella/0000-0002-6545-3962; Sullivan, Susan/0000-0002-4601-8420; Lee, Aven/0000-0002-4171-8532; Sullivan, Robert KP/0000-0003-3414-2448; Pow, David V/0000-0001-8522-4465; Colditz, Paul B/0000-0002-6408-8238; Miller, Stephanie M./0000-0002-5565-2001; Poronnik, Philip/0000-0002-6246-528X				Bjorkman ST, 2006, BRAIN RES, V1100, P110, DOI 10.1016/j.brainres.2006.04.119; Bruhn T, 2000, NEUROCHEM INT, V37, P277, DOI 10.1016/S0197-0186(00)00029-2; Chengyun D, 2006, NEUROL SCI, V27, P245, DOI 10.1007/s10072-006-0678-8; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Derouiche A, 2001, GLIA, V36, P330, DOI 10.1002/glia.1120; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021; JENSEN FE, 1991, ANN NEUROL, V29, P629, DOI 10.1002/ana.410290610; Jensen FE, 1999, EPILEPSIA, V40, pS51, DOI 10.1111/j.1528-1157.1999.tb00879.x; Johnston MV, 2002, NEUROSCIENTIST, V8, P212, DOI 10.1177/1073858402008003007; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; KANNER BI, 1978, FEBS LETT, V94, P245, DOI 10.1016/0014-5793(78)80947-8; KUSHNER PD, 1991, J NEUROPATH EXP NEUR, V50, P263, DOI 10.1097/00005072-199105000-00008; Lee A, 2007, GLIA, V55, P119, DOI 10.1002/glia.20439; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Messing A, 2003, GLIA, V43, P87, DOI 10.1002/glia.10219; Mishra OP, 1999, BRAIN RES BULL, V48, P233, DOI 10.1016/S0361-9230(98)00170-1; NAGY D, 1994, J NEUROSCI RES, V38, P336, DOI 10.1002/jnr.490380312; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pow DV, 2004, DEV BRAIN RES, V153, P1, DOI 10.1016/j.devbrainres.2004.06.019; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; SULLIVAN RKP, 1994, GLIA, V45, P155; Tao F, 2001, NEUROSCIENCE, V102, P503, DOI 10.1016/S0306-4522(00)00485-1; Tessler S, 1999, NEUROSCIENCE, V88, P1083, DOI 10.1016/S0306-4522(98)00301-7; TORP R, 1995, EXP BRAIN RES, V103, P51; Vessal M, 2005, BRAIN RES, V1044, P190, DOI 10.1016/j.brainres.2005.02.058; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	35	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29414	29423		10.1074/jbc.M704152200	http://dx.doi.org/10.1074/jbc.M704152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684014	hybrid			2022-12-27	WOS:000249788000038
J	Abudula, A; Grabbe, A; Brechmann, M; Polaschegg, C; Herrmann, N; Goldbeck, I; Dittmann, K; Wienands, J				Abudula, Abulizi; Grabbe, Annika; Brechmann, Markus; Polaschegg, Christian; Herrmann, Nadine; Goldbeck, Ingo; Dittmann, Kai; Wienands, Juergen			SLP-65 signal transduction requires Src homology 2 domain-mediated membrane anchoring and a kinase-independent adaptor function of Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; NON-ITAM TYROSINE; T-CELL; B-LYMPHOCYTES; CUTTING EDGE; MOLECULAR-CLONING; LINKER PROTEIN; SH2 DOMAIN; IG-ALPHA; KAPPA-B	The family of SLPs ((S) under bar rc homology 2 domain-containing (l) under bar eukocyte adaptor (p) under bar roteins) are cytoplasmic signal effectors of lymphocyte antigen receptors. A main function of SLP is to orchestrate the assembly of Ca2+-mobilizing enzymes at the inner leaflet of the plasma membrane. For this purpose, SLP-76 in T cells utilizes the transmembrane adaptor LAT, but the mechanism of SLP-65 membrane anchoring in B cells remains an enigma. We now employed two genetic reconstitution systems to unravel structural requirements of SLP-65 for the initiation of Ca2+ mobilization and subsequent activation of gene transcription. First, mutational analysis of SLP-65 in DT40 B cells revealed that its C-terminal Src homology 2 domain controls efficient tyrosine phosphorylation by the kinase Syk, plasma membrane recruitment, as well as downstream signaling to NFAT activation. Second, we dissected these processes by expressing SLP-65 in SLP-76-deficient T cells and found that a kinase-independent adaptor function of Syk is required to link phosphorylated SLP-65 to Ca2+ mobilization. These approaches unmask a mechanistic complexity of SLP-65 activation and coupling to signaling cascades in that Syk is upstream as well as downstream of SLP-65. Moreover, membrane anchoring of the SLP-65-assembled Ca2+ initiation complex, which appears to be fundamentally different from that of closely related SLP-76, does not necessarily involve a B cell-specific component.	Univ Gottingen, Inst Cell & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Wienands, J (corresponding author), Univ Gottingen, Inst Cell & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	jwienan@uni-goettingen.de	Herrmann, Nadine/L-3362-2019	Herrmann, Nadine/0000-0003-4924-2281				Boerth NJ, 2000, J BIOL CHEM, V275, P5143, DOI 10.1074/jbc.275.7.5143; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; Coppolino MG, 2001, J CELL SCI, V114, P4307; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Engels N, 2001, EUR J IMMUNOL, V31, P2126, DOI 10.1002/1521-4141(200107)31:7<2126::AID-IMMU2126>3.0.CO;2-O; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Geng LP, 1999, J IMMUNOL, V163, P5753; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Grabbe A, 2006, BLOOD, V108, P3761, DOI 10.1182/blood-2006-02-005397; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Kabak S, 2002, MOL CELL BIOL, V22, P2524, DOI 10.1128/MCB.22.8.2524-2535.2002; Kohler F, 2005, NAT IMMUNOL, V6, P204, DOI 10.1038/ni1163; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Patterson HCK, 2006, IMMUNITY, V25, P55, DOI 10.1016/j.immuni.2006.04.014; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Sayegh CE, 2000, IMMUNOL REV, V175, P187, DOI 10.1034/j.1600-065X.2000.017507.x; Stork B, 2004, IMMUNITY, V21, P681, DOI 10.1016/j.immuni.2004.09.007; Stork B, 2007, EMBO J, V26, P1140, DOI 10.1038/sj.emboj.7601557; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Swamy M, 2006, IMMUNOL LETT, V104, P131, DOI 10.1016/j.imlet.2005.11.004; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamamoto T, 2001, FEBS LETT, V491, P272, DOI 10.1016/S0014-5793(01)02208-6; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	43	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29059	29066		10.1074/jbc.M704043200	http://dx.doi.org/10.1074/jbc.M704043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681949	hybrid			2022-12-27	WOS:000249642100080
J	Correll, RN; Pang, C; Finlin, BS; Dailey, AM; Satin, J; Andres, DA				Correll, Robert N.; Pang, Chunyan; Finlin, Brian S.; Dailey, Alexandria M.; Satin, Jonathan; Andres, Douglas A.			Plasma membrane targeting is essential for Rem-mediated Ca2+ channel inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING; BETA-SUBUNITS; CALMODULIN BINDS; RGK FAMILY; RAS; MEMBER; PHOSPHORYLATION; GEM; EXPRESSION; SURFACE	The small GTPase Rem is a potent negative regulator of high voltage-activated Ca2+ channels and a known interacting partner for Ca2+ channel accessory beta subunits. The mechanism for Rem-mediated channel inhibition remains controversial, although it has been proposed that Ca-V beta association is required. Previous work has shown that a C-terminal truncation of Rem (Rem-(1-265)) displays reduced in vivo binding to membrane-localized beta 2a and lacks channel regulatory function. In this paper, we describe a role for the Rem C terminus in plasma membrane localization through association with phosphatidylinositol lipids. Moreover, Rem-(1-265) can associate with beta 2a in vitro and beta 1b in vivo, suggesting that the C terminus does not directly participate in Ca-V beta association. Despite demonstrated beta 1b binding, Rem-(1-265) was not capable of regulating a CaV1.2-beta 1b channel complex, indicating that beta subunit binding is not sufficient for channel regulation. However, fusion of the CAAX domain from K-Ras4B or H-Ras to the Rem-(1-265) C terminus restored membrane localization and Ca2+ channel regulation, suggesting that beta binding and membrane localization are independent events required for channel inhibition.	Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, BBSRB Rm B-179,741 S Limestone St, Lexington, KY 40536 USA.	dandres@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL072743, R56HL074091, R01HL072936, R01HL074091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020171, P20 RR20171] Funding Source: Medline; NHLBI NIH HHS [R01 HL074091, HL074091, HL072936, R01 HL072936-04, T32 HL072743, R01 HL072936, R56 HL074091] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 2006, METHOD ENZYMOL, V407, P484, DOI 10.1016/S0076-6879(05)07039-4; Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Crump SM, 2006, AM J PHYSIOL-HEART C, V291, pH1959, DOI 10.1152/ajpheart.00956.2005; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Opatowsky Y, 2006, FEBS LETT, V580, P5959, DOI 10.1016/j.febslet.2006.09.067; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; Seu L, 2006, J GEN PHYSIOL, V128, P605, DOI 10.1085/jgp.200609631; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28431	28440		10.1074/jbc.M706176200	http://dx.doi.org/10.1074/jbc.M706176200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686775	Green Accepted, hybrid			2022-12-27	WOS:000249642100017
J	Li, MH; Jang, JH; Na, HK; Cha, YN; Surh, YJ				Li, Mei-Hua; Jang, Jung-Hee; Na, Hye-Kyung; Cha, Young-Nam; Surh, Young-Joon			Carbon monoxide produced by heme oxygenase-1 in response to nitrosative stress induces expression of glutamate-cysteine ligase in PC12 cells via activation of phosphatidylinositol 3-kinase and Nrf2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HUMAN NEUROBLASTOMA-CELLS; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; OXIDATIVE STRESS; NITRIC-OXIDE; GENE-EXPRESSION; INTRACELLULAR GLUTATHIONE; NF-E2-RELATED FACTOR-2; TRANSCRIPTION FACTOR	Induction of heme oxygenase-1 (HO-1) expression has been associated with adaptive cytoprotection against a wide array of toxic insults, but the underlying molecular mechanisms remain largely unresolved. In this study, we investigated the potential role of carbon monoxide(CO), one of the by-products of the HO-1reaction, in the adaptive survival response to peroxynitrite-induced PC12 cell death. Upon treatment of rat pheochromocytoma (PC12) cells with the peroxynitrite generator 3-morpholinosydnonimine hydrochloride (SIN-1), the cellular GSH level decreased initially, but was gradually restored to the basal level. This was accompanied by increased expression of the catalytic subunit of glutamate-cysteine ligase (GCLC), the rate-limiting enzyme in GSH biosynthesis. The SIN-1-induced GCLC up-regulation was preceded by induction of HO-1 and subsequent CO production. Inhibition of HO activity by zinc protoporphyrin IX or knockdown of HO-1 gene expression by small interfering RNA abrogated the up-regulation of GCLC expression and the subsequent GSH restoration induced by SIN-1. In contrast, additional exposure to the CO-releasing molecule (CO-RM) restored the GSH level previously reduced by inhibition of CO production using zinc protoporphyrin IX. Furthermore, CO-RM treatment up-regulated GCLC expression through activation of Nrf2. The CO-RM-induced activation of Nrf2 was under the control of the phosphatidylinositol 3-kinase/Akt signaling pathway. In conclusion, CO produced by HO-1 rescues PC12 cells from nitrosative stress through induction of GCLC, which is mediated by activation of phosphatidylinositol 3-kinase/Akt and subsequently Nrf2 signaling.	Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea; Seoul Natl Univ, Inst Canc Res, Seoul 110799, South Korea; Inha Univ, Coll Med, Dept Pharmacol & Toxicol, Inchon 382751, South Korea	Seoul National University (SNU); Seoul National University (SNU); Inha University	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	li, meihua/D-7286-2013					Abraham NG, 2003, CIRC RES, V93, P507, DOI 10.1161/01.RES.0000091828.36599.34; Anwar AA, 2005, FREE RADICAL BIO MED, V39, P227, DOI 10.1016/j.freeradbiomed.2005.03.012; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Botta D, 2004, FREE RADICAL BIO MED, V37, P632, DOI 10.1016/j.freeradbiomed.2004.05.027; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Iles KE, 2005, FREE RADICAL BIO MED, V38, P547, DOI 10.1016/j.freeradbiomed.2004.11.012; Jackson RM, 1998, FREE RADICAL BIO MED, V25, P463, DOI 10.1016/S0891-5849(98)00101-4; Kang KW, 2002, NITRIC OXIDE-BIOL CH, V7, P244, DOI 10.1016/S1089-8603(02)00117-9; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Lee BS, 2006, BIOCHEM BIOPH RES CO, V343, P965, DOI 10.1016/j.bbrc.2006.03.058; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Li MH, 2006, FREE RADICAL BIO MED, V41, P1079, DOI 10.1016/j.freeradbiomed.2006.06.010; Li MH, 2006, BIOCHEM BIOPH RES CO, V342, P984, DOI 10.1016/j.bbrc.2006.02.046; Li MH, 2005, FREE RADICAL BIO MED, V39, P890, DOI 10.1016/j.freeradbiomed.2005.05.015; Li WG, 2006, J BIOL CHEM, V281, P27251, DOI 10.1074/jbc.M602746200; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Matsumoto H, 2006, MOL CELL BIOCHEM, V291, P21, DOI 10.1007/s11010-006-9190-y; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Salvemini D, 1998, DRUG NEWS PERSPECT, V11, P204; Srisook K, 2006, BIOCHEM PHARMACOL, V71, P307, DOI 10.1016/j.bcp.2005.10.042; Srisook K, 2004, BIOCHEM PHARMACOL, V68, P1709, DOI 10.1016/j.bcp.2004.07.001; Srisook K, 2005, NITRIC OXIDE-BIOL CH, V12, P70, DOI 10.1016/j.niox.2004.12.002; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997; TROCINO RA, 1995, DIABETES, V44, P992, DOI 10.2337/diabetes.44.8.992; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	54	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28577	28586		10.1074/jbc.M701916200	http://dx.doi.org/10.1074/jbc.M701916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681938	hybrid			2022-12-27	WOS:000249642100032
J	Sun, JP; Luo, Y; Yu, X; Wang, WQ; Zhou, B; Liang, FB; Zhang, ZY				Sun, Jin-Peng; Luo, Yong; Yu, Xiao; Wang, Wei-Qing; Zhou, Bo; Liang, Fubo; Zhang, Zhong-Yin			Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; PLASMA-MEMBRANE; COLORECTAL-CANCER; DOWN-REGULATION; CAAX MOTIF; PRL-1; INVASION; METASTASIS; EXPRESSION; PIP2	The phosphatase of regenerating liver ( PRL) phosphatases are implicated in a number of tumorigenesis and metastasis processes. The PRLs are unique among protein-tyrosine phosphatases in that they have extremely low phosphatase activity, a high propensity for trimer formation, and a polybasic region that precedes the C-terminal prenylation motif. To investigate the functional significance of these distinctive biochemical and structural features, we established a cell-based system in which ectopic PRL1 expression increased cell proliferation and migration, whereas knockdown of endogenous PRL1 abrogated these cellular activities. We showed that the intrinsic PRL1 phosphatase activity is obligatory for its biological function. We provided evidence that trimerization may be a general property for all PRL enzymes, and that PRL1 trimer formation is essential for the PRL1-mediated cell growth and migration. This finding indicates a novel mechanism for phosphatase regulation. We further demonstrated that the conserved C-terminal polybasic region is important for specific phosphoinositide recognition by PRL1. Both the polybasic residues and the adjacent prenylation motif are required for proper PRL1 subcellular localization and full biological activity.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Zhang, ZY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	zyzhang@iupui.edu	sun, Jinpeng/AAR-9196-2020; SUN, JINPENG/F-9551-2013	Yu, Xiao/0000-0003-1119-8334	NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arena S, 2005, CELL MOL LIFE SCI, V62, P2092, DOI 10.1007/s00018-005-5205-1; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chenette EJ, 2006, MOL BIOL CELL, V17, P3108, DOI 10.1091/mbc.E05-09-0896; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Jeong DG, 2005, J MOL BIOL, V345, P401, DOI 10.1016/j.jmb.2004.10.061; Kaadige MR, 2006, J BIOL CHEM, V281, P28831, DOI 10.1074/jbc.M605624200; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Kozlov G, 2004, J BIOL CHEM, V279, P11882, DOI 10.1074/jbc.M312905200; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Rouleau C, 2006, MOL CANCER THER, V5, P219, DOI 10.1158/1535-7163.MCT-05-0289; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Sun JP, 2005, BIOCHEMISTRY-US, V44, P12009, DOI 10.1021/bi0509191; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Wang WQ, 2004, J BIOL CHEM, V279, P30459, DOI 10.1074/jbc.M402217200; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	46	60	63	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29043	29051		10.1074/jbc.M703537200	http://dx.doi.org/10.1074/jbc.M703537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656357	hybrid			2022-12-27	WOS:000249642100078
J	Hata, S; Doi, N; Kitamura, F; Sorimachi, H				Hata, Shoji; Doi, Naoko; Kitamura, Fujiko; Sorimachi, Hiroyuki			Stomach-specific calpain, nCL-2/calpain 8, is active without calpain regulatory subunit and oligomerizes through C2-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; TISSUE-SPECIFIC CALPAIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PROTEASE ACTIVITY; MU-CALPAIN; GENE; AUTOLYSIS; P94; ACTIVATION	Calpains constitute a family of intracellular Ca2+-regulated cysteine proteases that are indispensable in the regulation of a wide variety of cellular functions. The improper activation of calpain causes lethality or various disorders, such as muscular dystrophies and tumor formation. nCL-2/calpain 8 is predominantly expressed in the stomach, where it appears to be involved in membrane trafficking in the gastric surface mucus cells (pit cells). Although the primary structure of nCL-2 is quite similar to that of the ubiquitous m-calpain large subunit, the enzymatic properties of nCL-2 have never been reported. Here, to characterize nCL-2, the recombinant protein was prepared using an Escherichia coli expression system and purified to homogeneity. nCL-2 was stably produced as a soluble and active enzyme without the conventional calpain regulatory subunit (30K). Purified nCL-2 showed Ca2+-dependent activity, with half-maximal activity at about 0.3 mM Ca2+, similar to that of m-calpain, whereas its optimal pH and temperature were comparatively low. Immunoprecipitation analysis revealed that nCL-2 exists in both monomeric and homo-oligomeric forms, but not as a heterodimer with 30K or 30K-2, and that the oligomerization occurs through domains other than the 5EF-hand domain IV, most probably through domain III, suggesting a novel regulatory system for nCL-2.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Calpain Project, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Calpain Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/C-6448-2009; Sorimachi, Hiroyuki/Q-6956-2017	Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bordone L, 2002, J BIOL CHEM, V277, P26673, DOI 10.1074/jbc.M112037200; Cao Y, 2001, DEV GROWTH DIFFER, V43, P563; Davis TL, 2007, J MOL BIOL, V366, P216, DOI 10.1016/j.jmb.2006.11.037; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; Duan WR, 2002, BIOCHEM BIOPH RES CO, V295, P261, DOI 10.1016/S0006-291X(02)00655-1; DUTT P, 2006, BMC DEV BIOL, V6, DOI DOI 10.1186/1471-1213X-1186-1183; Friedrich P, 2005, BIOL CHEM, V386, P609, DOI 10.1515/BC.2005.071; Friedrich P, 2004, EUR J NEUROSCI, V19, P1819, DOI 10.1111/j.1460-9568.2004.03313.x; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hata S, 2006, J BIOL CHEM, V281, P11214, DOI 10.1074/jbc.M509244200; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Schad E, 2002, BIOCHEM J, V362, P383, DOI 10.1042/0264-6021:3620383; Shinozaki K, 1998, INT J MOL MED, V1, P797; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	41	27	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27847	27856		10.1074/jbc.M703168200	http://dx.doi.org/10.1074/jbc.M703168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646163	hybrid			2022-12-27	WOS:000249455600033
J	Jin, HJ; Shen, XH; Baggett, BR; Kong, XM; LiWang, PJ				Jin, Hongjun; Shen, Xiaohong; Baggett, Brandi Renee; Kong, Xiangming; LiWang, Patricia J.			The human CC chemokine MIP-1 beta dimer is not competent to bind to the CCR5 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFLAMMATORY PROTEIN 1-BETA; FUSION INHIBITOR T-20; SIDE-CHAIN RESONANCES; C-13/N-15-ENRICHED PROTEINS; GLYCOSAMINOGLYCAN BINDING; FUNCTIONAL-RESPONSES; NMR ASSIGNMENTS; BACKBONE AMIDE; FACTOR-I	Chemokine dimerization has been the subject of much interest in recent years as evidence has accumulated that different quaternary states of chemokines play different biological roles; the monomer is believed to be the receptor-binding unit, whereas the dimer has been implicated in binding cell surface glycosaminoglycans. However, although several studies have provided evidence for this paradigm by making monomeric chemokine variants or dimer-impaired chemokines, few have provided direct evidence of the receptor function of a chemokine dimer. We have produced a covalent dimer of the CC chemokine macrophage inflammatory protein-1 beta (MIP-1 beta) by placing a disulfide bond at the center of its dimer interface through a single amino acid substitution (MIP-1 beta-A10C). This variant was shown to be a nondissociating dimer by SDS-PAGE and analytical ultracentrifugation. NMR reveals a structure largely the same as the wild type protein. In studies of glycosaminoglycan binding, MIP-1 beta-A10C binds to a heparin-Sepharose column as tightly as the wild type protein and more tightly than monomeric variants. However, MIP-1 beta-A10C neither binds nor activates the MIP-1 beta receptor CCR5. It was found that the ability to activate CCR5 was recovered upon reduction of the intermolecular disulfide cross-link by incubation with I mM dithiothreitol. This work provides the first definitive evidence that the CC chemokine MIP-1 beta dimer is not able to bind or activate its receptor and implicates the CC chemokine monomer as the sole receptor-interacting unit.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	LiWang, PJ (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	pliwang@tamu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; Chackerian B, 1999, P NATL ACAD SCI USA, V96, P2373, DOI 10.1073/pnas.96.5.2373; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fernando H, 2004, J BIOL CHEM, V279, P36175, DOI 10.1074/jbc.C400283200; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; Jin HJ, 2005, BIOCHEM BIOPH RES CO, V338, P987, DOI 10.1016/j.bbrc.2005.10.062; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Leong SR, 1997, PROTEIN SCI, V6, P609; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Lowman HB, 1997, PROTEIN SCI, V6, P598; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; McCornack MA, 2004, BIOCHEMISTRY-US, V43, P10090, DOI 10.1021/bi049751u; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; MEUNIER A, 1997, BIOCHEMISTRY-US, V36, P4412; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rajarathnam K, 2006, BIOCHEMISTRY-US, V45, P7882, DOI 10.1021/bi0605944; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Veldkamp CT, 2005, PROTEIN SCI, V14, P1071, DOI 10.1110/ps.041219505; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	49	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27976	27983		10.1074/jbc.M702654200	http://dx.doi.org/10.1074/jbc.M702654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644519	hybrid			2022-12-27	WOS:000249455600047
J	Luo, J; Kintner, DB; Shull, GE; Sun, D				Luo, Jing; Kintner, Douglas B.; Shull, Gary E.; Sun, Dandan			ERK1/2-p90(RSK)-mediated phosphorylation of Na+/H+ exchanger isoform 1 - A role in ischemic neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; RIBOSOMAL S6 KINASE; MEK1 PROTEIN-KINASE; INTRACELLULAR PH; DEPENDENT ACTIVATION; MEDIATED REGULATION; REPERFUSION INJURY; OXIDATIVE TOXICITY; RAT MYOCARDIUM	The function and regulation of Na+/H+ exchanger isoform 1 (NHE1) following cerebral ischemia are not well understood. In this study, we demonstrate that extracellular signal-related kinases (ERK1/2) play a role in stimulation of neuronal NHE1 following in vitro ischemia. NHE1 activity was significantly increased during 10-60 min reoxygenation (REOX) after 2-h oxygen and glucose deprivation (OGD). OGD/REOX not only increased the V-max for NHE1 but also shifted the K-m toward decreased [H+](i). These changes in NHE1 kinetics were absent when MAPK/ERK kinase (MEK) was inhibited by the MEK inhibitor U0126. There were no changes in the levels of phosphorylated ERK1/2 (p-ERK1/2) after 2 h OGD. The p-ERK1/2 level was significantly increased during 10 - 60 min REOX, which was accompanied by nuclear translocation. U0126 abolished REOX-induced elevation and translocation of p-ERK1/2. We further examined the ERK/90-kDa ribosomal S6 kinase (p90(RSK)) signaling pathways. At 10 min REOX, phosphorylated NHE1 was increased with a concurrent elevation of phosphorylation of p90(RSK), a known NHE1 kinase. Inhibition of MEK activity with U0126 abolished phosphorylation of both NHE1 and p90RSK. Moreover, neuroprotection was observed with U0126 or genetic ablation or pharmacological inhibition of NHE1 following OGD/REOX. Taken together, these results suggest that activation of ERK1/2-p90(RSK) pathways following in vitro ischemia phosphorylates NHE1 and increases its activity, which subsequently contributes to neuronal damage.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Physiol, Madison, WI 53792 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; University of Cincinnati	Sun, D (corresponding author), Univ Wisconsin, Clin Hlth Ctr, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	sun@neurosurg.wisc.edu	sun, dandan/GZG-6540-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048216] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS48216] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Cuello F, 2007, MOL PHARMACOL, V71, P799, DOI 10.1124/mol.106.029900; Diarra A, 1999, NEUROSCIENCE, V93, P1003, DOI 10.1016/S0306-4522(99)00230-4; Haworth RS, 2006, BIOCHEM J, V399, P493, DOI 10.1042/BJ20051628; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Kelly MP, 1997, CIRC RES, V80, P853; Kintner DB, 2005, AM J PHYSIOL-CELL PH, V289, pC934, DOI 10.1152/ajpcell.00092.2005; Kintner DB, 2004, AM J PHYSIOL-CELL PH, V287, pC12, DOI 10.1152/ajpcell.00560.2003; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Luo J, 2005, J NEUROSCI, V25, P11256, DOI 10.1523/JNEUROSCI.3271-05.2005; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MABE H, 1983, J CEREBR BLOOD F MET, V3, P109, DOI 10.1038/jcbfm.1983.13; Maekawa N, 2006, CIRCULATION, V113, P2516, DOI 10.1161/CIRCULATIONAHA.105.563486; Malo ME, 2007, J BIOL CHEM, V282, P6292, DOI 10.1074/jbc.M611073200; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Moor AN, 2001, J BIOL CHEM, V276, P16113, DOI 10.1074/jbc.M100519200; Mukhin YV, 2004, J BIOL CHEM, V279, P1845, DOI 10.1074/jbc.M304907200; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Noshita N, 2002, J NEUROSCI, V22, P7923; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Shackelford DA, 2003, MOL BRAIN RES, V115, P173, DOI 10.1016/S0169-328X(03)00206-7; Snabaitis AK, 2006, J BIOL CHEM, V281, P20252, DOI 10.1074/jbc.M600268200; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takeishi Y, 1999, CIRC RES, V85, P1164; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Yao H, 2001, AM J PHYSIOL-CELL PH, V281, pC1205, DOI 10.1152/ajpcell.2001.281.4.C1205	40	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28274	28284		10.1074/jbc.M702373200	http://dx.doi.org/10.1074/jbc.M702373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17664275	hybrid			2022-12-27	WOS:000249455600077
J	Hodges, AR; Krementsova, EB; Trybus, KM				Hodges, Alex R.; Krementsova, Elena B.; Trybus, Kathleen M.			Engineering the processive run length of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAND-OVER-HAND; DYNACTIN INCREASES; WEAK BINDING; MOTOR; ACTIN; MECHANISM; DOMAIN; COORDINATION; MICROTUBULES; MAGNESIUM	The processive motor myosin V has a high affinity for actin in the weak binding states when compared with non-processive myosins. Here we test whether this feature is essential for myosin V to walk processively along an actin filament. The net charge of loop 2, a surface loop implicated in the initial weak binding between myosin and actin, was increased or decreased to correspondingly change the affinity of myosin V for actin in the weak binding state, without changing the velocity of movement. Processive run lengths of single molecules were determined by total internal reflection fluorescence microscopy. Reducing the net positive charge of loop 2 significantly decreased both the affinity of myosin V for actin and the processive run length. Conversely, the addition of positive charge to loop 2 increased actin affinity and processive run length. We hypothesize that a high affinity for actin allows the detached head of a stepping myosin V to find its next actin binding site more quickly, thus decreasing the probability of run termination.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078097] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIGMS NIH HHS [GM 078097] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali MY, 2007, P NATL ACAD SCI USA, V104, P4332, DOI 10.1073/pnas.0611471104; Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Culver-Hanlon TL, 2006, NAT CELL BIOL, V8, P264, DOI 10.1038/ncb1370; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; Dunn AR, 2007, NAT STRUCT MOL BIOL, V14, P246, DOI 10.1038/nsmb1206; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 2005, CELL MOL LIFE SCI, V62, P1462, DOI 10.1007/s00018-005-5015-5; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Krementsova EB, 2006, J BIOL CHEM, V281, P6079, DOI 10.1074/jbc.M510041200; LI SJ, 1992, J BIOL CHEM, V267, P855; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Warshaw DM, 2005, BIOPHYS J, V88, pL30, DOI 10.1529/biophysj.105.061903; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	34	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27192	27197		10.1074/jbc.M703968200	http://dx.doi.org/10.1074/jbc.M703968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640878	hybrid			2022-12-27	WOS:000249304900060
J	Wang, Q; Tullius, TD; Levin, JR				Wang, Qun; Tullius, Thomas D.; Levin, Judith R.			Effects of discontinuities in the DNA template on abortive initiation and promoter escape by Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; IN-VITRO; ELONGATION COMPLEXES; NONTEMPLATE STRAND; CHAIN INITIATION; BRANCHED PATHWAY; ALPHA-SUBUNIT; UPSTREAM DNA	Using singly gapped or nicked templates containing the T7A1 promoter, we have measured several kinetic parameters related to the process of transcription initiation by Escherichia coli RNA polymerase, confirming and extending previous results using a population of randomly gapped templates. A reduced probability of transcript abortion at RNA lengths of 6 and 7 nucleotides and a lower ratio of abortive to productive initiation events was observed for some discontinuous templates, consistent with models attributing abortive initiation to the accumulation of strain in the initiating complex. The effect of DNA discontinuity on abortion of shorter RNA transcripts (2 - 3 nucleotides) was less pronounced; abortion at these short chain lengths may primarily be attributed to the low stability of the RNA-DNA hybrid. Certain discontinuities had significant effects on the intrinsic catalytic capacity of the open complex and also on the partitioning between productive and unproductive complexes, suggesting that subtle changes in the conformation of the open complex can profoundly affect its function. The rate and efficiency of promoter escape were not correlated with the stability of the open promoter complex despite previous suggestions to the contrary. We conclude that the stability of the open promoter complex is only one of several factors that contribute to the overall rate of promoter escape.	Boston Univ, Goucher Coll, Dept Biol Sci & Chem, Baltimore, MD 21204 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Boston University; Boston University	Levin, JR (corresponding author), Boston Univ, Goucher Coll, Dept Biol Sci & Chem, 1021 Dulaney Valley Rd, Baltimore, MD 21204 USA.	jlevin@goucher.edu	Tullius, Thomas D./A-9685-2008	Tullius, Thomas D./0000-0003-4425-796X	NIGMS NIH HHS [GM 41930, R01 GM041930-14, R01 GM041930] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041930] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; Bar-Nahum G, 2001, CELL, V106, P443, DOI 10.1016/S0092-8674(01)00461-5; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Brodolin K, 2005, J MOL BIOL, V350, P930, DOI 10.1016/j.jmb.2005.05.048; BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Davis CA, 2005, P NATL ACAD SCI USA, V102, P285, DOI 10.1073/pnas.0405779102; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Guo H, 2003, P NATL ACAD SCI USA, V100, P3743, DOI 10.1073/pnas.0737062100; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Hochheimer YB, 2005, P NATL ACAD SCI USA, V102, P1157, DOI 10.1073/pnas.0408973102; Hsu LM, 2006, BIOCHEMISTRY-US, V45, P8841, DOI 10.1021/bi060247u; Hsu LLM, 2003, BIOCHEMISTRY-US, V42, P3777, DOI 10.1021/bi026954e; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; JOHNSON J, 1996, THESIS J HOPKINS U B; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; Kapanidis AN, 2006, SCIENCE, V314, P1144, DOI 10.1126/science.1131399; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Levin JR, 2000, J BIOL CHEM, V275, P6885, DOI 10.1074/jbc.275.10.6885; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCMAHAN SA, 1994, BIOCHEMISTRY-US, V33, P12092, DOI 10.1021/bi00206a012; MILLS JB, 1994, BIOCHEMISTRY-US, V33, P1797, DOI 10.1021/bi00173a024; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Roberts CW, 1996, CELL, V86, P495; Ross W, 2005, P NATL ACAD SCI USA, V102, P291, DOI 10.1073/pnas.0405814102; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; Susa M, 2002, J BIOL CHEM, V277, P15407, DOI 10.1074/jbc.M112481200; UPTAIN SM, 1997, STRUCTURAL FUNCTIONA; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vo NV, 2003, BIOCHEMISTRY-US, V42, P3798, DOI 10.1021/bi026962v; Vo NV, 2003, BIOCHEMISTRY-US, V42, P3787, DOI 10.1021/bi0269613; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; Zaychikov E, 1997, J BIOL CHEM, V272, P2259	56	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26917	26927		10.1074/jbc.M702473200	http://dx.doi.org/10.1074/jbc.M702473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650506	hybrid			2022-12-27	WOS:000249304900031
J	Suzuki, S; Singhirunnusorn, P; Mori, A; Yamaoka, S; Kitajima, I; Saiki, I; Sakurai, H				Suzuki, Shunsuke; Singhirunnusorn, Pattama; Mori, Akinori; Yamaoka, Shoji; Kitajima, Isao; Saiki, Ikuo; Sakurai, Hiroaki			Constitutive activation of TAK1 by HTLV-1 tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; MEDIATED ACTIVATION; TERMINAL KINASE; PROTEIN; PATHWAY; IL-1; COMPLEXES; MEMBRANE; CATENIN; TRAF6	HTLV-1 Tax oncoprotein induces persistent activation of the transcription factor NF-kappa B and CREB (cAMP-response element-binding protein)/ATF. Transforming growth factor-beta-activated kinase 1 (TAK1) has been shown to play a critical role in these transcription factors. Here, we found that TAK1 was constitutively activated in Tax-positive HTLV-1-transformed T cells. Tax induced persistent overexpression of TAK1-binding protein 2 ( TAB2), but not TAB3, which is essential for TAK1 activation. Surprisingly, TAK1 was not involved in the activation of NF-kappa B. On the other hand, JNK and p38 mitogen-activated protein kinases were activated by TAK1. In addition, ATF2, but not CREB, was a target for the TAK1-JNK pathway, and p38 negatively regulated TAK1 activity through TAB1 phosphorylation. These results indicate that Tax-mediated TAK1 activation is important for the activation of ATF2 rather than NF-kappa B.	Toyama Univ, Inst Nat Med, Dic Pathogen Biochem, Toyama 9300194, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo 1138519, Japan; Toyama Univ, Dept Clin & Mol Pathol, Grad Sch Med & Pharmaceut Sci, Toyama 9300194, Japan; Toyama Univ, 21st Century Ctr Excellence Program, Toyama 9300194, Japan	University of Toyama; Tokyo Medical & Dental University (TMDU); University of Toyama; University of Toyama	Sakurai, H (corresponding author), Toyama Univ, Inst Nat Med, Dic Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@inm.u-toyama.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Gohda J, 2007, BIOCHEM BIOPH RES CO, V357, P225, DOI 10.1016/j.bbrc.2007.03.125; Hong S, 2007, J BIOL CHEM, V282, P12119, DOI 10.1074/jbc.M610392200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; Miura H, 2005, EXP CELL RES, V308, P29, DOI 10.1016/j.yexcr.2005.04.005; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sato S, 2006, INT IMMUNOL, V18, P1405, DOI 10.1093/intimm/dxl082; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Uemura N, 2006, J BIOL CHEM, V281, P7863, DOI 10.1074/jbc.M509834200; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wu XF, 2007, EMBO REP, V8, P510, DOI 10.1038/sj.embor.7400931; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	32	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25177	25181		10.1074/jbc.C700065200	http://dx.doi.org/10.1074/jbc.C700065200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17626013	hybrid			2022-12-27	WOS:000249014100002
J	Zhang, W; Watanabe, K; Wang, CCC; Tang, Y				Zhang, Wenjun; Watanabe, Kenji; Wang, Clay C. C.; Tang, Yi			Investigation of early tailoring reactions in the oxytetracycline biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II POLYKETIDE SYNTHASE; ENGINEERED BIOSYNTHESIS; STREPTOMYCES-RIMOSUS; GENE-CLUSTER; HETEROLOGOUS EXPRESSION; ANTIBIOTIC MITHRAMYCIN; AKLANONIC ACID; FATTY-ACID; TETRACYCLINES; CYCLIZATION	Tetracyclines are aromatic polyketides biosynthesized by bacterial type II polyketide synthases. The amidated tetracycline backbone is biosynthesized by the minimal polyketide synthases and an amidotransferase homologue OxyD. Biosynthesis of the key intermediate 6-methylpretetramid requires two early tailoring steps, which are cyclization of the linearly fused tetracyclic scaffold and regioselective C-methylation of the aglycon. Using a heterologous host (CH999)/ vector pair, we identified the minimum set of enzymes from the oxytetracycline biosynthetic pathway that is required to afford 6-methylpretetramid in vivo. Only two cyclases (OxyK and OxyN) are necessary to completely cyclize and aromatize the amidated tetracyclic aglycon. Formation of the last ring via C-1/C-18 aldol condensation does not require a dedicated fourth-ring cyclase, in contrast to the biosynthetic mechanism of other tetracyclic aromatic polyketides, such as daunorubicin and tetracenomycin. Acetyl-derived polyketides do not undergo spontaneous fourth- ring cyclization and form only anthracene carboxylic acids as demonstrated both in vivo and in vitro. OxyF was identified to be the C-6 C-methyltransferase that regioselectively methylates pretetramid to yield 6-methylpretetramid. Reconstitution of 6-methylpretetramid in a heterologous host sets the stage for a more systematic investigation of additional tetracycline downstream tailoring enzymes and is a key step toward the engineered biosynthesis of tetracycline analogs.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA; Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; University of Southern California	Tang, Y (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA.	yitang@ucla.edu	Watanabe, Kenji/N-2012-2015; Wang, Clay/ABG-9056-2021	Watanabe, Kenji/0000-0002-0463-4831; Wang, Clay/0000-0003-2955-7569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075857] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM75857] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Bililign T, 2004, CHEM BIOL, V11, P959, DOI 10.1016/j.chembiol.2004.04.016; BUTLER MJ, 1990, DEV IND MICROBIOL, V31, P41; Deseo MA, 2005, J ANTIBIOT, V58, P822, DOI 10.1038/ja.2005.110; ECKARDT K, 1985, J ANTIBIOT, V38, P1034, DOI 10.7164/antibiotics.38.1034; Hautala A, 2003, J ANTIBIOT, V56, P143, DOI 10.7164/antibiotics.56.143; Hertweck C, 2004, CHEM BIOL, V11, P461, DOI 10.1016/j.chembiol.2004.03.018; Hertweck C, 2007, NAT PROD REP, V24, P162, DOI 10.1039/b507395m; Hopwood D.A., 1985, GENETIC MANIPULATION; Hunter I. S., 2002, MICROBIAL SECONDARY, P141; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Jakobi K, 2004, J AM CHEM SOC, V126, P2298, DOI 10.1021/ja0390698; Kantola J, 2000, MICROBIOL-UK, V146, P155, DOI 10.1099/00221287-146-1-155; Kendrew SG, 1999, BIOCHEMISTRY-US, V38, P4794, DOI 10.1021/bi9827924; KIM ES, 1994, GENE, V141, P141, DOI 10.1016/0378-1119(94)90144-9; Korman TP, 2004, BIOCHEMISTRY-US, V43, P14529, DOI 10.1021/bi048133a; Kunzel E, 1997, CHEM-EUR J, V3, P1675, DOI 10.1002/chem.19970031017; Lee TS, 2005, J AM CHEM SOC, V127, P12254, DOI 10.1021/ja051429z; Lombo F, 2000, ANGEW CHEM INT EDIT, V39, P796, DOI 10.1002/(SICI)1521-3773(20000218)39:4<796::AID-ANIE796>3.0.CO;2-N; Lomovskaya N, 1998, J BACTERIOL, V180, P2379, DOI 10.1128/JB.180.9.2379-2386.1998; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; MCCORMICK JR, 1965, J AM CHEM SOC, V87, P1794, DOI 10.1021/ja01086a034; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P2201, DOI 10.1021/ja01010a063; MCCORMICK JR, 1969, J AM CHEM SOC, V91, P206, DOI 10.1021/ja01029a046; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P7126, DOI 10.1021/ja01027a045; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P7127, DOI 10.1021/ja01027a046; MCCORMICK JR, 1965, J AM CHEM SOC, V87, P1793, DOI 10.1021/ja01086a033; MCCORMICK JRD, 1963, J AM CHEM SOC, V85, P1692, DOI 10.1021/ja00894a037; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MCDOWALL KJ, 1990, GENETICS PRODUCT FOR, P105; Peric-Concha N, 2005, J BIOL CHEM, V280, P37455, DOI 10.1074/jbc.M503191200; Petkovic H, 1999, J BIOL CHEM, V274, P32829; Petkovic H, 2006, MICROBIOL MOL BIOL R, V70, P704, DOI 10.1128/MMBR.00004-06; Prado L, 1999, MOL GEN GENET, V261, P216, DOI 10.1007/s004380050960; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Rohr J, 1998, CHEM COMMUN, P437, DOI 10.1039/a707446h; SCHUMACHER RW, 1995, J NAT PROD, V58, P613, DOI 10.1021/np50118a024; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; Tang Y, 2004, PLOS BIOL, V2, P227, DOI 10.1371/journal.pbio.0020031; Thompson TB, 2004, J BIOL CHEM, V279, P37956, DOI 10.1074/jbc.M406144200; Winter JM, 2007, J BIOL CHEM, V282, P16362, DOI 10.1074/jbc.M611046200; Wohlert SE, 2001, J NAT PROD, V64, P1077, DOI 10.1021/np010067f; Xu Z, 2007, J AM CHEM SOC, V129, P6022, DOI 10.1021/ja069045b; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1999, CHEM BIOL, V6, P607; Zhang WJ, 2006, J NAT PROD, V69, P1633, DOI 10.1021/np060290i; Zhang WJ, 2006, APPL ENVIRON MICROB, V72, P2573, DOI 10.1128/AEM.72.4.2573-2580.2006	49	50	55	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25717	25725		10.1074/jbc.M703437200	http://dx.doi.org/10.1074/jbc.M703437200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17631493	hybrid			2022-12-27	WOS:000249014100059
J	Borutaite, V; Brown, GC				Borutaite, Vilmante; Brown, Guy C.			Mitochondrial regulation of caspase activation by cytochrome oxidase and tetramethylphenylenediamine via cytosolic cytochrome c redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAUROSPORINE-INDUCED APOPTOSIS; MECHANISM; SYSTEM; CELLS	Cytochrome c release from mitochondria induces caspase activation in cytosols; however, it is unclear whether the redox state of cytosolic cytochrome c can regulate caspase activation. By using cytosol isolated from mammalian cells, we find that oxidation of cytochrome c by added cytochrome oxidase stimulates caspase activation, whereas reduction of cytochrome c by added tetramethylphenylenediamine (TMPD) or yeast lactate dehydrogenase/cytochrome c reductase blocks caspase activation. Scrape-loading of cells with this reductase inhibited caspase activation induced by staurosporine. Similarly, incubating intact cells with ascorbate plus TMPD to reduce intracellular cytochrome c strongly inhibited staurosporine-induced cell death, apoptosis, and caspase activation but not cytochrome c release, indicating that cytochrome c redox state can regulate caspase activation. In homogenates from healthy cells cytochrome c was rapidly reduced, whereas in homogenates from apoptotic cells added cytochrome c was rapidly oxidized by some endogenous process. This oxidation was prevented if mitochondria were removed from the homogenate or if cytochrome oxidase was inhibited by azide. This suggests that permeabilization of the outer mitochondrial membrane during apoptosis functions not just to release cytochrome c but also to maintain it oxidized via cytochrome oxidase, thus maximizing caspase activation. However, this activation can be blocked by adding TMPD, which may have some therapeutic potential.	Kaunas Univ Med, Biomed Res Inst, LT-50009 Kaunas, Lithuania; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Lithuanian University of Health Sciences; University of Cambridge	Borutaite, V (corresponding author), Kaunas Univ Med, Biomed Res Inst, Eiveniu 4, LT-50009 Kaunas, Lithuania.	vilbor@vector.kmu.lt	Brown, Guy C./HHC-1102-2022	Brown, Guy/0000-0002-3610-1730				Borutaite V, 2001, FEBS LETT, V500, P114, DOI 10.1016/S0014-5793(01)02593-5; Bustamante J, 2004, FREE RADICAL BIO MED, V37, P1490, DOI 10.1016/j.freeradbiomed.2004.06.038; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Chen Quan, 2003, Korean Journal of Biological Sciences, V7, P1; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Duan S, 2003, J BIOL CHEM, V278, P1346, DOI 10.1074/jbc.M209269200; Gilmore KJ, 2001, CELL DEATH DIFFER, V8, P631, DOI 10.1038/sj.cdd.4400858; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Hampton MB, 1998, BIOCHEM J, V329, P95; Hancock JT, 2001, FREE RADICAL BIO MED, V31, P697, DOI 10.1016/S0891-5849(01)00646-3; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200; Pan ZH, 1999, CELL DEATH DIFFER, V6, P683, DOI 10.1038/sj.cdd.4400544; SARTI P, 1992, ARCH BIOCHEM BIOPHYS, V299, P8, DOI 10.1016/0003-9861(92)90237-Q; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Suto D, 2005, BIOCHEM J, V392, P399, DOI 10.1042/BJ20050580; TREWHELLA J, 1988, BIOCHEMISTRY-US, V27, P1121, DOI 10.1021/bi00404a007; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	19	79	86	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31124	31130		10.1074/jbc.M700322200	http://dx.doi.org/10.1074/jbc.M700322200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17690099	hybrid			2022-12-27	WOS:000250309200002
J	Osei-Owusu, P; Sun, XG; Drenan, RM; Steinberg, TH; Blumer, KJ				Osei-Owusu, Patrick; Sun, Xiaoguang; Drenan, Ryan M.; Steinberg, Thomas H.; Blumer, Kendall J.			Regulation of RGS2 and second messenger signaling in vascular smooth muscle cells by cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; TERMINAL CYSTEINE RESIDUES; GTPASE-ACTIVATING PROTEINS; END RULE PATHWAY; ADENYLYL-CYCLASE; PLASMA-MEMBRANE; 3RD-INTRACELLULAR LOOP; RECIPROCAL REGULATION; CELLULAR MECHANISM; ANGIOTENSIN-II	RGS2, a GTPase-activating protein (GAP) for G(q)alpha, regulates vascular relaxation and blood pressure. RGS2 can be phosphorylated by type I alpha cGMP-dependent protein kinase (cGKI alpha), increasing its GAP activity. To understand how RGS2 and cGKI alpha regulate vascular smooth muscle signaling and function, we identified signaling pathways that are controlled by cGMP in an RGS2-dependent manner and discovered new mechanisms whereby cGK activity regulates RGS2. We show that RGS2 regulates vasoconstrictor-stimulated Ca2+ store release, capacitative Ca2+ entry, and noncapacitative Ca2+ entry and that RGS2 is required for cGMP-mediated inhibition of vasoconstrictor-elicited phospholipase C beta activation, Ca2+ store release, and capacitative Ca2+ entry. RGS2 is degraded in vascular smooth muscle cells via the proteasome. Inhibition of cGK activity blunts RGS2 degradation. However, inactivation of the cGKI alpha phosphorylation sites in RGS2 does not stabilize the protein, suggesting that cGK activity regulates RGS2 degradation by other mechanisms. cGK activation promotes association of RGS2 with the plasma membrane by a mechanism requiring its cGKI alpha phosphorylation sites. By regulating GAP activity, plasma membrane association, and degradation, cGKI alpha therefore may control a cycle of RGS2 activation and inactivation. By diminishing cGK activity, endothelial dysfunction may impair RGS2 activation, thereby blunting vascular relaxation and contributing to hypertension.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	kblumer@cellbiology.wustl.edu	Osei-Owusu, Patrick/AAH-9063-2019; Blumer, Kendall J/C-5268-2012; Osei-Owusu, Patrick/L-9104-2018		NHLBI NIH HHS [HL075632] Funding Source: Medline; NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bodenstein J, 2007, MOL PHARMACOL, V71, P1040, DOI 10.1124/mol.106.029397; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Brueggemann LI, 2005, BIOCHEM J, V388, P237, DOI 10.1042/BJ20041360; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GILL DL, 2004, SCI STKE, pE39; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Jerius H, 1998, SURGERY, V123, P46, DOI 10.1067/msy.1998.82476; Kanaide H, 2003, CIRC RES, V93, P1015, DOI 10.1161/01.RES.0000105920.33926.60; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Luker GD, 2003, CANCER RES, V63, P1780; Moneer Z, 2005, BIOCHEM J, V389, P821, DOI 10.1042/BJ20050145; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Osterhout JL, 2003, J BIOL CHEM, V278, P19309, DOI 10.1074/jbc.M210124200; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Roy AA, 2006, CELL SIGNAL, V18, P336, DOI 10.1016/j.cellsig.2005.05.004; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Schoeber JP, 2006, J BIOL CHEM, V281, P29669, DOI 10.1074/jbc.M606233200; SIDEROVSKI DP, 2004, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A000028.01; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sun XG, 2005, MOL PHARMACOL, V67, P631, DOI 10.1124/mol.104.007724; TAKATA S, 1990, AM J HYPERTENS, V3, pS227, DOI 10.1093/ajh/3.8.227; Takida S, 2005, MOL PHARMACOL, V67, P132, DOI 10.1124/mol.104.003418; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taylor Colin W, 2002, Novartis Found Symp, V246, P91; Taylor CW, 2004, BIOL RES, V37, P641, DOI 10.4067/s0716-97602004000400020; Thuillez C, 2005, J HUM HYPERTENS, V19, pS21, DOI 10.1038/sj.jhh.1001889; Tikhonova IG, 2006, BIOCHEM BIOPH RES CO, V341, P715, DOI 10.1016/j.bbrc.2005.12.221; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2004, METHOD ENZYMOL, V389, P89; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wang X, 2007, EMBO J, V26, P2768, DOI 10.1038/sj.emboj.7601701; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	73	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31656	31665		10.1074/jbc.M706360200	http://dx.doi.org/10.1074/jbc.M706360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17681944	hybrid			2022-12-27	WOS:000250309200057
J	Chang, YF; Chan, WK; Imam, JS; Wilkinson, MF				Chang, Yao-Fu; Chan, Wai-Kin; Imam, J. Saadi; Wilkinson, Miles F.			Alternatively spliced T-cell receptor transcripts are up-regulated in response to disruption of either splicing elements or reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA-DECAY; NONSENSE-MEDIATED DECAY; PREMATURE TERMINATION CODON; EXON-JUNCTION COMPLEX; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; DEPENDENT MANNER; MAMMALIAN-CELLS; SITE SELECTION; HUMAN SMG-1	Nonsense mutations create premature termination codons ( PTCs), leading to the generation of truncated proteins, some of which have deleterious gain-of-function or dominant-negative activity. Protecting cells from such aberrant proteins is nonsensemediated decay ( NMD), an RNA surveillance pathway that degrades transcripts harboring PTCs. Asecond response to nonsense mutations is the up-regulation of alternatively spliced transcripts that skip the PTC. This nonsense-associated altered splicing ( NAS) response has the potential to rescue protein function, but the mechanism by which it is triggered has been controversial. Some studies suggest that, like NMD, NAS is triggered as a result of nonsense mutations disrupting reading frame, whereas other studies suggest thatNASis triggered when nonsense mutations disrupt exonic splicing enhancers ( ESEs). Using T-cell receptor-beta( TCR beta), which naturally acquires PTCs at high frequency, we provide evidence that both mechanisms act on a single type of mRNA. Mutations that disrupt consensus ESE sites up-regulated an alternatively spliced TCR beta transcript that skipped the mutations independently of reading frame disruption and the NMD factor UPF1. In contrast, reading frame disrupting mutations that did not disrupt consensus ESE sites elicited UPF1-dependent up-regulation of the alternatively spliced TCR beta transcript. Restoration of reading frame prevented this up-regulation. Our results suggest that the response of an mRNA to a nonsense mutation depends on its context.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Unit 1000, Houston, TX 77030 USA.	mwilkins@mdanderson.org	Chan, Waikin/AAI-4995-2020	Imam, J Saadi/0000-0003-3463-838X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-058595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker KE, 2006, RNA, V12, P1441, DOI 10.1261/rna.92706; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Brogna S, 2002, MOL CELL, V10, P93, DOI 10.1016/S1097-2765(02)00565-8; Buhler M, 2005, RNA, V11, P139, DOI 10.1261/rna.7183805; Buhler M, 2002, EMBO REP, V3, P646, DOI 10.1093/embo-reports/kvf129; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Caputi M, 2002, GENE DEV, V16, P1754, DOI 10.1101/gad.997502; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chan WK, 2007, EMBO J, V26, P1820, DOI 10.1038/sj.emboj.7601628; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; Chin SY, 2004, GENE DEV, V18, P745, DOI 10.1101/gad.1170204; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Dahlberg JE, 2003, RNA, V9, P1, DOI 10.1261/rna.2121703; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; Di Blasi C, 2001, BRAIN, V124, P698, DOI 10.1093/brain/124.4.698; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gehring NH, 2005, MOL CELL, V20, P65, DOI 10.1016/j.molcel.2005.08.012; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Gersappe A, 1999, J BIOL CHEM, V274, P22452, DOI 10.1074/jbc.274.32.22452; Ginjaar IB, 2000, EUR J HUM GENET, V8, P793, DOI 10.1038/sj.ejhg.5200535; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grimson A, 2004, MOL CELL BIOL, V24, P7483, DOI 10.1128/MCB.24.17.7483-7490.2004; Gudikote JP, 2002, EMBO J, V21, P125, DOI 10.1093/emboj/21.1.125; Gudikote JP, 2005, NAT STRUCT MOL BIOL, V12, P801, DOI 10.1038/nsmb980; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Kunz JB, 2006, RNA, V12, P1015, DOI 10.1261/rna.12506; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Longman D, 2007, GENE DEV, V21, P1075, DOI 10.1101/gad.417707; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Mangiarotti G, 1999, BIOCHEMISTRY-US, V38, P3996, DOI 10.1021/bi9822022; Maquat LE, 2002, GENE DEV, V16, P1743, DOI 10.1101/gad.1014502; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Metzstein MM, 2006, PLOS GENET, V2, P2143, DOI 10.1371/journal.pgen.0020180; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Mohn F, 2005, RNA, V11, P147, DOI 10.1261/rna.7182905; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Nathanson L, 2003, RNA, V9, P9, DOI 10.1261/rna.2990203; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schell T, 2002, GENOME BIOL, V3; Singh G, 2003, TRENDS BIOCHEM SCI, V28, P464, DOI 10.1016/S0968-0004(03)00176-2; Stroupe ME, 2006, J MOL BIOL, V360, P743, DOI 10.1016/j.jmb.2006.05.049; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Usuki F, 2006, MOL THER, V14, P351, DOI 10.1016/j.ymthe.2006.04.011; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; van Deutekom JCT, 2001, HUM MOL GENET, V10, P1547, DOI 10.1093/hmg/10.15.1547; Wachtel C, 2004, RNA, V10, P1740, DOI 10.1261/rna.7480804; Wang J, 2002, MOL CELL, V10, P951, DOI 10.1016/S1097-2765(02)00635-4; Wang J, 2002, J BIOL CHEM, V277, P18489, DOI 10.1074/jbc.M111781200; Wang J, 2002, SCIENCE, V297, P108, DOI 10.1126/science.1069757; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001	67	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29738	29747		10.1074/jbc.M704372200	http://dx.doi.org/10.1074/jbc.M704372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693403	hybrid			2022-12-27	WOS:000249981200002
J	Echevarria, M; Munoz-Cabello, AM; Sanchez-Silva, R; Toledo-Aral, JJ; Lopez-Barneo, J				Echevarria, Miriam; Munoz-Cabello, Ana M.; Sanchez-Silva, Rocio; Toledo-Aral, Juan J.; Lopez-Barneo, Jose			Development of cytosolic hypoxia and hypoxia-inducible factor stabilization are facilitated by aquaporin-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; WATER CHANNEL; XENOPUS OOCYTES; CO2 PERMEABILITY; MESSENGER-RNA; RAT-KIDNEY; PC12 CELLS; OXYGEN; MEMBRANE; INDUCTION	O-2 is essential for aerobic life, and the classic view is that it diffuses freely across the plasma membrane. However, measurements of O-2 permeability of lipid bilayers have indicated that it is much lower than previously thought, and therefore, the existence of membrane O-2 channels has been suggested. Wehypothesized that, besides its role as a water channel, aquaporin-1 (AQP-1) could also work as an O-2 transporter, because this transmembrane protein appears to be CO2-permeable and is highly expressed in cells with rapid O2 turnover (erythrocytes and microvessel endothelium). Here we show that in mammalian cells overexpressing AQP-1 and exposed to hypoxia, the loss of cytosolic O-2, as well as stabilization of the O-2-dependent hypoxia-inducible transcription factor and expression of its target genes, is accelerated. In normoxic endothelial cells, knocking down AQP-1 produces induction of hypoxia-inducible genes. Moreover, lung AQP-1 is markedly up-regulated in animals exposed to hypoxia. These data suggest that AQP-1 has O-2 permeability and thus could facilitate O-2 diffusion across the cell membrane.	Univ Seville, Hosp Univ Virgen Rocio, Dept Fisiol Med & Bioffis, Lab Invest Biomed,Edificio Labs, Seville 41013, Spain	University of Sevilla; Virgen del Rocio University Hospital	Lopez-Barneo, J (corresponding author), Univ Seville, Hosp Univ Virgen Rocio, Dept Fisiol Med & Bioffis, Lab Invest Biomed,Edificio Labs, 2 Planta,Ave Manuel Siurot S-N, Seville 41013, Spain.	lbarneo@us.es	Cabello, Ana Maria Muñoz/E-5292-2016; Toledo-Aral, Juan J/F-2613-2015; IBIS, NEUROBIOLOGIA/O-9922-2015; Echevarría, Miriam/E-6682-2010; IBIS, TERAPIA CELULA/P-3297-2015	Cabello, Ana Maria Muñoz/0000-0002-8047-768X; Toledo-Aral, Juan J/0000-0001-7512-7135; Echevarría, Miriam/0000-0002-4758-9428; 				Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Carter EP, 1998, BIOPHYS J, V74, P2121, DOI 10.1016/S0006-3495(98)77919-6; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAPMAN JD, 1981, BRIT J CANCER, V43, P546, DOI 10.1038/bjc.1981.79; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Del Toro R, 2003, J BIOL CHEM, V278, P22316, DOI 10.1074/jbc.M212576200; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; FISCHKOFF S, 1975, J GEN PHYSIOL, V65, P663, DOI 10.1085/jgp.65.5.663; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Herrera M, 2007, AM J PHYSIOL-RENAL, V292, pF1443, DOI 10.1152/ajprenal.00353.2006; Herrera M, 2006, HYPERTENSION, V48, P157, DOI 10.1161/01.HYP.0000223652.29338.77; Ivanov II, 2004, BIOCHEM BIOPH RES CO, V322, P746, DOI 10.1016/j.bbrc.2004.07.187; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Murillo-Carretero MI, 1999, J AM SOC NEPHROL, V10, P696; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; OBESO J, 1990, LAB INVEST, V63, P259; Piruat JI, 2005, J BIOL CHEM, V280, P42676, DOI 10.1074/jbc.M507044200; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RALEIGH JA, 1987, BRIT J CANCER, V56, P395, DOI 10.1038/bjc.1987.213; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; SUBCZYNSKI WK, 1992, J GEN PHYSIOL, V100, P69, DOI 10.1085/jgp.100.1.69; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; Vacca A, 2001, BRIT J HAEMATOL, V113, P415, DOI 10.1046/j.1365-2141.2001.02738.x; Wang Y, 2007, J STRUCT BIOL, V157, P534, DOI 10.1016/j.jsb.2006.11.008; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Zhou BY, 2007, AM J PHYSIOL-CELL PH, V292, pC1280, DOI 10.1152/ajpcell.00070.2006	44	95	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30207	30215		10.1074/jbc.M702639200	http://dx.doi.org/10.1074/jbc.M702639200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17673462	hybrid			2022-12-27	WOS:000249981200051
J	Brower, JV; Rodic, N; Seki, T; Jorgensen, M; Fliess, N; Yachnis, AT; McCarrey, JR; Oh, SP; Terada, N				Brower, Jeffrey V.; Rodic, Nemanja; Seki, Tsugio; Jorgensen, Marda; Fliess, Naime; Yachnis, Anthony T.; McCarrey, John R.; Oh, S. Paul; Terada, Naohiro			Evolutionarily conserved mammalian adenine nucleotide translocase 4 is essential for spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						t	ADENINE-NUCLEOTIDE TRANSLOCATOR; MITOCHONDRIAL PERMEABILITY TRANSITION; ADP/ATP CARRIER; PSEUDOAUTOSOMAL-REGION; GERM-CELLS; MOUSE; GENE; EXPRESSION; INACTIVATION; CHROMOSOMES	The adenine nucleotide translocases (Ant) facilitate the transport of ADP and ATP by an antiport mechanism across the inner mitochondrial membrane, thus playing an essential role in cellular energy metabolism. We recently identified a novel member of the Ant family in mouse, Ant4, of which gene configuration as well as amino acid homology is well conserved among mammals. The conservation of Ant4 in mammals, along with the absence of Ant4 in nonmammalian species, suggests a unique and indispensable role for this ADP/ATP carrier in mammalian development. Of interest, in contrast to its paralog Ant2, which is encoded by the X chromosome and ubiquitously expressed in somatic cells, Ant4 is encoded by an autosome and selectively expressed in testicular germ cells. Immunohistochemical examination as well as RNA expression analysis using separated spermatogenic cell types revealed that Ant4 expression was particularly high in spermatocytes. When we generated Ant4-deficient mice by targeted disruption, a significant reduction in testicular size was observed without any other distinguishable abnormalities in the mice. Histological examination as well as stage-specific gene expression analysis in adult and neonatal testes revealed a severe reduction of spermatocytes accompanied by increased apoptosis. Subsequently, the Ant4-deficient male mice were infertile. Taken together, these data elucidated the indispensable role of Ant4 in murine spermatogenesis. Considering the unique conservation and chromosomal location of the Ant family genes in mammals, the Ant4 gene may have arisen in mammalian ancestors and been conserved in mammals to serve as the sole and essential mitochondrial ADP/ATP carrier during spermatogenesis where the sex chromosome-linked Ant2 gene is inactivated.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA; Univ Texas, Dept Biol, San Antonio, TX 78249 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, POB 100275, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu		Yachnis, Anthony/0000-0002-6971-0698	NCRR NIH HHS [RR17001] Funding Source: Medline; NIDDK NIH HHS [DK59699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR017001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY J, 2005, SYNOPSIS, V26, P678; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bradley J, 2004, NAT GENET, V36, P872, DOI 10.1038/ng1390; Carra E, 2004, BIOCHEM BIOPH RES CO, V322, P333, DOI 10.1016/j.bbrc.2004.07.112; CECI JD, 1994, MAMM GENOME, V5, pS124; Charchar FJ, 2003, GENOME RES, V13, P281, DOI 10.1101/gr.390503; Chen KF, 2004, MAMM GENOME, V15, P996, DOI 10.1007/s00335-004-2405-1; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Ellison JW, 1996, GENOMICS, V36, P369, DOI 10.1006/geno.1996.0478; Emerson JJ, 2004, SCIENCE, V303, P537, DOI 10.1126/science.1090042; ERICKSON RP, 1980, P NATL ACAD SCI-BIOL, V77, P6086, DOI 10.1073/pnas.77.10.6086; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; FOLGERO T, 1993, HUM REPROD, V8, P1863, DOI 10.1093/oxfordjournals.humrep.a137950; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Graves JAM, 2006, CELL, V124, P901, DOI 10.1016/j.cell.2006.02.024; Guo R, 2004, MOL REPROD DEV, V67, P264, DOI 10.1002/mrd.20026; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163; KAO SH, 1995, BIOL REPROD, V52, P729, DOI 10.1095/biolreprod52.4.729; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KHALIL S, 2004, AFR J MATH PHYS, V1, P101; Kim YH, 2007, DEV BIOL, V302, P463, DOI 10.1016/j.ydbio.2006.10.004; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Lestienne P, 1997, MOL HUM REPROD, V3, P811, DOI 10.1093/molehr/3.9.811; Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3; Lodi T, 2006, BIOCHEM BIOPH RES CO, V341, P810, DOI 10.1016/j.bbrc.2006.01.034; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; McCarrey JR, 2005, ANN NY ACAD SCI, V1061, P226, DOI 10.1196/annals.1336.025; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; METTUS RV, 1994, ONCOGENE, V9, P3077; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103; Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ohta H, 2001, INT J ANDROL, V24, P15, DOI 10.1046/j.1365-2605.2001.00257.x; Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341; Richardson LL, 2000, BIOL REPROD, V62, P789, DOI 10.1095/biolreprod62.3.789; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; Santamaria M, 2004, GENE, V333, P51, DOI 10.1016/j.gene.2004.02.013; Spiropoulos J, 2002, MOL HUM REPROD, V8, P719, DOI 10.1093/molehr/8.8.719; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Sweeney C, 1996, DEVELOPMENT, V122, P53; Toder R, 1998, MAMM GENOME, V9, P373, DOI 10.1007/s003359900772; Turner JMA, 2006, DEV CELL, V10, P521, DOI 10.1016/j.devcel.2006.02.009; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Wang PJ, 2004, TRENDS ENDOCRIN MET, V15, P79, DOI 10.1016/j.tem.2004.01.007; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	54	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29658	29666		10.1074/jbc.M704386200	http://dx.doi.org/10.1074/jbc.M704386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681941	hybrid			2022-12-27	WOS:000249788000062
J	Huang, XD; Masselli, A; Frisch, SM; Hunton, IC; Jiang, Y; Wang, JYJ				Huang, XiaoDong; Masselli, Anja; Frisch, Steven M.; Hunton, Irina C.; Jiang, Yong; Wang, Jean Y. J.			Blockade of tumor necrosis factor-induced bid cleavage by caspase-resistant Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RETINOBLASTOMA PROTEIN FUNCTION; CELL-DEATH; INDUCED APOPTOSIS; C-ABL; INTERACTING PROTEIN; TNF RECEPTOR-1; ACTIVATION; PATHWAY; INDUCTION	Tumor necrosis factor-alpha (TNF) activates caspase-8 to cleave effector caspases or Bid, resulting in type-1 or type-2 apoptosis, respectively. We show here that TNF also induces caspase-8-dependent C-terminal cleavage of the retinoblastoma protein (Rb). Interestingly, fibroblasts from Rb-MI/MI mice, in which the C-terminal caspase cleavage site is mutated, exhibit a defect in Bid cleavage despite caspase-8 activation. Recent results suggest that TNF receptor endocytosis is required for the activation of caspase-8. Consistent with this notion, inhibition of V-ATPase, which plays an essential role in acidification and degradation of endosomes, specifically restores Bid cleavage in Rb-MI/MI cells. Inhibition of V-ATPase sensitizes Rb-MI/MI but not wild-type fibroblasts to TNF-induced apoptosis and stimulates inflammation-associated colonic apoptosis in Rb-MI/MI but not wild-type mice. These results suggest that Rb cleavage is required for Bid cleavage in TNF-induced type-2 apoptosis, and this requirement can be supplanted by the inhibition of V-ATPase.	Univ Calif San Diego, Ctr Canc, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Moores Canc Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Div Hematol Oncol, Dept Med, La Jolla, CA 92093 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; West Virginia University; West Virginia University	Wang, JYJ (corresponding author), Univ Calif San Diego, Ctr Canc, Div Biol Sci, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; BEG AA, 1996, SCIENCE, V274, P784; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Borges HL, 2005, P NATL ACAD SCI USA, V102, P15587, DOI 10.1073/pnas.0503925102; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Helfer B, 2006, CANCER RES, V66, P4273, DOI 10.1158/0008-5472.CAN-05-4183; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Inoue T, 2005, J BIOENERG BIOMEMBR, V37, P393, DOI 10.1007/s10863-005-9478-8; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Park SM, 2005, CURR OPIN CELL BIOL, V17, P610, DOI 10.1016/j.ceb.2005.09.010; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	64	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29401	29413		10.1074/jbc.M702261200	http://dx.doi.org/10.1074/jbc.M702261200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686781	Green Published, hybrid			2022-12-27	WOS:000249788000037
J	Koh, CY; Kazimirova, M; Trimnell, A; Takac, P; Labuda, M; Nuttall, PA; Kini, RM				Koh, Cho Yeow; Kazimirova, Maria; Trimnell, Adama; Takac, Peter; Labuda, Milan; Nuttall, Patricia A.; Kini, R. Manjunatha			Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HUMAN PRETHROMBIN-2; GLOSSINA-MORSITANS-MORSITANS; CRYSTAL-STRUCTURE; SALIVARY-GLANDS; ACTIVE-SITE; ANTICOAGULANT PEPTIDE; SLOW-BINDING; HIRUDIN; COMPLEX	Tick saliva contains potent antihemostatic molecules that help ticks obtain their enormous blood meal during prolonged feeding. We isolated thrombin inhibitors present in the salivary gland extract from partially fed female Amblyomma variegatum, the tropical bont tick, and characterized the most potent, variegin, one of the smallest (32 residues) thrombin inhibitors found in nature. Full-length variegin and two truncated variants were chemically synthesized. Despite its small size and flexible structure, variegin binds thrombin with strong affinity (K-i similar to 10.4 pM) and high specificity. Results using the truncated variants indicated that the seven residues at the N terminus affected the binding kinetics; when removed, the binding characteristics changed from fast to slow. Further, the thrombin active site binding moiety of variegin is in the region of residues 8-14, and the exosite-I binding moiety is within residues 15-32. Our results show that variegin is structurally and functionally similar to the rationally designed thrombin inhibitor, hirulog. However, compared with hirulog, variegin is a more potent inhibitor, and its inhibitory activity is largely retained after cleavage by thrombin.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Singapore 117543, Singapore; Slovak Acad Sci, Inst Zool, SK-84506 Bratislava, Slovakia; Seattle Biomed Res Inst, Seattle, WA 98109 USA; NERC, Ctr Ecol & Hydrol, Oxford OX1 3SR, England; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA USA	National University of Singapore; Slovak Academy of Sciences; Center for Infectious Disease Research; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Prot Sci Lab, Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Kazimirova, Maria/U-8222-2017; Kini, Manjunatha/H-8029-2012; Koh, Cho Yeow/J-4635-2019; Nuttall, Pat A/I-6142-2012	Kazimirova, Maria/0000-0001-6904-8342; Koh, Cho Yeow/0000-0003-0002-4603; Nuttall, Pat A/0000-0002-0385-8294; Kini, Manjunatha/0000-0002-6100-3251	Natural Environment Research Council [CEH010021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; Bates SM, 2006, BRIT J HAEMATOL, V134, P3, DOI 10.1111/j.1365-2141.2006.06134.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cappello M, 1998, P NATL ACAD SCI USA, V95, P14290, DOI 10.1073/pnas.95.24.14290; Cappello M, 1996, AM J TROP MED HYG, V54, P475, DOI 10.4269/ajtmh.1996.54.475; Champagne DE, 2005, PATHOPHYSIOL HAEMO T, V34, P221, DOI 10.1159/000092428; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Davie EW, 2003, J BIOL CHEM, V278, P50819, DOI 10.1074/jbc.X300009200; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Gurm HS, 2005, AM HEART J, V149, pS43, DOI 10.1016/j.ahj.2004.10.022; Hirsh J, 2005, BLOOD, V105, P453, DOI 10.1182/blood-2003-12-4195; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; Ibrahim MA, 2001, EXP APPL ACAROL, V25, P675, DOI 10.1023/A:1016136207308; Kazimirova M, 2002, EXP APPL ACAROL, V28, P97, DOI 10.1023/A:1025398100044; Kazimirova M, 2002, MED VET ENTOMOL, V16, P301, DOI 10.1046/j.1365-2915.2002.00379.x; Lane DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOESKEJUNGBLUT C, 1995, J BIOL CHEM, V270, P28629, DOI 10.1074/jbc.270.48.28629; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P3368, DOI 10.1021/bi036177y; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Salzet M, 2000, J BIOL CHEM, V275, P30774, DOI 10.1074/jbc.M000787200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schwienhorst A, 2006, CELL MOL LIFE SCI, V63, P2773, DOI 10.1007/s00018-006-6219-z; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Soejima K, 2001, J BIOCHEM, V130, P269, DOI 10.1093/oxfordjournals.jbchem.a002982; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STRUBE KH, 1993, J BIOL CHEM, V268, P8590; Subburaju S, 1997, TOXICON, V35, P1239, DOI 10.1016/S0041-0101(97)00014-7; van de L. A., 1996, EMBO J, V15, P6011; VANDE LA, 1995, EMBO J, V14, P5149; WITTING JI, 1992, BIOCHEM J, V283, P737, DOI 10.1042/bj2830737; Yonemura H, 2004, J BIOCHEM, V135, P577, DOI 10.1093/jb/mvh070; ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034	47	76	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29101	29113		10.1074/jbc.M705600200	http://dx.doi.org/10.1074/jbc.M705600200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684009	hybrid			2022-12-27	WOS:000249788000005
J	Sot, B; Freund, SMV; Fersht, AR				Sot, Begona; Freund, Stefan M. V.; Fersht, Alan R.			Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR P53; FULL-LENGTH P53; CORE DOMAIN; STRUCTURAL BASIS; IN-VIVO; COMPLEX; MITOCHONDRIA; DEATH; MUTATIONS	The p53 transcription-independent apoptosis in mitochondria, mediated by its interaction with the pro-apoptotic and the anti-apoptotic members of the Bcl2 family of proteins, has been described in vivo, especially in radiosensitive tissues. We have characterized the interaction of p53 with both the pro-apoptotic Bak and the anti-apoptotic Bcl-x(L) proteins, comparing their affinity and their interaction surfaces, using biophysical techniques such as fluorescence anisotropy, analytical ultracentrifugation, and NMR. We have shown that both proteins interact with only the p53 core domain and not with its N- and C-terminal regions. Further, p53 has a higher affinity for Bcl-x(L) than for Bak, which is consistent with the previously described sequential binding of Bcl-x(L) and Bak by p53. Interestingly, although the interaction with both proteins is electrostatic in character, they have different binding sites. Using NMR spectroscopy, we have determined that Bcl-x(L) interacts with the DNA binding site of p53, but Bak does not interact with this site. A new potential interaction surface for Bak is proposed.	MRC, Ctr Prot Engn, Cambridge CB2 0QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, England.	arf25@cam.ac.uk	Sot, Begoña/H-2882-2015; Fersht, Alan R/B-2189-2008	Sot, Begoña/0000-0001-8763-0651; 	Medical Research Council [MC_U105474168] Funding Source: Medline; MRC [MC_U105474168] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bauer JH, 2006, AGING CELL, V5, P437, DOI 10.1111/j.1474-9726.2006.00228.x; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440-1681.2004.03975.x; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Hainaut P, 2000, ADV CANCER RES, V77, P81; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Palacios G, 2006, ONCOGENE, V25, P6133, DOI 10.1038/sj.onc.1209641; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Xu HB, 2006, BIOCHEM BIOPH RES CO, V341, P938, DOI 10.1016/j.bbrc.2005.12.227; Yamada Y, 2005, ACTA CRYSTALLOGR D, V61, P731, DOI 10.1107/S0907444905009595; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103	41	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29193	29200		10.1074/jbc.M705544200	http://dx.doi.org/10.1074/jbc.M705544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699158	hybrid			2022-12-27	WOS:000249788000015
J	Kallio, JM; Linder, MB; Rouvinen, J				Kallio, Johanna M.; Linder, Markus B.; Rouvinen, Juha			Crystal structures of hydrophobin HFBII in the presence of detergent implicate the formation of fibrils and monolayer films	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODERMA-REESEI; RESOLUTION STRUCTURE; SC3; MEMBRANE; WATER	Hydrophobins are small, amphiphilic proteins secreted by filamentous fungi. Their functionality arises from a patch of hydrophobic residues on the protein surface. Spontaneous self-assembly of hydrophobins leads to the formation of an amphiphilic layer that remarkably reduces the surface tension of water. We have determined by x-ray diffraction two new crystal structures of Trichoderma reesei hydrophobin HFBII in the presence of a detergent. The monoclinic crystal structure (2.2 angstrom resolution, R = 22, R-free = 28) is composed of layers of hydrophobin molecules where the hydrophobic surface areas of the molecules are aligned within the layer. Viewed perpendicular to the aligned hydrophobic surface areas, the molecules in the layer pack together to form six-membered rings, thus leaving small pores in the layer. Similar packing has been observed in the atomic force microscopy images of the self-assembled layers of class II hydrophobin, indicating that the crystal structure resembles that of natural hydrophobin film. The orthorhombic crystal structure (1.0 A resolution, R = 13, Rfree = 15) is composed of fiber-like arrays of protein molecules. Rodlet structures have been observed on amphiphilic layers formed by class I hydrophobins; fibrils of class II hydrophobins appear by vigorous shaking. We propose that the structure of the fibrils and/or rodlets is similar to that observed in the crystal structure.	Univ Joensuu, Dept Chem, FIN-80101 Joensuu, Finland; VTT Tech Res Ctr Finland, Espoo 02044, Finland	University of Eastern Finland; VTT Technical Research Center Finland	Kallio, JM (corresponding author), Univ Joensuu, Dept Chem, POB 111, FIN-80101 Joensuu, Finland.	johanna.kallio@joensuu.fi	Linder, Markus B/E-5879-2011; Linder, Markus/N-8043-2019; Hakanpää, Johanna M/A-6958-2011	Linder, Markus B/0000-0002-7271-6441; Linder, Markus/0000-0002-7271-6441; Hakanpää, Johanna M/0000-0003-0110-1439; Rouvinen, Juha/0000-0003-1843-5718; Kallio, Johanna/0000-0001-7330-8928				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; De Vocht ML, 2002, PROTEIN SCI, V11, P1199, DOI 10.1110/ps.4540102; Hakanpaa J, 2006, ACTA CRYSTALLOGR D, V62, P356, DOI 10.1107/S0907444906000862; Hakanpaa J, 2004, J BIOL CHEM, V279, P534, DOI 10.1074/jbc.M309650200; Hakanpaa J, 2004, ACTA CRYSTALLOGR D, V60, P163, DOI 10.1107/S0907444903024430; Hakanpaa J, 2006, PROTEIN SCI, V15, P2129, DOI 10.1110/ps.062326706; HEKTOR HJ, 2005, CURR OPIN BIOTECH, V16, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kwan AHY, 2006, P NATL ACAD SCI USA, V103, P3621, DOI 10.1073/pnas.0505704103; Linder MB, 2005, FEMS MICROBIOL REV, V29, P877, DOI 10.1016/j.femsre.2005.01.004; Linder MB, 2004, BIOCHEMISTRY-US, V43, P11873, DOI 10.1021/bi0488202; Ma H, 2006, MYCOL RES, V110, P879, DOI 10.1016/j.mycres.2006.06.010; Mackay JP, 2001, STRUCTURE, V9, P83, DOI 10.1016/S0969-2126(00)00559-1; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; NakariSetala T, 1996, EUR J BIOCHEM, V235, P248, DOI 10.1111/j.1432-1033.1996.00248.x; NakariSetala T, 1997, EUR J BIOCHEM, V248, P415, DOI 10.1111/j.1432-1033.1997.00415.x; Paananen A, 2003, BIOCHEMISTRY-US, V42, P5253, DOI 10.1021/bi034031t; Ritva S, 2003, J APPL CRYSTALLOGR, V36, P499, DOI 10.1107/S0021889803000578; Scholtmeijer K, 2001, APPL MICROBIOL BIOT, V56, P1, DOI 10.1007/s002530100632; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Szilvay GR, 2007, BIOCHEMISTRY-US, V46, P2345, DOI 10.1021/bi602358h; Szilvay GR, 2006, BIOCHEMISTRY-US, V45, P8590, DOI 10.1021/bi060620y; Torkkeli M, 2002, BIOPHYS J, V83, P2240, DOI 10.1016/S0006-3495(02)73984-2; Wang X, 2005, BIOPHYS J, V88, P3434, DOI 10.1529/biophysj.104.057794; Wang XQ, 2004, PROTEIN SCI, V13, P810, DOI 10.1110/ps.03367304; WESSELS JGH, 1994, ANNU REV PHYTOPATHOL, V32, P413, DOI 10.1146/annurev.py.32.090194.002213; WESSELS JGH, 1991, PLANT CELL, V3, P793; WOSTEN HAB, 1994, J BACTERIOL, V176, P7085; Wosten HAB, 2000, BBA-REV BIOMEMBRANES, V1469, P79, DOI 10.1016/S0304-4157(00)00002-2; Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0; WOSTEN HAB, 1993, PLANT CELL, V5, P1567	33	48	53	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28733	28739		10.1074/jbc.M704238200	http://dx.doi.org/10.1074/jbc.M704238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636262	hybrid			2022-12-27	WOS:000249642100047
J	Yazicioglu, MN; Goad, DL; Ranganathan, A; Whitehurst, AW; Goldsmith, EJ; Cobb, MH				Yazicioglu, Mustafa N.; Goad, Daryl L.; Ranganathan, Aarati; Whitehurst, Angelique W.; Goldsmith, Elizabeth J.; Cobb, Melanie H.			Mutations in ERK2 binding sites affect nuclear entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ERK2; DOCKING INTERACTIONS; PROTEIN-KINASE; SIGNAL; IDENTIFICATION; TRANSLOCATION; LOCALIZATION; RECOGNITION; TRANSPORT; DOMAIN	The MAPK ERK2 can enter and exit the nucleus by an energy-independent process that is facilitated by direct interactions with nuclear pore proteins. Several studies also suggest that the localization of ERK2 can be influenced by carrier proteins. Using import reconstitution assays, we examined a group of ERK2 mutants defective in known protein interactions to determine structural properties of ERK2 that contribute to its nuclear entry. ERK2 mutants defective in binding to substrates near the active site or to basic/hydrophobic docking (D) motifs were imported normally. Several ERK2 mutants defective in interactions with FXF motifs displayed slowed rates of nuclear import. The import-impaired mutants also showed reduced binding to a recombinant C-terminal fragment of nucleoporin 153 that is rich in FXF motifs. Despite the deficit revealed in some mutants via reconstitution assays, all but one of the ERK2 mutants accumulated in nuclei of stimulated cells in a manner comparable with the wild type protein; the mutant most defective in import remained in the cytoplasm. These results further support the idea that direct interactions with nucleoporins are involved in ERK2 nuclear entry and that multiple events contribute to the ligand-dependent relocalization of these protein kinases.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Blvd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [R37 DK034128, DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Aebersold DM, 2004, MOL CELL BIOL, V24, P10000, DOI 10.1128/MCB.24.22.10000-10015.2004; Arvind R, 2005, INT J ONCOL, V27, P1499; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Casar B, 2007, EMBO J, V26, P635, DOI 10.1038/sj.emboj.7601523; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103; Lorenzen JA, 2001, DEVELOPMENT, V128, P1403; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Nakopoulou L, 2005, APMIS, V113, P693, DOI 10.1111/j.1600-0463.2005.apm_236.x; Polychronopoulos S, 2006, J BIOL CHEM, V281, P25601, DOI 10.1074/jbc.M605185200; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ranganathan A, 2006, ARCH BIOCHEM BIOPHYS, V449, P8, DOI 10.1016/j.abb.2006.02.023; Ranganathan A, 2006, J BIOL CHEM, V281, P15645, DOI 10.1074/jbc.M513866200; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	41	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28759	28767		10.1074/jbc.M703460200	http://dx.doi.org/10.1074/jbc.M703460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656361	hybrid			2022-12-27	WOS:000249642100050
J	Asano, R; Watanabe, Y; Kawaguchi, H; Fukazawa, H; Nakanishi, T; Umetsu, M; Hayashi, H; Katayose, Y; Unno, M; Kudo, T; Kumagai, I				Asano, Ryutaro; Watanabe, Yasuhiro; Kawaguchi, Hiroko; Fukazawa, Hidesuke; Nakanishi, Takeshi; Umetsu, Mitsuo; Hayashi, Hiroki; Katayose, Yu; Unno, Michiaki; Kudo, Toshio; Kumagai, Izumi			Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; REFOLDING SYSTEM; EFFICIENT ROUTE; KINASE-ACTIVITY; DIABODY; EGFR; EFFICACY; ANTIGEN; HETERODIMERIZATION	We previously reported the marked in vitro and in vivo antitumor activity of hEx3, a humanized diabody (small recombinant bispecific antibody) with epidermal growth factor receptor (EGFR) and CD3 retargeting. Here, we fabricated a tetravalent IgG-like bispecific antibody with two kinds of single-chain Fv (scFv), i.e. humanized anti-EGFR scFv and anti-CD3 scFv, that contains the same four variable domains as hEx3, on the platform of human IgG1 (hEx3-scFv-Fc). hEx3-scFv-Fc prepared from mammalian cells showed specific binding to both EGFR and CD3 target antigens. At one-thousandth (0.1-100 fmol/ml) of the dose of normal hEx3, hEx3-scFv-Fc showed intense cytotoxicity to an EGFR-positive cell line in a growth-inhibition assay using lymphokine-activated killer cells with the T-cell phenotype (T-LAK cells). The enhanced antitumor effect was more clearly observed when peripheral blood mononuclear cells (PBMCs) were used as effector cells, indicating the utility of IgG-like fabrication. These results suggested that the intense antitumor activity is attributable to the multivalency and the presence of the fused human Fc, a hypothesis that was supported by the results of flow cytometry, PBMC proliferation assay, and protein kinase inhibition assay. Furthermore, the growth inhibition effects of hEx3-scFv-Fc were considerably superior to those of the approved therapeutic antibody, cetuximab, which recognizes the same EGFR antigen even when using PBMCs as effector cells. The high potency of hEx3-scFv-Fc may translate into improved antitumor therapy and lower costs of production because of the smaller doses needed.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Surg, Div Gastroenterol Surg, Sendai, Miyagi 980, Japan; Tohoku Univ, Cell Res Ctr Biomed Res, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University	Kumagai, I (corresponding author), Aoba 6-6-11-606,Aoba-ku, Sendai, Miyagi, Japan.	kmiz@kuma.che.tohoku.ac.jp	Unno, Michiaki/A-8633-2010; Unno, Michiaki/AAX-5246-2020; Asano, Ryutaro/G-7822-2016	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416; Hayashi, Hiroki/0000-0001-9953-603X				Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41; Asano R, 2002, J BIOCHEM, V132, P903, DOI 10.1093/oxfordjournals.jbchem.a003303; Asano R, 2002, FEBS LETT, V528, P70, DOI 10.1016/S0014-5793(02)03254-4; Asano R, 2006, CLIN CANCER RES, V12, P4036, DOI 10.1158/1078-0432.CCR-06-0059; BOHLEN H, 1993, CANCER RES, V53, P4310; Bremer E, 2005, J BIOL CHEM, V280, P10025, DOI 10.1074/jbc.M413673200; Cao Y, 2003, ADV DRUG DELIVER REV, V55, P171, DOI 10.1016/S0169-409X(02)00178-3; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Coloma MJ, 1997, J IMMUNOL, V158, P733; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; GILL GN, 1984, J BIOL CHEM, V259, P7755; Hayashi H, 2004, CANCER IMMUNOL IMMUN, V53, P497, DOI 10.1007/s00262-003-0465-9; Jung G, 2001, INT J CANCER, V91, P225, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7; Kodama H, 2002, IMMUNOL LETT, V81, P99, DOI 10.1016/S0165-2478(01)00343-1; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006; Levene AP, 2005, J ROY SOC MED, V98, P146, DOI 10.1258/jrsm.98.4.146; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Pfosser A, 1999, INT J CANCER, V80, P612, DOI 10.1002/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Takemura S, 2000, PROTEIN ENG, V13, P583, DOI 10.1093/protein/13.8.583; Takemura S, 2002, CANCER IMMUNOL IMMUN, V51, P33, DOI 10.1007/s00262-001-0245-3; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5; Xie ZG, 2005, J IMMUNOL METHODS, V296, P95, DOI 10.1016/j.jim.2004.11.005; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	34	46	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27659	27665		10.1074/jbc.M704719200	http://dx.doi.org/10.1074/jbc.M704719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644522	hybrid			2022-12-27	WOS:000249455600013
J	Ringgaard, S; Lowe, J; Gerdes, K				Ringgaard, Simon; Lowe, Jan; Gerdes, Kenn			Centromere pairing by a plasmid-encoded type I ParB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-DNA SEGREGATION; PROKARYOTIC ACTIN HOMOLOG; PARTITIONING PROTEIN; CELL-CYCLE; R1; INCOMPATIBILITY; MECHANISM; OPERATOR; AUTOREGULATION; RECOGNITION	Thepar2 locus of Escherichia coli plasmid pB171 encodes two trans-acting proteins, ParA and ParB, and two cis-acting sites, parC1 and parC2, to which ParB binds cooperatively. ParA is related to MinD and oscillates in helical structures and thereby positions ParB/parC-carrying plasmids regularly over the nucleoid. ParB ribbon-helix-helix dimers bind cooperatively to direct repeats in parC1 and parC2. Using four different assays we obtain solid evidence that ParB can pair parC1- and parC2 encoding DNA fragments in vitro. Convincingly, electron microscopy revealed that ParB mediates binary pairing of parC fragments. In addition to binary complexes, ParB mediated the formation of higher order complexes consisting of several DNA fragments joined by ParB at centromere site parC. N-terminal truncated versions of ParB still possessing specific DNA binding activity were incompetent in pairing, hence identifying the N terminus of ParB as a requirement for ParB-mediated centromere pairing. These observations suggest that centromere pairing is an important intermediate step in plasmid partitioning mediated by the common type I loci.	Univ So Denmark, Dept Biochem & Mol Biol, Odense 5230, Denmark; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Newcastle, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Southern Denmark; MRC Laboratory Molecular Biology; Newcastle University - UK	Gerdes, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, Odense 5230, Denmark.	Kenn.Gerdes@newcastle.ac.uk	Gerdes, Kenn/AAS-5548-2021; Löwe, Jan/B-3882-2011; Gerdes, Kenn/M-2420-2014; Löwe, Jan/X-6998-2019	Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612; Ringgaard, Simon/0000-0002-4980-5964; Lowe, Jan/0000-0002-5218-6615	Medical Research Council [MC_U105184326] Funding Source: Medline; MRC [MC_U105184326] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi S, 2006, J MOL BIOL, V356, P850, DOI 10.1016/j.jmb.2005.11.088; Barilla D, 2005, EMBO J, V24, P1453, DOI 10.1038/sj.emboj.7600619; Barilla D, 2007, P NATL ACAD SCI USA, V104, P1811, DOI 10.1073/pnas.0607216104; Becker E, 2006, EMBO J, V25, P5919, DOI 10.1038/sj.emboj.7601443; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Bouet JY, 2006, MOL MICROBIOL, V62, P1447, DOI 10.1111/j.1365-2958.2006.05454.x; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; DAM M, 1994, J MOL BIOL, V236, P1289, DOI 10.1016/0022-2836(94)90058-2; Ebersbach G, 2005, ANNU REV GENET, V39, P453, DOI 10.1146/annurev.genet.38.072902.091252; Ebersbach G, 2005, MOL MICROBIOL, V56, P1430, DOI 10.1111/j.1365-2958.2005.04643.x; Ebersbach G, 2004, MOL MICROBIOL, V52, P385, DOI 10.1111/j.1365-2958.2004.04002.x; Ebersbach G, 2001, P NATL ACAD SCI USA, V98, P15078, DOI 10.1073/pnas.261569598; Ebersbach G, 2006, MOL MICROBIOL, V61, P1428, DOI 10.1111/j.1365-2958.2006.05322.x; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; Garner EC, 2004, SCIENCE, V306, P1021, DOI 10.1126/science.1101313; Garner EC, 2007, SCIENCE, V315, P1270, DOI 10.1126/science.1138527; Gerdes K, 2004, CELL, V116, P359, DOI 10.1016/S0092-8674(04)00116-3; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Golovanov AP, 2003, MOL MICROBIOL, V50, P1141, DOI 10.1046/j.1365-2958.2003.03750.x; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; Jensen RB, 1999, EMBO J, V18, P4076, DOI 10.1093/emboj/18.14.4076; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Lim GE, 2005, P NATL ACAD SCI USA, V102, P17658, DOI 10.1073/pnas.0507222102; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Ringgaard S, 2007, J BIOL CHEM, V282, P3134, DOI 10.1074/jbc.M609092200; Tobe T, 1999, INFECT IMMUN, V67, P5455, DOI 10.1128/IAI.67.10.5455-5462.1999	32	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28216	28225		10.1074/jbc.M703733200	http://dx.doi.org/10.1074/jbc.M703733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644524	hybrid			2022-12-27	WOS:000249455600071
J	Wakita, M; Masuda, S; Motohashi, K; Hisabori, T; Ohta, H; Takamiya, KI				Wakita, Masahiro; Masuda, Shinji; Motohashi, Ken; Hisabori, Toru; Ohta, Hiroyuki; Takamiya, Ken-Ichiro			The significance of type II and PrxQ peroxiredoxins for antioxidative stress response in the purple bacterium Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; GENE-EXPRESSION; THIOREDOXIN; REDOX; YEAST; RESISTANCE; TRANSPORT; HOMOLOG	Two peroxiredoxins, classified as Type II and PrxQ were characterized in the purple non-sulfur photosynthetic bacterium Rhodobacter sphaeroides. Both recombinant proteins showed remarkable thioredoxin-dependent peroxidase activity with broad substrate specificity in vitro. Nevertheless, PrxQ of R. sphaeroides, unlike typical PrxQs studied to date, does not contain one of the two conserved catalytic Cys residues. We found that R. sphaeroides PrxQ and other PrxQ-like proteins from several organisms conserve a different second Cys residue, indicating that these proteins should be categorized into a novel PrxQ subfamily. Disruption of either the Type II or PrxQ gene in R. sphaeroides had a dramatic effecton cell viability when the cells were grown under aerobic light or oxidative stress conditions created by exogenous addition of reactive oxygen species to the medium. Growth rates of the mutants were significantly decreased compared with that of wild type under aerobic but not anaerobic conditions. These results indicate that the peroxiredoxins are crucial for antioxidative stress response in this bacterium. The gene disruptants also demonstrated reduced levels of photopigment synthesis, suggesting that the peroxiredoxins are directly or indirectly involved in regulated synthesis of the photosynthetic apparatus.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Res Ctr Evolving Earth & Planets, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Agcy, ATP Syst Project Exploratory Res Adv Technol, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Masuda, S (corresponding author), Tokyo Inst Technol, Ctr Biol Resources & Informat, Yokohama, Kanagawa 2268501, Japan.	shmasuda@bio.titech.ac.jp	Ohta, Hiroyuki/B-1840-2014; Masuda, Shinji/A-2703-2014; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Ohta, Hiroyuki/0000-0002-1068-3242; Masuda, Shinji/0000-0002-5349-4927; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; Bauer C, 2003, PHILOS T R SOC B, V358, P147, DOI 10.1098/rstb.2002.1189; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; BORLAND CF, 1989, J PHOTOCH PHOTOBIO B, V3, P227; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; Finkemeier I, 2005, J BIOL CHEM, V280, P12168, DOI 10.1074/jbc.M413189200; Glaeser J, 2005, MICROBIOL-SGM, V151, P1927, DOI 10.1099/mic.0.27789-0; HALLIWELL B, 1999, FREE RADICAL BIO MED, P188; Hosoya-Matsuda N, 2005, J BIOL CHEM, V280, P840, DOI 10.1074/jbc.M411493200; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Kiba A, 2005, PLANT CELL PHYSIOL, V46, P1007, DOI 10.1093/pcp/pci109; KIM K, 1985, J BIOL CHEM, V260, P5394; Kong W, 2000, BIOCHEM J, V351, P107, DOI 10.1042/0264-6021:3510107; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Masuda S, 2004, J BACTERIOL, V186, P235, DOI 10.1128/JB.186.1.235-239.2004; MATSUURA K, 1994, J PLANT RES, V107, P191, DOI 10.1007/BF02346017; MCEWAN AG, 1994, ANTON LEEUW INT J G, V66, P151, DOI 10.1007/BF00871637; MEINHARDT SW, 1985, ARCH BIOCHEM BIOPHYS, V236, P130, DOI 10.1016/0003-9861(85)90612-5; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122; Pasternak C, 1997, MICROBIOL-UK, V143, P83, DOI 10.1099/00221287-143-1-83; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rouhier N, 2004, PLANT PHYSIOL, V134, P1027, DOI 10.1104/pp.103.035865; SHIMADA H, 1992, PLANT CELL PHYSIOL, V33, P471; Simon R., 1983, BIOTECHNOLOGY, V1, P37; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Wang G, 2006, BBA-GEN SUBJECTS, V1760, P1596, DOI 10.1016/j.bbagen.2006.05.005; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wong CM, 2004, J BIOL CHEM, V279, P23207, DOI 10.1074/jbc.M402095200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zamocky M, 2006, FEBS LETT, V580, P6655, DOI 10.1016/j.febslet.2006.11.017; Zeilstra-Ryalls JH, 2004, CELL MOL LIFE SCI, V61, P417, DOI 10.1007/s00018-003-3242-1; Zeller T, 2005, J BACTERIOL, V187, P7232, DOI 10.1128/JB.187.21.7232-7242.2005; Zeller T, 2004, MICROBIOL-SGM, V150, P3451, DOI 10.1099/mic.0.27308-0	41	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27792	27801		10.1074/jbc.M702855200	http://dx.doi.org/10.1074/jbc.M702855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644813	hybrid			2022-12-27	WOS:000249455600028
J	Fischer, A; Hekman, M; Kuhlmann, J; Rubio, I; Wiese, S; Rapp, UR				Fischer, Andreas; Hekman, Mirko; Kuhlmann, Juergen; Rubio, Ignacio; Wiese, Stefan; Rapp, Ulf R.			B- and C-RAF display essential differences in their binding to Ras - The isotype-specific N terminus of B-RAF facilitates ras binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACIO-CUTANEOUS SYNDROME; CYSTEINE-RICH DOMAIN; PROTEIN-KINASE; MAP KINASE; H-RAS; BIOLOGICAL-ACTIVITY; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; ZINC-FINGER; LIPID RAFTS	Recruitment of RAF kinases to the plasma membrane was initially proposed to be mediated by Ras proteins via interaction with the RAF Ras binding domain (RBD). Data reporting that RAF kinases possess high affinities for particular membrane lipids support a new model in which Ras-RAF interactions may be spatially restricted to the plane of the membrane. Although the coupling features of Ras binding to the isolated RAF RBD were investigated in great detail, little is known about the interactions of the processed Ras with the functional and full-length RAF kinases. Here we present a quantitative analysis of the binding properties of farnesylated and nonfarnesylated H-Ras to both full-length B- and C-RAF in the presence and absence of lipid environment. Although isolated RBD fragments associate with high affinity to both farnesylated and nonfarnesylated H-Ras, the full-length RAF kinases revealed fundamental differences with respect to Ras binding. In contrast to C-RAF that requires farnesylated H-Ras, cytosolic B- RAF associates effectively and with significantly higher affinity with both farnesylated and nonfarnesylated H-Ras. To investigate the potential farnesyl binding site(s) we prepared several N-terminal fragments of C-RAF and found that in the presence of cysteine-rich domain only the farnesylated form of H-Ras binds with high association rates. The extreme N terminus of B- RAF turned out to be responsible for the facilitation of lipid independent Ras binding to B- RAF, since truncation of this region resulted in a protein that changed its kinase properties and resembles C-RAF. In vivo studies usingPC12andCOS7cells support in vitro results. Co-localization measurements using labeled Ras and RAF documented essential differences between B- and C-RAF with respect to association with Ras. Taken together, these data suggest that the activation of B- RAF, in contrast to C-RAF, may take place both at the plasma membrane and in the cytosolic environment.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Jena, Ctr Mol Biomed, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97080 Wurzburg, Germany	University of Wurzburg; Max Planck Society; Friedrich Schiller University of Jena; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de	Fischer, Andreas/B-7715-2008					Augsten M, 2006, EMBO REP, V7, P46, DOI 10.1038/sj.embor.7400560; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Fridman M, 2000, BIOCHEMISTRY-US, V39, P15603, DOI 10.1021/bi001224x; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hekman M, 2005, FEBS LETT, V579, P464, DOI 10.1016/j.febslet.2004.11.105; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; RAJALINGAM K, 2007, BIOCHIM BIOPHYS ACTA; Rapp UR, 2006, CANCER CELL, V9, P9, DOI 10.1016/j.ccr.2005.12.022; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Thapar R, 2004, J MOL BIOL, V343, P1391, DOI 10.1016/j.jmb.2004.08.106; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Weber CK, 2001, CANCER RES, V61, P3595; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	55	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26503	10.1074/jbc.M607458200	http://dx.doi.org/10.1074/jbc.M607458200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635919	hybrid			2022-12-27	WOS:000249239600055
J	Hatori, Y; Majima, E; Tsuda, T; Toyoshima, C				Hatori, Yuta; Majima, Eiji; Tsuda, Takeo; Toyoshima, Chikashi			Domain organization and movements in heavy metal ion pumps - Papain digestion of CopA, a Cu+-transporting ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; WILSONS-DISEASE PROTEIN; P-TYPE ATPASES; ARCHAEOGLOBUS-FULGIDUS; CALCIUM-PUMP; ESCHERICHIA-COLI; BINDING DOMAIN; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; LISTERIA-MONOCYTOGENES	To study domain organization and movements in the reaction cycle of heavy metal ion pumps, CopA, a bacterial Cu+-ATPase from Thermotoga maritima was cloned, overexpressed, and purified, and then subjected to limited proteolysis using papain. Stable analogs of intermediate states were generated using AMPPCP as a nonhydrolyzable ATP analog and AlFx as a phosphate analog, following conditions established for Ca2+-ATPase (SERCA1). Characteristic digestion patterns obtained for different analog intermediates show that CopA undergoes domain rearrangements very similar to those of SERCA1. Digestion sites were identified on the loops connecting the A-domain and the transmembrane helices M2 and M3 as well as on that connecting the N-terminal metal binding domain (NMBD) and the first transmembrane helix, Ma. These digestion sites were protected in the E1P center dot ADP and E2P analogs, whereas the M2-A-domain loop was cleaved specifically in the absence of ions to be transported, just as in SERCA1. ATPase activity was lost when the link between the NMBD and the transmembrane domain was cleaved, indicating that the NMBD plays a critical role in ATP hydrolysis in T. maritima CopA. The change in susceptibility of the loop between the NMBD and Ma helix provides evidence that the NMBD is associated to the A-domain and recruited into domain rearrangements and that the Ma helix is the counterpart of the M1 helix in SERCA1 and Mb and Mc are uniquely inserted before M2.	Univ Tokyo, Inst Mol & Cellular Biol, Tokyo 1130032, Japan; ProteNova Co Ltd, Naruto 7720051, Japan	University of Tokyo	Toyoshima, C (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Tokyo 1130032, Japan.	ct@iam.u-tokyo.ac.jp	Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ALLEN G, 1980, BIOCHEM J, V187, P545, DOI 10.1042/bj1870545; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arguello JM, 2003, ANN NY ACAD SCI, V986, P212, DOI 10.1111/j.1749-6632.2003.tb07162.x; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; Bal N, 2003, BIOCHEM J, V369, P681, DOI 10.1042/BJ20021416; Bredeston LM, 2004, J BIOL CHEM, V279, P41619, DOI 10.1074/jbc.M403116200; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Dmitriev O, 2006, P NATL ACAD SCI USA, V103, P5302, DOI 10.1073/pnas.0507416103; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Good N E, 1972, Methods Enzymol, V24, P53; Grotz N, 2006, BBA-MOL CELL RES, V1763, P595, DOI 10.1016/j.bbamcr.2006.05.014; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Inesi G, 2006, BIOCHEMISTRY-US, V45, P13769, DOI 10.1021/bi061255d; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; POST RL, 1972, J BIOL CHEM, V247, P6530; Rice WJ, 2006, BIOCHEM BIOPH RES CO, V348, P124, DOI 10.1016/j.bbrc.2006.07.012; Sazinsky MH, 2006, BIOCHEMISTRY-US, V45, P9949, DOI 10.1021/bi0610045; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; SOENSEN TL, 2004, SCIENCE, V304, P1672; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Yang Y, 2007, BBA-BIOMEMBRANES, V1768, P495, DOI 10.1016/j.bbamem.2006.09.013	52	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25213	25221		10.1074/jbc.M703520200	http://dx.doi.org/10.1074/jbc.M703520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616523	hybrid			2022-12-27	WOS:000249014100006
J	Barrett, D; Wang, TSA; Yuan, Y; Zhang, Y; Kahne, D; Walker, S				Barrett, Dianah; Wang, Tsung-Shing Andrew; Yuan, Yanqiu; Zhang, Yi; Kahne, Daniel; Walker, Suzanne			Analysis of glycan polymers produced by peptidoglycan glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; MOENOMYCIN-A; LIPID-II; BACTERIAL TRANSGLYCOSYLASE; KINETIC CHARACTERIZATION; STAPHYLOCOCCUS-AUREUS; ANTIBIOTICS	Bacterial cells are surrounded by a cross-linked polymer called peptidoglycan, the integrity of which is necessary for cell survival. The carbohydrate chains that form the backbone of peptidoglycan are made by peptidoglycan glycosyltransferases (PGTs), highly conserved membrane-bound enzymes that are thought to be excellent targets for the development of new antibacterials. Although structural information on these enzymes recently became available, their mechanism is not well understood because of a dearth of methods to monitor PGT activity. Here we describe a direct, sensitive, and quantitative SDS-PAGE method to analyze PGT reactions. We apply this method to characterize the substrate specificity and product length profile for two different PGT domains, PBP1A from Aquifex aeolicus and PBP1A from Escherichia coli. We show that both disaccharide and tetrasaccharide diphospholipids (Lipid II and Lipid IV) serve as substrates for these PGTs, but the product distributions differ significantly depending on which substrate is used as the starting material. Reactions using the disaccharide substrate are more processive and yield much longer glycan products than reactions using the tetrasaccharide substrate. We also show that the SDS-PAGE method can be applied to provide information on the roles of invariant residues in catalysis. A comprehensive mutational analysis shows that the biggest contributor to turnover of 14 mutated residues is an invariant glutamate located in the center of the active site cleft. The assay and results described provide new information about the process by which PGTs assemble bacterial cell walls.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Kahne, D (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	kahne@chemistry.harvard.edu	Wang, Tsung-Shing/AAF-4974-2019	Wang, Tsung-Shing/0000-0002-4690-3438	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076710] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM076710, GM076710] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2006, J AM CHEM SOC, V128, P14012, DOI 10.1021/ja065905c; ANDERSON JS, 1966, ARCH BIOCHEM BIOPHYS, V116, P487, DOI 10.1016/0003-9861(66)90056-7; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chen L, 2003, P NATL ACAD SCI USA, V100, P5658, DOI 10.1073/pnas.0931492100; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; Lovering AL, 2007, SCIENCE, V315, P1402, DOI 10.1126/science.1136611; Macheboeuf P, 2006, FEMS MICROBIOL REV, V30, P673, DOI 10.1111/j.1574-6976.2006.00024.x; Offant J, 2006, BBA-PROTEINS PROTEOM, V1764, P1036, DOI 10.1016/j.bbapap.2006.03.012; Ostash B, 2005, CURR OPIN CHEM BIOL, V9, P459, DOI 10.1016/j.cbpa.2005.08.014; Ostash B, 2007, CHEM BIOL, V14, P257, DOI 10.1016/j.chembiol.2007.01.008; PERLSTEIN DL, 2007, IN PRESS J AM CHEM S; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; Schwartz B, 2002, BIOCHEMISTRY-US, V41, P12552, DOI 10.1021/bi026205x; Spratt BG, 1996, MOL MICROBIOL, V19, P639, DOI 10.1046/j.1365-2958.1996.442924.x; Taylor JG, 2006, J AM CHEM SOC, V128, P15084, DOI 10.1021/ja065907x; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; Terrak M, 2006, J BACTERIOL, V188, P2528, DOI 10.1128/JB.188.7.2528-2532.2006; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VanNieuwenhze MS, 2002, J AM CHEM SOC, V124, P3656, DOI 10.1021/ja017386d; Vollmer W, 2004, J BACTERIOL, V186, P5978, DOI 10.1128/jb.186.18.5978-5987.2004; Welzel P, 2005, CHEM REV, V105, P4610, DOI 10.1021/cr040634e; Ye XY, 2001, J AM CHEM SOC, V123, P3155, DOI 10.1021/ja010028q; Yuan YQ, 2007, P NATL ACAD SCI USA, V104, P5348, DOI 10.1073/pnas.0701160104; Zhang Y, 2007, J AM CHEM SOC, V129, P3080, DOI 10.1021/ja069060g	32	60	62	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					31964	31971		10.1074/jbc.M705440200	http://dx.doi.org/10.1074/jbc.M705440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17704540	Green Published, hybrid, Green Accepted			2022-12-27	WOS:000250480300017
J	Wu, H; Kao, SC; Barrientos, T; Baldwin, SH; Olson, EN; Crabtree, GR; Zhou, B; Chang, CP				Wu, Hai; Kao, Shih-Chu; Barrientos, Tomasa; Baldwin, Scott H.; Olson, Eric N.; Crabtree, Gerald R.; Zhou, Bin; Chang, Ching-Pin			Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-VALVE FORMATION; IN-VIVO; GENE-EXPRESSION; FETAL LOSS; NF-ATC; CALCINEURIN; CELLS; DSCR1; MORPHOGENESIS; HYPERTROPHY	Patients with Down syndrome have characteristic heart valve lesions resulting from endocardial cushion defects. The Down syndrome critical region 1 ( DSCR1) gene, identified at the conserved trisomic 21 region in those patients, encodes a calcineurin inhibitor that inactivates nuclear factor of activated T cells ( NFATc) activity. Here, we identify a regulatory sequence in the promoter region of human DSCR1 that dictates specific expression of a reporter gene in the endocardium, defined by the temporal and spatial expression of Nfatc1 during heart valve development. Activation of this evolutionally conserved DSCR1 regulatory sequence requires calcineurin and NFATc1 signaling in the endocardium. NFATc1 proteins bind to the regulatory sequence and trigger its enhancer activity. NFATc1 is sufficient to induce the expression of Dscr1 in cells that normally have undetectable or minimal NFATc1 or DSCR1. Pharmacologic inhibition of calcineurin or genetic Nfatc1 null mutation in mice abolishes the endocardial activity of this DSCR1 enhancer. Furthermore, in mice lacking endocardial NFATc1, the endogenous Dscr1 expression is specifically inhibited in the endocardium but not in the myocardium. Thus, our studies indicate that the DSCR1 gene is a direct transcriptional target of NFATc1 proteins within the endocardium during a critical window of heart valve formation.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Vanderbilt Univ, Dept Pediat Cardiol, Nashville, TN 37232 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University	Chang, CP (corresponding author), CCSR Bldg,Rm 3115-C,269 Campus Dr, Stanford, CA 94305 USA.	chingpin@stanford.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078881] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078881, R01 HL078881-01A2, R01 HL078881-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Chang CP, 2004, J CLIN INVEST, V113, P1051, DOI 10.1172/JCI200420049; Chang CP, 2003, GENESIS, V36, P7, DOI 10.1002/gene.10186; Chang CP, 2004, CELL, V118, P649, DOI 10.1016/j.cell.2004.08.010; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; EPSTEIN CJ, 1990, AM J MED GENET, P31; FERENCZ C, 1989, J PEDIATR-US, V114, P79, DOI 10.1016/S0022-3476(89)80605-5; GEGGEL RL, 1993, J PEDIATR-US, V122, P821, DOI 10.1016/S0022-3476(06)80036-3; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Lange AW, 2005, DEV DYNAM, V233, P954, DOI 10.1002/dvdy.20433; Lange AW, 2004, DEV BIOL, V266, P346, DOI 10.1016/j.ydbio.2003.10.036; Morris JK, 1999, PRENATAL DIAG, V19, P142, DOI 10.1002/(SICI)1097-0223(199902)19:2<142::AID-PD486>3.3.CO;2-Z; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Roper RJ, 2006, PLOS GENET, V2, P231, DOI 10.1371/journal.pgen.0020050; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sanna B, 2006, P NATL ACAD SCI USA, V103, P7327, DOI 10.1073/pnas.0509340103; Spencer K, 2001, PRENATAL DIAG, V21, P788, DOI 10.1002/pd.134; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhou B, 2005, DEVELOPMENT, V132, P1137, DOI 10.1242/dev.01640	31	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30673	30679		10.1074/jbc.M703622200	http://dx.doi.org/10.1074/jbc.M703622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17693409	Green Accepted, hybrid			2022-12-27	WOS:000250136300035
J	Anghel, SI; Bedu, E; Vivier, CD; Descombes, P; Desvergne, B; Wahli, W				Anghel, Silvia I.; Bedu, Elodie; Vivier, Celine Delucinge; Descombes, Patrick; Desvergne, Beatrice; Wahli, Walter			Adipose tissue integrity as a prerequisite for systemic energy balance - A critical role for peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PPAR-GAMMA; GENE-EXPRESSION; INSULIN-RESISTANCE; IGF-I; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MICE; MUSCLE; GLYCERONEOGENESIS; DIFFERENTIATION	Peroxisome proliferator- activated receptor gamma ( PPAR gamma) is an essential regulator of adipocyte differentiation, maintenance, and survival. Deregulations of its functions are associated with metabolic diseases. We show here that deletion of one PPAR gamma allele not only affected lipid storage but, more surprisingly, also the expression of genes involved in glucose uptake and utilization, the pentose phosphate pathway, fatty acid synthesis, lipolysis, and glycerol export as well as in IR/ IGF- 1 signaling. These deregulations led to reduced circulating adiponectin levels and an energy crisis in theWAT, reflected in a decrease to nearly half of its intracellular ATP content. In addition, there was a decrease in the metabolic rate and physical activity of the PPAR gamma(+/-) mice, which was abolished by thiazolidinedione treatment, thereby linking regulation of the metabolic rate and physical activity to PPAR gamma. It is likely that the PPAR gamma(+/-) phenotype was due to the observed WAT dysfunction, since the gene expression profiles associated with metabolic pathways were not affected either in the liver or the skeletal muscle. These findings highlight novel roles of PPAR gamma in the adipose tissue and underscore the multifaceted action of this receptor in the functional fine tuning of a tissue that is crucial for maintaining the organism in good health.	Univ Lausanne, Natl Res Ctr Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Geneva, Sch Med, Natl Res Ctr Frontiers Genet, CH-1211 Geneva, Switzerland	University of Lausanne; University of Geneva	Wahli, W (corresponding author), Univ Lausanne, Natl Res Ctr Frontiers Genet, Ctr Integrat Genom, Genopode Bldg, CH-1015 Lausanne, Switzerland.	walter.wahli@unil.ch	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Agostini M, 2004, ENDOCRINOLOGY, V145, P1527, DOI 10.1210/en.2003-1271; Allen T, 2006, DIABETES, V55, P2523, DOI 10.2337/db06-0618; Anghel SI, 2007, CELL RES, V17, P486, DOI 10.1038/cr.2007.48; Atsumi T, 2005, DIABETES, V54, P3349, DOI 10.2337/diabetes.54.12.3349; Beale EG, 2003, TRENDS BIOCHEM SCI, V28, P402, DOI 10.1016/S0968-0004(03)00163-4; Boden G, 2005, DIABETES, V54, P880, DOI 10.2337/diabetes.54.3.880; Cadoudal T, 2005, BIOCHIMIE, V87, P27, DOI 10.1016/j.biochi.2004.12.005; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; Clement K, 2000, INT J OBESITY, V24, P391, DOI 10.1038/sj.ijo.0801191; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Duan SZ, 2007, J CLIN INVEST, V117, P812, DOI 10.1172/JCI28859; Feige JN, 2007, J BIOL CHEM, V282, P19152, DOI 10.1074/jbc.M702724200; Frick F, 2000, AM J PHYSIOL-ENDOC M, V278, pE729, DOI 10.1152/ajpendo.2000.278.4.E729; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Gerfault V, 1999, GEN COMP ENDOCR, V114, P396, DOI 10.1006/gcen.1999.7271; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gosmain Y, 2005, J LIPID RES, V46, P697, DOI 10.1194/jlr.M400261-JLR200; Gosmain Y, 2004, DIABETES, V53, P321, DOI 10.2337/diabetes.53.2.321; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hegele RA, 2000, GENOME RES, V10, P652, DOI 10.1101/gr.10.5.652; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Ioudina M, 2004, BRAIN RES, V1004, P188, DOI 10.1016/j.brainres.2003.12.046; Jan V, 2004, ANTIVIR THER, V9, P555; Jitrapakdee S, 2005, J BIOL CHEM, V280, P27466, DOI 10.1074/jbc.M503836200; Jo SH, 2006, J IMMUNOL, V177, P3737, DOI 10.4049/jimmunol.177.6.3737; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemasters JJ, 2005, GASTROENTEROLOGY, V129, P351, DOI 10.1053/j.gastro.2005.06.006; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Ogura T, 2003, FEBS LETT, V542, P65, DOI 10.1016/S0014-5793(03)00339-9; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Rieusset J, 2004, MOL ENDOCRINOL, V18, P2363, DOI 10.1210/me.2003-0325; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; SAITO K, 2006, BIOCHIM BIOPHYS ACTA, V1761, P7093; Simha V, 2006, CURR OPIN LIPIDOL, V17, P162, DOI 10.1097/01.mol.0000217898.52197.18; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vickers MH, 2001, ENDOCRINOLOGY, V142, P3964, DOI 10.1210/en.142.9.3964; VOET D, 1990, BIOCHEMISTRY-US, P577; Wang T, 2006, ANNU REV PHYSIOL, V68, P223, DOI 10.1146/annurev.physiol.68.040104.105739; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	70	40	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29946	29957		10.1074/jbc.M702490200	http://dx.doi.org/10.1074/jbc.M702490200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699161	hybrid			2022-12-27	WOS:000249981200024
J	Lee, HHC; Walker, JA; Williams, JR; Goodier, RJ; Payne, JA; Moss, SJ				Lee, Henry H. C.; Walker, Joshua A.; Williams, Jeffery R.; Goodier, Richard J.; Payne, John A.; Moss, Stephen J.			Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL LOCALIZATION; INTRACELLULAR DOMAINS; NEURONAL MATURATION; MOUSE CEREBELLUM; EXPRESSION; TRANSMISSION; MODULATION; RECEPTORS; TERMINUS; SUBUNITS	The potassium chloride cotransporter KCC2 plays a major role inthemaintenanceoftransmembranechloridepotentialinmature neurons; thus KCC2 activity is critical for hyperpolarizing membrane currents generated upon the activation of gamma aminobutyric acid type A and glycine ( Gly) receptors that underlie fast synaptic inhibition in the adult central nervous system. However, to date an understanding of the cellular mechanism that neurons use to modulate the functional expression of KCC2 remains rudimentary. Using Escherichia coli expression coupled with in vitro kinase assays, we first established that protein kinaseC( PKC) can directly phosphorylate serine (940) ( Ser(940)) within the C- terminal cytoplasmic domain of KCC2. We further demonstrated that Ser(940) is the major site for PKC- dependent phosphorylation for full- length KCC2 molecules when expressed in HEK- 293 cells. Phosphorylation of Ser(940) increased the cell surface stability of KCC2 in this system by decreasing its rate of internalization from the plasma membrane. Coincident phosphorylation of Ser(940) increased the rate of ion transport by KCC2. It was further evident that phosphorylation of endogenous KCC2 in cultured hippocampal neurons is regulated by PKC- dependent activity. Moreover, in keeping with our recombinant studies, enhancing PKC- dependent phosphorylation increased the targeting of KCC2 to the neuronal cell surface. Our studies thus suggest that PKC- dependent phosphorylation of KCC2 may play a central role in modulating both the functional expression of this critical transporter in the brain and the strength of synaptic inhibition.	Univ Penn, Dept Neurosci, Sch Med, Philadelphia, PA 19104 USA; Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Pennsylvania; University of California System; University of California Davis; University of London; University College London	Moss, SJ (corresponding author), Univ Penn, Dept Neurosci, Sch Med, 215 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	Lee, Henry/GVS-2114-2022; Lee, Henry HC/S-6014-2016	Lee, Henry HC/0000-0003-4975-7330	NINDS NIH HHS [NS-047478, NS-036296, NS-048045] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036296, R01NS048045, R01NS047478, R29NS036296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adragna NC, 2004, J MEMBRANE BIOL, V201, P109, DOI 10.1007/s00232-004-0695-6; Bergeron MJ, 2006, J BIOL CHEM, V281, P15959, DOI 10.1074/jbc.M600015200; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Fiumelli H, 2005, NEURON, V48, P773, DOI 10.1016/j.neuron.2005.10.025; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Karadsheh MF, 2001, J NEUROPHYSIOL, V85, P995, DOI 10.1152/jn.2001.85.2.995; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Lee H, 2005, EUR J NEUROSCI, V21, P2593, DOI 10.1111/j.1460-9568.2005.04084.x; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1997, NEUROPHARMACOLOGY, V36, P1377, DOI 10.1016/S0028-3908(97)00111-1; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Price TJ, 2005, CURR TOP MED CHEM, V5, P547, DOI 10.2174/1568026054367629; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Senawongse P, 2005, J CHEM INF MODEL, V45, P1147, DOI 10.1021/ci050047+; Staley KJ, 2004, ADV EXP MED BIOL, V548, P104; Stein V, 2004, J COMP NEUROL, V468, P57, DOI 10.1002/cne.10983; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Takayama C, 2006, NEUROSCIENCE, V143, P757, DOI 10.1016/j.neuroscience.2006.08.044; Takayama C, 2007, NEUROSCI RES, V57, P322, DOI 10.1016/j.neures.2006.10.016; Uvarov P, 2005, J NEUROCHEM, V95, P1144, DOI 10.1111/j.1471-4159.2005.03434.x; Wake H, 2007, J NEUROSCI, V27, P1642, DOI 10.1523/JNEUROSCI.3104-06.2007; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656	28	198	201	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29777	29784		10.1074/jbc.M705053200	http://dx.doi.org/10.1074/jbc.M705053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693402	hybrid			2022-12-27	WOS:000249981200006
J	Young, JE; Gouw, L; Propp, S; Sopher, BL; Taylor, J; Lin, A; Hermel, E; Logvinova, A; Chen, SF; Chen, S; Bredesen, DE; Truant, R; Ptacek, LJ; La Spada, AR; Ellerby, LM				Young, Jessica E.; Gouw, Launce; Propp, Stephanie; Sopher, Bryce L.; Taylor, Jillian; Lin, Amy; Hermel, Evan; Logvinova, Anna; Chen, Sylvia F.; Chen, Shiming; Bredesen, Dale E.; Truant, Ray; Ptacek, Louis J.; La Spada, Albert R.; Ellerby, Lisa M.			Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTIN REDUCES TOXICITY; MACHADO-JOSEPH-DISEASE; CONE-ROD DYSTROPHY; NUCLEAR-LOCALIZATION; EXPANDED POLYGLUTAMINE; EMBRYONIC LETHALITY; ANDROGEN RECEPTOR; MUTANT HUNTINGTIN; MOUSE MODEL; CAG REPEAT	Spinocerebellar ataxia type 7 ( SCA7) is a polyglutamine ( polyQ) disorder characterized by specific degeneration of cerebellar, brainstem, and retinal neurons. Although they share little sequence homology, proteins implicated in polyQ disorders have common properties beyond their characteristic polyQ tract. These include the production of proteolytic fragments, nuclear accumulation, and processing by caspases. Here we report that ataxin-7 is cleaved by caspase-7, and we map two putative caspase-7 cleavage sites to Asp residues at positions 266 and 344 of the ataxin-7 protein. Site-directed mutagenesis of these two caspase-7 cleavage sites in the polyQ-expanded form of ataxin-7 produces an ataxin-7 D266N/D344N protein that is resistant to caspase cleavage. Although ataxin-7 displays toxicity, forms nuclear aggregates, and represses transcription in human embryonic kidney 293T cells in a polyQ length-dependent manner, expression of the non-cleavable D266N/D344N form of polyQ-expanded ataxin-7 attenuated cell death, aggregate formation, and transcriptional interference. Expression of the caspase-7 truncation product of ataxin-7-69Q or -92Q, which removes the putative nuclear export signal and nuclear localization signals of ataxin-7, showed increased cellular toxicity. We also detected N-terminal polyQ-expanded ataxin-7 cleavage products in SCA7 transgenic mice similar in size to those generated by caspase-7 cleavage. In a SCA7 transgenic mouse model, recruitment of caspase-7 into the nucleus by polyQ-expanded ataxin-7 correlated with its activation. Our results, thus, suggest that proteolytic processing of ataxin-7 by caspase-7 may contribute to SCA7 disease pathogenesis.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Neurol, San Francisco, CA 94143 USA; Univ Washington, Med Ctr, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Med Med Genet, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Neurol Neurogenet, Seattle, WA 98195 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Touro Univ Coll Osteopath Med, Vallejo, CA 94592 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Buck Institute for Research on Aging; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; McMaster University; Touro University California; Washington University (WUSTL)	Ellerby, LM (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	lellerby@buckinstitute.org	La Spada, Albert/AAG-8809-2020	Achenbach, Jillian/0000-0002-1054-3784	NEI NIH HHS [R01 EY012543, EY14061] Funding Source: Medline; NINDS NIH HHS [NS40251A] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014061, R01EY012543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Einum DD, 2001, NEUROGENETICS, V3, P83, DOI 10.1007/s100480000100; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GOUW LG, 1994, NEUROLOGY, V44, P1441, DOI 10.1212/WNL.44.8.1441; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hardy JA, 2004, P NATL ACAD SCI USA, V101, P12461, DOI 10.1073/pnas.0404781101; Helmlinger D, 2006, BIOCHEM SOC SYMP, V73, P155; Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lines MA, 2002, OPHTHALMOLOGY, V109, P1862, DOI 10.1016/S0161-6420(02)01187-9; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Mushegian AR, 2000, BIOCHEMISTRY-US, V39, P6809, DOI 10.1021/bi992694y; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Taylor J, 2006, J BIOL CHEM, V281, P2730, DOI 10.1074/jbc.M506751200; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	60	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30150	30160		10.1074/jbc.M705265200	http://dx.doi.org/10.1074/jbc.M705265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17646170	hybrid			2022-12-27	WOS:000249981200045
J	Im, E; Kazlauskas, A				Im, Eunok; Kazlauskas, Andrius			Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-BETA-RECEPTOR; CELLULAR-TRANSFORMATION; MACULAR DEGENERATION; ANGIOGENESIS; ACTIVATION; RHO; DISEASE; CELLS; REQUIREMENT	Src family kinases (SFKs) are one of the signaling enzymes that contribute to angiogenesis, but their precise input to the various phases of the angiogenic program has not been defined. Using an in vitro model system, we discovered that SFKs promoted the formation of tubes and prevented their regression. They suppressed regression by activating the ERK pathway that antagonized the Rho/ROCK pathway, which was essential for regression. These studies reveal that SFKs contribute to several phases of the angiogenic program and identify the downstream effectors by which SFKs stabilize tubes.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	ak@eri.harvard.edu			NATIONAL EYE INSTITUTE [R03EY016385, R01EY018344] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY018344, EY016385] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GITLIN JD, 1983, MICROVASC RES, V26, P74, DOI 10.1016/0026-2862(83)90056-0; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Halstead JR, 2006, CURR BIOL, V16, P1850, DOI 10.1016/j.cub.2006.07.066; Halstead JR, 2005, TRENDS PHARMACOL SCI, V26, P654, DOI 10.1016/j.tips.2005.10.004; Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029; Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100; Im E, 2006, CELL CYCLE, V5, P2057, DOI 10.4161/cc.5.18.3210; Janiak A, 2006, MOL BIOL CELL, V17, P1606, DOI 10.1091/mbc.E05-06-0549; Jin W, 2007, CANCER RES, V67, P3192, DOI 10.1158/0008-5472.CAN-06-3526; Knott RM, 1999, DIABETOLOGIA, V42, P870, DOI 10.1007/s001250051240; LANG R, 1994, DEVELOPMENT, V120, P3395; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje; Qiao YF, 2006, SCIENCE, V311, P1293, DOI 10.1126/science.1122224; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Thamilselvan V, 2007, FASEB J, V21, P1730, DOI 10.1096/fj.06-6545com; Tolloczko B, 2002, AM J PHYSIOL-LUNG C, V282, pL1305, DOI 10.1152/ajplung.00304.2001; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Werdich Xiang Q., 2005, Angiogenesis, V8, P315	38	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29122	29129		10.1074/jbc.M702637200	http://dx.doi.org/10.1074/jbc.M702637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684019	hybrid			2022-12-27	WOS:000249788000007
J	Morten, IJ; Gosal, WS; Radford, SE; Hewitt, EW				Morten, Isobel J.; Gosal, Walraj S.; Radford, Sheena E.; Hewitt, Eric W.			Investigation into the role of macrophages in the formation and degradation of beta(2)-microglobulin amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS; DISULFIDE BOND; CELL-CULTURE; BETA-2-MICROGLOBULIN; PROTEIN; AGGREGATION; PATHOGENESIS; DEPOLYMERIZATION; PHAGOCYTOSIS	Dialysis related amyloidosis is a serious complication of longterm hemodialysis in which beta(2)-microglobulin (beta(2)m) forms amyloid fibrils that deposit predominantly in cartilaginous tissues. How these fibrils form in vivo, however, is poorly understood. Here we perform a systematic investigation into the role of macrophages in the formation and degradation of beta(2)m amyloid fibrils, building on observations that macrophages are found in association with beta(2)m amyloid deposits in vivo and that these cells contain intra-lysosomal beta(2)m amyloid. In live cell imaging experiments we demonstrate that macrophages internalize monomeric beta(2)m, whereupon it is sorted to lysosomes. At lysosomal pH beta(2)m self-associates in vitro to form amyloid-like fibrils with an array of morphologies as visualized by atomic force microscopy. Cleavage of the monomeric protein by both macrophages and lysosomal proteases isolated from these cells results in the rapid degradation of the monomeric protein, preventing amyloid formation. Incubation of macrophages with preformed fibrils revealed that macrophages internalize amyloid-like fibrils formed extracellularly, but in marked contrast with the monomeric protein, the fibrils were not degraded within macrophage lysosomes. Correspondingly beta(2)m fibrils were highly resistant to degradation by high concentrations of lysosomal proteases isolated from macrophages. Despite their enormous degradative capacity, therefore, macrophage lysosomes cannot ameliorate dialysis-related amyloidosis by degrading pre-existing amyloid fibrils, but lysosomal proteases may play a protective role by eliminating amyloid precursors before beta(2)m fibrils can accumulate in what may represent an otherwise fibrillogenic environment.	Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hewitt, EW (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England.	e.w.hewitt@leeds.ac.uk	Gosal, Walraj/J-5260-2012	Gosal, Walraj/0000-0003-3396-1505; Radford, Sheena/0000-0002-3079-8039; Hewitt, Eric/0000-0002-6238-6303	Biotechnology and Biological Sciences Research Council [SF16972] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARGILES A, 1994, NEPHROL DIAL TRANSPL, V9, P662, DOI 10.1093/ndt/9.6.662; Argiles A, 2002, NEPHROL DIAL TRANSPL, V17, P1136, DOI 10.1093/ndt/17.6.1136; Badman MK, 1998, CELL TISSUE RES, V291, P285, DOI 10.1007/s004410050998; Borysik AJ, 2007, KIDNEY INT, V72, P174, DOI 10.1038/sj.ki.5002270; CAMPISTOL JM, 1992, AM J PATHOL, V141, P241; Chen CS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-21; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DeLano W.L., 2000, PYMOL MOL GRAPHICS S; Elimova E, 2004, FASEB J, V18, P1749, DOI 10.1096/fj.03-1436fje; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Floege J, 1996, NEPHRON, V72, P9, DOI 10.1159/000188801; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Garcia-Garcia M, 1999, KIDNEY INT, V55, P899, DOI 10.1046/j.1523-1755.1999.055003899.x; Gargar C, 1999, KIDNEY INT, V55, P1983, DOI 10.1046/j.1523-1755.1999.00430.x; GEJYO F, 1986, NEW ENGL J MED, V314, P585; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Heegaard NHH, 2005, BIOCHEMISTRY-US, V44, P4397, DOI 10.1021/bi047594t; IIDA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1235, DOI 10.1006/bbrc.1994.1837; INOUE H, 1995, NEPHROL DIAL TRANSPL, V10, P2077; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kluve-Beckerman B, 1999, AM J PATHOL, V155, P123, DOI 10.1016/S0002-9440(10)65107-3; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; LeVine H, 1997, ARCH BIOCHEM BIOPHYS, V342, P306, DOI 10.1006/abbi.1997.0137; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Mimmi MC, 2006, FEBS J, V273, P2461, DOI 10.1111/J.1742-4658.2006.05254.x; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; Monti M, 2004, J MOL BIOL, V336, P253, DOI 10.1016/j.jmb.2003.10.082; Morten I. J., 2007, PROTEIN REV PROTEI B, V6, P217; MORTEN IJ, 2007, THESIS U LEEDS; Myers SL, 2006, BIOCHEMISTRY-US, V45, P2311, DOI 10.1021/bi052434i; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; O'Neill KD, 2003, NEPHROL DIAL TRANSPL, V18, P46, DOI 10.1093/ndt/18.1.46; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; OHASHI K, 1992, KIDNEY INT, V41, P1646, DOI 10.1038/ki.1992.237; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Relini A, 2006, J BIOL CHEM, V281, P16521, DOI 10.1074/jbc.M513827200; SARGENT MA, 1989, CLIN RADIOL, V40, P277, DOI 10.1016/S0009-9260(89)80201-6; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Stoppini M, 2005, BBA-PROTEINS PROTEOM, V1753, P23, DOI 10.1016/j.bbapap.2005.07.019; Stoppini M, 2000, KIDNEY INT, V57, P349, DOI 10.1046/j.1523-1755.2000.00851.x; Tagouri YM, 1996, LAB INVEST, V74, P290; Tennent GA, 1999, METHOD ENZYMOL, V309, P26; Tjelle TE, 2000, BIOESSAYS, V22, P255, DOI 10.1002/(SICI)1521-1878(200003)22:3<255::AID-BIES7>3.0.CO;2-R; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Yamaguchi I, 2003, KIDNEY INT, V64, P1080, DOI 10.1046/j.1523-1755.2003.00167.x; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com	60	27	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29691	29700		10.1074/jbc.M705004200	http://dx.doi.org/10.1074/jbc.M705004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686767	hybrid			2022-12-27	WOS:000249788000065
J	Zhong, ZH; Jiang, WQ; Cesare, AJ; Neumann, AA; Wadhwa, R; Reddel, RR				Zhong, Ze-Huai; Jiang, Wei-Qin; Cesare, Anthony J.; Neumann, Axel A.; Wadhwa, Renu; Reddel, Roger R.			Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; PROMYELOCYTIC LEUKEMIA BODIES; TELANGIECTASIA-LIKE DISORDER; DNA-REPAIR; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; TARGETED DISRUPTION; CATALYTIC SUBUNIT; SYNDROME GENE; NBS1	Immortalized human cells are able to maintain their telomeres by telomerase or by a recombination-mediated DNA replication mechanism known as alternative lengthening of telomeres (ALT). We showed previously that overexpression of Sp100 protein can suppress ALT and that this was associated with sequestration of the MRE11/RAD50/NBS1 (MRN) recombination protein complex by Sp100. In the present study, we determined whether MRN proteins are required for ALT activity. ALT cells were depleted of MRN proteins by small hairpin RNA-mediated knockdown, which was maintained for up to 100 population doublings. Knockdown of NBS1 had no effect on the level of RAD50 or MRE11, but knockdown of RAD50 also depleted cells of NBS1, and knockdown of MRE11 depleted cells of all three MRN proteins. Depletion of NBS1, with or without depletion of other members of the complex, resulted in inhibition of ALT-mediated telomere maintenance, as evidenced by decreased numbers of ALT-associated promyelocytic leukemia bodies and decreased telomere length. In some clones there was an initial period of rapid shortening followed by stabilization of telomere length, whereas in others there was continuous shortening at a rate within the reported range for normal human somatic cells lacking a telomere maintenance mechanism. In contrast, depletion of NBS1 in telomerase-positive cells did not result in telomere shortening. A recent study showed that NBS1 was required for the formation of extrachromosomal telomeric circles (Compton, S. A., Choi, J. H., Cesare, A. J., Ozgur, S., and Griffith, J. D. (2007) Cancer Res. 67, 1513-1519), also a marker for ALT. We conclude that the MRN complex, and especially NBS1, is required for the ALT mechanism.	Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Natl Inst Adv Ind Sci & Technol, Cell Proliferat Res Grp, Res Inst Cell Engn, Tsukuba, Ibaraki 3058562, Japan	Children's Medical Research Institute - Australia; University of Sydney; National Institute of Advanced Industrial Science & Technology (AIST)	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Cesare, Anthony J/F-4691-2010; Reddel, Roger R/A-6635-2014; Neumann, Axel/D-3319-2012; Wadhwa, Renu/L-8898-2018; Cesare, Anthony/N-7415-2019	Cesare, Anthony J/0000-0002-0864-1254; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192; Cesare, Anthony/0000-0002-0864-1254				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Compton SA, 2007, CANCER RES, V67, P1513, DOI 10.1158/0008-5472.CAN-06-3672; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Gallego ME, 2001, P NATL ACAD SCI USA, V98, P1711, DOI 10.1073/pnas.98.4.1711; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Jiang WQ, 2007, ONCOGENE, V26, P4635, DOI 10.1038/sj.onc.1210260; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Ueno M, 2003, MOL CELL BIOL, V23, P6553, DOI 10.1128/MCB.23.18.6553-6563.2003; van Engelen BGM, 2001, HUM IMMUNOL, V62, P1324, DOI 10.1016/S0198-8859(01)00345-7; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	49	114	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29314	29322		10.1074/jbc.M701413200	http://dx.doi.org/10.1074/jbc.M701413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693401	hybrid			2022-12-27	WOS:000249788000028
J	Perez-Pinera, P; Zhang, W; Chang, YC; Vega, JA; Deuel, TF				Perez-Pinera, Pablo; Zhang, Wei; Chang, Yunchao; Antonio Vega, Jose; Deuel, Thomas F.			Anaplastic lymphoma kinase is activated through the Pleiotrophin/Receptor protein-tyrosine phosphatase beta/zeta signaling pathway - An alternative mechanism of receptor tyrosine kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; NON-HODGKINS-LYMPHOMA; NEURITE OUTGROWTH; BETA-ADDUCIN; ALK; GROWTH; PHOSPHORYLATION; GENE; IDENTIFICATION; EXPRESSION	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) first discovered as the constitutively active nucleophosmin ALK oncoprotein in anaplastic large cell lymphomas (ALCL). Fulllength ALK has a critical role in normal development and differentiation. Activated full-length ALK also is found in different malignant cancers. Nevertheless, the ligand to activate ALK remained unknown until recently, when ALK was proposed to be the physiological receptor of the cytokine pleiotrophin (PTN, Ptn). However, earlier studies had demonstrated that receptor protein tyrosine phosphatase (RPTP) beta/zeta is a physiological PTN receptor. We now demonstrate that phosphorylation of ALK in PTN-stimulated cells is mediated through the PTN/ RPTP beta/zeta signaling pathway. ALK is phosphorylated independently of a direct interaction of PTN with ALK. The data thus support a unique model of ALK activation. In cells not stimulated by PTN, RPTP beta/zeta dephosphorylates ALK at the site(s) in ALK that is undergoing autophosphorylation through autoactivation. In contrast, when RPTP beta/zeta is inactivated in PTN-stimulated cells, the sites that are autophosphorylated in ALK no longer can be dephosphorylated by RPTP beta/zeta; thus, autoactivation and tyrosine phosphorylation of ALK rapidly increase. The data indicate that the PTN/ RPTP beta/zeta signaling pathway is a critical regulator of the steady state levels of tyrosine phosphorylation and activation of ALK; the data support the conclusion that ALK phosphorylation and activation in PTN-stimulated cells are increased through a unique " alternative mechanism of RTK activation."	Scripps Res Inst, La Jolla, CA 92037 USA; Univ San Pablo CEU, Madrid, Spain	Scripps Research Institute; San Pablo CEU University	Deuel, TF (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tfdeuel@scripps.edu	Vega, Jose A/AAG-3209-2021	Perez-Pinera, Pablo/0000-0002-9167-0004	NCI NIH HHS [CA84400] Funding Source: Medline; NIDDK NIH HHS [2 T32 DK007022-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Dewang PM, 2005, CURR MED CHEM, V12, P1; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; Fukada M, 2006, FEBS LETT, V580, P4051, DOI 10.1016/j.febslet.2006.06.041; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; LEBEAU MM, 1989, LEUKEMIA, V3, P866; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Pariser H, 2005, P NATL ACAD SCI USA, V102, P12407, DOI 10.1073/pnas.0505901102; Pariser H, 2005, BIOCHEM BIOPH RES CO, V335, P232, DOI 10.1016/j.bbrc.2005.07.060; Pariser H, 2005, BIOCHEM BIOPH RES CO, V332, P664, DOI 10.1016/j.bbrc.2005.05.007; Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Schlessinger J, 1993, Harvey Lect, V89, P105; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tamura H, 2006, NEUROSCI LETT, V399, P33, DOI 10.1016/j.neulet.2006.01.045; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Zhang N, 2006, BIOCHEM BIOPH RES CO, V343, P653, DOI 10.1016/j.bbrc.2006.03.006	33	107	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28683	28690		10.1074/jbc.M704505200	http://dx.doi.org/10.1074/jbc.M704505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17681947	hybrid			2022-12-27	WOS:000249642100042
J	Schoenwaelder, SM; Ono, A; Sturgeon, S; Chan, SM; Mangin, P; Maxwell, MJ; Turnbull, S; Mulchandani, M; Anderson, K; Kauffenstein, G; Rewcastle, GW; Kendall, J; Gachet, C; Salem, HH; Jackson, SP				Schoenwaelder, Simone M.; Ono, Akiko; Sturgeon, Sharelle; Chan, Siew Mei; Mangin, Pierre; Maxwell, Mhairi J.; Turnbull, Shannon; Mulchandani, Megha; Anderson, Karen; Kauffenstein, Gilles; Rewcastle, Gordon W.; Kendall, Jackie; Gachet, Christian; Salem, Hatem H.; Jackson, Shaun P.			Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha(IIb)beta(3) adhesive function in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; BETA-GAMMA-SUBUNITS; CLASS-IA PI3K; CELL-ADHESION; COUPLED RECEPTORS; P2 RECEPTORS; ACTIVATION; AGGREGATION; 3-KINASE; KINASE	Phosphoinositide (PI) 3-kinases play an important role in regulating the adhesive function of a variety of cell types through affinity modulation of integrins. Two type IPI3-kinase isoforms(p110 beta and p110 gamma) have been implicated in G(i)-dependent integrin alpha IIb beta 3 regulation in platelets, however, the mechanisms by which they coordinate their signaling function remains unknown. By employing isoform-selective PI 3-kinase inhibitors and knock-out mouse models we have identified a unique mechanism of PI 3-kinase signaling co-operativity in platelets. We demonstrate that p110 beta is primarily responsible for Gi-dependent phosphatidylinositol 3,4-bisphosphate (PI(3,4) P-2) production in ADP-stimulated platelets and is linked to the activation of Rap1b and AKT. In contrast, defective integrin alpha(IIb)beta(3) activation in p110 gamma(-/)-platelets was not associated with alterations in the levels of PI(3,4) P2 or active Rap1b/ AKT. Analysis of the effects of active site pharmacological inhibitors confirmed that p110 gamma principally regulated integrin alpha(IIb)beta(3) activation through a non-catalytic signaling mechanism. Inhibitionof the kinase function of PI 3-kinases, combined with deletion of p110 gamma, led to a major reduction in integrin alpha(IIb)beta(3) activation, resulting in a profound defect in platelet aggregation, hemostatic plug formation, and arterial thrombosis. These studies demonstrate a kinaseindependent signaling function for p110 gamma in platelets. Moreover, they demonstrate that the combined catalytic and non-catalytic signaling function of p110 beta and p110 gamma is critical for P2Y(12)/ Gi-dependent integrin alpha(IIb)beta(3) regulation. These findings have potentially important implications for the rationale design of novel antiplatelet therapies targeting PI 3-kinase signaling pathways.	Monash Univ, Alfred Med Res & Educ Precint, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; EFS Alsace, INSERM U 311, Strasbourg, France; Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland 1020, New Zealand	Monash University; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Auckland	Jackson, SP (corresponding author), Monash Univ, Alfred Med Res & Educ Precint, Australian Ctr Blood Dis, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	Shaun.Jackson@med.monash.edu.au	Kauffenstein, Gilles/K-2867-2015; Maxwell, Mhairi/G-5492-2011; Schoenwaelder, Simone/E-9506-2011; Gachet, Christian/H-9156-2016; Mangin, Pierre/H-9354-2016	Kauffenstein, Gilles/0000-0003-4994-8305; Jackson, Shaun/0000-0002-4750-1991; Anderson, Karen/0000-0002-7394-6660; Schoenwaelder, Simone/0000-0003-0465-5840				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cosemans JMEM, 2006, BLOOD, V108, P3045, DOI 10.1182/blood-2006-03-006338; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; Eltit JM, 2006, J BIOL CHEM, V281, P12143, DOI 10.1074/jbc.M511218200; Feigelson SW, 2003, J BIOL CHEM, V278, P51203, DOI 10.1074/jbc.M303601200; Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gachet C, 2005, PHARMACOL THERAPEUT, V108, P180, DOI 10.1016/j.pharmthera.2005.03.009; Gachet C, 2005, SEMIN THROMB HEMOST, V31, P162, DOI 10.1055/s-2005-869521; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Gukovsky I, 2004, GASTROENTEROLOGY, V126, P554, DOI 10.1053/j.gastro.2003.11.017; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Lian LR, 2005, BLOOD, V106, P110, DOI 10.1182/blood-2004-05-2005; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Mangin P, 2006, BLOOD, V107, P4346, DOI 10.1182/blood-2005-10-4244; Maxwell MJ, 2007, BLOOD, V109, P566, DOI 10.1182/blood-2006-07-028282; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Paul BZS, 2003, J THROMB HAEMOST, V1, P814, DOI 10.1046/j.1538-7836.2003.00099.x; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Piccio L, 2002, J IMMUNOL, V168, P1940, DOI 10.4049/jimmunol.168.4.1940; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SADHU C, 2003, Patent No. 20040266780; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Shankar H, 2004, BLOOD, V104, P1335, DOI 10.1182/blood-2004-01-0069; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Van Kolen K, 2004, J NEUROCHEM, V89, P442, DOI 10.1111/j.1471-4159.2004.02339.x; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang J, 2007, MOL CANCER THER, V6, P1143, DOI 10.1158/1535-7163.MCT-06-0555; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103; ZHAO JJ, 2006, SCI STKE	69	71	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28648	28658		10.1074/jbc.M704358200	http://dx.doi.org/10.1074/jbc.M704358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673465	hybrid			2022-12-27	WOS:000249642100039
J	Xie, LL; Jiang, Y; Ouyang, P; Chen, J; Doan, H; Herndon, B; Sylvester, JE; Zhang, K; Molteni, A; Reichle, M; Zhang, RQ; Haub, MD; Baybutt, RC; Wang, WQ				Xie, Linglin; Jiang, Yu; Ouyang, Ping; Chen, Jie; Doan, Hieu; Herndon, Betty; Sylvester, Jessica E.; Zhang, Ke; Molteni, Agostino; Reichle, Marie; Zhang, Rongqing; Haub, Mark D.; Baybutt, Richard C.; Wang, Weiqun			Effects of dietary calorie restriction or exercise on the PI3K and ras signaling pathways in the skin of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ENERGY RESTRICTION; INTESTINAL TUMORIGENESIS; MESSENGER-RNA; CANCER; PROTEIN; RATS; CARCINOGENESIS; INHIBITION; EXPRESSION	Weight control by exercise and dietary calorie restriction (DCR) has been associated with reduced cancer risk, but the underlying mechanisms are not well understood. This study was designed to compare the effects of weight loss by increasing physical activity or decreasing calorie intake on tumor promoter-induced Ras-MAPK and PI3K-Akt pathways. SENCAR mice were randomly assigned to one of the following five groups: ad libitum-fed sedentary control, ad libitum-fed exercise (AL+Exe), exercise but pair-fed at the amount as controls (PF+Exe), 20% DCR, and 20% DCR plus exercise (DCR+Exe). After 10 weeks, body weight and body fat significantly decreased in the groups of DCR, DCR + Exe, and PF + Exe when compared with the controls. AL + Exe did not induce weight loss due to, at least in part, increased food intake. Plasma IGF-1 levels reduced significantly in DCR and DCR+Exe but not PF+Exe. The protein H-Ras and activated Ras-GTP significantly decreased in TPA-induced skin tissues of DCR-fed mice but not exercised mice. PI3K protein, phosphoserine Akt, and p42/p44-MAPK were reduced, however, in both DCR and PF+Exe groups. Immunohistochemistry demonstrated that the significantly reduced H-Ras occurred in subcutaneous fat cells, while the reduced PI3K and PCNA took place only in the epidermis. Plasma leptin decreased in PF + Exe, DCR, and DCR + Exe, while the caspase-3 activity increased in DCR+Exe only. Genomic microarray analysis further indicated that the expression of 34 genes relevant to PI3K and 31 genes to the MAPK pathway were significantly regulated by either DCR or PF+Exe treatments. The reduced PI3K in PF+Exe mice was partially reversed by IGF-1 treatment. The overall results of this study demonstrated that DCR abrogated both Ras and PI3K signaling, which might inhibit TPA-induced proliferation and anti-apoptosis. Selective inhibition of PI3K by PF+Exe but not AL+Exe seems more attributable to the magnitude of the caloric deficit and/or body fat loss than diet versus exercise comparison.	Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Stat, Manhattan, KS 66506 USA; Univ Missouri, Sch Med, Kansas City, MO 64108 USA	Kansas State University; Kansas State University; Kansas State University; University of Missouri System; University of Missouri Kansas City	Wang, WQ (corresponding author), Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA.	wwang@ksu.edu	Haub, Mark/E-7846-2010		NATIONAL CANCER INSTITUTE [R01CA106397] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106397] Funding Source: Medline; NCRR NIH HHS [P20 RR15563] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Berstein L M, 2005, Adv Gerontol, V16, P51; Birt DF, 2001, CANCER EPIDEM BIOMAR, V10, P679; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; Dean DJ, 1998, AGING-CLIN EXP RES, V10, P303, DOI 10.1007/BF03339792; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Figlewicz DP, 2001, PHYSIOL BEHAV, V73, P229, DOI 10.1016/S0031-9384(01)00486-3; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; HAGAN H, 2003, EMBO REP, V3, P418; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; HURSTING SD, 1993, CANCER RES, V53, P2750; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV, V6; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; KLURFELD DM, 1989, J NUTR, V119, P286, DOI 10.1093/jn/119.2.286; Kritchevsky D, 2003, J NUTR, V133, p3827S, DOI 10.1093/jn/133.11.3827S; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; Liu YH, 2002, CANCER EPIDEM BIOMAR, V11, P299; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lu J, 2007, EXP BIOL MED, V232, P473; Mai V, 2003, CANCER RES, V63, P1752; MARIANO B, 1987, ANNU REV BIOCHEM, V56, P779; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Michna L, 2006, CARCINOGENESIS, V27, P2108, DOI 10.1093/carcin/bgl057; Miyazawa-Hoshimoto S, 2005, AM J PHYSIOL-ENDOC M, V288, pE1128, DOI 10.1152/ajpendo.00003.2004; Mukherjee P, 1999, JNCI-J NATL CANCER I, V91, P512, DOI 10.1093/jnci/91.6.512; Palmqvist R, 2002, GUT, V50, P642, DOI 10.1136/gut.50.5.642; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Proebstle TM, 1996, EUR J CANCER, V32A, P1664, DOI 10.1016/0959-8049(95)00534-X; Przybyszewski J, 2001, CARCINOGENESIS, V22, P1421, DOI 10.1093/carcin/22.9.1421; Rambaratsingh RA, 2003, J BIOL CHEM, V278, P52792, DOI 10.1074/jbc.M308240200; ROEBUCK BD, 1981, CANCER RES, V41, P888; Roth GS, 2002, HORM METAB RES, V34, P378, DOI 10.1055/s-2002-33469; Rusch HP, 1944, CANCER RES, V4, P116; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smolle J, 1995, AM J DERMATOPATH, V17, P555, DOI 10.1097/00000372-199512000-00005; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu YP, 2003, CANCER RES, V63, P4384; Wu YP, 2002, CANCER RES, V62, P1030; Zhu ZJ, 2002, MOL CARCINOGEN, V35, P51, DOI 10.1002/mc.10073	54	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28025	28035		10.1074/jbc.M604857200	http://dx.doi.org/10.1074/jbc.M604857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646168	Green Submitted, hybrid			2022-12-27	WOS:000249455600052
J	Bu, Y; Gelman, IH				Bu, Yahao; Gelman, Irwin H.			v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; HISTONE DEACETYLASE INHIBITORS; TRANSCRIPTION FACTOR USF; REPRESS TRANSCRIPTION; MOLECULAR-CLONING; TRICHOSTATIN-A; FACTOR FAMILY; SP1 SITE; EXPRESSION; PROTEIN	SSeCKS ( (S) under bar -rc (s) under bar uppr (e) under bar ssed (C) under bar (k) under bar inase (s) under bar ubstrate), also called gravin/AKAP12, is a large scaffolding protein with metastasis suppressor activity. Two major isoforms of SSeCKS are expressed in most cell and tissue types under the control of two independent promoters, designated alpha and beta, separated by 68 kb. SSeCKS transcript and protein levels are severely decreased in Src- and Ras-transformed fibroblasts and in many epithelial tumors. By dissecting its promoters with progressive deletion analysis, we identified the sequence between -106 and -49 in the alpha proximal promoter as the minimal v-Src-responsive element, which contains E- and GC-boxes bound by USF1 and Sp1/Sp3, respectively. Both E- and GC-boxes are crucial for v-Src-responsive and basal promoter activities. v-Src does not alter USF1 binding levels at the E- box, but it increases Sp1/Sp3 binding to the GC-box despite no change in their cellular protein abundance. SSeCKS alpha and beta transcript levels in v-Src/3T3 cells can be restored by treatment with the histone deacetylase inhibitor, trichostatin A, but not with the DNA demethylation agent, 5-azacytidine. Chromatin changes are found only on the alpha promoter even though the beta proximal promoter contains a similar E- and GC-box arrangement. Recruitment of HDAC1 is necessary and sufficient to cause repression of alpha proximal promoter activity, and the addition of Sp1 and/or Sp3 potentiates the repression. Our data suggest that suppression of the beta promoter is facilitated by Src- induced changes in the alpha promoter chromatinization mediated by a USF1-Sp1-Sp3 complex.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14209 USA	Roswell Park Cancer Institute	Gelman, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14209 USA.	Irwin.gelman@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA094108, R55CA094108] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA094108, CA 94108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Camus A, 2001, MECH DEVELOP, V105, P79, DOI 10.1016/S0925-4773(01)00384-7; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ENOMOTO H, 1994, ONCOGENE, V9, P2785; Erlichman J, 1999, EUR J BIOCHEM, V263, P797, DOI 10.1046/j.1432-1327.1999.00561.x; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Ge YB, 2003, J BIOL CHEM, V278, P49901, DOI 10.1074/jbc.M305085200; Gelman IH, 2006, MOL CANCER RES, V4, P151, DOI 10.1158/1541-7786.MCR-05-0252; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Grove BD, 2001, J VASC RES, V38, P163, DOI 10.1159/000051043; Gupta AK, 2002, AM J PHYSIOL-CELL PH, V283, pC1065, DOI 10.1152/ajpcell.00100.2002; Hadjiagapiou C, 2005, AM J PHYSIOL-GASTR L, V288, pG1118, DOI 10.1152/ajpgi.00312.2004; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hasleton MD, 2003, BIOCHEM J, V373, P925, DOI 10.1042/BJ20030388; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Huang YC, 2006, J CELL PHYSIOL, V209, P363, DOI 10.1002/jcp.20741; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473; Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OZAKI T, 1994, CANCER RES, V54, P646; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pan J, 1996, FEBS LETT, V383, P21; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; Provot S, 2000, ONCOGENE, V19, P4736, DOI 10.1038/sj.onc.1203837; QURESHI SA, 1992, ONCOGENE, V7, P121; Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Scholz G, 1996, MOL CELL BIOL, V16, P481; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Streb JW, 2005, J BIOL CHEM, V280, P4125, DOI 10.1074/jbc.M412466200; Streb JW, 2004, J BIOL CHEM, V279, P56014, DOI 10.1074/jbc.M408828200; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Sung J, 2005, CARCINOGENESIS, V26, P487, DOI 10.1093/carcin/bgh318; Tao JC, 2006, J BIOL CHEM, V281, P23932, DOI 10.1074/jbc.M601813200; Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xia W, 2001, CANCER RES, V61, P5644; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang XP, 2002, J LIPID RES, V43, P297; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zhao SJ, 2003, CANCER RES, V63, P2624	71	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26725	26739		10.1074/jbc.M702885200	http://dx.doi.org/10.1074/jbc.M702885200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626016	hybrid			2022-12-27	WOS:000249304900011
J	Ghanei, H; Abeyrathne, PD; Lam, JS				Ghanei, Hamed; Abeyrathne, Priyanka D.; Lam, Joseph S.			Biochemical characterization of MsbA from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MSBA; ATPASE ACTIVITY; ABC TRANSPORTER; P-GLYCOPROTEIN; DRUG-RESISTANCE; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; BACTERIAL; SYSTEM; FAMILY	Lipopolysaccharide of Pseudomonas aeruginosa is a major constituent of the outer membrane, and it is composed of three distinct regions: lipid A, core oligosaccharide, and O antigen. Lipid A and core oligosaccharides ( OS) are synthesized and assembled at the cytoplasmic side of the inner membrane and then translocated to the periplasmic side of the membrane where lipid A-core becomes the acceptor of the O antigens. Here we show that MsbA encoded by pA4997 of the P. aeruginosa genome is a member of the ABC transporter family, but this protein has distinctive features when compared with other MsbA proteins. msbA is an essential gene in this organism since mutation in this gene is lethal to the bacterium. Disruption of the chromosomal msbA was achieved only when a functional copy of the gene was provided in trans. msbA from Escherichia-coli (msbA(Ec)) could not cross complement the msbA merodiploid cells of P. aeruginosa. MsbA was expressed and purified, and the kinetic of its ATPase activity is vastly different than that of MsbA(Ec). The activity of MsbA could be selectively stimulated by different truncated versions of core OS of P. aeruginosa LPS. Specifically, phosphate substituents in the lipid A-core are important for stimulating ATPase activity of MsbA. Expression of MsbAEc but not MsbA(Pa) conferred resistance to erythromycin in P. aeruginosa.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Lam, JS (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca						AUSUBEL F, 1997, SHORT PROTOCOL MOL B; BAUER AW, 1959, ARCH INTERN MED, V104, P208, DOI 10.1001/archinte.1959.00270080034004; Bedoux G, 2004, J MASS SPECTROM, V39, P505, DOI 10.1002/jms.611; Benabdelhak H, 2005, BIOCHEM J, V386, P489, DOI 10.1042/BJ20041282; Buxbaum E, 1999, EUR J BIOCHEM, V265, P54, DOI 10.1046/j.1432-1327.1999.00643.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEHERTOGH DA, 1985, ANTIMICROB AGENTS CH, V27, P670, DOI 10.1128/AAC.27.4.670; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; DROGE W, 1970, EUR J BIOCHEM, V14, P175, DOI 10.1111/j.1432-1033.1970.tb00276.x; Ghosheh O, 2001, DRUG METAB DISPOS, V29, P1525; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Kuhnke G, 2006, MOL MEMBR BIOL, V23, P173, DOI 10.1080/09687860500473630; Lambert O, 1998, BIOPHYS J, V74, P918, DOI 10.1016/S0006-3495(98)74015-9; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Lingwood D, 2006, COMP BIOCHEM PHYS A, V144, P451, DOI 10.1016/j.cbpa.2006.03.016; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Meredith TC, 2006, ACS CHEM BIOL, V1, P33, DOI 10.1021/cb0500015; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Orlowski S, 2006, CELL MOL LIFE SCI, V63, P1038, DOI 10.1007/s00018-005-5554-9; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; POON KKH, 2003, 103 GEN C AM SOC MIC; RAETZ CR, 2002, ANNU REV BIOCHEM, V71, P625; Rahim R, 2000, MICROBIOL-UK, V146, P2803, DOI 10.1099/00221287-146-11-2803; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Scott HN, 2003, PLASMID, V50, P74, DOI 10.1016/S0147-619X(03)00030-1; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SKOZA L, 1976, BIOCHEM J, V159, P457, DOI 10.1042/bj1590457; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; Toulmay A, 2007, BIOCHIMIE, V89, P249, DOI 10.1016/j.biochi.2006.07.020; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; van Veen HW, 2001, RES MICROBIOL, V152, P365, DOI 10.1016/S0923-2508(01)01208-6; Walsh AG, 2000, MOL MICROBIOL, V35, P718, DOI 10.1046/j.1365-2958.2000.01741.x; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; WESTPHAL O, 1983, PROG ALLERGY, V33, P9; Woebking B, 2005, J BACTERIOL, V187, P6363, DOI 10.1128/JB.187.18.6363-6369.2005; Zhao X, 2002, ANTIMICROB AGENTS CH, V46, P2035, DOI 10.1128/AAC.46.6.2035-2037.2002; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	50	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26939	26947		10.1074/jbc.M702952200	http://dx.doi.org/10.1074/jbc.M702952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17644517	hybrid			2022-12-27	WOS:000249304900033
J	Pullikotil, P; Benjannet, S; Mayne, J; Seidah, NG				Pullikotil, Philomena; Benjannet, Suzanne; Mayne, Janice; Seidah, Nabil G.			The proprotein convertase SKI-1/S1P - Alternate translation and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; FEVER VIRUS GLYCOPROTEIN; ELEMENT-BINDING PROTEINS; TRANSCRIPTION FACTOR; CELLULAR TRAFFICKING; SECRETORY PATHWAY; SITE-1 PROTEASE; CLEAVAGE; FURIN; PRECURSOR	Subtilisin kexin isozyme-1 (SKI-1) represents the first mammalian member of secretory subtilisin-like processing enzymes that cleaves after nonbasic residues. It is synthesized as an inactive precursor that undergoes three sequential autocatalytic processing steps of its N-terminal prosegment and an ectodomain shedding at a site near the transmembrane domain. The various cellular functions of SKI-1 emphasize the need to understand the sites of its activation and shedding. We have previously shown that SKI-1 undergoes autocatalytic shedding at the sequence KHQKLL(9532) down arrow resulting in a membrane-bound stump called St-1 (amino acids 954-1052). However, little is known about the cellular localization of SKI-1 or its shed forms. In the present study, we have further identified a smaller C-terminal fragment St-2 generated closer to the transmembrane domain. By sequencing and mass spectrometric analysis, the start site and the molecular mass of St-2 were determined. Site- directed mutagenesis revealed the critical amino acid involved in this novel process. Mutation of Met(990) to M990A, M990I, and M990L failed to generate St-2, suggesting an internal alternate translation event at Met990, as confirmed by an in vitro transcription/translation assay. Confocal microscopy defined the subcellular localization of SKI-1 and its fragments. The data show that most of membrane-bound SKI-1 and its stumps St-1 and St-2 localize to the Golgi and can enter the endosomal/lysosomal compartments but do not sort to the cell surface. Deletion studies showed that the transmembrane domain of SKI-1 determines its trafficking. Finally, rSt-1 and rSt-2 seem to affect the processing of ATF6 by SKI-1, but cellular stress does not regulate the production of St-2.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P14741, DOI 10.1021/bi051691k; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Basak A, 2005, J MOL MED, V83, P844, DOI 10.1007/s00109-005-0710-0; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kim T, 2006, MOL BIOL CELL, V17, P789, DOI 10.1091/mbc.E05-08-0755; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 2001, SCI STKE, pE1; Kozak M, 2006, GENE, V382, P1, DOI 10.1016/j.gene.2006.06.004; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Nassoury N, 2007, TRAFFIC, V8, P718, DOI 10.1111/j.1600-0854.2007.00562.x; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Pasquato A, 2006, J BIOL CHEM, V281, P23471, DOI 10.1074/jbc.M513675200; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Richer MJ, 2004, P NATL ACAD SCI USA, V101, P10560, DOI 10.1073/pnas.0401406101; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sanchez AJ, 2006, J VIROL, V80, P514, DOI 10.1128/JVI.80.1.514-525.2006; Seidah NG, 2006, BIOL CHEM, V387, P871, DOI 10.1515/BC.2006.110; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 2002, ENZYMES, V22, P237; Stirling J, 2006, MOL BIOL CELL, V17, P413, DOI 10.1091/mbc.E05-06-0500; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Vincent MJ, 2003, J VIROL, V77, P8640, DOI 10.1128/JVI.77.16.8640-8649.2003; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Wouters S, 1999, FEBS LETT, V456, P97, DOI 10.1016/S0014-5793(99)00938-2; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; YE SQ, 1993, J BIOL CHEM, V268, P8497	54	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27402	27413		10.1074/jbc.M703200200	http://dx.doi.org/10.1074/jbc.M703200200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623657	hybrid			2022-12-27	WOS:000249304900082
J	Li, X; Liu, H; Qin, L; Tamasi, J; Bergenstock, M; Shapses, S; Feyen, JHM; Notterman, DA; Partridge, NC				Li, Xin; Liu, Hao; Qin, Ling; Tamasi, Joseph; Bergenstock, Marika; Shapses, Sue; Feyen, Jean H. M.; Notterman, Daniel A.; Partridge, Nicola C.			Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; TRABECULAR BONE; RECEPTOR; CELLS; PTH; OSTEOBLASTS; FRAGMENT; FAMILY; HISTOMORPHOMETRY; OSTEOPOROSIS	Parathyroid hormone ( PTH) stimulates bone formation when injected daily but causes severe bone loss with continuous infusion. The mechanism of its paradoxical effects is still elusive. In this study, we compared changes in the gene expression profile in bone induced by intermittent or continuous treatment with three different PTH peptides, PTH-(1-34), -(1-31), and -(3-34), in Sprague-Dawley female rats. PTH-( 1 - 34) regulated numerous genes (similar to 1,000), but differentially, in both regimes. PTH-( 1 - 31) regulated a similar number of genes in the intermittent regimen but fewer in the continuous regimen, consistent with its less potent catabolic effect. PTH-( 3 - 34) regulated very few genes in both regimes, which suggests the protein kinase C pathway plays a limited role in mediating the dual effects of PTH, whereas the cAMP-ependent protein kinase A pathway appears to predominate. In the intermittent treatment, many genes encoding signaling mediators, transcription factors, cytokines, and proteases/ protease inhibitors are regulated rapidly and cyclically with each PTH injection; genes associated with skeletal development show a slowly accruing pattern of expression. With continuous treatment, some genes are regulated from 6 h, and the mRNA levels are sustained with a longer infusion, whereas others show a kinetic decrease and then increase later. Significant up-regulation of genes stimulating osteoclastogenesis in the anabolic regime suggests a provocative and paradoxical theme for the anabolic effect of PTH that a full anabolic response requires a transient up-regulation of genes classically associated with a resorptive response. Ingenuity pathway analysis was performed on the microarray data. A novel signaling network was established that is differentially regulated in the two PTH treatment regimes. Key regulators are suggested to be AREG, CCL2, WNT4, and cAMP-responsive element modulator.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Core Express Facil Canc Inst New Jersey, Dept Pediat, New Brunswick, NJ 08901 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat Mol Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Bristol-Myers Squibb; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln,Res Tower 561, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Shapses, Sue/0000-0002-3128-2325; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brauner-Osborne H, 2001, BBA-GENE STRUCT EXPR, V1518, P237, DOI 10.1016/S0167-4781(01)00197-X; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353; CIVITELLI R, 1994, J BONE MINER RES, V9, P1407; Eriksen EF, 2002, J BONE MINER RES, V17, pN95; Fraher LJ, 1999, J CLIN ENDOCR METAB, V84, P2739, DOI 10.1210/jc.84.8.2739; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gay CV, 2000, CRIT REV EUKAR GENE, V10, P213; Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683; Gunness M. E., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P321; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; Inoue S, 2004, J INVEST DERMATOL, V122, P565, DOI 10.1046/j.0022-202X.2004.12628.x; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200; Li XQ, 2005, J BIOL CHEM, V280, P38317, DOI 10.1074/jbc.M505853200; Marks Sandy C. Jr., 1996, P3; Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349; Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003-0024; Nagel DE, 2004, J CELL BIOCHEM, V93, P1107, DOI 10.1002/jcb.20249; Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood-2004-12-4940; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Robbins MJ, 2002, MOL BRAIN RES, V106, P136, DOI 10.1016/S0169-328X(02)00420-5; ROSENBLATT, 1981, CALCIF TISSUE INT, V33, P153; Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330; Satoh W, 2006, DEVELOPMENT, V133, P989, DOI 10.1242/dev.02274; Slegtenhorst-Eegdeman KE, 1998, MOL HUM REPROD, V4, P649, DOI 10.1093/molehr/4.7.649; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF792, DOI 10.1152/ajprenal.2000.278.5.F792; Tsingotjidou A, 2002, BONE, V30, P677, DOI 10.1016/S8756-3282(02)00698-1; Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001; von Stechow D, 2004, J CELL BIOCHEM, V93, P476, DOI 10.1002/jcb.20174; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275	42	136	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					33086	33097		10.1074/jbc.M705194200	http://dx.doi.org/10.1074/jbc.M705194200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17690103	hybrid			2022-12-27	WOS:000250625400057
J	Yeo, HJ; Yokoyama, T; Walkiewicz, K; Kim, Y; Grass, S; Geme, JW				Yeo, Hye-Jeong; Yokoyama, Takeshi; Walkiewicz, Katarzyna; Kim, Youngchang; Grass, Susan; St. Geme, Joseph W., III			The structure of the Haemophilus influenzae HMW1 pro-piece reveals a structural domain essential for bacterial two-partner secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS FILAMENTOUS HEMAGGLUTININ; BORDETELLA-PERTUSSIS; CRYSTAL-STRUCTURE; SERRATIA-MARCESCENS; PROTEIN SECRETION; VIRULENCE FACTOR; AUTOTRANSPORTER; PATHWAY; ADHESIN; GENES	In pathogenic Gram-negative bacteria, many virulence factors are secreted via the two-partner secretion pathway, which consists of an exoprotein called TpsA and a cognate outer membrane translocator called TpsB. The HMW1 and HMW2 adhesins are major virulence factors in nontypeable Haemophilus influenzae and are prototype two-partner secretion pathway exoproteins. A key step in the delivery of HMW1 and HMW2 to the bacterial surface involves targeting to the HMW1B and HMW2B outer membrane translocators by an N-terminal region called the secretion domain. Here we present the crystal structure at 1.92 angstrom of the HMW1 pro-piece (HMW1-PP), a region that contains the HMW1 secretion domain and is cleaved and released during HMW1 secretion. Structural analysis of HMW1-PP revealed a right-handed beta-helix fold containing 12 complete parallel coils and one large extra-helical domain. Comparison of HMW1-PP and the Bordetella pertussis FHA secretion domain (Fha30) reveals limited amino acid homology but shared structural features, suggesting that diverse TpsA proteins have a common structural domain required for targeting to cognate TpsB proteins. Further comparison of HMW1-PP and Fha30 structures may provide insights into the keen specificity of TpsA-TpsB interactions.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	University of Houston System; University of Houston; United States Department of Energy (DOE); Argonne National Laboratory; Duke University; Duke University	Yeo, HJ (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.	hyeo@uh.edu		Kim, Youngchang/0000-0002-1610-4889; Yokoyama, Takeshi/0000-0002-5362-8606	NIAID NIH HHS [AI068943] Funding Source: Medline; NIDCD NIH HHS [DC02873] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002873] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARENKAMP SJ, 1994, INFECT IMMUN, V62, P3320, DOI 10.1128/IAI.62.8.3320-3328.1994; BARENKAMP SJ, 1992, INFECT IMMUN, V60, P1302, DOI 10.1128/IAI.60.4.1302-1313.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buscher AZ, 2006, MOL MICROBIOL, V61, P470, DOI 10.1111/j.1365-2958.2006.05236.x; Buscher AZ, 2004, J BACTERIOL, V186, P4209, DOI 10.1128/JB.186.13.4209-4217.2004; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; Czerwinski EW, 2005, J BIOL CHEM, V280, P3740, DOI 10.1074/jbc.M409655200; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Grass S, 2000, MOL MICROBIOL, V36, P55, DOI 10.1046/j.1365-2958.2000.01812.x; Grass S, 2003, MOL MICROBIOL, V48, P737, DOI 10.1046/j.1365-2958.2003.03450.x; Hegde SS, 2005, SCIENCE, V308, P1480, DOI 10.1126/science.1110699; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; Hodak H, 2006, MOL MICROBIOL, V61, P368, DOI 10.1111/j.1365-2958.2006.05242.x; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jacob-Dubuisson F, 2004, BBA-MOL CELL RES, V1694, P235, DOI 10.1016/j.bbamcr.2004.03.008; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; Jenkins J, 1998, J STRUCT BIOL, V122, P236, DOI 10.1006/jsbi.1998.3985; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Lambert-Buisine C, 1998, MOL MICROBIOL, V28, P1283, DOI 10.1046/j.1365-2958.1998.00892.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meli AC, 2006, J BIOL CHEM, V281, P158, DOI 10.1074/jbc.M508524200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otto BR, 2005, J BIOL CHEM, V280, P17339, DOI 10.1074/jbc.M412885200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RenauldMongenie G, 1996, J BACTERIOL, V178, P1053, DOI 10.1128/jb.178.4.1053-1060.1996; SCHONHERR R, 1993, MOL MICROBIOL, V9, P1229, DOI 10.1111/j.1365-2958.1993.tb01252.x; St Geme JW, 1998, INFECT IMMUN, V66, P364; St Geme JW, 2002, CELL MICROBIOL, V4, P191; Steinbacher S, 1996, P NATL ACAD SCI USA, V93, P10584, DOI 10.1073/pnas.93.20.10584; Surana NK, 2006, J BIOL CHEM, V281, P18051, DOI 10.1074/jbc.M600036200; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Yeo HJ, 2004, EMBO J, V23, P1245, DOI 10.1038/sj.emboj.7600142; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	39	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31076	31084		10.1074/jbc.M705750200	http://dx.doi.org/10.1074/jbc.M705750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699157	hybrid			2022-12-27	WOS:000250136300075
J	Shenoy, SK; Barak, LS; Xiao, KH; Ahn, S; Berthouze, M; Shukla, AK; Luttrell, LM; Lefkowitz, RJ				Shenoy, Sudha K.; Barak, Larry S.; Xiao, Kunhong; Ahn, Seungkirl; Berthouze, Magali; Shukla, Arun K.; Luttrell, Louis M.; Lefkowitz, Robert J.			Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; DEPENDENT ENDOCYTOSIS; CLATHRIN ADAPTER; VISUAL ARRESTIN; CELL; BETA-ARRESTIN2; KINASE; MONOUBIQUITINATION	beta-Arrestin2 and its ubiquitination play crucial roles in both internalization and signaling of seven-transmembrane receptors (7TMRs). To understand the connection between ubiquitination and the endocytic and signaling functions of beta-arrestin, we generated a beta-arrestin2 mutant that is defective in ubiquitination (beta-arrestin2(OK)), by mutating all of the ubiquitin acceptor lysines to arginines and compared its properties with the wild type and a stably ubiquitinated beta-arrestin2-ubiquitin (Ub) chimera. In vitro translated beta-arrestin2 and beta-arrestin2(OK) displayed equivalent binding to recombinant beta(2)-adrenergic receptor (beta(2)AR) reconstituted in vesicles, whereas beta-arrestin2-Ub bound similar to 4-fold more. In cellular coimmunoprecipitation assays, beta-arrestin2(OK) bound nonreceptor partners, such as AP-2 and c-Raf and scaffolded phosphorylated ERK robustly but displayed weak binding to clathrin. Moreover, beta-arrestin2(OK) was recruited only transiently to activated receptors at the membrane, did not enhance receptor internalization, and decreased the amount of phosphorylated ERK assimilated into isolated beta(2)AR complexes. Although the wild type beta-arrestin2 formed ERK signaling complexes with the beta(2)AR at the membrane, a stably ubiquitinated beta-arrestin2-Ub chimera not only stabilized the ERK signalosomes but also led to their endosomal targeting. Interestingly, in cellular fractionation assays, the ubiquitination state of beta-arrestin2 favors its distribution in membrane fractions, suggesting that ubiquitination increases the propensity of beta-arrestin for membrane association. Our findings suggest that although beta-arrestin ubiquitination is dispensable for beta-arrestin cytosol to membrane translocation and its "constitutive" interactions with some cytosolic proteins, it nevertheless is a prerequisite both for the formation of tight complexes with 7TMRs in vivo and for membrane compartment interactions that are crucial for downstream endocytic and signaling processes.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Med Univ S Carolina, Dept Med Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Shenoy, SK (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	sudha@receptor-biol.duke.edu	Shenoy, Sudha/AAN-4075-2021; Lefkowitz, Robert/AAW-2649-2021; Xiao, Kunhong/AAG-4275-2020	Shenoy, Sudha/0000-0002-2565-4663; Xiao, Kunhong/0000-0002-1069-1226; Luttrell, Louis/0000-0003-2805-6949; shukla, arun/0000-0003-2910-8288	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080525, R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037, R01 HL016037, R01 HL080525, HL080525, R01 HL080525-02] Funding Source: Medline; NIDDK NIH HHS [R56 DK055524, DK55524, R01 DK055524] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2007, ANNU REV PHYSIOL, V69, P535, DOI 10.1146/annurev.physiol.69.022405.154804; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Jafri F, 2006, J BIOL CHEM, V281, P19346, DOI 10.1074/jbc.M512643200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Milano SK, 2006, J BIOL CHEM, V281, P9812, DOI 10.1074/jbc.M512703200; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Scott MGH, 2006, MOL CELL BIOL, V26, P3432, DOI 10.1128/MCB.26.9.3432-3445.2006; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shenoy SK, 2007, CIRC RES, V100, P1142, DOI 10.1161/01.RES.0000261939.88744.5a; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700	45	98	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29549	29562		10.1074/jbc.M700852200	http://dx.doi.org/10.1074/jbc.M700852200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666399	Green Accepted, hybrid			2022-12-27	WOS:000249788000052
J	Todi, SV; Laco, MN; Winborn, BJ; Travis, SM; Wen, HM; Paulson, HL				Todi, Sokol V.; Laco, Mario N.; Winborn, Brett J.; Travis, Sue M.; Wen, Hsiang M.; Paulson, Henry L.			Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; VALOSIN-CONTAINING PROTEIN; TRANSITIONAL ENDOPLASMIC-RETICULUM; UBIQUITIN-MEDIATED PROTEOLYSIS; BULBAR MUSCULAR-ATROPHY; DEUBIQUITINATING ENZYMES; INTRANUCLEAR INCLUSIONS; NUCLEAR-LOCALIZATION; BRAZILIAN FAMILIES; CAG REPEAT	Ataxin-3, a deubiquitinating enzyme, is the disease protein in spinocerebellar ataxia type 3, one of many neurodegenerative disorders caused by polyglutamine expansion. Little is known about the cellular regulation of ataxin-3. This is an important issue, since growing evidence links disease protein context to pathogenesis in polyglutamine disorders. Expanded ataxin-3, for example, is more neurotoxic in fruit fly models when its active site cysteine is mutated (1). We therefore sought to determine the influence of ataxin-3 enzymatic activity on various cellular properties. Here we present evidence that the catalytic activity of ataxin-3 regulates its cellular turnover, ubiquitination, and subcellular distribution. Cellular protein levels of catalytically inactive ataxin-3 were much higher than those of active ataxin-3, in part reflecting slower degradation. In vitro studies revealed that inactive ataxin-3 was more slowly degraded by the proteasome and that this degradation occurred independent of ubiquitination. Slower degradation of inactive ataxin-3 correlated with reduced interaction with the proteasome shuttle protein, VCP/p97. Enzymatically active ataxin-3 also showed a greater tendency to concentrate in the nucleus, where it colocalized with the proteasome in subnuclear foci. Taken together, these and other findings suggest that the catalytic activity of this disease-linked deubiquitinating enzyme regulates several of its cellular properties, which in turn may influence disease pathogenesis.	Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Mol Biol, Iowa City, IA 52242 USA; Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal; Univ Coimbra, Fac Med, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal	University of Iowa; University of Iowa; Universidade de Coimbra; Universidade de Coimbra	Paulson, HL (corresponding author), Univ Iowa, Dept Neurol, EMRB Rm 240B, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu		TODI, SOKOL/0000-0003-4399-5549; Noro Laco, Mario/0000-0003-4823-3340	NINDS NIH HHS [R01 NS38712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Berke SJS, 2005, J BIOL CHEM, V280, P32026, DOI 10.1074/jbc.M506084200; Bichelmeier U, 2007, J NEUROSCI, V27, P7418, DOI 10.1523/JNEUROSCI.4540-06.2007; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Fujigasaki H, 2000, EXP NEUROL, V165, P248, DOI 10.1006/exnr.2000.7479; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Katsuno M, 2006, EXP NEUROL, V200, P8, DOI 10.1016/j.expneurol.2006.01.021; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koeppen AH, 2005, CEREBELLUM, V4, P62, DOI 10.1080/14734220510007950; Kordasiewicz HB, 2006, HUM MOL GENET, V15, P1587, DOI 10.1093/hmg/ddl080; Lerer I, 1996, EUR J HUM GENET, V4, P3; Mao Y, 2005, P NATL ACAD SCI USA, V102, P12700, DOI 10.1073/pnas.0506344102; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Paulson HL, 2000, P NATL ACAD SCI USA, V97, P12957, DOI 10.1073/pnas.210395797; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Sakai T, 1996, NEUROLOGY, V46, P846; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Seilhean D, 2004, ACTA NEUROPATHOL, V108, P81, DOI 10.1007/s00401-004-0855-x; STEVANIN G, 1995, AM J HUM GENET, V57, P1247; STEVANIN G, 1995, J MED GENET, V32, P827, DOI 10.1136/jmg.32.10.827; Takahashi J, 2001, J NEUROPATH EXP NEUR, V60, P369, DOI 10.1093/jnen/60.4.369; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	43	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29348	29358		10.1074/jbc.M704126200	http://dx.doi.org/10.1074/jbc.M704126200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693639	hybrid			2022-12-27	WOS:000249788000031
J	Wang, JL; Liu, X; Hande, MP; Wong, AC; Jin, YJ; Yin, YX				Wang, Jianli; Liu, Xin; Hande, M. Prakash; Wong, Alan C.; Jin, Y. Jenny; Yin, Yuxin			TAp73 is a downstream target of p53 in controlling the cellular defense against stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; P73 GENE; CYCLE CONTROL; P53-INDUCED APOPTOSIS; TRANSCRIPTION TARGET; POTENTIAL MEDIATOR; SPONTANEOUS TUMORS; OXIDATIVE STRESS	TAp73 is a p53 tumor suppressor gene homologue that is known to be mainly involved in apoptosis. We report here that TAp73 is necessary for the cellular response to oxidative stress and that TAp73 functions as a downstream target of p53 in this process. We show that p53 physically interacts with the TAp73 promoter under stress conditions that lead to cell death. Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription. TAp73 expression is highly increased under oxidative stress in a p53-dependent manner. Furthermore, knockdown of TAp73 expression inhibits the cellular apoptotic response to oxidative damage. In contrast, the ectopic expression of TAp73 in p53(-/-) mouse embryonic fibroblasts induces oxidative cell death. Our findings demonstrate that p53 is a direct transcriptional regulator of TAp73. Our data reveal a new pathway for cellular protection against oxidative damage and provide evidence that TAp73 is a stress-response gene and a downstream effector in the p53 pathway.	Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117579, Singapore	Columbia University; National University of Singapore	Yin, YX (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, VC-11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	Hande, M. Prakash/B-1645-2008	Hande, M. Prakash/0000-0002-4511-6256	NCI NIH HHS [R01 CA093677, R01 CA102447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102447, R01CA093677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Catani MV, 2002, BIOCHEM J, V364, P441, DOI 10.1042/BJ20011713; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Coates PJ, 2006, J PATHOL, V210, P385, DOI 10.1002/path.2080; Corn PG, 1999, CANCER RES, V59, P3352; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mai M, 1998, CANCER RES, V58, P2347; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schwartz DI, 1999, BREAST CANCER RES TR, V58, P25, DOI 10.1023/A:1006237031070; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Stirewalt DL, 1999, LEUKEMIA, V13, P985, DOI 10.1038/sj.leu.2401418; Stoffel A, 2004, LEUKEMIA RES, V28, P1341, DOI 10.1016/j.leukres.2004.04.010; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhao RB, 2000, GENE DEV, V14, P981	60	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29152	29162		10.1074/jbc.M703408200	http://dx.doi.org/10.1074/jbc.M703408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693405	hybrid			2022-12-27	WOS:000249788000010
J	Butcher, NJ; Broadhurst, GM; Minchin, RF				Butcher, Neville J.; Broadhurst, Gysell M.; Minchin, Rodney F.			Polyamine-dependent regulation of spermidine-spermine N-1-acetyltransferase mRNA translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CODING REGION; HUMAN-MELANOMA CELLS; CANCER-CELLS; POSTTRANSCRIPTIONAL REGULATION; DIFFERENTIAL INDUCTION; GENE-EXPRESSION; ANALOGS; N1-ACETYLTRANSFERASE; ELEMENT; N-1,N-11-DIETHYLNORSPERMINE	Spermidine-spermine N-1-acetyltransferase (SSAT) is induced in response to an elevation in intracellular polyamine pools. The increased enzyme activity is the result of an increase in gene transcription, mRNA translation, and protein stability. Induction of SSAT by polyamine analogues can lead to intracellular polyamine depletion and apoptosis. The mechanism by which polyamines alter the translational efficiency of SSAT mRNA is not well understood. In this study, we investigated the regulation of SSAT translation by the polyamine analogue N-1,N-11-diethylnorspermine ( DENSPM). DENSPM induced expression of both FLAG-tagged SSAT and SSAT fused to Renilla luciferase in a time- and concentration-dependent manner. This effect was not inhibited by actinomycin D indicating that changes in gene transcription did not explain the enhanced expression in the presence of DENSPM. Furthermore, because FLAG-SSAT did not contain the 5'- or 3'-untranslated regions of SSAT, translational regulation involved the coding sequence only. By contrast, cycloheximide completely inhibited induction by DENSPM, indicating a requirement for new protein synthesis. Deletion constructs identified two regions of the SSAT protein-coding RNA sequence that conferred polyamine responsiveness. Using these regions as probes in RNA electrophoretic mobility shift assays, we observed specific binding of a cytoplasmic protein. In addition, we found that the interaction between the RNA probes and the binding protein could be inhibited by DENSPM in a concentration-dependent manner. These results suggest that polyamines regulate SSAT mRNA translational efficiency by inhibiting a repressor protein from binding to regions of the coding sequence of the SSAT transcript.	Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, St Lucia, Qld 4072, Australia	University of Queensland	Butcher, NJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	n.butcher@uq.edu.au		Minchin, Rodney/0000-0002-3178-4835; Butcher, Neville/0000-0002-0709-5589				BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chopra S, 1998, BIOCHEM PHARMACOL, V55, P1119, DOI 10.1016/S0006-2952(97)00601-1; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; Coleman CS, 2001, BIOCHEM J, V358, P137, DOI 10.1042/0264-6021:3580137; Creaven PJ, 1997, INVEST NEW DRUG, V15, P227, DOI 10.1023/A:1005827231849; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; Green ML, 1998, BIOL REPROD, V59, P1251, DOI 10.1095/biolreprod59.5.1251; Hector S, 2004, MOL CANCER THER, V3, P813; Ichimura S, 2004, INT J RADIAT BIOL, V80, P369, DOI 10.1080/09553000410001695886; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Kramer DL, 1998, BIOCHEM SOC T, V26, P609, DOI 10.1042/bst0260609; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Marverti G, 2001, EUR J CANCER, V37, P281, DOI 10.1016/S0959-8049(00)00389-0; Minchin RF, 2006, INT J CANCER, V118, P509, DOI 10.1002/ijc.21359; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PORTER CW, 1994, CANCER RES, V54, P5917; REDMAN B, 1999, P AM SOC CLIN ON ATL; Spencer CM, 1999, DNA CELL BIOL, V18, P39, DOI 10.1089/104454999315600; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; Streiff RR, 2001, INVEST NEW DRUG, V19, P29, DOI 10.1023/A:1006448516938; Tai NW, 2004, BIOCHEM J, V378, P999, DOI 10.1042/BJ20031396; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wallace HM, 2003, BIOCHEM SOC T, V31, P393, DOI 10.1042/BST0310393; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wolff JC, 2003, CLIN CANCER RES, V9, P5922; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	37	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28530	28539		10.1074/jbc.M701265200	http://dx.doi.org/10.1074/jbc.M701265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690107	hybrid			2022-12-27	WOS:000249642100027
J	Chen, XM; Splinter, PL; O'Hara, SP; LaRusso, NF				Chen, Xian-Ming; Splinter, Patrick L.; O'Hara, Steven P.; LaRusso, Nicholas F.			A cellular Micro-RNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; NF-KAPPA-B; EPITHELIAL-CELLS; DOWN-REGULATION; DEFENSE; PATHWAY; DIFFERENTIATION; APOPTOSIS; PROTEINS; TLR4	Toll-like receptors (TLRs) are important pathogen recognition molecules and are key to epithelial immune responses to microbial infection. However, the molecular mechanisms that regulate TLR expression in epithelia are obscure. Micro-RNAs play important roles in a wide range of biological events through post-transcriptional suppression of target mRNAs. Here we report that human biliary epithelial cells (cholangiocytes) express let-7 family members, micro-RNAs with complementarity to TLR4 mRNA. We found that let-7 regulates TLR4 expression via post-transcriptional suppression in cultured human cholangiocytes. Infection of cultured human cholangiocytes with Cryptosporidium parvum, a parasite that causes intestinal and biliary disease, results in decreased expression of primary let-7i and mature let-7 in a MyD88/NF-kappa B-dependent manner. The decreased let-7 expression is associated with C. parvum-induced up-regulation of TLR4 in infected cells. Moreover, experimentally induced suppression or forced expression of let-7i causes reciprocal alterations in C. parvum-induced TLR4 protein expression, and consequently, infection dynamics of C. parvum in vitro. These results indicate that let-7i regulates TLR4 expression in cholangiocytes and contributes to epithelial immune responses against C. parvum infection. Furthermore, the data raise the possibility that micro-RNA-mediated post-transcriptional pathways may be critical to host-cell regulatory responses to microbial infection in general.	Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Miles & Shirley Fiterman Ctr Digest Dis, Rochester, MN 55905 USA	Mayo Clinic	Chen, XM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA.	xianmingchen@creighton.edu; larusso.nicholas@mayo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031, R01DK057993] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI071321-02, AI071321, R01 AI071321, R01 AI071321-01, R01 AI071321-03] Funding Source: Medline; NIDDK NIH HHS [DK24031, R01 DK057993, R01 DK024031, DK57993] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brandenburg K, 2003, EUR J BIOCHEM, V270, P3271, DOI 10.1046/j.1432-1033.2003.03719.x; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen XM, 2005, J IMMUNOL, V175, P7447, DOI 10.4049/jimmunol.175.11.7447; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Eckmann L, 2005, SPRINGER SEMIN IMMUN, V27, P181, DOI 10.1007/s00281-005-0207-5; Eun CS, 2006, DIGEST DIS SCI, V51, P693, DOI 10.1007/s10620-006-3193-0; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Gatti G, 2006, J LEUKOCYTE BIOL, V79, P989, DOI 10.1189/jlb.1005597; Guerrant RL, 1997, EMERG INFECT DIS, V3, P51, DOI 10.3201/eid0301.970106; Harada K, 2004, HEPATOLOGY, V40, P925, DOI 10.1002/hep.20379; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jo YJ, 2004, GASTROENTEROLOGY, V126, pA171; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Modlin RL, 2004, NAT MED, V10, P1173, DOI 10.1038/nm1104-1173; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Strober W, 2004, NAT MED, V10, P898, DOI 10.1038/nm0904-898; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tzipori S, 2002, MICROBES INFECT, V4, P1047, DOI 10.1016/S1286-4579(02)01629-5; Viswanathan VK, 2004, ADV DRUG DELIVER REV, V56, P727, DOI 10.1016/j.addr.2003.09.005; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	38	366	401	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28929	28938		10.1074/jbc.M702633200	http://dx.doi.org/10.1074/jbc.M702633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660297	Green Accepted, hybrid			2022-12-27	WOS:000249642100067
J	Gardoni, F; Mauceri, D; Marcello, E; Sala, C; Di Luca, M; Jeromin, A				Gardoni, Fabrizio; Mauceri, Daniela; Marcello, Elena; Sala, Carlo; Di Luca, Monica; Jeromin, Andreas			SAP97 directs the localization of Kv4.2 to spines in hippocampal neurons - Regulation by CaMKII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-ASSOCIATED PROTEIN-97; NMDA RECEPTOR; KINASE-II; POTASSIUM CHANNEL; EXPRESSION; PHOSPHORYLATION; TRAFFICKING; PSD-95; MODULATION; SUBUNITS	The pore-forming alpha-subunit Kv4.2 is a key constituent of the A-type channel and critically involved in the regulation of dendritic excitability and plasticity. Here we show that Kv4.2 is enriched in the postsynaptic density (PSD) fraction and specifically interacts with synapse-associated protein 97 (SAP97). This interaction requires an intact C terminus of Kv4.2 and occurs via the PDZ domains of SAP97. Pharmacologically induced translocation of SAP97 to spines also drives Kv4.2 to the PSD, whereas SAP97 lentivirally based RNA interference reduces Kv4.2 in the PSD. In addition, calcium/calmodulin-dependent protein kinase II (CaMKII)-dependent SAP97 phosphorylation regulates the subcellular localization of Kv4.2. These results show that SAP97-CaMKII pathway plays an important role for the trafficking of Kv4.2 to dendrites and spines.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Univ Milan, Cellular & Mol Pharmacol Sect, Inst Neurosci, CNR, I-20129 Milan, Italy; Univ Texas, Ctr Learning & Memory, Austin, TX 78712 USA	University of Milan; University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Texas System; University of Texas Austin	Jeromin, A (corresponding author), Allen Inst Brain Sci, 551 N 34th St, Seattle, WA 98103 USA.	andreasj@alleninstitute.org	DiLuca, Monica/A-7632-2012; Mauceri, Daniela/C-4969-2014; Marcello, Elena/A-4687-2015; Gardoni, Fabrizio/A-3135-2009; Sala, Carlo/A-2493-2009	DiLuca, Monica/0000-0003-2298-615X; Mauceri, Daniela/0000-0003-1225-4633; Marcello, Elena/0000-0003-0452-762X; Gardoni, Fabrizio/0000-0003-4598-5563; Sala, Carlo/0000-0003-0662-9523	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U24NS050606] Funding Source: NIH RePORTER; NINDS NIH HHS [U24NS050606] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Folco EJ, 2004, AM J PHYSIOL-HEART C, V287, pH681, DOI 10.1152/ajpheart.00152.2004; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2003, J BIOL CHEM, V278, P44745, DOI 10.1074/jbc.M303576200; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jeromin A, 2003, J NEUROPHYSIOL, V90, P2741, DOI 10.1152/jn.00464.2003; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Lai HC, 2006, NAT REV NEUROSCI, V7, P548, DOI 10.1038/nrn1938; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Mauceri D, 2007, J NEUROCHEM, V100, P1032, DOI 10.1111/j.1471-4159.2006.04267.x; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Rhodes KJ, 2004, J NEUROSCI, V24, P7903, DOI 10.1523/JNEUROSCI.0776-04.2004; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Varga AW, 2004, J NEUROSCI, V24, P3643, DOI 10.1523/JNEUROSCI.0154-04.2004; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200	29	37	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28691	28699		10.1074/jbc.M701899200	http://dx.doi.org/10.1074/jbc.M701899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17635915	hybrid			2022-12-27	WOS:000249642100043
J	Nakamura, Y; Tsuchiya, M; Ohta, H				Nakamura, Yuki; Tsuchiya, Mami; Ohta, Hiroyuki			Plastidic phosphatidic acid phosphatases identified in a distinct subfamily of lipid phosphate phosphatases with prokaryotic origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST ENVELOPE; SYNTHASE GENES; ARABIDOPSIS; DEFICIENT; MEMBRANES; GROWTH; ENZYME; MUTANT; ROLES; PEA	Plastidic phosphatidic acid phosphatase ( PAP) dephosphorylates phosphatidic acid to yield diacylglycerol, which is a precursor for galactolipids, a primary and indispensable component of photosynthetic membranes. Despite its functional importance, the molecular characteristics and phylogenetic origin of plastidic PAP were unknown because no potential homologs have been found. Here, we report the isolation and characterization of plastidic PAPs in Arabidopsis that belong to a distinct lipid phosphate phosphatase (LPP) subfamily with prokaryotic origin. Because no homolog of mammalian LPP was found in cyanobacteria, we sought an LPP ortholog in a more primitive organism, Chlorobium tepidum, and its homologs in cyanobacteria. Arabidopsis had five homologs of cyanobacterial LPP, three of which ( LPP gamma, LPP epsilon 1, and LPP epsilon 2) localized to chloroplasts. Complementation of yeast Delta dpp1 Delta lpp1 Delta pah1 by plastidic LPPs rescued the relevant phenotype in vitro and in vivo, suggesting that they function as PAPs. Of the three LPPs, LPP gamma activity best resembled the native activity. The three plastidic LPPs were differentially expressed both in green and nongreen tissues, with LPP gamma expressed the highest in shoots. A knock-out mutant for LPP gamma could not be obtained, although a lpp epsilon 1lpp epsilon 2 double knock-out showed no significant changes in lipid composition. However, lpp gamma homozygous mutant was isolated only under ectopic overexpression of LPP gamma, suggesting that loss of LPP gamma may cause lethal effect on plant viability. Thus, in Arabidopsis, there are three isoforms of plastidic PAP that belong to a distinct subfamily of LPP, and LPP gamma may be the primary plastidic PAP.	Tokyo Inst Technol, Ctr Biol Resources & Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Res Ctr Evolving Earth & Planets, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; Tokyo Institute of Technology	Ohta, H (corresponding author), Tokyo Inst Technol, Ctr Biol Resources & Informat, Midori Ku, 4259-B-65 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	ohta.h.ab@m.titech.ac.jp	Ohta, Hiroyuki/B-1840-2014; Nakamura, Yuki/AAY-2551-2021	Ohta, Hiroyuki/0000-0002-1068-3242; Nakamura, Yuki/0000-0003-2897-4301				ANDREWS J, 1985, PLANT PHYSIOL, V78, P459, DOI 10.1104/pp.78.3.459; [Anonymous], METHODS CHLOROPLAST; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERTRAMS M, 1976, PLANTA, V132, P161, DOI 10.1007/BF00388898; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK MA, 1983, FEBS LETT, V164, P111, DOI 10.1016/0014-5793(83)80030-1; Carman GM, 2006, TRENDS BIOCHEM SCI, V31, P694, DOI 10.1016/j.tibs.2006.10.003; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Jarvis P, 2000, P NATL ACAD SCI USA, V97, P8175, DOI 10.1073/pnas.100132197; Johnson-Brousseau SA, 2004, PLANT J, V39, P761, DOI 10.1111/j.1365-313X.2004.02147.x; JOYARD J, 1979, FEBS LETT, V102, P147, DOI 10.1016/0014-5793(79)80947-3; Katagiri T, 2005, PLANT J, V43, P107, DOI 10.1111/j.1365-313X.2005.02431.x; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; KENNEDY EP, 1957, FED PROC, V16, P853; Kobayashi K, 2004, PLANT PHYSIOL, V134, P640, DOI 10.1104/pp.103.032656; Kocsis MG, 1996, LIPIDS, V31, P785, DOI 10.1007/BF02522974; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; MALHERBE A, 1992, J BIOL CHEM, V267, P23546; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakamura Y, 2005, J BIOL CHEM, V280, P7469, DOI 10.1074/jbc.M408799200; Ohshima Y, 2001, PLANT CELL PHYSIOL, V42, P1119, DOI 10.1093/pcp/pce141; OHTA H, 1994, PLANT LIPID METABOLISM, P152; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; Pierrugues O, 2001, J BIOL CHEM, V276, P20300, DOI 10.1074/jbc.M009726200; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; Stukey J, 1997, PROTEIN SCI, V6, P469; Xu CC, 2005, PLANT CELL, V17, P3094, DOI 10.1105/tpc.105.035592; Xu CC, 2003, EMBO J, V22, P2370, DOI 10.1093/emboj/cdg234; Yamaryo Y, 2003, PLANT CELL PHYSIOL, V44, P844, DOI 10.1093/pcp/pcg110; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	34	78	89	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29013	29021		10.1074/jbc.M704385200	http://dx.doi.org/10.1074/jbc.M704385200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652095	hybrid			2022-12-27	WOS:000249642100075
J	Wang, JG; Mahmud, SA; Bitterman, PB; Huo, YQ; Slungaard, A				Wang, Jianguo; Mahmud, Shawn A.; Bitterman, Peter B.; Huo, Yuqing; Slungaard, Arne			Histone deacetylase inhibitors suppress TF-kappa B-dependent agonist-driven tissue factor expression in endothelial cells and monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; ADHESION MOLECULE-1 GENE; TRICHOSTATIN-A; TRANSCRIPTIONAL REGULATION; EOSINOPHIL PEROXIDASE; EPITHELIAL-CELLS; ACTIVATION; ACETYLATION; CANCER; THROMBOSIS	Histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), can regulate gene expression by promoting acetylation of histones and transcription factors. Human tissue factor (TF) expression is partly governed by a unique, NF-kappa B-related "TF-kappa B" promoter binding site. We find that TSA and four other HDACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by similar to 90% TF activity and protein level induction in human umbilical vein endothelial cells stimulated by the physiologic agonists tumor necrosis factor (TNF)-alpha, interleukin-1 beta, lipopolysaccharide, and HOSCN without affecting expression of the NF-kappa B-regulated adhesion molecules ICAM-1 and E-selectin. TSA and butyrate also blunt TF induction similar to 50% in vitro in peripheral blood mononuclear cells and in vivo in thioglycolate-elicited murine peritoneal macrophages. In human umbilical vein endothelial cells, TSA attenuates by similar to 70% TNF-alpha stimulation of TF mRNA transcription without affecting that of ICAM-1. By electrophoretic mobility shift assay analyses, TNF-alpha and lipopolysaccharide induce strong p65/p50 and p65/c-Rel heterodimer binding to both NF-kappa B and TF-kappa B probes. TSA nearly abolishes TF-kappa B binding without affecting NF-kappa B binding. A chromatin immunoprecipitation assay and a promoter-luciferase reporter system confirm that TSA inhibits TF-kappa B but not NF-kappa B activation. Chromatin immunoprecipitation and small interfering RNA inhibitor studies demonstrate that HDAC3 plays a significant role in TNF-alpha-mediated TF induction. Thus, HDACi transcriptionally inhibit agonist-induced TF expression in endothelial cells and monocytes by a TF-kappa B- and HDAC3-dependent mechanism. We conclude that histone deacetylases, particularly HDAC3, play a hitherto unsuspected role in regulating TF expression and raise the possibility that HDACi might be a novel therapy for thrombotic disorders.	Univ Minnesota, Sect Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Sect Pulm & Crit Care, Minneapolis, MN 55455 USA; Univ Minnesota, Cardiol Sect, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Vasc Biol Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Slungaard, A (corresponding author), Mayo Mail Code 480,420 Delaware St,SE, Minneapolis, MN 55455 USA.	slung001@umn.edu		BITTERMAN, PETER/0000-0002-7995-7117; Mahmud, Shawn/0000-0001-5169-651X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL078679, HL070937] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arlandson M, 2001, J BIOL CHEM, V276, P215, DOI 10.1074/jbc.M004881200; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; CARSON SD, 1987, BLOOD, V70, P490; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Choi JH, 2005, ARTERIOSCL THROM VAS, V25, P2404, DOI 10.1161/01.ATV.0000184758.07257.88; Chou J, 2004, BLOOD, V104, P3190, DOI 10.1182/blood-2004-03-0935; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Day SM, 2005, BLOOD, V105, P192, DOI 10.1182/blood-2004-06-2225; Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Gray SG, 2004, INT J ONCOL, V24, P773; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Huang LL, 2006, J CELL PHYSIOL, V209, P611, DOI 10.1002/jcp.20781; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Huber D, 2002, BLOOD, V99, P3637, DOI 10.1182/blood.V99.10.3637; Inoue K, 2006, ARTERIOSCL THROM VAS, V26, P2652, DOI 10.1161/01.ATV.0000247247.89787.e7; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Mackman N, 2004, ARTERIOSCL THROM VAS, V24, P1015, DOI 10.1161/01.ATV.0000130465.23430.74; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra N, 2001, P NATL ACAD SCI USA, V98, P2628, DOI 10.1073/pnas.051507098; Nandiwada SL, 2006, J IMMUNOL, V177, P401, DOI 10.4049/jimmunol.177.1.401; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Rahman A, 1999, J IMMUNOL, V162, P5466; Reilly CM, 2004, J IMMUNOL, V173, P4171, DOI 10.4049/jimmunol.173.6.4171; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Ruan QR, 2001, J VASC RES, V38, P13, DOI 10.1159/000051025; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Sitter T, 1996, AM J PHYSIOL-REG I, V271, pR1256, DOI 10.1152/ajpregu.1996.271.5.R1256; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; Steffel J, 2006, CIRCULATION, V113, P722, DOI 10.1161/CIRCULATIONAHA.105.567297; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200; Tilley R, 2006, SEMIN THROMB HEMOST, V32, P5, DOI 10.1055/s-2006-933335; Vernia P, 2003, EUR J CLIN INVEST, V33, P244, DOI 10.1046/j.1365-2362.2003.01130.x; Wang JG, 2006, BLOOD, V107, P558, DOI 10.1182/blood-2005-05-2152; Wang JG, 2006, J IMMUNOL, V177, P8714, DOI 10.4049/jimmunol.177.12.8714; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Xu YX, 2005, INT J MOL MED, V15, P169; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	70	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28408	28418		10.1074/jbc.M703586200	http://dx.doi.org/10.1074/jbc.M703586200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17675290	hybrid			2022-12-27	WOS:000249642100015
J	Gu, L; Husain-Ponnampalam, R; Hoffmann-Benning, S; Henry, RW				Gu, Liping; Husain-Ponnampalam, Rhonda; Hoffmann-Benning, Susanne; Henry, R. William			The protein kinase CK2 phosphorylates SNAP190 to negatively regulate SNAP(c) DNA binding and human U6 transcription by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL SEQUENCE ELEMENT; SNRNA GENE-TRANSCRIPTION; OCT-1 POU DOMAIN; COMPLEX SNAP(C); ACTIVATING PROTEIN; CASEIN KINASE-2; BETA-SUBUNIT; HUMAN-CELLS; PROMOTER; RESIDUES	Human U6 small nuclear RNA gene transcription by RNA polymerase III requires the general transcription factor SNAP(C), which binds to human small nuclear RNA core promoter elements and nucleates pre-initiation complex assembly with the Brf2-TFIIIB complex. Multiple components in this pathway are phosphorylated by the protein kinase CK2, including the Bdp1 subunit of the Brf2-TFIIIB complex, and RNA polymerase III, with negative and positive outcomes for U6 transcription, respectively. However, a role for CK2 phosphorylation of SNAPC in U6 transcription has not been defined. In this report, we investigated the role of CK2 in modulating the transcriptional properties of SNAPC and demonstrate that within SNAP(C), CK2 phosphorylates the N-terminal half of the SNAP190 subunit at two regions (amino acids 20 - 63 and 514-545) that each contain multiple CK2. consensus sites. SNAP190 phosphorylation by CK2 inhibits both SNAPC DNA binding and U6 transcription activity. Mutational analyses of SNAP190 support a model wherein CK2 phosphorylation triggers an allosteric inhibition. of the SNAP190 Myb DNA binding domain.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Henry, RW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	henryrw@msu.edu			NIGMS NIH HHS [R01-GM59805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai L, 1996, MOL CELL BIOL, V16, P5419; BYFORD MF, 1991, BIOCHEM J, V280, P261, DOI 10.1042/bj2800261; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Ghavidel A, 1999, MOL CELL BIOCHEM, V191, P143, DOI 10.1023/A:1006885522221; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005; Gu LP, 2005, J BIOL CHEM, V280, P27697, DOI 10.1074/jbc.M503206200; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hinkley CS, 2003, J BIOL CHEM, V278, P18649, DOI 10.1074/jbc.M204247200; Hovde S, 2002, GENE DEV, V16, P2772, DOI 10.1101/gad.1021002; Hu P, 2004, MOL CELL, V16, P81, DOI 10.1016/j.molcel.2004.09.008; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Jawdekar GW, 2006, J BIOL CHEM, V281, P31050, DOI 10.1074/jbc.M603810200; Jiang XZ, 2004, BIOCHEMISTRY-US, V43, P15567, DOI 10.1021/bi0483965; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Reina JH, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000134; RESING KA, 1995, BIOCHEMISTRY-US, V34, P9477, DOI 10.1021/bi00029a024; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Sarno S, 1999, MOL CELL BIOCHEM, V191, P13, DOI 10.1023/A:1006857016712; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1	40	12	12	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27887	27896		10.1074/jbc.M702269200	http://dx.doi.org/10.1074/jbc.M702269200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17670747	hybrid			2022-12-27	WOS:000249455600037
J	Annis, DS; Gunderson, KA; Mosher, DF				Annis, Douglas S.; Gunderson, Kristin A.; Mosher, Deane F.			Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; C-TERMINAL REGION; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; BIOPHYSICAL CHARACTERIZATION; TYPE-1; REPEATS; ASSIGNMENTS; EXPRESSION; EPITOPES	Thrombospondins (TSPs) undergo conformational changes upon removal of calcium. The eight C-type and five N-type calcium-binding repeats of TSP-2 form a circuitous wire that, in 2 mM calcium, interacts at its ends with more N-terminal epidermal growth factor (EGF)-like modules, EGF2 and EGF3, and the C-terminal lectin-like module. These components, along with the other EGF-like module(s), form the signature domain of TSPs. Characterization of conformation-sensitive epitopes of monoclonal antibodies to human TSP-2 and its TSP-1 homolog have given insights into the structure of the signature domain in the absence of calcium. The epitope for 4B6.13 anti-TSP-2 was localized to His-722 and Leu-703 in repeat 1C of the wire; recognition only occurred in constructs that included EGF3, the rest of the wire, and the lectin-like module and in the presence of calcium. The epitope for C6.7 anti-TSP-1 was localized to Glu-609 in the EGF2 module. The C6.7 epitope was preferentially recognized when EGF2 was expressed in the context of EGF1, EGF3, the wire, and the lectin-like module. Preferential recognition of the C6.7 epitope did not require calcium. Rotary shadowing electron microscopy of TSP-1 has shown elongation of the stalk and diminution of the C-terminal globule. We propose a model whereby at low calcium concentrations the lectin-like module drops away from EGF3 concomitant with changes in conformation of the wire and loss of the 4B6.13 epitope. A critical feature of the model is interaction of repeat 12N of the wire with EGF2 in both the presence and absence of calcium.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Rm 4285 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NHLBI NIH HHS [R01 HL 054462] Funding Source: Medline; NIAMS NIH HHS [P60 AR 20614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; Adams JC, 2004, INT J BIOCHEM CELL B, V36, P1102, DOI 10.1016/j.biocel.2004.01.022; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Annis DS, 2006, J THROMB HAEMOST, V4, P459, DOI 10.1111/j.1538-7836.2006.01723.x; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chen H, 1996, FEBS LETT, V387, P36, DOI 10.1016/0014-5793(96)00460-7; CHEN H, 1994, J BIOL CHEM, V269, P32226; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Misenheimer TM, 2005, J BIOL CHEM, V280, P41229, DOI 10.1074/JBC.M504696200; Misenheimer TM, 2003, BIOCHEMISTRY-US, V42, P5125, DOI 10.1021/bi026983p; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Wiltscheck R, 1997, PROTEIN SCI, V6, P1734, DOI 10.1002/pro.5560060814	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27067	27075		10.1074/jbc.M703804200	http://dx.doi.org/10.1074/jbc.M703804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620335	hybrid			2022-12-27	WOS:000249304900048
J	Calvo, E; Tokumasu, F; Marinotti, O; Villeval, JL; Ribeiro, JMC; Francischetti, IMB				Calvo, Eric; Tokumasu, Fuyuki; Marinotti, Osvaldo; Villeval, Jean-Luc; Ribeiro, Jose M. C.; Francischetti, Ivo M. B.			Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha 2 beta 1, and von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT FEMALE MOSQUITO; THROMBUS FORMATION; AGGREGATION INHIBITOR; ACTIVATION; INTEGRIN; ADHESION; GPVI; EXPRESSION; RECEPTOR; CLONING	Blood-sucking arthropods have evolved a number of inhibitors of platelet aggregation and blood coagulation. In this study we have molecularly and functionally characterized aegyptin, a member of the family of 30-kDa salivary allergens from Aedes aegypti, whose function remained elusive thus far. Aegyptin displays a unique sequence characterized by glycine, glutamic acid, and aspartic acid repeats and was shown to specifically block collagen-induced human platelet aggregation and granule secretion. Plasmon resonance experiments demonstrate that aegyptin binds to collagen types I-V (Kd approximate to 1 nM) but does not interact with vitronectin, fibronectin, laminin, fibrinogen, and von Willebrand factor (vWf). In addition, aegyptin attenuates platelet adhesion to soluble or fibrillar collagen. Furthermore, aegyptin inhibits vWf interaction with collagen type III under static conditions and completely blocks platelet adhesion to collagen under flow conditions at high shear rates. Notably, aegyptin prevents collagen but not convulxin binding to recombinant glycoprotein VI. These findings suggest that aegyptin recognizes specific binding sites for glycoprotein VI, integrin alpha 2 beta 1, and vWf, thereby preventing collagen interaction with its three major ligands. Aegyptin is a novel tool to study collagen-platelet interaction and a prototype for development of molecules with antithrombotic properties.	NIH, NIAID, Biol Sect, Lab Malaria & Vector, Bethesda, MD 20892 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Paris 11, INSERM, Inst Gustave Roussy, F-94805 Villejuif, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Irvine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Francischetti, IMB (corresponding author), NIH, NIAID, Biol Sect, Lab Malaria & Vector, 12735 Twinbrook Pkwy Rm 2E-28, Bethesda, MD 20892 USA.	ifrancischetti@niaid.nih.gov	Tokumasu, Fuyuki/GQP-4413-2022; Calvo, Eric/ABB-4935-2021	Tokumasu, Fuyuki/0000-0003-2790-1071; Calvo, Eric/0000-0001-7880-2730; Ribeiro, Jose/0000-0002-9107-0818; Marinotti, Osvaldo/0000-0002-7173-7160; Villeval, Jean-Luc/0000-0002-0562-925X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000099, Z01AI000810] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999, Z01 AI000810-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andersen JF, 2003, J BIOL CHEM, V278, P4611, DOI 10.1074/jbc.M211438200; Atkinson BT, 2003, J THROMB HAEMOST, V1, P1278, DOI 10.1046/j.1538-7836.2003.00245.x; Auger JM, 2005, FASEB J, V19, P825, DOI 10.1096/fj.04-1940fje; Barnes CS, 2001, SEMIN THROMB HEMOST, V27, P337, DOI 10.1055/s-2001-16887; Barnes MJ, 1999, EXP GERONTOL, V34, P513, DOI 10.1016/S0531-5565(99)00038-8; Calvo E, 2006, J BIOL CHEM, V281, P1935, DOI 10.1074/jbc.M510359200; Calvo E, 2004, INSECT MOL BIOL, V13, P73, DOI 10.1111/j.1365-2583.2004.00463.x; Cazares-Raga FE, 2007, INSECT MOL BIOL, V16, P187, DOI 10.1111/j.1365-2583.2006.00712.x; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; Chen H, 2003, MOL CELL BIOL, V23, P4764, DOI 10.1128/MCB.23.14.4764-4777.2003; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; Cruz MA, 2005, BLOOD, V105, P1986, DOI 10.1182/blood-2004-04-1365; Davis JA, 2004, AM J SURG, V188, P778, DOI 10.1016/j.amjsurg.2004.08.061; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Francischetti IMB, 2007, J THROMB HAEMOST, V5, P155, DOI 10.1111/j.1538-7836.2006.02232.x; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Francischetti IMB, 2002, J EXP BIOL, V205, P2429; Furie B, 2005, J CLIN INVEST, V115, P3355, DOI 10.1172/JCI26987; Gibbins JM, 2004, J CELL SCI, V117, P3415, DOI 10.1242/jcs.01325; HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705; Heemskerk JWM, 2005, TRENDS CARDIOVAS MED, V15, P86, DOI 10.1016/j.tcm.2005.03.003; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jariyapan N, 2006, J MED ENTOMOL, V43, P867, DOI 10.1603/0022-2585(2006)43[867:AGAGPI]2.0.CO;2; Jarvis GE, 2002, BRIT J PHARMACOL, V137, P107, DOI 10.1038/sj.bjp.0704834; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; KELLER PM, 1993, J BIOL CHEM, V268, P5450; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Lasser G, 2006, BLOOD, V107, P423, DOI 10.1182/blood-2005-04-1425; Lecut C, 2004, J BIOL CHEM, V279, P52293, DOI 10.1074/jbc.M406342200; Lisman T, 2006, BLOOD, V108, P3753, DOI 10.1182/blood-2006-03-011965; Mans BJ, 2002, J BIOL CHEM, V277, P21371, DOI 10.1074/jbc.M112060200; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Moroi M, 1997, BLOOD, V90, P4413; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Munnix ICA, 2005, ARTERIOSCL THROM VAS, V25, P2673, DOI 10.1161/01.ATV.0000193568.71980.4a; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Nazareth RA, 2006, THROMB HAEMOSTASIS, V96, P7, DOI 10.1160/TH06-02-0105; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Penz S, 2005, FASEB J, V19, P898, DOI 10.1096/fj.04-2748com; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P543, DOI 10.1016/j.ibmb.2004.02.008; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; Ribeiro JMC, 2001, J EXP BIOL, V204, P3887; Ribeiro JMC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-6; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sarratt KL, 2005, BLOOD, V106, P1268, DOI 10.1182/blood-2004-11-4434; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Smethurst PA, 2007, J BIOL CHEM, V282, P1296, DOI 10.1074/jbc.M606479200; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Tokumasu F, 2003, J MICROSC-OXFORD, V211, P256, DOI 10.1046/j.1365-2818.2003.01219.x; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; VANZANTEN GH, 1995, ARTERIOSCL THROM VAS, V15, P1424, DOI 10.1161/01.ATV.15.9.1424; Vilahur G, 2004, THROMB HAEMOSTASIS, V92, P191, DOI 10.1160/TH03-11-0687; Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538-7836.2005.01429.x	64	80	86	0	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26928	26938		10.1074/jbc.M705669200	http://dx.doi.org/10.1074/jbc.M705669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650501	hybrid, Green Accepted			2022-12-27	WOS:000249304900032
J	Lin, BC; Wang, M; Blackmore, C; Desnoyers, LR				Lin, Benjamin C.; Wang, Manping; Blackmore, Craig; Desnoyers, Luc R.			Liver-specific activities of FGF19 require Klotho beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; FIBROBLAST-GROWTH-FACTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; TRANSGENIC MICE; METABOLIC-RATE; FIBROBLAST-GROWTH-FACTOR-19; EXPRESSION; CLONING	Hepatocyte function is regulated by members of the fibroblast growth factor (FGF) family of proteins, but little is known about the specific molecular mechanisms of this endocrine pathway. FGF19 regulates bile acid homeostasis and gall bladder filling; FGF19 binds only to FGF receptor 4 (FGFR4), but its liver-specific activity cannot be explained solely by the distribution of this receptor. Although it has been suggested that Klotho beta (KLB) may have a role in mediating FGF19 activity, we have provided for the first time definitive evidence that KLB is required for FGF19 binding to FGFR4, intracellular signaling, and downstream modulation of gene expression. We have shown that FGFR4 is widely distributed in mouse, whereas KLB distribution is more restricted. Liver was the only organ in which both genes were abundantly expressed. We show that in mice, FGF19 injection triggers liver-specific induction of c-Fos and repression of CYP7A1. The tissue-specific activity of FGF19 supports the unique intersection of KLB and FGFR4 distribution in liver. These studies define KLB as a novel FGFR4 co-receptor required for FGF19 liver specific functions.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Desnoyers, LR (corresponding author), 1 DNA Way, San Francisco, CA 94080 USA.	desnoyer@gene.com						Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Fu L, 2004, ENDOCRINOLOGY, V145, P2594, DOI 10.1210/en.2003-1671; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; LI YC, 1990, J BIOL CHEM, V265, P12012; Lundasen T, 2006, J INTERN MED, V260, P530, DOI 10.1111/j.1365-2796.2006.01731.x; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Trauner M, 2004, CURR OPIN GASTROEN, V20, P220, DOI 10.1097/00001574-200405000-00006; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485	25	210	231	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27277	27284		10.1074/jbc.M704244200	http://dx.doi.org/10.1074/jbc.M704244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627937	hybrid			2022-12-27	WOS:000249304900069
J	Nishi, K; Saigo, K				Nishi, Kenji; Saigo, Kaoru			Cellular internalization of green fluorescent protein fused with herpes simplex virus protein VP22 via a lipid raft-mediated endocytic pathway independent of caveolae and rho family GTPases but dependent on dynamin and Arf6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-FUSION PROTEINS; TRANSPORT VESICLES; ANCHORED PROTEINS; PLASMA-MEMBRANE; EARLY ENDOSOMES; CELLS; DELIVERY; PEPTIDE; TRANSDUCTION; RECEPTOR	VP22 is a structural protein of the herpes simplex virus and has been reported to possess unusual trafficking properties. Here we examined the mechanism of cellular uptake of VP22 using a fusion protein between the C-terminal half of VP22 and green fluorescent protein (GFP). Adsorption of VP22-GFP onto a cell surface required heparan sulfate proteoglycans and basic amino acids, in particular, Arg-164 of VP22. Inhibitor treatment, RNA interference, expression of dominant-negative mutant genes, and confocal microscopy all indicated that VP22-GFP enters cells through an endocytic pathway independent of clathrin and caveolae but dependent on dynamin and Arf6 activity. As with CD59 ( a lipid raft marker), cell-surface VP22-GFP signals were resistant to Triton X-100 treatment but only partially overlapped cell-surface CD59 signals. Furthermore, unlike other lipid raft-mediated endocytic pathways, no Rho family GTPase was required for VP22-GFP internalization. Internalized VP22 initially entered early endosomes and then moved to lysosomes and possibly recycling endosomes.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Nishi, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kennishi@biochem.s.u-tokyo.ac.jp; saigo@biochem.s.u-tokyo.ac.jp						AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Arnaoutova I, 2003, MOL BIOL CELL, V14, P4448, DOI 10.1091/mbc.E02-11-0758; Boenicke L, 2003, J MOL MED-JMM, V81, P205, DOI 10.1007/s00109-003-0421-3; Brewis ND, 2003, MOL THER, V7, P262, DOI 10.1016/S1525-0016(02)00054-0; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cheng ZJ, 2006, MOL BIOL CELL, V17, P3197, DOI 10.1091/mbc.E05-12-1101; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gauthier NC, 2005, MOL BIOL CELL, V16, P4852, DOI 10.1091/mbc.E05-05-0398; Gauthier NC, 2004, J BIOL CHEM, V279, P9481, DOI 10.1074/jbc.M312040200; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hashimoto S, 2004, J BIOL CHEM, V279, P37677, DOI 10.1074/jbc.M404196200; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Narita K, 2005, FASEB J, V19, P1558, DOI 10.1096/fj.04-2714fje; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Noguchi H, 2005, CELL TRANSPLANT, V14, P637, DOI 10.3727/000000005783982648; Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROBERT GP, 2003, TRAFFIC, V4, P724; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sauvonnet N, 2005, J CELL BIOL, V168, P155, DOI 10.1083/jcb.200406174; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stroh C, 2003, ONCOGENE, V22, P5367, DOI 10.1038/sj.onc.1206544; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Ui-Tei K, 2000, FEBS LETT, V479, P79, DOI 10.1016/S0014-5793(00)01883-4; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/j.ymthe.2003.08.001	75	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27503	27517		10.1074/jbc.M703810200	http://dx.doi.org/10.1074/jbc.M703810200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17644515	hybrid			2022-12-27	WOS:000249304900091
J	Yang, HL; Cabral, F				Yang, Hailing; Cabral, Fernando			Heightened sensitivity to paclitaxel in class IVa beta-tubulin-transfected cells is lost as expression increases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ALPHA-TUBULIN; MICROTUBULE DYNAMICS; CONFERS RESISTANCE; STRUCTURAL BASIS; CHO-CELLS; ISOTYPES; MUTATIONS; BINDING; OVEREXPRESSION	Stably transfected Chinese hamster ovary cell lines expressing increasing levels of beta 4a, a class IV neuronal-specific beta-tubulin, were compared for effects on microtubule organization, assembly, and sensitivity to antimitotic drugs. It was found that beta 4a reduced microtubule assembly in proportion to its abundance and thereby caused supersensitivity to microtubule disruptive drugs such as colcemid, vinblastine, and nocodazole. However, the response to paclitaxel was more complex. Low expression of beta 4a caused supersensitivity to paclitaxel, whereas higher expression resulted in the loss of supersensitivity. The results suggest that beta 4a may possess an enhanced ability to bind paclitaxel that increases sensitivity to the drug and acts substoichiometrically. At high levels of beta 4a expression, however, microtubule disruptive effects counteract the assembly promoting pressure exerted by paclitaxel binding, and drug supersensitivity is lost. beta 4a-Tubulin differs from the more ubiquitous beta 4b isotype at relatively few amino acid residues, yet beta 4b expression has little effect on microtubule assembly or drug response. To determine which amino acids mediate the effects of beta 4a expression, beta 4a and beta 4b were altered by site-directed mutagenesis and expressed in Chinese hamster ovary cells. The introduction of N332S or N335S mutations into beta 4b-tubulin was sufficient to confer microtubule disruption and increased colcemid sensitivity. On the other hand, mutation of Ala(115) to serine in beta 4atubulin almost completely reversed heightened sensitivity to paclitaxel, but introduction of an S115A mutation into beta 4b had no effect, suggesting that a complex interaction of multiple amino acids are necessary to produce this phenotype.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System	Cabral, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fanin, Houston, TX 77030 USA.	fernando.r.cabral@uth.tmc.edu			NCI NIH HHS [CA 85935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085935] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1983, J CELL BIOL, V97, P1055, DOI 10.1083/jcb.97.4.1055; AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; Barlow SB, 2002, J CELL SCI, V115, P3469; Bhattacharya R, 2004, MOL BIOL CELL, V15, P3123, DOI 10.1091/mbc.E04-01-0060; Blade K, 1999, J CELL SCI, V112, P2213; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; BOLLAG DM, 1995, CANCER RES, V55, P2325; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CABRAL F, 1991, PHARMACOL THERAPEUT, V52, P159, DOI 10.1016/0163-7258(91)90006-8; Cabral F., 2000, DRUG RESIST UPDATE, V3, P1; CLEVELAND DW, 1987, J CELL BIOL, V104, P381, DOI 10.1083/jcb.104.3.381; DELANO WL, 2005, MACPYMOL; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Fulton C., 1976, CELL MOTILITY, P987; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; GONZALEZGARAY ML, 1995, CELL MOTIL CYTOSKEL, V31, P259, DOI 10.1002/cm.970310403; Hari M, 2006, MOL CANCER THER, V5, P270, DOI 10.1158/1535-7163.MCT-05-0190; Hari M, 2003, CELL MOTIL CYTOSKEL, V56, P45, DOI 10.1002/cm.10132; Hari M, 2003, MOL CANCER THER, V2, P597; Jaffrezou JP, 1995, ONCOL RES, V7, P517; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nettles JH, 2004, SCIENCE, V305, P866, DOI 10.1126/science.1099190; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rosenbaum J, 2000, CURR BIOL, V10, pR801, DOI 10.1016/S0960-9822(00)00767-3; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; TAKOUDJU M, 1988, FEBS LETT, V227, P96, DOI 10.1016/0014-5793(88)80875-5; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; Wang HW, 2005, NATURE, V435, P911, DOI 10.1038/nature03606; Wang YQ, 2006, BIOCHEMISTRY-US, V45, P185, DOI 10.1021/bi051207d; Wang YQ, 2004, BIOCHEMISTRY-US, V43, P8965, DOI 10.1021/bi049637b; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260	43	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27058	27066		10.1074/jbc.M704101200	http://dx.doi.org/10.1074/jbc.M704101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627938	hybrid			2022-12-27	WOS:000249304900047
J	Hayakawa, H; Hayakawa, M; Kume, A; Tominaga, S				Hayakawa, Hiroko; Hayakawa, Morisada; Kume, Akihiro; Tominaga, Shin-ichi			Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VARIANT FORM; GENE-PRODUCT; MURINE MODEL; IL-1 RECEPTOR; TH2 CELLS; EXPRESSION; PROTEIN; IDENTIFICATION; TRANSCRIPTION	The ST2 gene produces a soluble secreted form and a transmembrane form, referred to as soluble ST2 and ST2L, respectively. A recent study has reported that interleukin (IL)-33 is a specific ligand of ST2L and induces production of T helper type 2 (Th2) cytokines. Although soluble ST2 is highly produced in sera of asthmatic patients and plays a critical role for production of Th2 cytokines, the function of soluble ST2 in relation to IL-33 signaling remains unclear. Here we show antagonistic effects of soluble ST2 on IL-33 signaling using a murine thymoma EL-4 cells stably expressing ST2L and a murine model of asthma. Soluble ST2 directly bound to IL-33 and suppressed activation of NF-kappa B in EL-4 cells stably expressing ST2L, suggesting that the complex of soluble ST2 and IL-33 fails to bind to ST2L. In a murine model of asthma, pretreatment with soluble ST2 reduced production of IL-4, IL-5, and IL-13 from IL-33-stimulated splenocytes. These results indicate that soluble ST2 acts as a negative regulator of Th2 cytokine production by the IL-33 signaling. Our study provides a molecular mechanism wherein soluble ST2 modulates the biological activity of IL-33 in allergic airway inflammation.	Jichi Med Univ, Dept Biochem, Tochigi 3290498, Japan; Jichi Med Univ, Div Genet Therapeut, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University	Hayakawa, M (corresponding author), Jichi Med Univ, Dept Biochem, 3311-1 Yakushiji, Tochigi 3290498, Japan.	morisada@jichi.ac.jp		Hayakawa, Morisada/0000-0002-1869-2450				Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Donovan CE, 1999, J IMMUNOL, V163, P6827; Gachter T, 1996, J BIOL CHEM, V271, P124; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326, DOI 10.1165/ajrcmb.25.3.4482; GIRI JG, 1994, J IMMUNOL, V153, P5802; Hayakawa M, 2005, BBA-GENE STRUCT EXPR, V1728, P53, DOI 10.1016/j.bbaexp.2005.01.012; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Iwahana H, 2004, BBA-GENE STRUCT EXPR, V1681, P1, DOI 10.1016/j.bbaexp.2004.08.013; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kuroiwa K, 2001, BIOCHEM BIOPH RES CO, V284, P1104, DOI 10.1006/bbrc.2001.5090; Lecart S, 2002, EUR J IMMUNOL, V32, P2979, DOI 10.1002/1521-4141(2002010)32:10<2979::AID-IMMU2979>3.0.CO;2-5; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Oshikawa K, 2002, CLIN EXP ALLERGY, V32, P1520, DOI 10.1046/j.1365-2745.2002.01494.x; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; SATO TA, 1993, J IMMUNOL, V150, P2717; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Sweet MJ, 2001, J IMMUNOL, V166, P6633, DOI 10.4049/jimmunol.166.11.6633; Tago K, 2001, EUR J BIOCHEM, V268, P6526, DOI 10.1046/j.1432-1327.2001.02603.x; Tago K, 2001, BIOCHEM BIOPH RES CO, V285, P1377, DOI 10.1006/bbrc.2001.5306; Tajima S, 2003, CHEST, V124, P1206, DOI 10.1378/chest.124.4.1206; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; Takezako N, 2006, BIOCHEM BIOPH RES CO, V341, P425, DOI 10.1016/j.bbrc.2005.12.206; Tominaga S, 1999, BIOCHEM BIOPH RES CO, V264, P14, DOI 10.1006/bbrc.1999.1469; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Tsutsui H, 2000, IMMUNOL REV, V174, P192, DOI 10.1034/j.1600-0528.2002.017418.x; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang JG, 1997, J BIOL CHEM, V272, P9474	38	413	446	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26369	26380		10.1074/jbc.M704916200	http://dx.doi.org/10.1074/jbc.M704916200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623648	hybrid			2022-12-27	WOS:000249239600042
J	Trisler, K; Looger, LL; Sharma, V; Baker, M; Benson, DE; Trauger, S; Schultz, PG; Smider, VV				Trisler, Kirk; Looger, Loren L.; Sharma, Vikram; Baker, Martin; Benson, David E.; Trauger, Sunia; Schultz, Peter G.; Smider, Vaughn V.			A metalloantibody that irreversibly binds a protein antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL LIBRARIES; MONOCLONAL-ANTIBODIES; BOTULINUM NEUROTOXIN; PROTEOLYTIC ANTIBODY; MOLECULAR EVOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RATIONAL DESIGN; LIGHT-CHAIN; METAL	Antibody affinity is critically important in therapeutic applications, as well as steady state diagnostic assays. Picomolar affinity antibodies, approaching the association limit of protein-protein interactions, have been discovered for highly potent antigens, but even such high-affinity binders have off-rates sufficient to negate therapeutic efficacy. To cross this affinity threshold, antibodies that tether their targets in a manner other than reversible non-covalent interaction will be required. Here we report the design and construction of an antibody that forms an irreversible complex with a protein antigen in a metal-dependent reaction. The complex resists thermal and chemical denaturation, as well as attempts to remove the coordinating metal ion. Such irreversibly binding antibodies could facilitate the development of next generation "reactive antibody" therapeutics and diagnostics.	Scripps Howard Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; IntegriGen Inc, Novato, CA 94949 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Scripps Ctr Mass Spect, Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Wayne State University; Scripps Research Institute	Smider, VV (corresponding author), Scripps Howard Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,SR202, La Jolla, CA 92037 USA.	vvsmider@scripps.edu		Trauger, Sunia/0000-0002-1678-8715; Smider, Vaughn/0000-0003-3488-6383				ANGELES TS, 1993, BIOCHEM BIOPH RES CO, V197, P696, DOI 10.1006/bbrc.1993.2535; Armentano F, 2006, IMMUNOL LETT, V103, P51, DOI 10.1016/j.imlet.2005.10.008; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P6385, DOI 10.1073/pnas.90.14.6385; Benson DE, 2000, P NATL ACAD SCI USA, V97, P6292, DOI 10.1073/pnas.97.12.6292; BERK L, 1949, NEW ENGL J MED, V240, P754, DOI 10.1056/NEJM194905122401903; Blake DA, 1996, J BIOL CHEM, V271, P27677, DOI 10.1074/jbc.271.44.27677; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chmura AJ, 2001, P NATL ACAD SCI USA, V98, P8480, DOI 10.1073/pnas.151260298; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; Corneillie TM, 2003, J AM CHEM SOC, V125, P3436, DOI 10.1021/ja029363k; Cotton F. A., 1999, ADV INORGANIC CHEM; De Boeck M, 2003, MUTAT RES-FUND MOL M, V533, P135, DOI 10.1016/j.mrfmmm.2003.07.012; Delehanty JB, 2003, BIOCHEMISTRY-US, V42, P14173, DOI 10.1021/bi034839d; ECK MJ, 1989, J BIOL CHEM, V264, P17595; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Geylis V, 2006, AUTOIMMUN REV, V5, P33, DOI 10.1016/j.autrev.2005.06.007; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Hellinga HW, 1998, FOLD DES, V3, pR1, DOI 10.1016/S1359-0278(98)00001-7; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JASELSKIS B, 1958, J AM CHEM SOC, V80, P1283, DOI 10.1021/ja01539a003; KALOGERAKOS T, 1979, EUR J BIOCHEM, V93, P339, DOI 10.1111/j.1432-1033.1979.tb12828.x; KAVERI SV, 1991, MOL IMMUNOL, V28, P773, DOI 10.1016/0161-5890(91)90120-9; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Lacroix-Desmazes S, 2005, P NATL ACAD SCI USA, V102, P4109, DOI 10.1073/pnas.0500586102; Lacroix-Desmazes S, 2002, NEW ENGL J MED, V346, P662, DOI 10.1056/NEJMoa011979; Leonard B, 2006, J IMMUNOL METHODS, V317, P56, DOI 10.1016/j.jim.2006.09.006; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; Miyanaga A, 2001, BIOCHEM BIOPH RES CO, V288, P1169, DOI 10.1006/bbrc.2001.5897; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; Rajpal A, 2005, P NATL ACAD SCI USA, V102, P8466, DOI 10.1073/pnas.0503543102; Ramsland PA, 2006, BIOCHEM J, V395, P473, DOI 10.1042/BJ20051739; Razai A, 2005, J MOL BIOL, V351, P158, DOI 10.1016/j.jmb.2005.06.003; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Street AG, 1999, STRUCTURE, V7, pR105, DOI 10.1016/S0969-2126(99)80062-8; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; ZHOU YQ, 1992, BIOPHYS CHEM, V42, P201, DOI 10.1016/0301-4622(92)85010-2	47	13	13	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26344	26353		10.1074/jbc.M704675200	http://dx.doi.org/10.1074/jbc.M704675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17617633	hybrid			2022-12-27	WOS:000249239600039
J	Miele, C; Paturzo, F; Teperino, R; Sakane, F; Fiory, F; Oriente, F; Ungaro, P; Valentino, R; Beguinot, F; Formisano, P				Miele, Claudia; Paturzo, Flora; Teperino, Raffaele; Sakane, Fumio; Fiory, Francesca; Oriente, Francesco; Ungaro, Paola; Valentino, Rossella; Beguinot, Francesco; Formisano, Pietro			Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; SKELETAL-MUSCLE; TYROSINE PHOSPHORYLATION; DIABETES-MELLITUS; MOLECULAR-CLONING; HYPERGLYCEMIA; ACTIVATION; ALPHA; TRANSPORT; ZETA	Although chronic hyperglycemia reduces insulin sensitivity and leads to impaired glucose utilization, short term exposure to high glucose causes cellular responses positively regulating its own metabolism. We show that exposure of L6 myotubes overexpressing human insulin receptors to 25 mM glucose for 5 min decreased the intracellular levels of diacylglycerol (DAG). This was paralleled by transient activation of diacylglycerol kinase (DGK) and of insulin receptor signaling. Following 30- min exposure, however, both DAG levels and DGK activity returned close to basal levels. Moreover, the acute effect of glucose on DAG removal was inhibited by > 85% by the DGK inhibitor R59949. DGK inhibition was also accompanied by increased protein kinase C-alpha (PKC alpha) activity, reduced glucose- induced insulin receptor activation, and GLUT4 translocation. Glucose exposure transiently redistributed DGK isoforms alpha and delta, from the prevalent cytosolic localization to the plasma membrane fraction. However, antisense silencing of DGK alpha, but not of DGK alpha expression, was sufficient to prevent the effect of high glucose on PKC alpha activity, insulin receptor signaling, and glucose uptake. Thus, the short term exposure of skeletal muscle cells to glucose causes a rapid induction of DGK, followed by a reduction of PKC alpha activity and transactivation of the insulin receptor signaling. The latter may mediate, at least in part, glucose induction of its own metabolism.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Sapporo Medical University	Formisano, P (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; Sakane, Fumio/H-2693-2017; ORIENTE, Francesco/J-6652-2018	Sakane, Fumio/0000-0003-0857-0377; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526; Teperino, Raffaele/0000-0001-8815-1409	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; CAPALDO B, 1986, J CLIN INVEST, V77, P1285, DOI 10.1172/JCI112432; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; Ceolotto G, 1999, DIABETES, V48, P1316, DOI 10.2337/diabetes.48.6.1316; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; Crotty T, 2006, P NATL ACAD SCI USA, V103, P15485, DOI 10.1073/pnas.0604104103; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Fiory F, 2005, MOL CELL BIOL, V25, P10803, DOI 10.1128/MCB.25.24.10803-10814.2005; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Fukunaga-Takenaka R, 2005, GENES CELLS, V10, P311, DOI 10.1111/j.1365-2443.2005.00842.x; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Hou W, 1996, CELL SIGNAL, V8, P487, DOI 10.1016/S0898-6568(96)00104-0; Imai S, 2005, J BIOL CHEM, V280, P39870, DOI 10.1074/jbc.M500669200; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1986, J BIOL CHEM, V261, P5597; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liu LZ, 2006, MOL BIOL CELL, V17, P2322, DOI 10.1091/mbc.E05-10-0969; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; PREISS J, 1986, J BIOL CHEM, V261, P8597; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; SACCA L, 1981, METABOLISM, V30, P457, DOI 10.1016/0026-0495(81)90180-3; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stenina OI, 2005, CURR PHARM DESIGN, V11, P2367, DOI 10.2174/1381612054367283; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Takahashi N, 2007, BIOCHEM BIOPH RES CO, V360, P244, DOI 10.1016/j.bbrc.2007.06.040; Tomas E, 2002, ANN NY ACAD SCI, V967, P43; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; Yki-Jarvinen H, 1998, DIABETES METAB REV, V14, pS45, DOI 10.1002/(SICI)1099-0895(199809)14:1+<S45::AID-DMR230>3.3.CO;2-Z; Zulian SE, 2006, J NEUROSCI RES, V84, P1012, DOI 10.1002/jnr.21010	46	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2007	282	44					31835	31843		10.1074/jbc.M702481200	http://dx.doi.org/10.1074/jbc.M702481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	224WY	17675299	hybrid			2022-12-27	WOS:000250480300003
J	Abad, M; Menendez, C; Fuchtbauer, A; Serrano, M; Fuchtbauer, EM; Palmero, I				Abad, Maria; Menendez, Camino; Fuchtbauer, Annette; Serrano, Manuel; Fuchtbauer, Ernst-Martin; Palmero, Ignacio			Ing1 mediates p53 accumulation and chromatin modification in response to oncogenic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERICENTRIC HETEROCHROMATIN; PREMATURE SENESCENCE; HISTONE MODIFICATION; CELL-PROLIFERATION; PLANT HOMEODOMAIN; MAMMALIAN-CELLS; PHD FINGER; RAS; ACETYLATION; PROTEINS	ING proteins are putative tumor suppressor proteins linked to the p53 pathway and to the chromatin modification machinery. Here we have analyzed the role of the products of the murine Ing1 locus in cellular tumor-protective responses, using mouse primary fibroblasts where the Ing1 locus has been inactivated by the integration of a beta geo cassette. We show that Ing1-deficient mouse embryonic fibroblasts display a defective senescence-like antiproliferative response against oncogenic Ras, affecting several senescence-specific markers. This phenotype is accompanied by a reduced accumulation of p53, which can be explained by the reduced basal p53 protein stability in the Ing1-deficient background. Ing1 deficiency also results in defects in the appearance of heterochromatic marks upon expression of oncogenic Ras, suggestive of impaired heterochromatin formation during oncogene-induced senescence. Our results support an important role for the Ing1 locus in protection against oncogenic stress in vivo, both as a mediator of p53 activation and as a regulator of chromatin remodeling processes.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Aarhus University	Palmero, I (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Serrano, Manuel/H-2634-2015; Abad, Maria/I-3911-2015; Palmero, Ignacio/B-4346-2013; Abad, Maria/AAI-2366-2019; Vivancos, Ana/AAG-8331-2019	Serrano, Manuel/0000-0001-7177-9312; Abad, Maria/0000-0002-1462-2498; Abad, Maria/0000-0002-1462-2498; Vivancos, Ana/0000-0003-2888-6512; Menendez, Maria del Camino/0000-0002-3535-2490				Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Coles AH, 2007, CANCER RES, V67, P2054, DOI 10.1158/0008-5472.CAN-06-3558; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Ferbeyre G, 2000, GENE DEV, V14, P2015; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gonzalez L, 2006, ONCOGENE, V25, P5173, DOI 10.1038/sj.onc.1209526; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Groth A, 2000, J BIOL CHEM, V275, P27473; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; Kataoka H, 2003, CANCER RES, V63, P5785; Kichina JV, 2006, ONCOGENE, V25, P857, DOI 10.1038/sj.onc.1209118; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leung KM, 2002, CANCER RES, V62, P4890; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nouman GS, 2003, J CLIN PATHOL, V56, P491, DOI 10.1136/jcp.56.7.491; Palacios A, 2006, FEBS LETT, V580, P6903, DOI 10.1016/j.febslet.2006.11.055; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi XB, 2005, J CELL BIOCHEM, V96, P1127, DOI 10.1002/jcb.20625; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172	43	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31060	31067		10.1074/jbc.M701639200	http://dx.doi.org/10.1074/jbc.M701639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17693408	hybrid			2022-12-27	WOS:000250136300073
J	Klieber, MA; Underhill, C; Hammond, GL; Muller, YA				Klieber, Michael A.; Underhill, Caroline; Hammond, Geoffrey L.; Muller, Yves A.			Corticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN CONFORMATIONAL-CHANGE; AMINO-ACID SUBSTITUTION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; REACTIVE CENTER; HINGE REGION; MECHANISM; CORTISOL; ALPHA(1)-ANTITRYPSIN; AFFINITY	Corticosteroid-binding globulin (CBG) is a serine proteinase inhibitor (serpin) family member that transports glucocorticoids in blood and regulates their access to target cells. The 1.9 angstrom crystal structure of rat CBG shows that its steroid-binding site resembles the thyroxin-binding site in the related serpin, thyroxin-binding globulin, and mutagenesis studies have confirmed the contributions of key residues that constitute the steroid-binding pocket. Unlike thyroxin-bound thyroxin-binding globulin, the cortisol-bound CBG displays an "active" serpin conformation with the proteinase-sensitive, reactive center loop (RCL) fully expelled from the regulatory beta-sheet A. Moreover, the CBG structure allows us to predict that complete insertion of the proteolytically cleaved RCL into the serpin fold occurs in concert with a displacement and unwinding of helix D that would disrupt the steroid-binding site. This allosteric coupling between RCL positioning and occupancy of the CBG steroid-binding site, which resembles the ligand (glycosamino-glycan)dependent activation of the thrombin inhibitory serpins heparin cofactor II and anti-thrombin RCLs, ensures both optimal recognition of CBG by target proteinases and efficient release of steroid to sites of action.	Univ Erlangen Nurnberg, Dept Biol, Lehrstuhl Bioeth, D-91052 Erlangen, Germany; Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 4H4, Canada	University of Erlangen Nuremberg; Child & Family Research Institute; University of British Columbia; University of British Columbia	Muller, YA (corresponding author), Henkestr 91, D-91052 Erlangen, Germany.	ymuller@biologie.uni-erlangen.de	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				AVVAKUMOV GV, 1994, J STEROID BIOCHEM, V49, P191, DOI 10.1016/0960-0760(94)90010-8; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Emptoz-Bonneton A, 2000, J CLIN ENDOCR METAB, V85, P361, DOI 10.1210/jc.85.1.361; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Garrel Dominique R., 1993, Wound Repair and Regeneration, V1, P10; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRENOT C, 1994, BIOCHEMISTRY-US, V33, P8969, DOI 10.1021/bi00196a015; HAMMOND GL, 1990, J CLIN ENDOCR METAB, V71, P34, DOI 10.1210/jcem-71-1-34; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horvath AJ, 2005, J BIOL CHEM, V280, P43168, DOI 10.1074/jbc.M505598200; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Law RHP, 2005, J BIOL CHEM, V280, P22356, DOI 10.1074/jbc.M412043200; Mager DE, 2006, ADV DRUG DELIVER REV, V58, P1326, DOI 10.1016/j.addr.2006.08.002; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; ORAVA M, 1994, GENE, V144, P259, DOI 10.1016/0378-1119(94)90387-5; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Petersen HH, 2006, MOL CELL BIOL, V26, P7236, DOI 10.1128/MCB.00400-06; Reichheld SE, 2006, J MOL BIOL, V361, P382, DOI 10.1016/j.jmb.2006.06.035; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SMITH CL, 1991, J BIOL CHEM, V266, P18555; SMITH CL, 1992, J STEROID BIOCHEM, V42, P671, DOI 10.1016/0960-0760(92)90107-T; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Strickler SS, 2006, BIOCHEMISTRY-US, V45, P2761, DOI 10.1021/bi0600143; VANBAELEN H, 1993, STEROIDS, V58, P275, DOI 10.1016/0039-128X(93)90072-U; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2; Yamasaki M, 2002, J MOL BIOL, V315, P113, DOI 10.1006/jmbi.2001.5056; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	50	101	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29594	29603		10.1074/jbc.M705014200	http://dx.doi.org/10.1074/jbc.M705014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17644521	hybrid			2022-12-27	WOS:000249788000056
J	Kojic, LD; Joshi, B; Lajoie, P; Le, PU; Cox, ME; Turbin, DA; Wiseman, SM; Nabi, IR				Kojic, Liliana D.; Joshi, Bharat; Lajoie, Patrick; Le, Phuong U.; Cox, Michael E.; Turbin, Dmitry A.; Wiseman, Sam M.; Nabi, Ivan R.			Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EXPRESSION; CAVEOLAE; INTERNALIZATION; CANCER; MACROPINOCYTOSIS; LOCALIZATION; ESTROGEN; PATHWAY; KINASE	Autocrine motility factor (AMF) is internalized via a receptor-mediated, dynamin-dependent, cholesterol-sensitive raft pathway to the smooth endoplasmic reticulum that is negatively regulated by caveolin-1. Expression of AMF and its receptor (AMFR) is associated with tumor progression and malignancy; however, the extent to which the raft-dependent uptake of AMF is tumor cell-specific has yet to be addressed. By Western blot and cell surface fluorescence-activated cell sorter (FACS) analysis, AMFR expression is increased in tumorigenic MCF7 and metastatic MDA-231 and MDA-435 breast cancer cell lines relative to dysplastic MCF10A mammary epithelial cells. AMF uptake, determined by FACS measurement of protease-insensitive internalized fluorescein-conjugated AMF, was increased in MCF7 and MDA-435 cells relative to MCF-10A and caveolin-1-expressing MDA-231 cells. Uptake of fluorescein-conjugated AMF was dynamin-dependent, methyl-beta-cyclodextrin- and genistein-sensitive, reduced upon overexpression of caveolin-1 in MDA-435 cells, and increased upon short hairpin RNA reduction of caveolin-1 in MDA-231 cells. Tissue microarray analysis of invasive primary human breast carcinomas showed that AMFR expression had no impact on survival but did correlate significantly with expression of phospho-Akt. Phospho-Akt expression was increased in AMF-internalizing MCF7 and MDA-435 breast carcinoma cells. AMF-uptake in these cells was reduced by phosphatidylinositol 3-kinase inhibition but not by regulators of macropinocytosis such as amiloride, phorbol ester, or actin cytoskeleton disruption by cytochalasin D. The raft-dependent endocytosis of AMF therefore follows a distinct phosphatidylinositol 3-kinase-dependent pathway that is up-regulated in more aggressive tumor cells.	Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; British Columbia Canc Agcy, Prostate Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, St Pauls Hosp, Dept Surg, Vancouver, BC V6T NZ, Canada	University of British Columbia; National Research Council Canada; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Nabi, IR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	irnabi@interchange.ubc.ca	Nabi, Ivan/GWZ-5144-2022; Nabi, Ivan R/C-5493-2009	Nabi, Ivan/0000-0002-0670-0513; Lajoie, Patrick/0000-0002-1614-176X				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Goetz JG, 2006, BIOCHEM SOC T, V34, P370, DOI 10.1042/BST0340370; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; Jiang WG, 2006, J HISTOCHEM CYTOCHEM, V54, P231, DOI 10.1369/jhc.5A6785.2005; Joshi B, 2005, ONCOGENE, V24, P2204, DOI 10.1038/sj.onc.1208206; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lajoie P, 2007, J CELL MOL MED, V11, P644, DOI 10.1111/j.1582-4934.2007.00083.x; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; NABI IR, 1990, CANCER RES, V50, P409; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nagai Y, 1996, DERMATOLOGY, V192, P8, DOI 10.1159/000246304; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; OTTO T, 1994, CANCER RES, V54, P3120; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; REINER A, 1990, CANCER RES, V50, P7057; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Tsutsumi S, 2003, CANCER RES, V63, P242; Watanabe H, 1996, CANCER RES, V56, P2960; WATANABE H, 1991, CANCER RES, V51, P2699; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Yu D, 2004, PROSTATE, V59, P370, DOI 10.1002/pros.20010; Zhou KM, 1998, J CELL SCI, V111, P283	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29305	29313		10.1074/jbc.M704069200	http://dx.doi.org/10.1074/jbc.M704069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690101	hybrid			2022-12-27	WOS:000249788000027
J	Li, ZZ; Lu, JZ; Xu, PY; Xie, XY; Chen, LY; Xu, T				Li, Zhengzheng; Lu, Jingze; Xu, Pingyong; Xie, Xiangyang; Chen, Liangyi; Xu, Tao			Mapping the interacting domains of STIM1 and Orai1 in Ca2+ release-activated Ca2+ channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL INTERACTION MOLECULE-1; CRAC CHANNEL; STORE; DEPLETION; SENSOR; ENTRY; OLIGOMERIZATION; IDENTIFICATION; PROTEIN	STIM1 and Orai1 are essential components of Ca2+ release-activated Ca2+ channels (CRACs). After endoplasmic reticulum Ca2+ store depletion, STIM1 in the endoplasmic reticulum aggregates and migrates toward the cell periphery to co-localize with Orai1 on the opposing plasma membrane. Little is known about the roles of different domains of STIM1 and Orai1 in protein clustering, migration, interaction, and, ultimately, opening CRAC channels. Here we demonstrate that the coiled-coil domain in the C terminus of STIM1 is crucial for its aggregation. Amino acids 425-671 of STIM1, which contain a serine-proline-rich region, are important for the correct targeting of the STIM1 cluster to the cell periphery after calcium store depletion. The polycationic region in the C-terminal tail of STIM1 also helps STIM1 targeting but is not essential for CRAC channel activation. The cytoplasmic C terminus but not the N terminus of Orai1 is required for its interaction with STIM1. We further identify a highly conserved region in the N terminus of Orai1 (amino acids 74-90) that is necessary for CRAC channel opening. Finally, we show that the transmembrane domain of Orai1 participates in Orai1-Orai1 interactions.	Chinese Acad Sci, Natl Key Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Chen, LY (corresponding author), Chinese Acad Sci, Natl Key Lab Biomacromol, Inst Biophys, Datun Rd 15,Chaoyang Dist, Beijing 100101, Peoples R China.	chen_liangyi@yahoo.com	Li, Zhengzheng/N-1415-2013; Xu, Pingyong/G-5472-2010; Xu, Tao/G-5474-2010; Chen, Liangyi/F-1352-2010	Chen, Liangyi/0000-0003-1270-7321				Baba Y, 2006, P NATL ACAD SCI USA, V103, P16704, DOI 10.1073/pnas.0608358103; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chen LY, 2003, DIABETES, V52, P1723, DOI 10.2337/diabetes.52.7.1723; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Draber P, 2005, TRENDS IMMUNOL, V26, P621, DOI 10.1016/j.it.2005.09.006; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065; Lorin-Nebel C, 2007, J PHYSIOL-LONDON, V580, P67, DOI 10.1113/jphysiol.2006.124883; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, J GEN PHYSIOL, V128, P373, DOI 10.1085/jgp.200609588; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200; Takahashi Y, 2007, BIOCHEM BIOPH RES CO, V356, P45, DOI 10.1016/j.bbrc.2007.02.107; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yang XF, 2006, J BIOL CHEM, V281, P15457, DOI 10.1074/jbc.M513246200; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	37	195	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29448	29456		10.1074/jbc.M703573200	http://dx.doi.org/10.1074/jbc.M703573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702753	hybrid			2022-12-27	WOS:000249788000042
J	Erdogan, M; Pozzi, A; Bhowmick, N; Moses, HL; Zent, R				Erdogan, Mete; Pozzi, Ambra; Bhowmick, Neil; Moses, Harold L.; Zent, Roy			Signaling pathways regulating TC21-induced tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; H-RAS; PROTEIN; TC21; ACTIVATION; KINASE; TARGET; GROWTH; IDENTIFICATION; TRANSFORMATION	TC21(R-Ras2), a Ras-related GTPase with transforming potential similar to H-, K- and N-Ras, is implicated in the pathogenesis of human cancers. Transforming growth factor beta (TGF-beta), a cytokine that plays a significant role in modulating tumorigenesis, normally prevents uncontrolled cell proliferation but paradoxically induces proliferation in H-Ras-transformed cancer cells. Although TC21 activates some pathways that mediate cellular transformation by the classical Ras proteins, the mechanisms through which TC21 induces tumor formation and how TGF-beta regulates TC21 transformed cells is not known. To better understand the role of TC21 in cancer progression, we overexpressed an activated G23V mutant of TC21 in a nontumorigenic murine mammary epithelial (EpH4) cell line. Mutant TC21-expressing cells were significantly more oncogenic than cells expressing activated G12V H-Ras both in vivo and in vitro. TC21-induced transformation and proliferation required activation of p38 MApK, mTOR (the mammalian target of rapamycin), and phosphoinositide 3-kinase but not Akt/PKB. Transformation by TC21 rendered EpH4 cells insensitive to the growth inhibitory effects of TGF-beta, and the soft agar growth of these cells was increased upon TGF-beta stimulation. Despite losing responsiveness to TGF-beta-mediated growth inhibition, both Smad-dependent and independent pathways remained intact in TC21-transformed cells. Thus, overexpression of active TC21 in EpH4 cells induces tumorigenicity through the phosphoinositide 3-kinase, p38 MAPK, and mTOR pathways, and these cells lose their sensitivity to the normal growth inhibitory role of TGF-beta.	Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA; Vet Affairs Hosp, Dept Med, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Zent, R (corresponding author), Vanderbilt Univ, Med Ctr, Rm C3210, Nashville, TN 37232 USA.	roy.zent@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NCI NIH HHS [CA 102162, R01-CA94849, CA 085492] Funding Source: Medline; NIDDK NIH HHS [R01-DK 69921, R01-DK074359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094849, R01CA102162, R01CA085492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921, R01DK074359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Barker KT, 1998, BRIT J CANCER, V78, P296, DOI 10.1038/bjc.1998.490; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; HUANG Y, 1995, ONCOGENE, V11, P1255; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pozzi A, 2006, MOL BIOL CELL, V17, P2046, DOI 10.1091/mbc.E05-08-0800; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Sharma R, 2005, ONCOLOGY-BASEL, V69, P10, DOI 10.1159/000087283; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420	31	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27713	27720		10.1074/jbc.M703037200	http://dx.doi.org/10.1074/jbc.M703037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656362	hybrid			2022-12-27	WOS:000249455600019
J	Lee, J; Kumagai, A; Dunphy, WG				Lee, Joon; Kumagai, Akiko; Dunphy, William G.			The Rad9-Hus1-Rad1 checkpoint interaction of TopBP1 with ATR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; XENOPUS EGG EXTRACTS; REPLICATION CHECKPOINT; POLYMERASE-ALPHA; HUMAN CLASPIN; CLAMP LOADER; CHK1; ACTIVATION; PHOSPHORYLATION; PROTEIN	TopBP1 serves as an activator of the ATR-ATRIP complex in response to the presence of incompletely replicated or damaged DNA. This process involves binding of ATR to the ATR-activating domain of TopBP1, which is located between BRCT domains VI and VII. TopBP1 displays increased binding to ATR-ATRIP in Xenopus egg extracts containing checkpoint-inducing DNA templates. We show that an N-terminal region of TopBP1 containing BRICT repeats I-II is essential for this checkpoint-stimulated binding of TopBP1 to ATR-ATRIP. The BRCT I-II region of TopBP1 also binds specifically to the Rad9-Hus1-Rad1 (9-1-1) complex in Xenopus egg extracts. This binding occurs via the C-terminal domain of Rad9 and depends upon phosphorylation of its Ser-373 residue. Egg extracts containing either a mutant of TopBP1 lacking the BRCT I-II repeats or a mutant of Rad9 with an alanine substitution at Ser-373 are defective in checkpoint regulation. Furthermore, an isolated C-terminal fragment from Rad9 is an effective inhibitor of checkpoint signaling in egg extracts. These findings suggest that interaction of the 9-1-1 complex with the BRCT I-II region of TopBP1 is necessary for binding of ATR-ATRIP to the ATR-activating domain of TopBP1 and the ensuing activation of ATR.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dunphy, WG (corresponding author), CALTECH, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070891, R37GM043974, R01GM043974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM043974, GM070891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Greer DA, 2003, CANCER RES, V63, P4829; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hashimoto Y, 2006, GENES CELLS, V11, P993, DOI 10.1111/j.1365-2443.2006.00998.x; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 2006, CELL CYCLE, V5, P1265, DOI 10.4161/cc.5.12.2834; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2006, MOL BIOL CELL, V17, P1559, DOI 10.1091/mbc.E05-09-0865; MacDougall CA, 2007, GENE DEV, V21, P898, DOI 10.1101/gad.1522607; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2006, MOL CELL, V24, P891, DOI 10.1016/j.molcel.2006.11.027; Majka J, 2006, J BIOL CHEM, V281, P27855, DOI 10.1074/jbc.M605176200; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Perry JA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-12; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; St Onge RP, 2003, J BIOL CHEM, V278, P26620, DOI 10.1074/jbc.M303134200; Wang H, 2002, GENETICS, V160, P1295; Yan S, 2006, J CELL BIOL, V173, P181, DOI 10.1083/jcb.200601076; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	43	216	218	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28036	28044		10.1074/jbc.M704635200	http://dx.doi.org/10.1074/jbc.M704635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17636252	Green Accepted, hybrid			2022-12-27	WOS:000249455600053
J	Park, MY; Moon, JH; Lee, KS; Choi, HI; Chung, J; Hong, HJ; Kim, E				Park, Min-Young; Moon, Ji-Hyun; Lee, Ki-Sung; Choi, Hye-In; Chung, Jongkyeong; Hong, Hyo Jeong; Kim, Eunhee			FAF1 suppresses I kappa B kinase (IKK) activation by disrupting the IKK complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-ASSOCIATED FACTOR-1; NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; PROTEIN; BETA; TRANSCRIPTION; ASSOCIATION; GAMMA; PHOSPHORYLATION; IDENTIFICATION	This study presents a molecular inhibitory mechanism by Fas-associated factor 1 (FAF1) on I kappa B kinase (IKK) activation, where divergent NF-kappa B-activating stimuli converge. FAF1 interacts with IKK beta in response to proinflammatory stimuli (such as tumor necrosis factor-a, interleukin-1 beta, and lipopolysaccharide) and suppresses IKK activation. Interaction of the leucine-zipper domain of IKK beta with FAF1 affected the IKK heterocomplex (IKK alpha/beta) and homocomplex (IKK alpha/alpha, IKK beta/beta) formations and attenuated IKK gamma recruitment to IKK beta. Overexpression of FAF1 reduced the level of IKK,13 activity, whereas FAF1 depletion increased the activity. These results indicate that FAF1 inhibits IKK activation and its downstream signaling by interrupting the IKK complex assembly through physical interaction with IKK beta. Taken together, FAF1 robustly suppresses NF-kappa B activation through the inhibition of IKK activation in combination with previously reported cytoplasmic retention of NF-kappa B p65 (Park, M. Y., Jang, H. D., Lee, S. Y., Lee, K. J., and Kim, E. (2004) J. Biol. Chem. 279, 2544-2549). Such redundant suppression would prevent inadvertent activation of the NF-kappa B pathway.	Chungnam Natl Univ, Sch Biosci & Biotechnol, Dept Biol, Taejon 305764, South Korea; PaiChai Univ, Res Ctr Biomed Resources, Taejon 302835, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Lab Antibody Engn, Taejon 305333, South Korea	Chungnam National University; Pai Chai University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Chungnam Natl Univ, Sch Biosci & Biotechnol, Dept Biol, 220 Gungdong,Yuseong-gu, Taejon 305764, South Korea.	eunhee@cnu.ac.kr		Choi, Hye-In/0000-0003-4348-0780				Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Frohlich T, 1998, J CELL SCI, V111, P2353; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Kim HJ, 2005, J BIOL CHEM, V280, P8125, DOI 10.1074/jbc.M406297200; Kim M, 2006, P NATL ACAD SCI USA, V103, P16358, DOI 10.1073/pnas.0603238103; Kim S, 2006, J NEUROSCI, V26, P2403, DOI 10.1523/JNEUROSCI.4691-05.2006; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Olsen BB, 2003, FEBS LETT, V546, P218, DOI 10.1016/S0014-5793(03)00575-1; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Park MY, 2005, INT J CANCER, V115, P412, DOI 10.1002/ijc.20857; Park MY, 2004, J BIOL CHEM, V279, P2544, DOI 10.1074/jbc.M304565200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ryu SW, 1999, BIOCHEM BIOPH RES CO, V262, P388, DOI 10.1006/bbrc.1999.1217; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Song EJ, 2005, MOL CELL BIOL, V25, P2511, DOI 10.1128/MCB.25.6.2511-2524.2005; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	31	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27572	27577		10.1074/jbc.C700106200	http://dx.doi.org/10.1074/jbc.C700106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17684021	hybrid			2022-12-27	WOS:000249455600004
J	Salanova, B; Choi, M; Rolle, S; Wellner, M; Luft, FC; Kettritz, R				Salanova, Birgit; Choi, Mira; Rolle, Susanne; Wellner, Maren; Luft, Friedrich C.; Kettritz, Ralph			beta 2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappa B activation of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHED MEMBRANE MICROPARTICLES; LEUKOCYTE-PLATELET ADHESION; IIB-IIIA; MONOCLONAL-ANTIBODIES; WHOLE-BLOOD; P-SELECTIN; INTEGRINS; CELLS; FLOW; PHARMACOKINETICS	Microparticles from various cells are generated during inflammation. Platelet-derived microparticles (PMPs) harbor receptors that are not genuinely expressed by neutrophils. We tested whether or not functional glycoprotein IIb/IIIa (GPIIb/ IIIa) receptors can be acquired by neutrophils via PMPs and whether these receptors participate in pro-inflammatory signaling. Surface expression was analyzed by flow cytometry and confocal microscopy. NF-kappa B activation was analyzed by Western blot experiments, electrophoretic mobility shift assays, and reverse transcription-PCR. Cell adhesion and spreading were estimated by myeloperoxidase assay and light microscopy. We found that PMPs transfer GPIIb/IIIa receptors to isolated and whole blood neutrophils via PMPs. We used specific antibodies in granulocyte macrophage colony-stimulating factor-treated neutrophils and observed that acquired GPIlb/Illa receptors colocalized with beta 2-integrins and cooperated in NF-kappa B activation. We show that Src and Syk non-receptor tyrosine kinases, as well as the actin cytoskeleton, control NF-kappa B activation. In contrast to NF-kappa B, acquisition of GPIIb/IIIa receptors was not necessary to induce adhesion to fibronectin or phosphatidylinositol 3-kinase/Akt signaling. When granulocyte macrophage colony-stimulating factor-stimulated neutrophils were incubated on fibronectin, strong NF-kappa B activation was observed, but only after loading with PMPs. Blocking either beta 2-integrins or GPIIb/ IIIa receptors abrogated this effect. Therapeutic GPIIb/IIIa inhibitors were similarly effective. The compounds also inhibited NF-kappa B-dependent tumor necrosis factor-alpha mRNA up-regulation. The data implicate GPIIb/IIIa receptors as new therapeutic targets in neutrophil-induced inflammation.	Charite Univ Med Berlin, Fac Med, Max Delbruck Ctr Mol Med, Helios Klin,Franz Volhard Clin, D-13125 Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettritz, R (corresponding author), Franz Volhard Clin, Div Nephrol, Schwanebecker Chaussee 50, D-13125 Berlin, Germany.	kettritz@charite.de		Choi, Mira/0000-0002-0286-1491; Luft, Friedrich/0000-0002-8635-1199; Kettritz, Ralph/0000-0001-5821-6718				ALTIERI DC, 1988, J IMMUNOL, V141, P2656; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BARRETT JS, 1994, CLIN PHARMACOL THER, V56, P377, DOI 10.1038/clpt.1994.152; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; Coller BS, 1999, AM HEART J, V138, pS1, DOI 10.1053/hj.1999.v138.99078; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Daniel L, 2006, KIDNEY INT, V69, P1416, DOI 10.1038/sj.ki.5000306; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; Faull RJ, 1996, J AM SOC NEPHROL, V7, P1091; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Forlow SB, 2000, BLOOD, V95, P1317, DOI 10.1182/blood.V95.4.1317.004k30_1317_1323; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GEMMELL CH, 1993, J BIOL CHEM, V268, P14586; Gilchrist IC, 2001, CIRCULATION, V104, P406, DOI 10.1161/hc2901.093504; Kettritz R, 2004, J BIOL CHEM, V279, P2657, DOI 10.1074/jbc.M309778200; KONSTANTOPOULOS K, 1995, CIRCULATION, V91, P1427, DOI 10.1161/01.CIR.91.5.1427; Konstantopoulos K, 1998, CIRCULATION, V98, P873, DOI 10.1161/01.CIR.98.9.873; Kuijper PHM, 1998, THROMB HAEMOSTASIS, V80, P443, DOI 10.1055/s-0037-1615227; LEE YJ, 1993, THROMB RES, V72, P295, DOI 10.1016/0049-3848(93)90138-E; Lo SC, 2006, J BIOMED SCI, V13, P787, DOI 10.1007/s11373-006-9107-5; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004; Merten M, 1999, CIRCULATION, V99, P2577, DOI 10.1161/01.CIR.99.19.2577; Nomura S, 2003, THROMB HAEMOSTASIS, V89, P506; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; RINDER CS, 1992, BLOOD, V79, P1201; RINDER HM, 1991, BLOOD, V78, P1730; Seshiah PN, 2002, CIRCULATION, V105, P174, DOI 10.1161/hc0202.102248; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; SHATTIL SJ, 1987, BLOOD, V70, P307; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Tan KT, 2005, ANN MED, V37, P61, DOI 10.1080/07853890410018943; Wagner DD, 2005, ARTERIOSCL THROM VAS, V25, P1321, DOI 10.1161/01.ATV.0000166521.90532.44	39	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27960	27969		10.1074/jbc.M704039200	http://dx.doi.org/10.1074/jbc.M704039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644514	hybrid			2022-12-27	WOS:000249455600045
J	Faye, A; Esnous, C; Price, NT; Onfray, MA; Girard, J; Prip-Buus, C				Faye, Audrey; Esnous, Catherine; Price, Nigel T.; Onfray, Marie Anne; Girard, Jean; Prip-Buus, Carina			Rat liver carnitine palmitoyltransferase 1 forms an oligomeric complex within the outer mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; MALONYL-COA SENSITIVITY; FATTY-ACID OXIDATION; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; SUBSTRATE SELECTIVITY; STRUCTURAL MODEL; CPT I; ACETYLTRANSFERASE; OCTANOYLTRANSFERASE	Carnitine palmitoyltransferase (CPT) 1A catalyzes the rate-limiting step in the transport of long chain acyl-CoAs from cytoplasm to the mitochondrial matrix by converting them to acyl-carnitines. Located within the outer mitochondrial membrane, CPT1A activity is inhibited by malonyl-CoA, its allosteric inhibitor. In this study, we investigate for the first time the quaternary structure of rat CPT1A. Chemical cross-linking studies using intact mitochondria isolated from fed rat liver or from Saccharomyces cerevisiae expressing CPT1A show that CPT1A self-assembles into an oligomeric complex. Size exclusion chromatography experiments using solubilized mitochondrial extracts suggest that the fundamental unit of its quaternary structure is a trimer. When studied in blue native-PAGE, the CPT1A hexamer could be observed, however, suggesting that under these native conditions CPT1A trimers might be arranged as dimers. Moreover, the oligomeric state of CPT1A was found unchanged by starvation and by streptozotocin-induced diabetes, conditions characterized by changes in malonyl-CoA sensitivity of CPT1A. Finally, gel filtration analysis of several yeast-expressed chimeric CPTs demonstrates that the first 147 N-terminal residues of CPT1A, encompassing its two transmembrane segments, trigger trimerization independently of its catalytic C-terminal domain. Deletion of residues 1 - 82, including transmembrane 1, did not abrogate oligomerization, but the latter is limited to a trimer by the presence of the large catalytic C-terminal domain on the cytosolic face of mitochondria. Based on these findings, we proposed that the oligomeric structure of CPT1A would allow the newly formed acylcarnitines to gain direct access into the intermembrane space, hence facilitating substrate channeling.	Univ Paris 05, Inst Cochin, Dept Endocrinol, Metab Ctr,Fac Med,UMR 8104, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prip-Buus, C (corresponding author), Univ Paris 05, Inst Cochin, Dept Endocrinol, Metab Ctr,Fac Med,UMR 8104, 24,Rue Faubourg St, F-75014 Paris, France.	prip-buus@cochin.inserm.fr	PRIP-BUUS, Carina/P-9084-2017	Prip-Buus, Carina/0000-0002-2153-7857				Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; Borthwick K, 2006, J BIOL CHEM, V281, P32946, DOI 10.1074/jbc.M600843200; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1987, J BIOL CHEM, V262, P4968; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; ESSER V, 1993, J BIOL CHEM, V268, P5817; Faye A, 2005, BIOCHEM J, V387, P67, DOI 10.1042/BJ20041533; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Gobin S, 2003, J BIOL CHEM, V278, P50428, DOI 10.1074/jbc.M310130200; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Hsiao YS, 2006, J BIOL CHEM, V281, P28480, DOI 10.1074/jbc.M602622200; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2005, J BIOL CHEM, V280, P738, DOI 10.1074/jbc.M409894200; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Lopez-Vinas E, 2007, J BIOL CHEM, V282, P18212, DOI 10.1074/jbc.M700885200; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McGarry JD, 2000, BIOCHEM J, V349, P179, DOI 10.1042/0264-6021:3490179; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Pan Y, 2002, J BIOL CHEM, V277, P47184, DOI 10.1074/jbc.M208055200; PAULY DF, 1988, J BIOL CHEM, V263, P18160; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Rufer AC, 2006, STRUCTURE, V14, P713, DOI 10.1016/j.str.2006.01.008; SAGGERSON ED, 1981, FEBS LETT, V132, P166, DOI 10.1016/0014-5793(81)81152-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Turkaly P, 1999, FEBS LETT, V460, P241, DOI 10.1016/S0014-5793(99)01354-X; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; Wolfgang MJ, 2006, J BIOL CHEM, V281, P37265, DOI 10.1074/jbc.R600016200; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7	51	25	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26908	26916		10.1074/jbc.M705418200	http://dx.doi.org/10.1074/jbc.M705418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650509	hybrid			2022-12-27	WOS:000249304900030
J	Heiss, EH; Schilder, YDC; Dirsch, VM				Heiss, Elke H.; Schilder, Yvonne D. C.; Dirsch, Verena M.			Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENE-INDUCED SENESCENCE; SMOOTH-MUSCLE-CELLS; HISTONE H2AX PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; CELLULAR SENESCENCE; DNA-DAMAGE; CHEMOPREVENTIVE AGENT; TELOMERASE ACTIVITY; OXIDATIVE STRESS; ATM ACTIVATION	The induction of senescence, an irreversible growth arrest, in cancer cells is regarded as a mean to halt tumor progression. The phytoalexin resveratrol ( RV) is known to possess a variety of cancer-preventive, - therapeutic, and - chemosensitizing properties. We report here that chronic treatment with RV in a subapoptotic concentration induces senescence-like growth arrest in tumor cells. In contrast to the widely accepted antioxidant property of RV, we demonstrate that one causative stimulus for senescence induction by chronic RV is an increased level of reactive oxygen species (ROS). The ROS formed upon RV exposure include hydrogen peroxide and superoxide and originate largely from mitochondria. Consistently, co-incubation with the antioxidant N-acetyl cysteine interfered with RV-mediated reactivation of the senescence program. Molecular mediators on the way from increased ROS levels to the observed growth arrest include p38 MAPK, p53, and p21. Moreover, we provide evidence that RV-initiated replication stress, apparent by activation of the ataxia telangiectasia-mutated kinase pathway, is associated with increased ROS levels and senescence induction. This is the first report linking cell cycle effects with a pro-oxidant and pro-senescent effect of RV in cancer cells.	Univ Vienna, Dept Pharmacognosy, A-1090 Vienna, Austria	University of Vienna	Heiss, EH (corresponding author), Univ Vienna, Dept Pharmacognosy, Althanstr 14, A-1090 Vienna, Austria.	elke.heiss@univie.ac.at	Heiss, Elke/B-6086-2015	Heiss, Elke/0000-0001-7618-5505; Dirsch, Verena/0000-0002-9261-5293				Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fuggetta MP, 2006, J EXP CLIN CANC RES, V25, P189; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Furukawa A, 2003, BIOCHEM PHARMACOL, V66, P1769, DOI 10.1016/S0006-2952(03)00541-0; Furumoto K, 1998, LIFE SCI, V63, P935, DOI 10.1016/S0024-3205(98)00351-8; Haider UGB, 2003, MOL PHARMACOL, V63, P925, DOI 10.1124/mol.63.4.925; Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Kuki S, 2006, CIRC J, V70, P1076, DOI 10.1253/circj.70.1076; Lanzilli G, 2006, INT J ONCOL, V28, P641; Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002; Lin HY, 2006, FASEB J, V20, P1742, DOI 10.1096/fj.06-5743fje; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Moon SK, 2006, BIOCHEM BIOPH RES CO, V350, P662, DOI 10.1016/j.bbrc.2006.09.092; Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001; Myohanen SK, 1998, CANCER RES, V58, P591; Naderi W, 2006, MECH AGEING DEV, V127, P25, DOI 10.1016/j.mad.2005.08.006; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orallo F, 2006, CURR MED CHEM, V13, P87, DOI 10.2174/092986706775197953; Passos JF, 2005, EXP GERONTOL, V40, P466, DOI 10.1016/j.exger.2005.04.006; Passos JF, 2006, FREE RADICAL RES, V40, P1277, DOI 10.1080/10715760600917151; Probin V, 2006, J PHARMACOL EXP THER, V319, P551, DOI 10.1124/jpet.106.107771; Sareen D, 2006, INVEST OPHTH VIS SCI, V47, P3708, DOI 10.1167/iovs.06-0119; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Schultz J, 2004, J NATL CANCER I, V96, P1497, DOI 10.1093/jnci/96.20.1497; Sengottuvelan M, 2006, BBA-GEN SUBJECTS, V1760, P1175, DOI 10.1016/j.bbagen.2006.03.008; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Takahashi Y, 2004, LIFE SCI, V75, P301, DOI 10.1016/j.lfs.2003.12.014; Tanaka T, 2007, CELL PROLIFERAT, V40, P1; Tanaka T, 2006, CELL CYCLE, V5, P1940, DOI 10.4161/cc.5.17.3191; Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165; Won JJ, 2006, NAT CHEM BIOL, V2, P369, DOI 10.1038/nchembio800; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	49	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26759	26766		10.1074/jbc.M703229200	http://dx.doi.org/10.1074/jbc.M703229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626009	hybrid			2022-12-27	WOS:000249304900015
J	Bewry, NN; Bolick, SCE; Wright, KL; Harton, JA				Bewry, Nadine N.; Bolick, Sophia C. E.; Wright, Kenneth L.; Harton, Jonathan A.			GTP-dependent recruitment of CIITA to the class II major histocompatibility complex promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; LEUCINE-RICH REPEATS; IFN-GAMMA; TRANSCRIPTIONAL COACTIVATOR; TRANSACTIVATOR CIITA; SELF-ASSOCIATION; EXPRESSION; MHC; GENE; ENHANCEOSOME	We previously established that the class II transactivator CIITA binds GTP and disruption of the GTP binding ability of CIITA results in increased cytoplasmic CIITA, loss of nuclear CIITA, and thus diminished class II major histocompatibility complex transcription. Because of its role in facilitating nuclear localization, whether GTP binding is also required for CIITA-mediated transactivation of major histocompatibility class II genes remains unclear. We now show that recruitment of CIITA to the human leukocyte antigen ( HLA)-DR promoter and activation of HLA-DR transcription is also GTP-dependent. After restoration of nuclear expression, CIITA mutants defective in GTP binding lack full transcriptional activation capacity. Although the availability of the activation domain of CIITA is unaltered, GTP mutants no longer cooperate with CREB-binding protein, p300, and pCAF and are defective in recruitment to the HLA-DR promoter.	Albany Med Ctr, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	Albany Medical College; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Harton, JA (corresponding author), Albany Med Ctr, Ctr Immunol & Microbial Dis, 47 New Scotland Rd, Albany, NY 12208 USA.	hartonj@mail.amc.edu	Harton, Jonathan/F-2848-2010; Harton, Jonathan A/AAW-5283-2021	Harton, Jonathan/0000-0002-0350-1877; Harton, Jonathan A/0000-0002-0350-1877	NCI NIH HHS [K01CA095582, K01 CA095582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA095582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gialitakis M, 2006, NUCLEIC ACIDS RES, V34, P765, DOI 10.1093/nar/gkj462; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Greer SF, 2004, J IMMUNOL, V173, P376, DOI 10.4049/jimmunol.173.1.376; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2002, HUM IMMUNOL, V63, P588, DOI 10.1016/S0198-8859(02)00400-7; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Krawczyk M, 2004, J IMMUNOL, V173, P6200, DOI 10.4049/jimmunol.173.10.6200; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Masternak K, 2000, GENE DEV, V14, P1156; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Mudhasani R, 2005, MOL IMMUNOL, V42, P673, DOI 10.1016/j.molimm.2004.09.021; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Raval A, 2003, J IMMUNOL, V170, P922, DOI 10.4049/jimmunol.170.2.922; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Rigaud G, 1996, J IMMUNOL, V156, P4254; Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wang Y, 2005, J IMMUNOL, V174, P5687, DOI 10.4049/jimmunol.174.9.5687; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26178	26184		10.1074/jbc.M611747200	http://dx.doi.org/10.1074/jbc.M611747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623662	hybrid			2022-12-27	WOS:000249239600021
J	Suzuki-Inoue, K; Kato, Y; Inoue, O; Kaneko, MK; Mishima, K; Yatomi, Y; Yamazaki, Y; Narimatsu, H; Ozaki, Y				Suzuki-Inoue, Katsue; Kato, Yukinari; Inoue, Osamu; Kaneko, Mika Kato; Mishima, Kazuhiko; Yatomi, Yutaka; Yamazaki, Yasuo; Narimatsu, Hisashi; Ozaki, Yukio			Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGGREGATION-INDUCING FACTOR; MURINE COLON ADENOCARCINOMA-26; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEIN; DC-SIGN; GLYCOPROTEIN; TUMORS; MARKER; EXPRESSION; AGGRUS	Podoplanin ( aggrus), a transmembrane sialoglycoprotein, is involved in tumor cell-induced platelet aggregation, tumor metastasis, and lymphatic vessel formation. However, the mechanism by which podoplanin induces these cellular processes including its receptor has not been elucidated to date. Podoplanin induced platelet aggregation with a long lag phase, which is dependent upon Src and phospholipase C gamma 2 activation. However, it does not bind to glycoprotein VI. This mode of platelet activation was reminiscent of the snake toxin rhodocytin, the receptor of which has been identified by us as a novel platelet activation receptor, C-type lectin-like receptor 2 ( CLEC-2) ( Suzuki-Inoue, K., Fuller, G. L., Garcia, A., Eble, J. A., Pohlmann, S., Inoue, O., Gartner, T. K., Hughan, S. C., Pearce, A. C., Laing, G. D., Theakston, R. D., Schweighoffer, E., Zitzmann, N., Morita, T., Tybulewicz, V. L., Ozaki, Y., and Watson, S. P. ( 2006) Blood 107, 542-549). Therefore, we sought to evaluate whether CLEC-2 serves as a physiological counterpart for podoplanin. Association between CLEC-2 and podoplanin was confirmed by flow cytometry. Furthermore, their association was dependent on sialic acid on O-glycans of podoplanin. Recombinant CLEC-2 inhibited platelet aggregation induced by podoplanin-expressing tumor cells or lymphatic endothelial cells, suggesting that CLEC-2 is responsible for platelet aggregation induced by endo-genously expressed podoplanin on the cell surfaces. These findings suggest that CLEC-2 is a physiological target protein of podoplanin and imply that it is involved in podoplanin-induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin.	Univ Yamanashi, Fac Med, Dept Clin Lab & Med, Yamanashi 4093898, Japan; AIST, Res Ctr Med Glyosci, Tsukuba, Ibaraki 3058568, Japan; Saitama Med Univ Int Med Ctr, Saitama, Japan; Univ Tokyo, Grad Sch Med, Dept Lab Med, Hongo, Tokyo 1138655, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	University of Yamanashi; National Institute of Advanced Industrial Science & Technology (AIST); Saitama Medical University; University of Tokyo; Meiji Pharmaceutical University	Suzuki-Inoue, K (corresponding author), Univ Yamanashi, Fac Med, Dept Clin Lab & Med, 111Shimokato Chuo, Yamanashi 4093898, Japan.	katsuei@yamanashi.ac.jp	Narimatsu, Hisashi/M-4757-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Yamazaki, Yasuo/0000-0001-5297-9837; K. Kaneko, Mika/0000-0002-4158-9208; Yatomi, Yutaka/0000-0003-1719-4297; Kato, Yukinari/0000-0001-5385-8201				Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Colonna M, 2000, EUR J IMMUNOL, V30, P697; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; Fuller GLJ, 2007, J BIOL CHEM, V282, P12397, DOI 10.1074/jbc.M609558200; Gupta GP, 2004, J CLIN INVEST, V114, P1691, DOI 10.1172/JCI200423823; Kaneko M, 2004, J BIOL CHEM, V279, P38838, DOI 10.1074/jbc.M407210200; Kaneko MK, 2007, FEBS LETT, V581, P331, DOI 10.1016/j.febslet.2006.12.044; Kato Y, 2005, TUMOR BIOL, V26, P195, DOI 10.1159/000086952; Kato Y, 2004, ONCOGENE, V23, P8552, DOI 10.1038/sj.onc.1207869; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; Kato Y, 2006, BIOCHEM BIOPH RES CO, V349, P1301, DOI 10.1016/j.bbrc.2006.08.171; Kisucka J, 2006, P NATL ACAD SCI USA, V103, P855, DOI 10.1073/pnas.0510412103; Mishima K, 2006, ACTA NEUROPATHOL, V111, P483, DOI 10.1007/s00401-006-0063-y; Mishima K, 2006, ACTA NEUROPATHOL, V111, P563, DOI 10.1007/s00401-006-0033-4; Miura Y, 2002, J BIOL CHEM, V277, P46197, DOI 10.1074/jbc.M204029200; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; SUGIMOTO Y, 1991, CANCER RES, V51, P921; Suzuki-Inoue K, 2006, BLOOD, V107, P542, DOI 10.1182/blood-2005-05-1994; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; WATANABE M, 1988, CANCER RES, V48, P6411; WATSON AA, J BIOL CHEM, V282, P3165; Yatomi Y, 2006, CURR PHARM DESIGN, V12, P575, DOI 10.2174/138161206775474404; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061	31	330	379	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					25993	26001		10.1074/jbc.M702327200	http://dx.doi.org/10.1074/jbc.M702327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616532	hybrid			2022-12-27	WOS:000249239600003
J	Waas, WF; Druzina, Z; Hanan, M; Schimmel, P				Waas, William F.; Druzina, Zhanna; Hanan, Melanie; Schimmel, Paul			Role of a tRNA base modification and its precursors in frameshifting in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; Y-BASE; RIBOSOMAL FRAMESHIFT; BINDING-SITES; ANTICODON; VIRUS	Little is known about the role of specific base modifications of transfer RNAs. Wyosine bases are tRNA(Phe)- specific modifications that are distinguished by differentiated, lateral side chains and base methylations appended to the core ring structure of a universally conserved G37, adjacent to the anticodon of Phe tRNAs. Based on previous data, we hypothesized that this modification was needed for - 1 frameshifting. Using a reporter system incorporating a SCV-LA yeast virus slippery site for detecting - 1 frameshifts in vivo, yeast strains were created that enabled chemical-genetic dissection of the role of different functional groups of wyebutosine that are added in a three-step post-transcriptional set of reactions. With this system, hypo-modification increased Phe-specific frameshifting, with incremental changes in frameshift efficiency after specific intermediates in the progression of wyebutosine synthesis. These data combined with investigations of wild-type and hypomodified tRNA binding to ribosomes suggest that frameshift efficiency is kinetically and not thermodynamically controlled. The progressive nature of frameshift efficiency with the stage of modification is consistent with a stepwise evolution and tuning of frameshift potential. The stepwise tuning of frameshift efficiency could explain why tRNAPhe in some eukaryotes is not fully modified but, rather, hypomodified to capture a specific frameshift potential.	Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; ALTWEGG M, 1979, NUCLEIC ACIDS RES, V7, P93, DOI 10.1093/nar/7.1.93; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; BLOBSTEIN SH, 1973, BIOCHEMISTRY-US, V12, P188, DOI 10.1021/bi00726a002; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; Brierley I, 2006, VIRUS RES, V119, P29, DOI 10.1016/j.virusres.2005.10.008; Carlson BA, 2001, VIROLOGY, V279, P130, DOI 10.1006/viro.2000.0692; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; de Pereda JM, 2004, J BIOL CHEM, V279, P8111, DOI 10.1074/jbc.M311449200; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; DINMAN JD, 1995, YEAST, V11, P1115, DOI 10.1002/yea.320111202; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gurvich OL, 2003, EMBO J, V22, P5941, DOI 10.1093/emboj/cdg561; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; Hung M, 1998, J VIROL, V72, P4819, DOI 10.1128/JVI.72.6.4819-4824.1998; ICHO T, 1989, J BIOL CHEM, V264, P6716; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; Jacobs JL, 2007, NUCLEIC ACIDS RES, V35, P165, DOI 10.1093/nar/gkl1033; Kalhor HR, 2005, BIOCHEM BIOPH RES CO, V334, P433, DOI 10.1016/j.bbrc.2005.06.111; KAN LS, 1975, BIOCHEMISTRY-US, V14, P3278, DOI 10.1021/bi00685a038; Katunin V I, 1994, Mol Biol (Mosk), V28, P66; Konevega AL, 2004, RNA, V10, P90, DOI 10.1261/rna.5142404; KRZYZOSIAK WJ, 1983, NUCLEIC ACIDS RES, V11, P6913, DOI 10.1093/nar/11.19.6913; KUCHINO Y, 1982, NUCLEIC ACIDS RES, V10, P6421, DOI 10.1093/nar/10.20.6421; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Lopinski JD, 2000, MOL CELL BIOL, V20, P1095, DOI 10.1128/MCB.20.4.1095-1103.2000; MAELICKE A, 1973, BIOPOLYMERS, V12, P27, DOI 10.1002/bip.1973.360120104; McCloskey J A, 2000, Nucleic Acids Symp Ser, P267; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; Meskauskas A, 2005, MOL CELL BIOL, V25, P10863, DOI 10.1128/MCB.25.24.10863-10874.2005; Meskauskas A, 2003, RNA, V9, P982, DOI 10.1261/rna.2165803; NAKANISHI K, 1971, NATURE-NEW BIOL, V234, P107, DOI 10.1038/newbio234107b0; Noma A, 2006, EMBO J, V25, P2142, DOI 10.1038/sj.emboj.7601105; Noon KR, 2003, J BACTERIOL, V185, P5483, DOI 10.1128/JB.185.18.5483-5490.2003; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Plant EP, 2006, RNA, V12, P666, DOI 10.1261/rna.2225206; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; SMITH DWE, 1985, J BIOL CHEM, V260, P147; Soboleva N. G., 2003, Molekulyarnaya Biologiya (Moscow), V37, P121; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Stuart JW, 2003, J MOL BIOL, V334, P901, DOI 10.1016/j.jmb.2003.09.058; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; THEIBE R, 1973, FEBS LETT, V38, P27; THIEBE R, 1968, EUR J BIOCHEM, V5, P546, DOI 10.1111/j.1432-1033.1968.tb00404.x; TZENG TH, 1992, J VIROL, V66, P999, DOI 10.1128/JVI.66.2.999-1006.1992; Waas WF, 2005, J BIOL CHEM, V280, P37616, DOI 10.1074/jbc.M506939200; Zhou SL, 2004, BIOORG CHEM, V32, P82, DOI 10.1016/j.bioorg.2003.09.005	52	70	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26026	26034		10.1074/jbc.M703391200	http://dx.doi.org/10.1074/jbc.M703391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623669	hybrid			2022-12-27	WOS:000249239600006
J	Tuttle, SW; Maity, A; Oprysko, PR; Kachur, AV; Ayene, IS; Biaglow, JE; Koch, CJ				Tuttle, Stephen W.; Maity, Amit; Oprysko, Patricia R.; Kachur, Alexander V.; Ayene, Iraimoudi S.; Biaglow, John E.; Koch, Cameron J.			Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration - Implications for the mechanism of HIF-1 alpha stabilization under moderate hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; HIF-ALPHA; HYDROGEN-PEROXIDE; INDUCIBLE FACTOR; MAMMALIAN-CELLS; DEFICIENT CELLS; CYTOCHROME-C; DNA-DAMAGE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; APOPTOSIS	The oxidative pentose phosphate cycle (OPPC) is necessary to maintain cellular reducing capacity during periods of increased oxidative stress. Metabolic flux through the OPPC increases stoichiometrically in response to a broad range of chemical oxidants, including those that generate reactive oxygen species (ROS). Here we show that OPPC sensitivity is sufficient to detect low levels of ROS produced metabolically as a function of the percentage of O-2. We observe a significant decrease in OPPC activity in cells incubated under severe and moderate hypoxia (ranging from <0.01 to 4% O-2), whereas hyperoxia (95% O-2) results in a significant increase in OPPC activity. These data indicate that metabolic ROS production is directly dependent on oxygen concentration. Moreover, we have found no evidence to suggest that ROS, produced by mitochondria, are needed to stabilize hypoxia-inducible factor 1 alpha(HIF-1 alpha) under moderate hypoxia. Myxothiazol, an inhibitor of mitochondrial electron transfer, did not prevent HIF-1 alpha stabilization under moderate hypoxia. Moreover, the levels of HIF-1 alpha that we observed after exposure to moderate hypoxia were comparable between rho(0) cells, which lack functional mitochondria, and the wild-type cells. Finally, we find no evidence for stabilization of HIF-1 alpha in response to the non-toxic levels of H2O2 generated by the enzyme glucose oxidase. Therefore, we conclude that the oxygen dependence of the prolyl hydroxylase reaction is sufficient to mediate HIF-1 alpha stability under moderate as well as severe hypoxia.	[Tuttle, Stephen W.; Maity, Amit; Oprysko, Patricia R.; Kachur, Alexander V.; Biaglow, John E.; Koch, Cameron J.] Univ Penn, Dept Radiat Oncol, Sch Med, Philadelphia, PA 19104 USA; [Ayene, Iraimoudi S.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA	University of Pennsylvania; Lankenau Medical Center; Lankenau Institute for Medical Research	Tuttle, SW (corresponding author), Univ Penn, Dept Radiat Oncol, Sch Med, 195 John Morgan Bldg, Philadelphia, PA 19104 USA.	tuttle@xrt.upenn.edu		Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA092108, R01CA091053, R01CA044982, R37CA044982, R01CA109604, R01CA074071, R01CA093638] Funding Source: NIH RePORTER; NCI NIH HHS [CA109604, CA44982, CA74071, CA91053, CA92108, CA93638] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Au SWN, 2000, STRUCTURE, V8, P293, DOI 10.1016/S0969-2126(00)00104-0; Biaglow JE, 2000, BIOCHEM BIOPH RES CO, V273, P846, DOI 10.1006/bbrc.2000.3024; BIAGLOW JE, 1992, INT J RADIAT ONCOL, V22, P665, DOI 10.1016/0360-3016(92)90499-8; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Cheng ML, 2004, FREE RADICAL BIO MED, V36, P580, DOI 10.1016/j.freeradbiomed.2003.11.031; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; Efferth T, 2001, J LEUKOCYTE BIOL, V69, P340; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Fico A, 2004, CELL DEATH DIFFER, V11, P823, DOI 10.1038/sj.cdd.4401420; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Horan AD, 1999, RADIAT RES, V152, P144, DOI 10.2307/3580087; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; KOCH CJ, 1995, BRIT J CANCER, V72, P869, DOI 10.1038/bjc.1995.426; KOCH CJ, 1984, RADIAT RES, V97, P434, DOI 10.2307/3576294; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee J, 1996, INT J CANCER, V67, P372, DOI 10.1002/(SICI)1097-0215(19960729)67:3<372::AID-IJC11>3.0.CO;2-A; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Tuttle S, 2000, RADIAT RES, V153, P781, DOI 10.1667/0033-7587(2000)153[0781:GPDATO]2.0.CO;2; TUTTLE SW, 1994, INT J RADIAT ONCOL, V29, P357, DOI 10.1016/0360-3016(94)90289-5; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; VARNES ME, 1984, BIOCHEM PHARMACOL, V33, P1671, DOI 10.1016/0006-2952(84)90290-9; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	42	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2007	282	51					36790	36796		10.1074/jbc.M700327200	http://dx.doi.org/10.1074/jbc.M700327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241GX	17666400	hybrid			2022-12-27	WOS:000251646000003
J	Bennetts, B; Parker, MW; Cromer, BA				Bennetts, Brett; Parker, Michael W.; Cromer, Brett A.			Inhibition of skeletal muscle ClC-1 chloride channels by low intracellular pH and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW GATING RELAXATIONS; TEMPERATURE-DEPENDENCE; CYTOPLASMIC DOMAIN; DYNAMIC EXERCISE; RAT DIAPHRAGM; CL-CHANNEL; FIBERS; CONDUCTANCE; FATIGUE; DOMINANT	Skeletal muscle acidosis during exercise has long been thought to be a cause of fatigue, but recent studies have shown that acidosis maintains muscle excitability and opposes fatigue by decreasing the sarcolemmal chloride conductance. ClC-1 is the primary sarcolemmal chloride channel and has a clear role in controlling muscle excitability, but recombinant ClC- 1 has been reported to be activated by acidosis. Following our recent finding that intracellular ATP inhibits ClC- 1, we investigated here the interaction between pH and ATP regulation of ClC-1. We found that, in the absence of ATP, intracellular acidosis from pH 7.2to 6.2 inhibited ClC- 1 slightly by shifting the voltage dependence of common gating to more positive potentials, similar to the effect of ATP. Importantly, the effects of ATP and acidosis were cooperative, such that ATP greatly potentiated the effect of acidosis. Adenosine had a similar effect to ATP at pH 7.2, but acidosis did not potentiate this effect, indicating that the phosphates of ATP are important for this cooperativity, possibly due to electrostatic interactions with protonatable residues of ClC-1. A protonatable residue identified by molecular modeling, His- 847, was found to be critical for both pH and ATP modulation and may be involved in such electrostatic interactions. These findings are now consistent with, and provide a molecular explanation for, acidosis opposing fatigue by decreasing the chloride conductance of skeletal muscle via inhibition of ClC-1. The modulation of ClC- 1 by ATP is a key component of this molecular mechanism.	St Vincents Inst, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Cromer, BA (corresponding author), Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia.	brett.cromer@florey.edu.au	Parker, Michael W/F-9069-2013; Cromer, Brett/AAQ-6533-2020	Parker, Michael W/0000-0002-3101-1138; Cromer, Brett/0000-0003-0743-1535				Accardi A, 2000, J GEN PHYSIOL, V116, P433, DOI 10.1085/jgp.116.3.433; Aromataris EC, 2001, MOL PHARMACOL, V60, P200, DOI 10.1124/mol.60.1.200; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Bennetts B, 2001, J PHYSIOL-LONDON, V535, P83, DOI 10.1111/j.1469-7793.2001.t01-1-00083.x; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; Chen MF, 1997, J PHYSIOL-LONDON, V504, P75, DOI 10.1111/j.1469-7793.1997.075bf.x; Chen TY, 1998, J GEN PHYSIOL, V112, P715, DOI 10.1085/jgp.112.6.715; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; CORFU NA, 1991, EUR J BIOCHEM, V199, P659, DOI 10.1111/j.1432-1033.1991.tb16168.x; Duffield M, 2003, J GEN PHYSIOL, V121, P149, DOI 10.1085/jgp.20028741; Dutka TL, 2004, J PHYSIOL-LONDON, V560, P451, DOI 10.1113/jphysiol.2004.069112; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Estevez R, 2004, J PHYSIOL-LONDON, V557, P363, DOI 10.1113/jphysiol.2003.058453; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; Hebeisen S, 2005, BIOPHYS J, V89, P1710, DOI 10.1529/biophysj.104.056093; HERMANSEN L, 1972, J APPL PHYSIOL, V32, P304, DOI 10.1152/jappl.1972.32.3.304; HUTTER OF, 1967, J PHYSIOL-LONDON, V189, P403, DOI 10.1113/jphysiol.1967.sp008176; Karatzaferi C, 2001, PFLUG ARCH EUR J PHY, V442, P467, DOI 10.1007/s004240100552; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; METZGER JM, 1987, J APPL PHYSIOL, V62, P1392, DOI 10.1152/jappl.1987.62.4.1392; Meyer S, 2006, STRUCTURE, V14, P299, DOI 10.1016/j.str.2005.10.008; Meyer S, 2007, NAT STRUCT MOL BIOL, V14, P60, DOI 10.1038/nsmb1188; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; Papponen H, 2005, EXP NEUROL, V191, P163, DOI 10.1016/j.expneurol.2004.07.018; Pedersen TH, 2005, J GEN PHYSIOL, V125, P237, DOI 10.1085/jgp.200409173; Pedersen TH, 2004, SCIENCE, V305, P1144, DOI 10.1126/science.1101141; Pusch M, 1997, J GEN PHYSIOL, V109, P105, DOI 10.1085/jgp.109.1.105; Pusch M, 2002, HUM MUTAT, V19, P423, DOI 10.1002/humu.10063; ROOS A, 1978, AM J PHYSIOL, V235, pC49, DOI 10.1152/ajpcell.1978.235.1.C49; Ruff RL, 1996, ACTA PHYSIOL SCAND, V156, P159, DOI 10.1046/j.1365-201X.1996.189000.x; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Rychkov GY, 2001, J PHYSIOL-LONDON, V530, P379, DOI 10.1111/j.1469-7793.2001.0379k.x; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; SAHLIN K, 1978, J APPL PHYSIOL, V45, P474, DOI 10.1152/jappl.1978.45.3.474; SAHLIN K, 1976, PFLUG ARCH EUR J PHY, V367, P143, DOI 10.1007/BF00585150; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Sejersted OM, 2000, PHYSIOL REV, V80, P1411, DOI 10.1152/physrev.2000.80.4.1411; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THOMPSON LV, 1992, AM J PHYSIOL, V262, pC1507, DOI 10.1152/ajpcell.1992.262.6.C1507; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; WILSON JR, 1988, J APPL PHYSIOL, V64, P2333, DOI 10.1152/jappl.1988.64.6.2333	47	54	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32780	32791		10.1074/jbc.M703259200	http://dx.doi.org/10.1074/jbc.M703259200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17693413	hybrid, Green Accepted			2022-12-27	WOS:000250625400027
J	Messens, J; Collet, JF; Van Belle, K; Brosens, E; Loris, R; Wyns, L				Messens, Joris; Collet, Jean-Francois; Van Belle, Karolien; Brosens, Elke; Loris, Remy; Wyns, Lode			The oxidase DsbA folds a protein with a nonconsecutive disulfide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHYTASE; BOND FORMATION; IN-VIVO; PERIPLASMIC PROTEIN; RIBONUCLEASE; ISOMERASE; ENZYME; GENE; OXIDOREDUCTASES; IDENTIFICATION	One of the last unsolved problems of molecular biology is how the sequential amino acid information leads to a functional protein. Correct disulfide formation within a protein is hereby essential. We present periplasmic ribonuclease I (RNase I) from Escherichia coli as a new endogenous substrate for the study of oxidative protein folding. One of its four disulfides is between nonconsecutive cysteines. In general view, the folding of proteins with nonconsecutive disulfides requires the protein disulfide isomerase DsbC. In contrast, our study with RNase I shows that DsbA is a sufficient catalyst for correct disulfide formation in vivo and in vitro. DsbA is therefore more specific than generally assumed. Further, we show that the redox potential of the periplasm depends on the presence of glutathione and the Dsb proteins to maintain it at -165 mV. We determined the influence of this redox potential on the folding of RNase I. Under the more oxidizing conditions of dsb(-) strains, DsbC becomes necessary to correct non-native disulfides, but it cannot substitute for DsbA. Altogether, DsbA folds a protein with a nonconsecutive disulfide as long as no incorrect disulfides are formed.	Vrije Univ Brussel VIB, Ultrastrutture Lab, B-1050 Brussels, Belgium; Vlaams Inst Biotechnol, Dept Mol & Cellular Interact, Brussels, Belgium; Univ Catholique Louvain, Duve Inst, B-1200 Brussels, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Universite Catholique Louvain	Messens, J (corresponding author), Vrije Univ Brussel VIB, Ultrastrutture Lab, Pleinlaan 2, B-1050 Brussels, Belgium.	joris.messens@vub.ac.be	Loris, Remy/GPG-0894-2022; Messens, Joris/AAH-3008-2020; Collet, Jean Francois/F-2105-2010	Messens, Joris/0000-0002-2128-8264; Collet, Jean-Francois/0000-0001-8069-7036; Loris, Remy/0000-0002-8862-3338				Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Berkmen M, 2005, J BIOL CHEM, V280, P11387, DOI 10.1074/jbc.M411774200; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; Ewis HE, 2005, FEMS MICROBIOL LETT, V253, P295, DOI 10.1016/j.femsle.2005.09.046; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; GreinerStoeffele T, 1996, ANAL BIOCHEM, V240, P24, DOI 10.1006/abio.1996.0326; HABER E, 1961, J BIOL CHEM, V236, P422; Hiniker A, 2005, J BIOL CHEM, V280, P33785, DOI 10.1074/jbc.M505742200; Hiniker A, 2004, TRENDS BIOCHEM SCI, V29, P516, DOI 10.1016/j.tibs.2004.08.002; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Ida K, 2001, J MOL BIOL, V314, P103, DOI 10.1006/jmbi.2001.5127; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; Lim D, 2000, NAT STRUCT BIOL, V7, P108; Marcyjaniak M, 2004, J BIOL CHEM, V279, P43982, DOI 10.1074/jbc.M406735200; Messens J, 2006, INT J BIOCHEM CELL B, V38, P1050, DOI 10.1016/j.biocel.2005.12.011; MILLER JH, 1972, EXP MOL GENETICS; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Pittman MS, 2005, J BIOL CHEM, V280, P32254, DOI 10.1074/jbc.M503075200; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	33	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31302	31307		10.1074/jbc.M705236200	http://dx.doi.org/10.1074/jbc.M705236200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17702751	hybrid			2022-12-27	WOS:000250309200019
J	Choi, JH; Williams, J; Cho, J; Falck, JR; Shears, SB				Choi, Jae H.; Williams, Jason; Cho, Jaiesoon; Falck, J. R.; Shears, Stephen B.			Purification, sequencing, and molecular identification of a mammalian PP-InsP(5) kinase that is activated when cells are exposed to hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIS-DIPHOSPHOINOSITOL TETRAKISPHOSPHATE; INOSITOL HEXAKISPHOSPHATE KINASE-2; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; PYROPHOSPHATES; PENTAKISPHOSPHATE; METABOLISM; PROTEIN; FAMILY; 1,4,5-TRISPHOSPHATE	Mammalian cells utilize multiple signaling mechanisms to protect against the osmotic stress that accompanies plasma membrane ion transport, solute uptake, and turnover of protein and carbohydrates (Schliess, F., and Haussinger, D. (2002) Biol. Chem. 383, 577-583). Recently, osmotic stress was found to increase synthesis of bisdiphosphoinositol tetrakisphosphate ((PP)(2)-InsP(4)), a high energy inositol pyrophosphate (Pesesse, X., Choi, K., Zhang, T., and Shears, S. B. (2004) J. Biol. Chem. 279, 43378-43381). Here, we describe the purification from rat brain of a diphosphoinositol pentakisphosphate kinase (PPIP5K) that synthesizes (PP)(2)-InsP(4). Partial amino acid sequence, obtained by mass spectrometry, matched the sequence of a 160-kDa rat protein containing a putative ATP-grasp kinase domain. BLAST searches uncovered two human isoforms (PPIP5K1 (160 kDa) and PPIP5K2 (138 kDa)). Recombinant human PPIP5K1, expressed in Escherichia coli, was found to phosphorylate diphosphoinositol pentakisphosphate (PP-InsP(5)) to (PP)(2)-InsP(4) (V-max = 8.3 nmol/mg of protein/min; K-m = 0.34 mu M). Overexpression in human embryonic kidney cells of either PPIP5K1 or PPIP5K2 substantially increased levels of (PP)(2)-InsP(4), whereas overexpression of a catalytically dead PPIP5K1(D332A) mutant had no effect. PPIP5K1 and PPIP5K2 were more active against PP-InsP5 than InsP6, both in vitro and in vivo. Analysis by confocal immunofluorescence showed PPIP5K1 to be distributed throughout the cytoplasm but excluded from the nucleus. Immunopurification of overexpressed PPIP5K1 from osmotically stressed HEK cells (0.2 M sorbitol; 30 min) revealed a persistent, 3.9 +/- 0.4-fold activation when compared with control cells. PPIP5Ks are likely to be important signaling enzymes.	NIEHS, Inositide Siganling Grp, Lab Signal Transduct, NIH,DHHS, Res Triangle Pk, NC 27709 USA; NIEHS, Prot Microcharacterizat Core Facil, Struct Biol Lab, NIH,DHHS, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shears, SB (corresponding author), NIEHS, Inositide Siganling Grp, Lab Signal Transduct, NIH,DHHS, POB 12233, Res Triangle Pk, NC 27709 USA.	shears@niehs.nih.gov	shears, stephen/C-6335-2019	shears, stephen/0000-0001-7309-8916; Falck, John/0000-0002-9219-7845	Intramural NIH HHS [Z01 ES080046-19] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101564, Z01ES080046] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; Alcazar-Roman AR, 2006, NAT CELL BIOL, V8, P711, DOI 10.1038/ncb1427; Alfieri RR, 2007, PFLUG ARCH EUR J PHY, V454, P173, DOI 10.1007/s00424-006-0195-x; Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Cho J, 2006, J BIOTECHNOL, V126, P248, DOI 10.1016/j.jbiotec.2006.04.028; Choi K, 2005, CELL SIGNAL, V17, P1533, DOI 10.1016/j.cellsig.2005.03.021; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hand CE, 2007, BIOORG MED CHEM LETT, V17, P183, DOI 10.1016/j.bmcl.2006.09.066; Hidaka K, 2002, J BIOL CHEM, V277, P32730, DOI 10.1074/jbc.M205476200; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Miller GJ, 2005, MOL CELL, V18, P201, DOI 10.1016/j.molcel.2005.03.016; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Mullaney EJ, 2003, BIOCHEM BIOPH RES CO, V312, P179, DOI 10.1016/j.bbrc.2003.09.176; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; Pesesse X, 2005, BIOCHEM BIOPH RES CO, V336, P157, DOI 10.1016/j.bbrc.2005.08.049; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Riley AM, 2006, CHEMBIOCHEM, V7, P1114, DOI 10.1002/cbic.200600037; Safrany ST, 2004, MOL PHARMACOL, V66, P1585, DOI 10.1124/mol.104.002667; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Seeds AM, 2007, BIOCHEM SOC SYMP, V74, P183, DOI 10.1042/BSS2007c16; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 2007, BIOCHEM SOC SYMP, V74, P211, DOI 10.1042/BSS2007c18; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	57	84	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30763	30775		10.1074/jbc.M704655200	http://dx.doi.org/10.1074/jbc.M704655200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702752	Green Accepted, hybrid			2022-12-27	WOS:000250136300045
J	Voigt, J; Woestemeyer, J; Frank, R				Voigt, Juergen; Woestemeyer, Johannes; Frank, Ronald			The chaotrope-soluble glycoprotein GP2 is a precursor of the insoluble glycoprotein framework of the Chlamydomonas cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEINS; VOLVOX-CARTERI; CROSS-LINKING; CONSTITUENT GLYCOPROTEINS; MOLECULAR-ORGANIZATION; EXTRACELLULAR-MATRIX; POLYACRYLAMIDE-GELS; PROLYL HYDROXYLASE; MASS-SPECTROMETRY; AMINO-ACID	The cell wall of the unicellular green alga Chlamydomonas reinhardtii consists of an insoluble, hydroxyproline-rich glycoprotein framework and several chaotrope-soluble, hydroxyproline-containing glycoproteins. Up to now, there have been no data concerning the amino acid sequences of the hydroxyproline-containing polypeptides of the insoluble wall fraction. Matrix-assisted laser desorption ionization time-of-flight analyses of peptides released from the insoluble cell wall fraction by trypsin treatment revealed the presence of 14 peptide fragments that could be attributed to non-glycosylated domains of the chaotrope-soluble cell wall glycoprotein GP2. However, these peptides cover only 15% of the GP2 polypeptide backbone. Considerably more information concerning the presence of GP2 in the insoluble cell wall fraction was obtained by an immunochemical approach. For this purpose, 407 overlapping pentadecapeptides covering the whole known amino acid sequence of GP2 were chemically synthesized and probed with a polyclonal antibody raised against the deglycosylated, insoluble cell wall fraction. This particular antibody reacted with 297 of the 407 GP2-derived peptides. The peptides that were recognized by this antibody are distributed over the whole known GP2 sequence. The epitopes recognized by polyclonal antibodies raised against the 64- and 45-kDa constituents purified from the deglycosylation products of the insoluble cell wall fraction are also distributed over the whole GP2 backbone, although the corresponding antigens are considerably smaller than GP2. The significance of the latter results for the structure of the insoluble cell wall fraction is discussed.	Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Jena, Inst Microbiol, D-07743 Jena, Germany; Helmholtz Ctr Infect Res, Dept Biol Chem, D-38124 Braunschweig, Germany	Leipzig University; Friedrich Schiller University of Jena; Helmholtz Association; Helmholtz-Center for Infection Research	Voigt, J (corresponding author), Univ Leipzig, Inst Biochem, Johannisallee 30, D-04103 Leipzig, Germany.	juergen.voigt@medizin.uni-leipzig.de	Voigt, Juergen/H-2163-2011	Voigt, Juergen/0000-0002-8104-6443				ADAIR WS, 1987, J CELL BIOL, V105, P2373, DOI 10.1083/jcb.105.5.2373; ADAIR WS, 1990, P NATL ACAD SCI USA, V87, P7355, DOI 10.1073/pnas.87.19.7355; Arnott D, 1998, ANAL BIOCHEM, V258, P1, DOI 10.1006/abio.1998.2566; BALDWIN TC, 1992, PLANT J, V2, P733, DOI 10.1046/j.1365-313X.1992.t01-14-00999.x; BIGGS KJ, 1990, PLANT PHYSIOL, V92, P197, DOI 10.1104/pp.92.1.197; BLANKENSTEIN P, 1986, PLANTA, V169, P238, DOI 10.1007/BF00392320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; EPSTEIN L, 1984, PHYTOCHEMISTRY, V23, P1241, DOI 10.1016/S0031-9422(00)80433-1; ERTL H, 1992, EMBO J, V11, P2055, DOI 10.1002/j.1460-2075.1992.tb05263.x; Estevez JM, 2006, PLANT PHYSIOL, V142, P458, DOI 10.1104/pp.106.084244; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GOLDMAN MHD, 1992, PLANT CELL, V4, P1041, DOI 10.1105/tpc.4.9.1041; Goodenough U.W., 1986, J CELL BIOL, V103, P924; GOODENOUGH UW, 1985, J CELL BIOL, V101, P1550, DOI 10.1083/jcb.101.4.1550; GOODENOUGH UW, 1988, J CELL SCI, V90, P717; GOODENOUGH UW, 1988, J CELL SCI, V90, P735; Grossman AR, 2003, EUKARYOT CELL, V2, P1137, DOI 10.1128/EC.2.6.1137-1150.2003; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HILLS GJ, 1975, J MOL BIOL, V96, P431, DOI 10.1016/0022-2836(75)90170-9; Hoffmann XK, 2005, PLANT PHYSIOL, V139, P999, DOI 10.1104/pp.105.065037; HOLST O, 1989, EUR J BIOCHEM, V181, P345, DOI 10.1111/j.1432-1033.1989.tb14730.x; IMAM SH, 1985, J CELL BIOL, V101, P1599, DOI 10.1083/jcb.101.4.1599; Keskiaho K, 2007, PLANT CELL, V19, P256, DOI 10.1105/tpc.106.042739; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kilz S, 2002, J MASS SPECTROM, V37, P331, DOI 10.1002/jms.287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; Liu XN, 2001, PLANT MOL BIOL REP, V19, P261, DOI 10.1007/BF02772898; Maniatis T., 1982, MOL CLONING; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; ROBERTS K, 1972, J ULTRA MOL STRUCT R, V40, P599, DOI 10.1016/S0022-5320(72)80046-7; ROBERTS K, 1974, PHILOS T R SOC B, V268, P129, DOI 10.1098/rstb.1974.0021; ROBERTS K, 1985, J CELL SCI, P105; RUBENSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086; RUBENSTEIN AL, 1995, PLANT CELL, V7, P2211; SAUER A, 1985, PLANTA, V164, P287, DOI 10.1007/BF00396094; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; Serpe MD, 1999, ADV BOT RES, V30, P207; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Shrager J, 2003, PLANT PHYSIOL, V131, P401, DOI 10.1104/pp.016899; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; Sumper M, 1998, INT REV CYTOL, V180, P51; TANAKA M, 1981, J BIOL CHEM, V256, P1397; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA H, 1993, CURR GENET, V24, P296, DOI 10.1007/BF00336779; VOGELER HP, 1990, PLANT SCI, V71, P119, DOI 10.1016/0168-9452(90)90075-Y; Voigt J, 1996, PLANT CELL PHYSIOL, V37, P91, DOI 10.1093/oxfordjournals.pcp.a028919; VOIGT J, 1987, PLANTA, V172, P463, DOI 10.1007/BF00393861; Voigt J, 2004, BBA-GENE STRUCT EXPR, V1679, P180, DOI 10.1016/j.bbaexp.2004.06.007; VOIGT J, 1985, PLANTA, V164, P379, DOI 10.1007/BF00402950; VOIGT J, 1985, BIOCHEM J, V226, P259, DOI 10.1042/bj2260259; Voigt J, 2003, PLANT CELL, V15, P1399, DOI 10.1105/tpc.010611; Voigt J, 2001, EUR J BIOCHEM, V268, P6449, DOI 10.1046/j.0014-2956.2001.02593.x; VOIGT J, 1986, Z NATURFORSCH C, V41, P885; Waffenschmidt S, 1999, PLANT PHYSIOL, V121, P1003, DOI 10.1104/pp.121.3.1003; WAFFENSCHMIDT S, 1993, PLANT CELL, V5, P809, DOI 10.1105/tpc.5.7.809; WOESSNER JP, 1994, PLANT MOL BIOL, V26, P947, DOI 10.1007/BF00028861; WOESSNER JP, 1994, PROTOPLASMA, V181, P245, DOI 10.1007/BF01666399; WOESSNER JP, 1989, PLANT CELL, V1, P901; WU HM, 1993, P NATL ACAD SCI USA, V90, P6829, DOI 10.1073/pnas.90.14.6829	66	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30381	30392		10.1074/jbc.M701673200	http://dx.doi.org/10.1074/jbc.M701673200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17673458	hybrid			2022-12-27	WOS:000250136300006
J	Zhang, Y; Sawada, T; Jing, XF; Yokote, H; Yan, XM; Sakaguchi, K				Zhang, Yueqiang; Sawada, Takahiro; Jing, Xuefeng; Yokote, Hideyuki; Yan, Xiaomei; Sakaguchi, Kazushige			Regulation of ephexin1, a guanine nucleotide exchange factor of Rho family GTPases, by fibroblast growth factor receptor-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85 BETA-PIX; TARGET RECOGNITION; EPHA4; MORPHOGENESIS; SPECIFICITY; INHIBITION; ACTIVATION; COLLAPSE; PATHWAY; EMBRYOS	Fibroblast growth factor (FGF) signal is implicated in not only cell proliferation, but cell migration and morphological changes. Several different Rho family GTPases downstream of the Ras/ERK pathway are postulated to mediate the latter functions. However, none have been recognized to be directly coupled to FGF receptors (FGFRs). We have previously reported that EphA4 and FGFRs hetero-oligomerize through their cytoplasmic domains, trans-activate each other, and transduce a signal for cell proliferation through a docking protein, FRS2 alpha (Yokote, H., Fujita, K., Jing, X., Sawada, T., Liang, S., Yao, L., Yan, X., Zhang, Y., Schlessinger, J., and Sakaguchi, K. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 18866-18871). Here, we have found that ephexin1, a guanine nucleotide exchange factor for Rho family GTPases, constitutes another downstream component of the receptor complex. Ephexin1 directly binds to the kinase domain of FGFR mainly through its DH and PH domains. The binding appears to become weaker and limited to the DH domain when FGFRs become activated. FGFR-mediated phosphorylation of ephexin1 enhances the guanine nucleotide exchange activity toward RhoA without affecting the activity to Rac1 or Cdc42. The FGFR-mediated tyrosine phosphorylation includes, but is not limited to, the residue (Tyr-87) phosphorylated by Src family kinase, which is known to be activated following EphA4 activation. The Tyr-to-Asp mutations that mimic the tyrosine phosphorylation in some of the putative FGFR-mediated phosphorylation sites increase the nucleotide exchange activity for RhoA without changing the activity for Rac1 or Cdc42. From these results, we conclude that ephexin1 is located immediately downstream of the EphA4-FGFR complex and the function is altered by the FGFR-mediated tyrosine phosphorylation at multiple sites.	Wakayama Med Univ, Inst Adv Med, Dept Mol Cell Biol, Wakayama 6418509, Japan	Wakayama Medical University	Sakaguchi, K (corresponding author), Wakayama Med Univ, Inst Adv Med, Dept Mol Cell Biol, 811-1 Kimiidera, Wakayama 6418509, Japan.	ksaka@wakayama-med.ac.jp	ZHANG, YUEQIANG/C-1742-2012; Zhang, Yueqiang/AAE-9649-2020					Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; McFarlane S, 1996, NEURON, V17, P245, DOI 10.1016/S0896-6273(00)80156-7; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Watabe-Uchida M, 2006, NEURON, V51, P727, DOI 10.1016/j.neuron.2006.07.020; Winning RS, 2002, DIFFERENTIATION, V70, P46, DOI 10.1046/j.1432-0436.2002.700105.x; Yokote H, 2005, P NATL ACAD SCI USA, V102, P18866, DOI 10.1073/pnas.0509741102; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	21	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31103	31112		10.1074/jbc.M704430200	http://dx.doi.org/10.1074/jbc.M704430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702745	hybrid			2022-12-27	WOS:000250136300078
J	Brown, MD; Bry, L; Li, ZG; Sacks, DB				Brown, Matthew D.; Bry, Lynn; Li, Zhigang; Sacks, David B.			IQGAP1 regulates Salmonella invasion through interactions with actin, Rac1, and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL; NUCLEOTIDE EXCHANGE; BACTERIAL INVASION; RHO GTPASES; IDENTIFICATION; TYPHIMURIUM; PROTEIN; CYTOSKELETAL; CALMODULIN; SOPE2	To infect host cells, Salmonella utilizes an intricate system to manipulate the actin cytoskeleton and promote bacterial uptake. Proteins injected into the host cell by Salmonella activate the Rho GTPases, Rac1 and Cdc42, to induce actin polymerization. Following uptake, a different set of proteins inactivates Rac1 and Cdc42, returning the cytoskeleton to normal. Although the signaling pathways allowing Salmonella to invade host cells are beginning to be understood, many of the contributing factors remain to be elucidated. IQGAP1 is a multidomain protein that influences numerous cellular functions, including modulation of Rac1/Cdc42 signaling and actin polymerization. Here, we report that IQGAP1 regulates Salmonella invasion. Through its interaction with actin, IQGAP1 co-localizes with Rac1, Cdc42, and actin at sites of bacterial uptake, whereas infection promotes the interaction of IQGAP1 with both Rac1 and Cdc42. Knockdown of IQGAP1 significantly reduces Salmonella invasion and abrogates activation of Cdc42 and Rac1 by Salmonella. Overexpression of IQGAP1 significantly increases the ability of Salmonella to enter host cells and required interaction with both actin and Cdc42/Rac1. Together, these data identify IQGAP1 as a novel regulator of Salmonella invasion.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sacks, DB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735; Bry, Lynn/0000-0002-8792-8527				Bakshi CS, 2000, J BACTERIOL, V182, P2341, DOI 10.1128/JB.182.8.2341-2344.2000; Bensenor LB, 2007, J CELL SCI, V120, P658, DOI 10.1242/jcs.03376; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Friebel A, 2001, J BIOL CHEM, V276, P34035, DOI 10.1074/jbc.M100609200; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Jeong HW, 2007, J BIOL CHEM, V282, P20752, DOI 10.1074/jbc.M700487200; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Le Clainche C, 2007, J BIOL CHEM, V282, P426, DOI 10.1074/jbc.M607711200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mataraza JM, 2007, CELL SIGNAL, V19, P1857, DOI 10.1016/j.cellsig.2007.04.011; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Patel JC, 2006, J CELL BIOL, V175, P453, DOI 10.1083/jcb.200605144; Patel JC, 2005, TRENDS PHARMACOL SCI, V26, P564, DOI 10.1016/j.tips.2005.09.005; Pizarro-Cerda J, 2006, CELL, V124, P715, DOI 10.1016/j.cell.2006.02.012; Raffatellu M, 2005, INFECT IMMUN, V73, P146, DOI 10.1128/IAI.73.1.146-154.2005; Ren JG, 2005, J BIOL CHEM, V280, P34548, DOI 10.1074/jbc.M507321200; Ren JG, 2007, P NATL ACAD SCI USA, V104, P10465, DOI 10.1073/pnas.0611308104; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schlumberger MC, 2003, J BIOL CHEM, V278, P27149, DOI 10.1074/jbc.M302475200; SHI J, 2006, MOL BIOL, P4698; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	44	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30265	30272		10.1074/jbc.M702537200	http://dx.doi.org/10.1074/jbc.M702537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693642	hybrid			2022-12-27	WOS:000249981200057
J	Tsukamoto, H; Takakura, Y; Yamamoto, T				Tsukamoto, Hiroshi; Takakura, Yoshimitsu; Yamamoto, Takeshi			Purification, cloning, and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-JEJUNI; CHEMOENZYMATIC SYNTHESIS; ENZYMATIC-SYNTHESIS; SIGNAL PEPTIDES; SIALIC-ACID; SIALYLTRANSFERASE; ALPHA-2,6-SIALYLTRANSFERASE; IDENTIFICATION; CONSTRUCTION; LIPOPROTEIN	A novel sialyltransferase, alpha/beta- galactoside alpha- 2,3- sialyltransferase, was purified from the cell lysate of a luminous marine bacterium, Photobacterium phosphoreum JT- ISH- 467, isolated from the Japanese common squid ( Todarodes pacificus). The gene encoding the enzyme was cloned from the genomic library of the bacterium using probes derived from the NH2- terminal and internal amino acid sequences. An open reading frame of 409 amino acids was identified, and the sequence had 32% identity with that of beta- galactoside alpha- 2,6- sialyltrasferase in Photobacterium damselae JT0160. DNA fragments that encoded the full- length protein and a protein that lacked the sequence between the 2nd and 24th residues at the NH2 terminus were amplified by polymerase chain reactions and cloned into an expression vector. The full- length and truncated proteins were expressed in Escherichia coli, producing active enzymes of 0.25 and 305 milliunits, respectively, per milliliter of the medium in the lysate of E. coli. The truncated enzyme was much more soluble without detergent than the full- length enzyme. The enzyme catalyzed the transfer of N- acetylneuraminic acid from CMP- N- acetylneuraminic acid to disaccharides, such as lactose and N- acetyllactosamine, with low apparent Km and to monosaccharides, such as alpha- methyl- galactopyranoside and beta- methylgalactopyranoside, with much lower apparent Km. Thus, this sialyltransferase is unique and should be very useful for achieving high productivity in E. coli with a wide substrate range.	Japan Tobacco Inc, Glycotechnol Business Unit, Shizuoka 4380802, Japan	Japan Tobacco Inc.	Yamamoto, T (corresponding author), Japan Tobacco Inc, Glycotechnol Business Unit, Shizuoka 4380802, Japan.	takeshi.yamamoto@ims.jti.co.jp		Yamamoto, Takeshi/0000-0002-0525-6481				Babu MM, 2006, J BACTERIOL, V188, P2761, DOI 10.1128/JB.188.8.2761-2773.2006; Babu MM, 2002, BIOINFORMATICS, V18, P641, DOI 10.1093/bioinformatics/18.4.641; Blixt O, 2005, CARBOHYD RES, V340, P1963, DOI 10.1016/j.carres.2005.06.008; Bozue JA, 1999, J BIOL CHEM, V274, P4106, DOI 10.1074/jbc.274.7.4106; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Disney MD, 2004, CHEM BIOL, V11, P1701, DOI 10.1016/j.chembiol.2004.10.011; Elliott S, 2003, NAT BIOTECHNOL, V21, P414, DOI 10.1038/nbt799; Fukae K, 2004, GLYCOCONJUGATE J, V21, P243, DOI 10.1023/B:GLYC.0000045096.89408.50; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2002, INFECT IMMUN, V70, P787, DOI 10.1128/IAI.70.2.787-793.2002; HAYGOOD MG, 1993, CRIT REV MICROBIOL, V19, P191, DOI 10.3109/10408419309113529; Izumi M, 2001, J AM CHEM SOC, V123, P10909, DOI 10.1021/ja011382r; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; Kajihara Y, 1996, J ORG CHEM, V61, P8632, DOI 10.1021/jo961214v; LAI JS, 1980, J BIOL CHEM, V255, P5384; Maniatis T., 1982, MOL CLONING; Narimatsu H, 2004, GLYCOCONJUGATE J, V21, P17, DOI 10.1023/B:GLYC.0000043742.99482.01; Ni LS, 2006, BIOCHEMISTRY-US, V45, P2139, DOI 10.1021/bi0524013; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; Paarup T, 2002, J APPL MICROBIOL, V92, P941, DOI 10.1046/j.1365-2672.2002.01604.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Regan T, 1999, ANTON LEEUW INT J G, V75, P369, DOI 10.1023/A:1002019420453; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Thyssen A., 2005, BERGEYS MANUAL SYSTE, V2, P546; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Werz DB, 2005, CHEM-EUR J, V11, P3194, DOI 10.1002/chem.200500025; Yamamoto T, 1998, J BIOCHEM-TOKYO, V123, P94; Yamamoto T, 1996, J BIOCHEM-TOKYO, V120, P104; Yamamoto T, 1998, BIOSCI BIOTECH BIOCH, V62, P210, DOI 10.1271/bbb.62.210; Yu H, 2005, J AM CHEM SOC, V127, P17618, DOI 10.1021/ja0561690; Yu H, 2006, ANGEW CHEM INT EDIT, V45, P3938, DOI 10.1002/anie.200600572	42	35	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29794	29802		10.1074/jbc.M701907200	http://dx.doi.org/10.1074/jbc.M701907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702755	hybrid			2022-12-27	WOS:000249981200008
J	Hurley, TD; Yang, J; Zhang, LL; Goodwin, KD; Zou, Q; Cortese, M; Dunker, AK; DePaoli-Roach, AA				Hurley, Thomas D.; Yang, Jie; Zhang, Lili; Goodwin, Kristie D.; Zou, Qin; Cortese, Marc; Dunker, A. Keith; DePaoli-Roach, Anna A.			Structural basis for regulation of protein phosphatase 1 by inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLASE-PHOSPHATASE; CRYSTAL-STRUCTURE; SYNERGISTIC PHOSPHORYLATION; PHOSPHOPROTEIN PHOSPHATASE; ACTIVATION; KINASE; IDENTIFICATION	The functional specificity of type 1 protein phosphatases (PP1) depends on the associated regulatory/targeting and inhibitory subunits. To gain insights into the mechanism of PP1 regulation by inhibitor-2, an ancient and intrinsically disordered regulator, we solved the crystal structure of the complex to 2.5 angstrom resolution. Our studies show that, when complexed with PP1c, I-2 acquires three regions of order: site 1, residues 12-17, binds adjacent to a region recognized by many PP1 regulators; site 2, amino acids 44-56, interacts along the RVXF binding groove through an unsuspected sequence, KSQKW; and site 3, residues 130-169, forms alpha-helical regions that lie across the substrate-binding cleft. Specifically, residues 148-151 interact at the catalytic center, displacing essential metal ions, accounting for both rapid inhibition and slower inactivation of PP1c. Thus, our structure provides novel insights into the mechanism of PP1 inhibition and subsequent reactivation, has broad implications for the physiological regulation of PP1, and highlights common inhibitory interactions among phosphoprotein phosphatase family members.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	DePaoli-Roach, AA (corresponding author), 635 Barnhill Dr, Indianapolis, IN 46202 USA.	adepaoli@iupui.edu	; Cortese, Marc/G-4026-2010	HURLEY, THOMAS/0000-0002-5942-1163; Cortese, Marc/0000-0002-5903-0525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063285, R01DK036569] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R56LM007688, R01LM007688] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK036569, R01-DK063285] Funding Source: Medline; NLM NIH HHS [LM007688-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		[Anonymous], 2004, PERS VIS RAYTR VERS; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 2003, HDB CELLULAR SIGNALI, V1, P613; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; Garner, 1999, Genome Inform Ser Workshop Genome Inform, V10, P41; Gibbons JA, 2005, J BIOL CHEM, V280, P15903, DOI 10.1074/jbc.M500871200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Helps NR, 1999, FEBS LETT, V463, P72, DOI 10.1016/S0014-5793(99)01573-2; Helps NR, 1998, FEBS LETT, V438, P131, DOI 10.1016/S0014-5793(98)01286-1; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Huang H, 2000, J BIOMOL NMR, V17, P359, DOI 10.1023/A:1008355428294; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; Kirchhefer U, 2005, CARDIOVASC RES, V68, P98, DOI 10.1016/j.cardiores.2005.05.019; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Leach C, 2003, J BIOL CHEM, V278, P26015, DOI 10.1074/jbc.M300782200; Li MG, 2007, BIOCHEMISTRY-US, V46, P2380, DOI 10.1021/bi602369m; Meiselbach H, 2006, CHEM BIOL, V13, P49, DOI 10.1016/j.chembiol.2005.10.009; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Osawa Y, 1996, EUR J BIOCHEM, V242, P793, DOI 10.1111/j.1432-1033.1996.0793r.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496; Zambrano CA, 2004, FREE RADICAL BIO MED, V36, P1393, DOI 10.1016/j.freeradbiomed.2004.03.007; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	55	146	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28874	28883		10.1074/jbc.M703472200	http://dx.doi.org/10.1074/jbc.M703472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636256	hybrid			2022-12-27	WOS:000249642100062
J	Janz, JM; Sakmar, TP; Min, KC				Janz, Jay M.; Sakmar, Thomas P.; Min, K. Christopher			A novel interaction between atrophin-interacting protein 4 and beta-p21-activated kinase-interactive exchange factor is mediated by an SH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; BETA-PIX-A; DOWN-REGULATION; C-CBL; GENE-PRODUCT; SH3 DOMAIN; BINDING; FAMILY; PAK; ACTIVATION	Cross-talk between G protein-coupled receptors and receptor tyrosine kinase signaling pathways is crucial to the efficient relay and integration of cellular information. Here we identify and define the novel binding interaction of the E3 ubiquitin ligase atrophin-interacting protein 4 (AIP4) with the GTP exchange factor beta-p21-activated kinase-interactive exchange factor (beta PIX). We demonstrate that this interaction is mediated in part by the beta PIX-SH3 domain binding to a proline-rich stretch of AIP4. Analysis of the interaction by isothermal calorimetry is consistent with a heterotrimeric complex with one AIP4-derived peptide binding to two beta PIX-SH3 domains. We determined the crystal structure of the beta PIX-SH3 center dot AIP4 complex to 2.0-angstrom resolution. In contrast to the calorimetry results, the crystal structure shows a monomeric complex in which AIP4 peptide binds the beta PIX-SH3 domain as a canonical Class I ligand with an additional type II polyproline helix that makes extensive contacts with another face of beta PIX. Taken together, the novel interaction between AIP4 and beta PIX represents a new regulatory node for G protein-coupled receptor and receptor tyrosine kinase signal integration. Our structure of the beta PIX-SH3 center dot AIP4 complex provides important insight into the mechanistic basis for beta PIX scaffolding of signaling components, especially those involved in cross-talk.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Ellison Med Fdn, Bethesda, MD 20814 USA	Rockefeller University; Columbia University	Janz, JM (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave,Box 187, New York, NY 10021 USA.	jjanz@rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NEI NIH HHS [K08-EY015540] Funding Source: Medline; PHS HHS [T3ZEY007138] Funding Source: Medline; NATIONAL EYE INSTITUTE [K08EY015540] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn SJ, 2003, CANCER LETT, V193, P99, DOI 10.1016/S0304-3835(03)00004-1; Bae JY, 2005, J CELL BIOCHEM, V94, P1010, DOI 10.1002/jcb.20357; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Feng QY, 2006, NAT CELL BIOL, V8, P945, DOI 10.1038/ncb1453; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gu CP, 2006, P NATL ACAD SCI USA, V103, P14447, DOI 10.1073/pnas.0606624103; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925; Hoelz A, 2006, J MOL BIOL, V358, P509, DOI 10.1016/j.jmb.2006.02.027; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Natarajan Kanchana, 2006, V332, P51; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Schmidt MHH, 2006, ONCOGENE, V25, P3071, DOI 10.1038/sj.onc.1209329; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stofega MR, 2004, MOL BIOL CELL, V15, P2965, DOI 10.1091/mbc.E03-08-0604; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	52	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28893	28903		10.1074/jbc.M702678200	http://dx.doi.org/10.1074/jbc.M702678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652093	hybrid			2022-12-27	WOS:000249642100064
J	Turnock, DC; Izquierdo, L; Ferguson, MAJ				Turnock, Daniel C.; Izquierdo, Luis; Ferguson, Michael A. J.			The de Novo synthesis of GDP-fucose is essential for flagellar adhesion and cell growth in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; NUCLEOTIDE SUGAR TRANSPORTERS; LEISHMANIA-MEXICANA; MANNOSE PYROPHOSPHORYLASE; GALACTOSE METABOLISM; DRUG TARGET; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS; FUNCTIONAL EXPRESSION; CRUZI EPIMASTIGOTES; CLONING	The protozoan parasite Trypanosoma brucei causes human African sleeping sickness in sub-Saharan Africa. The parasite makes several essential glycoproteins, which has led to the investigation of the sugar nucleotides and glycosyltransferases required to synthesize these structures. Fucose is a common sugar in glycoconjugates from many organisms; however, the sugar nucleotide donor GDP-fucose was only recently detected in T. brucei, and the importance of fucose metabolism in this organism is not known. In this paper, we identified the genes encoding functional GDP-fucose biosynthesis enzymes in T. brucei and created conditional null mutants of TbGMD, the gene encoding the first enzyme in the pathway from GDP-mannose to GDP-fucose, in both bloodstream form and procyclic form parasites. Under nonpermissive conditions, both life cycle forms of the parasite became depleted in GDP-fucose and suffered growth arrest, demonstrating that fucose metabolism is essential to both life cycle stages. In procyclic form parasites, flagellar detachment from the cell body was also observed under nonpermissive conditions, suggesting that fucose plays a significant role in flagellar adhesion. Fluorescence microscopy of epitope-tagged TbGMD revealed that this enzyme is localized in glycosomes, despite the absence of PTS-1 or PTS-2 target sequences.	Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Izquierdo, Luis/L-9291-2015; Ferguson, Michael A. J./F-7829-2010	Izquierdo, Luis/0000-0002-3704-9874; Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust [071463] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barboza M, 2005, FEBS J, V272, P3803, DOI 10.1111/j.1742-4658.2005.04787.x; Basombrio MA, 2002, J PARASITOL, V88, P489, DOI 10.1645/0022-3395(2002)088[0489:TDOTGG]2.0.CO;2; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRUN R, 1979, ACTA TROP, V36, P289; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; Davis AJ, 2004, J BIOL CHEM, V279, P12462, DOI 10.1074/jbc.M312365200; de Lederkremer RM, 2001, CURR PHARM DESIGN, V7, P1165, DOI 10.2174/1381612013397519; DEJESUS AR, 1993, J CELL SCI, V106, P1023; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1985, BIOCHIM BIOPHYS ACTA, V842, P39, DOI 10.1016/0304-4165(85)90290-9; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; Guther MLS, 2003, BIOCHEMISTRY-US, V42, P14532, DOI 10.1021/bi034869g; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Jarvinen N, 2001, EUR J BIOCHEM, V268, P6458, DOI 10.1046/j.0014-2956.2001.02601.x; Kessler PS, 2005, J BIOL CHEM, V280, P9030, DOI 10.1074/jbc.M412033200; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; Ma B, 2006, GLYCOBIOLOGY, V16, p158R, DOI 10.1093/glycob/cwl040; MacRae JI, 2006, MOL BIOCHEM PARASIT, V147, P126, DOI 10.1016/j.molbiopara.2006.02.011; Maki M, 2003, GLYCOBIOLOGY, V13, P295, DOI 10.1093/glycob/cwg035; Maki M, 2002, EUR J BIOCHEM, V269, P593, DOI 10.1046/j.0014-2956.2001.02688.x; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Muramatsu T, 2004, GLYCOCONJUGATE J, V21, P41, DOI 10.1023/B:GLYC.0000043746.77504.28; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; Nozaki T, 1996, MOL BIOCHEM PARASIT, V82, P245, DOI 10.1016/0166-6851(96)02741-7; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; Opperdoes FR, 2006, MOL BIOCHEM PARASIT, V147, P193, DOI 10.1016/j.molbiopara.2006.02.010; Park SH, 1998, J BIOL CHEM, V273, P5685, DOI 10.1074/jbc.273.10.5685; Pastuszak I, 1998, J BIOL CHEM, V273, P30165, DOI 10.1074/jbc.273.46.30165; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; Rocha GM, 2006, J STRUCT BIOL, V154, P89, DOI 10.1016/j.jsb.2005.11.008; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; SNARY D, 1981, MOL BIOCHEM PARASIT, V3, P343, DOI 10.1016/0166-6851(81)90035-9; Stewart J, 2005, INT J PARASITOL, V35, P861, DOI 10.1016/j.ijpara.2005.03.008; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; Tonetti M, 2003, J BIOL CHEM, V278, P21559, DOI 10.1074/jbc.M301543200; Turnock DC, 2007, EUKARYOT CELL, V6, P1450, DOI 10.1128/EC.00175-07; Urbaniak MD, 2006, EUKARYOT CELL, V5, P1906, DOI 10.1128/EC.00156-06; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	59	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28853	28863		10.1074/jbc.M704742200	http://dx.doi.org/10.1074/jbc.M704742200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640865	hybrid			2022-12-27	WOS:000249642100060
J	Chen, Y; Anderson, DE; Rajagopalan, M; Erickson, HP				Chen, Yaodong; Anderson, David E.; Rajagopalan, Malini; Erickson, Harold P.			Assembly dynamics of mycobacterium tuberculosis FtsZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVISION PROTEIN FTSZ; BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI; NUCLEOTIDE TURNOVER; FITTING PROGRAMS; SMALL-MOLECULE; IN-VITRO; GTP; PROTOFILAMENT; HYDROLYSIS	We have investigated the assembly of FtsZ from Mycobacterium tuberculosis (MtbFtsZ). Electron microscopy confirmed the previous observation that MtbFtsZ assembled into long, two-stranded filaments at PH 6.5. However, we found that assembly at pH 7.2 or 7.7 produced predominantly short, one-stranded protofilaments, similar to those of Escherichia coli FtsZ (EcFtsZ). Near pH 7, which is close to the pH of M. tuberculosis cytoplasm, MtbFtsZ formed a mixture of single- and two-stranded filaments. We developed a fluorescence resonance energy transfer assay to measure the kinetics of initial assembly and the dynamic properties at steady state. Assembly of MtbFtsZ reached a plateau after 60-100 s, about 10 times slower than EcFtsZ. The initial assembly kinetics were similar at pH 6.5 and 7.7, despite the striking difference in the polymer structures. Both were fit with a cooperative assembly mechanism involving a weak dimer nucleus, similar to EcFtsZ but with slower kinetics. Subunit turnover and GTPase at steady state were also about 10 times slower for MtbFtsZ than for EcFtsZ. Specifically, the half-time for subunit turnover in vitro at PH 7.7 was 42 s for MtbFtsZ compared with 5.5 s for EcFtsZ. Photo-bleaching studies in vivo showed a range of turnover half-times with an average of 25 s for MtbFtsZ as compared with 9 s for EcFtsZ.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Univ Texas Hlth Ctr, Tyler, TX 75708 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu	Chen, Yaodong/X-8923-2019; Chen, Yaodong/C-6138-2011	Anderson, David/0000-0001-9334-6438; Chen, Yaodong/0000-0002-3751-0923	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048417, R21AI064502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI048417-06A1, AI48417, AI64502, R01 AI048417, R21 AI064502] Funding Source: Medline; NIGMS NIH HHS [R01 GM066014-04, R01 GM066014, GM66014] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P1; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Chen YD, 2005, J BIOL CHEM, V280, P22549, DOI 10.1074/jbc.M500895200; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Dziadek J, 2002, MICROBIOL-SGM, V148, P961, DOI 10.1099/00221287-148-4-961; Dziadek J, 2003, MICROBIOL-SGM, V149, P1593, DOI 10.1099/mic.0.26023-0; Flyvbjerg H, 1996, PHYS REV E, V54, P5538, DOI 10.1103/PhysRevE.54.5538; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Huang Q, 2006, J MED CHEM, V49, P463, DOI 10.1021/jm050920y; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; Leung AKW, 2004, J MOL BIOL, V342, P953, DOI 10.1016/j.jmb.2004.07.061; Lu CL, 1999, CELL STRUCT FUNCT, V24, P285, DOI 10.1247/csf.24.285; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; Rajagopalan M, 2005, BIOCHEM BIOPH RES CO, V331, P1171, DOI 10.1016/j.bbrc.2005.03.239; Rajagopalan M, 2005, FEMS MICROBIOL LETT, V250, P9, DOI 10.1016/j.femsle.2005.06.043; Rao M, 2001, MICROBIOL-UK, V147, P1017, DOI 10.1099/00221287-147-4-1017; Redick SD, 2005, J BACTERIOL, V187, P2727, DOI 10.1128/JB.187.8.2727-2736.2005; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Tadros M, 2006, FEBS LETT, V580, P4941, DOI 10.1016/j.febslet.2006.07.083; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P56, DOI 10.1093/jac/dkg287; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	35	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27736	27743		10.1074/jbc.M703788200	http://dx.doi.org/10.1074/jbc.M703788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644520	Green Accepted, hybrid			2022-12-27	WOS:000249455600022
J	Johnson, AR; Pavlovsky, AG; Ortwine, DF; Prior, F; Man, CF; Bornemeier, DA; Banotai, CA; Mueller, WT; Mcconnell, P; Yan, C; Baragi, V; Lesch, C; Roark, WH; Wilson, M; Datta, K; Guzman, R; Han, HK; Dyer, RD				Johnson, Adam R.; Pavlovsky, Alexander G.; Ortwine, Daniel F.; Prior, Faith; Man, Chiu-Fai; Bornemeier, Dirk A.; Banotai, Craig A.; Mueller, W. Thomas; Mcconnell, Patrick; Yan, Chunhong; Baragi, Vijay; Lesch, Charles; Roark, W. Howard; Wilson, Michael; Datta, Kaushik; Guzman, Roberto; Han, Hyo-Kyung; Dyer, Richard D.			Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CATALYTIC DOMAIN; II COLLAGEN; EXPRESSION; MMP-13; OSTEOARTHRITIS; ARTHRITIS; POTENT; CLONING; DESIGN	Matrix metalloproteinase-13 (MMP13) is a Zn2+ -dependent protease that catalyzes the cleavage of type 11 collagen, the main structural protein in articular cartilage. Excess MMP13 activity causes cartilage degradation in osteoarthritis, making this protease an attractive therapeutic target. However, clinically tested MMP inhibitors have been associated with a painful, joint-stiffening musculoskeletal side effect that may be due to their lack of selectivity. In our efforts to develop a disease-modifying osteciarthritis drug, we have discovered MMP13 inhibitors that differ greatly from previous MMP inhibitors; they do not bind to the catalytic zinc ion, they are noncompetitive with respect to substrate binding, and they show extreme selectivity for inhibiting MMP13. By structure-based drug design, we generated an orally active MMP13 inhibitor that effectively reduces cartilage damage in vivo and does not induce joint fibroplasias in a rat model of musculoskeletal syndrome side effects. Thus, highly selective inhibition of MMP13 in patients may overcome the major safety and efficacy challenges that have limited previously tested non-selective NIMP inhibitors. MMP13 inhibitors such as the ones described here will help further define the role of this protease in arthritis and other diseases and may soon lead to drugs that safely halt cartilage damage in patients.	Pfizer Global Res & Dev, Dept Inflammat Mol Sci, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Discovery Technologies, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Inflammat Pharmacol, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Inflammat Chem, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept World Wide Safety Sci, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Johnson, AR (corresponding author), Pfizer Global Res & Dev, 700 Chesterfield Pkwy, St Louis, MO 63017 USA.	adam.johnson@pfizer.com		Bornemeier, Dirk/0000-0002-2271-6240				Aranapakam V, 2003, J MED CHEM, V46, P2376, DOI 10.1021/jm0205550; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bluteau G, 2002, BIORHEOLOGY, V39, P247; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Chen JM, 2000, J AM CHEM SOC, V122, P9648, DOI 10.1021/ja001547g; Clark IM, 2003, EXPERT OPIN THER TAR, V7, P19, DOI 10.1517/14728222.7.1.19; Drummond AH, 1999, ANN NY ACAD SCI, V878, P228, DOI 10.1111/j.1749-6632.1999.tb07688.x; Engel CK, 2005, CHEM BIOL, V12, P181, DOI 10.1016/j.chembiol.2004.11.014; Freemont AJ, 1999, ANN RHEUM DIS, V58, P357, DOI 10.1136/ard.58.6.357; Janusz MJ, 2002, OSTEOARTHR CARTILAGE, V10, P785, DOI 10.1053/joca.2002.0823; Joronen K, 2004, ANN RHEUM DIS, V63, P656, DOI 10.1136/ard.2003.009720; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; Leatherbarrow RJ, 2005, GRAFIT VERSION 5; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milner JM, 2003, ARTHRITIS RHEUM-US, V48, P1057, DOI 10.1002/art.10873; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; O'Brien PM, 2000, J MED CHEM, V43, P156, DOI 10.1021/jm9903141; Otterness IG, 1999, MATRIX BIOL, V18, P331, DOI 10.1016/S0945-053X(99)00026-8; OTWINOWSKI Z, 2000, METHOD ENZYMOL, V28, P235; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; Peterson JT, 2002, DRUG DEVELOP RES, V55, P29, DOI 10.1002/ddr.10032; PROCKOP DJ, 1960, ANAL BIOCHEM, V1, P228, DOI 10.1016/0003-2697(60)90050-6; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Renkiewicz R, 2003, ARTHRITIS RHEUM, V48, P1742, DOI 10.1002/art.11030; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGEL IH, 1975, ENZYME KINETICS, P125; Skotnicki JS, 2003, CURR OPIN DRUG DISC, V6, P742; Spinale FG, 2000, CIRCULATION, V102, P1944, DOI 10.1161/01.CIR.102.16.1944; Uchinami H, 2006, HEPATOLOGY, V44, P420, DOI 10.1002/hep.21268; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WELGUS HG, 1983, J BIOL CHEM, V258, P4162; Wernicke D, 1996, J RHEUMATOL, V23, P590; Wernicke D, 2006, AUTOIMMUNITY, V39, P307, DOI 10.1080/08916930600807709; YE QZ, 1992, BIOCHEM BIOPH RES CO, V186, P143, DOI 10.1016/S0006-291X(05)80786-7; Zhang XL, 2000, J MOL BIOL, V301, P513, DOI 10.1006/jmbi.2000.3988	43	173	181	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27781	27791		10.1074/jbc.M703286200	http://dx.doi.org/10.1074/jbc.M703286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623656	hybrid			2022-12-27	WOS:000249455600027
J	Mehta, NR; Lopez, PHH; Vyas, AA; Schnaar, RL				Mehta, Niirai R.; Lopez, Pablo H. H.; Vyas, Alka A.; Schnaar, Ronald L.			Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CNS AXON REGENERATION; ADHESION MOLECULES; FAMILY-MEMBER; COMPLEX; GROWTH; MAG; RHO; LIGANDS; SIGNAL; BRAIN	In the injured nervous system, myelin-associated glycoprotein (MAG) on residual myelin binds to receptors on axons, inhibits axon outgrowth, and limits functional recovery. Conflicting reports identify gangliosides (GD1a and GT1b) and glycosylphosphatidylinositol-anchored Nogo receptors (NgRs) as exclusive axonal receptors for MAG. We used enzymes and pharmacological agents to distinguish the relative roles of gangliosides and NgRs in MAG-mediated inhibition of neurite outgrowth from three nerve cell types, dorsal root ganglion neurons (DRGNs), cerebellar granule neurons (CGNs), and hippocampal neurons. Primary rat neurons were cultured on control substrata and substrata adsorbed with full-length native MAG extracted from purified myelin. The receptors responsible for MAG inhibition of neurite outgrowth varied with nerve cell type. In DRGNs, most of the MAG inhibition was via NgRs, evidenced by reversal of inhibition by phosphatidylinositol-specific phospholipase C (PI-PLC), which cleaves glycosylphosphatidylinositol anchors, or by NEP1-40, a peptide inhibitor of NgR. A smaller percentage of MAG inhibition of DRGN outgrowth was via gangliosides, evidenced by partial reversal by addition of sialidase to cleave GDla and GT1b or by P4, an inhibitor of ganglioside biosynthesis. Combining either PI-PLC and sialiclase or NEP1-40 and P4 was additive. In contrast to DRGNs, in CGNs MAG inhibition was exclusively via gangliosides, whereas inhibition of hippocampal neuron outgrowth was mostly reversed by sialidase or P4 and only modestly reversed by PI-PLC or NEP1-40 in a nonadditive fashion. A soluble proteolytic fragment of native MAG, dMAG, also inhibited neurite outgrowth. In DRGNs, dMAG inhibition was exclusively NgR-dependent, whereas in CGNs it was exclusively ganglioside-dependent. An inhibitor of Rho kinase reversed MAG-mediated inhibition in all nerve cells, whereas a peptide inhibitor of the transducer p75(NTR) had cell-specific effects quantitatively similar to NgR blockers. Our data indicate that MAG inhibits axon outgrowth via two independent receptors, gangliosides and NgRs.	Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Schnaar, Ronald L/S-8967-2016; López, Pablo/GXA-3179-2022	Schnaar, Ronald L/0000-0002-7701-5484; 	NIGMS NIH HHS [T32GM008763] Funding Source: Medline; NINDS NIH HHS [R37NS037096, R37 NS037096-26, R37 NS037096] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS037096] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE A, 1995, J LIPID RES, V36, P611; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Lauren J, 2007, J BIOL CHEM, V282, P5715, DOI 10.1074/jbc.M609797200; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li RX, 1998, GLYCOBIOLOGY, V8, P597, DOI 10.1093/glycob/8.6.597; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Lunn MPT, 2000, J NEUROCHEM, V75, P404, DOI 10.1046/j.1471-4159.2000.0750404.x; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Moustafa I, 2004, J BIOL CHEM, V279, P40819, DOI 10.1074/jbc.M404965200; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Pan BH, 2005, EXP NEUROL, V195, P208, DOI 10.1016/j.expneurol.2005.04.017; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schnaar RL, 2004, ARCH BIOCHEM BIOPHYS, V426, P163, DOI 10.1016/j.abb.2004.02.019; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Spencer T, 2003, CURR OPIN NEUROBIOL, V13, P133, DOI 10.1016/S0959-4388(03)00012-6; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Tang S, 2001, MOL CELL NEUROSCI, V18, P259, DOI 10.1006/mcne.2001.1020; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Venkatesh K, 2007, J CELL BIOL, V177, P393, DOI 10.1083/jcb.200702102; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	54	67	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27875	27886		10.1074/jbc.M704055200	http://dx.doi.org/10.1074/jbc.M704055200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640868	Green Accepted, hybrid			2022-12-27	WOS:000249455600036
J	Bao, S; Li, Y; Lei, X; Wohltmann, M; Jin, W; Bohrer, A; Semenkovich, CF; Ramanadham, S; Tabas, I; Turk, J				Bao, Shunzhong; Li, Yankun; Lei, Xiaoyong; Wohltmann, Mary; Jin, Wu; Bohrer, Alan; Semenkovich, Clay F.; Ramanadham, Sasanka; Tabas, Ira; Turk, John			Attenuated free cholesterol loading-induced apoptosis but preserved phospholipid composition of peritoneal macrophages from mice that do not express group VIA phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONIC-ACID RELEASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; MECHANISM-BASED DISCRIMINATION; ENDOPLASMIC-RETICULUM STRESS; INSULIN SECRETORY RESPONSES; PANCREATIC-ISLETS EXPRESS; FAS-MEDIATED APOPTOSIS; VASCULAR SMOOTH-MUSCLE; ELECTROSPRAY-IONIZATION; P388D(1) MACROPHAGES	Mouse macrophages undergo ER stress and apoptosis upon free cholesterol loading (FCL). We recently generated iPLA2 beta-null mice, and here we demonstrate that iPLA(2)beta- null macrophages have reduced sensitivity to FCL-induced apoptosis, although they and wild-type (WT) cells exhibit similar increases in the transcriptional regulator CHOP. iPLA(2)beta-null macrophages are also less sensitive to apoptosis induced by the sarcoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin and the scavenger receptor A ligand fucoidan, and restoring iPLA(2)beta expression with recombinant adenovirus increases apoptosis toward WT levels. WT and iPLA2 beta-null macrophages incorporate [H-3] arachidonic acid ([H-3] AA]) into glycerophosphocholine lipids equally rapidly and exhibit identical zymosan-induced, cPLA2 beta-catalyzed [H-3] AA release. In contrast, although WT macrophages exhibit robust [H-3] AA release upon FCL, this is attenuated in iPLA(2)beta-null macrophages and increases toward WT levels upon restoring iPLA(2)beta expression. Recent reports indicate that iPLA(2)beta modulates mitochondrial cytochrome c release, and we find that thapsigargin and fucoidan induce mitochondrial phospholipid loss and cytochrome c release into WT macrophage cytosol and that these events are blunted in iPLA(2)beta-null cells. Immunoblotting studies indicate that iPLA(2)beta associates with mitochondria in macrophages subjected to ER stress. AA incorporation into glycerophosphocholine lipids is unimpaired in iPLA(2)beta-null macrophages upon electrospray ionization-tandem mass spectrometry analyses, and their complex lipid composition is similar to WT cells. These findings suggest that iPLA(2)beta participates in ER stress-induced macrophage apoptosis caused by FCL or thapsigargin but that deletion of iPLA(2)beta does not impair macrophage arachidonate incorporation or phospholipid composition.	Washington Univ, Sch Med, Div Endocrinol Metabol & Lipid Res, St Louis, MO 63110 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat, New York, NY 10032 USA; Columbia Univ, Dept Cell Biol, New York, NY 10032 USA	Washington University (WUSTL); Columbia University; Columbia University; Columbia University	Turk, J (corresponding author), Washington Univ, Sch Med, Div Endocrinol Metabol & Lipid Res, Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	jturk@wustl.edu		Semenkovich, Clay/0000-0003-1163-1871	NCRR NIH HHS [P41 RR000954-30, P41 RR000954, P41 RR 00954] Funding Source: Medline; NHLBI NIH HHS [P01 HL057278, P01 HL 57278] Funding Source: Medline; NIDDK NIH HHS [R37 DK034388, P60 DK 20579, P60 DK020579-269005, P60 DK020579, P30 DK056341, P30 DK056341-07, P30 DK056341-06, R37 DK 34388, P30 DK 56341, R37 DK034388-23, P30 DK056341-069003] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline; PHS HHS [R01 69455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388, P60DK020579, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Barrett LE, 2006, P NATL ACAD SCI USA, V103, P5155, DOI 10.1073/pnas.0510477103; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; Brustovetsky T, 2005, J NEUROCHEM, V94, P980, DOI 10.1111/j.1471-4159.2005.03248.x; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Gadd ME, 2006, J BIOL CHEM, V281, P6931, DOI 10.1074/jbc.M510845200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Guo ZH, 2003, J BIOL CHEM, V278, P1856, DOI 10.1074/jbc.M211075200; HALLBERG A, 1984, BIOCHIM BIOPHYS ACTA, V796, P328, DOI 10.1016/0005-2760(84)90134-6; Han XL, 2006, J AM SOC MASS SPECTR, V17, P264, DOI 10.1016/j.jasms.2005.11.003; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; Hsu FF, 2003, J AM SOC MASS SPECTR, V14, P352, DOI 10.1016/S1044-0305(03)00064-3; Hyoda K, 2006, BIOCHEM BIOPH RES CO, V340, P286, DOI 10.1016/j.bbrc.2005.12.007; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; MURPHY RC, 1990, METHOD ENZYMOL, V187, P90; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; QIU ZH, 1993, J BIOL CHEM, V268, P24506; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Ramanadham S, 2000, BBA-MOL CELL BIOL L, V1484, P251, DOI 10.1016/S1388-1981(00)00022-6; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Seimon TA, 2006, P NATL ACAD SCI USA, V103, P19794, DOI 10.1073/pnas.0609671104; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Song HW, 2004, J AM SOC MASS SPECTR, V15, P1780, DOI 10.1016/j.jasms.2004.08.012; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Vivekananda J, 2001, AM J PHYSIOL-LUNG C, V281, pL98, DOI 10.1152/ajplung.2001.281.1.L98; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Williams SD, 2000, J LIPID RES, V41, P1585; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	103	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27100	27114		10.1074/jbc.M701316200	http://dx.doi.org/10.1074/jbc.M701316200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627946	Green Accepted, hybrid			2022-12-27	WOS:000249304900051
J	Chew, V; Lam, KP				Chew, Valerie; Lam, Kong-Peng			Leupaxin negatively regulates B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PAXILLIN LD MOTIFS; LYN-DEFICIENT MICE; ANTIGEN RECEPTOR; KINASE LYN; LIPID RAFTS; PTP-PEST; IL-2 EXPRESSION; ADAPTER PROTEIN; DOWN-REGULATION	The role of the paxillin superfamily of adaptor proteins in B cell antigen receptor (BCR) signaling has not been studied previously. We show here that leupaxin (LPXN), a member of this family, was tyrosine-phosphorylated and recruited to the plasma membrane of human BJAB lymphoma cells upon BCR stimulation and that it interacted with Lyn (a critical Src family tyrosine kinase in BCR signaling) in a BCR-induced manner. LPXN contains four leucine-rich sequences termed LD motifs, and serial truncation and specific domain deletion of LPXN indicated that its LD3 domain is involved in the binding of Lyn. Of a total of 11 tyrosine sites in LPXN, we mutated Tyr(22), Tyr(72), Tyr(198), and Tyr(257) to phenylalanine and demonstrated that LPXN was phosphorylated by Lyn only at Tyr(72) and that this tyrosine site is proximal to the LD3 domain. The overexpression of LPXN in mouse A20 B lymphoma cells led to the suppression of BCR-induced activation of JNK, p38 MAPK, and, to a lesser extent, Akt, but not ERK and NF kappa B, suggesting that LPXN can selectively repress BCR signaling. We further show that LPXN suppressed the secretion of interleukin-2 by BCR-activated A20 B cells and that this inhibition was abrogated in the Y72F LPXN mutant, indicating that the phosphorylation of Tyr(72) is critical for the biological function of LPXN. Thus, LPXN plays an inhibitory role in BCR signaling and B cell function.	Singapore Immunol Network, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Lam, KP (corresponding author), Singapore Immunol Network, Lab 6-15,61 Biopolis Dr, Singapore 138673, Singapore.	lam_kong_peng@immunol.a-star.edu.sg	Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333				Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Cantrell D, 2002, SEMIN IMMUNOL, V14, P19, DOI 10.1006/smim.2001.0338; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gary-Gouy H, 2002, J IMMUNOL, V168, P232, DOI 10.4049/jimmunol.168.1.232; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; Jhun BS, 2006, BIOCHEM BIOPH RES CO, V351, P986, DOI 10.1016/j.bbrc.2006.10.138; Kabak S, 2002, MOL CELL BIOL, V22, P2524, DOI 10.1128/MCB.22.8.2524-2535.2002; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; Motoda K, 2000, IMMUNOLOGY, V100, P370, DOI 10.1046/j.1365-2567.2000.00046.x; Ng CH, 2007, BLOOD, V110, P259, DOI 10.1182/blood-2006-10-055194; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Perchonock CE, 2006, MOL CELL BIOL, V26, P6005, DOI 10.1128/MCB.02067-05; Plas DR, 1998, J MOL MED-JMM, V76, P589, DOI 10.1007/s001090050254; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Rathore VB, 2007, BIOCHEM J, V403, P275, DOI 10.1042/BJ20061618; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Romanova LY, 2004, J CELL SCI, V117, P3759, DOI 10.1242/jcs.01206; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC2288, DOI 10.1152/ajpcell.00503.2006; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC581, DOI 10.1152/ajpcell.00636.2005; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tsubata T, 2001, Int Rev Immunol, V20, P675, DOI 10.3109/08830180109045584; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; Watanabe N, 2005, MOL CELL BIOCHEM, V269, P13, DOI 10.1007/s11010-005-2149-6; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yamasaki S, 2004, SEMIN IMMUNOL, V16, P421, DOI 10.1016/j.smim.2004.08.021; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; Yu TC, 2004, ACTA BIOCH BIOPH SIN, V36, P741, DOI 10.1093/abbs/36.11.741; Zhang J, 2000, MOL CARCINOGEN, V27, P177, DOI 10.1002/(SICI)1098-2744(200003)27:3<177::AID-MC4>3.3.CO;2-J	56	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27181	27191		10.1074/jbc.M704625200	http://dx.doi.org/10.1074/jbc.M704625200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640867	hybrid			2022-12-27	WOS:000249304900059
J	Dinnen, RD; Drew, L; Petrylak, DP; Mao, YH; Cassai, N; Szmulewicz, J; Brandt-Rauf, P; Fine, RL				Dinnen, Richard D.; Drew, Lisa; Petrylak, Daniel P.; Mao, Yuehua; Cassai, Nicholas; Szmulewicz, Joseph; Brandt-Rauf, Paul; Fine, Robert L.			Activation of targeted necrosis by a p53 peptide - A novel death pathway that circumvents apoptotic resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; C-TERMINAL PEPTIDE; MUTANT P53; BCL-2; MITOCHONDRIA; SUPEROXIDE; INDUCTION; GROWTH; GENE	Cancer cells escape apoptosis by intrinsic or acquired mechanisms of drug resistance. An alternative strategy to circumvent resistance to apoptosis could be through redirection into other death pathways, such as necrosis. However, necrosis is a nonspecific, nontargeted process resulting in cell lysis and inflammation of both cancer and normal cells and is therefore not a viable alternative. Here, we report that a C-terminal peptide of p53, called p53p-Ant, induced targeted necrosis only in multiple mutant p53 human prostate cancer lines and not normal cells, because the mechanism of cytotoxicity by p53p-Ant is dependent on the presence of high levels of mutant p53. Topotecan-and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines. A massive loss of ATP pools and intracellular generation of reactive oxygen species was involved in the mechanism of targeted necrosis, which was inhibited by O-2(center dot-) scavengers. We hypothesize that targeted necrosis by p53p-Ant is dependent on mutant p53, is mediated by O-2(center dot-) loss and ATP, and can circumvent chemotherapy resistance to apoptosis. Targeted necrosis, as an alternative pathway for selective killing of cancer cells, may overcome the problems of nonspecificity in utilizing the necrotic pathway.	Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Environm Hlth, New York, NY 10032 USA; Suny Downstate Med Ctr, Harbor Vet Affairs Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11203 USA	Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Fine, RL (corresponding author), Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, 650 W 168th St,BB 20-05, New York, NY 10032 USA.	rlf20@columbia.edu			PHS HHS [R01 85828] Funding Source: Medline; NIOSH CDC HHS [R01 OH 07590] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH007590] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NIOSH CDC HHS; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DiPaola RS, 1999, SEMIN ONCOL, V26, P112; Do TN, 2003, ONCOGENE, V22, P1431, DOI 10.1038/sj.onc.1206258; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; Eguchi Y, 1997, CANCER RES, V57, P1835; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Haldar S, 1996, CANCER RES, V56, P1253; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Howell SB, 2000, MOL UROL, V4, P225; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; ISAACS WB, 1991, CANCER RES, V51, P4716; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li Y, 2005, INT J CANCER, V115, P55, DOI 10.1002/ijc.20838; Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1; MacGrogan D, 1997, SEMIN CANCER BIOL, V8, P11, DOI 10.1006/scbi.1997.0048; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miyake H, 2003, ONCOL REP, V10, P469; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Prabhakaran K, 2004, TOXICOL APPL PHARM, V195, P194, DOI 10.1016/j.taap.2003.11.012; RAFFO AJ, 1995, CANCER RES, V55, P4438; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rokhlin OW, 1998, CANCER RES, V58, P5870; Schomber T, 2004, BLOOD, V103, P4511, DOI 10.1182/blood-2003-07-2397; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Senatus PB, 2006, MOL CANCER THER, V5, P20, DOI 10.1158/1535-7163.MCT-05-0181; Shih CM, 2004, J CELL BIOCHEM, V91, P384, DOI 10.1002/jcb.10761; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Urasaki Y, 2001, CANCER RES, V61, P1964; Wang LG, 2001, CANCER RES, V61, P7544	38	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26675	26686		10.1074/jbc.M701864200	http://dx.doi.org/10.1074/jbc.M701864200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636258	hybrid			2022-12-27	WOS:000249304900006
J	Goto, T; Abe, Y; Kakuta, Y; Takeshita, K; Imoto, T; Ueda, T				Goto, Takashi; Abe, Yoshito; Kakuta, Yoshimitsu; Takeshita, Kohei; Imoto, Taiji; Ueda, Tadashi			Crystal structure of tapes japonica lysozyme with substrate analogue - Structural basis of the catalytic mechanism and manifestation of its chitinase activity accompanied by quaternary structural change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; OYSTER CRASSOSTREA-VIRGINICA; INVERTEBRATE LYSOZYMES; ASTERIAS-RUBENS; HEN; ENZYME; RESOLUTION; REFINEMENT; EVOLUTION; PURIFICATION	Tapes japonica lysozyme (TJL) is classified as a member of the recently established i-type lysozyme family. In this study, we solved the crystal structure of TJL complexed with a trimer of N-acetylglucosamine to 1.6A resolution. Based on structure and mutation analyses, we demonstrated that Glu-18 and Asp-30 are the catalytic residues of TJL. Furthermore, the present findings suggest that the catalytic mechanism of TJL is a retaining mechanism that proceeds through a covalent sugar-enzyme intermediate. On the other hand, the quaternary structure in the crystal revealed a dimer formed by the electrostatic interactions of catalytic residues (Glu-18 and Asp-30) in one molecule with the positive residues at the C terminus in helix 6 of the other molecule. Gel chromatography analysis revealed that the TJL dimer remained intact under low salt conditions but that it dissociated to TJL monomers under high salt conditions. With increasing salt concentrations, the chitinase activity of TJL dramatically increased. Therefore, this study provides novel evidence that the lysozyme activity of TJL is modulated by its quaternary structure.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, Fukuoka 8128592, Japan; Sojo Univ, Fac Biotechnol & Life Sci, Kumamoto 8600082, Japan	Kyushu University; Sojo University	Ueda, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128592, Japan.	ueda@phar.kyushu-u.ac.jp	Abe, Yoshito/D-8370-2012; Abe, Yoshito/AAH-6141-2021	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490				Bachali S, 2004, EUR J BIOCHEM, V271, P237, DOI 10.1046/j.1432-1033.2003.03915.x; Bachali S, 2002, J MOL EVOL, V54, P652, DOI 10.1007/s00239-001-0061-6; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Carballal MJ, 1997, J INVERTEBR PATHOL, V70, P96, DOI 10.1006/jipa.1997.4670; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evrard C, 1998, J MOL BIOL, V276, P151, DOI 10.1006/jmbi.1997.1499; Fradkov A, 1996, FEBS LETT, V390, P145, DOI 10.1016/0014-5793(96)00644-8; FUKAMIZO T, 1982, J BIOCHEM-TOKYO, V91, P619, DOI 10.1093/oxfordjournals.jbchem.a133733; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ito Y, 1999, PROTEIN ENG, V12, P327, DOI 10.1093/protein/12.4.327; Ito Y, 1999, EUR J BIOCHEM, V259, P456, DOI 10.1046/j.1432-1327.1999.00064.x; JOLLES J, 1975, EUR J BIOCHEM, V54, P19, DOI 10.1111/j.1432-1033.1975.tb04108.x; Jolles J, 1996, J MOL EVOL, V43, P523, DOI 10.1007/BF02337523; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCHENERY JG, 1979, COMP BIOCHEM PHYS B, V63, P25, DOI 10.1016/0305-0491(79)90228-1; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nilsen IW, 1999, FEBS LETT, V464, P153, DOI 10.1016/S0014-5793(99)01693-2; Nilsen IW, 2001, GENE, V269, P27, DOI 10.1016/S0378-1119(01)00457-7; Olsen OM, 2003, COMP BIOCHEM PHYS B, V136, P107, DOI 10.1016/S1096-4959(03)00174-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Stulik K, 2003, J BIOCHEM BIOPH METH, V56, P1, DOI 10.1016/S0165-022X(03)00053-8; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; Takeshita K, 2004, PROTEIN EXPRES PURIF, V36, P254, DOI 10.1016/j.pep.2004.05.001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsujihata Y, 2000, J IMMUNOL, V165, P3606, DOI 10.4049/jimmunol.165.7.3606; UEDA T, 1991, J BIOCHEM-TOKYO, V110, P719, DOI 10.1093/oxfordjournals.jbchem.a123647; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WEAVER LH, 1995, J MOL BIOL, V245, P54, DOI 10.1016/S0022-2836(95)80038-7; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wicki J, 2002, METHOD ENZYMOL, V354, P84; Xue QG, 2007, CELL MOL LIFE SCI, V64, P82, DOI 10.1007/s00018-006-6386-y; Xue QG, 2004, COMP BIOCHEM PHYS B, V139, P11, DOI 10.1016/j.cbpc.2004.05.011; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Yip VLY, 2004, ORG BIOMOL CHEM, V2, P2707, DOI 10.1039/b408880h	46	56	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27459	27467		10.1074/jbc.M704555200	http://dx.doi.org/10.1074/jbc.M704555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631496	hybrid			2022-12-27	WOS:000249304900087
J	Caposio, P; Gugliesi, F; Zannetti, C; Sponza, S; Mondini, M; Medico, E; Hiscott, J; Young, HA; Gribaudo, G; Gariglio, M; Landolfo, S				Caposio, Patrizia; Gugliesi, Francesca; Zannetti, Claudia; Sponza, Simone; Mondini, Michele; Medico, Enzo; Hiscott, John; Young, Howard A.; Gribaudo, Giorgio; Gariglio, Marisa; Landolfo, Santo			A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; EPITHELIAL ICAM-1 EXPRESSION; GENE-EXPRESSION; HIN-200 FAMILY; ACTIVATION; TRANSCRIPTION; ALPHA; SP1; INFLAMMATION	The human IFI16 gene is an interferon-inducible gene implicated in the regulation of endothelial cell proliferation and tube morphogenesis. Immunohistochemical analysis has demonstrated that this gene is highly expressed in endothelial cells in addition to hematopoietic tissues. In this study, gene array analysis of human umbilical vein endothelial cells overexpressing IFI16 revealed an increased expression of genes involved in immunomodulation, cell growth, and apoptosis. Consistent with these observations, IFI16 triggered expression of adhesion molecules such as ICAM-1 and E-selectin or chemokines such as interleukin-8 or MCP-1. Treatment of cells with short hairpin RNA targeting IFI16 significantly inhibited ICAM-1 induction by interferon (IFN)-gamma demonstrating that IFI16 is required for proinflammatory gene stimulation. Moreover, functional analysis of the ICAM-1 promoter by deletion- or site-specific mutation demonstrated that NF-kappa B is the main mediator of IFI16-driven gene induction. NF-kappa B activation appears to be triggered by IFI16 through a novel mechanism involving suppression of I kappa B alpha mRNA and protein expression. Support for this finding comes from the observation that IFI16 targeting with specific short hairpin RNA down-regulates NF-kappa B binding activity to its cognate DNA and inhibits ICAM-1 expression induced by IFN-gamma. Using transient transfection and luciferase assay, electrophoretic mobility shift assay, and chromatin immunoprecipitation, we demonstrate indeed that activation of the NF-kappa B response is mediated by IFI16-induced block of Sp1-like factor recruitment to the promoter of the I kappa B alpha gene, encoding the main NF-kappa B inhibitor. Activation of NF-kappa B accompanied by induction of proinflammatory molecules was also observed when I kappa B alpha expression was down-regulated by specific small interfering RNA, resulting in an outcome similar to that observed with IFI16 overexpression. Taken together, these data implicate IFI16 as a novel regulator of endothelial proinflammatory activity and provide new insights into the physiological functions of the IFN-inducible gene IFI16.	Univ Turin, Sch Med, Dept Publ Hlth & Microbiol, Lab Viral Pathogenesis, I-10126 Turin, Italy; Univ Turin, Inst Canc Res & Treatment, I-10126 Turin, Italy; McGill Univ, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; NCI, Canc Res Ctr, Expt Immunol Lab, Natl Inst Hlth, Frederick, MD 21702 USA; Univ Piemonte Orientale, Dept Clin & Expt Med, I-28100 Novara, Italy	University of Turin; University of Turin; Lady Davis Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Eastern Piedmont Amedeo Avogadro	Landolfo, S (corresponding author), Univ Turin, Sch Med, Dept Publ Hlth & Microbiol, Lab Viral Pathogenesis, Via Santena 9, I-10126 Turin, Italy.	santo.landolfo@unito.it	Mondini, Michele/T-4568-2019; Medico, Enzo/AAC-3185-2021; Gribaudo, Giorgio/A-8872-2011; Young, Howard/A-6350-2008	Mondini, Michele/0000-0001-5803-0083; Medico, Enzo/0000-0002-3917-2438; Gariglio, Marisa/0000-0002-5187-0140; Gribaudo, Giorgio/0000-0002-1583-9146; /0000-0001-6389-5129; Young, Howard/0000-0002-3118-5111				Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Albrecht M, 2005, BIOCHEM BIOPH RES CO, V327, P679, DOI 10.1016/j.bbrc.2004.12.056; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; Bekisz J, 2004, GROWTH FACTORS, V22, P243, DOI 10.1080/08977190400000833; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Caposio P, 2004, J VIROL, V78, P3190, DOI 10.1128/JVI.78.6.3190-3195.2004; Chang YJ, 2004, MOL PHARMACOL, V65, P589, DOI 10.1124/mol.65.3.589; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Fujiuchi N, 2004, J BIOL CHEM, V279, P20339, DOI 10.1074/jbc.M400344200; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Gugliesi F, 2005, J LEUKOCYTE BIOL, V77, P820, DOI 10.1189/jlb.0904507; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kempe S, 2005, NUCLEIC ACIDS RES, V33, P5308, DOI 10.1093/nar/gki836; Kong JSW, 2006, AUTOIMMUN REV, V5, P471, DOI 10.1016/j.autrev.2006.02.014; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Ludlow LEA, 2005, EXP CELL RES, V308, P1, DOI 10.1016/j.yexcr.2005.03.032; Luu P, 1997, J VIROL, V71, P6683, DOI 10.1128/JVI.71.9.6683-6691.1997; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Mondini M, 2007, ANN NY ACAD SCI, V1110, P47, DOI 10.1196/annals.1423.006; Mondini M, 2006, ARTHRITIS RHEUM, V54, P3939, DOI 10.1002/art.22266; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Parmar S, 2005, CANC TREAT, V126, P45, DOI 10.1007/0-387-24361-5_3; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SEELIG HP, 1994, ARTHRITIS RHEUM-US, V37, P1672, DOI 10.1002/art.1780371117; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Uchida K, 2005, IMMUNOLOGY, V116, P53, DOI 10.1111/j.1365-2567.2005.02197.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0	47	59	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2007	282	46							33515	10.1074/jbc.M701846200	http://dx.doi.org/10.1074/jbc.M701846200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	229XP	17699163	hybrid			2022-12-27	WOS:000250840200032
J	Fridy, PC; Otto, JC; Dollins, DE; York, JD				Fridy, Peter C.; Otto, James C.; Dollins, D. Eric; York, John D.			Cloning and characterization of two human VIP1-like inositol hexakisphosphate and diphosphoinositol pentakisphosphate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; POLYPHOSPHATE KINASES; TELOMERE LENGTH; ACTIVE-SITE; PYROPHOSPHATES; TETRAKISPHOSPHATE; IDENTIFICATION; DICTYOSTELIUM; METABOLISM	Eukaryotes possess numerous inositol phosphate ( IP) and diphosphoinositol phosphate ( PP-IPs or inositol pyrophosphates) species that act as chemical codes important for intracellular signaling pathways. Production of IP and PP-IP molecules occurs through several classes of evolutionarily conserved inositol phosphate kinases. Here we report the characterization of a human inositol hexakisphosphate ( IP6) and diphosphoinositol pentakisphosphate ( PP-IP5 or IP7) kinase with similarity to the yeast enzyme Vip1, a recently identified IP6/IP7 kinase ( Mulugu, S., Bai, W., Fridy, P. C., Bastidas, R. J., Otto, J. C., Dollins, D. E., Haystead, T. A., Ribeiro, A. A., and York, J. D. ( 2007) Science 316, 106-109). Recombinant human VIP1 exhibits in vitro IP6 and IP7 kinase activities and restores IP7 synthesis when expressed in mutant yeast. Expression of human VIP1 in HEK293T cells engineered to produce high levels of IP7 results in dramatic increases in bisdiphosphoinositol tetrakisphosphate ( PP2-IP4 or IP8). Northern blot analysis indicates that human VIP1 is expressed in a variety of tissues and is enriched in skeletal muscle, heart, and brain. The subcellular distribution of tagged human VIP1 is indicative of a cytoplasmic non-membrane localization pattern. We also characterized human and mouse VIP2, an additional gene product with nearly 90% similarity to VIP1 in the kinase domain, and observed both IP6 and IP7 kinase activities. Our data demonstrate that human VIP1 and VIP2 function as IP6 and IP7 kinases that act along with the IP6K/Kcs1-class of kinases to convert IP6 to IP8 in mammalian cells, a process that has been found to occur in response to various stimuli and signaling events.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, DUMC Box 3813, Durham, NC 27710 USA.	yorkj@duke.edu		Fridy, Peter/0000-0002-8208-9154	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070272] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline; NIDDK NIH HHS [R33 DK070272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Caffrey JJ, 1999, FEBS LETT, V442, P99, DOI 10.1016/S0014-5793(98)01636-6; Choi JH, 2007, J BIOL CHEM, V282, P30763, DOI 10.1074/jbc.M704655200; Choi K, 2005, CELL SIGNAL, V17, P1533, DOI 10.1016/j.cellsig.2005.03.021; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; EUROPEFINNER GN, 1991, BIOCHEM BIOPH RES CO, V181, P191, DOI 10.1016/S0006-291X(05)81400-7; Feoktistova A, 1999, GENETICS, V152, P895; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Ingram SW, 2003, BIOCHEM J, V369, P519, DOI 10.1042/BJ20020733; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Irvine R, 2007, SCIENCE, V316, P845, DOI 10.1126/science.1143339; Laussmann T, 2000, EUR J BIOCHEM, V267, P2447, DOI 10.1046/j.1432-1327.2000.01264.x; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Lim D, 2000, NAT STRUCT BIOL, V7, P108; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Mullaney EJ, 2003, BIOCHEM BIOPH RES CO, V312, P179, DOI 10.1016/j.bbrc.2003.09.176; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; OTTO JC, 2007, IN PRESS P NATL ACAD; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; York JD, 2004, SCIENCE, V306, P2053, DOI 10.1126/science.1107225; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2006, BBA-MOL CELL BIOL L, V1761, P552, DOI 10.1016/j.bbalip.2006.04.014; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200	49	85	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30754	30762		10.1074/jbc.M704656200	http://dx.doi.org/10.1074/jbc.M704656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690096	hybrid			2022-12-27	WOS:000250136300044
J	Vorup-Jensen, T; Chi, LL; Gjelstrup, LC; Jensen, UB; Jewett, CA; Xie, C; Shimaoka, M; Linhardt, RJ; Springer, TA				Vorup-Jensen, Thomas; Chi, Lianli; Gjelstrup, Louise C.; Jensen, Uffe B.; Jewett, Craig A.; Xie, Can; Shimaoka, Motomu; Linhardt, Robert J.; Springer, Timothy A.			Binding between the Integrin alpha X beta 2 (CD11c/CD18) and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; PROTEIN INTERACTIONS; MAC-1 CD11B/CD18; ACTIVATION; AFFINITY; CONFORMATION; RECOGNITION; DERIVATIVES; ADHESION; LIGAND	The interactions between cell surface receptors and sulfated glucosamineglycans serve ubiquitous roles in cell adhesion and receptor signaling. Heparin, a highly sulfated polymer of uronic acids and glucosamine, binds strongly to the integrin receptor alpha X beta 2 (p150,95, CD11c/CD18). Here, we analyze the structural motifs within heparin that constitute high affinity binding sites for the I domain of integrin alpha X beta 2. Heparin oligomers with chain lengths of 10 saccharide residues or higher provide strong inhibition of the binding by the alpha X I domain to the complement fragment iC3b. By contrast, smaller oligomers or the synthetic heparinoid fondaparinux were not able to block the binding. Semipurified heparin oligomers with 12 saccharide residues identified the fully sulfated species as the most potent antagonist of iC3b, with a 1.3 mu M affinity for the alpha XI domain. In studies of direct binding by the alpha XI domain to immobilized heparin, we found that the interaction is conformationally regulated and requires Mg2+. Furthermore, the fully sulfated heparin fragment induced conformational change in the ectodomain of the alpha X beta 2 receptor, also demonstrating allosteric linkage between heparin binding and integrin conformation.	Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Univ Aarhus, Inst Med Microbiol & Immunol, Biophys Immunol Lab, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Human Genet, DK-8000 Aarhus C, Denmark; Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Dept Chem & Chem Biol, Troy, NY 12180 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Aarhus University; Aarhus University; Rensselaer Polytechnic Institute	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@idi.harvard.edu	Chi, Lianli/B-9149-2015; Jensen, Uffe Birk/E-6066-2017; Jensen, Uffe Birk/ABA-8306-2021; Vorup-Jensen, Thomas/N-9082-2016	Chi, Lianli/0000-0003-1126-1022; Jensen, Uffe Birk/0000-0002-6205-6355; Jensen, Uffe Birk/0000-0002-6205-6355; Vorup-Jensen, Thomas/0000-0002-4140-6563; Xie, Can/0000-0002-7412-3236	NHLBI NIH HHS [R01 HL052622-09, R01 HL052622, HL52622, R01 HL062244, R01 HL062244-05A1] Funding Source: Medline; NIAID NIH HHS [R01 AI072765, AI72765] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060, R01 GM038060-19, GM038060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200; COOMBE DR, 1994, BLOOD, V84, P739; de Kort M, 2005, DRUG DISCOV TODAY, V10, P769, DOI 10.1016/S1359-6446(05)03457-4; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HOFFMAN J, 1983, CARBOHYD RES, V117, P328, DOI 10.1016/0008-6215(83)88103-8; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Karlsson R, 1999, J MOL RECOGNIT, V12, P285, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<285::AID-JMR469>3.0.CO;2-Y; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Pavlov G, 2003, EUR BIOPHYS J BIOPHY, V32, P437, DOI 10.1007/s00249-003-0316-9; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vorup-Jensen T, 2005, P NATL ACAD SCI USA, V102, P1614, DOI 10.1073/pnas.0409057102; Vorup-Jensen T, 2003, P NATL ACAD SCI USA, V100, P1873, DOI 10.1073/pnas.0237387100; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Zhang FM, 2004, CLIN APPL THROMB-HEM, V10, P249, DOI 10.1177/107602960401000307	28	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30869	30877		10.1074/jbc.M706114200	http://dx.doi.org/10.1074/jbc.M706114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699512	Green Accepted, hybrid			2022-12-27	WOS:000250136300055
J	Garrity, J; Gardner, JG; Hawse, W; Wolberger, C; Escalante-Semerena, JC				Garrity, Jane; Gardner, Jeffrey G.; Hawse, William; Wolberger, Cynthia; Escalante-Semerena, Jorge C.			N-Lysine propionylation controls the activity of propionyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-ENTERICA; POSTTRANSLATIONAL MODIFICATIONS; CALORIE RESTRICTION; ESCHERICHIA-COLI; ACID CYCLE; IN-VIVO; PROTEIN; ENZYME; ACETYLATION; NAD(+)	Reversible protein acetylation is a ubiquitous means for the rapid control of diverse cellular processes. Acetyltransferase enzymes transfer the acetyl group from acetyl-CoA to lysine residues, while deacetylase enzymes catalyze removal of the acetyl group by hydrolysis or by an NAD(+)-dependent reaction. Propionylcoenzyme A (CoA), like acetyl-CoA, is a high energy product of fatty acid metabolism and is produced through a similar chemical reaction. Because acetyl-CoA is the donor molecule for protein acetylation, we investigated whether proteins can be propionylated in vivo, using propionyl-CoA as the donor molecule. We report that the Salmonella enterica propionyl-CoA synthetase enzyme PrpE is propionylated in vivo at lysine 592; propionylation inactivates PrpE. The propionyl-lysine modification is introduced by bacterial Gcn-5- related N-acetyltransferase enzymes and can be removed by bacterial and human Sir2 enzymes (sirtuins). Like the sirtuin deacetylation reaction, sirtuincatalyzed depropionylation is NAD(+)-dependent and produces a byproduct, O-propionyl ADP-ribose, analogous to the O-acetyl ADP-ribose sirtuin product of deacetylation. Only a subset of the human sirtuins with deacetylase activity could also depropionylate substrate. The regulation of cellular propionyl-CoA by propionylation of PrpE parallels regulation of acetylCoA by acetylation of acetyl-CoA synthetase and raises the possibility that propionylation may serve as a regulatory modification in higher organisms.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	escalante@bact.wisc.edu		Garrity, Jane/0000-0003-2266-6463; Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203, T32GM008349] Funding Source: NIH RePORTER; NCRR NIH HHS [U54 RR020839.] Funding Source: Medline; NIGMS NIH HHS [T32 GM08349, R01 GM062203, GM62203] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRASS EP, 1990, J NUTR, V120, P290, DOI 10.1093/jn/120.3.290; Brinsmade SR, 2007, J BIOL CHEM, V282, P12629, DOI 10.1074/jbc.M611439200; Brock M, 2004, EUR J BIOCHEM, V271, P3227, DOI 10.1111/j.1432-1033.2004.04255.x; Chen Y, 2007, MOL CELL PROTEOMICS, V6, P812, DOI 10.1074/mcp.M700021-MCP200; Clark RSB, 2005, CRIT CARE MED, V33, pS407, DOI 10.1097/01.CCM.0000191712.96336.51; DAWSON RMC, 1986, DATA BIOCH RES, P122; Gardner JG, 2006, J BACTERIOL, V188, P5460, DOI 10.1128/JB.00215-06; Grubisha O, 2006, J BIOL CHEM, V281, P14057, DOI 10.1074/jbc.M513741200; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Horswill AR, 2001, J BIOL CHEM, V276, P19094, DOI 10.1074/jbc.M100244200; Horswill AR, 2002, BIOCHEMISTRY-US, V41, P2379, DOI 10.1021/bi015647q; Horswill AR, 1999, MICROBIOL-UK, V145, P1381, DOI 10.1099/13500872-145-6-1381; Horswill AR, 2001, BIOCHEMISTRY-US, V40, P4703, DOI 10.1021/bi015503b; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; MIYAKOSHI S, 1987, AGR BIOL CHEM TOKYO, V51, P2381; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Sambrook J., 2001, MOL CLONING LAB MANU; SASSE J, 1991, CURRENT PROTOCOLS MO; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Sawers G, 2001, MOL MICROBIOL, V39, P1285, DOI 10.1046/j.1365-2958.2001.02316.x; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Shih YP, 2005, PROTEIN SCI, V14, P936, DOI 10.1110/ps.041129605; Smith BC, 2007, J AM CHEM SOC, V129, P5802, DOI 10.1021/ja070162w; Smith JS, 2002, METHOD ENZYMOL, V353, P282; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2003, GENETICS, V163, P545; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; STUMPF DA, 1980, PEDIATR RES, V14, P1127, DOI 10.1203/00006450-198010000-00008; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Walsh CT, 2005, ANGEW CHEM INT EDIT, V44, P7342, DOI 10.1002/anie.200501023; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	44	153	159	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30239	30245		10.1074/jbc.M704409200	http://dx.doi.org/10.1074/jbc.M704409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17684016	hybrid			2022-12-27	WOS:000249981200054
J	Woeller, CF; Fox, JT; Perry, C; Stover, PJ				Woeller, Collynn F.; Fox, Jennifer T.; Perry, Cheryll; Stover, Patrick J.			A ferritin-responsive internal ribosome entry site regulates folate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SERINE HYDROXYMETHYLTRANSFERASE; MESSENGER-RNA SEQUENCES; BINDING PROTEIN-BETA; HEAVY-CHAIN; 3'-UNTRANSLATED REGION; TRANSLATIONAL REGULATION; INCREASES TRANSLATION; POLY(A) TAIL; INITIATION; SUBUNIT	Cytoplasmic serine hydroxymethyltransferase ( cSHMT) enzyme levels are elevated by the expression of the heavy chain ferritin ( H ferritin) cDNA in cultured cells without corresponding changes in mRNA levels, resulting in enhanced folate- dependent de novo thymidylate biosynthesis and impaired homocysteine remethylation. In this study, the mechanism wherebyH ferritin regulates cSHMT expression was determined. cSHMT translation is shown to be regulated by an H ferritin- responsive internal ribosome entry site ( IRES) located within the cSHMT mRNA 5'- untranslated region ( 5'- UTR). The cSHMT 5'-UTR exhibited IRES activity during in vitro translation of bicistronic mRNAtemplates, and in MCF- 7 and HeLa cells transfected with bicistronic mRNAs. IRES activity was depressed in H ferritindeficient mouse embryonic fibroblasts and elevated in cells expressing theHferritin cDNA. Hferritin was shown to interact with the mRNA- binding protein CUGBP1, a protein known to interact with the alpha and beta subunits of eukaryotic initiation factor eIF2. Small interference RNA- mediated depletion of CUGBP1 decreased IRES activity from bicistronic templates that included the cSHMT 3'- UTR in the bicistronic construct. The identification of this H ferritin- responsive IRES represents a mechanism that accounts for previous observations that H ferritin regulates folate metabolism.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	pjs13@cornell.edu	Woeller, Collynn/U-3877-2019	Woeller, Collynn/0000-0001-7197-5057	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abalea V, 1998, CARCINOGENESIS, V19, P1053, DOI 10.1093/carcin/19.6.1053; ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Bradrick SS, 2006, NUCLEIC ACIDS RES, V34, P1293, DOI 10.1093/nar/gkl019; Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69; Christensen KE, 2006, BIOESSAYS, V28, P595, DOI 10.1002/bies.20420; DORMOYRACLET V, 2005, RNA BIOL, V2, P112; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Ghosh B, 2000, MOL CELL BIOCHEM, V209, P9, DOI 10.1023/A:1007024119640; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; Hensley LL, 2003, J BIOL CHEM, V278, P32702, DOI 10.1074/jbc.M304200200; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Izquierdo JM, 2000, BIOCHEM J, V346, P849, DOI 10.1042/0264-6021:3460849; Jackson RJ, 2005, BIOCHEM SOC T, V33, P1231, DOI 10.1042/BST0331231; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Kim YK, 2002, BIOCHEM BIOPH RES CO, V297, P224, DOI 10.1016/S0006-291X(02)02154-X; Koh DCY, 2003, J BIOL CHEM, V278, P20565, DOI 10.1074/jbc.M210212200; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Lie YS, 1999, DEVELOPMENT, V126, P4989; Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d; LOO D, 1994, CELL BIOL LAB HDB, P45; Lopez-Lastra M, 2005, BIOL RES, V38, P121, DOI 10.4067/S0716-97602005000200003; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MACEJAK DG, 1990, ENZYME, V44, P310, DOI 10.1159/000468767; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Miyazaki E, 2002, GUT, V50, P413, DOI 10.1136/gut.50.3.413; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Oltean S, 2005, J BIOL CHEM, V280, P32662, DOI 10.1074/jbc.M501964200; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Seydoux G, 1996, CURR OPIN GENET DEV, V6, P555, DOI 10.1016/S0959-437X(96)80083-9; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Simandan T, 1998, BIOCHEM J, V335, P233, DOI 10.1042/bj3350233; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2005, J BIOL CHEM, V280, P20549, DOI 10.1074/jbc.M409563200; Westerman DA, 1999, BRIT J HAEMATOL, V107, P512; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Xing J, 2004, J MOL BIOL, V344, P675, DOI 10.1016/j.jmb.2004.09.058; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; ZHU LJ, 1995, ENDOCRINOLOGY, V136, P4106, DOI 10.1210/en.136.9.4106	55	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29927	29935		10.1074/jbc.M706264200	http://dx.doi.org/10.1074/jbc.M706264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702748	hybrid			2022-12-27	WOS:000249981200022
J	Bolger, TA; Zhao, X; Cohen, TJ; Tsai, CC; Yao, TP				Bolger, Timothy A.; Zhao, Xuan; Cohen, Todd J.; Tsai, Chih-Cheng; Yao, Tso-Pang			The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYGLUTAMINE-INDUCED DISEASE; CREB-BINDING PROTEIN; AXH DOMAIN; MEF2; IDENTIFICATION; NEUROTOXICITY; AGGREGATION; INHIBITION; REPRESSES; INTERACTS	Ataxin-1 is a neurodegenerative disorder protein whose mutant form causes spinocerebellar ataxia type-1 (SCA1). Evidence suggests that ataxin-1 may function as a transcription repressor. However, neither the importance of this putative transcriptional repression activity in neural cytotoxicity nor the transcriptional targets of ataxin-1 are known. Here we identify the MEF2-HDAC4 transcriptional complex involved in neuron survival as a target of ataxin-1. We show that ataxin-1 binds specifically to histone deacetylase-4 (HDAC4) and MEF2 and colocalizes with them in nuclear inclusion bodies. Significantly, these interactions are greatly reduced by the S776A mutation, which largely abrogates the cytotoxicity of ataxin-1. Supporting the importance of these interactions, we show that wild type ataxin-1 represses MEF2- dependent transcription, whereas the S776A mutant is less potent. Furthermore, overexpression of MEF2 can partially reverse cytotoxicity caused by ataxin-1. Our results identify the MEF2-HDAC4 complex as a target for ataxin-1 transcriptional repression activity and suggest a novel pathogenic mechanism whereby ataxin-1 sequesters and inhibits the neuronal survival factor MEF2.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Duke University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Yao, TP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	yao00001@mc.duke.edu						BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Liu N, 2006, CELL, V127, P1299, DOI 10.1016/j.cell.2006.12.012; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Orr HT, 2001, HUM MOL GENET, V10, P2307, DOI 10.1093/hmg/10.20.2307; Paulson H, 2003, NAT MED, V9, P825, DOI 10.1038/nm0703-825; Qi YP, 1997, J NEUROSCI, V17, P1217; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; STEFFAN JS, 2001, P NATL ACAD SCI USA, V413, P739; Takahashi-Fujigasaki J, 2006, NEUROPATH APPL NEURO, V32, P92, DOI 10.1111/j.1365-2990.2005.00705.x; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	31	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29186	29192		10.1074/jbc.M704182200	http://dx.doi.org/10.1074/jbc.M704182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17646162	hybrid			2022-12-27	WOS:000249788000014
J	Janssen, BJC; Halff, EF; Lambris, JD; Gros, P				Janssen, Bert J. C.; Halff, Els F.; Lambris, John D.; Gros, Piet			Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE INHIBITOR; ACTIVATION; INSIGHTS; ANALOGS; BINDING; DESIGN; FRAGMENT; SYSTEM	Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and the exact mode of action of compstatin are unknown. Here we present the crystal structure of compstatin in complex with C3c, a major proteolytic fragment of C3. The structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5. This binding site is part of the structurally stable MG-ring formed by domains MG1-6 and is far away from any other known binding site on C3. Compstatin does not alter the conformation of C3c, whereas compstatin itself undergoes a large conformational change upon binding. We propose a model in which compstatin sterically hinders the access of the substrate C3 to the convertase complexes, thus blocking complement activation and amplification. These insights are instrumental for further development of compstatin as a potential therapeutic.	Univ Utrecht, Fac Sci, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Utrecht University; University of Pennsylvania	Gros, P (corresponding author), Univ Utrecht, Fac Sci, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands.	p.gros@chem.uu.nl	Janssen, Bert/I-3338-2016; Gros, Piet/I-5569-2016; Gros, Piet/AAD-6452-2019; Lambris, John/Q-5633-2018; Halff, Els F/M-9110-2015	Janssen, Bert/0000-0002-8101-8370; Gros, Piet/0000-0002-7782-2585; Gros, Piet/0000-0002-7782-2585; Lambris, John/0000-0002-9370-5776; Halff, Els F/0000-0001-5814-0899	NIAID NIH HHS [AI30040] Funding Source: Medline; NIGMS NIH HHS [GM069736, GM62134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM069736, R01GM062134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; Bureeva S, 2005, DRUG DISCOV TODAY, V10, P1535, DOI 10.1016/S1359-6446(05)03592-0; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiane AE, 1999, XENOTRANSPLANTATION, V6, P52, DOI 10.1034/j.1399-3089.1999.00007.x; Fredslund F, 2006, J MOL BIOL, V361, P115, DOI 10.1016/j.jmb.2006.06.009; Furlong ST, 2000, IMMUNOPHARMACOLOGY, V48, P199, DOI 10.1016/S0162-3109(00)00205-8; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164; Janssen BJC, 2007, MOL IMMUNOL, V44, P3, DOI 10.1016/j.molimm.2006.06.017; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Katragadda M, 2004, J BIOL CHEM, V279, P54987, DOI 10.1074/jbc.M409963200; Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028; Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200; Nilsson B, 1998, BLOOD, V92, P1661, DOI 10.1182/blood.V92.5.1661; Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104; Ponnuraj K, 2004, MOL CELL, V14, P17, DOI 10.1016/S1097-2765(04)00160-1; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 2003, MOL IMMUNOL, V39, P557, DOI 10.1016/S0161-5890(02)00212-2; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; Soulika AM, 2000, CLIN IMMUNOL, V96, P212, DOI 10.1006/clim.2000.4903; Soulika AM, 2003, J IMMUNOL, V171, P1881, DOI 10.4049/jimmunol.171.4.1881; Soulika AM, 2006, MOL IMMUNOL, V43, P2023, DOI 10.1016/j.molimm.2005.12.002; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263	33	99	110	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29241	29247		10.1074/jbc.M704587200	http://dx.doi.org/10.1074/jbc.M704587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684013	hybrid, Green Published			2022-12-27	WOS:000249788000020
J	Thompson, D; Pusch, M; Whistler, JL				Thompson, Dawn; Pusch, Margareta; Whistler, Jennifer L.			Changes in G protein-coupled receptor sorting protein affinity regulate postendocytic targeting of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; ENDOCYTIC RECYCLING SIGNAL; BETA-2-ADRENERGIC RECEPTOR; MEMBRANE TRAFFICKING; INTERNALIZATION; RESENSITIZATION; DESENSITIZATION; IDENTIFICATION; ENDOSOMES; TOLERANCE	After activation, most G protein-coupled receptors (GPCRs) are regulated by a cascade of events involving desensitization and endocytosis. Internalized receptors can then be recycled to the plasma membrane, retained in an endosomal compartment, or targeted for degradation. The GPCR-associated sorting protein, GASP, has been shown to preferentially sort a number of native GPCRs to the lysosome for degradation after endocytosis. Here we show that a mutant beta(2) adrenergic receptor and a mutant mu opioid receptor that have previously been described as lacking "recycling signals" due to mutations in their C termini in fact bind to GASP and are targeted for degradation. We also show that a mutant dopamine D1 receptor, which has likewise been described as lacking a recycling signal, does not bind to GASP and is therefore not targeted for degradation. Together, these results indicate that alteration of receptors in their C termini can expose determinants with affinity for GASP binding and consequently target receptors for degradation.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Oakland, CA 94608 USA.	Jennifer.whistler@ucsf.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH068442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015232] Funding Source: NIH RePORTER; NIDA NIH HHS [DA015232] Funding Source: Medline; NIMH NIH HHS [MH068442] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bartlett SE, 2005, P NATL ACAD SCI USA, V102, P11521, DOI 10.1073/pnas.0502418102; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Chen LW, 2003, LIFE SCI, V73, P115, DOI 10.1016/S0024-3205(03)00250-9; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Enquist J, 2007, MOL PHARMACOL, V71, P494, DOI 10.1124/mol.106.030858; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Martini L, 2007, FASEB J, V21, P802, DOI 10.1096/fj.06-7132com; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Szeto HH, 2001, ANESTH ANALG, V93, P581, DOI 10.1097/00000539-200109000-00010; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tappe-Theodor A, 2007, J NEUROSCI, V27, P4165, DOI 10.1523/JNEUROSCI.5648-06.2007; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VON ZM, 1992, J BIOL CHEM, V267, P3530; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308	26	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29178	29185		10.1074/jbc.M704014200	http://dx.doi.org/10.1074/jbc.M704014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17635908	hybrid			2022-12-27	WOS:000249788000013
J	Grigg, JC; Vermeiren, CL; Heinrichs, DE; Murphy, MEP				Grigg, Jason C.; Vermeiren, Christie L.; Heinrichs, David E.; Murphy, Michael E. P.			Heme coordination by Staphylococcus aureus IsdE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEIN; OUTER-MEMBRANE PROTEIN; HEMOGLOBIN RECEPTOR; CONFORMATIONAL-CHANGE; DEGRADING ENZYMES; CRYSTAL-STRUCTURE; BINDING-PROTEIN; IRON; IDENTIFICATION; TRANSPORT	Staphylococcus aureus is a Gram-positive bacterial pathogen and a leading cause of hospital acquired infections. Because the free iron concentration in the human body is too low to support growth, S. aureus must acquire iron from host sources. Heme iron is the most prevalent iron reservoir in the human body and a predominant source of iron for S. aureus. The iron-regulated surface determinant (Isd) system removes heme from host heme proteins and transfers it to IsdE, the cognate substrate-binding lipoprotein of an ATP-binding cassette transporter, for import and subsequent degradation. Herein, we report the crystal structure of the soluble portion of the IsdE lipoprotein in complex with heme. The structure reveals a bi-lobed topology formed by an N- and C-terminal domain bridged by a single alpha-helix. The structure places IsdE as a member of the helical backbone metal receptor superfamily. A six-coordinate heme molecule is bound in the groove established at the domain interface, and the heme iron is coordinated in a novel fashion for heme transporters by Met(78) and His(229). Both heme propionate groups are secured by H-bonds to IsdE main chain and side chain groups. Of these residues, His(229) is essential for IsdE-mediated heme uptake by S. aureus when growth on heme as a sole iron source is measured. Multiple sequence alignments of homologues from several other Gram-positive bacteria, including the human pathogens pyogenes, Bacillus anthracis, and Listeria monocytogenes, suggest that these other systems function equivalently to S. aureus IsdE with respect to heme binding and transport.	Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	University of British Columbia; Western University (University of Western Ontario)	Murphy, MEP (corresponding author), Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada.	Michael.Murphy@ubc.ca	Heinrichs, David/ABD-5702-2021; Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014; Heinrichs, David/0000-0002-7217-2456				Ahn SH, 2005, INFECT IMMUN, V73, P722, DOI 10.1128/IAI.73.2.722-729.2005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andrade MA, 2002, GENOME BIOL, V3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; Bertini I, 2006, CHEM REV, V106, P90, DOI 10.1021/cr050241v; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Chan ACK, 2006, J MOL BIOL, V362, P1108, DOI 10.1016/j.jmb.2006.08.001; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Deresinski S, 2005, CLIN INFECT DIS, V40, P562, DOI 10.1086/427701; Deurenberg RH, 2007, CLIN MICROBIOL INFEC, V13, P222, DOI 10.1111/j.1469-0691.2006.01573.x; Dryla A, 2003, MOL MICROBIOL, V49, P37, DOI 10.1046/j.1365-2958.2003.03542.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Muller A, 2006, ANGEW CHEM INT EDIT, V45, P5132, DOI 10.1002/anie.200601198; Murphy ER, 2002, INFECT IMMUN, V70, P5390, DOI 10.1128/IAI.70.10.5390-5403.2002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Pilpa RM, 2006, J MOL BIOL, V360, P435, DOI 10.1016/j.jmb.2006.05.019; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Radtke AL, 2006, CELL MICROBIOL, V8, P1720, DOI 10.1111/j.1462-5822.2006.00795.x; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Schneider S, 2006, J BIOL CHEM, V281, P32606, DOI 10.1074/jbc.M607516200; Sebulsky MT, 2004, J BIOL CHEM, V279, P53152, DOI 10.1074/jbc.M409793200; Sebulsky MT, 2003, J BIOL CHEM, V278, P49890, DOI 10.1074/jbc.M305073200; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Speziali CD, 2006, J BACTERIOL, V188, P2048, DOI 10.1128/JB.188.6.2048-2055.2006; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Tenover FC, 2004, EMERG INFECT DIS, V10, P2052, DOI 10.3201/eid1011.040797_10; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Weems JJ, 2001, POSTGRAD MED, V110, P24, DOI 10.3810/pgm.2001.10.1042; Wu RY, 2005, J BIOL CHEM, V280, P2840, DOI 10.1074/jbc.M409526200	60	79	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28815	28822		10.1074/jbc.M704602200	http://dx.doi.org/10.1074/jbc.M704602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666394	hybrid			2022-12-27	WOS:000249642100056
J	Kawamata, Y; Imamura, T; Babendure, JL; Lu, JC; Yoshizaki, T; Olefsky, JM				Kawamata, Yuji; Imamura, Takeshi; Babendure, Jennie L.; Lu, Juu-Chin; Yoshizaki, Takeshi; Olefsky, Jerrold M.			Tumor necrosis factor receptor-1 can function through a G alpha(q/11)-beta-arrestin-1 signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTORS; PROTEIN-COUPLED RECEPTOR; 3RD INTRACELLULAR LOOP; NF-KAPPA-B; 3T3-L1 ADIPOCYTES; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; TNF-ALPHA; HETEROLOGOUS DESENSITIZATION; PHOSPHOLIPASE-C	Tumor necrosis factor-alpha ( TNF alpha) is a proinflammatory cytokine secreted from macrophages and adipocytes. It is well known that chronic TNF alpha exposure can lead to insulin resistance both in vitro and in vivo and that elevated blood levels of TNF alpha are observed in obese and/or diabetic individuals. TNF alpha has many acute biologic effects, mediated by a complex intracellular signaling pathway. In these studies we have identified new G-protein signaling components to this pathway in 3T3-L1 adipocytes. We found that beta-arrestin-1 is associated with TRAF2 ( TNFreceptor-associated factor 2), an adaptor protein of TNF receptors, and that TNF alpha acutely stimulates tyrosine phosphorylation of G alpha(q/11) with an increase in G alpha(q/11) activity. Small interfering RNA-mediated knockdown of beta-arrestin-1 inhibits TNF alpha-induced tyrosine phosphorylation of G alpha(q/11) by interruption of Src kinase activation. TNF alpha stimulates lipolysis in 3T3-L1 adipocytes, and beta-arrestin-1 knockdown blocks the effects of TNF alpha to stimulate ERK activation and glycerol release. TNF alpha also led to activation of JNK with increased expression of the proinflammatory gene, monocyte chemoattractant protein-1 and matrix metalloproteinase 3, and beta-arrestin-1 knockdown inhibited both of these effects. Taken together these results reveal novel elements of TNF alpha action; 1) the trimeric G-protein component G alpha(q/11) and the adapter protein beta-arrestin-1 can function as signaling molecules in the TNF alpha action cascade; 2) beta-arrestin-1 can couple TNF alpha stimulation to ERK activation and lipolysis; 3) beta-arrestin-1 and G alpha(q/11) can mediate TNF alpha-induced phosphatidylinositol 3-kinase activation and inflammatory gene expression.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Lu, Juu-Chin/ABB-3198-2020	Lu, Juu-Chin/0000-0001-8523-6992; Kawamata, Yuji/0000-0001-5652-4899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; Doan JES, 2004, J IMMUNOL, V172, P7654, DOI 10.4049/jimmunol.172.12.7654; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hupfeld CJ, 2003, P NATL ACAD SCI USA, V100, P161, DOI 10.1073/pnas.0235674100; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Laurencikiene J, 2007, J LIPID RES, V48, P1069, DOI 10.1194/jlr.M600471-JLR200; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liao W, 2006, ENDOCRINOLOGY, V147, P2245, DOI 10.1210/en.2005-1638; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Puls A, 1999, J CELL SCI, V112, P2983; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Usui I, 2005, MOL ENDOCRINOL, V19, P2760, DOI 10.1210/me.2004-0429; Usui I, 2004, EMBO J, V23, P2821, DOI 10.1038/sj.emboj.7600297; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Wang HL, 1997, J NEUROCHEM, V68, P1728; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	44	26	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28549	28556		10.1074/jbc.M705869200	http://dx.doi.org/10.1074/jbc.M705869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664271	hybrid			2022-12-27	WOS:000249642100029
J	Neumann, M; Stocklein, W; Leimkuhler, S				Neumann, Meina; Stoecklein, Walter; Leimkuehler, Silke			Transfer of the molybdenum cofactor synthesized by Rhodobacter capsulatus MoeA to XdhC and MobA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; TRIMETHYLAMINE-N-OXIDE; ESCHERICHIA-COLI; XANTHINE DEHYDROGENASE; DIMETHYLSULFOXIDE REDUCTASE; RHODOPSEUDOMONAS-CAPSULATA; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; GENE-PRODUCTS; BIOSYNTHESIS	The molybdenum cofactor (Moco) exists in different variants in the cell and can be directly inserted into molybdoenzymes utilizing the molybdopterin (MPT) form of Moco. In bacteria such as Rhodobacter capsulatus and Escherichia coli, MPT is further modified by attachment of a GMP nucleotide, forming MPT guanine dinucleotide (MGD). In this work, we analyzed the distribution and targeting of different forms of Moco to their respective user enzymes by proteins that bind Moco and are involved in its further modification. The R. capsulatus proteins MogA, MoeA, MobA, and XdhC were purified, and their specific interactions were analyzed. Interactions between the protein pairs MogA-MoeA, MoeA-XdhC, MoeA-MobA, and XdhC-MobA were identified by surface plasmon resonance measurements. In addition, the transfer of Moco produced by the MogA-MoeA complex to XdhC was investigated. A direct competition of MobA and XdhC for Moco binding was determined. In vitro analyses showed that XdhC bound to MobA, prevented the binding of Moco to MobA, and thereby inhibited MGD biosynthesis. The data were confirmed by in vivo studies in R. capsulatus cells showing that overproduction of XdhC resulted in a 50% decrease in the activity of bis-MGD-containing Me2SO reductase. We propose that, in bacteria, the distribution of Moco in the cell and targeting to the respective user enzymes are accomplished by specific proteins involved in Moco binding and modification.	Univ Potsdam, Inst Biochem & Biol, Dept Prot Analyt, D-14476 Potsdam, Germany; Univ Potsdam, Inst Biochem & Biol, Dept Analyt Biochem, D-14476 Potsdam, Germany	University of Potsdam; University of Potsdam	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, Dept Prot Analyt, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de	Neumann-Schaal, Meina/AAM-6389-2021	Leimkuhler, Silke/0000-0003-3238-2122				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Genes O, 2005, J BIOL CHEM, V280, P15644, DOI 10.1074/jbc.M501119200; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOSHI MS, 1994, ARCH BIOCHEM BIOPHYS, V308, P331, DOI 10.1006/abbi.1994.1047; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KLIPP W, 1988, J BACTERIOL, V170, P693, DOI 10.1128/jb.170.2.693-699.1988; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Leimkuhler S, 1999, J BACTERIOL, V181, P5930; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Leimkuhler S, 1999, FEMS MICROBIOL LETT, V174, P239, DOI 10.1016/S0378-1097(99)00147-0; Llamas A, 2004, J BIOL CHEM, V279, P55241, DOI 10.1074/jbc.M409862200; Llamas A, 2006, J BIOL CHEM, V281, P18343, DOI 10.1074/jbc.M601415200; Loschi L, 2004, J BIOL CHEM, V279, P50391, DOI 10.1074/jbc.M408876200; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; MCEWAN AG, 1985, BIOCHIM BIOPHYS ACTA, V806, P410, DOI 10.1016/0005-2728(85)90248-8; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MCEWAN AG, 1983, ARCH MICROBIOL, V136, P300, DOI 10.1007/BF00425221; McLuskey K, 2003, J BIOL CHEM, V278, P23706, DOI 10.1074/jbc.M301485200; MILLER JB, 1987, J BACTERIOL, V169, P1853, DOI 10.1128/jb.169.5.1853-1860.1987; Neumann M, 2007, BIOCHEMISTRY-US, V46, P9586, DOI 10.1021/bi700630p; Neumann M, 2006, J BIOL CHEM, V281, P15701, DOI 10.1074/jbc.M601617200; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Nichols JD, 2005, J BIOL CHEM, V280, P7817, DOI 10.1074/jbc.M413783200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; POLLOCK D, 1988, GENE, V65, P269, DOI 10.1016/0378-1119(88)90463-5; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Vergnes A, 2006, J BIOL CHEM, V281, P2170, DOI 10.1074/jbc.M505902200; WANG G, 1993, J BACTERIOL, V175, P3031, DOI 10.1128/JB.175.10.3031-3042.1993; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	42	33	34	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28493	28500		10.1074/jbc.M704020200	http://dx.doi.org/10.1074/jbc.M704020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686778	hybrid			2022-12-27	WOS:000249642100023
J	Wei, J; Fujita, M; Nakai, M; Waragai, M; Watabe, K; Akatsu, H; Rockenstein, E; Masliah, E; Hashimoto, M				Wei, Jianshe; Fujita, Masayo; Nakai, Masaaki; Waragai, Masaaki; Watabe, Kazuhiko; Akatsu, Hiroyasu; Rockenstein, Edward; Masliah, Eliezer; Hashimoto, Makoto			Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; GAMMA-SYNUCLEIN; BODY DEMENTIA; NEURODEGENERATIVE DISORDERS; PROTEIN AGGREGATION; TERMINAL HYDROLASE; NEURONAL CELLS; MUTATION	Two missense mutations (P123H and V70M) of beta-synuclein (beta-syn), the homologue of alpha-syn, have been recently identified in dementia with Lewy bodies. However, the mechanism through which these mutations influence the pathogenesis of dementia with Lewy bodies is unclear. To investigate the role of the beta-syn mutations in neurodegeneration, each mutant was stably transfected into B103 neuroblastoma cells. Cells overexpressing mutated beta-syn had eosinophilic cytoplasmic inclusion bodies immunopositive for mutant beta-syn, and electron microscopy revealed that these cells were abundant in various cytoplasmic membranous inclusions resembling the histopathology of lysosomal storage disease. Consistent with these findings, the inclusion bodies were immunopositive for lysosomal markers, including cathepsin B, LAMP-2, GM2 ganglioside, and ATP13A2, which has recently been linked to PARK9. Notably, formation of these lysosomal inclusions was greatly stimulated by co-expression of alpha-syn, was dependent on the phosphorylation of beta-syn at Ser-129, and was more efficient with the A53T familial mutant of alpha-syn compared with wild type. Furthermore, the inclusion formation in cells overexpressing mutant beta-syn and transfected with alpha-syn was significantly suppressed by treatment with autophagy-lysosomal inhibitors, which were associated with impaired clearance of syn proteins and enhanced apoptosis, indicating that formation of lysosomal inclusions might be protective. Collectively, the results demonstrated unambiguously that overexpression of beta-syn mutants ( P123H and V70M) in neuroblastoma cells results in an enhanced lysosomal pathology. We suggest that these missense mutations of beta-syn might play a causative role in stimulating neurodegeneration.	Tokyo Metropolitan Inst Neurosci, Lab Chem & Metab, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Lab Mol Neuropathol, Tokyo 1838526, Japan; Fukushimura Hosp, Choju Med Inst, Aichi 4418124, Japan; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; University of California System; University of California San Diego	Hashimoto, M (corresponding author), Tokyo Metropolitan Inst Neurosci, Lab Chem & Metab, 2-6 Musashidai, Tokyo 1838526, Japan.	mhashimoto@tmin.ac.jp		Watabe, Kazuhiko/0000-0002-0245-3834				Baba M, 1998, AM J PATHOL, V152, P879; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; Di Fonzo A, 2007, NEUROLOGY, V68, P1557, DOI 10.1212/01.wnl.0000260963.08711.08; Dufty BM, 2007, AM J PATHOL, V170, P1725, DOI 10.2353/ajpath.2007.061232; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Eyal A, 2006, P NATL ACAD SCI USA, V103, P5917, DOI 10.1073/pnas.0509707103; Fan Y, 2006, HUM MOL GENET, V15, P3002, DOI 10.1093/hmg/ddl242; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fujita M, 2007, J BIOL CHEM, V282, P5736, DOI 10.1074/jbc.M606175200; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, P3827; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Hashimoto M, 2004, J BIOL CHEM, V279, P23622, DOI 10.1074/jbc.M313784200; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V237, P611, DOI 10.1006/bbrc.1997.6978; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Iwata A, 2003, HUM MOL GENET, V12, P2625, DOI 10.1093/hmg/ddg283; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Ohtake H, 2004, NEUROLOGY, V63, P805, DOI 10.1212/01.WNL.0000139870.14385.3C; OZAWA H, 1992, ARCH BIOCHEM BIOPHYS, V294, P427, DOI 10.1016/0003-9861(92)90707-4; Park JY, 2003, BIOCHEMISTRY-US, V42, P3696, DOI 10.1021/bi020604a; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAUCHI S, 1989, ACTA NEUROPATHOL, V78, P380, DOI 10.1007/BF00688174; Takeda A, 1998, AM J PATHOL, V152, P367; Takenouchi T, 2001, MOL CELL NEUROSCI, V17, P141, DOI 10.1006/mcne.2000.0923; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wang YL, 2004, BRAIN RES, V1019, P1, DOI 10.1016/j.brainres.2004.05.023; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wilson CA, 2004, J CELL BIOL, V165, P335, DOI 10.1083/jcb.200403061; Yamin G, 2005, BIOCHEMISTRY-US, V44, P9096, DOI 10.1021/bi048778a; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	47	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28904	28914		10.1074/jbc.M703711200	http://dx.doi.org/10.1074/jbc.M703711200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652097	hybrid			2022-12-27	WOS:000249642100065
J	Goo, SY; Han, YS; Kim, WH; Lee, KH; Park, SJ				Goo, Sung Young; Han, Yang Soo; Kim, Woo Hyang; Lee, Kyu-Ho; Park, Soon-Jung			Vibrio vulnificus IlpA-induced cytokine production is mediated by toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; BORRELIA-BURGDORFERI LIPOPROTEINS; CUTTING EDGE; EPITHELIAL-CELLS; BACTERIAL LIPOPROTEINS; MEMBRANE PROTEINS; ACTIVATION; LIPOPOLYSACCHARIDE; PATHOGENESIS; CLONING	Vibrio vulnificus is a pathogenic bacterium causing primary septicemia, which follows a classical septic shock pathway, including an overwhelming inflammatory cytokine response. In this study, we identified a putative lipoprotein of V. vulnifilcus, encoded by the i1pA gene, as one of the surface proteins that specifically reacted with the antibodies raised against outer membrane proteins of V. vulnificus. Using a mutant V. vulnificus in which its ilpA gene was knocked out, we found that ilpA is important in the production of interferon-gamma in human peripheral blood mononuclear cells. Production of tumor necrosis factor-a and interleukin-6 is also induced by the recombinant IlpA (rIlpA) in human monocytes. Lipidation of the rIlpA was observed by in vivo labeling in Escherichia coli. Experiments using the mutant IIpA, which is unable to be modified by lipidation, indicate that the lipid moiety of this protein has an essential property for cytokine production in human cells. Pretreatment of monocytes with antibodies against Toll-like receptor 2 (TLR2) inhibited production of both tumor necrosis factor-a and interleukin-6. The role of TLR2 in lIpA,-induced cytokine production was confirmed by an in vitro assay, in which only the TLR2-expressing cells showed a dramatic induction of nuclear factor-kappa B activity by rIlpA. In addition, rIlpA treatment resulted in induction of TLR2 transcription in human cell,;. In comparison with the wild type V vulnificus, the ilpA mutant showed a reduced mortality in mice. These results demonstrate that lIpA of V vulnificus functions as an immunostimulant to human cells via TLR2.	Yonsei Univ, Coll Med, Dept Environm Med Biol, Inst Trop Med,Brain Korea 21 Project, Seoul 120752, South Korea; Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, South Korea	Yonsei University; Yonsei University Health System; Hankuk University Foreign Studies	Park, SJ (corresponding author), Yonsei Univ, Coll Med, Dept Environm Med Biol, Inst Trop Med,Brain Korea 21 Project, Seoul 120752, South Korea.	sjpark615@yuhs.ac.kr		Park, Soon-Jung/0000-0002-0423-1944				AISEN P, 1972, BIOCHEMISTRY-US, V11, P3461, DOI 10.1021/bi00768a021; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BAHRANI K, 1990, BIOCHEM CELL BIOL, V68, P547, DOI 10.1139/o90-078; BLAKEWAY JM, 1979, INT J COSMETIC SCI, V1, P1, DOI 10.1111/j.1467-2494.1979.tb00197.x; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chambaud I, 1999, TRENDS MICROBIOL, V7, P493, DOI 10.1016/S0966-842X(99)01641-8; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; ERIK SC, 2006, J INFECT DIS, V193, P849; Fan JJ, 2001, INFECT IMMUN, V69, P5943, DOI 10.1128/IAI.69.9.5943-5948.2001; Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001; Fisette PL, 2003, J BIOL CHEM, V278, P46252, DOI 10.1074/jbc.M306587200; Gehring AJ, 2004, J IMMUNOL, V173, P2660, DOI 10.4049/jimmunol.173.4.2660; Goo SY, 2006, INFECT IMMUN, V74, P5586, DOI 10.1128/IAI.00171-06; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; Harvey HA, 2002, INFECT IMMUN, V70, P5808, DOI 10.1128/IAI.70.10.5808-5815.2002; Hellman J, 2002, J BIOL CHEM, V277, P14274, DOI 10.1074/jbc.M109696200; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; HOGAN MM, 1988, J IMMUNOL, V141, P4196; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jan G, 1996, CURR MICROBIOL, V32, P38, DOI 10.1007/s002849900007; JOANNE LF, 1995, J IMMUNOL, V155, P2515; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim YR, 2003, BIOCHEM BIOPH RES CO, V304, P405, DOI 10.1016/S0006-291X(03)00613-2; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; Lee JH, 2004, INFECT IMMUN, V72, P4905, DOI 10.1128/IAI.72.8.4905-4910.2004; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; MCPHERSON VL, 1991, MICROBIOS, V67, P141; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MILTON DL, 1992, J BACTERIOL, V174, P7235, DOI 10.1128/jb.174.22.7235-7244.1992; Muhlradt PF, 1998, INFECT IMMUN, V66, P4804; Paranjpye RN, 2005, INFECT IMMUN, V73, P1411, DOI 10.1128/IAI.73.3.1411-1422.2005; Paranjpye RN, 1998, INFECT IMMUN, V66, P5659, DOI 10.1128/IAI.66.12.5659-5668.1998; Pecora ND, 2006, J IMMUNOL, V177, P422, DOI 10.4049/jimmunol.177.1.422; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rangel-Frausto MS, 2005, ARCH MED RES, V36, P672, DOI 10.1016/j.arcmed.2005.06.006; REED L. J., 1938, AMER JOUR HYG, V27, P493; SALGADO A, 1994, HAEMOSTASIS, V24, P132; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimizu T, 2005, J IMMUNOL, V175, P4641, DOI 10.4049/jimmunol.175.7.4641; Shin SH, 2002, FEMS IMMUNOL MED MIC, V33, P133, DOI 10.1111/j.1574-695X.2002.tb00582.x; Soler-Rodriguez AM, 2000, J IMMUNOL, V164, P2674, DOI 10.4049/jimmunol.164.5.2674; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STORM MS, 2000, MICROB INFECT, V2, P177; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; THEISEN M, 1992, INFECT IMMUN, V60, P826, DOI 10.1128/IAI.60.3.826-831.1992; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; WEIMAR W, 1985, ANTIVIR RES, V5, P49, DOI 10.1016/0166-3542(85)90014-2; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; WRIGHT AC, 1986, FEMS MICROBIOL LETT, V35, P255, DOI 10.1111/j.1574-6968.1986.tb01538.x; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zuppardo AB, 1998, INFECT IMMUN, V66, P2601, DOI 10.1128/IAI.66.6.2601-2606.1998	61	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27647	27658		10.1074/jbc.M701876200	http://dx.doi.org/10.1074/jbc.M701876200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640874	hybrid			2022-12-27	WOS:000249455600012
J	Kale, S; Arjunan, P; Furey, W; Jordan, F				Kale, Sachin; Arjunan, Palaniappa; Furey, William; Jordan, Frank			A dynamic loop at the active center of the Escherichio coli pyruvate dehydrogenase complex E1 component modulates substrate utilization and chemical communication with the E2 component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIAMIN DIPHOSPHATE; REDUCTIVE ACETYLATION; MULTIENZYME COMPLEX; NUCLEOTIDE-SEQUENCE; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; 1',4'-IMINOPYRIMIDINE TAUTOMER; YEAST TRANSKETOLASE; LIPOYL DOMAINS; SUBUNIT; ESCHERICHIA-COLI-K12	Our crystallographic studies have shown that two active center loops (an inner loop formed by residues 401-413 and outer loop formed by residues 541-557) of the El component of the Escherichia coli pyruvate dehydrogenase complex become organized only on binding a substrate analog that is capable of forming a stable thiamin diphosphate-bound covalent intermediate. We showed that residue His-407 on the inner loop has a key role in the mechanism, especially in the reductive acetylation of the E. coli dihydrolipoamide transacetylase component, whereas crystallographic results showed a role of this residue in a disorder-order transformation of these two loops, and the ordered conformation gives rise to numerous new contacts between the inner loop and the active center. We present mapping of the conserved residues on the inner loop. Kinetic, spectroscopic, and crystallographic studies on some inner loop variants led us to conclude that charged residues flanking His-407 are important for stabilization/ordering of the inner loop thereby facilitating completion of the active site. The results further suggest that a disorder to order transition of the dynamic inner loop is essential for substrate entry to the active site, for sequestering active site chemistry from undesirable side reactions, as well as for communication between the El and E2 components of the E. coli pyruvate dehydrogenase multienzyme complex.	Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jordan, F (corresponding author), Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA.	frjordan@newark.rutgers.edu			NCRR NIH HHS [S10RR020932] Funding Source: Medline; NIGMS NIH HHS [GM 50380, GM61791] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR020932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 2006, J BIOL CHEM, V281, P15296, DOI 10.1074/jbc.M600656200; Baykal A, 2006, BIOORG CHEM, V34, P380, DOI 10.1016/j.bioorg.2006.09.006; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DeLano W.L, PYMOL MOL GRAPHICS S; Fiedler E, 2001, J BIOL CHEM, V276, P16051, DOI 10.1074/jbc.M007936200; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GUNSALUS IC, 1954, MECHANISM ENZYME ACT, P545; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; KALE S, 2007, THESIS RUTGERS U NEW; Kitagawa M, 2005, DNA RES, V12, P291, DOI 10.1093/dnares/dsi012; KOIKE M, 1960, J BIOL CHEM, V235, P1924; KRISHNAMOORTHY C, 2006, ACTA CRYSTALLOGR D, V62, P1382; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Massy V, 1963, ENZYMES, V7, P275; Nemeria N, 2005, J BIOL CHEM, V280, P21473, DOI 10.1074/jbc.M502691200; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Nemeria N, 2007, P NATL ACAD SCI USA, V104, P78, DOI 10.1073/pnas.0609973104; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YH, 2004, BIOCHEMISTRY-US, V43, P14037, DOI 10.1021/bi049027b; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; Wei W, 2003, PROTEIN EXPRES PURIF, V28, P140, DOI 10.1016/S1046-5928(02)00674-5; Wikner C, 1997, BIOCHEMISTRY-US, V36, P15643, DOI 10.1021/bi971606b; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	36	32	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28106	28116		10.1074/jbc.M704326200	http://dx.doi.org/10.1074/jbc.M704326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635929	hybrid			2022-12-27	WOS:000249455600060
J	Sato, T; Furukawa, K				Sato, Takeshi; Furukawa, Kiyoshi			Sequential action of Ets-1 and Sp1 in the activation of the human beta-1,4-galactosyltransferase v gene involved in abnormal glycosylation characteristic of cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; TRANSCRIPTION FACTOR SP1; HAMSTER-KIDNEY CELLS; LINKED OLIGOSACCHARIDES; GALACTOSYLTRANSFERASE GENE; HEPATOCELLULAR-CARCINOMA; COOPERATIVE INTERACTIONS; GROWTH-FACTOR; T-CELLS; EXPRESSION	\Malignant transformation is associated with increased gene expression of beta-1,4-galactosyltransferase (beta-1,4-GaIT) V, which contributes to the biosynthesis of highly branched N-linked oligosaccharides characteristic of cancer cells. Our previous study showed that expression of the human beta-1,4-GaIT V gene is regulated by Spl (Sato, T., and Furukawa, K. (2004) J. BioL Chem. 279, 39574-39583), and a subsequent study showed that the gene expression is also activated by Ets-1, a product of the oncogene (Sato, T., and Furukawa, K. (2005) Glycoconj. J. 22, 365). Herein we report the mechanism of beta-1,4-GaIT V gene activation by these transcription factors. The gene expression and promoter activity of beta-1,4-GaIT V increased when the ets-1 cDNA was transfected into A549 cells, which contain a small amount of Ets-1, but decreased dramatically when the dominant-negative ets-1 cDNA was transfected into HepG2 cells, which contain a large amount of Ets-1. Luciferase assays using deletion constructs of the beta-1,4-GaIT V gene promoter showed that promoter region - 116 to + 22 is critical for the transcriptional activation of the gene by Ets-1. Despite the presence of one Ets-1-binding site, which overlapped the Sp1-binding site, electrophoretic mobility shift assays showed that the region bound preferentially to Spl rather than to Ets-1. To solve this problem, we examined the transcriptional regulation of the human Spl gene by Ets-1 and found that the gene expression and promoter activity of Sp1 are regulated by Ets-1 in cancer cells. Functional analyses of two Ets-1-binding sites in the Sp1 gene promoter showed that only Ets-1-binding site -413 to -404 is involved in the activation of the gene by Ets-1. These results indicate that Ets-1 enhances expression of the beta-1,4-GaIT V gene through activation of the Sp1 gene in cancer cells.	Nagaoka Univ Technol, Dept Bioengn, Lab Glycobiol, Nagaoka, Niigata 94021, Japan	Nagaoka University of Technology	Sato, T (corresponding author), Nagaoka Univ Technol, Dept Bioengn, Lab Glycobiol, Kamitomioka 1603-1, Nagaoka, Niigata 94021, Japan.	taksato@vos.nagaokaut.ac.jp						Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Asada M, 1997, CANCER RES, V57, P1073; BHAT NK, 1989, J IMMUNOL, V142, P672; BOLON I, 1995, AM J PATHOL, V147, P1298; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Charron M, 1999, MOL CELL BIOL, V19, P5823; Davidson B, 2001, CLIN CANCER RES, V7, P551; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; Granovsky M, 2000, NAT MED, V6, P306; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Jiang JH, 2006, J BIOL CHEM, V281, P9482, DOI 10.1074/jbc.M504489200; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kita D, 2001, CANCER RES, V61, P7985; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lietard J, 1997, AM J PATHOL, V151, P1663; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nakayama T, 1996, AM J PATHOL, V149, P1931; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; PIERCE M, 1986, J BIOL CHEM, V261, P772; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raimondi LP, 2004, FEBS LETT, V576, P487, DOI 10.1016/j.febslet.2004.09.066; Santiago FS, 2004, CIRC RES, V95, P479, DOI 10.1161/01.RES.0000141135.36279.67; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; Sato T, 2005, EUR J PHARM SCI, V25, P221, DOI 10.1016/j.ejps.2005.02.011; SATO T, 1993, J BIOCHEM-TOKYO, V114, P890, DOI 10.1093/oxfordjournals.jbchem.a124273; Sato T, 2004, J BIOL CHEM, V279, P39574, DOI 10.1074/jbc.M405805200; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SATO T, 2005, GLYCOCONJ J, V22, P365; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1990, ONCOGENE, V5, P1761; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Withers DA, 2000, J BIOL CHEM, V275, P40588, DOI 10.1074/jbc.M007262200; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; Zhang W, 2000, BIOCHEM J, V347, P511, DOI 10.1042/0264-6021:3470511; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	47	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27702	27712		10.1074/jbc.M611862200	http://dx.doi.org/10.1074/jbc.M611862200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17656364	hybrid			2022-12-27	WOS:000249455600018
J	Cabrita, LD; Irving, JA; Pearce, MC; Whisstock, JC; Bottomley, SP				Cabrita, Lisa D.; Irving, James A.; Pearce, Mary C.; Whisstock, James C.; Bottomley, Stephen P.			Aeropin from the extremophile Pyrobaculum aerophilum bypasses the serpin misfolding trap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA(1)-ANTITRYPSIN POLYMERIZATION; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; GUANIDINIUM CHLORIDE; FOLDING DEFECT; UNFOLDED STATE; F-HELIX; PROTEIN; STABILITY	Serpins are metastable proteinase inhibitors. Serpin metastability drives both a large conformational change that is utilized during proteinase inhibition and confers an inherent structural flexibility that renders serpins susceptible to aggregation under certain conditions. These include point mutations ( the basis of a number of important human genetic diseases), small changes in pH, and an increase in temperature. Many studies of serpins from mesophilic organisms have highlighted an inverse relationship: mutations that confer a marked increase in serpin stability compromise inhibitory activity. Here we present the first biophysical characterization of a metastable serpin from a hyperthermophilic organism. Aeropin, from the archaeon Pyrobaculum aerophilum, is both highly stable and an efficient proteinase inhibitor. We also demonstrate that because of high kinetic barriers, aeropin does not readily form the partially unfolded precursor to serpin aggregation. We conclude that stability and activity are not mutually exclusive properties in the context of the serpin fold, and propose that the increased stability of aeropin is caused by an unfolding pathway that minimizes the formation of an aggregation-prone intermediate ensemble, thereby enabling aeropin to bypass the misfolding fate observed with other serpins.	Monash Univ, Dept Biochem & Mol Biol, Brisbane, Qld 3800, Australia; Monash Univ, ARC Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia	Monash University; Monash University	Bottomley, SP (corresponding author), Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.	james.whisstock@med.monash.edu.au; steve.bottomley@med.monash.edu.au	Irving, James A/I-8467-2015; Irving, James/P-3860-2019	Irving, James/0000-0003-3204-6356; Whisstock, James/0000-0003-4200-5611; Cabrita, Lisa/0000-0003-2963-8078				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Cabrita LD, 2004, EUR BIOPHYS J BIOPHY, V33, P83, DOI 10.1007/s00249-003-0356-1; Cabrita LD, 2002, BIOCHEMISTRY-US, V41, P4575, DOI 10.1021/bi0158932; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; Chang WSW, 1997, PROTEIN SCI, V6, P89; Crowther DC, 2003, BIOCHEMISTRY-US, V42, P2355, DOI 10.1021/bi0259305; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Devlin GL, 2002, J MOL BIOL, V324, P859, DOI 10.1016/S0022-2836(02)01088-4; Devlin GL, 2003, J BIOL CHEM, V278, P48644, DOI 10.1074/jbc.M308376200; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; Dunstone MA, 2000, PROTEIN SCI, V9, P417; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FANE B, 1991, J BIOL CHEM, V266, P11640; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Gilis D, 2003, J MOL BIOL, V325, P581, DOI 10.1016/S0022-2836(02)01221-4; Greaves RB, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-18; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2004, PROTEIN ENG DES SEL, V17, P325, DOI 10.1093/protein/gzh036; Irving JA, 2003, STRUCTURE, V11, P387, DOI 10.1016/S0969-2126(03)00057-1; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Kleiger G, 2001, BIOCHEMISTRY-US, V40, P14484, DOI 10.1021/bi011016k; Konagurthu AS, 2006, PROTEINS, V64, P559, DOI 10.1002/prot.20921; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; McHugh CA, 2004, PROTEIN SCI, V13, P2736, DOI 10.1110/ps.04897904; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; Pace C N, 1986, Methods Enzymol, V131, P266; Pearce MC, 2000, J BIOL CHEM, V275, P28513, DOI 10.1074/jbc.M004310200; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; Prasanna V, 1999, PROTEINS, V34, P356; Purkayastha P, 2005, BIOCHEMISTRY-US, V44, P2642, DOI 10.1021/bi048662e; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Suhre K, 2003, J BIOL CHEM, V278, P17198, DOI 10.1074/jbc.M301327200; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; Toth EA, 2000, J MOL BIOL, V301, P433, DOI 10.1006/jmbi.2000.3970; Tran ST, 2001, ARCH BIOCHEM BIOPHYS, V385, P322, DOI 10.1006/abbi.2000.2186; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; Whisstock JC, 2006, CURR OPIN STRUC BIOL, V16, P761, DOI 10.1016/j.sbi.2006.10.005; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363; Zhang Q, 2007, EMBO REP, V8, P658, DOI 10.1038/sj.embor.7400986	64	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26802	26809		10.1074/jbc.M705020200	http://dx.doi.org/10.1074/jbc.M705020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635906	hybrid			2022-12-27	WOS:000249304900020
J	Chen, YJ; Wang, YN; Chang, WC				Chen, Yun-Ju; Wang, Ying-Nai; Chang, Wen-Chang			ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR P300; PROTEIN-KINASE; A431 CELLS; IN-VITRO; CBP; SP1; COMPLEX	We previously reported that the epidermal growth factor (EGF) regulates the gene expression of keratin 16 by activating the extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling which in turn enhances the recruitment of p300 to the keratin 16 promoter. The recruited p300 functionally cooperates with Sp1 and c-Jun to regulate the gene expression of keratin 16. This study investigated in detail the molecular events incurred upon p300 whereby EGF caused an enhanced interaction between p300 and Sp1. EGF apparently induced time- and dose-dependent phosphorylation of p300, both in vitro and in vivo, through the activation of ERK2. The six potential ERK2 phosphorylation sites, including three threonine and three serine residues as revealed by sequential analysis, were first identified in vitro. Confirmation of these six sites in vivo indicated that these three serine residues (Ser-2279, Ser-2315, and Ser-2366) on the C terminus of p300 were the major signaling targets of EGF. Furthermore, the C-terminal serine phosphorylation of p300 stimulated its histone acetyltransferase activity and enhanced its interaction with Sp1. These serine phosphorylation sites on p300 controlled the p300 recruitment to the keratin 16 promoter. When all three serine residues on p300 were replaced by alanine, EGF could no longer induce the gene expression of keratin 16. Taken together, these results strongly suggested that the ERK2-mediated C-terminal serine phosphorylation of p300 was a key event in the regulation of EGF-induced keratin 16 expression. These results also constituted the first report identifying the unique p300 phosphorylation sites induced by ERK2 in vivo.	Natl Cheng Kung Univ, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 701, Taiwan; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Celplular Oncol, Houston, TX 77030 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Texas System; UTMD Anderson Cancer Center	Chang, WC (corresponding author), Natl Cheng Kung Univ, Dept Pharmacol, Tainan 701, Taiwan.	wcchang@mail.ncku.edu.tw						Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Chan HM, 2001, J CELL SCI, V114, P2363; Chang WC, 2003, PROSTAG OTH LIPID M, V71, P277, DOI 10.1016/S1098-8823(03)00048-0; Chen LC, 2004, BBA-MOL CELL BIOL L, V1683, P38, DOI 10.1016/j.bbalip.2004.04.003; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P581, DOI 10.1056/NEJM199503023320907; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Gusterson RJ, 2004, INT J BIOCHEM CELL B, V36, P893, DOI 10.1016/j.biocel.2003.10.004; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Machesney M, 1998, AM J PATHOL, V152, P1133; McClowry TL, 2002, J MED VIROL, V66, P96, DOI 10.1002/jmv.2116; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; WETZELS RHW, 1991, AM J PATHOL, V138, P751; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	38	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27215	27228		10.1074/jbc.M700264200	http://dx.doi.org/10.1074/jbc.M700264200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623675	hybrid			2022-12-27	WOS:000249304900063
J	Kressler, D; Hock, MB; Kralli, A				Kressler, Dieter; Hock, M. Benjamin; Kralli, Anastasia			Coactivators PGC-1 beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; N-COR; MOLECULAR DETERMINANTS; COREPRESSOR BINDING; PEPTIDE ANTAGONISTS; TISSUE-SPECIFICITY; ACTIVATION DOMAIN; STEROID-RECEPTORS; INTERACTION MOTIF; ALPHA ACTIVATION	PGC-1 beta is a transcriptional coactivator that enhances strongly and in a hormone-dependent manner the activity of the estrogen receptor alpha (ER alpha) while having only weak effects on similar steroid hormone receptors, such as ER alpha or the glucocorticoid receptor. Notably, PGC-1 beta enhances ER alpha transcriptional activity not only in response to agonist ligands, such as estradiol, but also to selective ER modulators, such as tamoxifen. Here, we dissect the molecular mechanisms underlying the ability of PGC-1 beta to act selectively on ER alpha and to promote the agonist activity of tamoxifen. We show that receptor selectivity is achieved by PGC-1 beta interactions with not just the ligand binding domain (LBD), which is highly conserved among nuclear receptors, but also the N-terminal domain and the hinge/AF-2a region of ER alpha, which are less well conserved. PGC-1 beta interacts directly with the hinge/AF-2a and LBD regions but indirectly and via the coactivator SRC-1 with the N-terminal domain. The three ER alpha surfaces and SRC-1 collectively enable efficient coactivation by PGC-1 beta. Similar ER alpha surfaces and interactions enable PGC-1 beta to coactivate transcription by tamoxifen-bound ER alpha. Surprisingly, PGC-1 beta coactivation of tamoxifen-bound ER alpha depends partially on one of the LXXLL motifs of PGC-1 beta and on Lys(362) of the ER alpha LBD (i. e. surfaces implicated in agonist-dependent interactions). Our findings suggest that tamoxifen-induced changes in the ER alpha LBD promote interactions with the coactivator PGC-1 beta, which then cooperates with SRC-1 to enable tamoxifen agonism.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Basel, Div Biochem, CH-4056 Basel, Switzerland	Scripps Research Institute; University of Basel	Kralli, A (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey PinesRd, La Jolla, CA 92037 USA.	kralli@scripps.edu	Kressler, Dieter/C-2218-2012	Kressler, Dieter/0000-0003-4855-3563	NIDDK NIH HHS [DK 064951] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064951] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Hentschke M, 2002, BIOCHEM BIOPH RES CO, V299, P872, DOI 10.1016/S0006-291X(02)02753-5; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McDonnell DP, 2001, ANN NY ACAD SCI, V949, P16; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200	56	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26897	26907		10.1074/jbc.M705596200	http://dx.doi.org/10.1074/jbc.M705596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631495	hybrid			2022-12-27	WOS:000249304900029
J	Kundu, P; Alioua, A; Stefani, E; Toro, L				Kundu, Pallob; Alioua, Abderrahmane; Stefani, Enrico; Toro, Ligia			Regulation of Mouse Slo Gene Expression - Multiple promoters, transcription start sites, and genomic action of estrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; RNA-POLYMERASE-II; TISSUE-SPECIFIC EXPRESSION; RESPONSE ELEMENT SEQUENCE; LARGE-CONDUCTANCE; ALPHA-SUBUNIT; BETA-SUBUNIT; RECEPTOR; 17-BETA-ESTRADIOL; IDENTIFICATION	The large conductance, voltage- and Ca2+ -activated K+ channel plays key roles in diverse body functions influenced by estrogen, including smooth muscle and neural activities. Inmouse( m), estrogen up-regulates the transcript levels of its pore-forming alpha-subunit (Slo, KCNMA1), yet the underlying genomic mechanism(s) is( are) unknown. We first mapped the promoters and regulatory motifs within the mSlo 5 5 '-flanking sequence to subsequently identify genomic regions and mechanisms required for estrogen regulation. mSlo gene has at least two TATA-less promoters with distinct potencies that may direct mSlo transcription from multiple transcription start sites. These qualities mark mSlo as a prototype gene with promoter plasticity capable of generating multiple mRNAs and the potential to adapt to organismal needs. mSlo promoters contain multiple estrogen-responsive sequences, e. g. two quasi-perfect estrogen-responsive elements, ERE1 and ERE2, and Sp1 sites. Accordingly, mSlo promoter activity was highly enhanced by estrogen and blocked by estrogen antagonist ICI 182,780. When promoters are embedded in a 4.91-kb backbone, estrogen responsiveness involves a classical genomic mechanism, via ERE1 and ERE2, that may be complemented by Sp factors, particularly Sp1. Simultaneous but not individual ERE1 and ERE2 mutations caused significant loss of estrogen action. ERE2, which is closer to the proximal promoter, up-regulates this promoter via a classical genomic mechanism. ERE2 strategic position together with ERE1 and ERE2 independence and Sp contribution should ensure mSlo estrogen responsiveness. Thus, the mSlo gene seems to have uniquely evolved to warrant estrogen regulation. Estrogen-mediated mSlo genomic regulation has important implications on long term estrogenic effects affecting smooth muscle and neural functions.	Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Cardiovasc Res Labs, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kundu, P (corresponding author), Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, BH 509A CHS,POB 957115, Los Angeles, CA 90095 USA.	pallob@ucla.edu			NHLBI NIH HHS [HL 54970] Funding Source: Medline; NICHD NIH HHS [HD 046510] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajic VB, 2004, NAT BIOTECHNOL, V22, P1467, DOI 10.1038/nbt1032; BECKER MN, 1995, J NEUROSCI, V15, P6250; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bohm RA, 2000, J EXP BIOL, V203, P693; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 1996, J NEUROSCI, V16, P1827; Brenner R, 1996, DEV BIOL, V177, P536, DOI 10.1006/dbio.1996.0183; Burdyga T, 2005, NATURE, V437, P290, DOI 10.1038/nature04146; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Chang WM, 2000, J BIOL CHEM, V275, P3991, DOI 10.1074/jbc.275.6.3991; Chen YH, 2006, ENDOCRINOLOGY, V147, P4496, DOI 10.1210/en.2005-1655; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Dhulipala PDK, 1999, BBA-GENE STRUCT EXPR, V1444, P254, DOI 10.1016/S0167-4781(98)00276-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Eghbali M, 2003, J BIOL CHEM, V278, P45311, DOI 10.1074/jbc.M306564200; Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI 10.1210/en.2005-1120; Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458; Fukue Y, 2005, NUCLEIC ACIDS RES, V33, P3821, DOI 10.1093/nar/gki700; Gu N, 2007, J PHYSIOL-LONDON, V580, P859, DOI 10.1113/jphysiol.2006.126367; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Higgins KJ, 2006, ENDOCRINOLOGY, V147, P3285, DOI 10.1210/EN.2006-0081; Holdiman AJ, 2002, MOL CELL ENDOCRINOL, V192, P1, DOI 10.1016/S0303-7207(02)00136-3; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Jacobson D, 2003, BIOCHEM BIOPH RES CO, V303, P660, DOI 10.1016/S0006-291X(03)00408-X; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jamali K, 2003, ENDOCRINE, V20, P227, DOI 10.1385/ENDO:20:3:227; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Koos RD, 2005, ANN NY ACAD SCI, V1041, P233, DOI 10.1196/annals.1282.037; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee MP, 2005, GENOME RES, V15, P1189, DOI 10.1101/gr.3873705; Lim CY, 2004, GENE DEV, V18, P1606, DOI 10.1101/gad.1193404; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu R, 2006, J PHYSIOL-LONDON, V570, P65, DOI 10.1113/jphysiol.2005.098913; Maston GA, 2006, ANNU REV GENOM HUM G, V7, P29, DOI 10.1146/annurev.genom.7.080505.115623; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Schmid CD, 2006, NUCLEIC ACIDS RES, V34, pD82, DOI 10.1093/nar/gkj146; SCHUG J, 2003, CURRENT PROTOCOLS BI, P1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stokes K, 2004, J MOL ENDOCRINOL, V33, P315, DOI 10.1677/jme.1.01456; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Takai Daiya, 2003, In Silico Biology, V3, P235; Vernier-Magnin S, 2005, BBA-GENE STRUCT EXPR, V1731, P23, DOI 10.1016/j.bbaexp.2005.05.002; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Werner ME, 2005, J PHYSIOL-LONDON, V567, P545, DOI 10.1113/jphysiol.2005.093823; Yang F, 2004, J BIOL CHEM, V279, P35403, DOI 10.1074/jbc.M404055200; Zhu N, 2005, FEBS LETT, V579, P4856, DOI 10.1016/j.febslet.2005.07.069	61	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27478	27492		10.1074/jbc.M704777200	http://dx.doi.org/10.1074/jbc.M704777200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635926	hybrid			2022-12-27	WOS:000249304900089
J	Kishii, R; Falzon, L; Yoshida, T; Kobayashi, H; Inouye, M				Kishii, Ryuta; Falzon, Liliana; Yoshida, Takeshi; Kobayashi, Hiroshi; Inouye, Masayori			Structural and functional studies of the HAMP domain of EnvZ, an osmosensing transmembrane histidine kinase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; SIGNAL-TRANSDUCTION; LINKER REGION; CHIMERIC CHEMORECEPTORS; MUTATIONAL ANALYSIS; BACILLUS-SUBTILIS; PROTEIN; SENSOR; BINDING; OMPR	The HAMP domain plays an essential role in signal transduction not only in histidine kinase but also in a number of other signal-transducing receptor proteins. Here we expressed the EnvZHAMPdomain (Arg(180)-Thr(235)) with the R218K mutation ( termed L-RK) or with LRK connected with domain A ( Arg180 Arg(289)) ( termed LARK) of EnvZ, an osmosensing transmembrane histidine kinase in Escherichia coli, by fusing it with protein S. The LRK and LARK proteins were purified after removing protein S. The CD analysis of the isolated L protein revealed that it consists of a random structure or is unstructured. This suggests that the EnvZ HAMP domain by itself is unable to form a stable structure and that this structural fragility may be important for its role in signal transduction. Interestingly the substitution of Ala(193) in the EnvZ HAMP domain with valine or leucine in Tez1A1, a chimeric protein of Tar and EnvZ, caused a constitutive OmpC phenotype. The CD analysis of LARK(A193L) revealed that this mutated HAMP domain possesses considerable secondary structures and that the thermostability of this entire LARK( A193L) became substantially lower than that of LARK or just domain A, indicating that the structure of the HAMP domain with the A193L mutation affects the stability of downstream domain A. This results in cooperative thermodenaturation of domain A with the mutated HAMP domain. These results are discussed in light of the recently solved NMR structure of the HAMP domain from a thermophilic bacterium (Hulko, M., Berndt, F., Gruber, M., Linder, J. U., Truffault, V., Schultz, A., Martin, J., Schultz, J. E., Lupas, A. N., and Coles, M. ( 2006) Cell 126, 929 - 940).	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Kyorin Pharmaceut Co Ltd, Discovery Res Labs, Tochigi 3290114, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Kyorin Pharmaceutical Co Ltd	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@umdnj.edu		Yoshida, Takeshi/0000-0003-0133-5067	NIGMS NIH HHS [GM076587A] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleman JA, 2003, J BACTERIOL, V185, P4872, DOI 10.1128/JB.185.16.4872-4882.2003; Appleman JA, 2003, J BACTERIOL, V185, P89, DOI 10.1128/JB.185.1.89-97.2003; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Hulko M, 2006, CELL, V126, P929, DOI 10.1016/j.cell.2006.06.058; Inouye M., 2003, HISTIDINE KINASES SI, P25; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; Kristich CJ, 2004, J BACTERIOL, V186, P5950, DOI 10.1128/JB.186.17.5950-5955.2004; Kristich CJ, 2003, MOL MICROBIOL, V47, P1353, DOI 10.1046/j.1365-2958.2003.03375.x; Kumita H, 2003, BBA-PROTEINS PROTEOM, V1646, P136, DOI 10.1016/S1570-9639(02)00555-1; Ma QH, 2005, J BACTERIOL, V187, P193, DOI 10.1128/JB.187.1.193-201.2005; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; Tomenius H, 2005, J BACTERIOL, V187, P7317, DOI 10.1128/JB.187.21.7317-7324.2005; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Ward SM, 2006, J BACTERIOL, V188, P3944, DOI 10.1128/JB.00117-06; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2004, J BIOL CHEM, V279, P48152, DOI 10.1074/jbc.M401024200; Zhu Y, 2003, J BIOL CHEM, V278, P22812, DOI 10.1074/jbc.M300916200	38	25	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26401	26408		10.1074/jbc.M701342200	http://dx.doi.org/10.1074/jbc.M701342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635923	hybrid			2022-12-27	WOS:000249239600045
J	Kong, L; Yu, XP; Bai, XH; Zhang, WF; Zhang, Y; Zhao, WM; Jia, JH; Tang, W; Zhou, YB; Liu, CJ				Kong, Li; Yu, Xiu-Ping; Bai, Xiao-Hui; Zhang, Wei-Fang; Zhang, Yan; Zhao, Wei-Ming; Jia, Ji-Hui; Tang, Wei; Zhou, Ya-Bin; Liu, Chuan-ju			RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE; DEPENDENT APOPTOSIS; E6 ONCOPROTEINS; GENE-EXPRESSION; RETINOBLASTOMA; PROTEIN; GROWTH; TRANSCRIPTION; INACTIVATION	Although human papillomavirus (HPV) infections are the primary cause of cervical cancer, the molecular mechanism by which HPV induces cervical cancer remains largely unclear. We used two-dimensional electrophoresis with mass spectrometry to study protein expression profiling between HPV16-positive cervical mucosa epithelial H8 cells and cervical cancer Caski cells to identify 18 differentially expressed proteins. Among them, retinoblastoma-binding protein 4 (RbAp48) was selected, and its differentiation expression was verified with both additional cervical cancer-derived cell lines and human tissues of cervical intraepithelial neoplasia and cervical cancer. Suppression of RbAp48 using small interfering RNA approach in H8 cells significantly stimulated cell proliferation and colony formation and inhibited senescence-like phenotype. Remarkably, H8 cells acquired transforming activity if RpAp48 was suppressed, because H8 cells stably transfected with RbAp48 small interfering RNA led to tumor formation in nude mice. In addition, overexpression of RbAp48 significantly inhibited cell growth and tumor formation. This RbAp48-mediated transformation of HPV16 is probably because of the regulation by RbAp48 of tumor suppressors retinoblastoma and p53, apoptosis-related enzymes caspase-3 and caspase-8, and oncogenic genes, including E6, E7, cyclin D1 (CCND1), and c-MYC. In brief, RbAp48, previously unknown in cervical carcinogenesis, was isolated in a global screen and identified as a critical mediator controlling the transforming activity of HPV16 in cervical cancer.	Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Peoples R China; Shandong Univ, Sch Med, Jinan 250012, Peoples R China; NYU, Med Ctr, Dept Orthopaed Surg, New York, NY 10016 USA; Chinese Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Shandong University; Shandong University; New York University; New York University	Yu, XP (corresponding author), Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Peoples R China.	yuxp@sdu.edu.cn; chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021; Tang, Wei/A-6254-2016	Tang, Wei/0000-0002-4573-3502; liu, chuanju/0000-0002-7181-8032; Bai, Xiaohui/0000-0002-4027-7798	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022, R21AR052676, K01AR053210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG029388] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01 AR053210-01A2, R03 AR052022, R21 AR052676-02, R21 AR052676, K01 AR053210, R03 AR052022-02, R21 AR052676-01A1, AR052022, AR050620, R03 AR052022-03] Funding Source: Medline; NIA NIH HHS [R03 AG029388, R03 AG029388-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Au WW, 2007, GYNECOL ONCOL, V104, P276, DOI 10.1016/j.ygyno.2006.10.015; Bae SM, 2005, GYNECOL ONCOL, V99, P26, DOI 10.1016/j.ygyno.2005.05.041; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Castagna A, 2004, PROTEOMICS, V4, P3246, DOI 10.1002/pmic.200400835; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Franco EL, 2003, CANCER J, V9, P348, DOI 10.1097/00130404-200309000-00004; Franco ELF, 1996, OBSTET GYN CLIN N AM, V23, P597; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Govan VA, 2005, ANN NY ACAD SCI, V1056, P328, DOI 10.1196/annals.1352.016; Greenbaum D, 2002, BIOINFORMATICS, V18, P585, DOI 10.1093/bioinformatics/18.4.585; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; Ishimaru N, 2006, MOL CELL BIOL, V26, P2924, DOI 10.1128/MCB.26.8.2924-2935.2006; Jia XW, 2006, CELL BIOL INT, V30, P183, DOI 10.1016/j.cellbi.2005.08.014; Jones EE, 2006, CURR MOL MED, V6, P795; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Laj A, 1999, MOL CELL BIOL, V19, P6632; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li GC, 2003, INT J CANCER, V105, P762, DOI 10.1002/ijc.11148; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; LUI CQ, 1999, ZHONG HUA BING LI XU, V28, P24; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Naghashfar Z, 1996, CANCER LETT, V100, P47, DOI 10.1016/0304-3835(95)04071-4; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Nicolas E, 2001, NUCLEIC ACIDS RES, V29, P3131, DOI 10.1093/nar/29.15.3131; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Torres-Roca JF, 2005, CANCER RES, V65, P7169, DOI 10.1158/0008-5472.CAN-05-0656; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wright Jason D, 2002, Curr Womens Health Rep, V2, P259; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yim EK, 2004, DNA CELL BIOL, V23, P826, DOI 10.1089/dna.2004.23.826; You W, 2005, OBSTET GYNECOL, V105, P1405, DOI 10.1097/01.AOG.0000163254.98217.91; Zhang TF, 2003, ANTICANCER RES, V23, P3735; Zhang TF, 2003, ANTICANCER RES, V23, P4621; ZHENG J, 1994, INT J CANCER, V58, P713, DOI 10.1002/ijc.2910580516; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	56	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26381	26391		10.1074/jbc.M702195200	http://dx.doi.org/10.1074/jbc.M702195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616526	hybrid			2022-12-27	WOS:000249239600043
J	Nilsen, T; Rosendal, KR; Sorensen, V; Wesche, J; Olsnes, S; Wiedlocha, A				Nilsen, Trine; Rosendal, Ken R.; Sorensen, Vigdis; Wesche, Jorgen; Olsnes, Sjur; Wiedlocha, Antoni			A nuclear export sequence located on a beta-strand in fibroblast growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOCYTOPLASMIC TRANSPORT; INTRACELLULAR PROTEIN; LOCALIZATION SIGNALS; ACTIVATION DOMAIN; IMPORTIN-BETA; FACTOR MUTANT; REV PROTEIN; TRANSLOCATION; PHOSPHORYLATION	Receptor-bound and endocytosed fibroblast growth factor-1 (FGF-1) is able to cross the vesicle membrane and translocate to cytosol and nucleus. This suggests an intracellular role of FGF-1, which also signals by activating transmembrane FGF receptors. Phosphorylation of internalized FGF-1 by nuclear protein kinase C delta induces rapid export from the nuclei by a leptomycin B-sensitive pathway. In the present work, we have searched for and identified a Leu-rich nuclear export sequence (NES) at the C terminus of FGF-1 required for its nuclear export and able to confer nuclear export activity to a reporter protein in an in vivo system. Mutants where hydrophobic amino acids within the NES were exchanged for alanine exhibited reduced or abolished nuclear export. As demonstrated in co-immunoprecipitation experiments, a complex containing FGF-1, exportin-1, and its co-factor Ran-GTP, was formed in vitro. Formation of this complex in vivo was demonstrated by a peroxisomal targeting assay. Formation of the FGF-1-exportin-1-Ran-GTP complex in vitro as well as nuclear export of FGF-1 in vivo was dependent on phosphorylation of FGF-1, and it was abolished by leptomycin B. The FGF-1 NES was found to be situated along a beta-strand, which has not been reported before, since NESs usually are alpha-helical.	Rikshosp Radiumhosp Med Ctr, Inst Canc Res, Ctr Canc Biomed, N-0310 Oslo, Norway	University of Oslo	Wiedlocha, A (corresponding author), Rikshosp Radiumhosp Med Ctr, Inst Canc Res, Ctr Canc Biomed, N-0310 Oslo, Norway.	antoni.wiedlocha@rr-research.no	Wesche, Jorgen/ABH-7524-2020	Christoffersen, Trine Eker/0000-0002-2908-133X; Wesche, Jorgen/0000-0002-9200-9162				Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Klingenberg O, 2000, J CELL SCI, V113, P1827; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; Mizukoshi E, 1999, BIOCHEM J, V343, P461, DOI 10.1042/0264-6021:3430461; Munoz R, 1997, ONCOGENE, V15, P525, DOI 10.1038/sj.onc.1201226; Nilsen T, 2004, J BIOL CHEM, V279, P4794, DOI 10.1074/jbc.M309653200; NILSEN T, 2006, CELL BIOL LAB HDB, P275; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Siebrasse JP, 2002, J CELL BIOL, V158, P849, DOI 10.1083/jcb.200201130; Skjerpen CS, 2002, J BIOL CHEM, V277, P23864, DOI 10.1074/jbc.M112193200; Skjerpen CS, 2002, EMBO J, V21, P4058, DOI 10.1093/emboj/cdf402; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Sorensen V, 2006, J CELL SCI, V119, P4332, DOI 10.1242/jcs.03209; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wesche J, 2005, BIOCHEMISTRY-US, V44, P6071, DOI 10.1021/bi047403m; Wesche J, 2000, BIOCHEMISTRY-US, V39, P15091, DOI 10.1021/bi001831k; Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752; Wiedlocha A, 2005, MOL BIOL CELL, V16, P794; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	55	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26245	26256		10.1074/jbc.M611234200	http://dx.doi.org/10.1074/jbc.M611234200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616529	hybrid			2022-12-27	WOS:000249239600029
J	Wong, MM; Cox, LK; Chrivia, JC				Wong, Madeline M.; Cox, Linda K.; Chrivia, John C.			The chromatin remodeling protein, SRCAP, is critical for deposition of the histone variant H2A.Z at promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACETYLATION; GENES; TRANSCRIPTION; RECRUITMENT; COMPLEX; GENOME; HTZ1; ACTIVATION	Studies in Saccharomyces cerevisiae indicate the histone variant H2A. Z is deposited at promoters by the chromatin remodeling protein Swr1 and plays a critical role in the regulation of transcription. In higher eukaryotes, however, little is known about the distribution, method of deposition, and function of H2A. Z at promoters. Using biochemical studies, we demonstrated previously that SRCAP ( SNF-2-related CREB-binding protein activator protein), the human ortholog of Swr1, could catalyze deposition of H2A. Z into nucleosomes. To address whether SRCAP directs H2A. Z deposition in vivo, promoters targeted by SRCAP were identified by a chromatin immunoprecipitation ( ChIP)-on-chip assay. ChIP assays on a subset of these promoters confirmed the presence of SRCAP on inactive and active promoters. The highest levels of SRCAP were observed on the active SP-1, G3BP, and FAD synthetase promoters. Detailed analyses of these promoters indicate sites of SRCAP binding overlap or occur adjacent to the sites of H2A. Z deposition. Knockdown of SRCAP levels using siRNA resulted in loss of SRCAP at these promoters, decreased deposition of H2A. Z and acetylated H2A. Z, and a decrease in levels of SP-1, G3BP, and FAD synthetase mRNA. Thus, these studies provide the first evidence that SRCAP is recruited to promoters and is critical for the deposition of H2A.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Chrivia, JC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	Chrivia@slu.edu			NIDDK NIH HHS [DK 066307] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Babiarz JE, 2006, GENE DEV, V20, P700, DOI 10.1101/gad.1386306; Bruce K, 2005, NUCLEIC ACIDS RES, V33, P5633, DOI 10.1093/nar/gki874; Chen IY, 2006, J BIOL CHEM, V281, P19369, DOI 10.1074/jbc.M601443200; Eissenberg JC, 2005, MOL CELL BIOL, V25, P6559, DOI 10.1128/MCB.25.15.6559-6569.2005; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Jackson JD, 2000, NUCLEIC ACIDS RES, V28, P3811, DOI 10.1093/nar/28.19.3811; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Lambert JR, 2003, MOL ENDOCRINOL, V17, P1085, DOI 10.1210/me.2001-0183; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Monroy MA, 2003, MOL ENDOCRINOL, V17, P2519, DOI 10.1210/me.2003-0208; Myers FA, 2006, NUCLEIC ACIDS RES, V34, P4025, DOI 10.1093/nar/gkl543; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Ruhl DD, 2006, BIOCHEMISTRY-US, V45, P5671, DOI 10.1021/bi060043d; Viens A, 2006, MOL CELL BIOL, V26, P5325, DOI 10.1128/MCB.00584-06; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036	26	113	118	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26132	26139		10.1074/jbc.M703418200	http://dx.doi.org/10.1074/jbc.M703418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17617668	hybrid			2022-12-27	WOS:000249239600016
J	Jackson, AA; Cronin, KR; Zachariah, R; Carew, JA				Jackson, Audrey A.; Cronin, Katherine R.; Zachariah, Roshini; Carew, Josephine A.			CCAAT/enhancer-binding protein-beta participates in insulin-responsive expression of the factor VII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VII; ASPARAGINE SYNTHETASE GENE; AMINO-ACID LIMITATION; ACTIVATING TRANSCRIPTION FACTOR-3; FACTOR PROCOAGULANT ACTIVITY; CORONARY-HEART-DISEASE; STRESS-INDUCIBLE GENE; NUCLEAR FACTOR 4; TISSUE FACTOR; MYOCARDIAL-INFARCTION	Expression of the human coagulation factor VII (FVII) gene by hepatoma cells was modulated in concert with levels of glucose and insulin in the culture medium. In low glucose medium without insulin, amounts of both FVII mRNA and secreted FVII protein were coordinately increased; in the presence of glucose with insulin, both were decreased. Analysis of the FVII promoter showed that these effects could be reproduced in a reporter-gene system, and a small promoter element immediately upstream of the translation start site of the gene, which mediated these effects, was identified. Mutation of this element largely abrogated the glucose/insulin-responsive change in expression of the reporter gene. Several members of the CCAAT/enhancer-binding protein family were found to be capable of binding the identified sequence element but not the mutated element. The expression of a FVII minigene directed by a segment of the native FVII promoter responded to co-expressed activating and inhibiting forms of CCAAT/enhancer-binding protein beta.	Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School	Carew, JA (corresponding author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy,W Roxbury, Boston, MA 02132 USA.	josephine_carew@hms.harvard.edu						Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; Bach RR, 2006, ARTERIOSCL THROM VAS, V26, P456, DOI 10.1161/01.ATV.0000202656.53964.04; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; Bozzini C, 2004, THROMB HAEMOSTASIS, V92, P541, DOI 10.1160/Th04-02-0130; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; Butenas S, 2004, NAT MED, V10, P1155, DOI 10.1038/nm1104-1155b; Carew JA, 1998, BLOOD, V92, P1639, DOI 10.1182/blood.V92.5.1639.417k10_1639_1645; Carew JA, 2000, BLOOD, V96, P4370; Carew JA, 2003, J THROMB HAEMOST, V1, P2179, DOI 10.1046/j.1538-7836.2003.00424.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Carr ME, 2001, J DIABETES COMPLICAT, V15, P44, DOI 10.1016/S1056-8727(00)00132-X; Chen C, 2005, BIOCHEM J, V391, P649, DOI 10.1042/BJ20050882; Chen VM, 2006, BIOCHEMISTRY-US, V45, P12020, DOI 10.1021/bi061271a; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; De Stavola BL, 2007, J THROMB HAEMOST, V5, P461, DOI 10.1111/j.1538-7836.2007.02330.x; Dietzen DJ, 2004, BLOOD, V103, P3038, DOI 10.1182/blood-2003-07-2399; Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P281, DOI 10.1055/s-0037-1615188; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FAIR DS, 1983, J LAB CLIN MED, V101, P372; Fernandez J, 2003, J BIOL CHEM, V278, P50000, DOI 10.1074/jbc.M305903200; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Funk M, 2006, CLIN CHEM, V52, P1190, DOI 10.1373/clinchem.2005.059360; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Girelli D, 2000, NEW ENGL J MED, V343, P774, DOI 10.1056/NEJM200009143431104; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; Hunault M, 1999, BLOOD, V93, P1237, DOI 10.1182/blood.V93.4.1237.404k02_1237_1244; Hunault M, 1997, ARTERIOSCL THROM VAS, V17, P2825, DOI 10.1161/01.ATV.17.11.2825; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kavlie A, 2003, THROMB HAEMOSTASIS, V90, P194, DOI 10.1160/TH02-09-0050; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Mackman N, 2005, ARTERIOSCL THROM VAS, V25, P2273, DOI 10.1161/01.ATV.0000183884.06371.52; Marcinkowska E, 2006, EXP CELL RES, V312, P2054, DOI 10.1016/j.yexcr.2006.03.003; McGlynn LK, 1996, MOL CELL BIOL, V16, P1936; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1989, ATHEROSCLEROSIS, V78, P19, DOI 10.1016/0021-9150(89)90154-8; MOHROE DM, 2007, J THROMB HAEMOST, V5, P1097; Moneva MH, 2002, CURR DRUG TARGETS, V3, P203, DOI 10.2174/1389450023347803; Nagaizumi K, 2002, BRIT J HAEMATOL, V119, P1052, DOI 10.1046/j.1365-2141.2002.03933.x; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Persson E, 2006, BIOCHEM BIOPH RES CO, V341, P28, DOI 10.1016/j.bbrc.2005.12.146; Peyvandi F, 2005, J THROMB HAEMOST, V3, P803, DOI 10.1111/j.1538-7836.2005.01232.x; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; REIJNEN MJ, 1994, BLOOD COAGUL FIBRIN, V5, P341; Reiner AP, 2007, J THROMB HAEMOST, V5, P42, DOI 10.1111/j.1538-7836.2006.02279.x; Romisch J, 1999, BLOOD COAGUL FIBRIN, V10, P471; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato H, 2004, BIOCHEM BIOPH RES CO, V325, P109, DOI 10.1016/j.bbrc.2004.10.009; SCHREIBER E, 1989, SOMAT CELL MOLEC GEN, V15, P591, DOI 10.1007/BF01534920; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Stauffer DR, 1998, J BIOL CHEM, V273, P2277, DOI 10.1074/jbc.273.4.2277; TIDD T, 1999, THROMB HAEMOST S, V476, P1476; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; van't Hooft FM, 1999, BLOOD, V93, P3432, DOI 10.1182/blood.V93.10.3432.410k16_3432_3441; Wolberg AS, 1999, BLOOD COAGUL FIBRIN, V10, P201, DOI 10.1097/00001721-199906000-00007; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	77	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31156	31165		10.1074/jbc.M704694200	http://dx.doi.org/10.1074/jbc.M704694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17675296	hybrid			2022-12-27	WOS:000250309200005
J	Sridharan, R; Smale, ST				Sridharan, Rupa; Smale, Stephen T.			Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; CENTROMERIC HETEROCHROMATIN; REMODELING COMPLEXES; TRANSCRIPTION FACTOR; GENE ENCODES; CHROMATIN; FAMILY; REPRESSION; MECHANISM; PURIFICATION	Ikaros is the founding member of a small family of C2H2 zinc-finger DNA-binding proteins that carry out critical functions during lymphocyte development. Although interactions between Ikaros and various proteins have been reported, Ikaros-containing complexes have not been purified to determine their composition and identify the predominant interacting partners. In this study, a tandem affinity purification-mass spectrometry strategy was developed for the isolation of complexes formed by Ikaros and by Helios, a T-cell-restricted member of the Ikaros family that remains largely uncharacterized. This strategy, which appears to be well suited for general use in mammalian cells, relies on an N-terminal polypeptide containing a double FLAG epitope, followed by a tobacco etch virus protease cleavage site and calmodulin binding peptide. In extracts from a murine thymocyte line, Ikaros and Helios associated under moderate stringency conditions only with other members of the Ikaros family. However, under low stringency conditions, both tagged proteins assembled into higher molecular weight complexes. Mass spectrometry revealed that both proteins associated predominantly with subunits of NuRD, an ATP-dependent nucleosome remodeling complex implicated in transcriptional repression and activation and previously reported to associate with Ikaros. Further analysis of the affinity-purified Ikaros revealed that several serines and threonines are phosphorylated in the thymocyte line, with apparent changes upon thymocyte maturation. These results support the hypothesis that the NuRD complex makes major contributions to the functions of both Ikaros and Helios and that the activities of these proteins may be regulated in part by changes in phosphorylation.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Smale, ST (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 6-730 MRL,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	smale@mednet.ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043736] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; GROVES T, 1995, J IMMUNOL, V154, P5011; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Harker N, 2002, MOL CELL, V10, P1403, DOI 10.1016/S1097-2765(02)00711-6; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kellum R, 2003, CURR TOP MICROBIOL, V274, P53; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Koipally J, 2002, J BIOL CHEM, V277, P27697, DOI 10.1074/jbc.M201694200; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Smale ST, 2006, NAT IMMUNOL, V7, P367, DOI 10.1038/ni0406-367; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Westman BJ, 2003, J BIOL CHEM, V278, P42419, DOI 10.1074/jbc.M306817200; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314	46	88	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30227	30238		10.1074/jbc.M702541200	http://dx.doi.org/10.1074/jbc.M702541200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681952	hybrid			2022-12-27	WOS:000249981200053
J	Chen, ZP; Knutson, E; Wang, S; Martinez, LA; Albrecht, T				Chen, Zhenping; Knutson, Eugene; Wang, Shuo; Martinez, Luis A.; Albrecht, Thomas			Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEINS; DNA-DAMAGE; INFECTED FIBROBLASTS; ONCOPROTEIN MDM2; GENE-EXPRESSION; DEGRADATION; VIRUS; LIGASE; ACTIVATION; PATHWAYS	Human cytomegalovirus (HCMV) induces serum- or density-arrested human lung (LU) cells to traverse the cell cycle, providing it with a strategy to replicate in post-mitotic cells that are its cellular substrate in vivo. HCMV infection also induces high cellular levels of p53, seemingly in contradiction to the observed cell cycle progression. This study was undertaken to examine the mechanism(s) of the increased p53 abundance. HCMV infection caused a 4-fold increase in p53 that preceded a substantial increase in p53 transcripts by more than 24 h. p53 was stabilized in HCMV-infected cells (from a half-life of less than 30 min to about 8 h) and was less sensitive to proteasome-mediated degradation. Ubiquitination of p53 in mock-infected LU cells was sensitive to inhibition by trans-4-iodo, 4'-boranylchalcone, consistent with HDM2-catalyzing ubiquitination of p53. In HCMV-infected cells, ubiquitination of p53 was essentially undetectable. Although HDM2 had a nuclear distribution in mock-infected LU cells, in HCMV-infected cells HDM2 was translocated to the cytoplasm beginning at 12 h and demonstrated decreased cellular abundance thereafter. HDM2 was stabilized in the HCMV-infected cells by MG132, indicating a shift from p53 to HDM2 ubiquitination. p53 demonstrated a predominantly nuclear distribution in HCMV-infected cells through 48 h, resulting in p53 and HDM2 in distinct subcellular compartments. The principal mechanism responsible for increased p53 stabilization was nuclear export and degradation of HDM2. Thus, HCMV uses a shift from p53 to HDM2 ubiquitination and destabilization to obtain protracted high levels of p53, while promoting cell cycle traverse.	Univ Texas, Med Branch, Infect Dis & Toxicol Opt Imaging Ctr, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Albrecht, T (corresponding author), Univ Texas, Med Branch, Infect Dis & Toxicol Opt Imaging Ctr, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	talbrech@utmb.edu			NCRR NIH HHS [RR14712] Funding Source: Medline; NIDCR NIH HHS [DE11389] Funding Source: Medline; NIEHS NIH HHS [ES06676, ES10018] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUBAKAR S, 1990, BIOCHEM BIOPH RES CO, V166, P953, DOI 10.1016/0006-291X(90)90903-Z; ALBRECHT T, 1980, J GEN VIROL, V51, P83, DOI 10.1099/0022-1317-51-1-83; ALBRECHT T, 1980, LAB INVEST, V42, P1; Albrecht T, 1989, Subcell Biochem, V15, P157; ALBRECHT T, 1992, J INVEST DERMATOL, V98, pS29, DOI 10.1111/1523-1747.ep12462169; ALBRECHT T, 1980, AM J CLIN PATHOL, V73, P648, DOI 10.1093/ajcp/73.5.648; BOLDOGH I, 1990, SCIENCE, V247, P561, DOI 10.1126/science.1689075; BOLDOGH I, 1991, ARCH VIROL, V118, P163, DOI 10.1007/BF01314027; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; Bresnahan WA, 1998, J BIOL CHEM, V273, P22075, DOI 10.1074/jbc.273.34.22075; Bresnahan WA, 1997, J GEN VIROL, V78, P1993, DOI 10.1099/0022-1317-78-8-1993; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Castillo JP, 2002, GENE, V290, P19, DOI 10.1016/S0378-1119(02)00566-8; CAVALLO T, 1981, J GEN VIROL, V56, P97, DOI 10.1099/0022-1317-56-1-97; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen ZP, 2001, J VIROL, V75, P3613, DOI 10.1128/JVI.75.8.3613-3625.2001; Chi SW, 2005, J BIOL CHEM, V280, P38795, DOI 10.1074/jbc.M508578200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Collot-Teixeira S, 2004, REV MED VIROL, V14, P301, DOI 10.1002/rmv.431; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Deb SP, 2003, MOL CANCER RES, V1, P1009; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Evers DL, 2004, MICROBES INFECT, V6, P1084, DOI 10.1016/j.micinf.2004.05.026; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gandhi MK, 2004, LANCET INFECT DIS, V4, P725, DOI 10.1016/S1473-3099(04)01202-2; Gaspar M, 2006, P NATL ACAD SCI USA, V103, P2821, DOI 10.1073/pnas.0511148103; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; HORODNICEANU F, 1977, NATURE, V270, P615, DOI 10.1038/270615a0; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Kumar SK, 2003, J MED CHEM, V46, P2813, DOI 10.1021/jm030213+; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine A J, 1989, Princess Takamatsu Symp, V20, P221; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MUGANDA P, 1994, J VIROL, V68, P8028, DOI 10.1128/JVI.68.12.8028-8034.1994; Muganda P, 1998, CELL MOL BIOL, V44, P321; NOKTA M, 1987, VIROLOGY, V157, P259, DOI 10.1016/0042-6822(87)90268-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rawlinson William, 2003, Aust Fam Physician, V32, P789; RIMSZA LM, 1996, MOL DIAGN, V1, P291; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SAITO Y, 1990, NEUROSCI LETT, V120, P1, DOI 10.1016/0304-3940(90)90153-Z; Shen YH, 2004, CIRC RES, V94, P1310, DOI 10.1161/01.RES.0000129180.13992.43; Song YJ, 2005, J VIROL, V79, P2597, DOI 10.1128/JVI.79.4.2597-2603.2005; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Speir E, 1995, SCAND J INFECT DIS, P78; STANTON GJ, 1977, P SOC EXP BIOL MED, V156, P109; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang J, 2000, FEBS LETT, V474, P213, DOI 10.1016/S0014-5793(00)01604-5; Wang X, 2005, NAT MED, V11, P515, DOI 10.1038/nm1236; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang ZG, 2006, J VIROL, V80, P3833, DOI 10.1128/JVI.80.8.3833-3843.2006; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	75	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29284	29295		10.1074/jbc.M705349200	http://dx.doi.org/10.1074/jbc.M705349200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698841	hybrid			2022-12-27	WOS:000249788000025
J	McEwen, DP; Schumacher, SM; Li, QJ; Benson, MD; Iniguez-Lluhi, JA; Van Genderen, KM; Martens, JR				McEwen, Dyke P.; Schumacher, Sarah M.; Li, Qiuju; Benson, Mark D.; Iniguez-Lluhi, Jorge A.; Van Genderen, Kristin M.; Martens, Jeffrey R.			Rab-GTPase-dependent endocytic recycling of KV1.5 in atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; POTASSIUM CHANNEL; TYROSINE KINASE; EXPRESSION; TRAFFICKING; INTERNALIZATION; DYNACTIN; RECEPTOR; PROTEIN; OVEREXPRESSION	The number of ion channels expressed on the cell surface shapes the complex electrical response of excitable cells. Maintaining a balance between anterograde and retrograde trafficking of channel proteins is vital in regulating steady-state cell surface expression. Kv1.5 is an important voltage-gated K+ channel in the cardiovascular system underlying the ultra-rapid rectifying potassium current (Ik(ur)), a major repolarizing current in atrial myocytes, and regulating the resting membrane potential and excitability of smooth muscle cells. Defects in the expression of Kv1.5 are associated with pathological states such as chronic atrial fibrillation and hypoxic pulmonary hypertension. There is, thus, substantial interest in understanding the mechanisms regulating cell surface channel levels. Here, we investigated the internalization and recycling of Kv1.5 in the HL-1 immortalized mouse atrial myocytes. Kinetic studies indicate that Kv1.5 is rapidly internalized to a perinuclear region where it co-localizes with the early endosomal marker, EEA1. Importantly, we identified that a population of Kv1.5, originating on the cell surface, internalized and recycled back to the plasma membrane. Notably, Kv1.5 recycling processes are driven by specific Rab-dependent endosomal compartments. Thus, co-expression of GDP-locked Rab4S22N and Rab11S25N dominant-negative mutants decreased the steady-state Kv1.5 surface levels, whereas GTPase-deficient Rab4Q67L and Rab11Q70L mutants increased steady-state Kv1.5 surface levels. These data reveal an unexpected dynamic trafficking of Kv1.5 at the myocyte plasma membrane and demonstrate a role for recycling in the maintenance of steady-state ion channel surface levels.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Martens, JR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRBIII,1500 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	martensj@umich.edu		Schumacher, Sarah/0000-0002-4941-7267; Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NHLBI NIH HHS [HL0270973] Funding Source: Medline; NIDDK NIH HHS [R01 DK061656-02, R01 DK061656, R01 DK061656-01, R01 DK061656-04, R01 DK061656-05, R01 DK061656-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; Benson MD, 2007, P NATL ACAD SCI USA, V104, P1805, DOI 10.1073/pnas.0606702104; Brundel BJJM, 2001, J AM COLL CARDIOL, V37, P926, DOI 10.1016/S0735-1097(00)01195-5; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Choi WS, 2005, CIRC RES, V97, P363, DOI 10.1161/01.RES.0000179535.06458.f8; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; Feng JL, 1997, CIRC RES, V80, P572, DOI 10.1161/01.RES.80.4.572; Filipeanu CM, 2006, J BIOL CHEM, V281, P11097, DOI 10.1074/jbc.M511460200; Gong Q, 2007, J BIOL CHEM, V282, P13087, DOI 10.1074/jbc.M700767200; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kato M, 2005, BIOCHEM BIOPH RES CO, V337, P343, DOI 10.1016/j.bbrc.2005.09.053; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moudgil R, 2006, MICROCIRCULATION, V13, P615, DOI 10.1080/10739680600930222; Neel NF, 2005, CYTOKINE GROWTH F R, V16, P637, DOI 10.1016/j.cytogfr.2005.05.008; Nesti E, 2004, MOL BIOL CELL, V15, P4073, DOI 10.1091/mbc.E03-11-0788; O'Connell KMS, 2005, J CELL SCI, V118, P2155, DOI 10.1242/jcs.02348; Olson TM, 2006, HUM MOL GENET, V15, P2185, DOI 10.1093/hmg/ddl143; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; Rolf S, 2000, N-S ARCH PHARMACOL, V362, P22, DOI 10.1007/s002100000257; Saxena SK, 2006, BIOCHEM BIOPH RES CO, V340, P726, DOI 10.1016/j.bbrc.2005.12.036; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seebohm G, 2007, CIRC RES, V100, P686, DOI 10.1161/01.RES.0000260250.83824.8f; Soldati T, 2006, NAT REV MOL CELL BIO, V7, P897, DOI 10.1038/nrm2060; Tanabe Y, 2006, BIOCHEM BIOPH RES CO, V345, P1116, DOI 10.1016/j.bbrc.2006.05.030; Uhlig M, 2005, MOL CELL ENDOCRINOL, V235, P1, DOI 10.1016/j.mce.2005.02.004; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; van der Sluijs P, 2001, METHOD ENZYMOL, V329, P111; VanWagoner DR, 1997, CIRC RES, V80, P772; Wakabayashi Y, 2005, P NATL ACAD SCI USA, V102, P15087, DOI 10.1073/pnas.0503702102; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; White SM, 2004, AM J PHYSIOL-HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Yuan XJ, 1998, AM J PHYSIOL-LUNG C, V274, pL621, DOI 10.1152/ajplung.1998.274.4.L621; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang L, 2007, AM J PHYSIOL-CELL PH, V293, pC152, DOI 10.1152/ajpcell.00480.2006	45	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29612	29620		10.1074/jbc.M704402200	http://dx.doi.org/10.1074/jbc.M704402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673464	hybrid			2022-12-27	WOS:000249788000058
J	Chamberlain, PP; Qian, X; Stiles, AR; Cho, J; Jones, DH; Lesley, SA; Grabau, EA; Shears, SB; Spraggon, G				Chamberlain, Philip P.; Qian, Xun; Stiles, Amanda R.; Cho, Jaiesoon; Jones, David H.; Lesley, Scott A.; Grabau, Elizabeth A.; Shears, Stephen B.; Spraggon, Glen			Integration of inositol phosphate signaling pathways via human ITPK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,3,4-TRISPHOSPHATE 5/6-KINASE; HEXAKISPHOSPHATE; PROTEINS; MODEL; PENTAKISPHOSPHATE; PURIFICATION; SPECIFICITY; EXPRESSION; 3-KINASE; CELLS	Inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) is a reversible, poly-specific inositol phosphate kinase that has been implicated as a modifier gene in cystic fibrosis. Upon activation of phospholipase C at the plasma membrane, inositol 1,4,5-trisphosphate enters the cytosol and is inter-converted by an array of kinases and phosphatases into other inositol phosphates with diverse and critical cellular activities. In mammals it has been established that inositol 1,3,4-trisphosphate, produced from inositol 1,4,5-trisphosphate, lies in a branch of the metabollic pathway that is separate from inositol 3,4,5,6-tetrakisphosphate, which inhibits plasma membrane chloride channels. We have determined the molecular mechanism for communication between these two pathways, showing that phosphate is transferred between inositol phosphates via ITPK1-bound nucleotide. Intersubstrate phosphate transfer explains how competing substrates are able to stimulate each others' catalysis by ITPK1. We further show that these features occur in the human protein, but not in plant or protozoan homologues. The high resolution structure of human ITPK1 identifies novel secondary structural features able to impart substrate selectivity and enhance nucleotide binding, thereby promoting intersubstrate phosphate transfer. Our work describes a novel mode of substrate regulation and provides insight into the enzyme evolution of a signaling mechanism from a metabolic role.	Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA; NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Virginia Polytech Inst & State Univ, Dept Plant Pathol, Blacksburg, VA 24061 USA	Novartis; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Virginia Polytechnic Institute & State University	Shears, SB (corresponding author), Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA.	shears@niehs.nih.gov; gspraggo@gnf.org	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 ES999999, Z01 ES080046-19] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Field J, 2000, MOL BIOCHEM PARASIT, V108, P119, DOI 10.1016/S0166-6851(00)00197-3; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Ho MWY, 2002, CURR TOP MEMBR, V53, P345, DOI 10.1016/S1063-5823(02)53041-6; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lesley SA, 2001, PROTEIN EXPRES PURIF, V22, P159, DOI 10.1006/prep.2001.1465; Lesley SA, 2002, P NATL ACAD SCI USA, V99, P11664, DOI 10.1073/pnas.142413399; Leyman A, 2007, CELL SIGNAL, V19, P1497, DOI 10.1016/j.cellsig.2007.01.024; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Miller GJ, 2005, MOL CELL, V18, P201, DOI 10.1016/j.molcel.2005.03.016; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian X, 2005, BIOCHEM J, V389, P389, DOI 10.1042/BJ20050297; Renstrom E, 2002, J BIOL CHEM, V277, P26717, DOI 10.1074/jbc.C200314200; Riley AM, 2006, FEBS LETT, V580, P324, DOI 10.1016/j.febslet.2005.12.016; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Shi JR, 2003, PLANT PHYSIOL, V131, P507, DOI 10.1104/pp.014258; SOBOLL S, 1978, EUR J BIOCHEM, V87, P377, DOI 10.1111/j.1432-1033.1978.tb12387.x; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210, DOI 10.1152/ajpcell.1993.264.5.C1210; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; Yang L, 2006, J CELL SCI, V119, P1320, DOI 10.1242/jcs.02836; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200	38	30	34	5	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28117	28125		10.1074/jbc.M703121200	http://dx.doi.org/10.1074/jbc.M703121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17616525	hybrid, Green Accepted			2022-12-27	WOS:000249455600061
J	Wielputz, MO; Lee, IH; Dinudom, A; Boulkroun, S; Farman, N; Cook, DI; Korbmacher, C; Rauh, R				Wielpuetz, Mark O.; Lee, Il-Ha; Dinudom, Anuwat; Boulkroun, Sheerazed; Farman, Nicolette; Cook, David I.; Korbmacher, Christoph; Rauh, Robert			(NDRG2) stimulates amiloride-sensitive Na+ currents in Xenopus laevis oocytes and fisher rat thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; RENAL COLLECTING DUCT; INDUCIBLE KINASE SGK; SURFACE EXPRESSION; LIDDLES-SYNDROME; CYSTIC-FIBROSIS; N-MYC; ENAC; ALDOSTERONE; SERUM	Regulation of the epithelial sodium channel (ENaC) is highly complex and may involve several aldosterone-induced regulatory proteins. The N-Myc downstream-regulated gene 2 (NDRG2) has been identified as an early aldosterone-induced gene. Therefore, we hypothesized that NDRG2 may affect ENaC function. To test this hypothesis we measured the amiloride-sensitive (2 mu m) whole cell current (Delta I-ami) in Xenopus laevis oocytes expressing ENaC alone or co-expressing ENaC and NDRG2. Co-expression of NDRG2 significantly increased Delta I-ami in some, but not, all batches of oocytes tested. An inhibitory effect of NDRG2 was never observed. Using a chemiluminescence assay we demonstrated that the NDRG2-induced increase in ENaC currents was accompanied by a similar increase in channel surface expression. The stimulatory effect of NDRG2 was preserved in oocytes maintained in a low sodium bath solution to prevent sodium feedback inhibition. These findings suggest that the stimulatory effect of NDRG2 is independent of sodium feedback regulation. Furthermore, the stimulatory effect of NDRG2 on ENaC was at least in part additive to that of Sgk1. A short isoform of NDRG2 also stimulated Delta I-ami. Overexpression of NDRG2 and ENaC in Fisher rat thyroid cells confirmed the stimulatory effect of NDRG2 on ENaC-mediated short-circuit current (Isc-ami). In addition, small interference RNA against NDRG2 largely reduced ISC-ami in Fisher rat thyroid cells. Our results indicate that NDRG2 is a likely candidate to contribute to aldosterone-mediated ENaC regulation.	Univ Erlangen Nurnberg, Inst Zellular & Mol Physiol, D-91054 Erlangen, Germany; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Coll France, INSERM, U772, F-75231 Paris, France	University of Erlangen Nuremberg; University of Sydney; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellular & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de	Boulkroun, Sheerazed/M-4459-2017; Rauh, Robert/F-4129-2014; Wielpuetz, Mark/ABE-1790-2020; Boulkroun, Sheerazed/AAX-8348-2021; Wielpütz, Mark Oliver/ADP-0499-2022	Boulkroun, Sheerazed/0000-0002-8796-7534; Rauh, Robert/0000-0002-9406-3939; Wielpuetz, Mark/0000-0001-6962-037X; Boulkroun, Sheerazed/0000-0002-8796-7534; Wielpütz, Mark Oliver/0000-0001-6962-037X				Boulkroun S, 2005, PFLUG ARCH EUR J PHY, V451, P388, DOI 10.1007/s00424-005-1410-x; Boulkroun S, 2002, J BIOL CHEM, V277, P31506, DOI 10.1074/jbc.M200272200; Burchfield JG, 2004, J BIOL CHEM, V279, P18623, DOI 10.1074/jbc.M401504200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Drummond HA, 2006, AM J PHYSIOL-CELL PH, V290, pC404, DOI 10.1152/ajpcell.00210.2005; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hongo S, 2006, J CELL BIOCHEM, V98, P185, DOI 10.1002/jcb.20763; Hu XL, 2006, CELL TISSUE RES, V325, P67, DOI 10.1007/s00441-005-0137-5; Huang AM, 2000, GENETICS, V156, P1219; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Kraus C, 2007, CELL PHYSIOL BIOCHEM, V19, P239, DOI 10.1159/000100643; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Rauh R, 2006, PFLUG ARCH EUR J PHY, V452, P290, DOI 10.1007/s00424-005-0026-5; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Verrey F, 2003, CELL PHYSIOL BIOCHEM, V13, P21, DOI 10.1159/000070246; Wagner CA, 2000, J PHYSIOL-LONDON, V526, P35, DOI 10.1111/j.1469-7793.2000.00035.x; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	49	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28264	28273		10.1074/jbc.M702168200	http://dx.doi.org/10.1074/jbc.M702168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652085	hybrid			2022-12-27	WOS:000249455600076
J	Athanasopoulos, AN; Schneider, D; Keiper, T; Alt, V; Pendurthi, UR; Liegibel, UM; Sommer, U; Nawroth, PP; Kasperk, C; Chavakis, T				Athanasopoulos, Athanasios N.; Schneider, Darius; Keiper, Tanja; Alt, Volker; Pendurthi, Usha R.; Liegibel, Ute M.; Sommer, Ulrike; Nawroth, Peter P.; Kasperk, Christian; Chavakis, Triantafyllos			Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in Osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; BONE-FORMATION; EXTRACELLULAR-MATRIX; CYR61 CCN1; ANGIOGENESIS; EXPRESSION; VEGF; PRODUCT; REPAIR; MECHANISMS	Angiogenesis is indispensable during fracture repair, and vascular endothelial growth factor ( VEGF) is critical in this process. CCN1 ( CYR61) is an extracellular matrix signaling molecule that has been implicated in neovascularization through its interactions with several endothelial integrin receptors. CCN1 has been shown to be up-regulated during the reparative phase of fracture healing; however, the role of CCN1 therein remains unclear. Here, the regulation of CCN1 expression in osteoblasts and the functional consequences thereof were studied. Stimulation of osteoblasts with VEGF resulted in a dose- and time-dependent up-regulation of CCN1 mRNA and protein. An up-regulation of both cell surface-associated CCN1 as well as extracellular matrix-associated CCN1 in osteoblasts was found. The supernatant of VEGF-prestimulated osteoblasts was chemotactic for endothelial cells, increasing their migration and stimulated capillary-like sprout formation. These effects could be attributed to the presence of CCN1 in the osteoblast supernatant as they were prevented by an antibody against CCN1 or by small interfering RNA-mediated knockdown of osteoblast CCN1. Moreover, the supernatant of VEGF-prestimulated osteoblasts induced angiogenesis in Matrigel plugs in vivo in a CCN1-dependent manner. In addition, blockade of CCN1 prevented bone fracture healing in mice. Taken together, the present work demonstrates a potential paracrine loop consisting of the VEGF-mediated up-regulation of CCN1 in osteoblasts that attracts endothelial cells and promotes angiogenesis. Such a loop could be operative during fracture healing.	NCI, EIB, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Heidelberg, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Hosp Giessen Marburg, Dept Trauma Surg, D-35385 Giessen, Germany; Univ Texas, Hlth Ctr Tyler, Biomed Res Div, Tyler, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; University Hospital of Giessen & Marburg; University of Texas System; University of Texas at Tyler	Chavakis, T (corresponding author), NCI, EIB, Natl Inst Hlth, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Chavakis, Triantafyllos/ABE-8845-2020		NHLBI NIH HHS [R01 HL058869-06, R01 HL058869, R01 HL058869-05A3] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010664] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanasopoulos AN, 2006, BLOOD, V107, P2720, DOI 10.1182/blood-2005-08-3140; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Barcelos LS, 2005, J LEUKOCYTE BIOL, V78, P352, DOI 10.1189/jlb.1104682; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; DECKER B, 1995, ANAT RECORD, V242, P310, DOI 10.1002/ar.1092420304; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Haigh JJ, 2000, DEVELOPMENT, V127, P1445; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kasperk C, 1997, CALCIFIED TISSUE INT, V61, P464, DOI 10.1007/s002239900369; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Korff T, 1999, J CELL SCI, V112, P3249; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Liegibel UM, 2002, J EXP MED, V196, P1387, DOI 10.1084/jem.20021017; Mandracchia V J, 2001, Clin Podiatr Med Surg, V18, P55; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Pendurthi UR, 2005, CANCER RES, V65, P9705, DOI 10.1158/0008-5472.CAN-05-0982; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Radke S, 2006, J ORTHOP RES, V24, P945, DOI 10.1002/jor.20097; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006; Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086-200009000-00033; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; TRUETA J, 1963, J BONE JOINT SURG BR, V45, P402, DOI 10.1302/0301-620X.45B2.402; TRUETA J, 1960, J BONE JOINT SURG BR, V42, P367, DOI 10.1302/0301-620X.42B2.367; Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953; Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756-3282(96)00133-0; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zhou DM, 2005, J APPL PHYSIOL, V98, P2344, DOI 10.1152/japplphysiol.01093.2004	45	72	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26746	26753		10.1074/jbc.M705200200	http://dx.doi.org/10.1074/jbc.M705200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626014	hybrid, Green Accepted			2022-12-27	WOS:000249304900013
J	Lauer-Fields, JL; Cudic, M; Wei, S; Mari, F; Fields, GB; Brew, K				Lauer-Fields, Janelle L.; Cudic, Mare; Wei, Shuo; Mari, Frank; Fields, Gregg B.; Brew, Keith			Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; NMR-SPECTROSCOPY; SECONDARY STRUCTURE; MASS-SPECTROMETRY; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ENDOTHELIN; TIMP-1; PEPTIDE	The sarafotoxins and endothelins are similar to 25-residue peptides that spontaneously fold into a defined tertiary structure with specific pairing of four cysteines into two disulfide bonds. Their structures show an interesting topological similarity to the core of the metalloproteinase interaction sites of the tissue inhibitors of metalloproteinases. Previous work indicates that sarafotoxins and endothelins can be engineered to eliminate or greatly reduce their vasopressive action and that their structural framework can withstand multiple sequence changes. When sarafotoxin 6b, which possesses modest matrix metalloproteinase inhibitory activity, was C-terminally truncated to remove its toxic vasopressive activity, the metalloproteinase inhibitory activity was essentially abolished. However, further changes, based on the sequences of peptides selected from libraries of sarafotoxin variants or suggested by analogy with tissue inhibitors of metalloproteinases, progressively enhanced the matrix metalloproteinase inhibitory activity. Peptide variants with multiple substitutions folded correctly and formed native disulfide bonds. Improvements in matrix metalloproteinase affinity have generated a peptide with micromolar K-i values for matrix metalloproteinase-1 and -9 that are selective inhibitors of different metalloproteinases. Characterization of its solution structure indicates a close similarity to sarafotoxin but with a more extended C-terminal helix. The effects of N- acetylation and other changes, as well as docking studies, support the hypothesis that the engineered sarafo-toxins bind to matrix metalloproteinases in a manner analogous to the tissue inhibitors of metalloproteinases.	Florida Atlantic Univ, Coll Biomed Sci, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University; State University System of Florida; Florida Atlantic University	Brew, K (corresponding author), Florida Atlantic Univ, Coll Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	kbrew@fau.edu	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Wei, Shuo/0000-0001-8203-4922	NATIONAL CANCER INSTITUTE [R01CA098799] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98799, R01 CA098799] Funding Source: Medline; NCRR NIH HHS [P41 RR 001081] Funding Source: Medline; NIAMS NIH HHS [AR 40994] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham David, 2005, Current Vascular Pharmacology, V3, P369; AIMOTO S, 1990, BIOCHEM INT, V21, P1051; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Arumugam S, 2003, J MOL BIOL, V327, P719, DOI 10.1016/S0022-2836(03)00180-3; ATKINS AR, 1994, INT J PEPT PROT RES, V44, P372; ATKINS AR, 1995, BIOCHEMISTRY-US, V34, P2026, DOI 10.1021/bi00006a024; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; CODY WL, 1995, BIOPOLYMERS, V37, P89, DOI 10.1002/bip.360370205; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DUCANCEL F, 1993, J BIOL CHEM, V268, P3052; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fernandez-Patron C, 1999, CIRC RES, V85, P906; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gray GA, 1996, PHARMACOL THERAPEUT, V72, P109, DOI 10.1016/S0163-7258(96)00101-5; Hayashi MAF, 2004, PEPTIDES, V25, P1243, DOI 10.1016/j.peptides.2004.05.010; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Iyer S, 2007, J BIOL CHEM, V282, P364, DOI 10.1074/jbc.M607625200; JANES RW, 1994, NAT STRUCT BIOL, V1, P311, DOI 10.1038/nsb0594-311; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KIMURA S, 1988, BIOCHEM BIOPH RES CO, V156, P1182, DOI 10.1016/S0006-291X(88)80757-5; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lauer-Fields JL, 2007, J BIOL CHEM, V282, P142, DOI 10.1074/jbc.M605236200; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; Maskos K, 2007, J MOL BIOL, V366, P1222, DOI 10.1016/j.jmb.2006.11.072; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MILLS RG, 1991, FEBS LETT, V282, P247, DOI 10.1016/0014-5793(91)80488-O; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAKAJIMA K, 1989, J CARDIOVASC PHARM, V13, pS8, DOI 10.1097/00005344-198900135-00004; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Price WS, 1999, ANNU REP NMR SPECTRO, V38, P289, DOI 10.1016/S0066-4103(08)60040-X; Quinton L, 2005, ANAL CHEM, V77, P6630, DOI 10.1021/ac050575k; RAMALINGAM K, 1993, BIOCHEMISTRY-US, V32, P11155, DOI 10.1021/bi00092a027; Ramnath Nithya, 2004, Curr Oncol Rep, V6, P96, DOI 10.1007/s11912-004-0020-7; Schneidman-Duhovny D, 2003, PROTEINS, V52, P107, DOI 10.1002/prot.10397; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	54	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26948	26955		10.1074/jbc.M611612200	http://dx.doi.org/10.1074/jbc.M611612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626018	hybrid			2022-12-27	WOS:000249304900034
J	Rimon, A; Tzubery, T; Padan, E				Rimon, Abraham; Tzubery, Tzvi; Padan, Etana			Monomers of the NhaA Na+/H+ antiporter of Escherichia coli are fully functional yet dimers are beneficial under extreme stress conditions at alkaline pH in the presence of Na+ or Li+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL-CHANGE; HUMAN ERYTHROCYTE-MEMBRANE; ANION TRANSPORT PROTEIN; PROJECTION STRUCTURE; OLIGOMERIC STATE; CORYNEBACTERIUM-GLUTAMICUM; STRUCTURAL INTERACTIONS; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; ION-TRANSPORT	NhaA, the Na+/ H+ antiporter of Escherichia coli, exists in the native membrane as a homodimer of which two monomers have been suggested to be attached by a beta-hairpin at the periplasmic side of the membrane. Constructing a mutant deleted of the beta-hairpin, NhaA/Delta( Pro(45)- Asn(58)), revealed that in contrast to the dimeric mobility of native NhaA, the mutant has the mobility of a monomer in a blue native gel. Intermolecular cross-linking that monitors dimers showed that the mutant exists only as monomers in the native membrane, proteoliposomes, and when purified in beta-dodecyl maltoside micelles. Furthermore, pull-down experiments revealed that, whereas as expected for a dimer, hemagglutinin-tagged wild-type NhaA co-purified with His-tagged NhaA on a Ni2+- NTA affinity column, a similar version of the mutant did not. Remarkably, under routine stress conditions ( 0.1 M LiCl, pH 7 or 0.6 M NaCl, pH 8.3), the monomeric form of NhaA is fully functional. It conferred salt resistance to NhaA- and NhaB-deleted cells, and whether in isolated membrane vesicles or reconstituted into proteoliposomes exhibited Na+/ H+ antiporter activity and pH regulation very similar to wild- type dimers. Remarkably, under extreme stress conditions ( 0.1 M LiCl or 0.7 M NaCl at pH 8.5), the dimeric native NhaA was much more efficient than the monomeric mutant in conferring extreme stress resistance.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brett CL, 2005, AM J PHYSIOL-CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Hilger D, 2005, BIOPHYS J, V89, P1328, DOI 10.1529/biophysj.105.062232; HILGER D, 2007, IN PRESS BIOPHYS J; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; IANOWSKI R, 2001, NAT STRUCT BIOL, V8, P316; Kozachkov L, 2007, BIOCHEMISTRY-US, V46, P2419, DOI 10.1021/bi602393s; Kramer R, 2004, BBA-BIOENERGETICS, V1658, P31, DOI 10.1016/j.bbabio.2004.05.006; Maris AE, 2005, J MOL BIOL, V350, P843, DOI 10.1016/j.jmb.2005.05.057; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; MURAKAMI S, 2006, NATURE; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; ORLOWSKI I, 2004, PFLUGERS ARCH, V447, P549; Padan E, 2005, BBA-BIOMEMBRANES, V1717, P67, DOI 10.1016/j.bbamem.2005.09.010; Padan E, 2004, BBA-BIOENERGETICS, V1658, P2, DOI 10.1016/j.bbabio.2004.04.018; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; PINNER E, 1993, J BIOL CHEM, V268, P1729; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 2003, BLUE NATIVE ELECTROP, P105; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Screpanti E, 2006, J MOL BIOL, V362, P192, DOI 10.1016/j.jmb.2006.07.019; Slepkov ER, 2007, BIOCHEM J, V401, P623, DOI 10.1042/BJ20061062; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; Van Dort HM, 2001, J BIOL CHEM, V276, P46968, DOI 10.1074/jbc.M107855200; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; Venturi M, 2000, J BIOL CHEM, V275, P4734, DOI 10.1074/jbc.275.7.4734; Venturi M., 2002, PRACTICAL GUIDE MEMB, P179; Vinothkumar KR, 2006, J BIOL CHEM, V281, P4795, DOI 10.1074/jbc.M508993200; Vinothkumar KR, 2005, EMBO J, V24, P2720, DOI 10.1038/sj.emboj.7600727; Wakabayashi S, 2003, J BIOL CHEM, V278, P43580, DOI 10.1074/jbc.M306690200; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Yamaguchi T, 2005, TRENDS PLANT SCI, V10, P615, DOI 10.1016/j.tplants.2005.10.002; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	65	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26810	26821		10.1074/jbc.M704469200	http://dx.doi.org/10.1074/jbc.M704469200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635927	hybrid			2022-12-27	WOS:000249304900021
J	Wang, YL; Stieglitz, KA; Bubunenko, M; Court, DL; Stec, B; Roberts, MF				Wang, Yanling; Stieglitz, Kimberly A.; Bubunenko, Mikhail; Court, Donald L.; Stec, Boguslaw; Roberts, Mary F.			The structure of the R184A mutant of the inositol monophosphatase encoded by suhB and implications for its functional interactions in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SENSITIVE GROWTH; GENE-PRODUCT; PROTEIN; MUTATION; DOCKING; RECOMBINATION; REPLACEMENT; SUPPRESSES; BACTERIAL	The Escherichia coli product of the suhB gene, SuhB, is an inositol monophosphatase (IMPase) that is best known as a suppressor of temperature-sensitive growth phenotypes in E. coli. To gain insights into these biological diverse effects, we determined the structure of the SuhB R184A mutant protein. The structure showed a dimer organization similar to other IMPases, but with an altered interface suggesting that the presence of Arg-184 in the wild-type protein could shift the monomer-dimer equilibrium toward monomer. In parallel, a gel shift assay showed that SuhB forms a tight complex with RNA polymerase (RNA pol) that inhibits the IMPase catalytic activity of SuhB. A variety of SuhB mutant proteins designed to stabilize the dimer interface did not show a clear correlation with the ability of a specific mutant protein to complement the Delta suhB mutation when introduced extragenically despite being active IMPases. However, the loss of sensitivity to RNA pol binding, i.e. in G173V, R184I, and L96F/R184I, did correlate strongly with loss of complementation of Delta suhB. Because residue 184 forms the core of the SuhB dimer, it is likely that the interaction with RNA polymerase requires monomeric SuhB. The exposure of specific residues facilitates the interaction of SuhB with RNA pol (or another target with a similar binding surface) and it is this heterodimer formation that is critical to the ability of SuhB to rescue temperature-sensitive phenotypes in E. coli.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; NIH, NCI, Ctr Canc Res, Gene Regulat & Chrosome Biol Lab, Ft Detrick, MD 21702 USA; SAIC Frederick, Basic Res Program, Chestnut Hill, MA 02467 USA; Burnham Inst, Med Res, La Jolla, CA 92037 USA	Boston College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Sanford Burnham Prebys Medical Discovery Institute	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu		Stec, Boguslaw/0000-0002-8696-0349; Stieglitz, Kimberly/0000-0001-6086-3682	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; NIGMS NIH HHS [GM 64481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064481] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arifuzzaman M, 2006, GENOME RES, V16, P686, DOI 10.1101/gr.4527806; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; Bubunenko M, 2007, J BACTERIOL, V189, P2844, DOI 10.1128/JB.01713-06; CHANG SF, 1991, J BIOL CHEM, V266, P3654; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P4145, DOI 10.1021/bi992424f; Chen LJ, 1999, APPL ENVIRON MICROB, V65, P4559; Court DL, 2002, ANNU REV GENET, V36, P361, DOI 10.1146/annurev.genet.36.061102.093104; DeLano W.L, PYMOL MOL GRAPHICS S; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; INADA T, 1995, BIOCHIMIE, V77, P294, DOI 10.1016/0300-9084(96)88139-9; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Johnson KA, 2001, BIOCHEMISTRY-US, V40, P618, DOI 10.1021/bi0016422; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KOZLOFF LM, 1991, J BACTERIOL, V173, P2053, DOI 10.1128/jb.173.6.2053-2060.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MATSUHISA A, 1995, J BACTERIOL, V177, P200, DOI 10.1128/jb.177.1.200-205.1995; Morgan AJ, 2004, J AM CHEM SOC, V126, P15370, DOI 10.1021/ja047360x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Salwinski L, 2003, CURR OPIN STRUC BIOL, V13, P377, DOI 10.1016/S0959-440X(03)00070-8; SHIBA K, 1984, J BACTERIOL, V160, P696, DOI 10.1128/JB.160.2.696-701.1984; Stieglitz KA, 2002, J BIOL CHEM, V277, P22863, DOI 10.1074/jbc.M201042200; THOMASON LC, 2005, CURRENT PROTOCOLS MO; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; YANO R, 1990, J BACTERIOL, V172, P2124, DOI 10.1128/jb.172.4.2124-2130.1990; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	29	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26989	26996		10.1074/jbc.M701210200	http://dx.doi.org/10.1074/jbc.M701210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17652087	hybrid			2022-12-27	WOS:000249304900039
J	Corratge, C; Zimmermann, S; Lambilliotte, RRL; Plassard, C; Marmeisse, R; Thibaud, JB; Lacombe, B; Sentenac, H				Corratge, Claire; Zimmermann, Sabine; Lambilliotte, Raphael; Plassard, Claude; Marmeisse, Roland; Thibaud, Jean-Baptiste; Lacombe, Benoit; Sentenac, Herve			Molecular and functional characterization of a Na+-K+ transporter from the Trk family in the ectomycorrhizal fungus Hebeloma cylindrosporumk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY POTASSIUM; PINE PINUS-PINASTER; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; GLYCINE RESIDUES; ION-TRANSPORT; YEAST; CHANNEL; GENE; SELECTIVITY	Ectomycorrhizal symbiosis between fungi and woody plants strongly improves plant mineral nutrition and constitutes a major biological process in natural ecosystems. Molecular identification and functional characterization of fungal transport systems involved in nutrient uptake are crucial steps toward understanding the improvement of plant nutrition and the symbiotic relationship itself. In the present report a transporter belonging to the Trk family is identified in the model ectomycorrhizal fungus Hebeloma cylindrosporum and named HcTrk1. The Trk family is still poorly characterized, although it plays crucial roles in K+ transport in yeasts and filamentous fungi. In Saccharomyces cerevisiae K+ uptake is mainly dependent on the activity of Trk transporters thought to mediateH(+): K+ symport. The ectomycorrhizal HcTrk1 transporter was functional when expressed in Xenopus oocytes, enabling the first electrophysiological characterization of a transporter from the Trk family. HcTrk1 mediates instantaneously activating inwardly rectifying currents, is permeable to both K+ and Na+, and displays channellike functional properties. The whole set of data and particularly a phenomenon reminiscent of the anomalous mole fraction effect suggest that the transport does not occur according to the classical alternating access model. Permeation appears to occur through a single-file pore, where interactions between Na+ and K+ might result in Na+: K+ co-transport activity. HcTrk1 is expressed in external hyphae that explore the soil when the fungus grows in symbiotic condition. Thus, it could play a major role in both the K+ and Na+ nutrition of the fungus ( and of the plant) in nutrient-poor soils.	INRA, CNRS, UMR 5004, SupAgro,UMII, F-34060 Montpellier, France; CNRS, UCBL 1, Ecol Microbienne, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); VetAgro Sup	Sentenac, H (corresponding author), INRA, CNRS, UMR 5004, SupAgro,UMII, Pl Viala, F-34060 Montpellier, France.	sentenac@supagro.inra.fr	Lacombe, Benoit/B-1202-2013	Sentenac, Herve/0000-0003-3641-4822; THIBAUD, Jean-Baptiste/0000-0002-0824-6465; corratge-faillie, claire/0000-0002-5738-6712; Plassard, Claude/0000-0002-5844-438X; Lacombe, Benoit/0000-0001-9924-3093; Marmeisse, Roland/0000-0003-1653-3517; Zimmermann, Sabine D./0000-0002-5020-1447				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Aidley D.J., 1996, ION CHANNELS MOL ACT; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON JA, 1991, GENE, V99, P39, DOI 10.1016/0378-1119(91)90031-6; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Banuelos MA, 2000, MOL MICROBIOL, V37, P671, DOI 10.1046/j.1365-2958.2000.02040.x; Benito B, 2004, EUKARYOT CELL, V3, P359, DOI 10.1128/EC.3.2.359-368.2004; Benjdia M, 2006, NEW PHYTOL, V170, P401, DOI 10.1111/j.1469-8137.2006.01672.x; Berthomieu P, 2003, EMBO J, V22, P2004, DOI 10.1093/emboj/cdg207; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; Bertl A, 2003, MOL MICROBIOL, V47, P767, DOI 10.1046/j.1365-2958.2003.03335.x; Burgess T, 1996, MYCORRHIZA, V6, P189, DOI 10.1007/s005720050125; CAMACHO M, 1981, CURR MICROBIOL, V6, P295, DOI 10.1007/BF01566880; Casarin V, 2003, AGRONOMIE, V23, P461, DOI 10.1051/agro:2003020; Chalot M, 2002, PLANT SOIL, V244, P165, DOI 10.1023/A:1020240709543; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEBAUD JC, 1987, NEW PHYTOL, V105, P429, DOI 10.1111/j.1469-8137.1987.tb00880.x; DeFelice LJ, 2004, NATURE, V432, P279, DOI 10.1038/432279a; DeFelice LJ, 2007, ANNU REV PHYSIOL, V69, P87, DOI 10.1146/annurev.physiol.69.031905.164816; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; Haro R, 2003, BBA-BIOMEMBRANES, V1613, P1, DOI 10.1016/S0005-2736(03)00132-9; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Haro R, 2002, BBA-BIOMEMBRANES, V1564, P114, DOI 10.1016/S0005-2736(02)00408-X; Haro R, 1999, MOL MICROBIOL, V31, P511, DOI 10.1046/j.1365-2958.1999.01192.x; Harrison MJ, 2005, ANNU REV MICROBIOL, V59, P19, DOI 10.1146/annurev.micro.58.030603.123749; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hille B, 2001, ION CHANNELS EXCITAB, P1; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jargeat P, 2000, MOL GEN GENET, V263, P948, DOI 10.1007/PL00008695; Jargeat P, 2003, CURR GENET, V43, P199, DOI 10.1007/s00294-003-0387-2; Javelle A, 2001, FEBS LETT, V505, P393, DOI 10.1016/S0014-5793(01)02802-2; Jongmans AG, 1997, NATURE, V389, P682, DOI 10.1038/39493; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kiefer E, 2000, PLANT MOL BIOL REP, V18, P33, DOI 10.1007/BF02825291; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; Kuroda T, 2004, J MEMBRANE BIOL, V198, P177, DOI 10.1007/s00232-004-0671-1; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Lambilliotte R, 2004, NEW PHYTOL, V164, P505, DOI 10.1111/j.1469-8137.2004.01185.x; Landeweert R, 2001, TRENDS ECOL EVOL, V16, P248, DOI 10.1016/S0169-5347(01)02122-X; Lauger P., 1991, ELECTROGENIC ION PUM; LichtenbergFrate H, 1996, J MEMBRANE BIOL, V152, P169, DOI 10.1007/s002329900095; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Maathuis FJM, 1996, PHYSIOL PLANTARUM, V96, P158, DOI 10.1111/j.1399-3054.1996.tb00197.x; MARDIN F, 2007, NEW PHYSL, V176, P225; Marmeisse R, 2004, NEW PHYTOL, V163, P481, DOI 10.1111/j.1469-8137.2004.01148.x; MARX DH, 1969, PHYTOPATHOLOGY, V59, P153; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Maser P, 2002, FEBS LETT, V531, P157, DOI 10.1016/S0014-5793(02)03488-9; Molina ML, 2006, J BIOL CHEM, V281, P18837, DOI 10.1074/jbc.M600342200; Nielsen CB, 2004, PLOS BIOL, V2, P2234, DOI 10.1371/journal.pbio.0020422; PLASSARD C, 1994, CAN J BOT, V72, P189, DOI 10.1139/b94-026; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAPIOR S, 1987, T BRIT MYCOL SOC, V89, P41, DOI 10.1016/S0007-1536(87)80055-4; Rivetta A, 2005, BIOPHYS J, V89, P2412, DOI 10.1529/biophysj.105.066712; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; RYGIEWICZ PT, 1984, PLANT PHYSIOL, V76, P918, DOI 10.1104/pp.76.4.918; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEROMM P, 1990, NEW PHYTOL, V114, P93, DOI 10.1111/j.1469-8137.1990.tb00378.x; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SIMON L, 1993, NATURE, V363, P67, DOI 10.1038/363067a0; SMITH SE, 1997, MYCORRHIZAL SYMBOSIS; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Stein W., 1990, CHANNELS CARRIERS PU; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Tholema N, 2005, J BIOL CHEM, V280, P41146, DOI 10.1074/jbc.M507647200; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; Very AA, 2003, ANNU REV PLANT BIOL, V54, P575, DOI 10.1146/annurev.arplant.54.031902.134831; Zeng GF, 2004, J BIOL CHEM, V279, P3003, DOI 10.1074/jbc.M309760200	79	44	44	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26057	26066		10.1074/jbc.M611613200	http://dx.doi.org/10.1074/jbc.M611613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626012	Green Published, hybrid			2022-12-27	WOS:000249239600009
J	Sari, F; Braus, GH; Irniger, S				Sari, Fatih; Braus, Gerhard H.; Irniger, Stefan			A process independent of the anaphase-promoting complex contributes to instability of the yeast S phase cyclin Clb5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; APC-DEPENDENT PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; DESTRUCTION BOX; MITOTIC CYCLIN; PERSISTS UNTIL; G1 CYCLINS; DEGRADATION	Proteolytic destruction of many cyclins is induced by a multisubunit ubiquitin ligase termed the anaphase promoting complex/ cyclosome (APC/C). In the budding yeast Saccharomyces cerevisiae, the S phase cyclin Clb5 and the mitotic cyclins Clb1-4 are known as substrates of this complex. The relevance of APC/C in proteolysis of Clb5 is still under debate. Importantly, a deletion of the Clb5 destruction box has little influence on cell cycle progression. To understand Clb5 degradation in more detail, we applied in vivo pulse labeling to determine the half-life of Clb5 at different cell cycle stages and in the presence or absence of APC/C activity. Clb5 is significantly unstable, with a half-life of similar to 8-10 min, at cell cycle periods when APC/C is inactive and in mutants impaired in APC/C function. A Clb5 version lacking its cyclin destruction box is similarly unstable. The half-life of Clb5 is further decreased in a destruction box-dependent manner to 3-5 min in mitotic or G(1) cells with active APC/C. Clb5 instability is highly dependent on the function of the proteasome. We conclude that Clb5 proteolysis involves two different modes for targeting of Clb5 to the proteasome, an APC/C-dependent and an APC/C-independent mechanism. These different modes apparently have overlapping functions in restricting Clb5 levels in a normal cell cycle, but APC/C function is essential in the presence of abnormally high Clb5 levels.	Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Leibniz Univ Hannover, Inst Microbiol, D-30167 Hannover, Germany	University of Gottingen; Leibniz University Hannover	Irniger, S (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	sirnige@gwdg.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; Irniger S, 1997, J CELL SCI, V110, P1523; Jackson LP, 2006, MOL CELL BIOL, V26, P2456, DOI 10.1128/MCB.26.6.2456-2466.2006; Jacobson MD, 2000, MOL CELL BIOL, V20, P4483, DOI 10.1128/MCB.20.13.4483-4493.2000; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thornton BR, 2004, CELL CYCLE, V3, P629; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yeong FM, 2001, MOL CELL BIOL, V21, P5071, DOI 10.1128/MCB.21.15.5071-5081.2001; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	38	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26614	10.1074/jbc.M703744200	http://dx.doi.org/10.1074/jbc.M703744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620341	hybrid			2022-12-27	WOS:000249239600064
J	Benach, J; Wang, LL; Chen, Y; Ho, CK; Lee, SY; Seetharaman, J; Xiao, R; Acton, TB; Montelione, GT; Deng, HY; Sun, R; Tong, L				Benach, Jordi; Wang, Lili; Chen, Yang; Ho, Chi Kent; Lee, Shaoying; Seetharaman, Jayaraman; Xiao, Rong; Acton, Thomas B.; Montelione, Gaetano T.; Deng, Hongyu; Sun, Ren; Tong, Liang			Structural and functional studies of the abundant tegument protein ORF52 from murine gammaherpesvirus 68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; PSEUDORABIES VIRUS; VIRAL GENES; HERPESVIRUS; IDENTIFICATION; INFECTION; CLONING; MOUSE; MODEL; CONSTRUCTION	The tegument is a layer of proteins between the nucleocapsid and the envelope of herpesviruses. The functions of most tegument proteins are still poorly understood. In murine gammaherpesvirus 68, ORF52 is an abundant tegument protein of 135 residues that is required for the assembly and release of infectious virus particles. To help understand the molecular basis for the function of this protein, we have determined its crystal structure at 2.1 angstrom resolution. The structure reveals a dimeric association of this protein. Interestingly, an N-terminal alpha-helix that assumes different conformation in the two monomers of the dimer mediates the formation of an asymmetrical tetramer and contains many highly conserved residues. Structural and sequence analyses suggest that this helix is more likely involved in interactions with other components of the tegument or nucleocapsid of the virus and that ORF52 functions as a symmetrical dimer. The asymmetrical tetramer of ORF52 may be a "latent" form of the protein, when it is not involved in virion assembly. The self-association of ORF52 has been confirmed by co-immunoprecipitation and fluorescence resonance energy transfer experiments. Deletion of the N-terminal alpha-helix, as well as mutation of the conserved Arg(95) residue, abolished the function of ORF52. The results of the functional studies are fully consistent with the structural observations and indicate that the N-terminal alpha-helix is a crucial site of interaction for ORF52.	Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; Chinese Acad Sci, Ctr Infect & Immun, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ USA; Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Columbia University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Rutgers State University New Brunswick; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sun, R (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	rsun@mednet.ucla.edu; ltong@columbia.edu	Wang, Lili/AAJ-8511-2020	Wang, Lili/0000-0002-8315-531X; Tong, Liang/0000-0002-0563-6468; Montelione, Gaetano/0000-0002-9440-3059	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074958] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE015752] Funding Source: Medline; NIGMS NIH HHS [U54 GM074958] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 2005, METHOD ENZYMOL, V394, P210, DOI 10.1016/S0076-6879(05)94008-1; Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Blasdell K, 2003, J GEN VIROL, V84, P111, DOI 10.1099/vir.0.18731-0; Borst EM, 1999, J VIROL, V73, P8320, DOI 10.1128/JVI.73.10.8320-8329.1999; Bortz E, 2003, J VIROL, V77, P13425, DOI 10.1128/JVI.77.24.13425-13432.2003; Bortz E, 2007, J VIROL, V81, P10137, DOI 10.1128/JVI.01233-06; Bresnahan WA, 2000, P NATL ACAD SCI USA, V97, P14506, DOI 10.1073/pnas.97.26.14506; Britt WJ, 2004, HUM IMMUNOL, V65, P395, DOI 10.1016/j.humimm.2004.02.008; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castillo JP, 2002, GENE, V290, P19, DOI 10.1016/S0378-1119(02)00566-8; DeLano W.L., 2002, PYMOL MANUAL; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; Ebrahimi B, 2003, J GEN VIROL, V84, P99, DOI 10.1099/vir.0.18639-0; EFSTATHIOU S, 1990, J GEN VIROL, V71, P1365, DOI 10.1099/0022-1317-71-6-1365; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fuchs W, 2002, J VIROL, V76, P6729, DOI 10.1128/JVI.76.13.6729-6742.2002; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ishov AM, 2002, J VIROL, V76, P7705, DOI 10.1128/JVI.76.15.7705-7712.2002; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; Johannsen E, 2004, P NATL ACAD SCI USA, V101, P16286, DOI 10.1073/pnas.0407320101; Kattenhorn LM, 2004, J VIROL, V78, P11187, DOI 10.1128/JVI.78.20.11187-11197.2004; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Martinez-Guzman D, 2003, J VIROL, V77, P10488, DOI 10.1128/JVI.77.19.10488-10503.2003; Mettenleiter TC, 2004, VIRUS RES, V106, P167, DOI 10.1016/j.virusres.2004.08.013; Mettenleiter TC, 2002, J VIROL, V76, P1537, DOI 10.1128/JVI.76.4.1537-1547.2002; MISTRIKOVA J, 1985, ACTA VIROL, V29, P312; Nash AA, 1996, SEMIN VIROL, V7, P125, DOI 10.1006/smvy.1996.0016; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Connor CM, 2006, J VIROL, V80, P1574, DOI 10.1128/JVI.80.3.1574-1583.2006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAJCANI J, 1985, ACTA VIROL, V29, P51; ROLZMAN B, 2001, FIELDS VIROLOGY, P2399; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Smith GA, 1999, J VIROL, V73, P6405, DOI 10.1128/JVI.73.8.6405-6414.1999; Song MJ, 2005, P NATL ACAD SCI USA, V102, P3805, DOI 10.1073/pnas.0404521102; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Subak-Sharpe JH, 1998, VIRUS GENES, V16, P239, DOI 10.1023/A:1008068902673; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Varnum SM, 2004, J VIROL, V78, P10960, DOI 10.1128/JVI.78.20.10960-10966.2004; Weeks CM, 2003, METHOD ENZYMOL, V374, P37, DOI 10.1016/S0076-6879(03)74003-8; Zhu FX, 2002, P NATL ACAD SCI USA, V99, P5573, DOI 10.1073/pnas.082420599	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31534	31541		10.1074/jbc.M705637200	http://dx.doi.org/10.1074/jbc.M705637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17699518	hybrid			2022-12-27	WOS:000250309200045
J	Mistry, AC; Mallick, R; Frohlich, O; Klein, JD; Rehm, A; Chen, G; Sands, JM				Mistry, Abinash C.; Mallick, Rickta; Frohlich, Otto; Klein, Janet D.; Rehm, Armin; Chen, Guangping; Sands, Jeff M.			The UT-A1 urea transporter interacts with snapin, a SNARE-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BINDING PROTEIN; SYNTAXIN; SNAP-25; IDENTIFICATION; SPECIFICITY; COLOCALIZATION; SYNAPTOTAGMIN; AQUAPORIN-2; EXOCYTOSIS	The UT-A1 urea transporter mediates rapid transepithelial urea transport across the inner medullary collecting duct and plays a major role in the urinary concentrating mechanism. To transport urea, UT-A1 must be present in the plasma membrane. The purpose of this study was to screen for UT-A1-interacting proteins and to study the interactions of one of the identified potential binding partners with UT-A1. Using a yeast two-hybrid screen of a human kidney cDNA library with the UT-A1 intracellular loop (residues 409-594) as bait, we identified snapin, a ubiquitously expressed SNARE-associated protein, as a novel UT-A1 binding partner. Deletion analysis indicated that the C-terminal coiled-coil domain (H2) of snapin is required for UT-A1 interaction. Snapin binds to the intracellular loop of UT-A1 but not to the N- or C-terminal fragments. Glutathione S-transferase pulldown experiments and co-immunoprecipitation studies verified that snapin interacts with native UT-A1, SNAP23, and syntaxin-4 (t-SNARE partners), indicating that UT-A1 participates with the SNARE machinery in rat kidney inner medulla. Confocal microscopic analysis of immunofluorescent UT-A1 and snapin showed co-localization in both the cytoplasm and in the plasma membrane. When we co-injected UT-A1 with snapin cRNA in Xenopus oocytes, urea influx was significantly increased. In the absence of snapin, the influx was decreased when UT-A1 was combined with t- SNARE components syntaxin-4 and SNAP23. Weconclude that UT-A1 may be linked to the SNARE machinery via snapin and that this interaction may be functionally and physiologically important for urea transport.	Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Max Delbruck Ctr Mol Med, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Emory University; Emory University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sands, JM (corresponding author), Emory Univ, Sch Med, Dept Med, Div Renal, WMRB Rm 338,1639 Pierce Dr NE, Atlanta, GA 30322 USA.	jsands@emory.edu			NIDDK NIH HHS [R01-DK63657, P01 DK61521, R01 DK41707, R01 DK041707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041707, P01DK061521, R01DK063657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2005, PFLUG ARCH EUR J PHY, V450, P217, DOI 10.1007/s00424-005-1403-9; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chen GP, 2006, J BIOL CHEM, V281, P27436, DOI 10.1074/jbc.M605525200; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chou JL, 2004, J BIOL CHEM, V279, P46271, DOI 10.1074/jbc.M407206200; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Klein JD, 2006, J AM SOC NEPHROL, V17, P2680, DOI 10.1681/ASN.2006030246; Klein JD, 1997, AM J PHYSIOL-RENAL, V273, pF949, DOI 10.1152/ajprenal.1997.273.6.F949; Mandon B, 1997, AM J PHYSIOL-RENAL, V273, pF718, DOI 10.1152/ajprenal.1997.273.5.F718; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mistry AC, 2005, AM J PHYSIOL-RENAL, V288, pF455, DOI 10.1152/ajprenal.00296.2004; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Ruder C, 2005, MOL BIOL CELL, V16, P1245, DOI 10.1091/mbc.E04-09-0817; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Starcevic M, 2004, J BIOL CHEM, V279, P28393, DOI 10.1074/jbc.M402513200; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; Wendler F, 2001, TRAFFIC, V2, P606, DOI 10.1034/j.1600-0854.2001.20903.x; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	37	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30097	30106		10.1074/jbc.M705866200	http://dx.doi.org/10.1074/jbc.M705866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702749	hybrid			2022-12-27	WOS:000249981200040
J	Hasdemir, B; Bunnett, NW; Cottrell, GS				Hasdemir, Burcu; Bunnett, Nigel W.; Cottrell, Graeme S.			Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) mediates post-endocytic trafficking of protease-activated receptor 2 and calcitonin receptor-like receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; ACTIVITY-MODIFYING PROTEIN-1; COUPLED RECEPTOR; DOWN-REGULATION; EARLY ENDOSOMES; MOLECULAR-CLONING; UBIQUITIN; RESENSITIZATION; CLATHRIN; LYSOSOMES	The E3 ligase c-Cbl ubiquitinates protease-activated receptor 2 (PAR(2)), which is required for post-endocytic sorting of PAR(2) to lysosomes, where degradation arrests signaling. The mechanisms of post-endocytic sorting of ubiquitinated receptors are incompletely understood. Here, we investigated the role of hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), in post-endocytic sorting and signaling of PAR(2). In HEK-PAR(2) cells, PAR(2) activating peptide (PAR(2)-AP) induced PAR(2) trafficking from the cell surface to early endosomes containing endogenous HRS, and then to lysosomes. HRS overexpression or knockdown with small interfering RNA caused formation of enlarged HRS-positive endosomes, where activated PAR(2) and c-Cbl accumulated, and PAR(2) failed to traffic to lysosomes. Overexpression of HRS prevented PAR(2)-AP-induced degradation of PAR(2), as determined by Western blotting. Overexpression of HRS mutant lacking an ubiquitin-binding motif similarly caused retention of PAR(2) in enlarged endosomes. Moreover, HRS overexpression or knockdown caused retention of ubiquitin-resistant PAR(2)Delta 14K/R in enlarged HRS-containing endosomes, preventing recycling and resensitization of PAR(2)Delta 14K/R. HRS overexpression or knockdown similarly prevented lysosomal trafficking and recycling of calcitonin receptor-like receptor, a non-ubiquitinated receptor that traffics to lysosomes after sustained activation and recycles after transient activation. Thus, HRS plays a critically important role in the post-endocytic sorting of single receptors, PAR(2) and CLR, to both degradative and recycling pathways. This sorting role for HRS is independent of its ubiquitin-interacting motif, and it can regulate trafficking of both ubiquitinated and non-ubiquitinated PAR(2) and non-ubiquitinated CLR. The ultimate sorting decision to degradative or recycling pathways appears to occur downstream from HRS.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), 513 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu		Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R37DK039957, R56DK043207, R01DK043207, R01DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57840, DK39957, DK43207] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Clague MJ, 2002, CURR BIOL, V12, pR529, DOI 10.1016/S0960-9822(02)01030-8; Cottrell GS, 2007, J BIOL CHEM, V282, P12260, DOI 10.1074/jbc.M606338200; Cottrell GS, 2005, J COMP NEUROL, V490, P239, DOI 10.1002/cne.20669; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Hanyaloglu AC, 2007, J BIOL CHEM, V282, P3095, DOI 10.1074/jbc.M605398200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Lavezzari G, 2007, NEUROPHARMACOLOGY, V52, P100, DOI 10.1016/j.neuropharm.2006.07.011; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Morino C, 2004, EXP CELL RES, V297, P380, DOI 10.1016/j.yexcr.2004.03.038; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Scaife RM, 2000, J CELL SCI, V113, P215; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stern KA, 2007, MOL CELL BIOL, V27, P888, DOI 10.1128/MCB.02356-05; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Urbe S, 2005, ESSAYS BIOCHEM, V41, P81, DOI 10.1042/EB0410081; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200	44	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29646	29657		10.1074/jbc.M702974200	http://dx.doi.org/10.1074/jbc.M702974200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675298	hybrid			2022-12-27	WOS:000249788000061
J	Pau, VPT; Zhu, YF; Yuchi, ZG; Hoang, QQ; Yang, DSC				Pau, Victor P. T.; Zhu, Yongfang; Yuchi, Zhiguang; Hoang, Quyen Q.; Yang, Daniel S. C.			Characterization of the C-terminal domain of a potassium channel from Streptomyces lividans (KcsA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; ACTIVATION; RECONSTITUTION; REARRANGEMENTS; PURIFICATION; SELECTIVITY; STABILITY	KcsA, a potassium channel from Streptomyces lividans, is a good model for probing the general working mechanism of potassium channels. To date, the physiological activator of KcsA is still unknown, but in vitro studies showed that it could be opened by lowering the pH of the cytoplasmic compartment to 4. The C-terminal domain (CTD, residues 112-160) was proposed to be the modulator for this pH-responsive event. Here, we support this proposal by examining the pH profiles of: (a) thermal stability of KcsA with and without its CTD and (b) aggregation properties of a recombinant fragment of CTD. We found that the presence of the CTD weakened and enhanced the stability of KcsA at acidic and basic pH values, respectively. In addition, the CTD fragment oligomerized at basic pH values with a transition profile close to that of channel opening. Our results are consistent with the CTD being a pH modulator. We propose herein a mechanism on how this domain may contribute to the pH-dependent opening of KcsA.	McMaster Univ, Fac Hlth Sci, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Brandeis Univ, Rosenstiel Basic Med Res Ctr, Waltham, MA 02454 USA	McMaster University; Brandeis University	Yang, DSC (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Biochem & Biomed Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	yang@mcmaster.ca	Yuchi, Zhiguang/N-5184-2016	Yuchi, Zhiguang/0000-0003-2595-9106; Pau, Victor/0000-0002-3093-2330				Clapham DE, 1998, NAT STRUCT BIOL, V5, P342, DOI 10.1038/nsb0598-342; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B, 2001, ION CHANNELS EXCITAB, P1; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Iwamoto M, 2006, J BIOL CHEM, V281, P28379, DOI 10.1074/jbc.M602018200; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Li J, 2002, P NATL ACAD SCI USA, V99, P11605, DOI 10.1073/pnas.192439299; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; NORDENMAN B, 1977, THROMB RES, V11, P799, DOI 10.1016/0049-3848(77)90108-6; Noskov SY, 2006, BIOPHYS CHEM, V124, P279, DOI 10.1016/j.bpc.2006.05.033; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Ruta V, 2004, BIOCHEMISTRY-US, V43, P10071, DOI 10.1021/bi049463y; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Takeuchi K, 2007, J BIOL CHEM, V282, P15179, DOI 10.1074/jbc.M608264200; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	25	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29163	29169		10.1074/jbc.M703277200	http://dx.doi.org/10.1074/jbc.M703277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693406	hybrid			2022-12-27	WOS:000249788000011
J	Saska, I; Gillon, AD; Hatsugai, N; Dietzgen, RG; Hara-Nishimura, I; Anderson, MA; Craik, DJ				Saska, Ivana; Gillon, Amanda D.; Hatsugai, Noriyuki; Dietzgen, Ralf G.; Hara-Nishimura, Ikuko; Anderson, Marilyn A.; Craik, David J.			An asparaginyl endopeptidase mediates in vivo protein backbone cyclization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOTIDE KALATA B1; CIRCULAR PROTEINS; CYSTINE KNOT; MACROCYCLIC PEPTIDES; OLDENLANDIA-AFFINIS; FOLDING PATHWAYS; CONCANAVALIN-A; CELL-DEATH; PLANTS; BIOSYNTHESIS	Proteases can catalyze both peptide bond cleavage and formation, yet the hydrolysis reaction dominates in nature. This presents an interesting challenge for the biosynthesis of backbone cyclized (circular) proteins, which are encoded as part of precursor proteins and require post-translational peptide bond formation to reach their mature form. The largest family of circular proteins are the plant-produced cyclotides; extremely stable proteins with applications as bioengineering scaffolds. Little is known about the mechanism by which they are cyclized in vivo but a highly conserved Asn (occasionally Asp) residue at the C terminus of the cyclotide domain suggests that an enzyme with specificity for Asn (asparaginyl endopeptidase; AEP) is involved in the process. Nicotiana benthamiana does not endogenously produce circular proteins but when cDNA encoding the precursor of the cyclotide kalata B1 was transiently expressed in the plants they produced the cyclotide, together with linear forms not commonly observed in cyclotide-containing plants. Observation of these species over time showed that in vivo asparaginyl bond hydrolysis is necessary for cyclization. When AEP activity was suppressed, either by decreasing AEP gene expression or using a specific inhibitor, the amount of cyclic cyclotide in the plants was reduced compared with controls and was accompanied by the accumulation of extended linear species. These results suggest that an AEP is responsible for catalyzing both peptide bond cleavage and ligation of cyclotides in a single processing event.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; Univ Queensland, Queensland Dept Primary Ind & Fisheries, Brisbane, Qld 4072, Australia	University of Queensland; La Trobe University; Kyoto University; Queensland Department of Agriculture & Fisheries; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Anderson, Marilyn A/A-4259-2012; Craik, David/B-1695-2010; Hatsugai, Noriyuki/O-9156-2015; Dietzgen, Ralf Georg/A-5565-2010	Anderson, Marilyn A/0000-0002-8257-5128; Craik, David/0000-0003-0007-6796; Hatsugai, Noriyuki/0000-0002-5708-4263; Dietzgen, Ralf Georg/0000-0002-7772-2250				BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Basse CW, 2005, PLANT PHYSIOL, V138, P1774, DOI 10.1104/pp.105.061200; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHAPMAN S, 1992, PLANT J, V2, P549; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Cobos ES, 2002, BBA-PROTEINS PROTEOM, V1598, P98, DOI 10.1016/S0167-4838(02)00341-2; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; Craik DJ, 2006, CURR OPIN DRUG DISC, V9, P251; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719; GRAN L, 1973, LLOYDIA, V36, P174; Gran L., 1970, MEDDELELSER NORSK FA, V12, P173; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; HARLOW E, 1999, USING ANTIBODIES LAB, P267; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Jung R, 1998, PLANT CELL, V10, P343, DOI 10.1105/tpc.10.3.343; Kimura RH, 2006, ANGEW CHEM INT EDIT, V45, P973, DOI 10.1002/anie.200503882; Kuroyanagi M, 2005, J BIOL CHEM, V280, P32914, DOI 10.1074/jbc.M504476200; Lindholm P, 2002, MOL CANCER THER, V1, P365; Mulvenna JP, 2006, PLANT CELL, V18, P2134, DOI 10.1105/tpc.106.042812; Muntz K, 2002, J PLANT PHYSIOL, V159, P1281, DOI 10.1078/0176-1617-00853; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Warren EH, 2006, SCIENCE, V313, P1444, DOI 10.1126/science.1130660; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	42	180	194	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29721	29728		10.1074/jbc.M705185200	http://dx.doi.org/10.1074/jbc.M705185200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17698845	hybrid, Green Accepted			2022-12-27	WOS:000249788000068
J	Tsukumo, Y; Tomida, A; Kitahara, O; Nakamura, Y; Asada, S; Mori, K; Tsuruo, T				Tsukumo, Yoshinori; Tomida, Akihiro; Kitahara, Osamu; Nakamura, Yusuke; Asada, Shinichi; Mori, Kazutoshi; Tsuruo, Takashi			Nucleobindin 1 controls the unfolded protein response by inhibiting ATF6 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ATF6; ER STRESS; BINDING-PROTEIN; MESSENGER-RNA; NF-Y; ELEMENT; GOLGI; CLEAVAGE; CALNUC	In response to endoplasmic reticulum (ER) stress, activating transcription factor 6 (ATF6), an ER membrane-anchored transcription factor, is transported to the Golgi apparatus and cleaved by site-1 protease (S1P) to activate the unfolded protein response (UPR). Here, we identified nucleobindin 1 (NUCB1) as a novel repressor of the S1P-mediated ATF6 activation. NUCB1 is an ER stress-inducible gene with the promoter region having functional cis-elements for transcriptional activation by ATF6. Overexpression of NUCB1 inhibits S1P-mediated ATF6 cleavage without affecting ER-to-Golgi transport of ATF6, whereas knock-down of NUCB1 by siRNA accelerates ATF6 cleavage during ER stress. NUCB1 protein localizes in the Golgi apparatus, and disruption of the Golgi localization results in loss of the ATF6-inhibitiory activity. Consistent with these observations, NUCB1 can suppress physical interaction of S1P-ATF6 during ER stress. Together, our results demonstrate that NUCB1 is the first-identified, Golgi-localized negative feedback regulator in the ATF6-mediated branch of the UPR.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; Univ Tokyo, Inst Mol & Cellular BIosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo; Kyoto University	Tomida, A (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan.	akihiro.tomida@jfcr.or.jp	Mori, Kazutoshi/K-6106-2015					Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; KANAI Y, 1992, IMMUNOL LETT, V32, P43; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Lavoie C, 2002, MOL ENDOCRINOL, V16, P2462, DOI 10.1210/me.2002-0079; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; Miura K, 1996, GENOMICS, V34, P181, DOI 10.1006/geno.1996.0263; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243; Petersson U, 2004, BONE, V34, P949, DOI 10.1016/j.bone.2004.01.019; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; WENDEL M, 1995, J BIOL CHEM, V270, P6125, DOI 10.1074/jbc.270.11.6125; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	35	58	58	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29264	29272		10.1074/jbc.M705038200	http://dx.doi.org/10.1074/jbc.M705038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686766	hybrid			2022-12-27	WOS:000249788000023
J	Varnai, P; Toth, B; Toth, DJ; Hunyady, L; Balla, T				Varnai, Peter; Toth, Balazs; Toth, Daniel J.; Hunyady, Laszlo; Balla, Tamas			Visualization and manipulation of plasma membrane-endoplasmic reticulum contact sites indicates the presence of additional molecular components within the STIM1-Orai1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL INTERACTION MOLECULE-1; CA2+ STORE DEPLETION; CHANNEL FUNCTION; CRAC CHANNEL; CALCIUM-ENTRY; ORAI PROTEINS; STIM1; SENSOR; IDENTIFICATION; TRANSLOCATION	STIM1, a recently identified endoplasmic reticulum (ER) protein, rapidly translocates to a plasma membrane-adjacent ER compartment upon depletion of the ER Ca2+ stores. Here we use a novel means, namely a chemically inducible bridge formation between the plasma and ER membranes, to highlight the plasma membrane-adjacent ER compartment and show that this is the site where STIM1 and its Ca2+ channel partner, Orai1, form a productive interaction upon store depletion. By changing the length of the linkers connecting the plasma and ER membranes, we show that Orai1 requires a larger space than STIM1 between the two membranes. This finding suggests that Orai1 is part of a larger macromolecular cluster with an estimated 11-14-nm protrusion to the cytoplasm, whereas the cytoplasmic domain of STIM1 fits in a space calculated to be less than 6 nm. We finally show that agonist-induced translocation of STIM1 is rapidly reversible and only partially affects STIM1 in the juxtanuclear ER compartment. These studies are the first to detect juxtaposed areas between the ER and the plasma membrane in live cells, revealing novel details of STIM1-Orai1 interactions.	NIH, Sect Mol Signal Transduct, NICHD, Bethesda, MD 20892 USA; Semmelweis Univ, Sch Med, Dept Physiol, H-1086 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Semmelweis University	Balla, T (corresponding author), NIH, Sect Mol Signal Transduct, NICHD, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	ballat@mail.nih.gov	Toth, Balazs/B-4252-2012; Tóth, Dániel/M-7105-2019	Tóth, Dániel/0000-0001-6670-3348; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; Hauser CT, 2007, P NATL ACAD SCI USA, V104, P3693, DOI 10.1073/pnas.0611713104; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Inoue T, 2005, NAT METHODS, V2, P415, DOI 10.1038/NMETH763; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Mignen O, 2007, J PHYSIOL-LONDON, V579, P703, DOI 10.1113/jphysiol.2006.122432; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; ONG HL, 2007, J BIOL CHEM; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, BBA-MOL CELL RES, V1763, P1161, DOI 10.1016/j.bbamcr.2006.09.023; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Varnai P, 2006, J CELL BIOL, V175, P377, DOI 10.1083/jcb.200607116; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wedel B, 2007, J PHYSIOL-LONDON, V579, P679, DOI 10.1113/jphysiol.2006.125641; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	33	197	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29678	29690		10.1074/jbc.M704339200	http://dx.doi.org/10.1074/jbc.M704339200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684017	hybrid			2022-12-27	WOS:000249788000064
J	Arce, JDC; Gockel-Krzikalla, E; Rosl, F				Arce, Johanna De-Castro; Goeckel-Krzikalla, Elke; Roesl, Frank			Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de Novo methylation and heterochromatinization of the viral control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; CPG-BINDING PROTEINS; DNA METHYLATION; CANCER-CELLS; TRANSCRIPTIONAL CONTROL; AP-1 TRANSCRIPTION; GROWTH-INHIBITION; TYPE-16 DNA; GENE; CHROMATIN	Retinoic acid receptor beta 2 ( RAR beta 2) is often down-regulated during the multistep process to cervical cancer. In that way, its inhibitory function on the transcription factor AP-1, indispensable to maintain human papillomavirus (HPV) gene expression is relieved. Using HPV-18 positive HeLa cells as a model system, we show that ectopic expression of RAR beta 2 is able to down-regulate HPV-18 transcription by selectively abrogating the binding of AP-1 to the viral regulatory region in a ligand-independent manner. This resulted in down-regulation of the viral mRNAs at the level of initiation of transcription. Decreased oncogene expression was accompanied by a re-induction of cell cycle inhibitory proteins such as p53, p21(CIP1), and p27(KIP) as well as by a cessation of cellular growth. Reduced transcriptional activity as a consequence of AP-1 reduction by selective c-Jun degradation apparently targets the HPV-18 regulatory region for epigenetic modification such as de novo methylation and nucleosomal condensation. This mechanism is otherwise counterbalanced by active and abundant viral transcription in malignant cells, because RAR beta 2 itself becomes inactivated during cervical carcinogenesis. Hence, our study shows that the temporal co-existence of a potential repressor and viral oncoproteins is mutually exclusive and provides evidence of a cross-talk between nuclear receptor, AP-1, and the epigenetic machinery.	Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@dkfz.de						Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Badal S, 2004, VIROLOGY, V324, P483, DOI 10.1016/j.virol.2004.04.002; Badal V, 2003, J VIROL, V77, P6227, DOI 10.1128/JVI.77.11.6227-6234.2003; Berger J, 2002, J STEROID BIOCHEM, V80, P1, DOI 10.1016/S0960-0760(01)00179-0; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; BERNARD HU, 1994, ARCH DERMATOL, V130, P210, DOI 10.1001/archderm.130.2.210; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Brero A, 2005, J CELL BIOL, V169, P733, DOI 10.1083/jcb.200502062; BRUGERS WA, 2006, ONCOGENE, V26, P1650; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Carbone Michele, 2004, Cancer Res, V64, P5518, DOI 10.1158/0008-5472.CAN-04-0255; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; DECASTRO AJ, 2004, J BIOL CHEM, V279, P45408; Dedieu S, 2006, CELL SIGNAL, V18, P889, DOI 10.1016/j.cellsig.2005.08.001; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Geisen C, 1997, CANCER RES, V57, P1460; Geisen C, 2000, INT J CANCER, V85, P289, DOI 10.1002/(SICI)1097-0215(20000115)85:2<289::AID-IJC22>3.0.CO;2-T; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim K, 2003, J VIROL, V77, P12450, DOI 10.1128/JVI.77.23.12450-12459.2003; Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin F, 2000, CANCER RES, V60, P3271; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; NAFZ J, 1988, BIOCHEM J, V403, P4780; Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; Pavan B, 2006, CURR MED CHEM, V13, P3553, DOI 10.2174/092986706779026183; Pietrobono R, 2002, NUCLEIC ACIDS RES, V30, P3278, DOI 10.1093/nar/gkf434; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; ROSL F, 1993, J GEN VIROL, V74, P791, DOI 10.1099/0022-1317-74-5-791; Rosl F, 1997, J VIROL, V71, P362; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; Sato N, 2006, BIOCHEM BIOPH RES CO, V344, P845, DOI 10.1016/j.bbrc.2006.04.007; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Suzukawa K, 2002, ONCOGENE, V21, P2181, DOI 10.1038/sj.onc.1205281; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Wade PA, 2005, NAT GENET, V37, P212, DOI 10.1038/ng0305-212; Zhang Z, 2006, ONCOGENE, V25, P5436, DOI 10.1038/sj.onc.1209530; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	74	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28520	28529		10.1074/jbc.M702870200	http://dx.doi.org/10.1074/jbc.M702870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686773	hybrid			2022-12-27	WOS:000249642100026
J	Das, S; Chattopadhyay, R; Bhakat, KK; Boldogh, I; Kohno, K; Prasad, R; Wilson, SH; Hazra, TK				Das, Soumita; Chattopadhyay, Ranajoy; Bhakat, Kishor K.; Boldogh, Istvan; Kohno, Kimitoshi; Prasad, Rajendra; Wilson, Samuel H.; Hazra, Tapas K.			Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; TRANSCRIPTION FACTOR YB-1; HUMAN DNA GLYCOSYLASES; CELL NUCLEAR ANTIGEN; Y-BOX; ULTRAVIOLET-LIGHT; ENDONUCLEASE-VIII; MAMMALIAN-CELLS; MESSENGER-RNA; UVA RADIATION	The recently characterized enzyme NEIL2 (Nei-like-2), one of the four oxidized base-specific DNA glycosylases (OGG1, NTH1, NEIL1, and NEIL2) in mammalian cells, has poor base excision activity from duplex DNA. To test the possibility that one or more proteins modulate its activity in vivo, we performed mass spectrometric analysis of the NEIL2 immunocomplex and identified Y box-binding (YB-1) protein as a stably interacting partner of NEIL2. We show here that YB-1 not only interacts physically with NEIL2, but it also cooperates functionally by stimulating its base excision activity by 7-fold. Moreover, YB-1 interacts with the other NEIL2-associated BER proteins, namely, DNA ligase III alpha and DNA polymerase beta and thus could form a large multiprotein complex. YB-1, normally present in the cytoplasm, translocates to the nucleus during UVA-induced oxidative stress, concomitant with its increased association with and activation of NEIL2. NEIL2-initiated base excision activity is significantly reduced in YB-1-depleted cells. YB-1 thus appears to have a novel regulatory role in NEIL2-mediated repair under oxidative stress.	Univ Texas, Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Occupational & Environmental Health - Japan	Hazra, TK (corresponding author), 6-136 Med Res Bldg,Route 1079, Galveston, TX 77555 USA.	tkhazra@utmb.edu	Wilson, Samuel H/E-6644-2019; Bhakat, Kishor/C-8072-2012	Wilson, Samuel H/0000-0002-1702-5293; 	NATIONAL CANCER INSTITUTE [R01CA102271, R01CA081063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, Z01ES050158, Z01ES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021830] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES050159-11, Z01 ES050158-11] Funding Source: Medline; NCI NIH HHS [CA102271, CA81063, R01 CA081063, R01 CA102271] Funding Source: Medline; NIA NIH HHS [P01 AG021830] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, P01 ES06676] Funding Source: Medline; PHS HHS [E508457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Campalans A, 2007, J CELL SCI, V120, P23, DOI 10.1242/jcs.03312; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; Das A, 2006, DNA REPAIR, V5, P1439, DOI 10.1016/j.dnarep.2006.07.003; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hayakawa H, 2002, BIOCHEMISTRY-US, V41, P12739, DOI 10.1021/bi0201872; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Ise T, 1999, CANCER RES, V59, P342; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kappes UP, 2005, RADIAT RES, V164, P440, DOI 10.1667/RR3434.1; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kozmin S, 2005, P NATL ACAD SCI USA, V102, P13538, DOI 10.1073/pnas.0504497102; Kvam E, 1999, J INVEST DERMATOL, V113, P209, DOI 10.1046/j.1523-1747.1999.00653.x; LOWE NJ, 1995, J INVEST DERMATOL, V105, P739, DOI 10.1111/1523-1747.ep12325517; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Mitra S, 1997, MOL CELLS, V7, P305; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ogawa Y, 2003, INT J MOL MED, V11, P149; Ohga T, 1996, CANCER RES, V56, P4224; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; Petersen AB, 2000, J PHOTOCH PHOTOBIO B, V59, P123, DOI 10.1016/S1011-1344(00)00149-4; Pouget JP, 2000, CHEM RES TOXICOL, V13, P541, DOI 10.1021/tx000020e; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	56	105	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28474	28484		10.1074/jbc.M704672200	http://dx.doi.org/10.1074/jbc.M704672200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686777	hybrid, Green Accepted			2022-12-27	WOS:000249642100021
J	Pertusa, M; Morenilla-Palao, C; Carteron, C; Viana, F; Cabedo, H				Pertusa, Maria; Morenilla-Palao, Cruz; Carteron, Christelle; Viana, Felix; Cabedo, Hugo			Transcriptional control of cholesterol biosynthesis in Schwann cells by axonal neuregulin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; NEURON-DERIVED FACTOR; NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; MEVALONATE PATHWAY; STRIATAL NEURONS; PLASMA-MEMBRANE; REDUCTASE; EXPRESSION; GROWTH	A characteristic feature of many vertebrate axons is their wrapping by a lamellar stack of glially derived membranes known as the myelin sheath. Myelin is a cholesterol-rich membrane that allows for rapid saltatory nerve impulse conduction. Axonal neuregulins instruct glial cells on when and how much myelin they should produce. However, how neuregulin regulates myelin sheath development and thickness is unknown. Here we show that neuregulin receptors are activated by drops in plasma membrane cholesterol, suggesting that they can sense sterol levels. In Schwann cells neuregulin-1 increases the transcription of the 3-hydroxy-3-methylglutarylcoenzyme A reductase, the rate-limiting enzyme for cholesterol biosynthesis. Neuregulin activity is mediated by the phosphatidylinositol 3-kinase pathway and a cAMP-response element located on the reductase promoter. We propose that by activating neuregulin receptors, neurons exploit a cholesterol homeostatic mechanism forcing Schwann cells to produce new membranes for the myelin sheath. We also show that a strong phylogenetic correlation exists between myelination and cholesterol biosynthesis, and we propose that the absence of the sterol branch of the mevalonate pathway in invertebrates precluded the myelination of their nervous system.	UMH CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain; Hosp St Joan Alacant, Unidad Invest, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Cabedo, H (corresponding author), UMH CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain.	hugo.cabedo@umh.es	Viana, Felix/U-8533-2017; Cabedo, Hugo/F-9404-2016	Viana, Felix/0000-0003-1439-949X; Cabedo, Hugo/0000-0002-1322-6290; Pertusa, Maria/0000-0003-3856-9019; Morenilla-Palao, Cruz/0000-0002-8159-1206				Asslan R, 1999, BIOCHEM BIOPH RES CO, V260, P699, DOI 10.1006/bbrc.1999.0945; Belles X, 2005, ANNU REV ENTOMOL, V50, P181, DOI 10.1146/annurev.ento.50.071803.130356; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; Clayton RB, 1964, J LIPID RES, V15, P3; Di Croce L, 1999, MOL ENDOCRINOL, V13, P1225, DOI 10.1210/me.13.8.1225; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Du XM, 2006, MOL BIOL CELL, V17, P2735, DOI 10.1091/mbc.E05-11-1094; Edenfeld G, 2005, CURR OPIN NEUROBIOL, V15, P34, DOI 10.1016/j.conb.2005.01.007; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Freeman MR, 2006, TRENDS NEUROSCI, V29, P82, DOI 10.1016/j.tins.2005.12.002; Fu Q, 1998, J NEUROCHEM, V71, P549; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gould RM, 2005, BIOL BULL-US, V209, P49, DOI 10.2307/3593141; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Kanazawa A, 2001, FISHERIES SCI, V67, P997, DOI 10.1046/j.1444-2906.2001.00354.x; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Santos AC, 2004, DEV CELL, V6, P283, DOI 10.1016/S1534-5807(04)00023-1; Schweigreiter R, 2006, INT REV NEUROBIOL, V73, P219, DOI 10.1016/S0074-7742(06)73007-0; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942	45	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28768	28778		10.1074/jbc.M701878200	http://dx.doi.org/10.1074/jbc.M701878200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652086	hybrid			2022-12-27	WOS:000249642100051
J	Stensman, H; Larsson, C				Stensman, Helena; Larsson, Christer			Identification of acidic amino acid residues in the protein kinase C alpha V5 domain that contribute to its insensitivity to diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-ALPHA; CATALYTIC DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOPLASMIC DOMAIN; REGULATORY DOMAIN; HYDROPHOBIC MOTIF; PLASMA-MEMBRANE; LIVING CELLS; ACTIVATION; BINDING	The protein kinase C (PKC) isoforms are maintained in an inactive and closed conformation by intramolecular interactions. Upon activation these are disrupted by activators, binding proteins and cellular membrane. We have seen that autophosphorylation of two sites in the C-terminal V5 domain is crucial to keep PKC alpha insensitive to the activator diacylglycerol, which presumably is caused by a masking of the diacylglycerol-binding C1a domain. Here we demonstrate that the diacylglycerol sensitivity of the PKC beta isoforms also is suppressed by autophosphorylation of the V5 sites. To analyze conformational differences, a fusion protein ECFP-PKC alpha-EYFP was expressed in cells and the FRET signal was analyzed. The analogous mutant with autophosphorylation sites exchanged for alanine gave rise to a substantially lower FRET signal than wild-type PKC alpha indicating a conformational difference elicited by the mutations. Expression of the isolated PKC alpha V5 domain led to increased diacylglycerol sensitivity of PKC alpha. We identified acidic residues in the V5 domain that, when mutated to alanines or lysines, rendered PKC alpha sensitive to diacylglycerol. Furthermore, mutation to glutamate of four lysines in a lysine-rich cluster in the C2 domain gave a similar effect. Simultaneous reversal of the charges of the acidic residues in the V5 and the lysines in the C2 domain gave rise to a PKC alpha that was insensitive to diacylglycerol. We propose that these structures participate in an intramolecular interaction that maintains PKC alpha in a closed conformation. The disruption of this interaction leads to an unmasking of the C1a domain and thereby increased diacylglycerol sensitivity of PKC alpha.	Lund Univ, Malmo Univ Hosp, Ctr Mol Pathol, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Larsson, C (corresponding author), Lund Univ, Ctr Mol Pathol, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.	Christer.Larsson@med.lu.se						Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bolsover SR, 2003, J BIOL CHEM, V278, P10282, DOI 10.1074/jbc.M212145200; Braun DC, 2005, J BIOL CHEM, V280, P8164, DOI 10.1074/jbc.M413896200; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; Dries DR, 2007, J BIOL CHEM, V282, P826, DOI 10.1074/jbc.C600268200; Evans JH, 2006, MOL BIOL CELL, V17, P56, DOI 10.1091/mbc.e05-06-0499; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Grodsky N, 2006, BIOCHEMISTRY-US, V45, P13970, DOI 10.1021/bi061128h; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kolkova K, 2005, J NEUROCHEM, V92, P886, DOI 10.1111/j.1471-4159.2004.02919.x; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Leitges M, 2004, NEURON, V44, P585, DOI 10.1016/j.neuron.2004.10.024; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Lim ST, 2003, J BIOL CHEM, V278, P13795, DOI 10.1074/jbc.M208300200; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; Marin-Vicente C, 2005, MOL BIOL CELL, V16, P2848, DOI 10.1091/mbc.E05-01-0067; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rodriguez-Alfaro JA, 2004, J MOL BIOL, V335, P1117, DOI 10.1016/j.jmb.2003.10.080; Sanchez-Bautista S, 2006, J MOL BIOL, V362, P901, DOI 10.1016/j.jmb.2006.07.093; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Stensman H, 2004, J BIOL CHEM, V279, P40576, DOI 10.1074/jbc.M405560200; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Wang QMJ, 2004, MOL CANCER RES, V2, P129; Yeong SS, 2006, J BIOL CHEM, V281, P30768, DOI 10.1074/jbc.M511278200; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	45	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28627	28638		10.1074/jbc.M702248200	http://dx.doi.org/10.1074/jbc.M702248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673466	hybrid			2022-12-27	WOS:000249642100037
J	Barbaric, S; Luckenbach, T; Schmid, A; Blaschke, D; Horz, W; Korber, P				Barbaric, Slobodan; Luckenbach, Tim; Schmid, Andrea; Blaschke, Dorothea; Hoerz, Wolfram; Korber, Philipp			Redundancy of chromatin remodeling pathways for the induction of the yeast PHO5 promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE CHAPERONE ASF1; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; POSITIONED NUCLEOSOMES; SNF2 FAMILY; H2A VARIANT; TARGET SITE; SWI-SNF; GENE; COMPLEX	Induction of the yeast PHO5 and PHO8 genes leads to a prominent chromatin transition at their promoter regions as a prerequisite for transcription activation. Although induction of PHO8 is strictly dependent on Snf2 and Gcn5, there is no chromatin remodeler identified so far that would be essential for the opening of PHO5 promoter chromatin. Nonetheless, the nonessential but significant involvement of cofactors; can be identified if the chromatin opening kinetics are delayed in the respective mutants. Using this approach, we have tested individually all 15 viable Snf2 type ATPase deletion mutants for their effect on PHO5 promoter induction and opening. Only the absence of Snf2 and Ino80 showed a strong delay in chromatin remodeling kinetics. The snf2 ino80 double mutation had a synthetic kinetic effect but eventually still allowed strong PHO5 induction. The same was true for the snf2 gcn5 and ino80 gcn5 double mutants. This strongly suggests a complex network of redundant and mutually independent parallel pathways that lead to the remodeling of the PHO5 promoter. Further, chromatin remodeling kinetics at a transcriptionally inactive TATA box-mutated PHO5 promoter were affected neither under wild type conditions nor in the absence of Snf2 or Gcn5. This demonstrates the complete independence of promoter chromatin opening from downstream PHO5 transcription processes. Finally, the histone variant Htz1 has no prominent role for the kinetics of PHO5 promoter chromatin remodeling.	Univ Munich, Adolf Butenadt Inst, D-80336 Munich, Germany; Univ Zagreb, Fac Food Technol & Biotechnol, Biochem Lab, Zagreb 10000, Croatia	University of Munich; University of Zagreb	Korber, P (corresponding author), Univ Munich, Adolf Butenadt Inst, 44 Schillerstr, D-80336 Munich, Germany.	pkorber@lmu.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; Barbaric S, 2003, MOL CELL BIOL, V23, P3468, DOI 10.1128/MCB.23.10.3468-3476.2003; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; Collart MA, 1996, MOL CELL BIOL, V16, P6668; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Dhasarathy A, 2005, MOL CELL BIOL, V25, P2698, DOI 10.1128/MCB.25.7.2698-2707.2005; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Ertinger G., 1998, THESIS U MUNCHEN; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gregory PD, 1999, METH MOL B, V119, P417; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Guillemette B, 2006, BIOCHEM CELL BIOL, V84, P528, DOI 10.1139/O06-077; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; Hertel CB, 2005, MOL CELL BIOL, V25, P10755, DOI 10.1128/MCB.25.24.10755-10767.2005; Huang SD, 2005, GENETICS, V169, P1859, DOI 10.1534/genetics.104.038695; Jonsdottir S, 2000, ROBOT CIM-INT MANUF, V16, P465, DOI 10.1016/S0736-5845(00)00018-1; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Korber P, 2006, J BIOL CHEM, V281, P5539, DOI 10.1074/jbc.M513340200; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Li B, 2005, P NATL ACAD SCI USA, V102, P18385, DOI 10.1073/pnas.0507975102; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Liu X, 2006, GENOME RES, V16, P1517, DOI 10.1101/gr.5655606; Lorch Y, 2006, P NATL ACAD SCI USA, V103, P3090, DOI 10.1073/pnas.0511050103; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martens JA, 2005, GENE DEV, V19, P2695, DOI 10.1101/gad.1367605; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nourani A, 2004, EMBO J, V23, P2597, DOI 10.1038/sj.emboj.7600230; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Raisner RM, 2006, CURR OPIN GENET DEV, V16, P119, DOI 10.1016/j.gde.2006.02.005; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Roberts SM, 1997, GENETICS, V147, P451; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Springer M, 2003, PLOS BIOL, V1, P261, DOI 10.1371/journal.pbio.0000028; Stafford GA, 2001, MOL CELL BIOL, V21, P4568, DOI 10.1128/MCB.21.14.4568-4578.2001; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Thomas MR, 2005, P NATL ACAD SCI USA, V102, P9565, DOI 10.1073/pnas.0501122102; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Uhler JP, 2007, P NATL ACAD SCI USA, V104, P8011, DOI 10.1073/pnas.0702431104; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036	87	74	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27610	27621		10.1074/jbc.M700623200	http://dx.doi.org/10.1074/jbc.M700623200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17631505	hybrid			2022-12-27	WOS:000249455600008
J	Goedken, M; McCormick, S; Leidal, KG; Suzuki, K; Kameoka, Y; Astern, JM; Huang, M; Cherkasov, A; Nauseef, WM				Goedken, Melissa; McCormick, Sally; Leidal, Kevin G.; Suzuki, Kazuo; Kameoka, Yosuke; Astern, Joshua M.; Huang, Meilan; Cherkasov, Artem; Nauseef, William M.			Impact of two novel mutations on the structure and functoon of human myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; PROSTHETIC HEME MODIFICATION; MYELOID LYSOSOMAL-ENZYME; PEROXIDE-CHLORIDE SYSTEM; PROTEIN COVALENT BONDS; RAY CRYSTAL-STRUCTURE; LEUKEMIA-CELL LINE; ALPHA-AMINO-ACIDS; HYDROGEN-PEROXIDE; REACTIVE ALDEHYDES	The heme protein myeloperoxidase (MPO) contributes critically to O-2-dependent neutrophil antimicrobial activity. Two Japanese adults were identified with inherited MPO deficiency because of mutations at Arg-499 or Gly-501, conserved residues near the proximal histidine in the heme pocket. Because of the proximity of these residues to a critical histidine in the heme pocket, we examined the biosynthesis, function, and spectral properties of the peroxidase stably expressed in human embryonic kidney cells. Biosynthesis of normal MPO by human embryonic kidney cells faithfully mirrored events previously identified in cells expressing endogenous MPO. Mutant apopro-MPO was 90 kDa and interacted normally with the molecular chaperones ERp57, calreticulin, and calnexin in the endoplasmic reticulum. However, mutant precursors were not proteolytically processed into subunits of MPO, although secretion of the unprocessed precursors occurred normally. Although delta-[C-14]aminolevulinic acid incorporation demonstrated formation of pro-MPO in both mutants, neither protein was enzymatically active. The Soret band for each mutant was shifted from the normal 430 to similar to 412 nm, confirming that heme was incorporated but suggesting that the number of covalent bonds or other structural aspects of the heme pocket were disrupted by the mutations. These studies demonstrate that despite heme incorporation, mutations in the heme environs compromised the oxidizing potential of MPO.	Univ Iowa, Vet Affairs Med Ctr, Dept Med, Inflammat Program, Iowa City, IA 52241 USA; Natl Inst Infect Dis, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Biomed Innovat, Div Biomed Resources, Lab Genet Resources, Ibaraki 5670085, Japan; Univ N Carolina, Kidney Ctr, Chapel Hill, NC 27599 USA; Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; National Institute of Infectious Diseases (NIID); National Institute of Health Sciences - Japan; University of North Carolina; University of North Carolina Chapel Hill; University of British Columbia	Nauseef, WM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Inflammat Program, D160 MTF,2501 Crosspk Rd, Coralville, IA 52241 USA.	william-nauseef@uiowa.edu	Cherkasov, Artem/A-2134-2012	Nauseef, William/0000-0003-4032-757X	NHLBI NIH HHS [HL 53592] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053592] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)		Andersson E, 1998, J BIOL CHEM, V273, P4747, DOI 10.1074/jbc.273.8.4747; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; Battistuzzi G, 2006, BIOCHEMISTRY-US, V45, P12750, DOI 10.1021/bi061647k; BEERS RF, 1952, J BIOL CHEM, V195, P133; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Brogioni S, 2006, J RAMAN SPECTROSC, V37, P263, DOI 10.1002/jrs.1442; Bulow E, 2002, J LEUKOCYTE BIOL, V71, P279; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; DeGioia L, 1996, J BIOL INORG CHEM, V1, P476; DeLeo FR, 1998, J CLIN INVEST, V101, P2900, DOI 10.1172/JCI2649; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Dunford H. B., 1999, HEME PEROXIDASES; Dypbukt JM, 2005, FREE RADICAL BIO MED, V39, P1468, DOI 10.1016/j.freeradbiomed.2005.07.008; ELZANOWSKA H, 1995, FREE RADICAL BIO MED, V18, P437, DOI 10.1016/0891-5849(94)00150-I; Erdbrugger U, 2006, KIDNEY INT, V69, P1799, DOI 10.1038/sj.ki.5000354; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Ferrari RP, 2000, PEROXIDASE MULTIGENE FAMILY OF ENZYMES, P114; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PC, 2000, EUR J BIOCHEM, V267, P5858, DOI 10.1046/j.1432-1327.2000.01491.x; Furtmuller PG, 2006, ARCH BIOCHEM BIOPHYS, V445, P199, DOI 10.1016/j.abb.2005.09.017; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson M, 2006, ARCH BIOCHEM BIOPHYS, V445, P214, DOI 10.1016/j.abb.2005.08.009; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Huang LS, 2006, J BIOL CHEM, V281, P18983, DOI 10.1074/jbc.M602307200; Huang LS, 2006, ARCH BIOCHEM BIOPHYS, V446, P77, DOI 10.1016/j.abb.2005.11.011; Huang LS, 2005, J AM CHEM SOC, V127, P5345, DOI 10.1021/ja050278x; Hurst JK, 1999, ACCOUNTS CHEM RES, V32, P520, DOI 10.1021/ar9703488; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Kameoka Y, 2004, JPN J INFECT DIS, V57, pS12; KETTLE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P379, DOI 10.1016/0167-4889(90)90146-5; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Kooter IM, 1997, J BIOL INORG CHEM, V2, P191, DOI 10.1007/s007750050124; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Marchetti C, 2004, HUM MUTAT, V23, P496, DOI 10.1002/humu.20027; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; Moguilevsky N, 2000, PEROXIDASE MULTIGENE FAMILY OF ENZYMES, P38; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1986, BLOOD, V68, P442; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; Nauseef WM, 1999, J LAB CLIN MED, V134, P215, DOI 10.1016/S0022-2143(99)90200-7; NAUSEEF WM, 1989, BLOOD, V73, P290; Nauseef WM, 2000, REDOX REP, V5, P197, DOI 10.1179/135100000101535753; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; NAUSEEF WM, 2003, CALRETICULIN, P63; Ohashi YY, 2004, GENE, V327, P195, DOI 10.1016/j.gene.2003.11.023; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PERSAD AS, 2006, GENE EXPRESSION, V13, P1; STRAUSS RR, 1971, INFECT IMMUN, V3, P595, DOI 10.1128/IAI.3.4.595-602.1971; vanDalen CJ, 1997, BIOCHEM J, V327, P487; Winterbourn CC, 1997, ARCH BIOCHEM BIOPHYS, V338, P15, DOI 10.1006/abbi.1996.9773; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721; YAMADA M, 1990, BIOCHEM BIOPH RES CO, V166, P852, DOI 10.1016/0006-291X(90)90888-T; YAMADA M, 1981, BIOCHEMISTRY-US, V20, P766, DOI 10.1021/bi00507a018; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	79	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27994	28003		10.1074/jbc.M701984200	http://dx.doi.org/10.1074/jbc.M701984200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650507	Green Published, hybrid			2022-12-27	WOS:000249455600049
J	Kashlan, OB; Mueller, GM; Qamar, MZ; Poland, PA; Ahner, A; Rubenstein, RC; Hughey, RP; Brodsky, JL; Kleyman, TR				Kashlan, Ossama B.; Mueller, Gunhild M.; Qamar, Mohammad Z.; Poland, Paul A.; Ahner, Annette; Rubenstein, Ronald C.; Hughey, Rebecca P.; Brodsky, Jeffrey L.; Kleyman, Thomas R.			Small heat shock protein alpha A-crystallin regulates epithelial sodium channel expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; SUBUNIT STOICHIOMETRY; CHAPERONE FUNCTION; CYSTIC-FIBROSIS; ION CHANNELS; MEMBRANE; CELL; TRAFFICKING; TRANSPORT; PATHWAY	Integral membrane proteins are synthesized on the cytoplasmic face of the endoplasmic reticulum (ER). After being translocated or inserted into the ER, they fold and undergo post-translational modifications. Within the ER, proteins are also subjected to quality control checkpoints, during which misfolded proteins may be degraded by proteasomes via a process known as ER-associated degradation. Molecular chaperones, including the small heat shock protein alpha A-crystallin, have recently been shown to play a role in this process. We have now found that aA-crystallin is expressed in cultured mouse collecting duct cells, where apical Na+ transport is mediated by epithelial Na+ channels (ENaC). ENaC-mediated Na+ currents in Xenopus oocytes were reduced by co-expression of alpha A-crystallin.. This reduction in ENaC activity reflected a decrease in the number of channels expressed at the cell surface. Furthermore we observed that the rate of ENaC delivery to the cell surface of Xenopus oocytes was significantly reduced by co-expression of alpha A-crystallin, whereas the rate of channel retrieval remained unchanged. We also observed that aA-crystallin and ENaC co-immunoprecipitate. These data are consistent with the hypothesis that small heat shock proteins recognize ENaC subunits at ER. quality control checkpoints and can target ENaC subunits for ER-associated degradation.	Univ Pittsburgh, Dept Med, Div Renal & Electrolyte, Pittsburgh, PA 15216 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Hughey, RP (corresponding author), 933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu		Rubenstein, Ronald/0000-0002-3138-4006	NIDDK NIH HHS [DK065161, DK58046, F32 DK066883, R56 DK065161, R01 DK065161, R01 DK058046, DK066883, DK061296] Funding Source: Medline; NIGMS NIH HHS [R01 GM075061, GM75061, R01 GM075061-01A1, R01 GM075061-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065161, R56DK065161, T32DK061296, R01DK058046, F32DK066883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075061] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Ahner A, 2007, MOL BIOL CELL, V18, P806, DOI 10.1091/mbc.E06-05-0458; Bens M, 1999, J AM SOC NEPHROL, V10, P923; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Cashikar AG, 2005, J BIOL CHEM, V280, P23869, DOI 10.1074/jbc.M502854200; Ciampolillo F, 1996, AM J PHYSIOL-CELL PH, V271, pC1303, DOI 10.1152/ajpcell.1996.271.4.C1303; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; Jentsch S, 2007, TRENDS BIOCHEM SCI, V32, P6, DOI 10.1016/j.tibs.2006.11.005; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KNOWLES MR, 1995, CHEST, V107, pS71, DOI 10.1378/chest.107.2_Supplement.71S; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lentze N, 2004, EUR J BIOCHEM, V271, P2494, DOI 10.1111/j.1432-1033.2004.04180.x; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Pasta SY, 2004, MOL VIS, V10, P655; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Sun Y, 2005, CELL MOL LIFE SCI, V62, P2460, DOI 10.1007/s00018-005-5190-4; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang Yimao, 2002, Methods Mol Med, V70, P257	48	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28149	28156		10.1074/jbc.M703409200	http://dx.doi.org/10.1074/jbc.M703409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17664274	Green Accepted, hybrid			2022-12-27	WOS:000249455600064
J	Mani, RS; Fanta, M; Karimi-Busheri, F; Silver, E; Virgen, CA; Caldecott, KW; Cass, CE; Weinfeld, M				Mani, Raiam S.; Fanta, Mesfin; Karimi-Busheri, Feridoun; Silver, Elizabeth; Virgen, Cesar A.; Caldecott, Keith W.; Cass, Carol E.; Weinfeld, Michael			XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; TIME-RESOLVED FLUORESCENCE; BASE EXCISION-REPAIR; RAT-LIVER; POLY(ADP-RIBOSE) POLYMERASE; IRRADIATED THYMOCYTES; PROTEIN XRCC1; TRANSFER-RNA; LIGASE-III; END-GROUPS	Human polynucleotide kinase (hPNK) is required for processing and rejoining DNA strand break termini. The 5'-DNA kinase and 3'-phosphatase activities of hPNK can be stimulated by the "scaffold" protein XRCC1, but the mechanism remains to be fully elucidated. Using a variety of fluorescence techniques, we examined the interaction of hPNK with XRCC1 and substrates that model DNA single-strand breaks. hPNK binding to substrates with 5'-OH termini was only similar to 5-fold tighter than that to identical DNA molecules with 5'-phosphate termini, suggesting that hPNK remains bound to the product of its enzymatic activity. The presence of XRCC1 did not influence the binding of hPNK to substrates with 5'-OH termini, but sharply reduced the interaction of hPNK with DNA bearing a 5'-phosphate terminus. These data, together with kinetic data obtained at limiting enzyme concentration, indicate a dual function for the interaction of XRCC1 with hPNK. First, XRCC1 enhances the capacity of hPNK to discriminate between strand breaks with 5'-OH termini and those with 5'-phosphate termini; and second, XRCC1 stimulates hPNK activity by displacing hPNK from the phosphorylated DNA product.	Cross Canc Inst, Dept Expt Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Alberta; University of Alberta; University of Sussex	Weinfeld, M (corresponding author), Cross Canc Inst, Dept Expt Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	michaelw@cancerboard.ab.ca	Cass, Carol E/F-5861-2010; Caldecott, Keith/S-4245-2019; Karimi-Busheri, Feridoun/AAX-7541-2020	Caldecott, Keith/0000-0003-4255-9016; Karimi-Busheri, Feridoun/0000-0002-1936-0503	MRC [G0600776, G0001259] Funding Source: UKRI; Medical Research Council [G0600776, G0001259] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BERNARDI G, 1968, ADV ENZYMOL RAMB, V31, P1; Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; D'Alfonso L, 2003, EUR J BIOCHEM, V270, P2497, DOI 10.1046/j.1432-1033.2003.03621.x; Dobson CJ, 2006, NUCLEIC ACIDS RES, V34, P2230, DOI 10.1093/nar/gkl275; Eastberg JH, 2004, NUCLEIC ACIDS RES, V32, P653, DOI 10.1093/nar/gkh212; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Flora K, 1998, BIOPHYS J, V75, P1084, DOI 10.1016/S0006-3495(98)77598-8; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; HABRAKEN Y, 1988, EUR J BIOCHEM, V171, P59, DOI 10.1111/j.1432-1033.1988.tb13758.x; HENNER WD, 1983, J BIOL CHEM, V258, P711; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1998, NUCLEIC ACIDS RES, V26, P4395, DOI 10.1093/nar/26.19.4395; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; KarimiBusheri F, 1997, J CELL BIOCHEM, V64, P258, DOI 10.1002/(SICI)1097-4644(199702)64:2<258::AID-JCB9>3.0.CO;2-W; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; LENNARTZ M, 1975, INT J RADIAT BIOL, V27, P577, DOI 10.1080/09553007514550611; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; Mani RS, 2006, BIOCHEMISTRY-US, V45, P3534, DOI 10.1021/bi052652b; Mani RS, 2004, BIOCHEMISTRY-US, V43, P16505, DOI 10.1021/bi048615m; Mani RS, 2003, BIOCHEMISTRY-US, V42, P12077, DOI 10.1021/bi030127b; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Parsons JL, 2005, FEBS J, V272, P5753, DOI 10.1111/j.1742-4658.2005.04962.x; PHEIFFER BH, 1982, BIOCHEM BIOPH RES CO, V109, P1297, DOI 10.1016/0006-291X(82)91918-0; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Rasouli-Nia A, 2004, P NATL ACAD SCI USA, V101, P6905, DOI 10.1073/pnas.0400099101; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003	42	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28004	28013		10.1074/jbc.M704867200	http://dx.doi.org/10.1074/jbc.M704867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650498	hybrid			2022-12-27	WOS:000249455600050
J	Rexroth, S; Wong, CCL; Park, JH; Yates, JR; Barry, BA				Rexroth, Sascha; Wong, Catherine C. L.; Park, Jessica H.; Yates, John R., III; Barry, Bridgette A.			An activated glutamate residue identified in photosystern II at the interface between the manganese-stabilizing subunit and the D2 polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SITE-DIRECTED MUTANTS; MASS-SPECTROMETRY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; POSTTRANSLATIONAL MODIFICATIONS; WATER OXIDATION; REDOX COFACTOR; BINDING	Photosystem II (PSII) catalyzes the oxidation of water during oxygenic photosynthesis. PSII is composed both of intrinsic subunits, such as D1, D2, and CP47, and extrinsic subunits, such as the manganese-stabilizing subunit (MSP). Previous work has shown that amines covalently bind to amino acid residues in the CP47, D1, and D2 subunits of plant and cyanobacterial PSII, and that these covalent reactions are prevented by the addition of chloride in plant preparations depleted of the 18- and 24-kDa extrinsic subunits. It has been proposed that these reactive groups are carbonyl-containing, post-translationally modified amino acid side chains (Ouellette, A. J. A., Anderson, L. B., and Barry, B. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2204-2209 and Anderson, L. B., Ouellette, A. J. A., and Barry, B. A. (2000) J. Biol. Chem. 275, 4920-4927). To identify the amino acid binding site in the spinach D2 subunit, we have employed a biotin-amine labeling reagent, which can be used in conjunction with avidin affinity chromatography to purify biotinylated peptides from the PSII complex. Multidimensional chromatographic separation and multistage mass spectrometry localizes a novel post-translational modification in the D2 subunit to glutamate 303. We propose that this glutamate is activated for amine reaction by post-translational modification. Because the modified glutamate is located at a contact site between the D2 and manganese-stabilizing subunits, we suggest that the modification is important in vivo in stabilizing the interaction between these two PSII subunits. Consistent with this conclusion, mutations at the modified glutamate alter the steady-state rate of photosynthetic oxygen evolution.	Georgia Inst Technol, Sch Chem & Biochem, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University System of Georgia; Georgia Institute of Technology; Scripps Research Institute	Barry, BA (corresponding author), Georgia Inst Technol, Petit Inst Bioengn, 315 Ferst Dr, Atlanta, GA 30332 USA.	bridgette.barry@chemistry.gatech.edu	Rexroth, Sascha/H-3702-2011	Rexroth, Sascha/0000-0003-3819-2127; Wong, Catherine CL/0000-0001-7270-980X				ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Anderson LB, 2004, J AM CHEM SOC, V126, P8399, DOI 10.1021/ja0478781; Anderson LB, 2000, J BIOL CHEM, V275, P4920, DOI 10.1074/jbc.275.7.4920; Anderson LB, 2002, P NATL ACAD SCI USA, V99, P14676, DOI 10.1073/pnas.232591599; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1994, J BIOL CHEM, V269, P134; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; Cooper IB, 2007, PHOTOSYNTH RES, V92, P345, DOI 10.1007/s11120-007-9147-3; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ermakova-Gerdes S, 2001, J BACTERIOL, V183, P145, DOI 10.1128/JB.183.1.145-154.2001; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; Grabolle M, 2006, J BIOL CHEM, V281, P4580, DOI 10.1074/jbc.M509724200; Han Yonghua, 2005, Journal of Bioinformatics and Computational Biology, V3, P697; Hurst GB, 2004, J AM SOC MASS SPECTR, V15, P832, DOI 10.1016/S1044-0305(04)00154-0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Krause F, 2004, J BIOL CHEM, V279, P48369, DOI 10.1074/jbc.M406085200; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; Lindorff-Larsen K, 2001, J BIOL CHEM, V276, P33547, DOI 10.1074/jbc.M104841200; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Ma CL, 1996, BIOPHYS J, V71, P1961, DOI 10.1016/S0006-3495(96)79394-3; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MIYAO M, 1983, BIOCHIM BIOPHYS ACTA, V725, P87, DOI 10.1016/0005-2728(83)90227-X; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; Ouellette AJA, 1998, P NATL ACAD SCI USA, V95, P2204, DOI 10.1073/pnas.95.5.2204; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pevzner PA, 2001, GENOME RES, V11, P290, DOI 10.1101/gr.154101; Pevzner PA, 2000, J COMPUT BIOL, V7, P777, DOI 10.1089/10665270050514927; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sachs RK, 2003, J BIOL CHEM, V278, P44222, DOI 10.1074/jbc.M307148200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Searle BC, 2004, ANAL CHEM, V76, P2220, DOI 10.1021/ac035258x; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; Sinz A, 2005, J AM SOC MASS SPECTR, V16, P1921, DOI 10.1016/j.jasms.2005.07.020; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsur D, 2005, NAT BIOTECHNOL, V23, P1562, DOI 10.1038/nbt1168; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wincencjusz H, 1999, BIOCHEMISTRY-US, V38, P3719, DOI 10.1021/bi982295n; YAMAMOTO Y, 1981, FEBS LETT, V133, P265, DOI 10.1016/0014-5793(81)80520-0; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Yi XP, 2005, J BIOL CHEM, V280, P16170, DOI 10.1074/jbc.M501550200; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	63	4	4	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27802	27809		10.1074/jbc.M704394200	http://dx.doi.org/10.1074/jbc.M704394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666402	hybrid			2022-12-27	WOS:000249455600029
J	Sanchez-Sanchez, F; Martinez-Redondo, F; Aroca-Aguilar, JD; Coca-Prados, M; Escribano, J				Sanchez-Sanchez, Francisco; Martinez-Redondo, Francisco; Aroca-Aguilar, J. Daniel; Coca-Prados, Miguel; Escribano, Julio			Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN-ANGLE GLAUCOMA; INCREASES OUTFLOW RESISTANCE; OLFACTOMEDIN-HOMOLOGY DOMAIN; HUMAN CILIARY BODY; ENDOPLASMIC-RETICULUM; AQUEOUS-HUMOR; PHYSIOLOGICAL-FUNCTION; TIGR/MYOCILIN PROTEIN; EXTRACELLULAR-MATRIX; NEUTRAL PROTEASE	MYOC, a gene involved in different types of glaucoma, encodes myocilin, a secreted glycoprotein of unknown function, consisting of an N-terminal leucine-zipper-like domain, a central linker region, and a C-terminal olfactomedin-like domain. Recently, we have shown that myocilin undergoes an intracellular endoproteolytic processing. We show herein that the proteolytic cleavage in the linker region splits the two terminal domains. The C-terminal domain is secreted to the culture medium, whereas the N-terminal domain mainly remains intra-cellularly retained. In transiently transfected 293T cells, the cleavage was prevented by calpain inhibitors, such as calpeptin, calpain inhibitor IV, and calpastatin. Since calpains are calcium-activated proteases, we analyzed how changes in either intra- or extracellular calcium affected the cleavage of myocilin. Intracellular ionomycin-induced calcium uptake enhanced myocilin cleavage, whereas chelation of extracellular calcium by EGTA inhibited the proteolytic processing. Calpains I and II cleaved myocilin in vitro. However, in cells in culture, only RNA interference knockdown of calpain II reduced myocilin processing. Subcellular fractionation and digestion of the obtained fractions with proteinase K showed that full-length myocilin resides in the lumen of the endoplasmic reticulum together with a sub-population of calpain II. These data revealed that calpain II is responsible for the intracellular processing of myocilin in the lumen of the endoplasmic reticulum. We propose that this cleavage might regulate extracellular interactions of myocilin, contributing to the control of intraocular pressure.	Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, E-02006 Albacete, Spain; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA	Universidad de Castilla-La Mancha; Yale University	Escribano, J (corresponding author), Fac Med, Area Genet, Avda de Almansa,No 14, E-02006 Albacete, Spain.	julio.escribano@uclm.es	Escribano, Julio/D-9742-2015; , francisco/ABF-7718-2021; Aroca-Aguilar, Jose Daniel/R-5513-2019; Aroca-Aguilar, J.Daniel/B-7842-2008	Escribano, Julio/0000-0002-8919-8134; Aroca-Aguilar, Jose Daniel/0000-0001-6487-1612; Aroca-Aguilar, J.Daniel/0000-0001-6487-1612	NATIONAL EYE INSTITUTE [R01EY004873] Funding Source: NIH RePORTER; NEI NIH HHS [EY001785, EY04873] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503; Aroca-Aguilar JD, 2005, J BIOL CHEM, V280, P21043, DOI 10.1074/jbc.M501340200; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Bhatt A, 2002, J CELL SCI, V115, P3415; Branca D, 2004, BIOCHEM BIOPH RES CO, V322, P1098, DOI 10.1016/j.bbrc.2004.07.126; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; Croall DE, 1996, BBA-PROTEIN STRUCT M, V1298, P276, DOI 10.1016/S0167-4838(96)00138-0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; ELAMRANI N, 1993, BIOCHIMIE, V75, P849, DOI 10.1016/0300-9084(93)90038-T; Elbein A D, 1981, Ciba Found Symp, V80, P270; Escribano J, 2002, MOL VIS, V8, P315; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Fautsch MP, 2000, INVEST OPHTH VIS SCI, V41, P4163; Fautsch MP, 2006, INVEST OPHTH VIS SCI, V47, P213, DOI 10.1167/iovs.05-0334; Filla MS, 2002, INVEST OPHTH VIS SCI, V43, P151; Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899; Furutani Y, 2005, BIOCHEM J, V389, P675, DOI 10.1042/BJ20050120; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Gobeil S, 2006, EXP EYE RES, V82, P1017, DOI 10.1016/j.exer.2005.11.002; Goldwich A, 2003, INVEST OPHTH VIS SCI, V44, P1953, DOI 10.1167/iovs.02-0863; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gong G, 2004, HUM MOL GENET, V13, pR91, DOI 10.1093/hmg/ddh074; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Huang W, 2000, Ophthalmic Genet, V21, P155, DOI 10.1076/1381-6810(200009)21:3;1-Z;FT155; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Karali A, 2000, INVEST OPHTH VIS SCI, V41, P729; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YX, 2006, BIOCHEM BIOPH RES CO, V339, P797, DOI 10.1016/j.bbrc.2005.11.082; Lindsey JD, 2001, INVEST OPHTH VIS SCI, V42, P1781; Maertens B, 2007, J BIOL CHEM, V282, P10647, DOI 10.1074/jbc.M611339200; Oka T, 2006, J NEUROSCI RES, V83, P1342, DOI 10.1002/jnr.20827; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; PEMRICK SM, 1984, J CELL BIOL, V99, P2297, DOI 10.1083/jcb.99.6.2297; PERSSON H, 1993, BRAIN RES, V611, P272, DOI 10.1016/0006-8993(93)90513-M; PLUMB JA, 1989, CANCER RES, V49, P4435; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Russell P, 2001, INVEST OPHTH VIS SCI, V42, P983; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sakamoto Y, 2000, CURR EYE RES, V21, P571, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT571; Sarfarazi M, 1997, HUM MOL GENET, V6, P1667, DOI 10.1093/hmg/6.10.1667; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Sorimachi H, 2000, ADV EXP MED BIOL, V481, P383; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Stamer WD, 2006, EXP EYE RES, V83, P1386, DOI 10.1016/j.exer.2006.07.018; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Tamm ER, 2002, PROG RETIN EYE RES, V21, P395, DOI 10.1016/S1350-9462(02)00010-1; TAYLOR RG, 1995, J ANIM SCI, V73, P1351; Tekirian TL, 2001, MOL BRAIN RES, V96, P14, DOI 10.1016/S0169-328X(01)00250-9; Ueda J, 2002, INVEST OPHTH VIS SCI, V43, P1068; Vollrath D, 2006, EXP EYE RES, V82, P1030, DOI 10.1016/j.exer.2005.10.007	65	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27810	27824		10.1074/jbc.M609608200	http://dx.doi.org/10.1074/jbc.M609608200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650508	hybrid			2022-12-27	WOS:000249455600030
J	Tsegaye, Y; Richardson, CG; Bravo, JE; Mulcahy, BJ; Lynch, DV; Markham, JE; Jaworski, JG; Chen, M; Cahoon, EB; Dunn, TM				Tsegaye, Yoseph; Richardson, Christopher G.; Bravo, Janis E.; Mulcahy, Brendan J.; Lynch, Daniel V.; Markham, Jonathan E.; Jaworski, Jan G.; Chen, Ming; Cahoon, Edgar B.; Dunn, Teresa M.			Arabidopsis mutants lacking long chain base phosphate lyase are fumonisin-sensitive and accumulate trihydroxy-18 : 1 long chain base phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SACCHAROMYCES-CEREVISIAE; SPHINGOSINE-1-PHOSPHATE LYASE; SPHINGOLIPID METABOLISM; HEAT-STRESS; THALIANA; YEAST; EXPRESSION; APOPTOSIS; PROTEIN	The sphingoid long chain bases (LCBs) and their phosphorylated derivatives (LCB-Ps) are important signaling molecules in eukaryotic organisms. The cellular levels of LCB-Ps are tightly controlled by the coordinated action of the LCB kinase activity responsible for their synthesis and the LCB-P phosphatase and lyase activities responsible for their catabolism. Although recent studies have implicated LCB-Ps as regulatory molecules in plants, in comparison with yeast and mammals, much less is known about their metabolism and function in plants. To investigate the functions of LCB-Ps in plants, we have undertaken the identification and characterization of Arabidopsis genes that encode the enzymes of LCB-P metabolism. In this study the Arabidopsis At1g27980 gene was shown to encode the only detectable LCB-P lyase activity in Arabidopsis. The LCB-P lyase activity was characterized, and mutant plant lines lacking the lyase were generated and analyzed. Whereas in other organisms loss of LCB-P lyase activity is associated with accumulation of high levels of LCB/LCB-Ps and developmental abnormalities, the sphingolipid profiles of the mutant plants were remarkably similar to those of wild-type plants, and no developmental abnormalities were observed. Thus, these studies indicate that the lyase plays a minor role in maintenance of sphingolipid metabolism during normal plant development and growth. However, a clear role for the lyase was revealed upon perturbation of sphingolipid synthesis by treatment with the inhibitor of ceramide synthase, fumonisin B-1.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Williams Coll, Dept Biol, Williamstown, MA 01267 USA; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Uniformed Services University of the Health Sciences - USA; Williams College; Donald Danforth Plant Science Center	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil	Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915; Markham, Jennifer/0000-0003-2397-3131				ABBAS HK, 1994, PLANT PHYSIOL, V106, P1085, DOI 10.1104/pp.106.3.1085; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Asai T, 2000, PLANT CELL, V12, P1823, DOI 10.1105/tpc.12.10.1823; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Habeler G, 2002, NUCLEIC ACIDS RES, V30, P80, DOI 10.1093/nar/30.1.80; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Ikeda M, 2004, BIOCHEM BIOPH RES CO, V325, P338, DOI 10.1016/j.bbrc.2004.10.036; Kim S, 2000, GENETICS, V156, P1519; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Li GC, 2001, DEVELOPMENT, V128, P3473; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Liu K, 2005, BIOCHEM SOC T, V33, P1170, DOI 10.1042/BST0331170; Lynch DV, 2004, NEW PHYTOL, V161, P677, DOI 10.1111/j.1469-8137.2004.00992.x; Markham JE, 2007, RAPID COMMUN MASS SP, V21, P1304, DOI 10.1002/rcm.2962; Markham JE, 2006, J BIOL CHEM, V281, P22684, DOI 10.1074/jbc.M604050200; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; NG C, 2001, NATURE, V410, P569; Niu Y, 2007, J INTEGR PLANT BIOL, V49, P323, DOI 10.1111/j.1744-7909.2007.00446.x; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spassieva SD, 2002, PLANT J, V32, P561, DOI 10.1046/j.1365-313X.2002.01444.x; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WEIGEL D, 2002, ARABIDOPSIS LAB MANU, P55; Worrall D, 2003, TRENDS PLANT SCI, V8, P317, DOI 10.1016/S1360-1385(03)00128-6; Wright BS, 2003, ARCH BIOCHEM BIOPHYS, V415, P184, DOI 10.1016/S0003-9861(03)00261-3; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	47	60	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28195	28206		10.1074/jbc.M705074200	http://dx.doi.org/10.1074/jbc.M705074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635905	hybrid			2022-12-27	WOS:000249455600069
J	Mohler, PJ; Zhu, MY; Blade, AM; Ham, AJL; Shelness, GS; Swift, LL				Mohler, Peter J.; Zhu, Mei-Ying; Blade, Anna M.; Ham, Amy-Joan L.; Shelness, Gregory S.; Swift, Larry L.			Identification of a novel isoform of microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-B; ABETALIPOPROTEINEMIA GENE; LIVER-MICROSOMES; SIGNAL PEPTIDES; EXPRESSION; LOCALIZATION; MOUSE; LIPOPROTEINS; KNOCKOUT	Microsomal triglyceride transfer protein (MTP) has been studied extensively, primarily because of its role in the assembly of very low density lipoproteins by the liver and chylomicrons by the intestine. Recent studies have suggested that MTP may also play key roles in other cellular processes. In this paper we report the identification of a novel splice variant of MTP in mice. This isoform, MTP-B, has a unique first exon located similar to 2.7 kilobases upstream of canonical MTP (MTP-A) exon 1. The alternative exon encodes 35 amino acids compared with 20 amino acids encoded by exon 1 of MTP-A. MTP-B represents similar to 90% of total MTP mRNA in mouse adipocytes and 3T3-L1 cells and < 5% in mouse liver and intestine. Expression of the alternate isoform in mouse liver was confirmed by mass spectrometry. Co-transfection of COS cells with truncated forms of apoB and either MTP-A or MTP-B demonstrated that both isoforms are effective in the assembly and secretion of nascent apoB-containing lipoproteins. Confocal microscopy of 3T3-L1 cells transfected with enhanced green fluorescent protein or DsRed fusions of the two proteins revealed that MTP-A is localized to the endoplasmic reticulum, whereas MTP-B localizes primarily to the Golgi complex in these cells. We conclude that MTP-B functions similarly to MTP-A in lipoprotein assembly. However, in nonlipoproteinsecreting cells, such as the adipocyte, MTP-B may have different localization properties, perhaps reflecting a distinct role in lipid storage and mobilization.	Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Univ Iowa, Sch Med, Dept Internal Med, Iowa City, IA 52242 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Wake Forest University; University of Iowa	Swift, LL (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, 1161 21st Ave S, Nashville, TN 37232 USA.	larry.swift@vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL057984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57984, HL 49373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; Brozovic S, 2004, NAT MED, V10, P535, DOI 10.1038/nm1043; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CUHEL M, 2007, NEW ENGL J MED, V356, P148; Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HAM AL, 2005, ENCY MASS SPECTROM A, V3, P10; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hill KE, 2007, J BIOL CHEM, V282, P10972, DOI 10.1074/jbc.M700436200; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; JAMIL H, 1996, P NATL ACAD SCI USA, V93, P1191; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200; Nakamuta M, 1996, GENOMICS, V33, P313, DOI 10.1006/geno.1996.0200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shelton JM, 2000, J LIPID RES, V41, P532; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; Slight I, 2004, EXP CELL RES, V300, P11, DOI 10.1016/j.yexcr.2004.05.038; Swift LL, 2005, FEBS LETT, V579, P3183, DOI 10.1016/j.febslet.2005.05.009; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; Tabb DL, 2006, NAT PROTOC, V1, P2213, DOI 10.1038/nprot.2006.330; Valyi-Nagy K, 2002, LIPIDS, V37, P879, DOI 10.1007/s11745-002-0974-3; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	38	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26981	26988		10.1074/jbc.M700500200	http://dx.doi.org/10.1074/jbc.M700500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635917	hybrid			2022-12-27	WOS:000249304900038
J	Stuart, LM; Bell, SA; Stewart, CR; Silver, JM; Richard, J; Goss, JL; Tseng, AA; Zhang, A; El Khoury, JB; Moore, KJ				Stuart, Lynda M.; Bell, Susan A.; Stewart, Cameron R.; Silver, Jessica M.; Richard, James; Goss, Julie L.; Tseng, Anita A.; Zhang, Ailiang; El Khoury, Joseph B.; Moore, Kathryn J.			CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-TRANSFORMED CELLS; ALZHEIMERS-DISEASE; TYROSINE PHOSPHORYLATION; PLASMODIUM-FALCIPARUM; SCAVENGER RECEPTOR; PHAGOCYTOSIS; IDENTIFICATION; TRANSDUCTION; MONOCYTES; PROTEINS	The pattern recognition receptor CD36 initiates a signaling cascade that promotes microglial activation and recruitment to beta-amyloid deposits in the brain. In the present study we identify the focal adhesion-associated proteins p130Cas, Pyk2, and paxillin as novel members of the tyrosine kinase signaling pathway downstream of CD36 and show that assembly of this complex is essential for microglial migration. In primary microglia and macrophages exposed to beta-amyloid, the scaffolding protein p130Cas is rapidly tyrosine-phosphorylated and co-localizes with CD36 to membrane ruffles contemporaneous with F-actin polymerization. These beta-amyloid-stimulated events are not detected in CD36 null cells and are dependent on CD36 activation of Src family tyrosine kinases. Fyn, a Src kinase known to interact with CD36, co-precipitates with p130Cas and is an essential upstream intermediate in the signaling pathways leading to phosphorylation of the p130Cas substrate domain. Furthermore, the p130Cas-interacting kinase Pyk2 and the cytoskeletal adapter protein paxillin also demonstrate CD36-dependent phosphorylation, identifying these focal adhesion molecules as additional members of this beta-amyloid signaling cascade. Disruption of this p130Cas complex by small interfering RNA silencing inhibits p44/42 mitogen-activated protein kinase phosphorylation and microglial migration, illustrating the importance of this pathway in microglial activation and recruitment. Together, these data are the first to identify the signaling cascade that directly links CD36 to the actin cytoskeleton and, thus, implicates it in diverse processes such as cellular migration, adhesion, and phagocytosis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02114 USA; Univ Edinburgh, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Edinburgh	Moore, KJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, 55 Fruit St,GRJ1308, Boston, MA 02114 USA.	kmoore@molbio.mgh.harvard.edu	Moore, Kathryn/ABE-6416-2020; Stewart, Cameron R/E-6823-2011	Moore, Kathryn/0000-0003-2505-2547; Stewart, Cameron/0000-0002-3395-7859; Shaw, Anita/0000-0002-1004-2226	NIA NIH HHS [R01 AG 20255] Funding Source: Medline; Wellcome Trust [068089/Z/02/Z] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Combs CK, 1999, J NEUROSCI, V19, P928; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; Gustavsson A, 2004, J BIOL CHEM, V279, P22893, DOI 10.1074/jbc.M309693200; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howlett GJ, 2006, CURR OPIN LIPIDOL, V17, P541, DOI 10.1097/01.mol.0000245260.63505.4f; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Janciauskiene S, 2001, ATHEROSCLEROSIS, V158, P41, DOI 10.1016/S0021-9150(00)00767-X; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kunjathoor VV, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-23; Ly NP, 2005, P NATL ACAD SCI USA, V102, P14729, DOI 10.1073/pnas.0506233102; McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; Medeiros LA, 2004, J BIOL CHEM, V279, P10643, DOI 10.1074/jbc.M311735200; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200; Yipp BG, 2003, BLOOD, V101, P2850, DOI 10.1182/blood-2002-09-2841	36	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27392	27401		10.1074/jbc.M702887200	http://dx.doi.org/10.1074/jbc.M702887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623670	hybrid			2022-12-27	WOS:000249304900081
J	Klaile, E; Muller, MM; Kannicht, C; Otto, W; Singer, BB; Reutter, W; Obrink, B; Lucka, L				Klaile, Esther; Muller, Mario M.; Kannicht, Christoph; Otto, Wolfgang; Singer, Bernhard B.; Reutter, Werner; Obrink, Bjorn; Lucka, Lothar			The cell adhesion receptor carcinoembryonic antigen-related cell adhesion molecule 1 regulates nucleocytoplasmic trafficking of DNA polymerase delta-interacting protein 38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT CYTOPLASMIC DOMAIN; C-CAM; BILIARY GLYCOPROTEIN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; NUCLEAR ANTIGEN; CEACAM1; GROWTH; ASSOCIATION; MITOCHONDRIAL	The homophilic cell-cell adhesion receptor CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1, CD66a) acts as a regulator of contact-dependent cell survival, differentiation, and growth. It is involved in the control of proliferation in hematopoietic and epithelial cells and can act as a tumor suppressor. In this study, we identify DNA polymerase delta-interacting protein 38 (PDIP38) as a novel binding partner for CEACAM1-L and CEACAM1-S. We show that PDIP38 can occur in the nucleus, in the cytoplasm and at the plasma membrane in NBT-II, IEC18, RBE, and HeLa cells and that the distribution in NBT-II cells is influenced by the confluency of the cells. We also demonstrate that the interaction of CEACAM1 and PDIP38 is of functional importance in NBT-II cells, which co-express the long and the short CEACAM1 isoform. In subconfluent, proliferating NBT-II cells, perturbation of CEACAM1 by antibody clustering induces increased binding to PDIP38 and results in rapid recruitment of PDIP38 to the plasma membrane. The same treatment of confluent, quiescent NBT-II cells leads to a different response, i.e. translocation of PDIP38 to the nucleus. Together, our data show that PDIP38 can shuttle between the cytoplasmic and the nuclear compartments and that its subcellular localization is regulated by CEACAM1, implicating that PDIP38 may constitute a novel downstream target of CEACAM1 signaling.	Univ Med Berlin, Charite, Inst Biochem & Molekularbiol, D-14195 Berlin, Germany; Octapharma Pre Clin Res & Dev, Mol Biochem Dept, D-14195 Berlin, Germany; Univ Hosp Essen, Inst Anat, D-45147 Essen, Germany; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Octapharma; University of Duisburg Essen; Karolinska Institutet	Klaile, E (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, Von Eulers vag 3, SE-17177 Stockholm, Sweden.	esther.klaile@ki.se	Singer, Bernhard B./AAP-9999-2020	Muller, Mario/0000-0002-1898-5691; Klaile, Esther/0000-0001-7389-6862				Arakaki N, 2006, BBA-GEN SUBJECTS, V1760, P1364, DOI 10.1016/j.bbagen.2006.05.012; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; Booth JW, 2003, J BIOL CHEM, V278, P14037, DOI 10.1074/jbc.M211879200; BRUMMER J, 1995, ONCOGENE, V11, P1649; Budt M, 2002, BIOL CHEM, V383, P803, DOI 10.1515/BC.2002.084; Budt M, 2002, BIOCHEM BIOPH RES CO, V292, P749, DOI 10.1006/bbrc.2002.6704; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Greicius G, 2003, J LEUKOCYTE BIOL, V74, P126, DOI 10.1189/jlb.1202594; HSIEH JT, 1995, CANCER RES, V55, P190; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Klaile E, 2005, J CELL SCI, V118, P5513, DOI 10.1242/jcs.02660; Kleinerman DI, 1996, CANCER RES, V56, P3431; Kuespert K, 2006, CURR OPIN CELL BIOL, V18, P565, DOI 10.1016/j.ceb.2006.08.008; Kunath T, 1995, ONCOGENE, V11, P2375; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin SH, 1999, SEMIN ONCOL, V26, P227; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Ordonez C, 2000, CANCER RES, V60, P3419; Scheffrahn I, 2005, EXP CELL RES, V307, P427, DOI 10.1016/j.yexcr.2005.03.030; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Singer BB, 2005, EUR J IMMUNOL, V35, P1949, DOI 10.1002/eji.200425691; Singer BB, 2000, CANCER RES, V60, P1236; SINGER BB, UCSD NATURE MOL PAGE; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Valgardsdottir R, 2001, J BIOL CHEM, V276, P32056, DOI 10.1074/jbc.M011629200; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Wikstrom K, 1996, EXP CELL RES, V227, P360, DOI 10.1006/excr.1996.0285; Xie B, 2005, J BIOL CHEM, V280, P22375, DOI 10.1074/jbc.M414597200; Yu QG, 2006, J BIOL CHEM, V281, P39179, DOI 10.1074/jbc.M608864200; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	48	26	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26629	10.1074/jbc.M701807200	http://dx.doi.org/10.1074/jbc.M701807200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623671	hybrid			2022-12-27	WOS:000249239600066
J	Bendz, H; Ruhland, SC; Pandya, MJ; Hainzl, O; Riegelsberger, S; Brauchle, C; Mayer, MP; Buchner, J; Issels, RD; Noessner, E				Bendz, Henriette; Ruhland, Sibylle C.; Pandya, Maya J.; Hainzl, Otmar; Riegelsberger, Stefan; Braeuchle, Christoph; Mayer, Matthias P.; Buchner, Johannes; Issels, Rolf D.; Noessner, Elfriede			Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN DENDRITIC CELLS; CLASS-I MOLECULES; CD8(+) T-CELLS; CROSS-PRESENTATION; MURINE MACROPHAGES; EXOGENOUS ANTIGENS; PEPTIDE COMPLEXES; INFILTRATING LYMPHOCYTES; PRESENTATION PATHWAY	Heat shock proteins (HSPs) have shown promise for the optimization of protein-based vaccines because they can transfer exogenous antigens to dendritic cells and at the same time induce their maturation. Great care must be exercised in interpretating HSP-driven studies, as by-products linked to the recombinant generation of these proteins have been shown to mediate immunological effects. We generated highly purified human recombinant Hsp70 and demonstrated that it strongly enhances the cross-presentation of exogenous antigens resulting in better antigen-specific T cell stimulation. Augmentation of T cell stimulation was a direct function of the degree of complex formation between Hsp70 and peptides and correlated with improved antigen delivery to endosomal compartments. The Hsp70 activity was independent of TAP proteins and was not inhibited by exotoxin A or endosomal acidification. Consequently, Hsp70 enhanced cross-presentation of various antigenic sequences, even when they required different post-uptake processing and trafficking, as exemplified by the tumor antigens tyrosinase and Melan-A/MART-1. Furthermore, Hsp70 enhanced cross-presentation by different antigen-presenting cells (APCs), including dendritic cells and B cells. Importantly, enhanced cross-presentation and antigen-specific T cell activation were observed in the absence of innate signals transmitted by Hsp70. As Hsp70 supports the cross- presentation of different antigens and APCs and is inert to APC function, it may show efficacy in various settings of immune modulation, including induction of antigen-specific immunity or tolerance.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Munich, GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, Clin Cooperat grp, D-81377 Munich, Germany; Tech Univ Munich, Dept Chem, Lehrstuhl Biotechnol 4, D-85747 Garching, Germany; Univ Munich, Dept Chem & Biochem, Munich, Germany; Univ Munich, Ctr Nanosci, D-80539 Munich, Germany; Univ Heidelberg, ZMBH, D-6900 Heidelberg, Germany	University of Sheffield; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Technical University of Munich; University of Munich; University of Munich; Ruprecht Karls University Heidelberg	Bendz, H (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	henriette.bendz@gsf.de; noessner@gsf.de	Buchner, Johannes/A-2651-2010; Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Buchner, Johannes/0000-0003-1282-7737; Issels, Rolf/0000-0002-3494-6561				Ackerman AL, 2006, IMMUNITY, V25, P607, DOI 10.1016/j.immuni.2006.08.017; Amoscato AA, 1998, J IMMUNOL, V161, P4023; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Binder RJ, 2004, TISSUE ANTIGENS, V64, P442, DOI 10.1111/j.1399-0039.2004.00299.x; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Breloer M, 2001, EUR J IMMUNOL, V31, P2051, DOI 10.1002/1521-4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Calderwood SK, 2005, EUR J IMMUNOL, V35, P2518, DOI 10.1002/eji.200535002; Calderwood SK, 2007, FEBS LETT, V581, P3689, DOI 10.1016/j.febslet.2007.04.044; Castelli C, 2001, CANCER RES, V61, P222; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Chow AY, 2005, TRENDS IMMUNOL, V26, P72, DOI 10.1016/j.it.2004.11.008; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Flechtner JB, 2006, J IMMUNOL, V177, P1017, DOI 10.4049/jimmunol.177.2.1017; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Goletz TJ, 1997, HUM IMMUNOL, V54, P129, DOI 10.1016/S0198-8859(97)00081-5; Grundler W, 2001, CYTOMETRY, V44, P45, DOI 10.1002/1097-0320(20010501)44:1<45::AID-CYTO1081>3.3.CO;2-P; Guermonprez P, 2005, SPRINGER SEMIN IMMUN, V26, P257, DOI 10.1007/s00281-004-0176-0; Heit A, 2004, J IMMUNOL, V172, P1501, DOI 10.4049/jimmunol.172.3.1501; HIRAYAMA K, 1990, BIOCHEM BIOPH RES CO, V173, P639, DOI 10.1016/S0006-291X(05)80083-X; Hunter AC, 2002, DRUG DISCOV TODAY, V7, P998, DOI 10.1016/S1359-6446(02)02444-3; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kim DT, 1997, J IMMUNOL, V159, P1666; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; Lang A, 2005, J AM SOC NEPHROL, V16, P383, DOI 10.1681/ASN.2004040276; Li Z, 2004, METHODS, V32, P25, DOI 10.1016/S1046-2023(03)00183-X; Maecker HT, 2001, J IMMUNOL, V166, P7268, DOI 10.4049/jimmunol.166.12.7268; Marteau F, 2004, J LEUKOCYTE BIOL, V76, P796, DOI 10.1189/jlb.0104032; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Milani V, 2002, INT J HYPERTHER, V18, P563, DOI 10.1080/02656730210166140; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Noakes KL, 1999, FEBS LETT, V453, P95, DOI 10.1016/S0014-5793(99)00609-2; Noessner E, 2002, J IMMUNOL, V169, P5424, DOI 10.4049/jimmunol.169.10.5424; Norbury CC, 2006, IMMUNOLOGY, V117, P443, DOI 10.1111/j.1365-2567.2006.02335.x; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; Palliser D, 2005, J IMMUNOL, V174, P1879, DOI 10.4049/jimmunol.174.4.1879; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Rock KL, 2006, IMMUNITY, V25, P523, DOI 10.1016/j.immuni.2006.09.003; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Shen LJ, 2006, CURR OPIN IMMUNOL, V18, P85, DOI 10.1016/j.coi.2005.11.003; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046; Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; VISSEREN MJW, 1995, J IMMUNOL, V154, P3991; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang RB, 2006, BLOOD, V107, P1636, DOI 10.1182/blood-2005-06-2559; Wang XH, 2005, WORLD J GASTROENTERO, V11, P5614, DOI 10.3748/wjg.v11.i36.5614; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Ye ZY, 2007, J BIOL CHEM, V282, P4479, DOI 10.1074/jbc.M606802200	81	103	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31688	31702		10.1074/jbc.M704129200	http://dx.doi.org/10.1074/jbc.M704129200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17684010	hybrid			2022-12-27	WOS:000250309200060
J	DiGirolamo, DJ; Mukherjee, A; Fulzele, K; Gan, YJ; Cao, XM; Frank, SJ; Clemens, TL				DiGirolamo, Douglas J.; Mukherjee, Aditi; Fulzele, Keertik; Gan, Yujun; Cao, Xuemei; Frank, Stuart J.; Clemens, Thomas L.			Mode of growth hormone action in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MINERAL DENSITY; FACTOR-I; TYROSINE PHOSPHORYLATION; IGF-I; 3T3-F442A FIBROBLASTS; TRANSCRIPTION FACTOR; MOUSE OSTEOBLASTS; GENE-EXPRESSION; BODY GROWTH; GH RECEPTOR	Growth hormone (GH) affects bone size and mass in part through stimulating insulin-like growth factor type 1 (IGF-1) production in liver and bone. Whether GH acts independent of IGF-1 in bone remains unclear. To define the mode of GH action in bone, we have used a Cre/loxP system in which the type 1 IGF-1 receptor (Igf1r) has been disrupted specifically in osteoblasts in vitro and in vivo. Calvarial osteoblasts from mice homozygous for the floxed IGF-1R allele (IGF-1Rflox/flox) were infected with adenoviral vectors expressing Cre. Disruption of IGF-1RmRNA(> 90%) was accompanied by near elimination of IGF-1R protein but retention of GHR protein. GH-induced STAT5 activation was consistently greater in osteoblasts with an intact IGF-1R. Osteoblasts lacking IGF-1R retained GH-induced ERK and Akt phosphorylation and GH-stimulated IGF-1 and IGFBP-3 mRNA expression. GH-induced osteoblast proliferation was abolished by Cre-mediated disruption of the IGF-1R or co-incubation of cells with an IGF-1-neutralizing antibody. By contrast, GH inhibited apoptosis in osteoblasts lacking the IGF-1R. To examine the effects of GH on osteoblasts in vivo, mice wild type for the IGF-1R treated with GH subcutaneously for 7 days showed a doubling in the number of osteoblasts lining trabecular bone, whereas osteoblast numbers in similarly treated mice lacking the IGF-1R in osteoblasts were not significantly affected. These results indicate that although direct IGF1R-independent actions of GH on osteoblast apoptosis can be demonstrated in vitro, IGF-1R is required for anabolic effects of GH in osteoblasts in vivo.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Clemens, TL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	tclemens@uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052746] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR052746] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASHCOM G, 1992, ENDOCRINOLOGY, V131, P1915, DOI 10.1210/en.131.4.1915; BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320; BIRNBAUM RS, 1995, J ENDOCRINOL, V144, P251, DOI 10.1677/joe.0.1440251; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Choi HK, 2000, GROWTH HORM IGF RES, V10, P1, DOI 10.1016/S1096-6374(00)80002-7; Costoya JA, 1999, ENDOCRINOLOGY, V140, P5937, DOI 10.1210/en.140.12.5937; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fielder PJ, 1996, ENDOCRINOLOGY, V137, P1913, DOI 10.1210/en.137.5.1913; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423; Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003-0418; Karsenty G, 2000, MATRIX BIOL, V19, P85, DOI 10.1016/S0945-053X(00)00053-6; KASSEM M, 1994, GROWTH REGULAT, V4, P131; Klover P, 2007, ENDOCRINOLOGY, V148, P1489, DOI 10.1210/en.2006-1431; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; Landin-Wilhelmsen K, 2003, J BONE MINER RES, V18, P393, DOI 10.1359/jbmr.2003.18.3.393; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; MERRIMAN HL, 1990, CALCIFIED TISSUE INT, V46, P258, DOI 10.1007/BF02555005; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; Mohan S, 2003, ENDOCRINOLOGY, V144, P929, DOI 10.1210/en.2002-220948; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Morales O, 2004, ENDOCRINOLOGY, V145, P87, DOI 10.1210/en.2003-0718; MUNDY GR, 1995, BONE, V17, pS71, DOI 10.1016/8756-3282(95)00182-D; NILSSON A, 1995, J CLIN ENDOCR METAB, V80, P3483, DOI 10.1210/jc.80.12.3483; Rydziel S, 1997, J CELL BIOCHEM, V67, P176, DOI 10.1002/(SICI)1097-4644(19971101)67:2<176::AID-JCB3>3.0.CO;2-U; SCHEVEN BAA, 1991, GROWTH REGULAT, V1, P160; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SLOOTWEG MC, 1988, J ENDOCRINOL, V116, pR11, DOI 10.1677/joe.0.116R011; Slootweg MC, 1996, J ENDOCRINOL, V150, P465, DOI 10.1677/joe.0.1500465; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sotiropoulos A, 2006, P NATL ACAD SCI USA, V103, P7315, DOI 10.1073/pnas.0510033103; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; Szulc P, 2004, CALCIFIED TISSUE INT, V74, P322, DOI 10.1007/s00223-003-0090-9; Wang J, 2004, J ENDOCRINOL, V180, P247, DOI 10.1677/joe.0.1800247; Waxman D J, 2000, Novartis Found Symp, V227, P61; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674	48	81	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31666	31674		10.1074/jbc.M705219200	http://dx.doi.org/10.1074/jbc.M705219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17698843	hybrid			2022-12-27	WOS:000250309200058
J	Thompson, D; Lazennec, C; Plateau, P; Simonson, T				Thompson, Damien; Lazennec, Christine; Plateau, Pierre; Simonson, Thomas			Ammonium scanning in an enzyme active site - The chiral specificity of aspartyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; FREE-ENERGY CALCULATIONS; BARRIER HYDROGEN-BONDS; AMINO-ACID RECOGNITION; CRYSTAL-STRUCTURE; ELECTROSTATIC INTERACTIONS; CONFORMATIONAL-CHANGES; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; PROTON BINDING	D-Amino acids are largely excluded from protein synthesis, yet they are of great interest in biotechnology. Aspartyl-tRNA synthetase (AspRS) can misacylate tRNA(Asp) with D-aspartate instead of its usual substrate, L-Asp. We investigate how the preference for L-Asp arises, using molecular dynamics simulations. Asp presents a special problem, having pseudosymmetry broken only by its ammonium group, and AspRS must protect not only against D-Asp, but against an "inverted" orientation where the two substrate carboxylates are swapped. We compare L-Asp and D-Asp, in both orientations, and succinate, where the ammonium group is removed and the ligand has an additional negative charge. All possible ammonium positions on the ligand are thus scanned, providing information on electrostatic interactions. As controls, we simulate a Q199E mutation, obtaining a reduction in binding free energy in agreement with experiment, and we simulate TyrRS, which can misacylate tRNATyr with D-Tyr. For both TyrRS and AspRS, we obtain a moderate binding free energy difference Delta Delta G between the L- and D-amino acids, in agreement with their known ability to misacylate their tRNAs. In contrast, we predict that AspRS is strongly protected against inverted L- Asp binding. For succinate, kinetic measurements reveal a Delta Delta G of over 5 kcal/mol, favoring L- Asp. The simulations show how chiral discriminations arises from the structures, with two AspRS conformations acting in different ways and proton uptake by nearby histidines playing a role. A complex network of charges protects AspRS against most binding errors, making the engineering of its specificity a difficult challenge.	Ecole Polytech, Biochim Lab, Dept Biol, CNRS UMR 7654, F-91128 Palaiseau, France; Univ Ireland Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; University College Cork	Thompson, D (corresponding author), Ecole Polytech, Biochim Lab, Dept Biol, CNRS UMR 7654, F-91128 Palaiseau, France.	damien.thompson@tyndall.ie	Thompson, Damien/AFP-1709-2022; Simonson, Thomas/A-5733-2008; thompson, damien/G-6138-2015	Thompson, Damien/0000-0003-2340-5441; Simonson, Thomas/0000-0002-5117-7338; thompson, damien/0000-0003-2340-5441				Ador L, 2004, BIOCHEMISTRY-US, V43, P7028, DOI 10.1021/bi049617+; Alexov EG, 1997, BIOPHYS J, V72, P2075, DOI 10.1016/S0006-3495(97)78851-9; [Anonymous], 2016, GAUSSIAN 03 VERSION; Archontis G, 1998, J MOL BIOL, V275, P823, DOI 10.1006/jmbi.1997.1470; Archontis G, 2005, BIOPHYS J, V88, P3888, DOI 10.1529/biophysj.104.055996; Archontis G, 2001, J MOL BIOL, V306, P307, DOI 10.1006/jmbi.2000.4285; Archontis G, 2001, J AM CHEM SOC, V123, P11047, DOI 10.1021/ja010716+; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Arnez JG, 1994, RNA PROTEIN INTERACT, P52; Ataide SF, 2004, BIOCHEMISTRY-US, V43, P11836, DOI 10.1021/bi0490542; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BEGLOV D, 1994, J CHEM PHYS, V100, P9050, DOI 10.1063/1.466711; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Berthet-Colominas C, 1998, EMBO J, V17, P2947, DOI 10.1093/emboj/17.10.2947; BORESCH S, 1994, PROTEINS, V20, P25, DOI 10.1002/prot.340200105; Briand C, 2000, J MOL BIOL, V299, P1051, DOI 10.1006/jmbi.2000.3819; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Burkhard P, 2000, PROTEIN SCI, V9, P2294, DOI 10.1110/ps.9.12.2294; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; Fischer PM, 2003, CURR PROTEIN PEPT SC, V4, P339, DOI 10.2174/1389203033487054; Francklyn C, 2003, P NATL ACAD SCI USA, V100, P9650, DOI 10.1073/pnas.1934245100; Giege R., 2005, AMINOACYL TRNA SYNTH, P210; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Ibba M., 2005, AMINOACYL TRNA SYNTH; Kobayashi T, 2005, J MOL BIOL, V346, P105, DOI 10.1016/j.jmb.2004.11.034; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamb ML, 1997, CURR OPIN CHEM BIOL, V1, P449, DOI 10.1016/S1367-5931(97)80038-5; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McQuarrie D. A., 1975, STAT MECH; Meinnel Thierry, 1995, P251; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; Onesti S, 2000, BIOCHEMISTRY-US, V39, P12853, DOI 10.1021/bi001487r; Pallanck Leo, 1995, P371; POTERSZMAN A, 1994, J MOL BIOL, V244, P158, DOI 10.1006/jmbi.1994.1716; REED AE, 1988, CHEM REV, V88, P899, DOI 10.1016/0030-4018(75)90085-1; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; Simonson T, 2000, J PHYS CHEM B, V104, P6509, DOI 10.1021/jp0014317; Simonson T, 2004, J AM CHEM SOC, V126, P4167, DOI 10.1021/ja039788m; Simonson T, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P169; Simonson T, 2003, REP PROG PHYS, V66, P737, DOI 10.1088/0034-4885/66/5/202; Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; STOTE RH, 1991, J CHIM PHYS PCB, V88, P2419, DOI 10.1051/jcp/1991882419; Strajbl M, 2003, P NATL ACAD SCI USA, V100, P14834, DOI 10.1073/pnas.2436328100; Tajkhorshid E, 2000, BIOPHYS J, V78, P683, DOI 10.1016/S0006-3495(00)76626-4; Takita T, 2003, J MOL BIOL, V325, P677, DOI 10.1016/S0022-2836(02)01238-X; Thompson D, 2006, J PHYS CHEM B, V110, P16640, DOI 10.1021/jp062553n; Thompson D, 2006, CHEMBIOCHEM, V7, P337, DOI 10.1002/cbic.200500364; Thompson D, 2006, J BIOL CHEM, V281, P23792, DOI 10.1074/jbc.M602870200; Tugyi R, 2005, P NATL ACAD SCI USA, V102, P413, DOI 10.1073/pnas.0407677102; VANGUNSTEREN W, 1993, COMPUTER SIMULATION, P315; Wang JY, 2006, BIOPHYS J, V91, P2798, DOI 10.1529/biophysj.106.084301; Warshel A, 2003, ANNU REV BIOPH BIOM, V32, P425, DOI 10.1146/annurev.biophys.32.110601.141807; WARSHEL A, 1986, BIOCHEMISTRY-US, V25, P8368, DOI 10.1021/bi00374a006; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Warshel A., 1991, COMPUTER MODELLING C; WONG CF, 1986, J AM CHEM SOC, V108, P3830, DOI 10.1021/ja00273a048; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; Zeng J, 1999, PROTEIN SCI, V8, P50	69	22	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30856	30868		10.1074/jbc.M704788200	http://dx.doi.org/10.1074/jbc.M704788200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17690095	hybrid			2022-12-27	WOS:000250136300054
J	Fan, DW; Chen, ZQ; Chen, YP; Shang, YF				Fan, Dongwei; Chen, Zhongqiang; Chen, Yupeng; Shang, Yongfeng			Mechanistic roles of leptin in osteogenic stimulation in thoracic ligament Flavum cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTERIOR LONGITUDINAL LIGAMENT; RECEPTOR-REGULATED TRANSCRIPTION; BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; ENDOMETRIAL CARCINOGENESIS; MOLECULAR-MECHANISMS; STAT3 ACTIVATION; OSTEOCALCIN GENE; SPINAL LIGAMENTS; YELLOW LIGAMENT	Obesity is a risk factor for thoracic ossification of ligament flavum ( TOLF) that is characterized by ectopic bone formation in the spinal ligaments. Hyperleptinemia is a common feature of obese people, and leptin, an adipocyte- derived cytokine with proliferative and osteogenic effects in several cell types, is believed to be an important factor in the pathogenesis of TOLF. However, how leptin might stimulate cell osteogenic differentiation in TOLF is not totally understood. We reported here that leptin- induced osteogenic effect inTOLFcells is associated with activation of signaling molecules STAT3, JNK, and ERK1/ 2 but not p38. Blocking STAT3 phosphorylation with a selective inhibitor, AG490, significantly abolished leptin- induced osteogenic differentiation of TOLF cells, whereas blocking ERK1/ 2 and JNK phosphorylation with their selective inhibitors PD98059 and SP600125, respectively, had only marginal effects. In addition, we showed that STAT3 interacted with Runt- related transcription factor 2 ( Runx2) in the nucleus, and STAT3, Runx2, and steroid receptor coactivator steroid receptor coactivator- 1 were components of the transcription complex recruitedon Runx2 target gene promoters in response to leptin treatment. Our experiments identified STAT3, Runx2, and steroid receptor coactivator1 as critical molecules in mediating leptin- stimulated cell osteogenesis in TOLF.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ Third Hosp, Dept Orthoped, Beijing 100083, Peoples R China	Peking University; Peking University	Shang, YF (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	yshang@hsc.pku.edu.cn	Chen, Yupeng/T-5275-2019	Chen, Yupeng/0000-0001-8887-9547				Akhaddar A, 2002, JOINT BONE SPINE, V69, P319, DOI 10.1016/S1297-319X(02)00400-1; Al-Orainy IA, 1998, EUR J RADIOL, V29, P76, DOI 10.1016/S0720-048X(98)00030-8; Aleffi S, 2005, HEPATOLOGY, V42, P1339, DOI 10.1002/hep.20965; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Ben Hamouda K, 2003, J NEUROSURG, V99, P157, DOI 10.3171/spi.2003.99.2.0157; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Ciancaglini P, 2006, BRAZ J MED BIOL RES, V39, P603, DOI 10.1590/S0100-879X2006000500006; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Epstein N, 1996, J SPINAL DISORD, V9, P446; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Hegyi K, 2004, CELL BIOL INT, V28, P159, DOI 10.1016/j.cellbi.2003.12.003; Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330; Huitema LFA, 2006, CALCIFIED TISSUE INT, V78, P171, DOI 10.1007/s00223-005-1233-y; Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074; Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; MIYAMOTO S, 1993, SPINE, V18, P2267, DOI 10.1097/00007632-199311000-00021; NAKAMURA T, 1990, J SPINAL DISORD, V3, P288; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; Okano T, 1997, J ORTHOPAED RES, V15, P820, DOI 10.1002/jor.1100150606; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Salingcarnboriboon R, 2006, ENDOCRINOLOGY, V147, P2296, DOI 10.1210/en.2005-1020; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shirakura Y, 2000, BIOCHEM BIOPH RES CO, V267, P752, DOI 10.1006/bbrc.1999.2027; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Specchia N, 2001, J ORTHOP RES, V19, P294, DOI 10.1016/S0736-0266(00)00026-7; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Theilhaber J, 2002, GENOME RES, V12, P165, DOI 10.1101/gr.182601; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Vasudevan A, 2002, J CLIN NEUROSCI, V9, P311, DOI 10.1054/jocn.2001.0962; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang FM, 2005, VITAM HORM, V71, P345, DOI 10.1016/S0083-6729(05)71012-8; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306	48	35	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29958	29966		10.1074/jbc.M611779200	http://dx.doi.org/10.1074/jbc.M611779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702747	hybrid			2022-12-27	WOS:000249981200025
J	Jennings, MD; Blankley, RT; Baron, M; Golovanov, AP; Avis, JM				Jennings, Martin D.; Blankley, Richard T.; Baron, Martin; Golovanov, Alexander P.; Avis, Johanna M.			Specificity and autoregulation of notch binding by tandem WW domains in Suppressor of Deltex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; NEDD4 FAMILY; REGULATOR; RECOGNITION; LIGAND; GENE; SH3; AUTOINHIBITION	WW domains target proline-tyrosine (PY) motifs and frequently function as tandem pairs. When studied in isolation, single WW domains are notably promiscuous and regulatory mechanisms are undoubtedly required to ensure selective interactions. Here, we show that the fourth WW domain (WW4) of Suppressor of Deltex, a modular Nedd4-like protein that down-regulates the Notch receptor, is the primary mediator of a direct interaction with a Notch-PY motif. A natural Trp to Phe substitution in WW4 reduces its affinity for general PY sequences and enhances selective interaction with the Notch-PY motif via compensatory specificity-determining interactions with PY-flanking residues. When WW4 is paired with WW3, domain-domain association, impeding proper folding, competes with Notch-PY binding to WW4. This novel mode of autoinhibition is relieved by binding of another ligand to WW3. Such cooper-ativity may facilitate the transient regulatory interactions observed in vivo between Su(dx) and Notch in the endocytic pathway. The highly conserved tandem arrangement of WW domains in Nedd4 proteins, and similar arrangements in more diverse proteins, suggests domain-domain communication may be integral to regulation of their associated cellular activities.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England	University of Manchester; University of Manchester	Avis, JM (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	mbaron@manchester.ac.uk; a.golovanov@manchester.ac.uk; j.avis@manchester.ac.uk	Golovanov, Alexander P./ABN-0572-2022; Jennings, martin/E-5240-2010	Golovanov, Alexander P./0000-0002-8592-3984; Jennings, Martin/0000-0001-6173-0988	Wellcome Trust [074379] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; BUSSEAU I, 1994, GENETICS, V136, P585; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chong PA, 2006, J BIOL CHEM, V281, P17069, DOI 10.1074/jbc.M601493200; Cornell M, 1999, GENETICS, V152, P567; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fedoroff OY, 2004, J BIOL CHEM, V279, P34991, DOI 10.1074/jbc.M404987200; Flasza M, 2006, MOL MEMBR BIOL, V23, P269, DOI 10.1080/09687860600665010; Fostier M, 1998, GENETICS, V150, P1477; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gao YG, 2006, STRUCTURE, V14, P1755, DOI 10.1016/j.str.2006.09.014; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Long JF, 2005, NAT STRUCT MOL BIOL, V12, P722, DOI 10.1038/nsmb958; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Morvan J, 2004, TRAFFIC, V5, P383, DOI 10.1111/j.1398-9219.2004.00183.x; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Wilkin MB, 2005, MOL MEMBR BIOL, V22, P279, DOI 10.1080/09687860500129778; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	51	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29032	29042		10.1074/jbc.M703453200	http://dx.doi.org/10.1074/jbc.M703453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656366	hybrid, Green Accepted			2022-12-27	WOS:000249642100077
J	Kang, L; Chen, XC; Sebastian, BM; Pratt, BT; Bederman, IR; Alexander, JC; Previs, SF; Nagy, LE				Kang, Li; Chen, Xiaocong; Sebastian, Becky M.; Pratt, Brian T.; Bederman, Ilya R.; Alexander, James C.; Previs, Stephen F.; Nagy, Laura E.			Chronic ethanol and triglyceride turnover in white adipose tissue in rats - Inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CELLULAR PLASTICITY; PTEN PHOSPHATASE; SKELETAL-MUSCLE; METABOLISM; ADIPOCYTES; RESISTANCE; (H2O)-H-2; HUMANS; WATER	Chronic ethanol consumption disrupts whole-body lipid metabolism. Here we tested the hypothesis that regulation of triglyceride homeostasis in adipose tissue is vulnerable to long-term ethanol exposure. After chronic ethanol feeding, total body fat content as well as the quantity of epididymal adipose tissue of male Wistar rats was decreased compared with pair-fed controls. Integrated rates of in vivo triglyceride turnover in epididymal adipose tissue were measured using (H2O)-H-2 as a tracer. Triglyceride turnover in adipose tissue was increased due to a 2.3-fold increase in triglyceride degradation in ethanol-fed rats compared with pair-fed controls with no effect of ethanol on triglyceride synthesis. Because increased lipolysis accompanied by the release of free fatty acids into the circulation is associated with insulin resistance and liver injury, we focused on determining the mechanisms for increased lipolysis in adipose tissue after chronic ethanol feeding. Chronic ethanol feeding suppressed beta-adrenergic receptor-stimulated lipolysis in both in vivo and ex vivo assays; thus, enhanced triglyceride degradation during ethanol feeding was not due to increased beta-adrenergic-mediated lipolysis. Instead, chronic ethanol feeding markedly impaired insulin-mediated suppression of lipolysis in conscious rats during a hyperinsulinemic-euglycemic clamp as well as in adipocytes isolated from epididymal and subcutaneous adipose tissue. These data demonstrate for the first time that chronic ethanol feeding increased the rate of triglyceride degradation in adipose tissue. Furthermore, this enhanced rate of lipolysis was due to a suppression of the anti-lipolytic effects of insulin in adipocytes after chronic ethanol feeding.	Cleveland Clin Fdn, Dept Gastroenterol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathobiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Math, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Nagy, LE (corresponding author), Cleveland Clin Fdn, Dept Gastroenterol & Pathobiol, Lerner Res Inst, NE40,9500 Euclid Ave, Cleveland, OH 44195 USA.	laura.nagy@case.edu		Kang, Li/0000-0002-6990-1996	NATIONAL CANCER INSTITUTE [R24CA110943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA011876, R01AA011876] Funding Source: NIH RePORTER; NCI NIH HHS [1R24 CA110943-01] Funding Source: Medline; NIAAA NIH HHS [AA11876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Addolorato G, 2000, AM J GASTROENTEROL, V95, P2323; Ambrisko TD, 2002, CAN J VET RES, V66, P42; BARAONA E, 1979, J LIPID RES, V20, P289; Bederman IR, 2006, AM J PHYSIOL-ENDOC M, V290, pE1048, DOI 10.1152/ajpendo.00340.2005; Berk Paul D, 2005, Trans Am Clin Climatol Assoc, V116, P335; Brunengraber DZ, 2003, AM J PHYSIOL-ENDOC M, V285, pE917, DOI 10.1152/ajpendo.00128.2003; Chandramouli V, 1997, AM J PHYSIOL-ENDOC M, V273, pE1209, DOI 10.1152/ajpendo.1997.273.6.E1209; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Diraison F, 1997, J MASS SPECTROM, V32, P81, DOI 10.1002/(SICI)1096-9888(199701)32:1<81::AID-JMS454>3.0.CO;2-2; Dufner DA, 2005, AM J PHYSIOL-ENDOC M, V288, pE1277, DOI 10.1152/ajpendo.00580.2004; Granneman JG, 2005, AM J PHYSIOL-ENDOC M, V289, pE608, DOI 10.1152/ajpendo.00009.2005; HOLLEY DC, 1981, METABOLISM, V30, P894, DOI 10.1016/0026-0495(81)90068-8; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; JAMES DE, 1986, J BIOL CHEM, V261, P6366; KANG L, 2007, ALCOHOL CLIN EXP RES, V31, P1; Kang L, 2006, ENDOCRINOLOGY, V147, P4330, DOI 10.1210/en.2006-0120; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; Li PP, 2005, AM J PHYSIOL-ENDOC M, V289, pE617, DOI 10.1152/ajpendo.00010.2005; MERSMANN HJ, 1983, P SOC EXP BIOL MED, V172, P375, DOI 10.3181/00379727-172-41573; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Poirier LA, 2001, BIOCHEM J, V354, P323, DOI 10.1042/0264-6021:3540323; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Sebastian BM, 2005, AM J PHYSIOL-ENDOC M, V289, pE1077, DOI 10.1152/ajpendo.00296.2005; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Strawford A, 2004, AM J PHYSIOL-ENDOC M, V286, pE577, DOI 10.1152/ajpendo.00093.2003; Stumvoll M, 2001, HORM METAB RES, V33, P89, DOI 10.1055/s-2001-12403; TIENGO A, 1981, DIABETES, V30, P705, DOI 10.2337/diabetes.30.9.705; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Wan Q, 2005, ALCOHOL CLIN EXP RES, V29, P1450, DOI 10.1097/01.alc.0000174768.78427.f6; Wilkes JJ, 1996, ALCOHOL CLIN EXP RES, V20, P1016, DOI 10.1111/j.1530-0277.1996.tb01940.x; WILKES JJ, 1996, AM J PHYSIOL, V271, P477; Xu J, 2003, J BIOL CHEM, V278, P26929, DOI 10.1074/jbc.M300401200; Yang DW, 1998, ANAL BIOCHEM, V258, P315, DOI 10.1006/abio.1998.2632; Yeon JE, 2003, HEPATOLOGY, V38, P703, DOI 10.1053/jhep.2003.50368; YKIJARVINEN H, 1985, J CLIN ENDOCR METAB, V61, P941, DOI 10.1210/jcem-61-5-941	38	72	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28465	28473		10.1074/jbc.M705503200	http://dx.doi.org/10.1074/jbc.M705503200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686776	hybrid			2022-12-27	WOS:000249642100020
J	Koh, Y; Matsumi, S; Das, D; Amano, M; Davis, DA; Li, JF; Leschenko, S; Baldridge, A; Shioda, T; Yarchoan, R; Ghosh, AK; Mitsuya, H				Koh, Yasuhiro; Matsumi, Shintaro; Das, Debananda; Amano, Masayuki; Davis, David A.; Li, Jianfeng; Leschenko, Sofiya; Baldridge, Abigail; Shioda, Tatsuo; Yarchoan, Robert; Ghosh, Arun K.; Mitsuya, Hiroaki			Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; INTERFACE PEPTIDES; CRYSTAL-STRUCTURE; RESISTANCE; PROTEINASE; MONOMER; TMC114; PI; TIPRANAVIR; STABILITY	Dimerization of HIV-1 protease subunits is essential for its proteolytic activity, which plays a critical role in HIV-1 replication. Hence, the inhibition of protease dimerization represents a unique target for potential intervention of HIV-1. We developed an intermolecular fluorescence resonance energy transfer-based HIV-1-expression assay employing cyan and yellow fluorescent protein-tagged protease monomers. Using this assay, we identified non-peptidyl small molecule inhibitors of protease dimerization. These inhibitors, including darunavir and two experimental protease inhibitors, blocked protease dimerization at concentrations of as low as 0.01 mu M and blocked HIV-1 replication with IC50 values of 0.0002-0.48 mu M. These agents also inhibited the proteolytic activity of mature protease. Other approved anti-HIV-1 agents examined except tipranavir, a CCR5 inhibitor, and soluble CD4 failed to block the dimerization event. Once protease monomers dimerize to become mature protease, mature protease is not dissociated by this dimerization inhibition mechanism, suggesting that these agents block dimerization at the nascent stage of protease maturation. The proteolytic activity of mature protease that managed to undergo dimerization despite the presence of these agents is likely to be inhibited by the same agents acting as conventional protease inhibitors. Such a dual inhibition mechanism should lead to highly potent inhibition of HIV-1.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan; NCI, NIH, Expt Retrovirol Sect, Bethesda, MD 20892 USA; NCI, NIH, Retroviral Dis Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA; Purdue Univ, Dept Chem & Med Chem, W Lafayette, IN 47907 USA; Osaka Univ, Dept Viral Infect, Res Inst Microbial Dis, Osaka 5650871, Japan	Kumamoto University; Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus; Osaka University	Mitsuya, H (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hmitsuya@helix.nih.gov	Amano, Masayuki/N-7407-2016; Li, Jianfeng/F-5057-2014	Amano, Masayuki/0000-0003-0516-9502; Li, Jianfeng/0000-0002-8838-3872	NATIONAL CANCER INSTITUTE [Z01SC006738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053386, R37GM053386] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM53386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 2007, ANTIMICROB AGENTS CH, V51, P2143, DOI 10.1128/AAC.01413-06; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; Bannwarth L, 2006, J MED CHEM, V49, P4657, DOI 10.1021/jm060576k; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; Bowman MJ, 2005, CHEM BIOL, V12, P439, DOI 10.1016/j.chembiol.2005.02.004; Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151; Davis DA, 2006, ANTIVIR RES, V72, P89, DOI 10.1016/j.antiviral.2006.03.015; De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.6.2314-2321.2005; Fang GW, 1999, NAT MED, V5, P239, DOI 10.1038/5607; Frutos S, 2007, BIOPOLYMERS, V88, P164, DOI 10.1002/bip.20685; Gatanaga H, 2002, J BIOL CHEM, V277, P5952, DOI 10.1074/jbc.M108005200; Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y; Ghosh AK, 2002, ANTIVIR RES, V54, P29, DOI 10.1016/S0166-3542(01)00209-1; Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m; Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; Hoetelmans RM, 2003, 10 C RETR OPP INF BO; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONVALINKA J, 1995, J VIROL, V69, P7180, DOI 10.1128/JVI.69.11.7180-7186.1995; Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007; Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; Levy Y, 2004, J MOL BIOL, V340, P67, DOI 10.1016/j.jmb.2004.04.028; Levy Y, 2003, J PHYS CHEM B, V107, P3068, DOI 10.1021/jp0219956; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; MAIBAUM J, 1988, J MED CHEM, V31, P625, DOI 10.1021/jm00398a022; Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muzammil S, 2007, J VIROL, V81, P5144, DOI 10.1128/JVI.02706-06; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; Poveda E, 2006, AIDS, V20, P1558, DOI 10.1097/01.aids.0000237375.23692.f4; Prabu-Jeyabalan M, 2006, J VIROL, V80, P3607, DOI 10.1128/JVI.80.7.3607-3616.2006; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Thaisrivongs S, 1996, J MED CHEM, V39, P4349, DOI 10.1021/jm960541s; Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1358.2002; Youle M, 2006, HIV CLIN TRIALS, V7, P86, DOI 10.1310/2XVK-PBGL-735N-WH72	48	102	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28709	28720		10.1074/jbc.M703938200	http://dx.doi.org/10.1074/jbc.M703938200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17635930	hybrid			2022-12-27	WOS:000249642100045
J	Lanvin, O; Bianco, S; Kersual, N; Chalbos, D; Vanacker, JM				Lanvin, Olivia; Bianco, Stephanie; Kersual, Nathalie; Chalbos, Dany; Vanacker, Jean-Marc			Potentiation of ICI182,780 (fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; STEROID-HORMONE RECEPTORS; HUMAN LACTOFERRIN GENE; BREAST-CANCER CELLS; ERR-ALPHA; REGULATED TRANSCRIPTION; DEPENDENT DEGRADATION; NUCLEAR RECEPTORS; ORPHAN RECEPTOR; EXPRESSION	ICI182,780 (Fulvestrant) is a pure anti-estrogen used in adjuvant therapies of breast cancer. This compound not only inhibits the transcriptional activities of the estrogen receptor-alpha (ER alpha) but also induces its proteasome-dependent degradation. The latter activity is believed to be required for the antiproliferative effects of ICI182,780. Estrogen receptor-related receptor-alpha (ERR alpha) is an orphan member of the nuclear receptor superfamily that is expressed in a wide range of tissues including breast tumors, in which its high expression correlates with poor prognosis. Although not regulated by any natural ligand, ERR alpha can be deactivated by the synthetic molecule XCT790. Here we demonstrate that this compound also induces a proteasome degradation of ERR alpha. We also show that although it does not act directly on the steady-state level of ER alpha, XCT790 potentiates the ICI182,780-induced ER alpha degradation. We suggest that treatment with XCT790 could thus enhance the efficacy of ICI182,780 in ER alpha-dependent pathologies such as breast cancer.	Univ Lyon, Inst Genom Font, F-69003 Lyon, France; Univ Lyon 1, Ecole Normale Super, CNRS, INRA, F-69364 Lyon, France; INSERM, U826, F-34298 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vanacker, JM (corresponding author), Univ Lyon 1, ENS, CNRS, Inst Genom Font,UMR 5242,INRA, Batiment Rech,CRLC Val Daurelle Paul Lamarque, F-34298 Montpellier 5, France.	jean-marc.vanacker@ens-lyon.fr						Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Callige Mathilde, 2006, Nucl Recept Signal, V4, pe004; Carrier JC, 2004, J BIOL CHEM, V279, P52052, DOI 10.1074/jbc.M410337200; Cavallini A, 2005, EUR J CANCER, V41, P1487, DOI 10.1016/j.ejca.2005.04.008; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Fan MY, 2002, MOL ENDOCRINOL, V16, P315, DOI 10.1210/me.16.2.315; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Herzog B, 2006, J BIOL CHEM, V281, P99, DOI 10.1074/jbc.M509276200; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; LAUDET V, 2002, NUCL RECEPTOR FACTBO; Li L, 2006, J BIOL CHEM, V281, P1978, DOI 10.1074/jbc.M508545200; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LONG X, J BIOL CHEM, V281, P9607; Lu DS, 2001, CANCER RES, V61, P6755; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nichol D, 2006, J BIOL CHEM, V281, P32140, DOI 10.1074/jbc.M604803200; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Sun PM, 2005, J MOL MED, V83, P457, DOI 10.1007/s00109-005-0639-3; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Verma S, 2004, MOL CELL BIOL, V24, P8716, DOI 10.1128/MCB.24.19.8716-8726.2004; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	51	60	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28328	28334		10.1074/jbc.M704295200	http://dx.doi.org/10.1074/jbc.M704295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17631492	hybrid			2022-12-27	WOS:000249642100006
J	Bin, L; Thorburn, J; Thomas, LR; Clark, PE; Humphreys, R; Thorburn, A				Bin, Lianghua; Thorburn, Jacqueline; Thomas, Lance R.; Clark, Peter E.; Humphreys, Robin; Thorburn, Andrew			Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; DEATH DOMAIN FADD; IN-VIVO; TUMORICIDAL ACTIVITY; MONOCLONAL-ANTIBODY; SELECTIVE MUTANTS; DECOY RECEPTORS; TARGETING DEATH; CELL-DEATH; CANCER	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a cytokine that preferentially induces apoptosis in tumor cells compared with normal cells through two receptors (DR4 and DR5). Somatic mutations in these receptors have been found in different kinds of cancer; however, it is poorly understood how the mutations affect signaling. We found that point mutations (L334F, E326K, E338K, and K386N) that were identified in human tumors result in the DRS receptor losing its ability to form a functional death-inducing signaling complex and induce apoptosis. The mutant receptors also have a "dominant negative" effect whereby they inhibit the ability of TRAIL to induce apoptosis through functional DR4 receptors. This dominant negative mechanism is achieved through competition for TRAIL binding as shown by experiments where the ability of the mutant DR5 receptor to bind with the ligand was abolished, thus restoring TRAIL signaling through DR4. The inhibitory effect on signaling through the wild-type DR4 protein can be overcome if the inhibitory mechanism is bypassed by using a DR4-agonistic antibody that is not subject to this competition. This study provides a molecular basis for the use of specific therapeutic agonists of TRAIL receptors in people whose tumors harbor somatic DR5 mutations.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Urol, Nashville, TN 37232 USA; Human Genome Sci, Oncol Res Dept, Rockville, MD 20850 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Vanderbilt University; GlaxoSmithKline; Human Genome Sciences Inc	Thorburn, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Fitzsimos Campus,Mail Stop 8303, RC1 S Tower 6100, Aurora, CO 80045 USA.	Andrew.Thorburn@uchsc.edu	Clark, Peter/E-1423-2011	Clark, Peter/0000-0002-8006-7015	NATIONAL CANCER INSTITUTE [K08CA113452] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA113452, CA11421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Liao Q, 2001, ANTICANCER RES, V21, P3153; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; McDonald ER, 2001, J BIOL CHEM, V276, P14939, DOI 10.1074/jbc.M100399200; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Park WS, 2001, GASTROENTEROLOGY, V121, P1219, DOI 10.1053/gast.2001.28663; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Seki N, 2003, CANCER RES, V63, P207; Shin MS, 2001, CANCER RES, V61, P4942; Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041; Spierings DC, 2004, J HISTOCHEM CYTOCHEM, V52, P821, DOI 10.1369/jhc.3A6112.2004; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas LR, 2004, J BIOL CHEM, V279, P52479, DOI 10.1074/jbc.M409578200; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; TOLCHER AW, 2004, J CLIN ONCOL, V22, P3060; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586	37	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28189	28194		10.1074/jbc.M704210200	http://dx.doi.org/10.1074/jbc.M704210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17666396	hybrid			2022-12-27	WOS:000249455600068
J	Munesue, S; Yoshitomi, Y; Kusano, Y; Koyama, Y; Nishiyama, A; Nakanishi, H; Miyazaki, K; Ishimaru, T; Miyaura, S; Okayama, M; Oguri, K				Munesue, Seiichi; Yoshitomi, Yasuo; Kusano, Yuri; Koyama, Yoshie; Nishiyama, Akiko; Nakanishi, Hayao; Miyazaki, Kaoru; Ishimaru, Takeshi; Miyaura, Shuichi; Okayama, Minoru; Oguri, Kayoko			A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HEPATOCYTE GROWTH-FACTOR; ACTIN-CYTOSKELETAL ORGANIZATION; LUNG-CARCINOMA CELLS; TUMOR-METASTASIS; BINDING; SURFACE; EXPRESSION; MIGRATION; PROGELATINASE	The syndecans comprise a family of cell surface heparan sulfate proteoglycans exhibiting complex biological functions involving the interaction of heparan sulfate side chains with a variety of soluble and insoluble heparin-binding extracellular ligands. Here we demonstrate an inverse correlation between the expression level of syndecan-2 and the metastatic potential of three clones derived from Lewis lung carcinoma 3LL. This correlation was proved to be a causal relationship, because transfection of syndecan-2 into the higher metastatic clone resulted in the suppression of both spontaneous and experimental metastases to the lung. Although the expression levels of matrix metalloproteinase-2 (MMP-2) and its cell surface activators, such as membrane-type I matrix metalloproteinase and tissue inhibitor of metalloproteinase-2, were similar regardless of the metastatic potentials of the clones, elevated activation of MMP-2 was observed in the higher metastatic clone. Removal of heparan sulfate from the cell surface of low metastatic cells by treatment with heparitinase-I promoted MMP-2 activation, and transfection of syndecan-2 into highly metastatic cells suppressed MMP-2 activation. Furthermore, transfection of mutated syndecan-2 lacking glycosaminoglycan attachment sites into highly metastatic cells did not have any suppressive effect on MMP-2 activation, suggesting that this suppression was mediated by the heparan sulfate side chains of syndecan-2. Actually, MMP-2 was found to exhibit a strong binding ability to heparin, the dissociation constant value being 62 nM. These results indicate a novel function of syndecan-2, which acts as a suppressor for MMP-2 activation, causing suppression of metastasis in at least the metastatic system used in the present study.	Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kyoto 603, Japan; Natl Hosp Organnizat, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi 460, Japan; Aichi Canc Ctr, Div Oncol Pathol, Nagoya, Aichi 464, Japan; Yokohama City Univ, Kihara Inst Biol Res, Yokohama, Kanagawa 232, Japan; Seikagaku Corp, Cent Res Lab, Tokyo 207, Japan	Kyoto Sangyo University; Nagoya Medical Center; Aichi Cancer Center; Yokohama City University; Seikagaku Corporation	Oguri, K (corresponding author), Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kyoto 603, Japan.	ogurik@nnh.hosp.go.jp						Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Gallay P, 2004, MICROBES INFECT, V6, P617, DOI 10.1016/j.micinf.2004.02.004; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Isnard N, 2003, CELL BIOL INT, V27, P779, DOI 10.1016/S1065-6995(03)00167-7; ITANO N, 1993, J BIOCHEM, V114, P862, DOI 10.1093/oxfordjournals.jbchem.a124269; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Karihaloo A, 2004, MOL CELL BIOL, V24, P8745, DOI 10.1128/MCB.24.19.8745-8752.2004; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Munesue S, 2002, BIOCHEM J, V363, P201, DOI 10.1042/0264-6021:3630201; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKANISHI H, 1992, VIRCHOWS ARCH A, V420, P163, DOI 10.1007/BF02358808; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Su G, 2006, AM J PATHOL, V168, P2014, DOI 10.2353/ajpath.2006.050800; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YANG BH, 1995, ANAL BIOCHEM, V228, P299, DOI 10.1006/abio.1995.1354; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshitomi Y, 2004, CANCER LETT, V207, P165, DOI 10.1016/j.canlet.2003.11.037	39	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28164	28174		10.1074/jbc.M609812200	http://dx.doi.org/10.1074/jbc.M609812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623663	hybrid			2022-12-27	WOS:000249455600066
J	Deng, WG; Jayachandran, G; Wu, G; Xu, K; Roth, JA; Ji, L				Deng, Wu-Guo; Jayachandran, Gitanjali; Wu, Guanglin; Xu, Kai; Roth, Jack A.; Ji, Lin			Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2 beta in human lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE EXPRESSION; HUMAN BREAST-CANCER; CATALYTIC SUBUNIT; RNA COMPONENT; FACTOR AP-2; CUTANEOUS MELANOMA; CARCINOMA-CELLS; UP-REGULATION; HTERT; GENE	The up-regulated expression and telomerase activity of human telomerase reverse transcriptase ( hTERT) are hallmarks of tumorigenesis. The hTERT promoter has been shown to promote hTERT gene expression selectively in tumor cells but not in normal cells. However, little is known about how tumor cells differentially activate hTERT transcription and induce telomerase activity. In this study, we identified activating enhancerbinding protein-2 beta(AP-2 beta) as a novel transcription factor that specifically binds to and activates the hTERT promoter in human lung cancer cells. AP-2 beta was detected in hTERT promoter DNA-protein complexes formed in nuclear extracts prepared only from lung cancer cells but not from normal cells. We verified the tumor-specific binding activity of AP-2 beta for the hTERT promoter in vitro and in vivo and detected high expression levels of AP-2 beta in lung cancer cells. We found that ectopic expression of AP-2 beta reactivated hTERT promoter-driven reporter green fluorescent protein (GFP) gene and endogenous hTERT gene expression in normal cells, enhanced GFP gene expression in lung cancer cells, and prolonged the life span of primary lung bronchial epithelial cells. Furthermore, we found that inhibition of endogenous expression by AP-2 beta gene-specific small interfering RNAs effectively attenuated hTERT promoter-driven GFP expression, suppressed telomerase activity, accelerated telomere shortening, and inhibited tumor cell growth by induction of apoptosis in lung cancer cells. Our results demonstrate the tumor-specific activation of the hTERT promoter by AP-2 beta and imply the potential of AP-2 beta as a novel tumor marker or a cancer therapeutic target.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ji, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Unit 445,1515 Holcombe Blvd, Houston, TX 77030 USA.	lji@mdanderson.org		Deng, wuguo/0000-0002-1193-1500	NCI NIH HHS [R01CA116322, CA70970, CA16672, U01CA105352-01, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116322, U01CA105352, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boldrini L, 2002, INT J MOL MED, V10, P589; Carpenter EL, 2006, EXPERT OPIN BIOL TH, V6, P1031, DOI 10.1517/14712598.6.10.1031; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Deng WG, 2003, J IMMUNOL, V171, P6581, DOI 10.4049/jimmunol.171.12.6581; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood-2005-09-3691; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)00356-4; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirkpatrick KL, 2003, EUR J SURG ONCOL, V29, P321, DOI 10.1053/ejso.2002.1374; Kirkpatrick KL, 2003, BREAST CANCER RES TR, V77, P277, DOI 10.1023/A:1021849217054; Li H, 2006, ONCOGENE, V25, P5405, DOI 10.1038/sj.onc.1209534; Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023; Li HL, 2006, NEOPLASIA, V8, P568, DOI 10.1593/neo.06367; Ma HW, 2003, MOL CANCER RES, V1, P739; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Onoda N, 2004, SURG TODAY, V34, P389, DOI 10.1007/s00595-003-2729-6; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Ueda K, 2006, CANCER RES, V66, P9682, DOI 10.1158/0008-5472.CAN-06-1483; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	44	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26460	10.1074/jbc.M610579200	http://dx.doi.org/10.1074/jbc.M610579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630431	hybrid			2022-12-27	WOS:000249239600051
J	Lee, HR; Helquist, SA; Kool, ET; Johnson, KA				Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.			Base pair hydrogen bonds are essential for proofreading selectivity by the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; NONPOLAR ISOSTERE; MINOR-GROOVE; REPLICATION; EXONUCLEASE; FIDELITY; DIFLUOROTOLUENE; ADENINE; ACID	We have characterized the role of Watson-Crick hydrogen bonding in the 3'-terminal base pair on the 3'-5'exonuclease activity of the human mitochondrial DNA polymerase. Nonpolar nucleoside analogs of thymidine (dF) and deoxyadenosine (dQ) were used to eliminate hydrogen bonds while maintaining base pair size and shape. Exonuclease reactions were examined using pre-steady state kinetic methods. The time dependence of removal of natural nucleotides from the primer terminus paired opposite the nonpolar analogs dF and dQ were best fit to a double exponential function. The double exponential kinetics as well as the rates of excision (3-6s(-1) fast phase, 0.16 -0.3 s(-1) slow phase) are comparable with those observed during mismatch removal of natural nucleotides even when the analog was involved in a sterically correct base pair. Additionally, incorporation of the next correct base beyond a nonpolar analog was slow (0.04 -0.22 s(-1)), so that more than 95% of terminal base pairs were removed rather than extended. The polymerase responds to all 3'-terminal base pairs containing a nonpolar analog as if it were a mismatch regardless of the identity of the paired base, and kinetic partitioning between polymerase and exonuclease sites failed to discriminate between correct and incorrect base pairs. Thus, sterics alone are insufficient, whereas hydrogen bond formation is essential for proper proofreading selectivity by the mitochondrial polymerase. The enzyme may use the alignment and prevention of fraying provided by proper hydrogen bonding and minor groove hydrogen bonding interactions as critical criteria for correct base pair recognition.	[Lee, Harold R.; Johnson, Kenneth A.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Helquist, Sandra A.; Kool, Eric T.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; Stanford University	Johnson, KA (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu		Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [R01 GM044613, GM 044613, GM 072705, R01 GM044613-17A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072705, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUTLAG D, 1972, J BIOL CHEM, V247, P241; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Guckian KM, 2000, J AM CHEM SOC, V122, P6841, DOI 10.1021/ja994164v; Guckian KM, 2000, J AM CHEM SOC, V122, P2213, DOI 10.1021/ja9934854; Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100; Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930; Henry AA, 2003, CURR OPIN CHEM BIOL, V7, P727, DOI 10.1016/j.cbpa.2003.10.011; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; KOUCHAKDJIAN M, 1988, J MOL BIOL, V202, P139, DOI 10.1016/0022-2836(88)90526-8; Leconte AM, 2006, J AM CHEM SOC, V128, P6780, DOI 10.1021/ja060853c; Lee HR, 2008, J BIOL CHEM, V283, P14402, DOI 10.1074/jbc.M705007200; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; Spratt TE, 2001, BIOCHEMISTRY-US, V40, P2647, DOI 10.1021/bi002641c; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14411	14416		10.1074/jbc.M705006200	http://dx.doi.org/10.1074/jbc.M705006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	17650503	Green Published, hybrid			2022-12-27	WOS:000255941400028
J	Curreli, S; Arany, Z; Gerardy-Schahn, R; Mann, D; Stamatos, NM				Curreli, Sabrina; Arany, Zita; Gerardy-Schahn, Rita; Mann, Dean; Stamatos, Nicholas M.			Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADHESION MOLECULE; N-CAM; SECRETED SEMAPHORINS; HUMAN MONOCYTES; IN-VIVO; ACID; RECEPTOR; GLYCOPROTEINS; UNITS	Polysialic acid (PSA) is a unique linear homopolymer of alpha 2,8-linked sialic acid that has been identified as a posttranslational modification on only five mammalian proteins. Studied predominantly on neural cell adhesion molecule (NCAM) during development of the vertebrate nervous system, PSA modulates cell interactions mediated by NCAM and other adhesion molecules. An isoform of NCAM (CD56) on natural killer (NK) cells is the only protein known to be polysialylated in cells of the immune system, yet the function of PSA in NK cells remains unclear. Weshow here that neuropilin-2 (NRP-2), a receptor for the semaphorin and vascular endothelial growth factor families in neurons and endothelial cells, respectively, is expressed on the surface of human dendritic cells and is polysialylated. Expression of NRP-2 is up-regulated during dendritic cell maturation, coincident with increased expression of ST8Sia IV, one of the key enzymes of PSA biosynthesis, and with the appearance of PSA on the cell surface. PSA on NRP-2 is resistant to digestion with peptide N-glycosidase F but is sensitive to release under alkaline conditions, suggesting that PSA chains are added to O-linked glycans of NRP-2. Removal of polysialic acid from the surface of dendritic cells or binding of NRP-2 with specific IgG promoted dendritic cell-induced activation and proliferation of T lymphocytes. Thus, this newly recognized polysialylated protein on the surface of dendritic cells influences dendritic cell-T lymphocyte interactions through one or more of its distinct extracellular domains.	Univ Maryland, Med Syst, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Med Syst, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Med Syst, Div Infect Dis, Dept Med, Baltimore, MD 21201 USA; Hannover Med Sch, Zentrum Biochem, Abt Zellulare Chem, D-30625 Hannover, Germany	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Hannover Medical School	Stamatos, NM (corresponding author), Univ Maryland, Med Syst, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.	stamatos@umbi.umd.edu	Curreli, Sabrina/AAA-1380-2021	Curreli, Sabrina/0000-0003-1912-9608	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072176] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL72176-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Bourbie-Vaudaine S, 2006, J IMMUNOL, V177, P1460, DOI 10.4049/jimmunol.177.3.1460; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Chen CY, 2005, WORLD J SURG, V29, P271, DOI 10.1007/s00268-004-7818-1; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Cohen T, 2002, J PATHOL, V198, P77, DOI 10.1002/path.1179; Cohen T, 2001, BIOCHEM BIOPH RES CO, V284, P395, DOI 10.1006/bbrc.2001.4958; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; Friedl P, 2005, NAT REV IMMUNOL, V5, P532, DOI 10.1038/nri1647; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Galuska SP, 2006, J BIOL CHEM, V281, P31605, DOI 10.1074/jbc.M606516200; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kikutani H, 2003, NAT REV IMMUNOL, V3, P159, DOI 10.1038/nri1003; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LACKIE PM, 1991, DIFFERENTIATION, V47, P85, DOI 10.1111/j.1432-0436.1991.tb00226.x; Lajaunias F, 2005, EUR J IMMUNOL, V35, P243, DOI 10.1002/eji.200425273; MANZI AE, 1994, J BIOL CHEM, V269, P23617; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mendiratta SS, 2006, J BIOL CHEM, V281, P36052, DOI 10.1074/jbc.M608073200; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Nakata D, 2005, J BIOL CHEM, V280, P38305, DOI 10.1074/jbc.M508762200; Renzi MJ, 1999, J NEUROSCI, V19, P7870; RIEGER F, 1985, J CELL BIOL, V101, P285, DOI 10.1083/jcb.101.1.285; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stamatos NM, 2005, FEBS J, V272, P2545, DOI 10.1111/j.1742-4658.2005.04679.x; Stamatos NM, 2004, J LEUKOCYTE BIOL, V75, P307, DOI 10.1189/jlb.0503241; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211; Yuan L, 2002, DEVELOPMENT, V129, P4797; ZUBER C, 1992, J BIOL CHEM, V267, P9965	49	143	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30346	30356		10.1074/jbc.M702965200	http://dx.doi.org/10.1074/jbc.M702965200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699524	hybrid			2022-12-27	WOS:000250136300002
J	Mainardi, JL; Hugonnet, JE; Rusconi, F; Fourgeaud, M; Dubosth, L; Moumi, AN; Delfosse, V; Mayer, C; Gutmann, L; Rice, LB; Arthur, M				Mainardi, Jean-Luc; Hugonnet, Jean-Emmanuel; Rusconi, Filippo; Fourgeaud, Martine; Dubosth, Lionel; Moumi, Angele Nguekam; Delfosse, Vanessa; Mayer, Claudine; Gutmann, Laurent; Rice, Louis B.; Arthur, Michel			Unexpected inhibition of peptidoglycan LD-transpeptidase from enterococcus faecium by the beta-lactam imipenem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; RESISTANCE; MECHANISM; L,D-TRANSPEPTIDASES; IDENTIFICATION; EXPRESSION	The beta-lactam antibiotics mimic the D-alanyl(4)-D-alanine(5) extremity of peptidoglycan precursors and act as "suicide" substrates of the DD-transpeptidases that catalyze the last cross-linking step of peptidoglycan synthesis. We have previously shown that bypass of the DD-transpeptidases by the LD-transpeptidase of Enterococcus faecium (Ldt(fm)) leads to high level resistance to ampicillin. Ldtfm is specific for the L-lysyl(3)-D-alanine(4) bond of peptidoglycan precursors containing a tetrapeptide stem lacking D-alanine(5). This specificity was proposed to account for resistance, because the substrate of Ldt(fm) does not mimic beta-lactams in contrast to the D-alanyl(4)-D-alanine(5) extremity of pentapeptide stems used by the DD-transpeptidases. Here, we unexpectedly show that imipenem, a beta-lactam of the carbapenem class, totally inhibited Ldtfm at a low drug concentration that was sufficient to inhibit growth of the bacteria. Peptidoglycan cross-linking was also inhibited, indicating that Ldt(fm) is the in vivo target of imipenem. Stoichiometric and covalent modification of Ldt(fm) by imipenem was detected by mass spectrometry. The modification was mapped into the trypsin fragment of Ldt(fm) containing the catalytic Cys residue, and the Cys to Ala substitution prevented imipenem binding. The mass increment matched the mass of imipenem, indicating that inactivation of Ldt(fm) is likely to involve rupture of the beta-lactam ring and acylation of the catalytic Cys residue. Thus, the spectrum of activity of beta-lactams is not restricted to transpeptidases of the DD-specificity, as previously thought. Combination therapy with imipenem and ampicillin could therefore be active against E. faecium strains having the dual capacity to manufacture peptidoglycan with transpeptidases of the LD- and DD-specificities.	INSERM, U872, LRMA Pole 4, F-75006 Paris, France; Univ Paris 06, Ctr Rech Cordeliers, UMR S872, F-75006 Paris, France; Univ Paris 05, UMR S872, F-75006 Paris, France; Assistance Publ Hosp Paris, Hop Europeen Georges Pompidou, F-75015 Paris, France; CNRS, UMR 5153, F-75231 Paris, France; INSERM, U565, F-75231 Paris, France; Museum Natl Hist Nat, Mass Spectrometry Facil, USM 0503, F-75231 Paris, France; Museum Natl Hist Nat, Plateforme Spectrometrie Masse & Proteom Museum, Dept Rech Dev & Diversite Mol, USM0502, F-75005 Paris, France; CNRS, UMR 8041, F-75005 Paris, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med & Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Arthur, M (corresponding author), INSERM, U872, LRMA Pole 4, Equipe 12, F-75006 Paris, France.	michel.arthur@bhdc.jussieu.fr	HUGONNET, Jean-Emmanuel/H-3581-2014; MAINARDI, Jean-Luc/E-2714-2014; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/ABC-7914-2021	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; MAINARDI, Jean-Luc/0000-0002-4159-0129; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Rusconi, Filippo Matteo/0000-0003-1822-0397; Delfosse, Vanessa/0000-0002-7436-7935	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; ARTHUR M, 1994, ANTIMICROB AGENTS CH, V38, P1899, DOI 10.1128/AAC.38.9.1899; Bellais S, 2006, J BIOL CHEM, V281, P11586, DOI 10.1074/jbc.M600114200; Biarrotte-Sorin S, 2006, J MOL BIOL, V359, P533, DOI 10.1016/j.jmb.2006.03.014; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; Cremniter J, 2006, J BIOL CHEM, V281, P32254, DOI 10.1074/jbc.M606920200; FONTANA R, 1983, J BACTERIOL, V155, P1343, DOI 10.1128/JB.155.3.1343-1350.1983; Goffin C, 2002, MICROBIOL MOL BIOL R, V66, P702, DOI 10.1128/MMBR.66.4.702-738.2002; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; JAMIN M, 1995, ESSAYS BIOCHEM, V29, P1; KLARE I, 1992, ANTIMICROB AGENTS CH, V36, P783, DOI 10.1128/AAC.36.4.783; Macheboeuf P, 2006, FEMS MICROBIOL REV, V30, P673, DOI 10.1111/j.1574-6976.2006.00024.x; Magnet S, 2007, J BACTERIOL, V189, P3927, DOI 10.1128/JB.00084-07; Magnet S, 2007, J BIOL CHEM, V282, P13151, DOI 10.1074/jbc.M610911200; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Rice LB, 2004, ANTIMICROB AGENTS CH, V48, P3028, DOI 10.1128/AAC.48.8.3028-3032.2004; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933	24	90	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30414	30422		10.1074/jbc.M704286200	http://dx.doi.org/10.1074/jbc.M704286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17646161	hybrid			2022-12-27	WOS:000250136300009
J	Wu, H; Dombrovsky, L; Tempel, W; Martin, F; Loppnau, P; Goodfellow, GH; Grant, DM; Plotnikov, AN				Wu, Hong; Dombrovsky, Ludmila; Tempel, Wolfram; Martin, Fernando; Loppnau, Peter; Goodfellow, Geoffrey H.; Grant, Denis M.; Plotnikov, Alexander N.			Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CANCER; MOLECULAR-GENETICS; NAT1; POLYMORPHISMS; PROTEIN; RISK; PHARMACOGENETICS; IDENTIFICATION; EPIDEMIOLOGY; REVEALS	The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9- A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes.	Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; Structural Genomics Consortium; University of Toronto; University of Toronto	Plotnikov, AN (corresponding author), Univ Toronto, Struct Genom Consortium, 100 Coll St, Toronto, ON M5G 1L5, Canada.	alexander.plotnikov@utoronto.ca			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brockmoller J, 1996, CANCER RES, V56, P3915; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Filiadis IF, 1999, J UROLOGY, V161, P1672, DOI 10.1016/S0022-5347(05)69002-7; Goodfellow GH, 2000, BIOCHEM J, V348, P159, DOI 10.1042/0264-6021:3480159; Grant DM, 2000, PHARMACOLOGY, V61, P204, DOI 10.1159/000028402; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Gu J, 2005, MUTAT RES-GEN TOX EN, V581, P97, DOI 10.1016/j.mrgentox.2004.11.012; GUENGERICH FP, 1992, PHARMACOL THERAPEUT, V54, P17; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hein DW, 2000, DRUG METAB DISPOS, V28, P1425; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hughes NC, 1998, PHARMACOGENETICS, V8, P55, DOI 10.1097/00008571-199802000-00008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin HJ, 1998, PHARMACOGENETICS, V8, P269, DOI 10.1097/00008571-199806000-00009; Liu F, 2006, J MOL BIOL, V361, P482, DOI 10.1016/j.jmb.2006.06.029; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; Sandy J, 2005, PROTEIN SCI, V14, P775, DOI 10.1110/ps.041163505; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walraven JM, 2007, DRUG METAB DISPOS, V35, P1001, DOI 10.1124/dmd.107.015040; WEBER WW, 1985, PHARMACOL REV, V37, P25; Zhang NX, 2006, J MOL BIOL, V363, P188, DOI 10.1016/j.jmb.2006.08.026	37	98	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30189	30197		10.1074/jbc.M704138200	http://dx.doi.org/10.1074/jbc.M704138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17656365	hybrid			2022-12-27	WOS:000249981200049
J	Yuan, WH; Pan, W; Kong, J; Zheng, W; Szeto, FL; Wong, KE; Cohen, R; Klopot, A; Zhang, Z; Li, YC				Yuan, Weihua; Pan, Wei; Kong, Juan; Zheng, Wei; Szeto, Frances L.; Wong, Kari E.; Cohen, Ronald; Klopot, Anna; Zhang, Zhongyi; Li, Yan Chun			1,25-dihydroxyvitamin D-3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; NUCLEAR RECEPTOR; DNA ELEMENT; EXPRESSION; ACTIVATION; ENHANCER; BINDING; CELLS; BETA; MICE	We have shown that 1,25- dihydroxyvitamin D-3 ( 1,25( OH) 2D(3)) down- regulates renin expression. To explore the molecular mechanism, we analyzed the mouse Ren- 1c gene promoter by luciferase reporter assays. Deletion analysis revealed two DNA fragments from - 2725 to - 2647 ( distal fragment) and from - 117 to - 6 ( proximal fragment) that are sufficient to mediate the repression. Mutation of the cAMP response element ( CRE) in the distal fragment blunted forskolin stimulation as well as 1,25( OH) D-2(3) inhibition of the transcriptional activity, suggesting the involvement of CRE in 1,25( OH) D-2(3)- induced suppression. EMSA revealed that 1,25( OH)(2)D-3 markedly inhibited nuclear protein binding to the CRE in the promoter. ChIP and GSTpull- down assays demonstrated that ligandedVDRblocked the binding of CREB to the CRE by directly interacting with CREB with the ligand- binding domain, and the VDR- mediated repression can be rescued by CREB, CBP, or p300 overexpression. These data indicate that 1,25( OH)(2)D-3 suppresses renin gene expression at least in part by blocking the formation of CRE- CREB- CBP complex.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Div Biol Sci, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Li, YC (corresponding author), Univ Chicago, Dept Med, MC 4080,5841 S Maryland Ave, Chicago, IL 60637 USA.	cyan@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL085793] Funding Source: Medline; NIDDK NIH HHS [DK062072] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062072] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEL KJ, 1990, GENETICS, V124, P937; Adams DJ, 2006, J BIOL CHEM, V281, P31753, DOI 10.1074/jbc.M605720200; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Ausubel F. M, 1994, CURRENT PROTOCOLS MO; Bader M, 2000, J MOL MED, V78, P130, DOI 10.1007/s001090000089; DE CD, 1999, TRENDS BIOCHEM SCI, V24, P281; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353-06; Klar J, 2002, PFLUG ARCH EUR J PHY, V444, P335, DOI 10.1007/s00424-002-0818-9; Kong J, 2003, AM J PHYSIOL-REG I, V285, pR255, DOI 10.1152/ajpregu.00517.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XB, 2003, CIRC RES, V92, P1033, DOI 10.1161/01.RES.0000071355.82009.43; Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MOFFETT DF, 1993, HUMAN PHYSL FDN FRON, P420; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morello F, 2005, J CLIN INVEST, V115, P1913, DOI 10.1172/JCI24594; Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157; Nishishita T, 1998, J BIOL CHEM, V273, P10901, DOI 10.1074/jbc.273.18.10901; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pan L, 2005, J BIOL CHEM, V280, P20860, DOI 10.1074/jbc.M414618200; Pan L, 2005, HYPERTENSION, V45, P3, DOI 10.1161/01.HYP.0000149717.55920.45; Pan L, 2003, BBA-GENE STRUCT EXPR, V1625, P280, DOI 10.1016/S0167-4781(03)00016-2; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Qiao GL, 2005, J STEROID BIOCHEM, V96, P59, DOI 10.1016/j.jsbmb.2005.02.008; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037; Shi Q, 2001, HYPERTENSION, V38, P332, DOI 10.1161/01.HYP.38.3.332; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Ying LH, 1997, J BIOL CHEM, V272, P2412	48	345	369	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29821	29830		10.1074/jbc.M705495200	http://dx.doi.org/10.1074/jbc.M705495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17690094	hybrid			2022-12-27	WOS:000249981200011
J	Averbeck, N; Keppler-Ross, S; Dean, N				Averbeck, Nicole; Keppler-Ross, Sabine; Dean, Neta			Membrane topology of the Alg14 endoplasmic reticulum UDP-GlcNAc transferase subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE TRANSPORTER; N-LINKED GLYCOSYLATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDOGLYCAN BIOSYNTHESIS; CAMPYLOBACTER-JEJUNI; CRYSTAL-STRUCTURE; DOLICHOL PATHWAY; GENE DELETION; YEAST	N-linked glycosylation begins in the endoplasmic reticulum with the synthesis of a highly conserved dolichol-linked oligosaccharide precursor. The UDP-GlcNAc glycosyltransferase catalyzing the second sugar addition of this precursor consists in most eukaryotes of at least two subunits, Alg14 and Alg13. Alg14 is a membrane protein that recruits the soluble Alg13 catalytic subunit from the cytosol to the face of the endoplasmic reticulum ( ER) membrane where this reaction occurs. Here, we investigated the membrane topology of Saccharomyces cerevisiae Alg14 and its requirements for ER membrane association. Alg14 is predicted by most algorithms to contain one or more transmembrane spanning helices (transmembrane domains (TMDs)). We provide evidence that Alg14 contains a C-terminal cytosolic tail and an N terminus that resides within the ER lumen. However, we also demonstrate that Alg14 lacking this TMD is functional and remains peripherally associated with ER membranes, suggesting that additional domains can mediate ER association. These conclusions are based on the functional analysis of Alg13/Alg14 chimeras containing Alg13 fused at either end of Alg14 or truncated Alg14 variants lacking the predicted TMD; protease protection assays of Alg14 in intact ER membranes; and extraction of Alg14-containing ER membranes with high pH. These yeast Alg13-Alg14 chimeras recapitulate the phylogenetic diversity of Alg13-Alg14 domain arrangements that evolved in some protozoa. They encode single polypeptides containing an Alg13 domain fused to Alg14 domain in either orientation, including those lacking the Alg14 TMD. Thus, this Alg13-Alg14 UDP-GlcNAc transferase represents an unprecedented example of a bipartite glycosyltransferase that evolved by both fission and fusion.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dean, N (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Neta.Dean@stonybrook.edu			NIGMS NIH HHS [R01-GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Bickel T, 2005, J BIOL CHEM, V280, P34500, DOI 10.1074/jbc.M506358200; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; BUPP K, 1993, J BACTERIOL, V175, P1841, DOI 10.1128/JB.175.6.1841-1843.1993; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2005, J BIOL CHEM, V280, P36254, DOI 10.1074/jbc.M507569200; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; IKEDA M, 1990, NUCLEIC ACIDS RES, V18, P4014, DOI 10.1093/nar/18.13.4014; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; SIKORSKI RS, 1989, GENETICS, V122, P19; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; Tai VWF, 2001, BIOORGAN MED CHEM, V9, P1133, DOI 10.1016/S0968-0896(00)00334-5; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Weerapana E, 2006, GLYCOBIOLOGY, V16, p91R, DOI 10.1093/glycob/cwj099; Yoko-O T, 1998, EUR J BIOCHEM, V257, P630, DOI 10.1046/j.1432-1327.1998.2570630.x; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	28	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29081	29088		10.1074/jbc.M704410200	http://dx.doi.org/10.1074/jbc.M704410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686769	hybrid			2022-12-27	WOS:000249788000003
J	Cinar, B; Mukhopadhyay, NK; Meng, GY; Freeman, MR				Cinar, Bekir; Mukhopadhyay, Nishit K.; Meng, Gaoyuan; Freeman, Michael R.			Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; LIPID RAFTS; PLASMA-MEMBRANE; CARCINOMA-CELLS; ACTIVATION; PATHWAY; GROWTH; ESTROGEN	The serine-threonine kinase, Akt1/protein kinase B alpha is an important mediator of growth, survival, and metabolic signaling. Recent studies have implicated cholesterol-rich, lipid raft microdomains in survival signals mediated by Akt1. Here we address the role of lipid raft membranes as a potential site of intersection of androgenic and Akt1 signaling. A subpopulation of androgen receptor (AR) was found to localize to a lipid raft subcellular compartment in LNCaP prostate cancer cells. Endogenous AR interacted with endogenous Akt1 preferentially in lipid raft fractions and androgen substantially enhanced the interaction between the two proteins. The association of AR with Akt1 was inhibited by the anti-androgen, bicalutamide, but was not affected by inhibition of phosphoinositide 3-kinase (PI3K). Androgen promoted endogenous Akt1 activity in lipid raft fractions, in a PI3K-independent manner, within 10 min of treatment. Fusion of a lipid raft targeting sequence to AR enhanced localization of the receptor to rafts, and stimulated Akt1 activity in response to androgen, while reducing the cells' dependence on constitutive signaling through PI3K for cell survival. These findings suggest that signals channeled through AR and Akt1 intersect by a mechanism involving formation within lipid raft membranes of an androgen-responsive, extranuclear AR/Akt1 complex. Our results indicate that cholesterol-rich membrane microdomains play a role in transmitting nongenomic signals involving androgen and the Akt pathway in prostate cancer cells.	Harvard Univ, Childrens Hosp Boston, Urol Dis Res Ctr, Dept Urol Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp Boston, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Freeman, MR (corresponding author), John F Enders Res Labs, Suite 1161,300 Longwood Ave, Boston, MA 02115 USA.	michael.freeman@childrens.harvard.edu	CİNAR, BEKIR MURAT/AAL-4474-2021	CİNAR, BEKIR MURAT/0000-0002-7906-5039; Cinar, Bekir/0000-0003-4028-7600	NATIONAL CANCER INSTITUTE [R01CA112303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047556, P50DK065298] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112303] Funding Source: Medline; NIDDK NIH HHS [R01 DK087806, P50 DK65298, R37 DK47556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547; Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Barsoum I, 2006, TRENDS ENDOCRIN MET, V17, P223, DOI 10.1016/j.tem.2006.06.009; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bonaccorsi L, 2004, INT J CANCER, V112, P78, DOI 10.1002/ijc.20362; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Cinar B, 2004, BIOCHEM J, V379, P421, DOI 10.1042/BJ20031661; Cinar B, 2001, CANCER RES, V61, P7310; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Davies MA, 1999, CANCER RES, V59, P2551; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freeman MR, 2005, TRENDS ENDOCRIN MET, V16, P273, DOI 10.1016/j.tem.2005.06.002; Gatson JW, 2006, ENDOCRINOLOGY, V147, P2028, DOI 10.1210/en.2005-1395; Gill A, 2004, MOL ENDOCRINOL, V18, P97, DOI 10.1210/me.2003-0326; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; JAGLA M, 2007, IN PRESS ENDOCRINOLO; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; Korzeniowski M, 2003, BIOCHEMISTRY-US, V42, P5358, DOI 10.1021/bi027135x; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lin JQ, 1999, CANCER RES, V59, P2891; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Na SY, 2003, J IMMUNOL, V171, P1285, DOI 10.4049/jimmunol.171.3.1285; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rai D, 2005, MOL ENDOCRINOL, V19, P1606, DOI 10.1210/me.2004-0468; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Wen Y, 2000, CANCER RES, V60, P6841; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481; Zhuang LY, 2005, J CLIN INVEST, V115, P959; Zhuang LY, 2002, CANCER RES, V62, P2227	49	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29584	29593		10.1074/jbc.M703310200	http://dx.doi.org/10.1074/jbc.M703310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17635910	hybrid			2022-12-27	WOS:000249788000055
J	Plaza-Menacho, I; Mologni, L; Sala, E; Gambacorti-Passerini, C; Magee, AI; Links, TP; Hofstra, RMW; Barford, D; Isacke, CM				Plaza-Menacho, Ivan; Mologni, Luca; Sala, Elisa; Gambacorti-Passerini, Carlo; Magee, Anthony I.; Links, Thera P.; Hofstra, Robert M. W.; Barford, David; Isacke, Clare M.			Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY-THYROID CARCINOMA; ONCOGENIC RET; STI-571 INHIBITION; ANTITUMOR-ACTIVITY; CANCER-CELLS; B-RAF; RECEPTOR; MUTATIONS; NEOPLASIA; IMATINIB	Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAF(V600E). In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib center dot RETcomplex in which Sorafenib binds to and induces the DFG(out) conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val(804) gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Univ Milan, Dept Clin & Prevent Med, I-20052 Milan, Italy; Univ London Imperial Coll Sci Technol & Med, Sect Mol & Cellular Med, London SW7 2AZ, England; Univ Groningen, Med Ctr, Dept Endocrinol, NL-9700 RB Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Genet, NL-9700 RB Groningen, Netherlands; Inst Canc Res, Sect Struct Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Milan; Imperial College London; University of Groningen; University of Groningen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	Magee, Anthony/V-8345-2019; Piris, Alejandro/D-3830-2014; Mologni, Luca/AAC-1065-2022; Sala, Elisa/GQA-3928-2022; Plaza-Menacho, Ivan/K-8517-2017	Mologni, Luca/0000-0002-6365-5149; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Isacke, Clare/0000-0002-9222-3345; Plaza-Menacho, Ivan/0000-0003-4666-9431; sala, elisa/0000-0001-8603-3839; Hofstra, Robert/0000-0001-7498-3829	Medical Research Council [G0100471] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline; MRC [G0100471] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Carniti C, 2003, CANCER RES, V63, P2234; Cranston AN, 2006, CANCER RES, V66, P10179, DOI 10.1158/0008-5472.CAN-06-0884; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; de Groot JWB, 2006, SURGERY, V139, P806, DOI 10.1016/j.surg.2005.10.019; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; Drosten M, 2006, NAT CLIN PRACT ONCOL, V3, P564, DOI 10.1038/ncponc0610; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Knowles PP, 2006, J BIOL CHEM, V281, P33577, DOI 10.1074/jbc.M605604200; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Mologni L, 2005, PROTEIN EXPRES PURIF, V41, P177, DOI 10.1016/j.pep.2005.01.002; Mologni L, 2006, J MOL ENDOCRINOL, V37, P199, DOI 10.1677/jme.1.01999; Nagar B, 2002, CANCER RES, V62, P4236; Niculescu-Duvaz I, 2006, J MED CHEM, V49, P407, DOI 10.1021/jm050983g; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pierchala BA, 2006, J NEUROSCI, V26, P2777, DOI 10.1523/JNEUROSCI.3420-05.2006; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Scott RP, 2005, J BIOL CHEM, V280, P13442, DOI 10.1074/jbc.M500507200; Strock CJ, 2003, CANCER RES, V63, P5559; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443	36	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29230	29240		10.1074/jbc.M703461200	http://dx.doi.org/10.1074/jbc.M703461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17664273	hybrid			2022-12-27	WOS:000249788000019
J	Zhang, M; Lee, CH; Luo, DD; Krupa, A; Fraser, D; Phillips, A				Zhang, Mei; Lee, Chien-Hung; Luo, Dong Dong; Krupa, Aleksandra; Fraser, Donald; Phillips, Aled			Polarity of response to transforming growth factor-beta 1 in proximal tubular epithelial cells is regulated by beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 GENERATION; TGF-BETA; TGF-BETA-1 SYNTHESIS; SIGNALING PATHWAYS; TISSUE FIBROSIS; SMAD PROTEINS; RECEPTOR; GLUCOSE; KIDNEY	Transforming growth factor-beta 1 (TGF-beta 1)-mediated loss of proximal tubular epithelial cell-cell interaction is regulated in a polarized fashion. The aim of this study was to further explore the polarity of the TGF-beta 1 response and to determine the significance of R-Smad-beta-catenin association previously demonstrated to accompany adherens junction disassembly. Smad3 signaling response to TGF-beta 1 was assessed by activity of the Smad3-responsive reporter gene construct (SBE)(4)-Lux and by immunoblotting for phospho-Smad proteins. Similar results were obtained with both methods. Apical application of TGF-beta 1 led to increased Smad3 signaling compared with basolateral stimulation. Association of Smad proteins with beta-catenin was greater following basolateral TGF beta-1 stimulation, as was the expression of cytoplasmic Triton-soluble beta-catenin. Inhibition of beta-catenin expression by small interfering RNA augmented Smad3 signaling. Lithium chloride, a GSK-3 inhibitor, increased expression of beta-catenin and attenuated TGF-beta 1-dependent Smad3 signaling. Lithium chloride did not influence degradation of Smad3 but resulted in decreased nuclear translocation. Smad2 activation as assessed by Western blot analysis and activity of the Smad2-responsive reporter constructs ARE/MF1 was also greater following apical as compared with basolateral TGF beta-1 stimulation, suggesting that this is a generally applicable mechanism for the regulation of TGF-beta 1-dependent R-Smads. Caco-2 cells are a colonic carcinoma cell line, with known resistance to the anti-proliferative effects of TGF-beta 1 and increased expression of beta-catenin. We used this cell line to address the general applicability of our observations. Inhibition of beta-catenin in this cell line by small interfering RNA resulted in increased TGF-beta 1-dependent Smad3 phosphorylation and restoration of TGF-beta 1 anti-proliferative effects.	Cardiff Univ, Sch Med, Inst Nephrol, Cardiff CF14 4XN, Wales	Cardiff University	Phillips, A (corresponding author), Cardiff Univ, Sch Med, Inst Nephrol, Health Pk, Cardiff CF14 4XN, Wales.	PhillipsAO@cf.ac.uk		Fraser, Donald/0000-0003-0102-9342				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Agarwal R, 2002, AM J KIDNEY DIS, V39, P486, DOI 10.1053/ajkd.2002.31392; Arici M, 2003, J AM SOC NEPHROL, V14, P17, DOI 10.1097/01.ASN.0000042167.66685.EA; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Brunskill NJ, 1998, J CLIN INVEST, V101, P2140, DOI 10.1172/JCI1923; Chen AP, 2002, AM J PHYSIOL-GASTR L, V283, pG864, DOI 10.1152/ajpgi.00524.2001; Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05-4759com; De Muro P, 2004, PHARMACOL RES, V49, P293, DOI 10.1016/j.phrs.2003.10.003; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dong YF, 2005, J CELL BIOCHEM, V95, P1057, DOI 10.1002/jcb.20466; EDDY AA, 1995, KIDNEY INT, V47, P1546, DOI 10.1038/ki.1995.218; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Fraser D, 2003, AM J PATHOL, V163, P2565, DOI 10.1016/S0002-9440(10)63611-5; Fraser D, 2002, AM J PATHOL, V161, P1039, DOI 10.1016/S0002-9440(10)64265-4; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hou CC, 2005, AM J PATHOL, V166, P761, DOI 10.1016/S0002-9440(10)62297-3; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Li TF, 2006, J BIOL CHEM, V281, P21296, DOI 10.1074/jbc.M600514200; Mariadason JM, 2001, CANCER RES, V61, P3465; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Moustakas A, 2001, J CELL SCI, V114, P4359; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; PHILLIPS AO, 1995, AM J PATHOL, V147, P362; Phillips AO, 1996, KIDNEY INT, V50, P1546, DOI 10.1038/ki.1996.470; Piek E, 1999, J CELL SCI, V112, P4557; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Song JH, 2006, NEPHROL DIAL TRANSPL, V21, P683, DOI 10.1093/ndt/gfi310; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Tian YC, 2003, AM J PHYSIOL-RENAL, V285, pF130, DOI 10.1152/ajprenal.00408.2002; Tian YC, 2002, AM J PATHOL, V160, P1619, DOI 10.1016/S0002-9440(10)61109-1; Togawa A, 2003, AM J PATHOL, V163, P1645, DOI 10.1016/S0002-9440(10)63521-3; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Wang YP, 1997, J AM SOC NEPHROL, V8, P1537; Wolf G, 2004, KIDNEY INT, V66, P1849, DOI 10.1111/j.1523-1755.2004.00958.x; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhang M, 2006, AM J PATHOL, V169, P1282, DOI 10.2353/ajpath.2006.050921; Zhang XL, 2004, AM J PATHOL, V165, P763, DOI 10.1016/S0002-9440(10)63339-1	50	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28639	28647		10.1074/jbc.M700594200	http://dx.doi.org/10.1074/jbc.M700594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17623674	hybrid			2022-12-27	WOS:000249642100038
J	Konopka, G; Tekiela, J; Iverson, M; Wells, C; Duncan, SA				Konopka, Genevieve; Tekiela, Jackie; Iverson, Moriah; Wells, Clive; Duncan, Stephen A.			Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CANINE KIDNEY-CELLS; JAM FAMILY-MEMBERS; TIGHT JUNCTION; GROWTH-FACTOR; HEPG2 CELLS; IMMUNOGLOBULIN SUPERFAMILY; HEPATOCARCINOMA CELLS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS	Hepatocytes are polarized epithelial cells whose function depends upon their ability to distinguish between the apical and basolateral surfaces that are located at intercellular tight junctions. It has been proposed that the signaling cascades originating at these junctions influence cellular activity by controlling gene expression in the cell nucleus. To assess the validity of this proposal with regard to hepatocytes, we depleted expression of the tight junction protein junctional adhesion molecule-A (JAM-A) in the HepG2 human hepatocellular carcinoma cell line. Reduction of JAM-A resulted in a striking change in cell morphology, with cells forming sheets 1-2 cells thick instead of the normal multilayered clusters. In the absence of JAM-A, other tight junction proteins were mislocalized, and pseudo-canaliculi, which form the apical face of the hepatocyte, were consequently absent. There was a strong transcriptional induction of the adherens junction protein E-cadherin in cells with reduced levels of JAM-A. This increase in E-cadherin was partially responsible for the observed alterations in cell morphology and mislocalization of tight junction proteins. We therefore propose the existence of a novel mechanism of cross-talk between specific components of tight and adherens junctions that can be utilized to regulate adhesion between hepatic cells.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Duncan, SA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	duncans@mcw.edu		Konopka, Genevieve/0000-0002-3363-7302; Duncan, Stephen/0000-0002-2507-7827	NIDDK NIH HHS [R01 DK055743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Ara C, 2004, CELL COMMUN ADHES, V11, P13, DOI 10.1080/15419060490471757; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Battle MA, 2006, P NATL ACAD SCI USA, V103, P8419, DOI 10.1073/pnas.0600246103; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Carloni V, 1998, GASTROENTEROLOGY, V115, P433, DOI 10.1016/S0016-5085(98)70210-0; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Cera MR, 2004, J CLIN INVEST, V114, P729, DOI 10.1172/JCI200421231; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2007, MOL BIOL CELL, V18, P2203, DOI 10.1091/mbc.E07-02-0095; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cooke VG, 2006, ARTERIOSCL THROM VAS, V26, P2005, DOI 10.1161/01.ATV.0000234923.79173.99; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Duncan SA, 1997, DEVELOPMENT, V124, P279; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Ishigami A, 2005, CELL TISSUE RES, V320, P243, DOI 10.1007/s00441-004-1073-5; Kang LI, 2007, INT J BIOCHEM CELL B, V39, P576, DOI 10.1016/j.biocel.2006.10.016; Khandoga A, 2005, BLOOD, V106, P725, DOI 10.1182/blood-2004-11-4416; Kubitz R, 2001, HEPATOLOGY, V34, P340, DOI 10.1053/jhep.2001.25959; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu Y, 2000, J CELL SCI, V113, P2363; Lubeseder-Martellato C, 2002, AM J PATHOL, V161, P1749, DOI 10.1016/S0002-9440(10)64452-5; LUFT JH, 1966, FED PROC, V25, P1773; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Mandell KJ, 2006, INVEST OPHTH VIS SCI, V47, P2408, DOI 10.1167/iovs.05-0745; Mandell KJ, 2004, J BIOL CHEM, V279, P16254, DOI 10.1074/jbc.M309483200; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Nejjari M, 1999, INT J CANCER, V83, P518, DOI 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.3.CO;2-H; Parris JJ, 2005, DEV DYNAM, V233, P1517, DOI 10.1002/dvdy.20481; POUCELL S, 1992, HEPATOLOGY, V16, P1061, DOI 10.1002/hep.1840160433; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rehder D, 2006, EXP CELL RES, V312, P3389, DOI 10.1016/j.yexcr.2006.07.004; Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schmitt M, 2004, J HEPATOL, V41, P274, DOI 10.1016/j.jhep.2004.04.035; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; Shoda J, 2004, J LIPID RES, V45, P1813, DOI 10.1194/jlr.M400132-JLR200; Siwkowski AM, 2004, MOL PHARMACOL, V66, P572; SORMUNEN R, 1993, LAB INVEST, V68, P652; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Sprenger CC, 1999, CANCER RES, V59, P2370; Takaki Y, 2001, CELL TISSUE RES, V305, P399, DOI 10.1007/s004410100397; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; van der Wouden JM, 2002, EMBO J, V21, P6409, DOI 10.1093/emboj/cdf629; VANBUULOFFERS SC, 1994, ENDOCRINOLOGY, V135, P977, DOI 10.1210/en.135.3.977; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yamagata K, 2004, NEUROBIOL DIS, V17, P491, DOI 10.1016/j.nbd.2004.08.001; Yamamoto T, 2004, EXP CELL RES, V299, P427, DOI 10.1016/j.yexcr.2004.06.011; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Zegers MMP, 1998, BIOCHEM J, V336, P257, DOI 10.1042/bj3360257; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	84	37	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28137	28148		10.1074/jbc.M703592200	http://dx.doi.org/10.1074/jbc.M703592200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623668	hybrid			2022-12-27	WOS:000249455600063
J	Krilleke, D; DeErkenez, A; Schubert, W; Giri, I; Robinson, GS; Ng, YS; Shima, DT				Krilleke, Dominik; DeErkenez, Andrea; Schubert, William; Giri, Indrajit; Robinson, Gregory S.; Ng, Yin-Shan; Shima, David T.			Molecular mapping and functional characterization of the VEGF164 heparin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TISSUE FACTOR EXPRESSION; CRYSTAL-STRUCTURE; EXTRACELLULAR-MATRIX; ANGSTROM RESOLUTION; TYROSINE KINASE; TUMOR-CELLS; RECEPTOR; NEUROPILIN-1; KDR	The longer splice isoforms of vascular endothelial growth factor-A (VEGF-A), including mouse VEGF164, contain a highly basic heparin-binding domain (HBD), which imparts the ability of these isoforms to be deposited in the heparan sulfate-rich extracellular matrix and to interact with the prototype sulfated glycosaminoglycan, heparin. The shortest isoform, VEGF120, lacks this highly basic domain and is freely diffusible upon secretion Although the HBD has been attributed significant relevance to VEGF-A biology, the molecular determinants of the heparin-binding site are unknown. We used site-directed mutagenesis to identify amino acid residues that are critical for heparin binding activity of the VEGF164 HBD. We focused on basic residues and found Arg-13, Arg-14, and Arg-49 to be critical for heparin binding and interaction with extracellular matrix in tissue samples. We also examined the cellular and biochemical consequences of abolishing heparin-binding function, measuring the ability of the mutants to interact with VEGF receptors, induce endothelial cell gene expression, and trigger microvessel outgrowth. Induction of tissue factor expression, vessel outgrowth, and binding to VEGFR2 were unaffected by the HBD mutations. In contrast, the HBD mutants showed slightly decreased binding to the NRP1 (neuropilin-1) receptor, and analyses suggested the heparin and NRP1 binding sites to be distinct but overlapping. Finally, mutations that affect the heparin binding activity also led to an unexpected reduction in the affinity of VEGF164 binding specifically to VEGF164. This finding provides a potential basis for previous observations suggesting enhanced potency of VEGF164 versus VEGF120 in VEGFR1-mediated signaling in inflammatory cells.	UCL, Inst Ophthalmol, London EC1V 9EL, England; OSI Eyetech, Lexington, MA 02421 USA; Endothelial Cell Biol Lab, Canc Res UK, London WC2A 3PX, England	University of London; University College London; Cancer Research UK	Shima, DT (corresponding author), UCL, Inst Ophthalmol, Mortimer St, London EC1V 9EL, England.	d.shima@ucl.ac.uk	Ng, Wing Yin/HHN-1743-2022	Ng, Yin Shan/0000-0002-4982-1999				Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Cheng LL, 2004, J BIOL CHEM, V279, P30654, DOI 10.1074/jbc.M402488200; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5; Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Koopmann W, 1999, J IMMUNOL, V163, P2120; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1990, LAB INVEST, V63, P115; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200; Robinson CJ, 2001, J CELL SCI, V114, P853; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stauffer ME, 2002, J BIOMOL NMR, V23, P57, DOI 10.1023/A:1015346504499; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wung JL, 1996, BIOTECHNIQUES, V21, P808; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200; Zhu Wen-Hui, 2002, Angiogenesis, V5, P81, DOI 10.1023/A:1021509004829	66	71	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28045	28056		10.1074/jbc.M700319200	http://dx.doi.org/10.1074/jbc.M700319200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17626017	hybrid			2022-12-27	WOS:000249455600054
J	Satoh, T; Cowieson, NP; Hakamata, W; Ideo, H; Fukushima, K; Kurihara, M; Kato, R; Yamashita, K; Wakatsuki, S				Satoh, Tadashi; Cowieson, Nathan P.; Hakamata, Wataru; Ideo, Hiroko; Fukushima, Keiko; Kurihara, Masaaki; Kato, Ryuichi; Yamashita, Katsuko; Wakatsuki, Soichi			Structural basis for recognition of high mannose type glycoproteins by mammalian transport lectin VIP36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; PROTEIN; ERGIC-53; BINDING; RECEPTOR; LOCALIZATION; VESICLES; COMPLEX; DOMAIN	VIP36 functions as a transport lectin for trafficking certain high mannose type glycoproteins in the secretory pathway. Here we report the crystal structure of VIP36 exoplasmic/luminal domain comprising a carbohydrate recognition domain and a stalk domain. The structures of VIP36 in complex with Ca2+ and mannosyl ligands are also described. The carbohydrate recognition domain is composed of a 17-stranded antiparallel beta-sandwich and binds one Ca2+ adjoining the carbohydrate-binding site. The structure reveals that a coordinated Ca2+ ion orients the side chains of Asp(131), Asn(166), and His(190) for carbohydrate binding. This result explains the Ca2+-dependent carbohydrate binding of this protein. The Man-alpha-1,2-Man-alpha-1,2-Man, which corresponds to the D1 arm of high mannose type glycan, is recognized by eight residues through extensive hydrogen bonds. The complex structures reveal the structural basis for high mannose type glycoprotein recognition by VIP36 in a Ca2+-dependent and D1 arm-specific manner.	Struct Biol Res Ctr, Photon Factory Inst Mat Struct Sci, High Energy Accelerator Res Organizat, Tsukuba, Ibaraki 305, Japan; Univ Queensland, Insy Mol Biosci, Brisbane, Qld 4072, Australia; Natl Inst Hlth Sci, Div Organ Chem, Tokyo 158, Japan; Tokyo Inst Technol, Innovat Res Initiat, Yokohama, Kanagawa 227, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tokyo 101, Japan	High Energy Accelerator Research Organization (KEK); University of Queensland; National Institute of Health Sciences - Japan; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Wakatsuki, S (corresponding author), Struct Biol Res Ctr, Photon Factory Inst Mat Struct Sci, High Energy Accelerator Res Organizat, Tsukuba, Ibaraki 305, Japan.	soichi.wakatsuki@kek.jp	Hakamata, Wataru/T-6211-2019; Satoh, Tadashi/M-5157-2017	Satoh, Tadashi/0000-0002-4493-4978; Kato, Ryuichi/0000-0003-2087-2896; Wakatsuki, Soichi/0000-0001-5896-7968				ALLERHAND A, 1984, J AM CHEM SOC, V106, P2412, DOI 10.1021/ja00320a031; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Appenzeller-Herzog C, 2005, MOL BIOL CELL, V16, P1258, DOI 10.1091/mbc.E04-08-0708; Beignet J, 2004, J ORG CHEM, V69, P6341, DOI 10.1021/jo049061w; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahm T, 2001, MOL BIOL CELL, V12, P1481, DOI 10.1091/mbc.12.5.1481; DeLano W.L, PYMOL MOL GRAPHICS S; Dromer F, 2002, ANTIMICROB AGENTS CH, V46, P3869, DOI 10.1128/AAC.46.12.3869-3876.2002; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fullekrug J, 1999, J CELL SCI, V112, P2813; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2004, GLYCOBIOLOGY, V14, P739, DOI 10.1093/glycob/cwh082; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hiraki M, 2006, ACTA CRYSTALLOGR D, V62, P1058, DOI 10.1107/S0907444906023821; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; Kamiya Y, 2005, J BIOL CHEM, V280, P37178, DOI 10.1074/jbc.M505757200; Kawasaki N, 2007, J BIOCHEM, V141, P221, DOI 10.1093/jh/mvm024; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MEUWLY R, 1986, HELV CHIM ACTA, V69, P25, DOI 10.1002/hlca.19860690105; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Neve EPA, 2005, J MOL BIOL, V354, P556, DOI 10.1016/j.jmb.2005.09.077; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERS T, 1991, LIEBIGS ANN CHEM, P135; RINI JM, 1993, J BIOL CHEM, V268, P10126; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Satoh T, 2006, J BIOL CHEM, V281, P10410, DOI 10.1074/jbc.M512258200; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Shimada O, 2003, CELL STRUCT FUNCT, V28, P155; Shimada O, 2003, J HISTOCHEM CYTOCHEM, V51, P1057, DOI 10.1177/002215540305100809; TAI T, 1975, J BIOL CHEM, V250, P8569; Tanimoto T, 2002, CHEM PHARM BULL, V50, P280, DOI 10.1248/cpb.50.280; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	50	42	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28246	28255		10.1074/jbc.M703064200	http://dx.doi.org/10.1074/jbc.M703064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652092	hybrid			2022-12-27	WOS:000249455600074
J	Edderkaoui, M; Hong, P; Lee, JK; Pandol, SJ; Gukovskaya, AS				Edderkaoui, Mouad; Hong, Peggy; Lee, Jong K.; Pandol, Stephen J.; Gukovskaya, Anna S.			Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX PROTEINS; PANCREATIC-CANCER CELLS; FOCAL ADHESION KINASE; IGF-I; ALPHA-V-BETA-3 INTEGRIN; APOPTOSIS; PHOSPHORYLATION; PROLIFERATION; STATISTICS	We recently showed that extracellular matrix ( ECM) proteins, which are abundant in desmoplastic pancreatic tumor, are as potent as growth factors in inhibiting apoptosis in pancreatic cancer ( PaCa) cells. Here we show that fibronectin, a major ECM component, engages insulin-like growth factor-I receptor ( IGF-IR) to inhibit PaCa cell death. We found that fibronectin-induced protection from apoptosis is fully mediated by IGF-IR and is independent of IGF-I. Pharmacologic and molecular inhibitions of IGF-IR stimulated apoptosis and prevented the prosurvival effect of fibronectin in PaCa cells. Our data indicate that fibronectin protects from apoptosis through trans-activation of IGF-IR. We showed that fibronectin stimulated complex formation between its receptor beta 3 integrin and protein-tyrosine phosphatase SHP-2. This process of complex formation, in turn, prevents SHP- 2 from dephosphorylating IGF-IR resulting in sustained phosphorylation of IGF-IR and leading to the downstream activation of Akt kinase, up-regulation of antiapoptotic BclxL, and inhibition of apoptosis. Among ECM proteins tested only fibronectin and laminin but not vitronectin and collagen I stimulated trans-activation of IGF-IR. Interaction of fibronectin with beta 3 but not beta 1 integrin receptors mediates the survival pathway. In contrast, fibronectin-induced adhesion is mediated through beta 1 integrin receptor and is IGF-IR-independent. Thus, our results indicate that the prosurvival effect of fibronectin in PaCa cells is mediated by trans-activation of IGF-IR induced by the beta 3 integrin receptor. The data suggest IGF-IR as a key target for prevention of the prosurvival effects of ECM proteins and growth factors in pancreatic cancer.	W Los Angeles Vet Affairs Hlth Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90073 USA; Sungkyunkwan Univ, Sch Med, Seoul 135710, South Korea	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; Sungkyunkwan University (SKKU)	Gukovskaya, AS (corresponding author), W Los Angeles Vet Affairs Hlth Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu	Jee, Yong-Seok/AAJ-5187-2020	Gukovskaya, Anna/0000-0003-3737-5335; Edderkaoui, Mouad/0000-0002-2549-8242	NCI NIH HHS [R01 CA 119025-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA119025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; BERGMANN U, 1995, CANCER RES, V55, P2007; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Edderkaoui M, 2005, AM J PHYSIOL-GASTR L, V289, pG1137, DOI 10.1152/ajpgi.00197.2005; El Annabi S, 2001, FEBS LETT, V507, P247, DOI 10.1016/S0014-5793(01)02981-7; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karna E, 2002, INT J EXP PATHOL, V83, P239, DOI 10.1046/j.1365-2613.2002.00237.x; Linder S, 2001, HEPATO-GASTROENTEROL, V48, P1321; Ling Y, 2005, J BIOL CHEM, V280, P3151, DOI 10.1074/jbc.M411035200; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; Novosyadlyy R, 2006, LAB INVEST, V86, P710, DOI 10.1038/labinvest.3700426; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Perugini RA, 1998, CRIT REV EUKAR GENE, V8, P377, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.70; Sekharam M, 2003, CANCER RES, V63, P7708; Tai YT, 2003, CANCER RES, V63, P5850; TRIKHA M, 1994, CANCER RES, V54, P4993; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Watanabe I, 2003, PANCREAS, V26, P326, DOI 10.1097/00006676-200305000-00003; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6	30	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26646	26655		10.1074/jbc.M702836200	http://dx.doi.org/10.1074/jbc.M702836200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627944	hybrid			2022-12-27	WOS:000249304900003
J	Wen, XY; Duus, KM; Friedrich, TD; de Noronha, CMC				Wen, Xiaoyun; Duus, Karen M.; Friedrich, Thomas D.; de Noronha, Carlos M. C.			The HIV1 protein vpr acts to promote G(2) cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA-BINDING PROTEIN; NUCLEAR IMPORT; V PROTEIN; VIRION INCORPORATION; MUTATIONAL ANALYSIS; NONDIVIDING CELLS; CDT1 DEGRADATION; LOCALIZATION; DAMAGE	The roles of the HIV1 protein Vpr in virus replication and pathogenesis remain unclear. Expression of Vpr in dividing cells causes cell cycle arrest in G(2). Vpr also facilitates low titer infection of terminally differentiated macrophages, enhances transcription, promotes apoptosis, and targets cellular uracil N-glycosylase for degradation. Using co-immunoprecipitation and tandem mass spectroscopy, we found that HIV1 Vpr engages a DDB1- and cullin4A-containing ubiquitin-ligase complex through VprBP/DCAF1. HIV2 Vpr has two Vpr-like proteins, Vpr and Vpx, which cause G(2) arrest and facilitate macrophage infection, respectively. HIV2 Vpr, but not Vpx, engages the same set of proteins. We further demonstrate that the interaction between Vpr and the ubiquitin-ligase components as well as further assembly of the ubiquitin-ligase are necessary for Vpr-mediatedG(2) arrest. Our data support a model in which Vpr engages the ubiquitin ligase to deplete a cellular factor that is required for cell cycle progression into mitosis. Vpr, thus, functions like the HIV1 proteins Vif and Vpu to usurp cellular ubiquitin ligases for viral functions.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Albany Medical College	de Noronha, CMC (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, Med Sci Bldg 216,MC-151, Albany, NY 12208 USA.	DeNoroC@mail.AMC.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073178] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI073178] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Arias EE, 2006, NAT CELL BIOL, V8, P84, DOI 10.1038/ncb1346; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DeHart JL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-57; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Hu J, 2006, J BIOL CHEM, V281, P3753, DOI 10.1074/jbc.C500464200; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Jung SO, 2001, MOL CELLS, V12, P84; Kewalramani VN, 1996, VIROLOGY, V218, P326, DOI 10.1006/viro.1996.0201; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Li T, 2006, CELL, V124, P105, DOI 10.1016/j.cell.2005.10.033; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Liu C, 2005, EMBO J, V24, P3940, DOI 10.1038/sj.emboj.7600854; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; Precious B, 2005, J VIROL, V79, P13434, DOI 10.1128/JVI.79.21.13434-13441.2005; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Schrofelbauer B, 2007, P NATL ACAD SCI USA, V104, P4130, DOI 10.1073/pnas.0610167104; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; YAMSHITA M, 2005, PLOS PATHOG, V1; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028	57	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27046	27057		10.1074/jbc.M703955200	http://dx.doi.org/10.1074/jbc.M703955200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620334	hybrid			2022-12-27	WOS:000249304900046
J	Doz, E; Rose, S; Nigou, J; Gilleron, M; Puzo, G; Erard, F; Ryffel, B; Quesniaux, VFJ				Doz, Emilie; Rose, Stephanie; Nigou, Jerome; Gilleron, Martine; Puzo, Germain; Erard, Francois; Ryffel, Bernhard; Quesniaux, Valerie F. J.			Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, Mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; C-TYPE LECTIN; NITRIC-OXIDE SYNTHASE; SURFACTANT PROTEIN-A; MYO-INOSITOL ANCHOR; DC-SIGN; DENDRITIC CELLS; SELECTIVE RECOGNITION; MULTIACYLATED FORMS; 2-DEFICIENT MICE	Mycobacterium tuberculosis lipomannans ( LMs) modulate the hostinnate immune response. The total fraction of Mycobacterium bovis BCG LM was shown both to induce macrophage activation and pro-inflammatory cytokines through Toll-like receptor 2 ( TLR2) and to inhibit pro-inflammatory cytokine production by lipopolysaccharide (LPS)-activated macrophages through a TLR2-independent pathway. The pro-inflammatory activity was attributed to tri- and tetra-acylated forms of BCGLM but not the mono- and di-acylated ones. Here, we further characterize the negative activities of M. bovis BCGLM on primary murine macrophage activation. We show that di-acylated LMs exhibit a potent inhibitory effect on cytokine and NO secretion by LPS-activated macrophages. The inhibitory activity of mycobacterial mannose-capped lipoarabino-mannans on human phagocytes was previously attributed to their binding to the C-type lectins mannose receptor or specific intracellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN). However, we found that di-acylated LM inhibition of LPS-induced tumor necrosis factor secretion by murine macro-phages was independent of TLR2, mannose receptor, or the murine ortholog SIGNR1. We further determined that tri-acyl-LM, an agonist of TLR2/TLR1, promoted interleukin-12 p40 and NO secretion through the adaptor proteins MyD88 and TIRAP, whereas the fraction containing tetra-acylated LM activated macrophages in a MyD88-dependent fashion, mostly through TLR4. TLR4-dependent pro-inflammatory activity was also seen with M. tuberculosis LM, composed mostly of tri- acylated LM, suggesting that acylation degree per se might not be sufficient to determine TLR2 versus TLR4 usage. Therefore, LM acylation pattern determines the anti-inflammatory versus pro-inflammatory effects of LM through different pattern recognition receptors or signaling pathways and may represent an additional mean of regulating the host innate immunity by mycobacteria.	CNRS, IEM UMR6218, F-45071 Orleans 2, France; CNRS, Inst Pharmacol & Biol Struct, Dept Mecan Mol Infect Mycobact, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Quesniaux, VFJ (corresponding author), CNRS, IEM UMR6218, 3B Rue Ferollerie, F-45071 Orleans 2, France.	quesniaux@cnrs-orleans.fr	Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487; GILLERON, Martine/0000-0002-2581-3302; Doz-Deblauwe, Emilie/0000-0002-3126-4004				Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Cooper AM, 2002, J IMMUNOL, V168, P1322, DOI 10.4049/jimmunol.168.3.1322; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004; Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7; Ehlers S, 2003, J IMMUNOL, V170, P5210, DOI 10.4049/jimmunol.170.10.5210; Fallon PG, 2006, TRENDS IMMUNOL, V27, P470, DOI 10.1016/j.it.2006.08.002; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Fremond CM, 2007, J IMMUNOL, V179, P1178, DOI 10.4049/jimmunol.179.2.1178; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Garcia I, 2000, LAB INVEST, V80, P1385, DOI 10.1038/labinvest.3780146; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2006, CHEM BIOL, V13, P39, DOI 10.1016/j.chembiol.2005.10.013; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Heldwein KA, 2002, MICROBES INFECT, V4, P937, DOI 10.1016/S1286-4579(02)01611-8; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Kaufmann SHE, 2003, J EXP MED, V197, P1, DOI 10.1084/jem.20021964; Kaur D, 2006, P NATL ACAD SCI USA, V103, P13664, DOI 10.1073/pnas.0603049103; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Krutzik SR, 2004, SEMIN IMMUNOL, V16, P35, DOI 10.1016/j.smim.2003.10.005; Lanoue A, 2004, J EXP MED, V200, P1383, DOI 10.1084/jem.20040795; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Mohan AK, 2003, CURR OPIN RHEUMATOL, V15, P179, DOI 10.1097/00002281-200305000-00002; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Muller M, 1996, MOL MED, V2, P247, DOI 10.1007/BF03401621; Nagaoka K, 2005, INT IMMUNOL, V17, P827, DOI 10.1093/intimm/dxh264; Neyrolles O, 2006, TRENDS MICROBIOL, V14, P383, DOI 10.1016/j.tim.2006.07.007; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pitarque S, 2005, BIOCHEM J, V392, P615, DOI 10.1042/BJ20050709; Powlesland AS, 2006, J BIOL CHEM, V281, P20440, DOI 10.1074/jbc.M601925200; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Quesniaux V, 2004, MICROBES INFECT, V6, P946, DOI 10.1016/j.micinf.2004.04.016; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; Riviere M, 2004, J MOL BIOL, V344, P907, DOI 10.1016/j.jmb.2004.09.092; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2; Tailleux L, 2005, PLOS MED, V2, P1269, DOI 10.1371/journal.pmed.0020381; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TAILLEUX L, 2005, CURR IMMUNOL REV, V1, P101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taylor PR, 2004, J IMMUNOL, V172, P1157, DOI 10.4049/jimmunol.172.2.1157; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Torrelles JB, 2006, J IMMUNOL, V177, P1805, DOI 10.4049/jimmunol.177.3.1805; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vignal C, 2003, J IMMUNOL, V171, P2014, DOI 10.4049/jimmunol.171.4.2014; Wieland CW, 2007, MICROBES INFECT, V9, P134, DOI 10.1016/j.micinf.2006.10.018; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182	77	87	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26014	26025		10.1074/jbc.M702690200	http://dx.doi.org/10.1074/jbc.M702690200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17617634	hybrid			2022-12-27	WOS:000249239600005
J	Knecht, W; Cottrell, GS; Amadesi, S; Mohlin, J; Skaregarde, A; Gedda, K; Peterson, A; Chapman, K; Hollenberg, MD; Vergnolle, N; Bunnett, NW				Knecht, Wolfgang; Cottrell, Graeme S.; Amadesi, Silvia; Mohlin, Johanna; Skaregarde, Anita; Gedda, Karin; Peterson, Anders; Chapman, Kevin; Hollenberg, Morley D.; Vergnolle, Nathalie; Bunnett, Nigel W.			Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN; CAPSAICIN RECEPTOR; MOLECULAR-CLONING; PROTEASE-ACTIVATED-RECEPTOR-2 SENSITIZES; NEUROGENIC MECHANISM; THERMAL HYPERALGESIA; INHIBITOR RESISTANCE; VANILLOID RECEPTOR-1; PAIN PATHWAY; ION-CHANNEL	Although principally produced by the pancreas to degrade dietary proteins in the intestine, trypsins are also expressed in the nervous system and in epithelial tissues, where they have diverse actions that could be mediated by protease-activated receptors ( PARs). We examined the biological actions of human trypsin IV ( or mesotrypsin) and rat p23, inhibitor-resistant forms of trypsin. The zymogens trypsinogen IV and pro-p23 were expressed in Escherichia coli and purified to apparent homogeneity. Enteropeptidase cleaved both zymogens, liberating active trypsin IV and p23, which were resistant to soybean trypsin inhibitor and aprotinin. Trypsin IV cleaved N-terminal fragments of PAR(1), PAR(2), and PAR(4) at sites that would expose the tethered ligand (PAR(1) = PAR(4) > PAR(2)). Trypsin IV increased [Ca2(+)] (i) in transfected cells expressing human PAR(1) and PAR(2) with similar potencies (PAR(1), 0.5 mu M; PAR(2), 0.6 mu M). p23 also cleaved fragments of PAR(1) and PAR(2) and signaled to cells expressing these receptors. Trypsin IV and p23 increased [Ca2(+)] i in rat dorsal root ganglion neurons that responded to capsaicin and which thus mediate neurogenic inflammation and nociception. Intraplantar injection of trypsin IV and p23 in mice induced edema and granulocyte infiltration, which were not observed in PAR(1) (-/-)(trypsin IV) and PAR(2) (-/-) ( trypsin IV and p23) mice. Trypsin IV and p23 caused thermal hyperalgesia and mechanical allodynia and hyperalgesia in mice, and these effects were absent in PAR(2) (-/-) mice but maintained in PAR1 (-/-) mice. Thus, trypsin IV and p23 are inhibitor- resistant trypsins that can cleave and activate PARs, causing PAR(1)- and PAR(2)- dependent inflammation and PAR(2)- dependent hyperalgesia.	Univ Calif San Francisco, San Francisco, CA 94143 USA; AstraZeneca Res & Dev, Mol Pharmacol & Lead Generat, Molndal 43183, Sweden; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calgary, Dept Med, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; INSERM, Ctr Physiopathol Touluse Purpan, U563, F-310300 Toulouse, France; Univ Toulouse 3, F-31000 Toulouse, France	University of California System; University of California San Francisco; AstraZeneca; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Calgary; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bunnett, NW (corresponding author), Univ Calif San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu	Vergnolle, Nathalie/C-7677-2018; Hollenberg, Morley/AFV-6966-2022	Vergnolle, Nathalie/0000-0003-1825-6015; Cottrell, Graeme/0000-0001-9098-7627; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK57480, DK43207, DK39957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R56DK043207, R01DK043207, R01DK039957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amadesi S, 2004, J NEUROSCI, V24, P4300, DOI 10.1523/JNEUROSCI.5679-03.2004; Amadesi S, 2006, J PHYSIOL-LONDON, V575, P555, DOI 10.1113/jphysiol.2006.111534; Asfaha S, 2002, BRIT J PHARMACOL, V135, P1101, DOI 10.1038/sj.bjp.0704568; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Coelho AM, 2002, GASTROENTEROLOGY, V122, P1035, DOI 10.1053/gast.2002.32387; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Cottrell GS, 2007, GASTROENTEROLOGY, V132, P2422, DOI 10.1053/j.gastro.2007.03.101; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152; Diederichs S, 2004, CANCER RES, V64, P5564, DOI 10.1158/0008-5472.CAN-04-2004; EMI M, 1986, GENE, V41, P305; Fukuoka S, 2002, BBA-MOL BASIS DIS, V1588, P106, DOI 10.1016/S0925-4439(02)00153-9; Gallatz Katalin, 2007, Ideggyogy Sz, V60, P118; Grant AD, 2007, J PHYSIOL-LONDON, V578, P715, DOI 10.1113/jphysiol.2006.121111; Grishina Z, 2005, BRIT J PHARMACOL, V146, P990, DOI 10.1038/sj.bjp.0706410; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; Kawabata A, 2001, NEUROREPORT, V12, P715, DOI 10.1097/00001756-200103260-00020; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; Loew D, 2000, BIOCHEMISTRY-US, V39, P10812, DOI 10.1021/bi0003341; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Medveczky P, 2006, FEBS LETT, V580, P545, DOI 10.1016/j.febslet.2005.12.067; Minn A, 1998, GLIA, V22, P338, DOI 10.1002/(SICI)1098-1136(199804)22:4<338::AID-GLIA3>3.0.CO;2-#; Nakayama T, 2003, BRIT J PHARMACOL, V138, P121, DOI 10.1038/sj.bjp.0705008; Nemeth AL, 2007, FEBS J, V274, P1610, DOI 10.1111/j.1742-4658.2007.05708.x; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; Rowen L, 2005, MOL BIOL EVOL, V22, P1712, DOI 10.1093/molbev/msi166; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Szepessy E, 2006, FEBS J, V273, P2942, DOI 10.1111/j.1742-4658.2006.05305.x; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; Toth J, 2007, NEUROCHEM RES, V32, P1423, DOI 10.1007/s11064-007-9327-8; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang YF, 2006, J NEUROCHEM, V99, P759, DOI 10.1111/j.1471-4159.2006.04105.x; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMASHINA I, 1956, ACTA CHEM SCAND, V10, P739, DOI 10.3891/acta.chem.scand.10-0739; Yamashita K, 2003, CANCER RES, V63, P6575	58	84	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26089	26100		10.1074/jbc.M703840200	http://dx.doi.org/10.1074/jbc.M703840200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623652	hybrid			2022-12-27	WOS:000249239600012
J	McConlogue, L; Buttini, M; Anderson, JP; Brigham, EF; Chen, KS; Freedman, SB; Games, D; Johnson-Wood, K; Lee, M; Zeller, M; Liu, W; Motter, R; Sinha, S				McConlogue, Lisa; Buttini, Manuel; Anderson, John P.; Brigham, Elizabeth F.; Chen, Karen S.; Freedman, Stephen B.; Games, Dora; Johnson-Wood, Kelly; Lee, Michael; Zeller, Michelle; Liu, Weiqun; Motter, Ruth; Sinha, Sukanto			Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; BETA-SECRETASE BACE1; MOUSE MODEL; A-BETA; MEMORY DEFICITS; ASPARTYL PROTEASE; KNOCKOUT MICE; IN-VIVO; DISEASE; CLEAVAGE	The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta ( A beta) peptide, the major component of Alzheimer disease ( AD) plaques. To determine the role that BACE1 plays in the development of A beta-driven AD-like pathology, we have crossed PDAPP mice, a transgenic mouse model of AD overexpressing human mutated APP, onto mice with either a homozygous or heterozygous BACE1 gene knockout. Analysis of PDAPP/BACE(-/-) mice demonstrated that BACE1 is absolutely required for both A beta generation and the development of age-associated plaque pathology. Furthermore, synaptic deficits, a neurodegenerative pathology characteristic of AD, were also reversed in the bigenic mice. To determine the extent of BACE1 reduction required to significantly inhibit pathology, PDAPP mice having a heterozygous BACE1 gene knock-out were evaluated for A beta generation and for the development of pathology. Although the 50% reduction in BACE1 enzyme levels caused only a 12% decrease in A beta levels in young mice, it nonetheless resulted in a dramatic reduction in A beta plaques, neuritic burden, and synaptic deficits in older mice. Quantitative analyses indicate that brain A beta levels in young APP transgenic mice are not the sole determinant for the changes in plaque pathology mediated by reduced BACE1. These observations demonstrate that partial reductions of BACE1 enzyme activity and concomitant A beta levels lead to dramatic inhibition of A beta-driven AD-like pathology, making BACE1 an excellent target for therapeutic intervention in AD.	Elan Pharmaceut, San Francisco, CA 94010 USA; Elan Pharmaceut, Dept Biol, San Francisco, CA 94080 USA; Elan Pharmaceut, Dept Pharmacol, San Francisco, CA 94080 USA		McConlogue, L (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, San Francisco, CA 94010 USA.	lisa.mcconlogue@elan.com		Buttini, Manuel/0000-0003-1805-0279				Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; Buttini M, 2005, J NEUROSCI, V25, P9096, DOI 10.1523/JNEUROSCI.1697-05.2005; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chen KS, 1998, PROG BRAIN RES, V117, P327; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Danner S, 2002, NEUROBIOL AGING, V23, pS241; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; DICKSON DW, 1988, AM J PATHOL, V132, P86; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Grace EA, 2002, NEUROSCIENCE, V114, P265, DOI 10.1016/S0306-4522(02)00241-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KOBAYASHI D, 2007, IN PRESS NEUROBIOL A; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; McPhie DL, 2001, MOL BRAIN RES, V97, P103, DOI 10.1016/S0169-328X(01)00294-7; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ohno M, 2006, EUR J NEUROSCI, V23, P251, DOI 10.1111/j.1460-9568.2005.04551.x; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; RABE L, 2006, INT C ALZH DIS REL D; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shi XP, 2005, J ALZHEIMERS DIS, V7, P139; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Spires TL, 2004, REV NEUROSCIENCE, V15, P267, DOI 10.1515/REVNEURO.2004.15.4.267; Terry R., 1999, ALZHEIMER DIS, V2nd Edn, P187; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	58	240	282	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26326	26334		10.1074/jbc.M611687200	http://dx.doi.org/10.1074/jbc.M611687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616527	hybrid			2022-12-27	WOS:000249239600037
J	Smardon, AM; Kane, PM				Smardon, Anne M.; Kane, Patricia M.			RAVE is essential for the efficient assembly of the C subunit with the vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-ATPASE; GENE DELETION; VMA5P; LOCALIZATION; STATOR; ACIDIFICATION; COMPLEXES; VERSATILE; ROTATION; MUTANTS	The RAVE complex is required for stable assembly of the yeast vacuolar proton-translocating ATPase ( V-ATPase) during both biosynthesis of the enzyme and regulated reassembly of disassembled V-1 and V-0 sectors. It is not yet known how RAVE effects V-ATPase assembly. Previous work has shown that V-1 peripheral or stator stalk subunits E and G are critical for binding of RAVE to cytosolic V-1 complexes, suggesting that RAVE may play a role in docking of the V1 peripheral stalk to the V-0 complex at the membrane. Here we provide evidence for an interaction between the RAVE complex and V-1 subunit C, another subunit that has been assigned to the peripheral stalk. The C subunit is unique in that it is released from both V-1 and V-0 sectors during disassembly, suggesting that subunit C may control the regulated assembly of the V-ATPase. Mutants lacking subunit C have assembly phenotypes resembling that of RAVE mutants. Both are able to assemble V-1/ V-0 complexes in vivo, but these complexes are highly unstable in vitro, and V-ATPase activity is extremely low. We show that in the absence of the RAVE complex, subunit C is not able to stably assemble with the vacuolar ATPase. Our data support a model where RAVE, through its interaction with subunit C, is facilitating V-1 peripheral stalk subunit interactions with V-0 during V-ATPase assembly.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St,Syracuse, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063742] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063742, R01 GM63742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; Brace EJ, 2006, EUKARYOT CELL, V5, P2104, DOI 10.1128/EC.00347-05; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Dietz KJ, 2001, J EXP BOT, V52, P1969, DOI 10.1093/jexbot/52.363.1969; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Drory O, 2004, EMBO REP, V5, P1148, DOI 10.1038/sj.embor.7400294; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HARPER JW, 1993, CELL, V75, P805; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P221; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ochotny N, 2006, J BIOL CHEM, V281, P26102, DOI 10.1074/jbc.M601118200; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Sherman F., 1982, METHODS YEAST GENETI; Sipos G, 2004, MOL BIOL CELL, V15, P3196, DOI 10.1091/mbc.E03-10-0755; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang ZY, 2006, FEBS LETT, V580, P2006, DOI 10.1016/j.febslet.2006.03.001	50	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26185	26194		10.1074/jbc.M703627200	http://dx.doi.org/10.1074/jbc.M703627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623654	hybrid			2022-12-27	WOS:000249239600022
J	Wu, WJ; Baxter, JE; Wattam, SL; Hayward, DG; Fardilha, M; Knebel, A; Ford, EM; Silva, EFDE; Fry, AM				Wu, Wenjuan; Baxter, Joanne E.; Wattam, Samantha L.; Hayward, Daniel G.; Fardilha, Margarida; Knebel, Axel; Ford, Eleanor M.; da Cruz e Silva, Edgar F.; Fry, Andrew M.			Alternative splicing controls nuclear translocation of the cell cycle-regulated Nek2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIMA-RELATED KINASE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; CENTROSOMAL KINASE; CRYSTALLOGRAPHIC ANALYSIS; MOUSE SPERMATOCYTES; KARYOPHERIN ALPHA; MITOTIC REGULATOR; MITOSIS; LOCALIZATION	Nek2 is a cell cycle-regulated serine/threonine protein kinase that is up-regulated in human cancers. Functionally, it is implicated in control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. Two major splice variants have been described in vertebrates, Nek2A and Nek2B, that differ in their non-catalytic C termini. Recently, a third splice variant, Nek2C, was identified that lacks an eight-amino acid internal sequence within the C-terminal domain of Nek2A. This excision occurs at the same position as the Nek2A/Nek2B splice point. As predicted from their high degree of similarity, we show here that Nek2C shares many properties with Nek2A including kinase activity, dimerization, protein phosphatase 1 interaction, mitotic degradation, microtubule binding, and centrosome localization. Unexpectedly, though, the non-centrosomal pool of protein exhibits a marked difference in distribution for the three splice variants. Nek2C is mainly nuclear, Nek2B is mainly cytoplasmic, and Nek2A is evenly distributed within nuclei and cytoplasm. Mutagenesis experiments revealed a functional bipartite nuclear localization sequence (NLS) that spans the splice site leading to Nek2C having a strong NLS, Nek2A having a weak NLS, and Nek2B having no NLS. Finally, we identified a 28-kDa protein in nuclear extracts as a potential novel substrate of Nek2. Thus, alternative splicing provides an unusual mechanism for modulating Nek2 localization, enabling it to have both nuclear and cytoplasmic functions.	Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Aveiro, Ctr Biol Celuar, Lab Transducao Sinais, P-3810193 Aveiro, Portugal; Kinasource Ltd, Dundee DD1 5AN, Scotland	University of Leicester; Universidade de Aveiro	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England.	amf5@le.ac.uk	Wu, wenjuan/GPX-6968-2022; da Cruz e Silva, Edgar/G-2647-2010; da cruz e silva, edgar/C-3681-2008; Fardilha, Margarida/G-3182-2010	Fardilha, Margarida/0000-0001-7459-9173; Knebel, Axel/0000-0002-9197-6054	Biotechnology and Biological Sciences Research Council [BB/C000013/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Amador FC, 2004, NEUROTOXICOL TERATOL, V26, P387, DOI 10.1016/j.ntt.2003.12.007; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Cohen P, 2006, BIOCHEM J, V393, P1, DOI 10.1042/BJ20051545; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Di Agostino S, 2004, MOL BIOL CELL, V15, P1224, DOI 10.1091/mbc.E03-09-0638; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fardilha M, 2004, ANN NY ACAD SCI, V1030, P468, DOI 10.1196/annals.1329.059; Fletcher L, 2005, BBA-MOL CELL RES, V1744, P89, DOI 10.1016/j.bbamcr.2005.01.007; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Noguchi K, 2004, J BIOL CHEM, V279, P32716, DOI 10.1074/jbc.M404104200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200; Rhee K, 1997, DEVELOPMENT, V124, P2167; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Shu X, 2005, HUM MOL GENET, V14, P1183, DOI 10.1093/hmg/ddi129; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yin MJ, 2003, J BIOL CHEM, V278, P52454, DOI 10.1074/jbc.M308080200	46	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26431	26440		10.1074/jbc.M704969200	http://dx.doi.org/10.1074/jbc.M704969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626005	hybrid			2022-12-27	WOS:000249239600048
J	Yuyama, K; Sekino-Suzuki, N; Sanai, Y; Kasahara, K				Yuyama, Kohei; Sekino-Suzuki, Naoko; Sanai, Yutaka; Kasahara, Kohji			Translocation of activated heterotrimeric G protein G alpha(o) to ganglioside-enriched detergent-resistant membrane rafts in developing cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH CONES; LIPID RAFTS; RAT-BRAIN; TYROSINE KINASE; GRANULE CELLS; AXON GUIDANCE; IN-VITRO; DIFFERENTIATION; ASSOCIATION; DOMAINS	The association of gangliosides with specific proteins in the central nervous system was examined by co-immunoprecipitation with an anti-ganglioside antibody. The monoclonal antibody to the ganglioside GD3 immunoprecipitated phosphoproteins of 40, 53, 56, and 80 kDa from the rat cerebellum. Of these proteins, the 40-kDa protein was identified as the alpha-subunit of a heterotrimeric G protein, Go ( G alpha(o)). Using sucrose density gradient analysis of cerebellar membranes, G alpha(o), but not G beta gamma, was observed in detergent-resistant membrane (DRM) raft fractions in which GD3 was abundant after the addition of guanosine 5 '-O-( thiotriphosphate) (GTP gamma S), which stabilizes Go in its active form. On the other hand, both G alpha(o) and G beta gamma were excluded from the DRM raft fractions in the presence of guanyl-5 '-yl thiophosphate, which stabilizes Go in its inactive form. Only G alpha(o) was observed in the DRM fractions from the cerebellum on postnatal day 7, but not from that in adult. After pertussis toxin treatment, G alpha(o) was not observed in the DRM fractions, even from the cerebellum on postnatal day 7. These results indicate the activation-dependent translocation of G alpha(o) into the DRM rafts. Furthermore, G alpha o was concentrated in the neuronal growth cones. Treatment with stromal cell-derived factor-1 alpha, a physiological ligand for the G protein-coupled receptor, stimulated [S-35] GTP gamma S binding to G alpha(o) and caused G alpha(o) translocation to the DRM fractions and RhoA translocation to the membrane fraction, leading to the growth cone collapse of cerebellar granule neurons. The collapse was partly prevented by pretreatment with the cholesterol-sequestering and raftdisrupting agent methyl- beta-cyclodextrin. These results demonstrate the involvement of signal-dependent G alpha(o) translocation to the DRM in the growth cone behavior of cerebellar granule neurons.	Tokyo Metropolitan Inst Med Sci, Tokyo Metropolitan Org Med Res, Biomembrane Signaling Project 2, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo Metropolitan Org Med Res, Lab Glycobiol, Bunkyo Ku, Tokyo 1138613, Japan; PRESTO, Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Kasahara, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Tokyo Metropolitan Org Med Res, Biomembrane Signaling Project 2, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	kasahara@rinshoken.or.jp	Yuyama, Kohei/A-7454-2012	Kasahara, Kohji/0000-0001-7010-8365				Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bourova L, 2003, J NEUROCHEM, V85, P34, DOI 10.1046/j.1471-4159.2003.01667.x; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARTY DJ, 1994, METHOD ENZYMOL, V237, P63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; He Q, 2002, MOL CELL NEUROSCI, V19, P18, DOI 10.1006/mcne.2001.1060; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Kasahara K, 2002, NEUROCHEM RES, V27, P823, DOI 10.1023/A:1020265225916; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; LEVI G, 1989, DISSECTION TISSUE CU; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Nakai Y, 2002, J CELL BIOL, V159, P1097, DOI 10.1083/jcb.200209077; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1997, CELL MOL BIOL, V43, P293; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TAKAISHI K, 1995, ONCOGENE, V11, P39; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; YAMAKAWA T, 1978, TRENDS BIOCHEM SCI, V3, P128, DOI 10.1016/S0968-0004(78)80031-0; Yamashita T, 2005, P NATL ACAD SCI USA, V102, P2725, DOI 10.1073/pnas.0407785102; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P1880, DOI 10.1073/pnas.0307292101	48	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26392	26400		10.1074/jbc.M705046200	http://dx.doi.org/10.1074/jbc.M705046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623667	hybrid			2022-12-27	WOS:000249239600044
J	Pedone, KH; Hepler, JR				Pedone, Katherine H.; Hepler, John R.			The importance of N-terminal polycysteine and polybasic sequences for G(14)alpha and G(16)alpha palmitoylation, plasma membrane localization, and signaling function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; G-PROTEIN PALMITOYLATION; PHOSPHOLIPASE-C; GQ-ALPHA; LIPID MODIFICATIONS; DEFICIENT MUTANTS; AMINO-TERMINUS; ASSOCIATION; RECEPTOR; ACTIVATION	Plasma membrane targeting of G protein alpha (G alpha) subunits is essential for competent receptor-to-G protein signaling. Many G alpha are tethered to the plasma membrane by covalent lipid modifications at their N terminus. Additionally, it is hypothesized that G(q) family members (G(q)alpha, G(11)alpha, G(14)alpha, and G(16)alpha) in particular utilize a polybasic sequence of amino acids in their N terminus to promote membrane attachment and protein palmitoylation. However, this hypothesis has not been tested, and nothing is known about other mechanisms that control subcellular localization and signaling properties of G(14)alpha and G(16)alpha. Here we report critical biochemical factors that mediate membrane attachment and signaling function of G(14)alpha and G(16)alpha. We find that G(14)alpha and G(16)alpha are palmitoylated at distinct polycysteine sequences in their N termini and that the polycysteine sequence along with the adjacent polybasic region are both important for G(16)alpha-mediated signaling at the plasma membrane. Surprisingly, the isolated N termini of G(14)alpha and G(16)alpha expressed as peptides fused to enhanced green fluorescent protein each exhibit differential requirements for palmitoylation and membrane targeting; individual cysteine residues, but not the polybasic regions, determine lipid modification and subcellular localization. However, full-length G(16)alpha, more so than G(14)alpha, displays a functional dependence on single cysteines for membrane localization and activity, and its full signaling potential depends on the integrity of the polybasic sequence. Together, these findings indicate that G(14)alpha and G(16)alpha are palmitoylated at distinct polycysteine sequences, and that the adjacent polybasic domain is not required for G alpha palmitoylation but is important for localization and functional activity of heterotrimeric-G proteins.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hepler, JR (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	jhepler@emory.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037112, R01NS049195] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61847] Funding Source: Medline; NINDS NIH HHS [R01NS049195, R01NS037112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernstein Leah S., 2003, V237, P195; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Drmota T, 1999, BIOCHEM J, V340, P529, DOI 10.1042/0264-6021:3400529; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2005, CELL SIGNAL, V17, P1218, DOI 10.1016/j.cellsig.2004.12.008; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Johansson BB, 2005, FEBS J, V272, P5365, DOI 10.1111/j.1742-4658.2005.04934.x; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Kosloff M, 2003, EMBO J, V22, P459, DOI 10.1093/emboj/cdg054; Kosloff M, 2002, BIOCHEMISTRY-US, V41, P14518, DOI 10.1021/bi026729x; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levitzki A, 2002, CHEMBIOCHEM, V3, P815, DOI 10.1002/1439-7633(20020902)3:9<815::AID-CBIC815>3.0.CO;2-E; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Shu FJ, 2007, CELL SIGNAL, V19, P163, DOI 10.1016/j.cellsig.2006.06.002; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Zhang ZX, 2004, J BIOL CHEM, V279, P33937, DOI 10.1074/jbc.M403404200	61	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25199	25212		10.1074/jbc.M610297200	http://dx.doi.org/10.1074/jbc.M610297200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17620339	hybrid			2022-12-27	WOS:000249014100005
J	Benghezal, M; Roubaty, C; Veepuri, V; Knudsen, J; Conzelmann, A				Benghezal, Mohammed; Roubaty, Carole; Veepuri, Vijayanath; Knudsen, Jens; Conzelmann, Andreas			SLC1 and SLC4 encode partially redundant acyl-coenzyme A 1-acylglycerol-3-phosphate O-acyltransferases of budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-D; PHOSPHATIDIC-ACID; GPI ANCHOR; GENE; EXPRESSION; MEMBRANE; IDENTIFICATION; SPHINGOLIPIDS; PHOSPHATIDYLCHOLINE	Phosphatidic acid is the intermediate, from which all glycerophospholipids are synthesized. In yeast, it is generated from lysophosphatidic acid, which is acylated by Slc1p, an sn-2-specific, acyl-coenzyme A-dependent 1-acylglycerol-3-phosphate O-acyltransferase. Deletion of SLC1 is not lethal and does not eliminate all microsomal 1-acylglycerol-3-phosphate O-acyltransferase activity, suggesting that an additional enzyme may exist. Here we show that SLC4 (Yor175c), a gene of hitherto unknown function, encodes a second 1-acyl-sn-glycerol-3phosphate acyltransferase. SLC4 harbors a membrane-bound O-acyltransferase motif and down-regulation of SLC4 strongly reduces 1-acyl-sn-glycerol-3-phosphate acyltransferase activity in microsomes from slc1 Delta cells. The simultaneous deletion of SLC1 and SLC4 is lethal. Mass spectrometric analysis of lipids from slc1 Delta and slc4 Delta cells demonstrates that in vivo Slc1p and Slc4p generate almost the same glycerophospholipid profile. Microsomes from slc1 Delta and slc4 Delta cells incubated with [ C-14] oleoyl-coenzyme A in the absence of lysophosphatidic acid and without CTP still incorporate the label into glycerophospholipids, indicating that Slc1p and Slc4p can also use endogenous lysoglycerophospholipids as substrates. However, the lipid profiles generated by microsomes from slc1 Delta and slc4 Delta cells are different, and this suggests that Slc1p and Slc4p have a different substrate specificity or have access to different lyso-glycerophospholipid substrates because of a different subcellular location. Indeed, affinity-purified Slc1p displays Mg2+ - dependent acyltransferase activity not only toward lysophosphatidic acid but also lyso forms of phosphatidylserine and phosphatidylinositol. Thus, Slc1p and Slc4p may not only be active as 1-acylglycerol-3-phosphate O-acyltransferases but also be involved in fatty acid exchange at the sn-2position of mature glycerophospholipids.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Univ So Denmark, DK-5230 Odense M, Denmark	University of Fribourg; University of Southern Denmark	Conzelmann, A (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch		Benghezal, Mohammed/0000-0002-4207-0192				Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bosson R, 2006, MOL BIOL CELL, V17, P2636, DOI 10.1091/mbc.E06-02-0104; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Coon M, 2003, MOL CANCER THER, V2, P1067; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DEKROON AI, 2006, BIOCHIM BIOPHYS ACTA, V1771, P343; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Guan XL, 2006, YEAST, V23, P465, DOI 10.1002/yea.1362; HANSON BA, 1980, J LIPID RES, V21, P309; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Jansen G, 2005, GENE, V344, P43, DOI 10.1016/j.gene.2004.10.016; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; LEE KS, 1994, J BIOL CHEM, V269, P19725; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nebauer R, 2004, TOP CURR GENET, V6, P125; Noiriel A, 2004, EUR J BIOCHEM, V271, P3752, DOI 10.1111/j.1432-1033.2004.04317.x; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Waksman M, 1997, J BIOL CHEM, V272, P36; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200; Zou JT, 1997, PLANT CELL, V9, P909, DOI 10.1105/tpc.9.6.909	37	82	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30845	30855		10.1074/jbc.M702719200	http://dx.doi.org/10.1074/jbc.M702719200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17675291	Green Submitted, hybrid			2022-12-27	WOS:000250136300053
J	Hammel, M; Sfyroera, G; Pyrpassopoulos, S; Ricklin, D; Ramyar, KX; Pop, M; Jin, Z; Lambris, JD; Geisbrecht, BV				Hammel, Michal; Sfyroera, Georgia; Pyrpassopoulos, Serapion; Ricklin, Daniel; Ramyar, Kasra X.; Pop, Mihai; Jin, Zhongmin; Lambris, John D.; Geisbrecht, Brian V.			Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN-BINDING PROTEIN; CONFORMATIONAL-CHANGES; IMMUNE EVASION; COMPONENT C3; FACTOR-H; ACTIVATION; INNATE; PEPTIDOGLYCAN; RECOGNITION; COMPSTATIN	We report here the discovery and characterization of Ehp, a new secreted Staphylococcus aureus protein that potently inhibits the alternative complement activation pathway. Ehp was identified through a genomic scan as an uncharacterized secreted protein from S. aureus, and immunoblotting of conditioned S. aureus culture medium revealed that the Ehp protein was secreted at the highest levels during log-phase bacterial growth. The mature Ehp polypeptide is composed of 80 residues and is 44% identical to the complement inhibitory domain of S. aureus Efb ( extracellular fibrinogen-binding protein). We observed preferential binding by Ehp to native and hydrolyzed C3 relative to fully active C3b and found that Ehp formed a subnanomolar affinity complex with these various forms of C3 by binding to its thioester-containing C3d domain. Site-directed mutagenesis demonstrated that Arg(75) and Asn(82) are important in forming the Ehp.C3d complex, but loss of these side chains did not completely disrupt Ehp/C3dbinding. This suggested the presence of a second C3d-binding site in Ehp, which was mapped to the proximity of Ehp Asn(63). Further molecular level details of the Ehp/C3d interaction were revealed by solving the 2.7-angstrom crystal structure of an Ehp.C3d complex in which the low affinity site had been mutationally inactivated. Ehp potently inhibited C3b deposition onto sensitized surfaces by the alternative complement activation pathway. This inhibition was directly related to Ehp/C3d binding and was more potent than that seen for Efb-C. An altered conformation in Ehp-bound C3 was detected by monoclonal antibody C3-9, which is specific for a neoantigen exposed in activated forms of C3. Our results suggest that increased inhibitory potency of Ehp relative to Efb-C is derived from the second C3-binding site in this new protein.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19105 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA; Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA	University of Missouri System; University of Missouri Kansas City; University of Pennsylvania; Johns Hopkins University; University System of Maryland; University of Maryland College Park; United States Department of Energy (DOE); Argonne National Laboratory	Geisbrecht, BV (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, 5100 Rockhill Rd, Kansas City, MO 64110 USA.	GeisbrechtB@umkc.edu	Pop, Mihai/A-7987-2013; Pyrpassopoulos, Serapion/GWZ-1415-2022; Ricklin, Daniel/F-5104-2011; Lambris, John/Q-5633-2018	Pop, Mihai/0000-0001-9617-5304; Pyrpassopoulos, Serapion/0000-0002-9728-9239; Ricklin, Daniel/0000-0001-6140-0233; Lambris, John/0000-0002-9370-5776; Hammel, Michal/0000-0002-5610-9289	NIAID NIH HHS [AI30040] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins JN, 2002, MOL CELL PROTEOMICS, V1, P947, DOI 10.1074/mcp.M200066-MCP200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; BREDIUS RGM, 1992, INFECT IMMUN, V60, P4838, DOI 10.1128/IAI.60.11.4838-4847.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Geisbrecht BV, 2006, PROTEIN EXPRES PURIF, V46, P23, DOI 10.1016/j.pep.2005.09.003; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Guthridge JM, 2001, BIOCHEMISTRY-US, V40, P5931, DOI 10.1021/bi0101749; HACK CE, 1988, J IMMUNOL, V141, P1602; Hammel M, 2006, ACTA CRYSTALLOGR F, V62, P285, DOI 10.1107/S1744309106005926; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x; Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, J BIOL CHEM, V258, P4238; ISENMAN DE, 1981, MOL IMMUNOL, V18, P331, DOI 10.1016/0161-5890(81)90057-2; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419; KAWASAKI A, 1987, MICROBIOL IMMUNOL, V31, P551, DOI 10.1111/j.1348-0421.1987.tb03117.x; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Kraus D, 1998, INFECT IMMUN, V66, P399, DOI 10.1128/IAI.66.2.399-405.1998; Kronvall G, 1999, J MOL RECOGNIT, V12, P38, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<38::AID-JMR378>3.0.CO;2-Q; Lachmann PJ, 2002, P NATL ACAD SCI USA, V99, P8461, DOI 10.1073/pnas.132284499; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; Lee LYL, 2004, J INFECT DIS, V190, P571, DOI 10.1086/422259; Lee LYL, 2004, J BIOL CHEM, V279, P50710, DOI 10.1074/jbc.M408570200; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531; Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028; MORIKIS D, 2005, STRUCTURE DYNAMICS A; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Neth O, 2002, J IMMUNOL, V169, P4430, DOI 10.4049/jimmunol.169.8.4430; Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Rooijakkers SHM, 2005, TRENDS MICROBIOL, V13, P596, DOI 10.1016/j.tim.2005.10.002; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; Rooijakkers SHM, 2006, CELL MICROBIOL, V8, P1282, DOI 10.1111/j.1462-5822.2006.00709.x; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; SAKAR G, 1990, BIOTECHNIQUES, V8, P404; Sakiniene E, 1999, CLIN EXP IMMUNOL, V115, P95; SCHUHARD M, 2005, PROTEOMIC TECHNOLOGI; Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143; VERBRUGH HA, 1979, IMMUNOLOGY, V37, P615; WILKINSON BJ, 1978, INFECT IMMUN, V20, P388, DOI 10.1128/IAI.20.2.388-392.1978; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571; Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971	57	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30051	30061		10.1074/jbc.M704247200	http://dx.doi.org/10.1074/jbc.M704247200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699522	hybrid			2022-12-27	WOS:000249981200035
J	Petroski, MD; Zhou, XL; Dong, GQ; Daniel-Issakani, S; Payan, DG; Huang, JN				Petroski, Matthew D.; Zhou, Xiulan; Dong, GuoQiang; Daniel-Issakani, Sarkiz; Payan, Donald G.; Huang, Jianing			Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; POLYUBIQUITIN CHAIN; STRUCTURAL BASIS; DNA-REPAIR; COMPLEX; TRAF6; ACTIVATION; PROTEIN; LIGASE; DEGRADATION	Protein modification with lysine 63- linked ubiquitin chains has been implicated in the non- proteolytic regulation of signaling pathways. To understand the molecular mechanisms underlying this process, we have developed an in vitro system to examine the activity of the ubiquitin- conjugating enzyme UBC13- UEV1A with TRAF6 in which TRAF6 serves as both a ubiquitin ligase and substrate for modification. Although TRAF6 potently stimulates the activity of UBC13- UEV1A to synthesize ubiquitin chains, it is not appreciably ubiquitinated. We have determined that the presentation of Lys(63) of ubiquitin by UEV1A suppresses TRAF6 modification. Based on our observations, we propose that the modification of proteins with Lys(63)- linked ubiquitin chains occurs through a UEV1A- independent substrate modification and UEV1A- dependent Lys(63)- linked ubiquitin chain synthesis mechanism.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA		Petroski, MD (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	matt.petroski@yahoo.com						Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Brzovic PS, 2006, CELL CYCLE, V5, P2867, DOI 10.4161/cc.5.24.3592; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Pastushok L, 2005, J BIOL CHEM, V280, P17891, DOI 10.1074/jbc.M410469200; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rodrigo-Brenni MC, 2007, CELL, V130, P127, DOI 10.1016/j.cell.2007.05.027; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038	28	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29936	29945		10.1074/jbc.M703911200	http://dx.doi.org/10.1074/jbc.M703911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709375	hybrid			2022-12-27	WOS:000249981200023
J	Sum, CS; Tikhonova, IG; Neumann, S; Engel, S; Raaka, BM; Costanzi, S; Gershengorn, MC				Sum, Chi Shing; Tikhonova, Irina G.; Neumann, Susanne; Engel, Stanislav; Raaka, Bruce M.; Costanzi, Stefano; Gershengorn, Marvin C.			Identification of residues important for agonist recognition and activation in GPR40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR GPR40; PANCREATIC BETA-CELLS; INSULIN-SECRETION; CRYSTAL-STRUCTURE; FATTY-ACIDS; BINDING	GPR40 was formerly an orphan G protein-coupled receptor whose endogenous ligands have recently been identified as free fatty acids (FFAs). The receptor, now named FFA receptor 1, has been implicated in the pathophysiology of type 2 diabetes and is a drug target because of its role in FFA-mediated enhancement of glucose-stimulated insulin release. Guided by molecular modeling, we investigated the molecular determinants contributing to binding of linoleic acid, a C18 polyunsaturated FFA, and GW9508, a synthetic small molecule agonist. Twelve residues within the putative GPR40-binding pocket including hydrophilic/positively charged, aromatic, and hydrophobic residues were identified and were subjected to site-directed mutagenesis. Our results suggest that linoleic acid and GW9508 are anchored on their carboxylate groups by Arg183, Asn244, and Arg258. Moreover, His86, Tyr91, and His137 may contribute to aromatic and/or hydrophobic interactions with GW9508 that are not present, or relatively weak, with linoleic acid. The anchor residues, as well as the residues Tyr12, Tyr91, His137, and Leu186, appear to be important for receptor activation also. Interestingly, His137 and particularly His86 may interact with GW9508 in a manner dependent on its protonation status. The greater number of putative interactions between GPR40 and GW9508 compared with linoleic acid may explain the higher potency of GW9508.	NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biol Modelling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), 50 South Dr,Rm 4134, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov	Costanzi, Stefano/G-8990-2013; Neumann, Susanne/GPK-6035-2022; Engel, Stanislav/G-2799-2013	Engel, Stanislav/0000-0001-5916-5190; Costanzi, Stefano/0000-0003-3183-7332	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006, ZIADK013025, Z01DK011006, Z01DK047045, Z01DK013025] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2005, DNA CELL BIOL, V24, P54, DOI 10.1089/dna.2005.24.54; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Feng DD, 2006, ENDOCRINOLOGY, V147, P674, DOI 10.1210/en.2005-0225; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Fujiwara K, 2005, AM J PHYSIOL-ENDOC M, V289, pE670, DOI 10.1152/ajpendo.00035.2005; Garrido DM, 2006, BIOORG MED CHEM LETT, V16, P1840, DOI 10.1016/j.bmcl.2006.01.007; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jaschke H, 2006, J BIOL CHEM, V281, P9841, DOI 10.1074/jbc.C600014200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Latour MG, 2007, DIABETES, V56, P1087, DOI 10.2337/db06-1532; *LLC, 2005, MACR; McKeown SC, 2007, BIOORG MED CHEM LETT, V17, P1584, DOI 10.1016/j.bmcl.2006.12.084; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nolan CJ, 2006, DIABETES, V55, pS16, DOI 10.2337/db06-S003; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Poitout V, 2003, TRENDS ENDOCRIN MET, V14, P201, DOI 10.1016/S1043-2760(03)00086-9; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Shapiro H, 2005, BIOCHEM BIOPH RES CO, V335, P97, DOI 10.1016/j.bbrc.2005.07.042; Song FB, 2007, J MED CHEM, V50, P2807, DOI 10.1021/jm070130j; Steneberg R, 2005, CELL METAB, V1, P245, DOI 10.1016/j.cmet.2005.03.007; Stoddart LA, 2007, MOL PHARMACOL, V71, P994, DOI 10.1124/mol.106.031534; Surgand JS, 2006, PROTEINS, V62, P509, DOI 10.1002/prot.20768; Tikhonova IG, 2007, J MED CHEM, V50, P2981, DOI 10.1021/jm0614782; *TRIPOS ASS INC, 2006, SYBYL	29	95	101	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29248	29255		10.1074/jbc.M705077200	http://dx.doi.org/10.1074/jbc.M705077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699519	hybrid			2022-12-27	WOS:000249788000021
J	Lee, C; Kramer, G; Graham, DE; Appling, DR				Lee, Changkeun; Kramer, Gisela; Graham, David E.; Appling, Dean R.			Yeast mitochondrial initiator tRNA is methylated at guanosine 37 by the Trm5-encoded tRNA (guanine-N1-)-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C-1-TETRAHYDROFOLATE SYNTHASE; MESSENGER-RNAS; METHYLTRANSFERASE; TRANSLATION; GENE; PROTEIN; DNA; IDENTIFICATION; MECHANISM	The TRM5 gene encodes a tRNA (guanine-N1-)-methyttransferase (Trm5p) that methylates guanosine at position 37 (m(1)G37) in cytoplasmic tRNAs in Saccharomyces cerevisiae. Here we show that Trm5p is also responsible for m(1)G37 methylation of mitochondrial tRNAs. The TRMS open reading frame encodes 499 amino acids containing four potential initiator codons within the first 48 codons. Full-length Trm5p, purified as a fusion protein with maltose-binding protein, exhibited robust methyltransferase activity with tRNA isolated from a Delta trm5 mutant strain, as well as with a synthetic mitochondrial initiator tRNA (tRNA(f)(Met)). Primer extension demonstrated that the site of methylation was guanosine 37 in both mitochondrial tRNA(f)(Met) and tRNA(Ph). High pressure liquid chromatography analysis showed the methylated product to be m(1)G. Subcellular fractionation and immunoblotting of a strain expressing a green fluorescent protein-tagged version of the TRMS gene revealed that the enzyme was localized to both cytoplasm and mitochondria. The slightly larger mitochondrial form was protected from protease digestion, indicating a matrix localization. Analysis of N-terminal truncation mutants revealed that a Trm5p active in the cytoplasm could be obtained with a construct lacking amino acids 1-33 (Delta 1-33), whereas production of a Trm5p active in the mitochondria required these first 33 amino acids. Yeast expressing the Delta 1-33 construct exhibited a significantly lower rate of oxygen consumption, indicating that efficiency or accuracy of mitochondrial protein synthesis is decreased in cells lacking m(1)G37 methylation of mitochondrial tRNAs. These data suggest that this tRNA modification plays an important role in reading frame maintenance in mitochondrial protein synthesis.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	dappling@mail.utexas.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				BJORK GR, 1989, SCIENCE, V244, P986, DOI 10.1126/science.2471265; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; BROOM AD, 1964, BIOCHEMISTRY-US, V3, P494, DOI 10.1021/bi00892a005; Brule H, 2004, BIOCHEMISTRY-US, V43, P9243, DOI 10.1021/bi049671q; CANADAY J, 1980, NUCLEIC ACIDS RES, V8, P1445, DOI 10.1093/nar/8.7.1445; Chan SY, 2003, J BIOL CHEM, V278, P43051, DOI 10.1074/jbc.M308696200; Chang KJ, 2006, J BIOL CHEM, V281, P7775, DOI 10.1074/jbc.M511265200; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; Christian T, 2004, J MOL BIOL, V339, P707, DOI 10.1016/j.jmb.2004.04.025; CIGAN AM, 1987, GENE, V59, P1; DAUM G, 1982, J BIOL CHEM, V257, P3028; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Dunin-Horkawicz S, 2006, NUCLEIC ACIDS RES, V34, pD145, DOI 10.1093/nar/gkj084; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Garcia M, 2007, MOL BIOL CELL, V18, P362, DOI 10.1091/mbc.E06-09-0827; Graham DE, 2007, METHOD ENZYMOL, V425, P185; Hiley SL, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni002; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hou YM, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj018; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jackman JE, 2003, RNA, V9, P574, DOI 10.1261/rna.5070303; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li MZ, 2007, NAT METHODS, V4, P251, DOI 10.1038/NMETH1010; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MARTIN RP, 1978, NUCLEIC ACIDS RES, V5, P4579, DOI 10.1093/nar/5.12.4579; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; SIKORSKI RS, 1989, GENETICS, V122, P19; SINDHUPHAK T, 1985, BIOCHIM BIOPHYS ACTA, V824, P66, DOI 10.1016/0167-4781(85)90030-2; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SMITH JD, 1959, BIOCHEM J, V72, P294, DOI 10.1042/bj0720294; SMOLAR N, 1975, NUCLEIC ACIDS RES, V2, P993, DOI 10.1093/nar/2.6.993; Spencer AC, 2004, BIOCHEMISTRY-US, V43, P9743, DOI 10.1021/bi049639w; Takeda H, 2006, GENES CELLS, V11, P1353, DOI 10.1111/j.1365-2443.2006.01022.x; THOMAS RC, 1982, INTRACELLULAR PH ITS, P189; Tibbetts AS, 2003, J BIOL CHEM, V278, P31774, DOI 10.1074/jbc.M304962200; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Walkup AS, 2005, ARCH BIOCHEM BIOPHYS, V442, P196, DOI 10.1016/j.abb.2005.08.007; WOLFE CL, 1994, J BIOL CHEM, V269, P13361	44	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27744	27753		10.1074/jbc.M704572200	http://dx.doi.org/10.1074/jbc.M704572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652090	hybrid			2022-12-27	WOS:000249455600023
J	Yamaguchi, Y; Brenner, M; Hearing, VJ				Yamaguchi, Yuji; Brenner, Michaela; Hearing, Vincent J.			The regulation of skin pigmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-DAMAGE; MASTER REGULATOR; MELANIN CONTENT; MELANOCYTES; MELANOSOME; EXPRESSION; TYROSINASE; GROWTH; CELL; PATHOGENESIS		NCI, Natl Inst Hlth, Cell Biol Lab, Bethesda, MD 20892 USA; Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka 5650871, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Osaka University	Hearing, VJ (corresponding author), Nagoya City Univ, Dept Geriatr & Environm Dermatol, Nagoya, Aichi 467, Japan.	hearingv@nih.gov	Yamaguchi, Yuji/X-6681-2019; Yamaguchi, Yuji/B-9312-2008	Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010786] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agar N, 2005, MUTAT RES-FUND MOL M, V571, P121, DOI 10.1016/j.mrfmmm.2004.11.016; Ando H, 2007, J INVEST DERMATOL, V127, P751, DOI 10.1038/sj.jid.5700683; Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chi A, 2006, J PROTEOME RES, V5, P3135, DOI 10.1021/pr060363j; Costin GE, 2007, FASEB J, V21, P976, DOI 10.1096/fj.06-6649rev; Coudrier E, 2007, PIGM CELL RES, V20, P153, DOI 10.1111/j.1600-0749.2007.00376.x; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 2000, PIGM CELL RES, V13, P94, DOI 10.1034/j.1600-0749.13.s8.17.x; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Hearing V. J., 2005, MELANOCYTE MELANOMA; Hennessy A, 2005, PIGM CELL RES, V18, P220, DOI 10.1111/j.1600-0749.2005.00233.x; Hornyak Thomas J, 2006, Adv Dermatol, V22, P201; Hu ZZ, 2007, INT J MASS SPECTROM, V259, P147, DOI 10.1016/j.ijms.2006.09.024; Huang Y, 2003, J CELL PHYSIOL, V194, P162, DOI 10.1002/jcp.10199; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Incerti B, 2000, HUM MOL GENET, V9, P2781, DOI 10.1093/hmg/9.19.2781; Ito S, 2003, PIGM CELL RES, V16, P230, DOI 10.1034/j.1600-0749.2003.00037.x; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; Kadekaro AL, 2006, FRONT BIOSCI-LANDMRK, V11, P2157, DOI 10.2741/1958; KING RA, 2001, METABOLIC MOL BASES, P5587; Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x; Landi MT, 2002, JNCI-J NATL CANCER I, V94, P94, DOI 10.1093/jnci/94.2.94; Lavado A, 2006, FRONT BIOSCI-LANDMRK, V11, P743, DOI 10.2741/1832; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li W, 2004, BIOESSAYS, V26, P616, DOI 10.1002/bies.20042; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P135, DOI 10.1562/2004-08-03-RA-259.1; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miyamura Y, 2007, PIGM CELL RES, V20, P2, DOI 10.1111/j.1600-0749.2006.00358.x; Rees JL, 2000, PIGM CELL RES, V13, P135, DOI 10.1034/j.1600-0749.2000.130303.x; Richmond B, 2005, J INVEST DERMATOL, V124, P420, DOI 10.1111/j.0022-202X.2004.23585.x; Robinson SJ, 2002, ONCOGENE, V21, P8037, DOI 10.1038/sj.onc.1205913; Rouzaud F, 2006, FASEB J, V20, P1927, DOI 10.1096/fj.06-5922fje; Sarna T, 2006, PIGMENTARY SYSTEM PH, P311; Scott G, 2001, J INVEST DERMATOL, V117, P1412, DOI 10.1046/j.0022-202x.2001.01575.x; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; Smith DR, 2004, EXP CELL RES, V298, P521, DOI 10.1016/j.yexcr.2004.04.033; Sturm RA, 2006, TRENDS GENET, V22, P464, DOI 10.1016/j.tig.2006.06.010; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Tobin DJ, 2005, J INVEST DERM SYMP P, V10, P275, DOI 10.1111/j.1087-0024.2005.10117.x; Wakamatsu K, 2006, PIGM CELL RES, V19, P154, DOI 10.1111/j.1600-0749.2006.00293.x; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WATABE H, 2007, IN PRESS J INVESTIG; Wu XF, 2000, PIGM CELL RES, V13, P241, DOI 10.1034/j.1600-0749.2000.130405.x; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; YAMAGUCHI Y, 2007, J INVEST DERMATOL, V127, P720; Yamaguchi Y, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P101, DOI 10.1007/978-1-59259-994-3_6; Yamaguchi Y, 2007, J INVEST DERMATOL, V127, P1217, DOI 10.1038/sj.jid.5700629; Yamaguchi Y, 2006, FASEB J, V20, P1486, DOI 10.1096/fj.06-5725fje; Young Antony R, 2006, Prog Biophys Mol Biol, V92, P80, DOI 10.1016/j.pbiomolbio.2006.02.005	56	307	331	1	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27557	27561		10.1074/jbc.R700026200	http://dx.doi.org/10.1074/jbc.R700026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635904	hybrid			2022-12-27	WOS:000249455600002
J	Almeida, M; Han, L; Martin-Millan, M; Plotkin, LI; Stewart, SA; Roberson, PK; Kousteni, S; O'Brien, CA; Bellido, T; Parfitt, AM; Weinstein, RS; Jilka, RL; Manolagas, SC				Almeida, Maria; Han, Li; Martin-Millan, Marta; Plotkin, Lilian I.; Stewart, Scott A.; Roberson, Paula K.; Kousteni, Stavroula; O'Brien, Charles A.; Bellido, Teresita; Parfitt, A. Michael; Weinstein, Robert S.; Jilka, Robert L.; Manolagas, Stavros C.			Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MURINE BONE-MARROW; ESTROGEN-DEFICIENCY; OSTEOBLAST DIFFERENTIATION; PLASMA ESTRADIOL; CELL APOPTOSIS; MICE; DENSITY; MASS; GLUCOCORTICOIDS	Both aging and loss of sex steroids have adverse effects on skeletal homeostasis, but whether and how they may influence each others negative impact on bone remains unknown. We report herein that both female and male C57BL/6 mice progressively lost strength (as determined by load-to-failure measurements) and bone mineral density in the spine and femur between the ages of 4 and 31 months. These changes were temporally associated with decreased rate of remodeling as evidenced by decreased osteoblast and osteoclast numbers and decreased bone formation rate; as well as increased osteoblast and osteocyte apoptosis, increased reactive oxygen species levels, and decreased glutathione reductase activity and a corresponding increase in the phosphorylation of p53 and p66(shc), two key components of a signaling cascade that are activated by reactive oxygen species and influences apoptosis and lifespan. Exactly the same changes in oxidative stress were acutely reproduced by gonadectomy in 5-month-old females or males and reversed by estrogens or androgens in vivo as well as in vitro. We conclude that the oxidative stress that underlies physiologic organismal aging in mice may be a pivotal pathogenetic mechanism of the age-related bone loss and strength. Loss of estrogens or androgens accelerates the effects of aging on bone by decreasing defense against oxidative stress.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA; Cent Arkansas Vet hlth Care Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), 4301 W Markham,587, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu	Plotkin, Lilian/H-7188-2019; O'Brien, Charles A./AAL-5078-2020	Plotkin, Lilian/0000-0002-9537-4544; Almeida, Maria/0000-0002-6722-9200; Warren, Aaron D./0000-0002-0042-9021	NIAMS NIH HHS [R01 AR053643-02, R01 AR053643, R01 AR049794, R01 AR053643-03, R01 AR053643-01A2, R01 AR046191, R01 AR051187, R01 AR053643-04] Funding Source: Medline; NIA NIH HHS [P01 AG013918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046191, R01AR049794, R01AR053643, R01AR051187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107; Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464; Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Almeida M, 2006, J BONE MINER RES, V21, pS95; Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; Baba T, 2005, J BIOL CHEM, V280, P16417, DOI 10.1074/jbc.M500924200; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Burr DB, 1998, J BIOMECH, V31, P337, DOI 10.1016/S0021-9290(98)00016-5; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; CHEN XD, 2007, IN PRESS J BONE MINE; Chiang K, 2004, LIFE SCI, V75, P2425, DOI 10.1016/j.lfs.2004.04.035; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Darblade B, 2002, CIRC RES, V90, P413, DOI 10.1161/hh0402.105096; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deroo BJ, 2004, ENDOCRINOLOGY, V145, P5485, DOI 10.1210/en.2004-0471; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Duan YB, 2003, J BONE MINER RES, V18, P1766, DOI 10.1359/jbmr.2003.18.10.1766; Duan YB, 1999, J BONE MINER RES, V14, P1796, DOI 10.1359/jbmr.1999.14.10.1796; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756-3282(03)00236-9; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Hurh YJ, 2004, J TOXICOL ENV HEAL A, V67, P1939, DOI 10.1080/15287390490514598; Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004-1058; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039; KLEEREKOPER M, 1985, CALCIFIED TISSUE INT, V37, P594, DOI 10.1007/BF02554913; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550-06; Kutner, 1990, APPL LINEAR STAT MOD; Lacombe A, 2006, P NATL ACAD SCI USA, V103, P3793, DOI 10.1073/pnas.0505827103; Lapointe JR, 2005, ENDOCRINOLOGY, V146, P2583, DOI 10.1210/en.2004-1373; Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004-1021; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Li XM, 2002, GENOMICS, V79, P734, DOI 10.1006/geno.2002.6760; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Manolagas S.C, 2006, BONEKEY OSTEOVISION, V3, P5, DOI DOI 10.1138/20060193; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2004, KIDNEY INT, V66, pS41, DOI 10.1111/j.1523-1755.2004.09107.x; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 1996, PRINCIPLES BONE BIOL; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mishra DP, 2005, J BIOL CHEM, V280, P6181, DOI 10.1074/jbc.M405970200; MOBBS CV, 1985, ENDOCRINOLOGY, V116, P813, DOI 10.1210/endo-116-2-813; Moor AN, 2004, EXP EYE RES, V78, P933, DOI 10.1016/j.exer.2004.01.001; NELSON JF, 1975, ACTA ENDOCRINOL-COP, V80, P744, DOI 10.1530/acta.0.0800744; NELSON JF, 1992, ENDOCRINOLOGY, V130, P805, DOI 10.1210/en.130.2.805; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Qiu SJ, 2003, J BONE MINER RES, V18, P1657, DOI 10.1359/jbmr.2003.18.9.1657; QUARRIE JK, 2004, SCI AGING KNOWLEDGE, pRE5; Quintanilla RA, 2005, J BIOL CHEM, V280, P11615, DOI 10.1074/jbc.M411936200; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003-030964; SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233; Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756-3282(97)00100-2; Smith RG, 2005, ENDOCR REV, V26, P203, DOI 10.1210/er.2002-0017; Sudoh N, 2001, CIRCULATION, V103, P724; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vanderschueren D, 2000, BONE, V27, P611, DOI 10.1016/S8756-3282(00)00363-X; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003-1133; Wergedal JE, 2005, BONE, V36, P111, DOI 10.1016/j.bone.2004.09.012; XI H, 1993, TOXICOL APPL PHARM, V120, P29, DOI 10.1006/taap.1993.1083; Yen CH, 2001, LIFE SCI, V70, P403, DOI 10.1016/S0024-3205(01)01486-2	82	478	498	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27285	27297		10.1074/jbc.M702810200	http://dx.doi.org/10.1074/jbc.M702810200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623659	Green Accepted, hybrid			2022-12-27	WOS:000249304900070
J	Drisdel, RC; Sharp, D; Henderson, T; Hales, TG; Green, WN				Drisdel, Renaldo C.; Sharp, Douglas; Henderson, Tricia; Hales, Tim G.; Green, William N.			High affinity binding of epibatidine to serotonin type 3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; 5-HT3 RECEPTORS; BLOOD-PRESSURE; FUNCTIONAL EXPRESSION; CHOLINERGIC-RECEPTORS; SUBUNIT ALTERS; POTENT AGONIST; UP-REGULATION; SPINAL-CORD; IN-VITRO	Epibatidine and mecamylamine are ligands used widely in the study of nicotinic acetylcholine receptors (nAChRs) in the central and peripheral nervous systems. In the present study, we find that nicotine blocks only 75% of I-125-epibatidine binding to rat brain membranes, whereas ligands specific for serotonin type 3 receptors (5-HT(3)Rs) block the remaining 25%. I-125-Epibatidine binds with a high affinity to native 5-HT(3)Rs of N1E-115 cells and to receptors composed of only 5-HT3A subunits expressed in HEK cells. In these cells, serotonin, the 5-HT3R-specific antagonist MDL72222, and the 5-HT3R agonist chlorophenylbiguanide readily competed with I-125-epibatidine binding to 5-HT(3)Rs. Nicotine was a poor competitor for I-125-epibatidine binding to 5-HT(3)Rs. However, the noncompetitive nAChR antagonist mecamylamine acted as a potent competitive inhibitor of I-125-epibatidine binding to 5-HT(3)Rs. Epibatidine inhibited serotonin-induced currents mediated by endogenous 5-HT(3)Rs in neuroblastoma cell lines and 5-HT(3)ARs expressed in HEK cells in a competitive manner. Our results demonstrate that 5-HT(3)Rs are previously uncharacterized high affinity epibatidine binding sites in the brain and indicate that epibatidine and mecamylamine act as 5-HT3R antagonists. Previous studies that depended on epibatidine and mecamylamine as nAChR-specific ligands, in particular studies of analgesic properties of epibatidine, may need to be reinterpreted with respect to the potential role of 5-HT(3)Rs.	[Drisdel, Renaldo C.; Green, William N.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Hales, Tim G.] George Washington Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20037 USA; [Sharp, Douglas; Henderson, Tricia; Hales, Tim G.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA	University of Chicago; George Washington University; George Washington University	Green, WN (corresponding author), Univ Chicago, Dept Neurol, 947 E 58th St, Chicago, IL 60637 USA.	wgreen@midway.uchicago.edu			NIDA NIH HHS [P50 DA005010, R01 DA 13602, DA 05010] Funding Source: Medline; NINDS NIH HHS [R01 NS 43782, R01 NS 32693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032693, R01NS043782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013602, P50DA005010] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; ALHAIDER AA, 1991, J NEUROSCI, V11, P1881; Ali Z, 1996, NEUROSCI LETT, V208, P203, DOI 10.1016/0304-3940(95)12600-7; Alkadhi KA, 2001, EXP BIOL MED, V226, P1024, DOI 10.1177/153537020122601109; ALKONDON M, 1995, J PHARMACOL EXP THER, V274, P771; Anuradha K., 2004, Indian Journal of Experimental Biology, V42, P368; BADIO B, 1994, MOL PHARMACOL, V45, P563; Bitner RS, 1998, J NEUROSCI, V18, P5426, DOI 10.1523/JNEUROSCI.18-14-05426.1998; BONHAUS DW, 1995, J PHARMACOL EXP THER, V272, P1199; Boyce S, 2000, PAIN, V85, P443, DOI 10.1016/S0304-3959(99)00303-6; Broad LM, 2002, EUR J PHARMACOL, V452, P137, DOI 10.1016/S0014-2999(02)02273-2; Buisson B, 2000, NEUROPHARMACOLOGY, V39, P2561, DOI 10.1016/S0028-3908(00)00158-1; Butt CM, 2004, J PHARMACOL EXP THER, V308, P591, DOI 10.1124/jpet.103.059758; Connolly CN, 2004, BIOCHEM SOC T, V32, P529, DOI 10.1042/BST0320529; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; Costall B, 2004, CNS NEUROL DISORD-DR, V3, P27, DOI 10.2174/1568007043482624; Cucchiaro G, 2005, J PHARMACOL EXP THER, V313, P389, DOI 10.1124/jpet.104.079368; Curzon P, 1998, J PHARMACOL EXP THER, V287, P847; DAMAJ MI, 1994, BRAIN RES, V664, P34, DOI 10.1016/0006-8993(94)91950-X; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; Davila-Garcia MI, 2003, J NEUROCHEM, V85, P1237, DOI 10.1046/j.1471-4159.2003.01774.x; DECKER MW, 1999, J PHYSL, V92, P221; Dobelis P, 2003, J PHARMACOL EXP THER, V306, P1159, DOI 10.1124/jpet.103.053066; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Eertmoed AL, 1998, METHOD ENZYMOL, V293, P564; Farber L, 2004, SCAND J RHEUMATOL, V33, P2, DOI 10.1080/03009740410006943; Ferezou I, 2002, J NEUROSCI, V22, P7389; Ferreira HS, 2004, BRAIN RES, V1028, P48, DOI 10.1016/j.brainres.2004.08.063; FISHER M, 1994, J PHARMACOL EXP THER, V270, P702; Gerges NZ, 2002, NEUROPHARMACOLOGY, V43, P1070, DOI 10.1016/S0028-3908(02)00283-6; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Gilbert SD, 2001, PAIN, V89, P159, DOI 10.1016/S0304-3959(00)00358-4; Gnadisch D, 1999, NEUROREPORT, V10, P1631; GRANT KA, 1994, ALCOHOL CLIN EXP RES, V18, P410, DOI 10.1111/j.1530-0277.1994.tb00034.x; Gurley DA, 1998, NEUROSCI LETT, V247, P107, DOI 10.1016/S0304-3940(98)00306-1; HOFFMAN WE, 1978, J PHARMACOL EXP THER, V206, P644; Holladay MW, 1998, J MED CHEM, V41, P407, DOI 10.1021/jm9706224; Hope AG, 1999, MOL PHARMACOL, V55, P1037, DOI 10.1124/mol.55.6.1037; HOUGHTLING RA, 1995, MOL PHARMACOL, V48, P280; IWAMOTO ET, 1993, J PHARMACOL EXP THER, V265, P777; Khan IM, 1998, NEUROPHARMACOLOGY, V37, P1515, DOI 10.1016/S0028-3908(98)00143-9; LAMBERT JJ, 1989, BRIT J PHARMACOL, V97, P27, DOI 10.1111/j.1476-5381.1989.tb11920.x; Lawand NB, 1999, PAIN, V80, P291, DOI 10.1016/S0304-3959(98)00221-8; Lecchi M, 2005, EUR J NEUROSCI, V21, P3182, DOI 10.1111/j.1460-9568.2005.04150.x; LUMMIS SC, 1990, EUR J PHARMACOL, V189, P22; Machu TK, 2001, J PHARMACOL EXP THER, V299, P1112; Macor JE, 2001, BIOORG MED CHEM LETT, V11, P319, DOI 10.1016/S0960-894X(00)00670-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Marks MJ, 2006, MOL PHARMACOL, V70, P947, DOI 10.1124/mol.106.025338; McCallum S, 2006, PSYCHOPHARMACOLOGY, V184, P314, DOI 10.1007/s00213-005-0076-6; Moore KA, 2002, J APPL PHYSIOL, V92, P2529, DOI 10.1152/japplphysiol.00974.2001; Oortgiesen M, 1997, BRAIN RES, V747, P1, DOI 10.1016/S0006-8993(96)01200-0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Parker SL, 2004, MOL PHARMACOL, V65, P611, DOI 10.1124/mol.65.3.611; Radek RJ, 2004, BRAIN RES BULL, V64, P323, DOI 10.1016/j.brainresbull.2004.08.005; Rashid MH, 2006, PAIN, V125, P125, DOI 10.1016/j.pain.2006.05.011; Rashid MH, 2002, BRAIN RES, V953, P53, DOI 10.1016/S0006-8993(02)03270-5; Reeves DC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-27; Sacaan AI, 1996, J PHARMACOL EXP THER, V276, P509; SAXENA PR, 1990, J CARDIOVASC PHARM, V15, pS17, DOI 10.1097/00005344-199001001-00004; SEPULVEDA MI, 1994, NEUROPHARMACOLOGY, V33, P493, DOI 10.1016/0028-3908(94)90080-9; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; Stewart A, 2003, NEUROPHARMACOLOGY, V44, P214, DOI 10.1016/S0028-3908(02)00376-3; Stitzel JA, 2000, J PHARMACOL EXP THER, V293, P67; SULLIVAN JP, 1994, J PHARMACOL EXP THER, V271, P624; TSENG CJ, 1993, J PHARMACOL EXP THER, V265, P1511; Ulrich YM, 1997, NEUROPHARMACOLOGY, V36, P1119, DOI 10.1016/S0028-3908(97)00107-X; Wada Y, 1997, BRAIN RES, V759, P313, DOI 10.1016/S0006-8993(97)00366-1; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; Whiteaker P, 2000, BRIT J PHARMACOL, V131, P729, DOI 10.1038/sj.bjp.0703616; Young JM, 2001, CLIN THER, V23, P532, DOI 10.1016/S0149-2918(01)80059-X; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002; ZHANG L, 1995, NEUROREPORT, V6, P1464, DOI 10.1097/00001756-199507100-00025	73	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2008	283	15					9659	9665		10.1074/jbc.M703672200	http://dx.doi.org/10.1074/jbc.M703672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283YE	17702741	Green Published, hybrid			2022-12-27	WOS:000254671600020
J	Singleton, PA; Salgia, R; Moreno-Vinasco, L; Moitra, J; Sammani, S; Mirzapoiazova, T; Garcia, JGN				Singleton, Patrick A.; Salgia, Ravi; Moreno-Vinasco, Liliana; Moitra, Jaideep; Sammani, Saad; Mirzapoiazova, Tamara; Garcia, Joe G. N.			CD44 regulates hepatocyte growth factor-mediated vascular integrity - Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SIGNAL-TRANSDUCTION; CELL BARRIER ENHANCEMENT; NA+/H+ EXCHANGER NHE1; LIGHT-CHAIN KINASE; ACUTE LUNG INJURY; SPHINGOSINE 1-PHOSPHATE; MARCKS FAMILY; HYALURONAN-CD44 INTERACTION; CYTOSKELETAL REARRANGEMENT; RHO	The preservation of vascular endothelial cell ( EC) barrier integrity is critical to normal vessel homeostasis, with barrier dysfunction being a feature of inflammation, tumor angiogenesis, atherosclerosis, and acute lung injury. Therefore, agents that preserve or restore vascular integrity have important therapeutic implications. In this study, we explored the regulation of hepatocyte growth factor ( HGF)-mediated enhancement of EC barrier function via CD44 isoforms. We observed that HGF promoted c-Met association with CD44v10 and recruitment of c-Met into caveolin-enriched microdomains ( CEM) containing CD44s ( standard form). Treatment of EC with CD44v10-blocking antibodies inhibited HGF-mediated c-Met phosphorylation and c-Met recruitment to CEM. Silencing CD44 expression ( small interfering RNA) attenuated HGF-induced recruitment of c-Met, Tiam1 ( a Rac1 exchange factor), cortactin ( an actin cytoskeletal regulator), and dynamin 2 ( a vesicular regulator) to CEM as well as HGF-induced trans-EC electrical resistance. In addition, silencing Tiam1 or dynamin 2 reduced HGF-induced Rac1 activation, cortactin recruitment to CEM, and EC barrier regulation. We observed that both HGF- and high molecular weight hyaluronan ( CD44 ligand)-mediated protection from lipopolysaccharide-induced pulmonary vascular hyperpermeability was significantly reduced in CD44 knock-out mice, thus validating these in vitro findings in an in vivo murine model of inflammatory lung injury. Taken together, these results suggest that CD44 is an important regulator of HGF/c-Met-mediated in vitro and in vivo barrier enhancement, a process with essential involvement of Tiam1, Rac1, dynamin 2, and cortactin.	Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA	University of Chicago	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,W604, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [F32 HL68472, HL58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, F32HL068472] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; Bannerman DD, 1999, LAB INVEST, V79, P1181; Baumgartner M, 2004, AM J PHYSIOL-CELL PH, V287, pC844, DOI 10.1152/ajpcell.00094.2004; Bourguignon LYW, 2006, J INVEST DERMATOL, V126, P1356, DOI 10.1038/sj.jid.5700260; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cetin S, 2004, SURGERY, V136, P375, DOI 10.1016/j.surg.2004.05.013; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Gee K, 2004, ARCH IMMUNOL THER EX, V52, P13; GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022; Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21; Hippenstiel S, 2000, BLOOD, V95, P3044; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Ilangumaran S, 1998, BLOOD, V91, P3901; Jacobson JR, 2006, AM J PHYSIOL-LUNG C, V291, pL289, DOI 10.1152/ajplung.00343.2005; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kermorgant S, 2005, CELL CYCLE, V4, P352, DOI 10.4161/cc.4.3.1519; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Luscher TF, 1997, CLIN CARDIOL, V20, P3; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Marhaba R, 2004, J MOL HISTOL, V35, P211; Matsubara M, 2005, SEIKAGAKU, V77, P50; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Moriez R, 2005, AM J PATHOL, V167, P1071, DOI 10.1016/S0002-9440(10)61196-0; Noma K, 2006, AM J PHYSIOL-CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; PEARSON JD, 1991, RADIOLOGY, V179, P9, DOI 10.1148/radiology.179.1.2006310; Pedersen SF, 2006, PFLUG ARCH EUR J PHY, V452, P249, DOI 10.1007/s00424-006-0044-y; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Selbach M, 2005, TRENDS MICROBIOL, V13, P181, DOI 10.1016/j.tim.2005.02.007; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Su X, 2004, INTENS CARE MED, V30, P133, DOI 10.1007/s00134-003-2001-y; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Taher TEI, 1999, CURR TOP MICROBIOL, V246, P31; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tasaka S, 2005, AM J RESP CELL MOL, V32, P504, DOI 10.1165/rcmb.2004-0009OC; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Trent MS, 2006, J ENDOTOXIN RES, V12, P205, DOI 10.1179/096805106X118825; Triantafilou M, 2005, J ENDOTOXIN RES, V11, P5, DOI 10.1179/096805105225006641; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzircotis G, 2006, ONCOGENE, V25, P7401, DOI 10.1038/sj.onc.1209724; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Yao Q, 2005, J MOL BIOL, V348, P491, DOI 10.1016/j.jmb.2005.02.003; Zhao Y, 2000, J CELL BIOCHEM, V79, P496, DOI 10.1002/1097-4644(20001201)79:3<496::AID-JCB140>3.0.CO;2-5	78	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30643	30657		10.1074/jbc.M702573200	http://dx.doi.org/10.1074/jbc.M702573200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17702746	hybrid			2022-12-27	WOS:000250136300032
J	Niknejad, N; Morley, M; Dimitroulakos, J				Niknejad, Nima; Morley, Melissa; Dimitroulakos, Jim			Activation of the integrated stress response regulates lovastatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; SQUAMOUS-CELL CARCINOMAS; HMG-COA REDUCTASE; PHASE-I; TRANSLATIONAL CONTROL; MEVALONATE PATHWAY; 26S PROTEASOMES; ER STRESS	Lovastatin, a potent inhibitor of mevalonate synthesis, can readily induce apoptosis in a subset of human tumor types including head and neck squamous cell carcinomas (HNSCC). We recently identified activation of transcription factor (ATF) 4 as a lovastatin induced gene in HNSCC cells. ATF4 plays a significant role in regulating cellular responses to a wide variety of stress inducers known as the integrated stress response (ISR). These cell stresses lead to the phosphorylation of eukaryotic initiation factor (eIF) 2 alpha shutting down global protein translation. However, the translation of ATF4 is enhanced. In this study, lovastatin treatment induced eIF2 alpha phosphorylation and inhibited global protein translation. ATF4 expression was induced followed by increased ATF3 andCHOPexpression, targets of ATF4 activity, in SCC25 HNSCC cells. In CHOP (-)/(-) murine embryonic fibroblasts (MEFs), lovastatin- induced apoptosis was attenuated indicating a role for CHOP in this response. Furthermore, the eIF2 alpha kinase GCN2 mediates lovastatin induction of ATF4 and lovastatin- induced apoptosis was also attenuated in GCN2 (-)/(-) MEFs. The pro- drug version of lovastatin has potential proteasome inhibitory activity and recently a variety of well established proteasome inhibitors were shown to activate the ISR. In this study, neither the pro- drug nor the active forms of lovastatin had any significant effect on proteasome activity. Therefore, lovastatin, by targeting mevalonate synthesis, is a potent inducer of the ISR through a novel and as yet unrecognized mechanism.	Univ Ottawa, Ctr Canc Therapeut, Ottawa Reg Canc Ctr, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Dimitroulakos, J (corresponding author), Univ Ottawa, Ctr Canc Therapeut, Ottawa Reg Canc Ctr, Ottawa Hlth Res Inst, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 8L6, Canada.	jdimitroulakos@ohri.ca	Dimitroulakos, Jim/AAK-3398-2020					Alvarez C, 1999, EUR J CELL BIOL, V78, P1; Bence NF, 2005, METHOD ENZYMOL, V399, P481, DOI 10.1016/S0076-6879(05)99033-2; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005; Ishii Y, 2007, ANTI-CANCER AGENT ME, V7, P359, DOI 10.2174/187152007780618180; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; Knox JJ, 2005, EUR J CANCER, V41, P523, DOI 10.1016/j.ejca.2004.12.013; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Liang SH, 2006, BIOCHEM J, V393, P201, DOI 10.1042/BJ20050374; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; Sood R, 2000, GENETICS, V154, P787; Stangl K, 2002, BIOCHEM BIOPH RES CO, V291, P542, DOI 10.1006/bbrc.2002.6476; Thibault A, 1996, CLIN CANCER RES, V2, P483; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29748	29756		10.1074/jbc.M705859200	http://dx.doi.org/10.1074/jbc.M705859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699156	hybrid			2022-12-27	WOS:000249981200003
J	Zhang, HM; Im, SC; Waskell, L				Zhang, Haoming; Im, Sang-Choul; Waskell, Lucy			Cytochrome b(5) increases the rate of product formation by cytochrome p450 2B4 and competes with cytochrome p450 reductase for a binding site on cytochrome p450 2B4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ELECTRON-TRANSFER; P450 REDUCTASE; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; SPECTRAL CHARACTERIZATION; PROTEIN INTERACTIONS; NADPH; OXIDATION; COMPLEX	The kinetics of product formation by cytochrome P450 2B4 were compared in the presence of cytochrome b(5) ( cyt b(5)) and NADPH- cyt P450 reductase ( CPR) under conditions in which cytochrome P450 ( cyt P450) underwent a single catalytic cycle with two substrates, benzphetamine and cyclohexane. At a cyt P450: cyt b(5) molar ratio of 1: 1 under single turnover conditions, cyt P450 2B4 catalyzes the oxidation of the substrates, benzphetamine and cyclohexane, with rate constants of 18 +/- 2 and 29 +/- 4.5 s(-1), respectively. Approximately 500 pmol of norbenzphetamine and 58 pmol of cyclohexanol were formed per nmol of cyt P450. In marked contrast, at a cyt P450: CPR molar ratio of 1: 1, cyt P450 2B4 catalyzes the oxidation of benzphetamine congruent to 100- fold (k =0.15 +/- 0.05 s (-1)) and cyclohexane congruent to 10- fold ( k = 2.5 +/- 0.35 s(-1)) more slowly. Four hundred picomoles of norbenzphetamine and 21 pmol of cyclohexanol were formed per nmol of cyt P450. In the presence of equimolar concentrations of cyt P450, cyt b(5), and CPR, product formation is biphasic and occurs with fast and slow rate constants characteristic of catalysis by cyt b(5) and CPR. Increasing the concentration of cyt b5 enhanced the amount of product formed by cyt b(5) while decreasing the amount of product generated by CPR. Under steady- state conditions at all cyt b5: cyt P450 molar ratios examined, cyt b(5) inhibits the rate of NADPH consumption. Nevertheless, at low cyt b(5): cyt P450 molar ratios <= 1: 1, the rate of metabolism of cyclohexane and benzphetamine is enhanced, whereas at higher cyt b(5): cyt P450 molar ratios, cyt b(5) progressively inhibits both NADPH consumption and the rate of metabolism. It is proposed that the ability of cyt b(5) to enhance substrate metabolism by cyt P450 is related to its ability to increase the rate of catalysis and that the inhibitory properties of cyt b(5) are because of its ability to occupy the reductase- binding site on cyt P450 2B4, thereby preventing reduction of ferric cyt P450 and initiation of the catalytic cycle. It is proposed that cyt b(5) and CPR compete for a binding site on cyt P450 2B4.	Univ Michigan, Sch Med, Dept Anesthesiol, Res Serv, Ann Arbor, MI 48105 USA; Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Waskell, L (corresponding author), Univ Michigan, Sch Med, Dept Anesthesiol, Res Serv, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	waskell@umich.edu	Zhang, Haoming/AAE-3749-2020	Zhang, Haoming/0000-0002-8765-4394	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; BACKES WL, 1988, J BIOL CHEM, V263, P247; BHATTACHARYYA AK, 1991, BIOCHEMISTRY-US, V30, P759, DOI 10.1021/bi00217a027; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BOSTERLING B, 1982, J BIOL CHEM, V257, P4375; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Estabrook R W, 1978, Methods Enzymol, V52, P212; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; Guengerich FP, 2005, ARCH BIOCHEM BIOPHYS, V440, P204, DOI 10.1016/j.abb.2005.06.019; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Ivanov YD, 1999, ARCH BIOCHEM BIOPHYS, V362, P87, DOI 10.1006/abbi.1998.0981; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Loughran PA, 2000, BIOCHEMISTRY-US, V39, P15110, DOI 10.1021/bi001522u; Loughran PA, 2001, ARCH BIOCHEM BIOPHYS, V385, P311, DOI 10.1006/abbi.2000.2136; MIWA GT, 1979, J BIOL CHEM, V254, P5695; Mokashi V, 2003, ARCH BIOCHEM BIOPHYS, V412, P147, DOI 10.1016/S0003-9861(03)00040-7; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; OMURA T, 1964, J BIOL CHEM, V239, P2379; OPRIAN DD, 1982, J BIOL CHEM, V257, P8935; POMPON D, 1984, J BIOL CHEM, V259, P5377; Porter TD, 2002, J BIOCHEM MOL TOXIC, V16, P311, DOI 10.1002/jbt.10052; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shimada T, 2005, ARCH BIOCHEM BIOPHYS, V435, P207, DOI 10.1016/j.abb.2004.12.008; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; VELICK SF, 1956, J BIOL CHEM, V221, P265; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Yamaori S, 2003, BIOCHEM PHARMACOL, V66, P2333, DOI 10.1016/j.bcp.2003.08.004; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Zhang HM, 2003, BIOCHEMISTRY-US, V42, P11594, DOI 10.1021/bi034968u; Zhang HM, 2005, BIOCHEM BIOPH RES CO, V338, P499, DOI 10.1016/j.bbrc.2005.09.022	43	75	79	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29766	29776		10.1074/jbc.M703845200	http://dx.doi.org/10.1074/jbc.M703845200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693640	hybrid			2022-12-27	WOS:000249981200005
J	Mani, AR; Ippolito, S; Moreno, JC; Visser, TJ; Moore, KP				Mani, Ali R.; Ippolito, Silvia; Moreno, Jose C.; Visser, Theo J.; Moore, Kevin P.			The metabolism and dechlorination of chlorotyrosine in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; MYELOPEROXIDASE-CATALYZED OXIDATION; TYROSINE NITRATION; DEFICIENT MICE; HUMAN PLASMA; NITROTYROSINE; PROTEINS; CHLORINATION; SITE; 3-CHLOROTYROSINE	During inflammation, neutrophil- and monocyte-derived myeloperoxidase catalyzes the formation of hypochlorous acid, which can chlorinate tyrosine residues in proteins to form chlorotyrosine. However, little is known of the metabolism and disposition of chlorotyrosine in vivo. Following infusion of deuterium-labeled [D-4] chlorotyrosine into Sprague-Dawley rats, the major urinary metabolites were identified by mass spectrometry. 3-chloro-4-hydroxyphenylacetic acid was identified as the major chlorinated metabolite of chlorotyrosine and accounted for 3.6 +/- 0.3% of infused [D-4] chlorotyrosine. The striking observation was that similar to 40% ( 39 +/- 1%) of infused [D-4] chlorotyrosine was dechlorinated and excreted in the urine as deuterated 4-hydroxyphenylacetic acid, a major metabolite of tyrosine. 1.1 +/- 0.1% of infused [D-4] chlorotyrosine was excreted as [D-4] tyrosine. To determine whether protein-bound chlorotyrosine could undergo dechlorination, chlorinated albumin was incubated with liver homogenate from mutant rats, which did not synthesize albumin. There was similar to 20% decrease in the chlorotyrosine content over 1 h. This study is the first to describe the dechlorination of chlorotyrosine as the major metabolic pathway to eliminate this modified amino acid in vivo.	UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2PF, England; Erasmus Univ, Ctr Med, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands	University of London; University College London; UCL Medical School; Erasmus University Rotterdam	Moore, KP (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Med, Rowland Hill St, London NW3 2PF, England.	kmoore@medsch.ucl.ac.uk	Visser, Theo J/C-8059-2013; Mani, Alireza/H-3236-2015	Visser, Theo J/0000-0002-6997-284X; Mani, Alireza/0000-0003-0830-2022; Moreno, Jose C./0000-0001-5664-5308	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Baldus S, 2001, J CLIN INVEST, V108, P1759; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; COLE JR, 1994, APPL ENVIRON MICROB, V60, P3536, DOI 10.1128/AEM.60.10.3536-3542.1994; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Faleev NG, 2003, BBA-PROTEINS PROTEOM, V1647, P260, DOI 10.1016/S1570-9639(03)00063-3; FELL V, 1978, CLIN CHIM ACTA, V83, P259, DOI 10.1016/0009-8981(78)90114-6; Frost MT, 2000, BIOCHEM J, V345, P453, DOI 10.1042/0264-6021:3450453; Garner CE, 2006, TOXICOL APPL PHARM, V215, P23, DOI 10.1016/j.taap.2006.01.010; Gaut JP, 2002, ANAL BIOCHEM, V300, P252, DOI 10.1006/abio.2001.5469; Gnidehou S, 2004, FASEB J, V18, P1574, DOI 10.1096/fj.04-2023fje; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Irie Y, 2003, P NATL ACAD SCI USA, V100, P5634, DOI 10.1073/pnas.1131756100; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; KAY RR, 1993, P NATL ACAD SCI USA, V90, P487, DOI 10.1073/pnas.90.2.487; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mani AR, 2003, BIOCHEM J, V374, P521, DOI 10.1042/BJ20030670; Mavri-Damelin Demetra, 2007, Int J Biochem Cell Biol, V39, P555, DOI 10.1016/j.biocel.2006.10.007; Moreno JC, 2003, HORM RES, V60, P96, DOI 10.1159/000074509; Moreno JC, 2006, HORM RES, V65, P31; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Quensen JF, 1998, SCIENCE, V280, P722, DOI 10.1126/science.280.5364.722; ROCHE J, 1952, BIOCHIM BIOPHYS ACTA, V9, P161, DOI 10.1016/0006-3002(52)90143-1; Shao BH, 2006, J BIOL CHEM, V281, P9001, DOI 10.1074/jbc.C600011200; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Sun BL, 2002, SCIENCE, V298, P1023, DOI 10.1126/science.1074675; Valverde-R C, 2004, INT REV CYTOL, V234, P143, DOI 10.1016/S0074-7696(04)34004-0; Wilkening S, 2003, DRUG METAB DISPOS, V31, P1035, DOI 10.1124/dmd.31.8.1035; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	35	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29114	29121		10.1074/jbc.M704270200	http://dx.doi.org/10.1074/jbc.M704270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17686770	hybrid			2022-12-27	WOS:000249788000006
J	Davis, JA; Handford, PA; Redfield, C				Davis, Jason A.; Handford, Penny A.; Redfield, Christina			The N1317H substitution associated with Leber congenital amaurosis results in impaired interdomain packing in human CRB1 epidermal growth factor-like (EGF) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULES; CALCIUM-BINDING; HUMAN FIBRILLIN-1; RETINITIS-PIGMENTOSA; DROSOPHILA-CRUMBS; RETINAL DYSTROPHIES; MOLECULAR-GENETICS; MARFAN-SYNDROME; CHICK RETINA; FACTOR-IX	The calcium-binding epidermal growth factor-like (cbEGF) domain is a widely occurring module in proteins of diverse function. Amino acid substitutions that disrupt its structure or calcium affinity have been associated with various disorders. The extracellular portion of CRB1, the human homologue of Drosophila Crumbs, exhibits a modular domain organization that includes EGF and cbEGF domains. The N1317H substitution in the 19th cbEGF domain of CRB1 is associated with the serious visual disorder Leber congenital amaurosis. We have investigated the structure and Ca2+ binding of recombinant wild-type and N1317H CRB1 fragments ( EGF18-cbEGF19) using NMR and find that Ca2+ binding is altered, resulting in disruption of long range interactions between adjacent EGF domains in CRB1. From these observations, we propose that this substitution affects the structural integrity of CRB1 in the inter-photoreceptor matrix of the retina, where it is expressed. Furthermore, we identify disease-causing substitutions in other cbEGF-containing proteins that are likely to result in similar disruption of interdomain packing, supporting the hypothesis that the tandem cbEGF domain linkages are critical for the structure and function of proteins containing cbEGF domains.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Redfield, C (corresponding author), Univ Oxford, Dept Biochem, S Pk Rd, Oxford OX1 3QU, England.	christina.redfield@bioch.ox.ac.uk		Redfield, Christina/0000-0001-7297-7708	Wellcome Trust [079440] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; BARON M, 1992, PROTEIN SCI, V1, P81; Bernal S, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.7.e89; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169; den Hollander AI, 2004, HUM MUTAT, V24, P355, DOI 10.1002/humu.20093; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; den Hollander AI, 2001, AM J HUM GENET, V69, P198; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Dmitriev AV, 1999, VISUAL NEUROSCI, V16, P1157, DOI 10.1017/S095252389916615X; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Izaddoost S, 2002, NATURE, V416, P178, DOI 10.1038/nature720; JENSEN SA, 2005, J BIOL CHEM; Johnson K, 2002, CURR BIOL, V12, P1675, DOI 10.1016/S0960-9822(02)01180-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kantardzhieva A, 2006, FEBS J, V273, P1152, DOI 10.1111/j.1742-4658.2006.05140.x; Kantardzhieva A, 2005, INVEST OPHTH VIS SCI, V46, P2192, DOI 10.1167/iovs.04-1417; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lavallee CR, 2003, J NEUROPHYSIOL, V90, P3654, DOI 10.1152/jn.00736.2003; LI JD, 1994, INVEST OPHTH VIS SCI, V35, P2700; Lotery A J, 2001, Ophthalmic Genet, V22, P163, DOI 10.1076/opge.22.3.163.2222; Lotery AJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P415, DOI 10.1001/archopht.119.3.415; Makarova O, 2003, GENE, V302, P21, DOI 10.1016/S0378111902010843; McKay GJ, 2005, INVEST OPHTH VIS SCI, V46, P322, DOI 10.1167/iovs.04-0734; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Richard M, 2006, HUM MOL GENET, V15, pR235, DOI 10.1093/hmg/ddl195; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; van de Pavert SA, 2004, J CELL SCI, V117, P4169, DOI 10.1242/jcs.01301; van de Pavert SA, 2007, J NEUROSCI, V27, P564, DOI 10.1523/JNEUROSCI.3496-06.2007; van den Hurk JAJM, 2005, MOL VIS, V11, P263; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; YAMAMOTO F, 1992, EXP EYE RES, V54, P685, DOI 10.1016/0014-4835(92)90023-L; YOSHIKAMI S, 1980, NATURE, V286, P395, DOI 10.1038/286395a0	51	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28807	28814		10.1074/jbc.M704015200	http://dx.doi.org/10.1074/jbc.M704015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660513	hybrid			2022-12-27	WOS:000249642100055
J	Hishiki, T; Ohshima, T; Ego, T; Shimotohno, K				Hishiki, Takayuki; Ohshima, Takayuki; Ego, Takeshi; Shimotohno, Kunitada			BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HTLV-I TAX; BINDING-PROTEIN; HISTONE ACETYLTRANSFERASE; GENE-EXPRESSION; C-JUN; PROMOTER; CREB; DNA; PHOSPHORYLATION	By associating with cyclic AMP-responsive element-binding protein (CREB), the human T-cell leukemia virus type 1 (HTLV-1) Tax protein activates transcription from the HTLV-1 long terminal repeat (LTR), which contains multiple cyclic AMP-responsive elements. The transducers of regulated CREB activity (TORCs) were a recently identified family of CREB co-activators that bind to CREB to enhance CRE-mediated transcription. TORC3, a TORC family protein, dramatically enhances Tax-mediated transcription from the LTR. In this study, we performed a yeast two-hybrid screen using the N-terminal region of TORC3 as bait and identified B-cell chronic lymphatic leukemia protein 3 (BCL3) as a protein interacting with TORC3. This interaction was confirmed by glutathione S-transferase pulldown assays and co-immunoprecipitation experiments with detection by Western blotting. The ankyrin repeat domain of BCL3 interacted with TORC3. By using a luciferase assay, we determined that BCL3 inhibited transcription from the HTLV-1 LTR in a manner dependent on TORC3. Knockdown of endogenous BCL3 using RNA interference enhanced transcriptional activation of CRE. Treatment with trichostatin A, a potent inhibitor of the transcriptional co-repressor HDAC, partially reversed the inhibitory effect of BCL3. These results suggest that BCL3 functions as a repressor of HTLV-1 LTR-mediated transcription through interactions with TORC3. In addition to stimulating transcription from the HTLV-1 LTR, Tax also enhances BCL3 expression; thus, transcription from the LTR is regulated by both positive and negative feedback mechanisms.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Virol Oncol,Lab Human Tumor Viruses, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Tokushima Bunri Univ, Fac Pharmaceut Sci, Sanuki City, Kagawa 7692193, Japan	Kyoto University; Kyoto University; Tokushima Bunri University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Virol Oncol,Lab Human Tumor Viruses, 53 Kawaharacho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				Akagi T, 1996, ONCOGENE, V12, P1645; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Jamaluddin M, 2005, J VIROL, V79, P15302, DOI 10.1128/JVI.79.24.15302-15313.2005; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kashanchi F, 2005, ONCOGENE, V24, P5938, DOI 10.1038/sj.onc.1208973; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Koga H, 2004, J BIOL CHEM, V279, P52978, DOI 10.1074/jbc.M409021200; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	47	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28335	28343		10.1074/jbc.M702656200	http://dx.doi.org/10.1074/jbc.M702656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17644518	hybrid			2022-12-27	WOS:000249642100007
J	Sismey-Ragatz, AE; Green, DE; Otto, NJ; Rejzek, M; Field, RA; DeAngelis, PL				Sismey-Ragatz, Alison E.; Green, Dixy E.; Otto, Nigel J.; Rejzek, Martin; Field, Robert A.; DeAngelis, Paul L.			Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases - Monodisperse polymers and unnatural structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN OLIGOSACCHARIDES; IDENTIFICATION; EVOLUTION; HEPARIN; COMPLEX	Heparosan (-GlcUA-beta 1,4-GlcNAc-alpha 1,4-)(n) is a member of the glycosaminoglycan polysaccharide family found in the capsule of certain pathogenic bacteria as well as the precursor for the vertebrate polymers, heparin and heparan sulfate. The two heparosan synthases from the Gram-negative bacteria Pasteurella multocida, PmHS1 and PmHS2, were efficiently expressed and purified using maltose-binding protein fusion constructs. These relatively homologous synthases displayed distinct catalytic characteristics. PmHS1, but not PmHS2, was able to produce large molecular mass (100-800 kDa) monodisperse polymers in synchronized, stoichiometrically controlled reactions in vitro. PmHS2, but not PmHS1, was able to utilize many unnatural UDP-sugar analogs (including substrates with acetamido-containing uronic acids or longer acyl chain hexosamine derivatives) in vitro. Overall these findings reveal potential differences in the active sites of these two Pasteurella enzymes. In the future, these catalysts should allow the creation of a variety of heparosan and heparinoids with utility for medical applications.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	University of Oklahoma System; University of Oklahoma Health Sciences Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu		Field, Rob/0000-0001-8574-0275	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244] Funding Source: NIH RePORTER; Engineering and Physical Sciences Research Council [GR/S82046/01] Funding Source: researchfish; NHLBI NIH HHS [HL062244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chen M, 2006, BIOCHEMISTRY-US, V45, P12358, DOI 10.1021/bi060844g; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 2002, ANAT RECORD, V268, P317, DOI 10.1002/ar.10163; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; Duncan MB, 2006, BIOCHEM BIOPH RES CO, V339, P1232, DOI 10.1016/j.bbrc.2005.11.142; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Hodson N, 2000, J BIOL CHEM, V275, P27311; Ikegami-Kawai M, 2002, ANAL BIOCHEM, V311, P157, DOI 10.1016/S0003-2697(02)00425-6; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Jing W, 2004, J BIOL CHEM, V279, P42345, DOI 10.1074/jbc.M402744200; Kane TA, 2006, J BIOL CHEM, V281, P33192, DOI 10.1074/jbc.M606897200; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Liu ZY, 2002, CHEMBIOCHEM, V3, P348, DOI 10.1002/1439-7633(20020402)3:4<348::AID-CBIC348>3.0.CO;2-K; Rejzek M, 2007, CARBOHYD RES, V342, P460, DOI 10.1016/j.carres.2006.10.016; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Williams KJ, 2006, J BIOL CHEM, V281, P5391, DOI 10.1074/jbc.M510439200; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	22	68	74	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28321	28327		10.1074/jbc.M701599200	http://dx.doi.org/10.1074/jbc.M701599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17627940	hybrid			2022-12-27	WOS:000249642100005
J	Thatcher, LF; Carrie, C; Andersson, CR; Sivasithamparam, K; Whelan, J; Singh, KB				Thatcher, Louise F.; Carrie, Chris; Andersson, Carol R.; Sivasithamparam, Krishnapillai; Whelan, James; Singh, Karam B.			Differential gene expression and subcellular targeting of Arabidopsis glutathione S-transferase F8 is achieved through alternative transcription start sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE PROTEOME; ACID-INDUCED EXPRESSION; REVERSE TRANSCRIPTION; NEURAL-NETWORK; BRONZE2 GENE; PROMOTER; MITOCHONDRIAL; PROTEINS; PLANTS; INITIATION	Glutathione S-transferases (GSTs) play major roles in the protection of plants from biotic and abiotic stresses through the detoxification of xenobiotics and toxic endogenous products. This report describes additional complexity in the regulation of the well characterized stress-responsive Arabidopsis thaliana GSTF8 promoter. This complexity results from the use of multiple transcription start sites (TSS) to give rise to alternate GSTF8 transcripts with the potential to produce two in-frame proteins differing only in their N-terminal sequence. In addition to the originally mapped TSS ( Chen, W., Chao, G., and Singh, K. B. ( 1996) Plant J. 10, 955-966), a further nine TSS have been identified, with the majority clustered into a distinct group. The most 3' TSS gives rise to the major message (GSTF8-S) and the shorter form of the protein, whereas those originating from upstream TSS (GSTF8-L) are more weakly expressed and encode for the larger form of the protein. Differential tissue-specific and stress-responsive expression patterns were observed ( e. g. GSTF8-L is more highly expressed in leaves compared with roots, whereas GSTF8-S expression has the opposite pattern and is much more stress-responsive). Analysis of GSTF8-L and GSTF8-S proteins demonstrated that GSTF8-L is solely targeted to plastids, whereas GSTF8-S is cytoplasmic. In silico analysis revealed potential conservation of GSTF8-S across a wide range of plants; in contrast, conservation of GSTF8-L was confined to the Brassicaceae. These studies demonstrate that alternate TSS of the GSTF8 promoter are used to confer differential tissue-specific and stress-responsive expression patterns as well as to target the same protein to two different subcellular localizations.	Commonwealth Sci & Ind Res Org, Plant Ind, Wembley, WA 6913, Australia; Univ Western Australia, Sch Earth & Geog Sci, Crawley, WA 6009, Australia; Univ Western Australia, Australian Res Council Ctr Excellence Plant Energ, Crawley, WA 6009, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Western Australia; University of Western Australia	Singh, KB (corresponding author), Commonwealth Sci & Ind Res Org, Plant Ind, Private Bag 5, Wembley, WA 6913, Australia.	karam.singh@csiro.au	Singh, Karam B/C-3235-2012; Singh, Karam B/A-7790-2008; Whelan, James/F-6402-2011; Carrie, Chris/A-2638-2010; Thatcher, Louise F/A-1302-2010	Singh, Karam B/0000-0002-2777-7448; Whelan, James/0000-0001-5754-025X; Carrie, Chris/0000-0002-4240-4674; Thatcher, Louise F/0000-0001-7622-6610				Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bae MS, 2003, PLANT J, V36, P652, DOI 10.1046/j.1365-313X.2003.01907.x; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bassett CL, 2004, MOL GENET GENOMICS, V271, P752, DOI 10.1007/s00438-004-1031-7; BUCHANAN BB, 2000, BIOCH MOL BIOL PLANT, P292; CAREY M, 2000, TRANSCRIPTIONAL REGU, P97; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Chew O, 2003, PLANT MOL BIOL, V53, P341, DOI 10.1023/B:PLAN.0000006939.87660.4f; Chew O, 2003, J BIOL CHEM, V278, P46869, DOI 10.1074/jbc.M307525200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; CZARNECKA E, 1984, PLANT MOL BIOL, V3, P45, DOI 10.1007/BF00023415; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Flury T, 1996, PLANT PHYSIOL, V112, P1185, DOI 10.1104/pp.112.3.1185; Foley RC, 2006, PLANT PHYSIOL, V142, P245, DOI 10.1104/pp.106.079509; Foyer CH, 2001, TRENDS PLANT SCI, V6, P486, DOI 10.1016/S1360-1385(01)02086-6; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j; Frova C, 2003, PHYSIOL PLANTARUM, V119, P469, DOI 10.1046/j.1399-3054.2003.00183.x; Frova C, 2006, BIOMOL ENG, V23, P149, DOI 10.1016/j.bioeng.2006.05.020; Giacomelli L, 2006, PLANT PHYSIOL, V141, P685, DOI 10.1104/pp.106.080150; Gould GM, 1906, J AMER MED ASSOC, V47, P734; HAGEN G, 1988, J BIOL CHEM, V263, P6442; Heazlewood JL, 2005, PLANT PHYSIOL, V139, P598, DOI 10.1104/pp.105.065532; Huttemann M, 2002, BIOTECHNIQUES, V32, P730, DOI 10.2144/02324bm02; Jones AME, 2004, PHYTOCHEMISTRY, V65, P1805, DOI 10.1016/j.phytochem.2004.04.005; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Kohler RH, 2000, J CELL SCI, V113, P81; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kreuz K, 1996, PLANT PHYSIOL, V111, P349, DOI 10.1104/pp.111.2.349; Kuhn K, 2005, NUCLEIC ACIDS RES, V33, P337, DOI 10.1093/nar/gki179; Lescot M, 2002, NUCLEIC ACIDS RES, V30, P325, DOI 10.1093/nar/30.1.325; Logan DC, 2000, J EXP BOT, V51, P865, DOI 10.1093/jexbot/51.346.865; Lupold DS, 1999, J BIOL CHEM, V274, P3897, DOI 10.1074/jbc.274.6.3897; Mackenzie SA, 2005, TRENDS CELL BIOL, V15, P548, DOI 10.1016/j.tcb.2005.08.007; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Marrs KA, 1997, PLANT PHYSIOL, V113, P93, DOI 10.1104/pp.113.1.93; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; Meyer AJ, 2005, PHOTOSYNTH RES, V86, P435, DOI 10.1007/s11120-005-8425-1; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Moons A, 2005, VITAM HORM, V72, P155, DOI 10.1016/S0083-6729(05)72005-7; Murcha MW, 2007, PLANT PHYSIOL, V143, P199, DOI 10.1104/pp.106.090688; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Natesan SKA, 2005, J EXP BOT, V56, P787, DOI 10.1093/jxb/eri088; Pairoba CF, 2003, PLANT MOL BIOL, V53, P75, DOI 10.1023/B:PLAN.0000009267.76482.ce; Peeters N, 2001, BBA-MOL CELL RES, V1541, P54, DOI 10.1016/S0167-4889(01)00146-X; Peltier JB, 2006, MOL CELL PROTEOMICS, V5, P114, DOI 10.1074/mcp.M500180-MCP200; Peltier JB, 2004, J BIOL CHEM, V279, P49367, DOI 10.1074/jbc.M406763200; Perl-Treves R, 2004, MOL PLANT MICROBE IN, V17, P70, DOI 10.1094/MPMI.2004.17.1.70; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Reese MG, 2001, COMPUT CHEM, V26, P51, DOI 10.1016/S0097-8485(01)00099-7; Rogozin IB, 2001, BIOINFORMATICS, V17, P890, DOI 10.1093/bioinformatics/17.10.890; Sappl PG, 2004, PLANT MOL BIOL, V54, P205, DOI 10.1023/B:PLAN.0000028786.57439.b3; Sappl PG, 2004, PHYTOCHEMISTRY, V65, P1517, DOI 10.1016/j.phytochem.2004.04.021; Silva-Filho MC, 2003, CURR OPIN PLANT BIOL, V6, P589, DOI 10.1016/j.pbi.2003.09.008; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Tillett D, 2000, BIOTECHNIQUES, V28, P448, DOI 10.2144/00283st01; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; Wachter A, 2005, PLANT J, V41, P15, DOI 10.1111/j.1365-313X.2004.02269.x; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; Waters MT, 2004, PLANT J, V39, P655, DOI 10.1111/j.1365-313X.2004.02164.x; Zhang YJ, 2001, BIOTECHNIQUES, V31, P1286, DOI 10.2144/01316st02	72	62	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28915	28928		10.1074/jbc.M702207200	http://dx.doi.org/10.1074/jbc.M702207200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17670748	hybrid			2022-12-27	WOS:000249642100066
J	Hostetter, DR; Loeb, CRK; Chu, F; Craik, CS				Hostetter, Daniel R.; Loeb, Carly R. K.; Chu, Feixia; Craik, Charles S.			Hip is a pro-survival substrate of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTL-MEDIATED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; HEAT-SHOCK PROTEINS; CELL-DEATH; INHIBITS APOPTOSIS; CASPASE ACTIVATION; HSC70 COCHAPERONE; KEY MEDIATORS; TARGET-CELLS; PROTEASE	The extended substrate specificity of granzyme B (GrB) was used to identify substrates among the chaperone superfamily. This approach identified Hsp90 and Bag1-L as novel GrB substrates, and an additional GrB cleavage site was identified in the Hsc70/Hsp70-Interacting Protein, Hip. Hsp90, Bag1L, and Hip were validated as GrB substrates in vitro, and mutational analysis confirmed the additional cleavage site in Hip. Because the role of Hip in apoptosis is unknown, its proteolysis by GrB was used as a basis to test whether it has anti-apoptotic activity. Previous work on Hip was limited to in vitro characterization; therefore, it was important to demonstrate Hip cleavage in a physiological context and to show its relevance to natural killer (NK) cell-mediated death. Hip is cleaved at both GrB cleavage sites during NK-mediated cell death in a caspase-independent manner, and its cleavage is due solely to GrB and not other granule components. Furthermore, Hip is not cleaved upon stimulation of the Fas receptor in the Jurkat T-cell line, suggesting that Hip is a substrate unique to GrB. RNA interference-mediated reduction of Hip within the K562 cell line rendered the cells more susceptible to NK cell-mediated lysis, indicating that proteolysis by GrB of Hip contributes to death induction. The small effect of RNA interference-mediated Hip deficiency on cytotoxicity is in agreement with the inherent redundancy of NK cell-mediated cell death. The identification of additional members of the chaperone superfamily as GrB substrates and the validation of Hip as an anti-apoptotic protein contribute to understanding the interplay between stress response and apoptosis.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; Univ Calif San Francisco, Tetrad Grad Program, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.	craik@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [P01CA072006, P30CA082103] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA82103, CA072006] Funding Source: Medline; PHS HHS [15804, 12961, 01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Andrade F, 2003, ACTA HAEMATOL-BASEL, V111, P28, DOI 10.1159/000074484; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Backes C, 2005, NUCLEIC ACIDS RES, V33, pW208, DOI 10.1093/nar/gki433; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Boyd Sarah E., 2005, Journal of Bioinformatics and Computational Biology, V3, P551, DOI 10.1142/S021972000500117X; Boyd SE, 2004, 2004 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P372; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Bredemeyer AJ, 2006, J BIOL CHEM, V281, P37130, DOI 10.1074/jbc.M607969200; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Goping IS, 2006, J CELL SCI, V119, P858, DOI 10.1242/jcs.02791; Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; Karpinich NO, 2006, J CELL PHYSIOL, V208, P55, DOI 10.1002/jcp.20638; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kudoh M, 2002, CANCER RES, V62, P1904; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sarin A, 1998, J IMMUNOL, V161, P2810; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; Smith DF, 2004, CELL STRESS CHAPERON, V9, P109, DOI 10.1379/CSC-31.1; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; TEAM RDC, 2005, R LANGUAGE ENV STAT; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e; Velten M, 2000, BIOCHEMISTRY-US, V39, P307, DOI 10.1021/bi9917535; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; Waterhouse NJ, 2006, IMMUNOL CELL BIOL, V84, P72, DOI 10.1111/j.1440-1711.2005.01416.x; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P2197, DOI 10.1016/S0960-894X(02)00363-3; Yang JY, 2005, MOL BIOL CELL, V16, P3511, DOI 10.1091/mbc.E05-01-0080	47	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27865	27874		10.1074/jbc.M704312200	http://dx.doi.org/10.1074/jbc.M704312200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17620340	hybrid			2022-12-27	WOS:000249455600035
J	Chi, YH; Haller, K; Peloponese, JM; Jeang, KT				Chi, Ya-Hui; Haller, Kerstin; Peloponese, Jean-Marie, Jr.; Jeang, Kuan-Teh			Histone acetyltransferase hALP and nuclear membrane protein hsSUN1 function in de-condensation of mitotic chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-A; CHROMATIN-STRUCTURE; BUILDING-BLOCKS; GENE-EXPRESSION; ENVELOPE; ACETYLATION; LOCALIZATION; DYNAMICS; ACTIVATION; COMPONENTS	Replicated mammalian chromosomes condense to segregate during anaphase, and they de-condense at the conclusion of mitosis. Currently, it is not understood what the factors and events are that specify de-condensation. Here, we demonstrate that chromosome de-condensation needs the function of an inner nuclear membrane (INM) protein hsSUN1 and a membrane-associated histone acetyltransferase ( HAT), hALP. We propose that nascently reforming nuclear envelope employs hsSUN1 and hALP to acetylate histones for de-compacting DNA at the end of mitosis.	NIAID, NIH, Mol Microbiol Lab, Mol Virol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Chi, Ya-Hui/B-1080-2010; Jeang, Kuan-Teh/A-2424-2008	Chi, Ya-Hui/0000-0002-9216-0938; Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001023, ZIAAI001023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; Buendia B, 2001, CELL MOL LIFE SCI, V58, P1781, DOI 10.1007/PL00000818; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Burke B, 2001, NAT CELL BIOL, V3, pE273, DOI 10.1038/ncb1201-e273; Burke B, 2001, TRAFFIC, V2, P675, DOI 10.1034/j.1600-0854.2001.21001.x; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; DE IC, 2005, BIOESSAYS, V27, P164; Dechat T, 2004, J CELL SCI, V117, P6117, DOI 10.1242/jcs.01529; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fahrenkrog B, 2004, TRENDS BIOCHEM SCI, V29, P175, DOI 10.1016/j.tibs.2004.02.006; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gassmann R, 2005, CHROMOSOMA, V113, P385, DOI 10.1007/s00412-004-0326-0; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Haque F, 2006, MOL CELL BIOL, V26, P3738, DOI 10.1128/MCB.26.10.3738-3751.2006; Haraguchi T, 2000, J CELL SCI, V113, P779; Hasan S, 2006, FEBS LETT, V580, P1263, DOI 10.1016/j.febslet.2006.01.039; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Hodzic DM, 2004, J BIOL CHEM, V279, P25805, DOI 10.1074/jbc.M313157200; Holaska JM, 2002, CURR OPIN CELL BIOL, V14, P357, DOI 10.1016/S0955-0674(02)00329-0; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lee KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/mbc.01-06-0294; Lopez-Soler RI, 2001, J CELL BIOL, V154, P61, DOI 10.1083/jcb.200101025; Lv JJ, 2003, BIOCHEM BIOPH RES CO, V311, P506, DOI 10.1016/j.bbrc.2003.09.235; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Margalit A, 2005, J CELL BIOCHEM, V95, P454, DOI 10.1002/jcb.20433; Marshall WF, 2002, CURR BIOL, V12, pR185, DOI 10.1016/S0960-9822(02)00724-8; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Mattout-Drubezki A, 2003, CELL MOL LIFE SCI, V60, P2053, DOI 10.1007/s00018-003-3038-3; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Padmakumar VC, 2005, J CELL SCI, V118, P3419, DOI 10.1242/jcs.02471; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4; Somech R, 2005, J CELL SCI, V118, P4017, DOI 10.1242/jcs.02521; Somech R, 2005, PEDIATR RES, V57, p8R, DOI 10.1203/01.PDR.0000159566.54287.6C; Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taddei A, 2004, ANNU REV GENET, V38, P305, DOI 10.1146/annurev.genet.37.110801.142705; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Ulbert S, 2006, J CELL BIOL, V173, P469, DOI 10.1083/jcb.200512078; Wang Q, 2006, DNA CELL BIOL, V25, P554, DOI 10.1089/dna.2006.25.554; Worman HJ, 2004, J CLIN INVEST, V113, P349, DOI 10.1172/JCI200420832; Yang L, 1997, J CELL BIOL, V137, P1199, DOI 10.1083/jcb.137.6.1199	59	80	83	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27447	27458		10.1074/jbc.M703098200	http://dx.doi.org/10.1074/jbc.M703098200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631499	hybrid, Green Submitted			2022-12-27	WOS:000249304900086
J	Chou, CC; Chang, CW; Liu, JH; Chen, LF; Hsiao, CD; Chen, HW				Chou, Chih-Chine; Chang, Chingwen; Liu, Jyung-Hurng; Chen, Liang-Fu; Hsiao, Chwan-Deng; Chen, Hungwen			Small ubiquitin-like modifier modification regulates the DNA binding activity of glial cell missing Drosophila homolog a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; TRANSCRIPTIONAL REPRESSION; GCMA; PROTEIN; SUMOYLATION; COMPLEX; DEGRADATION; PROTEASOME; SYNCYTIN; KINASE	Glial cell missing Drosophila homolog a (GCMa) is an essential transcription factor for placental development, which controls the differentiation of the syncytiotrophoblast layer. Although the activity of GCMa can be post-translationally regulated by protein phosphorylation, ubiquitination, and acetylation, it is unknown whether GCMa activity can be regulated by sumoylation. In this report, we investigated the role of sumoylation in the regulation of GCMa activity. We demonstrated that Ubc9, the E2 component of the sumoylation machinery, specifically interacts with the N-terminal domain of GCMa and promotes GCMa sumoylation on lysine 156. Moreover, GCMa-mediated transcriptional activation was repressed by sumoylation but was enhanced in the presence of the SUMO-specific protease, SENP1. The repressive effect of sumoylation on GCMa transcriptional activity was attributed to decreased DNA binding activity of GCMa. Furthermore, structural analysis revealed a steric clash between the SUMO1 moiety of sumoylated GCMa and the DNA-binding surfaces of GCMa, which may destabilize the interaction between GCMa and its cognate DNA sequence. Our study demonstrates that GCMa is a new sumoylation substrate and its activity is down-regulated by sumoylation.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Chang, Ching-Wen/N-7867-2018; Hsiao, Chwan-Deng/D-7327-2013; Liu, Jyung-Hurng/C-1340-2010	Hsiao, Chwan-Deng/0000-0002-7012-1532; Chang, Ching-Wen/0000-0002-5693-3809; Liu, Jyung-Hurng/0000-0002-7173-0372				Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boyer-Guittaut M, 2005, J BIOL CHEM, V280, P9937, DOI 10.1074/jbc.M414149200; Chang C, 2004, BIOL REPROD, V71, P1956, DOI 10.1095/biolreprod.104.033340; Chang CW, 2005, MOL CELL BIOL, V25, P8401, DOI 10.1128/MCB.25.19.8401-8414.2005; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chuang HC, 2006, NUCLEIC ACIDS RES, V34, P1459, DOI 10.1093/nar/gkl048; Cohen SX, 2003, EMBO J, V22, P1835, DOI 10.1093/emboj/cdg182; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee H, 2006, GENE DEV, V20, P784, DOI 10.1101/gad.1392006; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337; Spengler ML, 2006, J BIOL CHEM, V281, P5567, DOI 10.1074/jbc.M600035200; Yang CS, 2005, J BIOL CHEM, V280, P10083, DOI 10.1074/jbc.M413986200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200	28	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27239	27249		10.1074/jbc.M700351200	http://dx.doi.org/10.1074/jbc.M700351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646165	Green Published, hybrid			2022-12-27	WOS:000249304900065
J	Hoffmann, M; Hornung, E; Busch, S; Kassner, N; Ternes, P; Braus, GH; Feussner, I				Hoffmann, Mareike; Hornung, Ellen; Busch, Silke; Kassner, Nina; Ternes, Philipp; Braus, Gerhard H.; Feussner, Ivo			A small membrane-peripheral region close to the active center determines regioselectivity of membrane-bound fatty acid desaturases from Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN DESATURASE; CRYSTAL-STRUCTURE; SPECIFICITY; TOPOLOGY; METABOLISM; PLANTS; SEEDS; GENE; IVY	Fatty acid desaturases catalyze the introduction of double bonds at specific positions of an acyl chain and are categorized according to their substrate specificity and regioselectivity. The current understanding of membrane-bound desaturases is based on mutant studies, biochemical topology analysis, and the comparison of related enzymes with divergent functionality. Because structural information is lacking, the principles of membrane-bound desaturase specificity are still not understood despite of substantial research efforts. Here we compare two membrane-bound fatty acid desaturases from Aspergillus nidulans: a strictly monofunctional oleoyl-Delta 12 desaturase and a processive bifunctional oleoyl-Delta 12/ linoleoyl-omega 3 desaturase. The high similarities in the primary sequences of the enzymes provide an ideal starting point for the systematic analysis of factors determining substrate specificity and bifunctionality. Based on the most current topology models, both desaturases were divided into nine domains, and the domains of the monofunctional Delta 12 desaturase were systematically exchanged for their respective corresponding matches of the bifunctional sister enzyme. Catalytic capacities of hybrid enzymes were tested by heterologous expression in yeast, followed by biochemical characterization of the resulting fatty acid patterns. The individual exchange of two domains of a length of 18 or 49 amino acids each resulted in bifunctional Delta 12/ omega 3 activity of the previously monofunctional parental enzyme. Sufficient determinants of fatty acid desaturase substrate specificity and bifunctionality could, thus, be narrowed down to a membrane-peripheral region close to the catalytic site defined by conserved histidine-rich motifs in the topology model.	Albrecht von Haller Inst Pflanzenwissensch, Abt Biochem Pflanze, D-37077 Gottingen, Germany; Inst Mikrobiol & Genet, Abt Mol Mikrobiol & Genet, D-37077 Gottingen, Germany; Univ Utrecht, Fac Scheikunde, HR Kruytgebouw N601, NL-3584 CH Utrecht, Netherlands	Utrecht University	Feussner, I (corresponding author), Albrecht von Haller Inst Pflanzenwissensch, Abt Biochem Pflanze, Justus Von Liebig Weg 11, D-37077 Gottingen, Germany.	ifeussn@gwdg.de	Feussner, Ivo/H-9320-2013; Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Feussner, Ivo/0000-0002-9888-7003; Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626; Ternes, Philipp/0000-0003-0886-5474				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Calvo AM, 2001, J BIOL CHEM, V276, P25766, DOI 10.1074/jbc.M100732200; Christie WW, 1998, LIPIDS, V33, P343, DOI 10.1007/s11745-998-0214-x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DAMUDE HG, 2005, Patent No. 2005047479; Damude HG, 2006, P NATL ACAD SCI USA, V103, P9446, DOI 10.1073/pnas.0511079103; Diaz AR, 2002, J BIOL CHEM, V277, P48099, DOI 10.1074/jbc.M208960200; Domergue F, 2003, PLANT PHYSIOL, V131, P1648, DOI 10.1104/pp.102.018317; Fox BG, 2004, ACCOUNTS CHEM RES, V37, P421, DOI 10.1021/ar030186h; Galagan JE, 2005, NATURE, V438, P1105, DOI 10.1038/nature04341; Guy JE, 2007, J BIOL CHEM, V282, P19863, DOI 10.1074/jbc.M702520200; Hastings N, 2001, P NATL ACAD SCI USA, V98, P14304, DOI 10.1073/pnas.251516598; Heilmann I, 2004, P NATL ACAD SCI USA, V101, P10266, DOI 10.1073/pnas.0402200101; Heinz Ernst, 1993, P33; Hornung E, 2005, BBA-MOL CELL BIOL L, V1738, P105, DOI 10.1016/j.bbalip.2005.11.004; Hornung E, 2005, BBA-MOL CELL BIOL L, V1686, P181, DOI 10.1016/j.bbalip.2004.11.001; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; Man WC, 2006, J BIOL CHEM, V281, P1251, DOI 10.1074/jbc.M508733200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Sayanova O, 2006, J BIOL CHEM, V281, P36533, DOI 10.1074/jbc.M605158200; Shanklin J, 2000, CURR OPIN PLANT BIOL, V3, P243, DOI 10.1016/S1369-5266(00)00071-6; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Somerville C., 2000, BIOCH MOL BIOL PLANT, P456; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; URSIN VM, 2003, Patent No. 03099216; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; Whittle E, 2005, J BIOL CHEM, V280, P28169, DOI 10.1074/jbc.M504205200	36	31	42	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26666	26674		10.1074/jbc.M705068200	http://dx.doi.org/10.1074/jbc.M705068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636265	hybrid			2022-12-27	WOS:000249304900005
J	Wang, KR; Nemoto, T; Yokota, Y				Wang, Kui-Rong; Nemoto, Tomoyuki; Yokota, Yoshifumi			RFX1 mediates the serum-induced immediate early response of Id2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; B-VIRUS ENHANCER; FACTOR-INDUCIBLE GENE; DNA-BINDING PROTEIN; REGULATORY FACTOR; GROWTH-FACTOR; C-MYC; TRANSCRIPTION FACTORS; DIMERIZATION DOMAIN; REPRESSION DOMAINS	Id2, a negative regulator of basic helix-loop-helix transcription factors, is involved in regulating cell differentiation and proliferation. To obtain insight into the role of Id2 in cell cycle control, we investigated the mechanisms underlying the immediate early response of Id2 expression to serum stimulation in NIH3T3 cells. Luciferase reporter analysis with deletion and point mutants demonstrated the serum response element of Id2 (Id2-SRE) to be a consensus binding site for RFX1 ((r) under bar egulatory (f) under bar actor for (X) under bar -box (1) under bar) present 3.0 kb upstream of the transcription initiation site of Id2. Gel shift and chromatin immunoprecipitation assays confirmed the binding of RFX1 to Id2-SRE in vitro and in vivo, respectively. In both assays, RFX1 binding was observed not only in serum-stimulated cells, but also in serum-starved cells. Knockdown of RFX1 by RNA interference disturbed the immediate early response of Id2 expression in cells and abrogated the Id2-SRE-mediated induction of luciferase activity by serum. These alterations were rescued by the introduction of RNA interference-resistant RFX1 into cells. On the other hand, in the Id2-SRE-mediated reporter assay, RFX1 with an N-terminal deletion abrogated the serum response, whereas RFX1 with a C-terminal deletion enhanced the reporter activity in serum-starved cells. Furthermore, HDAC1 was recruited to Id2-SRE in serum-starved cells. These results demonstrate that RFX1 mediates the immediate early response of the Id2 gene by serum stimulation and suggest that the function of RFX1 is regulated intramolecularly in its suppression in growth-arrested cells. Our results unveil a novel transcriptional control of immediate early gene expression.	Univ Fukui, Fac Med Sci, Dept Biochem & Bioinformat Sci, Fukui 9101193, Japan; Univ Fukui, Res & Educ Program Life Sci, Dept Gen Med, Div Neurol & Gastroenterol, Fukui 9101193, Japan	University of Fukui; University of Fukui	Yokota, Y (corresponding author), Univ Fukui, Fac Med Sci, Dept Biochem & Bioinformat Sci, 23-3 Matsuoka Shimaoaizuki, Fukui 9101193, Japan.	yokota@u-fukui.ac.jp						Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fan JS, 2006, NUCLEIC ACIDS RES, V34, P1492, DOI 10.1093/nar/gkj510; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gonda H, 2003, J EXP MED, V198, P1427, DOI 10.1084/jem.20030802; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARA E, 1994, J BIOL CHEM, V269, P2139; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Karaya K, 2005, NUCLEIC ACIDS RES, V33, P1924, DOI 10.1093/nar/gki339; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Lubelsky Y, 2005, MOL CELL BIOL, V25, P10665, DOI 10.1128/MCB.25.23.10665-10673.2005; Ma KW, 2006, J BIOL CHEM, V281, P21250, DOI 10.1074/jbc.M600521200; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Nilsson JA, 2004, CANCER RES, V64, P7296, DOI 10.1158/0008-5472.CAN-04-2133; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Xu Y, 2006, J BIOL CHEM, V281, P9260, DOI 10.1074/jbc.M511724200; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	43	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26167	26177		10.1074/jbc.M703448200	http://dx.doi.org/10.1074/jbc.M703448200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630394	hybrid			2022-12-27	WOS:000249239600020
J	Watashi, K; Inoue, D; Hijikata, M; Goto, K; Aly, HH; Shimotohno, K				Watashi, Koichi; Inoue, Daisuke; Hijikata, Makoto; Goto, Kaku; Aly, Hussein H.; Shimotohno, Kunitada			Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NONSTRUCTURAL PROTEINS; MEMBRANE ASSOCIATION; MULTIDRUG-RESISTANCE; REPLICATION COMPLEX; CYCLOSPORINE-A; ER-ALPHA; IDENTIFICATION; CYCLOPHILIN; INHIBITION	Hepatitis C virus ( HCV) is a major causative agent of hepatocellular carcinoma. HCV genome replication occurs in the replication complex ( RC) around the endoplasmic reticulum membrane. However, the mechanisms regulating the HCV RC remain widely unknown. Here, we used a chemical biology approach to show that estrogen receptor ( ESR) is functionally associated with HCV replication. We found that tamoxifen suppressed HCV genome replication. Part of ESR alpha resided on the endoplasmic reticulum membranes and interacted with HCV RNA polymerase NS5B. RNA interference- mediated knockdown of endogenous ESR alpha reduced HCV replication. Mechanistic analysis suggested that ESR alpha promoted NS5B association with the RC and that tamoxifen abrogated NS5B- RC association. Thus, ESR alpha regulated the presence of NS5B in the RC and stimulated HCV replication. Moreover, the ability of ESR alpha to regulate NS5B was suggested to serve as a potential novel target for anti-HCV therapeutics.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, 53 Kawaharacho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		Aly, Hussein H/0000-0002-2455-0694				Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Aizaki H, 2004, VIROLOGY, V324, P450, DOI 10.1016/j.virol.2004.03.034; Aly HH, 2007, J HEPATOL, V46, P26, DOI 10.1016/j.jhep.2006.08.018; Bartenschlager R, 2001, ANTIVIR RES, V52, P1, DOI 10.1016/S0166-3542(01)00164-4; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Goto K, 2006, BIOCHEM BIOPH RES CO, V343, P879, DOI 10.1016/j.bbrc.2006.03.059; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hino H, 1999, BIOCHEM BIOPH RES CO, V256, P184, DOI 10.1006/bbrc.1999.0288; Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1016/0270-9139(93)90219-D; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LOPES MCF, 1990, CANCER RES, V50, P2753; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Miyanari Y, 2003, J BIOL CHEM, V278, P50301, DOI 10.1074/jbc.M305684200; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Murata T, 2005, VIROLOGY, V340, P105, DOI 10.1016/j.virol.2005.06.015; Murata T, 2005, VIROLOGY, V331, P407, DOI 10.1016/j.virol.2004.10.036; OBRIAN CA, 1988, J NATL CANCER I, V80, P1628, DOI 10.1093/jnci/80.20.1628; OBRIAN CA, 1985, CANCER RES, V45, P2462; RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; Watashi K, 2007, REV MED VIROL, V17, P245, DOI 10.1002/rmv.534; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	46	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					32765	32772		10.1074/jbc.M704418200	http://dx.doi.org/10.1074/jbc.M704418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17704057	hybrid			2022-12-27	WOS:000250625400025
J	Capaldi, S; Guariento, M; Saccomani, G; Fessas, D; Perduca, M; Monaco, HL				Capaldi, Stefano; Guariento, Mara; Saccomani, Gianmaria; Fessas, Dimitrios; Perduca, Massimiliano; Monaco, Hugo L.			A single amino acid mutation in zebrafish (Danio rerio) liver bile acid-binding protein can change the stoichiometry of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; CRYSTAL-STRUCTURE; BIOCHEMICAL-CHARACTERIZATION; SEQUENCE; NMR; INSIGHTS; FAMILY; SITE; EVOLUTION; PROGRAM	In all of the liver bile acid-binding proteins (L-BABPs) studied so far, it has been found that the stoichiometry of binding is of two cholate molecules per internal binding site. In this paper, we describe the expression, purification, crystallization, and three-dimensional structure determination of zebrafish ( Danio rerio) L-BABP to 1.5 angstrom resolution, which is currently the highest available for a protein of this family. Since we have found that in zebrafish, the stoichiometry of binding in the protein cavity is of only one cholate molecule per wild type L-BABP, we examined the role of two crucial amino acids present in the binding site. Using site-directed mutagenesis, we have prepared, crystallized, and determined the three-dimensional structure of co-crystals of two mutants. The mutant G55R has the same stoichiometry of binding as the wild type protein, whereas the C91T mutant changes the stoichiometry of binding from one to two ligand molecules in the cavity and therefore appears to be more similar to the other members of the L-BABP family. Based on the presence or absence of a single disulfide bridge, it can be postulated that fish should bind a single cholate molecule, whereas amphibians and higher vertebrates should bind two. Isothermal titration calorimetry has also revealed the presence in the wild type protein and the G55R mutant of an additional binding site, different from the first and probably located on the surface of the molecule.	Univ Verona, Dept Sci & Technol, Biocrystallog Lab, I-37134 Verona, Italy; Univ Milan, Dept Food Sci Technol & Microbiol, I-20133 Milan, Italy	University of Verona; University of Milan	Monaco, HL (corresponding author), Univ Verona, Dept Sci & Technol, Biocrystallog Lab, Ca Vignal 1,Str Le Grazie 15, I-37134 Verona, Italy.	monaco@sci.univr.it	Perduca, Massimiliano/AAS-2666-2020	Perduca, Massimiliano/0000-0001-8291-0523; Monaco, Hugo L./0000-0002-2067-0365; capaldi, stefano/0000-0003-4632-8100				ALREFAI WA, 2007, IN PRESS PHARM RES; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Beringhelli T, 2001, BIOCHEMISTRY-US, V40, P12604, DOI 10.1021/bi011009w; Capaldi S, 2006, PROTEINS, V64, P79, DOI 10.1002/prot.20961; Castronuovo G, 1996, CARBOHYD RES, V287, P127, DOI 10.1016/0008-6215(96)00081-X; CECILIANI F, 1994, COMP BIOCHEM PHYS B, V109, P261, DOI 10.1016/0305-0491(94)90010-8; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cordoba OL, 1999, EUR J BIOCHEM, V265, P832, DOI 10.1046/j.1432-1327.1999.00804.x; Denovan-Wright EM, 2000, BBA-GENE STRUCT EXPR, V1492, P227, DOI 10.1016/S0167-4781(00)00102-0; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P8192, DOI 10.1021/bi034213n; Di Pietro SM, 2001, ARCH BIOCHEM BIOPHYS, V388, P81, DOI 10.1006/abbi.2001.2277; DiPietro SM, 1997, EUR J BIOCHEM, V249, P510; Gill SJ, 1988, BIOCH THERMODYNAMICS; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Jordal AEO, 2006, COMP BIOCHEM PHYS B, V145, P147, DOI 10.1016/j.cbpb.2006.05.007; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kramer W, 2001, J BIOL CHEM, V276, P7291, DOI 10.1074/jbc.M006877200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, INT CCP4 ESRF AECMB, V26, P27; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nichesola D, 2004, BIOCHEMISTRY-US, V43, P14072, DOI 10.1021/bi0489661; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Odani S, 2001, J BIOCHEM, V129, P69, DOI 10.1093/oxfordjournals.jbchem.a002838; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Press WH, 1989, NUMERICAL RECIPES AR, P521; Ragona L, 2006, J BIOL CHEM, V281, P9697, DOI 10.1074/jbc.M513003200; SANTOME JA, 1998, TREND COMPAR BIOCHEM, V4, P23; Sarropoulou E, 2005, AQUACULTURE, V243, P69, DOI 10.1016/j.aquaculture.2004.10.012; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SCAPIN G, 1988, FEBS LETT, V240, P196, DOI 10.1016/0014-5793(88)80367-3; Schaap FG, 2002, MOL CELL BIOCHEM, V239, P69, DOI 10.1023/A:1020519011939; SCHIEVANO E, 1994, BIOPOLYMERS, V34, P879, DOI 10.1002/bip.360340707; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tochtrop GP, 2003, BIOCHEMISTRY-US, V42, P11561, DOI 10.1021/bi0346502; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wyman J, 1990, BINDING LINKAGE FUNC, P49; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	45	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31008	31018		10.1074/jbc.M705399200	http://dx.doi.org/10.1074/jbc.M705399200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17670743	hybrid			2022-12-27	WOS:000250136300068
J	Nimonkar, AV; Amitani, I; Baskin, RJ; Kowalczykowski, SC				Nimonkar, Amitabh V.; Amitani, Ichiro; Baskin, Ronald J.; Kowalczykowski, Stephen C.			Single molecule Imaging of Tid1/Rdh54, a rad54 homolog that translocates on duplex DNA and can disrupt joint molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; BRANCH MIGRATION; PROCESSIVE TRANSLOCATION; LOOP FORMATION; PROTEIN; RECOMBINATION; CHROMATIN; COMPLEX	The Saccharomyces cerevisiae Tid1 protein is important for the recombinational repair of double-stranded DNA breaks during meiosis. Tid1 is a member of Swi2/Snf2 family of chromatin remodeling proteins and shares homology with Rad54. Members of this family hydrolyze ATP and promote 1) chromatin remodeling, 2) DNA topology alterations, and 3) displacement of proteins from DNA. All of these activities are presumed to require translocation of the protein on DNA. Here we use single-molecule visualization to provide direct evidence for the ability of Tid1 to translocate on DNA. Tid1 translocation is ATP-dependent, and the velocities are broadly distributed, with the average being 84 +/- 39 base pairs/ s. Translocation is processive, with the average molecule traveling similar to 10,000 base pairs before pausing or dissociating. Many molecules display simple monotonic unidirectional translocation, but the majority display complex translocation behavior comprising intermittent pauses, direction reversals, and velocity changes. Finally, we demonstrate that translocation by Tid1 on DNA can result in disruption of three-stranded DNA structures. The ability of Tid1 translocation to clear DNA of proteins and to migrate recombination intermediates may be of critical importance for DNA repair and chromosome dynamics.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave,Briggs Hall,Rm 310, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062653, R01GM064745, R37GM062653] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064745, GM-64745, GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chi P, 2006, J BIOL CHEM, V281, P26268, DOI 10.1074/jbc.M602983200; Dresser ME, 1997, GENETICS, V147, P533; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Galletto R, 2006, NATURE, V443, P875, DOI 10.1038/nature05197; Holzen TM, 2006, GENE DEV, V20, P2593, DOI 10.1101/gad.1447106; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Kiianitsa K, 2002, J BIOL CHEM, V277, P46205, DOI 10.1074/jbc.M207967200; Kiianitsa K, 2006, P NATL ACAD SCI USA, V103, P9767, DOI 10.1073/pnas.0604240103; Klein HL, 1997, GENETICS, V147, P1533; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lia G, 2006, MOL CELL, V21, P417, DOI 10.1016/j.molcel.2005.12.013; Massey TH, 2006, MOL CELL, V23, P457, DOI 10.1016/j.molcel.2006.06.019; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; McClure W R, 1980, Methods Enzymol, V64, P277; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5937, DOI 10.1021/bi027232q; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Prasad TK, 2007, J MOL BIOL, V369, P940, DOI 10.1016/j.jmb.2007.04.005; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara M, 1997, GENETICS, V147, P1545; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Sugiyama T, 2006, EMBO J, V25, P5539, DOI 10.1038/sj.emboj.7601412; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Thoma NH, 2005, NAT STRUCT MOL BIOL, V12, P350, DOI 10.1038/nsmb919; Zhang YL, 2006, MOL CELL, V24, P559, DOI 10.1016/j.molcel.2006.10.025	42	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30776	30784		10.1074/jbc.M704767200	http://dx.doi.org/10.1074/jbc.M704767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704061	hybrid			2022-12-27	WOS:000250136300046
J	Ranquet, C; Ollagnier-de-Choudens, S; Loiseau, L; Barras, F; Fontecave, M				Ranquet, Caroline; Ollagnier-de-Choudens, Sandrine; Loiseau, Laurent; Barras, Frederic; Fontecave, Marc			Cobalt stress in Escherichia coli - The effect on the iron-sulfur proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; TRANSFER-RNA; SALMONELLA-TYPHIMURIUM; CYSTEINE DESULFURASE; MIAB PROTEIN; INACTIVATION; SCAFFOLD; ISCA; IDENTIFICATION; BIOGENESIS	Cobalt is toxic for cells, but mechanisms of this toxicity are largely unknown. The biochemical and genetic experiments reported here demonstrate that iron-sulfur proteins are greatly affected in cobalt-treated Escherichia coli cells. Exposure of a wild-type strain to intracellular cobalt results in the inactivation of three selected iron-sulfur enzymes, the tRNA methylthio-transferase, aconitase, and ferrichrome reductase. Consistently, mutant strains lacking the [Fe-S] cluster assembly SUF machinery are hypersensitive to cobalt. Last, expression of iron uptake genes is increased in cells treated with cobalt. In vitro studies demonstrated that cobalt does not react directly with fully assembled [Fe-S] clusters. In contrast, it reacts with labile ones present in scaffold proteins (IscU, SufA) involved in iron-sulfur cluster biosynthesis. We propose a model wherein cobalt competes out iron during synthesis of [Fe-S] clusters in metabolically essential proteins.	Univ Grenoble 1, Lab Chim & Biol Metaux, iRTSV LCBM, CNRS,CEA Grenoble,UMR 5249, F-38054 Grenoble 09, France; CNRS, Chim Bacterienne Lab, UPR 9043, IBSM, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biol Metaux, iRTSV LCBM, CNRS,CEA Grenoble,UMR 5249, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr		Barras, Frederic/0000-0003-3458-2574; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201, DOI 10.1081/CLT-100102420; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GEHRKE CW, 1989, J CHROMATOGR, V471, P3, DOI 10.1016/S0021-9673(00)94152-9; Gully D, 2003, FEBS LETT, V548, P90, DOI 10.1016/S0014-5793(03)00746-4; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; JARVIS JQ, 1992, J OCCUP ENVIRON MED, V34, P620; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lamrani S, 1999, MOL MICROBIOL, V32, P327, DOI 10.1046/j.1365-2958.1999.01352.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Lever A. B. P., 1984, INORGANIC ELECT SPEC; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MANIATIS T, 1982, MOL CLONING LAB MAN; McCall KA, 2000, ANAL BIOCHEM, V284, P307, DOI 10.1006/abio.2000.4706; Miller, 1972, EXPT MOL GENETICS; Muller K, 1998, EUR J BIOCHEM, V258, P1001, DOI 10.1046/j.1432-1327.1998.2581001.x; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; Petros AK, 2006, INORG CHEM, V45, P9941, DOI 10.1021/ic052190q; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Rodrigue A, 2005, J BACTERIOL, V187, P2912, DOI 10.1128/JB.187.8.2912-2916.2005; Sambrook J, 1988, MOL CLONING LAB MANU; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; SJOGREN I, 1980, THORAX, V35, P653, DOI 10.1136/thx.35.9.653; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; VENKATESWERLU G, 1970, BIOCHEM J, V118, P497, DOI 10.1042/bj1180497	52	129	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30442	30451		10.1074/jbc.M702519200	http://dx.doi.org/10.1074/jbc.M702519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17642475	hybrid			2022-12-27	WOS:000250136300012
J	Moskovich, O; Fishelson, Z				Moskovich, Oren; Fishelson, Zvi			Live cell imaging of outward and inward vesiculation induced by the complement C5b-9 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; PROTEIN-KINASE-C; PLASMA-MEMBRANE; NUCLEATED CELLS; SUBLYTIC COMPLEMENT; EXTRACELLULAR CA-2+; HUMAN-NEUTROPHILS; LYSIS; RESISTANCE; EXPRESSION	Cells resist death induced by the complement membrane attack complex ( MAC, C5b-9) by removal of the MAC from their surface by an outward and/or inward vesiculation. To gain an insight into the route of MAC removal, human C9 was tagged with Alexa Fluor 488 and traced within live cells. Tagged C9-AF488 was active in lysis of erythrocytes and K562 cells. Upon treatment of K562 cells with antibody and human serum containing C9-AF488, C9-AF488 containing MAC bound to the cells. Within 5-10 min, the cells started shedding C5b-9-loaded vesicles (0.05-1 mu m) by outward vesiculation. Concomitantly, C9-AF488 entered the cells and accumulated in a perinuclear, late recycling compartment, co-localized with endocytosed transferrin-Texas Red. Similar results were obtained with fixed cells in which the MAC was labeled with antibodies directed to a C5b-9 neoepitope. Inhibition of protein kinase C reduced endocytosis of C5b-9. Kinetic analysis demonstrated that peripheral, trypsin-sensitive C5b-9 was cleared from cells at a slower rate relative to fully inserted, trypsin-resistant C5b-9. MAC formation is controlled by CD59, a ubiquitously expressed membrane complement regulator. Analysis at a cell population level showed that the amount of C5b-9-AF488 bound to K562 cells after complement activation was highly heterogeneous and inversely correlated with the CD59 level of expression. Efficient C9-AF488 vesiculation was observed in cells expressing low CD59 levels, suggesting that the protective impact of MAC elimination by vesiculation increases as the level of expression of CD59 decreases.	Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Fishelson, Z (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel.	lifish@post.tau.ac.il						Bentley CC, 2005, CELL MICROBIOL, V7, P945, DOI 10.1111/j.1462-5822.2005.00525.x; BHAKDI S, 1980, J IMMUNOL, V124, P2451; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; CARNEY DF, 1990, J IMMUNOL, V145, P623; CARNEY DF, 1985, J IMMUNOL, V134, P1804; CARNEY DF, 1986, J IMMUNOL, V137, P263; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Deng JS, 2003, INFECT IMMUN, V71, P6402, DOI 10.1128/IAI.71.11.6402-6410.2003; Donev RM, 2006, CANCER RES, V66, P2451, DOI 10.1158/0008-5472.CAN-05-3191; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Fishelson Z, 2001, INT IMMUNOL, V13, P983, DOI 10.1093/intimm/13.8.983; Fishelson Z, 1989, MECHANISMS ACTION TH, P273; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Jurianz K, 2001, INT J CANCER, V93, P848, DOI 10.1002/ijc.1406; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; KIM SH, 1987, J IMMUNOL, V138, P1530; KOSKI CL, 1983, P NATL ACAD SCI-BIOL, V80, P3816, DOI 10.1073/pnas.80.12.3816; Kraus S, 2001, CLIN EXP IMMUNOL, V123, P366, DOI 10.1046/j.1365-2249.2001.01477.x; Kraus S, 2000, EUR J IMMUNOL, V30, P1272; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERI S, 1990, IMMUNOLOGY, V71, P1; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; MORGAN BP, 1986, J IMMUNOL, V136, P3402; Morgan BP, 2005, XENOTRANSPLANTATION, V12, P258, DOI 10.1111/j.1399-3089.2005.00237.x; MORGAN BP, 1987, J IMMUNOL, V138, P246; MORGAN BP, 1989, BIOCHEM J, V264, P1; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Nilsson M, 2006, THROMB HAEMOSTASIS, V95, P982, DOI 10.1160/TH05-08-0572; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHANIAN S H, 1981, Critical Reviews in Immunology, V1, P165; PAPADIMITRIOU JC, 1994, VIRCHOWS ARCH, V424, P677, DOI 10.1007/BF01069750; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Pilzer D, 2005, INT IMMUNOL, V17, P1239, DOI 10.1093/intimm/dxh300; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; REITER Y, 1992, EUR J IMMUNOL, V22, P1207, DOI 10.1002/eji.1830220515; REITER Y, 1995, J IMMUNOL, V155, P2203; REITER Y, 1992, MOL IMMUNOL, V29, P771, DOI 10.1016/0161-5890(92)90187-3; Robertson SE, 2006, MOL BIOL CELL, V17, P645, DOI 10.1091/mbc.E05-07-0662; Sampaziotis F, 2002, MED HYPOTHESES, V58, P136, DOI 10.1054/mehy.2001.1476; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Sreedhar AS, 2003, J BIOL CHEM, V278, P35231, DOI 10.1074/jbc.M301371200; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406	48	77	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29977	29986		10.1074/jbc.M703742200	http://dx.doi.org/10.1074/jbc.M703742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17644516	hybrid			2022-12-27	WOS:000249981200027
J	Rendon, BE; Roger, T; Teneng, I; Zhao, M; Al-Abed, Y; Calandra, T; Mitchell, RA				Rendon, Beatriz E.; Roger, Thierry; Teneng, Ivo; Zhao, Ming; Al-Abed, Yousef; Calandra, Thierry; Mitchell, Robert A.			Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAUTOMERASE ACTIVE-SITE; FACTOR MIF; CANCER CELLS; TUMOR-GROWTH; PROSTATIC ADENOCARCINOMA; IN-VITRO; EXPRESSION; RHO; RAC; ANGIOGENESIS	Macrophage migration inhibitory factor ( MIF) is expressed and secreted in response to mitogens and integrin- dependent cell adhesion. Once released, autocrine MIF promotes the activation of RhoA GTPase leading to cell cycle progression in rodent fibroblasts. We now report that small interfering RNAmediated knockdown of MIF and MIF small molecule antagonism results in a greater than 90% loss of both the migratory and invasive potential of human lung adenocarcinoma cells. Correlating with these phenotypes is a substantial reduction in steady state as well as serum- induced effector binding activity of the Rho GTPase family member, Rac1, in MIF- deficient cells. Conversely, MIF overexpression by adenovirus in human lung adenocarcinoma cells induces a dramatic enhancement of cell migration, and co- expression of a dominant interfering mutant of Rac1 ( Rac1(N17)) completely abrogates this effect. Finally, our results indicate thatMIFdepletion results in defective partitioning of Rac1 to caveolin- containing membrane microdomains, raising the possibility that MIF promotes Rac1 activity and subsequent tumor cell motility through lipid raft stabilization.	Univ Louisville, Mol Targets Program, JG Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Feinstein Inst Med Res, Med Chem Lab, Manhasset, NY 11030 USA	University of Louisville; University of Louisville; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Northwell Health	Mitchell, RA (corresponding author), Univ Louisville, Mol Targets Program, JG Brown Canc Ctr, Delia Baxter Res Bldg,Suite 204B,580 S Preston St, Louisville, KY 40202 USA.	robert.mitchell@louisville.edu	Calandra, Thierry/D-9017-2015; Roger, Thierry/G-2007-2012	Calandra, Thierry/0000-0003-3051-1285; Roger, Thierry/0000-0002-9358-0109				Abe R, 2001, J IMMUNOL, V166, P747, DOI 10.4049/jimmunol.166.2.747; Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Festuccia C, 2005, THROMB HAEMOSTASIS, V93, P964, DOI 10.1160/TH04-09-0637; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Hauck CR, 2001, CANCER RES, V61, P7079; Katanaev VL, 1998, ANAL BIOCHEM, V264, P185, DOI 10.1006/abio.1998.2837; Kayser K, 2003, LUNG CANCER, V42, P171, DOI 10.1016/S0169-5002(03)00289-7; Liao H, 2003, J BIOL CHEM, V278, P76, DOI 10.1074/jbc.M208820200; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; Meyer-Siegler KL, 2002, CANCER-AM CANCER SOC, V94, P1449, DOI 10.1002/cncr.10354; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Minamoto T, 2000, CANCER DETECT PREV, V24, P1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Nicoletti F, 2005, J NEUROIMMUNOL, V168, P168, DOI 10.1016/j.jneuroim.2005.07.019; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Oka T, 2007, J BIOL CHEM, V282, P2011, DOI 10.1074/jbc.M605153200; Petrenko O, 2003, J BIOL CHEM, V278, P11078, DOI 10.1074/jbc.M211985200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395; Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sasaki Y, 2002, INT J MOL MED, V10, P579; Senter PD, 2002, P NATL ACAD SCI USA, V99, P144, DOI 10.1073/pnas.011569399; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Sun B, 2005, CLIN CANCER RES, V11, P1050; Swant JD, 2005, J BIOL CHEM, V280, P23066, DOI 10.1074/jbc.M500636200; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Tomiyasu M, 2002, CLIN CANCER RES, V8, P3755; White ES, 2003, CLIN CANCER RES, V9, P853; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	94	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29910	29918		10.1074/jbc.M704898200	http://dx.doi.org/10.1074/jbc.M704898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17709373	hybrid			2022-12-27	WOS:000249981200020
J	Biswas, SC; Shi, YJ; Sproul, A; Greene, LA				Biswas, Subhas C.; Shi, Yijie; Sproul, Andrew; Greene, Lloyd A.			Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURONAL APOPTOSIS; TERMINAL KINASE ACTIVATION; CELL-CYCLE MOLECULES; C-JUN; SYMPATHETIC NEURONS; TRANSCRIPTION FACTORS; STRESS-RESPONSE; RNA-SYNTHESIS; JNK PATHWAY; DNA-DAMAGE	Bim is a pro-apoptotic member of the Bcl-2 family that is induced and contributes to neuron death in response to nerve growth factor (NGF) deprivation. Past work has revealed that Bim is downstream of multiple independent transcriptional pathways in neurons, including those culminating in activation of the c-Jun, FoxO, and Myb transcription factors. This study addresses the issue of whether the three signaling pathways are redundant with respect to Bim induction or whether they act cooperatively. Examination of the proximal Bim promoter reveals binding sites for FoxO, Mybs, and, as shown here, c-Jun. We find that mutation of any one of these types of sites abolishes induction of a Bim promoter-driven reporter in response to NGF deprivation. Moreover, down-regulation of either c-Jun, FoxOs, or Mybs by short hairpin RNAs blocks induction of Bim promoter-reporter activity triggered by withdrawal of NGF. This was the case for reporters driven by either the proximal promoter or a promoter that also includes additional regulatory elements in the first intron of the Bim gene. Such short hairpin RNAs also suppressed the induction of endogenous Bim protein. These findings thus indicate that the Bim promoter acts as a coincidence detector that optimally responds to the simultaneous activation of three different pro-apoptotic transcriptional pathways. Such a mechanism provides a "fail-safe" that prevents neurons from dying by accidental activation of any single pathway. It also permits neurons to utilize individual pathways such as JNK signaling for other purposes without risk of demise.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Dept Sci Biol, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Biswas, SC (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	scb34@columbia.edu	biswas, subhas/E-7876-2013	Sproul, Andrew/0000-0001-6972-1592				ABBOTT JJ, 2007, NEUROBIOL AGING 0208; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Besirli CG, 2005, J CELL BIOL, V170, P401, DOI 10.1083/jcb.200501138; Biswas SC, 2005, J NEUROSCI, V25, P8349, DOI 10.1523/JNEUROSCI.1570-05.2005; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Biswas SC, 2007, J NEUROSCI, V27, P893, DOI 10.1523/JNEUROSCI.3524-06.2007; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Eriksson M, 2007, J CELL PHYSIOL, V210, P538, DOI 10.1002/jcp.20907; Gilley J, 2005, DNA CELL BIOL, V24, P563, DOI 10.1089/dna.2005.24.563; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA, 2007, BBA-MOL BASIS DIS, V1772, P392, DOI 10.1016/j.bbadis.2006.12.003; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Magrane J, 2005, J NEUROSCI, V25, P10960, DOI 10.1523/JNEUROSCI.1723-05.2005; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Shin DH, 2001, BRAIN RES, V892, P203, DOI 10.1016/S0006-8993(00)03300-X; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Waetzig V, 2006, PROG NEUROBIOL, V80, P84, DOI 10.1016/j.pneurobio.2006.08.002; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wyttenbach A, 2006, J NEUROCHEM, V96, P1213, DOI 10.1111/j.1471-4159.2005.03676.x; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yao MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005	36	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29368	29374		10.1074/jbc.M702634200	http://dx.doi.org/10.1074/jbc.M702634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17702754	hybrid			2022-12-27	WOS:000249788000033
J	Kong, M; Bui, TV; Ditsworth, D; Gruber, JJ; Goncharov, D; Krymskaya, VP; Lindsten, T; Thompson, CB				Kong, Mei; Bui, Thi V.; Ditsworth, Dara; Gruber, Josh J.; Goncharov, Dmitry; Krymskaya, Vera P.; Lindsten, Tullia; Thompson, Craig B.			The PP2A-associated protein alpha 4 plays a critical role in the regulation of cell spreading and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SENSITIVE SIGNAL-TRANSDUCTION; RHO-GTPASES; CATALYTIC SUBUNIT; ACTIN CYTOSKELETON; FOCAL ADHESION; GROWTH; YEAST; PHOSPHORYLATION; PATHWAY	Compared with kinases, the role of protein phosphatases in regulating biological functions is less well understood. Here we show that alpha 4, a non-catalytic subunit of the protein phosphatase 2A, plays a major role in the control of cell spreading, migration, and cytoskeletal architecture. Fibroblasts lacking alpha 4 were impaired in their ability to spread and migrate compared with wild-type cells, whereas enforced expression of alpha 4 promoted cell spreading and migration. These effects were not restricted to fibroblasts. Using a T cell-specific alpha 4 transgenic mouse model, increased alpha 4 expression was found to increase lymphocyte motility and chemotaxis. Elevated alpha 4 expression results in an increase in the GTP-bound state of Rac1, and GTP-bound Rac1 was dramatically reduced in alpha 4-deficient cells. A constitutively active mutant of Rac1 rescued the defects of cell spreading and migration caused by alpha 4 deletion, while inhibition of Rac1 blocked the ability of alpha 4 to promote cell migration. Together, these data define a novel role for the protein phosphatase 2A regulatory subunit alpha 4 in the regulation of cell spreading and migration.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 450 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu						Alahari SK, 2002, INT REV CYTOL, V220, P145; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Cinalli RM, 2005, EUR J IMMUNOL, V35, P786, DOI 10.1002/eji.200425729; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamelers IHL, 2005, J CELL BIOL, V171, P871, DOI 10.1083/jcb.200509172; INUI S, 1995, J IMMUNOL, V154, P2714; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kiely PA, 2006, MOL CELL BIOL, V26, P4041, DOI 10.1128/MCB.01868-05; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Onda M, 1997, GENOMICS, V46, P373, DOI 10.1006/geno.1997.5048; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schneider H, 2006, SCIENCE, V313, P1972, DOI 10.1126/science.1131078; Takahashi K, 2006, J CELL PHYSIOL, V206, P814, DOI 10.1002/jcp.20524; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang HM, 2003, MOL CELL BIOL, V23, P3116, DOI 10.1128/MCB.23.9.3116-3125.2003; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	36	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29712	29720		10.1074/jbc.M703159200	http://dx.doi.org/10.1074/jbc.M703159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693407	hybrid			2022-12-27	WOS:000249788000067
J	Long, BM; Badger, MR; Whitney, SM; Price, GD				Long, Benedict M.; Badger, Murray R.; Whitney, Spencer M.; Price, G. Dean			Analysis of carboxysomes from Synechococcus PCC7942 reveals multiple Rubisco complexes with carboxysomal proteins CcmM and CcaA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO2 CONCENTRATING MECHANISM; ARCHAEON METHANOSARCINA-THERMOPHILA; NITRATE ASSIMILATION OPERON; INORGANIC CARBON LIMITATION; STRAIN PCC 7942; CO2-CONCENTRATING MECHANISM; RIBULOSE 1,5-BISPHOSPHATE; HALOTHIOBACILLUS-NEAPOLITANUS; ANHYDRASE ACTIVITY; ACTIVE-SITE	In cyanobacteria, the key enzyme for photosynthetic CO2 fixation, ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco), is bound within proteinaceous polyhedral microcompartments called carboxysomes. Cyanobacteria with Form IB Rubisco produce beta-carboxysomes whose putative shell proteins are encoded by the ccm-type genes. To date, very little is known of the protein-protein interactions that form the basis of beta-carboxysome structure. In an effort to identify such interactions within the carboxysomes of the beta-cyanobacterium Synechococcus sp. PCC7942, we have used polyhistidine-tagging approaches to identify at least three carboxysomal subcomplexes that contain active Rubisco. In addition to the expected L8S8 Rubisco, which is the major component of carboxysomes, we have identified two Rubisco complexes containing the putative shell protein CcmM, one of which also contains the carboxysomal carbonic anhydrase, CcaA. The complex containing CcaA consists of Rubisco and the full-length 58-kDa form of CcmM (M58), whereas the other is made up of Rubisco and a short 35-kDa form of CcmM (M35), which is probably translated independently of M58 via an internal ribosomal entry site within the ccmM gene. We also show that the high CO2-requiring ccmM deletion mutant (Delta ccmM) can achieve nearly normal growth rates at ambient CO2 after complementation with both wild type and chimeric (His(6)-tagged) forms of CcmM. Although a significant amount of independent L8S8 Rubisco is confined to the center of the carboxysome, we speculate that the CcmM-CcaA-Rubisco complex forms an important assembly coordination within the carboxysome shell. A speculative carboxysome structural model is presented.	Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Canberra, ACT 0200, Australia	Australian National University	Price, GD (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Mol Plant Physiol Grp, Bldg 46,Sullivans Creek Rd, Canberra, ACT 0200, Australia.	dean.price@anu.edu.au	Whitney, Spencer M/C-9266-2009; Long, Benedict M/B-3799-2008; Price, G Dean/C-9505-2009	Whitney, Spencer M/0000-0003-2954-2359; Long, Benedict M/0000-0002-4616-2967; Price, G Dean/0000-0001-5906-4912; Badger, Murray/0000-0001-9428-2579				Aichi M, 1997, J BACTERIOL, V179, P4671, DOI 10.1128/jb.179.15.4671-4675.1997; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; Badger MR, 2006, J EXP BOT, V57, P249, DOI 10.1093/jxb/eri286; Badger MR, 2002, FUNCT PLANT BIOL, V29, P161, DOI 10.1071/PP01213; BADGER MR, 1989, PLANT PHYSIOL, V89, P51, DOI 10.1104/pp.89.1.51; BADGER MR, 1991, CAN J BOT, V69, P974, DOI 10.1139/b91-125; Baker RT, 2005, METHOD ENZYMOL, V398, P540, DOI 10.1016/S0076-6879(05)98044-0; Baker SH, 2000, ARCH MICROBIOL, V173, P278, DOI 10.1007/s002030000141; Berry S, 2005, PLANT BIOLOGY, V7, P342, DOI 10.1055/s-2005-837710; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cannon GC, 2003, CURR MICROBIOL, V46, P115, DOI 10.1007/s00284-002-3825-3; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; Emlyn-Jones D, 2006, PLANT CELL PHYSIOL, V47, P1630, DOI 10.1093/pcp/pcl028; Emlyn-Jones D, 2006, J PHYCOL, V42, P769, DOI 10.1111/j.1529-8817.2006.00236.x; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; Gonzales AD, 2005, CAN J BOT, V83, P735, DOI 10.1139/B05-056; Heinhorst S, 2006, J BACTERIOL, V188, P8087, DOI 10.1128/JB.00990-06; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Long BM, 2005, CAN J BOT, V83, P746, DOI 10.1139/B05-058; Ludwig M, 2000, J PHYCOL, V36, P1109, DOI 10.1046/j.1529-8817.2000.00028.x; Maeda S, 1998, J BACTERIOL, V180, P4080, DOI 10.1128/JB.180.16.4080-4088.1998; MORELL MK, 1994, J BIOL CHEM, V269, P8091; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRICE GD, 1995, AUST J PLANT PHYSIOL, V22, P285, DOI 10.1071/PP9950285; PRICE GD, 1989, PLANT PHYSIOL, V91, P514, DOI 10.1104/pp.91.2.514; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; PRICE GD, 1991, CAN J BOT, V69, P963, DOI 10.1139/b91-124; Price GD, 2004, P NATL ACAD SCI USA, V101, P18228, DOI 10.1073/pnas.0405211101; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; PRICE GD, 1993, J BACTERIOL, V175, P2871, DOI 10.1128/JB.175.10.2871-2879.1993; PRICE GD, 1989, PLANT PHYSIOL, V91, P505, DOI 10.1104/pp.91.2.505; REINHOLD L, 1991, CAN J BOT, V69, P984, DOI 10.1139/b91-126; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Satoh R, 1997, PLANT CELL PHYSIOL, V38, P769, DOI 10.1093/oxfordjournals.pcp.a029234; Sawaya MR, 2006, J BIOL CHEM, V281, P7546, DOI 10.1074/jbc.M510464200; Schmid MF, 2006, J MOL BIOL, V364, P526, DOI 10.1016/j.jmb.2006.09.024; SCHWARZ R, 1995, PLANT PHYSIOL, V108, P183, DOI 10.1104/pp.108.1.183; So AKC, 2002, FUNCT PLANT BIOL, V29, P183, DOI 10.1071/PP01179; So AKC, 2002, PLANTA, V214, P456, DOI 10.1007/s004250100638; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; SULTEMEYER D, 1995, PLANTA, V196, P217; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Thomas JC, 2006, P NATL ACAD SCI USA, V103, P18368, DOI 10.1073/pnas.0607718103; Woodger FJ, 2005, PLANT PHYSIOL, V139, P1959, DOI 10.1104/pp.105.069146; Woodger FJ, 2003, PLANT PHYSIOL, V133, P2069, DOI 10.1104/pp.103.029728; YU JW, 1992, PLANT PHYSIOL, V100, P794, DOI 10.1104/pp.100.2.794	53	133	140	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29323	29335		10.1074/jbc.M703896200	http://dx.doi.org/10.1074/jbc.M703896200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675289	hybrid			2022-12-27	WOS:000249788000029
J	Miras, S; Salvi, D; Piette, L; Seigneurin-Berny, D; Grunwald, D; Reinbothe, C; Joyard, J; Reinbothe, S; Rolland, N				Miras, Stephane; Salvi, Daniel; Piette, Laurie; Seigneurin-Berny, Daphne; Grunwald, Didier; Reinbothe, Christiane; Joyard, Jacques; Reinbothe, Steffen; Rolland, Norbert			Toc159- and Toc75-independent import of a transit sequence-less precursor into the inner envelope of chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOCHLOROPHYLLIDE OXIDOREDUCTASE-A; PROTEIN IMPORT; OUTER-MEMBRANE; IN-VITRO; PEPTIDE; BINDING; INSERTION; RECEPTOR; IDENTIFICATION; TRANSLOCATION	Chloroplast envelope quinone oxidoreductase (ceQORH) is an inner plastid envelope protein that is synthesized without cleavable chloroplast transit sequence for import. In the present work, we studied the in vitro-import characteristics of Arabidopsis ceQORH. We demonstrate that ceQORH import requires ATP and is dependent on proteinaceous receptor components exposed at the outer plastid surface. Competition experiments using small subunit precursor of ribulose-bisphosphate carboxylase/oxygenase and precursor of ferredoxin, as well as antibody blocking experiments, revealed that ceQORH import does not involve the main receptor and translocation channel proteins Toc159 and Toc75, respectively, which operate in import of proteins into the chloroplast. Molecular dissection of the ceQORH amino acid sequence by site-directed mutagenesis and subsequent import experiments in planta and in vitro highlighted that ceQORH consists of different domains that act concertedly in regulating import. Collectively, our results provide unprecedented evidence for the existence of a specific import pathway for transit sequence-less inner plastid envelope membrane proteins into chloroplasts.	Univ Grenoble 1, IRTSVUMR 5168, Lab Physiol Cellulaire Vegetale,CEA, CNRS UMR 5168, F-38054 Grenoble 9, France; Univ Grenoble 1, IRTSV, CEA, INSERM U607,Lab Canaux Calc Fonct & Pathol, F-38054 Grenoble 9, France; Univ Grenoble 1, CERMO, Lab Plastes & Differentiat Cellulaire, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Rolland, N (corresponding author), Univ Grenoble 1, IRTSVUMR 5168, Lab Physiol Cellulaire Vegetale,CEA, CNRS UMR 5168, 17 Rue Martyrs, F-38054 Grenoble 9, France.	norbert.rolland@cea.fr	ROLLAND, Norbert/B-4405-2012; Reinbothe, Steffen/AAW-9893-2021; SEIGNEURIN-BERNY, Daphne/C-8412-2017	ROLLAND, Norbert/0000-0003-1959-6636; SEIGNEURIN-BERNY, Daphne/0000-0002-7436-9885				Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Chigri F, 2006, P NATL ACAD SCI USA, V103, P16051, DOI 10.1073/pnas.0607150103; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Eckart K, 2002, EMBO REP, V3, P557, DOI 10.1093/embo-reports/kvf110; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Gutensohn M, 2006, J PLANT PHYSIOL, V163, P333, DOI 10.1016/j.jplph.2005.11.009; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hofmann NR, 2005, TRENDS PLANT SCI, V10, P450, DOI 10.1016/j.tplants.2005.07.009; Hormann F, 2004, J BIOL CHEM, V279, P34756, DOI 10.1074/jbc.M402817200; Ivanova Y, 2004, MOL BIOL CELL, V15, P3379, DOI 10.1091/mbc.E03-12-0923; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2004, CURR BIOL, V14, pR1064, DOI 10.1016/j.cub.2004.11.049; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; JOYARD J, 1983, J BIOL CHEM, V258, P1; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kessler F, 2004, TRENDS CELL BIOL, V14, P334, DOI 10.1016/j.tcb.2004.05.004; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim C, 2005, PLANT J, V42, P329, DOI 10.1111/j.1365-313X.2005.02374.x; Kindle KL, 1998, PLANT PHYSIOL, V116, P1179, DOI 10.1104/pp.116.3.1179; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Kouranov A, 1999, J BIOL CHEM, V274, P25181, DOI 10.1074/jbc.274.35.25181; Kubis S, 2004, PLANT CELL, V16, P2059, DOI 10.1105/tpc.104.023309; Lee DW, 2006, PLANT PHYSIOL, V140, P466, DOI 10.1104/pp.105.074575; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Nada A, 2004, J CELL SCI, V117, P3975, DOI 10.1242/jcs.01265; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Pinnaduwage P, 1996, J BIOL CHEM, V271, P32907, DOI 10.1074/jbc.271.51.32907; Reinbothe S, 2000, P NATL ACAD SCI USA, V97, P9795, DOI 10.1073/pnas.160242597; Reinbothe S, 2005, PLANT J, V42, P1, DOI 10.1111/j.1365-313X.2005.02353.x; REINBOTHE S, 1995, PLANT CELL, V7, P1933, DOI 10.1105/tpc.7.11.1933; Reinbothe S, 2004, P NATL ACAD SCI USA, V101, P2197, DOI 10.1073/pnas.0307284101; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Reumann S, 2005, MOL MEMBR BIOL, V22, P73, DOI 10.1080/09687860500041916; Richter S, 2002, J BIOL CHEM, V277, P43888, DOI 10.1074/jbc.M206020200; Samson F, 2002, NUCLEIC ACIDS RES, V30, P94, DOI 10.1093/nar/30.1.94; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schleiff E, 2005, EMBO REP, V6, P1023, DOI 10.1038/sj.embor.7400563; Schleiff E, 2001, BBA-MOL CELL RES, V1541, P22, DOI 10.1016/S0167-4889(01)00152-5; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; THEG SM, 1989, J BIOL CHEM, V264, P6730; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; Tsai LY, 1999, J BIOL CHEM, V274, P18735, DOI 10.1074/jbc.274.26.18735; Tu SL, 2000, PLANT CELL, V12, P1951, DOI 10.1105/tpc.12.10.1951; Tu SL, 2004, PLANT CELL, V16, P2078, DOI 10.1105/tpc.104.023952; VANTHOF R, 1993, J BIOL CHEM, V268, P4037	70	62	68	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29482	29492		10.1074/jbc.M611112200	http://dx.doi.org/10.1074/jbc.M611112200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17636260	hybrid, Green Published			2022-12-27	WOS:000249788000045
J	Brumshtein, B; Greenblatt, HM; Butters, TD; Shaaltiel, Y; Aviezer, D; Silman, I; Futerman, AH; Sussman, JL				Brumshtein, Boris; Greenblatt, Harry M.; Butters, Terry D.; Shaaltiel, Yoseph; Aviezer, David; Silman, Israel; Futerman, Anthony H.; Sussman, Joel L.			Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase - Insights into the mechanism of chemical chaperone action in Gaucher disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; X-RAY-STRUCTURE; ENZYME REPLACEMENT; DEFECTIVE ENZYME; INHIBITORS; THERAPY; GLUCOCEREBROSIDASE; HYDROLASES; MUTATIONS; MIGLUSTAT	Gaucher disease is caused by mutations in the gene encoding acid beta-glucosidase ( GlcCerase), resulting in glucosylceramide (GlcCer) accumulation. The only currently available orally administered treatment for Gaucher disease is N-butyl-deoxynojirimycin (Zavesca (TM), NB-DNJ), which partially inhibits GlcCer synthesis, thus reducing levels of GlcCer accumulation. NB-DNJ also acts as a chemical chaperone for GlcCerase, although at a different concentration than that required to completely inhibit GlcCer synthesis. We now report the crystal structures, at 2 A resolution, of complexes of NB-DNJ and N-nonyl-deoxynojirimycin (NN-DNJ) with recombinant human GlcCerase, expressed in cultured plant cells. Both inhibitors bind at the active site of GlcCerase, with the imino sugar moiety making hydrogen bonds to side chains of active site residues. The alkyl chains of NB-DNJ and NN-DNJ are oriented toward the entrance of the active site where they undergo hydrophobic interactions. Based on these structures, we make a number of predictions concerning (i) involvement of loops adjacent to the active site in the catalytic process, (ii) the nature of nucleophilic attack by Glu-340, and (iii) the role of a conserved water molecule located in a solvent cavity adjacent to the active site. Together, these results have significance for understanding the mechanism of action of GlcCerase and the mode of GlcCerase chaperoning by imino sugars.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Protalix Biotherapeut, IL-20100 Carmiel, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; University of Oxford	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115; Sussman, Joel/0000-0003-0306-3878				Alfonso P, 2005, BLOOD CELL MOL DIS, V35, P268, DOI 10.1016/j.bcmd.2005.05.007; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Brady RO, 1998, ARCH NEUROL-CHICAGO, V55, P1055, DOI 10.1001/archneur.55.8.1055; Brumshtein B, 2006, ACTA CRYSTALLOGR D, V62, P1458, DOI 10.1107/S0907444906038303; Butters TD, 2005, GLYCOBIOLOGY, V15, pR43, DOI 10.1093/glycob/cwi076; Caines MEC, 2007, J BIOL CHEM, V282, P14300, DOI 10.1074/jbc.M611455200; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERICKSON JS, 1973, J LIPID RES, V14, P133; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Futerman A.H., 2006, GAUCHER DIS; Futerman AH, 2004, TRENDS PHARMACOL SCI, V25, P147, DOI 10.1016/j.tips.2004.01.004; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; Jmoudiak M, 2005, BRIT J HAEMATOL, V129, P178, DOI 10.1111/j.1365-2141.2004.05351.x; Kolter T, 2003, CHEMBIOCHEM, V4, P260, DOI 10.1002/cbic.200390045; Larson SB, 2003, BIOCHEMISTRY-US, V42, P8411, DOI 10.1021/bi034144c; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Lieberman RL, 2007, NAT CHEM BIOL, V3, P101, DOI 10.1038/nchembio850; Liou B, 2006, J BIOL CHEM, V281, P4242, DOI 10.1074/jbc.M511110200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastores GM, 2003, EXPERT OPIN INV DRUG, V12, P273, DOI 10.1517/13543784.12.2.273; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Sawkar AR, 2006, ACS CHEM BIOL, V1, P235, DOI 10.1021/cb600187q; Sawkar AR, 2005, CHEM BIOL, V12, P1235, DOI 10.1016/j.chembiol.2005.09.007; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Shaaltiel Y, 2007, PLANT BIOTECHNOL J, V5, P579, DOI 10.1111/j.1467-7652.2007.00263.x; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yu L, 2006, BIOORGAN MED CHEM, V14, P7736, DOI 10.1016/j.bmc.2006.08.003	35	98	99	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29052	29058		10.1074/jbc.M705005200	http://dx.doi.org/10.1074/jbc.M705005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17666401	hybrid			2022-12-27	WOS:000249642100079
J	Ramaen, O; Joubert, A; Simister, P; Belgareh-Touze, N; Olivares-Sanchez, MC; Zeeh, JC; Chantalat, S; Golinelli-Cohen, MP; Jackson, CL; Biou, V; Cherfils, J				Ramaen, Odile; Joubert, Alexandra; Simister, Philip; Belgareh-Touze, Naima; Olivares-Sanchez, Maria Conception; Zeeh, Jean-Christophe; Chantalat, Sophie; Golinelli-Cohen, Marie-Pierre; Jackson, Catherine L.; Biou, Valerie; Cherfils, Jacqueline			Interactions between conserved domains within homodimers in the BIG1, BIG2, and GBF1 arf guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTORS; TRANS-GOLGI NETWORK; BREFELDIN-A; MEMBRANE ASSOCIATION; SEC7 DOMAIN; PROTEIN; LOCALIZATION; TRAFFICKING; ENDOCYTOSIS; MUTATIONS	Guanine nucleotide exchange factors carrying a Sec7 domain (ArfGEFs) activate the small GTP-binding protein Arf, a major regulator of membrane remodeling and protein trafficking in eukaryotic cells. Only two of the seven subfamilies of ArfGEFs (GBF and BIG) are found in all eukaryotes. In addition to the Sec7 domain, which catalyzes GDP/GTP exchange on Arf, the GBF and BIG ArfGEFs have five common homology domains. Very little is known about the functions of these noncatalytic domains, but it is likely that they serve to integrate upstream signals that define the conditions of Arf activation. Here we describe interactions between two conserved domains upstream of the Sec7 domain (DCB and HUS) that determine the architecture of the N-terminal regions of the GBF and BIG ArfGEFs using a combination of biochemical, yeast two-hybrid, and cellular assays. Our data demonstrate a strong interaction between DCB domains within GBF1, BIG1, and BIG2 to maintain homodimers and an interaction between DCB and HUS domains within each homodimer. The DCB/HUS interaction is mediated by the HUS box, the most conserved motif in large ArfGEFs after the Sec7 domain. In support of the in vitro data, we show that both the DCB and the HUS domains are necessary for GBF1 dimerization in mammalian cells and that the DCB domain is essential for yeast viability. We propose that the dimeric DCB-HUS structural unit exists in all members of the GBF and BIG ArfGEF groups and in the related Mon2p family and probably serves an important regulatory role in Arf activation.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Cherfils, J (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	cherfils@lebs.cnrs-gif.fr	Golinelli, Marie-Pierre/K-4287-2013; Jackson, Catherine/T-5688-2019; Jackson, Catherine/A-3421-2013; Olivares, Conchi/H-2794-2015	Golinelli, Marie-Pierre/0000-0002-6738-8631; Jackson, Catherine/0000-0002-0843-145X; Olivares, Conchi/0000-0001-7518-3858				Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Efe JA, 2005, J CELL SCI, V118, P4751, DOI 10.1242/jcs.02599; Garcia-Mata R, 2003, MOL BIOL CELL, V14, P2250, DOI 10.1091/mbc.E02-11-0730; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gillingham AK, 2006, J BIOL CHEM, V281, P2273, DOI 10.1074/jbc.M510176200; Grebe M, 2000, PLANT CELL, V12, P343, DOI 10.1105/tpc.12.3.343; Ishizaki R, 2006, GENES CELLS, V11, P949, DOI 10.1111/j.1365-2443.2006.00991.x; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jochum A, 2002, MOL CELL BIOL, V22, P4914, DOI 10.1128/MCB.22.13.4914-4928.2002; Kawamoto K, 2002, TRAFFIC, V3, P483, DOI 10.1034/j.1600-0854.2002.30705.x; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Monetta P, 2007, MOL BIOL CELL, V18, P2400, DOI 10.1091/mbc.E06-11-1005; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Mouratou B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-20; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Padilla PI, 2003, P NATL ACAD SCI USA, V100, P2322, DOI 10.1073/pnas.2628047100; Park SK, 2005, MOL BIOL CELL, V16, P3786, DOI 10.1091/mbc.E05-04-0289; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Peyroche A, 2001, J CELL SCI, V114, P2241; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; Shin HW, 2004, J BIOCHEM, V136, P761, DOI 10.1093/jb/mvh185; Shin HW, 2004, MOL BIOL CELL, V15, P5283, DOI 10.1091/mbc.E04-05-0388; Shinotsuka C, 2002, BIOCHEM BIOPH RES CO, V294, P254, DOI 10.1016/S0006-291X(02)00456-4; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; Wessels E, 2007, J VIROL, V81, P5238, DOI 10.1128/JVI.02680-06; Wessels E, 2006, DEV CELL, V11, P191, DOI 10.1016/j.devcel.2006.06.005; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567; Zeeh JC, 2006, J BIOL CHEM, V281, P11805, DOI 10.1074/jbc.M600149200; Zhao XH, 2002, MOL BIOL CELL, V13, P119, DOI 10.1091/mbc.01-08-0420	37	39	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28834	28842		10.1074/jbc.M705525200	http://dx.doi.org/10.1074/jbc.M705525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640864	Green Submitted, hybrid			2022-12-27	WOS:000249642100058
J	Caffaro, CE; Hirschberg, CB; Berninsone, PM				Caffaro, Carolina E.; Hirschberg, Carlos B.; Berninsone, Patricia M.			Functional redundancy between two Caenorhabditis elegans nucleotide sugar transporters with a novel transport mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGALACTOSAMINE; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; FRINGE CONNECTION; GLUCURONIC ACID; C-ELEGANS; IDENTIFICATION; GLYCOSYLATION; GALACTOSE	Transporters of nucleotide sugars regulate the availability of these substrates required for glycosylation reactions in the lumen of the Golgi apparatus and play an important role in the development of multicellular organisms. Caenorhabditis elegans has seven different sugars in its glycoconjugates, although 18 putative nucleotide sugar transporters are encoded in the genome. Among these, SQV-7, SRF-3, and CO3H5.2 exhibit partially overlapping substrate specificity and expression patterns. We now report evidence of functional redundancy between transporters CO3H5.2 and SRF-3. Reducing the activity of the CO3H5.2 gene product by RNA interference (RNAi) in SRF-3 mutants results in oocyte accumulation and abnormal gonad morphology, whereas comparable RNAi treatment of wild type or RNAi hypersensitive C elegans strains does not cause detectable defects. We hypothesize this genetic enhancement to be a mechanism to ensure adequate glycoconjugate biosynthesis required for normal tissue development in multicellular organisms. Furthermore, we show that transporters SRF-3 and CO3H5.2, which are closely related in the phylogenetic tree, share a simultaneous and independent substrate transport mechanism that is different from the competitive one previously demonstrated for transporter SQV-7, which shares a lower amino acid sequence identity with CO3H5.2 and SRF-3. Therefore, different mechanisms for transporting multiple nucleotide sugars may have evolved parallel to transporter amino acid divergence.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Boston University; Nevada System of Higher Education (NSHE); University of Nevada Reno	Hirschberg, CB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM-30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Appleford PJ, 2004, MOL MEMBR BIOL, V21, P247, DOI 10.1080/09687680410001712550; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Bredeston LM, 2005, J BIOL CHEM, V280, P32168, DOI 10.1074/jbc.M507035200; Caffaro CE, 2006, ACCOUNTS CHEM RES, V39, P805, DOI 10.1021/ar0400239; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hoflich J, 2004, J BIOL CHEM, V279, P30440, DOI 10.1074/jbc.M402429200; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Jarriault S, 2005, DEV BIOL, V287, P1, DOI 10.1016/j.ydbio.2005.08.014; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; Nishiwaki K, 2004, NAT CELL BIOL, V6, P31, DOI 10.1038/ncb1079; Nishiwaki K, 1999, GENETICS, V152, P985; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Xu XJ, 2005, FEBS LETT, V579, P549, DOI 10.1016/j.febslet.2004.12.026	30	12	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27970	27975		10.1074/jbc.M704485200	http://dx.doi.org/10.1074/jbc.M704485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652078	hybrid			2022-12-27	WOS:000249455600046
J	Hidvegi, T; Mirnics, K; Hale, P; Ewing, M; Beckett, C; Perlmutter, DH				Hidvegi, Tuncla; Mirnics, Karoly; Hale, Pamela; Ewing, Michael; Beckett, Caroline; Perlmutter, David H.			Regulator of G signaling 16 is a marker for the distinct encloplasmic reticulum stress state associated with aggregated mutant alpha(1)-antitrypsin Z in the classical form of alpha(1)-antitrypsin deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION DATA; ENDOPLASMIC-RETICULUM; ALPHA-1-ANTITRYPSIN DEFICIENCY; LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; IN-VIVO; ACCUMULATION; PATHWAY; DEGRADATION	In the classical form of alpha-antitrypsin deficiency, a mutant protein accumulates in a polymerized form in the encloplasmic reticulum (ER) of liver cells causing liver damage and carcinogenesis by a gain-of-toxic function mechanism. Recent studies have indicated that the accumulation of mutant alpha-antitrypsin Z in the ER specifically activates the autophagic response but not the unfolded protein response and that autophagy plays a critical role in disposal of insoluble alpha-antitrypsin Z. In this study, we used genomic analysis of the liver in a novel transgenic mouse model with inducible expression to screen for changes in gene expression that would potentially define how the liver responds to accumulation of this mutant protein. There was no unfolded protein response. Of several distinct gene expression profiles, marked up-regulation of regulator of G signaling (RS16) was particularly notable. RGS16 did not increase when model systems were exposed to classical inducers of ER stress, including tunicamycin and calcium ionophore, or when a nonpolymerogenic alpha-antitrypsin mutant accumulated in the ER. RGS16 was up-regulated in livers from patients with alpha-antitrypsin deficiency, and the degree of up-regulation correlated with the hepatic levels of insoluble alpha-antitrypsin Z protein. Taken together, these results indicate that expression of RGS16 is an excellent marker for the distinct form of "ER stress" that occurs in alpha-antitrypsin deficiency, presumably determined by the aggregation-prone properties of the mutant protein that characterizes the deficiency.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Vanderbilt Univ, Kennedy Ctr Human Dev, Dept Psychiat, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University	Perlmutter, DH (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, 3705 Fifth Ave, Pittsburgh, PA 15213 USA.	David.Perlmutter@chp.edu	Mirnics, Karoly/E-6730-2010; Hidvegi, Tunda/A-8041-2008	Mirnics, Karoly/0000-0002-5521-0254; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL037784] Funding Source: Medline; NIDDK NIH HHS [DK052526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Fremin C, 2007, HEPATOLOGY, V45, P1035, DOI 10.1002/hep.21551; Gohla A, 2007, P NATL ACAD SCI USA, V104, P3003, DOI 10.1073/pnas.0611434104; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Huang Jie, 2006, Comp Hepatol, V5, P8, DOI 10.1186/1476-5926-5-8; Kamauchi S, 2005, FEBS J, V272, P3461, DOI 10.1111/j.1742-4658.2005.04770.x; Kamimoto T, 2006, J BIOL CHEM, V281, P4467, DOI 10.1074/jbc.M509409200; Kimata Y, 2006, GENES CELLS, V11, P59, DOI 10.1111/j.1365-2443.2005.00921.x; Kruse KB, 2006, AM J PATHOL, V168, P1299, DOI 10.2353/ajpath.2006.051097; Kruse KB, 2006, MOL BIOL CELL, V17, P203, DOI 10.1091/mbc.e04-09-0779; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Lepre J, 2004, BIOINFORMATICS, V20, P1033, DOI 10.1093/bioinformatics/bth035; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Nair S, 2007, TOXICOL LETT, V168, P21, DOI 10.1016/j.toxlet.2006.10.012; Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200; Perlmutter DH, 2006, AUTOPHAGY, V2, P258, DOI 10.4161/auto.2882; Perlmutter DH, 2006, PEDIATR RES, V60, P233, DOI 10.1203/01.pdr.0000228350.61496.90; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Rudnick DA, 2005, HEPATOLOGY, V42, P514, DOI 10.1002/hep.20815; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; SVEGER T, 1988, ACTA PAEDIATR SCAND, V77, P847, DOI 10.1111/j.1651-2227.1988.tb10767.x; Teckman JH, 2004, AM J PHYSIOL-GASTR L, V286, pG851, DOI 10.1152/ajpgi.00175.2003; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1	34	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27769	27780		10.1074/jbc.M704330200	http://dx.doi.org/10.1074/jbc.M704330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635928	hybrid			2022-12-27	WOS:000249455600026
J	Almeida, M; Han, L; Martin-Millan, M; O'Brien, CA; Manolagas, SC				Almeida, Maria; Han, Li; Martin-Millan, Marta; O'Brien, Charles A.; Manolagas, Stavros C.			Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to Forkhead box O-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; BONE MASS; DIFFERENTIATED OSTEOBLASTS; OSTEOCYTE DEATH; MICE DEFICIENT; FACTOR FOXO3A; MURINE MODEL; DNA-REPAIR; PATHWAY; PROGENITORS	We have elucidated that oxidative stress is a pivotal pathogenetic factor of age-related bone loss and strength in mice, leading to, among other changes, a decrease in osteoblast number and bone formation. To gain insight into the molecular mechanism by which oxidative stress exerts such adverse effects, we have tested the hypothesis that induction of the Forkhead box O (FoxO) transcription factors by reactive oxygen species may antagonize Wnt signaling, an essential stimulus for osteoblastogenesis. In support of this hypothesis, we report herein that the expression of FoxO target genes increases, whereas the expression of Wnt target genes decreases, with increasing age in C57BL/6 mice. Moreover, we show that in osteoblastic cell models, oxidative stress (exemplified by H2O2) promotes the association of FoxOs with beta-catenin, beta-catenin is required for the stimulation of FoxO target genes by H2O2, and H2O2 promotes FoxO-mediated transcription at the expense of Wnt-/T-cell factor-mediated transcription and osteoblast differentiation. Furthermore, beta-catenin overexpression is sufficient to prevent FoxO-mediated suppression of T-cell factor transcription. These results demonstrate that diversion of the limited pool of beta-catenin from T-cell factor- to FoxO-mediated transcription in osteoblastic cells may account, at least in part, for the attenuation of osteoblastogenesis and bone formation by the age-dependent increase in oxidative stress.	Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), 4301 W Markham 587, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu	O'Brien, Charles A./AAL-5078-2020	Warren, Aaron D./0000-0002-0042-9021; Almeida, Maria/0000-0002-6722-9200	NIAMS NIH HHS [R01 AR 51187] Funding Source: Medline; NIA NIH HHS [P01 AG 13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CHEN XD, 2007, IN PRESS J BONE MINE; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653; DUNSTAN CR, 1993, CALCIFIED TISSUE INT, V53, pS113, DOI 10.1007/BF01673417; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; FROST HM, 1960, J BONE JOINT SURG AM, V42, P138, DOI 10.2106/00004623-196042010-00011; Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Katoh M, 2004, INT J ONCOL, V25, P1495; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Levasseur R, 2003, ENDOCRINOLOGY, V144, P2761, DOI 10.1210/en.2002-0071; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 2007, IN PRESS MOL ENDOCRI; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Staal F J, 2000, Hematol J, V1, P3, DOI 10.1038/sj.thj.6200001; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	52	381	407	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27298	27305		10.1074/jbc.M702811200	http://dx.doi.org/10.1074/jbc.M702811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623658	hybrid			2022-12-27	WOS:000249304900071
J	Gelinas, JN; Banko, JL; Hou, L; Sonenberg, N; Weeber, EJ; Klann, E; Nguyen, PV				Gelinas, Jennifer N.; Banko, Jessica L.; Hou, Lingfei; Sonenberg, Nahum; Weeber, Edwin J.; Klann, Eric; Nguyen, Peter V.			ERK and mTOR signaling couple beta-adrenergic receptors to translation initiation machinery to gate induction of protein synthesis-dependent long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL CA1 REGION; EXTRACELLULAR-REGULATED KINASE; SYNAPTIC PLASTICITY; LATE-PHASE; FREQUENCY STIMULATION; FACTOR 4E; MEMORY; ACTIVATION; PHOSPHORYLATION; PATHWAY	beta-Adrenergic receptors critically modulate long-lasting synaptic plasticity and long-term memory in the mammalian hippocampus. Persistent long-term potentiation of synaptic strength requires protein synthesis and has been correlated with some forms of hippocampal long-term memory. However, the intracellular processes that initiate protein synthesis downstream of the beta-adrenergic receptor are unidentified. Here we report that activation of beta-adrenergic receptors recruits ERK and mammalian target of rapamycin signaling to facilitate long-term potentiation maintenance at the level of translation initiation. Treatment of mouse hippocampal slices with a beta-adrenergic receptor agonist results in activation of eukaryotic initiation factor 4E and the eukaryotic initiation factor 4E kinase Mnk1, along with inhibition of the translation repressor 4E-BP. This coordinated activation of translation machinery requires concomitant ERK and mammalian target of rapamycin signaling. Taken together, our data identify distinct signaling pathways that converge to regulate beta-adrenergic receptor-dependent protein synthesis during long-term synaptic potentiation in the hippocampus. We suggest that beta-adrenergic receptors play a crucial role in gating the induction of long-lasting synaptic plasticity at the level of translation initiation, a mechanism that may underlie the ability of these receptors to influence the formation of long- lasting memories.	Univ Alberta, Sch Med, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Sch Med, Dept Psychiat, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Sch Med, Ctr Neurosci, Edmonton, AB T6G 2H7, Canada; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Alberta; University of Alberta; University of Alberta; Vanderbilt University; Vanderbilt University; Baylor College of Medicine; McGill University	Nguyen, PV (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	peter.nguyen@ualberta.ca	Banko, Jessica L/I-9354-2012; Weeber, Edwin J/A-5396-2012	Nguyen, Peter/0000-0002-1419-5975	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022574] Funding Source: NIH RePORTER; NIA NIH HHS [AG 022574] Funding Source: Medline; NINDS NIH HHS [NS 047384, NS 0304007] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Banko JL, 2005, J NEUROSCI, V25, P9581, DOI 10.1523/JNEUROSCI.2423-05.2005; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEADWYLER SA, 1987, SYNAPSE, V1, P90, DOI 10.1002/syn.890010112; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; DUNWIDDIE TV, 1992, J NEUROSCI, V12, P506; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Gelinas JN, 2005, J NEUROSCI, V25, P3294, DOI 10.1523/JNEUROSCI.4175-04.2005; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Govindarajan A, 2006, NAT REV NEUROSCI, V7, P575, DOI 10.1038/nrn1937; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Izquierdo I, 1998, NEUROBIOL LEARN MEM, V69, P219, DOI 10.1006/nlme.1998.3825; Ji JZ, 2003, BEHAV NEUROSCI, V117, P1378, DOI 10.1037/0735-7044.117.6.1378; Ji JZ, 2003, EUR J NEUROSCI, V17, P1947, DOI 10.1046/j.1460-9568.2003.02620.x; Johnson-Farley NN, 2005, J NEUROCHEM, V92, P72, DOI 10.1111/j.1471-4159.2004.02832.x; Johnston D., 1995, FDN CELLULAR NEUROPH; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Klann E, 2004, LEARN MEMORY, V11, P365, DOI 10.1101/lm.79004; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MADER S, 1995, MOL CELL BIOL, V15, P4990; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Murchison CF, 2004, CELL, V117, P131, DOI 10.1016/S0092-8674(04)00259-4; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; STANTON PK, 1984, J NEUROSCI, V4, P3080; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Walling SG, 2004, J NEUROSCI, V24, P598, DOI 10.1523/JNEUROSCI.4426-03.2004; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1	52	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27527	27535		10.1074/jbc.M701077200	http://dx.doi.org/10.1074/jbc.M701077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635924	hybrid			2022-12-27	WOS:000249304900093
J	Nguyen, AD; McDonald, JG; Bruick, RK; DeBose-Boyd, RA				Nguyen, Andrew D.; McDonald, Jeffrey G.; Bruick, Richard K.; DeBose-Boyd, Russell A.			Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of Insigs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; COENZYME-A REDUCTASE; ELEMENT-BINDING PROTEINS; STEROL-SENSING DOMAIN; FATTY-ACID SYNTHESIS; HAMSTER OVARY CELLS; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; CHOLESTEROL-BIOSYNTHESIS	Endoplasmic reticulum-associated degradation of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase represents one mechanism by which cholesterol synthesis is controlled in mammalian cells. The key reaction in this degradation is binding of reductase to Insig proteins in the endoplasmic reticulum, which is stimulated by the cholesterol precursor lanosterol. Conversion of lanosterol to cholesterol requires removal of three methyl groups, which consumes nine molecules of dioxygen. Here, we report that oxygen deprivation (hypoxia) slows demethylation of lanosterol and its metabolite 24,25-dihydrolanosterol, causing both sterols to accumulate in cells. In addition, hypoxia increases the amount of Insig-1 and Insig-2 in a response mediated by hypoxia-inducible factor (HIF)-1 alpha. Accumulation of lanosterol together with increased Insigs accelerates degradation of reductase, which ultimately slows a ratedetermining step in cholesterol synthesis. These results define a novel oxygen-sensing mechanism mediated by the combined actions of methylated intermediates in cholesterol synthesis and the hypoxia-activated transcription factor HIF-1 alpha.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu		Nguyen, Andrew/0000-0002-9492-9472	NCI NIH HHS [CA 115962] Funding Source: Medline; NHLBI NIH HHS [HL 70441, HL 20948] Funding Source: Medline; NIGMS NIH HHS [T32 GM 008203, GM 069338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115962] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338, T32GM008203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1952, Harvey Lect, V48, P68; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dolt KS, 2007, BIOCHEM BIOPH RES CO, V354, P148, DOI 10.1016/j.bbrc.2006.12.159; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gaylor JL, 2002, BIOCHEM BIOPH RES CO, V292, P1139, DOI 10.1006/bbrc.2001.2008; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014; HORIE M, 1990, J BIOL CHEM, V265, P18075; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim H, 2003, MECH AGEING DEV, V124, P941, DOI 10.1016/S0047-6374(03)00166-0; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Lee PCW, 2005, J BIOL CHEM, V280, P25242, DOI 10.1074/jbc.M502989200; Lee PCW, 2007, J LIPID RES, V48, P318, DOI 10.1194/jlr.M600476-JLR200; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUKODANI J, 1990, ARTERIOSCLEROSIS, V10, P106, DOI 10.1161/01.ATV.10.1.106; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; SPENCE JT, 1977, J BIOL CHEM, V252, P5852; Summons RE, 2006, PHILOS T R SOC B, V361, P951, DOI 10.1098/rstb.2006.1837; Sung FL, 2007, CANCER LETT, V253, P74, DOI 10.1016/j.canlet.2007.01.012; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P4702, DOI 10.1021/bi00181a030; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; WALKER KAM, 1993, J MED CHEM, V36, P2235, DOI 10.1021/jm00067a022; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WILLIAMS MT, 1977, CANCER RES, V37, P1377; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	61	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27436	27446		10.1074/jbc.M704976200	http://dx.doi.org/10.1074/jbc.M704976200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635920	hybrid			2022-12-27	WOS:000249304900085
J	Godovikova, V; Ritchie, HH				Godovikova, Valentina; Ritchie, Helena H.			Dynamic processing of recombinant dentin sialoprotein-phosphophoryn protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; RAT; DSP; SIALOPHOSPHOPROTEIN; IMMUNOLOCALIZATION; PHOSPHOPROTEIN; TRANSCRIPTS; EXPRESSION; CALCIUM; GENE	Dentin sialoprotein (DSP) and phosphophoryn (PP) are the two noncollagenous proteins classically linked to dentin but more recently found in bone, kidney, and salivary glands. These two proteins are derived from a single copy DSP-PP gene. Although this suggests that the DSP-PP gene is first transcribed into DSP-PP mRNAs, which later undergo processing to yield the DSP and PP proteins, this mechanism has not yet been demonstrated because of the inability to identify a DSP-PP precursor protein from any cell or tissue sample. To study this problem, we utilized a baculovirus expression system to produce recombinant DSP-PP precursor proteins from a DSP-PP240 cDNA, which represents one of several endogenous DSP-PP transcripts that influence various tooth mineralization phases. Our in vitro results demonstrate that DSP-PP240 precursor proteins are produced by this system and are capable of self-processing to yield both DSP and PP proteins. We further demonstrated that purified recombinant DSP-PP240, purified recombinant PP240, and the native highly phosphorylated protein (equivalent to the PP523 isoform) have proteolytic activity. These newly identified tissue proteases may play key roles in tissue modeling during organogenesis.	Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ritchie, HH (corresponding author), Univ Michigan, Sch Dent, Rm 2393,Dental Bldg,1011 N Univ Ave, Ann Arbor, MI 48109 USA.	helenar@umich.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011442] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11442] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRONCKERS ALJJ, 1994, J BONE MINER RES, V9, P833; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; Crossen R., 1996, BACULOVIRUS EXPRESSI; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; Godovikova V, 2006, DEV BIOL, V289, P507, DOI 10.1016/j.ydbio.2005.10.002; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Jo Y, 1999, J BIOCHEM MOL BIOL, V32, P60; LINDE A, 1980, J BIOL CHEM, V255, P5931; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; Linde A., 1985, CHEM BIOL MINERALIZE, P344; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P346, DOI 10.1021/bi00427a047; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; RITCHIE H, 1996, J DENT RES, V75, P153; Ritchie HH, 2000, BBA-GENE STRUCT EXPR, V1493, P27, DOI 10.1016/S0167-4781(00)00150-0; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ritchie HH, 1997, EUR J ORAL SCI, V105, P405, DOI 10.1111/j.1600-0722.1997.tb02137.x; Ritchie HH, 2001, BBA-GENE STRUCT EXPR, V1520, P212, DOI 10.1016/S0167-4781(01)00274-3; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Veis A, 1985, CHEM BIOL MINERALIZE, P170; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yamakoshi Y, 2006, J BIOL CHEM, V281, P38235, DOI 10.1074/jbc.M607767200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	26	16	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31341	31348		10.1074/jbc.M702605200	http://dx.doi.org/10.1074/jbc.M702605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17698853	hybrid			2022-12-27	WOS:000250309200023
J	Eichinger, A; Nasreen, A; Kim, HJ; Skerra, A				Eichinger, Andreas; Nasreen, Amber; Kim, Hyun Jin; Skerra, Arne			Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; MOLECULAR-STRUCTURE; CRYSTAL-STRUCTURE; GENETIC-VARIATION; PROGESTERONE; REFINEMENT; EXPRESSION; LIPOCALINS; ALIGNMENT; ERRORS	Human apolipoprotein D(ApoD) occurs in plasma associated with high density lipoprotein. Apart from the involvement in lipid metabolism, its binding activity for progesterone and arachidonic acid plays a role in cancer development and neurological diseases. The crystal structures of free ApoD and its complex with progesterone were determined at 1.8 angstrom resolution and reveal a lipocalin fold. The narrow, mainly uncharged pocket within the typical beta-barrel accommodates progesterone with its acetyl side chain oriented toward the bottom. The cavity adopts essentially the same shape in the absence of progesterone and allows complexation of arachidonic acid as another cognate ligand. Three of the four extended loops at the open end of the beta-barrel expose hydrophobic side chains, which is an unusual feature for lipocalins and probably effects association with the high density lipoprotein particle by mediating insertion into the lipid phase. This mechanism is in line with an unpaired Cys residue in the same surface region that can form a disulfide cross-link with apolipoprotein A-II.	Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Skerra, A (corresponding author), Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany.	skerra@wzw.tum.de	Skerra, Arne/A-2269-2013	Skerra, Arne/0000-0002-5717-498X				ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; AYRAULTJARRIER M, 1963, B SOC CHIM BIOL, V45, P703; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breustedt DA, 2005, J BIOL CHEM, V280, P484, DOI 10.1074/jbc.M410466200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campanacci V, 2004, FEBS LETT, V562, P183, DOI 10.1016/S0014-5793(04)00199-1; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cianci M, 2001, ACTA CRYSTALLOGR D, V57, P1219, DOI 10.1107/S0907444901009350; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Desai PP, 2002, ATHEROSCLEROSIS, V163, P329, DOI 10.1016/S0021-9150(02)00012-6; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Gursky O, 2005, CURR OPIN LIPIDOL, V16, P287, DOI 10.1097/01.mol.0000169348.61191.ac; Hall RE, 2004, PROSTATE, V58, P103, DOI 10.1002/pros.10343; Hansen T, 2006, PHARMACOGENOMICS J, V6, P120, DOI 10.1038/sj.tpj.6500350; Helisalmi S, 2004, J NEUROL, V251, P951, DOI 10.1007/s00415-004-0470-8; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahadik SP, 2002, SCHIZOPHR RES, V58, P55, DOI 10.1016/S0920-9964(01)00378-4; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; Miranda E, 2003, J SURG ONCOL, V83, P99, DOI 10.1002/jso.10245; Nasreen A, 2006, PROTEIN SCI, V15, P190, DOI 10.1110/ps.051775606; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; Peitsch M C, 1990, New Biol, V2, P197; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; Tao P, 1999, J MOL MODEL, V5, P189, DOI 10.1007/s008940050118; Thomas EA, 2003, CURR MOL MED, V3, P408, DOI 10.2174/1566524033479681; Vogt M, 2004, CHEMBIOCHEM, V5, P191, DOI 10.1002/cbic.200300703; Vogt M, 2001, J MOL RECOGNIT, V14, P79, DOI 10.1002/1099-1352(200101/02)14:1<79::AID-JMR521>3.0.CO;2-4; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YANG CY, 1994, BIOCHEMISTRY-US, V33, P12451, DOI 10.1021/bi00207a011; Zanotti G, 1998, ACTA CRYSTALLOGR D, V54, P1049, DOI 10.1107/S0907444998002303; Zeng CH, 1996, P NATL ACAD SCI USA, V93, P6626, DOI 10.1073/pnas.93.13.6626; Zhang XJ, 2006, NEUROPSYCHOBIOLOGY, V54, P40, DOI 10.1159/000095740	49	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31068	31075		10.1074/jbc.M703552200	http://dx.doi.org/10.1074/jbc.M703552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699160	hybrid			2022-12-27	WOS:000250136300074
J	Deponte, M; Sturm, N; Mittler, S; Harner, M; Mack, H; Becker, K				Deponte, Marcel; Sturm, Nicole; Mittler, Sarah; Harner, Max; Mack, Hildegard; Becker, Katja			Allosteric coupling of two different functional active sites in monomeric Plasmodium falciparum glyoxalase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RANDOM PATHWAY MECHANISM; SACCHAROMYCES-CEREVISIAE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; LEISHMANIA-MAJOR; HUMAN ENZYME; METAL-ION; YEAST; SPECIFICITY	Glyoxalase I (GloI) catalyzes the glutathione-dependent conversion of 2-oxoaldehydes to S-2-hydroxyacylglutathione derivatives. Studies on GloI from diverse organisms such as man, bacteria, yeast, and different parasites show striking differences among these potentially isofunctional enzymes as far as metal content and the number of active sites per subunit are concerned. So far, it is not known whether this structural variability is linked to catalytic or regulatory features in vivo. Here we show that recombinant GloI from the malaria parasite Plasmodium falciparum has a high- and a low-affinity binding site for the diastereomeric hemithioacetals formed by addition of glutathione to methylglyoxal. Both active sites of the monomeric enzyme are functional and have similar k(cat)(app) values. Proteolytic susceptibility studies and detailed analyses of the steady-state kinetics of active-site mutants suggest that both reaction centers can adopt two discrete conformations and are allosterically coupled. As a result of the positive homotropic allosteric coupling, P. falciparum GloI has an increased affinity at low substrate concentrations and an increased activity at higher substrate concentrations. This could also be the case for GloI from yeast and other organisms. Potential physiologically relevant differences between monomeric GloI and homodimeric GloI are discussed. Our results provide a strong basis for drug development strategies and significantly enhance our understanding of GloI kinetics and structure-function relationships. Furthermore, they extend the current knowledge on allosteric regulation of monomeric proteins in general.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany	University of Munich; Justus Liebig University Giessen	Deponte, M (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	marcel.deponte@gmx.de		Harner, Max/0000-0002-5513-1046; Deponte, Marcel/0000-0003-2141-917X; Mack, Hildegard/0000-0001-7559-1851				Akoachere M, 2005, BIOL CHEM, V386, P41, DOI 10.1515/BC.2005.006; Ariza A, 2006, MOL MICROBIOL, V59, P1239, DOI 10.1111/j.1365-2958.2006.05022.x; ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; Bisswanger H., 2002, ENZYME KINETICS; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; CLIFFE EE, 1961, BIOCHEM J, V79, P475, DOI 10.1042/bj0790475; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; Dakin HD, 1913, J BIOL CHEM, V14, P423; Frickel EM, 2001, J BIOL CHEM, V276, P1845, DOI 10.1074/jbc.M005760200; Gomes RA, 2005, FEBS J, V272, P4521, DOI 10.1111/j.1742-4658.2005.04872.x; HALL SS, 1976, J AM CHEM SOC, V98, P7460, DOI 10.1021/ja00439a077; HAN LPB, 1977, BIOCHEMISTRY-US, V16, P5478, DOI 10.1021/bi00644a013; He MM, 2000, BIOCHEMISTRY-US, V39, P8719, DOI 10.1021/bi000856g; Himo F, 2001, J AM CHEM SOC, V123, P10280, DOI 10.1021/ja010715h; Iozef R, 2003, FEBS LETT, V554, P284, DOI 10.1016/S0014-5793(03)01146-3; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1995, J BIOL CHEM, V270, P12957, DOI 10.1074/jbc.270.22.12957; MANNERVIK B, 1974, J BIOL CHEM, V249, P901; Martins AM, 2001, EUR J BIOCHEM, V268, P3930, DOI 10.1046/j.1432-1327.2001.02304.x; Martins AMTBS, 2001, FEBS LETT, V499, P41, DOI 10.1016/S0014-5793(01)02519-4; Miller AG, 2006, J BIOL CHEM, V281, P11864, DOI 10.1074/jbc.M513813200; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; RACKER E, 1951, J BIOL CHEM, V190, P685; RAE C, 1994, BIOCHEMISTRY-US, V33, P3548, DOI 10.1021/bi00178a011; Richter U, 2001, J AM CHEM SOC, V123, P6973, DOI 10.1021/ja0105966; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; SELLIN S, 1982, BIOCHEMISTRY-US, V21, P4850, DOI 10.1021/bi00263a004; Sukdeo N, 2004, BIOCHEM J, V384, P111, DOI 10.1042/BJ20041006; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; VANDERJAGT DL, 1972, BIOCHEMISTRY-US, V11, P3735, DOI 10.1021/bi00770a011; VANDERJAGT DL, 1975, BIOCHEMISTRY-US, V14, P3669, DOI 10.1021/bi00687a024; VANDERJAGT DL, 1989, GLUTATHIONE CHEM B A, P597; VARONCASTELLANO.R, 1995, COMPUTERSIZED DERIVA; Vickers TJ, 2004, P NATL ACAD SCI USA, V101, P13186, DOI 10.1073/pnas.0402918101; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024	42	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28419	28430		10.1074/jbc.M703271200	http://dx.doi.org/10.1074/jbc.M703271200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664277	hybrid			2022-12-27	WOS:000249642100016
J	Quan, S; Schneider, I; Pan, J; Von Hacht, A; Bardwell, JCA				Quan, Shu; Schneider, Irmhild; Pan, Jonathan; Von Hacht, Annekathrin; Bardwell, James C. A.			The CXXC motif is more than a redox rheostat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI THIOREDOXIN; ACTIVE-SITE; FORMATION INVIVO; IN-VIVO; EFFICIENT CATALYSIS; CRYSTAL-STRUCTURE; DSBA; ISOMERASE; PROTEINS	The CXXCactive-site motif of thiol-disulfide oxidoreductases is thought to act as a redox rheostat, the sequence of which determines its reduction potential and functional properties. We tested this idea by selecting for mutants of the CXXC motif in a reducing oxidoreductase ( thioredoxin) that complement null mutants of a very oxidizing oxidoreductase, DsbA. We found that altering the CXXC motif affected not only the reduction potential of the protein, but also its ability to function as a disulfide isomerase and also impacted its interaction with folding protein substrates and reoxidants. It is surprising that nearly all of our thioredoxin mutants had increased activity in disulfide isomerization in vitro and in vivo. Our results indicate that the CXXC motif has the remarkable ability to confer a large number of very specific properties on thioredoxin-related proteins.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Rm 4007,830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	Quan, Shu/O-4562-2015	Quan, Shu/0000-0002-6672-4947	PHS HHS [F007834, F007810] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 2001, J BACTERIOL, V183, P980, DOI 10.1128/JB.183.3.980-988.2001; Britto PJ, 2002, J BIOL CHEM, V277, P29018, DOI 10.1074/jbc.M204263200; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Carvalho AP, 2006, PROG BIOPHYS MOL BIO, V91, P229, DOI 10.1016/j.pbiomolbio.2005.06.012; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Collet JF, 2002, J BIOL CHEM, V277, P26886, DOI 10.1074/jbc.M203028200; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, DOI DOI 10.1385/1592598900; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Grzyska PK, 2005, BIOCHEMISTRY-US, V44, P3845, DOI 10.1021/bi048746n; Guddat LW, 1997, PROTEIN SCI, V6, P1893, DOI 10.1002/pro.5560060910; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hiniker A, 2005, J BIOL CHEM, V280, P33785, DOI 10.1074/jbc.M505742200; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Iqbalsyah TM, 2006, PROTEIN SCI, V15, P1945, DOI 10.1110/ps.062271506; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MORGAN RS, 1978, INT J PEPT PROT RES, V11, P209; Mossner E, 1998, PROTEIN SCI, V7, P1233; Pal D, 1998, J BIOMOL STRUCT DYN, V15, P1059, DOI 10.1080/07391102.1998.10509001; Pan JL, 2006, PROTEIN SCI, V15, P2217, DOI 10.1110/ps.062268106; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rensing C, 1997, J BACTERIOL, V179, P2769, DOI 10.1128/jb.179.8.2769-2771.1997; Ritz D, 2002, METHOD ENZYMOL, V347, P360; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Schultz LW, 1999, ACTA CRYSTALLOGR D, V55, P1533, DOI 10.1107/S0907444999008756; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Stafford SJ, 1999, FEMS MICROBIOL LETT, V174, P179, DOI 10.1111/j.1574-6968.1999.tb13566.x; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Tapley TL, 2007, J BIOL CHEM, V282, P10263, DOI 10.1074/jbc.M611541200; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zauhar RJ, 2000, BIOPOLYMERS, V53, P233, DOI 10.1002/(SICI)1097-0282(200003)53:3<233::AID-BIP3>3.3.CO;2-W; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	60	104	105	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28823	28833		10.1074/jbc.M705291200	http://dx.doi.org/10.1074/jbc.M705291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17675287	hybrid			2022-12-27	WOS:000249642100057
J	Schramm, VL				Schramm, Vern L.			Enzymatic transition state theory and transition state analogue design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PURINE NUCLEOSIDE PHOSPHORYLASE; ATOMIC MOTION; INHIBITORS; CATALYSIS; APOPTOSIS; DYNAMICS		Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schramm, VL (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.	vern@aecom.yu.edu			NIAID NIH HHS [AI49512] Funding Source: Medline; NIGMS NIH HHS [GM41916] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM041916] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagdassarian CK, 1996, J AM CHEM SOC, V118, P8825, DOI 10.1021/ja952781n; Balakrishnan K, 2006, BLOOD, V108, P2392, DOI 10.1182/blood-2006-03-007468; Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; Basu I, 2007, J BIOL CHEM, V282, P21477, DOI 10.1074/jbc.M702287200; BIGELEISEN J, 1958, ADV CHEM PHYS, V1, P15; Bjarnsholt T, 2007, PHILOS T R SOC B, V362, P1213, DOI 10.1098/rstb.2007.2046; CLELAND WW, 1982, METHOD ENZYMOL, V87, P625; English BP, 2006, NAT CHEM BIOL, V2, P87, DOI 10.1038/nchembio759; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, ORG LETT, V5, P3639, DOI 10.1021/ol035293q; Evans GB, 2001, J ORG CHEM, V66, P5723, DOI 10.1021/jo0155613; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Furneaux RH, 1999, J ORG CHEM, V64, P8411, DOI 10.1021/jo990903e; Gandhi V, 2005, BLOOD, V106, P4253, DOI 10.1182/blood-2005-03-1309; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; GRILLO MA, 2007, IN PRESS AMINO RES V; Harraghy N, 2007, ANAL BIOANAL CHEM, V387, P437, DOI 10.1007/s00216-006-0860-0; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Lewandowicz A, 2003, J BIOL CHEM, V278, P31465, DOI 10.1074/jbc.C300259200; LIENHARD GE, 1973, SCIENCE, V180, P149, DOI 10.1126/science.180.4082.149; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Pineda JRET, 2006, PHILOS T R SOC B, V361, P1433, DOI 10.1098/rstb.2006.1877; Ravandi F, 2006, EXPERT OPIN INV DRUG, V15, P1601, DOI 10.1517/13543784.15.12.1601; RODGERS J, 1982, J AM CHEM SOC, V104, P3263, DOI 10.1021/ja00376a003; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Schramm VL, 2001, CURR OPIN STRUC BIOL, V11, P657, DOI 10.1016/S0959-440X(01)00269-X; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; SIMS LB, 1972, J AM CHEM SOC, V94, P1364, DOI 10.1021/ja00759a059; Singh V, 2005, BIOCHEMISTRY-US, V44, P11647, DOI 10.1021/bi050863a; Singh V, 2006, J AM CHEM SOC, V128, P14691, DOI 10.1021/ja065419p; Tang BQ, 2006, BIOCHEM PHARMACOL, V72, P806, DOI 10.1016/j.bcp.2006.06.018; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002; Wolfenden R, 2003, BIOPHYS CHEM, V105, P559, DOI 10.1016/S0301-4622(03)00066-8	39	101	103	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28297	28300		10.1074/jbc.R700018200	http://dx.doi.org/10.1074/jbc.R700018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690091	hybrid			2022-12-27	WOS:000249642100002
J	Ding, G; Sonoda, H; Yu, H; Kajimoto, T; Goparaju, SK; Jahangeer, S; Okada, T; Nakamura, S				Ding, Guo; Sonoda, Hirofumi; Yu, Huan; Kajimoto, Taketoshi; Goparaju, Sravan K.; Jahangeer, Saleem; Okada, Taro; Nakamura, Shun-ichi			Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; DNA-DAMAGE; SIGNAL; ACTIVATION; RECEPTOR; LOCALIZATION; EXPRESSION; CELLS	Sphingosine kinase (SPHK) is a key enzyme producing important messenger sphingosine 1-phosphate and is implicated in cell proliferation and suppression of apoptosis. Because the extent of agonist-induced activation of SPHK is modest, signaling via SPHK may be regulated through its localization at specific intracellular sites. Although the SPHK1 isoform has been extensively studied and characterized, the regulation of expression and function of the other isoform, SPHK2, remain largely unexplored. Here we describe an important post-translational modification, namely, phosphorylation of SPHK2 catalyzed by protein kinase D (PKD), which regulates its localization. Upon stimulation of HeLa cells by tumor promoter phorbol 12-myristate 13-acetate, a serine residue in a novel and putative nuclear export signal, identified for the first time, in SPHK2 was phosphorylated followed by SPHK2 export from the nucleus. Constitutively active PKD phosphorylated this serine residue in the nuclear export signal both in vivo and in vitro. Moreover, down-regulation of PKDs through RNA interference resulted in the attenuation of both basal and phorbol 12-myristate 13-acetateinduced phosphorylation, which was followed by the accumulation of SPHK2 in the nucleus in a manner rescued by PKD overexpression. These results indicate that PKD is a physiologically relevant enzyme for SPHK2 phosphorylation, which leads to its nuclear export for subsequent cellular signaling.	Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol,Chuo Ku, Kusunoki Cho 7-5-1, Kobe, Hyogo 6500017, Japan.	snakamur@kobe-u.ac.jp	Goparaju, Sravan/H-3422-2011	Sonoda, Hirofumi/0000-0003-3353-1783				Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Carrero G, 2004, METHOD ENZYMOL, V375, P415; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; French KJ, 2003, CANCER RES, V63, P5962; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; Inagaki Y, 2003, BIOCHEM BIOPH RES CO, V311, P168, DOI 10.1016/j.bbrc.2003.09.194; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	45	109	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27493	27502		10.1074/jbc.M701641200	http://dx.doi.org/10.1074/jbc.M701641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635916	hybrid			2022-12-27	WOS:000249304900090
J	Maeda, H; Sahara, H; Mori, Y; Torigo, T; Kamiguchi, K; Tamura, Y; Tamura, Y; Hirata, K; Sato, N				Maeda, Hideki; Sahara, Hiroeki; Mori, Yoko; Torigo, Toshihiko; Kamiguchi, Kenjiro; Tamura, Yutaka; Tamura, Yasuaki; Hirata, Kouichi; Sato, Noriyuki			Biological heterogeneity of the peptide- binding motif of the 70-kDa heat shock protein by surface plasmon resonance analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HSP70; IMMUNOTHERAPY; CELLS; SPECIFICITY; DNAK; EXPRESSION; GP96	70-kDa heat shock protein family is a molecular chaperone that binds to a variety of client proteins and peptides in the cytoplasm. Several studies have revealed binding motifs between 70-kDa heat shock protein family and cytoplasmic proteins by conventional techniques such as phage display library screening. However, little is known about the binding motif based on kinetic parameters determined by surface plasmon resonance analysis. We investigated the major inducible cytosolic 70-kDa heat shock protein (Hsp70)-binding motif with the human leukocyte antigen B*2702-derived peptide Bw4 (RENL-RIALRY) by using a Biacore system based on surface plasmon resonance analysis. The K-D value of Hsp70-Bw4 interaction was 1.8 x 10(-6) M. Analyses with truncated Bw4 variant peptides showed the binding motif of Hsp70 to be seven residues, LRI-ALRY. To further study the characteristics of this motif, 126 peptides derived from Bw4, each with single amino acid substitution, were synthesized and analyzed for Hsp70 binding affinity. Interestingly, the Hsp70 binding affinity was abrogated when the residues were substituted for by acidic (Asp and Glu) ones at any position. In contrast, if the substitute residue was aromatic (Trp, Tyr, and Phe) or an Arg residue at any position, Hsp70 binding affinity was maintained. Thus, this study presents a new binding motif between Hsp70 and peptides derived from the natural protein human leukocyte antigen B*2702 and may also elucidate some characteristics of the Hsp70 binding characteristic, enhancing our understanding of Hsp70-binding determinants that may influence diverse cellular and physiological processes.	Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Chiba Univ, Grad Sch Med, Dept Bioinformat, Chiba 2608670, Japan; Sapporo Med Univ, Sch Med, Dept Surg, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Marine Biomed Inst, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Chiba University; Sapporo Medical University; Sapporo Medical University	Sahara, H (corresponding author), S 1 W 17,Chuo Ku, Sapporo, Hokkaido 0608556, Japan.	hsahara@sapmed.ac.jp						Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; Eisenlohr LC, 2007, NAT REV IMMUNOL, V7, P403, DOI 10.1038/nri2077; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Haug M, 2007, EUR J IMMUNOL, V37, P1053, DOI 10.1002/eji.200636811; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; Li Z, 1994, Behring Inst Mitt, P37; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Maier JT, 2002, IMMUNOGENETICS, V54, P67, DOI 10.1007/s00251-002-0444-x; Massa M, 2007, ARTHRITIS RHEUM, V56, P1648, DOI 10.1002/art.22567; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P111; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Nishikawa H, 2005, J EXP MED, V201, P681, DOI 10.1084/jem.20041959; Nossner E, 1996, J EXP MED, V183, P339, DOI 10.1084/jem.183.2.339; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Qian JF, 2005, CLIN CANCER RES, V11, P8808, DOI 10.1158/1078-0432.CCR-05-1553; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Sato K, 2001, BLOOD, V98, P1852, DOI 10.1182/blood.V98.6.1852; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Zhang Xinsheng, 2003, Biological Procedures Online, V5, P170, DOI 10.1251/bpo59; Zhang XS, 2005, VIROLOGY, V337, P162, DOI 10.1016/j.virol.2005.03.035; Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	39	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26956	26962		10.1074/jbc.M703436200	http://dx.doi.org/10.1074/jbc.M703436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626008	hybrid			2022-12-27	WOS:000249304900035
J	Niedziela-Majka, A; Chesnik, MA; Tomko, EJ; Lohman, TM				Niedziela-Majka, Anita; Chesnik, Marla A.; Tomko, Eric J.; Lohman, Timothy M.			Bacillus stearothermophilus PcrA monomer is a single-stranded DNA translocase but not a processive helicase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; BACTERIOPHAGE-T4 DDA HELICASE; ATP-DEPENDENT TRANSLOCATION; ESCHERICHIA-COLI; UVRD HELICASE; MISMATCH REPAIR; RECBCD ENZYME; STEP-SIZE; NUCLEOPROTEIN FILAMENTS; CRYSTAL-STRUCTURES	Structural studies of the Bacillus stearothermophilus PcrA protein along with biochemical studies of the single-stranded (ss) DNA translocation activity of PcrA monomers have led to the suggestion that a PcrA monomer possesses processive helicase activity in vitro. Yet definitive studies testing whether the PcrA monomer possesses processive helicase activity have not been performed. Here we show, using single turnover kinetic methods, that monomers of PcrA are able to translocate along ssDNA, in the 3 ' to 5 ' direction, rapidly and processively, whereas these same monomers display no detectable helicase activity under the same solution conditions in vitro. The PcrA monomer ssDNA translocation activity, although necessary, is not sufficient for processive helicase activity, and thus the translocase and helicase activities of PcrA are separable. These results also suggest that the helicase activity of PcrA needs to be activated either by self-assembly or through interactions with accessory proteins. This same behavior is displayed by both the Escherichia coli Rep and UvrD monomers. Hence, all three of these SF1 enzymes are ssDNA translocases as monomers but do not display processive helicase activity in vitro unless activated. The fact that the translocase and helicase activities are separable suggests that each activity may be used for different functions in vivo.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lohman, TM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid, St Louis, MO 63110 USA.	lohman@biochem.wustl.edu			NIGMS NIH HHS [GM 45948, T32 GM 08492, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, T32GM008492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1999, BBA-GENE STRUCT EXPR, V1444, P424, DOI 10.1016/S0167-4781(99)00024-X; Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Fischer CJ, 2004, J MOL BIOL, V344, P1265, DOI 10.1016/j.jmb.2004.10.004; Flores MJ, 2005, MOL MICROBIOL, V57, P1664, DOI 10.1111/j.1365-2958.2005.04753.x; Flores MJ, 2004, EMBO REP, V5, P983, DOI 10.1038/sj.embor.7400262; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Holbrook JA, 1999, BIOCHEMISTRY-US, V38, P8409, DOI 10.1021/bi990043w; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOHMAN TM, 2003, DNA HELICASES MOTORS, P303; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Mackintosh SG, 2006, NUCLEIC ACIDS RES, V34, P4154, DOI 10.1093/nar/gkl501; Maluf NK, 2003, J BIOL CHEM, V278, P31930, DOI 10.1074/jbc.M304223200; Maluf NK, 2003, J MOL BIOL, V325, P889, DOI 10.1016/S0022-2836(02)01276-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; Matson SW, 2006, NUCLEIC ACIDS RES, V34, P4089, DOI 10.1093/nar/gkl450; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Rasnik I, 2004, J MOL BIOL, V336, P395, DOI 10.1016/j.jmb.2003.12.031; REINBERG D, 1983, J BIOL CHEM, V258, P529; Robertson AB, 2006, J BIOL CHEM, V281, P19949, DOI 10.1074/jbc.M601604200; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Sikora B, 2006, J BIOL CHEM, V281, P36110, DOI 10.1074/jbc.M604412200; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 1998, NUCLEIC ACIDS RES, V26, P2374, DOI 10.1093/nar/26.10.2374; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; STRAUME M, 1992, METHOD ENZYMOL, V210, P117; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tomko EJ, 2007, MOL CELL, V26, P335, DOI 10.1016/j.molcel.2007.03.024; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Williams DJ, 2000, METHOD ENZYMOL, V321, P330; WONG I, 1992, J BIOL CHEM, V267, P7596; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Zhang WK, 2007, J MOL BIOL, V371, P336, DOI 10.1016/j.jmb.2007.05.050; Zhang XD, 2006, J BIOL CHEM, V281, P12655, DOI 10.1074/jbc.M513089200	78	91	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27076	27085		10.1074/jbc.M704399200	http://dx.doi.org/10.1074/jbc.M704399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631491	hybrid			2022-12-27	WOS:000249304900049
J	Szeto, SSW; Reinke, SN; Sykes, BD; Lemire, BD				Szeto, Samuel S. W.; Reinke, Stacey N.; Sykes, Brian D.; Lemire, Bernard D.			Ubiquinone-binding site mutations in the Saccharomyces cerevisiae succinate dehydrogenase generate superoxide and lead to the accumulation of succinate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; MITOCHONDRIAL SUCCINATE; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; OXIDATIVE STRESS; SDHD GENE; FUMARATE-HYDRATASE; ELECTRON-TRANSFER; ANCHOR SUBUNIT; II SUCCINATE	The mitochondrial succinate dehydrogenase (SDH) is an essential component of the electron transport chain and of the tricarboxylic acid cycle. Also known as complex II, this tetrameric enzyme catalyzes the oxidation of succinate to fumarate and reduces ubiquinone. Mutations in the human SDHB, SDHC, and SDHD genes are tumorigenic, leading to the development of several types of tumors, including paraganglioma and pheochromocytoma. The mechanisms linking SDH mutations to oncogenesis are still unclear. In this work, we used the yeast SDH to investigate the molecular and catalytic effects of tumorigenic or related mutations. We mutated Arg(47) of the Sdh3p subunit to Cys, Glu, and Lys and Asp(88) of the Sdh4p subunit to Asn, Glu, and Lys. Both Arg47 and Asp88 are conserved residues, and Arg47 is a known site of cancer causing mutations in humans. All of the mutants examined have reduced ubiquinone reductase activities. The SDH3 R47K, SDH4 D88E, and SDH4 D88N mutants are sensitive to hyperoxia and paraquat and have elevated rates of superoxide production in vitro and in vivo. We also observed the accumulation and secretion of succinate. Succinate can inhibit prolyl hydroxylase enzymes, which initiate a proliferative response through the activation of hypoxia-inducible factor 1 alpha. We suggest that SDH mutations can promote tumor formation by contributing to both reactive oxygen species production and to a proliferative response normally induced by hypoxia via the accumulation of succinate.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca		Reinke, Stacey/0000-0002-0758-0330				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Bayley JP, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-1; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V387, P441, DOI 10.1016/0005-2728(75)90084-5; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Fedotcheva NI, 2006, FREE RADICAL BIO MED, V41, P56, DOI 10.1016/j.freeradbiomed.2006.02.012; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; GUZY RD, 2006, J BIOL CHEM, V91, P807; Habano W, 2003, ONCOL REP, V10, P1375; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; Horsefield R, 2006, J BIOL CHEM, V281, P7309, DOI 10.1074/jbc.M508173200; Huang LS, 2005, ACTA CRYSTALLOGR D, V61, P380, DOI 10.1107/S0907444905000181; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; Johnson-Cadwell LI, 2007, J NEUROCHEM, V101, P1619, DOI 10.1111/j.1471-4159.2007.04516.x; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; KITA K, 1989, J BIOL CHEM, V264, P2672; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Mashego MR, 2005, FEMS YEAST RES, V5, P419, DOI 10.1016/j.femsyr.2004.11.008; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 2004, J BIOL CHEM, V279, P9432, DOI 10.1074/jbc.M311877200; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Schiavi F, 2005, JAMA-J AM MED ASSOC, V294, P2057, DOI 10.1001/jama.294.16.2057; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015; SILKIN Y, 2007, BIOCHIM BIOPHYS ACTA, V2, P143; SINGER TP, 1965, FLAVINS FLAVOPROTEIN, P391; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	63	81	83	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27518	27526		10.1074/jbc.M700601200	http://dx.doi.org/10.1074/jbc.M700601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636259	hybrid			2022-12-27	WOS:000249304900092
J	El-Shewy, HM; Lee, MH; Obeid, LM; Jaffa, AA; Luttrell, LM				El-Shewy, Hesham M.; Lee, Mi-Hye; Obeid, Lina M.; Jaffa, Ayad A.; Luttrell, Louis M.			The insulin-like growth factor type 1 and insulin-like growth factor type 2/Mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; FACTOR-II RECEPTOR; FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; BINDING-PROTEINS; SIGNALING PATHWAYS; DEPENDENT PATHWAY; ACTIVATION; RELAXIN	Insulin-like growth factor types 1 and 2 ( IGF-1; IGF-2) and insulin-like peptides are all members of the insulin superfamily of peptide hormones but bind to several distinct classes of membrane receptor. Like the insulin receptor, the IGF-1 receptor is a heterotetrameric receptor tyrosine kinase, whereas the IGF-2/ mannose 6-phosphate receptor is a single transmembrane domain protein that is thought to function primarily as clearance receptors. We recently reported that IGF-1 and IGF-2 stimulate the ERK1/2 cascade by triggering sphingosine kinase-dependent "transactivation" of G protein-coupled sphingosine-1-phosphate receptors. To determine which IGF receptors mediate this effect, we tested seven insulin family peptides, IGF-1, IGF-2, insulin, and insulin-like peptides 3, 4, 6, and 7, for the ability to activate ERK1/2 in HEK293 cells. Only IGF-1 and IGF-2 potently activated ERK1/2. Although IGF-2 was predictably less potent than IGF-1 in activating the IGF-1 receptor, they were equipotent stimulators of ERK1/2. Knockdown of IGF-1 receptor expression by RNA interference reduced the IGF-1 response to a greater extent than the IGF-2 response, suggesting that IGF-2 did not signal exclusively via the IGF-1 receptor. In contrast, IGF-2 receptor knockdown markedly reduced IGF-2 stimulated ERK1/2 phosphorylation, with no effect on the IGF-1 response. As observed previously, both the IGF-1 and the IGF-2 responses were sensitive to pertussis toxin and the sphingosine kinase inhibitor, dimethylsphingosine. These data indicate that endogenous IGF-1 and IGF-2 receptors can independently initiate ERK1/2 signaling and point to a potential physiologic role for IGF-2 receptors in the cellular response to IGF-2.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Res Serv Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St 816 St CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		obeid, lina/0000-0002-0734-0847; Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58283] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; DEL PL, 1997, SCIENCE, V278, P687; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Dupont Joelle, 2003, Birth Defects Research, V69, P257, DOI 10.1002/bdrc.10022; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; Hawkes C, 2006, J NEUROSCI, V26, P585, DOI 10.1523/JNEUROSCI.2730-05.2006; Hawkes C, 2004, BRAIN RES REV, V44, P117, DOI 10.1016/j.brainresrev.2003.11.002; Hawkes C, 2003, J COMP NEUROL, V458, P113, DOI 10.1002/cne.10578; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Janez A, 2000, J BIOL CHEM, V275, P26870; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOJIMA I, 1988, BIOCHEM BIOPH RES CO, V154, P9, DOI 10.1016/0006-291X(88)90642-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; Patel TB, 2004, PHARMACOL REV, V56, P371, DOI 10.1124/pr.56.3.4; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saito T, 2004, ENDOCRINOLOGY, V145, P4232, DOI 10.1210/en.2004-0401; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Shin HS, 2003, CIRC RES, V93, P302, DOI 10.1161/01.RES.0000086803.64109.9E; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14	51	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26150	26157		10.1074/jbc.M703276200	http://dx.doi.org/10.1074/jbc.M703276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620336	hybrid			2022-12-27	WOS:000249239600018
J	Hughes, E; Clayton, JC; Kitmitto, A; Esmann, M; Middleton, DA				Hughes, Eleri; Clayton, Jonathan C.; Kitmitto, Ashraf; Esmann, Mikael; Middleton, David A.			Solid-state NMR and functional measurements indicate that the conserved tyrosine residues of sarcolipin are involved directly in the inhibition of SERCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; MAGNETIC-RESONANCE-SPECTROSCOPY; ORIENTED LIPID-BILAYERS; CALCIUM-TRANSPORT; MEMBRANE-PROTEIN; PHOSPHOLAMBAN; ATPASE; RECONSTITUTION; OVEREXPRESSION; ASSOCIATION	The transmembrane protein sarcolipin regulates calcium storage in the sarcoplasmic reticulum of skeletal and cardiac muscle cells by modulating the activity of sarco(endo) plasmic reticulum Ca2+- ATPases (SERCAs). The highly conserved C-terminal region ((27)RSYQY-COOH) of sarcolipin helps to target the protein to the sarcoplasmic reticulum membrane and may also participate in the regulatory interaction between sarcolipin and SERCA. Here we used solid-state NMR measurements of local protein dynamics to illuminate the direct interaction between the Tyr(29) and Tyr(31) side groups of sarcolipin and skeletal muscle Ca2+- ATPase (SERCA1a) embedded in dioleoylphosphatidylcholine bilayers. Further solidstate NMR experiments together with functional measurements on SERCA1a in the presence of NAc-RSYQY, a peptide representing the conserved region of sarcolipin, suggest that the peptide binds to the same site as the parent protein at the luminal face of SERCA1a, where it reduces V-max for calcium transport and inhibits ATP hydrolysis with an IC50 of similar to 200 mu M. The inhibitory effect of NAc-RSYQY is remarkably sequence-specific, with the native aromatic residues being essential for optimal inhibitory activity. This combination of physical and functional measurements highlights the importance of aromatic and polar residues in the C-terminal region of sarcolipin for regulating calcium cycling and muscle contractility.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Med, Div Cardiovasc & Endocrine Sci, Manchester M13 9PT, Lancs, England; Aarhus Univ, Inst Physiol & Biophys, Dept Biophys, DK-8000 Aarhus, Denmark	University of Liverpool; University of Manchester; University of Manchester; Aarhus University	Middleton, DA (corresponding author), Univ Liverpool, Sch Biol Sci, Crown St, Liverpool L69 7ZB, Merseyside, England.	middleda@liv.ac.uk						Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Babu GJ, 2006, J BIOL CHEM, V281, P3972, DOI 10.1074/jbc.M508998200; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Buffy JJ, 2006, BIOCHEMISTRY-US, V45, P10939, DOI 10.1021/bi060728d; Buffy JJ, 2006, J MOL BIOL, V358, P420, DOI 10.1016/j.jmb.2006.02.005; Cady SD, 2007, J AM CHEM SOC, V129, P5719, DOI 10.1021/ja070305e; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; Gramolini AO, 2004, P NATL ACAD SCI USA, V101, P16807, DOI 10.1073/pnas.0407815101; Hellstern S, 2001, J BIOL CHEM, V276, P30845, DOI 10.1074/jbc.M102495200; Hughes E, 2005, BIOCHEMISTRY-US, V44, P4055, DOI 10.1021/bi0482351; Hughes E, 2003, J BIOL CHEM, V278, P20835, DOI 10.1074/jbc.M212208200; KARON BS, 1995, ANAL BIOCHEM, V227, P328, DOI 10.1006/abio.1995.1288; KIM HW, 1990, J BIOL CHEM, V265, P1702; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Klodos I, 2002, KIDNEY INT, V62, P2097, DOI 10.1046/j.1523-1755.2002.00654.x; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m; Minamisawa S, 2003, J BIOL CHEM, V278, P9570, DOI 10.1074/jbc.M213132200; NAGASH S, 2000, BIOCHEM J, V351, P195; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102; Patching SG, 2004, J AM CHEM SOC, V126, P3072, DOI 10.1021/ja037163i; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; SZYMANSKA G, 1991, MEMBRANE BIOCHEM, V9, P191; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; Takegoshi K, 2001, CHEM PHYS LETT, V344, P631, DOI 10.1016/S0009-2614(01)00791-6; Tatulian SA, 2002, BIOCHEMISTRY-US, V41, P741, DOI 10.1021/bi011148d; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Traaseth NJ, 2006, BIOCHEMISTRY-US, V45, P13827, DOI 10.1021/bi0607610; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Uemura N, 2004, EUR J CLIN INVEST, V34, P723, DOI 10.1111/j.1365-2362.2004.01422.x; Waterborg Jakob H., 1996, P7, DOI 10.1007/978-1-60327-259-9_2; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; Zamoon J, 2005, P NATL ACAD SCI USA, V102, P4747, DOI 10.1073/pnas.0406039102	43	19	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26603	10.1074/jbc.M611668200	http://dx.doi.org/10.1074/jbc.M611668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616528	hybrid			2022-12-27	WOS:000249239600063
J	Kizhatil, K; Davis, JQ; Davis, L; Hoffman, J; Hogan, BLM; Bennett, V				Kizhatil, Krishnakumar; Davis, Jonathan Q.; Davis, Lydia; Hoffman, Jan; Hogan, Brigid L. M.; Bennett, Vann			Ankyrin-G is a molecular partner of E-cadherin in epithelial cells and early embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; MEMBRANE CYTOSKELETAL COMPLEX; CYTOPLASMIC DOMAIN; ALPHA-CATENIN; PREIMPLANTATION EMBRYOS; CRYSTAL-STRUCTURE; LATERAL MEMBRANE; DILEUCINE MOTIF; BETA-CATENIN; ADHESION	E-cadherin is a ubiquitous component of lateral membranes in epithelial tissues and is required to form the first lateral membrane domains in development. Here, we identify ankyrin-G as a molecular partner of E-cadherin and demonstrate that ankyrin-G and beta-2-spectrin are required for accumulation of E-cadherin at the lateral membrane in both epithelial cells and early embryos. Ankyrin-G binds to the cytoplasmic domain of E-cadherin at a conserved site distinct from that of E-catenin. Ankyrin- G also recruits beta-2-spectrin to E-cadherin-beta-catenin complexes, thus providing a direct connection between E-cadherin and the spectrin/actin skeleton. In addition to restricting the membrane mobility of E-cadherin, ankyrin-G and beta-2-spectrin also are required for exit of E-cadherin from the trans-Golgi network in a microtubule-dependent pathway. Ankyrin- G and beta-2-spectrin co-localize with E-cadherin in preimplantation mouse embryos. Moreover, knockdown of either ankyrin-G or beta-2-spectrin in one cell of a two-cell embryo blocks accumulation of E-cadherin at sites of cell-cell contact. E-cadherin thus requires both ankyrin-G and beta-2-spectrin for its cellular localization in early embryos as well as cultured epithelial cells. We have recently reported that ankyrin-G and beta-2-spectrin collaborate in biogenesis of the lateral membrane (Kizhatil ,K., Yoon, W., Mohler, P. J., Davis, L. H., Hoffman, J. A., and Bennett, V. (2007) J. Biol. Chem. 282, 2029 - 2037). Together with the current findings, these data suggest a ankyrin/spectrin-based mechanism for coordinating membrane assembly with extracellular interactions of E-cadherin at sites of cell-cell contact.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	benne012@mc.duke.edu	Kizhatil, Krish/AAR-5868-2021	Kizhatil, Krishnakumar/0000-0003-3755-6101				Abdi KM, 2006, J BIOL CHEM, V281, P5741, DOI 10.1074/jbc.M506697200; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DAVIS L, 1989, J BIOL CHEM, V264, P9665; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Johnson MH, 2004, SEMIN CELL DEV BIOL, V15, P583, DOI 10.1016/j.semcdb.2004.04.002; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Kizhatil K, 2007, J BIOL CHEM, V282, P2029, DOI 10.1074/jbc.M608921200; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee G, 2006, NATURE, V440, P246, DOI 10.1038/nature04437; Lemaillet G, 2003, J BIOL CHEM, V278, P27333, DOI 10.1074/jbc.M303327200; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Lopez C, 2005, J BIOL CHEM, V280, P8221, DOI 10.1074/jbc.M413351200; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Miyashita Y, 2007, J BIOL CHEM, V282, P11540, DOI 10.1074/jbc.M608351200; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papoulas O, 2005, NAT CELL BIOL, V7, P612, DOI 10.1038/ncb1264; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Pradhan D, 2001, J BIOL CHEM, V276, P4175, DOI 10.1074/jbc.M009259200; REIMA I, 1985, DIFFERENTIATION, V30, P68, DOI 10.1111/j.1432-0436.1985.tb00515.x; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SOBEL JS, 1985, J CELL BIOL, V100, P333, DOI 10.1083/jcb.100.1.333; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	45	98	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26552	10.1074/jbc.M703158200	http://dx.doi.org/10.1074/jbc.M703158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620337	hybrid			2022-12-27	WOS:000249239600059
J	Uezu, A; Horiuchi, A; Kanda, K; Kikuchi, N; Umeda, K; Tsujita, K; Suetsugu, S; Araki, N; Yamamoto, H; Takenawa, T; Nakanishi, H				Uezu, Akiyoshi; Horiuchi, Ayaka; Kanda, Kousuke; Kikuchi, Naoya; Umeda, Kazuaki; Tsujita, Kazuya; Suetsugu, Shiro; Araki, Norie; Yamamoto, Hideyuki; Takenawa, Tadaomi; Nakanishi, Hiroyuki			SGIP1 alpha is an endocytic protein that directly interacts with phospholipids and Eps15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED PITS; ACTIN CYTOSKELETON; MEMBRANE CURVATURE; ENTH/ANTH DOMAINS; TUBULIN-BINDING; PLASMA-MEMBRANE; VESICLE; DYNAMIN; CELL	SGIP1 has been shown to be an endophilin-interacting protein that regulates energy balance, but its function is not fully understood. Here, we identified its splicing variant of SGIP1 and named it SGIP1 alpha. SGIP1 alpha bound to phosphatidylserine and phosphoinositides and deformed the plasma membrane and liposomes into narrow tubules, suggesting the involvement in vesicle formation during endocytosis. SGIP1 alpha furthermore bound to Eps15, an important adaptor protein of clathrin-mediated endocytic machinery. SGIP1 alpha was colocalized with Eps15 and the AP-2 complex. Upon epidermal growth factor (EGF) stimulation, SGIP1 alpha was colocalized with EGF at the plasma membrane, indicating the localization of SGIP1 alpha at clathrin-coated pits/vesicles. SGIP1 alpha overexpression reduced transferrin and EGF endocytosis. SGIP1 alpha knockdown reduced transferrin endocytosis but not EGF endocytosis; this difference may be due to the presence of redundant pathways in EGF endocytosis. These results suggest that SGIP1 alpha plays an essential role in clathrin-mediated endocytosis by interacting with phospholipids and Eps15.	Kumamoto Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kumamoto 8608556, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan	Kumamoto University; University of Tokyo; Kumamoto University	Nakanishi, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Pharmacol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hnakanis@gpo.kumamoto-u.ac.jp	Nakanishi, Hiroyuki/AAD-9324-2020; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/ABB-6033-2020	Nakanishi, Hiroyuki/0000-0003-3982-3314; Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Nakanishi, Hiroyuki/0000-0002-9765-0266				BALABAN N, 1992, CELL MOTIL CYTOSKEL, V21, P138, DOI 10.1002/cm.970210207; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; De Zeeuw CI, 1997, NEURON, V19, P1187, DOI 10.1016/S0896-6273(00)80411-0; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Johannessen LE, 2006, MOL CELL BIOL, V26, P389, DOI 10.1128/MCB.26.2.389-401.2006; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; KREMER L, 1988, ANAL BIOCHEM, V175, P91, DOI 10.1016/0003-2697(88)90365-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morgan JR, 2003, J BIOL CHEM, V278, P33583, DOI 10.1074/jbc.M304346200; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Murph MM, 2003, J CELL SCI, V116, P1969, DOI 10.1242/jcs.00397; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; POHL T, 1990, METHOD ENZYMOL, V182, P68; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.e04-07-0596; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Strachan LR, 2004, J CELL BIOL, V167, P545, DOI 10.1083/jcb.200405024; Subtil A, 1997, J CELL SCI, V110, P2441; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Traub LM, 2005, BBA-MOL CELL RES, V1744, P415, DOI 10.1016/j.bbamcr.2005.04.005; Trevaskis J, 2005, ENDOCRINOLOGY, V146, P3757, DOI 10.1210/en.2005-0282; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	43	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26481	10.1074/jbc.M703815200	http://dx.doi.org/10.1074/jbc.M703815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626015	hybrid			2022-12-27	WOS:000249239600053
J	Zigrino, P; Steiger, J; Fox, JW; Loffek, S; Schild, A; Nischt, R; Mauch, C				Zigrino, Paola; Steiger, Julia; Fox, Jay W.; Loeffek, Stefanie; Schild, Alexander; Nischt, Roswitha; Mauch, Cornelia			Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN; MATRIX METALLOPROTEINASES; CELL-CELL; INTEGRIN; EXPRESSION; PROTEIN; ADHESION; BINDING; HACAT; MDC9	ADAM-9 belongs to a family of transmembrane, disintegrin-containing metalloproteinases involved in protein ectodomain shedding and cell-cell and cell-matrix interactions. The aim of this study was to analyze the expression of ADAM-9 in skin and to assess the role of this proteolytic/adhesive protein in skin physiology. In normal skin, ADAM-9expression was detected in both the epidermis and dermis and in vitro in keratinocytes and fibroblasts. Here we report that ADAM-9 functions as a cell adhesion molecule via its disintegrin-cysteine-rich domain. Using solid phase binding assays and antibody inhibition experiments, we demonstrated that the recombinant disintegrin-cysteine-rich domain of ADAM-9 specifically interacts with the beta 1 integrin subunit on keratinocytes. This was corroborated by co-immunoprecipitation. In addition, engagement of integrin receptors by the disintegrin-cysteine-rich domain resulted in ERK phosphorylation and increased MMP-9 synthesis. Treatment with the ERK inhibitor PD98059 inhibited MMP-9 induction. Furthermore, the presence of the soluble disintegrin-cysteine-rich domain did not interfere with cell migration on different substrates. However, keratinocytes adhering to the immobilized disintegrin-cysteine-rich domain showed increased motility, which was partially due to the induction of MMP-9 secretion. In summary, our results indicate that the ADAM-9 adhesive domain plays a role in regulating the motility of cells by interaction with beta 1 integrins and modulates MMP synthesis.	Univ Cologne, Dept Dermatol, D-50937 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50937 Cologne, Germany; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Bonn, Inst Phys Chem, D-53115 Bonn, Germany	University of Cologne; University of Cologne; University of Virginia; University of Bonn	Zigrino, P (corresponding author), Univ Cologne, Dept Dermatol, Kerpener Str 62, D-50937 Cologne, Germany.	Paola.Zigrino@uni-koeln.de		Zigrino, Paola/0000-0002-7470-0064				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; BREITKREUTZ D, 1993, DIFFERENTIATION, V54, P201, DOI 10.1111/j.1432-0436.1993.tb01602.x; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Holvoet S, 2003, EXP CELL RES, V290, P108, DOI 10.1016/S0014-4827(03)00293-3; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huang J, 2005, MOL BIOL CELL, V16, P4982, DOI 10.1091/mbc.E05-03-0258; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kamiguti AS, 1998, BRAZ J MED BIOL RES, V31, P853, DOI 10.1590/S0100-879X1998000700001; Kim MH, 2000, J IMMUNOL, V164, P5883, DOI 10.4049/jimmunol.164.11.5883; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; Lafuste P, 2005, MOL BIOL CELL, V16, P861, DOI 10.1091/mbc.e04-03-0226; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LARJAVA H, 1991, AM J MED SCI, V301, P63, DOI 10.1097/00000441-199101000-00012; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; O'Shea C, 2003, INT J CANCER, V105, P754, DOI 10.1002/ijc.11161; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Schlondorff J, 1999, J CELL SCI, V112, P3603; Smyth N, 2000, METH MOL B, V139, P49; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Tousseyn Thomas, 2006, Birth Defects Research, V78, P24, DOI 10.1002/bdrc.20066; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhou M, 2001, BIOCHEM BIOPH RES CO, V280, P574, DOI 10.1006/bbrc.2000.4155; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	42	45	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30785	30793		10.1074/jbc.M701658200	http://dx.doi.org/10.1074/jbc.M701658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704059	hybrid			2022-12-27	WOS:000250136300047
J	Daugherty, BL; Ward, C; Smith, T; Ritzenthaler, JD; Koval, M				Daugherty, Brandy L.; Ward, Christina; Smith, Tekla; Ritzenthaler, Jeffrey D.; Koval, Michael			Regulation of heterotypic claudin compatibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; EPITHELIAL-CELLS; PERMEABILITY BARRIER; OCCLUDIN; DOMAINS; MICE; MODULATION; EXPRESSION; PEPTIDE; COMPLEX	Tissue barrier function is directly mediated by tight junction transmembrane proteins known as claudins. Cells that form tight junctions typically express multiple claudin isoforms which suggests that heterotypic (head-to-head) binding between different claudin isoforms may play a role in regulating paracellular permeability. However, little is known about motifs that control heterotypic claudin compatibility. We found that although claudin-3 and claudin-4 were heteromerically compatible when expressed in the same cell, they did not heterotypically interact despite having extracellular loop (EL) domains that are highly conserved at the amino acid level. Claudin-1 and -5, which were heterotypically compatible with claudin-3, did not heterotypically bind to claudin-4. In contrast, claudin-4 chimeras containing either the first EL domain or the second EL domain of claudin-3 were able to heterotypically bind to claudin-1, claudin-3, and claudin-5. Moreover, a single point mutation in the first extracellular loop domain of claudin-3 to convert Asn(44) to the corresponding amino acid in claudin-4 (Thr) produced a claudin capable of heterotypic binding to claudin-4 while still retaining the ability to bind to claudin-1 and -5. Thus, control of heterotypic claudin-claudin interactions is sensitive to small changes in the EL domains.	Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA	Emory University	Koval, M (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	mhkoval@emory.edu	Koval, Michael/C-6366-2015	Koval, Michael/0000-0002-5422-5614	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, R01HL083120] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL083120-02, HL083120, R01 HL083120, P01-HL019737-26, P01 HL019737-300018, P01 HL019737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandre MD, 2005, J CELL SCI, V118, P2683, DOI 10.1242/jcs.02406; Amasheh S, 2005, CELL TISSUE RES, V321, P89, DOI 10.1007/s00441-005-1101-0; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003; Das Sarma J, 2005, CELL COMMUN ADHES, V12, P237, DOI 10.1080/15419060500511875; Everett RS, 2006, MOL PHARMACOL, V69, P492, DOI 10.1124/mol.105.017251; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Haubrich S, 1996, MOL BIOL CELL, V7, P1995, DOI 10.1091/mbc.7.12.1995; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hou JH, 2005, J CELL SCI, V118, P5109, DOI 10.1242/jcs.02631; Kojima S, 2002, J MEMBRANE BIOL, V186, P81, DOI 10.1007/s00232-001-0137-7; Koval M, 2006, CELL COMMUN ADHES, V13, P127, DOI 10.1080/15419060600726209; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Nusrat A, 2005, MOL BIOL CELL, V16, P1725, DOI 10.1091/mbc.E04-06-0465; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Turksen K, 2002, DEVELOPMENT, V129, P1775; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Wang FS, 2003, AM J RESP CELL MOL, V29, P62, DOI 10.1165/rcmb.2002-0180OC; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yu ASL, 2005, AM J PHYSIOL-CELL PH, V288, pC1231, DOI 10.1152/ajpcell.00581.2004	33	121	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30005	30013		10.1074/jbc.M703547200	http://dx.doi.org/10.1074/jbc.M703547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699514	hybrid			2022-12-27	WOS:000249981200030
J	Sugai, R; Takemae, K; Tokuda, H; Nishiyama, KI				Sugai, Rie; Takemae, Kazuhisa; Tokuda, Hajime; Nishiyama, Ken-ichi			Topology inversion of SecG is essential for cytosolic SecA-dependent stimulation of protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; ESCHERICHIA-COLI SECA; PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; PRECURSOR PROTEIN; PLASMA-MEMBRANE; DIMERIC SECA; SECRETORY PROTEINS; CATALYTIC CYCLE; LOW-TEMPERATURE	SecG, a subunit of the protein translocon, undergoes a cycle of topology inversion. To further examine the role of this topology inversion, we analyzed the activity of membrane vesicles carrying a SecG-PhoA fusion protein (SecG-PhoA inverted membrane vesicles (IMVs)). In the absence of externally added SecA, SecG-PhoA IMVs were as active in protein translocation as SecG(+) IMVs per SecA. Consistent with this observation, insertion of membrane-bound SecA into SecG-PhoA IMVs was normally observed. On the other hand, externally added SecA did not affect the activity of SecG-PhoA IMVs, but it caused > 10-fold stimulation of the translocation activity of SecG(+) IMVs, indicating that the topology inversion of SecG, which cannot occur in SecG-PhoA IMVs, is essential for cytosolic SecA-dependent stimulation of protein translocation. SecG-PhoA IMVs generated a 46-kDa fragment of SecA upon trypsin treatment. The accumulation of this membrane-inserted SecA in the SecG-PhoA IMVs was responsible for the loss of the soluble SecA-dependent stimulation. Moreover, fixation of the inverted SecG topology was found to be dependent on soluble SecA. The dual functions of SecG in protein translocation will be discussed.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Nishiyama, KI (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	unishiy@mail.ecc.u-tokyo.ac.jp						AKITA M, 1990, J BIOL CHEM, V265, P8164; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanada M, 1996, FEBS LETT, V381, P25, DOI 10.1016/0014-5793(96)00066-X; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; Nagamori S, 2002, J BIOCHEM, V132, P629, DOI 10.1093/oxfordjournals.jbchem.a003266; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; NISHIYAMA K, 1995, BIOCHEM BIOPH RES CO, V217, P217, DOI 10.1006/bbrc.1995.2766; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Nishiyame K, 2005, BBA-GENE STRUCT EXPR, V1729, P166, DOI 10.1016/j.bbaexp.2005.05.003; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Rusch SL, 2007, BBA-BIOMEMBRANES, V1768, P5, DOI 10.1016/j.bbamem.2006.08.013; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Slius EO, 2006, J BACTERIOL, V188, P1188, DOI 10.1128/JB.188.3.1188-1190.2006; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1987, J BIOL CHEM, V262, P2358	58	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29540	29548		10.1074/jbc.M704716200	http://dx.doi.org/10.1074/jbc.M704716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17704542	hybrid			2022-12-27	WOS:000249788000051
J	Beisswenger, C; Coyne, CB; Shchepetov, M; Weiser, JN				Beisswenger, Christoph; Coyne, Carolyn B.; Shchepetov, Mikhail; Weiser, Jeffrey N.			Role of p38 MAP kinase and transforming growth factor-beta signaling in transepithelial migration of invasive bacterial pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONTYPABLE HAEMOPHILUS-INFLUENZAE; AIRWAY EPITHELIAL-CELLS; LIPOTEICHOIC ACID LTA; STREPTOCOCCUS-PNEUMONIAE; P38 MAPK; ENDOTHELIAL PERMEABILITY; MUCIN TRANSCRIPTION; TIGHT JUNCTIONS; LUNG	Streptococcus pneumoniae and Haemophilus influenzae are human pathogens that often asymptomatically colonize the mucosal surface of the upper respiratory tract, but also occasionally cause invasive disease. The ability of these species to traverse the epithelium of the airway mucosa was modeled in vitro using polarized respiratory epithelial cells in culture. Migration across the epithelial barrier was preceded by loss of transepithelial resistance. Membrane products of S. pneumoniae that included lipoteichoic acid induced disruption of the epithelial barrier in a Toll-like receptor 2-dependent manner. This result correlates with a recent genetic study that associates increased TLR2 signaling with increased rates of invasive pneumococcal disease in humans. Loss of transepithelial resistance by the TLR2 ligand correlated with activation of p38 MAP kinase and transforming growth factor ( TGF)-beta signaling. Activation of p38 MAPK and TGF-beta signaling in epithelial cells upon nasal infection with S. pneumoniae was also demonstrated in vivo. Inhibition of either p38 MAPK or TGF-beta signaling was sufficient to inhibit the migration of S. pneumoniae or H. influenzae. Our data shows that diverse bacteria utilize common mechanisms, including MAPK and TGF-beta signaling pathways to disrupt epithelial barriers and promote invasion.	Univ Penn, Dept Microbiol & Pediat, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiser, JN (corresponding author), Univ Penn, Dept Microbiol & Pediat, Sch Med, Philadelphia, PA 19104 USA.	weiser@mail.med.upenn.edu	Beisswenger, Christoph/GRO-6580-2022	Weiser, Jeffrey/0000-0001-7168-8090	NIAID NIH HHS [AI138446, AI44231] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044231, R01AI044231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Birukova AA, 2005, FEBS LETT, V579, P4031, DOI 10.1016/j.febslet.2005.06.018; Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Chen ML, 2006, INFECT IMMUN, V74, P6581, DOI 10.1128/IAI.00958-06; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Chow EK, 2005, EMBO J, V24, P4071, DOI 10.1038/sj.emboj.7600867; Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Ehrhardt C, 2002, CELL TISSUE RES, V308, P391, DOI 10.1007/s00441-002-0548-5; Gould JM, 2002, J INFECT DIS, V186, P361, DOI 10.1086/341658; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Han SH, 2003, INFECT IMMUN, V71, P5541, DOI 10.1128/IAI.71.10.5541-5548.2003; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kapus A, 2006, BIOCHEM CELL BIOL, V84, P870, DOI 10.1139/O06-202; Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976; Kim JY, 2005, INFECT IMMUN, V73, P7107, DOI 10.1128/IAI.73.11.7107-7112.2005; KLEIN RA, 1994, CARBOHYD RES, V256, P189, DOI 10.1016/0008-6215(94)84209-4; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; McCool TL, 2002, J EXP MED, V195, P359, DOI 10.1084/jem.20011576; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; Mikami F, 2006, J BIOL CHEM, V281, P22397, DOI 10.1074/jbc.M602124200; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; N'Guessan PD, 2006, AM J PHYSIOL-LUNG C, V290, pL1131, DOI 10.1152/ajplung.00383.2005; Nelson AL, 2007, INFECT IMMUN, V75, P83, DOI 10.1128/IAI.01475-06; Ratner AJ, 2006, J BIOL CHEM, V281, P12994, DOI 10.1074/jbc.M511431200; Ratner AJ, 2005, P NATL ACAD SCI USA, V102, P3429, DOI 10.1073/pnas.0500599102; RAYNER CFJ, 1995, INFECT IMMUN, V63, P442, DOI 10.1128/IAI.63.2.442-447.1995; Ring A, 1998, J CLIN INVEST, V102, P347, DOI 10.1172/JCI2406; Schmeck B, 2006, AM J PHYSIOL-LUNG C, V290, pL730, DOI 10.1152/ajplung.00271.2005; Schmeck B, 2004, J BIOL CHEM, V279, P53241, DOI 10.1074/jbc.M313702200; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; van Schilfgaarde M, 1999, MICROB PATHOGENESIS, V26, P249, DOI 10.1006/mpat.1998.0269; VANSCHILFGAARDE M, 1995, INFECT IMMUN, V63, P4729, DOI 10.1128/IAI.63.12.4729-4737.1995; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; Weiser JN, 2003, P NATL ACAD SCI USA, V100, P4215, DOI 10.1073/pnas.0637469100	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28700	28708		10.1074/jbc.M703576200	http://dx.doi.org/10.1074/jbc.M703576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17650505	hybrid			2022-12-27	WOS:000249642100044
J	Fernando, R; Foster, JS; Bible, A; Strom, A; Pestell, RG; Rao, M; Saxton, A; Baek, SJ; Yamaguchi, K; Donnell, R; Cekanova, M; Wimalasena, J				Fernando, Romaine; Foster, James S.; Bible, Amber; Stroem, Anders; Pestell, Richard G.; Rao, Mahadev; Saxton, Arnold; Baek, Seung Joon; Yamaguchi, Kiyoshi; Donnell, Robert; Cekanova, Maria; Wimalasena, Jay			Breast cancer cell proliferation is inhibited by bad - Regulation of CYCLIN D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; CYCLE PROGRESSION; SIGNALING PATHWAY; E-CDK2 ACTIVATION; PHOSPHORYLATION; D1; APOPTOSIS; ESTROGEN; SURVIVAL; PROTEIN	Recent investigations suggest that functions of the proapoptotic BCL2 family members, including BAD, are not limited to regulation of apoptosis. Here we demonstrate that BAD inhibits G(1) to S phase transition in MCF7 breast cancer cells independent of apoptosis. BAD overexpression inhibited G1 transit and cell growth as well as cyclin D1 expression. Inhibition of cyclin D1 expression was mediated through inhibition of transcription activated by AP1. Chromatin immunoprecipitation assays indicated that BAD is localized at the 12-O-tetradecanoylphorbol-13-acetate-response element (TRE) and cAMP-response element (CRE) in the cyclin D1 promoter. This was shown to reflect direct binding interactions of BAD with c-Jun, and this interaction inhibited the activity of AP1 complexes at TRE. BAD did not interact with phosphorylated forms of c-Jun. Our data suggest that inhibitory TRE/CRE-c-Jun-BAD complexes are present at the cyclin D1 promoter in quiescent cells. Estrogen stimulation displaced BAD from TRE/CRE elements in MCF7 cells, whereas BAD overexpression inhibited estrogen-induced cyclin D1 synthesis and cell proliferation. Inhibition of endogenous BAD in MCF7 cells markedly increased the proliferative fraction and DNA synthesis, activated Cdks, and increased cyclin D1 protein levels. This action of BAD required serine residues Ser(75) and Ser(99). Both phosphorylated and unphosphorylated forms of BAD localized to the nuclei of human breast epithelial cells. Thus, we demonstrate a novel role for BAD in cell cycle regulation dependent upon its phosphorylation state and independent of the BAD/BCL2 interaction and apoptosis.	Univ Tennessee, Med Ctr, Grad Sch Med, Knoxville, TN 37920 USA; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA; NCI, Dept Oncol, Natl Inst Hlth, Washington, DC 20057 USA; Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA; Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Wimalasena, J (corresponding author), Univ Tennessee, Med Ctr, Grad Sch Med, 1924 Alcoa Hwy, Knoxville, TN 37920 USA.	jwimalas@mc.utmck.edu	Cekanova, Maria/M-8085-2017	Cekanova, Maria/0000-0002-9651-1619; Webb, Amber/0000-0002-7431-0533; Saxton, Arnold/0000-0003-3345-5127; Baek, Seung/0000-0001-7866-7778				Ahamed S, 2001, MOL CARCINOGEN, V30, P88, DOI 10.1002/1098-2744(200102)30:2&lt;88::AID-MC1017&gt;3.0.CO;2-E; Alle KM, 1998, CLIN CANCER RES, V4, P847; Altucci L, 1996, ONCOGENE, V12, P2315; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Campo PA, 2002, CELL GROWTH DIFFER, V13, P409; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Crescenzi E, 2001, GYNECOL ONCOL, V81, P184, DOI 10.1006/gyno.2001.6128; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Dees C, 1997, MOL CARCINOGEN, V18, P107, DOI 10.1002/(SICI)1098-2744(199702)18:2<107::AID-MC6>3.0.CO;2-D; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Dumay A, 2006, ONCOGENE, V25, P3196, DOI 10.1038/sj.onc.1209344; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	41	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28864	28873		10.1074/jbc.M700785200	http://dx.doi.org/10.1074/jbc.M700785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17670745	hybrid			2022-12-27	WOS:000249642100061
J	Iwaki, S; Sano, T; Takagi, T; Osumi, M; Kihara, A; Igarashi, Y				Iwaki, Soichiro; Sano, Takamitsu; Takagi, Tomoko; Osumi, Masako; Kihara, Akio; Igarashi, Yasuyuki			Intracellular trafficking pathway of yeast long-chain base kinase Lcb4, from its synthesis to its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-VACUOLE JUNCTIONS; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; SPHINGOID BASE; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; SECRETORY PATHWAY; SHUTTLE VECTORS	Sphingoid long-chain base 1-phosphates act as bioactive lipid molecules in eukaryotic cells. In budding yeast, long-chain base 1-phosphates are synthesized mainly by the long-chain base kinase Lcb4. We recently reported that, soon after yeast cells enter into the stationary phase, Lcb4 is rapidly degraded by being delivered to the vacuole in a palmitoylation- and phosphorylation-dependent manner. In this study, we investigated the complete trafficking pathway of Lcb4, from its synthesis to its degradation. After membrane anchoring by palmitoylation at the Golgi apparatus, Lcb4 is delivered to the plasma membrane ( PM) through the late Sec pathway and then to the endoplasmic reticulum ( ER). The yeast ER consists of a cortical network juxtaposed to the PM ( cortical ER) with tubular connections to the nuclear envelope ( nuclear ER). Remarkably, the localization of Lcb4 is restricted to the cortical ER. As the cells reach the stationary phase, G(1) cell cycle arrest initiates Lcb4 degradation and its delivery to the vacuole via the Golgi apparatus. The protein transport pathway from the PM to the ER found in this study has not been previously reported. We speculate that this novel pathway is mediated by the PM-ER contact.	Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Bhiofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Div Biol, Dept Life Sci, Grad Sch Arts & Sci,Meguro Ku, Tokyo 1538902, Japan; Japan Womens Univ, Bunkyo Ku, Electron Microscopy Lab, Open Res Ctr, Tokyo 1128681, Japan; Integrated Imaging Res Support, Chiyoda Ku, Tokyo 1020093, Japan; Hokkaido Univ, Kita Ku, Lab Biomembrane & Biofunct Chem, Fac Adv Life Sci, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; University of Tokyo; Japan Womens University; Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomembrane & Bhiofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	Sano, Takamitsu/F-9410-2012; KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Baumann NA, 2005, BIOCHEMISTRY-US, V44, P5816, DOI 10.1021/bi048296z; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Brachmann CB, 1998, YEAST, V14, P115; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; de Martin PE, 2005, J CELL SCI, V118, P65, DOI 10.1242/jcs.01583; Dong XW, 2003, MOL CELL BIOL, V23, P6574, DOI 10.1128/MCB.23.18.6574-6584.2003; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Humbel BM, 2001, YEAST, V18, P433, DOI 10.1002/yea.694; Iwaki S, 2005, J BIOL CHEM, V280, P6520, DOI 10.1074/jbc.M410908200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Juschke C, 2005, J CELL BIOL, V169, P613, DOI 10.1083/jcb.200503033; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kihara A, 2005, MOL CELL BIOL, V25, P9189, DOI 10.1128/MCB.25.21.9189-9197.2005; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kihara A, 2007, PROG LIPID RES, V46, P126, DOI 10.1016/j.plipres.2007.03.001; KONOMI M, 2000, PLANT MORPHOL, V12, P20; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kvam E, 2005, MOL BIOL CELL, V16, P3987, DOI 10.1091/mbc.e05-04-0290; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Li YF, 2004, J BIOL CHEM, V279, P45226, DOI 10.1074/jbc.M407600200; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, METHOD ENZYMOL, V311, P223; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sano T, 2005, J BIOL CHEM, V280, P36674, DOI 10.1074/jbc.M503147200; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Takagi T, 2003, J ELECTRON MICROSC, V52, P161, DOI 10.1093/jmicro/52.2.161; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	52	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28485	28492		10.1074/jbc.M701607200	http://dx.doi.org/10.1074/jbc.M701607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686782	Green Published, hybrid			2022-12-27	WOS:000249642100022
J	Conners, R; Konarev, AV; Forsyth, J; Lovegrove, A; Marsh, J; Joseph-Horne, T; Shewry, P; Brady, RL				Conners, Rebecca; Konarev, Alexander V.; Forsyth, Jane; Lovegrove, Alison; Marsh, Justin; Joseph-Horne, Timothy; Shewry, Peter; Brady, R. Leo			An unusual helix-turn-helix protease inhibitory motif in a novel trypsin inhibitor from seeds of veronica (Veronica hederifolia L.)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; CRYSTAL-STRUCTURE; STRUCTURAL MOTIF; ACTIVE-SITE; CYCLOTIDES; RESOLUTION; DISCOVERY; PEPTIDES; GEOMETRY; COMPLEX	The storage tissues of many plants contain protease inhibitors that are believed to play an important role in defending the plant from invasion by pests and pathogens. These proteinaceous inhibitor molecules belong to a number of structurally distinct families. We describe here the isolation, purification, initial inhibitory properties, and three-dimensional structure of a novel trypsin inhibitor from seeds of Veronica hederifolia (VhTI). The VhTI peptide inhibits trypsin with a submicromolar apparent K-i and is expected to be specific for trypsin-like serine proteases. VhTI differs dramatically in structure from all previously described families of trypsin inhibitors, consisting of a helix-turn-helix motif, with the two a helices tightly associated by two disulfide bonds. Unusually, the crystallized complex is in the form of a stabilized acyl-enzyme intermediate with the scissile bond of the VhTI inhibitor cleaved and the resulting N-terminal portion of the inhibitor remaining attached to the trypsin catalytic serine 195 by an ester bond. A synthetic, truncated version of the VhTI peptide has also been produced and co-crystallized with trypsin but, surprisingly, is seen to be uncleaved and consequently forms a noncovalent complex with trypsin. The VhTI peptide shows that effective enzyme inhibitors can be constructed from simple helical motifs and provides a new scaffold on which to base the design of novel serine protease inhibitors.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; All Russian Inst Plant Protect, R-196608 St Petersburg AL5 2JQ, Russia; Rothamsted Res, Harpenden AL5 2JQ, Herts, England	University of Bristol; All-Russian Institute of Plant Protection; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Brady, RL (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	L.Brady@bris.ac.uk	Conners, Rebecca/C-2608-2013; Konarev, Alexander/Y-9620-2019; Konarev, Alexander/G-2126-2015	Konarev, Alexander/0000-0002-5148-2850; Konarev, Alexander/0000-0002-5148-2850; Conners, Rebecca/0000-0002-8653-1771	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004157, BB/C502414/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1999, SEED PROTEINS; BIRK Y, 2003, PLANT PROTEASE INHIB, P23; BODE W, 1992, PROTEIN SCI, V1, P426; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200; KONAREV A V, 1986, Biokhimiya, V51, P195; Konarev AV, 2004, PHYTOCHEMISTRY, V65, P3003, DOI 10.1016/j.phytochem.2004.08.022; Konarev AV, 2002, PHYTOCHEMISTRY, V59, P279, DOI 10.1016/S0031-9422(01)00463-0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI MJ, 1986, NUTR TOXICOLOGICAL S; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; McBride JD, 2002, BIOPOLYMERS, V66, P79, DOI 10.1002/bip.10228; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otlewski J, 2005, EMBO J, V24, P1303, DOI 10.1038/sj.emboj.7600611; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shewry PR, 1997, ADV BOT RES, V26, P135, DOI 10.1016/S0065-2296(08)60120-2; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	37	43	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27760	27768		10.1074/jbc.M703871200	http://dx.doi.org/10.1074/jbc.M703871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640870	hybrid, Green Published			2022-12-27	WOS:000249455600025
J	Nishimura, K; Segawa, H; Goto, T; Morishita, M; Masago, A; Takahashi, H; Ohmiya, Y; Sakaguchi, T; Asada, M; Imamura, T; Shimotono, K; Takayama, K; Yoshida, T; Nakanishi, M				Nishimura, Ken; Segawa, Hiroaki; Goto, Takahiro; Morishita, Mariko; Masago, Akinori; Takahashi, Hitoshi; Ohmiya, Yoshihiro; Sakaguchi, Takemasa; Asada, Masahiro; Imamura, Toru; Shimotono, Kunitada; Takayama, Kozo; Yoshida, Tetsuya; Nakanishi, Mahito			Persistent and stable gene expression by a cytoplasmic RNA replicon based on a noncytopathic variant Sendai virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIG-I; MESSENGER-RNA; V-PROTEINS; ACTIVATION; EFFICIENT; VECTORS; CDNA; LUCIFERASE; INITIATION; INDUCTION	Persistent and stable expression of foreign genes has been achieved in mammalian cells by integrating the genes into the host chromosomes. However, this approach has several shortcomings in practical applications. For example, large scale production of protein pharmaceutics frequently requires laborious amplification of the inserted genes to optimize the gene expression. The random chromosomal insertion of exogenous DNA also results occasionally in malignant transformation of normal tissue cells, raising safety concerns in medical applications. Here we report a novel cytoplasmic RNA replicon capable of expressing installed genes stably without chromosome insertion. This system is based on the RNA genome of a noncytopathic variant Sendai virus strain, Cl.151. We found that this variant virus establishes stable symbiosis with host cells by escaping from retinoic acid-inducible gene I-interferon regulatory factor 3-mediated antiviral machinery. Using a cloned genome cDNA of Sendai virus Cl. 151, we developed a recombinant RNA installed with exogenous marker genes that was maintained stably in the cytoplasm as a high copy replicon (about 4 x 104 copies/cell) without interfering with normal cellular function. Strong expression of the marker genes persisted for more than 6 months in various types of cultured cells and for at least two months in rat colonic mucosa without any apparent side effects. This stable RNA replicon is a potentially valuable genetic platform for various biological applications.	Natl Inst Adv Ind Sci & Technol, Biotherapeut Res Lab, Tsukuba, Ibaraki 3058562, Japan; Natl Inst Adv Ind Sci & Technol, Signalling Mol Res Lab, Tsukuba, Ibaraki 3058562, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028471, Japan; Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo 1428501, Japan; Osaka Univ, Res Inst Microbial Dis, Osaka, Japan; Kyoto Univ, Inst Virus Res, Dept Oncol, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, Osaka 5638577, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Virol, Minami Ku, Hiroshima 7348551, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Japan Society for the Promotion of Science; Hoshi University; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Hiroshima University	Nakanishi, M (corresponding author), Natl Inst Adv Ind Sci & Technol, Biotherapeut Res Lab, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	mahito-nakanishi@aist.go.jp	Sakaguchi, Takemasa/H-1488-2019; ASADA, MASAHIRO/M-4086-2018; Nakanishi, Mahito/I-9888-2018	Sakaguchi, Takemasa/0000-0002-3754-1252; ASADA, MASAHIRO/0000-0001-6092-2080; Nakanishi, Mahito/0000-0002-7068-7587; Nishimura, Ken/0000-0002-0716-4142				Bitzer M, 2003, J GENE MED, V5, P543, DOI 10.1002/jgm.426; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Eguchi A, 2000, J BIOL CHEM, V275, P17549, DOI 10.1074/jbc.M910004199; Enjuanes L, 2003, N COMP BIOC, V38, P151; Fujita S, 2006, BIOL PHARM BULL, V29, P1728, DOI 10.1248/bpb.29.1728; Garcin D, 1998, VIROLOGY, V243, P340, DOI 10.1006/viro.1998.9063; Goto T, 2006, PHARM RES-DORDR, V23, P384, DOI 10.1007/s11095-005-9175-7; Griesenbach U, 2005, CURR OPIN MOL THER, V7, P346; Gubbay O, 2001, J GEN VIROL, V82, P2895, DOI 10.1099/0022-1317-82-12-2895; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; Hasan MK, 1997, J GEN VIROL, V78, P2813, DOI 10.1099/0022-1317-78-11-2813; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Inoue M, 2004, J GENE MED, V6, P1069, DOI 10.1002/jgm.597; Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513; Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009; Jackson DA, 2006, MOL THER, V14, P613, DOI 10.1016/j.ymthe.2006.03.026; JOLLY DJ, 1999, COLD SPRING HARBOR M, V36, P209; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; KATO K, 1991, J BIOL CHEM, V266, P3361; KIRCHMAIER AL, 1995, J VIROL, V69, P1280, DOI 10.1128/JVI.69.2.1280-1283.1995; Komatsu T, 2004, VIROLOGY, V325, P137, DOI 10.1016/j.virol.2004.04.025; KONDO T, 1993, J BIOL CHEM, V268, P21924; Kovacs GR, 2003, J VIROL METHODS, V111, P29, DOI 10.1016/S0166-0934(03)00132-0; Lamb R. A., 2001, Fundamental virology, P689; MATSUMOTO T, 1961, J IMMUNOL, V87, P590; MATSUMOTO T, 1954, NAGOYA J MED SCI, V17, P93; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; Nakajima Y, 2004, BIOSCI BIOTECH BIOCH, V68, P565, DOI 10.1271/bbb.68.565; Nienhuis AW, 2006, MOL THER, V13, P1031, DOI 10.1016/j.ymthe.2006.03.001; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; Strahle L, 2003, J VIROL, V77, P7903, DOI 10.1128/JVI.77.14.7903-7913.2003; Strahle L, 2006, VIROLOGY, V351, P101, DOI 10.1016/j.virol.2006.03.022; TAKAGI T, 1995, J BIOCHEM-TOKYO, V118, P390, DOI 10.1093/oxfordjournals.jbchem.a124919; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026; Yoneda A, 2000, NAT BIOTECHNOL, V18, P641, DOI 10.1038/76487; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; YOSHIDA T, 1979, VIROLOGY, V92, P139, DOI 10.1016/0042-6822(79)90220-4; Yoshizaki M, 2006, J GENE MED, V8, P1151, DOI 10.1002/jgm.938	45	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27383	27391		10.1074/jbc.M702028200	http://dx.doi.org/10.1074/jbc.M702028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623660	hybrid			2022-12-27	WOS:000249304900080
J	Frasca, F; Pandini, G; Malaguarnera, R; Mandarino, A; Messina, RL; Sciacca, L; Belfiore, A; Vigneri, R				Frasca, Francesco; Pandini, Giuseppe; Malaguarnera, Roberta; Mandarino, Angelo; Messina, Rosa Linda; Sciacca, Laura; Belfiore, Antonino; Vigneri, Riccardo			Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; TYROSINE KINASE; CRK-II; PHOSPHORYLATION; PROTEIN; SUBSTRATE; SRC; ACTIVATION; DOMAIN	c-Abl is a cytoplasmic tyrosine kinase involved in several signal transduction pathways. Here we report that c-Abl is involved also in insulin receptor signaling. Indeed, c-Abl tyrosine kinase is activated upon insulin stimulation. Inhibition of c-Abl tyrosine kinase by STI571 attenuates the effect of insulin on Akt/GSK-3 beta phosphorylation and glycogen synthesis, and at the same time, it enhances the effect of insulin on ERK activation, cell proliferation, and migration. This effect of STI571 is specific to c-Abl inhibition, because it does not occur in Abl-null cells and is restored in c-Abl-reconstituted cells. Numerous evidences suggest that focal adhesion kinase ( FAK) is involved in mediating this c-Abl effect. First, anti-phosphotyrosine blots indicate that c-Abl tyrosine kinase activation is concomitant with FAK dephosphorylation in response to insulin, whereas c-Abl inhibition is accompanied by FAK phosphorylation in response to insulin, a response similar to that observed with IGF-I. Second, the c-Abl effects on insulin signaling are not observed in cells devoid of FAK (FAK(-/-) cells). Taken together these results suggest that c-Abl activation by insulin, via a modification of FAK response, may play an important role in directing mitogenic versus metabolic insulin receptor signaling.	Interna & Med Specialist Endcrinol, Dipartimento Med, I-95122 Catania, Italy; Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Magna Graecia University of Catanzaro	Frasca, F (corresponding author), Interna & Med Specialist Endcrinol, Dipartimento Med, PO Garibaldi Nesima, I-95122 Catania, Italy.	f.frasca@unict.it	Belfiore, Antonino/B-4652-2011; Frasca, Francesco/J-1332-2018; Pandini, Giuseppe/AAB-9650-2019; SCIACCA, Laura/AAS-2896-2020; Sciacca, Laura/B-9368-2014; Vigneri, Riccardo/M-3968-2017	Belfiore, Antonino/0000-0002-6181-4193; Frasca, Francesco/0000-0002-5556-3201; Pandini, Giuseppe/0000-0003-3747-7649; SCIACCA, Laura/0000-0002-3258-7200; Sciacca, Laura/0000-0002-3258-7200; Vigneri, Riccardo/0000-0002-4401-3140				Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Cheung AT, 2000, DIABETES, V49, P810, DOI 10.2337/diabetes.49.5.810; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang DS, 2006, ENDOCRINOLOGY, V147, P3333, DOI 10.1210/en.2005-0382; Huang DS, 2002, J BIOL CHEM, V277, P18151, DOI 10.1074/jbc.M104252200; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Koval AP, 1998, BIOCHEM J, V330, P923; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Lin WH, 2001, GENOMICS, V74, P12, DOI 10.1006/geno.2001.6541; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith KM, 2001, J BIOL CHEM, V276, P24372, DOI 10.1074/jbc.M100786200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; VanderZon GCM, 1996, BIOCHEMISTRY-US, V35, P10377, DOI 10.1021/bi960350r; Wang QH, 1998, MOL BIOL CELL, V9, P3057, DOI 10.1091/mbc.9.11.3057; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	37	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26077	26088		10.1074/jbc.M705008200	http://dx.doi.org/10.1074/jbc.M705008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620332	hybrid			2022-12-27	WOS:000249239600011
J	Bruchas, MR; Yang, T; Schreiber, S; DeFino, M; Kwan, SC; Li, S; Chavkin, C				Bruchas, Michael R.; Yang, Tao; Schreiber, Selena; DeFino, Mia; Kwan, Steven C.; Li, Shuang; Chavkin, Charles			Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADMINISTERED NOR-BINALTORPHIMINE; RHESUS-MONKEYS; POTENT; ASTROCYTES; ASSAY; 5'-GUANIDINONALTRINDOLE; PHOSPHORYLATION; ANTINOCICEPTION; IDENTIFICATION; PHARMACOLOGY	Norbinaltorphimine ( NorBNI), guanidinonaltrindole, and atrans-( 3R, 4R)- dimethyl- 4-( 3- hydroxyphenyl) piperidine ( JDTic) are selective kappa opioid receptor ( KOR) antagonists having very long durations of action in vivo despite binding non- covalently in vitro and having only moderately high affinities. Consistent with this, we found that antagonist treatment significantly reduced the subsequent analgesic response of mice to the KOR agonist U50,488 in the tail- withdrawal assay for 14 - 21 days. Receptor protection assays were designed to distinguish between possible explanations for this anomalous effect, and we found that mice pretreated with the readily reversible opioid antagonists naloxone or buprenorphine before norBNI responded strongly in the tail- flick analgesia assay to a subsequent challenge with U50,488 1 week later. Protection by a rapidly cleared reagent indicates that norBNI did not persist at the site of action. In vitro binding of [ H-3] U69,593 to KOR showed that K-d and Bmax values were not significantly affected by prior in vivo norBNI exposure, indicating that the agonist binding site was intact. Consistent with the concept that the long- lasting effects might be caused by a functional disruption of KOR signaling, both norBNI and JDTic were found to stimulate c- Jun N- terminal kinase ( JNK) phosphorylation in HEK293 cells expressing KOR- GFP but not in untransfected cells. Similarly, norBNI increased phospho- JNK in both the striatum and spinal cord in wild type mice but not in KOR knock- out mice. Pretreatment of mice with the JNK inhibitor SP600125 before norBNI attenuated the long acting antagonism. Together, these results suggest that the long duration KOR antagonists disrupt KOR signaling by activating JNK.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010; Bruchas, Michael/G-7616-2012	Li, Shuang/0000-0003-1684-0031	NIDA NIH HHS [R37 DA011672, F32 DA020430, R01 DA011672-05, K05 DA020570, F32-DA20430, R37-DA11672, R01 DA011672-04, KO5-DA20570, K05 DA020570-01, R01 DA011672, K05 DA020570-02] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA020570, F32DA020430, R37DA011672, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beardsley PM, 2005, PSYCHOPHARMACOLOGY, V183, P118, DOI 10.1007/s00213-005-0167-4; Beguin C, 2005, BIOORG MED CHEM LETT, V15, P2761, DOI 10.1016/j.bmcl.2005.03.113; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blkbulatov RV, 2007, BIOORG MED CHEM LETT, V17, P2229, DOI 10.1016/j.bmcl.2007.01.100; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x; BROADBEAR JH, 1994, PSYCHOPHARMACOLOGY, V115, P311, DOI 10.1007/BF02245071; Bruchas MR, 2006, J BIOL CHEM, V281, P18081, DOI 10.1074/jbc.M513640200; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V267, P1269; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; Clarke S, 2002, EUR J NEUROSCI, V16, P1705, DOI 10.1046/j.1460-9568.2002.02239.x; Dhawan BN, 1996, PHARMACOL REV, V48, P567; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; Jewett DC, 1995, BEHAV PHARMACOL, V6, P815; JONES DNC, 1992, EUR J PHARMACOL, V215, P345, DOI 10.1016/0014-2999(92)90055-9; Jones RM, 2000, EUR J PHARMACOL, V396, P49, DOI 10.1016/S0014-2999(00)00208-9; Kam AYF, 2004, J PHARMACOL EXP THER, V310, P301, DOI 10.1124/jpet.104.065078; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Ko MCH, 1999, J PHARMACOL EXP THER, V291, P1113; Kukkonen JP, 1998, BIOCHEM BIOPH RES CO, V243, P41, DOI 10.1006/bbrc.1997.8054; Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; Metcalf MD, 2005, AAPS J, V7, pE704, DOI 10.1208/aapsj070371; Negus SS, 2002, PSYCHOPHARMACOLOGY, V163, P412, DOI 10.1007/s00213-002-1038-x; Piros ET, 1996, NEUROCHEM RES, V21, P1277, DOI 10.1007/BF02532368; PORTOGHESE PS, 1987, J MED CHEM, V30, P238, DOI 10.1021/jm00385a002; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; SADEE W, 1982, J PHARMACOL EXP THER, V223, P157; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Simpson DS, 2007, J MED CHEM, V50, P3596, DOI 10.1021/jm070393d; Smith C, 2006, MOL PHARMACOL, V70, P1264, DOI 10.1124/mol.106.024612; SMITH CB, 1990, PROG CLIN BIOL RES, V328, P65; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Thomas JB, 2004, J MED CHEM, V47, P1070, DOI 10.1021/jm030467v; Thomas JB, 2003, J MED CHEM, V46, P3127, DOI 10.1021/jm030094y; Thomas JB, 2001, J MED CHEM, V44, P2687, DOI 10.1021/jm015521r; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; YOUNG AM, 1984, J PHARMACOL EXP THER, V229, P118; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	46	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29803	29811		10.1074/jbc.M705540200	http://dx.doi.org/10.1074/jbc.M705540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702750	Green Accepted, hybrid			2022-12-27	WOS:000249981200009
J	Luo, WB; Wang, YF; Reiser, G				Luo, Weibo; Wang, Yingfei; Reiser, Georg			P24A, a type I transmembrane protein, controls ARF1-dependent resensitization of protease-activated receptor-2 by influence on receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED TRANSPORT VESICLES; ADP-RIBOSYLATION FACTORS; INTRACELLULAR TRAFFICKING; CHEMOKINE GRO/CINC-1; SECRETORY PATHWAY; FAMILY-MEMBERS; RAT ASTROCYTES; GOLGI; MEMBRANE; COATOMER	Protease-activated receptor-2 (PAR- 2), the second member of the G protein-coupled PAR family, is irreversibly activated by trypsin or tryptase and then targeted to lysosomes for degradation. Intracellular presynthesized receptors stored at the Golgi apparatus repopulate the cell surface after trypsin stimulation, thereby leading to rapid resensitization to trypsin signaling. However, the molecular mechanisms of the exocytic trafficking of PAR- 2 from the Golgi apparatus to the plasma membrane remain largely unclear. Here we show that p24A, a type I transmembrane protein, which is a crucial constituent of the Golgi apparatus, associates with PAR- 2 at the Golgi apparatus. The protein interaction occurs between the N-terminal region of p24A (residues 1-105; p24A-GL (GOLD domain with a small linker)) and the second extracellular loop of PAR-2. After receptor activation, PAR- 2 dissociates from p24A. Importantly, we found that ADP-ribosylation factor 1 regulated the dissociation process and initiated PAR- 2 trafficking to the plasma membrane. Conversely, overexpression of the fragment p24A-GL, but not other mutants containing the functional coiled-coil domain of p24A, arrested PAR- 2 at the Golgi apparatus and inhibited receptor trafficking to the plasma membrane, which consequently prevented resensitization of PAR-2. These findings identify a new function of p24A as a regulator of signal-dependent trafficking that regulates the life cycle of PAR- 2, Thus, we reveal a new molecular mechanism underlying resensitization of PAR-2.	Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University	Reiser, G (corresponding author), Univ Magdeburg, Fak Med, Inst Neurobiochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@med.ovgu.de		Luo, Weibo/0000-0002-1992-0320; wang, yingfei/0000-0002-8723-252X				Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Blum R, 1999, J CELL SCI, V112, P537; Blum R, 1996, J BIOL CHEM, V271, P17183, DOI 10.1074/jbc.271.29.17183; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Carney GE, 2004, BIOL CELL, V96, P271, DOI 10.1016/j.biolcel.2004.01.004; Ciufo LF, 2000, J BIOL CHEM, V275, P8382, DOI 10.1074/jbc.275.12.8382; Contreras I, 2004, PLANT J, V38, P685, DOI 10.1111/j.1365-313X.2004.02075.x; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Dong CM, 2007, BBA-BIOMEMBRANES, V1768, P853, DOI 10.1016/j.bbamem.2006.09.008; Dong CM, 2006, J BIOL CHEM, V281, P38543, DOI 10.1074/jbc.M605734200; Emery G, 2000, J CELL SCI, V113, P2507; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Kaiser C, 2000, P NATL ACAD SCI USA, V97, P3783, DOI 10.1073/pnas.97.8.3783; Luo WB, 2006, J BIOL CHEM, V281, P7927, DOI 10.1074/jbc.M510784200; Luo WB, 2005, BRAIN RES, V1047, P159, DOI 10.1016/j.brainres.2005.04.040; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Satoh AK, 2005, DEVELOPMENT, V132, P1487, DOI 10.1242/dev.01704; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Shen XY, 2006, P NATL ACAD SCI USA, V103, P2635, DOI 10.1073/pnas.0510599103; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Wang YF, 2007, BIOCHEM J, V401, P65, DOI 10.1042/BJ20060732; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	41	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30246	30255		10.1074/jbc.M703205200	http://dx.doi.org/10.1074/jbc.M703205200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693410	hybrid			2022-12-27	WOS:000249981200055
J	Truscott, M; Denault, JB; Goulet, B; Leduy, L; Salvesen, GS; Nepveu, A				Truscott, Mary; Denault, Jean-Bernard; Goulet, Brigitte; Leduy, Lam; Salvesen, Guy S.; Nepveu, Alain			Carboxyl-terminal proteolytic processing of CUX1 by a caspase enables transcriptional activation in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE STIMULATION; CUT HOMEODOMAIN PROTEIN; KAPPA-B ACTIVATION; S-PHASE; DNA-BINDING; HEMATOPOIETIC-CELLS; APOPTOSIS; CLEAVAGE; DIFFERENTIATION; CYCLE	Proteolytic processing at the end of the G(1) phase generates a CUX1 isoform, p110, which functions either as a transcriptional activator or repressor and can accelerate entry into S phase. Here we describe a second proteolytic event that generates an isoform lacking two active repression domains in the COOH terminus. This processing event was inhibited by treatment of cells with synthetic and natural caspase inhibitors. In vitro, several caspases generated a processed isoform that co-migrated with the in vivo generated product. In cells, recombinant CUX1 proteins in which the region of cleavage was deleted or in which Asp residues were mutated to Ala, were not proteolytically processed. Importantly, this processing event was not associated with apoptosis, as assessed by terminal dUTP nick end labeling assay, cytochrome c localization, poly(ADP-ribose) polymerase cleavage, and fluorescence-activated cell sorting. Moreover, processing was observed in S phase but not in early G(1), suggesting that it is regulated through the cell cycle. The functional importance of this processing event was revealed in reporter and cell cycle assays. Arecombinant, processed, CUX1 protein was a more potent transcriptional activator of several cell cycle-related genes and was able to accelerate entry into S phase, whereas mutants that could not be processed were inactive in either assay. Conversely, cells treated with the quinoline-Val Asp-2,6-difluorophenoxymethylketone caspase inhibitor proliferated more slowly and exhibited delayed S phase entry following exit from quiescence. Together, our results identify a substrate of caspases in proliferating cells and suggest a mechanism by which caspases can accelerate cell cycle progression.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	McGill University; McGill University; McGill University; McGill University; Sanford Burnham Prebys Medical Discovery Institute	Nepveu, A (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain.nepveu@mcgill.ca	/AAB-8315-2020; Denault, Jean-Bernard/AAC-5945-2019	Truscott, Mary/0000-0002-2324-6383				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown NM, 2007, J BIOL CHEM, V282, P2144, DOI 10.1074/jbc.M607961200; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Frost V, 2001, ONCOGENE, V20, P2737, DOI 10.1038/sj.onc.1204367; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2002, CANCER RES, V62, P6625; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sansregret L, 2006, MOL CELL BIOL, V26, P2441, DOI 10.1128/MCB.26.6.2441-2455.2006; Santaguida M, 2005, J BIOL CHEM, V280, P32712, DOI 10.1074/jbc.M505417200; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Truscott M, 2004, J BIOL CHEM, V279, P49787, DOI 10.1074/jbc.M409484200; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Yao SL, 1996, CANCER RES, V56, P4551; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30216	30226		10.1074/jbc.M702328200	http://dx.doi.org/10.1074/jbc.M702328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17681953	hybrid			2022-12-27	WOS:000249981200052
J	Cheng, XY; Liu, JX; Asuncion-Chin, M; Blaskova, E; Bannister, JP; Dopico, AM; Jaggar, JH				Cheng, Xiaoyang; Liu, Jianxi; Asuncion-Chin, Maria; Blaskova, Eva; Bannister, John P.; Dopico, Alejandro M.; Jaggar, Jonathan H.			A novel Ca(V)1.2 N terminus expressed in smooth muscle cells of resistance size arteries modifies channel regulation by auxiliary subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; ALPHA(1C) SUBUNIT; CA2+ CHANNELS; SUBCELLULAR-LOCALIZATION; LARGE-CONDUCTANCE; BLOOD-PRESSURE; CLONING; HETEROGENEITY	Voltage-dependent L-type Ca2+ (Ca(V)1.2) channels are the principal Ca2+ entry pathway in arterial myocytes. Ca(V)1.2 channels regulate multiple vascular functions and are implicated in the pathogenesis of human disease, including hypertension. However, the molecular identity of Ca(V)1.2 channels expressed in myocytes of myogenic arteries that regulate vascular pressure and blood flow is unknown. Here, we cloned Ca(V)1.2 subunits from resistance size cerebral arteries and demonstrate that myocytes contain a novel, cysteine rich N terminus that is derived from exon 1 (termed "exon 1c"), which is located within CACNA1C, the Ca(V)1.2 gene. Quantitative PCR revealed that exon 1c was predominant in arterial myocytes, but rare in cardiac myocytes, where exon 1a prevailed. When co-expressed with alpha(2)delta subunits, Ca(V)1.2 channels containing the novel exon 1c-derived N terminus exhibited: 1) smaller whole cell current density, 2) more negative voltages of half activation (V-1/2,V-act) and half-inactivation (V-1/2,V-inact), and 3) reduced plasma membrane insertion, when compared with channels containing exon 1b. beta(1b) and beta(2a) subunits caused negative shifts in the V-1/2,V-act and (V1/2,inact) of exon 1b-containing Ca(V)1.2 alpha(1)/alpha(2)delta currents that were larger than those in exon 1c-containing Ca(V)1.2 alpha(1)/alpha(2)delta currents. In contrast, beta(3) similarly shifted V-1/2,V-act and V-1/2,V-inact of currents generated by exon 1b- and exon 1c-containing channels. beta subunits isoform-dependent differences in current inactivation rates were also detected between N-terminal variants. Data indicate that through novel alternative splicing at exon 1, the Ca(V)1.2 N terminus modifies regulation by auxiliary subunits. The novel exon 1c should generate distinct voltage-dependent Ca2+ entry in arterial myocytes, resulting in tissue-specific Ca2+ signaling.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Jaggar, JH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	jjaggar@physio1.utmem.edu	Cheng, Xiaoyang/N-9970-2019; Tuluc, Petronel/C-2527-2011; Cheng, Xiaoyang/M-1257-2017; Cheng, Xiaoyang/A-1729-2012	Cheng, Xiaoyang/0000-0003-1446-2815; Cheng, Xiaoyang/0000-0003-1446-2815; Cheng, Xiaoyang/0000-0003-1446-2815	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077424, R01HL077678, R01HL067061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011560, R37AA011560, R29AA011560] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067061-05, R01 HL077678-03, HL77678, HL77424, R01 HL077424, R01 HL067061, HL67061, R01 HL077678] Funding Source: Medline; NIAAA NIH HHS [R29 AA011560, AA11560, R37 AA011560, R01 AA011560] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arien H, 2003, J BIOL CHEM, V278, P29231, DOI 10.1074/jbc.M301401200; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Bogdanov Y, 2000, EUR J NEUROSCI, V12, P894, DOI 10.1046/j.1460-9568.2000.00981.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387; Felix R, 1997, J NEUROSCI, V17, P6884; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gollasch M, 1997, KIDNEY BLOOD PRESS R, V20, P355, DOI 10.1159/000174250; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Jaggar JH, 2005, CIRC RES, V97, P805, DOI 10.1161/01.RES.0000186180.47148.7b; Jaggar JH, 2001, AM J PHYSIOL-CELL PH, V281, pC439, DOI 10.1152/ajpcell.2001.281.2.C439; Klugbauer N, 2003, J BIOENERG BIOMEMBR, V35, P639, DOI 10.1023/B:JOBB.0000008028.41056.58; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Liao P, 2005, CARDIOVASC RES, V68, P197, DOI 10.1016/j.cardiores.2005.06.024; LIU W, 2003, ANN J PHYSL HEART CI, V285, pH97; Lyford GL, 2002, AM J PHYSIOL-CELL PH, V283, pC1001, DOI 10.1152/ajpcell.00140.2002; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Nelson MT, 1990, AM J PHYSIOL, V259, P3; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Pietrzykowski AZ, 2004, J NEUROSCI, V24, P8322, DOI 10.1523/JNEUROSCI.1536-04.2004; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Restituito S, 2001, BIOPHYS J, V81, P89, DOI 10.1016/S0006-3495(01)75682-2; Saada N, 2003, BIOCHEM BIOPH RES CO, V302, P23, DOI 10.1016/S0006-291X(03)00097-4; Saada NI, 2005, CELL CALCIUM, V37, P301, DOI 10.1016/j.ceca.2004.11.003; Sandoval A, 2004, FEBS LETT, V576, P21, DOI 10.1016/j.febslet.2004.08.054; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; Sonkusare S, 2006, VASC PHARMACOL, V44, P131, DOI 10.1016/j.vph.2005.10.005; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tang ZZ, 2007, CELL CALCIUM, V41, P417, DOI 10.1016/j.ceca.2006.08.002; Tang ZZ, 2004, J BIOL CHEM, V279, P44335, DOI 10.1074/jbc.M407023200; TIWARI S, 2006, P NATL ACAD SCI US; Triggle DJ, 2006, CURR PHARM DESIGN, V12, P443, DOI 10.2174/138161206775474503; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138	46	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29211	29221		10.1074/jbc.M610623200	http://dx.doi.org/10.1074/jbc.M610623200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699517	hybrid, Green Accepted			2022-12-27	WOS:000249788000017
J	Suzuki, F; Morishima, S; Tanaka, T; Muramatsu, I				Suzuki, Fumiko; Morishima, Shigeru; Tanaka, Takashi; Muramatsu, Ikunobu			Snapin, a new regulator of receptor signaling, augments alpha(1A)-adrenoceptor-operated calcium influx through TRPC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-C-GAMMA; PC12 CELLS; NEUTRAL ANTAGONISM; POTENTIAL PROTEIN; INVERSE AGONISM; PLASMA-MEMBRANE; CA2+ ENTRY; CHANNELS; SUBTYPES	Activation of G(q)-protein-coupled receptors, including the alpha(1A)-adrenoceptor (alpha(1A)-AR), causes a sustained Ca2+ influx via receptor-operated Ca2+ (ROC) channels, following the transient release of intracellular Ca2+. Transient receptor potential canonical (TRPC) channel is one of the candidate proteins constituting the ROC channels, but the precise mechanism linking receptor activation to increased influx of Ca2+ via TRPCs is not yet fully understood. We identified Snapin as a protein interacting with the C terminus of the alpha(1A)-AR. In receptor-expressing PC12 cells, co-transfection of Snapin augmented alpha(1A)-AR-stimulated sustained increases in intracellular Ca2+ ([Ca2+](i)) via ROC channels. By altering the Snapin binding C-terminal domain of the alpha(1A)-AR or by reducing cellular Snapin with short interfering RNA, the sustained increase in [Ca2+](i) in Snapin-alpha(1A)-AR co-expressing PC12 cells was attenuated. Snapin co-immunoprecipitated with TRPC6 and alpha(1A)-AR, and these interactions were augmented upon alpha(1A)-AR activation, increasing the recruitment of TRPC6 to the cell surface. Our data suggest a new receptor-operated signaling mechanism where Snapin links the alpha(1A)-AR to TRPC6, augmenting Ca2+ influx via ROC channels.	Univ Fukui, Dept Biochem & Bioinformat Sci, Div Pharmacol, Fukui 9101193, Japan	University of Fukui	Muramatsu, I (corresponding author), Univ Fukui, Dept Biochem & Bioinformat Sci, Div Pharmacol, 23-3 Matsuoka Shimoazizuki, Fukui 9101193, Japan.	muramatu@u-fukui.ac.jp						Ambudkar IS, 2006, CELL CALCIUM, V40, P495, DOI 10.1016/j.ceca.2006.08.011; Ambudkar IS, 2006, TRENDS PHARMACOL SCI, V27, P25, DOI 10.1016/j.tips.2005.11.008; Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Dietrich A, 2005, PFLUG ARCH EUR J PHY, V451, P72, DOI 10.1007/s00424-005-1460-0; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fagni L, 2004, SEMIN CELL DEV BIOL, V15, P289, DOI 10.1016/j.semcdb.2003.12.018; Groschner K, 2005, N-S ARCH PHARMACOL, V371, P251, DOI 10.1007/s00210-005-1054-6; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Israilova M, 2004, J PHARMACOL EXP THER, V309, P259, DOI 10.1124/jpet.103.061796; Kida H, 2005, J MEMBRANE BIOL, V208, P55, DOI 10.1007/s00232-005-0819-7; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; Ohta T, 2004, NEUROSCI LETT, V358, P161, DOI 10.1016/j.neulet.2004.01.028; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Redondo PC, 2004, J PHYSIOL-LONDON, V558, P99, DOI 10.1113/jphysiol.2004.064899; Rossier O, 1999, MOL PHARMACOL, V56, P858, DOI 10.1124/mol.56.5.858; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Suzuki F, 2000, BRIT J PHARMACOL, V129, P1569, DOI 10.1038/sj.bjp.0703242; Suzuki F, 2002, BRIT J PHARMACOL, V135, P600, DOI 10.1038/sj.bjp.0704503; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Taniguchi T, 1999, BRIT J PHARMACOL, V127, P962, DOI 10.1038/sj.bjp.0702609; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Tian JH, 2005, J NEUROSCI, V25, P10546, DOI 10.1523/JNEUROSCI.3275-05.2005; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Wiktorek M, 1996, BIOCHEM BIOPH RES CO, V224, P645, DOI 10.1006/bbrc.1996.1079; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x; Zhu J, 2000, BRIT J PHARMACOL, V131, P546, DOI 10.1038/sj.bjp.0703584	37	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29563	29573		10.1074/jbc.M702063200	http://dx.doi.org/10.1074/jbc.M702063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17684020	hybrid			2022-12-27	WOS:000249788000053
J	Bush-Pelc, LA; Marino, F; Chen, Z; Pineda, AO; Mathews, FS; Di Cera, E				Bush-Pelc, Leslie A.; Marino, Francesca; Chen, Zhiwei; Pineda, Agustin O.; Mathews, F. Scott; Di Cera, Enrico			Important role of the Cys-191-Cys-220 disulfide bond in thrombin function and allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-ACTIVATED ENZYME; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; PROTEIN-C; ANTICOAGULANT THROMBIN; SUBSTRATE RECOGNITION; POTENT ANTICOAGULANT; MUTANT W215A/E217A; CATALYTIC-ACTIVITY; MOLECULAR-SURFACE	Little is known on the role of disulfide bonds in the catalytic domain of serine proteases. The Cys-191-Cys-220 disulfide bond is located between the 190 strand leading to the oxyanion hole and the 220-loop that contributes to the architecture of the primary specificity pocket and the Na+ binding site in allosteric proteases. Removal of this bond in thrombin produces an similar to 100-fold loss of activity toward several chromogenic and natural substrates carrying Arg or Lys at P1. Na+ activation is compromised, and no fluorescence change can be detected in response to Na+ binding. A 1.54-angstrom resolution structure of the C191A/C220A mutant in the free form reveals a conformation similar to the Na+-free slow form of wild type. The lack of disulfide bond exposes the side chain of Asp-189 to solvent, flips the backbone Oatom of Gly-219, and generates disorder in portions of the 186 and 220 loops defining the Na+ site. This conformation, featuring perturbation of the Na+ site but with the active site accessible to substrate, offers a possible representation of the recently identified E* form of thrombin. Disorder in the 186 and 220 loops and the flip of Gly-219 are corrected by the active site inhibitor H-D-Phe-Pro-Arg-CH2Cl, as revealed by the 1.8-angstrom resolution structure of the complex. We conclude that the Cys-191-Cys-220 disulfide bond confers stability to the primary specificity pocket by shielding Asp-189 from the solvent and orients the backbone O atom of Gly-219 for optimal substrate binding. In addition, the disulfide bond stabilizes the 186 and 220 loops that are critical for Na+ binding and activation.	Washington Univ, Sch Med, Dept Biochem & Mol Bio Phys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Bio Phys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			NHLBI NIH HHS [HL 49413, HL 58141, HL 73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL073813, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhavan S, 2000, THROMB HAEMOSTASIS, V84, P989; Akhavan S, 1999, BRIT J HAEMATOL, V105, P667, DOI 10.1046/j.1365-2141.1999.01423.x; Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Bode W, 2006, BLOOD CELL MOL DIS, V36, P122, DOI 10.1016/j.bcmd.2005.12.027; BODE W, 1992, PROTEIN SCI, V1, P426; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush LA, 2006, J BIOL CHEM, V281, P7183, DOI 10.1074/jbc.M512082200; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; Di Cera E, 2007, PHYS CHEM CHEM PHYS, V9, P1292, DOI 10.1039/b616819a; DIBELLA EE, 1995, J BIOL CHEM, V270, P163, DOI 10.1074/jbc.270.1.163; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Gruber A, 2007, BLOOD, V109, P3733, DOI 10.1182/blood-2006-07-035147; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HAGEMAN TC, 1975, ARCH BIOCHEM BIOPHYS, V171, P327, DOI 10.1016/0003-9861(75)90039-9; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; Kenesi E, 2003, BIOCHEM BIOPH RES CO, V309, P749, DOI 10.1016/j.bbrc.2003.08.064; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; Lefkowitz JB, 2000, BRIT J HAEMATOL, V108, P182, DOI 10.1046/j.1365-2141.2000.01810.x; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2006, BIOCHEMISTRY-US, V45, P2987, DOI 10.1021/bi052481a; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Silva FP, 2006, BIOPHYS CHEM, V119, P282, DOI 10.1016/j.bpc.2005.10.001; Singh RR, 2003, BBA-PROTEINS PROTEOM, V1651, P85, DOI 10.1016/S1570-9639(03)00238-3; Sun WY, 2000, BLOOD, V95, P711, DOI 10.1182/blood.V95.2.711; Varallyay V, 1997, BIOCHEM BIOPH RES CO, V230, P592, DOI 10.1006/bbrc.1996.6009; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; Vindigni A, 1998, PROTEIN SCI, V7, P1728, DOI 10.1002/pro.5560070807; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; Wang ECW, 1997, PROTEIN ENG, V10, P405, DOI 10.1093/protein/10.4.405; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	48	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27165	27170		10.1074/jbc.M703202200	http://dx.doi.org/10.1074/jbc.M703202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636263	hybrid			2022-12-27	WOS:000249304900057
J	Dimitrov, JD; Roumenina, LT; Doltchinkova, VR; Mihaylova, NM; Lacroix-Desmazes, S; Kaveri, SV; Vassilev, TL				Dimitrov, Jordan D.; Roumenina, Lubka T.; Doltchinkova, Virjinia R.; Mihaylova, Nikolina M.; Lacroix-Desmazes, Sebastien; Kaveri, Srinivas V.; Vassilev, Tchavdar L.			Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOPORPHYRIN-IX; ANTIGEN-BINDING; STRUCTURAL PLASTICITY; AUTOANTIBODIES; OXIDATION; IMMUNOGLOBULIN; RECOGNITION; PLASMA; SERUM; IONS	Various pathological processes are accompanied by release of high amounts of free heme into the circulation. We demonstrated by kinetic, thermodynamic, and spectroscopic analyses that antibodies have an intrinsic ability to bind heme. This binding resulted in a decrease in the conformational freedom of the antibody paratopes and in a change in the nature of the noncovalent forces responsible for the antigen binding. The antibodies use the molecular imprint of the heme molecule to interact with an enlarged panel of structurally unrelated epitopes. Upon heme binding, monoclonal as well as pooled immunoglobulin G gained an ability to interact with previously unrecognized bacterial antigens and intact bacteria. IgG-heme complexes had an enhanced ability to trigger complement-mediated bacterial killing. It was also shown that heme, bound to immunoglobulins, acted as a cofactor in redox reactions. The potentiation of the antibacterial activity of IgG after contact with heme may represent a novel and inducible innate-type defense mechanism against invading pathogens.	Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Dept Immunol, Sofia 1113, Bulgaria; Univ Sofia, Dept Biochem, Sofia 1164, Bulgaria; Univ Sofia, Dept Biophys & Radiol, Sofia 1164, Bulgaria; Univ Paris 06, Ctr Rech Cordeliers, UMR S872, F-75006 Paris, France; Univ Paris 05, UMR S872, F-75006 Paris, France; INSERM, U872, F-75006 Paris, France	Bulgarian Academy of Sciences; Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences; University of Sofia; University of Sofia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Vassilev, TL (corresponding author), Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Dept Immunol, Acad G Bonchev St,Block 26, Sofia 1113, Bulgaria.	jdd@microbio.bas.bg; vassilev@microbio.bas.bg	Doltchinkova, Virjinia/AAK-2672-2020; Dimitrov, Jordan/N-2141-2014; Roumenina, Lubka/P-5906-2019; Roumenina, Lubka/L-2638-2017; Mihaylova, Nikolina/HHM-8871-2022; Mihaylova, Nikolina M/K-3386-2013	Roumenina, Lubka/0000-0002-9940-0324; Dimitrov, Jordan/0000-0001-8536-8995; Doltchinkova, Virjinia/0000-0003-3096-7311; Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				AFT RL, 1983, J BIOL CHEM, V258, P2069; AFT RL, 1984, J BIOL CHEM, V259, P301; Amzel LM, 2000, METHOD ENZYMOL, V323, P167; Arruda MA, 2005, MEM I OSWALDO CRUZ, V100, P799, DOI 10.1590/S0074-02762005000700022; Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Balla J, 2003, NEPHROL DIAL TRANSPL, V18, P8, DOI 10.1093/ndt/gfg1034; BHOITESOLOMON V, 1990, FEBS LETT, V266, P9, DOI 10.1016/0014-5793(90)81493-8; Bian K, 2003, P NATL ACAD SCI USA, V100, P5712, DOI 10.1073/pnas.0931291100; Bouvet JP, 2001, J AUTOIMMUN, V16, P163, DOI 10.1006/jaut.2000.0472; Brancaleon L, 2004, BIOPHYS CHEM, V109, P351, DOI 10.1016/j.bpc.2003.12.008; Brancaleon L, 2002, BIOPHYS CHEM, V96, P77, DOI 10.1016/S0301-4622(02)00035-2; Camejo G, 1998, J LIPID RES, V39, P755; Carroll MC, 2005, ADV IMMUNOL, V86, P137, DOI 10.1016/S0065-2776(04)86004-8; Caughey WS, 1998, P NATL ACAD SCI USA, V95, P12117, DOI 10.1073/pnas.95.21.12117; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dimitrov JD, 2007, SCAND J IMMUNOL, V65, P230, DOI 10.1111/j.1365-3083.2006.01893.x; Dimitrov JD, 2006, J BIOL CHEM, V281, P439, DOI 10.1074/jbc.M509190200; Dimitrov JD, 2007, MOL IMMUNOL, V44, P1854, DOI 10.1016/j.molimm.2006.10.002; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; FAZEKAS G, 1990, EUR J IMMUNOL, V20, P2719, DOI 10.1002/eji.1830201229; Ghosh K, 2005, BIOCHEMISTRY-US, V44, P16729, DOI 10.1021/bi0511585; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; Grinshtein N, 2003, BIOCHEMISTRY-US, V42, P6977, DOI 10.1021/bi020647r; Howlett D, 1997, FEBS LETT, V417, P249, DOI 10.1016/S0014-5793(97)01290-8; INNIS WSA, 1985, BIOCHEM MED METAB B, V34, P151, DOI 10.1016/0006-2944(85)90106-1; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; Kettle AJ, 2004, J BIOL CHEM, V279, P18521, DOI 10.1074/jbc.M400334200; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; LECLERC E, 1993, ARCH BIOCHEM BIOPHYS, V306, P163, DOI 10.1006/abbi.1993.1495; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; McIntyre JA, 2006, AUTOIMMUN REV, V5, P76, DOI 10.1016/j.autrev.2005.07.009; McIntyre JA, 2004, THROMB RES, V114, P579, DOI 10.1016/j.thromres.2004.08.008; McIntyre JA, 2005, J AUTOIMMUN, V24, P311, DOI 10.1016/j.jaut.2005.03.005; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MORRIS SJ, 1987, BIOCHEMISTRY-US, V26, P2175, DOI 10.1021/bi00382a016; MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811; Nguyen HP, 2003, NAT STRUCT BIOL, V10, P1019, DOI 10.1038/nsb1014; NOVOGRODSKY A, 1989, J IMMUNOL, V143, P3981; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Schuermann JP, 2005, J MOL BIOL, V347, P965, DOI 10.1016/j.jmb.2005.02.008; SEARS DA, 1970, J CLIN INVEST, V49, P5, DOI 10.1172/JCI106222; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; Sinha N, 2002, CURR PROTEIN PEPT SC, V3, P601, DOI 10.2174/1389203023380431; Spolaore B, 2005, BIOCHEMISTRY-US, V44, P16079, DOI 10.1021/bi051374d; STENZEL KH, 1981, J IMMUNOL, V127, P2469; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Tracz MJ, 2007, J AM SOC NEPHROL, V18, P414, DOI 10.1681/ASN.2006080894; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; WATSON CD, 1988, BIOCHEM INT, V16, P1067; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Xu Y, 2007, P NATL ACAD SCI USA, V104, P3681, DOI 10.1073/pnas.0611094104; Yin J, 2003, J MOL BIOL, V330, P651, DOI 10.1016/S0022-2836(03)00631-4; Zhang M, 2007, MOL IMMUNOL, V44, P103, DOI 10.1016/j.molimm.2006.06.022; Zhou ZH, 2007, CELL HOST MICROBE, V1, P51, DOI 10.1016/j.chom.2007.01.002	68	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26696	26706		10.1074/jbc.M702751200	http://dx.doi.org/10.1074/jbc.M702751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636257	hybrid			2022-12-27	WOS:000249304900008
J	Frauenschuh, A; Power, CA; Deruaz, M; Ferreira, BR; Silva, JS; Teixeira, MM; Dias, JM; Martin, T; Wells, TNC; Proudfoot, AEI				Frauenschuh, Achim; Power, Christine A.; Deruaz, Maud; Ferreira, Beatriz R.; Silva, Joao S.; Teixeira, Mauro M.; Dias, Joao M.; Martin, Thierry; Wells, Timothy N. C.; Proudfoot, Amanda E. I.			Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOPIC-DERMATITIS; IDENTIFICATION; RECEPTORS; TRANSMISSION; MIP-1-BETA; RANTES; SALIVA	Ticks are blood-feeding parasites that secrete a number of immuno-modulatory factors to evade the host immune response. Saliva isolated from different species of ticks has recently been shown to contain chemokine neutralizing activity. To characterize this activity, we constructed a cDNA library from the salivary glands of the common brown dog tick, Rhipicephalus sanguineus. Pools of cDNA clones from the library were transfected into HEK293 cells, and the conditioned media from the transfected cells were tested for chemokine binding activity by chemical cross-linking to radiolabeled CCL3 followed by SDS-PAGE. By de-convolution of a single positive pool of 270 clones, we identified a full-length cDNA encoding a protein of 114 amino acids, which after signal peptide cleavage was predicted to yield a mature protein of 94 amino acids that we called Evasin-1. Recombinant Evasin-1 was produced in HEK293 cells and in insect cells. Using surface plasmon resonance we were able to show that Evasin-1 was exquisitely selective for 3 CC chemokines, CCL3 and CCL4 and the closely related chemokine CCL18, with K-D values of 0.16, 0.81, and 3.21 nM, respectively. The affinities for CCL3 and CCL4 were confirmed in competition receptor binding assays. Analysis by size exclusion chromatography demonstrated that Evasin-1 was monomeric and formed a 1: 1 complex with CCL3. Thus, unlike the other chemokine-binding proteins identified to date from viruses and from the parasitic worm Schistosoma mansoni, Evasin-1 is highly specific for a subgroup of CC chemokines, which may reflect a specific role for these chemokines in host defense against parasites.	Merck Serona Geneva Res Ctr, CH-1211 Geneva, Switzerland; Univ Sao Paulo, Sch Med, Dept Biochem & Immunol, BR-14049900 Ribeirao Preto, Brazil; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-1270901 Belo Horizonte, MG, Brazil	Universidade de Sao Paulo; Universidade Federal de Minas Gerais	Power, CA (corresponding author), Merck Serona Geneva Res Ctr, 9 Chemin Mines, CH-1211 Geneva, Switzerland.	christine.power@merckserono.net; amanda.proudfoot@merckserono.net	Ferreira, Beatriz Rossetti/C-2003-2012; Silva, Joao/A-4484-2008; Teixeira, Mauro M/A-4587-2008	Ferreira, Beatriz Rossetti/0000-0002-6781-2236; Silva, Joao/0000-0002-3410-3927; Teixeira, Mauro M/0000-0002-6944-3008; Wells, Timothy/0000-0001-9796-847X				Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alexander JM, 2002, CELL, V111, P343, DOI 10.1016/S0092-8674(02)01007-3; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Alouani S, 2000, METH MOL B, V138, P135; Brossard M, 2004, PARASITOLOGY, V129, pS161, DOI 10.1017/S0031182004004834; Bryant NA, 2003, EMBO J, V22, P833, DOI 10.1093/emboj/cdg092; Burns JM, 2002, J BIOL CHEM, V277, P2785, DOI 10.1074/jbc.M109884200; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Ferreira BR, 1996, VET PARASITOL, V62, P161, DOI 10.1016/0304-4017(95)00838-1; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hajnicka V, 2005, PARASITOLOGY, V130, P333, DOI 10.1017/S0031182004006535; Hajnicka V, 2001, PARASITE IMMUNOL, V23, P483, DOI 10.1046/j.1365-3024.2001.00403.x; JONES LD, 1989, J GEN VIROL, V70, P1895, DOI 10.1099/0022-1317-70-7-1895; Kocakova P, 2003, FOLIA PARASIT, V50, P79, DOI 10.14411/fp.2003.014; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Nuttall PA, 1998, PARASITOLOGY, V116, pS65, DOI 10.1017/S003118200008495X; Pivarcsi A, 2005, CURR ALLERGY ASTHM R, V5, P284, DOI 10.1007/s11882-005-0068-y; Proudfoot AEI, 2000, METH MOL B, V138, P75; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Schoeler GB, 2001, ANN TROP MED PARASIT, V95, P755, DOI 10.1080/0003498012011118; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith P, 2005, J EXP MED, V202, P1319, DOI 10.1084/jem.20050955; Tasaki Y, 1999, GENOMICS, V55, P353, DOI 10.1006/geno.1998.5670; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000	30	98	101	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27250	27258		10.1074/jbc.M704706200	http://dx.doi.org/10.1074/jbc.M704706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640866	hybrid			2022-12-27	WOS:000249304900066
J	Kalamajski, S; Oldberg, A				Kalamajski, Sebastian; Oldberg, Ake			Fibromodulin binds collagen type I via Glu-353 and Lys-355 in leucine-rich repeat 11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SMALL PROTEOGLYCANS; DECORIN; LUMICAN; PROTEIN; IDENTIFICATION; EXPRESSION; BIGLYCAN; REVEALS; FIBRILLOGENESIS	Fibromodulin belongs to the small leucine-rich repeat proteoglycan family, interacts with collagen type I, and controls collagen fibrillogenesis and assembly. Here, we show that a major fibromodulin-binding site for collagen type I is located in leucine-rich repeat 11 in the C terminus of the leucine-rich repeat domain. We identified Glu-353 and Lys-355 in repeat 11 as essential for binding, and the synthetic peptide RLDGNEIKR, including Glu-353 and Lys-355, inhibits the binding of fibromodulin to collagen in vitro. Fibromodulin and lumican compete for the same binding region on collagen, and fibromodulin can inhibit the binding of lumican to collagen type I. However, the peptide RLDGNEIKR does not inhibit the binding of lumican to collagen, suggesting separate but closely situated fibromodulin- and lumican-binding sites in collagen. The collagen-binding Glu-353 and Lys-355 residues in fibromodulin are exposed on the exterior of the beta-sheet-loop structure of the leucine-rich repeat, which resembles the location of interacting residues in other leucine-rich repeat proteins, e. g. decorin.	Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden	Lund University	Oldberg, A (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B12, S-22184 Lund, Sweden.	Ake.Oldberg@med.lu.se		Kalamajski, Sebastian/0000-0002-6600-9302				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; Baffi MO, 2006, DEV BIOL, V296, P363, DOI 10.1016/j.ydbio.2006.06.002; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; Bevilacqua MA, 2005, J BIOL CHEM, V280, P31809, DOI 10.1074/jbc.M414677200; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Faraonio R, 2002, CELL DEATH DIFFER, V9, P862, DOI 10.1038/sj.cdd.4401053; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; Font B, 1996, MATRIX BIOL, V15, P341, DOI 10.1016/S0945-053X(96)90137-7; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Geng YQ, 2006, MATRIX BIOL, V25, P484, DOI 10.1016/j.matbio.2006.08.259; Gill MR, 2002, OSTEOARTHR CARTILAGE, V10, P751, DOI 10.1053/joca.2002.0527; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hakkinen L, 1996, J DENT RES, V75, P1767, DOI 10.1177/00220345960750101001; Heathfield TF, 2004, J BIOL CHEM, V279, P6286, DOI 10.1074/jbc.M307765200; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kalamajski S, 2007, J BIOL CHEM, V282, P16062, DOI 10.1074/jbc.M700073200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Mayr C, 2005, BLOOD, V105, P1566, DOI 10.1182/blood-2004-04-1233; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; Shimizu A, 2004, J BIOL CHEM, V279, P16285, DOI 10.1074/jbc.M307230200; Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712	40	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26740	26745		10.1074/jbc.M704026200	http://dx.doi.org/10.1074/jbc.M704026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623650	hybrid			2022-12-27	WOS:000249304900012
J	Madsen, DH; Engelholm, LH; Ingvarsen, S; Hillig, T; Wagenaar-Miller, RA; Kjoller, L; Gardsvoll, H; Hoyer-Hansen, G; Holmbeck, K; Bugge, TH; Behrendt, N				Madsen, Daniel H.; Engelholm, Lars H.; Ingvarsen, Signe; Hillig, Thore; Wagenaar-Miller, Rebecca A.; Kjoller, Lars; Gardsvoll, Henrik; Hoyer-Hansen, Gunilla; Holmbeck, Kenn; Bugge, Thomas H.; Behrendt, Niels			Extracellular Collagenases and the Endocytic receptor, urokinase plasminogen activator receptor-associated Protein/Endo180, cooperate in fibroblast-mediated collagen degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; MANNOSE RECEPTOR; I COLLAGEN; TRANSMEMBRANE GLYCOPROTEIN; BINDING-PROPERTIES; LECTIN RECEPTOR; ENDO180; CELLS; CANCER; FIBRONECTIN	The collagens of the extracellular matrix are the most abundant structural proteins in the mammalian body. In tissue remodeling and in the invasive growth of malignant tumors, collagens constitute an important barrier, and consequently, the turnover of collagen is a rate-limiting process in these events. A recently discovered turnover route with importance for tumor growth involves intracellular collagen degradation and is governed by the collagen receptor, urokinase plasminogen activator receptor-associated protein (uPARAP or Endo 180). The interplay between this mechanism and extracellular collagenolys is is not known. In this report, we demonstrate the existence of a new, composite collagen breakdown pathway. Thus, fibroblast-mediated collagen degradation proceeds preferentially as a sequential mechanism in which extracellular collagenolysis is followed by uPARAP/Endo180-mediated endocytosis of large collagen fragments. First, we show that collagen that has been pre-cleaved by a mammalian collagenase is taken up much more efficiently than intact, native collagen by uPARAP/Endo 180-positive cells. Second, we demonstrate that this preference is governed by the acquisition of a gelatin-like structure by the collagen, occurring upon collagenase-mediated cleavage under native conditions. Third, we demonstrate that the growth of uPARAP/Endo 180-deficient fibroblasts on a native collagen matrix leads to substantial extracellular accumulation of well defined collagen fragments, whereas, wild-type fibroblasts possess the ability to direct an organized and complete degradation sequence comprising both the initial cleavage, the endocytic uptake, and the intracellular breakdown of collagen.	Finsen Lab, DK-2200 Copenhagen, Denmark; NIH, NIDCR, Craniofacial & Skeletal Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Behrendt, N (corresponding author), Finsen Lab, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	niels.behrendt@finsenlab.dk		Behrendt, Niels/0000-0003-1833-3922; Wagenaar-Miller, Rebecca/0000-0002-5807-0111; Holmbeck, Kenn/0000-0002-4472-3257; Engelholm, Lars/0000-0002-6616-1232; Madsen, Daniel Hargboel/0000-0002-3183-6201; Hillig, Thore/0000-0002-2085-5183; Ingvarsen, Signe Ziir/0000-0001-7800-6443	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699, ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000676] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; BEHRENDT N, 1993, FEBS LETT, V336, P394, DOI 10.1016/0014-5793(93)80844-K; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ENGEL J, 1962, ARCH BIOCHEM BIOPHYS, V97, P150, DOI 10.1016/0003-9861(62)90057-7; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gardsvoll H, 2007, PROTEIN EXPRES PURIF, V52, P384, DOI 10.1016/j.pep.2006.11.013; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HIGHBERGER JH, 1979, BIOCHEM BIOPH RES CO, V89, P202, DOI 10.1016/0006-291X(79)90964-1; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Honardoust HA, 2006, HISTOPATHOLOGY, V49, P634, DOI 10.1111/j.1365-2559.2006.02559.x; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Howard MJ, 2002, J BIOL CHEM, V277, P32320, DOI 10.1074/jbc.M203631200; ISACKE CM, 1990, MOL CELL BIOL, V10, P2606, DOI 10.1128/MCB.10.6.2606; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lee HJ, 2006, MOL BIOL CELL, V17, P4812, DOI 10.1091/mbc.E06-06-0486; Leitinger B, 2007, MATRIX BIOL, V26, P146, DOI 10.1016/j.matbio.2006.10.007; Martinez-Pomares L, 2006, EUR J IMMUNOL, V36, P1074, DOI 10.1002/eji.200535685; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; Messent AJ, 1998, J CELL SCI, V111, P1127; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mousavi SA, 2005, BIOCHEM J, V387, P39, DOI 10.1042/BJ20040966; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; Napper CE, 2006, BIOCHEM J, V395, P579, DOI 10.1042/BJ20052027; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Sameni M, 2001, BIOL CHEM, V382, P785, DOI 10.1515/BC.2001.094; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schnack N. B., 2002, INT J CANCER, V98, P656; Sheikh H, 2000, J CELL SCI, V113, P1021; STARK M, 1968, EUR J BIOCHEM, V6, P534, DOI 10.1111/j.1432-1033.1968.tb00477.x; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; Sturge J, 2003, J CELL BIOL, V162, P789, DOI 10.1083/jcb.200302124; Sturge J, 2006, J CELL BIOL, V175, P337, DOI 10.1083/jcb.200602125; Sulek J, 2007, J HISTOCHEM CYTOCHEM, V55, P347, DOI 10.1369/jhc.6A7133.2006; Thomas EK, 2005, J BIOL CHEM, V280, P22596, DOI 10.1074/jbc.M501155200; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	59	102	105	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27037	27045		10.1074/jbc.M701088200	http://dx.doi.org/10.1074/jbc.M701088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623673	hybrid			2022-12-27	WOS:000249304900045
J	DikanovO, SA; Hollan, JT; Endeward, B; Kolling, DRJ; Samoilova, RI; Prisner, TF; Crofts, AR				DikanovO, Sergei A.; Hollan, J. Todd; Endeward, Burkhard; Kolling, Derrick R. J.; Samoilova, Rimma I.; Prisner, Thomas F.; Crofts, Antony R.			Hydrogen bonds between nitrogen donors and the semiquinone in the Q(i)-site of the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN ECHO; PRIMARY ACCEPTOR QUINONE; MITOCHONDRIAL CYTOCHROME BC(1); BACTERIAL REACTION CENTERS; PURE QUADRUPOLE-RESONANCE; RHODOBACTER-SPHAEROIDES; PARAMAGNETIC-RESONANCE; ENVELOPE MODULATION; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE	The ubisemiquinone stabilized at the Q(i)-site of the bc(1) complex of Rhodobacter sphaeroides forms a hydrogen bond with a nitrogen from the local protein environment, tentatively identified as ring N from His-217. The interactions of N-14 and N-15 have been studied by X-band (similar to 9.7 GHz) and S-band (3.4 GHz) pulsed EPR spectroscopy. The application of S-band spectroscopy has allowed us to determine the complete nuclear quadrupole tensor of the 14N involved in H-bond formation and to assign it unambiguously to the N (epsilon) of His-217. This tensor has distinct characteristics in comparison with H-bonds between semiquinones and N-delta in other quinone-processing sites. The experiments with 15N showed that the N (epsilon) of His-217 was the only nitrogen carrying any considerable unpaired spin density in the ubiquinone environment, and allowed calculation of the isotropic and anisotropic couplings with the N (epsilon) of His-217. From these data, we could estimate the unpaired spin density transferred onto 2s and 2p orbitals of nitrogen and the distance from the nitrogen to the carbonyl oxygen of 2.38 +/- 0.13 A. The hyperfine coupling of other protein nitrogens with semiquinone is < 0.1MHz. This did not exclude the nitrogen of the Asn-221 as a possible hydrogen bond donor to the methoxy oxygen of the semiquinone. Amechanistic role for this residue is supported by kinetic experiments with mutant strains N221T, N221H, N221I, N221S, N221P, and N221D, all of which showed some inhibition but retained partial turnover.	Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60438 Frankfurt, Germany; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; University of Illinois System; University of Illinois Urbana-Champaign	Crofts, AR (corresponding author), Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA.	a-crofts@life.uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487; Endeward, Burkhard/0000-0001-7790-1024; Prisner, Thomas F./0000-0003-2850-9573	FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954, R01GM035438] Funding Source: NIH RePORTER	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; ASTASHKIN AV, 1995, J CHEM PHYS, V102, P5583, DOI 10.1063/1.469289; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; BOSCH MK, 1995, CHEM PHYS LETT, V239, P306, DOI 10.1016/0009-2614(95)00481-I; Crofts AR, 2006, BBA-BIOENERGETICS, V1757, P1019, DOI 10.1016/j.bbabio.2006.02.009; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 2004, PHOTOSYNTH RES, V80, P223, DOI 10.1023/B:PRES.0000030444.52579.10; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P493; CROFTS AR, 2005, BIOPHYSICAL STRUCTUR, P123; de Vries S., 1982, FUNCTION QUINONES EN, P235; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; Dikanov SA, 2006, J BIOL CHEM, V281, P27416, DOI 10.1074/jbc.M604103200; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Flores M, 2007, BIOPHYS J, V92, P671, DOI 10.1529/biophysj.106.092460; Fritscher J, 2006, APPL MAGN RESON, V30, P251, DOI 10.1007/BF03166200; Fritscher J, 2004, PHYS CHEM CHEM PHYS, V6, P4950, DOI 10.1039/b408764j; FUESS H, 1977, ACTA CRYSTALLOGR B, V33, P654, DOI 10.1107/S0567740877004415; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HOLLAND JT, 2007, THESIS U ILLINOIS UR; Huang LS, 2005, J MOL BIOL, V351, P573, DOI 10.1016/j.jmb.2005.05.053; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JEFFREY GA, 1997, INTRO HYDROGEN BONDI, P184; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MEINHARDT SW, 1984, ADV PHOTOSYNTHESIS R, V1, P649; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MORTON JR, 1978, J MAGN RESON, V30, P577, DOI 10.1016/0022-2364(78)90284-6; Mulkidjanian AY, 2007, PHOTOCH PHOTOBIO SCI, V6, P19, DOI 10.1039/b517522d; O'Malley PJ, 1998, J AM CHEM SOC, V120, P11732, DOI 10.1021/ja981755x; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; Rich PR, 2004, BBA-BIOENERGETICS, V1658, P165, DOI 10.1016/j.bbabio.2004.04.021; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Sinnecker S, 2004, J AM CHEM SOC, V126, P3280, DOI 10.1021/ja0392014; Sinnecker S, 2006, PHYS CHEM CHEM PHYS, V8, P5659, DOI 10.1039/b612568a; Slichter C. P., 1990, PRINCIPLES MAGNETIC, P485; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; TOWNES CH, 1949, J CHEM PHYS, V17, P782, DOI 10.1063/1.1747400; WEBER A, 1998, P 29 C AMPERE 13 ISM, V2, P1138; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yap LL, 2007, J BIOL CHEM, V282, P8777, DOI 10.1074/jbc.M611595200; Yap LL, 2006, J BIOL CHEM, V281, P16879, DOI 10.1074/jbc.M602544200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	70	30	30	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25831	25841		10.1074/jbc.M702333200	http://dx.doi.org/10.1074/jbc.M702333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616531	Green Accepted, hybrid			2022-12-27	WOS:000249014100069
J	Li, X; Qin, L; Bergenstock, M; Bevelock, LM; Novack, DV; Partridge, NC				Li, Xin; Qin, Ling; Bergenstock, Marika; Bevelock, Laura M.; Novack, Deborah V.; Partridge, Nicola C.			Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B LIGAND; OSTEOCLASTOGENESIS IN-VITRO; BONE-RESORPTION; RECEPTOR ACTIVATOR; PROTEIN-KINASE; OSTEOPROTEGERIN LIGAND; GENE-EXPRESSION; STROMAL CELLS; TNF-ALPHA; DC-STAMP	The clinical findings that alendronate blunted the anabolic effect of human parathyroid hormone ( PTH) on bone formation suggest that active resorption is involved and enhances the anabolic effect. PTH signals via its receptor on the osteoblast membrane, and osteoclasts are impacted indirectly via the products of osteoblasts. Microarray with RNA from rats injected with human PTH or vehicle showed a strong association between the stimulation of monocyte chemoattractant protein-1 ( MCP-1) and the anabolic effects of PTH. PTH rapidly and dramatically stimulated MCP-1 mRNA in the femora of rats receiving daily injections of PTH or in primary osteoblastic and UMR 106-01 cells. The stimulation of MCP-1 mRNA was dose-dependent and a primary response to PTH signaling via the cAMP-dependent protein kinase pathway in vitro. Studies with the mouse monocyte cell line RAW 264.7 and mouse bone marrow proved that osteoblastic MCP-1 can potently recruit osteoclast monocyte precursors and facilitate receptor activator of NF-kappa B ligand-induced osteoclastogenesis and, in particular, enhanced fusion. Our model suggests that PTH-induced osteoblastic expression of MCP-1 is involved in recruitment and differentiation at the stage of multinucleation of osteoclast precursors. This information provides a rationale for increased osteoclast activity in the anabolic effects of PTH in addition to receptor activator of NF-kappa B ligand stimulation to initiate greater bone remodeling.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln,Res Tower 561, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Partridge, Nicola/0000-0002-5406-4814; Novack, Deborah/0000-0001-7101-5582	NIDDK NIH HHS [DK 48109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CHAKRAVARTHY BR, 1990, BIOCHEM BIOPH RES CO, V171, P1105, DOI 10.1016/0006-291X(90)90798-R; Chen AR, 2005, OBES RES, V13, P1311, DOI 10.1038/oby.2005.159; Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362; CIVITELLI R, 1988, AM J PHYSIOL, V225, pE660; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P153; Dai JC, 2006, BONE, V38, P509, DOI 10.1016/j.bone.2005.10.007; DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756-3282(95)00113-R; Fan X, 2001, AM J PHYSIOL-ENDOC M, V280, pE103, DOI 10.1152/ajpendo.2001.280.1.E103; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Graves DT, 1999, HISTOL HISTOPATHOL, V14, P1347, DOI 10.14670/HH-14.1347; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006-2952(01)00861-9; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259; Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Votta BJ, 2000, J CELL PHYSIOL, V183, P196, DOI 10.1002/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.3.CO;2-#; Weir EC, 1996, J BONE MINER RES, V11, P1474; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; Wuyts A, 1997, METHOD ENZYMOL, V287, P13; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	42	150	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2007	282	45					33098	33106		10.1074/jbc.M611781200	http://dx.doi.org/10.1074/jbc.M611781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226YW	17690108	hybrid			2022-12-27	WOS:000250625400058
J	Hung, HC; Maurer, C; Kay, SA; Weber, F				Hung, Hsiu-Cheng; Maurer, Christian; Kay, Steve A.; Weber, Frank			Circadian transcription depends on limiting amounts of the transcription co-activator nejire/CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME QUANTITATIVE PCR; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; DROSOPHILA-MELANOGASTER; CLOCK; CBP; ACTIVATION; CBP/P300; PATHWAYS; MUTATION	The circadian clock orchestrates physiological and behavioral activities, including metabolism, neuronal activity, and cell proliferation in synchrony with the environmental cycle of day and night. Here we show that the Drosophila ortholog of the CBP/ p300 family of transcription co-activators, nejire (nej), is an intrinsic component of the circadian clock that performs regulatory functions for circadian controlled transcription. Screening of overexpression mutants revealed that gain of nej function was associated with a loss of behavioral and molecular rhythms. Overexpression of NEJ suppresses the long period phenotype of a mutation in the clock gene period (per). NEJ physically interacts through two binding sites with CLOCK and the CLOCK center dot CYCLE (CLK center dot CYC) complex. Induction of CLK center dot CYC-dependent transcripts upon induction of nej expression from a heat-shock promoter showed that NEJ is limiting. Reduced CLK center dot CYC-mediated transcription in a nej hypomorphic mutant indicates an essential function of NEJ/CBP for CLK center dot CYC activity and a regulation of circadian transcription by availability of the co-activator. Competition for recruitment of NEJ/CBP provides a potential mechanism for cross-talk between circadian transcription and other CBP-dependent physiological processes.	Univ Heidelberg, Biochem Zent Heidelberg, D-69120 Heidelberg, Germany; Scripps Res Inst, La Jolla, CA 92037 USA	Ruprecht Karls University Heidelberg; Scripps Research Institute	Weber, F (corresponding author), Univ Heidelberg, Biochem Zent Heidelberg, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	Frank.Weber@bzh.uni-heidelberg.de	Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER; NIMH NIH HHS [MH51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 2003, EMBO J, V22, P3367, DOI 10.1093/emboj/cdg318; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Costa SL, 1996, CELL GROWTH DIFFER, V7, P1479; Curtis AM, 2004, J BIOL CHEM, V279, P7091, DOI 10.1074/jbc.M311973200; Cyran SA, 2003, CELL, V112, P329, DOI 10.1016/S0092-8674(03)00074-6; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Ganguly-Fitzgerald I, 2006, SCIENCE, V313, P1775, DOI 10.1126/science.1130408; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glossop NRJ, 2003, NEURON, V37, P249, DOI 10.1016/S0896-6273(03)00002-3; Goodman RH, 2000, GENE DEV, V14, P1553; Hamblen MJ, 1998, GENETICS, V149, P165; Hardin PE, 2005, CURR BIOL, V15, pR714, DOI 10.1016/j.cub.2005.08.019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim EY, 2002, NEURON, V34, P69, DOI 10.1016/S0896-6273(02)00639-6; Lee C, 1999, MOL CELL BIOL, V19, P5316; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; Lim C, 2007, MOL CELL BIOL, V27, P4876, DOI 10.1128/MCB.02155-06; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marek KW, 2000, NEURON, V25, P537, DOI 10.1016/S0896-6273(00)81058-2; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pennartz CMA, 2002, NATURE, V416, P286, DOI 10.1038/nature728; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rosato E, 2006, EUR J HUM GENET, V14, P729, DOI 10.1038/sj.ejhg.5201547; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Takahata S, 2000, GENES CELLS, V5, P739, DOI 10.1046/j.1365-2443.2000.00363.x; Weber F, 2006, J NEUROCHEM, V98, P248, DOI 10.1111/j.1471-4159.2006.03865.x; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097	35	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31349	31357		10.1074/jbc.M702319200	http://dx.doi.org/10.1074/jbc.M702319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17635913	hybrid			2022-12-27	WOS:000250309200024
J	Yao, SYM; Ng, AML; Slugoski, MD; Smith, KM; Mulinta, R; Karpinski, E; Cass, CE; Baldwin, SA; Young, JD				Yao, Sylvia Y. M.; Ng, Amy M. L.; Slugoski, Melissa D.; Smith, Kyla M.; Mulinta, Ras; Karpinski, Edward; Cass, Carol E.; Baldwin, Stephen A.; Young, James D.			Conserved glutamate residues are critically involved in Na+/Nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NUCLEOSIDE TRANSPORTER; ESCHERICHIA-COLI; FUNCTIONAL EXPRESSION; LACTOSE PERMEASE; NA+/PROLINE TRANSPORTER; SUBSTRATE-TRANSLOCATION; MOLECULAR-CLONING; ACIDIC RESIDUES; PROTEINS HCNT3; CNT FAMILY	Human concentrative nucleoside transporter 1 ( hCNT1), the first discovered of three human members of the SLC28 ( CNT) protein family, is a Na+/nucleoside cotransporter with 650 amino acids. The potential functional roles of 10 conserved aspartate and glutamate residues in hCNT1 were investigated by site-directed mutagenesis and heterologous expression in Xenopus oocytes. Initially, each of the 10 residues was replaced by the corresponding neutral amino acid ( asparagine or glutamine). Five of the resulting mutants showed unchanged Na+-dependent uridine transport activity ( D172N, E338Q, E389Q, E413Q, and D565N) and were not investigated further. Three were retained in intracellular membranes ( D482N, E498Q, and E532Q) and thus could not be assessed functionally. The remaining two ( E308Q and E322Q) were present in normal quantities at cell surfaces but exhibited low intrinsic transport activities. Charge replacement with the alternate acidic amino acid enabled correct processing of D482E and E498D, but not of E532D, to cell surfaces and also yielded partially functional E308D and E322D. Relative to wild-type hCNT1, only D482E exhibited normal transport kinetics, whereas E308D, E308Q, E322D, E322Q, and E498D displayed increased K-50(Na+) and/ or K-m(uridine) values and diminished V-max(Na+) and V-max(uridine) values. E322Q additionally exhibited uridine-gated uncoupled Na+ transport. Together, these findings demonstrate roles for Glu-308, Glu-322, and Glu-498 in Na+/nucleoside cotransport and suggest locations within a common cation/nucleoside translocation pore. Glu-322, the residue having the greatest influence on hCNT1 transport function, exhibited uridine-protected inhibition by p-chloromercuriphenyl sulfonate and 2-aminoethyl methanethiosulfonate when converted to cysteine.	Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Astbury Ctr Struct Mol Biol, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; Chen NH, 2004, J BIOL CHEM, V279, P5508, DOI 10.1074/jbc.M306294200; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kaback HR, 2005, CR BIOL, V328, P557, DOI 10.1016/j.crvi.2005.03.008; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; Pirch T, 2002, J BIOL CHEM, V277, P8790, DOI 10.1074/jbc.M111008200; POURCHER T, 1993, J BIOL CHEM, V268, P3209; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; Quick M, 2001, J BIOL CHEM, V276, P1728, DOI 10.1074/jbc.M005521200; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROTHSTEIN A, 1970, CURRENT TOPICS MEMBR, V1, P135; Slugoski MD, 2007, BIOCHEMISTRY-US, V46, P1684, DOI 10.1021/bi061692s; Smith FM, 2007, MOL MEMBR BIOL, V24, P53, DOI 10.1080/09687860600942534; Smith KM, 2005, J BIOL CHEM, V280, P25436, DOI 10.1074/jbc.M409454200; Smith KM, 2004, J PHYSIOL-LONDON, V558, P807, DOI 10.1113/jphysiol.2004.068189; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Weinglass AB, 2001, BIOCHEMISTRY-US, V40, P769, DOI 10.1021/bi002171m; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Young JD, 2001, CURR TOP MEMBR, V50, P329; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476; Zhu QS, 2007, METHODS, V41, P439, DOI 10.1016/j.ymeth.2006.08.004	54	18	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30607	30617		10.1074/jbc.M703285200	http://dx.doi.org/10.1074/jbc.M703285200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17704058	hybrid			2022-12-27	WOS:000250136300029
J	Scarchilli, L; Camaioni, A; Bottazzi, B; Negri, V; Doni, A; Deban, L; Bastone, A; Salvatori, G; Mantovani, A; Siracusa, G; Salustri, A				Scarchilli, Laura; Camaioni, Antonella; Bottazzi, Barbara; Negri, Veronica; Doni, Andrea; Deban, Livija; Bastone, Antonio; Salvatori, Giovanni; Mantovani, Alberto; Siracusa, Gregorio; Salustri, Antonietta			PTX3 interacts with inter-alpha-trypsin inhibitor - Implications for hyaluronan organization and cumulus oophorus expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; FACTOR-STIMULATED GENE-6; LONG PENTRAXIN PTX3; CELL-OOCYTE COMPLEX; C-REACTIVE PROTEIN; EXTRACELLULAR-MATRIX; HEAVY-CHAINS; IN-VIVO; COVALENT TRANSFER; GRANULOSA-CELLS	Pentraxin 3 (PTX3) and heavy chains (HCs) of inter-alpha-trypsin inhibitor (I alpha I) are essential for hyaluronan ( HA) organization within the extracellular matrix of the cumulus oophorus, which is critical for in vivo oocyte fertilization and female fertility. In this study, we examined the possibility that these molecules interact and cooperate in this function. We show that HCs and PTX3 colocalize in the cumulus matrix and coimmunoprecipitate from cumulus matrix extracts. Coimmunoprecipitation experiments and solid-phase binding assays performed with purified human I alpha I and recombinant PTX3 demonstrate that their interaction is direct and not mediated by other matrix components. PTX3 does not bind to I alpha I subcomponent bikunin and, accordingly, bikunin does not compete for the binding of PTX3 to I alpha I, indicating that PTX3 interacts with I alpha I subcomponent HC only. Recombinant PTX3-specific N-terminal region, but not the PTX3-pentraxin C-terminal domain, showed the same ability as full-length protein to bind to HCs and to enable HA organization and matrix formation by Ptx3(-/-) cumulus cell oocyte complexes cultured in vitro. Furthermore, a monoclonal antibody raised against PTX3 N terminus, which inhibits PTX3/I alpha I interaction, also prevents recombinant full-length PTX3 from restoring a normal phenotype to in vitro-cultured Ptx3(-/-) cumuli. These results indicate that PTX3 directly interacts with HCs of I alpha I and that such interaction is essential for organizing HA in the viscoelastic matrix of cumulus oophorus, highlighting a direct functional link between the two molecules.	Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; Ist Clin Humanitas, Res Lab Immunol & Inflammat, I-20089 Milan, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; SigmaTau SpA, I-00040 Rome, Italy	University of Rome Tor Vergata; IRCCS Humanitas Research Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Salustri, A (corresponding author), Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy.	salustri@med.uniroma2.it	Camaioni, Antonella/AAB-5294-2020; Mantovani, Alberto/HCI-7449-2022; Camaioni, Antonella/AAB-5285-2020; bottazzi, barbara/ABH-9274-2020	Camaioni, Antonella/0000-0002-7059-2617; Mantovani, Alberto/0000-0001-5578-236X; Camaioni, Antonella/0000-0002-7059-2617; bottazzi, barbara/0000-0002-1930-9257; Doni, Andrea/0000-0001-9203-5814; SALUSTRI, ANTONIETTA/0000-0002-8731-1041				ALMUTLAQ H, 1993, HISTOCHEM J, V25, P219, DOI 10.1007/BF00163818; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camozzi M, 2006, J BIOL CHEM, V281, P22605, DOI 10.1074/jbc.M601023200; Capon C, 2003, BIOCHIMIE, V85, P101, DOI 10.1016/S0300-9084(03)00066-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; CHERR GN, 1990, DEV GROWTH DIFFER, V32, P353; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; EPPIG JJ, 1979, J EXP ZOOL, V208, P111, DOI 10.1002/jez.1402080112; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; Introna M, 1996, BLOOD, V87, P1862; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE GW, 1993, J IMMUNOL, V150, P1804; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MICHALSKI C, 1994, VOX SANG, V67, P329, DOI 10.1111/j.1423-0410.1994.tb01269.x; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nagyova E, 2004, BIOL REPROD, V71, P1838, DOI 10.1095/biolreprod.104.029595; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; POWERS RW, 1995, AM J PHYSIOL, V269, P290; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Russell DL, 2006, SEMIN REPROD MED, V24, P217, DOI 10.1055/s-2006-948551; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; YUDIN AI, 1988, CELL TISSUE RES, V251, P555, DOI 10.1007/BF00214003; Zahedi K, 1996, J BIOL CHEM, V271, P14897, DOI 10.1074/jbc.271.25.14897; Zahedi K, 1997, J BIOL CHEM, V272, P2143; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	46	118	121	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30161	30170		10.1074/jbc.M703738200	http://dx.doi.org/10.1074/jbc.M703738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17675295	hybrid			2022-12-27	WOS:000249981200046
J	Shi, ML; Foo, SY; Tan, SM; Mitchell, EP; Law, SKA; Lescar, J				Shi, MinLong; Foo, Shen Yun; Tan, Suet-Mien; Mitchell, Edward P.; Law, S. K. Alex; Lescar, Julien			A structural hypothesis for the transition between bent and extended conformations of the leukocyte beta 2 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(L)BETA(2) HYBRID DOMAIN; I-LIKE DOMAIN; CRYSTAL-STRUCTURE; TERMINAL REGION; SUBUNIT; REVEALS; COMPLEX; MODEL; ACTIVATION; EXPRESSION	Integrins mediate cell adhesion in response to activation signals that trigger conformational changes within their ectodomain. It is thought that a compact bent conformation of the molecule represents its physiological low affinity state and extended conformations its active state. We have determined the structure of two integrin fragments of the beta 2 subunit. The first structure, consisting of the plexin-semaphorin-integrin domain, hybrid, integrin-epidermal growth factor 1 ( I-EGF1), and I-EGF2 domains (PHE2), showed an L-shaped conformation with the bend located between the I-EGF1 and I-EGF2 domains. The second structure, which includes, in addition, the I-EGF3 domain, showed an extended conformation. The major reorientation of I-EGF2 with respect to the other domains in the two structures is accompanied by a change of torsion angle of the disulfide bond between Cys(461)-Cys(492) by 180 and the conversion of a short alpha-helix ( residues Ser(468)-Cys(475)) into a flexible coil. Based on the PHE2 structure, we introduced a disulfide bond between the plexin-semaphorin-integrin domain and I-EGF2 domains in the beta 2 subunit. The resultant alpha L beta 2 integrin ( leukocyte function-associated antigen-1) variant was locked in a bent state and could not be detected with the monoclonal antibody KIM127 in Mg2+/EGTA. However, it retained the binding activity to ICAM-1. These results provide a structural hypothesis for our understanding of the transition between the resting and active states of leukocyte function-associated antigen-1.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; European Synchrotron Radiation Facility (ESRF)	Law, SKA (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	alaw@ntu.edu.sg; julien@ntu.edu.sg	shi, minlong/G-8734-2013; Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Tan, Suet-Mien/0000-0003-2371-8739				Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Cheng M, 2007, J BIOL CHEM, V282, P18225, DOI 10.1074/jbc.M701386200; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P17; DeLano WL, 2002, PYMOL USERS MANUAL; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwasaki K, 2005, J STRUCT BIOL, V150, P259, DOI 10.1016/j.jsb.2005.03.005; Jordan PA, 2005, BLOOD, V105, P1500, DOI 10.1182/blood-2004-02-0608; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Shi ML, 2005, J BIOL CHEM, V280, P30586, DOI 10.1074/jbc.M502525200; Staunton DE, 2006, ADV IMMUNOL, V91, P111, DOI 10.1016/S0065-2776(06)91003-7; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tan SM, 2001, FEBS LETT, V505, P27, DOI 10.1016/S0014-5793(01)02778-8; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	38	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30198	30206		10.1074/jbc.M701670200	http://dx.doi.org/10.1074/jbc.M701670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17673459	hybrid			2022-12-27	WOS:000249981200050
J	Wang, CG; Rauscher, FJ; Cress, WD; Chen, JD				Wang, Chuangui; Rauscher, Frank J., III; Cress, W. Douglas; Chen, Jiandong			Regulation of E2F1 function by the nuclear corepressor KAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; DNA-DAMAGE; MDM2 INTERACTION; CELL-SURVIVAL; EXPRESSION; P53; APOPTOSIS; REPRESSION; DOMAIN; COLOCALIZES	KAP1 is a nuclear corepressor with conserved domains for RING finger, B boxes, leucine zipper alpha helical coiled- coil region, plant homeo domain finger, and bromo domain. The plant homeo domain finger and bromo domain of KAP1 cooperatively function as a transcription repression domain by recruiting the histone deacetylase complex NuRD and histone H3 lysine 9- specific methyltransferase SETDB1. Here we report that KAP1 binds the E2F1 transcription factor in a retinoblastoma protein ( pRb)- independent fashion and inhibits E2F1 activity. KAP1 stimulates formation of E2F1- HDAC1 complex and inhibits E2F1 acetylation. Ectopic expression of KAP1 represses E2F1 transcription and apoptosis functions independent of pRb. Depletion of endogenous KAP1 in pRb- deficient Saos2 cells by RNA interference increases E2F1 acetylation level, stimulates E2F1 transcriptional activity, and sensitizes apoptosis response to DNA damage. Therefore, KAP1 contributes to the negative regulation of E2F1 and may serve as a partial backup to prevent E2F1- mediated apoptosis in the absence of pRb.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; The Wistar Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, MRC 3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	jiandong.chen@moffitt.org						Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Lu WG, 2002, CANCER RES, V62, P1305; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Okamoto K, 2006, BIOCHEM BIOPH RES CO, V351, P216, DOI 10.1016/j.bbrc.2006.10.022; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Weber P, 2002, DEVELOPMENT, V129, P2329; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	34	73	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29902	29909		10.1074/jbc.M704757200	http://dx.doi.org/10.1074/jbc.M704757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17704056	hybrid			2022-12-27	WOS:000249981200019
J	Fischer, A; Montal, M				Fischer, Audrey; Montal, Mauricio			Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; CLOSTRIDIAL-NEUROTOXINS; SUBSTRATE RECOGNITION; NEUROBLASTOMA-CELLS; SYNAPTOTAGMIN-I; BINDING; RECEPTOR; TOXIN	Clostridial botulinum neurotoxins (BoNTs) exert their neuroparalytic action by arresting synaptic exocytosis. Intoxication requires the disulfide-linked, di-chain protein to undergo conformational changes in response to pH and redox gradients across the endosomal membrane with consequent formation of a protein-conducting channel by the heavy chain (HC) that translocates the light chain (LC) protease into the cytosol. Here, we investigate the role of the disulfide bridge in the dynamics of protein translocation. We utilize a single channel/single molecule assay to characterize in real time the BoNT channel and chaperone activities in Neuro 2A cells under conditions that emulate those prevalent across endosomes. We show that the disulfide bridge must remain intact throughout LC translocation; premature reduction of the disulfide bridge after channel formation arrests translocation. The disulfide bridge must be on the trans compartment to achieve productive translocation of LC; disulfide disruption on the cis compartment or within the bilayer during translocation aborts it. We demonstrate that a peptide linkage between LC and HC in place of a disulfide bridge is insufficient for productive LC translocation. The disulfide linkage, therefore, dictates the outcome of translocation: productive passage of cargo or abortive channel occlusion by cargo. Based on these and previous findings we suggest a sequence of events for BoNT LC translocation to be HC insertion, coupled LC unfolding, and protein conduction through the HC channel in an N to C terminus orientation and ultimate release of the LC from the HC by reduction of the disulfide bridge concomitant with LC refolding in the cytosol.	Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Montal, M (corresponding author), Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mmontal@ucsd.edu	Taylor, Graham/A-4027-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI065359] Funding Source: Medline; NIGMS NIH HHS [T32 GM08326, T32 GM008326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2004, BIOCHEMISTRY-US, V43, P6637, DOI 10.1021/bi036278w; Arndt JW, 2006, BIOCHEMISTRY-US, V45, P3255, DOI 10.1021/bi052518r; Arndt JW, 2005, BIOCHEMISTRY-US, V44, P9574, DOI 10.1021/bi0505924; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Carpaneto A, 1999, EXP BRAIN RES, V124, P193, DOI 10.1007/s002210050614; Chai Q, 2006, NATURE, V444, P1096, DOI 10.1038/nature05411; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; FINKELSTEIN A, 1990, J PHYSIOLOGY PARIS, V84, P188; Fischer A, 2007, P NATL ACAD SCI USA, V104, P10447, DOI 10.1073/pnas.0700046104; Fischer A, 2006, NEUROTOX RES, V9, P93, DOI 10.1007/BF03033926; GAMBALE F, 1988, BIOPHYS J, V53, P771, DOI 10.1016/S0006-3495(88)83157-6; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Ginalski K, 2000, FEBS LETT, V482, P119, DOI 10.1016/S0014-5793(00)01954-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jin RS, 2006, NATURE, V444, P1092, DOI 10.1038/nature05387; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lascola CD, 1998, J NEUROSCI, V18, P1679; Mahrhold S, 2006, FEBS LETT, V580, P2011, DOI 10.1016/j.febslet.2006.02.074; Nishiki T, 1996, NEUROSCI LETT, V208, P105, DOI 10.1016/0304-3940(96)12557-X; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Simpson LL, 2004, ANNU REV PHARMACOL, V44, P167, DOI 10.1146/annurev.pharmtox.44.101802.121554; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Tsukamoto K, 2005, J BIOL CHEM, V280, P35164, DOI 10.1074/jbc.M507596200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yowler BC, 2002, J BIOL CHEM, V277, P32815, DOI 10.1074/jbc.M205258200	34	112	122	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29604	29611		10.1074/jbc.M703619200	http://dx.doi.org/10.1074/jbc.M703619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17666397	hybrid			2022-12-27	WOS:000249788000057
J	French, AC; Luscher, B; Litchfield, DW				French, Ashley C.; Luscher, Bernhard; Litchfield, David W.			Development of a stabilized form of the regulatory CK2 beta subunit that inhibits cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; II BETA-SUBUNIT; CASEIN KINASE-2; AUTOPHOSPHORYLATION SITE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; PHOSPHORYLATION; EXPRESSION; CYCLE	A number of cancers are characterized by elevated expression of CK2 (formerly casein kinase II), which has been implicated as a key component in cell proliferation and transformation. Two lines of evidence, (a) deregulated expression of CK2 and (b) CK2 beta ubiquitination and degradation of these in a proteasome-dependent manner prompted further investigation of the regulation of CK2 beta protein stability. We demonstrate that mutating six surface-exposed lysine residues to arginine (6KR) to interfere with ubiquitin attachment can stabilize CK2 beta. Examination of 6KR expression in cells revealed increased stability over time and increased its steady-state expression level compared with CK2 beta. In cells, 6KR was no longer sensitive to proteasome inhibition but maintained an elevated expression level. In our studies, 6KR functioned as a normal CK2 regulatory subunit, because it participated in CK2 beta dimerization, associated with catalytic subunits, was autophosphorylated, and formed active, stable CK2 tetramers. The physiological role of CK2 beta stabilization was investigated in cell proliferation assays, which showed a significant decrease in proliferation in cells expressing 6KR compared with CK2 beta. Overall, our results indicate that a stabilized form of CK2 beta can be used to inhibit cell proliferation.	Univ Western Ontario, Schulich Sch Med & Dent, Siebens Drake Med Res Inst, Dept Biochem,Regulatory Biol & Funct Genom Res Gr, London, ON N6A 5C1, Canada; Univ Aachen, Rhein Westfal TH, Klinikum, Inst Biochem, D-52057 Aachen, Germany	Western University (University of Western Ontario); RWTH Aachen University	Litchfield, DW (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Siebens Drake Med Res Inst, Dept Biochem,Regulatory Biol & Funct Genom Res Gr, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; Boldyreff B, 1996, FEBS LETT, V379, P153, DOI 10.1016/0014-5793(95)01497-7; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lebrin F, 2001, ONCOGENE, V20, P2010, DOI 10.1038/sj.onc.1204307; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Lieberman SL, 2004, DEV BIOL, V268, P271, DOI 10.1016/j.ydbio.2003.12.009; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Vilk G, 2002, J CELL BIOCHEM, V84, P84, DOI 10.1002/jcb.1268; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467	48	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29667	29677		10.1074/jbc.M706457200	http://dx.doi.org/10.1074/jbc.M706457200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681943	hybrid			2022-12-27	WOS:000249788000063
J	He, WX; Shi, Q; Hu, XY; Yan, RQ				He, Wanxia; Shi, Qi; Hu, Xiangyou; Yan, Riqiang			The membrane topology of RTN3 and its effect on binding of RTN3 to BACE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; NEURITE OUTGROWTH; ENDOPLASMIC-RETICULUM; AXON REGENERATION; GENE FAMILY; IN-VITRO; NOGO-A; INHIBITOR; IDENTIFICATION	Reticulon 3 (RTN3) has recently been shown to modulate Alzheimer BACE1 activity and to play a role in the formation of dystrophic neurites present in Alzheimer brains. Despite the functional importance of this protein in Alzheimer disease pathogenesis, the functional correlation to the structural domain of RTN3 remained unclear. RTN3 has two long transmembrane domains, but its membrane topology was not known. We report here that the first transmembrane domain dictates membrane integration and its membrane topology. RTN3 adopts a omega-shape structure with two ends facing the cytosolic side. Subtle changes in RTN3 membrane topology can disrupt its binding to BACE1 and its inhibitory effects on BACE1 activity. Thus, the determination of RTN3 membrane topology may provide an important structural basis for our understanding of its cellular functions.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org		Yan, Riqiang/0000-0001-7195-7617	NATIONAL INSTITUTE ON AGING [R01AG025493] Funding Source: NIH RePORTER; NIA NIH HHS [AG025493] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; He WX, 2006, J MOL BIOL, V363, P625, DOI 10.1016/j.jmb.2006.07.094; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hu XY, 2007, EMBO J, V26, P2755, DOI 10.1038/sj.emboj.7601707; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Murayama KS, 2006, EUR J NEUROSCI, V24, P1237, DOI 10.1111/j.1460-9568.2006.05005.x; Oertle T, 2003, FASEB J, V17, P1238, DOI 10.1096/fj.02-1166hyp; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Strittmatter SM, 2002, J MOL NEUROSCI, V19, P117, DOI 10.1007/s12031-002-0021-7; Tang BL, 2007, J NEUROCHEM, V100, P314, DOI 10.1111/j.1471-4159.2006.04215.x; Tie JK, 2005, J BIOL CHEM, V280, P16410, DOI 10.1074/jbc.M500765200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Wakana Y, 2005, BIOCHEM BIOPH RES CO, V334, P1198, DOI 10.1016/j.bbrc.2005.07.012; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	27	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29144	29151		10.1074/jbc.M704181200	http://dx.doi.org/10.1074/jbc.M704181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17699523	hybrid			2022-12-27	WOS:000249788000009
J	Fehr, D; Burr, SE; Gibert, M; d'Alayer, J; Frey, J; Popoff, MR				Fehr, Desiree; Burr, Sarah E.; Gibert, Maryse; d'Alayer, Jacques; Frey, Joachim; Popoff, Michel R.			Aeromonas exoenzyme T of Aeromonas salmonicida is a bifunctional protein that targets the host cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOT; PERFRINGENS IOTA-TOXIN; GTPASE-ACTIVATING PROTEIN; ADP-RIBOSYLATING TOXIN; III SECRETION SYSTEM; SUBSP SALMONICIDA; VIRULENCE; RIBOSYLTRANSFERASE; CLOSTRIDIUM; ACTIN	Type III protein secretion has been shown recently to be important in the virulence of the fish pathogen Aeromonas salmonicida. The ADP-ribosylating toxin Aeromonas exoenzyme T (AexT) is one effector protein targeted for secretion via this system. In this study, we identified muscular and nonmuscular actin as substrates of the ADP-ribosylating activity of AexT. Furthermore, we show that AexT also functions as a GTPase-activating protein ( GAP), displaying GAP activity against monomeric GTPases of the Rho family, specifically Rho, Rac, and Cdc42. Transfection of fish cells with wild type AexT resulted in depolymerization of the actin cytoskeleton and cell rounding. Point mutations within either the GAP or the ADP-ribosylating active sites of AexT (Arg-143 as well as Glu-398 and Glu-401, respectively) abolished enzymatic activity, yet did not prevent actin filament depolymerization. However, inactivation of the two catalytic sites simultaneously did. These results suggest that both the GAP and ADP-ribosylating domains of AexT contribute to its biological activity. This is the first bacterial virulence factor to be described that has a specific actin ADP-ribosylation activity and GAP activity toward Rho, Rac, and Cdc42, both enzymatic activities contributing to actin filament depolymerization.	Univ Bern, Inst Vet Bacteriol, CH-3001 Bern, Switzerland; Inst Pasteur, Unite Bacteries Anaerobies & Toxines, F-75724 Paris 15, France; Inst Pasteur, Plateforme Anal & Microsequencage Prot, F-75724 Paris 15, France	University of Bern; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Frey, J (corresponding author), Univ Bern, Inst Vet Bacteriol, Langgasstr 122,Postfach, CH-3001 Bern, Switzerland.	joachim.frey@vbi.unibe.ch		Burr, Sarah/0000-0002-1780-3403				Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Belloy L, 2003, MICROBIOL-SGM, V149, P185, DOI 10.1099/mic.0.25864-0; Braman J, 1996, Methods Mol Biol, V57, P31; Braun M, 2002, J BACTERIOL, V184, P1851, DOI 10.1128/JB.184.7.1851-1858.2002; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Burr SE, 2005, MICROBIOL-SGM, V151, P2111, DOI 10.1099/mic.0.27926-0; Burr SE, 2003, DIS AQUAT ORGAN, V57, P167, DOI 10.3354/dao057167; Burr SE, 2003, J BACTERIOL, V185, P6583, DOI 10.1128/JB.185.22.6583-6591.2003; Burr SE, 2002, J BACTERIOL, V184, P5966, DOI 10.1128/JB.184.21.5966-5970.2002; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; Coye LH, 2004, MOL MICROBIOL, V54, P89, DOI 10.1111/j.1365-2958.2004.04262.x; Dacanay A, 2006, MICROBIOL-SGM, V152, P1847, DOI 10.1099/mic.0.28768-0; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Fehr D, 2006, MICROBIOL-SGM, V152, P2809, DOI 10.1099/mic.0.28889-0; Fraylick JE, 2001, INFECT IMMUN, V69, P5318, DOI 10.1128/IAI.69.9.5318-5328.2001; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Ganesan AK, 1999, J BIOL CHEM, V274, P21823, DOI 10.1074/jbc.274.31.21823; Garrity-Ryan L, 2004, INFECT IMMUN, V72, P546, DOI 10.1128/IAI.72.1.546-558.2004; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Hochmann H, 2006, BIOCHEMISTRY-US, V45, P1271, DOI 10.1021/bi051810w; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Lesnick ML, 2001, MOL MICROBIOL, V39, P1464, DOI 10.1046/j.1365-2958.2001.02360.x; Litvak Y, 2007, J BACTERIOL, V189, P2558, DOI 10.1128/JB.01358-06; Maresso A. W., 2006, COMPREHENSIVE SOURCE, P257, DOI [DOI 10.1016/B978-012088445-2/50019-6, 10.1016/B978-012088445-2/50019-6]; Maresso AW, 2004, J BIOL CHEM, V279, P38402, DOI 10.1074/jbc.M405707200; Marvaud JC, 2002, J BIOL CHEM, V277, P43659, DOI 10.1074/jbc.M207828200; Masignani V., 2006, COMPREHENSIVE SOURCE, P213; Mota LJ, 2005, ANN MED, V37, P234, DOI 10.1080/07853890510037329; Nagahama M, 2000, J BACTERIOL, V182, P2096, DOI 10.1128/JB.182.8.2096-2103.2000; NELSON M, 1992, METHOD ENZYMOL, V216, P279; PAWELRAMMINGEN U, 2000, MOL MICROBIOL, V36, P737; Perelle S, 1996, FEBS LETT, V395, P191, DOI 10.1016/0014-5793(96)01035-6; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; Popoff MR, 2000, HANDB EXP PHARM, V145, P275; Popovic M., 2006, COMPREHENSIVE SOURCE, P157; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sousa S, 2005, NAT CELL BIOL, V7, P954, DOI 10.1038/ncb1308; Stuber K, 2003, J CLIN MICROBIOL, V41, P3854, DOI 10.1128/JCM.41.8.3854-3856.2003; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; Sundin C, 2004, FEMS MICROBIOL LETT, V234, P87, DOI 10.1016/j.femsle.2004.03.014; Tezcan-Merdol D, 2001, MOL MICROBIOL, V39, P606, DOI 10.1046/j.1365-2958.2001.02258.x; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Vipond R, 1998, INFECT IMMUN, V66, P1990, DOI 10.1128/IAI.66.5.1990-1998.1998; VIRET JF, 1993, BIOTECHNIQUES, V14, P325; WONG KR, 1989, J BACTERIOL, V171, P2523, DOI 10.1128/jb.171.5.2523-2527.1989	51	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28843	28852		10.1074/jbc.M704797200	http://dx.doi.org/10.1074/jbc.M704797200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17656370	hybrid			2022-12-27	WOS:000249642100059
J	Han, JH; Zhou, H; Li, ZH; Xu, RM; Zhang, ZG				Han, Junhong; Zhou, Hui; Li, Zhizhong; Xu, Rui-Ming; Zhang, Zhiguo			Acetylation of lysine 56 of histone H3 catalyzed by RTT109 and regulated by ASF1 is required for replisome integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; EUKARYOTIC CELLS; STRUCTURAL BASIS; S-PHASE; H3; YEAST; CHROMATIN; FORK; COMPLEX	In budding yeast, acetylation of histone H3 lysine 56 (H3-K56) is catalyzed by the Rtt109-Vps75 histone acetyltransferase (HAT) complex, with Rtt109 being the catalytic subunit, and histone chaperone Asf1 is required for this modification. Cells lacking Rtt109 are susceptible to perturbations in DNA replication. However, how Asf1 regulates acetylation of H3-K56 and how loss of H3-K56 acetylation affects DNA replication are unclear. We show that at low concentrations the Rtt109-Vps75 HAT complex acetylates H3-K56 in vitro when H3/H4 is complexed with Asf1, but not H3/H4 tetramers, recapitulating the in vivo requirement of Asf1 for H3-K56 acetylation using recombinant proteins. Moreover, the Rtt109-Vps75 complex interacts with Asf1-H3/H4 but not Asf1. In vivo, the Rtt109-Asf1 interaction is also dependent on the ability of Asf1 to bind H3/H4. Furthermore, the Rtt109 homolog in Schizosaccharomyces pombe (SpRtt109) also displayed an Asf1-dependent H3-K56 HAT activity in vitro. These results indicate that Asf1 regulates H3-K56 acetylation by presenting histones H3 and H4 to Rtt109-Vps575 for acetylation, and this mechanism is likely to be conserved. Finally, we have shown that cells lacking Rtt109 or expressing H3-K56 mutants exhibited significant reduction in the association of three proteins with stalled DNA replication forks and hyper-recombination of replication forks stalled at replication fork barriers of the ribosomal DNA locus compared with wild-type cells. Taken together, these studies provide novel insight into the role of Asf1 in the regulation of H3-K56 acetylation and the function of this modification in DNA replication.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; NYU, Skirball Inst Biomed, Helen & MArtin S Kimmel Ctr Biol & Med, Sch Med,Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Mayo Clinic; New York University; New York University	Zhang, ZG (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	Zhang.Zhiguo@mayo.edu	xu, rui/GRX-5734-2022; Han, Junhong/L-5264-2013	Han, Junhong/0000-0002-3371-8698				Adkins MW, 2007, J BIOL CHEM, V282, P1334, DOI 10.1074/jbc.M608025200; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Cobb JA, 2005, GENE DEV, V19, P3055, DOI 10.1101/gad.361805; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; English CM, 2006, CELL, V127, P495, DOI 10.1016/j.cell.2006.08.047; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Han JH, 2007, J BIOL CHEM, V282, P14158, DOI 10.1074/jbc.M700611200; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Huang SB, 2005, P NATL ACAD SCI USA, V102, P13410, DOI 10.1073/pnas.0506176102; Huang SB, 2007, EMBO J, V26, P2274, DOI 10.1038/sj.emboj.7601670; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Luke B, 2006, CURR BIOL, V16, P786, DOI 10.1016/j.cub.2006.02.071; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mousson F, 2005, P NATL ACAD SCI USA, V102, P5975, DOI 10.1073/pnas.0500149102; Natsume R, 2007, NATURE, V446, P338, DOI 10.1038/nature05613; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tsubota T, 2007, MOL CELL, V25, P703, DOI 10.1016/j.molcel.2007.02.006; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; van Holde KE., 1989, SPRINGER SERIES MOL; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 2003, MOL CELL, V11, P283, DOI 10.1016/S1097-2765(03)00052-2; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Xhemalce B, 2007, J BIOL CHEM, V282, P15040, DOI 10.1074/jbc.M701197200; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	46	140	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28587	28596		10.1074/jbc.M702496200	http://dx.doi.org/10.1074/jbc.M702496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17690098	hybrid			2022-12-27	WOS:000249642100033
J	Vernaleken, A; Veyhl, M; Gorboulev, V; Kottra, G; Palm, D; Burckhardt, BC; Burckhardt, G; Pipkorn, R; Beier, N; van Amsterdam, C; Koepsell, H				Vernaleken, Alexandra; Veyhl, Maike; Gorboulev, Valentin; Kottra, Gabor; Palm, Dieter; Burckhardt, Birgitta-Christina; Burckhardt, Gerhard; Pipkorn, Ruediger; Beier, Norbert; van Amsterdam, Christoph; Koepsell, Hermann			Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D- glucose cotransporter SGLT1 with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED PROTEIN; XENOPUS-LAEVIS OOCYTES; TRANSPORT MODIFIER RS1; INTESTINAL GLUCOSE; NA+/GLUCOSE COTRANSPORTER; PLASMA-MEMBRANE; SUGAR-TRANSPORT; MESSENGER-RNA; EXPRESSION; CELLS	The human gene RSC1A1 codes for a 67-kDa protein named RS1 that mediates transcriptional and post- transcriptional regulation of Na+-D-glucose cotransporter SGLT1. The post- transcriptional regulation occurs at the trans-Golgi network (TGN). We identified two tripeptides in human RS1 (Gln-Cys-Pro (QCP) and Gln-Ser-Pro (QSP)) that induce posttranscriptional down-regulation of SGLT1 at the TGN leading to 40-50% reduction of SGLT1 in plasma membrane. For effective intracellular concentrations IC50 values of 2.0 nM (QCP) and 0.16 nM (QSP) were estimated. Down-regulation of SGLT1 by tripeptides was attenuated by intracellular monosaccharides including non-metabolized methyl-alpha-D-glucopyranoside and 2-deoxyglucose. In small intestine post- transcriptional regulation of SGLT1 may contribute to glucose-dependent regulation of liver metabolism and intestinal mobility. QCP and QSP are transported by the H+- peptide cotransporter PepT1 that is colocated with SGLT1 in small intestinal enterocytes. Using coexpression of SGLT1 and PepT1 in Xenopus oocytes or polarized Caco-2 cells that contain both transporters we demonstrated that the tripeptides were effective when applied to the extracellular compartment. After a 1-h perfusion of intact rat small intestine with QSP, glucose absorption was reduced by 30%. The data indicate that orally applied tripeptides can be used to down-regulate small intestinal glucose absorption, e. g. in diabetes mellitus.	Univ Wurzburg, Dept Anat & Cell Biol, D-97070 Wurzburg, Germany; Tech Univ Munich, Dept Food & Nutr, D-85350 Freising Weihenstephan, Germany; Univ Gottingen, Inst Physiol & Pathophysiol, D-37073 Gottingen, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Diabet Res Dept Merck KGaA, D-64293 Darmstadt, Germany	University of Wurzburg; Technical University of Munich; University of Gottingen; Helmholtz Association; German Cancer Research Center (DKFZ); Merck KGaA	Koepsell, H (corresponding author), Univ Wurzburg, Dept Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany.	Hermann@Koepsell.de						Asano T, 2004, CURR MED CHEM, V11, P2717, DOI 10.2174/0929867043364360; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Casirola DM, 2006, METABOLISM, V55, P832, DOI 10.1016/j.metabol.2006.02.011; CHANTRET I, 1988, CANCER RES, V48, P1936; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; Coblitz B, 2006, FEBS LETT, V580, P1531, DOI 10.1016/j.febslet.2006.02.014; Conde C, 2006, PLANT PHYSIOL, V141, P1563, DOI 10.1104/pp.106.080804; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; Diez-Sampedro A, 2003, P NATL ACAD SCI USA, V100, P11753, DOI 10.1073/pnas.1733027100; DUBASH J, 2004, BIOORG MED CHEM LETT, V14, P5121; FERRARIS RP, 1989, ANNU REV PHYSIOL, V51, P125, DOI 10.1146/annurev.ph.51.030189.001013; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; Freeman SL, 2006, AM J PHYSIOL-GASTR L, V291, pG439, DOI 10.1152/ajpgi.00079.2006; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Hirsh AJ, 1998, J BIOL CHEM, V273, P14545, DOI 10.1074/jbc.273.23.14545; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; Jiang W, 2005, MOL CELL BIOL, V25, P6496, DOI 10.1128/MCB.25.15.6496-6508.2005; Jungermann K, 1999, HEPATO-GASTROENTEROL, V46, P1414; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Katsuno K, 2007, J PHARMACOL EXP THER, V320, P323, DOI 10.1124/jpet.106.110296; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; Khoursandi S, 2004, AM J PHYSIOL-CELL PH, V287, pC1041, DOI 10.1152/ajpcell.00197.2004; Kipp H, 2003, AM J PHYSIOL-CELL PH, V285, pC737, DOI 10.1152/ajpcell.00041.2003; Korn T, 2001, J BIOL CHEM, V276, P45330, DOI 10.1074/jbc.M105975200; Kroiss M, 2006, AM J PHYSIOL-RENAL, V291, pF1201, DOI 10.1152/ajprenal.00067.2006; Lambotte S, 1996, DNA CELL BIOL, V15, P769, DOI 10.1089/dna.1996.15.769; Liu MT, 1999, J NEUROSCI, V19, P10305; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Martin MG, 2000, AM J PHYSIOL-GASTR L, V278, pG591, DOI 10.1152/ajpgi.2000.278.4.G591; Meier JJ, 2002, REGUL PEPTIDES, V107, P1, DOI 10.1016/S0167-0115(02)00039-3; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIYAMOTO K, 1993, BIOCHEM J, V295, P211, DOI 10.1042/bj2950211; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; O'Donovan DG, 2004, J CLIN ENDOCR METAB, V89, P3431, DOI 10.1210/jc.2004-0334; Osswald C, 2005, MOL CELL BIOL, V25, P78, DOI 10.1128/MCB.25.1.78-87.2005; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Puntheeranurak T, 2007, BIOCHEMISTRY-US, V46, P2797, DOI 10.1021/bi061917z; RAYBOULD HE, 1995, NEUROGASTROENT MOTIL, V7, P9, DOI 10.1111/j.1365-2982.1995.tb00203.x; Rayner CK, 2001, DIABETES CARE, V24, P371, DOI 10.2337/diacare.24.2.371; Reinhardt J, 1999, BBA-BIOMEMBRANES, V1417, P131, DOI 10.1016/S0005-2736(98)00250-8; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Schmitt BM, 2002, BIOPHYS J, V82, P1345, DOI 10.1016/S0006-3495(02)75490-8; Sharp PA, 1996, GUT, V39, P545, DOI 10.1136/gut.39.4.545; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thorens B, 2004, CURR OPIN CLIN NUTR, V7, P471, DOI 10.1097/01.mco.0000134368.91900.84; Valentin M, 2000, BBA-BIOMEMBRANES, V1468, P367, DOI 10.1016/S0005-2736(00)00277-7; Van de Laar FA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005061; Vayro S, 1999, AM J PHYSIOL-CELL PH, V276, pC1053, DOI 10.1152/ajpcell.1999.276.5.C1053; Vayro S, 2001, EUR J BIOCHEM, V268, P5460, DOI 10.1046/j.0014-2956.2001.02488.x; VEYHL M, 1993, J BIOL CHEM, V268, P25041; Veyhl M, 2003, J MEMBRANE BIOL, V196, P71, DOI 10.1007/s00232-003-0626-y; Veyhl M, 2006, AM J PHYSIOL-RENAL, V291, pF1213, DOI 10.1152/ajprenal.00068.2006; Wang YF, 1997, PHARMACEUT RES, V14, P1563, DOI 10.1023/A:1012174217220; Wideman RD, 2004, HORM METAB RES, V36, P782, DOI 10.1055/s-2004-826164; Zeuthen T, 2002, J PHYSIOL-LONDON, V542, P71, DOI 10.1113/jphysiol.2001.014530; Zhou LB, 2003, J CELL BIOCHEM, V90, P339, DOI 10.1002/jcb.10631	66	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28501	28513		10.1074/jbc.M705416200	http://dx.doi.org/10.1074/jbc.M705416200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686765	hybrid			2022-12-27	WOS:000249642100024
J	Yegneswaran, S; Kojima, Y; Nguyen, PM; Gale, AJ; Heeb, MJ; Griffin, JH				Yegneswaran, Subramanian; Kojima, Yumi; Nguyen, Phuong M.; Gale, Andrew J.; Heeb, Mary J.; Griffin, John H.			Factor va residues 311-325 represent an activated protein C binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; PEPTIDE-BOND CLEAVAGES; BOVINE FACTOR-V; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX; MEDIATED CLEAVAGES; FACTOR VA(R506Q); INACTIVATION; SITE; FLUORESCENCE	Activated protein C (APC) inactivates factor Va (fVa) by pro-teolytically cleaving fVa heavy chain at Arg(506), Arg(306), and Arg(679). Factor Xa (fXa) protects fVa from inactivation by APC. To test the hypothesis that fXa and APC share overlapping fVa binding sites, 15 amino acid-overlapping peptides representing the heavy chain (residues 1-709) of fVa were screened for inhibition of fVa inactivation by APC. As reported, VP311-325, a peptide comprising residues 311-325 in fVa, dose-dependently and potently inhibited fVa-dependent prothrombin activation by fXa in the absence of APC. This peptide also inhibited the inactivation of fVa by APC, suggesting that this region of fVa interacts with APC. The peptide inhibited the APC-dependent cleavage of both Arg(506) and Arg(306) because inhibition was observed with plasma-derived fVa and recombinant R506Q and RR306/679QQ fVa. VP311-325 altered the fluorescence emission of dansyl-active site-labeled APC(i) but not a dansyl-active site-labeled thrombin control, showing that the peptide binds to APCi. This peptide also inhibited the resonance energy transfer between membrane-bound fluorescein-labeled fVa (donor) and rhodamine-active site-labeled S360C-APC (acceptor). These data suggest that peptide VP311-325 represents both an APC and fXa binding region in fVa.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547				Autin L, 2006, PROTEINS, V63, P440, DOI 10.1002/prot.20848; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Friedrich U, 2001, J BIOL CHEM, V276, P24122, DOI 10.1074/jbc.M011567200; Gale AJ, 2000, BLOOD, V96, P585; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Koppaka V, 1996, BIOPHYS J, V70, P2930, DOI 10.1016/S0006-3495(96)79863-6; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LU RL, 1989, J BIOL CHEM, V264, P12956; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nicolaes GAF, 2002, ARTERIOSCL THROM VAS, V22, P530, DOI 10.1161/01.ATV.0000012665.51263.B7; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; Norstrom EA, 2006, J BIOL CHEM, V281, P31486, DOI 10.1074/jbc.M606441200; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200	34	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28353	28361		10.1074/jbc.M704316200	http://dx.doi.org/10.1074/jbc.M704316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17646160	hybrid			2022-12-27	WOS:000249642100009
J	Jang, BC; Sung, SH; Park, JG; Park, JW; Bae, JH; Shin, DH; Park, GY; Han, SB; Suh, SI				Jang, Byeong-Churl; Sung, Su-Haeng; Park, Jong-Gu; Park, Jong-Wook; Bae, Jae Hoon; Shin, Dong Hoon; Park, Gi-Young; Han, Seung-Bum; Suh, Seong-Il			Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL REGULATION; ENDOPLASMIC-RETICULUM; NEURONAL CELLS; MESSENGER-RNA; UP-REGULATION; KAPPA-B; PROSTAGLANDIN; ACTIVATION	COX-2 and its products, including prostaglandin E-2, are involved in many inflammatory processes. Glucosamine (GS) is an amino monosaccharide and has been widely used for alternative regimen of (osteo) arthritis. However, the mechanism of action of GS on COX-2 expression remains unclear. Here we describe a new action mechanism of glucosamine hydrochloride (GS-HCl) to tackle endogenous and agonist-driven COX-2 at protein level. GS-HCl (but not GS sulfate, N-acetyl GS, or galactosamine HCl) resulted in a shift in the molecular mass of COX-2 from 72-74 to 66-70 kDa and concomitant inhibition of prostaglandin E2 production in a concentration-dependent manner in interleukin (IL)-1 beta-treated A549 human lung epithelial cells. Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification. Specifically, the effect of low concentration of GS-HCl (I mm) or of tunicamycin (0.1 mu g/ml) to produce the aglycosylated COX-2 was rescued by the proteasomal inhibitor MG132 but not by the lysosomal or caspase inhibitors. However, the proteasomal inhibitors did not show an effect at 5 mm GS-HCl, which produced the aglycosylated or completely deglycosylated form of COX-2. Notably, GS-HCl (5 mm) also facilitated degradation of the higher molecular species of COX-2 in IL-1 beta-treated A549 cells that was retarded by MG132. GS-HCl (5 mm) was also able to decrease the molecular mass of endogenous and IL-1 beta- or tumor necrosis factor-a-driven COX-2 in different human cell lines, including Hep2 (bronchial) and H292 (laryngeal). However, GS-HCl did not affect COX-1 protein expression. These results demonstrate for the first time that GS-HCl inhibits COX-2 activity by preventing COX-2 co-translational N-glycosylation and by facilitating COX-2 protein turnover during translation in a proteasome-dependent manner.	Keimyung Univ, Sch Med, Chron Dis Res Ctr, Inst Med Sci, Taejon 700712, South Korea; Keimyung Univ, Sch Med, Dept Rehabil Med, Taejon 700712, South Korea; Keimyung Univ, Sch Med, Div Pulm & Dev Internal Med, Taejon 700712, South Korea	Keimyung University; Keimyung University; Keimyung University	Jang, BC (corresponding author), Keimyung Univ, Sch Med, Chron Dis Res Ctr, Inst Med Sci, 194 Dongsan-dong,Jung-gu, Taejon 700712, South Korea.	jangbc12@kmu.ac.kr; seong@dsmc.or.kr						Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; Chen JJ, 2005, MOL BIOL CELL, V16, P5579, DOI 10.1091/mbc.E05-08-0778; Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Comunale MA, 2004, PROTEOMICS, V4, P826, DOI 10.1002/pmic.200300625; D'Alessandris C, 2004, FASEB J, V18, P959, DOI 10.1096/fj.03-0725fje; DAVIDSON MB, 1994, BBA-GEN SUBJECTS, V1201, P113, DOI 10.1016/0304-4165(94)90159-7; Fenton JI, 2000, OSTEOARTHR CARTILAGE, V8, P258, DOI 10.1053/joca.1999.0299; Figueiredo-Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIA T, 1992, P NATL ACAD SCI USA, V89, P7384; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Hua J, 2005, INFLAMM RES, V54, P127, DOI 10.1007/s00011-004-1333-6; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063-4584(03)00028-1; Li GT, 2005, P NATL ACAD SCI USA, V102, P15809, DOI 10.1073/pnas.0507155102; Liu WV, 2003, CANCER RES, V63, P3632; Mbonye UR, 2006, J BIOL CHEM, V281, P35770, DOI 10.1074/jbc.M608281200; Nakamura H, 2004, CLIN EXP RHEUMATOL, V22, P293; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Qiu W, 2006, J LIPID RES, V47, P1749, DOI 10.1194/jlr.M500363-JLR200; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; Williams Gary W, 2005, Curr Pain Headache Rep, V9, P377, DOI 10.1007/s11916-005-0017-4; Woo KJ, 2006, BIOCHEM BIOPH RES CO, V342, P1334, DOI 10.1016/j.bbrc.2006.02.105	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27622	27632		10.1074/jbc.M610778200	http://dx.doi.org/10.1074/jbc.M610778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635918	Green Published, hybrid			2022-12-27	WOS:000249455600009
J	Knappe, M; Bodevin, S; Selinka, HC; Spillmann, D; Streeck, RE; Chen, XJS; Lindahl, U; Sapp, M				Knappe, Maren; Bodevin, Sabrina; Selinka, Hans-Christoph; Spillmann, Dorothe; Streeck, Rolf E.; Chen, Xiaojiang S.; Lindahl, Ulf; Sapp, Martin			Surface-exposed amino acid residues of HPV16 l1 protein mediating interaction with cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-33; HERPES-SIMPLEX-VIRUS; MINOR CAPSID PROTEIN; INITIAL INTERACTION; GLYCOPROTEIN-C; BINDING; RECEPTOR; PARTICLES; INFECTION; GLYCOSAMINOGLYCANS	Efficient infection of cells by human papillomaviruses (HPVs) and pseudovirions requires primary interaction with cell surface proteoglycans with apparent preference for species carrying heparan sulfate (HS) side chains. To identify residues contributing to virus/cell interaction, we performed point mutational analysis of the HPV16 major capsid protein, L1, targeting surface-exposed amino acid residues. Replacement of lysine residues 278, 356, or 361 for alanine reduced cell binding and infectivity of pseudovirions. Various combinations of these amino acid exchanges further decreased cell attachment and infectivity with residual infectivity of less than 5% for the triple mutant, suggesting that these lysine residues cooperate in HS binding. Single, double, or triple exchanges for arginine did not impair infectivity, demonstrating that interaction is dependent on charge distribution rather than sequence-specific. The lysine residues are located within a pocket on the capsomere surface, which was previously proposed as the putative receptor binding site. Fab fragments of binding-neutralizing antibody H16.56E that recognize an epitope directly adjacent to lysine residues strongly reduced HS-mediated cell binding, further corroborating our findings. In contrast, mutation of basic surface residues located in the cleft between capsomeres outside this pocket did not significantly reduce interaction with HS or resulted in assembly-deficient proteins. Computer-simulated heparin docking suggested that all three lysine residues can form hydrogen bonds with 2-O-, 6-O-, and N-sulfate groups of a single HS molecule with a minimal saccharide domain length of eight monomer units. This prediction was experimentally confirmed in binding experiments using capsid protein, heparin molecules of defined length, and sulfate group modifications.	Univ Mainz, Inst Med Microbiol, D-55101 Mainz, Germany; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ So Calif, Dept Mol & Computat Biol, Los Angeles, CA 90089 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Ctr Mol & Tumor Virol,Dept MIcrobiol & Immunol, Shreveport, LA 71130 USA	Johannes Gutenberg University of Mainz; Uppsala University; University of Southern California; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Knappe, M (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, 1501 Kings Highway, Shreveport, LA 71130 USA.	msapp1@lsuhsc.edu		Selinka, Hans-Christoph/0000-0001-6112-2368	NCRR NIH HHS [P20-RR018724] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018724] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bergsdorf C, 2003, FEBS LETT, V536, P120, DOI 10.1016/S0014-5793(03)00039-5; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Booy FP, 1998, J MOL BIOL, V281, P95, DOI 10.1006/jmbi.1998.1920; Buck CB, 2005, J VIROL, V79, P2839, DOI 10.1128/JVI.79.5.2839-2846.2005; Buck CB, 2004, J VIROL, V78, P751, DOI 10.1128/JVI.78.2.751-757.2004; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Giroglou T, 2001, VACCINE, V19, P1783, DOI 10.1016/S0264-410X(00)00370-4; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Goodfellow IG, 2001, J VIROL, V75, P4918, DOI 10.1128/JVI.75.10.4918-4921.2001; Handa A, 2000, J GEN VIROL, V81, P2077, DOI 10.1099/0022-1317-81-8-2077; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713; Ho Y, 2005, J MOL BIOL, V349, P1060, DOI 10.1016/j.jmb.2005.04.024; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; Jackson T, 2003, VIRUS RES, V91, P33, DOI 10.1016/S0168-1702(02)00258-7; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Kreuger J, 2003, METHOD ENZYMOL, V363, P327; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; Leder C, 2001, J VIROL, V75, P9201, DOI 10.1128/JVI.75.19.9201-9209.2001; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Mardberg K, 2002, J GEN VIROL, V83, P291, DOI 10.1099/0022-1317-83-2-291; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; Modis Y, 2002, EMBO J, V21, P4754, DOI 10.1093/emboj/cdf494; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Roden RBS, 1996, J VIROL, V70, P3298, DOI 10.1128/JVI.70.5.3298-3301.1996; Rommel O, 2005, J MED VIROL, V75, P114, DOI 10.1002/jmv.20245; Roth SD, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-83; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; Selinka HC, 2003, J VIROL, V77, P12961, DOI 10.1128/JVI.77.24.12961-12967.2003; Selinka HC, 2002, VIROLOGY, V299, P279, DOI 10.1006/viro.2001.1493; SELINKA HC, 2003, PAPILLOMAVIRUS REP, V14, P259; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0; Trybala E, 1996, VIROLOGY, V218, P35, DOI 10.1006/viro.1996.0163; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; VOLPERS C, 1995, J GEN VIROL, V76, P2661, DOI 10.1099/0022-1317-76-11-2661; VOLPERS C, 1995, J VIROL, V69, P3258, DOI 10.1128/JVI.69.6.3258-3264.1995; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Zautner AE, 2006, J VIROL, V80, P6629, DOI 10.1128/JVI.01988-05	62	100	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27913	27922		10.1074/jbc.M705127200	http://dx.doi.org/10.1074/jbc.M705127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640876	hybrid			2022-12-27	WOS:000249455600040
J	Leich, F; Stohr, N; Rietz, A; Ulbrich-Hofmann, R; Arnold, U				Leich, Franziska; Stoehr, Nadine; Rietz, Anne; Ulbrich-Hofmann, Renate; Arnold, Ulrich			Endocytotic internalization as a crucial factor for the cytotoxicity of Ribonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC RIBONUCLEASE; INHIBITOR INTERACTION; BIOLOGICAL ACTIONS; CATALYTIC ACTIVITY; ANTITUMOR-ACTIVITY; STERIC BLOCKADE; CATHEPSIN-S; CELLS; RNASE; PROTEIN	The cytotoxic action of ribonucleases (RNases) requires the interaction of the enzyme with the cellular membrane, its internalization, translocation to the cytosol, and the degradation of ribonucleic acid. The interplay of these processes as well as the role of the thermodynamic and proteolytic stability, the catalytic activity, and the evasion from the intracellular ribonuclease inhibitor (RI) has not yet been fully elucidated. As cytosolic internalization is indispensable for the cytotoxicity of extracellular ribonucleases, we investigated the extent of cytosolic internalization of a cytotoxic, RI-evasive RNase A variant (G88R-RNase A) and of various similarly cytotoxic but RI-sensitive RNase A tandem enzyme variants in comparison to the internalization of the non-cytotoxic and RI-sensitive RNase A. After incubation of K-562 cells with the RNase A variants for 36 h, the internalized amount of RNases was analyzed by rapid cell disruption followed by subcellular fractionation and semiquantitative immunoblotting. The data indicate that an enhanced cellular uptake and an increased entry of the RNases into the cytosol can outweigh the abolishment of catalytic activity by RI. As all RNase A variants proved to be resistant to the proteases present in the different subcellular fractions for more than 100 h, our results suggest that the cytotoxic potency of RNases is determined by an efficient internalization into the cytosol.	Univ Halle Wittenberg, Dept Biochem & Biotechnol, Halle, Germany; Univ Halle Wittenberg, Inst Biochem & Biotechnol, D-06120 Halle, Germany; Univ Halle Wittenberg, Interdisciplinary Ctr Appl Med & Human Biol Res, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Arnold, U (corresponding author), Univ Halle Wittenberg, Dept Biochem & Biotechnol, Kurt-Mothes Str 3, Halle, Germany.	ulrich.arnold@biochemtech.uni-halle.de						Arnold U, 2006, BIOTECHNOL LETT, V28, P1615, DOI 10.1007/s10529-006-9145-0; Benito A, 2005, MOL BIOSYST, V1, P294, DOI 10.1039/b502847g; BOHLEY P, 1969, FEBS LETT, V5, P233, DOI 10.1016/0014-5793(69)80341-8; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bosch M, 2004, BIOCHEMISTRY-US, V43, P2167, DOI 10.1021/bi035729+; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; De Lorenzo C, 2002, FEBS LETT, V516, P208, DOI 10.1016/S0014-5793(02)02527-9; De Lorenzo C, 2007, FEBS LETT, V581, P296, DOI 10.1016/j.febslet.2006.12.034; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; Ellis RJ, 2006, BIOL CHEM, V387, P485, DOI 10.1515/BC.2006.064; Fuchs SM, 2005, PROTEIN SCI, V14, P1538, DOI 10.1110/ps.051393805; Futami J, 2005, J BIOSCI BIOENG, V99, P95, DOI 10.1263/jbb.99.95; Futami J, 2001, BIOCHEMISTRY-US, V40, P7518, DOI 10.1021/bi010248g; Gaur D, 2001, J BIOL CHEM, V276, P24978, DOI 10.1074/jbc.M102440200; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Krauss J, 2005, BIOCHEM BIOPH RES CO, V331, P595, DOI 10.1016/j.bbrc.2005.03.215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Lee JE, 2005, BIOCHEMISTRY-US, V44, P15760, DOI 10.1021/bi051668z; Leich F, 2006, J MOL BIOL, V358, P1305, DOI 10.1016/j.jmb.2006.03.007; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Libonati M, 2004, BIOCHEM J, V380, P311, DOI 10.1042/BJ20031922; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Monti DM, 2004, J BIOL CHEM, V279, P39195, DOI 10.1074/jbc.C400311200; Naddeo N, 2005, FEBS LETT, V579, P2663, DOI 10.1016/j.febslet.2005.03.087; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; Newton DL, 1997, PROTEIN ENG, V10, P463, DOI 10.1093/protein/10.4.463; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; Newton DL, 2001, CRIT REV ONCOL HEMAT, V39, P79, DOI 10.1016/S1040-8428(01)00116-0; Pavlakis N, 2006, EXPERT OPIN BIOL TH, V6, P391, DOI 10.1517/14712598.6.4.391; Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768; Pouckova P, 2006, NEOPLASMA, V53, P79; Rodriguez M, 2007, J CELL SCI, V120, P1405, DOI 10.1242/jcs.03427; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Schmid H, 1997, BIOL CHEM, V378, P61, DOI 10.1515/bchm.1997.378.2.61; SCHMID H, 1993, RENAL PHYSIOL BIOCH, V16, P222; Schmid H, 2002, BIOL CHEM, V383, P1277, DOI 10.1515/BC.2002.143; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; Smith MR, 1999, EXP CELL RES, V247, P220, DOI 10.1006/excr.1998.4317; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Tada H, 2004, FEBS LETT, V568, P39, DOI 10.1016/j.febslet.2004.05.007; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	50	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27640	27646		10.1074/jbc.M702240200	http://dx.doi.org/10.1074/jbc.M702240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635931	hybrid			2022-12-27	WOS:000249455600011
J	Lewis, AL; Cao, H; Patel, SK; Diaz, S; Ryan, W; Carlin, AF; Thon, V; Lewis, WG; Varki, A; Chen, X; Nizet, V				Lewis, Amanda L.; Cao, Hongzhi; Patel, Silpa K.; Diaz, Sandra; Ryan, Wesley; Carlin, Aaron F.; Thon, Vireak; Lewis, Warren G.; Varki, Ajit; Chen, Xi; Nizet, Victor			NeuA sialic acid O-acetylesterase activity modulates O-acetylation of capsular polysaccharide in Group B Streptococcus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; CHEMOENZYMATIC SYNTHESIS; PSEUDOMONAS-AERUGINOSA; SOMATIC ANTIGENS; SERUM RESISTANCE; FORM VARIATION; C3 DEPOSITION; SEROGROUP-Y; SYNTHETASE; GENE	Group B Streptococcus (GBS) is a common cause of neonatal sepsis and meningitis. A major GBS virulence determinant is its sialic acid (Sia)-capped capsular polysaccharide. Recently, we discovered the presence and genetic basis of capsular Sia O-acetylation in GBS. We now characterize a GBS Sia O-acetylesterase that modulates the degree of GBS surface O-acetylation. The GBS Sia O-acetylesterase operates cooperatively with the GBS CMP-Sia synthetase, both part of a single polypeptide encoded by the neuA gene. NeuA de-O-acetylation of free 9-O-acetyl-N-acetylneuraminic acid (Neu5,9AC(2)) was enhanced by CTP and Mg2+, the substrate and co-factor, respectively, of the N-terminal GBS CMP-Sia synthetase domain. In contrast, the homologous bifunctional NeuA esterase from Escherichia coli K1 did not display cofactor dependence. Further analyses showed that in vitro, GBS NeuA can operate via two alternate enzymatic pathways: de-O-acetylation of Neu5,9AC(2) followed by CMP activation of Neu5Ac or activation of Neu5,9AC(2) followed by de-O-acetylation of CMP-Neu5,9AC(2). Consistent with in vitro esterase assays, genetic deletion of GBS neuA led to accumulation of intracellular O-acetylated Sias, and overexpression of GBS NeuA reduced O-acetylation of Sias on the bacterial surface. Site-directed mutagenesis of conserved asparagine residue 301 abolished esterase activity but preserved CMP-Sia synthetase activity, as evidenced by hyper-O-acetylation of capsular polysaccharide Sias on GBS expressing only the N301A NeuAallele. These studies demonstrate a novel mechanism regulating the extent of capsular Sia O-acetylation in intact bacteria and provide a genetic strategy for manipulating GBS O-acetylation in order to explore the role of this modification in GBS pathogenesis and immunogenicity.	Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA USA; Univ Calif San Diego, Dept Med, La Jolla, CA USA; Univ Calif San Diego, Sch Med, Dept Cell & Mol Med, La Jolla, CA USA; Univ Calif San Diego, Skaggs Res Inst, Dept Biochem, La Jolla, CA 92037 USA; Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Novartis; University of California System; University of California Davis	Varki, A (corresponding author), Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Carlin, Aaron/AAK-3806-2021; Nizet, Victor/AAF-3190-2019; Chen, Xi/H-1811-2018; Lewis, Warren G/W-4369-2019	Chen, Xi/0000-0002-3160-614X; Lewis, Warren G/0000-0003-1210-6403; CAO, HONGZHI/0000-0003-4736-3143; Nizet, Victor/0000-0003-3847-0422; Lewis, Amanda/0000-0001-6195-3030	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051796] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373, R01GM076360, R37GM032373] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL57345, P01 HL057345] Funding Source: Medline; NICHD NIH HHS [R01-HD051796, R01 HD051796] Funding Source: Medline; NIGMS NIH HHS [R01 GM032373, GM32373, R01 GM076360-02, R01 GM076360, R01-GM076360, R37 GM032373] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoh CC, 2004, PROG LIPID RES, V43, P534, DOI 10.1016/j.plipres.2004.09.002; AMBROSE MG, 1992, BIOCHEMISTRY-US, V31, P775, DOI 10.1021/bi00118a019; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Aoyagi Y, 2005, J IMMUNOL, V174, P418, DOI 10.4049/jimmunol.174.1.418; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BUTOR C, 1993, J BIOL CHEM, V268, P10197; Carlin AF, 2007, J BACTERIOL, V189, P1231, DOI 10.1128/JB.01155-06; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Chaffin DO, 2002, MOL MICROBIOL, V45, P109, DOI 10.1046/j.1365-2958.2002.02988.x; Charland N, 1996, FEMS IMMUNOL MED MIC, V14, P195, DOI 10.1111/j.1574-695X.1996.tb00287.x; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; Daines DA, 2000, FEMS MICROBIOL LETT, V189, P281, DOI 10.1111/j.1574-6968.2000.tb09244.x; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; Edwards M, 2006, INFECTIOUS DIS FETUS, P404; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; Fahr C, 2001, J INVEST DERMATOL, V116, P254, DOI 10.1046/j.1523-1747.2001.01237.x; Feng L, 2005, J BACTERIOL, V187, P758, DOI 10.1128/JB.187.2.758-764.2005; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HUESO P, 1988, ITAL J BIOCHEM, V37, P302; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Jurcisek J, 2005, INFECT IMMUN, V73, P3210, DOI 10.1128/IAI.73.6.3210-3218.2005; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Krishna M, 1997, J EXP MED, V185, P1997, DOI 10.1084/jem.185.11.1997; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Lewis AL, 2006, J BIOL CHEM, V281, P11186, DOI 10.1074/jbc.M513772200; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; Liu GC, 2004, J BIOL CHEM, V279, P17738, DOI 10.1074/jbc.M400143200; Lo YC, 2003, J MOL BIOL, V330, P539, DOI 10.1016/S0022-2836(03)00637-5; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Paoletti LC, 2003, EXPERT OPIN BIOL TH, V3, P975, DOI 10.1517/14712598.3.6.975; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Shen YQ, 2004, BIOL CHEM, V385, P145, DOI 10.1515/BC.2004.033; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; Steenbergen SM, 2006, J BACTERIOL, V188, P6195, DOI 10.1128/JB.00466-06; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; VANN WF, 1978, J BACTERIOL, V133, P1300, DOI 10.1128/JB.133.3.1300-1306.1978; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1985, J BIOL CHEM, V260, P6600; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Vogel U, 1997, INFECT IMMUN, V65, P4022, DOI 10.1128/IAI.65.10.4022-4029.1997; WESSELS MR, 1989, P NATL ACAD SCI USA, V86, P8983, DOI 10.1073/pnas.86.22.8983; Yu H, 2006, BIOTECHNOL LETT, V28, P107, DOI 10.1007/s10529-005-4955-z; Yu H, 2004, BIOORGAN MED CHEM, V12, P6427, DOI 10.1016/j.bmc.2004.09.030; Yu H, 2006, ANGEW CHEM INT EDIT, V45, P3938, DOI 10.1002/anie.200600572	61	42	45	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27562	27571		10.1074/jbc.M700340200	http://dx.doi.org/10.1074/jbc.M700340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646166	Green Accepted, hybrid			2022-12-27	WOS:000249455600003
J	Gills, JJ; Castillo, SS; Zhang, CY; Petukhov, PA; Memmott, RM; Hollingshead, M; Warfel, N; Han, JH; Kozikowski, AP; Dennis, PA				Gills, Joell J.; Castillo, S. Sianna; Zhang, Chunyu; Petukhov, Pavel A.; Memmott, Regan M.; Hollingshead, Melinda; Warfel, Noel; Han, Jiahuai; Kozikowski, Alan P.; Dennis, Phillip A.			Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38 alpha, through MKK3/6-independent and -dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; PLECKSTRIN HOMOLOGY DOMAIN; CYCLE CHECKPOINT PATHWAY; PROTEIN-KINASE; CANCER-CELLS; SIGNAL-TRANSDUCTION; ANTITUMOR-ACTIVITY; APOPTOSIS; IMATINIB; AUTOPHOSPHORYLATION	Previously, we identified five active phosphatidylinositol ether lipid analogues (PIAs) that target the pleckstrin homology domain of Akt and selectively induce apoptosis in cancer cells with high levels of Akt activity. To examine specificity, PIAs were screened against a panel of 29 purified kinases. No kinase was inhibited, but one isoform of p38, p38 alpha, was uniformly activated 2-fold. Molecular modeling of p38 alpha revealed the presence of two regions that could interact with PIAs, one in the activation loop and a heretofore unappreciated region in the upper lobe that resembles a pleckstrin homology domain. In cells, two phases of activation were observed, an early phase that was independent of the upstream kinase MKK3/6 and inhibited by the p38 inhibitor SB203580 and a latter phase that was coincident with MKK3/6 activation. In short term xenograft experiments that employed immunohistochemistry and immunoblotting, PIA administration increased phosphorylation of p38 but not MKK3/6 in tumors in a statistically significant manner. Although PIAs rapidly activated p38 with similar time and dose dependence as Akt inhibition, p38 activation and Akt inhibition were independent events induced by PIAs. Using SB203580 or p38 alpha(-/-) cells, we showed that p38 alpha is not required for PIA-induced apoptosis but is required forH(2)O(2)- and anisomycin-induced apoptosis. Nonetheless, activation of p38a contributes to PIA-induced apoptosis, because reconstitution of p38a into p38 alpha(-/-) cells increased apoptosis. These studies indicate that p38 alpha is activated by PIAs through a novel mechanism and show that p38 alpha activation contributes to PIA-induced cell death. Independent modulation of Akt and p38 alpha could account for the profound cytotoxicity of PIAs.	NIH, NCI, Ctr Canc Res, Med Oncol Branch, Bethesda, MD 20889 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; NIH, NCI, Div Canc Treatment & Diagnosis, Dev Therapeut Program, Frederick, MD 21701 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Scripps Research Institute	Dennis, PA (corresponding author), NIH, NCI, Ctr Canc Res, Med Oncol Branch, Bethesda, MD 20889 USA.	pdennis@nih.gov	Zhang, Chun-yu/HDP-5776-2022; Han, J/G-4671-2010	Memmott, Regan/0000-0001-5881-9252; Warfel, Noel/0000-0001-6410-9011	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010450] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; CANMAN CE, 1994, CANCER RES, V54, P5054; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diskin R, 2004, J BIOL CHEM, V279, P47040, DOI 10.1074/jbc.M404595200; Diskin R, 2007, J MOL BIOL, V365, P66, DOI 10.1016/j.jmb.2006.08.043; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Gills JJ, 2006, MOL CANCER THER, V5, P713, DOI 10.1158/1535-7163.MCT-05-0484; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Habiro A, 2004, BIOCHEM BIOPH RES CO, V316, P71, DOI 10.1016/j.bbrc.2004.02.017; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Meuillet EJ, 2004, ONCOL RES, V14, P513, DOI 10.3727/0965040042380487; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Warfel NA, 2006, CLIN CANCER RES, V12, P3502, DOI 10.1158/1078-0432.CCR-05-1837; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	40	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27020	27029		10.1074/jbc.M701108200	http://dx.doi.org/10.1074/jbc.M701108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631503	hybrid			2022-12-27	WOS:000249304900043
J	Sinani, D; Adle, DJ; Kim, H; Lee, J				Sinani, Devis; Adle, David J.; Kim, Heejeong; Lee, Jaekwon			Distinct mechanisms for ctr1-mediated copper and cisplatin transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; OVARIAN-CARCINOMA CELLS; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; CELLULAR PHARMACOLOGY; WILSON-DISEASE; HUMAN CTR1; YEAST	The Ctr1 family of integral membrane proteins is necessary for high affinity copper uptake in eukaryotes. Ctr1 is also involved in cellular accumulation of cisplatin, a platinum-based anticancer drug. Although the physiological role of Ctr1 has been revealed, the mechanism of action of Ctr1 remains to be elucidated. To gain a better understanding of Ctr1-mediated copper and cisplatin transport, we have monitored molecular dynamics and transport activities of yeast Saccharomyces cerevisiae Ctr1 and its mutant alleles. Co-expression of functional Ctr1 monomers fused with either cyan or yellow fluorescent protein resulted in fluorescence resonance energy transfer ( FRET), which is consistent with multimer assembly of Ctr1. Copper near the Km value of Ctr1 enhanced FRET in a manner that correlated with cellular copper transport. In vitro crosslinking of Ctr1 confirmed that copper-induced FRET reflects conformational changes within pre-existing Ctr1 complexes. FRET assays in membrane-disrupted cells and protein extracts showed that intact cell structure is necessary for Ctr1 activity. Despite Ctr1-dependent cellular accumulation, cisplatin did not change Ctr1 FRET nor did it attenuate copper-induced FRET. A Ctr1 allele defective in copper transport enhanced cellular cisplatin accumulation. N-terminal methionine-rich motifs that are dispensable for copper transport play a critical role for cisplatin uptake. Taken together, our data reveal functional roles for structural remodeling of the Ctr1 multimeric complex in copper transport and suggest distinct mechanisms employed by Ctr1 for copper and cisplatin transport.	Univ Nebraska, Dept Biochem, Redox Biol Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Lee, J (corresponding author), Univ Nebraska, Dept Biochem, Redox Biol Ctr, N210 Beadle Ctr, Lincoln, NE 68588 USA.	jlee7@unlnotes.unl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079209] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 17675] Funding Source: Medline; NIDDK NIH HHS [DK 79209, R01 DK079209] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Ausubel F.M., 1987, CURRENT PROTOCOL MOL; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cerpa Waldo, 2005, Molecular Aspects of Medicine, V26, P405, DOI 10.1016/j.mam.2005.07.011; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; DEROME L, 1987, FEMS MICROBIOL LETT, V43, P283, DOI 10.1016/0378-1097(87)90413-7; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Eisses JF, 2005, J BIOL CHEM, V280, P37159, DOI 10.1074/jbc.M508822200; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; FARNWORTH PG, 1989, CHEM-BIOL INTERACT, V69, P319, DOI 10.1016/0009-2797(89)90118-X; Giaccone G, 2000, DRUGS, V59, P9, DOI 10.2165/00003495-200059004-00002; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Guo Y, 2004, J BIOL CHEM, V279, P46393, DOI 10.1074/jbc.M407777200; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Holzer AK, 2004, CLIN CANCER RES, V10, P6744, DOI 10.1158/1078-0432.CCR-04-0748; Holzer AK, 2004, MOL PHARMACOL, V66, P817, DOI 10.1124/mol.104.001198; Holzer AK, 2006, CANCER RES, V66, P10944, DOI 10.1158/0008-5472.CAN-06-1710; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Jiang JF, 2005, INORG CHEM, V44, P9787, DOI 10.1021/ic051180m; Kaler SG, 1998, AM J CLIN NUTR, V67, p1029S, DOI 10.1093/ajcn/67.5.1029S; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Komatsu M, 2000, CANCER RES, V60, P1312; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Lee SH, 2006, INTERMETALLICS, V14, P1, DOI 10.1016/j.intermet.2005.02.010; Lin XJ, 2002, MOL PHARMACOL, V62, P1154, DOI 10.1124/mol.62.5.1154; Linder M, 1991, BIOCH COPPER; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; O'Dwyer PJ, 2000, DRUGS, V59, P19, DOI 10.2165/00003495-200059004-00003; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Safaei R, 2005, CRIT REV ONCOL HEMAT, V53, P13, DOI 10.1016/j.critrevonc.2004.09.007; Samimi G, 2004, MOL PHARMACOL, V66, P25, DOI 10.1124/mol.66.1.25; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Singh A, 2006, J BIOL CHEM, V281, P13355, DOI 10.1074/jbc.M512042200; Uriu-Adams Janet Y., 2005, Molecular Aspects of Medicine, V26, P268, DOI 10.1016/j.mam.2005.07.015; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZELAZOWSKI AJ, 1984, ARCH BIOCHEM BIOPHYS, V229, P246; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	76	83	88	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26775	26785		10.1074/jbc.M703973200	http://dx.doi.org/10.1074/jbc.M703973200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627943	hybrid, Green Published			2022-12-27	WOS:000249304900017
J	Evdokimov, AA; Sclavi, B; Zinoviev, VV; Malygin, EG; Hattman, S; Buckle, M				Evdokimov, Alexey A.; Sclavi, Bianca; Zinoviev, Victor V.; Malygin, Ernst G.; Hattman, Stanley; Buckle, Malcolm			Study of bacteriophage T4-encoded dam DNA (Adenine-N-6)-methyltransferase binding with substrates by rapid laser UV cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; ESCHERICHIA-COLI; PHAGE-T4 DNA; FLUORESCENCE SPECTROSCOPY; METHYLTRANSFERASE; METHYLATION; RECOGNITION; BASE; IDENTIFICATION; SEQUENCE	DNA methyltransferases of the Dam family ( including bacteriophage T4-encoded Dam DNA (adenine- N-6)-methyltransferase ( T4Dam)) catalyze methyl group transfer from S-adenosyl-L-methionine ( AdoMet), producing S-adenosyl-Lhomocysteine ( AdoHcy) and methylated adenine residues in palindromic GATC sequences. In this study, we describe the application of direct ( i. e. no exogenous cross-linking reagents) laser UV cross-linking as a universal non-perturbing approach for studying the characteristics of T4Dam binding with substrates in the equilibrium and transient modes of interaction. UV irradiation of the enzyme center dot substrate complexes using an Nd3(+): yttrium aluminum garnet laser at 266nm resulted in up to 3 and > 15% yields of direct T4Dam cross-linking to DNA and AdoMet, respectively. Consequently, we were able to measure equilibrium constants and dissociation rates for enzyme center dot substrate complexes. In particular, we demonstrate that both reaction substrates, specific DNA and AdoMet( or product AdoHcy), stabilized the ternary complex. The improved substrate affinity for the enzyme in the ternary complex significantly reduced dissociation rates ( up to 2 orders of magnitude). Several of the parameters obtained ( such as dissociation rate constants for the binary T4Dam center dot AdoMet complex and for enzyme complexes with a non-fluorescent hemimethylated DNA duplex) were previously inaccessible by other means. However, where possible, the results of laser UV cross-linking were compared with those of fluorescence analysis. Our study suggests that rapid laser UV cross-linking efficiently complements standard DNA methyltransferase-related tools and is a method of choice to probe enzyme-substrate interactions in cases in which data cannot be acquired by other means.	Fedral State Res Inst State Res Ctr Virol & Biote, Novosibirsk 630559, Russia; Ecole Normale Super, CNRS, Lab Biotechnol & Pharmacol Genet Appliq, UMR 8113, F-94235 Cachan, France; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	State Research Center of Virology & Biotechnology VECTOR; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; University of Rochester	Buckle, M (corresponding author), Fedral State Res Inst State Res Ctr Virol & Biote, Novosibirsk 630559, Russia.	buckle@lbpa.ens-cachan.fr	Sclavi, Bianca/AAT-4554-2021; Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014; sclavi, bianca/F-8536-2010	Sclavi, Bianca/0000-0002-3883-8592; 	FIC NIH HHS [TW05755] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; AHMAD I, 1994, GENE, V142, P67, DOI 10.1016/0378-1119(94)90356-5; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; Beck C, 2002, BIOCHEMISTRY-US, V41, P14103, DOI 10.1021/bi025979a; Bheemanaik S, 2006, BIOCHEM J, V399, P177, DOI 10.1042/BJ20060854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; Casadesus J, 2006, MICROBIOL MOL BIOL R, V70, P830, DOI 10.1128/MMBR.00016-06; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; COPELAND RA, 2000, ENZYMES PRCTICAL INT; Dimitrov SI, 2000, METH MOL B, V148, P395; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Fersht A., 1985, ENZYME STRUCTURE MEC; FINTA C, 1995, GENE, V164, P65, DOI 10.1016/0378-1119(95)00439-D; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hattman S, 2004, PROG NUCLEIC ACID RE, V77, P67, DOI 10.1016/S0079-6603(04)77003-8; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; Holz B, 1999, J BIOL CHEM, V274, P15066, DOI 10.1074/jbc.274.21.15066; Horton JR, 2006, J MOL BIOL, V358, P559, DOI 10.1016/j.jmb.2006.02.028; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; Liebert K, 2004, J MOL BIOL, V341, P443, DOI 10.1016/j.jmb.2004.05.033; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2004, J BIOL CHEM, V279, P50012, DOI 10.1074/jbc.M409786200; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; Mashhoon N, 2004, J BIOL CHEM, V279, P52075, DOI 10.1074/jbc.M408182200; Mashhoon N, 2006, J BIOMOL SCREEN, V11, P497, DOI 10.1177/1087057106287933; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Pingoud V, 2005, MOL BIOSYST, V1, P135, DOI 10.1039/b503091a; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; POWELL LM, 1993, J MOL BIOL, V234, P60, DOI 10.1006/jmbi.1993.1563; REICH NO, 1990, J BIOL CHEM, V265, P8929; SCHLAGMAN SL, 1983, GENE, V22, P139, DOI 10.1016/0378-1119(83)90098-7; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SOM S, 1990, J BIOL CHEM, V265, P4278; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Tuzikov FV, 1997, MOL BIOL+, V31, P73; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Vilkaitis G, 2000, J BIOL CHEM, V275, P38722, DOI 10.1074/jbc.M005278200; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WENZEL C, 1993, NUCLEIC ACIDS RES, V21, P4604, DOI 10.1093/nar/21.19.4604; Wong DL, 2000, BIOCHEMISTRY-US, V39, P15410, DOI 10.1021/bi001164v; Yang Z, 2003, NAT STRUCT BIOL, V10, P849, DOI 10.1038/nsb973; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481; Zinoviev VV, 2003, J BIOL CHEM, V278, P7829, DOI 10.1074/jbc.M210769200	54	6	6	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26067	26076		10.1074/jbc.M700866200	http://dx.doi.org/10.1074/jbc.M700866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630395	hybrid			2022-12-27	WOS:000249239600010
J	Vitovski, S; Phillips, JS; Sayers, J; Croucher, PI				Vitovski, Srdjan; Phillips, Jennifer S.; Sayers, Jon; Croucher, Peter I.			Investigating the interaction between osteoprotegerin and receptor activator of NF-kappa B or tumor necrosis factor-related apoptosis-inducing ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; PROSTATE-CANCER CELLS; KINETIC-ANALYSIS; BONE-RESORPTION; SURVIVAL FACTOR; TNF FAMILY; TRAIL; MEMBER; DIFFERENTIATION; METASTASIS	Osteoprotegerin (OPG) binds the ligand for receptor activator of nuclear factor kappa B (RANKL) to prevent association with its receptor RANK and inhibit osteoclast-mediated bone resorption. OPG has been reported, recently, to inhibit tumor necrosis factor-related apoptosis-induced ligand (TRAIL)-induced tumor cell apoptosis. This raises the possibility that OPG may play a unique role in regulating these two signaling pathways. However, there are little data on the interactions between OPG, RANKL, and TRAIL, and the relative affinity of OPG for these two ligands is unknown. In the present study we examined the ability of OPG to bind native human TRAIL and RANKL under physiological conditions. Native TRAIL was expressed in Escherichia coli, purified to homogeneity, and shown to induce human myeloma cell apoptosis. OPG inhibited native TRAIL from binding the TRAILR1 at 37 degrees C in vitro. Similarly, OPG prevented RANKL from binding to RANK. TRAIL also prevented OPG-mediated inhibition of RANKL from binding RANK. The affinity of OPG for native TRAIL and RANKL at 37 degrees C was determined by plasmon surface resonance analysis. OPG had a binding affinity for TRAIL of 45 nM, whereas the affinity of OPG for RANKL was 23 nM. These data suggest that OPG can bind both RANKL and TRAIL and that the affinity of OPG for these two ligands is of a similar order of magnitude. Furthermore, OPG prevented TRAIL-mediated reductions in cell viability, whereas TRAIL inhibited OPG-mediated inhibition of osteoclastogenesis in vitro. This highlights the pivotal role of OPGin regulating the biology of both RANKL and TRAIL.	Univ Sheffield, Sch Med & Biomed Sci, Sect Inst Inflammat & Immun, Sect Musculoskeletal Sci,Acad Unit Bone Biol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Croucher, PI (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Sect Inst Inflammat & Immun, Sect Musculoskeletal Sci,Acad Unit Bone Biol, Sheffield S10 2TN, S Yorkshire, England.	p.croucher@sheffield.ac.uk	Sayers, Jon R/AAP-6179-2020; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443; Croucher, Peter/0000-0002-7102-2413				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASKENAZI A, 1999, J CLIN INVEST, V104, P155; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Cha SS, 1999, ACTA CRYSTALLOGR D, V55, P1101, DOI 10.1107/S090744499900164X; Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008-5472.CAN-06-1287; Holen I, 2002, CANCER RES, V62, P1619; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nyambo R, 2004, J BONE MINER RES, V19, P1712, DOI 10.1359/JBMR.040703; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shipman CM, 2003, CANCER RES, V63, P912; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willard D, 2000, PROTEIN EXPRES PURIF, V20, P48, DOI 10.1006/prep.2000.1278; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood-2004-03-1196; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586	43	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31601	31609		10.1074/jbc.M706078200	http://dx.doi.org/10.1074/jbc.M706078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17702740	hybrid			2022-12-27	WOS:000250309200052
J	Handschin, C; Chin, S; Li, P; Liu, F; Maratos-Flier, E; LeBrasseur, NK; Yan, Z; Spiegelman, BM				Handschin, Christoph; Chin, Sherry; Li, Ping; Liu, Fenfen; Maratos-Flier, Eleftheria; LeBrasseur, Nathan K.; Yan, Zhen; Spiegelman, Bruce M.			Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1 alpha muscle-specific knock-out animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL BIOGENESIS; SIGNALING PATHWAYS; GENE-EXPRESSION; RECEPTOR-ALPHA; PGC-1 FAMILY; ERR-ALPHA; MECHANISMS; PAX7	The transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) is a key integrator of neuromuscular activity in skeletal muscle. Ectopic expression of PGC-1 alpha in muscle results in increased mitochondrial number and function as well as an increase in oxidative, fatigue-resistant muscle fibers. Whole body PGC-1 alpha knock-out mice have a very complex phenotype but do not have a marked skeletal muscle phenotype. We thus analyzed skeletal muscle-specific PGC-1 alpha knock-out mice to identify a specific role for PGC-1 alpha in skeletal muscle function. These mice exhibit a shift from oxidative type I and IIa toward type IIx and IIb muscle fibers. Moreover, skeletal muscle-specific PGC-1 alpha knock-out animals have reduced endurance capacity and exhibit fiber damage and elevated markers of inflammation following treadmill running. Our data demonstrate a critical role for PGC-1 alpha in maintenance of normal fiber type composition and of muscle fiber integrity following exertion.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Univ, Sch Med, Diabet & Metab Unit, Boston, MA 02118 USA	Harvard University; Harvard Medical School; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, Smith Bldg,1 Jimmy Fund Way, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097; LeBrasseur, Nathan/0000-0002-2002-0418; Yan, Zhen/0000-0002-4826-9813	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061562, P30DK040561, R56DK054477, R01DK054477] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050429, R01 AR050429] Funding Source: Medline; NIDDK NIH HHS [R01 DK054477, P30 DK040561-12, P30 DK040561, DK61562, DK54477] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Dalakas MC, 2006, NAT CLIN PRACT RHEUM, V2, P219, DOI 10.1038/ncprheum0140; Disatnik MH, 1998, J NEUROL SCI, V161, P77, DOI 10.1016/S0022-510X(98)00258-5; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; Grundtman Cecilia, 2006, Curr Rheumatol Rep, V8, P188, DOI 10.1007/s11926-996-0024-4; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C., 2005, DRUG DISCOV TODAY, V2, P151; Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Olguin HC, 2007, J CELL BIOL, V177, P769, DOI 10.1083/jcb.200608122; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Salomonsson S, 2006, AUTOIMMUNITY, V39, P177, DOI 10.1080/08916930600622256; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Timmons JA, 2005, FASEB J, V19, P750, DOI 10.1096/fj.04-1980com; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	31	442	478	2	42	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30014	30021		10.1074/jbc.M704817200	http://dx.doi.org/10.1074/jbc.M704817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702743	Green Published, hybrid, Green Accepted			2022-12-27	WOS:000249981200031
J	Verykokakis, M; Papadaki, C; Vorgia, E; Le Gallic, L; Mavrothalassitis, G				Verykokakis, Mihalis; Papadaki, Chara; Vorgia, Elena; Le Gallic, Lionel; Mavrothalassitis, George			The RAS-dependent ERF control of cell proliferation and differentiation is mediated by c-Myc repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; TRANSCRIPTIONAL REPRESSION; NONPERMISSIVE CELLS; MYC/MAX/MAD NETWORK; CYCLE PROGRESSION; HUMAN TROPHOBLAST; GENE-EXPRESSION; BREAST-CANCER; IN-VIVO	The ERF transcriptional repressor is a downstream effector of the RAS/ERK pathway that interacts with and is directly phosphorylated by ERKs in vivo and in vitro. This phosphorylation results in its cytoplasmic export and inactivation, although lack of ERK activity allows its immediate nuclear accumulation and repressor function. Nuclear ERFs arrest cell cycle progression in G(1) and can suppress ras-dependent tumorigenicity. Here we provide evidence that ERF function is mediated by its ability to repress transcription of c-Myc. Promoter reporter assays indicate a DNA binding-dependent and repressor domain-dependent Myc transcriptional repression. Chromatin immunoprecipitations in primary cells suggest that ERF specifically binds on the c-Myc promoter in an E2F4/5-dependent manner and only under conditions that the physiological c-Myc transcription is stopped. Cellular systems overexpressing nuclear ERF exhibit reduced c-Myc mRNA and tumorigenic potential. Elimination of Erf in animal models results in increased c-Myc expression, whereas Erf (-/-) primary fibroblasts fail to down-regulate Myc in response to growth factor withdrawal. Finally, elimination of c-Myc in primary mouse embryo fibroblasts negates the ability of nuclear ERF to suppress proliferation. Thus Erf provides a direct link between the RAS/ERK signaling and the transcriptional regulation of c-Myc and suggests that RAS/ERK attenuation actively regulates cell fate.	Univ Crete, Sch Med, Iraklion 71003, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71003, Crete, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Iraklion 71003, Crete, Greece.	mavro@imbb.forth.gr		Le Gallic, Lionel/0000-0001-7147-9846; PAPADAKI, CHARA/0000-0002-4591-3757				Bain M, 2003, J GEN VIROL, V84, P41, DOI 10.1099/vir.0.18633-0; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Carroll JS, 2002, CANCER RES, V62, P3126; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dakour J, 1999, PLACENTA, V20, P119, DOI 10.1053/plac.1998.0336; Dang CV, 1999, MOL CELL BIOL, V19, P1; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; de Nigris F, 2001, CANCER RES, V61, P2267; DEAN M, 1986, J BIOL CHEM, V261, P9161; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; HIRNINGFOLZ U, 1992, CYTOGENET CELL GENET, V61, P289, DOI 10.1159/000133425; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Le Gallic L, 2004, MOL CELL BIOL, V24, P1206, DOI 10.1128/MCB.24.3.1206-1218.2004; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Liu J, 2006, CURR TOP MICROBIOL, V302, P1; MARTINOLI MG, 1992, MOL REPROD DEV, V31, P1, DOI 10.1002/mrd.1080310102; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Papadaki C, 2007, MOL CELL BIOL, V27, P5201, DOI 10.1128/MCB.02237-06; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perkins KJ, 2007, MOL BIOL CELL, V18, P2864, DOI 10.1091/mbc.E06-12-1069; Polychronopoulos S, 2006, J BIOL CHEM, V281, P25601, DOI 10.1074/jbc.M605185200; Qiu Q, 2004, MOL HUM REPROD, V10, P677, DOI 10.1093/molehr/gah088; QUINN LM, 2004, DEV CAMB, V31, P1411; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rodriguez JL, 2006, BIOCHEM J, V398, P431, DOI 10.1042/BJ20060380; RONCALLI M, 1994, PLACENTA, V15, P399, DOI 10.1016/0143-4004(94)90007-8; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi Y, 2000, GENE DEV, V14, P804; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; WATSON PH, 1991, CANCER RES, V51, P3996; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Wright E, 2005, J GEN VIROL, V86, P535, DOI 10.1099/vir.0.80352-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	70	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30285	30294		10.1074/jbc.M704428200	http://dx.doi.org/10.1074/jbc.M704428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17699159	hybrid			2022-12-27	WOS:000249981200059
J	Xiao, BL; Tian, XX; Xie, WJ; Jones, PP; Cai, ST; Wang, XH; Jiang, DW; Kong, HH; Zhang, L; Chen, KY; Walsh, MP; Cheng, HP; Chen, SRW				Xiao, Bailong; Tian, Xixi; Xie, Wenjun; Jones, Peter P.; Cai, Shitian; Wang, Xianhua; Jiang, Dawei; Kong, Huihui; Zhang, Lin; Chen, Keyun; Walsh, Michael P.; Cheng, Heping; Chen, S. R. Wayne			Functional consequence of protein kinase A-dependent phosphorylation of the cardiac ryanodine receptor - Sensitization of store overload-induced Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM CA2+; HEART-FAILURE; PKA PHOSPHORYLATION; PURKINJE-FIBERS; FAILING HEARTS; SUDDEN-DEATH; CHANNEL; CALCIUM	The phosphorylation of the cardiac Ca2(+)-release channel ( ryanodine receptor, RyR2) by protein kinase A (PKA) has been extensively characterized, but its functional consequence remains poorly defined and controversial. We have previously shown that RyR2 is phosphorylated by PKA at two major sites, serine 2030 and serine 2808, of which Ser-2030 is the major PKA site responding to beta-adrenergic stimulation. Here we investigated the effect of the phosphorylation of RyR2 by PKA on the properties of single channels and on spontaneous Ca2(+) release during sarcoplasmic reticulum Ca2(+) overload, a process we have referred to as store overload-induced Ca2(+) release ( SOICR). We found that PKA activated single RyR2 channels in the presence, but not in the absence, of luminal Ca2(+). On the other hand, PKA had no marked effect on the sensitivity of the RyR2 channel to activation by cytosolic Ca2(+). Importantly, the S2030A mutation, but not mutations of Ser-2808, diminished the effect of PKA on RyR2. Furthermore, a phosphomimetic mutation, S2030D, potentiated the response of RyR2 to luminal Ca2(+) and enhanced the propensity for SOICR in HEK293 cells. In intact rat ventricular myocytes, the activation of PKA by isoproterenol reduced the amplitude and increased the frequency of SOICR. Confocal line-scanning fluorescence microscopy further revealed that the activation of PKA by isoproterenol increased the rate of Ca2(+) release and the propagation velocity of spontaneous Ca2(+) waves, despite reduced wave amplitude and resting cytosolic Ca2(+). Collectively, our data indicate that PKA-dependent phosphorylation enhances the response of RyR2 to luminal Ca2(+) and reduces the threshold for SOICR and that this effect of PKA is largely mediated by phosphorylation at Ser-2030.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China	University of Calgary; University of Calgary; Peking University	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca	Kong, Huihui/F-9024-2012; Xiao, Bailong/B-6187-2012; Xie, Wenjun/O-4637-2019; Xie, Wenjun/G-3869-2015; Xie, Wenjun/AAD-6881-2021; Jones, Peter P/G-2618-2013; Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011	Xie, Wenjun/0000-0003-0493-062X; Xie, Wenjun/0000-0003-0493-062X; Xie, Wenjun/0000-0003-0493-062X; Heping, Cheng/0000-0002-9604-6702; Jones, Pete/0000-0001-7977-1737				BENKUSKY NA, 2007, IN PRESS CIRC RES; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2003, CIRC RES, V93, P487, DOI 10.1161/01.RES.0000091871.54907.6B; Carter S, 2006, CIRC RES, V98, P1506, DOI 10.1161/01.RES.0000227506.43292.df; Diaz ME, 1997, J PHYSIOL-LONDON, V501, P3, DOI 10.1111/j.1469-7793.1997.003bo.x; Eisner DA, 1998, CARDIOVASC RES, V38, P589, DOI 10.1016/S0008-6363(98)00062-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ginsburg KS, 2004, J PHYSIOL-LONDON, V556, P463, DOI 10.1113/jphysiol.2003.055384; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; Jiang DW, 2004, P NATL ACAD SCI USA, V101, P13062, DOI 10.1073/pnas.0402388101; Jiang DW, 2005, CIRC RES, V97, P1173, DOI 10.1161/01.RES.0000192146.85173.4b; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; KASS RS, 1982, BIOPHYS J, V38, P259, DOI 10.1016/S0006-3495(82)84557-8; Kubalova Z, 2005, P NATL ACAD SCI USA, V102, P14104, DOI 10.1073/pnas.0504298102; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Obayashi M, 2006, CARDIOVASC RES, V69, P140, DOI 10.1016/j.cardiores.2005.07.010; ORCHARD CH, 1983, NATURE, V304, P735, DOI 10.1038/304735a0; Pogwizd SM, 2004, TRENDS CARDIOVAS MED, V14, P61, DOI 10.1016/j.tcm.2003.12.002; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Shimoni Y, 2004, J PHYSIOL-LONDON, V555, P345, DOI 10.1113/jphysiol.2003.055590; Song LS, 2001, CIRC RES, V88, P794, DOI 10.1161/hh0801.090461; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; STERN MD, 1983, J GEN PHYSIOL, V82, P119, DOI 10.1085/jgp.82.1.119; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Trafford AW, 2000, CELL CALCIUM, V28, P269, DOI 10.1054/ceca.2000.0156; Uehara A, 2002, PFLUG ARCH EUR J PHY, V444, P202, DOI 10.1007/s00424-002-0791-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Viatchenko-Karpinski S, 2001, J PHYSIOL-LONDON, V533, P837, DOI 10.1111/j.1469-7793.2001.t01-1-00837.x; Wehrens XHT, 2006, P NATL ACAD SCI USA, V103, P511, DOI 10.1073/pnas.0510113103; WIER WG, 1983, P NATL ACAD SCI-BIOL, V80, P7367, DOI 10.1073/pnas.80.23.7367; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xiao BL, 2006, BIOCHEM J, V396, P7, DOI 10.1042/BJ20060116; Xiao BL, 2005, CIRC RES, V96, P847, DOI 10.1161/01.RES.0000163276.26083.e8; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22	37	55	58	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30256	30264		10.1074/jbc.M703510200	http://dx.doi.org/10.1074/jbc.M703510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693412	hybrid			2022-12-27	WOS:000249981200056
J	Frigerio, S; Campoli, C; Zorzan, S; Fantoni, LI; Crosatti, C; Drepper, F; Haehnel, W; Cattivelli, L; Morosinotto, T; Bassi, R				Frigerio, Sara; Campoli, Chiara; Zorzan, Simone; Fantoni, Luca Isaia; Crosatti, Cristina; Drepper, Friedel; Haehnel, Wolfgang; Cattivelli, Luigi; Morosinotto, Tomas; Bassi, Roberto			Photosynthetic antenna size in higher plants is controlled by the plastoquinone redox state at the post-transcriptional rather than transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; PHOTOSYSTEM-II MEMBRANES; CHLOROPHYLL-A-OXYGENASE; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; GENE-EXPRESSION; THYLAKOID MEMBRANES; ENERGY-DISSIPATION; ELECTRON-TRANSFER; PEA-CHLOROPLASTS	We analyze the effect of the plastoquinone redox state on the regulation of the light-harvesting antenna size at transcriptional and post-transcriptional levels. This was approached by studying transcription and accumulation of light-harvesting complexes in wild type versus the barley mutant viridis zb63, which is depleted in photosystem I and where plastoquinone is constitutively reduced. We show that the mRNA level of genes encoding antenna proteins is almost unaffected in the mutant; this stability of messenger level is not a peculiarity of antenna-encoding genes, but it extends to all photosynthesis-related genes. In contrast, analysis of protein accumulation by two-dimensional PAGE shows that the mutant undergoes strong reduction of its antenna size, with individual gene products having different levels of accumulation. We conclude that the plastoquinone redox state plays an important role in the long term regulation of chloroplast protein expression. However, its modulation is active at the post-transcriptional rather than transcriptional level.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, CEA CNRS, UMR 6191, LGBP, F-13288 Marseille, France; CRA Ctr Ric Genom, I-29017 Fiorenzuola Darda, Italy; Univ Modena, Dipartimento Sci Biomed, I-41100 Modena, Italy; Univ Freiburg, Inst Biol Biochem 2, D-79104 Freiburg, Germany; Univ Padua, Dipartimento Biol, I-35131 Padua, Italy	University of Verona; CEA; UDICE-French Research Universities; Aix-Marseille Universite; Universita di Modena e Reggio Emilia; University of Freiburg; University of Padua	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str LeGrazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	cattivelli, luigi/AAE-7046-2020; Morosinotto, Tomas/AAC-3188-2019	cattivelli, luigi/0000-0002-6067-4600; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446; Campoli, Chiara/0000-0001-7809-2927; Drepper, Friedel/0000-0002-2043-5795				ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; Arnaud N, 2006, J BIOL CHEM, V281, P23579, DOI 10.1074/jbc.M602135200; Ballottari M, 2004, EUR J BIOCHEM, V271, P4659, DOI 10.1111/j.1432-1033.2004.04426.x; Ballottari M, 2007, J BIOL CHEM, V282, P8947, DOI 10.1074/jbc.M606417200; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Caffarri S, 2005, PROTEOMICS, V5, P758, DOI 10.1002/pmic.200402008; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Chen YB, 2004, PLANT PHYSIOL, V136, P3737, DOI 10.1104/pp.104.038919; Close TJ, 2004, PLANT PHYSIOL, V134, P960, DOI 10.1104/pp.103.034462; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Durnford DG, 2003, PHYSIOL PLANTARUM, V118, P193, DOI 10.1034/j.1399-3054.2003.00078.x; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Fujibe T, 2006, BIOSCI BIOTECH BIOCH, V70, P1827, DOI 10.1271/bbb.50673; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 2004, J BIOL CHEM, V279, P13878, DOI 10.1074/jbc.M311154200; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Jackowski G, 2003, J PHOTOCH PHOTOBIO B, V70, P163, DOI 10.1016/S1011-1344(03)00076-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1102, P53, DOI 10.1016/0167-4838(92)90498-3; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Masuda T, 2003, PLANT MOL BIOL, V51, P757, DOI 10.1023/A:1022545118212; Mckim SM, 2006, PLANT PHYSIOL BIOCH, V44, P857, DOI 10.1016/j.plaphy.2006.10.018; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Minai L, 2006, PLANT CELL, V18, P159, DOI 10.1105/tpc.105.037705; Morosinotto T, 2006, FEBS J, V273, P4616, DOI 10.1111/j.1742-4658.2006.05465.x; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Mussgnug JH, 2005, PLANT CELL, V17, P3409, DOI 10.1105/tpc.105.035774; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nelson N, 2004, NAT REV MOL CELL BIO, V5, P971, DOI 10.1038/nrm1525; Nielsen VS, 1996, PHYSIOL PLANTARUM, V98, P637, DOI 10.1111/j.1399-3054.1996.tb05721.x; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; Peng LW, 2006, PLANT CELL, V18, P955, DOI 10.1105/tpc.105.037689; PETERGF, 1991, METHODS PLANT BIOCH, P195; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; Sakamoto W, 2003, PLANT CELL, V15, P2843, DOI 10.1105/tpc.017319; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; SIMPSON DJ, 1983, EUR J CELL BIOL, V31, P305; Tullberg A, 2000, PLANT CELL PHYSIOL, V41, P1045, DOI 10.1093/pcp/pcd031; Walters RG, 2005, J EXP BOT, V56, P435, DOI 10.1093/jxb/eri060; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wostrikoff K, 2004, EMBO J, V23, P2696, DOI 10.1038/sj.emboj.7600266; Wostrikoff K, 2007, P NATL ACAD SCI USA, V104, P6466, DOI 10.1073/pnas.0610586104; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827; YU JJ, 1990, PLANT CELL, V2, P315; Zaltsman A, 2005, PLANT J, V42, P609, DOI 10.1111/j.1365-313X.2005.02401.x; Zelisko A, 2005, P NATL ACAD SCI USA, V102, P13699, DOI 10.1073/pnas.0503472102; Zelisko A, 2004, J PLANT PHYSIOL, V161, P1157, DOI 10.1016/j.jplph.2004.01.006	59	55	61	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29457	29469		10.1074/jbc.M705132200	http://dx.doi.org/10.1074/jbc.M705132200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17675669	hybrid			2022-12-27	WOS:000249788000043
J	Hlavanda, E; Klement, E; Kokai, E; Vincze, O; Tokesi, N; Orosz, F; Medzihradszky, KF; Dombradi, V; Ovadi, J				Hlavanda, Emma; Klement, Eva; Kokai, Endre; Vincze, Orsolya; Tokesi, Natalia; Orosz, Ferenc; Medzihradszky, Katalin F.; Dombradi, Viktor; Ovadi, Judit			Phosphorylation blocks the activity of tubulin polymerization-promoting protein (TPPP) - Identification of sites targeted by different kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC DISORDER; MASS-SPECTROMETRY; P25; CONSERVATION; MICROTUBULES; ASSEMBLIES; PREDICTION; FAMILIES; DOMAINS	Tubulin polymerization- promoting protein (TPPP), an unfolded brain-specific protein interacts with the tubulin/microtubule system in vitro and in vivo, and is enriched in human pathological brain inclusions. Here we show that TPPP induces tubulin self-assembly into intact frequently bundled microtubules, and that the phosphorylation of specific sites distinctly affects the function of TPPP. In vitro phosphorylation of wild type and the truncated form (Delta 3-43TPPP) of human recombinant TPPP was performed by kinases involved in brain-specific processes. A stoichiometry of 2.9 +/- 0.3, 2.2 +/- 0.3, and 0.9 +/- 0.1 mol P/mol protein with ERK2, cyclin-dependent kinase 5 (Cdk5), and cAMP-dependent protein kinase (PKA), respectively, was revealed for the full-length protein, and 0.4-0.5 mol P/mol protein was detected with all three kinases when the N-terminal tail was deleted. The phosphorylation sites Thr(14), Ser(18), Ser(160) for Cdk5; Ser(18), Ser(160) for ERK2, and Ser(32) for PKA were identified by mass spectrometry. These sites were consistent with the bioinformatic predictions. The three N-terminal sites were also found to be phosphorylated in vivo in TPPP isolated from bovine brain. Affinity binding experiments provided evidence for the direct interaction between TPPP and ERK2. The phosphorylation of TPPP by ERK2 or Cdk5, but not by PKA, perturbed the structural alterations induced by the interaction between TPPP and tubulin without affecting the binding affinity (K-d = 2.5-2.7 mu M) or the stoichiometry (1 mol TPPP/mol tubulin) of the complex. The phosphorylation by ERK2 or Cdk5 resulted in the loss of microtubule-assembling activity of TPPP. The combination of our in vitro and in vivo data suggests that ERK2 can regulate TPPP activity via the phosphorylation of Thr(14) and/or Ser(18) in its unfolded N-terminal tail.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Proteom Res Grp, H-6726 Szeged, Hungary; Univ Debrecen, Res Ctr Mol Med, Dept Med Chem, Hungarian Acad Sci,Cell Biol & Signalling Res Grp, H-4032 Debrecen, Hungary; Eotvos Lorand Univ, Fac Sci, Dept Anat Cell & Dev Biol, H-1117 Budapest, Hungary; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Academy of Sciences; University of Debrecen; Eotvos Lorand University; University of California System; University of California San Francisco	Ovadi, J (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, Karolina 29, H-1113 Budapest, Hungary.	ovadi@enzim.hu		Ovadi, Judit/0000-0002-3420-682X				BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JW, 2006, J PROTEOME RES, V5, P879, DOI 10.1021/pr060048x; Chen JW, 2006, J PROTEOME RES, V5, P888, DOI 10.1021/pr060049p; Collins MO, 2005, J BIOL CHEM, V280, P5972, DOI 10.1074/jbc.M411220200; COVEY TR, 1991, METHODS PROTEIN SEQU, P411; DeGiorgis JA, 2005, J PROTEOME RES, V4, P306, DOI 10.1021/pr0498436; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Hlavanda E, 2002, BIOCHEMISTRY-US, V41, P8657, DOI 10.1021/bi020140g; Jamsa A, 2006, BIOCHEM BIOPH RES CO, V345, P324, DOI 10.1016/j.bbrc.2006.04.032; Kovacs GG, 2004, NEUROBIOL DIS, V17, P155, DOI 10.1016/j.nbd.2004.06.006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Lehotzky A, 2004, J CELL SCI, V117, P6249, DOI 10.1242/jcs.01550; Lindersson E, 2005, J BIOL CHEM, V280, P5703, DOI 10.1074/jbc.M410409200; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Martin CP, 2002, BBA-MOL BASIS DIS, V1586, P113; Murray AW, 1998, CELL, V92, P157, DOI 10.1016/S0092-8674(00)80910-1; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Olah J, 2006, FEBS LETT, V580, P5807, DOI 10.1016/j.febslet.2006.09.037; Orosz F, 2004, BIOL CELL, V96, P701, DOI 10.1016/j.biolcel.2004.08.002; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Thompson AJ, 2003, ANAL CHEM, V75, P3232, DOI 10.1021/ac034134h; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tirian L, 2003, P NATL ACAD SCI USA, V100, P13976, DOI 10.1073/pnas.2436331100; Trinidad JC, 2006, MOL CELL PROTEOMICS, V5, P914, DOI 10.1074/mcp.T500041-MCP200; ULLOA L, 1993, FEBS LETT, V330, P85, DOI 10.1016/0014-5793(93)80925-K; Veeranna GJ, 2000, MOL BRAIN RES, V76, P229, DOI 10.1016/S0169-328X(00)00003-6; Vincze O, 2006, BIOCHEMISTRY-US, V45, P13818, DOI 10.1021/bi061305e; Wang YY, 2007, CHINESE J CHEM, V25, P68, DOI 10.1002/cjoc.200790019; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WU CW, 1973, BIOCHEMISTRY-US, V12, P1400, DOI 10.1021/bi00731a021	39	51	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29531	29539		10.1074/jbc.M703466200	http://dx.doi.org/10.1074/jbc.M703466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17693641	hybrid			2022-12-27	WOS:000249788000050
J	Noguchi, M; Hosoda, K; Fujikura, J; Fujimoto, M; Iwakura, H; Tomita, T; Ishii, T; Arai, N; Hirata, M; Ebihara, K; Masuzaki, H; Itoh, H; Narumiya, S; Nakao, K				Noguchi, Michio; Hosoda, Kiminori; Fujikura, Junji; Fujimoto, Muneya; Iwakura, Hiroshi; Tomita, Tsutomu; Ishii, Takako; Arai, Naoki; Hirata, Masakazu; Ebihara, Ken; Masuzaki, Hiroaki; Itoh, Hiroshi; Narumiya, Shuh; Nakao, Kazuwa			Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; BINDING PROTEIN-RHO; VENTRAL BODY-WALL; ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; ROK-ALPHA; ADIPOSE CONVERSION; 3T3-L1 ADIPOCYTES; C/EBP-ALPHA; ROCK-I	Rho-associated kinase (ROCK) regulates reorganization of actin cytoskeleton. During adipogenesis, the structure of filamentous actin is converted from long stress fibers to cortical actin, suggesting that the ROCK is involved in adipogenesis. Two ROCK isoforms have been identified: ROCK-I and ROCK-II. However, pharmacological inhibitors of ROCK cannot distinguish two ROCK isoforms. In the present study, we examined the role of ROCK in adipogenesis and actin cytoskeleton using genetic and pharmacological approaches. Y-27632, which inhibits the activity of both ROCK isoforms, enhanced adipogenesis through the up-regulation of adipogenic transcription factors in 3T3-L1 cells. Furthermore, Y-27632 restored inhibition of adipogenesis by lysophosphatidic acid, which activates Rho. Regarding actin cytoskeleton, Y-27632 disrupted stress fibers in 3T3-L1 preadipocytes. Next, we analyzed adipogenesis of mouse embryonic fibroblasts (MEFs) derived from ROCK-I and ROCK-II knock-out mice, respectively. Adipogenesis of ROCK-II (-/-) MEFs was markedly enhanced compared with wild-type MEFs while that of ROCK-I (-/-) MEFs was not. In contrast to pharmacological approaches, no obvious alteration was found in actin cytoskeleton of ROCK-II(-/-) MEFs compared with wild-type MEFs. In 3T3-L1 cells, knockdown of ROCK-II by RNA interference enhanced the expression of adipogenic transcription factors while that of ROCK-I did not. Moreover, Y-27632 inhibited IRS-1 serine phosphorylation and enhanced Akt phosphorylation in 3T3-L1 preadipocytes. Similarly, Akt phosphorylation in ROCK-II (-/-) MEFs was augmented compared with wild-type MEFs. In conclusion, inhibition of ROCK-II, not ROCK-I, enhances adipogenesis accompanied by the up-regulation of adipogenic transcription factors. Augmentation of insulin signaling may contribute to the enhancement of adipogenesis.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Hosoda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kaeahara Cho, Kyoto 6068507, Japan.	kh@kuhp.kyoto-u.ac.jp	Fujikura, Junji/AAR-2684-2020	Iwakura, Hiroshi/0000-0001-8033-0736				Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Camp HS, 1997, J BIOL CHEM, V272, P10811; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farah S, 1998, J BIOL CHEM, V273, P4740, DOI 10.1074/jbc.273.8.4740; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; Furukawa N, 2005, CELL METAB, V2, P119, DOI 10.1016/j.cmet.2005.06.011; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Norisada N, 2004, METABOLISM, V53, P1532, DOI 10.1016/j.metabol.2004.06.020; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Shimokawa H, 1999, CARDIOVASC RES, V43, P1029, DOI 10.1016/S0008-6363(99)00144-3; Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Thumkeo D, 2005, GENES CELLS, V10, P825, DOI 10.1111/j.1365-2443.2005.00882.x; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	47	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29574	29583		10.1074/jbc.M705972200	http://dx.doi.org/10.1074/jbc.M705972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17681946	hybrid			2022-12-27	WOS:000249788000054
J	Cohen, S; Cahan, R; Ben-Dov, E; Nisnevitch, M; Zaritsky, A; Firer, MA				Cohen, Shmuel; Cahan, Rivka; Ben-Dov, Eitan; Nisnevitch, Marina; Zaritsky, Arieh; Firer, Michael A.			Specific targeting to murine myeloma cells of Cyt1Aa toxin from Bacillus thuringiensis subspecies israelensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTA DELTA-ENDOTOXIN; BIOCHEMICAL-CHARACTERIZATION; TOXICITY; GENES; PLASMID; DESTRUCTION; INCLUSIONS; SPHAERICUS; RESISTANCE; MECHANISM	Multiple myeloma is currently an incurable cancer of plasma B cells often characterized by overproduction of abnormally high quantities of a patient-specific, clonotypic immunoglobulin "M-protein." The M-protein is expressed on the cell membrane and secreted into the blood. We previously showed that ligand-toxin conjugates (LTC) incorporating the ribosome-inactivating Ricin-A toxin were very effective in specific cytolysis of the anti-ligand antibody-bearing target cells used as models for multiple myeloma. Here, we report on the incorporation of the membrane-disruptive Cyt1Aa toxin from Bacillus thuringiensis subsp. israelensis into LTCs targeted to murine myeloma cells. Proteolytically activated Cyt1Aa was conjugated chemically or genetically through either its amino or carboxyl termini to the major peptidic epitope VHFFKNIVTPRTP (p87-99) of the myelin basic protein. The recombinant fusion-encoding genes were cloned and expressed in acrystalliferous B. thuringiensis subsp. israelensis through the shuttle vector pHT315. Both chemically conjugated and genetically fused LTCs were toxic to anti-myelin basic protein-expressing murine hybridoma cells, but the recombinant conjugates were more active. LTCs comprising the Cyt1Aa toxin might be useful anticancer agents. As a membrane-acting toxin, Cyt1Aa is not likely to induce development of resistant cell lines.	Coll Judea & Samaria, Dept Chem Engn & Biotechnol, IL-44837 Ariel, Israel; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Achva Acad Coll, IL-79800 Mobile Post Shikmim, Israel	Ariel University; Ben Gurion University	Firer, MA (corresponding author), Coll Judea & Samaria, Dept Chem Engn & Biotechnol, IL-44837 Ariel, Israel.	firer@research.yosh.ac.il	Zaritsky, Arieh/K-2578-2012; Nisnevitch, Marina/K-8481-2012; FIrer, Michael/H-4467-2019	Zaritsky, Arieh/0000-0001-9333-6854; Nisnevitch, Marina/0000-0001-8493-713X; FIrer, Michael/0000-0002-8430-0486; Cahan, Rivka/0000-0001-9783-4033; Ben-Dov, Eitan/0000-0001-7685-6727				Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Alyahyaee SAS, 1996, BIOCONJUGATE CHEM, V7, P451, DOI 10.1021/bc960030k; Alyahyaee SAS, 1995, MICROBIOL-UK, V141, P3141, DOI 10.1099/13500872-141-12-3141; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Ben-Dov E, 1999, PLASMID, V42, P186, DOI 10.1006/plas.1999.1415; Berry C, 2002, APPL ENVIRON MICROB, V68, P5082, DOI 10.1128/AEM.68.10.5082-5095.2002; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONE EJ, 1989, FEMS MICROBIOL LETT, V58, P171, DOI 10.1111/j.1574-6968.1989.tb03039.x; Butko P, 1996, BIOCHEMISTRY-US, V35, P11355, DOI 10.1021/bi960970s; Butko P, 2003, APPL ENVIRON MICROB, V69, P2415, DOI 10.1128/AEM.69.5.2415-2422.2003; CRICKMORE N, 1995, FEMS MICROBIOL LETT, V131, P249; DEBRO L, 1986, J BACTERIOL, V165, P258, DOI 10.1128/jb.165.1.258-268.1986; Du JP, 1999, BIOCHEM J, V338, P185, DOI 10.1042/0264-6021:3380185; Firer MA, 2003, LEUKEMIA LYMPHOMA, V44, P681, DOI 10.1080/1042819031000063381; Khasdan V, 2001, ENVIRON MICROBIOL, V3, P798, DOI 10.1046/j.1462-2920.2001.00253.x; Khasdan V, 2003, FEMS MICROBIOL LETT, V227, P189, DOI 10.1016/S0378-1097(03)00679-7; KONI PA, 1994, MICROBIOL-SGM, V140, P1869, DOI 10.1099/13500872-140-8-1869; Laptev R, 2006, BRIT J CANCER, V95, P189, DOI 10.1038/sj.bjc.6603241; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; MacDonald GC, 2005, CURR OPIN DRUG DISC, V8, P177; Malumbres Marcos, 2006, Clin Transl Oncol, V8, P399, DOI 10.1007/s12094-006-0193-7; Manasherob R, 2003, MICROBIOL-SGM, V149, P3553, DOI 10.1099/mic.0.26271-0; Manceva SD, 2005, BIOCHEMISTRY-US, V44, P589, DOI 10.1021/bi048493y; Margalith Y, 2000, AGR ENVIRONM SER, P243; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Park HW, 2003, APPL ENVIRON MICROB, V69, P1331, DOI 10.1128/AEM.69.2.1331-1334.2003; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pommier Yves, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P429, DOI 10.2174/1568011043352777; Rihova B, 1997, CRIT REV BIOTECHNOL, V17, P149, DOI 10.3109/07388559709146611; SAMBROOK J, 2001, MOL CLONING LAB MANU, P312; Shukla GS, 2006, EXPERT OPIN BIOL TH, V6, P39, DOI 10.1517/14712598.6.1.39; STEWART GSAB, 1981, BIOCHEM J, V198, P101, DOI 10.1042/bj1980101; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; THOMAS WE, 1983, J CELL SCI, V60, P181; WARD ES, 1988, J MOL BIOL, V202, P527, DOI 10.1016/0022-2836(88)90283-5; Wirth MC, 2007, ENVIRON MICROBIOL, V9, P1393, DOI 10.1111/j.1462-2920.2007.01255.x; Wirth MC, 2001, APPL ENVIRON MICROB, V67, P3280, DOI 10.1128/AEM.67.7.3280-3284.2001; WU D, 1994, MOL MICROBIOL, V13, P965, DOI 10.1111/j.1365-2958.1994.tb00488.x; Yang HH, 2003, J CLIN ONCOL, V21, P4239, DOI 10.1200/JCO.2003.06.001	41	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28301	28308		10.1074/jbc.M703567200	http://dx.doi.org/10.1074/jbc.M703567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17626007	hybrid			2022-12-27	WOS:000249642100003
J	Geisler, DA; Broselid, C; Hederstedt, L; Rasmusson, AG				Geisler, Daniela A.; Broselid, Christian; Hederstedt, Lars; Rasmusson, Allan G.			Ca2+-binding and Ca2+-independent respiratory NADH and NADPH dehydrogenases of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE MITOCHONDRIA; ALTERNATIVE NAD(P)H DEHYDROGENASES; RED BEETROOT MITOCHONDRIA; CALCIUM-BINDING PROTEINS; ESCHERICHIA-COLI; PLANT-MITOCHONDRIA; EXTERNAL NAD(P)H; CYTOPLASMIC PH; CYTOSOLIC NADH	Type II NAD(P)H:quinone oxidoreductases are single polypeptide proteins widespread in the living world. They bypass the first site of respiratory energy conservation, constituted by the type I NADH dehydrogenases. To investigate substrate specificities and Ca2+ binding properties of seven predicted type II NAD(P)H dehydrogenases of Arabidopsis thaliana we have produced them as T7-tagged fusion proteins in Escherichia coli. The NDB1 and NDB2 enzymes were found to bind Ca2+, and a single amino acid substitution in the EF hand motif of NDB1 abolished the Ca2+ binding. NDB2 and NDB4 functionally complemented an E. coli mutant deficient in endogenous type I and type II NADH dehydrogenases. This demonstrates that these two plant enzymes can substitute for the NADH dehydrogenases in the bacterial respiratory chain. Three NDB-type enzymes displayed distinct catalytic profiles with substrate specificities and Ca2+ stimulation being considerably affected by changes in pH and substrate concentrations. Under physiologically relevant conditions, the NDB1 fusion protein acted as a Ca2+-dependent NADPH dehydrogenase. NDB2 and NDB4 fusion proteins were NADH-specific, and NDB2 was stimulated by Ca2+. The observed activity profiles of the NDB-type enzymes provide a fundament for understanding the mitochondrial system for direct oxidation of cytosolic NAD(P)H in plants. Our findings also suggest different modes of regulation and metabolic roles for the analyzed A. thaliana enzymes.	Lund Univ, Dept Cell & Organism Biol, SE-22362 Lund, Sweden	Lund University	Rasmusson, AG (corresponding author), Lund Univ, Dept Cell & Organism Biol, Solvegatan 35B, SE-22362 Lund, Sweden.	Allan.Rasmusson@cob.lu.se		Hederstedt, Lars/0000-0002-6650-6296				ARRON GP, 1980, PLANT PHYSIOL, V65, P591, DOI 10.1104/pp.65.4.591; Bernard L, 2006, FEBS J, V273, P3625, DOI 10.1111/j.1742-4658.2006.05370.x; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; Carneiro P, 2004, BBA-BIOENERGETICS, V1608, P45, DOI 10.1016/j.bbabio.2003.10.004; Carneiro P, 2007, J MOL BIOL, V368, P1114, DOI 10.1016/j.jmb.2007.02.080; Clifton R, 2005, PLANT MOL BIOL, V58, P193, DOI 10.1007/s11103-005-5514-7; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Duarte M, 2003, BIOCHEM J, V371, P1005, DOI 10.1042/BJ20021374; Duval FD, 2002, PLANT J, V32, P481, DOI 10.1046/j.1365-313X.2002.01409.x; Elhafez D, 2006, PLANT CELL PHYSIOL, V47, P43, DOI 10.1093/pcp/pci221; Escobar MA, 2006, PLANT J, V45, P775, DOI 10.1111/j.1365-313X.2005.02640.x; Escobar MA, 2004, PLANT PHYSIOL, V136, P2710, DOI 10.1104/pp.104.046698; FELLE H, 1986, BIOCHIM BIOPHYS ACTA, V848, P176, DOI 10.1016/0005-2728(86)90039-3; Felle HH, 2000, PLANT PHYSIOL, V124, P1373, DOI 10.1104/pp.124.3.1373; Felle HH, 2001, PLANT BIOLOGY, V3, P577, DOI 10.1055/s-2001-19372; FOX GG, 1995, PLANTA, V195, P324, DOI 10.1007/BF00202588; FREDLUND KM, 1991, PLANT PHYSIOL, V97, P99, DOI 10.1104/pp.97.1.99; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Howitt CA, 1999, J BACTERIOL, V181, P3994, DOI 10.1128/JB.181.13.3994-4003.1999; Igamberdiev AU, 2003, BBA-BIOENERGETICS, V1606, P117, DOI 10.1016/S0005-2728(03)00106-3; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P2041, DOI 10.1021/bi00510a047; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; LUETHY MH, 1991, PLANT PHYSIOL, V97, P1317, DOI 10.1104/pp.97.4.1317; LUETHY MH, 1995, PLANT PHYSIOL, V107, P443, DOI 10.1016/S0176-1617(11)81768-2; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Matsushita K, 2001, FEMS MICROBIOL LETT, V204, P271, DOI 10.1016/S0378-1097(01)00417-7; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Melo AMP, 2001, J BIOL CHEM, V276, P3947, DOI 10.1074/jbc.M008199200; Menz RI, 1996, PLANT PHYSIOL, V112, P607, DOI 10.1104/pp.112.2.607; Michalecka AM, 2004, PLANT J, V37, P415, DOI 10.1046/j.1365-313X.2003.01970.x; Michalecka AM, 2003, PLANT PHYSIOL, V133, P642, DOI 10.1104/pp.103.024208; MOLLER IM, 1981, PHYSIOL PLANTARUM, V53, P413, DOI 10.1111/j.1399-3054.1981.tb02724.x; MOLLER IM, 1981, BIOCHEM J, V194, P487, DOI 10.1042/bj1940487; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; MOLLER IM, 1993, J BIOENERG BIOMEMBR, V25, P377, DOI 10.1007/BF00762463; Moller IM, 1996, PLANT PHYSIOL, V112, P75, DOI 10.1104/pp.112.1.75; MOLLER JM, 1997, PHYSIOL PLANTARUM, V100, P85; Moore CS, 2003, PLANT PHYSIOL, V133, P1968, DOI 10.1104/pp.103.029363; NASH D, 1983, PLANT PHYSIOL, V71, P627, DOI 10.1104/pp.71.3.627; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; PROCYSHYN RM, 1994, J BIOL CHEM, V269, P1641; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Rasmusson AG, 2001, PLANT PHYSIOL BIOCH, V39, P1057, DOI 10.1016/S0981-9428(01)01334-1; RASMUSSON AG, 1993, BIOCHIM BIOPHYS ACTA, V1141, P107, DOI 10.1016/0005-2728(93)90196-M; Rasmusson AG, 1999, PLANT J, V20, P79, DOI 10.1046/j.1365-313X.1999.00576.x; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Rigoulet M, 2004, MOL CELL BIOCHEM, V256, P73, DOI 10.1023/B:MCBI.0000009888.79484.fd; ROBERTS JKM, 1984, P NATL ACAD SCI-BIOL, V81, P3379, DOI 10.1073/pnas.81.11.3379; ROBERTS TH, 1995, FEBS LETT, V373, P307, DOI 10.1016/0014-5793(95)01059-N; Sakano K, 2001, INT REV CYTOL, V206, P1; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SIEDOW JN, 2000, BIOCH MOL BIOL PLANT, P676; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P217; Svensson AS, 2002, FEBS LETT, V517, P79, DOI 10.1016/S0014-5793(02)02581-4; Svensson AS, 2001, PLANT J, V28, P73, DOI 10.1046/j.1365-313X.2001.01128.x; Trewavas A, 1999, PLANT PHYSIOL, V120, P1, DOI 10.1104/pp.120.1.1; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZOTTINI M, 1993, PLANT PHYSIOL, V102, P579, DOI 10.1104/pp.102.2.579	71	58	62	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28455	28464		10.1074/jbc.M704674200	http://dx.doi.org/10.1074/jbc.M704674200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17673460	hybrid			2022-12-27	WOS:000249642100019
J	Hodkinson, PS; Elliott, PA; Lad, Y; McHugh, BJ; MacKinnon, AC; Haslett, C; Sethi, T				Hodkinson, Philip S.; Elliott, Paul. A.; Lad, Yatish; McHugh, Brian J.; MacKinnon, Alison C.; Haslett, Christopher; Sethi, Tariq			Mammalian NOTCH-1 activates beta 1 integrins via the small GTPase R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL STEM-CELLS; ERK MAP KINASE; INTEGRIN ACTIVATION; INTRACELLULAR DOMAIN; VULVAL DEVELOPMENT; SIGNALING PATHWAY; BINDING DOMAIN; GROWTH-FACTOR; MOUSE NOTCH1; RECEPTOR	Notch is a central regulator of important cell fate decisions. Notch activation produces diverse cellular effects suggesting the presence of context-dependent control mechanisms. Genetic studies have demonstrated that Notch and integrin mutations have related phenotypes in key developmental processes such as vascular development and somitogenesis. We show that the intracellular domain of mammalian Notch-1 activates integrins without affecting integrin expression. Integrin activation is dependent on gamma-secretase-mediated intramembranous cleavage of membrane-bound Notch releasing intracellular Notch that activates R-Ras, independent of CSL-transcription. Notch also reverses H-Ras and Raf-mediated integrin suppression without affecting ERK phosphorylation. Membrane-bound Notch mutants that are inefficiently cleaved or intracellular Notch mutants lacking the ankyrin repeat sequence do not activate R-Ras or integrins. Co-expression of Msx2-interacting nuclear target ( MINT) protein with Notch or expression of intracellular Notch-1 truncation mutants lacking the C-terminal transactivation/PEST domain suppresses Notch transcriptional activity without affecting integrin activation. Notch ligand, Delta-like ligand-4, stimulates R-Ras-dependent alpha 5 beta 1 integrin-mediated adhesion, demonstrating the physiological relevance of this pathway. This new CSL-independent Notch/R-Ras pathway provides a molecular mechanism to explain Notch, integrin, and Ras cross-talk during the development of multicellular organisms.	Univ Edinburgh, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh EH16 4SA, Midlothian, Scotland	University of Edinburgh	Sethi, T (corresponding author), 47 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	t.sethi@ed.ac.uk	; Elliott, Tony/M-1057-2015	McHugh, Brian/0000-0003-4747-0643; Elliott, Tony/0000-0002-0715-9431	Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Campos LS, 2006, J BIOL CHEM, V281, P5300, DOI 10.1074/jbc.M511886200; Chong SW, 2005, TRENDS CELL BIOL, V15, P453, DOI 10.1016/j.tcb.2005.07.008; Clegg DO, 2003, FRONT BIOSCI-LANDMRK, V8, pD723, DOI 10.2741/1020; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Culi J, 2001, DEVELOPMENT, V128, P299; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DE SB, 1999, NATURE, V398, P518; deCelis JF, 1996, DEVELOPMENT, V122, P359; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eagar TN, 2004, IMMUNITY, V20, P407, DOI 10.1016/S1074-7613(04)00081-0; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Endo Y, 2002, DEVELOPMENT, V129, P863; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Furuhjelm J, 2003, J CELL SCI, V116, P3729, DOI 10.1242/jcs.00689; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Julich D, 2005, DEV CELL, V8, P575, DOI 10.1016/j.devcel.2005.01.016; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Komatsu M, 2005, NAT MED, V11, P1346, DOI 10.1038/nm1324; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lad Y, 2006, J BIOL CHEM, V281, P29501, DOI 10.1074/jbc.M513471200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Langdon T, 2006, DEV DYNAM, V235, P998, DOI 10.1002/dvdy.20735; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nagaraj R, 2004, INT J DEV BIOL, V48, P755, DOI 10.1387/ijdb.041881rn; Nagato M, 2005, J NEUROSCI RES, V80, P456, DOI 10.1002/jnr.20442; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shawber C, 1996, DEVELOPMENT, V122, P3765; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stump G, 2002, MECH DEVELOP, V114, P153, DOI 10.1016/S0925-4773(02)00043-6; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Sundaram MV, 2004, CURR BIOL, V14, pR311, DOI 10.1016/j.cub.2004.03.052; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Yin ZN, 1997, CELL GROWTH DIFFER, V8, P1339; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; zur Lage P, 1999, DEVELOPMENT, V126, P3149	71	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28991	29001		10.1074/jbc.M703601200	http://dx.doi.org/10.1074/jbc.M703601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17664272	Green Submitted, hybrid			2022-12-27	WOS:000249642100073
J	Nikolov, EN; Ivanova-Nikolova, TT				Nikolov, Emil N.; Ivanova-Nikolova, Tatyana T.			Dynamic integration of alpha-adrenergic and cholinergic signals in the Atria - Role of G protein-regulated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; FORM STABLE COMPLEXES; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; COUPLED RECEPTORS; POTASSIUM CHANNELS; ADENYLYL-CYCLASE; GIRK CHANNELS; INHIBITION; CELLS	Numerous heptahelical receptors use activation of heterotrimeric G proteins to convey a multitude of extracellular signals to appropriate effector molecules in the cell. Both high specificity and correct integration of these signals are required for reliable cell function. Yet the molecular machineries that allow each cell to merge information flowing across different receptors are not well understood. Here we demonstrate that G protein-regulated inwardly rectifying K+ (GIRK) channels can operate as dynamic integrators of alpha-adrenergic and cholinergic signals in atrial myocytes. Acting at the last step of the cholinergic signaling cascade, these channels are activated by direct interactions with beta gamma subunits of the inhibitory G proteins (G beta gamma), and efficiently translate M-2 muscarinic acetylcholine receptor (M2R) activation into membrane hyperpolarization. The parallel activation of alpha-adrenergic receptors imposed a distinctive " signature" on the function of M2R-activated GIRK1/4 channels, affecting both the probability of G beta gamma binding to the channel and its desensitization. This modulation of channel function was correlated with a parallel depletion of G beta and protein phosphatase 1 from the oligomeric GIRK1 complexes. Such plasticity of the immediate GIRK signaling environment suggests that multireceptor integration involves large protein networks undergoing dynamic changes upon receptor activation.	E Carolina Univ, Dept Pharmacol & Toxicol, Brody Sch Med, Greenville, NC 27834 USA	University of North Carolina; East Carolina University	Ivanova-Nikolova, TT (corresponding author), E Carolina Univ, Dept Pharmacol & Toxicol, Brody Sch Med, Brody Med Sci Bldg,Rm 6S-11, Greenville, NC 27834 USA.	ivanovanikolovat@ecu.edu						BRAUN AP, 1992, PFLUEGERS ARCH, V421, P43; Brown SG, 2005, AM J PHYSIOL-CELL PH, V289, pC543, DOI 10.1152/ajpcell.00025.2005; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Cho H, 2005, P NATL ACAD SCI USA, V102, P15241, DOI 10.1073/pnas.0408851102; Cho H, 2005, P NATL ACAD SCI USA, V102, P4643, DOI 10.1073/pnas.0408844102; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Clancy SM, 2005, MOL CELL NEUROSCI, V28, P375, DOI 10.1016/j.mcn.2004.10.009; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Ivanova-Nikolova TT, 1998, J GEN PHYSIOL, V112, P199, DOI 10.1085/jgp.112.2.199; Kawano T, 2007, MOL PHARMACOL, V71, P1179, DOI 10.1124/mol.106.032508; Keselman I, 2007, CHANNELS, V1, P113, DOI 10.4161/chan.4321; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koike-Tani M, 2005, J PHYSIOL-LONDON, V564, P489, DOI 10.1113/jphysiol.2004.079285; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei QB, 2003, MOL CELLS, V15, P1; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Nikolov EN, 2004, BIOPHYS J, V87, P3122, DOI 10.1529/biophysj.104.039487; Nikolov EN, 2004, J BIOL CHEM, V279, P23630, DOI 10.1074/jbc.M312861200; Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sadja R, 2003, NEURON, V39, P9, DOI 10.1016/S0896-6273(03)00402-1; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhu WZ, 2005, CIRC RES, V97, P244, DOI 10.1161/01.RES.0000176764.38934.86	36	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28669	28682		10.1074/jbc.M703677200	http://dx.doi.org/10.1074/jbc.M703677200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17684011	hybrid			2022-12-27	WOS:000249642100041
J	Pangrsic, T; Potokar, M; Stenovec, M; Kreft, M; Fabbretti, E; Nistri, A; Pryazhnikov, E; Khiroug, L; Giniatullin, R; Zorec, R				Pangrsic, Tina; Potokar, Maja; Stenovec, Matjaz; Kreft, Marko; Fabbretti, Elsa; Nistri, Andrea; Pryazhnikov, Evgeny; Khiroug, Leonard; Giniatullin, Rashid; Zorec, Robert			Exocytotic release of ATP from cultured Astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE-CORE VESICLES; VESICULAR GLUTAMATE; SYNAPTIC CURRENTS; RECEPTORS; P2X(3); DESENSITIZATION; OSCILLATIONS; MICROSCOPY; SECRETION; TRANSPORT	Astrocytes appear to communicate with each other as well as with neurons via ATP. However, the mechanisms of ATP release are controversial. To explore whether stimuli that increase [Ca2+](i) also trigger vesicular ATP release from astrocytes, we labeled ATP-containing vesicles with the fluorescent dye quinacrine, which exhibited a significant co-localization with atrial natriuretic peptide. The confocal microscopy study revealed that quinacrine-loaded vesicles displayed mainly non-directional spontaneous mobility with relatively short track lengths and small maximal displacements, whereas 4% of vesicles exhibited directional mobility. After ionomycin stimulation only non-directional vesicle mobility could be observed, indicating that an increase in [Ca2+](i) attenuated vesicle mobility. Total internal reflection fluorescence (TIRF) imaging in combination with epifluorescence showed that a high percentage of fluorescently labeled vesicles underwent fusion with the plasma membrane after stimulation with glutamate or ionomycin and that this event was Ca2+-dependent. This was confirmed by patch-clamp studies on HEK-293T cells transfected with P2X(3) receptor, used as sniffers for ATP release from astrocytes. Glutamate stimulation of astrocytes was followed by an increase in the incidence of small transient inward currents in sniffers, reminiscent of postsynaptic quantal events observed at synapses. Their incidence was highly dependent on extracellular Ca2+. Collectively, these findings indicate that glutamate-stimulated ATP release from astrocytes was most likely exocytotic and that after stimulation the fraction of quinacrine-loaded vesicles, spontaneously exhibiting directional mobility, disappeared.	Univ Ljubljana, Fac Med, Lab Neuroendocrinol Mol Cell Physiol, Inst Pathophysiol,Fac Med, SI-1000 Ljubljana, Slovenia; Celica Biomed Ctr, SI-1000 Ljubljana, Slovenia; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland; SISSA, Int Sch Adv Studies, I-34014 Trieste, Italy	University of Ljubljana; University of Helsinki; International School for Advanced Studies (SISSA)	Zorec, R (corresponding author), Univ Ljubljana, Fac Med, Lab Neuroendocrinol Mol Cell Physiol, Inst Pathophysiol,Fac Med, Zaloska 4, SI-1000 Ljubljana, Slovenia.	robert.zorec@mf.uni-lj.si	Giniatullin, Rashid/Y-9687-2018; Zorec, Robert/AAD-7180-2021	Zorec, Robert/0000-0002-7478-3875; Giniatullin, Rashid/0000-0002-1580-6280				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Anderson CM, 2004, J NEUROCHEM, V88, P246, DOI 10.1046/j.1471-4159.2003.02204.x; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 1998, J NEUROSCI, V18, P6822; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Axelrod D, 2003, METHOD ENZYMOL, V361, P1; Bal-Price A, 2002, GLIA, V40, P312, DOI 10.1002/glia.10124; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Fabbretti E, 2004, J BIOL CHEM, V279, P53109, DOI 10.1074/jbc.M409772200; Fabbro A, 2004, J PHYSIOL-LONDON, V560, P505, DOI 10.1113/jphysiol.2004.068924; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fellin T, 2006, PHYSIOLOGY, V21, P208, DOI 10.1152/physiol.00161.2005; Grandolfo M, 2005, NEUROREPORT, V16, P381, DOI 10.1097/00001756-200503150-00015; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Jarvis MF, 2002, P NATL ACAD SCI USA, V99, P17179, DOI 10.1073/pnas.252537299; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kolikova J, 2006, BRAIN CELL BIOL, V35, P75, DOI 10.1007/s11068-006-9000-1; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Krzan M, 2003, J NEUROSCI, V23, P1580; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; Ng YK, 2002, J PHYSIOL-LONDON, V542, P395, DOI 10.1113/jphysiol.2002.021733; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pangrsic T, 2006, J NEUROCHEM, V99, P514, DOI 10.1111/j.1471-4159.2006.04042.x; Pankratov Y, 2003, MOL CELL NEUROSCI, V24, P842, DOI 10.1016/S1044-7431(03)00233-1; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Potokar M, 2005, BIOCHEM BIOPH RES CO, V329, P678, DOI 10.1016/j.bbrc.2005.02.030; Potokar M, 2007, TRAFFIC, V8, P12, DOI 10.1111/j.1600-0854.2006.00509.x; Queiroz G, 1997, NEUROSCIENCE, V78, P1203, DOI 10.1016/S0306-4522(96)00637-9; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schutz GJ, 2004, MICROSC RES TECHNIQ, V63, P159, DOI 10.1002/jemt.20016; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Shakiryanova D, 2005, NAT NEUROSCI, V8, P173, DOI 10.1038/nn1377; Simonetti M, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-11; Sokolova E, 2004, BRIT J PHARMACOL, V141, P1048, DOI 10.1038/sj.bjp.0705701; Stenovec M, 2004, FASEB J, V18, P1270, DOI 10.1096/fj.03-1397fje; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Striedinger K, 2007, GLIA, V55, P652, DOI 10.1002/glia.20494; Wacker I, 1997, J CELL SCI, V110, P1453; Wilhelm A, 2004, NEUROSCI RES, V48, P249, DOI 10.1016/j.neures.2003.11.002; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	53	187	191	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28749	28758		10.1074/jbc.M700290200	http://dx.doi.org/10.1074/jbc.M700290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17627942	hybrid			2022-12-27	WOS:000249642100049
J	Tang, M; Cecconi, C; Bustamante, C; Rio, DC				Tang, Mei; Cecconi, Ciro; Bustamante, Carlos; Rio, Donald C.			Analysis of P element transposase protein-DNA interactions during the early stages of transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; DROSOPHILA-MELANOGASTER; MU-TRANSPOSASE; V(D)J RECOMBINATION; IN-VITRO; BINDING; ARCHITECTURE; TN5; CATALYSIS; COFACTOR	P elements are a family of transposable elements found in Drosophila that move by using a cut-and-paste mechanism and that encode a transposase protein that uses GTP as a cofactor for transposition. Here we used atomic force microscopy to visualize the initial interaction of transposase protein with P element DNA. The transposase first binds to one of the two P element ends, in the presence or absence of GTP, prior to synapsis. In the absence of GTP, these complexes remain stable but do not proceed to synapsis. In the presence of GTP or nonhydrolyzable GTP analogs, synapsis happens rapidly, whereas DNA cleavage is slow. Both atomic force microscopy and standard biochemical methods have been used to show that the P element transposase exists as a pre-formed tetramer that initially binds to either one of the two P element ends in the absence of GTP prior to synapsis. This initial single end binding may explain some of the aberrant P element-induced rearrangements observed in vivo, such as hybrid end insertion. The allosteric effect of GTP in promoting synapsis by P element transposase may be to orient a second site-specific DNA binding domain in the tetramer allowing recognition of a second high affinity transposase-binding site at the other transposon end.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genomics & Dev, Berkeley, CA 94720 USA; Univ Calif Berkeley, Ctr Integrat Genomics, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ Modena & Reggio Emilia, CNR, INFM, S3, I-41100 Modena, Italy; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Universita di Modena e Reggio Emilia; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Rio, DC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genomics & Dev, Berkeley, CA 94720 USA.	don_rio@berkeley.edu	Cecconi, Ciro/K-5028-2016	Cecconi, Ciro/0000-0002-6101-2609; Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061987] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; Auge-Gouillou C, 2005, J MOL BIOL, V351, P117, DOI 10.1016/j.jmb.2005.05.019; Auge-Gouillou C, 2005, MOL CELL BIOL, V25, P2861, DOI 10.1128/MCB.25.7.2861-2870.2005; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CURR OPIN GENET DEV, V3, P708, DOI 10.1016/S0959-437X(05)80087-5; Beall EL, 1998, EMBO J, V17, P2122, DOI 10.1093/emboj/17.7.2122; Beall EL, 1997, GENE DEV, V11, P2137, DOI 10.1101/gad.11.16.2137; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Catto LE, 2006, NUCLEIC ACIDS RES, V34, P1711, DOI 10.1093/nar/gkl076; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIG NL, 2002, MOBILE DNA, V2; Craigie R, 1996, CELL, V85, P137, DOI 10.1016/S0092-8674(00)81089-2; Curcio MJ, 2003, NAT REV MOL CELL BIO, V4, P865, DOI 10.1038/nrm1241; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Engels W.R, 1989, MOBILE DNA, P437; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Gray YHM, 1996, GENETICS, V144, P1601; Gueguen E, 2005, TRENDS MICROBIOL, V13, P543, DOI 10.1016/j.tim.2005.09.002; Halford SE, 2004, ANNU REV BIOPH BIOM, V33, P1, DOI 10.1146/annurev.biophys.33.110502.132711; Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hickman AB, 2005, NAT STRUCT MOL BIOL, V12, P715, DOI 10.1038/nsmb970; HOLMES V, 2001, THESIS U CALIFORNIA; Jones JM, 2004, IMMUNOL REV, V200, P233, DOI 10.1111/j.0105-2896.2004.00168.x; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lee CC, 1996, MOL CELL BIOL, V16, P5616; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lipkow K, 2004, MOL CELL BIOL, V24, P8301, DOI 10.1128/MCB.24.18.8301-8311.2004; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Mul YM, 1997, EMBO J, V16, P4441, DOI 10.1093/emboj/16.14.4441; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; Preston CR, 1996, GENETICS, V144, P1623; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; Reznikoff WS, 2003, MOL MICROBIOL, V47, P1199, DOI 10.1046/j.1365-2958.2003.03382.x; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Richardson JM, 2006, EMBO J, V25, P1324, DOI 10.1038/sj.emboj.7601018; Rio Donald C., 2002, P484; Rodgers KK, 1999, NUCLEIC ACIDS RES, V27, P2938, DOI 10.1093/nar/27.14.2938; Steiniger-White M, 2004, CURR OPIN STRUC BIOL, V14, P50, DOI 10.1016/j.sbi.2004.01.008; Tang M, 2005, GENE DEV, V19, P1422, DOI 10.1101/gad.1317605; Venken KJT, 2005, NAT REV GENET, V6, P167, DOI 10.1038/nrg1553; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Williams TL, 2004, J BIOL CHEM, V279, P5135, DOI 10.1074/jbc.M308156200; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yang JY, 1996, CELL, V85, P447, DOI 10.1016/S0092-8674(00)81122-8; Zhang L, 2001, NUCLEIC ACIDS RES, V29, P3566, DOI 10.1093/nar/29.17.3566	56	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29002	29012		10.1074/jbc.M704106200	http://dx.doi.org/10.1074/jbc.M704106200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17644523	hybrid			2022-12-27	WOS:000249642100074
J	Werneburg, NW; Guicciardi, ME; Bronk, SF; Kaufmann, SH; Gores, GJ				Werneburg, Nathan W.; Guicciardi, M. Eugenia; Bronk, Steve F.; Kaufmann, Scott H.; Gores, Gregory J.			Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BAX-DEPENDENT APOPTOSIS; ALPHA-INDUCED APOPTOSIS; TNF-ALPHA; CELL-DEATH; CHOLANGIOCARCINOMA CELLS; UP-REGULATION; HEPATOCYTE APOPTOSIS; MEDIATED APOPTOSIS	The present studies were performed to determine whether lysosomal permeabilization contributes to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) cytotoxicity and to reconcile a role for lysosomes with prior observations that Bcl-2 family members regulate TRAIL-induced apoptosis. In KMCH cholangiocarcinoma cells stably expressing Mcl-1 small interference RNA ( siRNA), treatment with TRAIL induced a redistribution of the cathepsin B from lysosomes to the cytosol. Pharmacological and small hairpin RNA-targeted inhibition of cathepsin B attenuated TRAIL-mediated apoptosis as assessed by morphological, biochemical, and clonogenic assays. Neither Bid siRNA nor Bak siRNA prevented cathepsin B release. In contrast, treatment of the cells with Bim siRNA or the JNK inhibitor SP600125 attenuated lysosomal permeabilization and cell death. Moreover, Bim and active Bax co-localized to lysosomes in TRAIL-treated cells in a JNK-dependent manner, and Bax siRNA reduced TRAIL-induced lysosomal permeabilization and cell death. Finally, BH3 domain peptides permeabilized isolated lysosomes in the presence of Bax. Collectively, these data suggest that TRAIL can trigger an apoptotic pathway that involves JNK-dependent activation of Bim, which in turn induces Bax-mediated permeabilization of lysosomes.	Mayo Clin, Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, 200 1st st SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA69008, R01 CA069008] Funding Source: Medline; NIDDK NIH HHS [DK63947, DK59427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059427, R01DK063947, R56DK059427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAO Y, 1994, CANCER RES, V54, P2468; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Burns TF, 2001, J BIOL CHEM, V276, P37879; Caruso JA, 2006, J BIOL CHEM, V281, P10954, DOI 10.1074/jbc.M508383200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng G, 2006, P NATL ACAD SCI USA, V103, P8499, DOI 10.1073/pnas.0602957103; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Feldstein AE, 2006, AM J PHYSIOL-GASTR L, V290, pG1339, DOI 10.1152/ajpgi.00509.2005; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Guicciardi ME, 2007, AM J PHYSIOL-GASTR L, V292, pG1337, DOI 10.1152/ajpgi.00497.2006; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2005, GASTROENTEROLOGY, V129, P269, DOI 10.1053/j.gastro.2005.05.022; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Kagedal K, 2005, INT J EXP PATHOL, V86, P309, DOI 10.1111/j.0959-9673.2005.00442.x; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Malhi H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Papadakis ES, 2006, FEBS LETT, V580, P1320, DOI 10.1016/j.febslet.2006.01.053; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Sayan BS, 2001, J CELL BIOL, V155, P719, DOI 10.1083/jcb.200106044; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Takada E, 2005, EXP CELL RES, V304, P518, DOI 10.1016/j.yexcr.2004.11.015; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang YJ, 2006, J BIOL CHEM, V281, P15258, DOI 10.1074/jbc.M512953200; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YAMADA H, 1984, J BIOCHEM, V95, P1155, DOI 10.1093/oxfordjournals.jbchem.a134704; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zu K, 2005, MOL CANCER THER, V4, P43	61	107	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28960	28970		10.1074/jbc.M705671200	http://dx.doi.org/10.1074/jbc.M705671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17686764	hybrid			2022-12-27	WOS:000249642100070
J	Jiang, L; Smith, JN; Anderson, SL; Ma, P; Mizzen, CA; Kelleher, NL				Jiang, Lihua; Smith, Jonell N.; Anderson, Shannon L.; Ma, Ping; Mizzen, Craig A.; Kelleher, Neil L.			Global assessment of combinatorial post-translational modification of core histones in yeast using contemporary mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-CAPTURE DISSOCIATION; SACCHAROMYCES-CEREVISIAE; HAT ACTIVITY; ACETYLATION; METHYLATION; H3; ACETYLTRANSFERASE; TRANSCRIPTION; COMPLEX; GCN5P	A global view of all core histones in yeast is provided by tandem mass spectrometry of intact histones H2A, H2B, H4, and H3. This allowed detailed characterization of > 50 distinct histone forms and their semiquantitative assessment in the deletion mutants gcn5 Delta, spt7 Delta, ahc1 Delta, and rtg2 Delta, affecting the chromatin remodeling complexes SAGA, SLIK, and ADA. The "top down" mass spectrometry approach detected dramatic decreases in acetylation on H3 and H2B in gcn5 Delta cells versus wild type. For H3 in wild type cells, tandem mass spectrometry revealed a direct correlation between increases of Lys(4) trimethylation and the 0, 1, 2, and 3 acetylation states of histone H3. The results show a wide swing from 10 to 80% Lys(4) trimethylation levels on those H3 tails harboring 0 or 3 acetylations, respectively. Reciprocity between these chromatin marks was apparent, since gcn5 Delta cells showed a 30% decrease in trimethylation levels on Lys(4) in addition to a decrease of acetylation levels on H3 in bulk chromatin. Deletion of Set1, the Lys(4) methyltransferase, was associated with the linked disappearance of both Lys(4) methylation and Lys(14) and Lys(18) or Lys(23) acetylation on H3. In sum, we have defined the "basis set" of histone forms present in yeast chromatin using a current mass spectrometric approach that both quickly profiles global changes and directly probes the connectivity of modifications on the same histone.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Stat, Urbana, IL 61801 USA; Univ Illinois, Dept Genom Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews,53 Rodger Adams Lab, Urbana, IL 61801 USA.	kelleher@scs.uiuc.edu	Ma, Ping/M-7746-2015	Ma, Ping/0000-0002-5728-3596	NIGMS NIH HHS [GM 067193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyne MT, 2006, J PROTEOME RES, V5, P248, DOI 10.1021/pr050269n; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; Fingerman IM, 2005, J BIOL CHEM, V280, P28761, DOI 10.1074/jbc.C500097200; Garcia BA, 2007, NAT METHODS, V4, P487, DOI 10.1038/nmeth1052; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lee KK, 2004, BIOCHEM SOC T, V32, P899, DOI 10.1042/BST0320899; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Meng FY, 2002, ANAL CHEM, V74, P2923, DOI 10.1021/ac020049i; Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Pesavento JJ, 2004, J AM CHEM SOC, V126, P3386, DOI 10.1021/ja039748i; PESAVENTO JJ, 2007, IN PRESS MOL CELL PR; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1839, DOI 10.1002/(SICI)1097-0231(199611)10:14<1839::AID-RCM718>3.0.CO;2-V; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Siuti N, 2006, J PROTEOME RES, V5, P233, DOI 10.1021/pr050268v; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Taverna SD, 2007, P NATL ACAD SCI USA, V104, P2086, DOI 10.1073/pnas.0610993104; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Yuan GC, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r70; Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zubarev RA, 2004, CURR OPIN BIOTECH, V15, P12, DOI 10.1016/j.copbio.2003.12.002; Zubarev RA, 2000, ANAL CHEM, V72, P563, DOI 10.1021/ac990811p	55	74	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27923	27934		10.1074/jbc.M704194200	http://dx.doi.org/10.1074/jbc.M704194200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652096	hybrid			2022-12-27	WOS:000249455600041
J	Kent, NA; Chambers, AL; Downs, JA				Kent, Nicholas A.; Chambers, Anna L.; Downs, Jessica A.			Dual chromatin remodeling roles for RSC during DNA double strand break induction and repair at the yeast MAT locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H2A; RECOMBINATION; COMPLEX; DAMAGE; ACCESSIBILITY; NUCLEOSOMES; ADAPTATION; MECHANISM	DNA double strand breaks (DSBs) are potentially serious chromosomal lesions. However, cells sometimes deliberately cleave their own DNA to facilitate certain chromosomal processes, and there is much interest in how such self-inflicted breaks are effectively managed. Eukaryotic DSBs occur in the context of chromatin and the RSC chromatin-remodeling AT Pase complex has been shown to promote DSB repair at the budding yeast MAT locus DSB, created by the HO endonuclease during mating type switching. We show that the role of RSC at MAT is highly specialized. The Rsc1p subunit of RSC directs nucleosome sliding immediately after DSB creation at both MA T and generally and is required for efficient DNA damage-induced histone H2A phosphorylation and strand resection during repair by homologous recombination. However, the Rsc2p and Rsc7p subunits are additionally required to set up a basal MAT locus structure. This RSC-dependent chromatin structure at MA T ensures accessibility to the HO endonuclease. The RSC complex therefore has chromatin remodeling roles both before and after DSB induction at MAT, promoting both DNA cleavage and subsequent repair.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Oxford; University of Cambridge; Cardiff University	Kent, NA (corresponding author), Univ Sussex, Med Res Council Genom Damage & Stability Ctr, Brighton BN1 9RQ, E Sussex, England.	kentn@cardiff.ac.uk	Kent, Nicholas/A-4503-2010	Kent, Nicholas/0000-0002-4114-1307; Downs, Jessica/0000-0002-6600-849X; Chambers, Anna/0000-0001-8133-6240	Wellcome Trust [076258] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cobb RM, 2006, ADV IMMUNOL, V91, P45, DOI 10.1016/S0065-2776(06)91002-5; Costelloe T, 2006, EXP CELL RES, V312, P2677, DOI 10.1016/j.yexcr.2006.06.031; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fazzio TG, 2003, MOL CELL, V12, P1333, DOI 10.1016/S1097-2765(03)00436-2; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang J, 2004, MOL CELL, V13, P739, DOI 10.1016/S1097-2765(04)00103-0; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Keeney S, 2006, BIOCHEM SOC T, V34, P523, DOI 10.1042/BST0340523; KENT NA, 1995, NUCLEIC ACIDS RES, V23, P3786, DOI 10.1093/nar/23.18.3786; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wilson B, 2006, GENETICS, V172, P795, DOI 10.1534/genetics.105.047589; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	30	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27693	27701		10.1074/jbc.M704707200	http://dx.doi.org/10.1074/jbc.M704707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17652077	hybrid			2022-12-27	WOS:000249455600017
J	El Gazzar, M; Yoza, BK; Hu, JYQ; Cousart, SL; McCall, CE				El Gazzar, Mohamed; Yoza, Barbara K.; Hu, Jean Y. -Q.; Cousart, Sue L.; McCall, Charles E.			Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HISTONE H3 PHOSPHORYLATION; HUMAN MONOCYTIC CELLS; GENE-REGULATION; C-JUN; TRANSCRIPTIONAL ACTIVATION; HETEROCHROMATIN PROTEIN-1; INFLAMMATORY GENES; DNA METHYLATION; CHROMATIN	Sustained silencing of potentially autotoxic acute proinflammatory genes like tumor necrosis factor alpha( TNF alpha) occurs in circulating leukocytes following the early phase of severe systemic inflammation. Aspects of this gene reprogramming suggest the involvement of epigenetic processes. We used THP-1 human promonocytes, which mimic gene silencing when rendered endotoxin-tolerant in vitro, to test whether TNF alpha proximal promoter nucleosomes and transcription factors adapt to an activation-specific profile by developing characteristic chromatin-based silencing marks. We found increased TNF alpha mRNA levels in endotoxin-responsive cells that was preceded by dissociation of heterochromatin-binding protein 1 alpha, demethylation of nucleosomal histone H3 lysine 9 ( H3( Lys(9))), increased phosphorylation of the adjacent serine 10 ( H3( Ser(10))), and recruitment of NF-kappa B RelA/p65 to the TNF alpha promoter. In contrast, endotoxin-tolerant cells repressed production of TNF alpha mRNA, retained binding of heterochromatin-binding protein 1 alpha, sustained methylation of H3( Lys9), reduced phosphorylation of H3( Ser10), and showed diminished binding of NF-kappa B RelA/p65 to the TNF alpha promoter. Similar levels of NF-kappa B p50 occurred at the TNF alpha promoter in the basal state, during active transcription, and in the silenced phenotype. RelB, which acts as a repressor of TNF alpha transcription, remained bound to the promoter during silencing. These results support an immunodeficiency paradigm where epigenetic changes at the promoter of acute proinflammatory genes mediate their repression during the late phase of severe systemic inflammation.	Wake Forest Univ, Sch Med, Sect Mol Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	El Gazzar, M (corresponding author), Wake Forest Univ, Sch Med, Sect Mol Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	melgazza@wfubmc.edu			NIAID NIH HHS [R01 AI 09169, R01 AI 065791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065791, R01AI009169] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Barthel R, 2003, J IMMUNOL, V171, P3612, DOI 10.4049/jimmunol.171.7.3612; Berger F, 2003, CHROMOSOME RES, V11, P277, DOI 10.1023/A:1022844127716; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Dormann HL, 2006, CELL CYCLE, V5, P2842, DOI 10.4161/cc.5.24.3540; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; GRANOWITZ EV, 1993, J IMMUNOL, V151, P1637; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; LE DB, 1996, EMBO J, V15, P6701; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; McCall CE, 2007, AM J RESP CRIT CARE, V175, P763, DOI 10.1164/rccm.200610-1436CP; Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; Natoli G, 2006, FEBS LETT, V580, P2843, DOI 10.1016/j.febslet.2006.02.072; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Vanden Berghe W, 2003, ADV EXP MED BIOL, V544, P181; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Xia YY, 1999, MOL CELL BIOL, V19, P7688; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yoza BK, 2006, J IMMUNOL, V177, P4080, DOI 10.4049/jimmunol.177.6.4080; Yoza BK, 2000, SHOCK, V13, P236, DOI 10.1097/00024382-200003000-00011	77	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26857	26864		10.1074/jbc.M704584200	http://dx.doi.org/10.1074/jbc.M704584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646159	hybrid			2022-12-27	WOS:000249304900025
J	Ling, X; Cheng, QY; Black, JD; Li, FZ				Ling, Xiang; Cheng, Qiuying; Black, Jennifer D.; Li, Fengzhi			Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE VARIANTS; SPINDLE CHECKPOINT; DIVISION; CANCER; ARREST; GENE; TUMORIGENESIS; INTERFERENCE; INHIBITION; CARCINOMAS	It has been previously shown that both survivin and the survivin splice variant survivin-2B are localized in mitochondria. Whereas the mechanism involved in blockade of mitochondria-mediated apoptosis by survivin has been extensively studied, the role of survivin-2B in regulation of apoptosis has not been well defined. In the present study, we report that in addition to mitochondria, survivin-2B is also localized in the microtubule organization center (MTOC) and, in contrast to other survivin isoforms (i.e. survivin and survivin-Delta Ex3), behaves as a proapoptotic molecule. We show that forced expression of survivin-2B blocks tubulin polymerization, ablates mitotic cells, and induces mitochondria-dependent apoptosis. The mitochondria-mediated apoptosis induced by survivin-2B was indicated by Smac release from mitochondria, activation of caspases 9 and 3, and loss of mitochondrial potential, while caspase-8 remained inactive. Further analysis of the mechanism for the mitochondria-associated events of apoptosis induced by forced expression of survivin-2B revealed down-regulation of the pro-survival factor Bcl-2 and up-regulation of the pro-apoptotic factor Bax in mitochondria, while the apoptosis-inducing factor (AIF) remains unchanged. Our studies further showed that taxol (paclitaxel) treatment of cancer cells not only up-regulates survivin but also down-regulates survivin-2B and that forced expression of survivin-2B sensitizes cells to taxol-induced cell growth inhibition and cell death, while silencing of endogenous survivin-2B transcripts by survivin-2B-specific siRNA made cells resistant to taxol treatment. These findings advance our current knowledge about survivin-2B and may help to develop novel approaches for cancer treatment.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [P30 CA016056, R01 CA109481, R01 CA109481-03, R01 CA 109481, CA 16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA109481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2004, J CELL BIOCHEM, V92, P656, DOI 10.1002/jcb.20140; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li F, 2005, BRIT J CANCER, V92, P212, DOI 10.1038/sj.bjc.6602340; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 2006, AM J PATHOL, V169, P1, DOI 10.2353/ajpath.2006.060121; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 2005, ONCOGENE, V24, P1385, DOI 10.1038/sj.onc.1208330; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Ling X, 2005, LUNG CANCER, V49, P353, DOI 10.1016/j.lungcan.2005.03.037; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; McGuire JJ, 2000, J BIOL CHEM, V275, P13012, DOI 10.1074/jbc.275.17.13012; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Spaulding B, 2006, HISTOPATHOLOGY, V49, P622, DOI 10.1111/j.1365-2559.2006.02556.x; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wu JG, 2005, J BIOL CHEM, V280, P9745, DOI 10.1074/jbc.M409350200; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	31	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27204	27214		10.1074/jbc.M705161200	http://dx.doi.org/10.1074/jbc.M705161200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17656368	hybrid, Green Accepted			2022-12-27	WOS:000249304900062
J	Stadthagen, G; Sambou, T; Guerin, M; Barilone, N; Boudou, F; Kordulakova, J; Charles, P; Alzari, PM; Lemassu, A; Daffe, M; Puzo, G; Gicquel, B; Riviere, M; Jackson, M				Stadthagen, Gustavo; Sambou, Tounkang; Guerin, Marcelo; Barilone, Nathalie; Boudou, Frederic; Kordulakova, Jana; Charles, Patricia; Alzari, Pedro M.; Lemassu, Anne; Daffe, Mamadou; Puzo, Germain; Gicquel, Brigitte; Riviere, Michel; Jackson, Mary			Genetic basis for the biosynthesis of methylglucose lipopolysaccharides in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYL-COENZYME-A; METHYLMANNOSE POLYSACCHARIDE; REVISED STRUCTURE; SMEGMATIS; ACID; POLYMETHYLPOLYSACCHARIDES; 6-O-METHYL-D-GLUCOSE; METHYLTRANSFERASE; IDENTIFICATION; PURIFICATION	Mycobacteria produce two unusual polymethylated polysaccharides, the 6-O-methylglucosyl-containing lipopolysaccharides (MGLP) and the 3-O-methylmannose polysaccharides, which have been shown to regulate fatty acid biosynthesis in vitro. A cluster of genes dedicated to the synthesis of MGLP was identified in Mycobacterium tuberculosis and Mycobacterium smegmatis. Overexpression of the putative glycosyltransferase gene Rv3032 in M. smegmatis greatly stimulated MGLP production, whereas the targeted disruption of Rv3032 in M. tuberculosis and that of the putative methyltransferase gene MSMEG2349 in M. smegmatis resulted in a dramatic reduction in the amounts of MGLP synthesized and in the accumulation of precursors of these molecules. Disruption of Rv3032 also led to a significant decrease in the glycogen content of the tubercle bacillus, indicating that the product of this gene is likely to be involved in the elongation of more than one alpha-(1 -> 4)-glucan in this bacterium. Results thus suggest that Rv3032 encodes the alpha-(1 -> 4)- glucosyltransferase responsible for the elongation of MGLP, whereas MSMEG2349 encodes the O-methyltransferase required for the 6-O-methylation of these compounds.	Inst Pasteur, Unite Genet Mycobacterienne, F-75015 Paris, France; Inst Pasteur, Unite Biochim Struct, F-75015 Paris, France; CNRS, Inst Pharmacol & Biol Struct, Dept Mecanismes Mol infect Mycobacteriennes, F-31077 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Jackson, M (corresponding author), Colorado State Univ, Dept Microbiol Immunol& Pathol, Ft Collins, CO 80523 USA.	Mary.Jackson@colostate.edu	Jackson, Mary/D-5345-2017; Guerin, Marcelo M/N-7245-2016; Kordulakova, Jana/I-3887-2014	Jackson, Mary/0000-0002-9212-0258; Guerin, Marcelo M/0000-0001-9524-3184; Kordulakova, Jana/0000-0003-2834-0165; Alzari, Pedro/0000-0002-4233-1903; Lemassu, Anne/0000-0002-9323-2497	NIAID NIH HHS [5R01 AI 064798-03, R01 AI064798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BUEDING E, 1964, J BIOL CHEM, V239, P4018; Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; FERGUSON JA, 1970, J BIOL CHEM, V245, P4213; FORSBERG LS, 1982, J BIOL CHEM, V257, P3555; GRAY GR, 1971, J BIOL CHEM, V246, P6835; GRELLERT E, 1972, J BIOL CHEM, V247, P3236; HARRIS LS, 1977, J BIOL CHEM, V252, P2470; HINDSGAUL O, 1984, BIOCHEMISTRY-US, V23, P577, DOI 10.1021/bi00298a028; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059; KAMISANGO K, 1987, J BIOL CHEM, V262, P4580; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; LEE YC, 1964, J BIOL CHEM, V239, P3602; LEE YC, 1966, J BIOL CHEM, V241, P1899; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LORNITZO FA, 1968, BIOCHIM BIOPHYS ACTA, V158, P329, DOI 10.1016/0304-4165(68)90286-9; MAGGIO JE, 1980, P NATL ACAD SCI-BIOL, V77, P2582, DOI 10.1073/pnas.77.5.2582; MAITRA SK, 1977, J BIOL CHEM, V252, P2459; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; Murakami T, 2006, J BACTERIOL, V188, P5915, DOI 10.1128/JB.00390-06; Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003; POMMIER MT, 1986, J GEN MICROBIOL, V132, P2433; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200; Tuffal G, 1998, GLYCOBIOLOGY, V8, P675, DOI 10.1093/glycob/8.7.675; TUFFAL G, 1995, EUR J BIOCHEM, V233, P377, DOI 10.1111/j.1432-1033.1995.377_1.x; Tuffal G, 1998, ANAL CHEM, V70, P1853, DOI 10.1021/ac971101r; TUNG KK, 1973, J BIOL CHEM, V248, P7126; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; WEISMAN LS, 1984, J BIOL CHEM, V259, P3457; WEISMAN LS, 1984, J BIOL CHEM, V259, P3464; YABUSAKI KK, 1978, P NATL ACAD SCI USA, V75, P691, DOI 10.1073/pnas.75.2.691; YABUSAKI KK, 1979, J BIOL CHEM, V254, P2314; YABUSAKI KK, 1979, J BIOL CHEM, V254, P7282; YAMADA H, 1979, J BIOL CHEM, V254, P1972	38	44	51	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27270	27276		10.1074/jbc.M702676200	http://dx.doi.org/10.1074/jbc.M702676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640872	Green Published, hybrid			2022-12-27	WOS:000249304900068
J	Veit, G; Zimina, EP; Franzke, CW; Kutsch, S; Siebolds, U; Gordon, MK; Bruckner-Tuderman, L; Koch, M				Veit, Guido; Zimina, Elena P.; Franzke, Claus-Werner; Kutsch, Stefanie; Siebolds, Udo; Gordon, Marion K.; Bruckner-Tuderman, Leena; Koch, Manuel			Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOHIDROTIC ECTODERMAL DYSPLASIA; CELL-SURFACE; LIPID RAFTS; PROPROTEIN CONVERTASE; CHOLESTEROL DEPLETION; ECTODYSPLASIN-A; GOLGI-APPARATUS; PROTEIN; ECTODOMAIN; PRECURSOR	Collagen XXIII belongs to the class of type II orientated transmembrane collagens. A common feature of these proteins is the presence of two forms of the molecule: a membrane-bound form and a shed form. Here we demonstrate that, in mouse lung, collagen XXIII is found predominantly as the full-length form, whereas in brain, it is present mostly as the shed form, suggesting that shedding is tissue-specific and tissue-regulated. To analyze the shedding process of collagen XXIII, a cell culture model was established. Mutations introduced into two putative proprotein convertase cleavage sites showed that altering the second cleavage site inactivated much of the shedding. This supports the idea that furin, a major physiological protease, is predominantly responsible for shedding. Furthermore, our studies indicate that collagen XXIII is localized in lipid rafts in the plasma membrane and that ectodomain shedding is altered by a cholesterol-dependent mechanism. Moreover, newly synthesized collagen XXIII either is cleaved inside the Golgi/trans-Golgi network or reaches the cell surface, where it becomes protected from processing by being localized in lipid rafts. These mechanisms allow the cell to regulate the amounts of cell surface-bound and secreted collagen XXIII.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Univ Cologne, Inst Pathol, D-50924 Cologne, Germany; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA	University of Cologne; University of Cologne; University of Cologne; University of Freiburg; University of Cologne; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Koch, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmannstr 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Koch, Manuel/AAG-9914-2021; Veit, Guido/C-9596-2009	Koch, Manuel/0000-0002-2962-7814; Veit, Guido/0000-0002-6758-2696	NEI NIH HHS [R01 EY009056, EY 09056] Funding Source: Medline; NIEHS NIH HHS [ES 05022] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Elomaa O, 2001, HUM MOL GENET, V10, P953, DOI 10.1093/hmg/10.9.953; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; HURTLEY SM, 1992, TRENDS BIOCHEM SCI, V17, P325, DOI 10.1016/0968-0004(92)90303-Q; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Koch M, 2006, J BIOL CHEM, V281, P21546, DOI 10.1074/jbc.M604131200; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Mayer G, 2004, J HISTOCHEM CYTOCHEM, V52, P567, DOI 10.1177/002215540405200502; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schneider P, 2001, J BIOL CHEM, V276, P18819, DOI 10.1074/jbc.M101280200; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Vaisanen T, 2006, J BIOL CHEM, V281, P33352, DOI 10.1074/jbc.M605896200; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921; Zimina EP, 2005, J BIOL CHEM, V280, P34019, DOI 10.1074/jbc.M503751200	48	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27424	27435		10.1074/jbc.M703425200	http://dx.doi.org/10.1074/jbc.M703425200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627939	hybrid			2022-12-27	WOS:000249304900084
J	Ha, SD; Ng, D; Lamothe, J; Valvano, MA; Han, JH; Kim, SO				Ha, Soon-Duck; Ng, Dennis; Lamothe, Julie; Valvano, Miguel A.; Han, Jiahuai; Kim, Sung Ouk			Mitochondrial proteins bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BACILLUS-ANTHRACIS; MESSENGER-RNA; INHALATIONAL ANTHRAX; MURINE MACROPHAGES; KINASE-KINASE; HOST RESPONSE; TNF-ALPHA; SUSCEPTIBILITY; SPORES	Anthrax lethal toxin (LeTx) induces rapid cell death of RAW246.7 macrophages. We recently found that a small population of these macrophages is spontaneously and temporally refractory to LeTx-induced cytotoxicity. Analysis of genomewide transcripts of a resistant clone before and after regaining LeTx sensitivity revealed that a reduction of two closely related mitochondrial proteins, Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3) and Bnip3-like (Bnip3L), correlates with LeTx resistance. Down-regulation of Bnip3 and Bnip3L was also found in "toxin-induced resistance" whereby sublethal doses of LeTx induce resistance to subsequent exposure to cytolytic toxin doses. The role of Bnip3 and Bnip3L in LeTx-induced cell death was confirmed by showing that overexpression of either Bnip3 or Bnip3L rendered the resistant cells susceptible to LeTx, whereas down-regulation of Bnip3 and Bnip3L in wildtype macrophages conferred resistance. The down-regulation of Bnip3 and Bnip3L mRNAs by LeTx occurred at both transcriptional and mRNA stability levels. Inhibition of the p38 pathway by lethal factor was responsible for the destabilization of Bnip3/Bnip3L mRNAs as confirmed by showing that p38 inhibitors stabilized Bnip3 and Bnip3L mRNAs and conferred resistance to LeTx cytotoxicity. Therefore, Bnip3/Bnip3L play a crucial role in LeTx-induced cytotoxicity, and down-regulation of Bnip3/Bnip3L is a mechanism of spontaneous or toxin-induced resistance of macrophages.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada; Univ Western Ontario, Infect Dis Res Grp, Siebens Drake Res Inst, London, ON N6G 2V4, Canada; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Scripps Research Institute	Kim, SO (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada.	sung.kim@schulich.uwo.ca	Kim, Sung Ouk/AAO-1795-2020; Han, J/G-4671-2010; KIM, Sung Ouk/A-1309-2008; Valvano, Miguel A/G-8759-2012	Kim, Sung Ouk/0000-0002-0282-6661; Valvano, Miguel A/0000-0001-8229-3641				ALBRINK WS, 1959, AM J PATHOL, V35, P1055; Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200; Baldari CT, 2006, TRENDS IMMUNOL, V27, P434, DOI 10.1016/j.it.2006.07.002; Batty S, 2006, CELL MICROBIOL, V8, P130, DOI 10.1111/j.1462-5822.2005.00606.x; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Brittingham KC, 2005, J IMMUNOL, V174, P5545, DOI 10.4049/jimmunol.174.9.5545; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cordoba-Rodriguez R, 2004, J BIOL CHEM, V279, P20563, DOI 10.1074/jbc.C300539200; Cote CK, 2006, INFECT IMMUN, V74, P469, DOI 10.1128/IAI.74.1.469-480.2006; Cote CK, 2004, MICROB PATHOGENESIS, V37, P169, DOI 10.1016/j.micpath.2004.06.013; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Firoved AM, 2005, AM J PATHOL, V167, P1309, DOI 10.1016/S0002-9440(10)61218-7; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Fukao T, 2004, LANCET INFECT DIS, V4, P166, DOI 10.1016/S1473-3099(04)00940-5; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Gutting BW, 2005, TOXICOL IN VITRO, V19, P221, DOI 10.1016/j.tiv.2004.08.007; Hanna P, 1999, J APPL MICROBIOL, V87, P285, DOI 10.1046/j.1365-2672.1999.00891.x; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HANNA PC, 1994, MOL MED, V1, P7; Hu HJ, 2006, CELL MICROBIOL, V8, P1634, DOI 10.1111/j.1462-5822.2006.00738.x; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kassam A, 2005, CELL MICROBIOL, V7, P281, DOI 10.1111/j.1462-5822.2004.00458.x; Khabar KSA, 2005, J INTERF CYTOK RES, V25, P1, DOI 10.1089/jir.2005.25.1; Kim SO, 2003, J BIOL CHEM, V278, P7413, DOI 10.1074/jbc.M209279200; Kim SO, 2006, CELL MICROBIOL, V8, P1958, DOI 10.1111/j.1462-5822.2006.00763.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; McAllister RD, 2003, AM J PATHOL, V163, P1735, DOI 10.1016/S0002-9440(10)63532-8; Moayeri M, 2004, INFECT IMMUN, V72, P4439, DOI 10.1128/IAI.72.8.4439-4447.2004; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Muehlbauer SM, 2007, CELL CYCLE, V6, P758, DOI 10.4161/cc.6.6.3991; Pandey J, 2004, MICROBES INFECT, V6, P835, DOI 10.1016/j.micinf.2004.04.013; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Popov SG, 2002, BIOCHEM BIOPH RES CO, V293, P349, DOI 10.1016/S0006-291X(02)00227-9; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Salles II, 2003, P NATL ACAD SCI USA, V100, P12426, DOI 10.1073/pnas.2134042100; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Shin S, 2000, CELL BIOL TOXICOL, V16, P137, DOI 10.1023/A:1007646227674; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Tang GQ, 1999, INFECT IMMUN, V67, P3055, DOI 10.1128/IAI.67.6.3055-3060.1999; Tournier JN, 2007, CELL MICROBIOL, V9, P555, DOI 10.1111/j.1462-5822.2006.00866.x; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Watters JW, 2001, CURR BIOL, V11, P1503, DOI 10.1016/S0960-9822(01)00476-6; WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200	61	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26275	26283		10.1074/jbc.M703668200	http://dx.doi.org/10.1074/jbc.M703668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623653	hybrid			2022-12-27	WOS:000249239600032
J	Yoon, S; Lee, MY; Park, SW; Moon, JS; Koh, YK; Ahn, YH; Park, BW; Kim, KS				Yoon, Sarah; Lee, Min-Young; Park, Sahng Wook; Moon, Jong-Seok; Koh, Yoo-Kyung; Ahn, Yong-Ho; Park, Byeong-Woo; Kim, Kyung-Sup			Up-regulation of Acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NEOPLASTIC TRANSFORMATION; ANTIBIOTIC CERULENIN; ACTIVATION; INHIBITION; PROTEIN; EXPRESSION; ONCOGENE; ERBB2; PATHWAY	Expression of the HER2 oncogene is increased in similar to 30% of human breast carcinomas and is closely correlated with the expression of fatty acid synthase ( FASN). In the present study, we determined the mechanism by which FASN and acetyl-CoA carboxylase alpha(ACC alpha) could be induced by HER2 overexpression. SK-BR-3 and BT-474 cells, breast cancer cells that overexpress HER2, expressed higher levels of FASN and ACC alpha compared with MCF-7 and MDA-MB-231 breast cancer cells in which HER2 expression is low. The induction of FASN and ACC alpha in BT474 cells were not mediated by the activation of SREBP-1. Exogenous HER2 expression in MDA-MB-231 cells induced the expression of FASN and ACC alpha, and the HER2- mediated increase in ACC alpha and FASN was inhibited by both LY294002, a phosphatidylinositol 3-kinase inhibitor, and rapamycin, a mammalian target of rapamycin ( mTOR) inhibitor. In addition, the activation of mTOR by the overexpression of RHEB in MDA-MB-231 cells increased the synthetic rates of both FASN and ACC alpha. On the other hand, FASN and ACC alpha were reduced in BT-474 cells by a blockade of the mTOR signaling pathway. These changes observed in their protein levels were not accompanied by changes in their mRNA levels. The 5' -and 3'-untranslated regions of both FASN and ACC alpha mRNAs were involved in selective translational induction that was mediated by mTOR signal transduction. These results strongly suggest that the major mechanism of HER2- mediated induction of FASN and ACC alpha in the breast cancer cells used in this study is translational regulation primarily through the mTOR signaling pathway.	Ctr Chron Metab Dis Res, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System	Kim, KS (corresponding author), Ctr Chron Metab Dis Res, Inst Genet Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project Med Sci, Seoul, South Korea.	kyungsup59@yumc.yonsei.ac.kr	AHN, Yong Ho/H-6712-2017	AHN, Yong Ho/0000-0002-4133-0757; Park, Sahng Wook/0000-0002-9594-7074; Park, Byeong-Woo/0000-0003-1353-2607				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Dendukuri N, 2007, CAN MED ASSOC J, V176, P1429, DOI 10.1503/cmaj.061011; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405; Johnston SRD, 2005, CLIN CANCER RES, V11, p889S; Jordan NJ, 2004, BREAST CANCER RES TR, V87, P167, DOI 10.1023/B:BREA.0000041623.21338.47; Kim Kyung-Sup, 1992, Yonsei Medical Journal, V33, P199; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; KUHAJDA FP, 1989, NEW ENGL J MED, V321, P636, DOI 10.1056/NEJM198909073211003; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; Mao JQ, 2003, P NATL ACAD SCI USA, V100, P7515, DOI 10.1073/pnas.1332670100; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Menendez JA, 2005, INT J CANCER, V115, P19, DOI 10.1002/ijc.20754; Menendez JA, 2005, MED HYPOTHESES, V64, P342, DOI 10.1016/j.mehy.2004.07.022; Menendez JA, 2004, MOL CARCINOGEN, V41, P164, DOI 10.1002/mc.20054; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Menendez JA, 2004, BREAST CANCER RES TR, V84, P183, DOI 10.1023/B:BREA.0000018409.59448.60; Menendez JA, 2004, INT J ONCOL, V24, P591; Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1817; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	55	158	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26122	26131		10.1074/jbc.M702854200	http://dx.doi.org/10.1074/jbc.M702854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17631500	hybrid			2022-12-27	WOS:000249239600015
J	Poncet-Montange, G; Assairi, L; Arold, S; Pochet, S; Labesse, G				Poncet-Montange, Guillaume; Assairi, Liliane; Arold, Stefan; Pochet, Sylvie; Labesse, Gilles			NAD kinases use substrate-assisted catalysis for specific recognition of NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TARGETS; COMPLEX; ENZYME	Here we describe the crystal structures of the NAD kinase (LmNADK1) from Listeria monocytogenes in complex with its substrate NAD, its product NADP, or two synthesized NAD mimics. We identified one of the NAD mimics, di-adenosine diphosphate, as a new substrate for LmNADK1, whereas we showed that the closely related compound di-5'-thioadenosine is a novel non-natural inhibitor for this enzyme. These structures suggest a mechanism involving substrate- assisted catalysis. Indeed, sequence/structure comparison and directed mutagenesis have previously shown that NAD kinases (NADKs) and the distantly related 6-phosphofructokinases share the same catalytically important GGDGT motif. However, in this study we have shown that these enzymes use the central aspartate of this motif differently. Although this acidic residue chelates the catalytic Mg2+ ion in 6-phosphofructokinases, it activates the phospho-acceptor (NAD) in NADKs. Sequence/structure comparisons suggest that the role of this aspartate would be conserved in NADKs and the related sphingosine and diacylglycerol kinases.	Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, F-34090 Montpellier, France; Univ Montpellier 2, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, F-34090 Montpellier, France; INSERM, U554, F-34090 Montpellier, France; Inst Curie, INSERM, U759, F-91405 Orsay, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Labesse, G (corresponding author), Univ Montpellier I, Ctr Biochim Struct, CNRS, UMR Atelier Bio & Chim Informat Struct 5048, 29 Rue Navacelles, F-34090 Montpellier, France.	labesse@cbs.cnrs.fr	Arold, Stefan/T-2612-2019	Labesse, Gilles/0000-0002-6861-3300; Arold, Stefan T/0000-0001-5278-0668; Poncet-Montange, Guillaume/0000-0002-9884-7378				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bakali HMA, 2007, J BIOL CHEM, V282, P19644, DOI 10.1074/jbc.M604852200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Garavaglia S, 2004, J BIOL CHEM, V279, P40980, DOI 10.1074/jbc.M406586200; Garavaglia S, 2003, J BACTERIOL, V185, P4844, DOI 10.1128/JB.185.16.4844-4850.2003; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Grose JH, 2006, P NATL ACAD SCI USA, V103, P7601, DOI 10.1073/pnas.0602494103; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Kawai S, 2001, EUR J BIOCHEM, V268, P4359, DOI 10.1046/j.1432-1327.2001.02358.x; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; Liu JY, 2005, J MOL BIOL, V354, P289, DOI 10.1016/j.jmb.2005.09.026; McCoy AJ, 2004, ACTA CRYSTALLOGR D, V60, P1220, DOI 10.1107/S0907444904009990; MOFFATT JG, 1964, CAN J CHEM, V42, P599, DOI 10.1139/v64-087; Mori S, 2005, BIOCHEM BIOPH RES CO, V327, P500, DOI 10.1016/j.bbrc.2004.11.163; Pignot M, 2000, EUR J ORG CHEM, V2000, P549; Pucci MJ, 2006, BIOCHEM PHARMACOL, V71, P1066, DOI 10.1016/j.bcp.2005.12.004; Raffaelli N, 2004, BIOCHEMISTRY-US, V43, P7610, DOI 10.1021/bi049650w; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zalacain M, 2003, J MOL MICROB BIOTECH, V6, P109, DOI 10.1159/000076741	32	35	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2007	282	47					33925	33934		10.1074/jbc.M701394200	http://dx.doi.org/10.1074/jbc.M701394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234FI	17686780	hybrid, Green Published			2022-12-27	WOS:000251145700005
J	Yao, D; Taguchi, T; Matsumura, T; Pestell, R; Edelstein, D; Giardino, I; Suske, G; Rabbani, N; Thornalley, PJ; Sarthy, VP; Hammes, HP; Brownlee, M				Yao, Dachun; Taguchi, Tetsuya; Matsumura, Takeshi; Pestell, Richard; Edelstein, Diane; Giardino, Ida; Suske, Guntram; Rabbani, Naila; Thornalley, Paul J.; Sarthy, Vijay P.; Hammes, Hans-Peter; Brownlee, Michael			High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 MAJOR PATHWAYS; DIABETIC-RETINOPATHY; HYPERGLYCEMIC DAMAGE; ADVANCED GLYCATION; O-GLYCOSYLATION; GLYOXALASE-I; EXPRESSION; SP1; ACTIVATION; MICE	Methylglyoxal is a highly reactive dicarbonyl degradation product formed from triose phosphates during glycolysis. Methylglyoxal forms stable adducts primarily with arginine residues of intracellular proteins. The biologic role of this covalent modification in regulating cell function is not known. Here we report that in mouse kidney endothelial cells, high glucose causes increased methylglyoxal modification of the corepressor mSin3A. Methylglyoxal modification of mSin3A results in increased recruitment of O-GlcNAc-transferase, with consequent increased modification of Sp3 by O-linked N-acetylglucosamine. This modification of Sp3 causes decreased binding to a glucose-responsive GC-box in the angiopoietin-2 (Ang-2) promoter, resulting in increased Ang-2 expression. Increased Ang-2 expression induced by high glucose increased expression of intracellular adhesion molecule 1 and vascular cell adhesion molecule 1 in cells and in kidneys from diabetic mice and sensitized microvascular endothelial cells to the proinflammatory effects of tumor necrosis factor alpha. This novel mechanism for regulating gene expression may play a role in the pathobiology of diabetic vascular disease.	Albert Einstein Coll Med, Juvenile Diabet Res Fdn Int Ctr Diabet Complicat, Bronx, NY 10461 USA; Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Foggia, Dept Biomed Sci, I-71100 Foggia, Italy; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Warwick, Clin Sci Res Inst, Syst Biol Ctr, Coventry CV2 2DX, W Midlands, England; Univ Warwick, Warwick Med Sch, Prot Damage & Syst Biol Res Grp, Coventry CV2 2DX, W Midlands, England; Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60093 USA; Univ Heidelberg, D-68167 Mannheim, Germany	Yeshiva University; Albert Einstein College of Medicine; Jefferson University; University of Foggia; Philipps University Marburg; University of Warwick; University of Warwick; Northwestern University; Feinberg School of Medicine; Ruprecht Karls University Heidelberg	Brownlee, M (corresponding author), Albert Einstein Coll Med, Juvenile Diabet Res Fdn Int Ctr Diabet Complicat, Bronx, NY 10461 USA.	brownlee@aecom.yu.edu	Hammes, Hans-Peter/S-3719-2019	Suske, Guntram/0000-0002-4807-0513; Thornalley, Paul/0000-0001-7659-443X; Rabbani, Naila/0000-0002-5819-2506				Ahmed N, 2003, BIOCHEM SOC T, V31, P1417; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chakraborty S, 2001, J CELL BIOCHEM, V82, P310, DOI 10.1002/jcb.1165; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Chow FY, 2005, J AM SOC NEPHROL, V16, P1711, DOI 10.1681/ASN.2004070612; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Fingerman IM, 2004, CELL, V117, P690, DOI 10.1016/j.cell.2004.05.021; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Karachalias N, 2003, BIOCHEM SOC T, V31, P1423; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Langley RR, 2003, CANCER RES, V63, P2971; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Navarro JF, 2006, AM J NEPHROL, V26, P562, DOI 10.1159/000098004; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; Rizkalla B, 2005, J HYPERTENS, V23, P153, DOI 10.1097/00004872-200501000-00026; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212; Singh AK, 2004, LAB INVEST, V84, P597, DOI 10.1038/labinvest.3700082; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Van Herreweghe F, 2002, P NATL ACAD SCI USA, V99, P949, DOI 10.1073/pnas.012432399; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yuan HT, 2002, KIDNEY INT, V61, P2078, DOI 10.1046/j.1523-1755.2002.00381.x	35	175	192	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					31038	31045		10.1074/jbc.M704703200	http://dx.doi.org/10.1074/jbc.M704703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17670746	hybrid			2022-12-27	WOS:000250136300071
J	Chen, J; He, R; Minshall, RD; Dinauer, MC; Ye, RD				Chen, Jia; He, Rong; Minshall, Richard D.; Dinauer, Mary C.; Ye, Richard D.			Characterization of a mutation in the Phox homology domain of the NADPH oxidase component p40(phox) identifies a mechanism for negative regulation of superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; LEUKEMIA CELL-LINE; PX DOMAIN; CYTOSOLIC COMPONENT; PROTEIN P40(PHOX); HUMAN NEUTROPHILS; MEMBRANE-BINDING; SH3 DOMAIN; ACTIVATION	The phagocyte oxidase (Phox) protein p40(phox) contains a Phox homology (PX) domain which, when expressed alone, interacts with phosphatidylinositol 3-phosphate (PtdIns ( 3) P). The functions of the PXdomain in p40(phox) localization, association with the cytoskeleton, and superoxide production were examined in transgenic COS-7 cells expressing gp91(phox), p22(phox), p67(phox), and p47(phox) (COSphox cells). Full-length p40(phox) exhibited a cytoplasmic localization pattern in resting cells. Upon stimulation with phorbol 12-myristate 13-acetate or fMet-Leu-Phe, p40(phox) translocated to plasma membrane in a p67(phox)- and p47(phox)-dependent manner. Heterologous expression of p40(phox) markedly enhanced superoxide production in phorbol 12-myristate 13-acetate - and fMet-Leu-Phe- stimulated COSphox cells. Unexpectedly, mutation of Arg-57 in the PX domain to Gln, which abrogated PtdIns (3) P binding, produced a dominant inhibitory effect on agonist-induced superoxide production and membrane translocation of p47(phox) and p67(phox). The mutant p40(phox) (p40R57Q) displayed increased association with actin and moesin and was found enriched in the Triton X-100-insoluble fraction along with p67(phox) and p47(phox). The enhanced cytoskeleton association of p67(phox) and p47(phox) and the dominant inhibitory effect produced by the p40R57Q were alleviated when a second mutation at Asp-289, which eliminated p40(phox) interaction with p67(phox), was introduced. Likewise, cytochalasin B treatment abolished the dominant inhibitory effect of p40R57Q on superoxide production. These findings suggest a dual regulatory mechanism through the PX domain of p40(phox); its interaction with the actin cytoskeleton may stabilize NADPH oxidase in resting cells, and its binding of PtdIns (3) P potentiates superoxide production upon agonist stimulation. Both functions require the association of p40(phox) with p67(phox).	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46020 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MC868, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, P01HL077806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033503, R56AI033503] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL045635, HL077806] Funding Source: Medline; NIAID NIH HHS [AI033503] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bouin AP, 1998, J BIOL CHEM, V273, P30097, DOI 10.1074/jbc.273.46.30097; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Ellson C, 2006, EMBO J, V25, P4468, DOI 10.1038/sj.emboj.7601346; Ellson CD, 2006, J EXP MED, V203, P1927, DOI 10.1084/jem.20052069; Grogan A, 1997, J CELL SCI, V110, P3071; He R, 2004, J IMMUNOL, V173, P7462, DOI 10.4049/jimmunol.173.12.7462; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Honbou K, 2007, EMBO J, V26, P1176, DOI 10.1038/sj.emboj.7601561; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Lopes LR, 2004, BIOCHEMISTRY-US, V43, P3723, DOI 10.1021/bi035636s; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; Someya A, 1999, J LEUKOCYTE BIOL, V66, P851, DOI 10.1002/jlb.66.5.851; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Suh CI, 2006, J EXP MED, V203, P1915, DOI 10.1084/jem.20052085; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; TUCKER KA, 1987, BLOOD, V70, P372; Ueyama T, 2007, MOL BIOL CELL, V18, P441, DOI 10.1091/mbc.E06-08-0731; Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Zhan Y, 2004, J CELL BIOCHEM, V92, P795, DOI 10.1002/jcb.20084; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	44	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30273	30284		10.1074/jbc.M704416200	http://dx.doi.org/10.1074/jbc.M704416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17698849	hybrid			2022-12-27	WOS:000249981200058
J	Accordi, B; Pillozzi, S; Dell'Orto, MC; Cazzaniga, G; Arcangeli, A; Kronnie, GT; Basso, G				Accordi, Benedetta; Pillozzi, Serena; Dell'Orto, Marta Campo; Cazzaniga, Giovanni; Arcangeli, Annarosa; Kronnie, Geertruy te; Basso, Giuseppe			Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD95 APO-1/FAS SYSTEM; SCATTER FACTOR; IN-VITRO; TYROSINE KINASE; TEL/AML1 FUSION; CELL-LINES; CARCINOMA CELLS; FACTOR HGF/SF; EXPRESSION; INVOLVEMENT	Expression of c-MET, the HGF (hepatocyte growth factor) tyrosine kinase receptor, was investigated in pediatric B-acute lymphoblastic leukemia (ALL) patients. c-MET was found to be expressed in normal B cells and in B-ALL patients with the t(12; 21) TEL-AML1 translocation, but it is not expressed in the most part of B-ALL without the t(12; 21). We also found that c-MET, related to proliferation and protection from apoptosis, is associated with the pro-apoptotic protein FAS in TEL-AML1 B-ALL cells and in normal B lymphocytes. The possible role of this protein complex in drug-induced apoptosis was thus investigated in REH TEL-AML1 B-ALL cell line. REH cells prestimulated with HGF and treated with doxorubicin had shown a higher apoptotic rate than non-HGF-prestimulated ones (p = 0.03). REH cells stimulated with IL-3 and treated with doxorubicin did not undergo apoptosis more than nonstimulated cells, demonstrating that increased proliferation in itself is not directly related to the higher apoptotic sensitivity observed with HGF stimulation. These results indicate that c-MET activation enhances specifically FAS-mediated apoptosis in TEL-AML1 ALL cells and, considering that the c-MET/FAS complex is present only in normal B lymphocytes and in TEL-AML1 leukemias, this implies that it may have an important contribution in cellular homeostasis and in high sensitivity of TEL-AML1 ALL to chemotherapeutic regimens.				benedetta.accordi@unipd.it	pillozzi, serena/K-5876-2016; Kronnie, Geertruy te/L-1014-2016; Cazzaniga, Giovanni/K-6338-2016	pillozzi, serena/0000-0001-8861-8718; /0000-0001-5636-1006; te Kronnie, Geertruy/0000-0001-7143-4795; BASSO, GIUSEPPE/0000-0002-2634-9302; Cazzaniga, Giovanni/0000-0003-2955-4528				Askenasy N, 2005, BLOOD, V105, P1396, DOI 10.1182/blood-2004-06-2364; Basso G, 2001, HAEMATOLOGICA, V86, P675; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Borset M, 1999, LEUKEMIA LYMPHOMA, V32, P249, DOI 10.3109/10428199909167385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Frost BM, 2004, BLOOD, V104, P2452, DOI 10.1182/blood-2003-12-4426; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1997, CANCER RES, V57, P3823; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; Karawajew L, 1997, LEUKEMIA, V11, P1245, DOI 10.1038/sj.leu.2400746; Kim WH, 2005, AM J PATHOL, V166, P1017, DOI 10.1016/S0002-9440(10)62323-1; Loh ML, 2006, BLOOD, V107, P4508, DOI 10.1182/blood-2005-08-3451; Loh ML, 1998, BLOOD, V92, P4792, DOI 10.1182/blood.V92.12.4792.424k30_4792_4797; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; McHale CM, 2004, AM J HEMATOL, V75, P254, DOI 10.1002/ajh.20030; Mitsiades N, 2001, CANCER RES, V61, P577; Nakamura M, 2007, J HEPATOL, V46, P77, DOI 10.1016/j.jhep.2006.07.032; Pons E, 1998, LEUKEMIA RES, V22, P797, DOI 10.1016/S0145-2126(98)00071-X; Posovszky C, 1999, LEUKEMIA, V13, P400, DOI 10.1038/sj.leu.2401327; Ramakers-van Woerden NL, 2000, BLOOD, V96, P1094; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Ravindranath Y, 2003, CURR OPIN ONCOL, V15, P23, DOI 10.1097/00001622-200301000-00004; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Ronen D, 1999, CELL GROWTH DIFFER, V10, P131; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Sakata S, 2003, CELL DEATH DIFFER, V10, P676, DOI 10.1038/sj.cdd.4401215; Shen K, 1997, BIOCHEM BIOPH RES CO, V230, P89, DOI 10.1006/bbrc.1996.5896; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; To C, 2002, EXP CELL RES, V273, P45, DOI 10.1006/excr.2001.5433; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Weimar IS, 1998, EXP HEMATOL, V26, P885; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080; Wuchter C, 2000, BRIT J HAEMATOL, V110, P154, DOI 10.1046/j.1365-2141.2000.02147.x	48	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29384	29393		10.1074/jbc.M706314200	http://dx.doi.org/10.1074/jbc.M706314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17673463	hybrid			2022-12-27	WOS:000249788000035
J	Fujiwara, H; Hayashi, Y; Sanzen, N; Kobayashi, R; Weber, CN; Emoto, T; Futaki, S; Niwa, H; Murray, P; Edgar, D; Sekiguchi, K				Fujiwara, Hironobu; Hayashi, Yoshitaka; Sanzen, Noriko; Kobayashi, Reiko; Weber, Charles N.; Emoto, Tomomi; Futaki, Sugiko; Niwa, Hitoshi; Murray, Patricia; Edgar, David; Sekiguchi, Kiyotoshi			Regulation of mesodermal differentiation of mouse embryonic stem cells by basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN-4; LAMININ ALPHA-5; EPITHELIOMESENCHYMAL TRANSFORMATION; ENDODERM DIFFERENTIATION; MATRIX; CANCER; DYSTROGLYCAN; EPITHELIUM; SURVIVAL; ABSENCE	Basement membranes (BMs) have been implicated in cell fate determination during development. Embryoid bodies (EBs) derived from mouse embryonic stem cells deficient in the laminin gamma 1 chain are incapable of depositing a BM, resulting in failure of primitive ectoderm epithelialization. To elucidate the mechanisms involved in this phenomenon, we compared the gene expression profiles of EBs with or without a BM to identify the genes showing BM-dependent expression. We found that the expressions of marker genes for the epithelial-mesenchymal transition (EMT), including the transcription factor Snai2, were up-regulated in LAMC1(-/-) EBs, whereas restoration of a BM to LAMC1(-/-) EBs suppressed the up-regulation of these genes. Overexpression of Snai2 induced the EMT in control EBs by molecular and morphological criteria, suggesting that suppression of the EMT regulatory genes is involved in BM-dependent epithelialization of primitive ectoderm. Despite the failure of primitive ectoderm epithelialization in BM-deficient EBs, mesodermal differentiation was not compromised, but rather accelerated. Furthermore, at later stages of control EB differentiation, the BM was disrupted at the gastrulation site where mesodermal markers were strongly expressed only in cells that had lost contact with the BM. Taken together, these results indicate that the BM prevents the EMT and precocious differentiation of primitive ectoderm toward mesoderm in EBs, implying that BMs are important for the control of mammalian gastrulation.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Aichi Med Univ, ERATO, Japan Sci & Technol Agcy, Sekiguchi Biomatrix Signaling Project, Aichi 4801195, Japan; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Sch Biomed Sci, Liverpool L69 3GE, Merseyside, England	Osaka University; Aichi Medical University; Japan Science & Technology Agency (JST); University of Liverpool; University of Liverpool	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hayashiy@riem.nagoya-u.ac.jp; sekiguch@protein.osaka-u.ac.jp	Fujiwara, Hironobu/A-5971-2016; Hayashi, Yoshitaka/I-6168-2014	Fujiwara, Hironobu/0000-0003-0883-3384; Hayashi, Yoshitaka/0000-0002-7557-4303; Murray, Patricia/0000-0003-1316-148X; Sanzen, Noriko/0000-0001-6518-403X	Medical Research Council [G0300296] Funding Source: Medline; MRC [G0300296] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005; Bajanca F, 2006, DEVELOPMENT, V133, P1635, DOI 10.1242/dev.02336; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Blaess S, 2004, J NEUROSCI, V24, P3402, DOI 10.1523/JNEUROSCI.5241-03.2004; BOUCAUT JC, 1984, NATURE, V307, P364, DOI 10.1038/307364a0; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; De Arcangelis A, 1999, DEVELOPMENT, V126, P3957; Duband JL, 1995, ACTA ANAT, V154, P63; Fukumoto S, 2006, J BIOL CHEM, V281, P5008, DOI 10.1074/jbc.M509295200; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Greenlee AR, 2005, TOXICOL IN VITRO, V19, P389, DOI 10.1016/j.tiv.2004.11.002; Gustafsson E, 2000, EXP CELL RES, V261, P52, DOI 10.1006/excr.2000.5042; HAUB O, 1991, DEVELOPMENT, V112, P397; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1991, CELL BIOL EXTRACELLU, P1; Hayashi Y, 2004, MATRIX BIOL, V23, P47, DOI 10.1016/j.matbio.2004.02.003; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; JONES CM, 1991, DEVELOPMENT, V111, P531; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Murray P, 2004, PHILOS T R SOC B, V359, P1009, DOI 10.1098/rstb.2003.1460; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; NADIJCKA M, 1974, J EMBRYOL EXP MORPH, V32, P675; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Verrou C, 1999, BIOL CHEM, V380, P1435, DOI 10.1515/BC.1999.184; Viebahn C, 1995, ACTA ANAT, V154, P79; Viebahn C, 1995, ACTA ANAT, V154, P99; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	50	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29701	29711		10.1074/jbc.M611452200	http://dx.doi.org/10.1074/jbc.M611452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17690109	hybrid, Green Published			2022-12-27	WOS:000249788000066
J	Jiang, L; Crews, ST				Jiang, Lan; Crews, Stephen T.			Transcriptional specificity of drosophila dysfusion and the control of tracheal fusion cell gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH-PAS PROTEIN; DNA-BINDING; DIOXIN RECEPTOR; SPINELESS; DOMAIN; EMBRYOGENESIS; LOCALIZATION; ADHESION; NEURONS; TISSUES	The Drosophila Dysfusion basic-helix-loop-helix-PAS ( bHLH-PAS) protein controls the transcription of genes that mediate tracheal fusion. Dysfusion is highly related to the mammalian Nxf protein that has been implicated in nervous system gene regulation. Toward the goal of understanding how Dysfusion controls fusion cell gene expression, the biochemical properties of Dysfusion were investigated using protein interaction experiments, cell culture-based transcription assays, and in vivo transgenic analyses. Dysfusion dimerizes with the Tango bHLH-PAS protein, and together they act as a DNA binding transcriptional activator. Dysfusion/Tango binds multiple NCGTG binding sites, with the following preference: TCGTG > GCGTG > ACGTG > CCGTG. This binding site promiscuity differs from the restricted binding site preferences of other bHLH-PAS/Tango heterodimers. However, it is identical to the binding site preferences of mammalian Nxf/Arnt, indicating that the specificity is evolutionarily conserved. Germ line transformation experiments using a fragment of the CG13196 Dysfusion target gene allowed identification of a fusion cell enhancer. Experiments in which NCGTG sites were mutated individually and in combination revealed that TCGTG sites were required for fusion cell expression but that the single ACGTG and GCGTG sites present were not. Finally, a reporter transgene containing four tandemly arranged TCGTG elements has strong expression in tracheal fusion cells. Transgenic misexpression of dysfusion further revealed that Dysfusion has the ability to activate transcription in multiple cell types, although it does this most effectively in tracheal cells and can only function at mid-embryogenesis and later.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Crews, ST (corresponding author), Fordham Hall CB 3280, Chapel Hill, NC 27599 USA.	steve_crews@unc.edu		Jiang23, Lan/0000-0002-1845-5500	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR021055] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR021055, S10 RR021055-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Chapman-Smith A, 2006, J BIOL CHEM, V281, P12535, DOI 10.1074/jbc.M512145200; CREWS ST, 2003, PAS PROTEINS REGULAT; Crews ST, 2006, GENE DEV, V20, P2773, DOI 10.1101/gad.1487706; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Emmons RB, 1999, DEVELOPMENT, V126, P3937; Estes P, 2001, DEV BIOL, V232, P157, DOI 10.1006/dbio.2001.0174; Gorr TA, 2006, J INSECT PHYSIOL, V52, P349, DOI 10.1016/j.jinsphys.2006.01.002; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; Hester I, 2007, BRAIN RES, V1135, P1, DOI 10.1016/j.brainres.2006.11.083; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jazwinska A, 2004, GENE EXPR PATTERNS, V4, P413, DOI 10.1016/j.modgep.2004.01.003; Jiang L, 2003, MOL CELL BIOL, V23, P5625, DOI 10.1128/MCB.23.16.5625-5637.2003; Jiang L, 2006, MOL CELL BIOL, V26, P6547, DOI 10.1128/MCB.00284-06; Kim MD, 2006, GENE DEV, V20, P2806, DOI 10.1101/gad.1459706; Kinoshita K, 2004, NUCLEIC ACIDS RES, V32, P3169, DOI 10.1093/nar/gkh637; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Manning Gerards, 1993, P609; Manning L, 1999, DEVELOPMENT, V126, P2063; Moser M, 2004, MOL BRAIN RES, V128, P141, DOI 10.1016/j.molbrainres.2004.06.023; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Ooe N, 2004, MOL CELL BIOL, V24, P608, DOI 10.1128/MCB.24.2.608-616.2004; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Pielage J, 2002, DEV BIOL, V249, P283, DOI 10.1006/dbio.2002.0770; Powell-Coffman JA, 2003, PAS PROTEINS: REGULATORS AND SENSORS OF DEVELOPMENT AND PHYSIOLOGY, P51; Samakovlis C, 1996, DEVELOPMENT, V122, P3531; SONNENFELD M, 1997, DEVELOPMENT, V124, P4583; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; Ward MP, 1998, DEVELOPMENT, V125, P1599; WHARTON JKA, 1994, DEVELOPMENT, V120, P3563; Zelzer E, 2000, MECH DEVELOP, V91, P163, DOI 10.1016/S0925-4773(99)00295-6; Zhu Q, 2007, FLY, V1, P55, DOI 10.4161/fly.3892	33	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28659	28668		10.1074/jbc.M703803200	http://dx.doi.org/10.1074/jbc.M703803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17652079	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000249642100040
J	McNally, DJ; Lamoureux, MP; Karlyshev, AV; Fiori, LM; Li, JJ; Thacker, G; Coleman, RA; Khieu, NH; Wren, BW; Brisson, JR; Jarrell, HC; Szymanski, CM				McNally, David J.; Lamoureux, Marc P.; Karlyshev, Andrey V.; Fiori, Laura M.; Li, Jianjun; Thacker, Gillian; Coleman, Russell A.; Khieu, Nam H.; Wren, Brendan W.; Brisson, Jean-Robert; Jarrell, Harold C.; Szymanski, Christine M.			Commonality and biosynthesis of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; POLYSACCHARIDE; LIPOOLIGOSACCHARIDE; PATHOGEN; LIPOPOLYSACCHARIDES; IDENTIFICATION; SPECTROMETRY; INFECTIONS; SEROSTRAIN; DIVERSITY	In this study we investigated the commonality and biosynthesis of the O-methyl phosphoramidate (MeOPN) group found on the capsular polysaccharide (CPS) of Campylobacter jejuni. High resolution magic angle spinning NMR spectroscopy was used as a rapid, high throughput means to examine multiple isolates, analyze the cecal contents of colonized chickens, and screen a library of CPS mutants for the presence of MeOPN. Sixty eight percent of C. jejuni strains were found to express the MeOPN with a high prevalence among isolates from enteritis, Guillain Barre , and Miller-Fisher syndrome patients. In contrast, MeOPN was not observed for any of the Campylobacter coli strains examined. The MeOPN was detected on C. jejuni retrieved from cecal contents of colonized chickens demonstrating that the modification is expressed by bacteria inhabiting the avian gastrointestinal tract. In C. jejuni 11168H, the cj1415-cj1418 cluster was shown to be involved in the biosynthesis of MeOPN. Genetic complementation studies and NMR/ mass spectrometric analyses of CPS from this strain also revealed that cj1421 and cj1422 encode MeOPN transferases. Cj1421 adds the MeOPN to C-3 of the beta-D-GalfNAc residue, whereas Cj1422 transfers the MeOPN to C-4 of D-glycero-alpha-L-glucoheptopyranose. CPS produced by the 11168H strain was found to be extensively modified with variable MeOPN, methyl, ethanolamine, and N-glycerol groups. These findings establish the importance of the MeOPN as a diagnostic marker and therapeutic target for C. jejuni and set the groundwork for future studies aimed at the detailed elucidation of the MeOPN biosynthetic pathway.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	National Research Council Canada; University of London; London School of Hygiene & Tropical Medicine	Jarrell, HC (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	harold.jarrell@nrc-cnrc.gc.ca; christine.szymanski@nrc-cnrc.gc.ca	Szymanski, Christine/A-3763-2014; Karlyshev, Andrey/D-2797-2011	Szymanski, Christine/0000-0002-8464-1352; Karlyshev, Andrey/0000-0003-3124-019X	Biotechnology and Biological Sciences Research Council [E20372] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahmed IH, 2002, MICROBIOL-SGM, V148, P1203, DOI 10.1099/00221287-148-4-1203; Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760; Altekruse SF, 1999, EMERG INFECT DIS, V5, P28, DOI 10.3201/eid0501.990104; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Champion OL, 2005, P NATL ACAD SCI USA, V102, P16043, DOI 10.1073/pnas.0503252102; Fouts DE, 2005, PLOS BIOL, V3, P72, DOI 10.1371/journal.pbio.0030015; Godschalk PCR, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-32; Gordon RW, 1997, POULTRY SCI, V76, P683, DOI 10.1093/ps/76.5.683; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110; Kanipes MI, 2006, J BACTERIOL, V188, P3273, DOI 10.1128/JB.188.9.3273-3279.2006; Karlyshev AV, 2005, APPL ENVIRON MICROB, V71, P4004, DOI 10.1128/AEM.71.7.4004-4013.2005; Karlyshev AV, 2005, MOL MICROBIOL, V55, P90, DOI 10.1111/j.1365-2958.2004.04374.x; Karlyshev AV, 2000, MOL MICROBIOL, V35, P529, DOI 10.1046/j.1365-2958.2000.01717.x; Li JJ, 2005, RAPID COMMUN MASS SP, V19, P1305, DOI 10.1002/rcm.1927; McKay D, 2001, J CLIN MICROBIOL, V39, P1917, DOI 10.1128/JCM.39.5.1917-1921.2001; McNally DJ, 2006, FEBS J, V273, P3975, DOI 10.1111/j.1742-4658.2006.05401.x; McNally DJ, 2006, CAN J CHEM, V84, P676, DOI 10.1139/V06-028; McNally DJ, 2005, FEBS J, V272, P4407, DOI 10.1111/j.1742-4658.2005.04856.x; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Miller WG, 2005, MICROBIOL-SGM, V151, P337, DOI 10.1099/mic.0.27327-0; MORAN ET, 1980, POULTRY SCI, V59, P1521, DOI 10.3382/ps.0591521; PAOLETTI LC, 1991, J CLIN INVEST, V202, P243; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Penner JL, 1997, J INFECT DIS, V176, pS135, DOI 10.1086/513778; REES JH, 1993, Q J MED, V86, P623, DOI 10.1093/qjmed/86.10.623; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; Rubinstein LJ, 1998, INFECT IMMUN, V66, P5450, DOI 10.1128/IAI.66.11.5450-5456.1998; Serino L, 2002, MOL MICROBIOL, V43, P437, DOI 10.1046/j.1365-2958.2002.02755.x; Silipo A, 2005, J BIOL CHEM, V280, P33660, DOI 10.1074/jbc.M506254200; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; YUKI N, 1995, J NEUROL SCI, V130, P112, DOI 10.1016/0022-510X(95)00045-4	37	75	82	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28566	28576		10.1074/jbc.M704413200	http://dx.doi.org/10.1074/jbc.M704413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17675288	hybrid			2022-12-27	WOS:000249642100031
J	Newbery, HJ; Loh, DH; O'Donoghue, JE; Tomlinson, VAL; Chau, YY; Boyd, JA; Bergmann, JH; Brownstein, D; Abbott, CM				Newbery, H. J.; Loh, D. H.; O'Donoghue, J. E.; Tomlinson, V. A. L.; Chau, Y.-Y.; Boyd, J. A.; Bergmann, J. H.; Brownstein, D.; Abbott, C. M.			Translation elongation factor eEF1A2 is essential for post-weaning survival in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOID-TISSUE INVOLUTION; FACTOR 1-ALPHA; ANIMAL-MODEL; WASTED WST; EXPRESSION; GENE; MOUSE; FACTOR-1-ALPHA; S1; EEF1A-2/S1	Translation elongation factor eEF1A, formerly known as EF-1 alpha, exists as two variant forms; eEF1A1, which is almost ubiquitously expressed, and eEF1A2, whose expression is restricted to muscle and brain at the level of whole tissues. Expression analysis of these genes has been complicated by a general lack of availability of antibodies that specifically recognize each variant form. Wasted mice (wst/wst) have a 15.8-kilo-base deletion that abolishes activity of eEF1A2, but before this study it was unknown whether the deletion also affected neighboring genes. We have generated a panel of anti-peptide antibodies and used them to show that eEF1A2 is expressed at high levels in specific cell types in tissues previously thought not to express this variant, such as pancreatic islet cells and enteroendocrine cells in colon crypts. Expression of eEF1A1 and eEF1A2 is shown to be generally mutually exclusive, and we relate the expression pattern of eEF1A2 to the phenotype seen in wasted mice. We then carried out a series of transgenic experiments to establish whether the expression of other genes is affected by the deletion in wasted mice. We show that aspects of the phenotype such as motor neuron degeneration relate precisely to the relative expression of eEF1A1 and eEF1A2, whereas the immune system abnormalities are likely to result from a stress response. We conclude that loss of eEF1A2 function is solely responsible for the abnormalities seen in these mice.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Queens Med Res Inst, Res Anim Pathol Core Facil, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Abbott, CM (corresponding author), Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	C.Abbott@ed.ac.uk	Abbott, Catherine M/C-7306-2013	O'Donoghue, Jean/0000-0001-6549-3430; Loh, Dawn/0000-0001-7876-5757; Abbott, Catherine/0000-0001-8794-7173				ABBOTT C, 1994, GENOMICS, V20, P94, DOI 10.1006/geno.1994.1131; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BARONE KS, 1993, CELL IMMUNOL, V148, P226, DOI 10.1006/cimm.1993.1105; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; Chang RY, 2007, J CELL BIOCHEM, V100, P267, DOI 10.1002/jcb.20969; Chuang SM, 2005, MOL CELL BIOL, V25, P403, DOI 10.1128/MCB.25.1.403-413.2005; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dominguez-Gerpe L, 1998, MECH AGEING DEV, V104, P195, DOI 10.1016/S0047-6374(98)00070-0; DominguezGerpe L, 1997, LIFE SCI, V61, P1019, DOI 10.1016/S0024-3205(97)00606-1; Fukuzuka K, 2000, AM J PHYSIOL-REG I, V278, pR1005, DOI 10.1152/ajpregu.2000.278.4.R1005; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; HORI T, 1993, CLIN IMMUNOL IMMUNOP, V68, P243, DOI 10.1006/clin.1993.1125; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; Jamsai D, 2003, MOL BIOTECHNOL, V23, P29, DOI 10.1385/MB:23:1:29; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; KAISERLIAN D, 1985, J IMMUNOL, V135, P1126; Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; LEE S, 1995, EXP CELL RES, V219, P589, DOI 10.1006/excr.1995.1268; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE S, 1993, J BIOL CHEM, V268, P24453; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lund A, 1996, GENOMICS, V36, P359, DOI 10.1006/geno.1996.0475; LUTSEP HL, 1989, J NEUROPATH EXP NEUR, V48, P519, DOI 10.1097/00005072-198909000-00003; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Nakamura M, 1998, RECEPTOR CHANNEL, V5, P255; Newbery HJ, 2005, J NEUROPATH EXP NEUR, V64, P295, DOI 10.1093/jnen/64.4.295; OXFORD M, 2000, NUCLEIC ACIDS RES, V28, pE84; Pan J, 2004, DEV BRAIN RES, V149, P1, DOI 10.1016/j.devbrainres.2003.10.011; Potter M, 1998, CELL IMMUNOL, V188, P111, DOI 10.1006/cimm.1998.1346; Pruett SB, 2000, BRAIN BEHAV IMMUN, V14, P270, DOI 10.1006/brbi.2000.0605; Rotimi CN, 2004, DIABETES, V53, P838, DOI 10.2337/diabetes.53.3.838; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; SHULTZ LD, 1982, NATURE, V297, P402, DOI 10.1038/297402a0; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; TEZUKA H, 1986, MUTAT RES, V161, P83, DOI 10.1016/0027-5107(86)90102-8; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Watanabe H, 2000, J NEUROCHEM, V75, P28, DOI 10.1046/j.1471-4159.2000.0750028.x	44	50	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28951	28959		10.1074/jbc.M703962200	http://dx.doi.org/10.1074/jbc.M703962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640869	hybrid			2022-12-27	WOS:000249642100069
J	Magnani, R; Nayak, NR; Mazarei, M; Dirk, LMA; Houtz, RL				Magnani, Roberta; Nayak, Nihar R.; Mazarei, Mitra; Dirk, Lynnette M. A.; Houtz, Robert L.			Polypeptide substrate specificity of PsLSMT - A set domain protein methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; GAMMA-TOCOPHEROL METHYLTRANSFERASE; LARGE SUBUNIT; P53 ACTIVITY; PURIFICATION; METHYLATION; GENE; EXPRESSION; MECHANISM; CHROMATOGRAPHY	Rubisco large subunit methyltransferase (PsLSMT) is a SET domain protein responsible for the trimethylation of Lys-14 in the large subunit of Rubisco. The polypeptide substrate specificity determinants for pea Rubisco large subunit methyltransferase were investigated using a fusion protein construct between the first 23 amino acids from the large subunit of Rubisco and human carbonic anhydrase II. A total of 40 conservative and non-conservative amino acid substitutions flanking the target Lys-14 methylation site (positions P-3 to P+3) were engineered in the fusion protein. The catalytic efficiency (k(cat)/ K-m) of PsLSMT was determined using each of the substitutions and a polypeptide consensus recognition sequence deduced from the results. The consensus sequence, represented by X-(Gly/Ser)-(Phe/Tyr)-Lys-(Ala/Lys/Arg)-(Gly/Ser)-pi, where X is any residue, Lys is the methylation site, and pi is any aromatic or hydrophobic residue, was used to predict potential alternative substrates for PsLSMT. Four chloroplast-localized proteins were identified including gamma-tocopherol methyltransferase (gamma-TMT). In vitro methylation assays using PsLSMT and a bacterially expressed form of gamma-TMT from Perilla frutescens confirmed recognition and methylation of gamma-TMT by PsLSMT in vitro. RNA interference-mediated knockdown of the PsLSMT homologue (NtLSMT) in transgenic tobacco plants resulted in a 2-fold decrease of alpha-tocopherol, the product of gamma-TMT. The results demonstrate the efficacy of consensus sequence-driven identification of alternative substrates for PsLSMT as well as identification of functional attributes of protein methylation catalyzed by LSMT.	Univ Kentucky, Dept Hort Plant Physiol Biochem, Program Mol Biol, Lexington, KY 40546 USA; Univ Tennessee, Dept Plant Sci, Knoxville, TN 37996 USA	University of Kentucky; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Houtz, RL (corresponding author), Univ Kentucky, Dept Hort Plant Physiol Biochem, Program Mol Biol, 401D Plant Sci Bldg, Lexington, KY 40546 USA.	rhoutz@uky.edu		Mazarei, Mitra/0000-0002-6116-7758				Banerjee AL, 2004, PROTEIN EXPRES PURIF, V37, P450, DOI 10.1016/j.pep.2004.06.031; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Collazo E, 2005, ANAL BIOCHEM, V342, P86, DOI 10.1016/j.ab.2005.04.007; Couture JF, 2006, CURR OPIN STRUC BIOL, V16, P753, DOI 10.1016/j.sbi.2006.10.002; Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P140, DOI 10.1038/nsmb1045; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; DellaPenna D, 2005, J PLANT PHYSIOL, V162, P729, DOI 10.1016/j.jplph.2005.04.004; Dirk LMA, 2007, BIOCHEMISTRY-US, V46, P3905, DOI 10.1021/bi6023644; Dirk LMA, 2006, ENZYMES, V24, P179, DOI 10.1016/S1874-6047(06)80009-0; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DURBAN E, 1978, J BIOL CHEM, V253, P1427; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; ISHIKO H, 1992, PHYTOCHEMISTRY, V31, P1499, DOI 10.1016/0031-9422(92)83094-F; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Koch M, 2003, EUR J BIOCHEM, V270, P84, DOI 10.1046/j.1432-1033.2003.03364.x; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; MCCURRY SD, 1982, METHOD ENZYMOL, V90, P515; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Patnaik D, 2004, J BIOL CHEM, V279, P53248, DOI 10.1074/jbc.M409604200; Sanchez-Machado DI, 2006, J CHROMATOGR A, V1105, P111, DOI 10.1016/j.chroma.2005.07.048; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHIGEOKA S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P220, DOI 10.1016/0005-2760(92)90311-I; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; Trievel RC, 2004, CRIT REV EUKAR GENE, V14, P147, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.10; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; WANG P, 1995, PROTEIN EXPRES PURIF, V6, P528, DOI 10.1006/prep.1995.1070; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Xiao B, 2006, ENZYMES, V24, P155, DOI 10.1016/S1874-6047(06)80008-9; Ying ZT, 1996, PLANT MOL BIOL, V32, P663, DOI 10.1007/BF00020207; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27857	27864		10.1074/jbc.M702069200	http://dx.doi.org/10.1074/jbc.M702069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635932	hybrid			2022-12-27	WOS:000249455600034
J	van Wonderen, JH; Knight, C; Oganesyan, VS; George, SJ; Zumft, WG; Cheesman, MR				van Wonderen, Jessica H.; Knight, Christopher; Oganesyan, Vasily S.; George, Simon J.; Zumft, Walter G.; Cheesman, Myles R.			Activation of the cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus - Reaction of oxidized enzyme with substrate drives a ligand switch at heme c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNETIC CIRCULAR-DICHROISM; PSEUDOMONAS-AERUGINOSA; THIOSPHAERA-PANTOTROPHA; THIOBACILLUS-DENITRIFICANS; HORSERADISH-PEROXIDASE; OXIDE REDUCTASE; PURIFICATION; SPECTROSCOPY; EPR	Cytochromes cd(1) are dimeric bacterial nitrite reductases, which contain two hemes per monomer. On reduction of both hemes, the distal ligand of heme d(1) dissociates, creating a vacant coordination site accessible to substrate. Heme c, which transfers electrons from donor proteins into the active site, has histidine/methionine ligainds except in the oxidized enzyme from Paracoccus pantotrophus where both ligands are histidine. During reduction of this enzyme, Tyr(25) dissociates from the distal side of heme d(1), and one heme c ligand is replaced by methionine. Activity is associated with histidine/methionine coordination at heme c, and it is believed that P.pantotrophus cytochrome cd(1) is unreactive toward substrate without reductive activation. However, we report here that the oxidized enzyme will react with nitrite to yield a novel species in which heme d(1) is EPR-silent. Magnetic circular dichroism studies indicate that heme d(1) is low-spin Fell, but EPR-silent as a result of spin coupling to a radical species formed during the reaction with nitrite. This reaction drives the switch to histidine/methionine ligation at Fell, heme c. Thus the enzyme is activated by exposure to its physiological substrate without the necessity of passing through the reduced state. This reactivity toward nitrite is also observed for oxidized cytochrome cd(1) from Pseudomonas stutzeri suggesting a more general involvement of the EPR-silent Fe-III heme d(1) species in nitrite reduction.	Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Ctr Metalloprotein Spectroscopy & Biol, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ Karlsruhe, Inst Appl Biosci, Div Mol Microbiol, D-76128 Karlsruhe, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of East Anglia; University of East Anglia; Helmholtz Association; Karlsruhe Institute of Technology; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cheesman, MR (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England.	m.cheesman@uea.ac.uk	van Wonderen, Jessica/A-9728-2013	George, Simon/0000-0002-4864-5479	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2002, BIOCHEM J, V366, P883, DOI 10.1042/BJ20020795; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BESSON S, 1995, ANAEROBE, V1, P219, DOI 10.1006/anae.1995.1021; Cheesman MR, 1996, J AM CHEM SOC, V118, P7373, DOI 10.1021/ja960344i; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; Cheesman MR, 2004, J AM CHEM SOC, V126, P4157, DOI 10.1021/ja038858m; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; GUDAT JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P376, DOI 10.1016/0005-2728(73)90044-3; HILL KE, 1978, J BIOL CHEM, V253, P489; HOUSEMANN ALP, 1995, BIOCHEMISTRY-US, V32, P4430; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; HUYNH BH, 1982, J BIOL CHEM, V257, P9576; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; LEGALL J, 1979, BIOCHEM BIOPH RES CO, V87, P355, DOI 10.1016/0006-291X(79)91804-7; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; MUHOBERAC BB, 1980, FED PROC, V39, P2061; MUHOBERAC BB, 1983, J BIOL CHEM, V258, P3019; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1998, BIOCHEMISTRY-US, V37, P13987, DOI 10.1021/bi981348y; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; Rinaldo S, 2007, J BIOL CHEM, V282, P14761, DOI 10.1074/jbc.M700933200; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; SAMYN B, 1994, EUR J BIOCHEM, V219, P585, DOI 10.1111/j.1432-1033.1994.tb19974.x; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SILVESTRINI MC, 1979, BIOCHEM J, V183, P701, DOI 10.1042/bj1830701; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1974, BIOCHIM BIOPHYS ACTA, V333, P28, DOI 10.1016/0005-2728(74)90159-5; Sjogren T, 2001, J BIOL CHEM, V276, P29450, DOI 10.1074/jbc.M103657200; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; VICKERY LE, 1978, BIOCHEM BIOPH RES CO, V80, P458, DOI 10.1016/0006-291X(78)90699-X; Walker FA, 1999, COORDIN CHEM REV, V185-6, P471, DOI 10.1016/S0010-8545(99)00029-6; WALSH TA, 1981, J INORG BIOCHEM, V14, P15, DOI 10.1016/S0162-0134(00)80011-2; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WALSH TA, 1981, J INORG BIOCHEM, V14, P1, DOI 10.1016/S0162-0134(00)80010-0; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P394; YAMANAKA T, 1961, BIOCHIM BIOPHYS ACTA, V53, P294, DOI 10.1016/0006-3002(61)90442-5; Zajicek RS, 2006, BIOCHEMISTRY-US, V45, P11208, DOI 10.1021/bi0604983; Zajicek RS, 2005, BIOCHEM SOC T, V33, P147, DOI 10.1042/BST0330147; Zajicek RS, 2004, FEBS LETT, V565, P48, DOI 10.1016/j.febslet.2004.03.072; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	58	15	16	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28207	28215		10.1074/jbc.M701242200	http://dx.doi.org/10.1074/jbc.M701242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623666	hybrid			2022-12-27	WOS:000249455600070
J	Kozlov, G; Peschard, P; Zimmerman, B; Lin, T; Moldoveanu, T; Mansur-Azzam, N; Gehring, K; Park, M				Kozlov, Guennadi; Peschard, Pascal; Zimmerman, Brandon; Lin, Tong; Moldoveanu, Tudor; Mansur-Azzam, Nura; Gehring, Kalle; Park, Morag			Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DOMAIN BINDING-SITE; HIV-1 VPR; RECEPTOR; ADAPTER; COMPLEX; MET; ACTIVATION; REFINEMENT; INTERACTS	Ligand-induced down-regulation by the ubiquitin-protein ligases, c-Cbl and Cbl-b, controls signaling downstream from many receptor-tyrosine kinases (RTK). Cbl proteins bind to phosphotyrosine residues on activated RTKs to affect ligand-dependent ubiquitylation of these receptors targeting them for degradation in the lysosome. Both c-Cbl and Cbl-b contain a ubiquitin-associated (UBA) domain, which is important for Cbl dimerization and tyrosine phosphorylation; however, the mechanism of UBA-mediated dimerization and its requirement for Cbl biological activity is unclear. Here, we report the crystal structure of the UBA domain of c-Cbl refined to 2.1-angstrom resolution. The structure reveals the protein is a symmetric dimer tightly packed along a large hydrophobic surface formed by helices 2 and 3. NMR chemical shift mapping reveals heterodimerization can occur with the related Cbl-b UBA domain via the same surface employed for homodimerization. Disruption of c-Cbl dimerization by site-directed mutagenesis impairs c-Cbl phosphorylation following activation of the Met/hepatocyte growth factor RTK and c-Cbl-dependent ubiquitination of Met. This provides direct evidence for a role of Cbl dimerization in terminating signaling following activation of RTKs.	McGill Univ, Dept Biochem Med, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Mol Oncol Grp, Ctr Hlth, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem Med, Montreal, PQ H3A 2T5, Canada.	kalle.gehring@mcgill.ca; morag.park@mcgill.ca	Moldoveanu, Tudor/N-8173-2018; Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Moldoveanu, Tudor/0000-0003-0791-318X; Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184; Peschard, Pascal/0000-0001-6395-5566	NCRR NIH HHS [RR 01646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bayrer JR, 2005, J BIOL CHEM, V280, P32989, DOI 10.1074/jbc.M507990200; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; BLAKE TJ, 1992, ONCOGENE, V7, P757; Chang YG, 2006, PROTEIN SCI, V15, P1248, DOI 10.1110/ps.051995006; Chim N, 2004, PROTEINS, V54, P784, DOI 10.1002/prot.10636; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hubbard SR, 2002, FRONT BIOSCI, V7, pD330, DOI 10.2741/hubbard; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Lowe ED, 2006, ACTA CRYSTALLOGR D, V62, P177, DOI 10.1107/S0907444905037777; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2007, MOL CELL, V27, P474, DOI 10.1016/j.molcel.2007.06.023; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Sasaki T, 2005, BIOCHEM BIOPH RES CO, V336, P530, DOI 10.1016/j.bbrc.2005.08.126; Schiering N, 2000, BIOCHEMISTRY-US, V39, P13376, DOI 10.1021/bi0012336; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Trempe JF, 2005, EMBO J, V24, P3178, DOI 10.1038/sj.emboj.7600797; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Yuan XM, 2004, EMBO J, V23, P1463, DOI 10.1038/sj.emboj.7600152	40	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27547	27555		10.1074/jbc.M703333200	http://dx.doi.org/10.1074/jbc.M703333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635922	hybrid			2022-12-27	WOS:000249304900095
J	Conchonaud, F; Nicolas, S; Amoureux, MC; Menager, C; Marguet, D; Lenne, PF; Rougon, G; Matarazzo, V				Conchonaud, Fabien; Nicolas, Stephane; Amoureux, Marie-Claude; Menager, Celine; Marguet, Didier; Lenne, Pierre-Francois; Rougon, Genevieve; Matarazzo, Valery			Polysialylation increases lateral diffusion of neural cell adhesion molecule in the cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; LIPID RAFTS; CORRELATION SPECTROSCOPY; PRECURSOR CELLS; NCAM; ORGANIZATION; PLASTICITY; RECEPTOR; GDNF; CYTOSKELETON	Polysialic acid (PSA) is a polymer of N-acetylneuraminic acid residues added post-translationally to the membrane-bound neural cell adhesion molecule ( NCAM). The large excluded volume created by PSA polymer is thought to facilitate cell migration by decreasing cell adhesion. Here we used live cell imaging ( spot fluorescence recovery after photobleaching and fluorescence correlation spectroscopy) combined with biochemical approaches in an attempt to uncover a link between cell motility and the impact of polysialylation on NCAM dynamics. We show that PSA regulates specifically NCAM lateral diffusion and this is dependent on the integrity of the cytoskeleton. However, whereas the glial-derivative neurotrophic factor chemotactic effect is dependent on PSA, the molecular dynamics of PSANCAM is not directly affected by glial-derivative neurotrophic factor. These findings reveal a new intrinsic mechanism by which polysialylation regulates NCAM dynamics and thereby a biological function like cell migration.	IBDML, Parc Sci Luminy, F-13288 Marseille 9, France; Univ Aix Marseille 2, Inst Biol Dev Marseille Luminy, F-13288 Marseille, France; Univ Aix Marseille 2, Ctr Immunol Marseille Luminy, MOSAIC Grp, F-13288 Marseille, France; CNRS, UMR 6216, F-13288 Marseille, France; CNRS, UMR 6102, F-13288 Marseille, France; INSERM, UMR 631, F-13288 Marseille, France; Univ Aix Marseille III, Inst Fresnel, F-13397 Marseille, France; CNRS, UMR 6133, F-13397 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Rougon, G (corresponding author), IBDML, Parc Sci Luminy, Case 907, F-13288 Marseille 9, France.	rougon@ibdm.univ-mrs.fr	Matarazzo, Valery/M-9040-2016; Marguet, Didier/B-9946-2008; Matarazzo, Valery/V-2359-2019; Marguet, Didier/AGO-5421-2022; ROUGON, Genevieve/G-2578-2013	Matarazzo, Valery/0000-0002-0833-203X; Matarazzo, Valery/0000-0002-0833-203X; Marguet, Didier/0000-0003-3198-5095; ROUGON, Genevieve/0000-0003-1316-8200; Lenne, Pierre-Francois/0000-0003-1066-7506				Doetsch F, 1997, J NEUROSCI, V17, P5046; Gambin Y, 2006, P NATL ACAD SCI USA, V103, P2098, DOI 10.1073/pnas.0511026103; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Hinsby AM, 2004, FRONT BIOSCI-LANDMRK, V9, P2227, DOI 10.2741/1393; Iwase T, 2005, J NEUROCHEM, V94, P1488, DOI 10.1111/j.1471-4159.2005.03290.x; Jacobson KA, 1997, BBA-BIOMEMBRANES, V1330, P138, DOI 10.1016/S0005-2736(97)00128-4; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lenne PF, 2006, EMBO J, V25, P3245, DOI 10.1038/sj.emboj.7601214; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Okabe S, 1999, NAT NEUROSCI, V2, P804, DOI 10.1038/12175; Paratcha G, 2006, MOL CELL NEUROSCI, V31, P505, DOI 10.1016/j.mcn.2005.11.007; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Povlsen GK, 2003, NEUROCHEM RES, V28, P127, DOI 10.1023/A:1021660531484; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Saarma M, 2001, TRENDS NEUROSCI, V24, P427, DOI 10.1016/S0166-2236(00)01864-6; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Thoumine O, 2005, BIOPHYS J, V89, pL40, DOI 10.1529/biophysj.105.071688; Torregrossa P, 2004, J BIOL CHEM, V279, P30707, DOI 10.1074/jbc.M403935200; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; Vutskits L, 2003, EUR J NEUROSCI, V17, P2119, DOI 10.1046/j.1460-9568.2003.02660.x; WANG C, 1994, J NEUROSCI, V14, P4446; Wawrezinieck L, 2005, BIOPHYS J, V89, P4029, DOI 10.1529/biophysj.105.067959; Wawrezinieck L, 2004, PROC SPIE, V5462, P92, DOI 10.1117/12.545014; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YANG PF, 1994, J BIOL CHEM, V269, P23039; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	39	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26266	26274		10.1074/jbc.M608590200	http://dx.doi.org/10.1074/jbc.M608590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623676	hybrid			2022-12-27	WOS:000249239600031
J	Li, JH; Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Zhang, XH; Wess, J				Li, Jian Hua; Han, Sung-Jun; Hamdan, Fadi F.; Kim, Soo-Kyung; Jacobson, Kenneth A.; Bloodworth, Lanh M.; Zhang, Xiaohong; Wess, Juergen			Distinct structural changes in a g protein-coupled receptor caused by different classes of agonist ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA(2) ADRENERGIC-RECEPTOR; DISULFIDE CROSS-LINKING; CONFORMATIONAL-CHANGES; INVERSE AGONISM; CYTOPLASMIC END; MOLECULAR-BASIS; IN-SITU; SULFHYDRYL REACTIVITY; CONSTITUTIVE ACTIVITY	The activity of Gprotein-coupled receptors can be modulated by different classes of ligands, including agonists that promote receptor signaling and inverse agonists that reduce basal receptor activity. The conformational changes in receptor structure induced by different agonist ligands are not well understood at present. In this study, we employed an in situ disulfide crosslinking strategy to monitor ligand-induced conformational changes in a series of cysteine-substituted mutant M-3 muscarinic acetylcholine receptors. The observed disulfide cross-linking patterns indicated that muscarinic agonists trigger a separation of the N-terminal segment of the cytoplasmic tail ( helix 8) from the cytoplasmic end of transmembrane domain I. In contrast, inverse muscarinic agonists were found to increase the proximity between these two receptor regions. These findings provide a structural basis for the opposing biological effects of muscarinic agonists and inverse agonists. This study also provides the first piece of direct structural information as to how the conformations induced by these two functionally different classes of ligands differ at the molecular level. Given the high degree of structural homology found among most G protein-coupled receptors, our findings should be of broad general relevance.	NIDDK, Natl Inst Hlth, Bioorgan Chem Lab, Mol Signaling Sect, Bethesda, MD 20892 USA; NIDDK, Natl Inst Hlth, Mol Recognit Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Natl Inst Hlth, Bioorgan Chem Lab, Mol Signaling Sect, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Han, Sung-Jun/B-9547-2012; Li, Jianhua/B-7671-2011; Jacobson, Kenneth Alan/A-1530-2009	Li, Jianhua/0000-0002-5744-3182; Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031129, ZIADK031129, ZIADK031126, Z01DK031126] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Goin JC, 2006, J BIOL CHEM, V281, P5416, DOI 10.1074/jbc.M507476200; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KOBILKA BK, 2006, BIOCHIM BIOPHYS ACTA, V768, P794; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lim WK, 2001, BIOCHEM J, V354, P337, DOI 10.1042/0264-6021:3540337; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Nelson CP, 2006, J PHARMACOL EXP THER, V316, P279, DOI 10.1124/jpet.105.094383; Nikolaev VO, 2006, J BIOL CHEM, V281, P24506, DOI 10.1074/jbc.M603266200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Santos N. M. D., 2006, J BIOL CHEM, V281, P12896; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Ward SDC, 2006, BIOCHEMISTRY-US, V45, P676, DOI 10.1021/bi051503q; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	49	40	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26284	26293		10.1074/jbc.M704875200	http://dx.doi.org/10.1074/jbc.M704875200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623649	hybrid			2022-12-27	WOS:000249239600033
J	Stauff, DL; Torres, VJ; Skaar, EP				Stauff, Devin L.; Torres, Victor J.; Skaar, Eric P.			Signaling and DNA-binding activities of the staphylococcus aureus HssR-HssS two-component system required for heme sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-CHAIN-REACTION; GENE-EXPRESSION; REGULATORY SYSTEM; ESCHERICHIA-COLI; VIRULENCE DETERMINANTS; BACTERIAL CHEMOTAXIS; TRANSDUCTION SYSTEM; IDENTIFICATION; IRON; OPERON	For the important human pathogen Staphylococcus aureus, host heme is a vital source of nutrient iron during infection. Paradoxically, heme is also toxic at high concentrations and is capable of killing S. aureus. To maintain cellular heme homeo-stasis, S. aureus employs the coordinated actions of the heme sensing two-component system (HssRS) and the heme regulated transporter efflux pump ( HrtAB). HssRS-dependent expression of HrtAB results in the alleviation of heme toxicity and tempered staphylococcal virulence. Although genetic experiments have defined the role of HssRS in the heme-dependent activation of hrtAB, the mechanism of this activation is not known. Furthermore, the global effect of HssRS on S. aureus gene expression has not been evaluated. Herein, we combine multi-variable difference gel electrophoresis with mass spectrometry to identify the heme-induced cytoplasmic HssRS regulon. These experiments establish hrtAB as the major target of activation by HssRS in S. aureus. In addition, we show that signaling between the sensor histidine kinase HssS and the response regulator HssR is necessary for growth of S. aureus in high concentrations of heme. Finally, we show that a direct repeat DNA sequence within the hrtAB promoter is required for heme-induced, HssR-dependent expression driven by this promoter and that phosphorylated HssR binds to this direct repeat upon exposure of S. aureus to high concentrations of heme. Taken together, these data establish the mechanism for HssRS-dependent expression of HrtAB and, in turn, provide a functional understanding for how S. aureus avoids heme-mediated toxicity.	Vanderbilt Univ, Med Ctr, Dept Immunol & Microbiol, Nashville, TN 37232 USA	Vanderbilt University	Skaar, EP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Immunol & Microbiol, Nashville, TN 37232 USA.	eric.skaar@vanderbilt.edu		Torres, Victor/0000-0002-7126-0489	NHLBI NIH HHS [T32 HL069765] Funding Source: Medline; NIAID NIH HHS [AI071487, AI69233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069233, F32AI071487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson KL, 2006, J BACTERIOL, V188, P6739, DOI 10.1128/JB.00609-06; Bae T, 2006, PLASMID, V55, P58, DOI 10.1016/j.plasmid.2005.05.005; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; Bronner S, 2004, FEMS MICROBIOL REV, V28, P183, DOI 10.1016/j.femsre.2003.09.003; Brunskill EW, 1996, J BACTERIOL, V178, P611, DOI 10.1128/jb.178.3.611-618.1996; BULLEN JJ, 1999, IRON INFECTION MOL P; Cheung AL, 2004, FEMS IMMUNOL MED MIC, V40, P1, DOI 10.1016/S0928-8244(03)00309-2; Clausen VA, 2003, J MOL MICROB BIOTECH, V5, P252, DOI 10.1159/000071077; DEISS A, 1983, SEMIN HEMATOL, V20, P81; Dubrac S, 2004, J BACTERIOL, V186, P1175, DOI 10.1128/JB.186.4.1175-1181.2004; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Everse J, 1997, FREE RADICAL BIO MED, V22, P1075, DOI 10.1016/S0891-5849(96)00499-6; Fabret C, 1998, J BACTERIOL, V180, P6375; Fournier B, 2001, MOL MICROBIOL, V41, P247, DOI 10.1046/j.1365-2958.2001.02515.x; Friedman DB, 2006, PLOS PATHOG, V2, P777, DOI 10.1371/journal.ppat.0020087; Fuchs S, 2007, J BACTERIOL, V189, P4275, DOI 10.1128/JB.00081-07; Giraudo AT, 1997, ARCH MICROBIOL, V168, P53, DOI 10.1007/s002030050469; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Mascher T, 2006, MICROBIOL MOL BIOL R, V70, P910, DOI 10.1128/MMBR.00020-06; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MIZUNO T, 1982, J BIOL CHEM, V257, P13692; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; Reniere ML, 2007, BIOMETALS, V20, P333, DOI 10.1007/s10534-006-9032-0; Richardson AR, 2006, MOL MICROBIOL, V61, P927, DOI 10.1111/j.1365-2958.2006.05290.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stojiljkovic I, 2001, EXPERT OPIN INV DRUG, V10, P309, DOI 10.1517/13543784.10.2.309; Stojiljkovic I, 1999, MOL MICROBIOL, V31, P429, DOI 10.1046/j.1365-2958.1999.01175.x; TAYLOR RK, 1981, J BACTERIOL, V147, P255, DOI 10.1128/JB.147.1.255-258.1981; Throup JP, 2001, BIOCHEMISTRY-US, V40, P10392, DOI 10.1021/bi0102959; Torres VJ, 2007, CELL HOST MICROBE, V1, P109, DOI 10.1016/j.chom.2007.03.001; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; Wardenburg JB, 2006, P NATL ACAD SCI USA, V103, P13831, DOI 10.1073/pnas.0603072103; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Yarwood JM, 2001, J BACTERIOL, V183, P1113, DOI 10.1128/JB.183.4.1113-1123.2001	47	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26111	26121		10.1074/jbc.M703797200	http://dx.doi.org/10.1074/jbc.M703797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635909	hybrid			2022-12-27	WOS:000249239600014
J	Ran, YC; Zhu, H; Liu, MY; Fabian, M; Olson, JS; Aranda, R IV; Phillips, GN; Dooley, DM; Lei, B				Ran, Yanchao; Zhu, Hui; Liu, Mengyao; Fabian, Marian; Olson, John S.; Aranda, Roman, IV; Phillips, George N., Jr.; Dooley, David M.; Lei, Benfang			Bis-methionine Ligation to heme iron in the streptococcal cell surface protein shp facilitates rapid hemin transfer to HtsA of the HtsABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; RECEPTOR HASR; UPTAKE SYSTEM; IDENTIFICATION; HEMOGLOBIN; MEMBRANE; HEMOPHORE; MYOGLOBIN; RESIDUES	The surface protein Shp of Streptococcus pyogenes rapidly transfers its hemin to HtsA, the lipoprotein component of the HtsABC transporter, in a concerted two-step process with one kinetic phase. The structural basis and molecular mechanism of this hemin transfer have been explored by mutagenesis and truncation of Shp. The heme-binding domain of Shp is in the amino-terminal region and is functionally active by itself, although inclusion of the COOH-terminal domain speeds up the process similar to 10-fold. Single alanine replacements of the axial methionine 66 and 153 ligands (Shp(M66A) and Shp(M153A)) cause formation of pentacoordinate hemin-Met complexes. The association equilibrium constants for hemin binding to wild-type, M66A, and M153A Shp are 5,300, 22,000, and 38 mu m(-1), respectively, showing that the Met(153)-Fe bond is critical for high affinity binding and that Met(66) destabilizes hemin binding to facilitate its rapid transfer. Shp(M66A) and Shp(M153A) rapidly bind to hemin-free HtsA (apoHtsA), forming stable transfer intermediates. These intermediates appear to be Shp-hemin-HtsA complexes with one axial ligand from each protein and decay to the products with rate constants of 0.4-3 s(-1). Thus, the M66A and M153A replacements alter the kinetic mechanism and unexpectedly slow down hemin transfer by stabilizing the intermediates. These results, in combination with the structure of the Shp heme-binding domain, allow us to propose a "plug-in" mechanism in which side chains from apoHtsA are inserted into the axial positions of hemin in Shp to extract it from the surface protein and pull it into the transporter active site.	Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77251 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Rice University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lei, B (corresponding author), Montana State Univ, Dept Vet Mol Biol, PO Box 173610, Bozeman, MT 59717 USA.	blei@montana.edu		Lei, Benfang Lei/0000-0001-8133-6021; Olson, John/0000-0002-0760-5403	NCRR NIH HHS [P20 RR020185-010002, P20 RR020185-037582, P20 RR020185-020002, P20 RR020185, P20 RR020185-047743] Funding Source: Medline; NHLBI NIH HHS [HL47020, R01 HL047020] Funding Source: Medline; NIAID NIH HHS [K22 AI057347-02, AI057347, K22 AI057347, K22 AI057347-01] Funding Source: Medline; NIGMS NIH HHS [GM08349, GM35649, R01 GM055807, GM27659, T32 GM008349, R01 GM035649, R01 GM027659, GM55807] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI057347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807, T32GM008349, R01GM027659, R01GM035649] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1995, J BIOL CHEM, V270, P23268, DOI 10.1074/jbc.270.40.23268; Burkhard KA, 2007, J BIOL CHEM, V282, P15126, DOI 10.1074/jbc.M611121200; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Eaton W A, 1981, Methods Enzymol, V76, P175; GRIFFITHS E, 1999, IRON INFECT MOL PHYS, P87; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; Lei BF, 2003, INFECT IMMUN, V71, P5962, DOI 10.1128/IAI.71.10.5962-5969.2003; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Liu XY, 2006, INFECT IMMUN, V74, P1222, DOI 10.1128/IAI.74.2.1222-1232.2006; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Moreira LM, 2006, BIOPHYS CHEM, V124, P62, DOI 10.1016/j.bpc.2006.05.030; NYGAARD TK, 2006, BMC MICROBIOL, V6; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Pettigrew, 1990, CYTOCHROME C EVOLUTI; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Sharp KH, 2007, J BIOL CHEM, V282, P10625, DOI 10.1074/jbc.M700234200; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06	24	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31380	31388		10.1074/jbc.M705967200	http://dx.doi.org/10.1074/jbc.M705967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17699155	hybrid, Green Accepted			2022-12-27	WOS:000250309200028
J	Chen, XM; Polleichtner, G; Kadurin, I; Grunder, S				Chen, Xuanmao; Polleichtner, Georg; Kadurin, Ivan; Gruender, Stefan			Zebrafish acid-sensing ion channel (ASIC) 4, characterization of homo- and heteromeric channels, and identification of regions important for activation by H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARANTULA TOXIN PSALMOTOXIN-1; HIPPOCAMPAL-NEURONS; SENSORY NEURONS; CATION CHANNEL; EXTRACELLULAR CALCIUM; NA+ CHANNELS; ASIC 1A; CURRENTS; SUBUNIT; FAMILY	There are four genes for acid-sensing ion channels (ASICs) in the genome of mammalian species. Whereas ASIC1 to ASIC3 form functional H+-gated Na+ channels, ASIC4 is not gated by H+, and its function is unknown. Zebrafish has two ASIC4 paralogs: zASIC4.1 and zASIC4.2. Whereas zASIC4.1 is gated by extracellular H+, zASIC4.2 is not. This differential response to H+ makes zASIC4 paralogs a good model to study the properties of this ion channel. In this study, we found that surface expression of homomeric zASIC4.2 is higher than that of zASIC4.1. Surface expression of zASIC4.1 was much increased by formation of heteromeric channels, suggesting that zASIC4.1 contributes to heteromeric ASICs in zebrafish neurons. Robust surface expression of H+-insensitive zASIC4.2 suggests that zASIC4.2 functions as a homomer and is gated by an as yet unknown stimulus, different from H+. Moreover, we identified a small region just distal to the first transmembrane domain that is crucial for the differential H+ response of the two paralogs. This post-TM1 domain may have a general role in gating of members of this gene family.	Univ Wurzburg, Dept Physiol 2, D-97070 Wurzburg, Germany	University of Wurzburg	Grunder, S (corresponding author), Univ Wurzburg, Dept Physiol 2, Rontgenring 9, D-97070 Wurzburg, Germany.	stefan.gruender@uni-wuerzburg.de	chen, xuanmao/I-7576-2013; Gründer, Stefan/I-2495-2019; Kadurin, Ivan/F-7759-2012	Gründer, Stefan/0000-0002-7635-9883; Kadurin, Ivan/0000-0002-7720-367X; Chen, Xuanmao/0000-0002-0057-8510				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Bruns JB, 2007, J BIOL CHEM, V282, P6153, DOI 10.1074/jbc.M610636200; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chen XM, 2007, J PHYSIOL-LONDON, V579, P657, DOI 10.1113/jphysiol.2006.120733; Chen XM, 2006, NEUROPHARMACOLOGY, V50, P964, DOI 10.1016/j.neuropharm.2006.01.007; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; Chu XP, 2003, J PHYSIOL-LONDON, V550, P385, DOI 10.1113/jphysiol.2003.043091; Coric T, 2005, J PHYSIOL-LONDON, V568, P725, DOI 10.1113/jphysiol.2005.087734; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Cottrell GA, 2001, FEBS LETT, V489, P71, DOI 10.1016/S0014-5793(01)02081-6; Grunder S, 2000, NEUROREPORT, V11, P1607; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Salinas M, 2006, J PHYSIOL-LONDON, V570, P339, DOI 10.1113/jphysiol.2005.095810; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Vukicevic M, 2004, AM J PHYSIOL-CELL PH, V287, pC682, DOI 10.1152/ajpcell.00127.2004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yagi J, 2006, CIRC RES, V99, P501, DOI 10.1161/01.RES.0000238388.79295.4c	40	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30406	30413		10.1074/jbc.M702229200	http://dx.doi.org/10.1074/jbc.M702229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17686779	hybrid, Green Published			2022-12-27	WOS:000250136300008
J	Feng, D; Zhao, X; Soromani, C; Toikkanen, J; Romisch, K; Vembar, SS; Brodsky, JL; Keranen, S; Jantti, J				Feng, Dejiang; Zhao, Xueqiang; Soromani, Christina; Toikkanen, Jaana; Romisch, Karin; Vembar, Shruthi S.; Brodsky, Jeffrey L.; Keranen, Sirkka; Jantti, Jussi			The transmembrane domain is sufficient for sbh1p function, its association with the sec61 complex, and interaction with rtn1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION COMPLEX; MISFOLDED SECRETORY PROTEIN; SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; HETEROLOGOUS PROTEINS; CONDUCTING CHANNEL; ER MEMBRANE; TRANSPORT	The Sec61 protein translocation complex in the endoplasmic reticulum ( ER) membrane is composed of three subunits. The alpha-subunit, called Sec61p in yeast, is a multispanning membrane protein that forms the protein conducting channel. The functions of the smaller, carboxyl-terminally tail-anchored beta subunit Sbh1p, its close homologue Sbh2p, and the gamma subunit Sss1p are not well understood. Here we show that co-translational protein translocation into the ER is reduced in sbh1 Delta sbh2 Delta cells, whereas there is a limited reduction of post-translational tranlocation and no effect on export of a mutant form of alpha-factor precursor for ER-associated degradation in the cytosol. The translocation defect and the temperature-sensitive growth phenotype of sbh1 Delta sbh2 Delta cells were rescued by expression of the transmembrane domain of Sbh1p alone, and the Sbh1p transmembrane domain was sufficient for coimmunoprecipitation with Sec61p and Sss1p. Furthermore, we show that Sbh1p co-precipitates with the ER transmembrane protein Rtn1p. Sbh1p-Rtn1p complexes do not appear to contain Sss1p and Sec61p. Our results define the transmembrane domain as the minimal functional domain of the Sec61 beta homologue Sbh1p in ER translocation, identify a novel interaction partner for Shb1p, and imply that Sbh1p has additional functions that are not directly linked protein translocation in association with the Sec61 complex.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; VTT Biotechnol, FI-02044 Espoo, Finland; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Helsinki; VTT Technical Research Center Finland; University of Cambridge; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jantti, J (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	jussi.jantti@helsinki.fi	Römisch, Karin/AAO-1210-2021; Vembar, Shruthi Sridhar/AAE-2479-2019	Römisch, Karin/0000-0003-0415-6558; ZHAO, XUEQIANG/0000-0002-4956-6932	NIGMS NIH HHS [GM75061, R01 GM075061-02, R01 GM075061-01A1, R01 GM075061] Funding Source: Medline; Wellcome Trust [042216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boisrame A, 2002, J CELL SCI, V115, P4947, DOI 10.1242/jcs.00187; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Davydenko SG, 2005, YEAST, V22, P993, DOI 10.1002/yea.1286; De Craene JO, 2006, MOL BIOL CELL, V17, P3009, DOI 10.1091/mbc.e06-01-0080; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Guo W, 2004, TRENDS CELL BIOL, V14, P61, DOI 10.1016/j.tcb.2003.12.008; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Helmers J, 2003, J BIOL CHEM, V278, P23686, DOI 10.1074/jbc.C300180200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; JANTTI J, 1994, J CELL SCI, V107, P3623; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; Kalies KU, 2005, EMBO J, V24, P2284, DOI 10.1038/sj.emboj.7600731; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 2004, TRENDS CELL BIOL, V14, P568, DOI 10.1016/j.tcb.2004.09.002; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; RUOHONEN L, 1995, J BIOTECHNOL, V39, P193, DOI 10.1016/0168-1656(95)00024-K; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Tagwerker C, 2006, YEAST, V23, P623, DOI 10.1002/yea.1380; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; Toikkanen JH, 2003, J BIOL CHEM, V278, P20946, DOI 10.1074/jbc.M213111200; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wiederkehr A, 2003, MOL BIOL CELL, V14, P4770, DOI 10.1091/mbc.E03-04-0229; Wiederkehr A, 2004, J CELL BIOL, V167, P875, DOI 10.1083/jcb.200408001; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	46	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30618	30628		10.1074/jbc.M701840200	http://dx.doi.org/10.1074/jbc.M701840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17699516	hybrid, Green Accepted			2022-12-27	WOS:000250136300030
J	Gould, SB; Fan, E; Hempel, F; Maier, UG; Kloesgen, RB				Gould, Sven B.; Fan, Enguo; Hempel, Franziska; Maier, Uwe-G.; Kloesgen, Ralf Bernd			Translocation of a phycoerythrin alpha subunit across five biological membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; CRYPTOPHYTE ALGA; COMPLEX; CHLOROPLASTS; PATHWAY; IMPORT; ULTRASTRUCTURE; REQUIREMENTS; LOCALIZATION; MECHANISM	Cryptophytes, unicellular algae, evolved by secondary endosymbiosis and contain plastids surrounded by four membranes. In contrast to cyanobacteria and red algae, their phycobiliproteins do not assemble into phycobilisomes and are located within the thylakoid lumen instead of the stroma. We identified two gene families encoding phycoerythrin alpha and light-harvesting complex proteins from an expressed sequence tag library of the cryptophyte Guillardia theta. The proteins bear a bipartite topogenic signal responsible for the transport of nuclear encoded proteins via the ER into the plastid. Analysis of the phycoerythrin alpha sequences revealed that more than half of them carry an additional, third topogenic signal comprising a twin arginine motif, which is indicative of Tat ( twin arginine transport)specific targeting signals. We performed import studies with several derivatives of one member using a diatom transformation system, as well as intact chloroplasts and thylakoid vesicles isolated from pea. We demonstrated the different targeting properties of each individual part of the tripartite leader and show that phycoerythrin alpha is transported across the thylakoid membrane into the thylakoid lumen and protease-protected. Furthermore, we showed that thylakoid transport of phycoerythrin alpha takes place by the Tat pathway even if the 36 amino acid long bipartite topogenic signal precedes the actual twin arginine signal. This is the first experimental evidence of a protein being targeted across five biological membranes.	Univ Marburg, D-35032 Marburg, Germany; Univ Halle Wittenberg, Inst Biol, D-06120 Halle, Germany	Philipps University Marburg; Martin Luther University Halle Wittenberg	Gould, SB (corresponding author), Univ Melbourne, Sch Bot, Melbourne, Vic 3010, Australia.	sbgould@gmail.com	Gould, Sven B/B-8192-2011	Gould, Sven/0000-0002-2038-8474				ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; Berghofer J, 1999, FEBS LETT, V460, P328, DOI 10.1016/S0014-5793(99)01365-4; Bhattacharya D, 2004, BIOESSAYS, V26, P50, DOI 10.1002/bies.10376; Broughton MJ, 2006, GENE, V369, P72, DOI 10.1016/j.gene.2005.10.026; Cavalier-Smith T, 1999, J EUKARYOT MICROBIOL, V46, P347, DOI 10.1111/j.1550-7408.1999.tb04614.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Dabney-Smith C, 2006, J BIOL CHEM, V281, P5476, DOI 10.1074/jbc.M512453200; DeRocher A, 2000, J CELL SCI, V113, P3969; DODGE JD, 1969, ARCH MIKROBIOL, V69, P266, DOI 10.1007/BF00408978; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; DWARTE D, 1983, PROTOPLASMA, V117, P130, DOI 10.1007/BF01288351; Fincher V, 1998, FEBS LETT, V423, P66, DOI 10.1016/S0014-5793(98)00066-0; Frielingsdorf S, 2007, J BIOL CHEM, V282, P24455, DOI 10.1074/jbc.M702630200; GANTT E, 1971, J CELL BIOL, V48, P280, DOI 10.1083/jcb.48.2.280; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gould SB, 2006, MOL BIOL EVOL, V23, P2413, DOI 10.1093/molbev/msl113; Gould SB, 2006, J MOL EVOL, V62, P674, DOI 10.1007/s00239-005-0099-y; Hou B, 2006, J MOL BIOL, V355, P957, DOI 10.1016/j.jmb.2005.11.029; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; KHORTH E, 2005, ENDOCYTOBIOS CELL RE, V15, P549; Kilian O, 2005, PLANT J, V41, P175, DOI 10.1111/j.1365-313X.2004.02294.x; LUDWIG M, 1989, J CELL BIOL, V108, P875, DOI 10.1083/jcb.108.3.875; MacColl R., 1987, PHYCOBILIPROTEINS; Marques JP, 2004, J EXP BOT, V55, P1697, DOI 10.1093/jxb/erh191; Marques JP, 2003, MOL GENET GENOMICS, V269, P381, DOI 10.1007/s00438-003-0846-y; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Molik S, 2001, J BIOL CHEM, V276, P42761, DOI 10.1074/jbc.M106690200; MORSCHEL E, 1977, ARCH MICROBIOL, V113, P83, DOI 10.1007/BF00428585; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Nassoury N, 2003, J CELL SCI, V116, P2867, DOI 10.1242/jcs.00517; REITH M, 1990, PLANT MOL BIOL, V15, P585, DOI 10.1007/BF00017833; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sommer MS, 2007, MOL BIOL EVOL, V24, P918, DOI 10.1093/molbev/msm008; SPEARBERNSTEIN L, 1985, PROTOPLASMA, V129, P1, DOI 10.1007/BF01282300; Wastl J, 2000, J BIOL CHEM, V275, P23194, DOI 10.1074/jbc.M003125200; WEHRMEYER W, 1970, ARCH MIKROBIOL, V71, P367, DOI 10.1007/BF00417133	40	21	21	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30295	30302		10.1074/jbc.M701869200	http://dx.doi.org/10.1074/jbc.M701869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17702756	hybrid			2022-12-27	WOS:000249981200060
J	Langlois, S; Maher, AC; Manias, JL; Shao, Q; Kidder, GM; Laird, DW				Langlois, Stephanie; Maher, Amy C.; Manias, Janet L.; Shao, Qing; Kidder, Gerald M.; Laird, Dale W.			Connexin levels regulate keratinocyte differentiation in the epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTO-DIGITAL DYSPLASIA; JUNCTIONAL INTERCELLULAR COMMUNICATION; NEONATAL MICE LACKING; OCULODENTODIGITAL DYSPLASIA; GAP-JUNCTIONS; SKIN DIFFERENTIATION; RETROVIRAL DELIVERY; RAT KERATINOCYTES; GENE DELIVERY; MOUSE SKIN	To understand the role of connexin43 (Cx43) in epidermal differentiation, we reduced Cx43 levels by RNA-mediated interference knockdown and impaired its functional status by over-expressing loss-of-function Cx43 mutants associated with the human disease oculodentodigital dysplasia ( ODDD) in rat epidermal keratinocytes. When Cx43 expression was knocked down by 50-75%, there was a coordinate 55-65% reduction in Cx26 level, gap junction-based dye coupling was reduced by 60%, and transepithelial resistance decreased. Importantly, the overall growth and differentiation of Cx43 knockdown organotypic epidermis was severely impaired as revealed by alterations in the levels of the differentiation markers loricrin and involucrin and by reductions in vital and cornified layer thicknesses. Conversely, although the expression of Cx43 mutants reduced the coupling status of rat epidermal keratinocytes by similar to 80% without altering the levels of endogenous Cx43 or Cx26, their ability to differentiate was not altered. In addition, we used a mouse model of ODDD and found that newborn mice harboring the loss-of-function Cx43(G60S) mutant had slightly reduced Cx43 levels, whereas Cx26 levels, epidermis differentiation, and barrier function remained unaltered. This properly differentiated epidermis was maintained even when Cx43 and Cx26 levels decreased by more than 70% in 3-week-old mutant mice. Our studies indicate that Cx43 and Cx26 collectively co-regulate epidermal differentiation from basal keratinocytes but play a more minimal role in the maintenance of established epidermis. Altogether, these studies provide an explanation as to why the vast majority of ODDD patients, where Cx43 function is highly compromised, do not suffer from skin disease.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg 00077, London, ON N6A 5C1, Canada.	dale.laird@schulich.uwo.ca	Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Laird, Dale W/0000-0002-4568-3285; 				Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; Brandner JM, 2004, J INVEST DERMATOL, V122, P1310, DOI 10.1111/j.0022-202X.2004.22529.x; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; Choudhry R, 1997, DEV DYNAM, V210, P417, DOI 10.1002/(SICI)1097-0177(199712)210:4<417::AID-AJA6>3.3.CO;2-0; Common JEA, 2002, BIOCHEM BIOPH RES CO, V298, P651, DOI 10.1016/S0006-291X(02)02517-2; Coutinho P, 2003, CELL BIOL INT, V27, P525, DOI 10.1016/S1065-6995(03)00077-5; Di WL, 2005, J CELL SCI, V118, P1505, DOI 10.1242/jcs.01733; Di WL, 2001, CELL COMMUN ADHES, V8, P415, DOI 10.3109/15419060109080763; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Galipeau J, 1999, CANCER RES, V59, P2384; Gemel J, 2004, J CELL SCI, V117, P2469, DOI 10.1242/jcs.01084; Giepmans BNG, 2006, ADV CARDIOL, V42, P41, DOI 10.1159/000092561; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; Gong XQ, 2007, J BIOL CHEM, V282, P19190, DOI 10.1074/jbc.M609653200; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hirao T, 2001, EXP DERMATOL, V10, P35, DOI 10.1034/j.1600-0625.2001.100105.x; Kelly SC, 2006, EUR J DERMATOL, V16, P241; Kretz M, 2004, EUR J CELL BIOL, V83, P647, DOI 10.1078/0171-9335-00422; Kretz M, 2003, J CELL SCI, V116, P3443, DOI 10.1242/jcs.00638; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Maass K, 2004, MOL BIOL CELL, V15, P4597, DOI 10.1091/mbc.E04-04-0324; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; Maher AC, 2005, CELL COMMUN ADHES, V12, P219, DOI 10.1080/15419060500511818; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Plum A, 2001, DEV BIOL, V231, P334, DOI 10.1006/dbio.2000.0148; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Qiu C, 2003, CURR BIOL, V13, P1697, DOI 10.1016/j.cub.2003.09.007; Rabionet R, 2002, TRENDS MOL MED, V8, P205, DOI 10.1016/S1471-4914(02)02327-4; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Richard G, 2005, CLIN DERMATOL, V23, P23, DOI 10.1016/j.clindermatol.2004.09.010; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005; RISEK B, 1992, DEVELOPMENT, V116, P639; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Rouan F, 2001, J CELL SCI, V114, P2105; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Suhonen TM, 2003, EUR J PHARM SCI, V20, P107, DOI 10.1016/S0928-0987(03)00176-3; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Troy TC, 1999, J CELL PHYSIOL, V180, P409, DOI 10.1002/(SICI)1097-4652(199909)180:3<409::AID-JCP12>3.0.CO;2-V; van Steensel MAM, 2005, AM J MED GENET A, V132A, P171, DOI 10.1002/ajmg.a.30412; Vreeburg M, 2007, AM J MED GENET A, V143A, P360, DOI 10.1002/ajmg.a.31558; Wiszniewski L, 2001, CELL COMMUN ADHES, V8, P409, DOI 10.3109/15419060109080762	49	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30171	30180		10.1074/jbc.M703623200	http://dx.doi.org/10.1074/jbc.M703623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17693411	hybrid			2022-12-27	WOS:000249981200047
J	Moskvin, OV; Kaplan, S; Gilles-Gonzalez, MA; Gomelsky, M				Moskvin, Oleg V.; Kaplan, Samuel; Gilles-Gonzalez, Marie-Alda; Gomelsky, Mark			Novel heme-based oxygen sensor with a revealing evolutionary history	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; C-TYPE HEME; BLUE-LIGHT; PHOTOSYSTEM FORMATION; CRYSTAL-STRUCTURES; GAF DOMAIN; APPA; PROTEIN; BINDING; PHOTORECEPTOR	To monitor fluctuations in oxygen concentration, cells use sensory proteins often containing heme cofactors. Here, we identify a new class of heme- binding oxygen sensors, reveal their unusual phylogenetic origin, and propose a sensing mode of a member of this class. We show that heme is bound noncovalently to the central region of AppA, an oxygen and light sensor from Rhodobacter sphaeroides. The addition of oxygen to ferrous AppA discoordinated the heme, and subsequent oxygen removal fully restored the heme coordination. In vitro, the extent of heme discoordination increased gradually with the rise in oxygen levels over a broad concentration range. This response correlated well with the gradual decrease in transcription of photosynthesis genes regulated by AppA and its partner repressor PpsR. We conclude that the AppA- PpsR regulatory system functions as an oxygen- dependent transcriptional rheostat. We identified a new domain embedded in the central region of AppA and designated it SCHIC for sensor containing heme instead of cobalamin. A phylogenetic analysis revealed that SCHIC domain proteins form a distinct cluster within a superfamily that includes vitamin B-12- binding proteins and other proteins that may bind other kinds of tetrapyrroles.	Univ Wyoming, Dept Biol Mol, Laramie, WY 82071 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Wyoming; University of Texas System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomelsky, M (corresponding author), Univ Wyoming, Dept Biol Mol, Dept 3944,1000 E Univ Ave, Laramie, WY 82071 USA.	gomelsky@uwyo.edu	gomelsky, mark/F-6209-2010; Moskvin, Oleg/C-5916-2015	Moskvin, Oleg/0000-0003-1499-8900; Gomelsky, Mark/0000-0003-4077-3932	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015640] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15640] Funding Source: Medline; NIGMS NIH HHS [GM15590] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Anderson S, 2005, BIOCHEMISTRY-US, V44, P7998, DOI 10.1021/bi0502691; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Braatsch S, 2004, J BACTERIOL, V186, P7726, DOI 10.1128/JB.186.22.7726-7735.2004; Braatsch S, 2002, MOL MICROBIOL, V45, P827, DOI 10.1046/j.1365-2958.2002.03058.x; Cary SPL, 2006, TRENDS BIOCHEM SCI, V31, P231, DOI 10.1016/j.tibs.2006.02.003; CHANG AL, 2001, BIOCHEMISTRY-US, V27, P3410; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; FU RD, 1994, J BACTERIOL, V176, P344, DOI 10.1128/JB.176.2.344-350.1994; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gomelsky L, 2003, MICROBIOL-SGM, V149, P377, DOI 10.1099/mic.0.25972-0; GOMELSKY M, 1995, J BACTERIOL, V177, P4609, DOI 10.1128/jb.177.16.4609-4618.1995; Gomelsky M, 1998, J BIOL CHEM, V273, P35319, DOI 10.1074/jbc.273.52.35319; Gomelsky M, 1997, J BACTERIOL, V179, P128, DOI 10.1128/jb.179.1.128-134.1997; Gomelsky M, 2002, TRENDS BIOCHEM SCI, V27, P497, DOI 10.1016/S0968-0004(02)02181-3; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; Jung A, 2006, J MOL BIOL, V362, P717, DOI 10.1016/j.jmb.2006.07.024; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Luschinsky Drennan C., 1994, Science, V266, P1669, DOI 10.1126/science.7992050; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; Moskvin OV, 2005, J BACTERIOL, V187, P2148, DOI 10.1128/JB.187.6.2148-2156.2005; Pappas CT, 2004, J BACTERIOL, V186, P4748, DOI 10.1128/JB.186.14.4748-4758.2004; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RZHETSKY A, 1992, J MOL EVOL, V35, P367, DOI 10.1007/BF00161174; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P126, DOI 10.1016/0003-9861(84)90137-1; Yoshioka S, 2005, BIOCHEMISTRY-US, V44, P15406, DOI 10.1021/bi0513352; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	43	53	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28740	28748		10.1074/jbc.M703261200	http://dx.doi.org/10.1074/jbc.M703261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17660296	hybrid			2022-12-27	WOS:000249642100048
J	Rothwell, PJ; Waksman, G				Rothwell, Paul J.; Waksman, Gabriel			A pre-equilibrium before nucleotide binding limits fingers subdomain closure by klentaq1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; HIV-1 REVERSE-TRANSCRIPTASE; STATE KINETIC-ANALYSIS; KLENOW FRAGMENT; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; MECHANISM; FIDELITY; BETA	Numerous studies have been undertaken to establish the mechanism of dNTP binding and template-directed incorporation by DNA polymerases. It has been established by kinetic experiments that a rate-limiting step, crucial for dNTP selection, occurs before chemical bond formation. Crystallographic studies indicated that this step may be due to a large open-to-closed conformational transition affecting the fingers subdomain. In previous studies, we established a fluorescence resonance energy transfer system to monitor the open-to-closed transition in the fingers subdomain of Klentaq1. By comparing the rates of the fingers subdomain closure with that of the rate-limiting step for Klentaq1, we showed that fingers subdomain motion was significantly faster than the rate-limiting step. We have now used this system to characterize DNA binding as well as to complete a more extensive characterization of incorporation of all four dNTPs. The data indicate that DNA binding occurs by a two-step association and that dissociation of the DNA is significantly slower in the case of the closed ternary complex. The data for nucleotide incorporation indicate a step occurring before dNTP binding, which differs for all four nucleotides. As the only difference between the (E.p/t) complexes is the templating base, it would suggest an important role for the templating base in initial ground state selection.	Birkbeck Coll, Inst Struct Mol Biol, London WC1E 7HX, England; UCL, London WC1E 7HX, England	University of London; Birkbeck University London; University of London; University College London	Waksman, G (corresponding author), Birkbeck Coll, Inst Struct Mol Biol, Malet St, London WC1E 7HX, England.	g.waksman@mail.cryst.bbk.ac.uk			Wellcome Trust [067879] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Fersht A., 1985, ENZYME STRUCTURE MEC; Jezewska MJ, 2002, J BIOL CHEM, V277, P20316, DOI 10.1074/jbc.M200918200; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim SJ, 2003, J BIOL CHEM, V278, P5072, DOI 10.1074/jbc.M208472200; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Li Y, 2001, CURR ORG CHEM, V5, P871, DOI 10.2174/1385272013375067; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Rothwell PJ, 2005, ADV PROTEIN CHEM, V71, P401, DOI 10.1016/S0065-3233(04)71011-6; Rothwell PJ, 2005, MOL CELL, V19, P345, DOI 10.1016/j.molcel.2005.06.032; Rothwell PJ, 2003, P NATL ACAD SCI USA, V100, P1655, DOI 10.1073/pnas.0434003100; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Shah AM, 2003, BIOCHEMISTRY-US, V42, P10709, DOI 10.1021/bi034885d; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	33	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28884	28892		10.1074/jbc.M704824200	http://dx.doi.org/10.1074/jbc.M704824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640877	hybrid			2022-12-27	WOS:000249642100063
J	Goralski, KB; McCarthy, TC; Hanniman, EA; Zabel, BA; Butcher, EC; Parlee, SD; Muruganandan, S; Sinal, CJ				Goralski, Kerry B.; McCarthy, Tanya C.; Hanniman, Elyisha A.; Zabel, Brian A.; Butcher, Eugene C.; Parlee, Sebastian D.; Muruganandan, Shanmugam; Sinal, Christopher J.			Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACYLATION-STIMULATING PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; NON-SHIVERING THERMOGENESIS; BROWN ADIPOSE-TISSUE; IN-VIVO; GENE-EXPRESSION; TNF-ALPHA; OBESITY; FAT	Obesity is an alarming primary health problem and is an independent risk factor for type 11 diabetes, cardiovascular diseases, and hypertension. Although the pathologic mechanisms linking obesity with these co-morbidities are most likely multifactorial, increasing evidence indicates that altered secretion of adipose-derived signaling molecules (adipokines; e.g. adiponectin., leptin, and tumor necrosis factor a) and local inflammatory responses are contributing factors. Chemerin (RARRES2 or TIG2) is a recently discovered chemoattractant protein that serves as a ligand for the G protein-coupled receptor CMKLR1 (ChemR23 or DEZ) and has a role in adaptive and innate immunity. Here we show an unexpected, high level expression of chemerin and its cognate receptor CMICLR1 in mouse and human adipocytes. Cultured 3T3-L1 adipocytes secrete chemerin protein, which triggers CMKLR1 signaling in adipocytes and other cell types and stimulates chemotaxis of CMKLR1-expressing cells. Adenoviral small hairpin RNA targeted knockdown of chemerin or CMKLR1 expression impairs differentiation of 3T3-L1 cells into adipocytes, reduces the expression of adipocyte genes involved in glucose and lipid homeostasis, and alters metabolic functions in mature adipocytes. We conclude that chemerin is a novel adipose-derived signaling molecule that regulates adipogenesis and adipocyte metabolism.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Coll Pharm, Dept Pharmacol, Halifax, NS B3H 3J5, Canada; Stanford Univ, Sch Med, Immunol Lab, Dept Pathol, Stanford, CA 94305 USA; Ctr Mol Biol & Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Dalhousie University; Dalhousie University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Sinal, CJ (corresponding author), Dalhousie Univ, Dept Pharmacol, Rm 5E ,Sir Charles Tupper Bldg,5850 Coll St, Halifax, NS B3H 4H7, Canada.	csinal@dal.ca	Muruganandan, Shanmugam/H-5673-2019	Goralski, Kerry/0000-0003-0040-5879; Sinal, Christopher/0000-0001-8301-3349; Shanmugam, Muruganandan/0000-0001-9552-2175	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059635, R01AI059635] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-59635] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Bullo M, 2005, AM J PHYSIOL-ENDOC M, V289, pE62, DOI 10.1152/ajpendo.00008.2005; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carmen GY, 2006, CELL SIGNAL, V18, P401, DOI 10.1016/j.cellsig.2005.08.009; Cianflone K, 2005, CLIN ENDOCRINOL, V62, P567, DOI 10.1111/j.1365-2265.2005.02260.x; Cianflone K, 2003, BBA-BIOMEMBRANES, V1609, P127, DOI 10.1016/S0005-2736(02)00686-7; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Diamond F., 2002, GROWTH GENET HORM, V18, P17; Eriksson P, 1998, DIABETOLOGIA, V41, P65, DOI 10.1007/s001250050868; Fajas L, 2003, ANN MED, V35, P79, DOI 10.1080/07853890310009999; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Goralski KB, 2006, DRUG METAB DISPOS, V34, P288, DOI 10.1124/dmd.105.007427; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143; HOGAN S, 1980, AM J PHYSIOL, V239, pE301; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hutley L, 2005, AM J MED SCI, V330, P280, DOI 10.1097/00000441-200512000-00005; JOHNSON PR, 1972, J LIPID RES, V13, P2; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; KAWAKAMI M, 1989, J CELL PHYSIOL, V138, P1, DOI 10.1002/jcp.1041380102; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Klaus S, 2004, CURR DRUG TARGETS, V5, P241, DOI 10.2174/1389450043490523; Lagace DC, 2004, ENDOCRINOLOGY, V145, P5493, DOI 10.1210/en.2004-0877; LeaCurrie YR, 1997, INT J OBESITY, V21, P1058, DOI 10.1038/sj.ijo.0800516; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maachi M, 2004, INT J OBESITY, V28, P993, DOI 10.1038/sj.ijo.0802718; MAEEA N, 2002, NAT MED, V8, P731; Mallow H, 2000, HORM METAB RES, V32, P500, DOI 10.1055/s-2007-978676; Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7; Nagpal S, 1997, J INVEST DERMATOL, V109, P91, DOI 10.1111/1523-1747.ep12276660; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Orlicky DJ, 2001, J LIPID RES, V42, P460; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rosen ED, 2000, GENE DEV, V14, P1293; Roytblat L, 2000, OBES RES, V8, P673, DOI 10.1038/oby.2000.86; Saleh J, 1998, J LIPID RES, V39, P884; Saleh J, 1999, AM J PHYSIOL-ENDOC M, V276, pE815, DOI 10.1152/ajpendo.1999.276.5.E815; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seboek D, 2004, J CLIN ENDOCR METAB, V89, P4833, DOI 10.1210/jc.2004-0271; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tiraby C, 2003, TRENDS ENDOCRIN MET, V14, P439, DOI 10.1016/j.tem.2003.10.001; TRAYHURN P, 1978, PFLUG ARCH EUR J PHY, V373, P189, DOI 10.1007/BF00584859; TRAYHURN P, 1979, PFLUG ARCH EUR J PHY, V380, P227, DOI 10.1007/BF00582901; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wittamer V, 2005, J IMMUNOL, V175, P487, DOI 10.4049/jimmunol.175.1.487; Wittamer V, 2004, J BIOL CHEM, V279, P9956, DOI 10.1074/jbc.M313016200; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zabel BA, 2005, J BIOL CHEM, V280, P34661, DOI 10.1074/jbc.M504868200; Zabel BA, 2006, EXP HEMATOL, V34, P1021, DOI 10.1016/j.exphem.2006.05.003; Zabel BA, 2006, EXP HEMATOL, V34, P1106, DOI 10.1016/j.exphem.2006.03.011	67	598	653	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28175	28188		10.1074/jbc.M700793200	http://dx.doi.org/10.1074/jbc.M700793200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635925	hybrid			2022-12-27	WOS:000249455600067
J	Liao, X; Wang, W; Chen, S; Wu, Q				Liao, Xudong; Wang, Wei; Chen, Shenghan; Wu, Qingyu			Role of glycosylation in corin zymogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROATRIAL NATRIURETIC PEPTIDE; SERINE-PROTEASE CORIN; INHIBITION; MATRIPTASE; DOMAIN; GENE; ENTEROPEPTIDASE; EXPRESSION; SECRETION; MECHANISM	The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase. Corin is made as a zymogen, which is activated by proteolytic cleavage. Previous studies showed that recombinant human corin expressed in HEK 293 cells was biologically active, but activated corin fragments were not detectashowed that recombinant rat corin was activated in HEK 293 cells, murine HL-1 cardiomyocytes, and rat neonatal cardiomyocytes. In these cells, activated corin represented a small fraction of the total corin molecules. The activation of recombinant rat corin was inhibited by small molecule trypsin inhibitors but not inhibitors for matrix metalloproteinases or cysteine proteases, suggesting that a trypsin-like protease activated corin in these cells. Glycosidase digestion showed that rat and human corin proteins contained substantial N-glycans but little O-glycans. Treatment of HEK 293 cells expressing rat corin with tunicamycin prevented corin activation and inhibited its pro-atrial natriuretic peptide processing activity. Similar effects of tunicamycin on endogenous corin activity were found in HL-1 cells. Mutations altering the two N-glycosylation sites in the protease domain of rat corin prevented its activation in HEK 293 and HL-1 cells. Our results indicate that N-linked oligosaccharides play an important role in corin activation.	Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin, Dept Nephrol, Cleveland, OH 44195 USA; Cleveland Clin, Dept Hypertens, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Wu, Q (corresponding author), Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44195 USA.	wuq@ccf.org		Wu, Qingyu/0000-0003-0561-9315				BURNETT JC, 1984, AM J PHYSIOL, V247, pF863, DOI 10.1152/ajprenal.1984.247.5.F863; Burnett JC, 2007, HYPERTENSION, V49, P765, DOI 10.1161/01.HYP.0000258567.67263.96; Calderone A, 2006, J CELL PHYSIOL, V207, P165, DOI 10.1002/jcp.20548; Chan JCY, 2005, P NATL ACAD SCI USA, V102, P785, DOI 10.1073/pnas.0407234102; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Dries DL, 2005, CIRCULATION, V112, P2403, DOI 10.1161/CIRCULATIONAHA.105.568881; GRANGER JP, 1989, AM J PHYSIOL, V257, pH502, DOI 10.1152/ajpheart.1989.257.2.H502; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jiang W, 2005, EUR J PHARMACOL, V507, P153, DOI 10.1016/j.ejphar.2004.11.023; Knappe S, 2003, J BIOL CHEM, V278, P52363, DOI 10.1074/jbc.M309991200; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; Langenickel TH, 2004, AM J PHYSIOL-HEART C, V287, pH1516, DOI 10.1152/ajpheart.00947.2003; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liao XD, 2006, FASEB J, V20, P1883, DOI 10.1096/fj.06-5717fje; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; McGrath MF, 2005, TRENDS ENDOCRIN MET, V16, P469, DOI 10.1016/j.tem.2005.10.007; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; Potter LR, 2005, CELL METAB, V1, P88, DOI 10.1016/j.cmet.2005.01.008; Rame JE, 2007, HYPERTENSION, V49, P857, DOI 10.1161/01.HYP.0000258566.95867.9e; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; Tran KL, 2004, AM J PHYSIOL-HEART C, V287, pH1625, DOI 10.1152/ajpheart.00298.2004; Wu CL, 2003, J BIOL CHEM, V278, P25847, DOI 10.1074/jbc.M301223200; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Wu QY, 2007, FRONT BIOSCI-LANDMRK, V12, P4179, DOI 10.2741/2379; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zheng XL, 2002, J BIOL CHEM, V277, P6858, DOI 10.1074/jbc.M109857200	39	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27728	27735		10.1074/jbc.M703687200	http://dx.doi.org/10.1074/jbc.M703687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660514	hybrid			2022-12-27	WOS:000249455600021
J	Nikitina, T; Ghosh, RP; Horowitz-Scherer, RA; Hansen, JC; Grigoryev, SA; Woodcock, CL				Nikitina, Tatiana; Ghosh, Rajarshi P.; Horowitz-Scherer, Rachel A.; Hansen, Jeffrey C.; Grigoryev, Sergei A.; Woodcock, Christopher L.			MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING DOMAIN; NUCLEOSOME CORE PARTICLE; 4-WAY JUNCTION DNA; METHYL-CPG; LINKER HISTONE; MICROCOCCAL NUCLEASE; CRYSTAL-STRUCTURE; PROTEIN MECP2; H1; RESOLUTION	hMeCP2 (human methylated DNA-binding protein 2), mutations of which cause most cases of Rett syndrome (RTT), is involved in the transmission of repressive epigenetic signals encoded by DNA methylation. The present work focuses on the modifications of chromatin architecture induced by MeCP2 and the effects of RTT-causing mutants. hMeCP2 binds to nuclel somes close to the linker DNA entry-exit site and protects similar to 11 bp of linker DNA from micrococcal nuclease. MeCP2 mutants differ in this property; the R106W mutant gives very little extra protection beyond the similar to 146-bp nucleosome core, whereas the large C-terminal truncation R294X reveals wild type behavior. Gel mobility assays show that linker DNA is essential for proper MeCP2 binding to nucleosomes, and electron microscopy visualization shows that the protein induces distinct conformational changes in the linker DNA. When bound to nucleosomes, MeCP2 is in close proximity to histone H3, which exits the nucleosome core close to the proposed MeCP2-binding site. These findings firmly establish nuclecisomal linker DNA as a crucial binding partner of MeCP2 and show that different RTT-causing mutations of MeCP2 are correspondingly defective in different aspects of the interactions that alter chromatin architecture.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Program Mol & Cell Biol, Amherst, MA 01003 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Colorado State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Woodcock, CL (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	chris@bio.umass.edu		ghosh, rajarshi/0000-0002-0020-6194; ghosh, rajarshi/0000-0003-2348-6333	NIGMS NIH HHS [GM070897, GM45916, GM66834] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066834, R01GM070897, R01GM045916, R29GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams VH, 2007, J BIOL CHEM, V282, P15057, DOI 10.1074/jbc.M700855200; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2003, NUCLEIC ACIDS RES, V31, P4264, DOI 10.1093/nar/gkg481; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; Chadwick LH, 2007, CURR OPIN GENET DEV, V17, P121, DOI 10.1016/j.gde.2007.02.003; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; DINGWALL C, 1981, NUCLEIC ACIDS RES, V9, P2659, DOI 10.1093/nar/9.12.2659; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galvao TC, 2005, NUCLEIC ACIDS RES, V33, P6603, DOI 10.1093/nar/gki971; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P2643, DOI 10.1093/nar/9.12.2643; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; KOCSIS E, 1991, J STRUCT BIOL, V107, P6, DOI 10.1016/1047-8477(91)90025-R; LaSalle JM, 2004, CURR TOP DEV BIOL, V59, P61, DOI 10.1016/S0070-2153(04)59003-8; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luikenhuis S, 2004, P NATL ACAD SCI USA, V101, P6033, DOI 10.1073/pnas.0401626101; McBryant SJ, 2006, CHROMOSOME RES, V14, P39, DOI 10.1007/s10577-006-1025-x; McGowan S, 2006, EMBO J, V25, P3144, DOI 10.1038/sj.emboj.7601201; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Moretti P, 2006, CURR OPIN GENET DEV, V16, P276, DOI 10.1016/j.gde.2006.04.009; Nikitina T, 2007, MOL CELL BIOL, V27, P864, DOI 10.1128/MCB.01593-06; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; Thastrom A, 2004, J MOL BIOL, V338, P695, DOI 10.1016/j.jmb.2004.03.032; Thatcher KN, 2006, EPIGENETICS-US, V1, P24; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Woodcock CL, 1998, METHOD CELL BIOL, V53, P167; Woodward M, 2006, SOFTW TEST VERIF REL, V16, P1, DOI 10.1002/stvr.342; Wu CY, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh121; Young TA, 2007, J MOL BIOL, V368, P1438, DOI 10.1016/j.jmb.2007.02.077	44	88	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28237	28245		10.1074/jbc.M704304200	http://dx.doi.org/10.1074/jbc.M704304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17660293	hybrid			2022-12-27	WOS:000249455600073
J	Shahi, P; Gulshan, K; Moye-Rowley, WS				Shahi, Puja; Gulshan, Kailash; Moye-Rowley, W. Scott			Negative transcriptional regulation of multidrug resistance gene expression by an Hsp70 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; BINDING-CASSETTE TRANSPORTER; NUCLEOTIDE EXCHANGE FACTOR; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL CRISTAE; MOLECULAR CHAPERONES; HEME ACTIVATION; PLASMA-MEMBRANE; ATP SYNTHASE; YEAST	One of the most common origins of multidrug resistance occurs via the overproduction of ATP-binding cassette ( ABC) transporter proteins. These ABC transporters then act as broad specificity drug pumps and efflux a wide range of toxic agents out of the cell. The yeast Saccharomyces cerevisiae exhibits multiple or pleiotropic drug resistance ( Pdr) often through the overproduction of a plasma membrane-localized ABC transporter protein called Pdr5p. Expression of the PDR5 gene is controlled by two zinc cluster-containing transcription factors called Pdr1p and Pdr3p. Cells that lack their mitochondrial genome ( rho(0) cells) strongly induce PDR5 transcription in a Pdr3p-dependent fashion. To identify proteins associated with Pdr3p that might act to regulate this factor, a tandem affinity purification ( TAP) moiety was fused to Pdr3p, and this recombinant protein was purified from yeast cells. The cytosolic Hsp70 chaperone Ssa1p co-purified with TAP-Pdr3p. Overexpression of Ssa1p repressed expression of PDR5 but had no effect on expression of other genes involved in the Pdr phenotype. This Ssa1p-mediated repression required the presence of Pdr3p and did not influence Pdr1p-dependent gene expression. Loss of the nucleotide exchange factor Fes1p mimicked Ssa1p-mediated repression of PDR5. Co-immunoprecipitation experiments indicated that Ssa1p was associated with Pdr3p but not Pdr1p in yeast cells. Finally, rho(0) cells had less Ssa1p bound to Pdr3p than rho(+) cells, consistent with Ssa1p-mediated repression of Pdr3p activity serving as a key regulatory step in control of multidrug resistance in yeast.	Univ Iowa, Dept Physiol & Mol Biophys, Iowa City, IA 52242 USA	University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Mol Biophys, 6-530 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	scott-moyerowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM 49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Dragovic Z, 2006, EMBO J, V25, P2519, DOI 10.1038/sj.emboj.7601138; Duttagupta R, 2003, MOL CELL BIOL, V23, P2623, DOI 10.1128/MCB.23.8.2623-2632.2003; Eisenman HC, 2004, MOL MICROBIOL, V53, P335, DOI 10.1111/j.1365-2958.2004.04134.x; Ernst R, 2005, METHOD ENZYMOL, V400, P460, DOI 10.1016/S0076-6879(05)00026-1; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hallstrom TC, 2000, MOL MICROBIOL, V36, P402, DOI 10.1046/j.1365-2958.2000.01858.x; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Hon T, 2005, GENETICS, V169, P1343, DOI 10.1534/genetics.104.037143; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones G, 2004, MOL CELL BIOL, V24, P3928, DOI 10.1128/MCB.24.9.3928-3937.2004; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KINTER M, 2000, WILEY INTERSCIENCE S, P1; Lan CG, 2004, J BIOL CHEM, V279, P27607, DOI 10.1074/jbc.M402777200; Lee HC, 2002, J BIOL CHEM, V277, P7430, DOI 10.1074/jbc.M106951200; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Moye-Rowley WS, 2005, GENE, V354, P15, DOI 10.1016/j.gene.2005.03.019; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sanglard D, 2002, LANCET INFECT DIS, V2, P73, DOI 10.1016/S1473-3099(02)00181-0; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; Shaner L, 2006, BIOCHEMISTRY-US, V45, P15075, DOI 10.1021/bi061279k; Sherman F, 1979, METHODS YEAST GENETI; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; Simonics T, 2000, CURR GENET, V38, P248, DOI 10.1007/s002940000164; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200; Zhang XT, 2005, J BIOL CHEM, V280, P2759, DOI 10.1074/jbc.M408333200	69	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26822	26831		10.1074/jbc.M704772200	http://dx.doi.org/10.1074/jbc.M704772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636264	hybrid			2022-12-27	WOS:000249304900022
J	Sossey-Alaoui, K; Li, XR; Cowell, JK				Sossey-Alaoui, Khalid; Li, Xiurong; Cowell, John K.			c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; PROTEIN N-WASP; ACTIN POLYMERIZATION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FILOPODIUM FORMATION; SIGNALING COMPLEX; TYROSINE KINASES; FAMILY PROTEINS; ACTIVATION; LOCALIZATION	The activity of the Wiskott-Aldrich syndrome-related WAVE3 protein is critical for the regulation of the Arp2/3-dependent cytoskeleton organization downstream of Rac-GTPase. The Ableson (Abl) non-receptor tyrosine kinase is also involved in the remolding of actin cytoskeleton in response to extracellular stimuli. Here we show that platelet-derived growth factor stimulation of cultured cells results in WAVE3-Abl interaction and localization to the cell periphery. WAVE3-Abl interaction promotes the tyrosine phosphorylation of WAVE3 by Abl, and STI-571, a specific inhibitor of Abl kinase activity, abrogates the Abl-mediated phosphorylation of WAVE3. We have also shown that Abl targets and phosphorylates four tyrosine residues in WAVE3 and that the Abl-dependent phosphorylation of WAVE3 is critical for the stimulation of lamellipodia formation and cell migration. Our results show that the activation of WAVE3 to promote actin remodeling is enhanced by the c-Ablmediated tyrosine phosphorylation of WAVE3.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sossey-Alaoui, K (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	khalid.sossey-alaoui@roswellpark.org		Cowell, John/0000-0002-2079-5950	NCI NIH HHS [CA16056] Funding Source: Medline; NINDS NIH HHS [NS35791] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a; Echarri A, 2004, MOL CELL BIOL, V24, P4979, DOI 10.1128/MCB.24.11.4979-4993.2004; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Kim Y, 2006, NATURE, V442, P814, DOI 10.1038/nature04976; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2003, MAMM GENOME, V14, P314, DOI 10.1007/s00335-002-2247-7; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stovold CF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-11; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yokoyama N, 2005, J BIOL CHEM, V280, P42219, DOI 10.1074/jbc.M506996200	36	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26257	26265		10.1074/jbc.M701484200	http://dx.doi.org/10.1074/jbc.M701484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623672	hybrid			2022-12-27	WOS:000249239600030
J	Sano, M; Tokudome, S; Shimizu, N; Yoshikawa, N; Ogawa, C; Shirakawa, K; Endo, J; Katayama, T; Yuasa, S; Ieda, M; Makino, S; Hattori, F; Tanaka, H; Fukuda, K				Sano, Motoaki; Tokudome, Satori; Shimizu, Noriaki; Yoshikawa, Noritada; Ogawa, Chie; Shirakawa, Kousuke; Endo, Jin; Katayama, Takaharu; Yuasa, Shinsuke; Ieda, Masaki; Makino, Shinji; Hattori, Fumiyuki; Tanaka, Hirotoshi; Fukuda, Keiichi			Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor gamma coactivator 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; MITOCHONDRIAL-FUNCTION; ENERGY-METABOLISM; HEART-FAILURE; PGC-1-ALPHA; DEGRADATION; UBIQUITIN; PGC-1; DISEASE; SUPPRESSION	Peroxisome proliferator- activated receptor gamma coactivator (PGC)-1 is a critical transcriptional regulator of energy metabolism. Here we found that PGC-1 alpha is a short lived and aggregation-prone protein. PGC-1 alpha localized throughout the nucleoplasm and was rapidly destroyed via the ubiquitin-proteasome pathway. Upon proteasome inhibition, PGC-1 alpha formed insoluble polyubiquitinated aggregates. Ubiquitination of PGC-1 alpha depended on the integrity of the C terminus-containing arginine-serine-rich domains and an RNA recognition motif. Interestingly, ectopically expressed C-terminal fragment of PGC-1 alpha was autonomously ubiquitinated and aggregated with promyelocytic leukemia protein. Cooperation of the N-terminal region containing two PEST-like motifs was required for prevention of aggregation and targeting of the polyubiquitinated PGC- 1 alpha for degradation. This region thereby negatively controlled the aggregation properties of the C-terminal region to regulate protein turnover and intranuclear compartmentalization of PGC-1 alpha. Exogenous expression of the PGC-1 alpha C-terminal fragment interfered with degradation of full-length PGC-1 alpha and enhanced its coactivation properties. We concluded that PGC-1 alpha function is critically regulated at multiple steps via intramolecular cooperation among several distinct structural domains of the protein.	Keio Univ, Sch Med, Dept Regenerta Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Div Cardiol, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Rheumatol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Allergy Res Hosp, Tokyo 1088639, Japan	Keio University; Keio University; Keio University; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo	Sano, M (corresponding author), Keio Univ, Sch Med, Dept Regenerta Med & Adv Cardiac Therapeut, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	msano@sc.itc.keio.ac.jp	Fukuda, Keiichi/L-3777-2013; Sano, Motoaki/L-3405-2013; Yuasa, Shinsuke/L-8310-2013	Yuasa, Shinsuke/0000-0001-5593-7552				Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Arany Z, 2006, P NATL ACAD SCI USA, V103, P10086, DOI 10.1073/pnas.0603615103; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Fu LW, 2005, MOL BIOL CELL, V16, P4905, DOI 10.1091/mbc.E05-01-0019; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; Janer A, 2006, J CELL BIOL, V174, P65, DOI 10.1083/jcb.200511045; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nalley K, 2006, NATURE, V442, P1054, DOI 10.1038/nature05067; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; RECHSTEINER M, 1989, RBC-CELL BIOL REV, V20, P235; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sano M, 2005, CELL METAB, V1, P216, DOI 10.1016/j.cmet.2005.03.009; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2007, CELL METAB, V5, P129, DOI 10.1016/j.cmet.2007.01.003; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Spector DL, 2001, J CELL SCI, V114, P2891; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Sun QY, 2006, FRONT BIOSCI-LANDMRK, V11, P1137, DOI 10.2741/1868; Tavanez JP, 2005, RNA, V11, P752, DOI 10.1261/rna.7217105; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200	46	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25970	25980		10.1074/jbc.M703634200	http://dx.doi.org/10.1074/jbc.M703634200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17620342	hybrid			2022-12-27	WOS:000249014100082
